Regulation	O
of	O
connexin32	B-Protein
and	O
connexin43	B-Protein
gene	O
expression	O
by	O
DNA	O
methylation	O
in	O
rat	O
liver	O
cells	O
.	O

Gap	O
junction	O
proteins	O
(	O
connexins	O
)	O
are	O
expressed	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
and	O
expression	O
is	O
often	O
reduced	O
in	O
neoplastic	O
cells	O
.	O

We	O
investigated	O
the	O
mechanisms	O
of	O
connexin32	B-Protein
(	O
Cx32	B-Protein
)	O
and	O
connexin43	B-Protein
(	O
Cx43	B-Protein
)	O
expression	O
in	O
hepatic	O
cells	O
using	O
MH1C1	O
rat	O
hepatoma	O
cells	O
and	O
freshly	O
isolated	O
,	O
adult	O
rat	O
hepatocytes	O
that	O
express	O
Cx32	B-Protein
but	O
not	O
Cx43	B-Protein
and	O
WB	O
-	O
F344	O
rat	O
liver	O
epithelial	O
cells	O
that	O
express	O
Cx43	B-Protein
but	O
not	O
Cx32	B-Protein
.	O

Southern	O
blotting	O
after	O
DNA	O
restriction	O
with	O
MspI	B-Protein
and	O
HpaII	B-Protein
indicated	O
that	O
two	O
MspI	B-Protein
/	O
HpaII	B-Protein
restriction	O
sites	O
in	O
the	O
Cx32	B-Protein
promoter	O
(	O
positions	O
-	O
147	O
and	O
-	O
847	O
)	O
were	O
methylated	O
in	O
WB	O
-	O
F344	O
cells	O
,	O
but	O
not	O
in	O
MH1C1	O
cells	O
or	O
hepatocytes	O
.	O

In	O
contrast	O
,	O
an	O
MspI	B-Protein
/	O
HpaII	B-Protein
restriction	O
site	O
in	O
the	O
Cx43	B-Protein
promoter	O
(	O
position	O
-	O
38	O
)	O
was	O
methylated	O
in	O
MH1C1	O
cells	O
,	O
but	O
not	O
in	O
WB	O
-	O
F344	O
cells	O
or	O
hepatocytes	O
.	O

Transient	O
transfection	O
of	O
the	O
cell	O
lines	O
with	O
connexin	O
promoter	O
-	O
luciferase	B-Protein
constructs	O
indicated	O
that	O
the	O
Cx32	B-Protein
promoter	O
was	O
7	O
-	O
fold	O
more	O
active	O
in	O
MH1C1	O
cells	O
and	O
the	O
Cx43	B-Protein
promoter	O
was	O
5	O
-	O
fold	O
more	O
active	O
in	O
WB	O
-	O
F344	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
transcription	O
of	O
Cx32	B-Protein
and	O
Cx43	B-Protein
in	O
hepatic	O
cells	O
is	O
controlled	O
by	O
promoter	O
methylation	O
and	O
by	O
cell	O
-	O
specific	O
transcription	O
factors	O
.	O

Similar	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
reduced	O
expression	O
of	O
these	O
genes	O
frequently	O
observed	O
in	O
neoplastic	O
cells	O
.	O

CheY	B-Protein
-	O
dependent	O
methylation	O
of	O
the	O
asparagine	O
receptor	O
,	O
McpB	B-Protein
,	O
during	O
chemotaxis	O
in	O
Bacillus	O
subtilis	O
.	O

For	O
the	O
Gram	O
-	O
positive	O
organism	O
Bacillus	O
subtilis	O
,	O
chemotaxis	O
to	O
the	O
attractant	O
asparagine	O
is	O
mediated	O
by	O
the	O
chemoreceptor	O
McpB	B-Protein
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
rapid	O
net	O
demethylation	O
of	O
B	O
.	O
subtilis	O
McpB	B-Protein
results	O
in	O
the	O
immediate	O
production	O
of	O
methanol	O
,	O
presumably	O
due	O
to	O
the	O
action	O
of	O
CheB	B-Protein
.	O

We	O
also	O
show	O
that	O
net	O
demethylation	O
of	O
McpB	B-Protein
occurs	O
upon	O
both	O
addition	O
and	O
removal	O
of	O
asparagine	O
.	O

After	O
each	O
demethylation	O
event	O
,	O
McpB	B-Protein
is	O
remethylated	O
to	O
nearly	O
prestimulus	O
levels	O
.	O

Both	O
remethylation	O
events	O
are	O
attributable	O
to	O
CheR	B-Protein
using	O
S	O
-	O
adenosylmethionine	O
as	O
a	O
substrate	O
.	O

Therefore	O
,	O
no	O
methyl	O
transfer	O
to	O
an	O
intermediate	O
carrier	O
need	O
be	O
postulated	O
to	O
occur	O
during	O
chemotaxis	O
in	O
B	O
.	O
subtilis	O
as	O
was	O
previously	O
suggested	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
remethylation	O
of	O
asparagine	O
-	O
bound	O
McpB	B-Protein
requires	O
the	O
response	O
regulator	O
,	O
CheY	B-Protein
-	O
P	O
,	O
suggesting	O
that	O
CheY	B-Protein
-	O
P	O
acts	O
in	O
a	O
feedback	O
mechanism	O
to	O
facilitate	O
adaptation	O
to	O
positive	O
stimuli	O
during	O
chemotaxis	O
in	O
B	O
.	O
subtilis	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
two	O
observations	O
:	O
a	O
cheRBCD	B-Protein
mutant	O
is	O
capable	O
of	O
transient	O
excitation	O
and	O
subsequent	O
oscillations	O
that	O
bring	O
the	O
flagellar	O
rotational	O
bias	O
below	O
the	O
prestimulus	O
value	O
in	O
the	O
tethered	O
cell	O
assay	O
,	O
and	O
the	O
cheRBCD	B-Protein
mutant	O
is	O
capable	O
of	O
swarming	O
in	O
a	O
Tryptone	O
swarm	O
plate	O
.	O

Transglycosylation	O
reactions	O
of	O
Bacillus	O
stearothermophilus	O
maltogenic	B-Protein
amylase	I-Protein
with	O
acarbose	O
and	O
various	O
acceptors	O
.	O

It	O
was	O
observed	O
that	O
Bacillus	O
stearothermophilus	O
maltogenic	B-Protein
amylase	I-Protein
cleaved	O
the	O
first	O
glycosidic	O
bond	O
of	O
acarbose	O
to	O
produce	O
glucose	O
and	O
a	O
pseudotrisaccharide	O
(	O
PTS	O
)	O
that	O
was	O
transferred	O
to	O
C	O
-	O
6	O
of	O
the	O
glucose	O
to	O
give	O
an	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
6	O
)	O
glycosidic	O
linkage	O
and	O
the	O
formation	O
of	O
isoacarbose	O
.	O

The	O
addition	O
of	O
a	O
number	O
of	O
different	O
carbohydrates	O
to	O
the	O
digest	O
gave	O
transfer	O
products	O
in	O
which	O
PTS	O
was	O
primarily	O
attached	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
6	O
)	O
to	O
D	O
-	O
glucose	O
,	O
D	O
-	O
mannose	O
,	O
D	O
-	O
galactose	O
,	O
and	O
methyl	O
alpha	O
-	O
D	O
-	O
glucopyranoside	O
.	O

With	O
D	O
-	O
fructopyranose	O
and	O
D	O
-	O
xylopyranose	O
,	O
PTS	O
was	O
linked	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
5	O
)	O
and	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
,	O
respectively	O
.	O

PTS	O
was	O
primarily	O
transferred	O
to	O
C	O
-	O
6	O
of	O
the	O
nonreducing	O
residue	O
of	O
maltose	O
,	O
cellobiose	O
,	O
lactose	O
,	O
and	O
gentiobiose	O
.	O

Lesser	O
amounts	O
of	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
3	O
)	O
and	O
/	O
or	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
transfer	O
products	O
were	O
also	O
observed	O
for	O
these	O
carbohydrate	O
acceptors	O
.	O

The	O
major	O
transfer	O
product	O
to	O
sucrose	O
gave	O
PTS	O
linked	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
to	O
the	O
glucose	O
residue	O
.	O
alpha	O
,	O
alpha	O
-	O
Trehalose	O
gave	O
two	O
major	O
products	O
with	O
PTS	O
linked	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
6	O
)	O
and	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
.	O

Maltitol	O
gave	O
two	O
major	O
products	O
with	O
PTS	O
linked	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
6	O
)	O
and	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
to	O
the	O
glucopyranose	O
residue	O
.	O

Raffinose	O
gave	O
two	O
major	O
products	O
with	O
PTS	O
linked	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
6	O
)	O
and	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
to	O
the	O
D	O
-	O
galactopyranose	O
residue	O
.	O

Maltotriose	O
gave	O
two	O
major	O
products	O
with	O
PTS	O
linked	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
6	O
)	O
and	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
4	O
)	O
to	O
the	O
nonreducing	O
end	O
glucopyranose	O
residue	O
.	O

Xylitol	O
gave	O
PTS	O
linked	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
5	O
)	O
as	O
the	O
major	O
product	O
and	O
D	O
-	O
glucitol	O
gave	O
PTS	O
linked	O
alpha	O
-	O
(	O
1	O
-	O
-	O
>	O
6	O
)	O
as	O
the	O
only	O
product	O
.	O

The	O
structures	O
of	O
the	O
transfer	O
products	O
were	O
determined	O
using	O
thin	O
-	O
layer	O
chromatography	O
,	O
high	O
-	O
performance	O
ion	O
chromatography	O
,	O
enzyme	O
hydrolysis	O
,	O
methylation	O
analysis	O
and	O
13C	O
NMR	O
spectroscopy	O
.	O

The	O
best	O
acceptor	O
was	O
gentiobiose	O
,	O
followed	O
closely	O
by	O
maltose	O
and	O
cellobiose	O
,	O
and	O
the	O
weakest	O
acceptor	O
was	O
D	O
-	O
glucitol	O
.	O

A	O
Plasmodium	O
chabaudi	O
chabaudi	O
high	O
molecular	O
mass	O
glycoprotein	O
translocated	O
to	O
the	O
host	O
cell	O
membrane	O
by	O
a	O
non	O
-	O
classical	O
secretory	O
pathway	O
.	O

We	O
have	O
purified	O
and	O
characterized	O
a	O
novel	O
high	O
molecular	O
mass	O
glycoprotein	O
of	O
P	O
.	O
chabaudi	O
chabaudi	O
(	O
Pc550gp	B-Protein
)	O
that	O
is	O
transported	O
to	O
the	O
erythrocyte	O
membrane	O
during	O
the	O
intraerythrocytic	O
cycle	O
.	O

Immuno	O
fluorescence	O
assays	O
with	O
polyclonal	O
monospecific	O
antibodies	O
against	O
Pc550gp	B-Protein
show	O
that	O
the	O
protein	O
to	O
be	O
localized	O
in	O
the	O
periphery	O
of	O
young	O
trophozoite	O
stages	O
i	O
.	O
e	O
.	O
,	O
on	O
the	O
plasma	O
membrane	O
or	O
parasitophorous	O
vacuole	O
membrane	O
.	O

However	O
,	O
in	O
late	O
trophozoites	O
and	O
schizonts	O
the	O
antigen	O
is	O
distributed	O
in	O
both	O
parasite	O
and	O
host	O
cell	O
membranes	O
.	O

These	O
results	O
were	O
confirmed	O
by	O
immunoblotting	O
of	O
isolated	O
parasites	O
and	O
infected	O
host	O
cell	O
membranes	O
at	O
different	O
stages	O
of	O
parasite	O
development	O
.	O

Moreover	O
,	O
alkali	O
extraction	O
of	O
purified	O
infected	O
erythrocyte	O
membranes	O
at	O
mature	O
stages	O
of	O
parasite	O
development	O
does	O
not	O
solubilize	O
Pc550gp	B-Protein
,	O
suggesting	O
that	O
it	O
is	O
an	O
integral	O
membrane	O
protein	O
.	O

In	O
addition	O
proteinase	O
K	O
digestion	O
of	O
intact	O
infected	O
host	O
cells	O
induced	O
the	O
disappearance	O
of	O
Pc550gp	B-Protein
.	O

Further	O
indicating	O
its	O
transmembrane	O
nature	O
and	O
that	O
it	O
presents	O
extracellular	O
domains	O
susceptible	O
to	O
proteolysis	O
.	O

Brefeldin	O
A	O
or	O
low	O
temperature	O
(	O
15	O
degrees	O
C	O
)	O
treatment	O
did	O
not	O
affect	O
the	O
translocation	O
of	O
Pc550gp	B-Protein
from	O
the	O
parasite	O
compartments	O
to	O
the	O
erythrocyte	O
membrane	O
,	O
indicating	O
that	O
the	O
secretion	O
of	O
Pc550gp	B-Protein
does	O
not	O
follow	O
the	O
classical	O
transport	O
pathway	O
described	O
in	O
most	O
eukaryotic	O
cells	O
.	O

Novel	O
roles	O
for	O
classical	O
factors	O
at	O
the	O
interface	O
between	O
translation	O
termination	O
and	O
initiation	O
.	O

The	O
pathway	O
of	O
bacterial	O
ribosome	O
recycling	O
following	O
translation	O
termination	O
has	O
remained	O
obscure	O
.	O

Here	O
,	O
we	O
elucidate	O
two	O
essential	O
steps	O
and	O
describe	O
the	O
roles	O
played	O
by	O
the	O
three	O
translation	O
factors	O
EF	B-Protein
-	I-Protein
G	I-Protein
,	O
RRF	B-Protein
,	O
and	O
IF3	B-Protein
.	O

Release	O
factor	O
RF3	B-Protein
is	O
known	O
to	O
catalyze	O
the	O
dissociation	O
of	O
RF1	B-Protein
or	O
RF2	B-Protein
from	O
ribosomes	O
after	O
polypeptide	O
release	O
.	O

We	O
show	O
that	O
the	O
next	O
step	O
is	O
dissociation	O
of	O
50S	O
subunits	O
from	O
the	O
70S	O
posttermination	O
complex	O
and	O
that	O
it	O
is	O
catalyzed	O
by	O
RRF	B-Protein
and	O
EF	B-Protein
-	I-Protein
G	I-Protein
and	O
requires	O
GTP	O
hydrolysis	O
.	O

Removal	O
of	O
deacylated	O
tRNA	O
from	O
the	O
resulting	O
30S	O
:	O
mRNA	O
:	O
tRNA	O
posttermination	O
complex	O
is	O
then	O
necessary	O
to	O
permit	O
rapid	O
30S	O
subunit	O
recycling	O
.	O

We	O
show	O
that	O
this	O
step	O
requires	O
initiation	O
factor	O
IF3	B-Protein
,	O
whose	O
role	O
was	O
previously	O
thought	O
to	O
be	O
restricted	O
to	O
promoting	O
specific	O
30S	O
initiation	O
complex	O
formation	O
from	O
free	O
30S	O
subunits	O
.	O

Effect	O
of	O
alternative	O
glycosylation	O
on	O
insulin	B-Protein
receptor	I-Protein
processing	O
.	O

The	O
mature	O
insulin	B-Protein
receptor	I-Protein
is	O
a	O
cell	O
surface	O
heterotetrameric	O
glycoprotein	O
composed	O
of	O
two	O
alpha	O
-	O
and	O
two	O
beta	O
-	O
subunits	O
.	O

In	O
3T3	O
-	O
L1	O
adipocytes	O
as	O
in	O
other	O
cell	O
types	O
,	O
the	O
receptor	O
is	O
synthesized	O
as	O
a	O
single	O
polypeptide	O
consisting	O
of	O
uncleaved	O
alpha	O
-	O
and	O
beta	O
-	O
subunits	O
,	O
migrating	O
as	O
a	O
190	O
-	O
kDa	O
glycoprotein	O
.	O

To	O
examine	O
the	O
importance	O
of	O
N	O
-	O
linked	O
glycosylation	O
on	O
insulin	B-Protein
receptor	I-Protein
processing	O
,	O
we	O
have	O
used	O
glucose	O
deprivation	O
as	O
a	O
tool	O
to	O
alter	O
protein	O
glycosylation	O
.	O

Western	O
blot	O
analysis	O
shows	O
that	O
glucose	O
deprivation	O
led	O
to	O
a	O
time	O
-	O
dependent	O
accumulation	O
of	O
an	O
alternative	O
proreceptor	O
of	O
170	O
kDa	O
in	O
a	O
subcellular	O
fraction	O
consistent	O
with	O
endoplasmic	O
reticulum	O
localization	O
.	O

Co	O
-	O
precipitation	O
assays	O
provide	O
evidence	O
that	O
the	O
alternative	O
proreceptor	O
bound	O
GRP78	B-Protein
,	O
an	O
endoplasmic	O
reticulum	O
molecular	O
chaperone	O
.	O

N	B-Protein
-	I-Protein
Glycosidase	I-Protein
F	I-Protein
treatment	O
shows	O
that	O
the	O
alternative	O
proreceptor	O
contained	O
N	O
-	O
linked	O
oligosaccharides	O
.	O

Yet	O
,	O
endoglycosidase	B-Protein
H	I-Protein
insensitivity	O
indicates	O
an	O
aberrant	O
oligosaccharide	O
structure	O
.	O

Using	O
pulse	O
-	O
chase	O
methodology	O
,	O
we	O
show	O
that	O
the	O
synthetic	O
rate	O
was	O
similar	O
between	O
the	O
normal	O
and	O
alternative	O
proreceptor	O
.	O

However	O
,	O
the	O
normal	O
proreceptor	O
was	O
processed	O
into	O
alpha	O
-	O
and	O
beta	O
-	O
subunits	O
(	O
t	O
(	O
(	O
1	O
)	O
/	O
(	O
2	O
)	O
)	O
=	O
1	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
6	O
h	O
)	O
,	O
while	O
the	O
alternative	O
proreceptor	O
was	O
degraded	O
(	O
t	O
(	O
(	O
1	O
)	O
/	O
(	O
2	O
)	O
)	O
=	O
5	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
6	O
h	O
)	O
.	O

Upon	O
refeeding	O
cells	O
that	O
were	O
initially	O
deprived	O
of	O
glucose	O
,	O
the	O
alternative	O
proreceptor	O
was	O
processed	O
to	O
a	O
higher	O
molecular	O
weight	O
form	O
and	O
gained	O
sensitivity	O
to	O
endoglycosidase	B-Protein
H	I-Protein
.	O

This	O
"	O
intermediate	O
"	O
form	O
of	O
the	O
proreceptor	O
was	O
also	O
degraded	O
,	O
although	O
a	O
small	O
fraction	O
escaped	O
degradation	O
,	O
resulting	O
in	O
cleavage	O
to	O
the	O
alpha	O
-	O
and	O
beta	O
-	O
subunits	O
.	O

These	O
data	O
provide	O
evidence	O
for	O
the	O
first	O
time	O
that	O
glucose	O
deprivation	O
leads	O
to	O
the	O
accumulation	O
of	O
an	O
alternative	O
proreceptor	O
,	O
which	O
can	O
be	O
post	O
-	O
translationally	O
glycosylated	O
with	O
the	O
readdition	O
of	O
glucose	O
inducing	O
both	O
accelerated	O
degradation	O
and	O
maturation	O
.	O

Meat	O
,	O
metabolic	O
genotypes	O
and	O
risk	O
for	O
colorectal	O
cancer	O
.	O

Persuasive	O
data	O
exist	O
as	O
to	O
the	O
importance	O
of	O
environmental	O
factors	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
colorectal	O
cancer	O
.	O

One	O
possibility	O
is	O
that	O
the	O
effect	O
of	O
environmental	O
factors	O
varies	O
between	O
individuals	O
,	O
perhaps	O
on	O
the	O
basis	O
of	O
inherited	O
variation	O
(	O
polymorphism	O
)	O
in	O
genes	O
which	O
influence	O
the	O
activation	O
or	O
inactivation	O
of	O
dietary	O
carcinogens	O
.	O

Thus	O
far	O
,	O
the	O
focus	O
has	O
been	O
on	O
acetylator	O
genes	O
(	O
NAT1	B-Protein
,	O
NAT2	B-Protein
)	O
and	O
the	O
activation	O
of	O
heterocyclic	O
amines	O
,	O
carcinogens	O
generated	O
by	O
cooking	O
meat	O
for	O
prolonged	O
periods	O
at	O
high	O
temperature	O
.	O

Three	O
case	O
-	O
control	O
studies	O
and	O
one	O
prospective	O
study	O
have	O
shown	O
a	O
consistent	O
trend	O
towards	O
higher	O
risks	O
for	O
cancer	O
with	O
higher	O
intakes	O
of	O
meat	O
in	O
rapid	O
acetylators	O
for	O
NAT1	B-Protein
,	O
NAT2	B-Protein
or	O
both	O
genotypes	O
.	O

Other	O
links	O
between	O
meat	O
,	O
cooking	O
methods	O
,	O
metabolic	O
genotypes	O
and	O
risk	O
for	O
cancer	O
might	O
include	O
enhanced	O
activation	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
and	O
N	O
-	O
nitroso	O
compounds	O
by	O
variant	O
genotypes	O
of	O
CYP1A1	B-Protein
and	O
CYP2E1	B-Protein
,	O
respectively	O
,	O
and	O
modulation	O
by	O
meat	O
of	O
the	O
protective	O
effect	O
of	O
the	O
E4	B-Protein
allele	O
of	O
apolipoprotein	B-Protein
E	I-Protein
on	O
risk	O
for	O
cancer	O
of	O
the	O
proximal	O
colon	O
.	O

Differential	O
expression	O
of	O
human	O
lysyl	O
hydroxylase	O
genes	O
,	O
lysine	O
hydroxylation	O
,	O
and	O
cross	O
-	O
linking	O
of	O
type	O
I	O
collagen	O
during	O
osteoblastic	O
differentiation	O
in	O
vitro	O
.	O

The	O
pattern	O
of	O
lysyl	O
hydroxylation	O
in	O
the	O
nontriple	O
helical	O
domains	O
of	O
collagen	O
is	O
critical	O
in	O
determining	O
the	O
cross	O
-	O
linking	O
pathways	O
that	O
are	O
tissue	O
specific	O
.	O

We	O
hypothesized	O
that	O
the	O
tissue	O
specificity	O
of	O
type	O
I	O
collagen	O
cross	O
-	O
linking	O
is	O
,	O
in	O
part	O
,	O
due	O
to	O
the	O
differential	O
expression	O
of	O
lysyl	O
hydroxylase	O
genes	O
(	O
Procollagen	B-Protein
-	I-Protein
lysine	I-Protein
,	I-Protein
2	I-Protein
-	I-Protein
oxyglutarate	I-Protein
,	I-Protein
5	I-Protein
-	I-Protein
dioxygenase	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
and	O
3	B-Protein
[	O
PLOD1	B-Protein
,	O
PLOD2	B-Protein
,	O
and	O
PLOD3	B-Protein
]	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
expression	O
patterns	O
of	O
these	O
three	O
genes	O
during	O
the	O
course	O
of	O
in	O
vitro	O
differentiation	O
of	O
human	O
osteoprogenitor	O
cells	O
(	O
bone	O
marrow	O
stromal	O
cells	O
[	O
BMSCs	O
]	O
)	O
and	O
normal	O
skin	O
fibroblasts	O
(	O
NSFs	O
)	O
.	O

In	O
addition	O
,	O
using	O
the	O
medium	O
and	O
cell	O
layer	O
/	O
matrix	O
fractions	O
in	O
these	O
cultures	O
,	O
lysine	O
hydroxylation	O
of	O
type	O
I	O
collagen	O
alpha	O
chains	O
and	O
collagen	O
cross	O
-	O
linking	O
chemistries	O
have	O
been	O
characterized	O
.	O

High	O
levels	O
of	O
PLOD1	B-Protein
and	O
PLOD3	B-Protein
genes	O
were	O
expressed	O
in	O
both	O
BMSCs	O
and	O
NSFs	O
,	O
and	O
the	O
expression	O
levels	O
did	O
not	O
change	O
in	O
the	O
course	O
of	O
differentiation	O
.	O

In	O
contrast	O
to	O
the	O
PLOD1	B-Protein
and	O
PLOD3	B-Protein
genes	O
,	O
both	O
cell	O
types	O
showed	O
low	O
PLOD2	B-Protein
gene	O
expression	O
in	O
undifferentiated	O
and	O
early	O
differentiated	O
conditions	O
.	O

However	O
,	O
fully	O
differentiated	O
BMSCs	O
,	O
but	O
not	O
NSFs	O
,	O
exhibited	O
a	O
significantly	O
elevated	O
level	O
(	O
6	O
-	O
fold	O
increase	O
)	O
of	O
PLOD2	B-Protein
mRNA	O
.	O

This	O
increase	O
coincided	O
with	O
the	O
onset	O
of	O
matrix	O
mineralization	O
and	O
with	O
the	O
increase	O
in	O
lysyl	O
hydroxylation	O
in	O
the	O
nontriple	O
helical	O
domains	O
of	O
alpha	O
chains	O
of	O
type	O
I	O
collagen	O
molecule	O
.	O

Furthermore	O
,	O
the	O
collagen	O
cross	O
-	O
links	O
that	O
are	O
derived	O
from	O
the	O
nontriple	O
helical	O
hydroxylysine	O
-	O
aldehyde	O
were	O
found	O
only	O
in	O
fully	O
differentiated	O
BMSC	O
cultures	O
.	O

The	O
data	O
suggests	O
that	O
PLOD2	B-Protein
expression	O
is	O
associated	O
with	O
lysine	O
hydroxylation	O
in	O
the	O
nontriple	O
helical	O
domains	O
of	O
collagen	O
and	O
,	O
thus	O
,	O
could	O
be	O
partially	O
responsible	O
for	O
the	O
tissue	O
-	O
specific	O
collagen	O
cross	O
-	O
linking	O
pattern	O
.	O

Phenylalanine	O
residues	O
in	O
the	O
active	O
site	O
of	O
tyrosine	B-Protein
hydroxylase	I-Protein
:	O
mutagenesis	O
of	O
Phe300	O
and	O
Phe309	O
to	O
alanine	O
and	O
metal	O
ion	O
-	O
catalyzed	O
hydroxylation	O
of	O
Phe300	O
.	O

Residues	O
Phe300	O
and	O
Phe309	O
of	O
tyrosine	B-Protein
hydroxylase	I-Protein
are	O
located	O
in	O
the	O
active	O
site	O
in	O
the	O
recently	O
described	O
three	O
-	O
dimensional	O
structure	O
of	O
the	O
enzyme	O
,	O
where	O
they	O
have	O
been	O
proposed	O
to	O
play	O
roles	O
in	O
substrate	O
binding	O
.	O

Also	O
based	O
on	O
the	O
structure	O
,	O
Phe300	O
has	O
been	O
reported	O
to	O
be	O
hydroxylated	O
due	O
to	O
a	O
naturally	O
occurring	O
posttranslational	O
modification	O
[	O
Goodwill	O
,	O
K	O
.	O
E	O
.	O
,	O
Sabatier	O
,	O
C	O
.	O
,	O
and	O
Stevens	O
,	O
R	O
.	O
C	O
.	O
(	O
1998	O
)	O
Biochemistry	O
37	O
,	O
13437	O
-	O
13445	O
]	O
.	O

Mutants	O
of	O
tyrosine	B-Protein
hydroxylase	I-Protein
with	O
alanine	O
substituted	O
for	O
Phe300	O
or	O
Phe309	O
have	O
now	O
been	O
purified	O
and	O
characterized	O
.	O

The	O
F309A	O
protein	O
possesses	O
40	O
%	O
less	O
activity	O
than	O
wild	O
-	O
type	O
tyrosine	B-Protein
hydroxylase	I-Protein
in	O
the	O
production	O
of	O
DOPA	O
,	O
but	O
full	O
activity	O
in	O
the	O
production	O
of	O
dihydropterin	O
.	O

The	O
F300A	O
protein	O
shows	O
a	O
2	O
.	O
5	O
-	O
fold	O
decrease	O
in	O
activity	O
in	O
the	O
production	O
of	O
both	O
DOPA	O
and	O
dihydropterin	O
.	O

The	O
K	O
(	O
6	O
-	O
MPH4	O
)	O
value	O
for	O
F300A	O
tyrosine	B-Protein
hydroxylase	I-Protein
is	O
twice	O
the	O
wild	O
-	O
type	O
value	O
.	O

These	O
results	O
are	O
consistent	O
with	O
Phe309	O
having	O
a	O
role	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
active	O
site	O
,	O
while	O
Phe300	O
contributes	O
less	O
than	O
1	O
kcal	O
/	O
mol	O
to	O
binding	O
tetrahydropterin	O
.	O

Characterization	O
of	O
Phe300	O
by	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
and	O
amino	O
acid	O
sequencing	O
showed	O
that	O
hydroxylation	O
only	O
occurs	O
in	O
the	O
isolated	O
catalytic	O
domain	O
after	O
incubation	O
with	O
a	O
large	O
excess	O
of	O
7	O
,	O
8	O
-	O
dihydropterin	O
,	O
DTT	O
,	O
and	O
Fe	O
(	O
2	O
+	O
)	O
.	O

The	O
modification	O
is	O
not	O
observed	O
in	O
the	O
untreated	O
catalytic	O
domain	O
or	O
in	O
the	O
full	O
-	O
length	O
protein	O
,	O
even	O
in	O
the	O
presence	O
of	O
excess	O
iron	O
.	O

These	O
results	O
establish	O
that	O
hydroxylation	O
of	O
Phe300	O
is	O
an	O
artifact	O
of	O
the	O
crystallography	O
conditions	O
and	O
is	O
not	O
relevant	O
to	O
catalysis	O
.	O

Development	O
of	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
using	O
a	O
monoclonal	O
antibody	O
against	O
alpha2	B-Protein
-	I-Protein
macroglobulin	I-Protein
,	O
for	O
the	O
diagnosis	O
of	O
systemic	O
lupus	O
erythematosus	O
.	O

OBJECTIVES	O
:	O
To	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
using	O
a	O
monoclonal	O
antibody	O
(	O
mab	O
)	O
directed	O
against	O
abnormally	O
glycosylated	O
serum	O
alpha2	B-Protein
-	I-Protein
macroglobulin	I-Protein
(	O
alpha2	B-Protein
-	I-Protein
M	I-Protein
)	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
Serum	O
alpha2	B-Protein
-	I-Protein
M	I-Protein
purified	O
by	O
HPLC	O
from	O
patients	O
with	O
SLE	O
was	O
injected	O
in	O
a	O
Balb	O
/	O
c	O
,	O
CB6	O
F1	O
female	O
mouse	O
and	O
hybrid	O
cell	O
lines	O
were	O
screened	O
using	O
alpha2	B-Protein
-	I-Protein
M	I-Protein
Glu	O
-	O
C	O
fragments	O
derived	O
from	O
SLE	O
and	O
normal	O
donors	O
(	O
NHS	O
)	O
.	O

A	O
mab	O
was	O
selected	O
and	O
used	O
to	O
develop	O
an	O
ELISA	O
by	O
which	O
sera	O
from	O
NHS	O
(	O
n	O
=	O
14	O
)	O
,	O
SLE	O
(	O
n	O
=	O
34	O
)	O
,	O
rheumatoid	O
arthritis	O
(	O
n	O
=	O
15	O
)	O
,	O
Sjogren	O
'	O
s	O
syndrome	O
(	O
n	O
=	O
11	O
)	O
,	O
mixed	O
connective	O
tissue	O
diseases	O
(	O
n	O
=	O
12	O
)	O
,	O
and	O
liver	O
diseases	O
(	O
n	O
=	O
11	O
)	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
affinity	O
of	O
the	O
mab	O
for	O
alpha2	B-Protein
-	I-Protein
M	I-Protein
from	O
SLE	O
,	O
but	O
not	O
from	O
the	O
other	O
diseases	O
,	O
was	O
higher	O
compared	O
to	O
NHS	O
,	O
as	O
demonstrated	O
by	O
immunoblotting	O
and	O
ELISA	O
.	O

CONCLUSIONS	O
:	O
The	O
ELISA	O
was	O
capable	O
of	O
recognizing	O
changes	O
of	O
glycosylation	O
of	O
alpha2	B-Protein
-	I-Protein
M	I-Protein
in	O
SLE	O
and	O
may	O
be	O
useful	O
for	O
its	O
differential	O
diagnosis	O
.	O

Efficient	O
adaptational	O
demethylation	O
of	O
chemoreceptors	O
requires	O
the	O
same	O
enzyme	O
-	O
docking	O
site	O
as	O
efficient	O
methylation	O
.	O

The	O
mechanistic	O
basis	O
of	O
sensory	O
adaptation	O
and	O
gradient	O
sensing	O
in	O
bacterial	O
chemotaxis	O
is	O
reversible	O
covalent	O
modification	O
of	O
transmembrane	O
chemoreceptors	O
,	O
methylation	O
,	O
and	O
demethylation	O
at	O
specific	O
glutamyl	O
residues	O
in	O
their	O
cytoplasmic	O
domains	O
.	O

These	O
reactions	O
are	O
catalyzed	O
by	O
a	O
dedicated	O
methyltransferase	O
CheR	B-Protein
and	O
a	O
dedicated	O
methylesterase	O
CheB	B-Protein
.	O

The	O
esterase	O
is	O
also	O
a	O
deamidase	O
that	O
creates	O
certain	O
methyl	O
-	O
accepting	O
glutamyls	O
by	O
hydrolysis	O
of	O
glutamine	O
side	O
chains	O
.	O

We	O
investigated	O
the	O
action	O
of	O
CheB	B-Protein
and	O
its	O
activated	O
form	O
,	O
phospho	O
-	O
CheB	B-Protein
,	O
on	O
a	O
truncated	O
form	O
of	O
the	O
aspartate	O
receptor	O
of	O
Escherichia	O
coli	O
that	O
was	O
missing	O
the	O
last	O
5	O
aa	O
of	O
the	O
intact	O
receptor	O
.	O

The	O
deleted	O
pentapeptide	O
is	O
conserved	O
in	O
several	O
chemoreceptors	O
in	O
enteric	O
and	O
related	O
bacteria	O
.	O

The	O
truncated	O
receptor	O
was	O
much	O
less	O
efficiently	O
demethylated	O
and	O
deamidated	O
than	O
intact	O
receptor	O
,	O
but	O
essentially	O
was	O
unperturbed	O
for	O
kinase	O
activation	O
or	O
transmembrane	O
signaling	O
.	O

CheB	B-Protein
bound	O
specifically	O
to	O
an	O
affinity	O
column	O
carrying	O
the	O
isolated	O
pentapeptide	O
,	O
implying	O
that	O
in	O
the	O
intact	O
receptor	O
the	O
pentapeptide	O
serves	O
as	O
a	O
docking	O
site	O
for	O
the	O
methylesterase	O
/	O
deamidase	O
and	O
that	O
the	O
truncated	O
receptor	O
was	O
inefficiently	O
modified	O
because	O
the	O
enzyme	O
could	O
not	O
dock	O
.	O

It	O
is	O
striking	O
that	O
the	O
same	O
pentapeptide	O
serves	O
as	O
an	O
activity	O
-	O
enhancing	O
docking	O
site	O
for	O
the	O
methyltransferase	O
CheR	B-Protein
,	O
the	O
other	O
enzyme	O
involved	O
in	O
adaptational	O
covalent	O
modification	O
of	O
chemoreceptors	O
.	O

A	O
shared	O
docking	O
site	O
raises	O
the	O
tantalizing	O
possibility	O
that	O
relative	O
rates	O
of	O
methylation	O
and	O
demethylation	O
could	O
be	O
influenced	O
by	O
competition	O
between	O
the	O
two	O
enzymes	O
at	O
that	O
site	O
.	O

Roles	O
of	O
cell	O
division	O
and	O
gene	O
transcription	O
in	O
the	O
methylation	O
of	O
CpG	O
islands	O
.	O

De	O
novo	O
methylation	O
of	O
CpG	O
islands	O
within	O
the	O
promoters	O
of	O
eukaryotic	O
genes	O
is	O
often	O
associated	O
with	O
their	O
transcriptional	O
repression	O
,	O
yet	O
the	O
methylation	O
of	O
CpG	O
islands	O
located	O
downstream	O
of	O
promoters	O
does	O
not	O
block	O
transcription	O
.	O

We	O
investigated	O
the	O
kinetics	O
of	O
mRNA	O
induction	O
,	O
demethylation	O
,	O
and	O
remethylation	O
of	O
the	O
p16	B-Protein
promoter	O
and	O
second	O
-	O
exon	O
CpG	O
islands	O
in	O
T24	O
cells	O
after	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
Aza	O
-	O
CdR	O
)	O
treatment	O
to	O
explore	O
the	O
relationship	O
between	O
CpG	O
island	O
methylation	O
and	O
gene	O
transcription	O
.	O

The	O
rates	O
of	O
remethylation	O
of	O
both	O
CpG	O
islands	O
were	O
associated	O
with	O
time	O
but	O
not	O
with	O
the	O
rate	O
of	O
cell	O
division	O
,	O
and	O
remethylation	O
of	O
the	O
p16	B-Protein
exon	O
2	O
CpG	O
island	O
occurred	O
at	O
a	O
higher	O
rate	O
than	O
that	O
of	O
the	O
p16	B-Protein
promoter	O
.	O

We	O
also	O
examined	O
the	O
relationship	O
between	O
the	O
remethylation	O
of	O
coding	O
sequence	O
CpG	O
islands	O
and	O
gene	O
transcription	O
.	O

The	O
kinetics	O
of	O
remethylation	O
of	O
the	O
p16	B-Protein
exon	O
2	O
,	O
PAX	B-Protein
-	I-Protein
6	I-Protein
exon	O
5	O
,	O
c	B-Protein
-	I-Protein
ABL	I-Protein
exon	O
11	O
,	O
and	O
MYF	B-Protein
-	I-Protein
3	I-Protein
exon	O
3	O
loci	O
were	O
examined	O
following	O
5	O
-	O
Aza	O
-	O
CdR	O
treatment	O
because	O
these	O
genes	O
contain	O
exonic	O
CpG	O
islands	O
which	O
are	O
hypermethylated	O
in	O
T24	O
cells	O
.	O

Remethylation	O
occurred	O
most	O
rapidly	O
in	O
the	O
p16	B-Protein
,	O
PAX	B-Protein
-	I-Protein
6	I-Protein
,	O
and	O
c	B-Protein
-	I-Protein
ABL	I-Protein
genes	O
,	O
shown	O
to	O
be	O
transcribed	O
prior	O
to	O
drug	O
treatment	O
.	O

These	O
regions	O
also	O
exhibited	O
higher	O
levels	O
of	O
remethylation	O
in	O
single	O
-	O
cell	O
clones	O
and	O
subclones	O
derived	O
from	O
5	O
-	O
Aza	O
-	O
CdR	O
-	O
treated	O
T24	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
de	O
novo	O
methylation	O
is	O
not	O
restricted	O
to	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
and	O
that	O
transcription	O
through	O
CpG	O
islands	O
does	O
not	O
inhibit	O
their	O
remethylation	O
.	O

Distinct	O
methylation	O
pattern	O
and	O
microsatellite	O
instability	O
in	O
sporadic	O
gastric	O
cancer	O
.	O

Aberrant	O
5	O
'	O
CpG	O
island	O
methylation	O
is	O
an	O
alternative	O
mechanism	O
of	O
gene	O
inactivation	O
during	O
the	O
development	O
of	O
cancer	O
as	O
demonstrated	O
for	O
several	O
tumor	O
-	O
suppressor	O
genes	O
.	O

Also	O
,	O
marked	O
relationship	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
DNA	O
methylation	O
has	O
been	O
reported	O
in	O
sporadic	O
colorectal	O
cancer	O
,	O
which	O
is	O
a	O
result	O
of	O
epigenetic	O
inactivation	O
of	O
hMLH1	B-Protein
in	O
association	O
of	O
promoter	O
hypermethylation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
5	O
'	O
CpG	O
island	O
hypermethylation	O
of	O
hMLH1	B-Protein
,	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
and	O
p16	B-Protein
in	O
61	O
primary	O
gastric	O
cancers	O
(	O
GCs	O
)	O
by	O
using	O
combined	O
bisulfite	O
restriction	O
analysis	O
(	O
COBRA	O
)	O
and	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
,	O
and	O
their	O
MSI	O
status	O
.	O

Of	O
61	O
GCs	O
investigated	O
,	O
5	O
(	O
8	O
.	O
1	O
%	O
)	O
tumors	O
presented	O
hMLH1	B-Protein
methylation	O
,	O
16	O
(	O
26	O
.	O
2	O
%	O
)	O
and	O
25	O
(	O
40	O
.	O
9	O
%	O
)	O
showed	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
and	O
p16	B-Protein
methylation	O
respectively	O
,	O
and	O
8	O
(	O
13	O
.	O
1	O
%	O
)	O
presented	O
high	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
H	O
)	O
.	O

Of	O
the	O
8	O
MSI	O
-	O
H	O
patients	O
,	O
5	O
presented	O
hMLH1	B-Protein
methylation	O
,	O
whereas	O
no	O
low	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
L	O
)	O
and	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
cases	O
exhibited	O
hMLH1	B-Protein
methylation	O
(	O
5	O
/	O
8	O
vs	O
.	O
0	O
/	O
43	O
,	O
p	O
<	O
0	O
.	O
00001	O
)	O
.	O

Furthermore	O
,	O
these	O
patients	O
also	O
presented	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
and	O
p16	B-Protein
hypermethylation	O
.	O

Our	O
data	O
showed	O
a	O
significant	O
correlation	O
between	O
hMLH1	B-Protein
methylation	O
and	O
MSI	O
in	O
GC	O
,	O
and	O
suggested	O
that	O
a	O
common	O
mechanism	O
of	O
aberrant	O
de	O
novo	O
methylation	O
can	O
be	O
postulated	O
in	O
these	O
cancers	O
.	O

Effect	O
of	O
HSP47	B-Protein
on	O
prolyl	O
4	O
-	O
hydroxylation	O
of	O
collagen	O
model	O
peptides	O
.	O

Prolyl	O
4	O
-	O
hydroxylation	O
,	O
the	O
most	O
important	O
post	O
-	O
translational	O
modification	O
in	O
collagen	O
biosynthesis	O
,	O
is	O
catalyzed	O
by	O
prolyl	O
4	O
-	O
hydroxylase	O
,	O
an	O
endoplasmic	O
reticulum	O
-	O
resident	O
enzyme	O
.	O

HSP47	B-Protein
is	O
a	O
collagen	O
-	O
binding	O
stress	O
protein	O
which	O
also	O
resides	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
Nagata	O
,	O
K	O
.	O
and	O
Yamada	O
,	O
K	O
.	O
M	O
.	O
(	O
1986	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
,	O
261	O
,	O
7531	O
-	O
7536	O
)	O
.	O

Both	O
prolyl	O
4	O
-	O
hydroxylase	O
and	O
HSP47	B-Protein
interact	O
with	O
procollagen	O
alpha	O
-	O
chains	O
during	O
their	O
folding	O
and	O
/	O
or	O
modification	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

Recent	O
study	O
has	O
revealed	O
that	O
a	O
simple	O
collagen	O
model	O
peptide	O
,	O
(	O
Pro	O
-	O
Pro	O
-	O
Gly	O
)	O
n	O
,	O
is	O
recognized	O
by	O
HSP47	B-Protein
as	O
well	O
as	O
by	O
prolyl	O
4	O
-	O
hydroxylase	O
in	O
vitro	O
(	O
Koide	O
et	O
al	O
.	O
,	O
manuscript	O
submitted	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
HSP47	B-Protein
on	O
the	O
prolyl	O
4	O
-	O
hydroxylation	O
of	O
such	O
collagen	O
model	O
peptides	O
.	O

To	O
monitor	O
the	O
enzymatic	O
hydroxylation	O
of	O
the	O
peptides	O
,	O
we	O
developed	O
a	O
non	O
-	O
RI	O
assay	O
system	O
based	O
on	O
reversed	O
-	O
phase	O
HPLC	O
.	O

When	O
HSP47	B-Protein
was	O
added	O
to	O
the	O
reaction	O
mixture	O
,	O
substrate	O
and	O
less	O
-	O
hydroxylated	O
materials	O
accumulated	O
.	O

This	O
effect	O
depended	O
on	O
the	O
peptide	O
-	O
binding	O
activity	O
of	O
HSP47	B-Protein
,	O
because	O
a	O
mutant	O
HSP47	B-Protein
without	O
collagen	O
-	O
binding	O
activity	O
did	O
not	O
show	O
any	O
inhibitory	O
effect	O
on	O
prolyl	O
4	O
-	O
hydroxylation	O
.	O

Kinetic	O
analysis	O
and	O
other	O
biochemical	O
analyses	O
suggest	O
that	O
HSP47	B-Protein
retards	O
the	O
enzymatic	O
reaction	O
competing	O
for	O
the	O
substrate	O
peptide	O
.	O

Mouse	O
K	O
-	O
Cl	O
cotransporter	O
KCC1	B-Protein
:	O
cloning	O
,	O
mapping	O
,	O
pathological	O
expression	O
,	O
and	O
functional	O
regulation	O
.	O

Although	O
K	O
-	O
Cl	O
cotransporter	O
(	O
KCC1	B-Protein
)	O
mRNA	O
is	O
expressed	O
in	O
many	O
tissues	O
,	O
K	O
-	O
Cl	O
cotransport	O
activity	O
has	O
been	O
measured	O
in	O
few	O
cell	O
types	O
,	O
and	O
detection	O
of	O
endogenous	O
KCC1	B-Protein
polypeptide	O
has	O
not	O
yet	O
been	O
reported	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
erythroid	O
KCC1	B-Protein
(	O
mKCC1	B-Protein
)	O
cDNA	O
and	O
its	O
flanking	O
genomic	O
regions	O
and	O
mapped	O
the	O
mKCC1	B-Protein
gene	O
to	O
chromosome	O
8	O
.	O

Three	O
anti	O
-	O
peptide	O
antibodies	O
raised	O
against	O
recombinant	O
mKCC1	B-Protein
function	O
as	O
immunoblot	O
and	O
immunoprecipitation	O
reagents	O
.	O

The	O
tissue	O
distributions	O
of	O
mKCC1	B-Protein
mRNA	O
and	O
protein	O
are	O
widespread	O
,	O
and	O
mKCC1	B-Protein
RNA	O
is	O
constitutively	O
expressed	O
during	O
erythroid	O
differentiation	O
of	O
ES	O
cells	O
.	O

KCC1	B-Protein
polypeptide	O
or	O
related	O
antigen	O
is	O
present	O
in	O
erythrocytes	O
of	O
multiple	O
species	O
in	O
which	O
K	O
-	O
Cl	O
cotransport	O
activity	O
has	O
been	O
documented	O
.	O

Erythroid	O
KCC1	B-Protein
polypeptide	O
abundance	O
is	O
elevated	O
in	O
proportion	O
to	O
reticulocyte	O
counts	O
in	O
density	O
-	O
fractionated	O
cells	O
,	O
in	O
bleeding	O
-	O
induced	O
reticulocytosis	O
,	O
in	O
mouse	O
models	O
of	O
sickle	O
cell	O
disease	O
and	O
thalassemia	O
,	O
and	O
in	O
the	O
corresponding	O
human	O
disorders	O
.	O

mKCC1	B-Protein
-	O
mediated	O
uptake	O
of	O
(	O
86	O
)	O
Rb	O
into	O
Xenopus	O
oocytes	O
requires	O
extracellular	O
Cl	O
(	O
-	O
)	O
,	O
is	O
blocked	O
by	O
the	O
diuretic	O
R	O
(	O
+	O
)	O
-	O
[	O
2	O
-	O
n	O
-	O
butyl	O
-	O
6	O
,	O
7	O
-	O
dichloro	O
-	O
2	O
-	O
cyclopentyl	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1	O
-	O
oxo	O
-	O
1H	O
-	O
indenyl	O
-	O
5	O
-	O
yl	O
-	O
)	O
oxy	O
]	O
acetic	O
acid	O
,	O
and	O
exhibits	O
an	O
erythroid	O
pattern	O
of	O
acute	O
regulation	O
,	O
with	O
activation	O
by	O
hypotonic	O
swelling	O
,	O
N	O
-	O
ethylmaleimide	O
,	O
and	O
staurosporine	O
and	O
inhibition	O
by	O
calyculin	O
and	O
okadaic	O
acid	O
.	O

These	O
reagents	O
and	O
findings	O
will	O
expedite	O
studies	O
of	O
KCC1	B-Protein
structure	O
-	O
function	O
relationships	O
and	O
of	O
the	O
pathobiology	O
of	O
KCC1	B-Protein
-	O
mediated	O
K	O
-	O
Cl	O
cotransport	O
.	O

Progesterone	O
metabolism	O
in	O
the	O
human	O
kidney	O
and	O
inhibition	O
of	O
11beta	B-Protein
-	I-Protein
hydroxysteroid	I-Protein
dehydrogenase	I-Protein
type	I-Protein
2	I-Protein
by	O
progesterone	O
and	O
its	O
metabolites	O
.	O

Progesterone	O
binds	O
with	O
high	O
affinity	O
to	O
the	O
mineralocorticoid	B-Protein
(	I-Protein
MC	I-Protein
)	I-Protein
receptor	I-Protein
,	O
but	O
confers	O
only	O
very	O
low	O
agonistic	O
MC	O
activity	O
.	O

Therefore	O
,	O
progesterone	O
is	O
a	O
potent	O
MC	O
antagonist	O
in	O
vitro	O
.	O

Although	O
progesterone	O
reaches	O
up	O
to	O
100	O
times	O
higher	O
plasma	O
levels	O
in	O
late	O
pregnancy	O
than	O
aldosterone	O
,	O
the	O
in	O
vivo	O
MC	O
antagonistic	O
effect	O
of	O
progesterone	O
seems	O
to	O
be	O
relatively	O
weak	O
.	O

One	O
explanation	O
for	O
this	O
phenomenon	O
could	O
be	O
local	O
metabolism	O
of	O
progesterone	O
in	O
the	O
human	O
kidney	O
,	O
similar	O
to	O
the	O
inactivation	O
of	O
cortisol	O
to	O
cortisone	O
by	O
the	O
11beta	B-Protein
-	I-Protein
hydroxysteroid	I-Protein
dehydrogenase	I-Protein
(	I-Protein
11beta	I-Protein
-	I-Protein
HSD	I-Protein
)	I-Protein
type	I-Protein
2	I-Protein
.	O

We	O
studied	O
the	O
metabolism	O
of	O
progesterone	O
in	O
the	O
human	O
kidney	O
in	O
vitro	O
and	O
found	O
reduction	O
to	O
20alpha	O
-	O
dihydro	O
(	O
DH	O
)	O
-	O
progesterone	O
as	O
the	O
main	O
metabolite	O
.	O

Ring	O
-	O
A	O
reduction	O
to	O
5alpha	O
-	O
DH	O
-	O
progesterone	O
,	O
20alpha	O
-	O
DH	O
-	O
5alpha	O
-	O
DH	O
-	O
progesterone	O
,	O
and	O
3beta	O
,	O
5alpha	O
-	O
tetrahydro	O
(	O
TH	O
)	O
-	O
progesterone	O
was	O
also	O
documented	O
.	O

We	O
further	O
showed	O
for	O
the	O
first	O
time	O
that	O
17	O
-	O
hydroxylation	O
of	O
progesterone	O
(	O
17alpha	O
-	O
OH	O
-	O
progesterone	O
,	O
17alpha	O
-	O
OH	O
,	O
20alpha	O
-	O
DH	O
-	O
progesterone	O
)	O
,	O
normally	O
localized	O
in	O
the	O
adrenals	O
and	O
the	O
gonads	O
,	O
occurs	O
in	O
the	O
human	O
adult	O
kidney	O
.	O

We	O
found	O
no	O
formation	O
of	O
deoxycorticosterone	O
from	O
progesterone	O
in	O
the	O
human	O
adult	O
kidney	O
.	O

Using	O
human	O
kidney	O
cortex	O
microsomes	O
,	O
we	O
tested	O
the	O
inhibitory	O
potency	O
of	O
progesterone	O
and	O
its	O
metabolites	O
on	O
the	O
11beta	B-Protein
-	I-Protein
HSD	I-Protein
type	I-Protein
2	I-Protein
.	O

The	O
most	O
potent	O
inhibitor	O
was	O
progesterone	O
itself	O
(	O
IC50	O
=	O
4	O
.	O
8	O
x	O
10	O
(	O
-	O
8	O
)	O
mol	O
/	O
L	O
)	O
,	O
followed	O
by	O
5alpha	O
-	O
DH	O
-	O
progesterone	O
(	O
IC50	O
=	O
2	O
.	O
4	O
x	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
,	O
20alpha	O
-	O
DH	O
-	O
progesterone	O
,	O
3beta	O
,	O
5alpha	O
-	O
TH	O
-	O
progesterone	O
,	O
17alpha	O
-	O
OH	O
-	O
progesterone	O
,	O
and	O
20alpha	O
-	O
DH	O
-	O
5alpha	O
-	O
DH	O
-	O
progesterone	O
(	O
IC50	O
between	O
7	O
.	O
7	O
x	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
and	O
1	O
.	O
3	O
x	O
10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
)	O
.	O

The	O
least	O
potent	O
inhibitor	O
was	O
17alpha	O
-	O
OH	O
,	O
20alpha	O
-	O
DH	O
-	O
progesterone	O
.	O

In	O
addition	O
to	O
progesterone	O
metabolism	O
by	O
the	O
kidney	O
,	O
the	O
inhibition	O
of	O
11beta	B-Protein
-	I-Protein
HSD	I-Protein
type	I-Protein
2	I-Protein
by	O
progesterone	O
and	O
its	O
metabolites	O
could	O
be	O
a	O
second	O
explanation	O
for	O
the	O
weak	O
MC	O
-	O
antagonist	O
activity	O
of	O
progesterone	O
in	O
vivo	O
.	O

Inhibition	O
of	O
11beta	B-Protein
-	I-Protein
HSD	I-Protein
type	I-Protein
2	I-Protein
leads	O
to	O
an	O
increase	O
of	O
intracellular	O
cortisol	O
in	O
a	O
way	O
that	O
the	O
local	O
equilibrium	O
between	O
the	O
MC	O
agonist	O
cortisol	O
and	O
the	O
antagonist	O
progesterone	O
is	O
shifted	O
to	O
the	O
agonist	O
side	O
.	O

Deglycosylation	O
of	O
a	O
bifunctional	O
lutropin	O
-	O
follitropin	O
agonist	O
reduced	O
its	O
follitropin	O
activity	O
more	O
than	O
its	O
lutropin	O
activity	O
.	O

OBJECTIVE	O
:	O
To	O
design	O
a	O
drug	O
that	O
blocks	O
the	O
gonadal	O
actions	O
of	O
lutropins	O
and	O
follitropins	O
.	O

DESIGN	O
:	O
Controlled	O
in	O
vitro	O
study	O
.	O

SETTING	O
:	O
Academic	O
laboratory	O
.	O

PATIENT	O
(	O
S	O
)	O
:	O
None	O
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
We	O
removed	O
three	O
glycosylation	O
signals	O
from	O
an	O
hCG	O
-	O
hFSH	O
chimera	O
known	O
to	O
have	O
high	O
affinity	O
for	O
LH	B-Protein
and	O
FSH	B-Protein
receptors	I-Protein
,	O
expecting	O
this	O
would	O
create	O
a	O
bifunctional	O
antagonist	O
(	O
dgCFC	O
)	O
.	O

To	O
offset	O
the	O
inhibition	O
of	O
subunit	O
combination	O
caused	O
by	O
deglycosylation	O
of	O
alpha	O
-	O
subunit	O
loop	O
2	O
,	O
we	O
prepared	O
dgCFC	O
as	O
a	O
single	O
-	O
chain	O
fusion	O
protein	O
containing	O
the	O
alpha	O
-	O
subunit	O
downstream	O
of	O
the	O
chimeric	O
beta	O
-	O
subunit	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
Receptor	O
binding	O
,	O
cyclic	O
adenosine	O
monophosphate	O
accumulation	O
.	O

RESULT	O
(	O
S	O
)	O
:	O
dgCFC	O
bound	O
LH	B-Protein
or	O
FSH	B-Protein
receptors	I-Protein
similar	O
to	O
hCG	O
or	O
hFSH	O
.	O

It	O
was	O
a	O
partial	O
agonist	O
and	O
had	O
one	O
tenth	O
the	O
efficacy	O
of	O
hFSH	O
and	O
two	O
thirds	O
the	O
efficacy	O
of	O
hCG	O
.	O

CONCLUSION	O
(	O
S	O
)	O
:	O
The	O
surprising	O
high	O
residual	O
lutropin	O
activity	O
of	O
dgCFC	O
indicated	O
that	O
its	O
FSH	O
residues	O
offset	O
the	O
effects	O
of	O
deglycosylation	O
,	O
suggesting	O
this	O
approach	O
to	O
preparing	O
a	O
bifunctional	O
antagonist	O
is	O
unlikely	O
to	O
lead	O
to	O
a	O
useful	O
drug	O
.	O

The	O
increased	O
lutropin	O
efficacy	O
of	O
dgCFC	O
relative	O
to	O
deglycosylated	O
hCG	O
supports	O
the	O
idea	O
that	O
oligosaccharides	O
modulate	O
glycoprotein	O
hormone	O
efficacy	O
through	O
an	O
influence	O
on	O
hormone	O
conformation	O
.	O

Regulation	O
of	O
thyrotropin	B-Protein
receptor	I-Protein
protein	O
expression	O
in	O
insect	O
cells	O
.	O

Expression	O
of	O
large	O
quantities	O
of	O
conformationally	O
intact	O
thyrotropin	B-Protein
receptor	I-Protein
(	O
TSHR	B-Protein
)	O
is	O
essential	O
to	O
understand	O
the	O
structure	O
-	O
function	O
relationship	O
of	O
the	O
receptor	O
.	O

We	O
expressed	O
three	O
different	O
constructs	O
of	O
full	O
-	O
length	O
human	O
TSHR	B-Protein
in	O
insect	O
cells	O
:	O
(	O
a	O
)	O
a	O
TSHR	B-Protein
cDNA	O
lacking	O
signal	O
sequence	O
(	O
TSHR	B-Protein
-	O
ns	O
)	O
,	O
(	O
b	O
)	O
a	O
TSHR	B-Protein
cDNA	O
containing	O
human	O
TSHR	B-Protein
signal	O
sequence	O
(	O
TSHR	B-Protein
-	O
hs	O
)	O
and	O
(	O
c	O
)	O
a	O
TSHR	B-Protein
cDNA	O
with	O
baculovirus	O
envelope	O
protein	O
encoded	O
signal	O
sequence	O
gp	O
-	O
67	O
(	O
TSHR	B-Protein
-	O
gp	O
)	O
.	O

No	O
unique	O
protein	O
band	O
,	O
corresponding	O
to	O
any	O
of	O
these	O
recombinant	O
proteins	O
,	O
was	O
visible	O
upon	O
Coomassie	O
Blue	O
staining	O
after	O
SDS	O
-	O
PAGE	O
.	O

However	O
,	O
Western	O
blot	O
using	O
TSHR	B-Protein
specific	O
monoclonal	O
antibody	O
showed	O
unique	O
bands	O
around	O
80	O
,	O
100	O
and	O
100	O
kDa	O
in	O
TSHR	B-Protein
-	O
ns	O
,	O
TSHR	B-Protein
-	O
hs	O
and	O
TSHR	B-Protein
-	O
gp	O
virus	O
infected	O
insect	O
cells	O
respectively	O
.	O

All	O
three	O
full	O
-	O
length	O
TSHR	B-Protein
proteins	O
could	O
neutralize	O
the	O
TSH	O
binding	O
inhibitory	O
immunoglobulin	O
(	O
TBII	O
)	O
activity	O
from	O
sera	O
of	O
experimental	O
animals	O
.	O

However	O
,	O
only	O
glycosylated	O
proteins	O
(	O
TSHR	B-Protein
-	O
hs	O
and	O
TSHR	B-Protein
-	O
gp	O
)	O
neutralized	O
the	O
TBII	O
activity	O
of	O
sera	O
from	O
autoimmune	O
thyroid	O
patients	O
,	O
confirming	O
the	O
importance	O
of	O
glycosylation	O
for	O
patient	O
autoantibody	O
reactivity	O
.	O

Expression	O
levels	O
of	O
full	O
-	O
length	O
TSHR	B-Protein
proteins	O
were	O
much	O
lower	O
than	O
the	O
levels	O
of	O
similarly	O
produced	O
corresponding	O
ectodomains	O
of	O
TSHR	B-Protein
proteins	O
.	O

Southern	O
blot	O
and	O
Northern	O
blot	O
analyses	O
showed	O
that	O
DNA	O
and	O
RNA	O
levels	O
in	O
full	O
-	O
length	O
TSHR	O
virus	O
infected	O
insect	O
cells	O
were	O
comparable	O
to	O
the	O
levels	O
found	O
in	O
cells	O
infected	O
with	O
viruses	O
encoding	O
only	O
the	O
ectodomain	O
of	O
TSHR	B-Protein
.	O

These	O
data	O
suggest	O
that	O
full	O
-	O
length	O
TSHR	B-Protein
expression	O
is	O
very	O
low	O
and	O
is	O
regulated	O
at	O
the	O
translational	O
level	O
.	O

BasT	B-Protein
,	O
a	O
membrane	O
-	O
bound	O
transducer	O
protein	O
for	O
amino	O
acid	O
detection	O
in	O
Halobacterium	O
salinarum	O
.	O

Halophilic	O
archaea	O
,	O
such	O
as	O
eubacteria	O
,	O
use	O
methyl	O
-	O
accepting	O
chemotaxis	O
proteins	O
(	O
MCPs	O
)	O
to	O
sense	O
their	O
environment	O
.	O

We	O
show	O
here	O
that	O
BasT	B-Protein
is	O
a	O
halobacterial	O
transducer	O
protein	O
(	O
Htp	O
)	O
responsible	O
for	O
chemotaxis	O
towards	O
five	O
attractant	O
amino	O
acids	O
.	O

The	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
exhibits	O
the	O
highly	O
conserved	O
regions	O
that	O
are	O
diagnostic	O
for	O
MCPs	O
:	O
the	O
signalling	O
domain	O
for	O
communication	O
with	O
the	O
histidine	O
kinase	O
and	O
the	O
methylation	O
sites	O
that	O
interact	O
with	O
the	O
methylation	O
/	O
demethylation	O
enzymes	O
for	O
adaptation	O
.	O

Hydropathy	O
analysis	O
predicts	O
an	O
enterobacterial	O
-	O
type	O
transducer	O
protein	O
topology	O
for	O
BasT	B-Protein
,	O
with	O
an	O
extracellular	O
putative	O
ligand	O
-	O
binding	O
domain	O
flanked	O
by	O
two	O
transmembrane	O
helices	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

BasT	B-Protein
-	O
inactivated	O
mutant	O
cells	O
are	O
missing	O
a	O
membrane	O
protein	O
radiolabelled	O
with	O
L	O
-	O
[	O
methyl	O
-	O
3H	O
]	O
-	O
methionine	O
in	O
wild	O
-	O
type	O
cells	O
,	O
confirming	O
that	O
BasT	B-Protein
is	O
methylatable	O
and	O
membrane	O
bound	O
.	O

Behavioural	O
analysis	O
of	O
the	O
basT	B-Protein
mutant	O
cells	O
by	O
capillary	O
and	O
chemical	O
-	O
in	O
-	O
plug	O
assays	O
demonstrates	O
complete	O
loss	O
of	O
chemotactic	O
responses	O
towards	O
five	O
(	O
leucine	O
,	O
isoleucine	O
,	O
valine	O
,	O
methionine	O
and	O
cysteine	O
)	O
of	O
the	O
six	O
attractant	O
amino	O
acids	O
for	O
Halobacterium	O
salinarum	O
,	O
whereas	O
they	O
still	O
respond	O
to	O
arginine	O
.	O

The	O
volatile	O
methyl	O
group	O
production	O
assays	O
also	O
corroborate	O
these	O
findings	O
and	O
confirm	O
that	O
BasT	B-Protein
signalling	O
induces	O
methyl	O
group	O
turnover	O
.	O

Our	O
data	O
identify	O
BasT	B-Protein
as	O
the	O
chemotaxis	O
transducer	O
protein	O
for	O
the	O
branched	O
chain	O
amino	O
acids	O
leucine	O
,	O
isoleucine	O
and	O
valine	O
as	O
well	O
as	O
for	O
methionine	O
and	O
cysteine	O
.	O

Thus	O
,	O
BasT	B-Protein
and	O
the	O
arginine	O
sensor	O
Car	B-Protein
cover	O
the	O
entire	O
spectrum	O
of	O
chemotactic	O
responses	O
towards	O
attractant	O
amino	O
acids	O
in	O
H	O
.	O
salinarum	O
.	O

Additional	O
N	O
-	O
glycosylation	O
at	O
Asn	O
(	O
13	O
)	O
rescues	O
the	O
human	O
LHbeta	B-Protein
-	O
subunit	O
from	O
disulfide	O
-	O
linked	O
aggregation	O
.	O

CG	O
,	O
LH	O
,	O
FSH	O
,	O
and	O
TSH	O
are	O
a	O
family	O
of	O
heterodimeric	O
glycoprotein	O
hormones	O
that	O
contain	O
a	O
common	O
alpha	O
-	O
subunit	O
,	O
but	O
differ	O
in	O
their	O
hormone	O
-	O
specific	O
beta	O
-	O
subunits	O
.	O

Despite	O
the	O
considerable	O
homology	O
between	O
LHbeta	B-Protein
and	O
CGbeta	B-Protein
,	O
we	O
previously	O
demonstrated	O
that	O
,	O
when	O
expressed	O
in	O
GH	O
(	O
3	O
)	O
cells	O
,	O
the	O
secreted	O
form	O
of	O
LHbeta	B-Protein
showed	O
mispaired	O
disulfide	O
-	O
linked	O
aggregation	O
in	O
addition	O
to	O
monomer	O
,	O
whereas	O
no	O
aggregation	O
was	O
observed	O
in	O
CGbeta	B-Protein
.	O

To	O
determine	O
the	O
domains	O
which	O
are	O
associated	O
with	O
the	O
LHbeta	B-Protein
-	O
aggregation	O
and	O
which	O
prevent	O
CGbeta	B-Protein
-	O
aggregation	O
,	O
mutant	O
beta	O
-	O
subunits	O
in	O
glycosylation	O
and	O
carboxy	O
-	O
terminus	O
were	O
expressed	O
in	O
GH	O
(	O
3	O
)	O
cells	O
,	O
and	O
the	O
occurrence	O
of	O
aggregation	O
was	O
assessed	O
by	O
continuous	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
/	O
cysteine	O
,	O
immunoprecipitation	O
with	O
anti	O
-	O
hCGbeta	B-Protein
serum	O
,	O
and	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
in	O
a	O
non	O
-	O
reducing	O
condition	O
.	O

No	O
aggregation	O
was	O
seen	O
when	O
N	O
-	O
linked	O
oligosaccharides	O
were	O
attached	O
to	O
the	O
Asn	O
(	O
13	O
)	O
of	O
LHbeta	B-Protein
.	O

Removal	O
of	O
the	O
carbohydrate	O
unit	O
at	O
the	O
Asn	O
(	O
13	O
)	O
of	O
CGbeta	B-Protein
caused	O
aggregation	O
,	O
although	O
the	O
amount	O
was	O
less	O
than	O
10	O
%	O
of	O
monomer	O
.	O

The	O
carboxy	O
-	O
terminal	O
regions	O
of	O
neither	O
LHbeta	B-Protein
nor	O
CGbeta	B-Protein
were	O
associated	O
with	O
their	O
aggregation	O
.	O

Both	O
CGbeta	B-Protein
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
CGbeta	B-Protein
lacking	O
N	O
-	O
glycosylation	O
at	O
Asn	O
(	O
13	O
)	O
(	O
CGbeta	O
-	O
N13	O
)	O
showed	O
aggregates	O
in	O
lysate	O
.	O

However	O
,	O
in	O
contrast	O
to	O
CGbeta	B-Protein
-	O
N13	O
,	O
CGbetaWT	B-Protein
revealed	O
no	O
aggregation	O
in	O
medium	O
.	O

These	O
results	O
indicate	O
that	O
the	O
backbone	O
structure	O
consisting	O
of	O
114	O
amino	O
acids	O
and	O
N	O
-	O
linked	O
glycosylation	O
at	O
Asn	O
(	O
30	O
)	O
is	O
involved	O
in	O
the	O
aggregation	O
of	O
LHbeta	B-Protein
.	O

Moreover	O
,	O
N	O
-	O
glycosylation	O
at	O
Asn	O
(	O
13	O
)	O
does	O
not	O
prevent	O
such	O
aggregation	O
,	O
but	O
instead	O
plays	O
an	O
important	O
role	O
in	O
correct	O
folding	O
for	O
both	O
LHbeta	B-Protein
-	O
and	O
CGbeta	B-Protein
-	O
subunits	O
to	O
be	O
secreted	O
as	O
monomer	O
.	O

Type	B-Protein
XIII	I-Protein
collagen	I-Protein
forms	O
homotrimers	O
with	O
three	O
triple	O
helical	O
collagenous	O
domains	O
and	O
its	O
association	O
into	O
disulfide	O
-	O
bonded	O
trimers	O
is	O
enhanced	O
by	O
prolyl	O
4	O
-	O
hydroxylase	O
.	O

Type	B-Protein
XIII	I-Protein
collagen	I-Protein
is	O
a	O
type	O
II	O
transmembrane	O
protein	O
predicted	O
to	O
consist	O
of	O
a	O
short	O
cytosolic	O
domain	O
,	O
a	O
single	O
transmembrane	O
domain	O
,	O
and	O
three	O
collagenous	O
domains	O
flanked	O
by	O
noncollagenous	O
sequences	O
.	O

Previous	O
studies	O
on	O
mRNAs	O
indicate	O
that	O
the	O
structures	O
of	O
the	O
collagenous	O
domain	O
closest	O
to	O
the	O
cell	O
membrane	O
,	O
COL1	O
,	O
the	O
adjacent	O
noncollagenous	O
domain	O
,	O
NC2	O
,	O
and	O
the	O
C	O
-	O
terminal	O
domains	O
COL3	O
and	O
NC4	O
are	O
subject	O
to	O
alternative	O
splicing	O
.	O

In	O
order	O
to	O
extend	O
studies	O
of	O
type	B-Protein
XIII	I-Protein
collagen	I-Protein
from	O
cDNAs	O
to	O
the	O
protein	O
level	O
we	O
have	O
produced	O
it	O
in	O
insect	O
cells	O
by	O
means	O
of	O
baculoviruses	O
.	O

Type	B-Protein
XIII	I-Protein
collagen	I-Protein
alpha	I-Protein
chains	I-Protein
were	O
found	O
to	O
associate	O
into	O
disulfide	O
-	O
bonded	O
trimers	O
,	O
and	O
hydroxylation	O
of	O
proline	O
residues	O
dramatically	O
enhanced	O
this	O
association	O
.	O

This	O
protein	O
contains	O
altogether	O
eight	O
cysteine	O
residues	O
,	O
and	O
interchain	O
disulfide	O
bonds	O
could	O
be	O
located	O
in	O
the	O
NC1	O
domain	O
and	O
possibly	O
at	O
the	O
junction	O
of	O
COL1	O
and	O
NC2	O
,	O
while	O
the	O
two	O
cysteine	O
residues	O
in	O
NC4	O
are	O
likely	O
to	O
form	O
intrachain	O
bonds	O
.	O

Pepsin	B-Protein
and	O
trypsin	O
/	O
chymotrypsin	O
digestions	O
indicated	O
that	O
the	O
type	B-Protein
XIII	I-Protein
collagen	I-Protein
alpha	I-Protein
chains	I-Protein
form	O
homotrimers	O
whose	O
three	O
collagenous	O
domains	O
are	O
in	O
triple	O
helical	O
conformation	O
.	O

The	O
thermal	O
stabilities	O
(	O
T	O
(	O
m	O
)	O
)	O
of	O
the	O
COL1	O
,	O
COL2	O
,	O
and	O
COL3	O
domains	O
were	O
38	O
,	O
49	O
and	O
40	O
degrees	O
C	O
,	O
respectively	O
.	O

The	O
T	O
(	O
m	O
)	O
of	O
the	O
central	O
collagenous	O
domain	O
is	O
unusually	O
high	O
,	O
which	O
in	O
the	O
light	O
of	O
this	O
domain	O
being	O
invariant	O
in	O
terms	O
of	O
alternative	O
splicing	O
suggests	O
that	O
the	O
central	O
portion	O
of	O
the	O
molecule	O
may	O
have	O
an	O
important	O
role	O
in	O
the	O
stability	O
of	O
the	O
molecule	O
.	O

All	O
in	O
all	O
,	O
most	O
of	O
the	O
type	B-Protein
XIII	I-Protein
collagen	I-Protein
ectodomain	O
appears	O
to	O
be	O
present	O
in	O
triple	O
helical	O
conformation	O
,	O
which	O
is	O
in	O
clear	O
contrast	O
to	O
the	O
short	O
or	O
highly	O
interrupted	O
triple	O
helical	O
domains	O
of	O
the	O
other	O
known	O
collagenous	O
transmembrane	O
proteins	O
.	O

Symmetric	O
and	O
asymmetric	O
DNA	O
methylation	O
in	O
the	O
human	O
IGF2	B-Protein
-	O
H19	B-Protein
imprinted	O
region	O
.	O

The	O
two	O
contiguous	O
IGF2	B-Protein
(	O
human	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
II	I-Protein
)	O
and	O
H19	B-Protein
genes	O
are	O
reciprocally	O
imprinted	O
in	O
both	O
human	O
and	O
mouse	O
.	O

In	O
most	O
tissues	O
,	O
IGF2	B-Protein
is	O
transcribed	O
only	O
from	O
the	O
paternal	O
chromosome	O
while	O
H19	B-Protein
is	O
transcribed	O
only	O
from	O
the	O
maternal	O
allele	O
.	O

The	O
presence	O
of	O
a	O
differential	O
methylation	O
region	O
(	O
DMR	O
)	O
on	O
the	O
two	O
parental	O
alleles	O
at	O
the	O
5	O
'	O
flanking	O
region	O
of	O
H19	B-Protein
has	O
been	O
proposed	O
to	O
constitute	O
the	O
gametic	O
imprint	O
,	O
which	O
controls	O
the	O
reciprocal	O
allelic	O
expression	O
of	O
the	O
two	O
genes	O
.	O

Using	O
bisulfite	O
genomic	O
sequencing	O
,	O
we	O
have	O
assessed	O
the	O
methylation	O
status	O
of	O
cytosine	O
(	O
including	O
154	O
CpG	O
sites	O
)	O
in	O
six	O
CpG	O
-	O
rich	O
regions	O
of	O
the	O
human	O
IGF2	B-Protein
-	O
H19	B-Protein
genes	O
.	O

In	O
a	O
CpG	O
island	O
near	O
promoter	O
P3	O
of	O
the	O
IGF2	B-Protein
gene	O
,	O
more	O
than	O
99	O
.	O
8	O
%	O
of	O
all	O
cytosines	O
were	O
converted	O
to	O
thymidine	O
by	O
sodium	O
bisulfite	O
mutagenesis	O
,	O
indicating	O
that	O
none	O
of	O
the	O
CpGs	O
was	O
methylated	O
.	O

In	O
the	O
IGF2	B-Protein
exon	O
8	O
-	O
9	O
region	O
,	O
mosaic	O
methylation	O
of	O
56	O
CpG	O
sites	O
was	O
observed	O
in	O
fetal	O
tissues	O
and	O
in	O
adult	O
blood	O
DNA	O
.	O

In	O
contrast	O
to	O
the	O
mosaic	O
methylation	O
of	O
IGF2	B-Protein
,	O
the	O
allelic	O
methylation	O
of	O
the	O
human	O
H19	B-Protein
DMR	O
was	O
uniform	O
.	O

In	O
the	O
CpG	O
region	O
located	O
2	O
kb	O
upstream	O
(	O
-	O
2362	O
to	O
-	O
1911	O
)	O
of	O
the	O
H19	B-Protein
transcription	O
site	O
,	O
all	O
25	O
CpG	O
sites	O
were	O
completely	O
methylated	O
on	O
only	O
one	O
parental	O
allele	O
.	O

Uniform	O
allele	O
-	O
specific	O
methylation	O
was	O
also	O
observed	O
in	O
the	O
CpG	O
island	O
proximal	O
to	O
the	O
H19	B-Protein
promoter	O
(	O
-	O
711	O
to	O
-	O
290	O
)	O
with	O
complete	O
methylation	O
of	O
all	O
25	O
CpG	O
sites	O
in	O
one	O
parental	O
allele	O
.	O

In	O
contrast	O
,	O
the	O
CpG	O
region	O
in	O
the	O
H19	B-Protein
promoter	O
(	O
-	O
292	O
to	O
+	O
15	O
)	O
was	O
mosaically	O
methylated	O
in	O
all	O
tissues	O
.	O

In	O
addition	O
,	O
cytosine	O
was	O
methylated	O
at	O
three	O
CpNpG	O
and	O
GpNpC	O
sites	O
on	O
the	O
top	O
DNA	O
strand	O
and	O
one	O
CpNpG	O
site	O
on	O
the	O
bottom	O
DNA	O
strand	O
from	O
the	O
fetal	O
brain	O
.	O

The	O
cytosines	O
at	O
CpG	O
sites	O
were	O
methylated	O
on	O
both	O
DNA	O
strands	O
(	O
symmetric	O
methylation	O
)	O
while	O
cytosines	O
at	O
the	O
CpNpG	O
and	O
GpNpC	O
sites	O
were	O
methylated	O
on	O
only	O
one	O
DNA	O
strand	O
(	O
asymmetric	O
methylation	O
)	O
.	O

The	O
asymmetric	O
methylation	O
was	O
associated	O
with	O
tissue	O
-	O
specific	O
disruption	O
of	O
H19	B-Protein
genomic	O
imprinting	O
in	O
fetal	O
brain	O
.	O

An	O
increase	O
in	O
histone	B-Protein
acetylation	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
antagonizing	O
the	O
immunoinhibitory	O
effect	O
are	O
necessary	O
for	O
augmentation	O
by	O
butyrate	O
of	O
in	O
vitro	O
anti	O
-	O
TNP	O
antibody	O
production	O
.	O

We	O
investigated	O
the	O
role	O
of	O
histone	B-Protein
acetylation	O
in	O
the	O
promotion	O
of	O
antigen	O
-	O
specific	O
antibody	O
production	O
in	O
murine	O
B	O
cells	O
induced	O
by	O
sodium	O
butyrate	O
(	O
NaBu	O
)	O
plus	O
interleukin	B-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
.	O

NaBu	O
dose	O
dependently	O
increased	O
the	O
acetylation	O
levels	O
of	O
histone	B-Protein
H4	I-Protein
at	O
concentrations	O
which	O
effectively	O
enhanced	O
anti	O
-	O
trinitrophenyl	O
(	O
TNP	O
)	O
antibody	O
production	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Among	O
other	O
short	O
-	O
chain	O
fatty	O
acids	O
and	O
NaBu	O
analogs	O
,	O
propionate	O
,	O
valerate	O
and	O
vinylacetate	O
were	O
effective	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
in	O
increasing	O
both	O
antibody	O
production	O
and	O
the	O
histone	B-Protein
H4	I-Protein
acetylation	O
level	O
,	O
but	O
acetate	O
,	O
alpha	O
-	O
,	O
beta	O
-	O
and	O
gamma	O
-	O
hydroxybutyrates	O
and	O
alpha	O
-	O
,	O
beta	O
-	O
and	O
gamma	O
-	O
aminobutyrates	O
were	O
not	O
effective	O
,	O
even	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

The	O
effect	O
of	O
the	O
specific	O
histone	B-Protein
deacetylase	O
inhibitor	O
trichostatin	O
A	O
(	O
TSA	O
)	O
,	O
which	O
enhances	O
anti	O
-	O
TNP	O
antibody	O
production	O
without	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
was	O
markedly	O
inhibited	O
by	O
adding	O
NaBu	O
simultaneously	O
.	O

However	O
,	O
the	O
effect	O
of	O
TSA	O
was	O
neither	O
inhibited	O
nor	O
potentiated	O
by	O
NaBu	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Splenic	O
B	O
cells	O
treated	O
with	O
NaBu	O
,	O
TSA	O
and	O
both	O
together	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
showed	O
almost	O
the	O
same	O
increased	O
acetylation	O
level	O
of	O
histone	B-Protein
H4	I-Protein
.	O

These	O
results	O
suggest	O
that	O
the	O
NaBu	O
-	O
induced	O
enhancement	O
of	O
anti	O
-	O
TNP	O
antibody	O
production	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
is	O
mediated	O
through	O
a	O
moderate	O
increase	O
in	O
the	O
level	O
of	O
histone	B-Protein
acetylation	O
and	O
that	O
NaBu	O
has	O
both	O
stimulating	O
and	O
inhibiting	O
activities	O
for	O
anti	O
-	O
TNP	O
antibody	O
production	O
,	O
the	O
latter	O
of	O
which	O
is	O
overcome	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

New	O
immunofluorescence	O
assays	O
for	O
detection	O
of	O
Human	O
herpesvirus	O
8	O
-	O
specific	O
antibodies	O
.	O

Several	O
assays	O
have	O
been	O
developed	O
for	O
detection	O
of	O
immunoglobulin	O
G	O
antibodies	O
to	O
Human	O
herpesvirus	O
8	O
(	O
HHV	O
-	O
8	O
)	O
,	O
including	O
immunofluorescence	O
assays	O
(	O
IFAs	O
)	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
.	O

However	O
,	O
the	O
specificity	O
and	O
sensitivity	O
of	O
these	O
assays	O
are	O
not	O
completely	O
defined	O
due	O
to	O
the	O
lack	O
of	O
a	O
"	O
gold	O
standard	O
.	O
"	O
Although	O
IFAs	O
based	O
on	O
primary	O
effusion	O
lymphoma	O
(	O
PEL	O
)	O
cell	O
lines	O
are	O
used	O
widely	O
,	O
the	O
assays	O
can	O
be	O
confounded	O
by	O
nonspecific	O
reactions	O
against	O
cellular	O
components	O
and	O
potential	O
cross	O
-	O
reaction	O
with	O
antibodies	O
against	O
other	O
herpesviruses	O
.	O

To	O
provide	O
more	O
reliable	O
IFAs	O
,	O
we	O
established	O
recombinant	O
Semliki	O
Forest	O
viruses	O
(	O
rSFVs	O
)	O
expressing	O
the	O
HHV	O
-	O
8	O
-	O
specific	O
proteins	O
ORF73	B-Protein
and	O
K8	B-Protein
.	I-Protein
1	I-Protein
and	O
used	O
BHK	O
-	O
21	O
cells	O
infected	O
with	O
these	O
rSFVs	O
for	O
IFA	O
(	O
ORF73	B-Protein
-	O
IFA	O
and	O
K8	B-Protein
.	I-Protein
1	I-Protein
-	O
IFA	O
)	O
.	O

Expression	O
of	O
the	O
HHV	O
-	O
8	O
-	O
specific	O
proteins	O
at	O
very	O
high	O
levels	O
by	O
the	O
rSFV	O
system	O
allowed	O
easy	O
scoring	O
for	O
IFA	O
and	O
thereby	O
increased	O
specificity	O
.	O

The	O
rSFV	O
system	O
also	O
allowed	O
detection	O
of	O
antibodies	O
against	O
glycosylation	O
-	O
dependent	O
epitopes	O
of	O
K8	B-Protein
.	I-Protein
1	I-Protein
.	O

Titers	O
measured	O
by	O
rSFV	O
-	O
based	O
IFAs	O
and	O
PEL	O
-	O
based	O
IFAs	O
correlated	O
well	O
(	O
correlation	O
coefficients	O
of	O
>	O
0	O
.	O
9	O
)	O
,	O
and	O
concordances	O
of	O
seroreactivities	O
between	O
rSFV	O
-	O
based	O
and	O
PEL	O
-	O
based	O
IFAs	O
were	O
>	O
97	O
%	O
(	O
kappa	O
>	O
0	O
.	O
93	O
)	O
.	O

K8	O
.	O
1	O
-	O
IFA	O
was	O
more	O
sensitive	O
than	O
either	O
ORF73	B-Protein
-	O
IFA	O
or	O
peptide	O
ELISAs	O
.	O

Using	O
PEL	O
-	O
based	O
lytic	O
IFA	O
as	O
a	O
reference	O
assay	O
,	O
the	O
sensitivity	O
and	O
specificity	O
of	O
K8	B-Protein
.	I-Protein
1	I-Protein
-	O
IFA	O
were	O
estimated	O
to	O
be	O
94	O
and	O
100	O
%	O
,	O
respectively	O
.	O

HHV	O
-	O
8	O
prevalences	O
determined	O
by	O
K8	B-Protein
.	I-Protein
1	I-Protein
-	O
IFA	O
among	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-	O
positive	O
(	O
HIV	O
(	O
+	O
)	O
)	O
Kaposi	O
'	O
s	O
sarcoma	O
(	O
KS	O
)	O
patients	O
,	O
HIV	O
(	O
+	O
)	O
KS	O
(	O
-	O
)	O
patients	O
,	O
and	O
healthy	O
controls	O
were	O
100	O
,	O
65	O
,	O
and	O
6	O
.	O
7	O
%	O
,	O
respectively	O
,	O
which	O
were	O
consistent	O
with	O
prior	O
reports	O
.	O

Therefore	O
,	O
our	O
rSFV	O
-	O
based	O
IFAs	O
may	O
provide	O
a	O
specific	O
and	O
sensitive	O
method	O
for	O
use	O
in	O
epidemiology	O
studies	O
.	O

In	O
addition	O
,	O
they	O
will	O
provide	O
a	O
basis	O
for	O
further	O
development	O
of	O
diagnostic	O
tests	O
for	O
HHV	O
-	O
8	O
infection	O
.	O

Evidence	O
that	O
the	O
lizard	O
helospectin	B-Protein
peptides	O
are	O
O	O
-	O
glycosylated	O
.	O

Six	O
forms	O
of	O
helospectin	B-Protein
(	O
a	O
vasoactive	O
intestinal	O
peptide	O
analogue	O
)	O
were	O
purified	O
from	O
the	O
venom	O
of	O
the	O
Heloderma	O
horridum	O
lizard	O
.	O

Their	O
identification	O
was	O
performed	O
by	O
combining	O
sequencing	O
by	O
automated	O
Edman	O
degradation	O
and	O
electrospray	O
mass	O
spectrometry	O
analysis	O
on	O
the	O
complete	O
peptides	O
and	O
their	O
tryptic	O
fragments	O
.	O

The	O
products	O
resulting	O
from	O
the	O
action	O
of	O
an	O
O	O
-	O
glycosidase	O
were	O
also	O
analysed	O
.	O

Two	O
forms	O
were	O
identified	O
as	O
the	O
previously	O
named	O
Hs1	B-Protein
and	O
Hs2	B-Protein
of	O
38	O
and	O
37	O
amino	O
-	O
acid	O
residues	O
,	O
respectively	O
.	O

Two	O
forms	O
corresponded	O
to	O
Hs1	B-Protein
and	O
Hs2	B-Protein
O	O
-	O
glycosylated	O
by	O
a	O
N	O
-	O
acetylhexosamine	O
-	O
hexose	O
motif	O
attached	O
to	O
the	O
Ser32	O
residue	O
.	O

Two	O
other	O
forms	O
were	O
not	O
completely	O
characterized	O
but	O
might	O
correspond	O
to	O
the	O
O	O
-	O
glycosylated	O
forms	O
bearing	O
a	O
phosphate	O
or	O
a	O
sulfate	O
group	O
.	O

The	O
glycosylation	O
did	O
not	O
affect	O
the	O
capacity	O
of	O
the	O
helospectins	B-Protein
to	O
recognize	O
and	O
to	O
activate	O
the	O
human	O
and	O
the	O
rat	O
VPAC1	B-Protein
and	O
VPAC2	B-Protein
receptors	O
.	O

Changes	O
in	O
methionine	O
adenosyltransferase	O
and	O
S	O
-	O
adenosylmethionine	O
homeostasis	O
in	O
alcoholic	O
rat	O
liver	O
.	O

Liver	O
-	O
specific	O
and	O
non	O
-	O
liver	O
-	O
specific	O
methionine	O
adenosyltransferase	O
(	O
MAT	O
)	O
are	O
products	O
of	O
two	O
genes	O
,	O
MAT1A	B-Protein
and	O
MAT2A	B-Protein
,	O
respectively	O
,	O
that	O
catalyze	O
the	O
formation	O
of	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
.	O

We	O
previously	O
showed	O
that	O
MAT2A	B-Protein
expression	O
was	O
associated	O
with	O
more	O
rapid	O
cell	O
growth	O
.	O

Changes	O
in	O
MAT	O
expression	O
have	O
not	O
been	O
examined	O
in	O
animal	O
models	O
of	O
alcoholic	O
liver	O
injury	O
,	O
which	O
is	O
the	O
focus	O
of	O
the	O
current	O
study	O
.	O

After	O
rats	O
were	O
fed	O
intragastrically	O
with	O
ethanol	O
and	O
high	O
fat	O
for	O
9	O
wk	O
,	O
the	O
mRNA	O
level	O
of	O
both	O
MAT	O
forms	O
doubled	O
but	O
only	O
the	O
protein	O
level	O
of	O
MAT2A	B-Protein
increased	O
.	O

Although	O
liver	O
-	O
specific	O
MAT	O
activity	O
did	O
not	O
change	O
,	O
it	O
was	O
32	O
%	O
lower	O
after	O
one	O
and	O
68	O
%	O
lower	O
after	O
eight	O
weekly	O
enteral	O
doses	O
of	O
lipopolysaccharide	O
.	O

Hepatic	O
levels	O
of	O
methionine	O
,	O
SAM	O
,	O
and	O
DNA	O
methylation	O
fell	O
by	O
approximately	O
40	O
%	O
.	O

c	B-Protein
-	I-Protein
myc	I-Protein
was	O
hypomethylated	O
,	O
and	O
its	O
mRNA	O
level	O
increased	O
.	O

Genome	O
-	O
wide	O
DNA	O
strand	O
break	O
increased	O
.	O

Thus	O
in	O
the	O
prefibrotic	O
stage	O
of	O
alcoholic	O
liver	O
injury	O
,	O
there	O
is	O
already	O
a	O
switch	O
in	O
MAT	O
expression	O
,	O
global	O
DNA	O
hypomethylation	O
,	O
increased	O
c	B-Protein
-	I-Protein
myc	I-Protein
expression	O
,	O
and	O
genome	O
-	O
wide	O
DNA	O
strand	O
break	O
.	O

These	O
changes	O
may	O
be	O
important	O
in	O
predisposing	O
this	O
liver	O
disease	O
to	O
malignant	O
degeneration	O
.	O

Hsl7p	B-Protein
,	O
the	O
yeast	O
homologue	O
of	O
human	O
JBP1	B-Protein
,	O
is	O
a	O
protein	O
methyltransferase	O
.	O

The	O
yeast	O
protein	O
Hsl7p	B-Protein
is	O
a	O
homologue	O
of	O
Janus	B-Protein
kinase	I-Protein
binding	I-Protein
protein	I-Protein
1	I-Protein
,	O
JBP1	B-Protein
,	O
a	O
newly	O
characterized	O
protein	O
methyltransferase	O
.	O

In	O
this	O
report	O
,	O
Hsl7p	B-Protein
also	O
is	O
shown	O
to	O
be	O
a	O
methyltransferase	O
.	O

It	O
can	O
be	O
crosslinked	O
to	O
[	O
(	O
3	O
)	O
H	O
]	O
S	O
-	O
adenosylmethionine	O
and	O
exhibits	O
in	O
vitro	O
protein	O
methylation	O
activity	O
.	O

Calf	O
histones	B-Protein
H2A	I-Protein
and	O
H4	B-Protein
and	O
bovine	O
myelin	B-Protein
basic	I-Protein
protein	I-Protein
were	O
methylated	O
by	O
Hsl7p	B-Protein
,	O
whereas	O
histones	B-Protein
H1	I-Protein
,	O
H2B	B-Protein
,	O
and	O
H3	B-Protein
and	O
bovine	O
cytochrome	B-Protein
c	I-Protein
were	O
not	O
.	O

We	O
demonstrated	O
that	O
JBP1	B-Protein
can	O
complement	O
Saccharomyces	O
cerevisiae	O
with	O
a	O
disrupted	O
HSL7	B-Protein
gene	O
as	O
judged	O
by	O
a	O
reduction	O
of	O
the	O
elongated	O
bud	O
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
in	O
the	O
JBP1	B-Protein
S	O
-	O
adenosylmethionine	O
consensus	O
binding	O
sequence	O
eliminated	O
all	O
complementation	O
by	O
JBP1	B-Protein
.	O

Therefore	O
,	O
we	O
conclude	O
the	O
yeast	O
protein	O
Hsl7p	B-Protein
is	O
a	O
sequence	O
and	O
functional	O
homologue	O
of	O
JBP1	B-Protein
.	O

These	O
data	O
provide	O
evidence	O
for	O
an	O
intricate	O
link	O
between	O
protein	O
methylation	O
and	O
macroscopic	O
changes	O
in	O
yeast	O
morphology	O
.	O

Rapid	O
induction	O
of	O
histone	B-Protein
hyperacetylation	O
and	O
cellular	O
differentiation	O
in	O
human	O
breast	O
tumor	O
cell	O
lines	O
following	O
degradation	O
of	O
histone	B-Protein
deacetylase	I-Protein
-	I-Protein
1	I-Protein
.	O

Quinidine	O
inhibits	O
proliferation	O
and	O
promotes	O
cellular	O
differentiation	O
in	O
human	O
breast	O
tumor	O
epithelial	O
cells	O
.	O

Previously	O
we	O
showed	O
quinidine	O
arrested	O
MCF	O
-	O
7	O
cells	O
in	O
G	O
(	O
1	O
)	O
phase	O
of	O
the	O
cell	O
cycle	O
and	O
led	O
to	O
a	O
G	O
(	O
1	O
)	O
to	O
G	O
(	O
0	O
)	O
transition	O
followed	O
by	O
apoptotic	O
cell	O
death	O
.	O

The	O
present	O
experiments	O
demonstrated	O
that	O
MCF	O
-	O
7	O
,	O
MCF	O
-	O
7ras	O
,	O
T47D	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
and	O
MDA	O
-	O
MB	O
-	O
435	O
cells	O
transiently	O
differentiate	O
before	O
undergoing	O
apoptosis	O
in	O
response	O
to	O
quinidine	O
.	O

The	O
cells	O
accumulated	O
lipid	O
droplets	O
,	O
and	O
the	O
cytokeratin	B-Protein
18	I-Protein
cytoskeleton	O
was	O
reorganized	O
.	O

Hyperacetylated	O
histone	B-Protein
H4	I-Protein
appeared	O
within	O
2	O
h	O
of	O
the	O
addition	O
of	O
quinidine	O
to	O
the	O
medium	O
,	O
and	O
levels	O
were	O
maximal	O
by	O
24	O
h	O
.	O

Quinidine	O
-	O
treated	O
MCF	O
-	O
7	O
cells	O
showed	O
elevated	O
p21	B-Protein
(	O
WAF1	B-Protein
)	O
,	O
hypophosphorylation	O
and	O
suppression	O
of	O
retinoblastoma	B-Protein
protein	O
,	O
and	O
down	O
-	O
regulation	O
of	O
cyclin	B-Protein
D1	I-Protein
,	O
similar	O
to	O
the	O
cell	O
cycle	O
response	O
observed	O
with	O
cells	O
induced	O
to	O
differentiate	O
by	O
histone	B-Protein
deacetylase	O
inhibitors	O
,	O
trichostatin	O
A	O
,	O
and	O
trapoxin	O
.	O

Quinidine	O
did	O
not	O
show	O
evidence	O
for	O
direct	O
inhibition	O
of	O
histone	B-Protein
deacetylase	O
enzymatic	O
activity	O
in	O
vitro	O
.	O

HDAC1	B-Protein
was	O
undetectable	O
in	O
MCF	O
-	O
7	O
cells	O
30	O
min	O
after	O
addition	O
of	O
quinidine	O
to	O
the	O
growth	O
medium	O
.	O

The	O
proteasome	O
inhibitors	O
MG	O
-	O
132	O
and	O
lactacystin	O
completely	O
protected	O
HDAC1	B-Protein
from	O
the	O
action	O
of	O
quinidine	O
.	O

We	O
conclude	O
that	O
quinidine	O
is	O
a	O
breast	O
tumor	O
cell	O
differentiating	O
agent	O
that	O
causes	O
the	O
loss	O
of	O
HDAC1	B-Protein
via	O
a	O
proteasomal	O
sensitive	O
mechanism	O
.	O

Glycosylation	O
influences	O
gating	O
and	O
pH	O
sensitivity	O
of	O
I	O
(	O
sK	O
)	O
.	O

The	O
KvLQT1	B-Protein
and	O
minK	B-Protein
subunits	O
that	O
coassemble	O
to	O
form	O
I	O
(	O
sK	O
)	O
channels	O
,	O
contain	O
potential	O
N	O
-	O
glycosylation	O
sites	O
.	O

To	O
examine	O
the	O
role	O
of	O
glycosylation	O
in	O
channel	O
function	O
,	O
a	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
deficient	O
in	O
glycosylation	O
(	O
Lec	O
-	O
1	O
)	O
and	O
its	O
parental	O
cell	O
line	O
(	O
Pro	O
-	O
5	O
)	O
were	O
transiently	O
transfected	O
with	O
human	O
KvLQT1	B-Protein
(	O
hKvLQT1	B-Protein
)	O
cDNA	O
,	O
alone	O
and	O
in	O
combination	O
with	O
the	O
rat	O
(	O
rminK	B-Protein
)	O
or	O
human	O
minK	B-Protein
(	O
hminK	B-Protein
)	O
cDNA	O
.	O

Functional	O
KvLQT1	B-Protein
and	O
I	O
(	O
sK	O
)	O
currents	O
were	O
expressed	O
in	O
both	O
cell	O
lines	O
,	O
although	O
amplitudes	O
were	O
larger	O
in	O
Pro	O
-	O
5	O
than	O
Lec	O
-	O
1	O
cells	O
transfected	O
with	O
hKvLQT1	B-Protein
and	O
hKvLQT1	B-Protein
/	O
hminK	B-Protein
.	O

For	O
I	O
(	O
sK	O
)	O
,	O
but	O
not	O
KvLQT1	B-Protein
,	O
the	O
voltage	O
-	O
dependence	O
of	O
activation	O
was	O
shifted	O
to	O
more	O
positive	O
voltages	O
and	O
the	O
activation	O
kinetics	O
were	O
slower	O
in	O
the	O
Lec	O
-	O
1	O
compared	O
to	O
the	O
Pro	O
-	O
5	O
cells	O
.	O

The	O
effect	O
of	O
extracellular	O
acidification	O
on	O
recombinant	O
KvLQT1	B-Protein
and	O
I	O
(	O
sK	O
)	O
currents	O
was	O
investigated	O
in	O
Pro	O
-	O
5	O
and	O
Lec	O
-	O
1	O
cells	O
.	O

Changing	O
external	O
pH	O
(	O
pH	O
(	O
o	O
)	O
)	O
from	O
7	O
.	O
4	O
to	O
6	O
.	O
0	O
significantly	O
decreased	O
the	O
amplitude	O
and	O
increased	O
the	O
half	O
-	O
activation	O
voltage	O
(	O
V	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
KvLQT1	B-Protein
currents	O
in	O
Pro	O
-	O
5	O
and	O
Lec	O
-	O
1	O
cells	O
.	O

In	O
Pro	O
-	O
5	O
cells	O
,	O
decreasing	O
pH	O
(	O
o	O
)	O
reduced	O
I	O
(	O
sK	O
)	O
amplitude	O
without	O
increasing	O
V	O
(	O
1	O
/	O
2	O
)	O
,	O
whether	O
rminK	B-Protein
or	O
hminK	B-Protein
was	O
coexpressed	O
with	O
hKvLQT	B-Protein
.	O

In	O
contrast	O
,	O
changing	O
pH	O
(	O
o	O
)	O
from	O
7	O
.	O
4	O
to	O
6	O
.	O
0	O
did	O
not	O
significantly	O
change	O
I	O
(	O
sK	O
)	O
amplitude	O
in	O
Lec	O
-	O
1	O
cells	O
.	O

Thus	O
,	O
oligosaccharides	O
attached	O
to	O
the	O
minK	B-Protein
subunit	O
affect	O
not	O
only	O
the	O
gating	O
properties	O
,	O
but	O
also	O
the	O
pH	O
sensitivity	O
of	O
I	O
(	O
sK	O
)	O
.	O

A	O
novel	O
post	O
-	O
translational	O
modification	O
of	O
yeast	O
elongation	B-Protein
factor	I-Protein
1A	I-Protein
.	O

Methylesterification	O
at	O
the	O
C	O
terminus	O
.	O

Protein	O
methylation	O
reactions	O
can	O
play	O
important	O
roles	O
in	O
cell	O
physiology	O
.	O

After	O
labeling	O
intact	O
Saccharomyces	O
cerevisiae	O
cells	O
with	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
[	O
methyl	O
-	O
(	O
3	O
)	O
H	O
]	O
methionine	O
,	O
we	O
identified	O
a	O
major	O
methylated	O
49	O
-	O
kDa	O
polypeptide	O
containing	O
[	O
(	O
3	O
)	O
H	O
]	O
methyl	O
groups	O
in	O
two	O
distinct	O
types	O
of	O
linkages	O
.	O

Peptide	O
sequence	O
analysis	O
of	O
the	O
purified	O
methylated	O
protein	O
revealed	O
that	O
it	O
is	O
eukaryotic	O
elongation	B-Protein
factor	I-Protein
1A	I-Protein
(	O
eEF1A	B-Protein
,	O
formerly	O
EF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
,	O
the	O
protein	O
that	O
forms	O
a	O
complex	O
with	O
GTP	O
and	O
aminoacyl	O
-	O
tRNAs	O
for	O
binding	O
to	O
the	O
ribosomal	O
A	O
site	O
during	O
protein	O
translation	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
eEF1A	B-Protein
is	O
methylated	O
on	O
several	O
internal	O
lysine	O
residues	O
to	O
give	O
mono	O
-	O
,	O
di	O
-	O
,	O
and	O
tri	O
-	O
N	O
-	O
epsilon	O
-	O
methyl	O
-	O
lysine	O
derivatives	O
.	O

We	O
confirm	O
this	O
finding	O
but	O
also	O
detect	O
methylation	O
that	O
is	O
released	O
as	O
volatile	O
methyl	O
groups	O
after	O
base	O
hydrolysis	O
,	O
characteristic	O
of	O
ester	O
linkages	O
.	O

In	O
cycloheximide	O
-	O
treated	O
cells	O
,	O
methyl	O
esterified	O
eEF1A	B-Protein
was	O
detected	O
largely	O
in	O
the	O
ribosome	O
and	O
polysome	O
fractions	O
;	O
little	O
or	O
no	O
methylated	O
protein	O
was	O
found	O
in	O
the	O
soluble	O
fraction	O
.	O

Because	O
the	O
base	O
-	O
labile	O
,	O
volatile	O
[	O
methyl	O
-	O
(	O
3	O
)	O
H	O
]	O
radioactivity	O
of	O
eEF1A	B-Protein
could	O
be	O
released	O
by	O
trypsin	O
treatment	O
but	O
not	O
by	O
carboxypeptidase	B-Protein
Y	I-Protein
or	O
chymotrypsin	B-Protein
treatment	O
,	O
we	O
suggest	O
that	O
the	O
methyl	O
ester	O
is	O
present	O
on	O
the	O
alpha	O
-	O
carboxyl	O
group	O
of	O
its	O
C	O
-	O
terminal	O
lysine	O
residue	O
.	O

From	O
the	O
results	O
of	O
pulse	O
-	O
chase	O
experiments	O
using	O
radiolabeled	O
intact	O
yeast	O
cells	O
,	O
we	O
find	O
that	O
the	O
N	O
-	O
methylated	O
lysine	O
residues	O
of	O
eEF1A	B-Protein
are	O
stable	O
over	O
4	O
h	O
,	O
whereas	O
the	O
eEF1A	B-Protein
carboxyl	O
methyl	O
ester	O
has	O
a	O
half	O
-	O
life	O
of	O
less	O
than	O
10	O
min	O
.	O

The	O
rapid	O
turnover	O
of	O
the	O
methyl	O
ester	O
suggests	O
that	O
the	O
methylation	O
/	O
demethylation	O
of	O
eEF1A	B-Protein
at	O
the	O
C	O
-	O
terminal	O
carboxyl	O
group	O
may	O
represent	O
a	O
novel	O
mode	O
of	O
regulation	O
of	O
the	O
activity	O
of	O
this	O
protein	O
in	O
yeast	O
.	O

Decreased	O
UDP	O
-	O
GlcNAc	O
levels	O
abrogate	O
proliferation	O
control	O
in	O
EMeg32	B-Protein
-	O
deficient	O
cells	O
.	O

The	O
hexosamine	O
pathway	O
provides	O
UDP	O
-	O
N	O
:	O
-	O
acetylhexosamine	O
donor	O
substrates	O
used	O
in	O
cytosolic	O
and	O
Golgi	O
-	O
mediated	O
glycosylation	O
of	O
proteins	O
and	O
for	O
formation	O
of	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
anchors	O
,	O
which	O
tether	O
proteins	O
to	O
the	O
outer	O
plasma	O
membrane	O
.	O

We	O
have	O
recently	O
identified	O
the	O
murine	O
glucosamine	B-Protein
-	I-Protein
6	I-Protein
-	I-Protein
phosphate	I-Protein
(	I-Protein
GlcN6P	I-Protein
)	I-Protein
acetyltransferase	I-Protein
,	O
EMeg32	B-Protein
,	O
as	O
a	O
developmentally	O
regulated	O
enzyme	O
on	O
the	O
route	O
to	O
UDP	O
-	O
N	O
:	O
-	O
acetylglucosamine	O
(	O
UDP	O
-	O
GlcNAc	O
)	O
.	O

Here	O
we	O
describe	O
embryos	O
and	O
cells	O
that	O
have	O
the	O
EMeg32	B-Protein
gene	O
inactivated	O
by	O
homologous	O
recombination	O
.	O

Homozygous	O
mutant	O
embryos	O
die	O
at	O
around	O
embryonic	O
day	O
(	O
E	O
)	O
7	O
.	O
5	O
with	O
a	O
general	O
proliferative	O
delay	O
of	O
development	O
.	O

In	O
vitro	O
differentiated	O
EMeg32	B-Protein
(	O
-	O
/	O
-	O
)	O
ES	O
cells	O
show	O
reduced	O
proliferation	O
.	O

Mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
deficient	O
for	O
EMeg32	B-Protein
exhibit	O
defects	O
in	O
proliferation	O
and	O
adhesiveness	O
,	O
which	O
could	O
be	O
complemented	O
by	O
stable	O
re	O
-	O
expression	O
of	O
EMeg32	B-Protein
or	O
by	O
nutritional	O
restoration	O
of	O
intracellular	O
UDP	O
-	O
GlcNAc	O
levels	O
.	O

Reduced	O
UDP	O
-	O
GlcNAc	O
levels	O
predominantly	O
translated	O
into	O
decreased	O
O	O
-	O
GlcNAc	O
modifications	O
of	O
cytosolic	O
and	O
nuclear	O
proteins	O
.	O

Interestingly	O
,	O
growth	O
-	O
impaired	O
EMeg32	B-Protein
(	O
-	O
/	O
-	O
)	O
MEFs	O
withstand	O
a	O
number	O
of	O
apoptotic	O
stimuli	O
and	O
express	O
activated	O
PKB	B-Protein
/	O
AKT	B-Protein
.	O

Thus	O
,	O
EMeg32	B-Protein
-	O
dependent	O
UDP	O
-	O
GlcNAc	O
levels	O
influence	O
cell	O
cycle	O
progression	O
and	O
susceptibility	O
to	O
apoptotic	O
stimuli	O
.	O

Post	O
-	O
translational	O
hydroxylation	O
at	O
the	O
N	O
-	O
terminus	O
of	O
the	O
prion	B-Protein
protein	I-Protein
reveals	O
presence	O
of	O
PPII	O
structure	O
in	O
vivo	O
.	O

The	O
transmissible	O
spongiform	O
encephalopathies	O
are	O
characterized	O
by	O
conversion	O
of	O
a	O
host	O
protein	O
,	O
PrP	B-Protein
(	I-Protein
C	I-Protein
)	I-Protein
(	O
cellular	O
prion	B-Protein
protein	I-Protein
)	O
,	O
to	O
a	O
protease	O
-	O
resistant	O
isoform	O
,	O
PrP	B-Protein
(	O
Sc	O
)	O
(	O
prion	B-Protein
protein	I-Protein
scrapie	O
isoform	O
)	O
.	O

The	O
importance	O
of	O
the	O
highly	O
flexible	O
,	O
N	O
-	O
terminal	O
region	O
of	O
PrP	B-Protein
has	O
recently	O
become	O
more	O
widely	O
appreciated	O
,	O
particularly	O
the	O
biological	O
activities	O
associated	O
with	O
its	O
metal	O
ion	O
-	O
binding	O
domain	O
and	O
its	O
potential	O
to	O
form	O
a	O
poly	O
(	O
L	O
-	O
proline	O
)	O
II	O
(	O
PPII	O
)	O
helix	O
.	O

Circular	O
dichroism	O
spectroscopy	O
of	O
an	O
N	O
-	O
terminal	O
peptide	O
,	O
PrP	B-Protein
(	O
37	O
-	O
53	O
)	O
,	O
showed	O
that	O
the	O
PPII	O
helix	O
is	O
formed	O
in	O
aqueous	O
buffer	O
;	O
as	O
it	O
also	O
contains	O
an	O
Xaa	O
-	O
Pro	O
-	O
Gly	O
consensus	O
sequence	O
,	O
it	O
may	O
act	O
as	O
a	O
substrate	O
for	O
the	O
collagen	O
-	O
modifying	O
enzyme	O
prolyl	O
4	O
-	O
hydroxylase	O
.	O

Direct	O
evidence	O
for	O
this	O
modification	O
was	O
obtained	O
by	O
mass	O
spectrometry	O
and	O
Edman	O
sequencing	O
in	O
recombinant	O
mouse	O
PrP	B-Protein
secreted	O
from	O
stably	O
transfected	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Almost	O
complete	O
conversion	O
of	O
proline	O
to	O
4	O
-	O
hydroxyproline	O
occurs	O
specifically	O
at	O
residue	O
Pro44	O
of	O
this	O
murine	O
protein	O
;	O
the	O
same	O
hydroxylated	O
residue	O
was	O
detected	O
,	O
at	O
lower	O
levels	O
,	O
in	O
PrP	B-Protein
(	O
Sc	O
)	O
from	O
the	O
brains	O
of	O
scrapie	O
-	O
infected	O
mice	O
.	O

Cation	O
binding	O
and	O
/	O
or	O
post	O
-	O
translational	O
hydroxylation	O
of	O
this	O
region	O
of	O
PrP	B-Protein
may	O
regulate	O
its	O
role	O
in	O
the	O
physiology	O
and	O
pathobiology	O
of	O
the	O
cell	O
.	O

Carboxymethylation	O
of	O
the	O
PP2A	O
catalytic	O
subunit	O
in	O
Saccharomyces	O
cerevisiae	O
is	O
required	O
for	O
efficient	O
interaction	O
with	O
the	O
B	O
-	O
type	O
subunits	O
Cdc55p	B-Protein
and	O
Rts1p	B-Protein
.	O

Protein	O
phosphatase	O
2A	O
(	O
PP2A	O
)	O
is	O
an	O
essential	O
eukaryotic	O
serine	O
/	O
threonine	O
phosphatase	O
known	O
to	O
play	O
important	O
roles	O
in	O
cell	O
cycle	O
regulation	O
.	O

Association	O
of	O
different	O
B	O
-	O
type	O
targeting	O
subunits	O
with	O
the	O
heterodimeric	O
core	O
(	O
A	O
/	O
C	O
)	O
enzyme	O
is	O
known	O
to	O
be	O
an	O
important	O
mechanism	O
of	O
regulating	O
PP2A	O
activity	O
,	O
substrate	O
specificity	O
,	O
and	O
localization	O
.	O

However	O
,	O
how	O
the	O
binding	O
of	O
these	O
targeting	O
subunits	O
to	O
the	O
A	O
/	O
C	O
heterodimer	O
might	O
be	O
regulated	O
is	O
unknown	O
.	O

We	O
have	O
used	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
as	O
a	O
model	O
system	O
to	O
investigate	O
the	O
hypothesis	O
that	O
covalent	O
modification	O
of	O
the	O
C	O
subunit	O
(	O
Pph21p	B-Protein
/	O
Pph22p	B-Protein
)	O
carboxyl	O
terminus	O
modulates	O
PP2A	O
complex	O
formation	O
.	O

Two	O
approaches	O
were	O
taken	O
.	O

First	O
,	O
S	O
.	O
cerevisiae	O
cells	O
were	O
generated	O
whose	O
survival	O
depended	O
on	O
the	O
expression	O
of	O
different	O
carboxyl	O
-	O
terminal	O
Pph21p	B-Protein
mutants	O
.	O

Second	O
,	O
the	O
major	O
S	O
.	O
cerevisiae	O
methyltransferase	O
(	O
Ppm1p	B-Protein
)	O
that	O
catalyzes	O
the	O
methylation	O
of	O
the	O
PP2A	O
C	O
subunit	O
carboxyl	O
-	O
terminal	O
leucine	O
was	O
identified	O
,	O
and	O
cells	O
deleted	O
for	O
this	O
methyltransferase	O
were	O
utilized	O
for	O
our	O
studies	O
.	O

Our	O
results	O
demonstrate	O
that	O
binding	O
of	O
the	O
yeast	O
B	O
subunit	O
,	O
Cdc55p	B-Protein
,	O
to	O
Pph21p	B-Protein
was	O
disrupted	O
by	O
either	O
acidic	O
substitution	O
of	O
potential	O
carboxyl	O
-	O
terminal	O
phosphorylation	O
sites	O
on	O
Pph21p	B-Protein
or	O
by	O
deletion	O
of	O
the	O
gene	O
for	O
Ppm1p	B-Protein
.	O

Loss	O
of	O
Cdc55p	B-Protein
association	O
was	O
accompanied	O
in	O
each	O
case	O
by	O
a	O
large	O
reduction	O
in	O
binding	O
of	O
the	O
yeast	O
A	O
subunit	O
,	O
Tpd3p	B-Protein
,	O
to	O
Pph21p	B-Protein
.	O

Moreover	O
,	O
decreased	O
Cdc55p	B-Protein
and	O
Tpd3p	B-Protein
binding	O
invariably	O
resulted	O
in	O
nocodazole	O
sensitivity	O
,	O
a	O
known	O
phenotype	O
of	O
CDC55	B-Protein
or	O
TPD3	B-Protein
deletion	O
.	O

Furthermore	O
,	O
loss	O
of	O
methylation	O
also	O
greatly	O
reduced	O
the	O
association	O
of	O
another	O
yeast	O
B	O
-	O
type	O
subunit	O
,	O
Rts1p	B-Protein
.	O

Thus	O
,	O
methylation	O
of	O
Pph21p	B-Protein
is	O
important	O
for	O
formation	O
of	O
PP2A	O
trimeric	O
and	O
dimeric	O
complexes	O
,	O
and	O
consequently	O
,	O
for	O
PP2A	O
function	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
methylation	O
and	O
phosphorylation	O
may	O
be	O
mechanisms	O
by	O
which	O
the	O
cell	O
dynamically	O
regulates	O
PP2A	O
complex	O
formation	O
and	O
function	O
.	O

Safety	O
and	O
pharmacokinetic	O
study	O
with	O
escalating	O
doses	O
of	O
3	O
-	O
acetyl	O
-	O
7	O
-	O
oxo	O
-	O
dehydroepiandrosterone	O
in	O
healthy	O
male	O
volunteers	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
safety	O
and	O
pharmacokinetics	O
of	O
3	O
-	O
acetyl	O
-	O
7	O
-	O
oxo	O
-	O
DHEA	O
(	O
3beta	O
-	O
acetoxyandrost	O
-	O
5	O
-	O
ene	O
-	O
7	O
,	O
17	O
-	O
dione	O
)	O
given	O
orally	O
.	O

DESIGN	O
:	O
A	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
escalating	O
dose	O
study	O
.	O

SETTING	O
:	O
The	O
Chicago	O
Center	O
for	O
Clinical	O
Research	O
.	O

PARTICIPANTS	O
:	O
Twenty	O
-	O
two	O
healthy	O
men	O
.	O

STUDY	O
METHOD	O
:	O
The	O
participants	O
received	O
placebo	O
(	O
n	O
=	O
6	O
)	O
or	O
3	O
-	O
acetyl	O
-	O
7	O
-	O
oxo	O
-	O
DHEA	O
(	O
n	O
=	O
16	O
)	O
at	O
50	O
mg	O
/	O
d	O
for	O
7	O
days	O
followed	O
by	O
a	O
7	O
-	O
day	O
washout	O
;	O
100	O
mg	O
/	O
d	O
for	O
7	O
days	O
followed	O
by	O
a	O
7	O
-	O
day	O
washout	O
;	O
and	O
200	O
mg	O
/	O
d	O
for	O
28	O
days	O
.	O

OUTCOME	O
MEASURES	O
:	O
Safety	O
parameters	O
,	O
evaluated	O
at	O
each	O
dose	O
level	O
,	O
included	O
measurement	O
of	O
total	O
testosterone	O
,	O
free	O
testosterone	O
,	O
dihydrotestosterone	O
,	O
estradiol	O
,	O
cortisol	O
,	O
thyroxin	O
and	O
insulin	B-Protein
levels	O
.	O

Analyses	O
for	O
7	O
-	O
oxo	O
-	O
DHEA	O
-	O
3beta	O
-	O
sulfate	O
(	O
DHEA	O
-	O
S	O
)	O
,	O
the	O
only	O
detectable	O
metabolic	O
product	O
of	O
the	O
administered	O
steroid	O
,	O
were	O
conducted	O
on	O
plasma	O
drawn	O
from	O
all	O
subjects	O
at	O
0	O
.	O
25	O
,	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
and	O
12	O
hours	O
after	O
the	O
final	O
100	O
mg	O
dose	O
of	O
3beta	O
-	O
acetyl	O
-	O
7	O
-	O
oxo	O
-	O
DHEA	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
differences	O
in	O
the	O
clinical	O
laboratory	O
values	O
or	O
in	O
reported	O
minor	O
adverse	O
experiences	O
,	O
between	O
treatment	O
and	O
placebo	O
groups	O
.	O

In	O
general	O
,	O
blood	O
hormone	O
concentrations	O
were	O
unaffected	O
by	O
the	O
treatment	O
with	O
3beta	O
-	O
acetyl	O
-	O
7	O
-	O
oxo	O
-	O
DHEA	O
and	O
remained	O
within	O
the	O
normal	O
range	O
.	O

No	O
changes	O
in	O
vital	O
signs	O
,	O
blood	O
chemistry	O
or	O
urinalysis	O
occurred	O
during	O
treatment	O
with	O
3beta	O
-	O
acetyl	O
-	O
7	O
-	O
oxo	O
-	O
DHEA	O
compared	O
to	O
placebo	O
.	O

The	O
administered	O
steroid	O
was	O
not	O
detected	O
in	O
the	O
blood	O
but	O
was	O
rapidly	O
converted	O
to	O
7	O
-	O
oxo	O
-	O
DHEA	O
-	O
S	O
,	O
the	O
concentrations	O
of	O
which	O
were	O
proportional	O
to	O
dose	O
.	O

This	O
steroid	O
sulfate	O
did	O
not	O
accumulate	O
;	O
plasma	O
concentrations	O
12	O
hours	O
after	O
the	O
3beta	O
-	O
acetyl	O
-	O
7	O
-	O
oxo	O
-	O
DHEA	O
dose	O
at	O
7	O
and	O
28	O
days	O
on	O
the	O
200	O
mg	O
/	O
d	O
dose	O
were	O
15	O
.	O
8	O
and	O
16	O
.	O
3	O
microg	O
/	O
L	O
respectively	O
.	O

The	O
mean	O
time	O
to	O
peak	O
plasma	O
level	O
of	O
7	O
-	O
oxo	O
-	O
DHEA	O
-	O
S	O
was	O
2	O
.	O
2	O
hours	O
;	O
the	O
mean	O
half	O
life	O
was	O
2	O
.	O
17	O
hours	O
.	O

The	O
apparent	O
clearance	O
averaged	O
172	O
L	O
/	O
h	O
,	O
and	O
the	O
apparent	O
mean	O
volume	O
of	O
distribution	O
was	O
540	O
L	O
.	O

CONCLUSION	O
:	O
These	O
results	O
indicate	O
that	O
3beta	O
-	O
acetyl	O
-	O
7	O
-	O
oxo	O
-	O
DHEA	O
is	O
safe	O
and	O
well	O
tolerated	O
in	O
normal	O
healthy	O
men	O
at	O
doses	O
up	O
to	O
200	O
mg	O
/	O
d	O
for	O
4	O
weeks	O
.	O

Aureusidin	B-Protein
synthase	I-Protein
:	O
a	O
polyphenol	O
oxidase	O
homolog	O
responsible	O
for	O
flower	O
coloration	O
.	O

Aurones	O
are	O
plant	O
flavonoids	O
that	O
provide	O
yellow	O
color	O
to	O
the	O
flowers	O
of	O
some	O
popular	O
ornamental	O
plants	O
,	O
such	O
as	O
snapdragon	O
and	O
cosmos	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
an	O
enzyme	O
responsible	O
for	O
the	O
synthesis	O
of	O
aurone	O
from	O
chalcones	O
in	O
the	O
yellow	O
snapdragon	O
flower	O
.	O

The	O
enzyme	O
(	O
aureusidin	B-Protein
synthase	I-Protein
)	O
is	O
a	O
39	O
-	O
kilodalton	O
,	O
copper	O
-	O
containing	O
glycoprotein	O
catalyzing	O
the	O
hydroxylation	O
and	O
/	O
or	O
oxidative	O
cyclization	O
of	O
the	O
precursor	O
chalcones	O
,	O
2	O
'	O
,	O
4	O
'	O
,	O
6	O
'	O
,	O
4	O
-	O
tetrahydroxychalcone	O
and	O
2	O
'	O
,	O
4	O
'	O
,	O
6	O
'	O
,	O
3	O
,	O
4	O
-	O
pentahydroxychalcone	O
.	O

The	O
complementary	O
DNA	O
encoding	O
aureusidin	B-Protein
synthase	I-Protein
is	O
expressed	O
in	O
the	O
petals	O
of	O
aurone	O
-	O
containing	O
varieties	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
that	O
aureusidin	B-Protein
synthase	I-Protein
belongs	O
to	O
the	O
plant	O
polyphenol	O
oxidase	O
family	O
,	O
providing	O
an	O
unequivocal	O
example	O
of	O
the	O
function	O
of	O
the	O
polyphenol	O
oxidase	O
homolog	O
in	O
plants	O
,	O
i	O
.	O
e	O
.	O
,	O
flower	O
coloration	O
.	O

E	B-Protein
-	I-Protein
cadherin	I-Protein
expression	O
is	O
silenced	O
by	O
5	O
'	O
CpG	O
island	O
methylation	O
in	O
acute	O
leukemia	O
.	O

E	B-Protein
-	I-Protein
Cadherin	I-Protein
is	O
a	O
transmembrane	O
glycoprotein	O
that	O
mediates	O
Ca2	O
+	O
-	O
dependent	O
intercellular	O
adhesion	O
in	O
normal	O
epithelium	O
.	O

In	O
tumors	O
of	O
epithelial	O
origin	O
,	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
expression	O
frequently	O
is	O
reduced	O
,	O
an	O
event	O
that	O
contributes	O
to	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

The	O
role	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
in	O
hematopoietic	O
tissues	O
is	O
less	O
clear	O
.	O

In	O
normal	O
bone	O
marrow	O
,	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
is	O
expressed	O
on	O
erythroid	O
progenitors	O
,	O
CD34	B-Protein
+	O
stem	O
cells	O
,	O
and	O
stromal	O
cells	O
,	O
where	O
it	O
likely	O
contributes	O
to	O
intercellular	O
interactions	O
during	O
hematopoiesis	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
nested	O
-	O
PCR	O
approach	O
to	O
examine	O
the	O
methylation	O
status	O
of	O
the	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
5	O
'	O
CpG	O
island	O
in	O
blood	O
and	O
bone	O
marrow	O
samples	O
from	O
normal	O
donors	O
and	O
in	O
bone	O
marrow	O
from	O
patients	O
with	O
acute	O
leukemia	O
.	O

In	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
bone	O
marrow	O
,	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
was	O
completely	O
unmethylated	O
.	O

In	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
expression	O
was	O
evident	O
by	O
reverse	O
transcription	O
-	O
PCR	O
.	O

Immunoblotting	O
confirmed	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
protein	O
expression	O
in	O
two	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
normal	O
donors	O
.	O

In	O
contrast	O
,	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
was	O
aberrantly	O
methylated	O
in	O
4	O
of	O
4	O
(	O
100	O
%	O
)	O
leukemia	O
cell	O
lines	O
,	O
14	O
of	O
44	O
(	O
32	O
%	O
)	O
acute	O
myelogenous	O
leukemias	O
,	O
and	O
18	O
of	O
33	O
(	O
53	O
%	O
)	O
acute	O
lymphoblastic	O
leukemias	O
.	O

Genomic	O
bisulfite	O
sequencing	O
of	O
primary	O
leukemias	O
confirmed	O
dense	O
methylation	O
across	O
the	O
CpG	O
island	O
.	O

Methylation	O
was	O
associated	O
with	O
loss	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
RNA	O
and	O
protein	O
in	O
leukemia	O
cell	O
lines	O
and	O
primary	O
leukemias	O
.	O

Following	O
treatment	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
,	O
a	O
methylated	O
leukemia	O
cell	O
line	O
expressed	O
both	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
transcript	O
and	O
protein	O
.	O

Our	O
results	O
show	O
that	O
methylation	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
occurs	O
commonly	O
in	O
acute	O
leukemia	O
and	O
suggests	O
a	O
hypothesis	O
for	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
down	O
-	O
regulation	O
in	O
leukemogenesis	O
.	O

Defect	O
in	O
N	O
-	O
glycosylation	O
of	O
proteins	O
is	O
tissue	O
-	O
dependent	O
in	O
congenital	O
disorders	O
of	O
glycosylation	O
Ia	O
.	O

The	O
biochemical	O
hallmark	O
of	O
Congenital	O
Disorders	O
of	O
Glycosylation	O
(	O
CDG	O
)	O
including	O
type	O
Ia	O
is	O
a	O
defective	O
N	O
-	O
glycosylation	O
of	O
serum	O
glycoproteins	O
.	O

Hypoglycosylated	O
forms	O
of	O
alpha1	B-Protein
-	I-Protein
antitrypsin	I-Protein
have	O
been	O
detected	O
by	O
Western	O
blot	O
in	O
serum	O
from	O
CDG	O
Ia	O
patients	O
.	O

In	O
contrast	O
we	O
were	O
not	O
able	O
to	O
detect	O
hypoglycosylation	O
in	O
alpha1	B-Protein
-	I-Protein
antitrypsin	I-Protein
synthesized	O
by	O
fibroblasts	O
,	O
keratinocytes	O
,	O
enterocytes	O
,	O
and	O
leukocytes	O
.	O

Similarly	O
no	O
hypoglycosylation	O
was	O
detectable	O
in	O
a	O
membrane	O
-	O
associated	O
N	O
-	O
linked	O
glycoprotein	O
,	O
the	O
facilitative	O
glucose	O
transporter	O
GLUT	B-Protein
-	I-Protein
1	I-Protein
and	O
also	O
in	O
serum	O
immunoglobulin	O
G	O
isolated	O
from	O
sera	O
of	O
CDG	O
Ia	O
patients	O
.	O

We	O
conclude	O
that	O
the	O
phenotypic	O
expression	O
of	O
CDG	O
Ia	O
is	O
tissue	O
-	O
dependent	O
.	O

Molecular	O
cloning	O
and	O
characterization	O
of	O
CHM1L	B-Protein
,	O
a	O
novel	O
membrane	O
molecule	O
similar	O
to	O
chondromodulin	B-Protein
-	I-Protein
I	I-Protein
.	O

Chondromodulin	B-Protein
-	I-Protein
I	I-Protein
(	O
ChM	B-Protein
-	I-Protein
I	I-Protein
)	O
is	O
a	O
cartilage	O
-	O
specific	O
glycoprotein	O
that	O
stimulates	O
the	O
growth	O
of	O
chondrocytes	O
and	O
inhibits	O
the	O
tube	O
formation	O
of	O
endothelial	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
a	O
novel	O
ChM	B-Protein
-	I-Protein
I	I-Protein
like	O
molecule	O
,	O
designated	O
ChM1L	B-Protein
.	O

Cloning	O
of	O
full	O
length	O
cDNAs	O
of	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
ChM1L	B-Protein
revealed	O
that	O
ChM1L	B-Protein
encodes	O
317	O
amino	O
acids	O
novel	O
type	O
II	O
transmembrane	O
protein	O
.	O

ChM1L	B-Protein
protein	O
was	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
N	O
-	O
glycosylated	O
and	O
non	O
-	O
N	O
-	O
glycosylated	O
protein	O
with	O
molecular	O
mass	O
of	O
45	O
and	O
40	O
kDa	O
,	O
respectively	O
.	O

In	O
adult	O
mouse	O
tissues	O
,	O
ChM1L	B-Protein
mRNA	O
was	O
highly	O
expressed	O
in	O
eye	O
,	O
skeletal	O
muscle	O
,	O
and	O
whole	O
rib	O
.	O

The	O
temporal	O
pattern	O
of	O
ChM1L	B-Protein
mRNA	O
was	O
examined	O
using	O
whole	O
embryo	O
at	O
day	O
10	O
to	O
19	O
of	O
gestation	O
.	O

After	O
day	O
11	O
,	O
ChM1L	B-Protein
mRNA	O
was	O
detected	O
and	O
its	O
level	O
was	O
progressively	O
elevated	O
in	O
association	O
with	O
development	O
of	O
mouse	O
embryo	O
.	O

These	O
data	O
suggest	O
that	O
ChM1L	B-Protein
is	O
a	O
novel	O
membrane	O
molecule	O
which	O
is	O
similar	O
to	O
ChM	B-Protein
-	I-Protein
I	I-Protein
that	O
plays	O
a	O
regulatory	O
role	O
in	O
eye	O
,	O
skeletal	O
muscle	O
,	O
and	O
development	O
of	O
embryo	O
.	O

Targeting	O
of	O
calsequestrin	O
to	O
the	O
sarcoplasmic	O
reticulum	O
of	O
skeletal	O
muscle	O
upon	O
deletion	O
of	O
its	O
glycosylation	O
site	O
.	O

The	O
glycoprotein	O
calsequestrin	O
(	O
CS	O
)	O
is	O
segregated	O
to	O
the	O
junctional	O
sarcoplasmic	O
reticulum	O
(	O
jSR	O
)	O
and	O
is	O
responsible	O
for	O
intraluminal	O
Ca	O
(	O
2	O
+	O
)	O
binding	O
.	O

A	O
chimeric	O
CS	O
-	O
hemoagglutinin	B-Protein
1	I-Protein
(	O
HA1	B-Protein
)	O
,	O
obtained	O
by	O
adding	O
the	O
nine	O
amino	O
acid	O
viral	O
epitope	O
hemoagglutinin	B-Protein
to	O
the	O
carboxy	O
terminal	O
of	O
CS	O
and	O
shown	O
to	O
be	O
correctly	O
segregated	O
to	O
skeletal	O
muscle	O
jSR	O
[	O
A	O
.	O
Nori	O
,	O
K	O
.	O
A	O
.	O
Nadalini	O
,	O
A	O
.	O
Martini	O
,	O
R	O
.	O
Rizzuto	O
,	O
A	O
.	O
Villa	O
,	O
and	O
P	O
.	O
Volpe	O
(	O
1997	O
)	O
.	O
Chimeric	O
calsequestrin	O
and	O
its	O
targeting	O
to	O
the	O
junctional	O
sarcoplasmic	O
reticulum	O
of	O
skeletal	O
muscle	O
.	O
Am	O
.	O
J	O
.	O
Physiol	O
.	O
272	O
,	O
C1420	O
-	O
C1428	O
]	O
lends	O
itself	O
as	O
a	O
molecular	O
tool	O
to	O
investigate	O
the	O
targeting	O
domains	O
of	O
CS	O
.	O

A	O
putative	O
targeting	O
mechanism	O
of	O
CS	O
to	O
jSR	O
implies	O
glycosylation	O
-	O
dependent	O
steps	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
Golgi	O
complex	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
CS	O
-	O
HA1DeltaGly	B-Protein
,	O
a	O
mutant	O
in	O
which	O
the	O
unique	O
N	O
-	O
glycosylation	O
site	O
Asn316	O
was	O
changed	O
to	O
Ile	O
,	O
was	O
engineered	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

The	O
mutant	O
cDNA	O
was	O
transiently	O
transfected	O
in	O
either	O
HeLa	O
cells	O
,	O
myoblasts	O
of	O
rat	O
skeletal	O
muscle	O
primary	O
cultures	O
,	O
or	O
regenerating	O
soleus	O
muscle	O
fibers	O
of	O
adult	O
rats	O
.	O

The	O
expression	O
and	O
intracellular	O
localization	O
of	O
CS	O
-	O
HA1DeltaGly	B-Protein
was	O
studied	O
by	O
double	O
-	O
labeling	O
epifluorescence	O
by	O
means	O
of	O
antibodies	O
against	O
either	O
CS	O
,	O
HA1	B-Protein
,	O
or	O
the	O
ryanodine	O
receptor	O
calcium	O
release	O
channel	O
.	O

CS	O
-	O
HA1DeltaGly	B-Protein
was	O
expressed	O
and	O
retained	O
to	O
ER	O
and	O
ER	O
/	O
sarcoplasmic	O
reticulum	O
of	O
HeLa	O
cells	O
and	O
myotubes	O
,	O
respectively	O
,	O
and	O
expressed	O
,	O
sorted	O
,	O
and	O
correctly	O
segregated	O
to	O
jSR	O
of	O
regenerating	O
soleus	O
muscle	O
fibers	O
.	O

Thus	O
,	O
the	O
targeting	O
mechanism	O
of	O
CS	O
in	O
vivo	O
appears	O
not	O
to	O
be	O
affected	O
by	O
glycosylation	O
-	O
that	O
is	O
,	O
the	O
sorting	O
,	O
docking	O
,	O
and	O
segregation	O
of	O
CS	O
are	O
independent	O
of	O
cotranslational	O
and	O
posttranslational	O
glycosylation	O
or	O
glycosylations	O
.	O

Targeting	O
of	O
HIF	O
-	O
alpha	O
to	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
ubiquitylation	O
complex	O
by	O
O2	O
-	O
regulated	O
prolyl	O
hydroxylation	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
a	O
transcriptional	O
complex	O
that	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
oxygen	O
.	O

In	O
oxygenated	O
and	O
iron	O
replete	O
cells	O
,	O
HIF	O
-	O
alpha	O
subunits	O
are	O
rapidly	O
destroyed	O
by	O
a	O
mechanism	O
that	O
involves	O
ubiquitylation	O
by	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	I-Protein
(	O
pVHL	B-Protein
)	O
E3	O
ligase	O
complex	O
.	O

This	O
process	O
is	O
suppressed	O
by	O
hypoxia	O
and	O
iron	O
chelation	O
,	O
allowing	O
transcriptional	O
activation	O
.	O

Here	O
we	O
show	O
that	O
the	O
interaction	O
between	O
human	O
pVHL	B-Protein
and	O
a	O
specific	O
domain	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
subunit	O
is	O
regulated	O
through	O
hydroxylation	O
of	O
a	O
proline	O
residue	O
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
P564	O
)	O
by	O
an	O
enzyme	O
we	O
have	O
termed	O
HIF	O
-	O
alpha	O
prolyl	O
-	O
hydroxylase	O
(	O
HIF	O
-	O
PH	O
)	O
.	O

An	O
absolute	O
requirement	O
for	O
dioxygen	O
as	O
a	O
cosubstrate	O
and	O
iron	O
as	O
cofactor	O
suggests	O
that	O
HIF	O
-	O
PH	O
functions	O
directly	O
as	O
a	O
cellular	O
oxygen	O
sensor	O
.	O

HIFalpha	O
targeted	O
for	O
VHL	B-Protein
-	O
mediated	O
destruction	O
by	O
proline	O
hydroxylation	O
:	O
implications	O
for	O
O2	O
sensing	O
.	O

HIF	O
(	O
hypoxia	O
-	O
inducible	O
factor	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
plays	O
a	O
pivotal	O
role	O
in	O
cellular	O
adaptation	O
to	O
changes	O
in	O
oxygen	O
availability	O
.	O

In	O
the	O
presence	O
of	O
oxygen	O
,	O
HIF	O
is	O
targeted	O
for	O
destruction	O
by	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
containing	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	I-Protein
protein	O
(	O
pVHL	B-Protein
)	O
.	O

We	O
found	O
that	O
human	O
pVHL	B-Protein
binds	O
to	O
a	O
short	O
HIF	O
-	O
derived	O
peptide	O
when	O
a	O
conserved	O
proline	O
residue	O
at	O
the	O
core	O
of	O
this	O
peptide	O
is	O
hydroxylated	O
.	O

Because	O
proline	O
hydroxylation	O
requires	O
molecular	O
oxygen	O
and	O
Fe	O
(	O
2	O
+	O
)	O
,	O
this	O
protein	O
modification	O
may	O
play	O
a	O
key	O
role	O
in	O
mammalian	O
oxygen	O
sensing	O
.	O

Genetic	O
and	O
clinical	O
features	O
of	O
human	O
pancreatic	O
ductal	O
adenocarcinomas	O
with	O
widespread	O
microsatellite	O
instability	O
.	O

The	O
incidences	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
underlying	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
defects	O
in	O
pancreatic	O
carcinogenesis	O
have	O
not	O
been	O
well	O
established	O
.	O

We	O
analyzed	O
100	O
sporadic	O
and	O
3	O
hereditary	O
pancreatic	O
ductal	O
adenocarcinomas	O
for	O
MSI	O
,	O
and	O
high	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
H	O
)	O
and	O
low	O
-	O
frequency	O
MSI	O
(	O
MSI	O
-	O
L	O
)	O
tumors	O
were	O
further	O
analyzed	O
for	O
frameshift	O
mutations	O
of	O
possible	O
target	O
genes	O
and	O
for	O
promoter	O
methylation	O
and	O
mutation	O
of	O
DNA	O
MMR	O
genes	O
,	O
including	O
hMLH1	B-Protein
,	O
hMSH2	B-Protein
,	O
hMSH3	B-Protein
,	O
and	O
hMSH6	B-Protein
genes	O
.	O

Among	O
the	O
100	O
sporadic	O
tumors	O
,	O
13	O
(	O
13	O
%	O
)	O
were	O
MSI	O
-	O
H	O
,	O
13	O
(	O
13	O
%	O
)	O
were	O
MSI	O
-	O
L	O
,	O
and	O
74	O
(	O
74	O
%	O
)	O
were	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
tumors	O
.	O

All	O
of	O
the	O
three	O
hereditary	O
tumors	O
from	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
patients	O
were	O
MSI	O
-	O
H	O
.	O

MSI	O
-	O
H	O
tumors	O
were	O
significantly	O
associated	O
with	O
poor	O
differentiation	O
and	O
the	O
presence	O
of	O
wild	O
-	O
type	O
K	B-Protein
-	I-Protein
RAS	I-Protein
and	O
p53	B-Protein
genes	O
.	O

Patients	O
with	O
MSI	O
-	O
H	O
tumors	O
had	O
a	O
significantly	O
longer	O
overall	O
survival	O
time	O
than	O
did	O
those	O
with	O
MSI	O
-	O
L	O
or	O
MSS	O
tumors	O
(	O
P	O
=	O
0	O
.	O
0057	O
)	O
.	O

Frameshift	O
mutations	O
of	O
hMSH3	B-Protein
,	O
hMLH3	B-Protein
,	O
BRCA	B-Protein
-	I-Protein
2	I-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
type	I-Protein
II	I-Protein
receptor	I-Protein
,	O
and	O
BAX	B-Protein
genes	O
were	O
detected	O
in	O
MSI	O
-	O
H	O
tumors	O
.	O

Hypermethylation	O
of	O
the	O
hMLH1	B-Protein
promoter	O
was	O
observed	O
in	O
6	O
(	O
46	O
%	O
)	O
of	O
the	O
13	O
sporadic	O
MSI	O
-	O
H	O
tumors	O
but	O
not	O
in	O
any	O
of	O
the	O
3	O
hereditary	O
MSI	O
-	O
H	O
tumors	O
or	O
13	O
MSI	O
-	O
L	O
tumors	O
.	O

All	O
of	O
the	O
3	O
HNPCC	O
cases	O
had	O
germ	O
-	O
line	O
hMLH1	B-Protein
mutation	O
accompanied	O
by	O
loss	O
of	O
heterogeneity	O
or	O
other	O
mutation	O
in	O
the	O
tumor	O
.	O

Our	O
results	O
suggest	O
that	O
pancreatic	O
carcinomas	O
with	O
MSI	O
-	O
H	O
represent	O
a	O
distinctive	O
oncogenic	O
pathway	O
because	O
they	O
exhibit	O
peculiar	O
clinical	O
,	O
pathological	O
,	O
and	O
molecular	O
characteristics	O
.	O

Our	O
results	O
also	O
suggest	O
the	O
principal	O
involvement	O
of	O
epigenetic	O
or	O
genetic	O
inactivation	O
of	O
the	O
hMLH1	B-Protein
gene	O
in	O
the	O
pathogenesis	O
of	O
pancreatic	O
carcinoma	O
with	O
MSI	O
-	O
H	O
.	O

The	O
acetylation	O
state	O
of	O
human	O
fetal	O
hemoglobin	O
modulates	O
the	O
strength	O
of	O
its	O
subunit	O
interactions	O
:	O
long	O
-	O
range	O
effects	O
and	O
implications	O
for	O
histone	B-Protein
interactions	O
in	O
the	O
nucleosome	O
.	O

The	O
source	O
of	O
the	O
70	O
-	O
fold	O
increased	O
tetramer	O
strength	O
of	O
liganded	O
fetal	O
hemoglobin	O
relative	O
to	O
that	O
of	O
adult	O
hemoglobin	O
between	O
pH	O
6	O
.	O
0	O
and	O
7	O
.	O
5	O
reported	O
earlier	O
[	O
Dumoulin	O
et	O
al	O
.	O
(	O
1997	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
272	O
,	O
31326	O
]	O
has	O
been	O
identified	O
as	O
the	O
N	O
-	O
terminal	O
Gly	O
residue	O
of	O
the	O
gamma	O
-	O
chain	O
,	O
which	O
is	O
replaced	O
by	O
Val	O
in	O
adult	O
hemoglobin	O
.	O

This	O
was	O
revealed	O
by	O
extending	O
the	O
study	O
of	O
the	O
pH	O
dependence	O
of	O
the	O
tetramer	O
-	O
dimer	O
equilibrium	O
of	O
these	O
hemoglobins	O
into	O
the	O
alkaline	O
range	O
as	O
far	O
as	O
pH	O
9	O
.	O

From	O
pH	O
7	O
.	O
5	O
to	O
9	O
.	O
0	O
,	O
the	O
70	O
-	O
fold	O
difference	O
in	O
the	O
association	O
equilibrium	O
constant	O
between	O
hemoglobins	O
F	O
and	O
A	O
lessened	O
progressively	O
.	O

This	O
behavior	O
was	O
attributed	O
to	O
the	O
difference	O
in	O
the	O
pK	O
(	O
a	O
)	O
8	O
.	O
1	O
of	O
Gly	O
-	O
1	O
(	O
gamma	O
)	O
compared	O
to	O
the	O
pK	O
(	O
a	O
)	O
7	O
.	O
1	O
value	O
of	O
Val	O
-	O
1	O
(	O
beta	O
)	O
of	O
hemoglobins	O
F	O
and	O
A	O
,	O
respectively	O
.	O

Evidence	O
for	O
this	O
conclusion	O
was	O
obtained	O
by	O
demonstrating	O
that	O
natural	O
hemoglobin	O
F	O
(	O
1	O
)	O
,	O
which	O
is	O
specifically	O
acetylated	O
at	O
Gly	O
-	O
1	O
(	O
gamma	O
)	O
and	O
hence	O
unable	O
to	O
be	O
protonated	O
,	O
behaves	O
like	O
HbA	O
and	O
not	O
HbF	O
in	O
its	O
tetramer	O
-	O
dimer	O
association	O
properties	O
over	O
the	O
pH	O
range	O
studied	O
.	O

An	O
increased	O
degree	O
of	O
protonation	O
of	O
the	O
gamma	O
-	O
chain	O
N	O
-	O
terminus	O
of	O
hemoglobin	O
F	O
from	O
pH	O
9	O
.	O
0	O
to	O
8	O
.	O
0	O
is	O
therefore	O
suggested	O
as	O
responsible	O
for	O
its	O
increased	O
tetramer	O
strength	O
representing	O
an	O
example	O
of	O
transmission	O
of	O
a	O
signal	O
from	O
its	O
positively	O
charged	O
N	O
-	O
terminal	O
tail	O
to	O
the	O
distant	O
subunit	O
allosteric	O
interface	O
where	O
the	O
equilibrium	O
constant	O
is	O
measured	O
.	O

An	O
analogy	O
is	O
made	O
between	O
the	O
effects	O
of	O
acetylation	O
of	O
the	O
fetal	O
hemoglobin	O
tetramer	O
on	O
the	O
strength	O
of	O
its	O
subunit	O
interactions	O
and	O
acetylation	O
of	O
some	O
internal	O
Lys	O
residues	O
within	O
the	O
N	O
-	O
terminal	O
segments	O
of	O
the	O
histone	O
octamer	O
around	O
which	O
DNA	O
is	O
wrapped	O
in	O
the	O
nucleosome	O
.	O

Synergism	O
of	O
Xist	B-Protein
RNA	O
,	O
DNA	O
methylation	O
,	O
and	O
histone	B-Protein
hypoacetylation	O
in	O
maintaining	O
X	O
chromosome	O
inactivation	O
.	O

Xist	B-Protein
RNA	O
expression	O
,	O
methylation	O
of	O
CpG	O
islands	O
,	O
and	O
hypoacetylation	O
of	O
histone	B-Protein
H4	I-Protein
are	O
distinguishing	O
features	O
of	O
inactive	O
X	O
chromatin	O
.	O

Here	O
,	O
we	O
show	O
that	O
these	O
silencing	O
mechanisms	O
act	O
synergistically	O
to	O
maintain	O
the	O
inactive	O
state	O
.	O

Xist	B-Protein
RNA	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
initiation	O
of	O
X	O
inactivation	O
,	O
but	O
not	O
required	O
for	O
maintenance	O
.	O

We	O
have	O
developed	O
a	O
system	O
in	O
which	O
the	O
reactivation	O
frequency	O
of	O
individual	O
X	O
-	O
linked	O
genes	O
can	O
be	O
assessed	O
quantitatively	O
.	O

Using	O
a	O
conditional	O
mutant	O
Xist	B-Protein
allele	O
,	O
we	O
provide	O
direct	O
evidence	O
for	O
that	O
loss	O
of	O
Xist	B-Protein
RNA	O
destabilizes	O
the	O
inactive	O
state	O
in	O
somatic	O
cells	O
,	O
leading	O
to	O
an	O
increased	O
reactivation	O
frequency	O
of	O
an	O
X	O
-	O
linked	O
GFP	B-Protein
transgene	O
and	O
of	O
the	O
endogenous	O
hypoxanthine	B-Protein
phosphoribosyl	I-Protein
transferase	I-Protein
(	O
Hprt	B-Protein
)	O
gene	O
in	O
mouse	O
embryonic	O
fibroblasts	O
.	O

Demethylation	O
of	O
DNA	O
,	O
using	O
5	O
-	O
azadC	O
or	O
by	O
introducing	O
a	O
mutation	O
in	O
Dnmt1	B-Protein
,	O
and	O
inhibition	O
of	O
histone	B-Protein
hypoacetylation	O
using	O
trichostatin	O
A	O
further	O
increases	O
reactivation	O
in	O
Xist	B-Protein
mutant	O
fibroblasts	O
,	O
indicating	O
a	O
synergistic	O
interaction	O
of	O
X	O
chromosome	O
silencing	O
mechanisms	O
.	O

Expression	O
of	O
Pichia	O
anomala	O
INV1	B-Protein
gene	O
in	O
Saccharomyces	O
cerevisiae	O
results	O
in	O
two	O
different	O
active	O
forms	O
of	O
hypoglycosylated	O
invertase	B-Protein
.	O

The	O
Pichia	O
anomala	O
invertase	B-Protein
gene	O
(	O
INV1	B-Protein
)	O
was	O
introduced	O
at	O
different	O
copy	O
numbers	O
into	O
a	O
sucrose	O
-	O
nonfermenting	O
mutant	O
of	O
Saccharomyces	O
cerevisiae	O
and	O
expressed	O
from	O
its	O
own	O
promoter	O
sequences	O
.	O

The	O
level	O
reached	O
in	O
the	O
production	O
of	O
invertase	B-Protein
by	O
the	O
transformants	O
(	O
up	O
to	O
540	O
units	O
/	O
10	O
(	O
10	O
)	O
cells	O
)	O
was	O
in	O
agreement	O
with	O
the	O
INV1	B-Protein
gene	O
dosage	O
.	O

Two	O
forms	O
of	O
multimeric	O
active	O
and	O
glycosylated	O
invertase	B-Protein
displaying	O
different	O
subcellular	O
locations	O
and	O
molecular	O
masses	O
could	O
be	O
detected	O
in	O
the	O
transformants	O
.	O

One	O
was	O
found	O
to	O
be	O
present	O
in	O
the	O
culture	O
medium	O
and	O
in	O
the	O
periplasm	O
,	O
and	O
the	O
other	O
could	O
only	O
be	O
detected	O
inside	O
the	O
cell	O
.	O

Each	O
of	O
the	O
two	O
heterologous	O
forms	O
of	O
invertase	B-Protein
was	O
shown	O
to	O
be	O
an	O
oligomer	O
composed	O
of	O
identical	O
subunits	O
.	O

The	O
difference	O
found	O
in	O
the	O
apparent	O
molecular	O
masses	O
of	O
their	O
monomers	O
(	O
81	O
.	O
5	O
and	O
78	O
.	O
3	O
kDa	O
,	O
respectively	O
)	O
seems	O
to	O
be	O
due	O
to	O
the	O
size	O
of	O
their	O
N	O
-	O
linked	O
oligosaccharide	O
chains	O
(	O
on	O
average	O
2	O
.	O
4	O
and	O
1	O
.	O
9	O
kDa	O
,	O
respectively	O
)	O
,	O
since	O
the	O
number	O
of	O
sugar	O
chains	O
(	O
9	O
)	O
and	O
the	O
molecular	O
mass	O
of	O
the	O
protein	O
moiety	O
(	O
60	O
.	O
5	O
kDa	O
)	O
are	O
identical	O
in	O
both	O
forms	O
.	O

The	O
shorter	O
size	O
of	O
their	O
oligosaccharides	O
must	O
also	O
be	O
the	O
reason	O
for	O
the	O
lower	O
apparent	O
molecular	O
masses	O
of	O
the	O
heterologous	O
invertases	O
when	O
compared	O
with	O
the	O
enzyme	O
purified	O
from	O
P	O
.	O
anomala	O
.	O

The	O
hypoglycosylated	O
invertase	B-Protein
accumulated	O
within	O
the	O
cells	O
of	O
the	O
transformants	O
to	O
an	O
unusual	O
level	O
(	O
up	O
to	O
130	O
units	O
/	O
10	O
(	O
10	O
)	O
cells	O
)	O
.	O

Such	O
accumulation	O
of	O
active	O
enzyme	O
inside	O
the	O
cells	O
,	O
as	O
well	O
as	O
its	O
underglycosylation	O
,	O
could	O
be	O
due	O
to	O
intrinsic	O
properties	O
of	O
the	O
P	O
.	O
anomala	O
invertase	B-Protein
that	O
are	O
determined	O
by	O
the	O
particular	O
primary	O
structure	O
of	O
its	O
protein	O
moiety	O
.	O

The	O
histone	B-Protein
acetyltransferase	O
,	O
hGCN5	B-Protein
,	O
interacts	O
with	O
and	O
acetylates	O
the	O
HIV	O
transactivator	O
,	O
Tat	B-Protein
.	O

Factor	O
acetyltransferase	O
activity	O
associated	O
with	O
several	O
histone	B-Protein
acetyltransferases	O
plays	O
a	O
key	O
role	O
in	O
the	O
control	O
of	O
transcription	O
.	O

Here	O
we	O
report	O
that	O
hGCN5	B-Protein
,	O
a	O
well	O
known	O
histone	B-Protein
acetyltransferase	O
,	O
specifically	O
interacts	O
with	O
and	O
acetylates	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
transactivator	O
protein	O
,	O
Tat	B-Protein
.	O

The	O
interaction	O
between	O
Tat	B-Protein
and	O
hGCN5	B-Protein
is	O
direct	O
and	O
involves	O
the	O
acetyltransferase	O
and	O
the	O
bromodomain	O
regions	O
of	O
hGCN5	B-Protein
,	O
as	O
well	O
as	O
a	O
limited	O
region	O
of	O
Tat	B-Protein
encompassing	O
the	O
cysteine	O
-	O
rich	O
domain	O
of	O
the	O
protein	O
.	O

Tat	B-Protein
lysines	O
50	O
and	O
51	O
,	O
target	O
of	O
acetylation	O
by	O
p300	B-Protein
/	O
CBP	B-Protein
,	O
were	O
also	O
found	O
to	O
be	O
acetylated	O
by	O
hGCN5	B-Protein
.	O

The	O
acetylation	O
of	O
these	O
two	O
lysines	O
by	O
p300	B-Protein
/	O
CBP	B-Protein
has	O
been	O
recently	O
shown	O
to	O
stimulate	O
Tat	B-Protein
transcriptional	O
activity	O
and	O
accordingly	O
,	O
we	O
have	O
found	O
that	O
hGCN5	B-Protein
can	O
considerably	O
enhance	O
Tat	B-Protein
-	O
dependent	O
transcription	O
of	O
the	O
HIV	O
-	O
1	O
long	O
terminal	O
repeat	O
.	O

These	O
data	O
highlight	O
the	O
importance	O
of	O
the	O
acetylation	O
of	O
lysines	O
50	O
and	O
51	O
in	O
the	O
function	O
of	O
Tat	B-Protein
,	O
since	O
different	O
histone	B-Protein
acetyltransferases	O
involved	O
in	O
distinct	O
signaling	O
pathways	O
,	O
GCN5	B-Protein
and	O
p300	B-Protein
/	O
CBP	B-Protein
,	O
converge	O
to	O
acetylate	O
Tat	B-Protein
on	O
the	O
same	O
site	O
.	O

Hydroxylating	O
activity	O
of	O
frog	O
epidermis	O
tyrosinase	B-Protein
.	O

Trypsin	O
activated	O
in	O
a	O
similar	O
way	O
both	O
the	O
tyrosine	B-Protein
hydroxylase	I-Protein
and	O
the	O
dopa	O
-	O
oxidasa	O
activities	O
of	O
frog	O
epidermis	O
tyrosinase	B-Protein
.	O

Several	O
electron	O
donors	O
reduced	O
or	O
eliminated	O
the	O
lag	O
period	O
for	O
the	O
hydroxylating	O
enzyme	O
.	O

4	O
x	O
10	O
(	O
-	O
5	O
)	O
M	O
dopa	O
was	O
particularly	O
effective	O
,	O
but	O
without	O
affecting	O
the	O
stationary	O
activity	O
after	O
lag	O
period	O
.	O

Tyrosine	B-Protein
hydroxylase	I-Protein
had	O
KM	O
=	O
2	O
.	O
6	O
X	O
10	O
(	O
-	O
3	O
)	O
M	O
for	O
tyrosine	O
and	O
2	O
x	O
10	O
(	O
-	O
3	O
)	O
M	O
dopa	O
was	O
a	O
competitive	O
inhibitor	O
with	O
Ki	O
=	O
5	O
x	O
10	O
(	O
-	O
4	O
)	O
M	O
.	O

The	O
enzyme	O
was	O
inactivated	O
during	O
its	O
actuation	O
.	O

Data	O
on	O
thermal	O
denaturation	O
were	O
similar	O
to	O
other	O
obtained	O
from	O
dopa	O
oxidase	O
.	O

Our	O
results	O
tend	O
to	O
confirm	O
our	O
previous	O
hypothesis	O
that	O
the	O
activatory	O
process	O
of	O
the	O
enzyme	O
is	O
accompanied	O
by	O
a	O
spatial	O
unfolding	O
of	O
the	O
enzyme	O
molecule	O
.	O

Canine	O
COL1A2	B-Protein
mutation	O
resulting	O
in	O
C	O
-	O
terminal	O
truncation	O
of	O
pro	O
-	O
alpha2	O
(	O
I	O
)	O
and	O
severe	O
osteogenesis	O
imperfecta	O
.	O

RNA	O
and	O
type	O
I	O
collagen	O
were	O
analyzed	O
from	O
cultured	O
skin	O
fibroblasts	O
of	O
a	O
Beagle	O
puppy	O
with	O
fractures	O
consistent	O
with	O
type	O
III	O
osteogenesis	O
imperfecta	O
(	O
OI	O
)	O
.	O

In	O
a	O
nonisotopic	O
RNAse	O
cleavage	O
assay	O
(	O
NIRCA	O
)	O
,	O
the	O
proband	O
'	O
s	O
RNA	O
had	O
a	O
unique	O
cleavage	O
pattern	O
in	O
the	O
region	O
of	O
COL1A2	B-Protein
encoding	O
the	O
C	B-Protein
-	I-Protein
propeptide	I-Protein
.	O

DNA	O
sequence	O
analyses	O
identified	O
a	O
mutation	O
in	O
which	O
nucleotides	O
3991	O
-	O
3994	O
(	O
"	O
CTAG	O
"	O
)	O
were	O
replaced	O
with	O
"	O
TGTCATTGG	O
.	O
"	O
The	O
first	O
seven	O
bases	O
of	O
the	O
inserted	O
sequence	O
were	O
identical	O
to	O
nucleotides	O
4002	O
-	O
4008	O
of	O
the	O
normal	O
canine	O
COL1A2	B-Protein
sequence	O
.	O

The	O
resulting	O
frameshift	O
changed	O
30	O
amino	O
acids	O
and	O
introduced	O
a	O
premature	O
stop	O
codon	O
.	O

Reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
with	O
primers	O
flanking	O
the	O
mutation	O
site	O
amplified	O
two	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
fragments	O
for	O
the	O
proband	O
and	O
a	O
single	O
product	O
for	O
the	O
control	O
.	O

Restriction	O
enzyme	O
digestions	O
also	O
were	O
consistent	O
with	O
a	O
heterozygous	O
mutation	O
in	O
the	O
proband	O
.	O

Type	O
I	O
procollagen	O
labeled	O
with	O
[	O
3H	O
]	O
proline	O
was	O
analyzed	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
.	O

Increased	O
density	O
of	O
pC	B-Protein
-	I-Protein
alpha2	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
suggested	O
comigration	O
with	O
the	O
similarly	O
sized	O
pro	O
-	O
alpha2	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
derived	O
from	O
the	O
mutant	O
allele	O
.	O

Furthermore	O
,	O
a	O
-	O
chains	O
were	O
overhydroxylated	O
and	O
the	O
ratio	O
of	O
alpha1	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
:	O
alpha2	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
was	O
3	O
.	O
2	O
:	O
1	O
,	O
consistent	O
with	O
the	O
presence	O
of	O
alpha1	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
homotrimers	O
.	O

Analyses	O
of	O
COL1A2	B-Protein
and	O
type	O
I	O
collagen	O
were	O
both	O
consistent	O
with	O
the	O
described	O
heterozygous	O
mutation	O
affecting	O
the	O
pro	O
-	O
alpha2	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
C	O
-	O
propeptide	O
and	O
confirmed	O
a	O
diagnosis	O
of	O
OI	O
.	O

Linking	O
global	O
histone	B-Protein
acetylation	O
to	O
the	O
transcription	O
enhancement	O
of	O
X	O
-	O
chromosomal	O
genes	O
in	O
Drosophila	O
males	O
.	O

It	O
has	O
become	O
well	O
established	O
for	O
several	O
genes	O
that	O
targeting	O
of	O
histone	B-Protein
acetylation	O
to	O
promoters	O
is	O
required	O
for	O
the	O
activation	O
of	O
transcription	O
.	O

In	O
contrast	O
,	O
global	O
patterns	O
of	O
acetylation	O
have	O
not	O
been	O
ascribed	O
to	O
any	O
particular	O
regulatory	O
function	O
.	O

In	O
Drosophila	O
,	O
a	O
specific	O
modification	O
of	O
H4	B-Protein
,	O
acetylation	O
at	O
lysine	O
16	O
,	O
is	O
enriched	O
at	O
hundreds	O
of	O
sites	O
on	O
the	O
male	O
X	O
chromosome	O
due	O
to	O
the	O
activity	O
of	O
the	O
male	O
-	O
specific	O
lethal	O
(	O
MSL	O
)	O
dosage	O
compensation	O
complex	O
.	O

Utilizing	O
chromatin	O
immunoprecipitation	O
,	O
we	O
have	O
determined	O
that	O
H4Ac16	B-Protein
is	O
present	O
along	O
the	O
entire	O
length	O
of	O
X	O
-	O
linked	O
genes	O
targeted	O
by	O
the	O
MSL	O
complex	O
with	O
relatively	O
modest	O
levels	O
of	O
acetylation	O
at	O
the	O
promoter	O
regions	O
and	O
high	O
levels	O
in	O
the	O
middle	O
and	O
/	O
or	O
3	O
'	O
end	O
of	O
the	O
transcription	O
units	O
.	O

We	O
propose	O
that	O
global	O
acetylation	O
by	O
the	O
MSL	O
complex	O
increases	O
the	O
expression	O
of	O
X	O
-	O
linked	O
genes	O
by	O
facilitating	O
transcription	O
elongation	O
rather	O
than	O
by	O
enhancing	O
promoter	O
accessibility	O
.	O

We	O
have	O
also	O
determined	O
that	O
H4Ac16	B-Protein
is	O
absent	O
from	O
a	O
region	O
of	O
the	O
X	O
chromosome	O
that	O
includes	O
a	O
gene	O
known	O
to	O
be	O
dosage	O
-	O
compensated	O
by	O
a	O
MSL	O
-	O
independent	O
mechanism	O
.	O

This	O
study	O
represents	O
the	O
first	O
biochemical	O
interpretation	O
of	O
the	O
very	O
large	O
body	O
of	O
cytological	O
observations	O
on	O
the	O
chromosomal	O
distribution	O
of	O
the	O
MSL	O
complex	O
.	O

Correlation	O
between	O
histone	B-Protein
lysine	O
methylation	O
and	O
developmental	O
changes	O
at	O
the	O
chicken	O
beta	B-Protein
-	I-Protein
globin	I-Protein
locus	O
.	O

Methylation	O
of	O
histones	B-Protein
at	O
specific	O
residues	O
plays	O
an	O
important	O
role	O
in	O
transcriptional	O
regulation	O
.	O

Chromatin	O
immunoprecipitation	O
of	O
dimethylated	O
lysine	O
9	O
on	O
histone	B-Protein
H3	I-Protein
across	O
53	O
kilobases	O
of	O
the	O
chicken	O
beta	B-Protein
-	I-Protein
globin	I-Protein
locus	O
during	O
erythropoiesis	O
shows	O
an	O
almost	O
complete	O
anticorrelation	O
between	O
regions	O
of	O
elevated	O
lysine	O
9	O
methylation	O
and	O
acetylation	O
.	O

Lysine	O
9	O
is	O
methylated	O
most	O
over	O
constitutive	O
condensed	O
chromatin	O
and	O
developmentally	O
inactive	O
globin	O
genes	O
.	O

In	O
contrast	O
,	O
lysine	O
4	O
methylation	O
of	O
histone	B-Protein
H3	I-Protein
correlates	O
with	O
H3	B-Protein
acetylation	O
.	O

These	O
results	O
lead	O
us	O
to	O
propose	O
a	O
mechanism	O
by	O
which	O
the	O
insulator	O
in	O
the	O
beta	B-Protein
-	I-Protein
globin	I-Protein
locus	O
can	O
protect	O
the	O
globin	O
genes	O
from	O
being	O
silenced	O
by	O
adjacent	O
condensed	O
chromatin	O
.	O

Purification	O
and	O
characterization	O
of	O
a	O
soluble	O
bioactive	O
amino	O
-	O
terminal	O
extracellular	O
domain	O
of	O
the	O
human	O
thyrotropin	B-Protein
receptor	I-Protein
.	O

The	O
amino	O
-	O
terminal	O
ectodomain	O
of	O
the	O
human	O
TSH	B-Protein
receptor	I-Protein
has	O
been	O
expressed	O
at	O
the	O
surface	O
of	O
CHO	O
cells	O
as	O
a	O
glycosylphosphatidylinositol	O
-	O
anchored	O
molecule	O
containing	O
a	O
10	O
-	O
residue	O
histidine	O
tag	O
close	O
to	O
its	O
C	O
terminus	O
.	O

The	O
soluble	O
ectodomain	O
could	O
be	O
released	O
from	O
the	O
cells	O
by	O
treatment	O
with	O
a	O
glycosylphosphatidylinositol	B-Protein
-	I-Protein
phospholipase	I-Protein
C	I-Protein
and	O
purified	O
to	O
apparent	O
homogeneity	O
by	O
cobalt	O
-	O
Sepharose	O
chromatography	O
.	O

Two	O
nanomoles	O
of	O
material	O
was	O
obtained	O
,	O
which	O
was	O
suitable	O
for	O
analysis	O
by	O
mass	O
spectrometry	O
.	O

This	O
allowed	O
the	O
identification	O
of	O
four	O
out	O
of	O
the	O
six	O
potential	O
N	O
-	O
glycosylation	O
sites	O
as	O
being	O
effectively	O
glycosylated	O
.	O

A	O
proportion	O
of	O
the	O
purified	O
soluble	O
ectodomain	O
displayed	O
specific	O
binding	O
of	O
(	O
125	O
)	O
I	O
-	O
labeled	O
TSH	B-Protein
,	O
allowing	O
for	O
the	O
first	O
time	O
performance	O
of	O
classical	O
saturation	O
binding	O
experiments	O
.	O

Two	O
classes	O
of	O
high	O
-	O
affinity	O
binding	O
sites	O
were	O
identified	O
:	O
site	O
A	O
,	O
K	O
(	O
d	O
)	O
0	O
.	O
014	O
nM	O
;	O
site	O
B	O
,	O
K	O
(	O
d	O
)	O
0	O
.	O
83	O
nM	O
.	O

The	O
significance	O
of	O
site	O
A	O
,	O
whose	O
affinity	O
is	O
much	O
higher	O
than	O
for	O
the	O
holoreceptor	O
at	O
the	O
surface	O
of	O
intact	O
cells	O
,	O
remains	O
to	O
be	O
clarified	O
.	O

The	O
purified	O
ectodomain	O
was	O
capable	O
of	O
inhibiting	O
efficiently	O
the	O
thyroid	O
stimulating	O
activity	O
of	O
immunoglobulins	O
from	O
patients	O
with	O
Graves	O
'	O
disease	O
.	O

It	O
allowed	O
computation	O
of	O
the	O
amounts	O
of	O
these	O
immunoglobulins	O
in	O
patient	O
'	O
s	O
serum	O
,	O
giving	O
values	O
up	O
to	O
10	O
microg	O
/	O
mL	O
.	O

Contrary	O
to	O
all	O
currently	O
available	O
assays	O
,	O
the	O
soluble	O
ectodomain	O
of	O
the	O
TSH	B-Protein
receptor	I-Protein
purified	O
in	O
a	O
functionally	O
competent	O
conformation	O
allows	O
direct	O
studies	O
of	O
its	O
interactions	O
with	O
TSH	B-Protein
and	O
autoantibodies	O
and	O
opens	O
the	O
way	O
to	O
structural	O
studies	O
.	O

HIF	B-Protein
-	I-Protein
1alpha	I-Protein
binding	O
to	O
VHL	B-Protein
is	O
regulated	O
by	O
stimulus	O
-	O
sensitive	O
proline	O
hydroxylation	O
.	O

Hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
is	O
a	O
global	O
transcriptional	O
regulator	O
of	O
the	O
hypoxic	O
response	O
.	O

Under	O
normoxic	O
conditions	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
is	O
recognized	O
by	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
-	I-Protein
suppressor	I-Protein
protein	O
(	O
VHL	B-Protein
)	O
,	O
a	O
component	O
of	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
complex	O
.	O

This	O
interaction	O
thereby	O
promotes	O
the	O
rapid	O
degradation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

Under	O
hypoxic	O
conditions	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
is	O
stabilized	O
.	O

We	O
have	O
previously	O
shown	O
that	O
VHL	B-Protein
binds	O
in	O
a	O
hypoxia	O
-	O
sensitive	O
manner	O
to	O
a	O
27	O
-	O
aa	O
segment	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
and	O
that	O
this	O
regulation	O
depends	O
on	O
a	O
posttranslational	O
modification	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

Through	O
a	O
combination	O
of	O
in	O
vivo	O
coimmunoprecipitation	O
assays	O
using	O
VHL	B-Protein
and	O
a	O
panel	O
of	O
point	O
mutants	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
this	O
region	O
,	O
as	O
well	O
as	O
MS	O
and	O
in	O
vitro	O
binding	O
assays	O
,	O
we	O
now	O
provide	O
evidence	O
that	O
this	O
modification	O
,	O
which	O
occurs	O
under	O
normoxic	O
conditions	O
,	O
is	O
hydroxylation	O
of	O
Pro	O
-	O
564	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

The	O
data	O
furthermore	O
show	O
that	O
this	O
proline	O
hydroxylation	O
is	O
the	O
primary	O
regulator	O
of	O
VHL	B-Protein
binding	O
.	O

2B4	B-Protein
(	O
CD244	B-Protein
)	O
and	O
CS1	B-Protein
:	O
novel	O
members	O
of	O
the	O
CD2	B-Protein
subset	O
of	O
the	O
immunoglobulin	O
superfamily	O
molecules	O
expressed	O
on	O
natural	O
killer	O
cells	O
and	O
other	O
leukocytes	O
.	O

2B4	B-Protein
is	O
a	O
member	O
of	O
the	O
CD2	B-Protein
subset	O
of	O
the	O
immunoglobulin	O
superfamily	O
molecules	O
expressed	O
on	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
other	O
leukocytes	O
.	O

It	O
is	O
the	O
high	O
affinity	O
ligand	O
for	O
CD48	B-Protein
.	O

Engagement	O
of	O
2B4	B-Protein
on	O
NK	O
-	O
cell	O
surfaces	O
with	O
specific	O
antibodies	O
or	O
CD48	B-Protein
can	O
trigger	O
cell	O
-	O
mediated	O
cytotoxicity	O
,	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
secretion	O
,	O
phosphoinositol	O
turnover	O
and	O
NK	O
-	O
cell	O
invasiveness	O
.	O

The	O
function	O
of	O
2B4	B-Protein
in	O
CD8	B-Protein
+	I-Protein
T	O
cells	O
and	O
myeloid	O
cells	O
remains	O
unknown	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
2B4	B-Protein
contains	O
unique	O
tyrosine	O
motifs	O
(	O
TxYxxV	O
/	O
I	O
)	O
that	O
associate	O
with	O
src	O
homology	O
2	O
domain	O
-	O
containing	O
protein	O
or	O
signaling	B-Protein
lymphocyte	I-Protein
activation	I-Protein
molecule	I-Protein
(	I-Protein
SLAM	I-Protein
)	I-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
,	O
whose	O
mutation	O
is	O
the	O
underlying	O
genetic	O
defect	O
in	O
the	O
X	O
-	O
linked	O
lymphoproliferative	O
disease	O
(	O
XLPD	O
)	O
.	O

Impaired	O
signaling	O
via	O
2B4	B-Protein
and	O
SLAM	O
is	O
implicated	O
in	O
the	O
immunopathogenesis	O
of	O
XLPD	O
.	O

CS1	B-Protein
is	O
a	O
novel	O
member	O
of	O
the	O
CD2	B-Protein
subset	O
that	O
contains	O
two	O
of	O
the	O
unique	O
tyrosine	O
motifs	O
present	O
in	O
2B4	B-Protein
and	O
SLAM	O
.	O

Signaling	O
through	O
2B4	B-Protein
,	O
CS1	B-Protein
and	O
other	O
members	O
of	O
the	O
CD2	B-Protein
subset	O
may	O
play	O
a	O
major	O
role	O
in	O
the	O
regulation	O
of	O
NK	O
cells	O
and	O
other	O
leukocyte	O
functions	O
.	O

N	O
-	O
glycosylation	O
of	O
CRF	B-Protein
receptor	I-Protein
type	I-Protein
1	I-Protein
is	O
important	O
for	O
its	O
ligand	O
-	O
specific	O
interaction	O
.	O

The	O
corticotropin	B-Protein
-	I-Protein
releasing	I-Protein
factor	I-Protein
(	I-Protein
CRF	I-Protein
)	I-Protein
receptor	I-Protein
type	I-Protein
1	I-Protein
(	O
CRFR1	B-Protein
)	O
contains	O
five	O
potential	O
N	O
-	O
glycosylation	O
sites	O
:	O
N38	O
,	O
N45	O
,	O
N78	O
,	O
N90	O
,	O
and	O
N98	O
.	O

Cells	O
expressing	O
CRFR1	B-Protein
were	O
treated	O
with	O
tunicamycin	O
to	O
block	O
receptor	O
glycosylation	O
.	O

The	O
nonglycosylated	O
receptor	O
did	O
not	O
bind	O
the	O
radioligand	O
and	O
had	O
a	O
decreased	O
cAMP	O
stimulation	O
potency	O
in	O
response	O
to	O
CRF	B-Protein
.	O

To	O
determine	O
which	O
of	O
the	O
polysaccharide	O
chain	O
(	O
s	O
)	O
is	O
/	O
are	O
involved	O
in	O
ligand	O
interaction	O
,	O
the	O
polysaccharide	O
chains	O
were	O
deleted	O
using	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
glycosylation	O
consensus	O
,	O
N	O
-	O
X	O
-	O
S	O
/	O
T	O
.	O

Two	O
sets	O
of	O
mutations	O
were	O
performed	O
for	O
each	O
glycosylation	O
site	O
:	O
N	O
to	O
Q	O
and	O
S	O
/	O
T	O
to	O
A	O
,	O
respectively	O
.	O

The	O
single	O
mutants	O
Q38	O
,	O
Q45	O
,	O
Q78	O
,	O
Q90	O
,	O
Q98	O
,	O
A40	O
,	O
A47	O
,	O
A80	O
,	O
A92	O
,	O
and	O
A100	O
and	O
the	O
double	O
mutants	O
A40	O
/	O
A47	O
and	O
A80	O
/	O
A100	O
were	O
well	O
expressed	O
,	O
bound	O
CRF	B-Protein
,	O
sauvagine	B-Protein
(	O
SVG	B-Protein
)	O
,	O
and	O
urotensin	B-Protein
-	I-Protein
I	I-Protein
(	O
UTS	B-Protein
-	I-Protein
I	I-Protein
)	O
with	O
a	O
normal	O
affinity	O
,	O
and	O
increased	O
cAMP	O
accumulation	O
with	O
a	O
high	O
efficiency	O
.	O

In	O
contrast	O
,	O
the	O
combined	O
mutations	O
A80	O
/	O
A92	O
/	O
A100	O
,	O
A40	O
/	O
A80	O
/	O
A92	O
/	O
A100	O
,	O
and	O
A40	O
/	O
A47	O
/	O
A80	O
/	O
A92	O
/	O
A100	O
had	O
low	O
levels	O
of	O
expression	O
,	O
did	O
not	O
bind	O
the	O
radioligand	O
,	O
and	O
had	O
a	O
decreased	O
cAMP	O
stimulation	O
.	O

These	O
data	O
indicate	O
the	O
requirement	O
for	O
three	O
or	O
more	O
polysaccharide	O
chains	O
for	O
normal	O
CRFR1	B-Protein
function	O
.	O

Reduced	O
rates	O
of	O
gene	O
loss	O
,	O
gene	O
silencing	O
,	O
and	O
gene	O
mutation	O
in	O
Dnmt1	B-Protein
-	O
deficient	O
embryonic	O
stem	O
cells	O
.	O

Tumor	O
suppressor	O
gene	O
inactivation	O
is	O
a	O
crucial	O
event	O
in	O
oncogenesis	O
.	O

Gene	O
inactivation	O
mechanisms	O
include	O
events	O
resulting	O
in	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
,	O
gene	O
mutation	O
,	O
and	O
transcriptional	O
silencing	O
.	O

The	O
contribution	O
of	O
each	O
of	O
these	O
different	O
pathways	O
varies	O
among	O
tumor	O
suppressor	O
genes	O
and	O
by	O
cancer	O
type	O
.	O

The	O
factors	O
that	O
influence	O
the	O
relative	O
utilization	O
of	O
gene	O
inactivation	O
pathways	O
are	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
detailed	O
quantitative	O
analysis	O
of	O
the	O
three	O
major	O
gene	O
inactivation	O
mechanisms	O
for	O
a	O
model	O
gene	O
at	O
two	O
different	O
genomic	O
integration	O
sites	O
in	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
.	O

In	O
addition	O
,	O
we	O
targeted	O
the	O
major	O
DNA	O
methyltransferase	O
gene	O
,	O
Dnmt1	B-Protein
,	O
to	O
investigate	O
the	O
relative	O
contribution	O
of	O
DNA	O
methylation	O
to	O
these	O
various	O
competing	O
gene	O
inactivation	O
pathways	O
.	O

Our	O
data	O
show	O
that	O
gene	O
loss	O
is	O
the	O
predominant	O
mode	O
of	O
inactivation	O
of	O
a	O
herpes	O
simplex	O
virus	O
thymidine	B-Protein
kinase	I-Protein
neomycin	O
phosphotransferase	O
reporter	O
gene	O
(	O
HSV	O
-	O
TKNeo	O
)	O
at	O
the	O
two	O
integration	O
sites	O
tested	O
and	O
that	O
this	O
event	O
is	O
significantly	O
reduced	O
in	O
Dnmt1	B-Protein
-	O
deficient	O
cells	O
.	O

Gene	O
silencing	O
by	O
promoter	O
methylation	O
requires	O
Dnmt1	B-Protein
,	O
suggesting	O
that	O
the	O
expression	O
of	O
Dnmt3a	B-Protein
and	O
Dnmt3b	B-Protein
alone	O
in	O
ES	O
cells	O
is	O
insufficient	O
to	O
achieve	O
effective	O
gene	O
silencing	O
.	O

We	O
used	O
a	O
novel	O
assay	O
to	O
show	O
that	O
missense	O
mutation	O
rates	O
are	O
also	O
substantially	O
reduced	O
in	O
Dnmt1	B-Protein
-	O
deficient	O
cells	O
.	O

This	O
is	O
the	O
first	O
direct	O
demonstration	O
that	O
DNA	O
methylation	O
affects	O
point	O
mutation	O
rates	O
in	O
mammalian	O
cells	O
.	O

Surprisingly	O
,	O
the	O
fraction	O
of	O
CpG	O
transition	O
mutations	O
was	O
not	O
reduced	O
in	O
Dnmt1	B-Protein
-	O
deficient	O
cells	O
.	O

Finally	O
,	O
we	O
show	O
that	O
methyl	O
group	O
-	O
deficient	O
growth	O
conditions	O
do	O
not	O
cause	O
an	O
increase	O
in	O
missense	O
mutation	O
rates	O
in	O
Dnmt1	B-Protein
-	O
proficient	O
cells	O
,	O
as	O
predicted	O
by	O
methyltransferase	O
-	O
mediated	O
mutagenesis	O
models	O
.	O

We	O
conclude	O
that	O
Dnmt1	B-Protein
deficiency	O
and	O
the	O
accompanying	O
genomic	O
DNA	O
hypomethylation	O
result	O
in	O
a	O
reduction	O
of	O
three	O
major	O
pathways	O
of	O
gene	O
inactivation	O
in	O
our	O
model	O
system	O
.	O

Induction	O
of	O
hepatitis	O
C	O
virus	O
E1	B-Protein
envelope	O
protein	O
-	O
specific	O
immune	O
response	O
can	O
be	O
enhanced	O
by	O
mutation	O
of	O
N	O
-	O
glycosylation	O
sites	O
.	O

Deglycosylation	O
of	O
viral	O
glycoproteins	O
has	O
been	O
shown	O
to	O
influence	O
the	O
number	O
of	O
available	O
epitopes	O
and	O
to	O
modulate	O
immune	O
recognition	O
of	O
antigens	O
.	O

We	O
investigated	O
the	O
role	O
played	O
by	O
N	O
-	O
glycans	O
in	O
the	O
immunogenicity	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
E1	B-Protein
envelope	O
glycoprotein	O
,	O
a	O
naturally	O
poor	O
immunogen	O
.	O

Eight	O
plasmids	O
were	O
engineered	O
,	O
encoding	O
E1	B-Protein
protein	O
mutants	O
in	O
which	O
the	O
four	O
N	O
-	O
linked	O
glycosylation	O
sites	O
of	O
the	O
protein	O
were	O
mutated	O
separately	O
or	O
in	O
combination	O
.	O

In	O
vitro	O
expression	O
studies	O
showed	O
an	O
influence	O
of	O
N	O
-	O
linked	O
glycosylation	O
on	O
expression	O
efficiency	O
,	O
instability	O
,	O
and	O
/	O
or	O
secretion	O
of	O
the	O
mutated	O
proteins	O
.	O

Immunogenicity	O
of	O
the	O
E1	B-Protein
mutants	O
was	O
studied	O
in	O
BALB	O
/	O
c	O
mice	O
following	O
intramuscular	O
and	O
intraepidermal	O
injection	O
of	O
the	O
plasmids	O
.	O

Whereas	O
some	O
mutations	O
had	O
no	O
or	O
only	O
minor	O
effects	O
on	O
the	O
antibody	O
titers	O
induced	O
,	O
mutation	O
of	O
the	O
fourth	O
glycosylation	O
site	O
(	O
N4	O
)	O
significantly	O
enhanced	O
the	O
anti	O
-	O
E1	B-Protein
humoral	O
response	O
in	O
terms	O
of	O
both	O
seroconversion	O
rates	O
and	O
antibody	O
titers	O
.	O

Moreover	O
,	O
antibody	O
induced	O
by	O
the	O
N4	O
mutant	O
was	O
able	O
to	O
recognize	O
HCV	O
-	O
like	O
particles	O
with	O
higher	O
titers	O
than	O
those	O
induced	O
by	O
the	O
wild	O
-	O
type	O
construct	O
.	O

Epitope	O
mapping	O
indicated	O
that	O
the	O
E1	B-Protein
mutant	O
antigens	O
induced	O
antibody	O
directed	O
at	O
two	O
major	O
domains	O
:	O
one	O
,	O
located	O
at	O
amino	O
acids	O
(	O
aa	O
)	O
313	O
to	O
332	O
,	O
which	O
is	O
known	O
to	O
be	O
reactive	O
with	O
sera	O
from	O
HCV	O
patients	O
,	O
and	O
a	O
second	O
one	O
,	O
located	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
E1	B-Protein
(	O
aa	O
192	O
to	O
226	O
)	O
.	O

Analysis	O
of	O
the	O
induced	O
immune	O
cellular	O
response	O
confirmed	O
the	O
induction	O
of	O
gamma	B-Protein
interferon	I-Protein
-	O
producing	O
cells	O
by	O
all	O
mutants	O
,	O
albeit	O
to	O
different	O
levels	O
.	O

These	O
results	O
show	O
that	O
N	O
-	O
linked	O
glycosylation	O
can	O
limit	O
the	O
antibody	O
response	O
to	O
the	O
HCV	O
E1	B-Protein
protein	O
and	O
reveal	O
a	O
potential	O
vaccine	O
candidate	O
with	O
enhanced	O
immunogenicity	O
.	O

Absence	O
of	O
post	O
-	O
translational	O
aspartyl	O
beta	O
-	O
hydroxylation	O
of	O
epidermal	O
growth	O
factor	O
domains	O
in	O
mice	O
leads	O
to	O
developmental	O
defects	O
and	O
an	O
increased	O
incidence	O
of	O
intestinal	O
neoplasia	O
.	O

The	O
BAH	B-Protein
genomic	O
locus	O
encodes	O
three	O
distinct	O
proteins	O
:	O
junctin	B-Protein
,	O
humbug	B-Protein
,	O
and	O
BAH	B-Protein
.	O

All	O
three	O
proteins	O
share	O
common	O
exons	O
,	O
but	O
differ	O
significantly	O
based	O
upon	O
the	O
use	O
of	O
alternative	O
terminal	O
exons	O
.	O

The	O
biological	O
roles	O
of	O
BAH	B-Protein
and	O
humbug	B-Protein
and	O
their	O
functional	O
relationship	O
to	O
junctin	B-Protein
remain	O
unclear	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
BAH	B-Protein
in	O
vivo	O
,	O
the	O
catalytic	O
domain	O
of	O
BAH	B-Protein
was	O
specifically	O
targeted	O
such	O
that	O
the	O
coding	O
regions	O
of	O
junctin	B-Protein
and	O
humbug	B-Protein
remained	O
undisturbed	O
.	O

BAH	B-Protein
null	O
mice	O
lack	O
measurable	O
BAH	B-Protein
protein	O
in	O
several	O
tissues	O
,	O
lack	O
aspartyl	O
beta	O
-	O
hydroxylase	O
activity	O
in	O
liver	O
preparations	O
,	O
and	O
exhibit	O
no	O
hydroxylation	O
of	O
the	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
domain	O
of	O
clotting	O
Factor	B-Protein
X	I-Protein
.	O

In	O
addition	O
to	O
reduced	O
fertility	O
in	O
females	O
,	O
BAH	B-Protein
null	O
mice	O
display	O
several	O
developmental	O
defects	O
including	O
syndactyly	O
,	O
facial	O
dysmorphology	O
,	O
and	O
a	O
mild	O
defect	O
in	O
hard	O
palate	O
formation	O
.	O

The	O
developmental	O
defects	O
present	O
in	O
BAH	B-Protein
null	O
mice	O
are	O
similar	O
to	O
defects	O
observed	O
in	O
knock	O
-	O
outs	O
and	O
hypomorphs	O
of	O
the	O
Notch	O
ligand	O
Serrate	B-Protein
-	I-Protein
2	I-Protein
.	O

In	O
this	O
work	O
,	O
beta	O
-	O
hydroxylation	O
of	O
Asp	O
residues	O
in	O
EGF	O
domains	O
is	O
demonstrated	O
for	O
a	O
soluble	O
form	O
of	O
a	O
Notch	O
ligand	O
,	O
human	O
Jagged	B-Protein
-	I-Protein
1	I-Protein
.	O

These	O
results	O
along	O
with	O
recent	O
reports	O
that	O
another	O
post	O
-	O
translational	O
modification	O
of	O
EGF	O
domains	O
in	O
Notch	O
gene	O
family	O
members	O
(	O
glycosylation	O
by	O
Fringe	O
)	O
alters	O
Notch	O
pathway	O
signaling	O
,	O
lends	O
credence	O
to	O
the	O
suggestion	O
that	O
aspartyl	O
beta	O
-	O
hydroxylation	O
may	O
represent	O
another	O
post	O
-	O
translational	O
modification	O
of	O
EGF	O
domains	O
that	O
can	O
modulate	O
Notch	O
pathway	O
signaling	O
.	O

Previous	O
work	O
has	O
demonstrated	O
increased	O
levels	O
of	O
BAH	B-Protein
in	O
certain	O
tumor	O
tissues	O
and	O
a	O
role	O
for	O
BAH	B-Protein
in	O
tumorigenesis	O
has	O
been	O
proposed	O
.	O

The	O
role	O
of	O
hydroxylase	O
in	O
tumor	O
formation	O
was	O
tested	O
directly	O
by	O
crossing	O
BAH	B-Protein
KO	O
mice	O
with	O
an	O
intestinal	O
tumor	O
model	O
,	O
APCmin	O
mice	O
.	O

Surprisingly	O
,	O
BAH	B-Protein
null	O
/	O
APCmin	O
mice	O
show	O
a	O
statistically	O
significant	O
increase	O
in	O
both	O
intestinal	O
polyp	O
size	O
and	O
number	O
when	O
compared	O
with	O
BAH	B-Protein
wild	O
-	O
type	O
/	O
APCmin	O
controls	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
contrast	O
to	O
expectations	O
,	O
loss	O
of	O
BAH	B-Protein
catalytic	O
activity	O
may	O
promote	O
tumor	O
formation	O
.	O

Molecular	O
cloning	O
of	O
ESET	B-Protein
,	O
a	O
novel	O
histone	B-Protein
H3	I-Protein
-	O
specific	O
methyltransferase	O
that	O
interacts	O
with	O
ERG	B-Protein
transcription	O
factor	O
.	O

The	O
ets	O
-	O
related	O
gene	O
erg	B-Protein
encodes	O
a	O
transcription	O
factor	O
that	O
is	O
implicated	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

To	O
identify	O
interacting	O
partners	O
of	O
ERG	B-Protein
,	O
we	O
screened	O
a	O
yeast	O
two	O
-	O
hybrid	O
cDNA	O
library	O
constructed	O
from	O
mouse	O
hematopoietic	O
cells	O
using	O
the	O
N	O
-	O
terminal	O
region	O
of	O
ERG	B-Protein
as	O
a	O
bait	O
.	O

We	O
isolated	O
a	O
4	O
.	O
6	O
kb	O
full	O
-	O
length	O
mouse	O
cDNA	O
encoding	O
a	O
1307	O
-	O
amino	O
acid	O
protein	O
migrating	O
as	O
a	O
180	O
kD	O
band	O
,	O
which	O
was	O
termed	O
ESET	B-Protein
(	O
ERG	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
with	I-Protein
SET	I-Protein
domain	I-Protein
)	O
.	O

ESET	B-Protein
is	O
92	O
%	O
identical	O
to	O
the	O
human	O
protein	O
SETDB1	B-Protein
(	O
SET	B-Protein
domain	I-Protein
,	I-Protein
bifurcated	I-Protein
1	I-Protein
)	O
.	O

The	O
interaction	O
between	O
ESET	B-Protein
and	O
ERG	B-Protein
was	O
supported	O
by	O
in	O
vitro	O
pull	O
-	O
down	O
using	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
fusion	O
protein	O
,	O
by	O
transfection	O
and	O
co	O
-	O
immunoprecipitation	O
experiments	O
,	O
and	O
by	O
association	O
of	O
endogenous	O
SETDB1	B-Protein
with	O
ERG	B-Protein
.	O

Since	O
ESET	B-Protein
possesses	O
evolutionarily	O
conserved	O
SET	O
,	O
preSET	O
,	O
and	O
postSET	O
domains	O
implicated	O
in	O
histone	B-Protein
methylation	O
,	O
we	O
tested	O
the	O
ability	O
of	O
ESET	B-Protein
to	O
methylate	O
core	O
histones	B-Protein
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrated	O
that	O
ESET	B-Protein
is	O
a	O
histone	B-Protein
H3	I-Protein
-	O
specific	O
methyltransferase	O
,	O
and	O
that	O
mutations	O
within	O
ESET	B-Protein
abolished	O
its	O
methyltransferase	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
raise	O
the	O
possibility	O
that	O
transcription	O
factor	O
ERG	B-Protein
may	O
participate	O
in	O
transcriptional	O
regulation	O
through	O
ESET	B-Protein
-	O
mediated	O
histone	B-Protein
methylation	O
.	O

Regulation	O
of	O
HIF	O
by	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumour	I-Protein
suppressor	I-Protein
:	O
implications	O
for	O
cellular	O
oxygen	O
sensing	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
is	O
central	O
in	O
coordinating	O
many	O
of	O
the	O
transcriptional	O
adaptations	O
to	O
hypoxia	O
.	O

Composed	O
of	O
a	O
heterodimer	O
of	O
alpha	O
and	O
beta	O
subunits	O
,	O
the	O
alpha	O
subunit	O
is	O
rapidly	O
degraded	O
in	O
normoxia	O
,	O
leading	O
to	O
inactivation	O
of	O
the	O
hypoxic	O
response	O
.	O

Many	O
models	O
for	O
a	O
molecular	O
oxygen	O
sensor	O
regulating	O
this	O
system	O
have	O
been	O
proposed	O
,	O
but	O
an	O
important	O
finding	O
has	O
been	O
the	O
ability	O
to	O
mimic	O
hypoxia	O
by	O
chelation	O
or	O
substitution	O
of	O
iron	O
.	O

A	O
key	O
insight	O
has	O
been	O
the	O
recognition	O
that	O
HIF	O
-	O
alpha	O
is	O
targeted	O
for	O
degradation	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
through	O
binding	O
to	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumour	I-Protein
suppressor	I-Protein
protein	O
(	O
pVHL	B-Protein
)	O
,	O
which	O
forms	O
the	O
recognition	O
component	O
of	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
complex	O
leading	O
to	O
ubiquitylation	O
of	O
HIF	O
-	O
alpha	O
.	O

Importantly	O
,	O
the	O
classical	O
features	O
of	O
regulation	O
by	O
iron	O
and	O
oxygen	O
availability	O
are	O
reflected	O
in	O
regulation	O
of	O
the	O
HIF	O
-	O
alpha	O
/	O
pVHL	B-Protein
interaction	O
.	O

It	O
has	O
recently	O
been	O
shown	O
that	O
HIF	O
-	O
alpha	O
undergoes	O
an	O
iron	O
-	O
and	O
oxygen	O
-	O
dependent	O
modification	O
before	O
it	O
can	O
interact	O
with	O
pVHL	B-Protein
,	O
and	O
that	O
this	O
results	O
in	O
hydroxylation	O
of	O
at	O
least	O
one	O
prolyl	O
residue	O
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
Pro	O
564	O
)	O
.	O

This	O
modification	O
is	O
catalysed	O
by	O
an	O
enzyme	O
termed	O
HIF	O
-	O
prolyl	O
hydroxylase	O
(	O
HIF	O
-	O
PH	O
)	O
,	O
and	O
compatible	O
with	O
all	O
previously	O
described	O
prolyl	O
-	O
4	O
-	O
hydroxylases	O
HIF	O
-	O
PH	O
also	O
requires	O
2	O
-	O
oxoglutarate	O
as	O
a	O
cosubstrate	O
.	O

The	O
key	O
position	O
of	O
this	O
hydroxylation	O
in	O
the	O
degradation	O
pathway	O
of	O
HIF	O
-	O
alpha	O
,	O
together	O
with	O
its	O
requirement	O
for	O
molecular	O
dioxygen	O
as	O
a	O
co	O
-	O
substrate	O
,	O
provides	O
the	O
potential	O
for	O
HIF	O
-	O
PH	O
to	O
function	O
directly	O
as	O
a	O
cellular	O
oxygen	O
sensor	O
.	O

However	O
,	O
the	O
ability	O
of	O
these	O
enzyme	O
(	O
s	O
)	O
to	O
account	O
for	O
the	O
full	O
range	O
of	O
physiological	O
regulation	O
displayed	O
by	O
the	O
HIF	O
system	O
remains	O
to	O
be	O
defined	O
.	O

Promoter	O
methylation	O
status	O
of	O
the	O
DNA	O
repair	O
genes	O
hMLH1	B-Protein
and	O
MGMT	B-Protein
in	O
gastric	O
carcinoma	O
and	O
metaplastic	O
mucosa	O
.	O

Hypermethylation	O
of	O
CpG	O
islands	O
in	O
the	O
promoter	O
region	O
is	O
associated	O
with	O
the	O
silencing	O
of	O
a	O
variety	O
of	O
tumor	O
suppressor	O
genes	O
.	O

DNA	O
repair	O
genes	O
human	O
Mut	B-Protein
L	I-Protein
homologue	I-Protein
1	I-Protein
(	O
hMLH1	B-Protein
)	O
and	O
O	B-Protein
(	I-Protein
6	I-Protein
)	I-Protein
-	I-Protein
methylguanine	I-Protein
-	I-Protein
DNA	I-Protein
methyltransferase	I-Protein
(	O
MGMT	B-Protein
)	O
have	O
been	O
shown	O
to	O
be	O
hypermethylated	O
in	O
certain	O
carcinomas	O
.	O

We	O
studied	O
DNA	O
methylation	O
of	O
CpG	O
islands	O
in	O
hMLH1	B-Protein
and	O
MGMT	B-Protein
in	O
50	O
gastric	O
carcinomas	O
and	O
10	O
intestinal	O
metaplastic	O
mucosa	O
samples	O
.	O

We	O
analyzed	O
the	O
methylation	O
status	O
of	O
hMLH1	B-Protein
and	O
MGMT	B-Protein
using	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
and	O
DNA	O
sequencing	O
analysis	O
.	O

We	O
measured	O
protein	O
levels	O
of	O
hMLH1	B-Protein
using	O
Western	O
blot	O
and	O
immunohistochemical	O
analysis	O
.	O

CpG	O
island	O
hypermethylation	O
of	O
hMLH1	B-Protein
and	O
MGMT	B-Protein
was	O
detected	O
in	O
11	O
(	O
22	O
%	O
)	O
and	O
8	O
(	O
16	O
%	O
)	O
of	O
the	O
50	O
gastric	O
tumors	O
,	O
respectively	O
.	O

Hypermethylation	O
of	O
the	O
promoter	O
was	O
more	O
common	O
in	O
intestinal	O
-	O
type	O
gastric	O
carcinomas	O
than	O
in	O
poorly	O
diffuse	O
-	O
type	O
gastric	O
carcinomas	O
(	O
p	O
=	O
0	O
.	O
016	O
and	O
0	O
.	O
021	O
,	O
respectively	O
;	O
Fisher	O
'	O
s	O
exact	O
test	O
)	O
.	O

However	O
,	O
hMLH1	B-Protein
promoter	O
hypermethylation	O
did	O
not	O
coincide	O
with	O
MGMT	B-Protein
promoter	O
hypermethylation	O
except	O
in	O
1	O
patient	O
.	O

Hypermethylation	O
of	O
the	O
hMLH1	B-Protein
promoter	O
but	O
not	O
the	O
MGMT	B-Protein
promoter	O
occurred	O
in	O
intestinal	O
metaplastic	O
mucosae	O
.	O

Immunohistochemical	O
analysis	O
revealed	O
a	O
corresponding	O
reduction	O
in	O
hMLH1	B-Protein
protein	O
expression	O
in	O
some	O
of	O
the	O
intestinal	O
metaplastic	O
mucosae	O
.	O

Our	O
results	O
suggest	O
that	O
at	O
least	O
two	O
types	O
of	O
promoter	O
methylation	O
participate	O
in	O
the	O
development	O
of	O
gastric	O
carcinoma	O
.	O

Tumor	O
-	O
specific	O
promoter	O
hypermethylation	O
of	O
hMLH1	B-Protein
may	O
be	O
an	O
early	O
event	O
in	O
carcinogenesis	O
in	O
the	O
stomach	O
.	O

Histone	B-Protein
deacetylases	O
and	O
cancer	O
:	O
causes	O
and	O
therapies	O
.	O

Together	O
,	O
histone	B-Protein
acetyltransferases	O
and	O
histone	B-Protein
deacetylases	O
(	O
HDACs	O
)	O
determine	O
the	O
acetylation	O
status	O
of	O
histones	B-Protein
.	O

This	O
acetylation	O
affects	O
the	O
regulation	O
of	O
gene	O
expression	O
,	O
and	O
inhibitors	O
of	O
HDACs	O
have	O
been	O
found	O
to	O
cause	O
growth	O
arrest	O
,	O
differentiation	O
and	O
/	O
or	O
apoptosis	O
of	O
many	O
tumours	O
cells	O
by	O
altering	O
the	O
transcription	O
of	O
a	O
small	O
number	O
of	O
genes	O
.	O

HDAC	O
inhibitors	O
are	O
proving	O
to	O
be	O
an	O
exciting	O
therapeutic	O
approach	O
to	O
cancer	O
,	O
but	O
how	O
do	O
they	O
exert	O
this	O
effect	O
?	O

Co	O
-	O
and	O
posttranslational	O
modification	O
of	O
the	O
alpha	B-Protein
(	I-Protein
1B	I-Protein
)	I-Protein
-	I-Protein
adrenergic	I-Protein
receptor	I-Protein
:	O
effects	O
on	O
receptor	O
expression	O
and	O
function	O
.	O

We	O
have	O
characterized	O
the	O
maturation	O
,	O
co	O
-	O
and	O
posttranslational	O
modifications	O
,	O
and	O
functional	O
properties	O
of	O
the	O
alpha	B-Protein
(	I-Protein
1B	I-Protein
)	I-Protein
-	I-Protein
adrenergic	I-Protein
receptor	I-Protein
(	O
AR	O
)	O
expressed	O
in	O
different	O
mammalian	O
cells	O
transfected	O
using	O
conventional	O
approaches	O
or	O
the	O
Semliki	O
Forest	O
virus	O
system	O
.	O

We	O
found	O
that	O
the	O
alpha	B-Protein
(	I-Protein
1B	I-Protein
)	I-Protein
-	I-Protein
AR	I-Protein
undergoes	O
N	O
-	O
linked	O
glycosylation	O
as	O
demonstrated	O
by	O
its	O
sensitivity	O
to	O
endoglycosidases	O
and	O
by	O
the	O
effect	O
of	O
tunicamycin	O
on	O
receptor	O
maturation	O
.	O

Pulse	O
-	O
chase	O
labeling	O
experiments	O
in	O
BHK	O
-	O
21	O
cells	O
demonstrate	O
that	O
the	O
alpha	B-Protein
(	I-Protein
1B	I-Protein
)	I-Protein
-	I-Protein
AR	I-Protein
is	O
synthesized	O
as	O
a	O
70	O
kDa	O
core	O
glycosylated	O
precursor	O
that	O
is	O
converted	O
to	O
the	O
90	O
kDa	O
mature	O
form	O
of	O
the	O
receptor	O
with	O
a	O
half	O
-	O
time	O
of	O
approximately	O
2	O
h	O
.	O

N	O
-	O
Linked	O
glycosylation	O
of	O
the	O
alpha	B-Protein
(	I-Protein
1B	I-Protein
)	I-Protein
-	I-Protein
AR	I-Protein
occurs	O
at	O
four	O
asparagines	O
on	O
the	O
N	O
-	O
terminus	O
of	O
the	O
receptor	O
.	O

Mutations	O
of	O
the	O
N	O
-	O
linked	O
glycosylation	O
sites	O
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
receptor	O
function	O
or	O
expression	O
.	O

Surprisingly	O
,	O
receptor	O
mutants	O
lacking	O
N	O
-	O
linked	O
glycosylation	O
migrated	O
as	O
heterogeneous	O
bands	O
in	O
SDS	O
-	O
PAGE	O
.	O

Our	O
findings	O
demonstrate	O
that	O
N	O
-	O
linked	O
glycosylation	O
and	O
phosphorylation	O
,	O
but	O
not	O
palmitoylation	O
or	O
O	O
-	O
linked	O
glycosylation	O
,	O
contribute	O
to	O
the	O
structural	O
heterogeneity	O
of	O
the	O
alpha	B-Protein
(	I-Protein
1B	I-Protein
)	I-Protein
-	I-Protein
AR	I-Protein
as	O
it	O
is	O
observed	O
in	O
SDS	O
-	O
PAGE	O
.	O

The	O
modifications	O
found	O
are	O
similar	O
in	O
the	O
different	O
mammalian	O
expression	O
systems	O
explored	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
Semliki	O
Forest	O
virus	O
system	O
can	O
provide	O
large	O
amounts	O
of	O
functional	O
and	O
fully	O
glycosylated	O
alpha	B-Protein
(	I-Protein
1B	I-Protein
)	I-Protein
-	I-Protein
AR	I-Protein
protein	O
suitable	O
for	O
biochemical	O
and	O
structural	O
studies	O
.	O

The	O
results	O
of	O
this	O
study	O
contribute	O
to	O
elucidate	O
the	O
basic	O
steps	O
involved	O
in	O
the	O
processing	O
of	O
G	O
protein	O
-	O
coupled	O
receptors	O
as	O
well	O
as	O
to	O
optimize	O
strategies	O
for	O
their	O
overexpression	O
.	O

Binding	O
mode	O
analysis	O
of	O
3	O
-	O
(	O
4	O
-	O
benzoyl	O
-	O
1	O
-	O
methyl	O
-	O
1H	O
-	O
2	O
-	O
pyrrolyl	O
)	O
-	O
N	O
-	O
hydroxy	O
-	O
2	O
-	O
propenamide	O
:	O
a	O
new	O
synthetic	O
histone	B-Protein
deacetylase	O
inhibitor	O
inducing	O
histone	B-Protein
hyperacetylation	O
,	O
growth	O
inhibition	O
,	O
and	O
terminal	O
cell	O
differentiation	O
.	O

The	O
binding	O
mode	O
of	O
3	O
-	O
(	O
4	O
-	O
aroyl	O
-	O
1H	O
-	O
2	O
-	O
pyrrolyl	O
)	O
-	O
N	O
-	O
hydroxy	O
-	O
2	O
-	O
propenamides	O
1a	O
-	O
c	O
,	O
belonging	O
to	O
a	O
recently	O
reported	O
class	O
of	O
synthetic	O
histone	B-Protein
deacetylase	O
(	O
HDAC	O
)	O
inhibitors	O
(	O
Massa	O
,	O
S	O
.	O
;	O
et	O
al	O
.	O
J	O
.	O
Med	O
.	O
Chem	O
.	O
2001	O
,	O
44	O
,	O
2069	O
-	O
2072	O
)	O
,	O
into	O
the	O
new	O
modeled	O
HDAC1	B-Protein
catalytic	O
core	O
is	O
presented	O
,	O
and	O
enzyme	O
/	O
inhibitor	O
interactions	O
are	O
discussed	O
.	O

HDAC1	B-Protein
X	O
-	O
ray	O
coordinates	O
were	O
obtained	O
by	O
virtual	O
"	O
mutation	O
"	O
of	O
those	O
of	O
histone	B-Protein
deacetylase	O
-	O
like	O
protein	O
,	O
a	O
bacterial	O
HDAC	O
homologue	O
.	O

In	O
in	O
vitro	O
antimaize	O
HD2	O
as	O
well	O
as	O
antimouse	O
HDAC1	B-Protein
assay	O
,	O
compounds	O
1a	O
-	O
c	O
showed	O
inhibitory	O
activities	O
in	O
the	O
low	O
micromolar	O
range	O
.	O

Similarly	O
,	O
1a	O
-	O
c	O
are	O
endowed	O
with	O
anti	O
-	O
HDAC	O
activity	O
in	O
vivo	O
:	O
on	O
mouse	O
A20	O
cells	O
,	O
1a	O
-	O
c	O
induced	O
histone	B-Protein
hyperacetylation	O
leading	O
to	O
a	O
highly	O
increased	O
acetylation	O
level	O
of	O
H4	B-Protein
as	O
compared	O
to	O
control	O
histones	B-Protein
.	O

Results	O
obtained	O
with	O
acid	O
-	O
urea	O
-	O
triton	O
polyacrylamide	O
gel	O
electrophoresis	O
have	O
been	O
confirmed	O
by	O
Western	O
Blot	O
experiments	O
.	O

Finally	O
,	O
compound	O
1a	O
,	O
chosen	O
as	O
a	O
representative	O
member	O
of	O
this	O
class	O
of	O
HDAC	O
inhibitors	O
,	O
resulted	O
endowed	O
with	O
antiproliferative	O
(	O
45	O
and	O
85	O
%	O
cell	O
growth	O
inhibition	O
at	O
40	O
and	O
80	O
microM	O
,	O
respectively	O
)	O
and	O
cellular	O
differentiation	O
(	O
18	O
and	O
21	O
%	O
of	O
benzidine	O
positive	O
cells	O
at	O
the	O
same	O
concentrations	O
)	O
activities	O
in	O
murine	O
erythroleukemic	O
cells	O
.	O

Hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	I-Protein
HIF	I-Protein
)	I-Protein
asparagine	I-Protein
hydroxylase	I-Protein
is	O
identical	O
to	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
FIH	B-Protein
)	O
and	O
is	O
related	O
to	O
the	O
cupin	O
structural	O
family	O
.	O

Activity	O
of	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
complex	O
is	O
controlled	O
by	O
oxygen	O
-	O
dependent	O
hydroxylation	O
of	O
prolyl	O
and	O
asparaginyl	O
residues	O
.	O

Hydroxylation	O
of	O
specific	O
prolyl	O
residues	O
by	O
2	O
-	O
oxoglutarate	O
(	O
2	O
-	O
OG	O
)	O
-	O
dependent	O
oxygenases	O
mediates	O
ubiquitinylation	O
and	O
proteasomal	O
destruction	O
of	O
HIF	O
-	O
alpha	O
.	O

Hydroxylation	O
of	O
an	O
asparagine	O
residue	O
in	O
the	O
C	O
-	O
terminal	O
transactivation	O
domain	O
(	O
CAD	O
)	O
of	O
HIF	O
-	O
alpha	O
abrogates	O
interaction	O
with	O
p300	B-Protein
,	O
preventing	O
transcriptional	O
activation	O
.	O

Yeast	O
two	O
-	O
hybrid	O
assays	O
recently	O
identified	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
FIH	B-Protein
)	O
as	O
a	O
protein	O
that	O
associates	O
with	O
the	O
CAD	O
region	O
of	O
HIF	O
-	O
alpha	O
.	O

Since	O
FIH	B-Protein
contains	O
certain	O
motifs	O
present	O
in	O
iron	O
-	O
and	O
2	O
-	O
OG	O
-	O
dependent	O
oxygenases	O
we	O
investigated	O
whether	O
FIH	B-Protein
was	O
the	O
HIF	B-Protein
asparaginyl	I-Protein
hydroxylase	I-Protein
.	O

Assays	O
using	O
recombinant	O
FIH	B-Protein
and	O
HIF	O
-	O
alpha	O
fragments	O
revealed	O
that	O
FIH	B-Protein
is	O
the	O
enzyme	O
that	O
hydroxylates	O
the	O
CAD	O
asparagine	O
residue	O
,	O
that	O
the	O
activity	O
is	O
directly	O
inhibited	O
by	O
cobalt	O
(	O
II	O
)	O
and	O
limited	O
by	O
hypoxia	O
,	O
and	O
that	O
the	O
oxygen	O
in	O
the	O
alcohol	O
of	O
the	O
hydroxyasparagine	O
residue	O
is	O
directly	O
derived	O
from	O
dioxygen	O
.	O

Sequence	O
analyses	O
involving	O
FIH	B-Protein
link	O
the	O
2	O
-	O
OG	O
oxygenases	O
with	O
members	O
of	O
the	O
cupin	O
superfamily	O
,	O
including	O
Zn	O
(	O
II	O
)	O
-	O
utilizing	O
phosphomannose	B-Protein
isomerase	I-Protein
,	O
revealing	O
structural	O
and	O
evolutionary	O
links	O
between	O
these	O
metal	O
-	O
binding	O
proteins	O
that	O
share	O
common	O
motifs	O
.	O

FIH	B-Protein
-	I-Protein
1	I-Protein
is	O
an	O
asparaginyl	O
hydroxylase	O
enzyme	O
that	O
regulates	O
the	O
transcriptional	O
activity	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
.	O

Mammalian	O
cells	O
adapt	O
to	O
hypoxic	O
conditions	O
through	O
a	O
transcriptional	O
response	O
pathway	O
mediated	O
by	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
,	O
HIF	O
.	O

HIF	O
transcriptional	O
activity	O
is	O
suppressed	O
under	O
normoxic	O
conditions	O
by	O
hydroxylation	O
of	O
an	O
asparagine	O
residue	O
within	O
its	O
C	O
-	O
terminal	O
transactivation	O
domain	O
,	O
blocking	O
association	O
with	O
coactivators	O
.	O

Here	O
we	O
show	O
that	O
the	O
protein	O
FIH	B-Protein
-	I-Protein
1	I-Protein
,	O
previously	O
shown	O
to	O
interact	O
with	O
HIF	O
,	O
is	O
an	O
asparaginyl	O
hydroxylase	O
.	O

Like	O
known	O
hydroxylase	O
enzymes	O
,	O
FIH	B-Protein
-	I-Protein
1	I-Protein
is	O
an	O
Fe	O
(	O
II	O
)	O
-	O
dependent	O
enzyme	O
that	O
uses	O
molecular	O
O	O
(	O
2	O
)	O
to	O
modify	O
its	O
substrate	O
.	O

Together	O
with	O
the	O
recently	O
discovered	O
prolyl	O
hydroxylases	O
that	O
regulate	O
HIF	O
stability	O
,	O
this	O
class	O
of	O
oxygen	O
-	O
dependent	O
enzymes	O
comprises	O
critical	O
regulatory	O
components	O
of	O
the	O
hypoxic	O
response	O
pathway	O
.	O

[	O
alpha	O
]	O
-	O
Secretase	O
ADAM10	B-Protein
as	O
well	O
as	O
[	B-Protein
alpha	I-Protein
]	I-Protein
APPs	I-Protein
is	O
reduced	O
in	O
platelets	O
and	O
CSF	O
of	O
Alzheimer	O
disease	O
patients	O
.	O

BACKGROUND	O
:	O
Members	O
of	O
membrane	O
-	O
bound	O
disintegrin	O
metalloproteinases	O
(	O
ADAMs	O
)	O
were	O
shown	O
to	O
be	O
capable	O
of	O
cleaving	O
amyloid	B-Protein
precursor	I-Protein
protein	I-Protein
(	O
APP	B-Protein
)	O
at	O
the	O
alpha	O
-	O
cleavage	O
site	O
in	O
different	O
cell	O
systems	O
.	O

One	O
of	O
the	O
candidate	O
alpha	O
-	O
secretases	O
identified	O
in	O
this	O
family	O
is	O
ADAM10	B-Protein
.	O

The	O
present	O
study	O
addresses	O
the	O
following	O
major	O
questions	O
:	O
1	O
)	O
Are	O
the	O
levels	O
of	O
an	O
alpha	O
-	O
secretase	O
candidate	O
(	O
i	O
.	O
e	O
.	O
,	O
ADAM10	B-Protein
)	O
reduced	O
in	O
accessible	O
cells	O
of	O
Alzheimer	O
Disease	O
(	O
AD	O
)	O
patients	O
?	O

2	O
)	O
Are	O
ADAM10	B-Protein
levels	O
in	O
the	O
peripheral	O
cells	O
of	O
AD	O
patients	O
related	O
to	O
a	O
concomitant	O
decrease	O
in	O
alpha	B-Protein
APPs	I-Protein
?	O

MATERIALS	O
AND	O
METHODS	O
:	O
Western	O
Blot	O
analysis	O
of	O
ADAM10	B-Protein
is	O
performed	O
on	O
platelet	O
homogenates	O
from	O
33	O
sporadic	O
AD	O
patients	O
and	O
on	O
26	O
age	O
-	O
matched	O
control	O
subjects	O
.	O

Moreover	O
,	O
the	O
levels	O
of	O
alpha	O
-	O
secretase	O
metabolite	O
(	O
alpha	B-Protein
APPs	I-Protein
)	O
are	O
tested	O
both	O
in	O
platelets	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
of	O
the	O
same	O
pool	O
of	O
subjects	O
by	O
means	O
of	O
Western	O
blot	O
with	O
a	O
specific	O
antibody	O
.	O

RESULTS	O
:	O
A	O
significant	O
decrease	O
of	O
platelet	O
ADAM10	B-Protein
levels	O
is	O
observed	O
in	O
patients	O
affected	O
by	O
probable	O
AD	O
when	O
compared	O
to	O
control	O
subjects	O
and	O
this	O
is	O
paralleled	O
by	O
a	O
reduced	O
level	O
of	O
alpha	B-Protein
APPs	I-Protein
released	O
from	O
platelets	O
.	O

Moreover	O
,	O
in	O
the	O
same	O
pool	O
of	O
AD	O
patients	O
,	O
alpha	B-Protein
APPs	I-Protein
levels	O
were	O
reduced	O
concomitantly	O
in	O
CSF	O
.	O

CONCLUSIONS	O
:	O
ADAM10	B-Protein
is	O
expressed	O
in	O
platelets	O
.	O

A	O
reduced	O
level	O
of	O
ADAM10	B-Protein
is	O
observed	O
in	O
platelets	O
obtained	O
from	O
AD	O
patients	O
compared	O
to	O
age	O
-	O
matched	O
controls	O
.	O

Further	O
,	O
in	O
the	O
same	O
pool	O
of	O
AD	O
patients	O
,	O
a	O
qualitatively	O
and	O
quantitatively	O
similar	O
decrease	O
in	O
alpha	B-Protein
APPs	I-Protein
is	O
present	O
both	O
in	O
thrombin	B-Protein
-	O
activated	O
platelets	O
and	O
CSF	O
,	O
thus	O
suggesting	O
that	O
alterations	O
of	O
APP	B-Protein
processing	O
might	O
occur	O
both	O
in	O
the	O
neuronal	O
compartment	O
and	O
peripheral	O
cells	O
.	O

Reduced	O
expression	O
of	O
the	O
insulin	B-Protein
-	I-Protein
induced	I-Protein
protein	I-Protein
1	I-Protein
and	O
p41	B-Protein
Arp2	B-Protein
/	I-Protein
3	I-Protein
complex	I-Protein
genes	I-Protein
in	O
human	O
gastric	O
cancers	O
.	O

Aberrantly	O
methylated	O
DNA	O
fragments	O
in	O
a	O
human	O
gastric	O
cancer	O
were	O
searched	O
for	O
by	O
a	O
genome	O
-	O
scanning	O
method	O
,	O
methylation	O
-	O
sensitive	O
-	O
representational	O
difference	O
analysis	O
(	O
MS	O
-	O
RDA	O
)	O
.	O

Six	O
DNA	O
fragments	O
flanked	O
by	O
CpG	O
islands	O
(	O
CGIs	O
)	O
and	O
hypermethylated	O
in	O
the	O
cancer	O
were	O
isolated	O
.	O

Four	O
of	O
the	O
6	O
fragments	O
possessed	O
genes	O
in	O
their	O
vicinities	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
analysis	O
of	O
the	O
4	O
genes	O
showed	O
reduced	O
expression	O
of	O
2	O
genes	O
in	O
cancers	O
:	O
Insulin	B-Protein
-	I-Protein
induced	I-Protein
protein	I-Protein
1	I-Protein
(	O
INSIG1	B-Protein
/	O
CL	B-Protein
-	I-Protein
6	I-Protein
)	O
and	O
p41	B-Protein
Arp2	O
/	O
3	O
complex	O
(	O
p41	B-Protein
-	O
Arc	O
)	O
.	O

As	O
for	O
INSIG1	B-Protein
,	O
a	O
DNA	O
fragment	O
was	O
derived	O
from	O
the	O
edge	O
of	O
a	O
CGI	O
in	O
the	O
promoter	O
region	O
.	O

The	O
edge	O
was	O
methylated	O
in	O
11	O
of	O
22	O
primary	O
gastric	O
cancers	O
,	O
whereas	O
the	O
center	O
was	O
not	O
methylated	O
in	O
any	O
cancer	O
.	O

INSIG1	B-Protein
expression	O
was	O
markedly	O
reduced	O
in	O
19	O
cancers	O
,	O
including	O
the	O
11	O
cancers	O
with	O
the	O
methylation	O
.	O

By	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
treatment	O
of	O
5	O
cell	O
lines	O
with	O
the	O
methylation	O
of	O
the	O
edge	O
,	O
partial	O
restoration	O
of	O
INSIG1	B-Protein
expression	O
was	O
detected	O
only	O
in	O
2	O
of	O
them	O
.	O

These	O
data	O
indicated	O
that	O
,	O
although	O
the	O
reduced	O
INSIG1	B-Protein
expression	O
in	O
cancers	O
was	O
associated	O
with	O
the	O
methylation	O
at	O
the	O
edge	O
of	O
the	O
CGI	O
in	O
the	O
promoter	O
region	O
,	O
the	O
methylation	O
was	O
likely	O
to	O
be	O
a	O
secondary	O
change	O
.	O

As	O
for	O
p41	B-Protein
-	O
Arc	O
,	O
a	O
DNA	O
fragment	O
was	O
derived	O
from	O
a	O
CGI	O
overlapping	O
exon	O
8	O
,	O
and	O
its	O
methylation	O
did	O
not	O
correlate	O
with	O
its	O
expression	O
.	O

However	O
,	O
methylation	O
of	O
a	O
CGI	O
in	O
the	O
promoter	O
region	O
with	O
a	O
marked	O
reduction	O
of	O
its	O
expression	O
was	O
observed	O
in	O
1	O
of	O
the	O
22	O
primary	O
cancers	O
.	O

INSIG1	B-Protein
and	O
p41	B-Protein
-	O
Arc	O
are	O
known	O
to	O
be	O
involved	O
in	O
cellular	O
differentiation	O
and	O
morphology	O
,	O
respectively	O
,	O
and	O
it	O
was	O
suggested	O
that	O
their	O
reduced	O
expressions	O
might	O
be	O
involved	O
in	O
gastric	O
cancer	O
development	O
or	O
progression	O
.	O

The	O
kyphoscoliotic	O
type	O
of	O
Ehlers	O
-	O
Danlos	O
syndrome	O
(	O
type	O
VI	O
)	O
:	O
differential	O
effects	O
on	O
the	O
hydroxylation	O
of	O
lysine	O
in	O
collagens	O
I	O
and	O
II	B-Protein
revealed	O
by	O
analysis	O
of	O
cross	O
-	O
linked	O
telopeptides	O
from	O
urine	O
.	O

The	O
kyphoscoliotic	O
type	O
of	O
Ehlers	O
-	O
Danlos	O
syndrome	O
(	O
EDS	O
type	O
VIA	O
)	O
(	O
OMIM	O
225400	O
)	O
is	O
an	O
autosomal	O
recessive	O
connective	O
tissue	O
disorder	O
that	O
results	O
from	O
mutations	O
in	O
the	O
lysyl	B-Protein
hydroxylase	I-Protein
1	I-Protein
gene	O
(	O
PLOD1	B-Protein
)	O
causing	O
underhydroxylation	O
of	O
lysine	O
residues	O
in	O
tissue	O
collagens	O
,	O
particularly	O
of	O
skin	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
pool	O
of	O
collagen	O
cross	O
-	O
linking	O
amino	O
acids	O
,	O
hydroxylysyl	O
pyridinoline	O
(	O
HP	O
)	O
and	O
lysyl	O
pyridinoline	O
(	O
LP	O
)	O
excreted	O
in	O
urine	O
has	O
an	O
abnormally	O
low	O
HP	O
/	O
LP	O
ratio	O
,	O
which	O
is	O
diagnostic	O
of	O
the	O
condition	O
.	O

Here	O
we	O
isolated	O
cross	O
-	O
linked	O
peptides	O
containing	O
these	O
residues	O
from	O
the	O
urine	O
of	O
a	O
child	O
with	O
EDS	O
VIA	O
homozygous	O
for	O
a	O
mutation	O
that	O
results	O
in	O
a	O
stop	O
codon	O
and	O
effective	O
null	O
expression	O
of	O
PLOD1	B-Protein
enzyme	O
activity	O
.	O

Peptides	O
that	O
had	O
originated	O
from	O
bone	O
type	O
I	O
collagen	O
and	O
cartilage	O
type	B-Protein
II	I-Protein
collagen	I-Protein
were	O
identified	O
.	O

A	O
cross	O
-	O
linked	O
N	O
-	O
telopeptide	O
fraction	O
that	O
is	O
derived	O
from	O
bone	O
type	O
I	O
collagen	O
contained	O
only	O
LP	O
,	O
no	O
HP	O
,	O
which	O
means	O
that	O
the	O
helical	O
lysines	O
at	O
residues	O
930	O
of	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
and	O
933	O
of	O
alpha	B-Protein
2	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
of	O
the	O
collagen	O
triple	O
-	O
helix	O
had	O
not	O
been	O
hydroxylated	O
.	O

The	O
equivalent	O
peptide	O
fraction	O
from	O
a	O
normal	O
child	O
'	O
s	O
urine	O
gave	O
a	O
ratio	O
of	O
HP	O
to	O
LP	O
of	O
1	O
.	O
5	O
:	O
1	O
typical	O
for	O
normal	O
bone	O
collagen	O
.	O

A	O
second	O
cross	O
-	O
linked	O
peptide	O
that	O
is	O
derived	O
from	O
the	O
C	O
-	O
telopeptide	O
domain	O
of	O
cartilage	O
type	B-Protein
II	I-Protein
collagen	I-Protein
showed	O
both	O
HP	O
and	O
LP	O
in	O
a	O
2	O
:	O
1	O
ratio	O
,	O
compared	O
with	O
18	O
:	O
1	O
for	O
the	O
equivalent	O
peptide	O
from	O
a	O
normal	O
child	O
'	O
s	O
urine	O
.	O

The	O
results	O
show	O
that	O
in	O
EDS	O
VIA	O
,	O
bone	O
type	O
I	O
collagen	O
is	O
more	O
markedly	O
underhydroxylated	O
than	O
cartilage	O
type	B-Protein
II	I-Protein
collagen	I-Protein
,	O
at	O
least	O
at	O
those	O
helical	O
sites	O
that	O
form	O
cross	O
-	O
links	O
.	O

The	O
residual	O
fraction	O
of	O
HP	O
found	O
in	O
the	O
urine	O
of	O
EDS	O
VI	O
patients	O
therefore	O
appears	O
to	O
be	O
contributed	O
in	O
significant	O
part	O
by	O
the	O
degradation	O
products	O
of	O
cartilage	O
.	O

Since	O
PLOD1	B-Protein
is	O
null	O
,	O
other	O
PLOD	O
genes	O
must	O
be	O
responsible	O
for	O
the	O
helical	O
hydroxylation	O
activity	O
that	O
results	O
in	O
HP	O
.	O

The	O
presented	O
approach	O
of	O
analyzing	O
urinary	O
cross	O
-	O
linked	O
C	O
-	O
telopeptide	O
fragments	O
of	O
type	B-Protein
II	I-Protein
collagen	I-Protein
may	O
allow	O
the	O
detection	O
of	O
chondrodysplasias	O
due	O
to	O
genetic	O
defects	O
in	O
lysyl	O
hydroxylase	O
isoforms	O
active	O
in	O
cartilage	O
.	O

Postsynthetic	O
trimethylation	O
of	O
histone	B-Protein
H4	I-Protein
at	O
lysine	O
20	O
in	O
mammalian	O
tissues	O
is	O
associated	O
with	O
aging	O
.	O

Methylation	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
histones	B-Protein
was	O
first	O
described	O
more	O
than	O
35	O
years	O
ago	O
,	O
but	O
its	O
biological	O
significance	O
has	O
remained	O
unclear	O
.	O

Proposed	O
functions	O
range	O
from	O
transcriptional	O
regulation	O
to	O
the	O
higher	O
order	O
packing	O
of	O
chromatin	O
in	O
progress	O
of	O
mitotic	O
condensation	O
.	O

Primarily	O
because	O
of	O
the	O
recent	O
discovery	O
of	O
the	O
SET	O
domain	O
-	O
depending	O
H3	B-Protein
-	O
specific	O
histone	B-Protein
methyltransferases	O
SUV39H1	B-Protein
and	O
Suv39h1	B-Protein
,	O
which	O
selectively	O
methylate	O
lysine	O
9	O
of	O
the	O
H3	B-Protein
N	O
terminus	O
,	O
this	O
posttranslational	O
modification	O
has	O
regained	O
scientific	O
interest	O
.	O

In	O
the	O
past	O
,	O
investigations	O
concerning	O
the	O
biological	O
significance	O
of	O
histone	B-Protein
methylation	O
were	O
largely	O
limited	O
because	O
of	O
a	O
lack	O
of	O
simple	O
and	O
sensitive	O
analytical	O
procedures	O
for	O
detecting	O
this	O
modification	O
.	O

The	O
present	O
work	O
investigated	O
the	O
methylation	O
pattern	O
of	O
histone	B-Protein
H4	I-Protein
both	O
in	O
different	O
mammalian	O
organs	O
of	O
various	O
ages	O
and	O
in	O
cell	O
lines	O
by	O
applying	O
mass	O
spectrometric	O
analysis	O
and	O
a	O
newly	O
developed	O
hydrophilic	O
-	O
interaction	O
liquid	O
chromatographic	O
method	O
enabling	O
the	O
simultaneous	O
separation	O
of	O
methylated	O
and	O
acetylated	O
forms	O
,	O
which	O
obviates	O
the	O
need	O
to	O
work	O
with	O
radioactive	O
materials	O
.	O

In	O
rat	O
kidney	O
and	O
liver	O
the	O
dimethylated	O
lysine	O
20	O
was	O
found	O
to	O
be	O
the	O
main	O
methylation	O
product	O
,	O
whereas	O
the	O
monomethyl	O
derivative	O
was	O
present	O
in	O
much	O
smaller	O
amounts	O
.	O

In	O
addition	O
,	O
for	O
the	O
first	O
time	O
a	O
trimethylated	O
form	O
of	O
lysine	O
20	O
of	O
H4	B-Protein
was	O
found	O
in	O
mammalian	O
tissue	O
.	O

A	O
significant	O
increase	O
in	O
this	O
trimethylated	O
histone	B-Protein
H4	I-Protein
was	O
detected	O
in	O
organs	O
of	O
animals	O
older	O
than	O
30	O
days	O
,	O
whereas	O
the	O
amounts	O
of	O
mono	O
-	O
and	O
dimethylated	O
forms	O
did	O
not	O
essentially	O
change	O
in	O
organs	O
from	O
young	O
(	O
10	O
days	O
old	O
)	O
or	O
old	O
animals	O
(	O
30	O
and	O
450	O
days	O
old	O
)	O
.	O

Trimethylated	O
H4	B-Protein
was	O
also	O
detected	O
in	O
transformed	O
cells	O
;	O
although	O
it	O
was	O
present	O
in	O
only	O
trace	O
amounts	O
in	O
logarithmically	O
growing	O
cells	O
,	O
we	O
found	O
an	O
increase	O
in	O
trimethylated	O
lysine	O
20	O
in	O
cells	O
in	O
the	O
stationary	O
phase	O
.	O

In	O
the	O
cystathionine	B-Protein
beta	I-Protein
-	I-Protein
synthase	I-Protein
knockout	O
mouse	O
,	O
elevations	O
in	O
total	O
plasma	O
homocysteine	O
increase	O
tissue	O
S	O
-	O
adenosylhomocysteine	O
,	O
but	O
responses	O
of	O
S	O
-	O
adenosylmethionine	O
and	O
DNA	O
methylation	O
are	O
tissue	O
specific	O
.	O

The	O
cystathionine	B-Protein
beta	I-Protein
-	I-Protein
synthase	I-Protein
knockout	O
mouse	O
provides	O
a	O
unique	O
opportunity	O
to	O
study	O
biochemical	O
consequences	O
of	O
a	O
defective	O
cystathionine	B-Protein
beta	I-Protein
-	I-Protein
synthase	I-Protein
enzyme	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
effect	O
of	O
elevated	O
plasma	O
total	O
homocysteine	O
caused	O
by	O
cystathionine	B-Protein
beta	I-Protein
-	I-Protein
synthase	I-Protein
deficiency	O
on	O
one	O
-	O
carbon	O
metabolism	O
in	O
10	O
homozygous	O
mutant	O
mice	O
and	O
10	O
age	O
-	O
and	O
sex	O
-	O
matched	O
wild	O
-	O
type	O
mice	O
.	O

Plasma	O
total	O
homocysteine	O
levels	O
,	O
S	O
-	O
adenosylmethionine	O
and	O
S	O
-	O
adenosylhomocysteine	O
concentrations	O
in	O
liver	O
,	O
kidney	O
and	O
brain	O
were	O
measured	O
by	O
HPLC	O
.	O

Tissue	O
DNA	O
methylation	O
status	O
was	O
measured	O
by	O
in	O
vitro	O
DNA	O
methyl	O
acceptance	O
.	O

Plasma	O
total	O
homocysteine	O
concentration	O
in	O
food	O
-	O
deprived	O
homozygous	O
mutant	O
mice	O
(	O
271	O
.	O
1	O
+	O
/	O
-	O
61	O
.	O
5	O
micro	O
mol	O
/	O
L	O
)	O
was	O
markedly	O
higher	O
than	O
in	O
wild	O
-	O
type	O
mice	O
(	O
7	O
.	O
4	O
+	O
/	O
-	O
2	O
.	O
9	O
micro	O
mol	O
/	O
L	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
liver	O
only	O
,	O
S	O
-	O
adenosylmethionine	O
concentrations	O
were	O
higher	O
in	O
the	O
homozygous	O
mutant	O
mice	O
(	O
35	O
.	O
6	O
+	O
/	O
-	O
5	O
.	O
9	O
nmol	O
/	O
g	O
)	O
than	O
in	O
wild	O
type	O
mice	O
(	O
19	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
1	O
nmol	O
/	O
g	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
tended	O
to	O
be	O
lower	O
in	O
kidney	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

In	O
contrast	O
,	O
S	O
-	O
adenosylhomocysteine	O
concentrations	O
were	O
significantly	O
higher	O
in	O
homozygous	O
mutant	O
mice	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
in	O
all	O
tissues	O
studied	O
.	O

Genomic	O
DNA	O
methylation	O
status	O
in	O
homozygous	O
mutant	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
was	O
lower	O
in	O
liver	O
(	O
P	O
=	O
0	O
.	O
037	O
)	O
and	O
tended	O
to	O
be	O
lower	O
in	O
kidney	O
(	O
P	O
=	O
0	O
.	O
077	O
)	O
but	O
did	O
not	O
differ	O
in	O
brain	O
(	O
P	O
=	O
0	O
.	O
46	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
are	O
consistent	O
with	O
the	O
predicted	O
role	O
of	O
cystathionine	B-Protein
beta	I-Protein
-	I-Protein
synthase	I-Protein
in	O
the	O
regulation	O
of	O
plasma	O
total	O
homocysteine	O
levels	O
and	O
tissue	O
S	O
-	O
adenosylhomocysteine	O
levels	O
.	O

However	O
,	O
the	O
fact	O
that	O
the	O
absence	O
of	O
the	O
enzyme	O
had	O
differential	O
effects	O
on	O
S	O
-	O
adenosylmethionine	O
concentrations	O
and	O
DNA	O
methylation	O
status	O
in	O
different	O
tissues	O
suggests	O
that	O
regulation	O
of	O
biological	O
methylation	O
is	O
a	O
complex	O
tissue	O
-	O
specific	O
phenomenon	O
.	O

Glycosylation	O
of	O
human	O
proteinase	B-Protein
-	I-Protein
activated	I-Protein
receptor	I-Protein
-	I-Protein
2	I-Protein
(	O
hPAR2	B-Protein
)	O
:	O
role	O
in	O
cell	O
surface	O
expression	O
and	O
signalling	O
.	O

We	O
have	O
analysed	O
the	O
role	O
of	O
N	O
-	O
linked	O
glycosylation	O
in	O
regulating	O
human	O
proteinase	B-Protein
-	I-Protein
activated	I-Protein
receptor	I-Protein
-	I-Protein
2	I-Protein
(	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
)	O
expression	O
and	O
function	O
.	O

Epitope	O
-	O
tagged	O
wild	O
-	O
type	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
(	O
wt	O
-	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
)	O
or	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
that	O
lacked	O
glycosylation	O
sequons	O
(	O
following	O
site	O
-	O
directed	O
mutagenesis	O
)	O
in	O
either	O
the	O
N	O
-	O
terminus	O
[	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N30A	O
(	O
Asn	O
(	O
30	O
)	O
-	O
-	O
>	O
Ala	O
)	O
]	O
,	O
extracellular	O
loop	O
2	O
[	O
ECL2	O
;	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N222Q	O
(	O
Asn	O
(	O
222	O
)	O
-	O
-	O
>	O
Gln	O
)	O
or	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N222A	O
(	O
Asn	O
(	O
222	O
)	O
-	O
-	O
>	O
Ala	O
)	O
]	O
or	O
both	O
(	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N30A	O
,	O
N222A	O
or	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N30A	O
,	O
N222Q	O
)	O
were	O
expressed	O
in	O
the	O
Chinese	O
-	O
hamster	O
ovary	O
(	O
CHO	O
)	O
fibroblast	O
cell	O
line	O
,	O
Pro5	O
.	O

Western	O
blot	O
analysis	O
of	O
wt	O
-	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
showed	O
mature	O
wt	O
-	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
to	O
have	O
a	O
molecular	O
mass	O
of	O
55	O
-	O
100	O
kDa	O
,	O
and	O
33	O
-	O
48	O
kDa	O
following	O
N	B-Protein
-	I-Protein
glycosidase	I-Protein
F	I-Protein
deglycosylation	O
.	O

FACS	O
analysis	O
and	O
immunocytochemistry	O
of	O
the	O
wt	O
-	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
and	O
PAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
mutant	O
cell	O
lines	O
revealed	O
that	O
removal	O
of	O
both	O
glycosylation	O
sequons	O
decreases	O
(	O
50	O
%	O
of	O
wt	O
-	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
)	O
cell	O
surface	O
expression	O
.	O

Western	O
blot	O
analysis	O
indicated	O
that	O
both	O
N	O
-	O
linked	O
sites	O
are	O
glycosylated	O
.	O

In	O
functional	O
studies	O
,	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N30A	O
displayed	O
a	O
selective	O
and	O
significant	O
increase	O
in	O
sensitivity	O
towards	O
tryptase	O
.	O

Interestingly	O
,	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N222A	O
displayed	O
a	O
loss	O
in	O
sensitivity	O
towards	O
all	O
PAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
agonists	O
tested	O
.	O

However	O
,	O
further	O
analysis	O
revealed	O
receptor	O
sensitivity	O
to	O
alanine	O
mutations	O
in	O
this	O
domain	O
,	O
as	O
the	O
more	O
conservative	O
substitution	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N222Q	O
displayed	O
no	O
change	O
in	O
response	O
to	O
PAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
agonists	O
.	O

hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N30A	O
,	O
N222Q	O
displayed	O
increased	O
sensitivity	O
towards	O
tryptase	O
,	O
but	O
a	O
loss	O
in	O
sensitivity	O
towards	O
trypsin	O
and	O
the	O
synthetic	O
peptide	O
SLIGRL	O
-	O
NH	O
(	O
2	O
)	O
,	O
although	O
this	O
loss	O
in	O
sensitivity	O
towards	O
trypsin	O
and	O
SLIGRL	O
-	O
NH	O
(	O
2	O
)	O
was	O
secondary	O
to	O
changes	O
in	O
cell	O
-	O
surface	O
expression	O
.	O

Finally	O
,	O
expression	O
of	O
sialic	O
-	O
acid	O
-	O
deficient	O
wt	O
-	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
in	O
the	O
CHO	O
Lec2	O
glycosylation	O
-	O
deficient	O
mutant	O
cell	O
line	O
,	O
showed	O
a	O
40	O
kDa	O
loss	O
in	O
molecular	O
mass	O
,	O
in	O
addition	O
to	O
a	O
marked	O
and	O
selective	O
increase	O
in	O
sensitivity	O
towards	O
tryptase	O
.	O

We	O
conclude	O
that	O
hPAR	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
N	O
-	O
linked	O
glycosylation	O
and	O
sialylation	O
regulates	O
receptor	O
expression	O
and	O
/	O
or	O
signalling	O
.	O

N	B-Protein
-	I-Protein
acetyltransferase	I-Protein
2	I-Protein
genotype	O
-	O
related	O
sulfapyridine	O
acetylation	O
and	O
its	O
adverse	O
events	O
.	O

Sulfapyridine	O
(	O
SP	O
)	O
,	O
one	O
of	O
the	O
metabolites	O
of	O
sulfasalazine	O
(	O
SASP	O
)	O
,	O
is	O
further	O
metabolized	O
into	O
N	O
-	O
acetylsulfapyridine	O
(	O
AcSP	O
)	O
by	O
polymorphic	O
N	B-Protein
-	I-Protein
acetyltransferase	I-Protein
2	I-Protein
(	O
NAT2	B-Protein
)	O
.	O

NAT2	B-Protein
activity	O
has	O
been	O
diagnosed	O
by	O
phenotyping	O
,	O
that	O
is	O
,	O
evaluating	O
plasma	O
concentrations	O
or	O
urinary	O
excretions	O
of	O
tentatively	O
administered	O
test	O
drugs	O
for	O
dose	O
individualization	O
and	O
avoidance	O
of	O
serious	O
adverse	O
events	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
NAT2	B-Protein
genotypes	O
and	O
the	O
pharmacokinetics	O
of	O
SP	O
in	O
healthy	O
Japanese	O
subjects	O
,	O
as	O
well	O
as	O
the	O
adverse	O
events	O
of	O
SASP	O
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Eight	O
healthy	O
subjects	O
and	O
13	O
IBD	O
patients	O
were	O
classified	O
into	O
three	O
groups	O
by	O
NAT2	B-Protein
genotyping	O
;	O
the	O
homozygote	O
for	O
the	O
wild	O
-	O
type	O
allele	O
(	O
Rapid	O
Types	O
)	O
,	O
the	O
compound	O
heterozygote	O
for	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
alleles	O
(	O
Intermediate	O
Types	O
)	O
,	O
and	O
the	O
homozygote	O
for	O
mutant	O
alleles	O
(	O
Slow	O
Types	O
)	O
.	O

A	O
single	O
oral	O
dose	O
of	O
40	O
mg	O
/	O
kg	O
SASP	O
was	O
administered	O
to	O
each	O
healthy	O
subject	O
,	O
and	O
plasma	O
and	O
urine	O
samples	O
were	O
taken	O
until	O
51	O
and	O
72	O
h	O
after	O
administration	O
,	O
respectively	O
.	O

Both	O
the	O
SP	O
and	O
AcSP	O
concentrations	O
in	O
each	O
sample	O
were	O
determined	O
by	O
the	O
HPLC	O
method	O
.	O

The	O
NAT2	B-Protein
genotypes	O
were	O
well	O
-	O
correlated	O
with	O
the	O
plasma	O
concentrations	O
or	O
urinary	O
excretions	O
of	O
SP	O
and	O
AcSP	O
in	O
8	O
healthy	O
subjects	O
,	O
except	O
for	O
one	O
Slow	O
Type	O
.	O

In	O
patients	O
with	O
IBD	O
,	O
skin	O
rash	O
was	O
seen	O
in	O
3	O
of	O
6	O
Rapid	O
Types	O
and	O
1	O
of	O
6	O
Intermediate	O
Types	O
,	O
consistent	O
with	O
the	O
concept	O
that	O
hypersensitive	O
reactions	O
are	O
independent	O
of	O
serum	O
SP	O
concentrations	O
.	O

In	O
contrast	O
,	O
SASP	O
dosing	O
-	O
related	O
acute	O
pancreatitis	O
was	O
found	O
in	O
the	O
Slow	O
Type	O
patient	O
.	O

In	O
this	O
case	O
,	O
the	O
NAT2	B-Protein
activity	O
was	O
diagnosed	O
by	O
genotyping	O
in	O
advance	O
,	O
and	O
the	O
medical	O
staff	O
could	O
pay	O
scrupulous	O
attention	O
,	O
resulting	O
in	O
no	O
serious	O
subjective	O
symptoms	O
such	O
as	O
abdominal	O
pain	O
,	O
anorexia	O
or	O
fever	O
.	O

Further	O
investigations	O
on	O
the	O
relationship	O
between	O
the	O
NAT2	B-Protein
genotype	O
and	O
adverse	O
events	O
are	O
required	O
,	O
although	O
genotyping	O
appeared	O
to	O
be	O
a	O
promising	O
method	O
to	O
avoid	O
such	O
serious	O
adverse	O
events	O
.	O

Histone	B-Protein
H3	I-Protein
lysine	O
4	O
methylation	O
is	O
mediated	O
by	O
Set1	B-Protein
and	O
promotes	O
maintenance	O
of	O
active	O
chromatin	O
states	O
in	O
fission	O
yeast	O
.	O

Methylation	O
of	O
histone	B-Protein
H3	I-Protein
at	O
lysine	O
4	O
(	O
H3	B-Protein
Lys	O
-	O
4	O
)	O
or	O
lysine	O
9	O
(	O
H3	B-Protein
Lys	O
-	O
9	O
)	O
is	O
known	O
to	O
define	O
active	O
and	O
silent	O
chromosomal	O
domains	O
respectively	O
from	O
fission	O
yeast	O
to	O
humans	O
.	O

However	O
,	O
in	O
budding	O
yeast	O
,	O
H3	B-Protein
Lys	O
-	O
4	O
methylation	O
is	O
also	O
necessary	O
for	O
silent	O
chromatin	O
assembly	O
at	O
telomeres	O
and	O
ribosomal	O
DNA	O
.	O

Here	O
we	O
demonstrate	O
that	O
deletion	O
of	O
set1	B-Protein
,	O
which	O
encodes	O
a	O
protein	O
containing	O
an	O
RNA	O
recognition	O
motif	O
at	O
its	O
amino	O
terminus	O
and	O
a	O
SET	O
domain	O
at	O
the	O
carboxy	O
terminus	O
,	O
abolishes	O
H3	B-Protein
Lys	O
-	O
4	O
methylation	O
in	O
fission	O
yeast	O
.	O

Unlike	O
in	O
budding	O
yeast	O
,	O
Set1	B-Protein
-	O
mediated	O
H3	B-Protein
Lys	O
-	O
4	O
methylation	O
is	O
not	O
required	O
for	O
heterochromatin	O
assembly	O
at	O
the	O
silent	O
mating	O
-	O
type	O
region	O
and	O
centromeres	O
in	O
fission	O
yeast	O
.	O

Our	O
analysis	O
suggests	O
that	O
H3	B-Protein
Lys	O
-	O
4	O
methylation	O
is	O
a	O
stable	O
histone	B-Protein
modification	O
present	O
throughout	O
the	O
cell	O
cycle	O
,	O
including	O
mitosis	O
.	O

The	O
loss	O
of	O
H3	B-Protein
Lys	O
-	O
4	O
methylation	O
in	O
set1Delta	B-Protein
cells	O
is	O
correlated	O
with	O
a	O
decrease	O
in	O
histone	B-Protein
H3	I-Protein
acetylation	O
levels	O
,	O
suggesting	O
a	O
mechanistic	O
link	O
between	O
H3	B-Protein
Lys	O
-	O
4	O
methylation	O
and	O
acetylation	O
of	O
the	O
H3	B-Protein
tail	O
.	O

We	O
suggest	O
that	O
methylation	O
of	O
H3	B-Protein
Lys	O
-	O
4	O
primarily	O
acts	O
in	O
the	O
maintenance	O
of	O
transcriptionally	O
poised	O
euchromatic	O
domains	O
,	O
and	O
that	O
this	O
modification	O
is	O
dispensable	O
for	O
heterochromatin	O
formation	O
in	O
fission	O
yeast	O
,	O
which	O
instead	O
utilizes	O
H3	B-Protein
Lys	O
-	O
9	O
methylation	O
.	O

Hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
asparaginyl	I-Protein
hydroxylase	I-Protein
(	O
FIH	B-Protein
-	I-Protein
1	I-Protein
)	O
catalyses	O
hydroxylation	O
at	O
the	O
beta	O
-	O
carbon	O
of	O
asparagine	O
-	O
803	O
.	O

Asparagine	O
-	O
803	O
in	O
the	O
C	O
-	O
terminal	O
transactivation	O
domain	O
of	O
human	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	I-Protein
HIF	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
-	I-Protein
subunit	I-Protein
is	O
hydroxylated	O
by	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
-	I-Protein
1	I-Protein
(	O
FIH	B-Protein
-	I-Protein
1	I-Protein
)	O
under	O
normoxic	O
conditions	O
causing	O
abrogation	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
/	O
p300	B-Protein
interaction	O
.	O

NMR	O
and	O
other	O
analyses	O
of	O
a	O
hydroxylated	O
HIF	O
fragment	O
produced	O
in	O
vitro	O
demonstrate	O
that	O
hydroxylation	O
occurs	O
at	O
the	O
beta	O
-	O
carbon	O
of	O
Asn	O
-	O
803	O
and	O
imply	O
production	O
of	O
the	O
threo	O
-	O
isomer	O
,	O
in	O
contrast	O
with	O
other	O
known	O
aspartic	O
acid	O
/	O
asparagine	O
hydroxylases	O
that	O
produce	O
the	O
erythro	O
-	O
isomer	O
.	O

Effect	O
of	O
the	O
alcohol	O
extract	O
of	O
the	O
seeds	O
of	O
Mucuna	O
pruriens	O
on	O
free	O
radicals	O
and	O
oxidative	O
stress	O
in	O
albino	O
rats	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
were	O
made	O
with	O
an	O
alcohol	O
extract	O
of	O
the	O
seeds	O
of	O
Mucuna	O
pruriens	O
(	O
Fabaceae	O
)	O
to	O
investigate	O
its	O
antioxidant	O
property	O
.	O

In	O
vitro	O
studies	O
were	O
carried	O
out	O
in	O
rat	O
liver	O
homogenate	O
to	O
investigate	O
the	O
chemical	O
interaction	O
of	O
various	O
phytochemicals	O
with	O
different	O
species	O
of	O
free	O
radicals	O
.	O

The	O
effect	O
was	O
also	O
checked	O
on	O
iron	O
-	O
induced	O
lipid	O
peroxidation	O
,	O
oxidation	O
of	O
GSH	O
content	O
,	O
and	O
its	O
interaction	O
with	O
hydroxyl	O
and	O
superoxide	O
radicals	O
.	O

There	O
was	O
no	O
change	O
on	O
the	O
rate	O
of	O
aerial	O
oxidation	O
of	O
GSH	O
content	O
but	O
it	O
significantly	O
inhibited	O
FeSO	O
(	O
4	O
)	O
induced	O
lipid	O
peroxidation	O
.	O

It	O
also	O
inhibited	O
the	O
specific	O
chemical	O
reactions	O
induced	O
by	O
superoxides	O
and	O
hydroxyl	O
radicals	O
.	O

The	O
removal	O
of	O
these	O
species	O
was	O
through	O
direct	O
chemical	O
interaction	O
.	O

An	O
in	O
vivo	O
study	O
on	O
albino	O
rats	O
for	O
30	O
days	O
showed	O
no	O
toxic	O
effect	O
up	O
to	O
a	O
dose	O
of	O
600	O
mg	O
/	O
kg	O
body	O
weight	O
,	O
on	O
oral	O
administration	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
level	O
of	O
TBA	O
-	O
reactive	O
substances	O
,	O
reduced	O
glutathione	O
content	O
and	O
SOD	O
activity	O
in	O
the	O
liver	O
.	O

The	O
activity	O
of	O
serum	O
GOT	B-Protein
,	O
GPT	B-Protein
and	O
alkaline	O
phosphatase	O
was	O
also	O
unchanged	O
.	O

Thus	O
it	O
could	O
be	O
concluded	O
that	O
the	O
alcohol	O
extract	O
of	O
the	O
seeds	O
of	O
M	O
.	O
pruriens	O
has	O
an	O
antilipid	O
peroxidation	O
property	O
,	O
which	O
is	O
mediated	O
through	O
the	O
removal	O
of	O
superoxides	O
and	O
hydroxyl	O
radicals	O
.	O

Induction	O
of	O
apoptosis	O
of	O
human	O
B	O
-	O
CLL	O
and	O
ALL	O
cells	O
by	O
a	O
novel	O
retinoid	O
and	O
its	O
nonretinoidal	O
analog	O
.	O

We	O
have	O
recently	O
described	O
a	O
novel	O
retinoid	O
6	O
-	O
[	O
3	O
-	O
(	O
1	O
-	O
adamantyl	O
)	O
-	O
4	O
-	O
hydroxyphenyl	O
]	O
-	O
2	O
-	O
naphthalenecarboxylic	O
acid	O
(	O
CD437	O
/	O
AHPN	O
)	O
that	O
induces	O
apoptosis	O
in	O
a	O
number	O
of	O
malignant	O
cell	O
types	O
.	O

We	O
now	O
describe	O
our	O
studies	O
examining	O
the	O
effects	O
of	O
CD437	O
and	O
a	O
nonretinoidal	O
analog	O
(	O
MM002	O
)	O
on	O
the	O
in	O
vitro	O
proliferation	O
of	O
the	O
ALL	O
-	O
REH	O
cell	O
line	O
,	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
growth	O
of	O
a	O
novel	O
Epstein	O
-	O
Barr	O
virus	O
-	O
negative	O
(	O
EBV	O
(	O
-	O
)	O
)	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B	O
-	O
CLL	O
)	O
cell	O
line	O
(	O
WSU	O
-	O
CLL	O
)	O
,	O
and	O
primary	O
cultures	O
of	O
human	O
B	O
-	O
CLL	O
and	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
cells	O
.	O

CD437	O
and	O
MM002	O
induce	O
apoptosis	O
in	O
both	O
cell	O
lines	O
,	O
as	O
indicated	O
by	O
the	O
activation	O
of	O
caspase	B-Protein
-	I-Protein
2	I-Protein
and	O
caspase	B-Protein
-	I-Protein
3	I-Protein
,	O
cleavage	O
of	O
poly	O
(	O
adenosine	O
diphosphate	O
-	O
ribose	O
)	O
(	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
)	O
polymerase	O
,	O
increase	O
in	O
annexin	B-Protein
V	I-Protein
binding	O
,	O
and	O
subsequent	O
nuclear	O
fragmentation	O
.	O

CD437	O
-	O
mediated	O
apoptosis	O
was	O
not	O
associated	O
with	O
the	O
modulation	O
of	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
,	O
Bax	B-Protein
,	O
or	O
Mcl	B-Protein
-	I-Protein
1	I-Protein
levels	O
,	O
but	O
was	O
associated	O
with	O
the	O
cleavage	O
of	O
the	O
antiapoptotic	O
protein	O
Bcl	B-Protein
-	I-Protein
X	I-Protein
(	I-Protein
L	I-Protein
)	I-Protein
to	O
a	O
proapoptotic	O
18	O
-	O
kD	O
form	O
.	O

This	O
cleavage	O
of	O
Bcl	B-Protein
-	I-Protein
X	I-Protein
(	I-Protein
L	I-Protein
)	I-Protein
was	O
dependent	O
on	O
caspase	B-Protein
-	I-Protein
3	I-Protein
activation	O
since	O
Bcl	B-Protein
-	I-Protein
X	I-Protein
(	I-Protein
L	I-Protein
)	I-Protein
cleavage	O
and	O
apoptosis	O
were	O
inhibited	O
by	O
the	O
caspase	B-Protein
-	I-Protein
3	I-Protein
inhibitor	O
Z	O
-	O
DVED	O
-	O
fmk	O
.	O

CD437	O
markedly	O
inhibited	O
the	O
growth	O
of	O
WSU	O
-	O
CLL	O
cells	O
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
.	O

Tumor	O
growth	O
inhibition	O
,	O
growth	O
delay	O
,	O
and	O
log	O
cell	O
kill	O
were	O
85	O
.	O
7	O
%	O
,	O
21	O
days	O
,	O
and	O
2	O
.	O
1	O
,	O
respectively	O
,	O
in	O
the	O
treated	O
mice	O
.	O

Moreover	O
,	O
1	O
of	O
the	O
5	O
treated	O
mice	O
was	O
tumor	O
-	O
free	O
longer	O
than	O
150	O
days	O
and	O
thus	O
was	O
considered	O
cured	O
.	O

Exposure	O
of	O
primary	O
cultures	O
of	O
both	O
B	O
-	O
CLL	O
and	O
ALL	O
cells	O
obtained	O
from	O
patients	O
to	O
CD437	O
and	O
MM002	O
resulted	O
in	O
their	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
CD437	O
and	O
MM002	O
analogs	O
may	O
have	O
a	O
potential	O
role	O
in	O
the	O
treatment	O
of	O
B	O
-	O
CLL	O
and	O
ALL	O
.	O

Biochemical	O
purification	O
and	O
pharmacological	O
inhibition	O
of	O
a	O
mammalian	O
prolyl	O
hydroxylase	O
acting	O
on	O
hypoxia	O
-	O
inducible	O
factor	O
.	O

The	O
product	O
of	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
gene	I-Protein
,	O
pVHL	B-Protein
,	O
targets	O
the	O
alpha	O
subunits	O
of	O
the	O
heterodimeric	O
transcription	O
factor	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
for	O
polyubiquitination	O
in	O
the	O
presence	O
of	O
oxygen	O
.	O

The	O
binding	O
of	O
pVHL	B-Protein
to	O
HIF	O
is	O
governed	O
by	O
the	O
enzymatic	O
hydroxylation	O
of	O
conserved	O
prolyl	O
residues	O
within	O
peptidic	O
motifs	O
present	O
in	O
the	O
HIFalpha	O
family	O
members	O
.	O

By	O
using	O
a	O
biochemical	O
purification	O
strategy	O
,	O
we	O
have	O
identified	O
a	O
human	O
homolog	O
of	O
Caenorhabditis	O
elegans	O
Egl9	B-Protein
as	O
a	O
HIF	O
prolyl	O
hydroxylase	O
.	O

In	O
addition	O
,	O
we	O
studied	O
the	O
activity	O
of	O
a	O
structurally	O
diverse	O
collection	O
of	O
low	O
molecular	O
weight	O
inhibitors	O
of	O
procollagen	O
prolyl	O
4	O
-	O
hydroxylase	O
as	O
potential	O
inhibitors	O
of	O
the	O
HIF	O
hydroxylase	O
.	O

A	O
model	O
compound	O
of	O
this	O
series	O
stabilized	O
HIF	O
in	O
a	O
variety	O
of	O
cells	O
,	O
leading	O
to	O
the	O
increased	O
production	O
of	O
its	O
downstream	O
target	O
,	O
vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	I-Protein
.	O

Control	O
of	O
CBP	B-Protein
co	O
-	O
activating	O
activity	O
by	O
arginine	O
methylation	O
.	O

The	O
histone	B-Protein
acetyltransferases	O
CREB	B-Protein
binding	I-Protein
protein	I-Protein
(	O
CBP	B-Protein
)	O
and	O
the	O
related	O
p300	B-Protein
protein	O
function	O
as	O
key	O
transcriptional	O
co	O
-	O
activators	O
in	O
multiple	O
pathways	O
.	O

In	O
the	O
case	O
of	O
transcriptional	O
activation	O
by	O
nuclear	O
receptors	O
,	O
ligand	O
promotes	O
the	O
recruitment	O
of	O
co	O
-	O
activators	O
of	O
the	O
p160	O
family	O
,	O
such	O
as	O
GRIP	B-Protein
-	I-Protein
1	I-Protein
.	O

Subsequently	O
,	O
the	O
p160	O
co	O
-	O
activators	O
recruit	O
other	O
co	O
-	O
activators	O
via	O
two	O
activation	O
domains	O
,	O
AD1	O
and	O
AD2	O
.	O

AD1	O
binds	O
CBP	B-Protein
or	O
p300	B-Protein
,	O
whereas	O
AD2	O
has	O
been	O
shown	O
to	O
activate	O
transcription	O
through	O
the	O
recruitment	O
of	O
the	O
arginine	O
methyltransferase	O
CARM1	B-Protein
.	O

Recently	O
,	O
the	O
KIX	O
domain	O
of	O
CBP	B-Protein
has	O
been	O
shown	O
to	O
be	O
methylated	O
by	O
CARM1	B-Protein
in	O
vitro	O
.	O

Here	O
,	O
we	O
report	O
that	O
another	O
domain	O
of	O
CBP	B-Protein
is	O
specifically	O
methylated	O
by	O
CARM1	B-Protein
on	O
conserved	O
arginine	O
residues	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
also	O
provide	O
functional	O
evidence	O
that	O
arginine	O
residues	O
methylated	O
by	O
CARM1	B-Protein
play	O
a	O
critical	O
role	O
in	O
GRIP	B-Protein
-	I-Protein
1	I-Protein
-	O
dependent	O
transcriptional	O
activation	O
and	O
in	O
hormone	O
-	O
induced	O
gene	O
activation	O
.	O

Altogether	O
,	O
our	O
data	O
provide	O
strong	O
evidence	O
that	O
arginine	O
methylation	O
represents	O
an	O
important	O
mechanism	O
for	O
modulating	O
co	O
-	O
activator	O
transcriptional	O
activity	O
.	O

The	O
hepatitis	O
C	O
virus	O
RNA	B-Protein
-	I-Protein
dependent	I-Protein
RNA	I-Protein
polymerase	I-Protein
membrane	O
insertion	O
sequence	O
is	O
a	O
transmembrane	O
segment	O
.	O

The	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
RNA	B-Protein
-	I-Protein
dependent	I-Protein
RNA	I-Protein
polymerase	I-Protein
(	O
RdRp	B-Protein
)	O
belongs	O
to	O
a	O
class	O
of	O
membrane	O
proteins	O
termed	O
tail	O
-	O
anchored	O
proteins	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
HCV	O
RdRp	B-Protein
C	O
-	O
terminal	O
membrane	O
insertion	O
sequence	O
traverses	O
the	O
phospholipid	O
bilayer	O
as	O
a	O
transmembrane	O
segment	O
.	O

Moreover	O
,	O
the	O
HCV	O
RdRp	B-Protein
was	O
found	O
to	O
be	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
or	O
an	O
ER	O
-	O
derived	O
modified	O
compartment	O
both	O
following	O
transient	O
transfection	O
and	O
in	O
the	O
context	O
of	O
a	O
subgenomic	O
replicon	O
.	O

An	O
absolutely	O
conserved	O
GVG	O
motif	O
was	O
not	O
essential	O
for	O
membrane	O
insertion	O
but	O
possibly	O
provides	O
a	O
docking	O
site	O
for	O
transmembrane	O
protein	O
-	O
protein	O
interactions	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
the	O
functional	O
architecture	O
of	O
the	O
HCV	O
replication	O
complex	O
.	O

Molecular	O
and	O
biochemical	O
characterisation	O
of	O
a	O
novel	O
sulphatase	O
gene	O
:	O
Arylsulfatase	B-Protein
G	I-Protein
(	O
ARSG	B-Protein
)	O
.	O

Molecular	O
analysis	O
has	O
provided	O
important	O
insights	O
into	O
the	O
biochemistry	O
and	O
genetics	O
of	O
the	O
sulphatase	O
family	O
of	O
enzymes	O
.	O

Through	O
bioinformatic	O
searches	O
of	O
the	O
EST	O
database	O
,	O
we	O
have	O
identified	O
a	O
novel	O
gene	O
consisting	O
of	O
11	O
exons	O
and	O
encoding	O
a	O
525	O
aa	O
protein	O
that	O
shares	O
a	O
high	O
degree	O
of	O
sequence	O
similarity	O
with	O
all	O
sulphatases	O
and	O
in	O
particular	O
with	O
arylsulphatases	O
,	O
hence	O
the	O
tentative	O
name	O
Arylsulfatase	B-Protein
G	I-Protein
(	O
ARSG	B-Protein
)	O
.	O

The	O
highest	O
homology	O
is	O
shared	O
with	O
Arylsulfatase	B-Protein
A	I-Protein
,	O
a	O
lysosomal	O
sulphatase	O
which	O
is	O
mutated	O
in	O
metachromatic	O
leukodistrophy	O
,	O
particularly	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
.	O

The	O
10	O
amino	O
acids	O
that	O
form	O
the	O
catalytic	O
site	O
are	O
strongly	O
conserved	O
.	O

The	O
murine	O
homologue	O
of	O
Arylsulfatase	B-Protein
G	I-Protein
gene	O
product	O
shows	O
87	O
%	O
identity	O
with	O
the	O
human	O
protein	O
.	O

To	O
test	O
the	O
function	O
of	O
this	O
novel	O
gene	O
we	O
transfected	O
the	O
full	O
-	O
length	O
cDNA	O
in	O
Cos7	O
cells	O
,	O
and	O
detected	O
an	O
Arylsulfatase	B-Protein
G	I-Protein
precursor	O
protein	O
of	O
62	O
kDa	O
.	O

After	O
glycosylation	O
the	O
precursor	O
is	O
maturated	O
in	O
a	O
70	O
kDa	O
form	O
,	O
which	O
localises	O
to	O
the	O
endoplasmic	O
reticulum	O
.	O

Northern	O
blot	O
analysis	O
of	O
Arylsulfatase	B-Protein
G	I-Protein
revealed	O
a	O
ubiquitous	O
expression	O
pattern	O
.	O

We	O
tested	O
the	O
sulphatase	O
activity	O
towards	O
two	O
different	O
artificial	O
substrates	O
4	O
-	O
methylumbelliferyl	O
(	O
4	O
-	O
MU	O
)	O
sulphate	O
and	O
p	O
-	O
nitrocatechol	O
sulphate	O
,	O
but	O
no	O
arylsulphatase	O
activity	O
was	O
detectable	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
characterise	O
the	O
function	O
of	O
Arylsulfatase	B-Protein
G	I-Protein
,	O
possibly	O
revealing	O
a	O
novel	O
metabolic	O
pathway	O
.	O

Gene	O
-	O
specific	O
targeting	O
of	O
H3K9	B-Protein
methylation	O
is	O
sufficient	O
for	O
initiating	O
repression	O
in	O
vivo	O
.	O

Covalent	O
modifications	O
of	O
chromatin	O
have	O
emerged	O
as	O
key	O
determinants	O
of	O
the	O
genome	O
'	O
s	O
transcriptional	O
competence	O
.	O

Histone	B-Protein
H3	I-Protein
lysine	O
9	O
(	O
H3K9	B-Protein
)	O
methylation	O
is	O
an	O
epigenetic	O
signal	O
that	O
is	O
recognized	O
by	O
HP1	O
and	O
correlates	O
with	O
gene	O
silencing	O
in	O
a	O
variety	O
of	O
organisms	O
.	O

Discovery	O
of	O
the	O
enzymes	O
that	O
catalyze	O
H3K9	B-Protein
methylation	O
has	O
identified	O
a	O
second	O
gene	O
-	O
specific	O
function	O
for	O
this	O
modification	O
in	O
transcriptional	O
repression	O
.	O

Whether	O
H3K9	B-Protein
methylation	O
is	O
causative	O
in	O
the	O
initiation	O
and	O
establishment	O
of	O
gene	O
repression	O
or	O
is	O
a	O
byproduct	O
of	O
the	O
process	O
leading	O
to	O
the	O
repressed	O
state	O
remains	O
unknown	O
.	O

To	O
investigate	O
the	O
role	O
of	O
HMTs	O
and	O
specifically	O
H3K9	B-Protein
methylation	O
in	O
gene	O
repression	O
,	O
we	O
have	O
employed	O
engineered	O
zinc	O
-	O
finger	O
transcription	O
factors	O
(	O
ZFPs	O
)	O
to	O
target	O
HMT	O
activity	O
to	O
a	O
specific	O
endogenous	O
gene	O
.	O

By	O
utilizing	O
ZFPs	O
that	O
recognize	O
the	O
promoter	O
of	O
the	O
endogenous	O
VEGF	B-Protein
-	I-Protein
A	I-Protein
gene	O
,	O
and	O
thus	O
employing	O
this	O
chromosomal	O
locus	O
as	O
an	O
in	O
vivo	O
reporter	O
,	O
we	O
show	O
that	O
ZFPs	O
linked	O
to	O
a	O
minimal	O
catalytic	O
HMT	O
domain	O
affect	O
local	O
methylation	O
of	O
histone	B-Protein
H3K9	I-Protein
and	O
the	O
consequent	O
repression	O
of	O
target	O
gene	O
expression	O
.	O

Furthermore	O
,	O
amino	O
acid	O
substitutions	O
within	O
the	O
HMT	O
that	O
ablate	O
its	O
catalytic	O
activity	O
effectively	O
eliminate	O
the	O
ability	O
of	O
the	O
ZFP	O
fusions	O
to	O
repress	O
transcription	O
.	O

Thus	O
,	O
H3K9	B-Protein
methylation	O
is	O
a	O
primary	O
signal	O
that	O
is	O
sufficient	O
for	O
initiating	O
a	O
gene	O
repression	O
pathway	O
in	O
vivo	O
.	O

Studies	O
on	O
the	O
inhibition	O
of	O
human	O
cytochromes	O
P450	O
by	O
selenocysteine	O
Se	O
-	O
conjugates	O
.	O

1	O
.	O

To	O
investigate	O
whether	O
cytochrome	O
P450	O
(	O
P450	O
)	O
inhibition	O
can	O
contribute	O
to	O
the	O
chemopreventive	O
activity	O
of	O
selenocysteine	O
Se	O
-	O
conjugates	O
(	O
SeCys	O
conjugates	O
)	O
,	O
21	O
SeCys	O
conjugates	O
were	O
screened	O
for	O
their	O
inhibitory	O
potency	O
towards	O
seven	O
of	O
the	O
most	O
important	O
human	O
P450s	O
.	O

2	O
.	O

The	O
majority	O
of	O
the	O
SeCys	O
conjugates	O
produced	O
near	O
complete	O
inhibition	O
of	O
CYP1A1	B-Protein
at	O
a	O
concentration	O
of	O
250	O
microm	O
.	O

The	O
most	O
potent	O
inhibitor	O
,	O
Se	O
-	O
benzyl	O
-	O
L	O
-	O
selenocysteine	O
,	O
displayed	O
an	O
IC50	O
of	O
12	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
2	O
microm	O
.	O

CYP2C9	B-Protein
,	O
-	B-Protein
2C19	I-Protein
and	O
-	B-Protein
2D6	I-Protein
were	O
moderately	O
(	O
50	O
-	O
60	O
%	O
)	O
inhibited	O
by	O
the	O
SeCys	O
conjugates	O
.	O

CYP1A2	B-Protein
,	O
-	B-Protein
2E1	I-Protein
and	O
-	B-Protein
3A4	I-Protein
were	O
least	O
inhibited	O
.	O

3	O
.	O

Studies	O
on	O
the	O
susceptibility	O
of	O
CYP1A1	B-Protein
to	O
SeCys	O
conjugates	O
implicated	O
a	O
thiol	O
-	O
reactive	O
intermediate	O
,	O
as	O
evidenced	O
by	O
reduced	O
inhibition	O
levels	O
in	O
the	O
presence	O
of	O
glutathione	O
and	O
N	O
-	O
acetyl	O
cysteine	O
.	O

Uncoupling	O
of	O
the	O
P450	O
-	O
catalytic	O
cycle	O
was	O
of	O
no	O
importance	O
as	O
ROS	O
scavengers	O
did	O
not	O
influence	O
inhibition	O
levels	O
.	O

4	O
.	O

P450	O
inhibition	O
by	O
two	O
physiologically	O
relevant	O
metabolite	O
classes	O
of	O
SeCys	O
conjugates	O
was	O
also	O
studied	O
.	O

N	O
-	O
acetylation	O
of	O
SeCys	O
conjugates	O
consistently	O
increased	O
the	O
inhibitory	O
potency	O
towards	O
CYP1A2	B-Protein
,	O
-	B-Protein
2C19	I-Protein
,	O
-	B-Protein
2E1	I-Protein
and	O
-	B-Protein
3A4	I-Protein
.	O

Beta	O
-	O
lyase	O
catalysed	O
bioactivation	O
of	O
alkyl	O
-	O
substituted	O
SeCys	O
conjugates	O
or	O
Se	O
-	O
benzyl	O
-	O
L	O
-	O
selenocysteine	O
produced	O
little	O
or	O
no	O
additional	O
inhibition	O
of	O
P450	O
activity	O
.	O

For	O
Se	O
-	O
phenyl	O
-	O
L	O
-	O
selenocysteine	O
,	O
however	O
,	O
significant	O
increases	O
in	O
P450	O
inhibition	O
were	O
obtained	O
by	O
beta	O
-	O
lyase	O
pre	O
-	O
incubation	O
.	O

5	O
.	O

It	O
is	O
concluded	O
that	O
the	O
potent	O
and	O
relatively	O
selective	O
CYP1A1	B-Protein
inhibition	O
exerted	O
by	O
SeCys	O
conjugates	O
may	O
contribute	O
to	O
their	O
chemopreventive	O
activity	O
.	O

Identification	O
of	O
a	O
lactoferrin	B-Protein
-	O
derived	O
peptide	O
possessing	O
binding	O
activity	O
to	O
hepatitis	O
C	O
virus	O
E2	B-Protein
envelope	O
protein	O
.	O

Bovine	O
and	O
human	O
lactoferrins	B-Protein
(	O
LF	B-Protein
)	O
prevent	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
in	O
cultured	O
human	O
hepatocytes	O
;	O
the	O
preventive	O
mechanism	O
is	O
thought	O
to	O
be	O
the	O
direct	O
interaction	O
between	O
LF	B-Protein
and	O
HCV	O
.	O

To	O
clarify	O
this	O
hypothesis	O
,	O
we	O
have	O
characterized	O
the	O
binding	O
activity	O
of	O
LF	B-Protein
to	O
HCV	O
E2	B-Protein
envelope	O
protein	O
and	O
have	O
endeavored	O
to	O
determine	O
which	O
region	O
(	O
s	O
)	O
of	O
LF	B-Protein
are	O
important	O
for	O
this	O
binding	O
activity	O
.	O

Several	O
regions	O
of	O
human	O
LF	B-Protein
have	O
been	O
expressed	O
and	O
purified	O
as	O
thioredoxin	O
-	O
fused	O
proteins	O
in	O
Escherichia	O
coli	O
.	O

Far	O
-	O
Western	O
blot	O
analysis	O
using	O
these	O
LF	B-Protein
fragments	O
and	O
the	O
E2	B-Protein
protein	O
,	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
revealed	O
that	O
the	O
93	O
carboxyl	O
amino	O
acids	O
of	O
LF	B-Protein
specifically	O
bound	O
to	O
the	O
E2	B-Protein
protein	O
.	O

The	O
93	O
carboxyl	O
amino	O
acids	O
of	O
LFs	B-Protein
derived	O
from	O
bovine	O
and	O
horse	O
cells	O
also	O
possessed	O
similar	O
binding	O
activity	O
to	O
the	O
E2	B-Protein
protein	O
.	O

In	O
addition	O
,	O
the	O
amino	O
acid	O
sequences	O
of	O
these	O
carboxyl	O
regions	O
appeared	O
to	O
show	O
partial	O
homology	O
to	O
CD81	B-Protein
,	O
a	O
candidate	O
receptor	O
for	O
HCV	O
,	O
and	O
the	O
binding	O
activity	O
of	O
these	O
carboxyl	O
regions	O
was	O
also	O
comparable	O
with	O
that	O
of	O
CD81	B-Protein
.	O

Further	O
deletion	O
analysis	O
identified	O
33	O
amino	O
acid	O
residues	O
as	O
the	O
minimum	O
binding	O
site	O
in	O
the	O
carboxyl	O
region	O
of	O
LF	B-Protein
,	O
and	O
the	O
binding	O
specificity	O
of	O
these	O
33	O
amino	O
acids	O
was	O
also	O
confirmed	O
by	O
using	O
33	O
maltose	O
-	O
binding	O
protein	O
-	O
fused	O
amino	O
acids	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
that	O
the	O
33	O
maltose	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	O
fused	O
amino	O
acids	O
prevented	O
HCV	O
infection	O
in	O
cultured	O
human	O
hepatocytes	O
.	O

In	O
addition	O
,	O
the	O
site	O
-	O
directed	O
mutagenesis	O
to	O
an	O
Ala	O
residue	O
in	O
both	O
terminal	O
residues	O
of	O
the	O
33	O
amino	O
acids	O
revealed	O
that	O
Cys	O
at	O
amino	O
acid	O
628	O
was	O
determined	O
to	O
be	O
critical	O
for	O
binding	O
to	O
the	O
E2	B-Protein
protein	O
.	O

These	O
results	O
led	O
us	O
to	O
consider	O
the	O
development	O
of	O
an	O
effective	O
anti	O
-	O
HCV	O
peptide	O
.	O

This	O
is	O
the	O
first	O
identification	O
of	O
a	O
natural	O
protein	O
-	O
derived	O
peptide	O
that	O
specifically	O
binds	O
to	O
HCV	O
E2	B-Protein
protein	O
and	O
prevents	O
HCV	O
infection	O
.	O

Glucocorticoid	O
suppression	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
:	O
a	O
role	O
for	O
histone	B-Protein
modifications	O
.	O

Corticosteroids	O
are	O
by	O
far	O
the	O
most	O
effective	O
treatment	O
for	O
chronic	O
inflammatory	O
diseases	O
such	O
as	O
asthma	O
.	O

Inflammation	O
in	O
asthma	O
is	O
characterized	O
by	O
the	O
increased	O
expression	O
of	O
multiple	O
inflammatory	O
genes	O
,	O
including	O
those	O
that	O
encode	O
cytokines	O
,	O
chemokines	O
,	O
adhesion	O
molecules	O
,	O
and	O
inflammatory	O
enzymes	O
and	O
receptors	O
.	O

Increased	O
expression	O
of	O
inflammatory	O
genes	O
is	O
regulated	O
by	O
pro	O
-	O
inflammatory	O
transcription	O
factors	O
,	O
such	O
as	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

These	O
bind	O
to	O
,	O
and	O
activate	O
,	O
co	O
-	O
activator	O
molecules	O
that	O
then	O
acetylate	O
core	O
histones	B-Protein
resulting	O
in	O
elevated	O
gene	O
transcription	O
.	O

Corticosteroids	O
reverse	O
histone	B-Protein
acetylation	O
at	O
the	O
site	O
of	O
inflammatory	O
gene	O
transcription	O
,	O
either	O
by	O
direct	O
binding	O
of	O
the	O
activated	O
glucocorticoid	B-Protein
receptor	I-Protein
to	O
NF	O
-	O
kappa	O
B	O
-	O
associated	O
co	O
-	O
activators	O
or	O
by	O
recruitment	O
of	O
histone	B-Protein
deacetylases	O
to	O
the	O
activated	O
transcription	O
complex	O
.	O

Understanding	O
how	O
corticosteroids	O
work	O
in	O
asthma	O
may	O
help	O
in	O
designing	O
novel	O
corticosteroids	O
with	O
fewer	O
systemic	O
effects	O
,	O
as	O
well	O
as	O
novel	O
anti	O
-	O
inflammatory	O
approaches	O
.	O

Probing	O
the	O
conformational	O
and	O
dynamical	O
effects	O
of	O
O	O
-	O
glycosylation	O
within	O
the	O
immunodominant	O
region	O
of	O
a	O
MUC1	B-Protein
peptide	O
tumor	O
antigen	O
.	O

MUC1	B-Protein
mucin	O
is	O
a	O
large	O
transmembrane	O
glycoprotein	O
,	O
the	O
extracellular	O
domain	O
of	O
which	O
is	O
formed	O
by	O
a	O
repeating	O
20	O
amino	O
acid	O
sequence	O
,	O
GVTSAPDTRPAPGSTAPPAH	O
.	O

In	O
normal	O
breast	O
epithelial	O
cells	O
,	O
the	O
extracellular	O
domain	O
is	O
densely	O
covered	O
with	O
highly	O
branched	O
complex	O
carbohydrate	O
structures	O
.	O

However	O
,	O
in	O
neoplastic	O
breast	O
tissue	O
,	O
the	O
extracellular	O
domain	O
is	O
under	O
-	O
glycosylated	O
,	O
resulting	O
in	O
the	O
exposure	O
of	O
a	O
highly	O
immunogenic	O
core	O
peptide	O
epitope	O
(	O
PDTRP	O
in	O
bold	O
above	O
)	O
,	O
as	O
well	O
as	O
in	O
the	O
exposure	O
of	O
normally	O
cryptic	O
core	O
Tn	O
(	O
GalNAc	O
)	O
,	O
STn	O
(	O
sialyl	O
alpha2	O
-	O
6	O
GalNAc	O
)	O
and	O
TF	O
(	O
Gal	O
beta1	O
-	O
3	O
GalNAc	O
)	O
carbohydrates	O
.	O

Here	O
,	O
we	O
report	O
the	O
results	O
of	O
1H	O
NMR	O
structural	O
studies	O
,	O
natural	O
abundance	O
13C	O
NMR	O
relaxation	O
measurements	O
and	O
distance	O
-	O
restrained	O
MD	O
simulations	O
designed	O
to	O
probe	O
the	O
structural	O
and	O
dynamical	O
effects	O
of	O
Tn	O
-	O
glycosylation	O
within	O
the	O
PDTRP	O
core	O
peptide	O
epitope	O
.	O

Two	O
synthetic	O
peptides	O
were	O
studied	O
:	O
a	O
nine	O
-	O
residue	O
MUC1	B-Protein
peptide	O
of	O
the	O
sequence	O
,	O
Thr1	O
-	O
Ser2	O
-	O
Ala3	O
-	O
Pro4	O
-	O
Asp5	O
-	O
Thr6	O
-	O
Arg7	O
-	O
Pro8	O
-	O
Ala9	O
,	O
and	O
a	O
Tn	O
-	O
glycosylated	O
version	O
of	O
this	O
peptide	O
,	O
Thr1	O
-	O
Ser2	O
-	O
Ala3	O
-	O
Pro4	O
-	O
Asp5	O
-	O
Thr6	O
(	O
alphaGalNAc	O
)	O
-	O
Arg7	O
-	O
Pro8	O
-	O
Ala9	O
.	O

The	O
results	O
of	O
these	O
studies	O
show	O
that	O
a	O
type	O
I	O
beta	O
-	O
turn	O
conformation	O
is	O
adopted	O
by	O
residues	O
PDTR	O
within	O
the	O
PDTRP	O
region	O
of	O
the	O
unglycosylated	O
MUC1	B-Protein
sequence	O
.	O

The	O
existence	O
of	O
a	O
similar	O
beta	O
-	O
turn	O
within	O
the	O
PDTRP	O
core	O
peptide	O
epitope	O
of	O
the	O
under	O
-	O
glycosylated	O
cancer	O
-	O
associated	O
MUC1	B-Protein
mucin	O
protein	O
might	O
explain	O
the	O
immunodominance	O
of	O
this	O
region	O
in	O
vivo	O
,	O
as	O
the	O
presence	O
of	O
defined	O
secondary	O
structure	O
within	O
peptide	O
epitope	O
regions	O
has	O
been	O
correlated	O
with	O
increased	O
immunogenicity	O
in	O
other	O
systems	O
.	O

Our	O
results	O
have	O
also	O
shown	O
that	O
Tn	O
glycosylation	O
at	O
the	O
central	O
threonine	O
within	O
the	O
PDTRP	O
core	O
epitope	O
region	O
shifts	O
the	O
conformational	O
equilibrium	O
away	O
from	O
the	O
type	O
I	O
beta	O
-	O
turn	O
conformation	O
and	O
toward	O
a	O
more	O
rigid	O
and	O
extended	O
state	O
.	O

The	O
significance	O
of	O
these	O
results	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
possible	O
roles	O
that	O
peptide	O
epitope	O
secondary	O
structure	O
and	O
glycosylation	O
state	O
may	O
play	O
in	O
MUC1	B-Protein
tumor	O
immunogenicity	O
.	O

Lysine	O
-	O
79	O
of	O
histone	B-Protein
H3	I-Protein
is	O
hypomethylated	O
at	O
silenced	O
loci	O
in	O
yeast	O
and	O
mammalian	O
cells	O
:	O
a	O
potential	O
mechanism	O
for	O
position	O
-	O
effect	O
variegation	O
.	O

Methylation	O
of	O
lysine	O
-	O
79	O
(	O
K79	O
)	O
within	O
the	O
globular	O
domain	O
of	O
histone	B-Protein
H3	I-Protein
by	O
Dot1	B-Protein
methylase	O
is	O
important	O
for	O
transcriptional	O
silencing	O
and	O
for	O
association	O
of	O
the	O
Sir	O
silencing	O
proteins	O
in	O
yeast	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
level	O
of	O
H3	B-Protein
-	O
K79	O
methylation	O
is	O
low	O
at	O
all	O
Sir	O
-	O
dependent	O
silenced	O
loci	O
but	O
not	O
at	O
other	O
transcriptionally	O
repressed	O
regions	O
.	O

Hypomethylation	O
of	O
H3	B-Protein
-	O
K79	O
at	O
the	O
telomeric	O
and	O
silent	O
mating	O
-	O
type	O
loci	O
,	O
but	O
not	O
the	O
ribosomal	O
DNA	O
,	O
requires	O
the	O
Sir	O
proteins	O
.	O

Overexpression	O
of	O
Sir3	B-Protein
concomitantly	O
extends	O
the	O
domain	O
of	O
Sir	O
protein	O
association	O
and	O
H3	B-Protein
-	O
K79	O
hypomethylation	O
at	O
telomeres	O
.	O

In	O
mammalian	O
cells	O
,	O
H3	B-Protein
-	O
K79	O
methylation	O
is	O
found	O
at	O
loci	O
that	O
are	O
active	O
for	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
but	O
not	O
at	O
recombinationally	O
inactive	O
loci	O
that	O
are	O
heterochromatic	O
.	O

These	O
results	O
suggest	O
that	O
H3	B-Protein
-	O
K79	O
methylation	O
is	O
an	O
evolutionarily	O
conserved	O
marker	O
of	O
active	O
chromatin	O
regions	O
,	O
and	O
that	O
silencing	O
proteins	O
block	O
the	O
ability	O
of	O
Dot1	B-Protein
to	O
methylate	O
histone	B-Protein
H3	I-Protein
.	O

Further	O
,	O
they	O
suggest	O
that	O
Sir	O
proteins	O
preferentially	O
bind	O
chromatin	O
with	O
hypomethylated	O
H3	B-Protein
-	O
K79	O
and	O
then	O
block	O
H3	B-Protein
-	O
K79	O
methylation	O
.	O

This	O
positive	O
feedback	O
loop	O
,	O
and	O
the	O
reverse	O
loop	O
in	O
which	O
H3	B-Protein
-	O
K79	O
methylation	O
weakens	O
Sir	O
protein	O
association	O
and	O
leads	O
to	O
further	O
methylation	O
,	O
suggests	O
a	O
model	O
for	O
position	O
-	O
effect	O
variegation	O
.	O

Cyclosporin	O
A	O
prevents	O
the	O
hypoxic	O
adaptation	O
by	O
activating	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
Pro	O
-	O
564	O
hydroxylation	O
.	O

The	O
mechanism	O
by	O
which	O
hypoxia	O
induces	O
gene	O
transcription	O
involves	O
the	O
inhibition	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	I-Protein
HIF	I-Protein
)	I-Protein
-	I-Protein
1alpha	I-Protein
prolyl	O
hydroxylase	O
activity	O
,	O
which	O
prevents	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	O
vHL	B-Protein
)	O
-	O
dependent	O
targeting	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
to	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O

HIF	B-Protein
-	I-Protein
1alpha	I-Protein
is	O
stabilized	O
,	O
translocates	O
to	O
the	O
nucleus	O
,	O
interacts	O
with	O
hypoxia	O
-	O
responsive	O
elements	O
,	O
and	O
promotes	O
the	O
activation	O
of	O
target	O
genes	O
.	O

This	O
report	O
shows	O
that	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
interferes	O
with	O
the	O
hypoxic	O
signaling	O
cascade	O
in	O
C6	O
glioma	O
cells	O
.	O

CsA	O
inhibits	O
hypoxia	O
-	O
dependent	O
gene	O
transcription	O
in	O
a	O
reporter	O
gene	O
assay	O
and	O
prevents	O
the	O
hypoxic	O
accumulation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

Addition	O
of	O
the	O
530	O
-	O
603	O
C	O
-	O
terminal	O
oxygen	O
-	O
dependent	O
degradation	O
(	O
ODD	O
)	O
domain	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
to	O
the	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
destabilized	O
the	O
protein	O
in	O
an	O
oxygen	O
-	O
dependent	O
manner	O
.	O

CsA	O
prevented	O
the	O
hypoxic	O
stabilization	O
of	O
an	O
ODD	O
.	O
GFP	B-Protein
fusion	O
protein	O
.	O

An	O
assay	O
for	O
2	O
-	O
oxoglutarate	O
-	O
dependent	O
dioxygenases	O
was	O
developed	O
using	O
a	O
light	O
mitochondrial	O
kidney	O
fraction	O
as	O
a	O
source	O
of	O
enzyme	O
.	O

It	O
uses	O
the	O
capacity	O
of	O
specific	O
peptides	O
to	O
stimulate	O
the	O
degradation	O
of	O
[	O
(	O
14	O
)	O
C	O
]	O
2	O
-	O
oxoglutarate	O
.	O

CsA	O
stimulated	O
the	O
enzymatic	O
activity	O
in	O
the	O
presence	O
of	O
a	O
peptide	O
that	O
mimicked	O
the	O
557	O
-	O
576	O
sequence	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

The	O
enzyme	O
promoted	O
[	O
(	O
35	O
)	O
S	O
]	O
vHL	B-Protein
binding	O
to	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
.	O
ODD	O
fusion	O
protein	O
.	O

This	O
association	O
increased	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

CsA	O
effects	O
were	O
not	O
observed	O
when	O
the	O
proline	O
residue	O
corresponding	O
to	O
Pro	O
-	O
564	O
in	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
sequence	O
was	O
replaced	O
by	O
a	O
hydroxyproline	O
or	O
an	O
alanine	O
residue	O
.	O

Finally	O
,	O
CsA	O
increased	O
vHL	B-Protein
-	O
ODD	O
interaction	O
during	O
hypoxia	O
.	O

We	O
conclude	O
that	O
CsA	O
destabilizes	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
by	O
promoting	O
hydroxylation	O
of	O
Pro	O
-	O
564	O
in	O
the	O
ODD	O
domain	O
.	O

Such	O
a	O
mechanism	O
may	O
prevent	O
hypoxic	O
adaptation	O
during	O
CsA	O
-	O
induced	O
nephrotoxicity	O
and	O
contribute	O
to	O
the	O
adverse	O
effects	O
of	O
this	O
drug	O
.	O

A	O
role	O
for	O
N	O
-	O
glycanase	O
in	O
the	O
cytosolic	O
turnover	O
of	O
glycoproteins	O
.	O

Successful	O
maturation	O
determines	O
the	O
intracellular	O
fate	O
of	O
secretory	O
and	O
membrane	O
proteins	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

Failure	O
of	O
proteins	O
to	O
fold	O
or	O
assemble	O
properly	O
can	O
lead	O
to	O
their	O
retention	O
in	O
the	O
ER	O
and	O
redirects	O
them	O
to	O
the	O
cytosol	O
for	O
degradation	O
by	O
the	O
proteasome	O
.	O

Proteasome	O
inhibitors	O
can	O
yield	O
deglycosylated	O
cytoplasmic	O
intermediates	O
that	O
are	O
the	O
result	O
of	O
an	O
N	O
-	O
glycanase	O
activity	O
,	O
believed	O
to	O
act	O
prior	O
to	O
destruction	O
of	O
these	O
substrates	O
by	O
the	O
proteasome	O
.	O

A	O
gene	O
encoding	O
a	O
yeast	O
peptide	O
:	O
N	O
-	O
glycanase	O
,	O
PNG1	B-Protein
,	O
has	O
been	O
cloned	O
,	O
but	O
this	O
N	O
-	O
glycanase	O
and	O
its	O
mammalian	O
homolog	O
were	O
reported	O
to	O
be	O
incapable	O
of	O
deglycosylating	O
full	O
-	O
length	O
glycoproteins	O
.	O

We	O
show	O
that	O
both	O
the	O
yeast	O
PNG1	B-Protein
enzyme	O
and	O
its	O
mammalian	O
homolog	O
display	O
N	O
-	O
glycanase	O
activity	O
towards	O
intact	O
glycoproteins	O
.	O

As	O
substrates	O
,	O
cytosolic	O
PNGase	B-Protein
activity	O
prefers	O
proteins	O
containing	O
high	O
-	O
mannose	O
over	O
those	O
bearing	O
complex	O
type	O
oligosaccharides	O
.	O

Importantly	O
,	O
PNG1	B-Protein
discriminates	O
between	O
non	O
-	O
native	O
and	O
folded	O
glycoproteins	O
,	O
consistent	O
with	O
a	O
role	O
for	O
N	O
-	O
glycanase	O
in	O
cytoplasmic	O
turnover	O
of	O
glycoproteins	O
.	O

Preclinical	O
evaluation	O
of	O
antineoplastic	O
activity	O
of	O
inhibitors	O
of	O
DNA	O
methylation	O
(	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
)	O
and	O
histone	B-Protein
deacetylation	O
(	O
trichostatin	O
A	O
,	O
depsipeptide	O
)	O
in	O
combination	O
against	O
myeloid	O
leukemic	O
cells	O
.	O

During	O
the	O
development	O
of	O
leukemia	O
,	O
genes	O
that	O
suppress	O
growth	O
and	O
induce	O
differentiation	O
can	O
be	O
silenced	O
by	O
aberrant	O
DNA	O
methylation	O
and	O
by	O
changes	O
in	O
chromatin	O
structure	O
that	O
involve	O
histone	B-Protein
deacetylation	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	O
positive	O
interaction	O
between	O
DNA	O
methylation	O
and	O
histone	B-Protein
deacetylation	O
takes	O
place	O
to	O
inhibit	O
transcription	O
.	O

Based	O
on	O
this	O
observation	O
,	O
our	O
working	O
hypothesis	O
was	O
that	O
a	O
combination	O
of	O
inhibitors	O
of	O
these	O
processes	O
should	O
produce	O
an	O
enhancement	O
of	O
their	O
antineoplastic	O
activity	O
on	O
leukemic	O
cells	O
.	O

The	O
cytosine	O
nucleoside	O
analog	O
,	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5AZA	O
)	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
DNA	O
methylation	O
,	O
which	O
can	O
activate	O
tumor	O
suppressor	O
genes	O
in	O
leukemic	O
cells	O
that	O
have	O
been	O
silenced	O
by	O
aberrant	O
methylation	O
.	O

In	O
clinical	O
trials	O
,	O
5AZA	O
was	O
demonstrated	O
to	O
be	O
an	O
active	O
antileukemic	O
agent	O
.	O

Histone	B-Protein
deacetylase	O
inhibitors	O
(	O
HDI	O
)	O
can	O
also	O
activate	O
gene	O
expression	O
in	O
leukemic	O
cell	O
lines	O
by	O
producing	O
changes	O
in	O
chromatin	O
configuration	O
,	O
and	O
show	O
antineoplastic	O
activity	O
in	O
preclinical	O
studies	O
.	O

In	O
this	O
report	O
,	O
we	O
investigated	O
the	O
in	O
vitro	O
antineoplastic	O
activity	O
of	O
5AZA	O
,	O
alone	O
and	O
in	O
combination	O
with	O
the	O
HDI	O
,	O
trichostatin	O
A	O
(	O
TSA	O
)	O
and	O
depsipeptide	O
(	O
FR901228	O
,	O
depsi	O
)	O
,	O
on	O
the	O
human	O
myeloid	O
leukemic	O
cell	O
lines	O
,	O
HL	O
-	O
60	O
and	O
KG1a	O
.	O

The	O
results	O
showed	O
that	O
the	O
combination	O
of	O
5AZA	O
with	O
TSA	O
or	O
depsi	O
produced	O
a	O
greater	O
inhibition	O
of	O
growth	O
and	O
DNA	O
synthesis	O
and	O
a	O
greater	O
loss	O
of	O
clonogenicity	O
than	O
either	O
agent	O
alone	O
.	O

These	O
results	O
suggest	O
that	O
5AZA	O
used	O
in	O
combination	O
with	O
HDI	O
may	O
be	O
an	O
interesting	O
chemotherapeutic	O
regimen	O
to	O
investigate	O
in	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
that	O
is	O
resistant	O
to	O
conventional	O
chemotherapy	O
.	O

Complex	O
-	O
type	O
biantennary	O
N	O
-	O
glycans	O
of	O
recombinant	O
human	O
transferrin	B-Protein
from	O
Trichoplusia	O
ni	O
insect	O
cells	O
expressing	O
mammalian	O
[	O
beta	O
]	O
-	O
1	O
,	O
4	O
-	O
galactosyltransferase	O
and	O
[	B-Protein
beta	I-Protein
]	I-Protein
-	I-Protein
1	I-Protein
,	I-Protein
2	I-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
II	I-Protein
.	O

A	O
novel	O
recombinant	O
baculovirus	O
expression	O
vector	O
was	O
used	O
to	O
produce	O
His	O
-	O
tagged	O
human	O
transferrin	B-Protein
in	O
a	O
transformed	O
insect	O
cell	O
line	O
(	O
Tn5beta4GalT	O
)	O
that	O
constitutively	O
expresses	O
a	O
mammalian	O
beta	O
-	O
1	O
,	O
4	O
-	O
galactosyltransferase	O
.	O

This	O
virus	O
encoded	O
the	O
His	O
-	O
tagged	O
human	O
transferrin	B-Protein
protein	O
in	O
conventional	O
fashion	O
under	O
the	O
control	O
of	O
the	O
very	O
late	O
polyhedrin	B-Protein
promoter	O
.	O

In	O
addition	O
,	O
to	O
enhance	O
the	O
synthesis	O
of	O
galactosylated	O
biantennary	O
N	O
-	O
glycans	O
,	O
this	O
virus	O
encoded	O
human	O
beta	B-Protein
-	I-Protein
1	I-Protein
,	I-Protein
2	I-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
II	I-Protein
under	O
the	O
control	O
of	O
an	O
immediate	O
-	O
early	O
(	O
ie1	B-Protein
)	O
promoter	O
.	O

Detailed	O
analyses	O
by	O
MALDI	O
-	O
TOF	O
MS	O
,	O
exoglycosidase	O
digestion	O
,	O
and	O
two	O
-	O
dimensional	O
HPLC	O
revealed	O
that	O
the	O
N	O
-	O
glycans	O
on	O
the	O
purified	O
recombinant	O
human	O
transferrin	B-Protein
produced	O
by	O
this	O
virus	O
-	O
host	O
system	O
included	O
four	O
different	O
fully	O
galactosylated	O
,	O
biantennary	O
,	O
complex	O
-	O
type	O
glycans	O
.	O

Thus	O
,	O
this	O
study	O
describes	O
a	O
novel	O
baculovirus	O
-	O
host	O
system	O
,	O
which	O
can	O
be	O
used	O
to	O
produce	O
a	O
recombinant	O
glycoprotein	O
with	O
fully	O
galactosylated	O
,	O
biantennary	O
N	O
-	O
glycans	O
.	O

Overexpression	O
of	O
the	O
CT	B-Protein
GalNAc	I-Protein
transferase	I-Protein
inhibits	O
muscular	O
dystrophy	O
in	O
a	O
cleavage	O
-	O
resistant	O
dystroglycan	O
mutant	O
mouse	O
.	O

Transgenic	O
mice	O
that	O
express	O
dystroglycan	B-Protein
containing	O
a	O
serine	O
to	O
alanine	O
point	O
mutation	O
at	O
the	O
normal	O
site	O
of	O
cleavage	O
(	O
DG	B-Protein
(	O
S654A	O
)	O
)	O
in	O
their	O
skeletal	O
muscles	O
fail	O
to	O
express	O
endogenously	O
cleaved	O
dystroglycan	B-Protein
and	O
have	O
muscular	O
dystrophy	O
[	O
Neuromusc	O
.	O
Disord	O
.	O
,	O
in	O
press	O
]	O
.	O

Dystrophic	O
DG	B-Protein
(	O
S654A	O
)	O
muscles	O
have	O
reduced	O
binding	O
of	O
antibodies	O
,	O
including	O
VIA4	O
-	O
1	O
,	O
that	O
recognize	O
carbohydrate	O
antigens	O
on	O
alpha	B-Protein
dystroglycan	I-Protein
,	O
a	O
finding	O
similar	O
to	O
muscles	O
in	O
some	O
forms	O
of	O
congenital	O
muscular	O
dystrophy	O
.	O

Here	O
we	O
describe	O
one	O
DG	B-Protein
(	O
S654A	O
)	O
transgenic	O
line	O
where	O
VIA4	O
-	O
1	O
antibody	O
binding	O
is	O
absent	O
in	O
skeletal	O
muscle	O
.	O

In	O
theory	O
,	O
the	O
absence	O
of	O
this	O
carbohydrate	O
antigen	O
should	O
inhibit	O
later	O
glycosylation	O
events	O
that	O
would	O
occur	O
on	O
the	O
structure	O
or	O
structures	O
this	O
antibody	O
binds	O
to	O
.	O

One	O
such	O
modification	O
is	O
likely	O
to	O
be	O
the	O
CT	O
carbohydrate	O
antigen	O
,	O
which	O
is	O
present	O
on	O
alpha	O
dystroglycan	O
in	O
muscles	O
overexpressing	O
the	O
CT	B-Protein
GalNAc	I-Protein
transferase	I-Protein
[	O
Dev	O
.	O
Biol	O
.	O
242	O
(	O
2002	O
)	O
58	O
]	O
.	O

To	O
test	O
the	O
relationship	O
between	O
the	O
VIA4	O
-	O
1	O
and	O
CT	O
carbohydrate	O
antigens	O
,	O
we	O
made	O
DG	B-Protein
(	O
S654A	O
)	O
/	O
CT	B-Protein
GalNAc	I-Protein
transferase	I-Protein
(	O
DG	B-Protein
(	O
S654A	O
)	O
/	O
CT	O
)	O
transgenic	O
mice	O
.	O

Surprisingly	O
,	O
dystroglycan	B-Protein
was	O
cleaved	O
,	O
and	O
alpha	B-Protein
dystroglycan	I-Protein
was	O
glycosylated	O
with	O
the	O
VIA4	O
-	O
1	O
antigen	O
,	O
in	O
DG	B-Protein
(	O
S654A	O
)	O
/	O
CT	O
muscles	O
.	O

In	O
addition	O
,	O
muscles	O
in	O
DG	B-Protein
(	O
S654A	O
)	O
/	O
CT	O
transgenic	O
mice	O
had	O
little	O
or	O
no	O
evidence	O
of	O
muscular	O
dystrophy	O
when	O
compared	O
to	O
DG	B-Protein
(	O
S654A	O
)	O
littermates	O
.	O

These	O
experiments	O
demonstrate	O
that	O
the	O
CT	B-Protein
GalNAc	I-Protein
transferase	I-Protein
can	O
affect	O
the	O
post	O
-	O
translational	O
processing	O
of	O
dystroglycan	B-Protein
and	O
the	O
extent	O
of	O
muscular	O
dystrophy	O
even	O
in	O
muscles	O
where	O
the	O
VIA4	O
-	O
1	O
antigen	O
is	O
not	O
present	O
.	O

Characterization	O
of	O
two	O
novel	O
proteins	O
,	O
NgRH1	B-Protein
and	O
NgRH2	B-Protein
,	O
structurally	O
and	O
biochemically	O
homologous	O
to	O
the	O
Nogo	B-Protein
-	I-Protein
66	I-Protein
receptor	I-Protein
.	O

Nogo	B-Protein
-	I-Protein
66	I-Protein
receptor	I-Protein
(	O
NgR	B-Protein
)	O
has	O
recently	O
been	O
identified	O
as	O
the	O
neuronal	O
receptor	O
of	O
the	O
myelin	O
-	O
associated	O
proteins	O
Nogo	B-Protein
-	I-Protein
A	I-Protein
,	O
oligodendrocyte	B-Protein
protein	I-Protein
(	O
OMgp	B-Protein
)	O
and	O
myelin	B-Protein
-	I-Protein
associated	I-Protein
glycoprotein	I-Protein
(	O
MAG	B-Protein
)	O
,	O
and	O
mediates	O
inhibition	O
of	O
axonal	O
regeneration	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Through	O
database	O
searches	O
,	O
we	O
have	O
identified	O
two	O
novel	O
proteins	O
(	O
NgRH1	B-Protein
and	O
NgRH2	B-Protein
)	O
that	O
turned	O
out	O
to	O
be	O
homologous	O
in	O
their	O
primary	O
structures	O
,	O
biochemical	O
properties	O
and	O
expression	O
patterns	O
to	O
NgR	B-Protein
.	O

Like	O
NgR	B-Protein
,	O
the	O
homologues	O
contain	O
eight	O
leucine	O
-	O
rich	O
repeats	O
(	O
LRR	O
)	O
flanked	O
by	O
a	O
leucine	O
-	O
rich	O
repeat	O
C	O
-	O
terminus	O
(	O
LRRCT	O
)	O
and	O
a	O
leucine	O
-	O
rich	O
repeat	O
N	O
-	O
terminus	O
(	O
LRRNT	O
)	O
,	O
and	O
also	O
have	O
a	O
C	O
-	O
terminal	O
GPI	O
signal	O
sequence	O
.	O

Northern	O
blot	O
analysis	O
showed	O
predominant	O
expression	O
of	O
NgRH1	B-Protein
and	O
NgRH2	B-Protein
mRNA	O
in	O
the	O
brain	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
on	O
rat	O
brain	O
slices	O
revealed	O
neuronal	O
expression	O
of	O
the	O
genes	O
.	O

NgRH1	B-Protein
and	O
NgRH2	B-Protein
were	O
detected	O
on	O
the	O
cell	O
surface	O
of	O
recombinant	O
cell	O
lines	O
as	O
N	O
-	O
glycosylated	O
GPI	O
anchored	O
proteins	O
and	O
,	O
consistent	O
with	O
other	O
GPI	O
anchored	O
proteins	O
,	O
were	O
localized	O
within	O
the	O
lipid	O
rafts	O
of	O
cellular	O
membranes	O
.	O

In	O
addition	O
,	O
an	O
N	O
-	O
terminal	O
proteolytic	O
fragment	O
of	O
NgR	B-Protein
comprising	O
the	O
majority	O
of	O
the	O
ectodomain	O
was	O
found	O
to	O
be	O
constitutively	O
secreted	O
from	O
cells	O
.	O

Our	O
data	O
indicate	O
that	O
NgR	B-Protein
,	O
NgRH1	B-Protein
and	O
NgRH2	B-Protein
constitute	O
a	O
novel	O
receptor	O
protein	O
family	O
,	O
which	O
may	O
play	O
related	O
roles	O
within	O
the	O
CNS	O
.	O

Synthesis	O
of	O
hydroxymethylglutathione	O
from	O
glutathione	O
and	O
L	O
-	O
serine	O
catalyzed	O
by	O
carboxypeptidase	B-Protein
Y	I-Protein
.	O

Hydroxymethylglutathione	O
(	O
gamma	O
-	O
L	O
-	O
glutamyl	O
-	O
L	O
-	O
cysteinyl	O
-	O
L	O
-	O
serine	O
;	O
hmGSH	O
)	O
occurs	O
in	O
many	O
species	O
belonging	O
to	O
the	O
family	O
Gramineae	O
,	O
but	O
the	O
biosynthetic	O
pathway	O
for	O
hmGSH	O
has	O
not	O
been	O
identified	O
.	O

We	O
found	O
that	O
carboxypeptidase	B-Protein
Y	I-Protein
(	O
CPY	B-Protein
)	O
,	O
but	O
not	O
carboxypeptidase	O
A	O
,	O
catalyzed	O
hmGSH	O
synthesis	O
from	O
glutathione	O
and	O
L	O
-	O
serine	O
in	O
vitro	O
at	O
acidic	O
pH	O
.	O

CPY	O
also	O
catalyzed	O
methylglutathione	O
synthesis	O
from	O
glutathione	O
and	O
L	O
-	O
alanine	O
.	O

These	O
findings	O
suggested	O
that	O
a	O
carboxypeptidase	O
-	O
like	O
enzyme	O
may	O
be	O
involved	O
in	O
hmGSH	O
synthesis	O
in	O
vivo	O
.	O

Transcriptional	O
elongation	O
by	O
RNA	O
polymerase	O
II	O
and	O
histone	B-Protein
methylation	O
.	O

mRNA	O
synthesis	O
in	O
eukaryotic	O
organisms	O
is	O
a	O
key	O
biological	O
process	O
that	O
is	O
regulated	O
at	O
multiple	O
levels	O
.	O

From	O
the	O
covalent	O
modifications	O
of	O
chromatin	O
by	O
a	O
number	O
of	O
chromatin	O
remodeling	O
complexes	O
during	O
the	O
initiation	O
and	O
activation	O
steps	O
of	O
transcription	O
to	O
the	O
processing	O
of	O
mRNA	O
transcripts	O
,	O
a	O
very	O
large	O
consortium	O
of	O
proteins	O
and	O
multiprotein	O
complexes	O
is	O
critical	O
for	O
gene	O
expression	O
by	O
RNA	O
polymerase	O
II	O
.	O

The	O
list	O
of	O
proteins	O
essential	O
for	O
the	O
successful	O
synthesis	O
of	O
mRNA	O
continues	O
to	O
grow	O
at	O
a	O
rapid	O
pace	O
.	O

Recent	O
advances	O
in	O
this	O
area	O
of	O
research	O
have	O
been	O
focused	O
on	O
transcription	O
through	O
chromatin	O
.	O

In	O
this	O
article	O
,	O
we	O
will	O
review	O
the	O
recent	O
literature	O
linking	O
the	O
key	O
biochemical	O
process	O
of	O
transcriptional	O
elongation	O
by	O
RNA	O
polymerase	O
II	O
to	O
histone	B-Protein
methylation	O
by	O
COMPASS	O
,	O
Dot1p	B-Protein
,	O
and	O
Set2	B-Protein
methyltransferases	O
.	O

Prolyl	O
hydroxylation	O
of	O
collagen	O
type	O
I	O
is	O
required	O
for	O
efficient	O
binding	O
to	O
integrin	B-Protein
alpha	I-Protein
1	I-Protein
beta	B-Protein
1	I-Protein
and	O
platelet	B-Protein
glycoprotein	I-Protein
VI	I-Protein
but	O
not	O
to	O
alpha	B-Protein
2	I-Protein
beta	B-Protein
1	I-Protein
.	O

Collagen	O
is	O
a	O
potent	O
adhesive	O
substrate	O
for	O
cells	O
,	O
an	O
event	O
essentially	O
mediated	O
by	O
the	O
integrins	B-Protein
alpha	I-Protein
1	I-Protein
beta	B-Protein
1	I-Protein
and	O
alpha	B-Protein
2	I-Protein
beta	B-Protein
1	I-Protein
.	O

Collagen	O
fibrils	O
also	O
bind	O
to	O
the	O
integrin	B-Protein
alpha	I-Protein
2	I-Protein
beta	B-Protein
1	I-Protein
and	O
the	O
platelet	B-Protein
receptor	I-Protein
glycoprotein	I-Protein
VI	I-Protein
to	O
activate	O
and	O
aggregate	O
platelets	O
.	O

The	O
distinct	O
triple	O
helical	O
recognition	O
motifs	O
for	O
these	O
receptors	O
,	O
GXOGER	O
and	O
(	O
GPO	O
)	O
n	O
,	O
respectively	O
,	O
all	O
contain	O
hydroxyproline	O
.	O

Using	O
unhydroxylated	O
collagen	O
I	O
produced	O
in	O
transgenic	O
plants	O
,	O
we	O
investigated	O
the	O
role	O
of	O
hydroxyproline	O
in	O
the	O
receptor	O
-	O
binding	O
properties	O
of	O
collagen	O
.	O

We	O
show	O
that	O
alpha	B-Protein
2	I-Protein
beta	B-Protein
1	I-Protein
but	O
not	O
alpha	B-Protein
1	I-Protein
beta	B-Protein
1	I-Protein
mediates	O
cell	O
adhesion	O
to	O
unhydroxylated	O
collagen	O
.	O

Soluble	O
recombinant	O
alpha	B-Protein
1	I-Protein
beta	B-Protein
1	I-Protein
binding	O
to	O
unhydroxylated	O
collagen	O
is	O
considerably	O
reduced	O
compared	O
with	O
bovine	O
collagens	O
,	O
but	O
binding	O
can	O
be	O
restored	O
by	O
prolyl	O
hydroxylation	O
of	O
recombinant	O
collagen	O
.	O

We	O
also	O
show	O
that	O
platelets	O
use	O
alpha	B-Protein
2	I-Protein
beta	B-Protein
1	I-Protein
to	O
adhere	O
to	O
the	O
unhydroxylated	O
recombinant	O
molecules	O
,	O
but	O
the	O
adhesion	O
is	O
weaker	O
than	O
on	O
fully	O
hydroxylated	O
collagen	O
,	O
and	O
the	O
unhydroxylated	O
collagen	O
fibrils	O
fail	O
to	O
aggregate	O
platelets	O
.	O

Prolyl	O
hydroxylation	O
is	O
thus	O
required	O
for	O
binding	O
of	O
collagen	O
to	O
platelet	B-Protein
glycoprotein	I-Protein
VI	I-Protein
and	O
to	O
cells	O
by	O
alpha	B-Protein
1	I-Protein
beta	B-Protein
1	I-Protein
.	O

These	O
observations	O
give	O
new	O
insights	O
into	O
the	O
molecular	O
basis	O
of	O
collagen	O
-	O
receptor	O
interactions	O
and	O
offer	O
new	O
selective	O
applications	O
for	O
the	O
recombinant	O
unhydroxylated	O
collagen	O
I	O
.	O

Mechanism	O
,	O
mutagenesis	O
,	O
and	O
chemical	O
rescue	O
of	O
a	O
beta	B-Protein
-	I-Protein
mannosidase	I-Protein
from	O
cellulomonas	O
fimi	O
.	O

The	O
chemical	O
mechanism	O
of	O
a	O
retaining	O
beta	B-Protein
-	I-Protein
mannosidase	I-Protein
from	O
Cellulomonas	O
fimi	O
has	O
been	O
characterized	O
through	O
steady	O
-	O
state	O
kinetic	O
analyses	O
with	O
a	O
range	O
of	O
substrates	O
,	O
coupled	O
with	O
chemical	O
rescue	O
studies	O
on	O
both	O
the	O
wild	O
-	O
type	O
enzyme	O
and	O
mutants	O
in	O
which	O
active	O
site	O
carboxyl	O
groups	O
have	O
been	O
replaced	O
.	O

Studies	O
with	O
a	O
series	O
of	O
aryl	O
beta	O
-	O
mannosides	O
of	O
vastly	O
different	O
reactivities	O
(	O
pK	O
(	O
a	O
)	O
(	O
lg	O
)	O
=	O
4	O
-	O
10	O
)	O
allowed	O
kinetic	O
isolation	O
of	O
the	O
glycosylation	O
and	O
deglycosylation	O
steps	O
.	O

Substrate	O
inhibition	O
was	O
observed	O
for	O
all	O
but	O
the	O
least	O
reactive	O
of	O
these	O
substrates	O
.	O

Bronsted	O
analysis	O
of	O
k	O
(	O
cat	O
)	O
revealed	O
a	O
downward	O
breaking	O
plot	O
(	O
beta	O
(	O
lg	O
)	O
=	O
-	O
0	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
05	O
)	O
that	O
is	O
consistent	O
with	O
a	O
change	O
in	O
rate	O
-	O
determining	O
step	O
(	O
glycosylation	O
to	O
deglycosylation	O
)	O
,	O
and	O
this	O
was	O
confirmed	O
by	O
partitioning	O
studies	O
with	O
ethylene	O
glycol	O
.	O

The	O
pH	O
dependence	O
of	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
follows	O
an	O
apparent	O
single	O
ionization	O
of	O
a	O
group	O
of	O
pK	O
(	O
a	O
)	O
=	O
7	O
.	O
65	O
that	O
must	O
be	O
protonated	O
for	O
catalysis	O
.	O

The	O
tentative	O
assignment	O
of	O
E429	O
as	O
the	O
acid	O
-	O
base	O
catalyst	O
of	O
Man2A	B-Protein
on	O
the	O
basis	O
of	O
sequence	O
alignments	O
with	O
other	O
family	O
2	O
glycosidases	O
was	O
confirmed	O
by	O
the	O
increased	O
turnover	O
rate	O
observed	O
for	O
the	O
mutant	O
E429A	O
in	O
the	O
presence	O
of	O
azide	O
and	O
fluoride	O
,	O
leading	O
to	O
the	O
production	O
of	O
beta	O
-	O
mannosyl	O
azide	O
and	O
beta	O
-	O
mannosyl	O
fluoride	O
,	O
respectively	O
.	O

A	O
pH	O
-	O
dependent	O
chemical	O
rescue	O
of	O
E429A	O
activity	O
is	O
also	O
observed	O
with	O
citrate	O
.	O

Substantial	O
oxocarbenium	O
ion	O
character	O
at	O
the	O
transition	O
state	O
was	O
demonstrated	O
by	O
the	O
alpha	O
-	O
deuterium	O
kinetic	O
isotope	O
effect	O
for	O
Man2A	B-Protein
E429A	O
of	O
alpha	O
-	O
D	O
(	O
V	O
)	O
=	O
1	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
01	O
.	O

Surprisingly	O
,	O
this	O
isotope	O
effect	O
was	O
substantially	O
greater	O
in	O
the	O
presence	O
of	O
azide	O
(	O
alpha	O
-	O
D	O
(	O
V	O
)	O
=	O
1	O
.	O
166	O
+	O
/	O
-	O
0	O
.	O
009	O
)	O
.	O

Likely	O
involvement	O
of	O
acid	O
/	O
base	O
catalysis	O
was	O
revealed	O
by	O
the	O
pH	O
dependence	O
of	O
k	O
(	O
cat	O
)	O
for	O
Man2A	B-Protein
E429A	O
,	O
which	O
follows	O
a	O
bell	O
-	O
shaped	O
profile	O
described	O
by	O
pK	O
(	O
a	O
)	O
values	O
of	O
6	O
.	O
1	O
and	O
8	O
.	O
4	O
,	O
substantially	O
different	O
from	O
that	O
of	O
the	O
wild	O
-	O
type	O
enzyme	O
.	O

The	O
glycosidic	O
bond	O
cleaving	O
activity	O
of	O
Man2A	B-Protein
E519A	O
and	O
E519S	O
nucleophile	O
mutants	O
is	O
restored	O
with	O
azide	O
and	O
fluoride	O
and	O
appears	O
to	O
correlate	O
with	O
the	O
corresponding	O
"	O
glycosynthase	O
"	O
activities	O
.	O

The	O
contribution	O
of	O
the	O
substrate	O
2	O
-	O
hydroxyl	O
to	O
stabilization	O
of	O
the	O
Man2A	B-Protein
glycosylation	O
transition	O
state	O
(	O
DeltaDeltaG	O
(	O
)	O
=	O
5	O
.	O
1	O
kcal	O
mol	O
(	O
-	O
1	O
)	O
)	O
was	O
probed	O
using	O
a	O
2	O
-	O
deoxymannose	O
substrate	O
.	O

This	O
value	O
,	O
surprisingly	O
,	O
is	O
comparable	O
to	O
that	O
found	O
from	O
equivalent	O
studies	O
with	O
beta	O
-	O
glucosidases	O
despite	O
the	O
geometric	O
differences	O
at	O
C	O
-	O
2	O
and	O
the	O
importance	O
of	O
hydrogen	O
bonding	O
at	O
that	O
position	O
.	O

Modes	O
of	O
stabilizing	O
the	O
mannosidase	O
transition	O
state	O
are	O
discussed	O
.	O

Occurrence	O
of	O
O	O
-	O
linked	O
Xyl	O
-	O
GlcNAc	O
and	O
Xyl	O
-	O
Glc	O
disaccharides	O
in	O
trocarin	B-Protein
,	O
a	O
factor	B-Protein
Xa	I-Protein
homolog	O
from	O
snake	O
venom	O
.	O

Trocarin	B-Protein
is	O
a	O
46515	O
-	O
Da	O
group	O
D	O
prothrombin	B-Protein
-	O
activating	O
glycoprotein	O
from	O
the	O
venom	O
of	O
the	O
Australian	O
elapid	O
,	O
Tropidechis	O
carinatus	O
.	O

Amino	O
acid	O
sequencing	O
and	O
functional	O
characterization	O
of	O
trocarin	B-Protein
demonstrated	O
that	O
it	O
is	O
a	O
structural	O
and	O
functional	O
homolog	O
of	O
mammalian	O
blood	O
coagulation	B-Protein
factor	I-Protein
(	I-Protein
F	I-Protein
)	I-Protein
Xa	I-Protein
.	O

In	O
this	O
study	O
we	O
show	O
that	O
,	O
in	O
contrast	O
to	O
mammalian	O
Xa	B-Protein
,	O
which	O
is	O
not	O
glycosylated	O
,	O
trocarin	B-Protein
contains	O
an	O
O	O
-	O
linked	O
carbohydrate	O
moiety	O
in	O
its	O
light	O
chain	O
and	O
an	O
N	O
-	O
linked	O
carbohydrate	O
oligosaccharide	O
in	O
its	O
heavy	O
chain	O
.	O

Mass	O
spectrometry	O
and	O
sugar	O
compositional	O
analysis	O
indicate	O
that	O
the	O
O	O
-	O
linked	O
carbohydrate	O
moiety	O
is	O
a	O
mixture	O
of	O
Xyl	O
-	O
GlcNAc	O
-	O
,	O
GlcNAc	O
-	O
,	O
Xyl	O
-	O
Glc	O
-	O
and	O
Glc	O
-	O
structures	O
linked	O
to	O
Ser	O
52	O
.	O

The	O
N	O
-	O
linked	O
carbohydrate	O
on	O
Asn	O
45	O
of	O
the	O
heavy	O
chain	O
is	O
a	O
sialylated	O
,	O
diantennary	O
oligosaccharide	O
that	O
is	O
located	O
at	O
the	O
lip	O
of	O
the	O
active	O
site	O
of	O
the	O
prothrombin	B-Protein
activator	O
.	O

Differential	O
glycosylation	O
regulates	O
processing	O
of	O
lipoprotein	O
receptors	O
by	O
gamma	O
-	O
secretase	O
.	O

The	O
low	B-Protein
density	I-Protein
lipoprotein	I-Protein
(	I-Protein
LDL	I-Protein
)	I-Protein
receptor	I-Protein
-	I-Protein
related	I-Protein
protein	I-Protein
1	I-Protein
(	O
LRP1	B-Protein
)	O
belongs	O
to	O
a	O
growing	O
number	O
of	O
cell	O
surface	O
proteins	O
that	O
undergo	O
regulated	O
proteolytic	O
processing	O
that	O
culminates	O
in	O
the	O
release	O
of	O
their	O
intracellular	O
domain	O
(	O
ICD	O
)	O
by	O
the	O
intramembranous	O
protease	O
gamma	O
-	O
secretase	O
.	O

Here	O
we	O
show	O
that	O
LRP1	B-Protein
is	O
differentially	O
glycosylated	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
and	O
that	O
carbohydrate	O
addition	O
reduces	O
proteolytic	O
cleavage	O
of	O
the	O
extracellular	O
domain	O
and	O
,	O
concomitantly	O
,	O
ICD	O
release	O
.	O

The	O
apolipoprotein	B-Protein
E	I-Protein
(	I-Protein
apoE	I-Protein
)	I-Protein
receptor	I-Protein
-	I-Protein
2	I-Protein
(	O
apoER2	B-Protein
)	O
,	O
another	O
member	O
of	O
the	O
LDL	O
receptor	O
family	O
with	O
functions	O
in	O
cellular	O
signal	O
transmission	O
,	O
also	O
undergoes	O
sequential	O
proteolytic	O
processing	O
,	O
resulting	O
in	O
intracellular	O
domain	O
release	O
into	O
the	O
cytoplasm	O
.	O

The	O
penultimate	O
processing	O
step	O
also	O
involves	O
cleavage	O
of	O
the	O
apoER2	B-Protein
extracellular	O
domain	O
.	O

The	O
rate	O
at	O
which	O
this	O
cleavage	O
step	O
occurs	O
is	O
determined	O
by	O
the	O
glycosylation	O
state	O
of	O
the	O
receptor	O
,	O
which	O
in	O
turn	O
is	O
regulated	O
by	O
the	O
alternative	O
splicing	O
of	O
an	O
exon	O
encoding	O
several	O
O	O
-	O
linked	O
sugar	O
attachment	O
sites	O
.	O

These	O
findings	O
suggest	O
a	O
role	O
for	O
differential	O
and	O
tissue	O
-	O
specific	O
glycosylation	O
as	O
a	O
physiological	O
switch	O
that	O
modulates	O
the	O
diverse	O
biological	O
functions	O
of	O
these	O
receptors	O
in	O
a	O
cell	O
-	O
type	O
specific	O
manner	O
.	O

Inactivation	O
of	O
p16	B-Protein
gene	O
in	O
leukemia	O
.	O

To	O
determine	O
the	O
frequency	O
of	O
p16	B-Protein
gene	O
inactivation	O
in	O
leukemia	O
cells	O
,	O
and	O
to	O
evaluate	O
their	O
value	O
in	O
the	O
prediction	O
of	O
their	O
clinical	O
outcome	O
.	O

Bone	O
marrow	O
or	O
peripheral	O
blood	O
samples	O
from	O
48	O
patients	O
with	O
leukemia	O
were	O
examined	O
by	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
MPCR	O
)	O
to	O
detect	O
p16	B-Protein
gene	O
homozygous	O
deletion	O
,	O
and	O
restriction	O
enzyme	O
PCR	O
to	O
detect	O
p16	B-Protein
gene	O
methylation	O
.	O

p16	B-Protein
gene	O
inactivation	O
were	O
detected	O
in	O
10	O
of	O
the	O
48	O
patients	O
(	O
20	O
.	O
4	O
%	O
)	O
.	O

They	O
were	O
five	O
patients	O
with	O
p16	B-Protein
homozygous	O
deletion	O
,	O
and	O
five	O
patients	O
with	O
p16	B-Protein
methylation	O
,	O
respectively	O
.	O

p16	B-Protein
gene	O
inactivation	O
correlates	O
with	O
adverse	O
prognosis	O
features	O
.	O

The	O
patients	O
with	O
p16	B-Protein
inactivation	O
had	O
poor	O
response	O
to	O
chemotherapy	O
,	O
and	O
had	O
significantly	O
shorter	O
survival	O
times	O
than	O
the	O
patients	O
in	O
whom	O
p16	B-Protein
gene	O
was	O
preserved	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
inactivation	O
of	O
p16	B-Protein
gene	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
and	O
the	O
progression	O
of	O
some	O
leukemia	O
.	O

The	O
detection	O
of	O
p16	B-Protein
gene	O
is	O
reliable	O
prognostic	O
factor	O
that	O
predict	O
shortened	O
survival	O
times	O
.	O

A	O
haploid	O
affair	O
:	O
core	O
histone	B-Protein
transitions	O
during	O
spermatogenesis	O
.	O

The	O
process	O
of	O
meiosis	O
reduces	O
a	O
diploid	O
cell	O
to	O
four	O
haploid	O
gametes	O
and	O
is	O
accompanied	O
by	O
extensive	O
recombination	O
.	O

Thus	O
,	O
the	O
dynamics	O
of	O
chromatin	O
during	O
meiosis	O
are	O
significantly	O
different	O
than	O
in	O
mitotic	O
cells	O
.	O

As	O
spermatogenesis	O
progresses	O
,	O
there	O
is	O
a	O
widespread	O
reorganization	O
of	O
the	O
haploid	O
genome	O
followed	O
by	O
extensive	O
DNA	O
compaction	O
.	O

It	O
has	O
become	O
increasingly	O
clear	O
that	O
the	O
dynamic	O
composition	O
of	O
chromatin	O
plays	O
a	O
critical	O
role	O
in	O
the	O
activities	O
of	O
enzymes	O
and	O
processes	O
that	O
act	O
upon	O
it	O
.	O

Therefore	O
,	O
an	O
analysis	O
of	O
the	O
role	O
of	O
histone	B-Protein
variants	O
and	O
modifications	O
in	O
these	O
processes	O
may	O
shed	O
light	O
upon	O
the	O
mechanisms	O
involved	O
and	O
the	O
control	O
of	O
chromatin	O
structure	O
in	O
general	O
.	O

Histone	B-Protein
variants	O
such	O
as	O
histone	B-Protein
H3	I-Protein
.	I-Protein
3	I-Protein
,	O
H2AX	B-Protein
,	O
and	O
macroH2A	B-Protein
appear	O
to	O
play	O
key	O
roles	O
in	O
the	O
various	O
stages	O
of	O
spermiogenesis	O
,	O
in	O
addition	O
to	O
the	O
specifically	O
modulated	O
acetylation	O
of	O
histone	B-Protein
H4	I-Protein
(	O
acH4	B-Protein
)	O
,	O
ubiquitination	O
of	O
histones	B-Protein
H2A	I-Protein
and	O
H2B	B-Protein
(	O
uH2A	B-Protein
,	O
uH2B	B-Protein
)	O
,	O
and	O
phosphorylation	O
of	O
histone	B-Protein
H3	I-Protein
(	O
H3p	B-Protein
)	O
.	O

This	O
review	O
will	O
examine	O
recent	O
discoveries	O
concerning	O
the	O
role	O
of	O
histone	B-Protein
modifications	O
and	O
variants	O
during	O
meiosis	O
and	O
spermatogenesis	O
.	O

HIF	B-Protein
prolyl	I-Protein
-	I-Protein
hydroxylase	I-Protein
2	I-Protein
is	O
the	O
key	O
oxygen	O
sensor	O
setting	O
low	O
steady	O
-	O
state	O
levels	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
normoxia	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
,	O
a	O
transcriptional	O
complex	O
conserved	O
from	O
Caenorhabditis	O
elegans	O
to	O
vertebrates	O
,	O
plays	O
a	O
pivotal	O
role	O
in	O
cellular	O
adaptation	O
to	O
low	O
oxygen	O
availability	O
.	O

In	O
normoxia	O
,	O
the	O
HIF	O
-	O
alpha	O
subunits	O
are	O
targeted	O
for	O
destruction	O
by	O
prolyl	O
hydroxylation	O
,	O
a	O
specific	O
modification	O
that	O
provides	O
recognition	O
for	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
complex	O
containing	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumour	I-Protein
suppressor	I-Protein
protein	O
(	O
pVHL	B-Protein
)	O
.	O

Three	O
HIF	O
prolyl	O
-	O
hydroxylases	O
(	O
PHD1	B-Protein
,	O
2	B-Protein
and	O
3	B-Protein
)	O
were	O
identified	O
recently	O
in	O
mammals	O
and	O
shown	O
to	O
hydroxylate	O
HIF	O
-	O
alpha	O
subunits	O
.	O

Here	O
we	O
show	O
that	O
specific	O
'	O
silencing	O
'	O
of	O
PHD2	B-Protein
with	O
short	O
interfering	O
RNAs	O
is	O
sufficient	O
to	O
stabilize	O
and	O
activate	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
normoxia	O
in	O
all	O
the	O
human	O
cells	O
investigated	O
.	O

'	O
Silencing	O
'	O
of	O
PHD1	B-Protein
and	O
PHD3	B-Protein
has	O
no	O
effect	O
on	O
the	O
stability	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
either	O
in	O
normoxia	O
or	O
upon	O
re	O
-	O
oxygenation	O
of	O
cells	O
briefly	O
exposed	O
to	O
hypoxia	O
.	O

We	O
therefore	O
conclude	O
that	O
,	O
in	O
vivo	O
,	O
PHDs	O
have	O
distinct	O
assigned	O
functions	O
,	O
PHD2	B-Protein
being	O
the	O
critical	O
oxygen	O
sensor	O
setting	O
the	O
low	O
steady	O
-	O
state	O
levels	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
normoxia	O
.	O

Interestingly	O
,	O
PHD2	B-Protein
is	O
upregulated	O
by	O
hypoxia	O
,	O
providing	O
an	O
HIF	O
-	O
1	O
-	O
dependent	O
auto	O
-	O
regulatory	O
mechanism	O
driven	O
by	O
the	O
oxygen	O
tension	O
.	O

Insulation	O
of	O
the	O
chicken	O
beta	B-Protein
-	I-Protein
globin	I-Protein
chromosomal	O
domain	O
from	O
a	O
chromatin	O
-	O
condensing	O
protein	O
,	O
MENT	B-Protein
.	O

Active	O
genes	O
are	O
insulated	O
from	O
developmentally	O
regulated	O
chromatin	O
condensation	O
in	O
terminally	O
differentiated	O
cells	O
.	O

We	O
mapped	O
the	O
topography	O
of	O
a	O
terminal	O
stage	O
-	O
specific	O
chromatin	O
-	O
condensing	O
protein	O
,	O
MENT	B-Protein
,	O
across	O
the	O
active	O
chicken	O
beta	B-Protein
-	I-Protein
globin	I-Protein
domain	O
.	O

We	O
observed	O
two	O
sharp	O
transitions	O
of	O
MENT	B-Protein
concentration	O
coinciding	O
with	O
the	O
beta	B-Protein
-	I-Protein
globin	I-Protein
boundary	O
elements	O
.	O

The	O
MENT	B-Protein
distribution	O
profile	O
was	O
opposite	O
to	O
that	O
of	O
acetylated	O
core	O
histones	B-Protein
but	O
correlated	O
with	O
that	O
of	O
histone	B-Protein
H3	I-Protein
dimethylated	O
at	O
lysine	O
9	O
(	O
H3me2K9	B-Protein
)	O
.	O

Ectopic	O
MENT	B-Protein
expression	O
in	O
NIH	O
3T3	O
cells	O
caused	O
a	O
large	O
-	O
scale	O
and	O
specific	O
remodeling	O
of	O
chromatin	O
marked	O
by	O
H3me2K9	O
.	O

MENT	B-Protein
colocalized	O
with	O
H3me2K9	B-Protein
both	O
in	O
chicken	O
erythrocytes	O
and	O
NIH	O
3T3	O
cells	O
.	O

Mutational	O
analysis	O
of	O
MENT	B-Protein
and	O
experiments	O
with	O
deacetylase	O
inhibitors	O
revealed	O
the	O
essential	O
role	O
of	O
the	O
reaction	O
center	O
loop	O
domain	O
and	O
an	O
inhibitory	O
affect	O
of	O
histone	B-Protein
hyperacetylation	O
on	O
the	O
MENT	B-Protein
-	O
induced	O
chromatin	O
remodeling	O
in	O
vivo	O
.	O

In	O
vitro	O
,	O
the	O
elimination	O
of	O
the	O
histone	B-Protein
H3	I-Protein
N	O
-	O
terminal	O
peptide	O
containing	O
lysine	O
9	O
by	O
trypsin	O
blocked	O
chromatin	O
self	O
-	O
association	O
by	O
MENT	B-Protein
,	O
while	O
reconstitution	O
with	O
dimethylated	O
but	O
not	O
acetylated	O
N	O
-	O
terminal	O
domain	O
of	O
histone	B-Protein
H3	I-Protein
specifically	O
restored	O
chromatin	O
self	O
-	O
association	O
by	O
MENT	B-Protein
.	O

We	O
suggest	O
that	O
histone	B-Protein
H3	I-Protein
modification	O
at	O
lysine	O
9	O
directly	O
regulates	O
chromatin	O
condensation	O
by	O
recruiting	O
MENT	B-Protein
to	O
chromatin	O
in	O
a	O
fashion	O
that	O
is	O
spatially	O
constrained	O
from	O
active	O
genes	O
by	O
gene	O
boundary	O
elements	O
and	O
histone	B-Protein
hyperacetylation	O
.	O

Requirement	O
for	O
neo1p	B-Protein
in	O
retrograde	O
transport	O
from	O
the	O
Golgi	O
complex	O
to	O
the	O
endoplasmic	O
reticulum	O
.	O

Neo1p	B-Protein
from	O
Saccharomyces	O
cerevisiae	O
is	O
an	O
essential	O
P	O
-	O
type	O
ATPase	O
and	O
potential	O
aminophospholipid	O
translocase	O
(	O
flippase	O
)	O
in	O
the	O
Drs2p	B-Protein
family	O
.	O

We	O
have	O
previously	O
implicated	O
Drs2p	B-Protein
in	O
protein	O
transport	O
steps	O
in	O
the	O
late	O
secretory	O
pathway	O
requiring	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
ARF	O
)	O
and	O
clathrin	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
epitope	O
-	O
tagged	O
Neo1p	B-Protein
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
Golgi	O
complex	O
and	O
is	O
required	O
for	O
a	O
retrograde	O
transport	O
pathway	O
between	O
these	O
organelles	O
.	O

Using	O
conditional	O
alleles	O
of	O
NEO1	B-Protein
,	O
we	O
find	O
that	O
loss	O
of	O
Neo1p	B-Protein
function	O
causes	O
cargo	O
-	O
specific	O
defects	O
in	O
anterograde	O
protein	O
transport	O
early	O
in	O
the	O
secretory	O
pathway	O
and	O
perturbs	O
glycosylation	O
in	O
the	O
Golgi	O
complex	O
.	O

Rer1	B-Protein
-	O
GFP	B-Protein
,	O
a	O
protein	O
that	O
cycles	O
between	O
the	O
ER	O
and	O
Golgi	O
complex	O
in	O
COPI	O
and	O
COPII	O
vesicles	O
,	O
is	O
mislocalized	O
to	O
the	O
vacuole	O
in	O
neo1	B-Protein
-	O
ts	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

These	O
phenotypes	O
suggest	O
that	O
the	O
anterograde	O
protein	O
transport	O
defect	O
is	O
a	O
secondary	O
consequence	O
of	O
a	O
defect	O
in	O
a	O
COPI	O
-	O
dependent	O
retrograde	O
pathway	O
.	O

We	O
propose	O
that	O
loss	O
of	O
lipid	O
asymmetry	O
in	O
the	O
cis	O
Golgi	O
perturbs	O
retrograde	O
protein	O
transport	O
to	O
the	O
ER	O
.	O

Fabrication	O
of	O
nickel	O
and	O
chromium	O
nanoparticles	O
using	O
the	O
protein	O
cage	O
of	O
apoferritin	O
.	O

The	O
iron	O
storage	O
protein	O
,	O
apoferritin	O
,	O
has	O
a	O
cavity	O
in	O
which	O
iron	O
is	O
oxidized	O
and	O
stored	O
as	O
a	O
hydrated	O
oxide	O
core	O
.	O

The	O
size	O
of	O
the	O
core	O
is	O
about	O
7	O
nm	O
in	O
diameter	O
and	O
is	O
regulated	O
by	O
the	O
cavity	O
size	O
.	O

The	O
cavity	O
can	O
be	O
utilized	O
as	O
a	O
nanoreactor	O
to	O
grow	O
inorganic	O
crystals	O
.	O

We	O
incubated	O
apoferritin	O
in	O
nickel	O
or	O
chromium	O
salt	O
solutions	O
to	O
fabricate	O
hydroxide	O
nanoparticles	O
in	O
the	O
cavity	O
.	O

By	O
using	O
a	O
solution	O
containing	O
dissolved	O
carbon	O
dioxide	O
and	O
by	O
precisely	O
controlling	O
the	O
pH	O
,	O
we	O
succeeded	O
in	O
fabricating	O
nickel	O
and	O
chromium	O
cores	O
.	O

During	O
the	O
hydroxylation	O
process	O
of	O
nickel	O
ions	O
a	O
large	O
portion	O
of	O
the	O
apoferritin	O
precipitated	O
through	O
bulk	O
precipitation	O
of	O
nickel	O
hydroxide	O
.	O

Bulk	O
precipitation	O
was	O
suppressed	O
by	O
adding	O
ammonium	O
ions	O
.	O

However	O
,	O
even	O
in	O
the	O
presence	O
of	O
ammonium	O
ions	O
the	O
core	O
did	O
not	O
form	O
using	O
a	O
degassed	O
solution	O
.	O

We	O
concluded	O
that	O
carbonate	O
ions	O
were	O
indispensable	O
for	O
core	O
formation	O
and	O
that	O
the	O
ammonium	O
ions	O
prevented	O
precipitation	O
in	O
the	O
bulk	O
solution	O
.	O

The	O
optimized	O
condition	O
for	O
nickel	O
core	O
formation	O
was	O
0	O
.	O
3	O
mg	O
/	O
mL	O
horse	O
spleen	O
apoferritin	O
and	O
5	O
mM	O
ammonium	O
nickel	O
sulfate	O
in	O
water	O
containing	O
dissolved	O
carbon	O
dioxide	O
.	O

The	O
pH	O
was	O
maintained	O
at	O
8	O
.	O
65	O
using	O
two	O
buffer	O
solutions	O
:	O
150	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
5	O
)	O
and	O
195	O
mM	O
CAPSO	O
(	O
pH	O
9	O
.	O
5	O
)	O
with	O
20	O
mM	O
ammonium	O
at	O
23	O
degrees	O
C	O
.	O

The	O
pH	O
had	O
not	O
changed	O
after	O
48	O
h	O
.	O

After	O
24	O
h	O
of	O
incubation	O
,	O
all	O
apoferritins	O
remained	O
in	O
the	O
supernatant	O
and	O
all	O
of	O
them	O
had	O
cores	O
.	O

Recombinant	O
L	B-Protein
-	I-Protein
ferritin	I-Protein
showed	O
less	O
precipitation	O
even	O
above	O
a	O
pH	O
of	O
8	O
.	O
65	O
.	O

A	O
chromium	O
core	O
was	O
formed	O
under	O
the	O
following	O
conditions	O
:	O
0	O
.	O
1	O
mg	O
/	O
mL	O
apoferritin	O
,	O
1	O
mM	O
ammonium	O
chromium	O
sulfate	O
,	O
100	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
5	O
)	O
with	O
a	O
solution	O
containing	O
dissolved	O
carbon	O
dioxide	O
.	O

About	O
80	O
%	O
of	O
the	O
supernatant	O
apoferritin	O
(	O
0	O
.	O
07	O
mg	O
/	O
mL	O
)	O
formed	O
a	O
core	O
.	O

In	O
nickel	O
and	O
chromium	O
core	O
formation	O
,	O
carbonate	O
ions	O
would	O
play	O
an	O
important	O
role	O
in	O
accelerating	O
the	O
hydroxylation	O
in	O
the	O
apoferritin	O
cavity	O
compared	O
to	O
the	O
bulk	O
solution	O
outside	O
.	O

Histone	B-Protein
hyperacetylation	O
in	O
mitosis	O
prevents	O
sister	O
chromatid	O
separation	O
and	O
produces	O
chromosome	O
segregation	O
defects	O
.	O

Posttranslational	O
modifications	O
of	O
core	O
histones	B-Protein
contribute	O
to	O
driving	O
changes	O
in	O
chromatin	O
conformation	O
and	O
compaction	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
role	O
of	O
histone	B-Protein
deacetylation	O
on	O
the	O
mitotic	O
process	O
by	O
inhibiting	O
histone	B-Protein
deacetylases	O
shortly	O
before	O
mitosis	O
in	O
human	O
primary	O
fibroblasts	O
.	O

Cells	O
entering	O
mitosis	O
with	O
hyperacetylated	O
histones	B-Protein
displayed	O
altered	O
chromatin	O
conformation	O
associated	O
with	O
decreased	O
reactivity	O
to	O
the	O
anti	O
-	O
Ser	O
10	O
phospho	O
H3	B-Protein
antibody	O
,	O
increased	O
recruitment	O
of	O
protein	B-Protein
phosphatase	I-Protein
1	I-Protein
-	I-Protein
delta	I-Protein
on	O
mitotic	O
chromosomes	O
,	O
and	O
depletion	O
of	O
heterochromatin	O
protein	O
1	O
from	O
the	O
centromeric	O
heterochromatin	O
.	O

Inhibition	O
of	O
histone	B-Protein
deacetylation	O
before	O
mitosis	O
produced	O
defective	O
chromosome	O
condensation	O
and	O
impaired	O
mitotic	O
progression	O
in	O
living	O
cells	O
,	O
suggesting	O
that	O
improper	O
chromosome	O
condensation	O
may	O
induce	O
mitotic	O
checkpoint	O
activation	O
.	O

In	O
situ	O
hybridization	O
analysis	O
on	O
anaphase	O
cells	O
demonstrated	O
the	O
presence	O
of	O
chromatin	O
bridges	O
,	O
which	O
were	O
caused	O
by	O
persisting	O
cohesion	O
along	O
sister	O
chromatid	O
arms	O
after	O
centromere	O
separation	O
.	O

Thus	O
,	O
the	O
presence	O
of	O
hyperacetylated	O
chromatin	O
during	O
mitosis	O
impairs	O
proper	O
chromosome	O
condensation	O
during	O
the	O
pre	O
-	O
anaphase	O
stages	O
,	O
resulting	O
in	O
poor	O
sister	O
chromatid	O
resolution	O
.	O

Lagging	O
chromosomes	O
consisting	O
of	O
single	O
or	O
paired	O
sisters	O
were	O
also	O
induced	O
by	O
the	O
presence	O
of	O
hyperacetylated	O
histones	B-Protein
,	O
indicating	O
that	O
the	O
less	O
constrained	O
centromeric	O
organization	O
associated	O
with	O
heterochromatin	O
protein	O
1	O
depletion	O
may	O
promote	O
the	O
attachment	O
of	O
kinetochores	O
to	O
microtubules	O
coming	O
from	O
both	O
poles	O
.	O

Hydroxylated	O
kininogens	B-Protein
and	O
kinins	B-Protein
.	O

Hydroxyprolyl	O
-	O
3	O
-	O
bradykinin	B-Protein
was	O
identified	O
in	O
the	O
digest	O
of	O
purified	O
human	O
high	B-Protein
molecular	I-Protein
weight	I-Protein
(	I-Protein
H	I-Protein
)	I-Protein
kininogen	I-Protein
with	O
plasma	B-Protein
kallikrein	I-Protein
.	O

Hydroxyproline	O
was	O
not	O
detected	O
in	O
the	O
heavy	O
and	O
light	O
chains	O
portions	O
of	O
H	B-Protein
kininogen	I-Protein
,	O
although	O
they	O
include	O
three	O
possible	O
sites	O
for	O
hydroxylation	O
of	O
proline	O
by	O
proline	O
hydroxylase	O
.	O

The	O
content	O
of	O
hydroxyprolyl	O
-	O
3	O
-	O
bradykinin	B-Protein
in	O
H	B-Protein
kininogen	I-Protein
from	O
individual	O
plasmas	O
varied	O
from	O
14	O
%	O
to	O
64	O
%	O
of	O
total	O
kinin	B-Protein
.	O

The	O
present	O
results	O
and	O
our	O
previous	O
results	O
indicate	O
that	O
only	O
kinin	B-Protein
moity	O
in	O
H	B-Protein
kininogen	I-Protein
from	O
human	O
and	O
monkey	O
plasmas	O
has	O
been	O
partially	O
hydroxylated	O
post	O
-	O
translationally	O
by	O
proline	O
-	O
4	O
-	O
hydroxylase	O
.	O

Purification	O
and	O
characterization	O
of	O
soluble	O
forms	O
of	O
human	O
and	O
rat	O
stem	B-Protein
cell	I-Protein
factor	I-Protein
recombinantly	O
expressed	O
by	O
Escherichia	O
coli	O
and	O
by	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Stem	B-Protein
cell	I-Protein
factor	I-Protein
(	O
SCF	B-Protein
)	O
is	O
a	O
novel	O
,	O
early	O
-	O
acting	O
hematopoietic	O
factor	O
.	O

It	O
was	O
isolated	O
from	O
the	O
medium	O
of	O
a	O
rat	O
cell	O
line	O
in	O
a	O
soluble	O
,	O
processed	O
form	O
(	O
Zsebo	O
et	O
al	O
.	O
,	O
1990	O
,	O
Cell	O
63	O
,	O
195	O
)	O
.	O

The	O
cloned	O
human	O
and	O
rat	O
genes	O
encode	O
the	O
soluble	O
form	O
plus	O
additional	O
C	O
-	O
terminal	O
amino	O
acids	O
including	O
a	O
hydrophobic	O
transmembrane	O
domain	O
(	O
Martin	O
et	O
al	O
.	O
,	O
1990	O
,	O
Cell	O
63	O
,	O
203	O
)	O
.	O

We	O
have	O
recombinantly	O
expressed	O
forms	O
of	O
human	O
and	O
rat	O
SCF	B-Protein
corresponding	O
to	O
the	O
soluble	O
,	O
processed	O
form	O
in	O
Escherichia	O
coli	O
and	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
.	O

After	O
expression	O
in	O
E	O
.	O
coli	O
,	O
folding	O
and	O
oxidation	O
of	O
the	O
SCF	B-Protein
polypeptides	O
are	O
required	O
.	O

The	O
SCFs	B-Protein
expressed	O
in	O
CHO	O
cells	O
are	O
secreted	O
into	O
the	O
medium	O
in	O
active	O
state	O
and	O
,	O
like	O
the	O
natural	O
SCF	B-Protein
,	O
are	O
glycosylated	O
.	O

Purification	O
of	O
the	O
recombinant	O
SCFs	B-Protein
is	O
described	O
.	O

Biological	O
and	O
biochemical	O
characterization	O
includes	O
activity	O
toward	O
responsive	O
human	O
and	O
mouse	O
cell	O
lines	O
,	O
N	O
-	O
terminal	O
amino	O
acid	O
sequences	O
,	O
disulfide	O
bond	O
linkages	O
,	O
and	O
sites	O
of	O
glycosylation	O
.	O

Inhibition	O
of	O
fusion	O
by	O
neutralizing	O
monoclonal	O
antibodies	O
to	O
the	O
haemagglutinin	B-Protein
-	I-Protein
neuraminidase	I-Protein
glycoprotein	O
of	O
Newcastle	O
disease	O
virus	O
.	O

The	O
majority	O
of	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
to	O
the	O
haemagglutinin	B-Protein
-	I-Protein
neuraminidase	I-Protein
(	O
HN	B-Protein
)	O
glycoprotein	O
of	O
Newcastle	O
disease	O
virus	O
prevent	O
attachment	O
of	O
the	O
virus	O
to	O
cellular	O
receptors	O
and	O
inhibits	O
virion	O
-	O
induced	O
fusion	O
from	O
without	O
(	O
FFWO	O
)	O
and	O
fusion	O
from	O
within	O
(	O
FFWI	O
)	O
mediated	O
by	O
the	O
virus	O
glycoprotein	O
-	O
laden	O
infected	O
cell	O
surface	O
.	O

For	O
these	O
antibodies	O
,	O
the	O
inhibition	O
of	O
fusion	O
is	O
presumed	O
to	O
be	O
the	O
result	O
of	O
the	O
prevention	O
of	O
HN	B-Protein
-	O
mediated	O
bridging	O
of	O
potential	O
fusion	O
partners	O
.	O

MAbs	O
against	O
antigenic	O
sites	O
3	O
and	O
4	O
neutralize	O
virus	O
infectivity	O
,	O
but	O
by	O
a	O
mechanism	O
other	O
than	O
the	O
prevention	O
of	O
attachment	O
,	O
the	O
exact	O
nature	O
of	O
which	O
remains	O
to	O
be	O
established	O
.	O

Antibodies	O
to	O
both	O
of	O
these	O
sites	O
effectively	O
inhibit	O
virion	O
-	O
induced	O
FFWO	O
,	O
even	O
when	O
the	O
inducing	O
virus	O
is	O
not	O
infectious	O
.	O

This	O
is	O
consistent	O
with	O
the	O
mechanism	O
of	O
neutralization	O
of	O
these	O
MAbs	O
involving	O
the	O
inhibition	O
of	O
an	O
early	O
,	O
post	O
-	O
attachment	O
step	O
in	O
infection	O
.	O

MAbs	O
to	O
site	O
3	O
also	O
inhibit	O
FFWI	O
,	O
but	O
those	O
to	O
site	O
4	O
do	O
not	O
,	O
even	O
when	O
added	O
at	O
high	O
concentrations	O
.	O

This	O
suggests	O
that	O
the	O
requirement	O
for	O
HN	B-Protein
may	O
be	O
different	O
in	O
the	O
two	O
modes	O
of	O
fusion	O
.	O

The	O
epitopes	O
recognized	O
by	O
MAbs	O
to	O
sites	O
3	O
and	O
4	O
have	O
been	O
delineated	O
by	O
the	O
identification	O
of	O
individual	O
nucleotide	O
substitutions	O
in	O
the	O
HN	B-Protein
genes	O
of	O
neutralization	O
escape	O
variants	O
.	O

Some	O
of	O
the	O
deduced	O
amino	O
acid	O
substitutions	O
result	O
in	O
additional	O
N	O
-	O
linked	O
glycosylation	O
sites	O
in	O
HN	B-Protein
,	O
which	O
are	O
utilized	O
and	O
presumably	O
account	O
for	O
the	O
escape	O
from	O
neutralization	O
.	O

The	O
influence	O
of	O
N	O
-	O
linked	O
glycosylation	O
on	O
the	O
antigenicity	O
and	O
immunogenicity	O
of	O
rubella	O
virus	O
E1	B-Protein
glycoprotein	O
.	O

Rubella	O
virus	O
E1	B-Protein
glycoprotein	O
contains	O
three	O
functional	O
N	O
-	O
linked	O
glycosylation	O
sites	O
.	O

The	O
role	O
of	O
N	O
-	O
linked	O
glycosylation	O
on	O
the	O
antigenicity	O
and	O
immunogenicity	O
of	O
E1	B-Protein
glycoprotein	O
was	O
studied	O
using	O
vaccinia	O
recombinants	O
expressing	O
E1	B-Protein
glycosylation	O
mutants	O
.	O

Expressed	O
E1	B-Protein
glycosylation	O
mutant	O
proteins	O
were	O
recognized	O
by	O
a	O
panel	O
of	O
E1	B-Protein
-	O
specific	O
monoclonal	O
antibodies	O
in	O
radioimmunoprecipitation	O
,	O
immunofluorescence	O
,	O
and	O
immunoblotting	O
,	O
indicating	O
that	O
carbohydrate	O
side	O
chains	O
on	O
E1	B-Protein
are	O
not	O
involved	O
in	O
the	O
constitution	O
of	O
epitopes	O
recognized	O
by	O
these	O
monoclonal	O
antibodies	O
.	O

This	O
observation	O
was	O
further	O
supported	O
by	O
the	O
fact	O
that	O
removal	O
of	O
oligosaccharides	O
on	O
E1	B-Protein
by	O
glycosidase	O
digestion	O
did	O
not	O
significantly	O
change	O
the	O
antigenicity	O
of	O
E1	B-Protein
.	O

All	O
the	O
glycosylation	O
mutants	O
were	O
capable	O
of	O
eliciting	O
anti	O
-	O
RV	O
E1	B-Protein
antibodies	O
.	O

The	O
single	O
glycosylation	O
mutants	O
(	O
G1	O
,	O
G2	O
,	O
and	O
G3	O
)	O
,	O
but	O
not	O
the	O
double	O
mutant	O
(	O
G23	O
)	O
or	O
the	O
triple	O
mutant	O
(	O
G123	O
)	O
,	O
were	O
found	O
to	O
be	O
capable	O
of	O
inducing	O
virus	O
neutralizing	O
antibodies	O
.	O

Among	O
the	O
single	O
glycosylation	O
mutants	O
,	O
only	O
G2	O
and	O
G3	O
were	O
active	O
in	O
producing	O
hemagglutination	O
inhibition	O
antibodies	O
in	O
mice	O
.	O

Our	O
findings	O
suggest	O
that	O
although	O
carbohydrate	O
on	O
E1	B-Protein
is	O
not	O
directly	O
involved	O
in	O
the	O
antigenic	O
structures	O
of	O
E1	B-Protein
,	O
it	O
is	O
important	O
in	O
maintaining	O
proper	O
protein	O
folding	O
and	O
stable	O
conformation	O
for	O
expression	O
of	O
immunological	O
epitopes	O
on	O
E1	B-Protein
.	O

Glycosylation	O
of	O
the	O
interleukin	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
type	I-Protein
I	I-Protein
is	O
required	O
for	O
optimal	O
binding	O
of	O
interleukin	O
-	O
1	O
.	O

The	O
two	O
types	O
of	O
cell	O
surface	O
receptors	O
for	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
are	O
glycoproteins	O
that	O
contain	O
N	O
-	O
glycosidic	O
chains	O
on	O
their	O
extracellular	O
portions	O
.	O

To	O
determine	O
the	O
role	O
of	O
glycosylation	O
of	O
the	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
type	I-Protein
I	I-Protein
(	O
IL	B-Protein
-	I-Protein
1RtI	I-Protein
)	O
in	O
the	O
binding	O
and	O
function	O
of	O
IL	O
-	O
1	O
,	O
we	O
used	O
four	O
plant	O
lectins	O
and	O
glycosidase	O
treatment	O
on	O
two	O
different	O
T	O
-	O
cell	O
lines	O
(	O
EL4	O
-	O
6	O
.	O
1	O
and	O
D10S	O
)	O
and	O
expressing	O
high	O
number	O
of	O
binding	O
sites	O
for	O
IL	O
-	O
1	O
.	O

The	O
lectins	O
wheat	O
germ	O
agglutinin	O
,	O
phytohemagglutinin	O
,	O
and	O
concanavalin	B-Protein
A	I-Protein
inhibited	O
in	O
a	O
dose	O
-	O
response	O
manner	O
the	O
IL	O
-	O
1	O
-	O
induced	O
proliferation	O
of	O
D10S	O
cells	O
.	O

Binding	O
of	O
IL	O
-	O
1	O
was	O
blocked	O
and	O
radioactive	O
IL	O
-	O
1	O
was	O
displaced	O
from	O
these	O
cells	O
by	O
these	O
lectins	O
.	O

Specific	O
sugars	O
(	O
GlcNAc	O
,	O
NeuAc	O
,	O
Gal	O
-	O
GlcNAc	O
-	O
Man	O
,	O
Man	O
,	O
or	O
alpha	O
-	O
MeMan	O
)	O
did	O
not	O
themselves	O
affect	O
IL	O
-	O
1	O
binding	O
but	O
reversed	O
the	O
blocking	O
effects	O
of	O
the	O
lectins	O
.	O

The	O
two	O
cell	O
lines	O
differed	O
in	O
their	O
responses	O
to	O
the	O
lectin	O
-	O
mediated	O
inhibition	O
of	O
IL	O
-	O
1	O
binding	O
.	O

Digestion	O
by	O
N	O
-	O
glycosidase	O
significantly	O
decreased	O
the	O
capacity	O
of	O
cells	O
to	O
bind	O
IL	O
-	O
1	O
,	O
and	O
reduced	O
by	O
approximately	O
20	O
,	O
000	O
D	O
the	O
M	O
(	O
r	O
)	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RtI	I-Protein
.	O

Neuraminidase	O
and	O
O	O
-	O
glycanase	O
treatment	O
did	O
not	O
alter	O
the	O
binding	O
of	O
IL	O
-	O
1	O
to	O
D10S	O
or	O
EL4	O
-	O
6	O
.	O
1	O
cells	O
.	O

This	O
study	O
demonstrates	O
that	O
glycosylation	O
of	O
the	O
extracellular	O
domain	O
of	O
the	O
IL	B-Protein
-	I-Protein
1RtI	I-Protein
is	O
due	O
to	O
N	O
-	O
linked	O
carbohydrates	O
,	O
that	O
the	O
degree	O
of	O
glycosylation	O
can	O
vary	O
in	O
cells	O
of	O
different	O
lineage	O
,	O
and	O
that	O
this	O
N	O
-	O
linked	O
glycosylation	O
appears	O
to	O
be	O
essential	O
for	O
optimal	O
binding	O
and	O
activity	O
of	O
IL	O
-	O
1	O
to	O
its	O
type	O
I	O
receptor	O
.	O

Expression	O
of	O
Cpgp40	B-Protein
/	I-Protein
15	I-Protein
in	O
Toxoplasma	O
gondii	O
:	O
a	O
surrogate	O
system	O
for	O
the	O
study	O
of	O
Cryptosporidium	O
glycoprotein	O
antigens	O
.	O

Cryptosporidium	O
parvum	O
is	O
a	O
waterborne	O
enteric	O
coccidian	O
that	O
causes	O
diarrheal	O
disease	O
in	O
a	O
wide	O
range	O
of	O
hosts	O
.	O

Development	O
of	O
successful	O
therapies	O
is	O
hampered	O
by	O
the	O
inability	O
to	O
culture	O
the	O
parasite	O
and	O
the	O
lack	O
of	O
a	O
transfection	O
system	O
for	O
genetic	O
manipulation	O
.	O

The	O
glycoprotein	O
products	O
of	O
the	O
Cpgp40	B-Protein
/	I-Protein
15	I-Protein
gene	O
,	O
gp40	B-Protein
and	O
gp15	B-Protein
,	O
are	O
involved	O
in	O
C	O
.	O
parvum	O
sporozoite	O
attachment	O
to	O
and	O
invasion	O
of	O
host	O
cells	O
and	O
,	O
as	O
such	O
,	O
may	O
be	O
good	O
targets	O
for	O
anticryptosporidial	O
therapies	O
.	O

However	O
,	O
the	O
function	O
of	O
these	O
antigens	O
appears	O
to	O
be	O
dependent	O
on	O
the	O
presence	O
of	O
multiple	O
O	O
-	O
linked	O
alpha	O
-	O
N	O
-	O
acetylgalactosamine	O
(	O
alpha	O
-	O
GalNAc	O
)	O
determinants	O
.	O

A	O
eukaryotic	O
expression	O
system	O
that	O
would	O
produce	O
proteins	O
bearing	O
glycosylation	O
patterns	O
similar	O
to	O
those	O
found	O
on	O
the	O
native	O
C	O
.	O
parvum	O
glycoproteins	O
would	O
greatly	O
facilitate	O
the	O
molecular	O
and	O
functional	O
characterization	O
of	O
these	O
antigens	O
.	O

As	O
a	O
unique	O
approach	O
to	O
this	O
problem	O
,	O
the	O
Cpgp40	B-Protein
/	I-Protein
15	I-Protein
gene	O
was	O
transiently	O
expressed	O
in	O
Toxoplasma	O
gondii	O
,	O
and	O
the	O
expressed	O
recombinant	O
glycoproteins	O
were	O
characterized	O
.	O

Antisera	O
to	O
gp40	B-Protein
and	O
gp15	B-Protein
reacted	O
with	O
the	O
surface	O
membranes	O
of	O
tachyzoites	O
expressing	O
the	O
Cpgp40	B-Protein
/	I-Protein
15	I-Protein
construct	O
,	O
and	O
this	O
reactivity	O
colocalized	O
with	O
that	O
of	O
antiserum	O
to	O
the	O
T	O
.	O
gondii	O
surface	O
protein	O
SAG1	B-Protein
.	O

Surface	O
membrane	O
localization	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
glycophosphatidylinositol	O
anchor	O
attachment	O
site	O
present	O
in	O
the	O
gp15	B-Protein
coding	O
sequence	O
.	O

The	O
presence	O
of	O
terminal	O
O	O
-	O
linked	O
alpha	O
-	O
GalNAc	O
determinants	O
on	O
the	O
T	O
.	O
gondii	O
recombinant	O
gp40	B-Protein
was	O
confirmed	O
by	O
reactivity	O
with	O
Helix	O
pomatia	O
lectin	O
and	O
the	O
monoclonal	O
antibody	O
4E9	O
,	O
which	O
recognizes	O
alpha	O
-	O
GalNAc	O
residues	O
,	O
and	O
digestion	O
with	O
alpha	O
-	O
N	O
-	O
acetylgalactosaminidase	O
.	O

In	O
addition	O
to	O
appropriate	O
localization	O
and	O
glycosylation	O
,	O
T	O
.	O
gondii	O
apparently	O
processes	O
the	O
gp40	B-Protein
/	I-Protein
15	I-Protein
precursor	O
into	O
the	O
gp40	B-Protein
and	O
gp15	B-Protein
component	O
glycopolypeptides	O
,	O
albeit	O
inefficiently	O
.	O

These	O
results	O
suggest	O
that	O
a	O
surrogate	O
system	O
using	O
T	O
.	O
gondii	O
for	O
the	O
study	O
of	O
Cryptosporidium	O
biology	O
may	O
be	O
useful	O
.	O

Aberrant	O
methylation	O
of	O
DAP	B-Protein
-	I-Protein
kinase	I-Protein
in	O
therapy	O
-	O
related	O
acute	O
myeloid	O
leukemia	O
and	O
myelodysplastic	O
syndromes	O
.	O

Death	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
kinase	I-Protein
(	O
DAP	B-Protein
-	I-Protein
kinase	I-Protein
)	O
,	O
a	O
proapoptotic	O
serine	O
/	O
threonine	O
kinase	O
,	O
is	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
.	O

We	O
studied	O
the	O
methylation	O
status	O
of	O
DAP	B-Protein
-	I-Protein
kinase	I-Protein
of	O
194	O
bone	O
marrow	O
samples	O
from	O
160	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
and	O
34	O
with	O
a	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
at	O
the	O
time	O
of	O
initial	O
diagnosis	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

Hypermethylation	O
of	O
DAP	B-Protein
-	I-Protein
kinase	I-Protein
was	O
present	O
in	O
27	O
.	O
5	O
%	O
(	O
44	O
of	O
160	O
)	O
of	O
AML	O
and	O
in	O
47	O
%	O
(	O
16	O
of	O
34	O
)	O
of	O
MDS	O
specimens	O
and	O
significantly	O
correlated	O
to	O
loss	O
of	O
DAP	O
-	O
kinase	O
expression	O
(	O
P	O
=	O
.	O
008	O
)	O
.	O

It	O
was	O
significantly	O
more	O
frequent	O
in	O
AML	O
secondary	O
to	O
therapy	O
for	O
other	O
malignancies	O
(	O
s	O
-	O
AML	O
;	O
14	O
of	O
29	O
,	O
48	O
.	O
3	O
%	O
)	O
,	O
as	O
compared	O
to	O
de	O
novo	O
AML	O
(	O
30	O
of	O
131	O
,	O
22	O
.	O
9	O
%	O
,	O
P	O
=	O
.	O
01	O
)	O
.	O

DAP	B-Protein
-	I-Protein
kinase	I-Protein
hypermethylation	O
in	O
AML	O
was	O
associated	O
with	O
myelodysplastic	O
changes	O
in	O
the	O
bone	O
marrow	O
at	O
the	O
time	O
of	O
the	O
initial	O
diagnosis	O
(	O
P	O
=	O
.	O
002	O
)	O
and	O
with	O
the	O
presence	O
of	O
cytogenetic	O
abnormalities	O
(	O
P	O
=	O
.	O
02	O
)	O
.	O

Alteration	O
in	O
the	O
apoptotic	O
response	O
due	O
to	O
the	O
loss	O
of	O
DAP	B-Protein
-	I-Protein
kinase	I-Protein
function	O
may	O
be	O
an	O
early	O
event	O
in	O
the	O
transformation	O
pathway	O
to	O
secondary	O
leukemia	O
via	O
myelodysplasia	O
.	O

Molecular	O
pathology	O
of	O
atypical	O
polypoid	O
adenomyoma	O
of	O
the	O
uterus	O
.	O

Atypical	O
polypoid	O
adenomyoma	O
(	O
APA	O
)	O
is	O
an	O
uncommon	O
and	O
benign	O
tumor	O
of	O
the	O
uterus	O
.	O

In	O
some	O
patients	O
,	O
however	O
,	O
APA	O
has	O
been	O
found	O
to	O
coexist	O
with	O
or	O
to	O
precede	O
the	O
development	O
of	O
an	O
endometrioid	O
adenocarcinoma	O
similarly	O
to	O
complex	O
endometrial	O
hyperplasia	O
.	O

The	O
molecular	O
changes	O
underlying	O
the	O
progression	O
from	O
APA	O
to	O
adenocarcinoma	O
are	O
unknown	O
.	O

DNA	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
of	O
6	O
APAs	O
was	O
evaluated	O
for	O
microsatellite	O
instability	O
(	O
MI	O
)	O
,	O
MLH	B-Protein
-	I-Protein
1	I-Protein
promoter	O
hypermethylation	O
,	O
and	O
CTNNB	B-Protein
-	I-Protein
1	I-Protein
mutations	O
.	O

Tissue	O
sections	O
were	O
also	O
subjected	O
to	O
MLH	B-Protein
-	I-Protein
1	I-Protein
,	O
MSH	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
immunostaining	O
.	O

MI	O
was	O
not	O
detected	O
in	O
any	O
case	O
.	O

Two	O
tumors	O
exhibited	O
MLH	B-Protein
-	I-Protein
1	I-Protein
promoter	O
hypermethylation	O
and	O
showed	O
focal	O
negative	O
MHL	O
-	O
1	O
immunostaining	O
;	O
1	O
of	O
these	O
showed	O
marked	O
architectural	O
complexity	O
and	O
cellular	O
pleomorphism	O
.	O

Five	O
cases	O
presented	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
nuclear	O
immunoreactivity	O
,	O
but	O
none	O
of	O
them	O
had	O
CTNNB	B-Protein
-	I-Protein
1	I-Protein
mutations	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
APA	O
and	O
complex	O
endometrial	O
hyperplasia	O
may	O
share	O
some	O
molecular	O
alterations	O
.	O

Some	O
APAs	O
exhibit	O
MLH	B-Protein
-	I-Protein
1	I-Protein
promoter	O
hypermethylation	O
with	O
focal	O
lack	O
of	O
MLH	B-Protein
-	I-Protein
1	I-Protein
immunostaining	O
,	O
a	O
molecular	O
abnormality	O
involved	O
in	O
the	O
transition	O
from	O
complex	O
atypical	O
hyperplasia	O
to	O
endometrioid	O
adenocarcinoma	O
.	O

A	O
common	O
polymorphism	O
in	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
(	O
ODD	O
)	O
domain	O
of	O
hypoxia	B-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
does	O
not	O
impair	O
Pro	O
-	O
564	O
hydroxylation	O
.	O

BACKGROUND	O
:	O
The	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
transcription	O
complex	O
,	O
which	O
is	O
activated	O
by	O
low	O
oxygen	O
tension	O
,	O
controls	O
a	O
diverse	O
range	O
of	O
cellular	O
processes	O
including	O
angiogenesis	O
and	O
erythropoiesis	O
.	O

Under	O
normoxic	O
conditions	O
,	O
the	O
alpha	O
subunit	O
of	O
HIF	O
is	O
rapidly	O
degraded	O
in	O
a	O
manner	O
dependent	O
on	O
hydroxylation	O
of	O
two	O
conserved	O
proline	O
residues	O
at	O
positions	O
402	O
and	O
564	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
(	O
ODD	O
)	O
domain	O
.	O

This	O
allows	O
subsequent	O
recognition	O
by	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumor	I-Protein
suppressor	I-Protein
protein	O
,	O
which	O
targets	O
HIF	O
for	O
degradation	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
prolyl	O
hydroxylation	O
of	O
HIF	O
is	O
inhibited	O
,	O
allowing	O
it	O
to	O
escape	O
VHL	O
-	O
mediated	O
degradation	O
.	O

The	O
transcriptional	O
regulation	O
of	O
the	O
erythropoietin	B-Protein
gene	O
by	O
HIF	O
raises	O
the	O
possibility	O
that	O
HIF	O
may	O
play	O
a	O
role	O
in	O
disorders	O
of	O
erythropoiesis	O
,	O
such	O
as	O
idiopathic	O
erythrocytosis	O
(	O
IE	O
)	O
.	O

RESULTS	O
:	O
Patients	O
with	O
IE	O
were	O
screened	O
for	O
changes	O
in	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
coding	O
sequence	O
,	O
and	O
a	O
change	O
in	O
the	O
ODD	O
domain	O
that	O
converts	O
Pro	O
-	O
582	O
to	O
Ser	O
was	O
identified	O
in	O
several	O
patients	O
.	O

This	O
same	O
change	O
,	O
however	O
,	O
was	O
also	O
detected	O
at	O
a	O
significant	O
frequency	O
,	O
0	O
.	O
073	O
,	O
in	O
unaffected	O
controls	O
compared	O
to	O
0	O
.	O
109	O
in	O
the	O
IE	O
patient	O
group	O
.	O

In	O
vitro	O
hydroxylation	O
assays	O
examining	O
this	O
amino	O
acid	O
change	O
failed	O
to	O
reveal	O
a	O
discernible	O
effect	O
on	O
HIF	O
hydroxylation	O
at	O
Pro	O
-	O
564	O
.	O

CONCLUSION	O
:	O
The	O
Pro582Ser	O
change	O
represents	O
a	O
common	O
polymorphism	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
that	O
does	O
not	O
impair	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
prolyl	O
hydroxylation	O
.	O

Although	O
the	O
Pro582Ser	O
polymorphism	O
is	O
located	O
in	O
the	O
ODD	O
domain	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
it	O
does	O
not	O
diminish	O
the	O
association	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
with	O
VHL	B-Protein
.	O

Thus	O
,	O
it	O
is	O
unlikely	O
that	O
this	O
polymorphism	O
accounts	O
for	O
the	O
erythrocytosis	O
in	O
the	O
group	O
of	O
IE	O
patients	O
studied	O
.	O

Expression	O
of	O
histone	B-Protein
acetyltransferases	O
was	O
down	O
-	O
regulated	O
in	O
poly	B-Protein
(	I-Protein
ADP	I-Protein
-	I-Protein
ribose	I-Protein
)	I-Protein
polymerase	I-Protein
-	I-Protein
1	I-Protein
-	O
deficient	O
murine	O
cells	O
.	O

NF	O
-	O
kappaB	O
-	O
dependent	O
,	O
as	O
well	O
as	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
-	O
1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-	O
dependent	O
,	O
reporter	O
gene	O
expression	O
was	O
significantly	O
impaired	O
in	O
cells	O
derived	O
from	O
poly	B-Protein
(	I-Protein
ADP	I-Protein
-	I-Protein
ribose	I-Protein
)	I-Protein
polymerase	I-Protein
-	I-Protein
1	I-Protein
(	O
PARP	B-Protein
-	I-Protein
1	I-Protein
)	O
-	O
knockout	O
(	O
PARP	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
)	O
mice	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
protein	O
acetylation	O
was	O
markedly	O
lower	O
in	O
PARP	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
cells	O
than	O
control	O
(	O
PARP	B-Protein
-	I-Protein
1	I-Protein
+	O
/	O
+	O
)	O
cells	O
.	O

Surprisingly	O
,	O
the	O
expression	O
levels	O
of	O
histone	B-Protein
acetyltransferases	O
(	O
HATs	O
)	O
,	O
p300	B-Protein
,	O
cAMP	B-Protein
response	I-Protein
element	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CBP	B-Protein
)	O
,	O
and	O
p300	B-Protein
/	I-Protein
CBP	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
(	O
PCAF	B-Protein
)	O
,	O
were	O
significantly	O
reduced	O
in	O
PARP	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
cells	O
,	O
as	O
compared	O
with	O
PARP	B-Protein
-	I-Protein
1	I-Protein
+	O
/	O
+	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
PARP	B-Protein
-	I-Protein
1	I-Protein
is	O
required	O
for	O
the	O
proper	O
expression	O
of	O
particular	O
HATs	O
.	O

Since	O
p300	B-Protein
and	O
CBP	B-Protein
are	O
coactivators	O
of	O
NF	O
-	O
kappaB	O
,	O
we	O
propose	O
here	O
that	O
PARP	B-Protein
-	I-Protein
1	I-Protein
participates	O
in	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
by	O
means	O
of	O
maintaining	O
the	O
expression	O
of	O
HATs	O
.	O

The	O
ITIM	O
-	O
bearing	O
CLECSF6	B-Protein
(	O
DCIR	B-Protein
)	O
is	O
down	O
-	O
modulated	O
in	O
neutrophils	O
by	O
neutrophil	O
activating	O
agents	O
.	O

The	O
recently	O
discovered	O
CLECSF6	B-Protein
protein	O
displays	O
the	O
features	O
of	O
a	O
receptor	O
involved	O
in	O
the	O
down	O
-	O
modulation	O
of	O
leukocyte	O
activation	O
.	O

Although	O
CLECSF6	B-Protein
has	O
been	O
the	O
focus	O
of	O
the	O
interest	O
of	O
many	O
researchers	O
lately	O
,	O
a	O
Western	O
blot	O
characterization	O
of	O
the	O
protein	O
is	O
still	O
lacking	O
.	O

This	O
highly	O
reduces	O
our	O
ability	O
to	O
gain	O
full	O
knowledge	O
of	O
the	O
biological	O
relevance	O
of	O
this	O
protein	O
in	O
cell	O
responses	O
.	O

We	O
produced	O
two	O
rabbit	O
polyclonal	O
antisera	O
that	O
detected	O
a	O
glycosylated	O
protein	O
at	O
approximately	O
35kDa	O
in	O
neutrophils	O
.	O

Four	O
different	O
CLECSF6	B-Protein
mRNA	O
species	O
have	O
been	O
discovered	O
to	O
date	O
.	O

When	O
deglycosylated	O
,	O
the	O
protein	O
displayed	O
the	O
molecular	O
weight	O
expected	O
for	O
the	O
longest	O
CLECSF6	B-Protein
form	O
.	O

Neutrophil	O
membrane	O
fractions	O
were	O
strongly	O
enriched	O
in	O
the	O
protein	O
.	O

We	O
showed	O
a	O
down	O
-	O
modulation	O
of	O
the	O
expression	O
of	O
this	O
protein	O
in	O
neutrophils	O
treated	O
with	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
-	I-Protein
colony	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
and	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
-	I-Protein
4	I-Protein
.	O

This	O
work	O
supports	O
the	O
hypothesis	O
that	O
CLECSF6	B-Protein
is	O
involved	O
in	O
the	O
control	O
of	O
inflammation	O
in	O
neutrophils	O
.	O

Epigenetic	O
switch	O
from	O
posttranscriptional	O
to	O
transcriptional	O
silencing	O
is	O
correlated	O
with	O
promoter	O
hypermethylation	O
.	O

Changes	O
in	O
the	O
distribution	O
of	O
methylcytosine	O
residues	O
along	O
a	O
transgene	O
locus	O
of	O
tobacco	O
(	O
Nicotiana	O
tabacum	O
)	O
in	O
relation	O
to	O
the	O
type	O
of	O
gene	O
silencing	O
were	O
studied	O
in	O
parental	O
plant	O
leaves	O
,	O
calli	O
,	O
and	O
regenerated	O
plants	O
derived	O
thereof	O
.	O

Parental	O
-	O
silenced	O
HeLo1	O
(	O
hemizygous	O
for	O
locus	O
1	O
)	O
plants	O
show	O
posttranscriptional	O
silencing	O
of	O
the	O
residing	O
nptII	B-Protein
(	O
neomycin	B-Protein
phosphotransferase	I-Protein
II	I-Protein
)	O
transgene	O
and	O
cytosine	O
methylation	O
restricted	O
to	O
the	O
3	O
'	O
end	O
and	O
center	O
part	O
of	O
the	O
transcribed	O
region	O
.	O

Here	O
,	O
we	O
report	O
that	O
with	O
an	O
increasing	O
number	O
of	O
cell	O
cycles	O
,	O
DNA	O
methylation	O
changes	O
gradually	O
,	O
and	O
methylation	O
is	O
introduced	O
into	O
the	O
promoter	O
during	O
cell	O
culture	O
and	O
more	O
slowly	O
in	O
vegetatively	O
propagated	O
plants	O
.	O

After	O
24	O
months	O
of	O
callus	O
in	O
vitro	O
cultivation	O
,	O
an	O
epigenetic	O
variant	O
,	O
designated	O
locus	O
1E	O
,	O
was	O
obtained	O
in	O
which	O
cytosine	O
methylation	O
of	O
symmetrical	O
(	O
CG	O
and	O
CNG	O
)	O
sites	O
was	O
almost	O
complete	O
within	O
the	O
5	O
'	O
end	O
of	O
the	O
nptII	B-Protein
-	O
transcribed	O
region	O
and	O
the	O
35S	O
promoter	O
.	O

Further	O
,	O
methylation	O
of	O
nonsymmetrical	O
sites	O
appeared	O
de	O
novo	O
in	O
the	O
promoter	O
,	O
whereas	O
this	O
type	O
of	O
methylation	O
was	O
significantly	O
reduced	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
transcribed	O
region	O
when	O
compared	O
with	O
locus	O
1	O
.	O

The	O
newly	O
established	O
epigenetic	O
patterns	O
were	O
stably	O
transmitted	O
from	O
calli	O
into	O
regenerated	O
plants	O
and	O
their	O
progeny	O
.	O

The	O
protein	O
and	O
steady	O
-	O
state	O
RNA	O
levels	O
remained	O
low	O
in	O
locus	O
1E	O
,	O
whereas	O
with	O
nuclear	O
run	O
-	O
on	O
assays	O
,	O
no	O
detectable	O
amounts	O
of	O
primary	O
transcripts	O
were	O
found	O
along	O
the	O
nptII	B-Protein
gene	O
,	O
indicating	O
that	O
the	O
methylated	O
promoter	O
became	O
inactivated	O
.	O

The	O
results	O
suggest	O
that	O
a	O
switch	O
between	O
posttranscriptional	O
and	O
transcriptional	O
gene	O
silencing	O
could	O
be	O
a	O
mechanism	O
leading	O
to	O
irrevocable	O
shut	O
down	O
of	O
gene	O
expression	O
within	O
a	O
finite	O
number	O
of	O
generations	O
.	O

Frequent	O
methylation	O
of	O
p16INK4A	B-Protein
and	O
p14ARF	B-Protein
genes	O
implicated	O
in	O
the	O
evolution	O
of	O
chronic	O
myeloid	O
leukaemia	O
from	O
its	O
chronic	O
to	O
accelerated	O
phase	O
.	O

The	O
frequency	O
and	O
mechanism	O
of	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
and	O
p14	B-Protein
(	I-Protein
ARF	I-Protein
)	I-Protein
gene	O
alterations	O
were	O
studied	O
in	O
cell	O
samples	O
from	O
30	O
patients	O
with	O
Philadelphia	O
(	O
Ph	O
)	O
chromosome	O
-	O
positive	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
,	O
both	O
at	O
diagnosis	O
and	O
at	O
the	O
onset	O
of	O
the	O
accelerated	O
phase	O
(	O
AP	O
)	O
of	O
the	O
disease	O
.	O

No	O
alterations	O
in	O
the	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
or	O
p14	B-Protein
(	I-Protein
ARF	I-Protein
)	I-Protein
genes	O
were	O
found	O
in	O
any	O
of	O
the	O
chronic	O
phase	O
(	O
CP	O
)	O
samples	O
.	O

DNA	O
sequencing	O
analyses	O
detected	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
or	O
p14	B-Protein
(	I-Protein
ARF	I-Protein
)	I-Protein
mutations	O
in	O
17	O
AP	O
samples	O
.	O

All	O
mutations	O
were	O
heterozygous	O
without	O
loss	O
of	O
the	O
other	O
allele	O
.	O

Aberrant	O
methylation	O
of	O
the	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
or	O
p14	B-Protein
(	I-Protein
ARF	I-Protein
)	I-Protein
promoters	O
was	O
found	O
in	O
14	O
of	O
30	O
AP	O
samples	O
.	O

The	O
most	O
common	O
situation	O
was	O
the	O
simultaneous	O
methylation	O
of	O
both	O
promoters	O
.	O

Our	O
data	O
indicate	O
that	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
and	O
p14	B-Protein
(	I-Protein
ARF	I-Protein
)	I-Protein
are	O
primary	O
targets	O
for	O
inactivation	O
by	O
promoter	O
methylation	O
in	O
the	O
acceleration	O
of	O
CML	O
.	O

Transcriptional	O
silencing	O
of	O
the	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
and	O
p14	B-Protein
(	I-Protein
ARF	I-Protein
)	I-Protein
genes	O
may	O
be	O
important	O
in	O
the	O
conversion	O
of	O
CML	O
from	O
the	O
CP	O
to	O
the	O
AP	O
.	O

mSin3A	B-Protein
/	O
histone	B-Protein
deacetylase	I-Protein
2	I-Protein
-	O
and	O
PRMT5	B-Protein
-	O
containing	O
Brg1	B-Protein
complex	O
is	O
involved	O
in	O
transcriptional	O
repression	O
of	O
the	O
Myc	B-Protein
target	O
gene	O
cad	B-Protein
.	O

The	O
role	O
of	O
hSWI	O
/	O
SNF	O
complexes	O
in	O
transcriptional	O
activation	O
is	O
well	O
characterized	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
their	O
function	O
in	O
transcriptional	O
repression	O
.	O

We	O
have	O
previously	O
shown	O
that	O
subunits	O
of	O
the	O
mSin3A	B-Protein
/	O
histone	B-Protein
deacetylase	I-Protein
2	I-Protein
(	O
HDAC2	B-Protein
)	O
corepressor	O
complex	O
copurify	O
with	O
hSWI	O
/	O
SNF	O
complexes	O
.	O

Here	O
we	O
show	O
that	O
the	O
type	O
II	O
arginine	O
-	O
specific	O
methyltransferase	O
PRMT5	B-Protein
,	O
which	O
is	O
involved	O
in	O
cyclin	O
E	O
repression	O
,	O
can	O
be	O
found	O
in	O
association	O
with	O
Brg1	B-Protein
and	O
hBrm	B-Protein
-	O
based	O
hSWI	O
/	O
SNF	O
complexes	O
.	O

We	O
also	O
show	O
that	O
hSWI	O
/	O
SNF	O
-	O
associated	O
PRMT5	B-Protein
can	O
methylate	O
hypoacetylated	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
more	O
efficiently	O
than	O
hyperacetylated	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
.	O

Protein	O
-	O
protein	O
interaction	O
studies	O
indicate	O
that	O
PRMT5	B-Protein
and	O
mSin3A	B-Protein
interact	O
with	O
the	O
same	O
hSWI	O
/	O
SNF	O
subunits	O
as	O
those	O
targeted	O
by	O
c	B-Protein
-	I-Protein
Myc	I-Protein
.	O

These	O
observations	O
prompted	O
us	O
to	O
examine	O
the	O
expression	O
profile	O
of	O
the	O
c	B-Protein
-	I-Protein
Myc	I-Protein
target	O
genes	O
,	O
carbamoyl	B-Protein
-	I-Protein
phosphate	I-Protein
synthase	I-Protein
-	O
aspartate	B-Protein
carbamoyltransferase	I-Protein
-	O
dihydroorotase	B-Protein
(	O
cad	B-Protein
)	O
and	O
nucleolin	B-Protein
(	O
nuc	B-Protein
)	O
.	O

We	O
found	O
that	O
cad	B-Protein
repression	O
is	O
altered	O
in	O
cells	O
that	O
express	O
inactive	O
Brg1	B-Protein
and	O
in	O
cells	O
treated	O
with	O
the	O
HDAC	O
inhibitor	O
depsipeptide	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
assays	O
,	O
we	O
found	O
that	O
Brg1	B-Protein
,	O
mSin3A	B-Protein
,	O
HDAC2	B-Protein
,	O
and	O
PRMT5	B-Protein
are	O
directly	O
recruited	O
to	O
the	O
cad	B-Protein
promoter	O
.	O

These	O
results	O
suggest	O
that	O
hSWI	O
/	O
SNF	O
complexes	O
,	O
through	O
their	O
ability	O
to	O
interact	O
with	O
activator	O
and	O
repressor	O
proteins	O
,	O
control	O
expression	O
of	O
genes	O
involved	O
in	O
cell	O
growth	O
and	O
proliferation	O
.	O

Centromere	O
silencing	O
and	O
function	O
in	O
fission	O
yeast	O
is	O
governed	O
by	O
the	O
amino	O
terminus	O
of	O
histone	B-Protein
H3	I-Protein
.	O

BACKGROUND	O
:	O
Centromeric	O
domains	O
often	O
consist	O
of	O
repetitive	O
elements	O
that	O
are	O
assembled	O
in	O
specialized	O
chromatin	O
,	O
characterized	O
by	O
hypoacetylation	O
of	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
and	O
methylation	O
of	O
lysine	O
9	O
of	O
histone	B-Protein
H3	I-Protein
(	O
K9	O
-	O
MeH3	B-Protein
)	O
.	O

Perturbation	O
of	O
this	O
underacetylated	O
state	O
by	O
transient	O
treatment	O
with	O
histone	B-Protein
deacetylase	O
inhibitors	O
leads	O
to	O
defective	O
centromere	O
function	O
,	O
correlating	O
with	O
delocalization	O
of	O
the	O
heterochromatin	O
protein	O
Swi6	B-Protein
/	O
HP1	B-Protein
.	O

Likewise	O
,	O
deletion	O
of	O
the	O
K9	O
-	O
MeH3	B-Protein
methyltransferase	O
Clr4	B-Protein
/	O
Suvar39	B-Protein
causes	O
defective	O
chromosome	O
segregation	O
.	O

Here	O
,	O
we	O
create	O
fission	O
yeast	O
strains	O
retaining	O
one	O
histone	B-Protein
H3	I-Protein
and	O
H4	B-Protein
gene	O
;	O
the	O
creation	O
of	O
these	O
strains	O
allows	O
mutation	O
of	O
specific	O
N	O
-	O
terminal	O
tail	O
residues	O
and	O
their	O
role	O
in	O
centromeric	O
silencing	O
and	O
chromosome	O
stability	O
to	O
be	O
investigated	O
.	O

RESULTS	O
:	O
Reduction	O
of	O
H3	B-Protein
/	O
H4	B-Protein
gene	O
dosage	O
to	O
one	O
-	O
third	O
does	O
not	O
affect	O
cell	O
viability	O
or	O
heterochromatin	O
formation	O
.	O

Mutation	O
of	O
lysines	O
9	O
or	O
14	O
or	O
serine	O
10	O
within	O
the	O
amino	O
terminus	O
of	O
histone	B-Protein
H3	I-Protein
impairs	O
centromere	O
function	O
,	O
leading	O
to	O
defective	O
chromosome	O
segregation	O
and	O
Swi6	B-Protein
delocalization	O
.	O

Surprisingly	O
,	O
silent	O
centromeric	O
chromatin	O
does	O
not	O
require	O
the	O
conserved	O
lysine	O
8	O
and	O
16	O
residues	O
of	O
histone	B-Protein
H4	I-Protein
.	O

CONCLUSIONS	O
:	O
To	O
date	O
,	O
mutation	O
of	O
conserved	O
N	O
-	O
terminal	O
residues	O
in	O
endogenous	O
histone	B-Protein
genes	O
has	O
only	O
been	O
performed	O
in	O
budding	O
yeast	O
,	O
which	O
lacks	O
the	O
Clr4	B-Protein
/	O
Suvar39	B-Protein
histone	O
methyltransferase	O
and	O
Swi6	B-Protein
/	O
HP1	B-Protein
.	O

We	O
demonstrate	O
the	O
importance	O
of	O
conserved	O
residues	O
within	O
the	O
histone	B-Protein
H3	I-Protein
N	O
terminus	O
for	O
the	O
maintenance	O
of	O
centromeric	O
heterochromatin	O
in	O
fission	O
yeast	O
.	O

In	O
sharp	O
contrast	O
,	O
mutation	O
of	O
two	O
conserved	O
lysines	O
within	O
the	O
histone	B-Protein
H4	I-Protein
tail	O
has	O
no	O
impact	O
on	O
the	O
integrity	O
of	O
centromeric	O
heterochromatin	O
.	O

Our	O
data	O
highlight	O
the	O
striking	O
divergence	O
between	O
the	O
histone	B-Protein
tail	O
requirements	O
for	O
the	O
fission	O
yeast	O
and	O
budding	O
yeast	O
silencing	O
pathways	O
.	O

Thermal	O
stability	O
and	O
aggregation	O
of	O
sulfolobus	O
solfataricus	O
beta	B-Protein
-	I-Protein
glycosidase	I-Protein
are	O
dependent	O
upon	O
the	O
N	O
-	O
epsilon	O
-	O
methylation	O
of	O
specific	O
lysyl	O
residues	O
:	O
critical	O
role	O
of	O
in	O
vivo	O
post	O
-	O
translational	O
modifications	O
.	O

Methylation	O
in	O
vivo	O
is	O
a	O
post	O
-	O
translational	O
modification	O
observed	O
in	O
several	O
organisms	O
belonging	O
to	O
eucarya	O
,	O
bacteria	O
,	O
and	O
archaea	O
.	O

Although	O
important	O
implications	O
of	O
this	O
modification	O
have	O
been	O
demonstrated	O
in	O
several	O
eucaryotes	O
,	O
its	O
biological	O
role	O
in	O
hyperthermophilic	O
archaea	O
is	O
far	O
from	O
being	O
understood	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
clarify	O
some	O
effects	O
of	O
methylation	O
on	O
the	O
properties	O
of	O
beta	B-Protein
-	I-Protein
glycosidase	I-Protein
from	O
Sulfolobus	O
solfataricus	O
,	O
by	O
a	O
structural	O
comparison	O
between	O
the	O
native	O
,	O
methylated	O
protein	O
and	O
its	O
unmethylated	O
counterpart	O
,	O
recombinantly	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

Analysis	O
by	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
indicated	O
similar	O
secondary	O
structure	O
contents	O
for	O
the	O
two	O
forms	O
of	O
the	O
protein	O
.	O

However	O
,	O
the	O
study	O
of	O
temperature	O
perturbation	O
by	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
and	O
turbidimetry	O
evidenced	O
denaturation	O
and	O
aggregation	O
events	O
more	O
pronounced	O
in	O
recombinant	O
than	O
in	O
native	O
beta	B-Protein
-	I-Protein
glycosidase	I-Protein
.	O

Red	O
Nile	O
fluorescence	O
analysis	O
revealed	O
significant	O
differences	O
of	O
surface	O
hydrophobicity	O
between	O
the	O
two	O
forms	O
of	O
the	O
protein	O
.	O

Unlike	O
the	O
native	O
enzyme	O
,	O
which	O
dissociated	O
into	O
SDS	O
-	O
resistant	O
dimers	O
upon	O
exposure	O
to	O
the	O
detergent	O
,	O
the	O
recombinant	O
enzyme	O
partially	O
dissociated	O
into	O
monomers	O
.	O

By	O
electrospray	O
mapping	O
,	O
the	O
methylation	O
sites	O
of	O
the	O
native	O
protein	O
were	O
identified	O
.	O

A	O
computational	O
analysis	O
of	O
beta	B-Protein
-	I-Protein
glycosidase	I-Protein
three	O
-	O
dimensional	O
structure	O
and	O
comparisons	O
with	O
other	O
proteins	O
from	O
S	O
.	O
solfataricus	O
revealed	O
analogies	O
in	O
the	O
localization	O
of	O
methylation	O
sites	O
in	O
terms	O
of	O
secondary	O
structural	O
elements	O
and	O
overall	O
topology	O
.	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
the	O
methylation	O
of	O
lysyl	O
residues	O
,	O
located	O
in	O
selected	O
domains	O
,	O
in	O
the	O
thermal	O
stabilization	O
of	O
beta	B-Protein
-	I-Protein
glycosidase	I-Protein
from	O
S	O
.	O
solfataricus	O
.	O

Pathways	O
for	O
phosphatidylcholine	O
biosynthesis	O
in	O
bacteria	O
.	O

Phosphatidylcholine	O
(	O
PC	O
)	O
is	O
the	O
major	O
membrane	O
-	O
forming	O
phospholipid	O
in	O
eukaryotes	O
with	O
important	O
structural	O
and	O
signalling	O
functions	O
.	O

Although	O
many	O
prokaryotes	O
lack	O
PC	O
,	O
it	O
can	O
be	O
found	O
in	O
significant	O
amounts	O
in	O
membranes	O
of	O
rather	O
diverse	O
bacteria	O
.	O

Two	O
pathways	O
for	O
PC	O
biosynthesis	O
are	O
known	O
in	O
bacteria	O
,	O
the	O
methylation	O
pathway	O
and	O
the	O
phosphatidylcholine	B-Protein
synthase	I-Protein
(	O
PCS	B-Protein
)	O
pathway	O
.	O

In	O
the	O
methylation	O
pathway	O
,	O
phosphatidylethanolamine	O
is	O
methylated	O
three	O
times	O
to	O
yield	O
PC	O
,	O
in	O
reactions	O
catalysed	O
by	O
one	O
or	O
several	O
phospholipid	O
N	O
-	O
methyltransferases	O
(	O
PMTs	O
)	O
.	O

In	O
the	O
PCS	O
pathway	O
,	O
choline	O
is	O
condensed	O
directly	O
with	O
CDP	O
-	O
diacylglyceride	O
to	O
form	O
PC	O
in	O
a	O
reaction	O
catalysed	O
by	O
PCS	O
.	O

Using	O
cell	O
-	O
free	O
extracts	O
,	O
it	O
was	O
demonstrated	O
that	O
Sinorhizobium	O
meliloti	O
,	O
Agrobacterium	O
tumefaciens	O
,	O
Rhizobium	O
leguminosarum	O
,	O
Bradyrhizobium	O
japonicum	O
,	O
Mesorhizobium	O
loti	O
and	O
Legionella	O
pneumophila	O
have	O
both	O
PMT	O
and	O
PCS	B-Protein
activities	O
.	O

In	O
addition	O
,	O
Rhodobacter	O
sphaeroides	O
has	O
PMT	O
activity	O
and	O
Brucella	O
melitensis	O
,	O
Pseudomonas	O
aeruginosa	O
and	O
Borrelia	O
burgdorferi	O
have	O
PCS	O
activities	O
.	O

Genes	O
from	O
M	O
.	O
loti	O
and	O
L	O
.	O
pneumophila	O
encoding	O
a	O
Pmt	B-Protein
or	O
a	O
Pcs	B-Protein
activity	O
and	O
the	O
genes	O
from	O
P	O
.	O
aeruginosa	O
and	O
Borrelia	O
burgdorferi	O
responsible	O
for	O
Pcs	B-Protein
activity	O
have	O
been	O
identified	O
.	O

Based	O
on	O
these	O
functional	O
assignments	O
and	O
on	O
genomic	O
data	O
,	O
one	O
might	O
predict	O
that	O
if	O
bacteria	O
contain	O
PC	O
as	O
a	O
membrane	O
lipid	O
,	O
they	O
usually	O
possess	O
both	O
bacterial	O
pathways	O
for	O
PC	O
biosynthesis	O
.	O

However	O
,	O
important	O
pathogens	O
such	O
as	O
Brucella	O
melitensis	O
,	O
P	O
.	O
aeruginosa	O
and	O
Borrelia	O
burgdorferi	O
seem	O
to	O
be	O
exceptional	O
as	O
they	O
possess	O
only	O
the	O
PCS	B-Protein
pathway	O
for	O
PC	O
formation	O
.	O

Rapid	O
screening	O
for	O
S	O
-	O
adenosylmethionine	O
-	O
dependent	O
methylation	O
products	O
by	O
enzyme	O
-	O
transferred	O
isotope	O
patterns	O
analysis	O
.	O

We	O
report	O
here	O
an	O
isotopic	O
labeling	O
and	O
mass	O
spectrometric	O
method	O
to	O
rapidly	O
identify	O
S	O
-	O
adenosylmethionine	O
(	O
AdoMet	O
)	O
-	O
dependent	O
methylation	O
products	O
.	O

In	O
the	O
presence	O
of	O
CH	O
(	O
3	O
)	O
-	O
and	O
CD	O
(	O
3	O
)	O
-	O
labeled	O
AdoMet	O
,	O
a	O
methyl	O
transfer	O
product	O
appears	O
as	O
a	O
doublet	O
separated	O
by	O
3	O
Da	O
in	O
a	O
mass	O
spectrum	O
,	O
while	O
other	O
compounds	O
show	O
their	O
normal	O
isotopic	O
distribution	O
.	O

Based	O
on	O
this	O
unique	O
isotopic	O
pattern	O
,	O
methylation	O
product	O
(	O
s	O
)	O
can	O
be	O
easily	O
detected	O
even	O
from	O
a	O
mixture	O
of	O
cellular	O
components	O
.	O

To	O
validate	O
our	O
method	O
,	O
the	O
product	O
of	O
human	O
thiopurine	B-Protein
methyltransferase	I-Protein
(	O
TPMT	B-Protein
,	O
EC	O
2	O
.	O
1	O
.	O
1	O
.	O
67	O
)	O
has	O
been	O
successfully	O
identified	O
from	O
both	O
an	O
in	O
vitro	O
assay	O
and	O
a	O
whole	O
-	O
cell	O
assay	O
.	O

This	O
method	O
is	O
generally	O
applicable	O
to	O
AdoMet	O
-	O
dependent	O
transmethylation	O
and	O
other	O
group	O
-	O
transfer	O
reactions	O
,	O
and	O
constitutes	O
the	O
first	O
example	O
of	O
a	O
general	O
strategy	O
of	O
enzyme	O
-	O
transferred	O
isotope	O
patterns	O
(	O
ETIPs	O
)	O
analysis	O
.	O

Subunit	O
-	O
specific	O
sulphation	O
of	O
oligosaccharides	O
relating	O
to	O
charge	O
-	O
heterogeneity	O
in	O
porcine	O
lutrophin	O
isoforms	O
.	O

Lutrophin	O
(	O
LH	O
)	O
consists	O
of	O
an	O
array	O
of	O
isoforms	O
with	O
different	O
charges	O
and	O
bioactivities	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
clarify	O
specifically	O
how	O
oligosaccharides	O
of	O
alpha	O
and	O
beta	O
subunits	O
contribute	O
to	O
LH	O
isoform	O
charges	O
.	O

Porcine	O
LH	O
(	O
pLH	O
)	O
was	O
separated	O
into	O
four	O
isoforms	O
by	O
isoelectric	O
focusing	O
(	O
IEF	O
)	O
,	O
followed	O
by	O
subunit	O
isolation	O
.	O

Their	O
oligosaccharides	O
were	O
released	O
by	O
hydrazinolysis	O
,	O
labelled	O
by	O
reduction	O
with	O
NaB3H4	O
,	O
and	O
fractionated	O
by	O
HPLC	O
with	O
a	O
Mono	O
Q	O
column	O
into	O
five	O
populations	O
differing	O
in	O
the	O
number	O
of	O
sulphate	O
(	O
S	O
)	O
and	O
sialic	O
acid	O
(	O
N	O
)	O
residues	O
,	O
designated	O
as	O
Neutral	O
,	O
N	O
-	O
1	O
,	O
S	O
-	O
1	O
,	O
S	O
-	O
N	O
and	O
S	O
-	O
2	O
.	O

Oligosaccharides	O
were	O
predominantly	O
sulphated	O
(	O
S	O
-	O
1	O
and	O
S	O
-	O
2	O
)	O
and	O
infrequently	O
sialylated	O
(	O
N	O
-	O
1	O
and	O
S	O
-	O
N	O
)	O
.	O

Further	O
analysis	O
,	O
including	O
concanavalin	B-Protein
A	I-Protein
(	O
Con	B-Protein
A	I-Protein
)	O
affinity	O
chromatography	O
,	O
desialylation	O
,	O
desulphation	O
,	O
sequential	O
exoglycosidase	O
digestion	O
and	O
methylation	O
,	O
clarified	O
the	O
structures	O
of	O
the	O
acidic	O
oligosaccharides	O
.	O

All	O
were	O
of	O
the	O
biantennary	O
complex	O
type	O
.	O

Their	O
two	O
peripheral	O
branches	O
were	O
SO4	O
-	O
4GalNAc	O
beta	O
1	O
-	O
4Glc	O
-	O
NAc	O
and	O
GalNAc	O
beta	O
1	O
-	O
4GlcNAc	O
or	O
GlcNAc	O
in	O
S	O
-	O
1	O
,	O
SO4	O
-	O
4GalNAc	O
beta	O
1	O
-	O
4GlcNAc	O
and	O
Sia	O
alpha	O
2	O
-	O
6Gal	O
beta	O
1	O
-	O
4GlcNAc	O
in	O
S	O
-	O
N	O
,	O
and	O
(	O
SO4	O
-	O
4GalNAc	O
beta	O
1	O
-	O
4GlcNAc	O
)	O
2	O
in	O
S	O
-	O
2	O
(	O
where	O
GalNAc	O
is	O
N	O
-	O
acetylgalactosamine	O
and	O
GlcNAc	O
is	O
N	O
-	O
acetylglucosamine	O
)	O
.	O

Ten	O
percent	O
of	O
S	O
-	O
1	O
and	O
of	O
S	O
-	O
N	O
had	O
a	O
bisecting	O
GlcNAc	O
residue	O
.	O

Sulphate	O
residues	O
occurred	O
in	O
nearly	O
the	O
same	O
amount	O
for	O
both	O
subunits	O
;	O
however	O
,	O
the	O
alpha	O
and	O
beta	O
subunits	O
were	O
sulphated	O
differently	O
.	O

S	O
-	O
1	O
predominated	O
in	O
the	O
alpha	O
subunit	O
,	O
while	O
S	O
-	O
1	O
and	O
S	O
-	O
2	O
were	O
major	O
components	O
in	O
the	O
beta	O
subunit	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
MTHFR	B-Protein
677C	O
>	O
T	O
polymorphism	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
hepatocellular	O
carcinoma	O
in	O
patients	O
with	O
alcoholic	O
cirrhosis	O
.	O

Methylenetetrahydrofolate	B-Protein
reductase	I-Protein
(	O
MTHFR	B-Protein
)	O
,	O
a	O
key	O
enzyme	O
in	O
folate	O
metabolism	O
,	O
plays	O
a	O
major	O
role	O
in	O
the	O
provision	O
of	O
methyl	O
groups	O
for	O
DNA	O
methylation	O
and	O
in	O
the	O
production	O
of	O
dTMP	O
for	O
DNA	O
synthesis	O
.	O

Different	O
polymorphisms	O
have	O
been	O
described	O
for	O
this	O
enzyme	O
,	O
the	O
most	O
studied	O
being	O
the	O
C677T	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
predisposition	O
to	O
colorectal	O
cancer	O
in	O
patients	O
who	O
consume	O
a	O
high	O
alcohol	O
diet	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
MTHFR	B-Protein
polymorphism	O
is	O
related	O
to	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
in	O
patients	O
with	O
alcoholic	O
cirrhosis	O
.	O

MTHFR	B-Protein
genotypes	O
were	O
determined	O
in	O
300	O
liver	O
transplant	O
patients	O
,	O
72	O
of	O
whom	O
had	O
alcoholic	O
cirrhosis	O
with	O
HCC	O
and	O
122	O
of	O
whom	O
had	O
alcoholic	O
cirrhosis	O
without	O
HCC	O
.	O

The	O
remaining	O
patients	O
were	O
transplanted	O
for	O
HCC	O
on	O
normal	O
liver	O
(	O
n	O
=	O
27	O
)	O
or	O
viral	O
cirrhosis	O
with	O
HCC	O
(	O
n	O
=	O
49	O
)	O
or	O
without	O
HCC	O
(	O
n	O
=	O
30	O
)	O
.	O

We	O
also	O
tested	O
80	O
healthy	O
subjects	O
.	O

Among	O
the	O
group	O
of	O
patients	O
transplanted	O
for	O
alcoholic	O
cirrhosis	O
,	O
the	O
frequency	O
of	O
MTHFR	B-Protein
variants	O
CC	O
versus	O
CT	O
and	O
TT	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
HCC	O
than	O
in	O
patients	O
without	O
macroscopic	O
evidence	O
of	O
HCC	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

This	O
difference	O
was	O
not	O
observed	O
between	O
patients	O
with	O
and	O
without	O
HCC	O
developed	O
either	O
on	O
viral	O
cirrhosis	O
or	O
on	O
non	O
-	O
cirrhotic	O
liver	O
.	O

If	O
we	O
considered	O
all	O
the	O
patients	O
transplanted	O
for	O
HCC	O
,	O
the	O
MTHFR	B-Protein
CC	O
genotype	O
was	O
significantly	O
higher	O
in	O
patients	O
who	O
had	O
developed	O
HCC	O
on	O
alcoholic	O
cirrhosis	O
rather	O
than	O
on	O
viral	O
cirrhosis	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
or	O
on	O
non	O
-	O
cirrhotic	O
livers	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

The	O
relative	O
risk	O
for	O
HCC	O
in	O
subjects	O
with	O
alcoholic	O
cirrhosis	O
and	O
the	O
CC	O
genotype	O
was	O
2	O
.	O
03	O
.	O

These	O
results	O
suggest	O
that	O
the	O
MTHFR	B-Protein
CC	O
genotype	O
increases	O
the	O
risk	O
to	O
develop	O
HCC	O
in	O
patients	O
who	O
consume	O
a	O
high	O
alcohol	O
diet	O
.	O

Mbd1	B-Protein
is	O
recruited	O
to	O
both	O
methylated	O
and	O
nonmethylated	O
CpGs	O
via	O
distinct	O
DNA	O
binding	O
domains	O
.	O

MBD1	B-Protein
is	O
a	O
vertebrate	O
methyl	O
-	O
CpG	O
binding	O
domain	O
protein	O
(	O
MBD	O
)	O
that	O
can	O
bring	O
about	O
repression	O
of	O
methylated	O
promoter	O
DNA	O
sequences	O
.	O

Like	O
other	O
MBD	O
proteins	O
,	O
MBD1	B-Protein
localizes	O
to	O
nuclear	O
foci	O
that	O
in	O
mice	O
are	O
rich	O
in	O
methyl	O
-	O
CpG	O
.	O

In	O
methyl	O
-	O
CpG	O
-	O
deficient	O
mouse	O
cells	O
,	O
however	O
,	O
Mbd1	B-Protein
remains	O
localized	O
to	O
heterochromatic	O
foci	O
whereas	O
other	O
MBD	O
proteins	O
become	O
dispersed	O
in	O
the	O
nucleus	O
.	O

We	O
find	O
that	O
Mbd1a	B-Protein
,	O
a	O
major	O
mouse	O
isoform	O
,	O
contains	O
a	O
CXXC	O
domain	O
(	O
CXXC	O
-	O
3	O
)	O
that	O
binds	O
specifically	O
to	O
nonmethylated	O
CpG	O
,	O
suggesting	O
an	O
explanation	O
for	O
methylation	O
-	O
independent	O
localization	O
.	O

Transfection	O
studies	O
demonstrate	O
that	O
the	O
CXXC	O
-	O
3	O
domain	O
indeed	O
targets	O
nonmethylated	O
CpG	O
sites	O
in	O
vivo	O
.	O

Repression	O
of	O
nonmethylated	O
reporter	O
genes	O
depends	O
on	O
the	O
CXXC	O
-	O
3	O
domain	O
,	O
whereas	O
repression	O
of	O
methylated	O
reporters	O
requires	O
the	O
MBD	O
.	O

Our	O
findings	O
indicate	O
that	O
MBD1	B-Protein
can	O
interpret	O
the	O
CpG	O
dinucleotide	O
as	O
a	O
repressive	O
signal	O
in	O
vivo	O
regardless	O
of	O
its	O
methylation	O
status	O
.	O

Recombinant	O
human	O
zona	O
pellucida	O
proteins	O
ZP1	B-Protein
,	O
ZP2	B-Protein
and	O
ZP3	B-Protein
co	O
-	O
expressed	O
in	O
a	O
human	O
cell	O
line	O
.	O

AIM	O
:	O
To	O
produce	O
biologically	O
active	O
recombinant	O
human	O
(	O
rh	O
)	O
ZP	O
proteins	O
in	O
a	O
human	O
cell	O
for	O
use	O
in	O
sperm	O
function	O
tests	O
.	O

METHODS	O
:	O
The	O
human	O
embryonic	O
kidney	O
cell	O
line	O
293T	O
was	O
employed	O
to	O
produce	O
rhZP1	B-Protein
,	O
rhZP2	B-Protein
and	O
rhZP3	B-Protein
proteins	O
individually	O
and	O
together	O
by	O
co	O
-	O
expression	O
.	O

Presence	O
of	O
these	O
proteins	O
in	O
the	O
culture	O
medium	O
and	O
cell	O
lysate	O
was	O
assessed	O
by	O
Western	O
blotting	O
analysis	O
.	O

The	O
effect	O
of	O
the	O
recombinant	O
proteins	O
on	O
the	O
human	O
AR	O
was	O
assessed	O
.	O

RESULTS	O
:	O
RhZP2	B-Protein
and	O
rhZP3	B-Protein
were	O
secreted	O
into	O
the	O
culture	O
medium	O
,	O
whereas	O
rhZP1	B-Protein
was	O
found	O
only	O
in	O
the	O
cell	O
lysate	O
.	O

Interestingly	O
,	O
when	O
all	O
zona	O
pellucida	O
proteins	O
were	O
co	O
-	O
expressed	O
in	O
the	O
same	O
cells	O
,	O
rhZP1	B-Protein
was	O
also	O
secreted	O
into	O
the	O
culture	O
medium	O
.	O

However	O
,	O
despite	O
the	O
presence	O
of	O
all	O
three	O
ZP	O
proteins	O
in	O
sufficient	O
concentration	O
and	O
evidence	O
of	O
heavy	O
glycosylation	O
on	O
gel	O
electrophoresis	O
,	O
biological	O
activity	O
to	O
induce	O
the	O
AR	O
was	O
not	O
observed	O
.	O

CONCLUSION	O
:	O
RhZP1	B-Protein
,	O
rhZP2	B-Protein
and	O
rhZP3	B-Protein
were	O
successfully	O
expressed	O
in	O
the	O
human	O
embryonic	O
kidney	O
cell	O
line	O
293T	O
.	O

It	O
appears	O
that	O
an	O
interaction	O
amongst	O
these	O
proteins	O
may	O
be	O
required	O
for	O
release	O
of	O
rhZP1	B-Protein
from	O
the	O
cell	O
.	O

Although	O
this	O
approach	O
is	O
not	O
satisfactory	O
for	O
producing	O
active	O
human	O
ZP	O
proteins	O
,	O
it	O
makes	O
a	O
significant	O
contribution	O
to	O
the	O
understanding	O
of	O
the	O
structural	O
and	O
functional	O
characteristics	O
of	O
the	O
ZP	O
proteins	O
.	O

Leu	O
-	O
574	O
of	O
human	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
is	O
a	O
molecular	O
determinant	O
of	O
prolyl	O
hydroxylation	O
.	O

Hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	I-Protein
HIF	I-Protein
)	I-Protein
-	I-Protein
1alpha	I-Protein
,	O
a	O
master	O
regulator	O
of	O
oxygen	O
homeostasis	O
,	O
regulates	O
genes	O
crucial	O
for	O
cell	O
growth	O
and	O
survival	O
.	O

In	O
normoxia	O
,	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
is	O
constantly	O
degraded	O
via	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O

The	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	O
VHL	B-Protein
)	O
E3	O
ubiquitin	B-Protein
ligase	O
binds	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
through	O
specific	O
recognition	O
of	O
hydroxylated	O
Pro	O
-	O
402	O
or	O
Pro	O
-	O
564	O
,	O
both	O
of	O
which	O
are	O
modified	O
by	O
the	O
oxygen	O
-	O
dependent	O
HIF	O
prolyl	O
hydroxylases	O
(	O
PHDs	O
/	O
HPHs	O
)	O
.	O

Despite	O
the	O
identification	O
of	O
a	O
conserved	O
Leu	O
-	O
X	O
-	O
X	O
-	O
Leu	O
-	O
Ala	O
-	O
Pro	O
motif	O
,	O
the	O
molecular	O
requirement	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
for	O
PHDs	O
/	O
HPHs	O
binding	O
remains	O
elusive	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
Leu	O
-	O
574	O
of	O
human	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
-	O
-	O
10	O
residues	O
downstream	O
of	O
Pro	O
-	O
564	O
-	O
-	O
is	O
essential	O
for	O
VHL	B-Protein
recognition	O
.	O

We	O
show	O
here	O
that	O
the	O
role	O
of	O
Leu	O
-	O
574	O
is	O
to	O
recruit	O
PHD2	B-Protein
/	O
HPH2	B-Protein
for	O
Pro	O
-	O
564	O
hydroxylation	O
.	O

An	O
antibody	O
specific	O
for	O
hydroxylated	O
Pro	O
-	O
564	O
has	O
been	O
used	O
to	O
determine	O
the	O
hydroxylation	O
status	O
;	O
mutation	O
or	O
deletion	O
of	O
Leu	O
-	O
574	O
results	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
ratio	O
of	O
the	O
hydroxylated	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
to	O
the	O
total	O
amount	O
.	O

The	O
nine	O
-	O
residue	O
spacing	O
between	O
Pro	O
-	O
564	O
and	O
Leu	O
-	O
574	O
is	O
not	O
obligatory	O
for	O
prolyl	O
hydroxylation	O
.	O

Furthermore	O
,	O
mutation	O
of	O
Leu	O
-	O
574	O
disrupts	O
the	O
binding	O
of	O
PHD2	B-Protein
/	O
HPH2	B-Protein
,	O
a	O
key	O
prolyl	O
hydroxylase	O
for	O
oxygen	O
-	O
dependent	O
proteolysis	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

Hence	O
,	O
our	O
findings	O
indicate	O
that	O
Leu	O
-	O
574	O
is	O
essential	O
for	O
recruiting	O
PHD2	B-Protein
/	O
HPH2	B-Protein
,	O
thereby	O
providing	O
a	O
molecular	O
basis	O
for	O
modulating	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
activity	O
.	O

Transferrin	B-Protein
microheterogeneity	O
in	O
fetal	O
blood	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
distribution	O
of	O
microheterogeneous	O
subfractions	O
of	O
transferrin	B-Protein
in	O
fetal	O
blood	O
and	O
the	O
influence	O
of	O
highly	O
sialylated	O
transferrins	B-Protein
on	O
fetal	O
growth	O
.	O

STUDY	O
METHOD	O
:	O
Serum	O
transferrin	B-Protein
concentrations	O
were	O
determined	O
by	O
a	O
standard	O
turbidimetric	O
assay	O
.	O

Microheterogeneous	O
transferrin	B-Protein
subfractions	O
were	O
assessed	O
by	O
crossed	O
immunoisoelectric	O
focusing	O
.	O

RESULTS	O
:	O
In	O
normal	O
term	O
infants	O
,	O
total	O
serum	O
transferrin	B-Protein
concentrations	O
and	O
percent	O
distribution	O
of	O
highly	O
sialylated	O
transferrins	B-Protein
(	O
>	O
or	O
=	O
5	O
-	O
sialo	O
-	O
transferrins	B-Protein
)	O
were	O
markedly	O
lower	O
;	O
the	O
percent	O
distributions	O
of	O
hyposialylated	O
transferrins	B-Protein
(	O
0	O
-	O
and	O
1	O
-	O
sialo	O
-	O
transferrins	B-Protein
)	O
were	O
apparently	O
higher	O
than	O
those	O
in	O
non	O
-	O
pregnant	O
and	O
pregnant	O
women	O
.	O

There	O
was	O
no	O
significant	O
positive	O
correlation	O
between	O
the	O
serum	O
concentrations	O
of	O
total	O
transferrin	B-Protein
or	O
highly	O
sialylated	O
transferrins	B-Protein
in	O
infants	O
'	O
blood	O
and	O
birth	O
weights	O
(	O
r	O
=	O
0	O
.	O
187	O
,	O
p	O
=	O
0	O
.	O
582	O
;	O
r	O
=	O
0	O
.	O
374	O
,	O
p	O
=	O
0	O
.	O
257	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O
The	O
transferrin	B-Protein
microheterogeneity	O
pattern	O
shifted	O
towards	O
reduced	O
glycosylation	O
and	O
sialylation	O
in	O
addition	O
to	O
a	O
decrease	O
in	O
total	O
transferrin	B-Protein
concentration	O
in	O
fetal	O
blood	O
compared	O
to	O
that	O
of	O
non	O
-	O
pregnant	O
and	O
pregnant	O
women	O
.	O

The	O
concentrations	O
of	O
serum	O
total	O
transferrin	B-Protein
and	O
the	O
highly	O
sialylated	O
transferrins	B-Protein
in	O
fetal	O
blood	O
,	O
if	O
higher	O
than	O
a	O
certain	O
level	O
,	O
did	O
not	O
seem	O
to	O
have	O
any	O
influence	O
on	O
normal	O
fetal	O
growth	O
.	O

Heterochromatin	O
and	O
tri	O
-	O
methylated	O
lysine	O
20	O
of	O
histone	B-Protein
H4	I-Protein
in	O
animals	O
.	O

Tri	O
-	O
methylated	O
lysine	O
20	O
on	O
histone	B-Protein
H4	I-Protein
(	O
Me	O
(	O
3	O
)	O
K20H4	B-Protein
)	O
is	O
a	O
marker	O
of	O
constitutive	O
heterochromatin	O
in	O
murine	O
interphase	O
and	O
metaphase	O
cells	O
.	O

Heterochromatin	O
marked	O
by	O
Me	O
(	O
3	O
)	O
K20H4	B-Protein
replicates	O
late	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Serum	O
starvation	O
increases	O
the	O
number	O
of	O
cells	O
that	O
exhibit	O
high	O
levels	O
of	O
Me	O
(	O
3	O
)	O
K20H4	B-Protein
at	O
constitutive	O
heterochromatin	O
.	O

Me	O
(	O
3	O
)	O
K20H4	B-Protein
is	O
also	O
present	O
at	O
the	O
centromeric	O
heterochromatin	O
of	O
most	O
meiotic	O
chromosomes	O
during	O
spermatogenesis	O
and	O
at	O
the	O
pseudoautosomal	O
region	O
,	O
as	O
well	O
as	O
at	O
some	O
telomeres	O
.	O

It	O
is	O
not	O
present	O
on	O
the	O
XY	O
-	O
body	O
.	O

During	O
murine	O
embryogenesis	O
the	O
maternal	O
pronucleus	O
contains	O
Me	O
(	O
3	O
)	O
K20H4	B-Protein
;	O
Me	O
(	O
3	O
)	O
K20H4	B-Protein
is	O
absent	O
from	O
the	O
paternal	O
pronucleus	O
.	O

On	O
Drosophila	O
polytene	O
chromosomes	O
Me	O
(	O
3	O
)	O
K20H4	B-Protein
is	O
present	O
in	O
a	O
'	O
punctate	O
pattern	O
'	O
at	O
many	O
chromosomal	O
bands	O
,	O
including	O
the	O
chromocenter	O
.	O

In	O
coccids	O
it	O
is	O
present	O
on	O
the	O
facultatively	O
heterochromatinised	O
paternal	O
chromosome	O
set	O
.	O

We	O
also	O
present	O
evidence	O
that	O
Me	O
(	O
3	O
)	O
K20H4	B-Protein
is	O
dependent	O
upon	O
H3	B-Protein
-	I-Protein
specific	I-Protein
Suv	I-Protein
(	I-Protein
3	I-Protein
)	I-Protein
9	I-Protein
histone	I-Protein
methyltransferase	I-Protein
activity	O
,	O
suggesting	O
that	O
there	O
may	O
be	O
'	O
epigenetic	O
cross	O
-	O
talk	O
'	O
between	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
.	O

The	O
histone	B-Protein
modification	O
pattern	O
of	O
active	O
genes	O
revealed	O
through	O
genome	O
-	O
wide	O
chromatin	O
analysis	O
of	O
a	O
higher	O
eukaryote	O
.	O

The	O
covalent	O
modification	O
of	O
nucleosomal	O
histones	B-Protein
has	O
emerged	O
as	O
a	O
major	O
determinant	O
of	O
chromatin	O
structure	O
and	O
gene	O
activity	O
.	O

To	O
understand	O
the	O
interplay	O
between	O
various	O
histone	B-Protein
modifications	O
,	O
including	O
acetylation	O
and	O
methylation	O
,	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
chromatin	O
structure	O
analysis	O
in	O
a	O
higher	O
eukaryote	O
.	O

We	O
found	O
a	O
binary	O
pattern	O
of	O
histone	B-Protein
modifications	O
among	O
euchromatic	O
genes	O
,	O
with	O
active	O
genes	O
being	O
hyperacetylated	O
for	O
H3	B-Protein
and	O
H4	B-Protein
and	O
hypermethylated	O
at	O
Lys	O
4	O
and	O
Lys	O
79	O
of	O
H3	B-Protein
,	O
and	O
inactive	O
genes	O
being	O
hypomethylated	O
and	O
deacetylated	O
at	O
the	O
same	O
residues	O
.	O

Furthermore	O
,	O
the	O
degree	O
of	O
modification	O
correlates	O
with	O
the	O
level	O
of	O
transcription	O
,	O
and	O
modifications	O
are	O
largely	O
restricted	O
to	O
transcribed	O
regions	O
,	O
suggesting	O
that	O
their	O
regulation	O
is	O
tightly	O
linked	O
to	O
polymerase	O
activity	O
.	O

Less	O
frequent	O
promoter	O
hypermethylation	O
of	O
DLC	B-Protein
-	I-Protein
1	I-Protein
gene	O
in	O
primary	O
breast	O
cancers	O
.	O

Absence	O
or	O
low	O
expression	O
of	O
DLC	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
tumor	O
suppressor	O
gene	O
,	O
in	O
breast	O
cancers	O
has	O
been	O
shown	O
recently	O
.	O

LOH	O
of	O
8p12	O
-	O
p22	O
,	O
on	O
which	O
DLC	B-Protein
-	I-Protein
1	I-Protein
is	O
located	O
,	O
is	O
frequent	O
in	O
breast	O
cancers	O
,	O
but	O
the	O
correlation	O
between	O
low	O
expression	O
of	O
DLC	B-Protein
-	I-Protein
1	I-Protein
and	O
LOH	O
has	O
not	O
been	O
confirmed	O
.	O

To	O
determine	O
the	O
implication	O
of	O
aberrant	O
methylation	O
,	O
one	O
of	O
the	O
most	O
frequent	O
mechanisms	O
of	O
silencing	O
the	O
tumor	O
suppressor	O
or	O
cancer	O
-	O
related	O
genes	O
,	O
we	O
examined	O
the	O
methylation	O
status	O
of	O
DLC	B-Protein
-	I-Protein
1	I-Protein
promoter	O
region	O
in	O
breast	O
cancer	O
cell	O
lines	O
and	O
primary	O
breast	O
tumors	O
.	O

The	O
hypermethylation	O
status	O
was	O
examined	O
by	O
MSP	O
and	O
25	O
%	O
of	O
cell	O
lines	O
harbored	O
a	O
methylated	O
allele	O
.	O

The	O
gene	O
silencing	O
by	O
methylation	O
was	O
also	O
confirmed	O
by	O
the	O
re	O
-	O
expression	O
of	O
DLC	B-Protein
-	I-Protein
1	I-Protein
by	O
the	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
treatment	O
in	O
DLC	B-Protein
-	I-Protein
1	I-Protein
hypermethylated	O
cell	O
line	O
.	O

But	O
the	O
methylation	O
of	O
DLC	B-Protein
-	I-Protein
1	I-Protein
gene	O
was	O
less	O
frequently	O
shown	O
in	O
primary	O
breast	O
cancers	O
(	O
10	O
%	O
)	O
.	O

These	O
data	O
suggest	O
that	O
hypermethylation	O
is	O
responsible	O
for	O
silencing	O
of	O
DLC	B-Protein
-	I-Protein
1	I-Protein
gene	O
in	O
a	O
limited	O
portion	O
of	O
breast	O
cancers	O
.	O

Glycosylation	O
of	O
the	O
ENV	B-Protein
spike	O
of	O
primate	O
immunodeficiency	O
viruses	O
and	O
antibody	O
neutralization	O
.	O

Neutralizing	O
antibody	O
titers	O
have	O
been	O
correlated	O
with	O
protection	O
following	O
vaccination	O
against	O
many	O
viral	O
pathogens	O
.	O

The	O
logical	O
target	O
of	O
protective	O
antibody	O
responses	O
elicited	O
by	O
potential	O
HIV	O
vaccines	O
should	O
be	O
the	O
viral	O
Env	B-Protein
spike	O
on	O
the	O
surface	O
of	O
the	O
virion	O
.	O

However	O
,	O
the	O
potency	O
and	O
titers	O
of	O
neutralizing	O
antibodies	O
that	O
arise	O
during	O
HIV	O
infection	O
are	O
generally	O
discouragingly	O
low	O
and	O
the	O
antibodies	O
that	O
do	O
arise	O
recognize	O
mainly	O
autologous	O
virus	O
.	O

This	O
is	O
thought	O
to	O
be	O
a	O
result	O
of	O
a	O
combination	O
of	O
immunodominance	O
of	O
hypervariable	O
regions	O
of	O
the	O
Env	B-Protein
protein	O
that	O
can	O
easily	O
escape	O
neutralization	O
,	O
antibody	O
reactivity	O
to	O
gp160	B-Protein
"	O
decoy	O
"	O
protein	O
in	O
cell	O
surface	O
debris	O
or	O
monomeric	O
gp120	B-Protein
,	O
conformational	O
constraints	O
within	O
the	O
Env	B-Protein
trimer	O
that	O
create	O
unfavorable	O
antibody	O
binding	O
conditions	O
and	O
extensive	O
glycosylation	O
of	O
the	O
exposed	O
regions	O
of	O
Env	B-Protein
within	O
the	O
trimer	O
.	O

This	O
review	O
will	O
describe	O
current	O
knowledge	O
regarding	O
glycosylation	O
as	O
a	O
mechanism	O
of	O
neutralization	O
resistance	O
and	O
discuss	O
experimental	O
approaches	O
used	O
to	O
overcome	O
this	O
resistance	O
.	O

Part	O
of	O
the	O
strategy	O
toward	O
development	O
of	O
an	O
optimally	O
immunogenic	O
Env	B-Protein
spike	O
will	O
likely	O
require	O
modification	O
of	O
Env	B-Protein
glycosylation	O
.	O

Comparison	O
of	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
MSP	O
)	O
with	O
reverse	B-Protein
transcriptase	I-Protein
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
in	O
peripheral	O
blood	O
of	O
gastric	O
cancer	O
patients	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
To	O
achieve	O
a	O
complete	O
cure	O
in	O
gastric	O
cancer	O
,	O
primary	O
and	O
recurrent	O
tumors	O
must	O
be	O
detected	O
at	O
an	O
early	O
stage	O
.	O

This	O
study	O
was	O
designed	O
to	O
compare	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
-	O
specific	O
reverse	B-Protein
transcriptase	I-Protein
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
MSP	O
)	O
for	O
p16	B-Protein
,	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
,	O
and	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
beta	I-Protein
(	O
RARbeta	B-Protein
)	O
genes	O
using	O
blood	O
samples	O
from	O
gastric	O
cancer	O
patients	O
.	O

METHODS	O
:	O
Preoperative	O
blood	O
samples	O
obtained	O
from	O
41	O
patients	O
with	O
gastric	O
cancer	O
,	O
including	O
9	O
with	O
early	O
-	O
stage	O
disease	O
,	O
and	O
were	O
subjected	O
to	O
RT	O
-	O
PCR	O
and	O
MSP	O
assays	O
.	O

RESULTS	O
:	O
Ten	O
of	O
41	O
(	O
24	O
%	O
)	O
patients	O
exhibited	O
a	O
CEA	O
-	O
specific	O
signal	O
by	O
RT	O
-	O
PCR	O
.	O

Positive	O
rates	O
were	O
11	O
,	O
13	O
,	O
50	O
,	O
and	O
50	O
%	O
in	O
stages	O
I	O
,	O
II	O
,	O
III	O
,	O
and	O
IV	O
,	O
respectively	O
.	O

A	O
significant	O
association	O
was	O
found	O
between	O
RT	O
-	O
PCR	O
results	O
and	O
stage	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
MSP	O
assay	O
detected	O
hypermethylation	O
of	O
p16	B-Protein
in	O
9	O
patients	O
(	O
22	O
%	O
)	O
,	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
in	O
9	O
patients	O
(	O
22	O
%	O
)	O
,	O
and	O
RARbeta	B-Protein
in	O
6	O
patients	O
(	O
15	O
%	O
)	O
.	O

Altogether	O
,	O
18	O
patients	O
(	O
44	O
%	O
)	O
showed	O
hypermethylation	O
.	O

The	O
positive	O
rates	O
were	O
37	O
,	O
50	O
,	O
40	O
,	O
and	O
75	O
%	O
in	O
stages	O
I	O
,	O
II	O
,	O
III	O
,	O
and	O
IV	O
,	O
respectively	O
.	O

A	O
significant	O
association	O
was	O
found	O
between	O
aberrant	O
methylation	O
and	O
venous	O
invasion	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Neither	O
the	O
CEA	O
-	O
specific	O
signal	O
nor	O
hypermethylation	O
was	O
detected	O
in	O
serum	O
from	O
control	O
volunteers	O
.	O

CONCLUSIONS	O
:	O
The	O
detection	O
rate	O
of	O
MSP	O
was	O
higher	O
than	O
that	O
of	O
RT	O
-	O
PCR	O
in	O
gastric	O
cancer	O
.	O

Both	O
assays	O
can	O
serve	O
as	O
markers	O
that	O
allow	O
selection	O
of	O
those	O
cases	O
requiring	O
more	O
intensive	O
screening	O
and	O
aggressive	O
postoperative	O
treatment	O
.	O

Superoxide	O
dismutase	O
and	O
catalase	B-Protein
are	O
required	O
to	O
detect	O
(	O
.	O
-	O
)	O
NO	O
from	O
both	O
coupled	O
and	O
uncoupled	O
neuronal	O
no	O
synthase	O
.	O

Despite	O
numerous	O
approaches	O
to	O
measuring	O
nitric	O
oxide	O
(	O
(	O
.	O
-	O
)	O
NO	O
)	O
formation	O
from	O
purified	O
NO	B-Protein
synthase	I-Protein
(	O
NOS	B-Protein
)	O
,	O
it	O
is	O
still	O
not	O
clear	O
whether	O
(	O
.	O
-	O
)	O
NO	O
is	O
a	O
direct	O
or	O
indirect	O
product	O
of	O
the	O
NO	O
synthase	O
reaction	O
.	O

The	O
direct	O
detection	O
of	O
catalytically	O
formed	O
(	O
.	O
-	O
)	O
NO	O
is	O
complicated	O
by	O
side	O
reactions	O
with	O
reactive	O
oxide	O
species	O
like	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
and	O
superoxide	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
therefore	O
to	O
reinvestigate	O
these	O
reactions	O
both	O
electrochemically	O
and	O
by	O
chemiluminescence	O
detection	O
with	O
particular	O
emphasis	O
on	O
the	O
requirement	O
for	O
cofactors	O
and	O
their	O
interference	O
with	O
(	O
.	O
-	O
)	O
NO	O
detection	O
.	O

Flavins	O
were	O
found	O
to	O
generate	O
large	O
amounts	O
of	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
and	O
were	O
therefore	O
excluded	O
from	O
subsequent	O
incubations	O
.	O

Under	O
conditions	O
of	O
both	O
coupled	O
and	O
uncoupled	O
catalysis	O
,	O
SOD	O
was	O
absolutely	O
required	O
to	O
detect	O
(	O
.	O
-	O
)	O
NO	O
from	O
NOS	O
.	O

H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
formation	O
took	O
place	O
also	O
in	O
the	O
presence	O
of	O
SOD	O
and	O
gave	O
a	O
smaller	O
yet	O
significant	O
interfering	O
signal	O
.	O

Similar	O
data	O
were	O
obtained	O
when	O
the	O
proposed	O
intermediate	O
N	O
(	O
omega	O
)	O
-	O
hydroxy	O
-	O
l	O
-	O
arginine	O
was	O
utilized	O
as	O
substrate	O
.	O

In	O
conclusion	O
,	O
standard	O
Clark	O
-	O
type	O
(	O
)	O
NO	O
electrodes	O
are	O
cross	O
-	O
sensitive	O
to	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
and	O
therefore	O
both	O
SOD	O
and	O
catalase	B-Protein
are	O
absolutely	O
required	O
to	O
specifically	O
detect	O
(	O
.	O
-	O
)	O
NO	O
from	O
NOS	O
.	O

Widespread	O
activation	O
of	O
antibiotic	O
biosynthesis	O
by	O
S	O
-	O
adenosylmethionine	O
in	O
streptomycetes	O
.	O

The	O
effect	O
of	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
on	O
the	O
production	O
of	O
various	O
antibiotics	O
was	O
investigated	O
to	O
determine	O
whether	O
SAM	O
-	O
dependent	O
methylation	O
is	O
required	O
in	O
biosynthetic	O
pathways	O
of	O
antibiotics	O
.	O

Pristinamycin	O
II	O
(	O
B	O
)	O
and	O
granaticin	O
do	O
not	O
require	O
SAM	O
-	O
dependent	O
methylation	O
in	O
their	O
biosynthesis	O
pathways	O
,	O
and	O
production	O
of	O
these	O
two	O
antibiotics	O
was	O
increased	O
about	O
2	O
-	O
fold	O
when	O
a	O
low	O
concentration	O
(	O
50	O
and	O
10	O
microM	O
,	O
respectively	O
)	O
of	O
SAM	O
was	O
treated	O
;	O
in	O
contrast	O
,	O
oleandomycin	O
and	O
avermectin	O
B1a	O
require	O
SAM	O
as	O
a	O
methyl	O
donor	O
in	O
their	O
biosynthesis	O
,	O
and	O
production	O
of	O
these	O
two	O
antibiotics	O
was	O
increased	O
5	O
-	O
fold	O
and	O
6	O
-	O
fold	O
,	O
depending	O
on	O
the	O
SAM	O
concentration	O
within	O
a	O
certain	O
range	O
.	O

We	O
also	O
found	O
that	O
the	O
transcription	O
of	O
a	O
pathway	O
-	O
specific	O
regulator	O
,	O
gra	B-Protein
-	I-Protein
ORF9	I-Protein
,	O
was	O
activated	O
by	O
exogenous	O
SAM	O
treatment	O
.	O

Production	O
of	O
oleandomycin	O
and	O
avermectin	O
B1a	O
was	O
decreased	O
by	O
using	O
a	O
methyltransferase	O
inhibitor	O
,	O
sinefungin	O
,	O
but	O
the	O
production	O
levels	O
of	O
these	O
antibiotics	O
were	O
restored	O
to	O
the	O
control	O
level	O
by	O
simultaneously	O
adding	O
SAM	O
and	O
sinefungin	O
.	O

Interestingly	O
,	O
we	O
have	O
found	O
a	O
similar	O
stimulatory	O
effect	O
of	O
S	O
-	O
adenosylhomocysteine	O
(	O
SAH	O
)	O
,	O
the	O
methylation	O
product	O
of	O
SAM	O
,	O
on	O
antibiotic	O
production	O
in	O
the	O
four	O
strains	O
.	O

Our	O
results	O
clearly	O
demonstrate	O
the	O
widespread	O
activation	O
of	O
antibiotic	O
production	O
using	O
SAM	O
in	O
streptomycetes	O
.	O

A	O
phosphatidylserine	O
-	O
binding	O
site	O
in	O
the	O
cytosolic	O
fragment	O
of	O
Clostridium	O
sordellii	O
lethal	O
toxin	O
facilitates	O
glucosylation	O
of	O
membrane	O
-	O
bound	O
Rac	O
and	O
is	O
required	O
for	O
cytotoxicity	O
.	O

Large	O
clostridial	O
toxins	O
glucosylate	O
some	O
small	O
G	O
proteins	O
on	O
a	O
threonine	O
residue	O
,	O
thereby	O
preventing	O
their	O
interactions	O
with	O
effector	O
molecules	O
and	O
regulators	O
.	O

We	O
show	O
that	O
the	O
glucosyltransferase	O
domain	O
of	O
lethal	O
toxin	O
from	O
Clostridium	O
sordellii	O
(	O
LT	B-Protein
(	I-Protein
cyt	I-Protein
)	I-Protein
;	O
amino	O
acids	O
1	O
-	O
546	O
)	O
,	O
which	O
is	O
released	O
into	O
the	O
cytosol	O
during	O
cell	O
infection	O
,	O
binds	O
preferentially	O
to	O
liposomes	O
containing	O
phosphatidylserine	O
as	O
compared	O
with	O
other	O
anionic	O
lipids	O
.	O

The	O
binding	O
of	O
LT	B-Protein
(	I-Protein
cyt	I-Protein
)	I-Protein
to	O
phosphatidylserine	O
increases	O
by	O
two	O
orders	O
of	O
magnitude	O
the	O
rate	O
of	O
glucosylation	O
of	O
liposome	O
-	O
bound	O
geranyl	O
-	O
geranylated	O
Rac	O
-	O
GDP	O
.	O

Limited	O
proteolysis	O
and	O
deletion	O
studies	O
show	O
that	O
the	O
binding	O
site	O
for	O
phosphatidylserine	O
lies	O
within	O
the	O
first	O
18	O
N	O
-	O
terminal	O
residues	O
of	O
LT	B-Protein
(	I-Protein
cyt	I-Protein
)	I-Protein
.	O

Deletion	O
of	O
these	O
residues	O
abolishes	O
the	O
effect	O
of	O
phosphatidylserine	O
on	O
the	O
activity	O
of	O
LT	B-Protein
(	I-Protein
cyt	I-Protein
)	I-Protein
on	O
liposome	O
-	O
bound	O
geranyl	O
-	O
geranylated	O
Rac	O
-	O
GDP	O
and	O
prevents	O
the	O
morphological	O
effects	O
induced	O
by	O
LT	B-Protein
(	I-Protein
cyt	I-Protein
)	I-Protein
microinjection	O
into	O
various	O
cells	O
,	O
but	O
it	O
does	O
not	O
affect	O
the	O
intrinsic	O
activity	O
of	O
LT	B-Protein
(	I-Protein
cyt	I-Protein
)	I-Protein
on	O
non	O
-	O
geranyl	O
-	O
geranylated	O
Rac	O
-	O
GDP	O
in	O
solution	O
.	O

We	O
conclude	O
that	O
the	O
avidity	O
of	O
LT	B-Protein
(	I-Protein
cyt	I-Protein
)	I-Protein
for	O
phosphatidylserine	O
facilitates	O
its	O
targeting	O
to	O
the	O
cytosolic	O
leaflet	O
of	O
cell	O
membranes	O
and	O
,	O
notably	O
,	O
the	O
plasma	O
membrane	O
,	O
where	O
this	O
anionic	O
lipid	O
is	O
abundant	O
and	O
where	O
several	O
targets	O
of	O
lethal	O
toxin	O
reside	O
.	O

Arginine	O
residues	O
as	O
stabilizing	O
elements	O
in	O
proteins	O
.	O

Site	O
-	O
specific	O
substitutions	O
of	O
arginine	O
for	O
lysine	O
in	O
the	O
thermostable	O
D	B-Protein
-	I-Protein
xylose	I-Protein
isomerase	I-Protein
(	O
XI	B-Protein
)	O
from	O
Actinoplanes	O
missouriensis	O
are	O
shown	O
to	O
impart	O
significant	O
heat	O
stability	O
enhancement	O
in	O
the	O
presence	O
of	O
sugar	O
substrates	O
most	O
probably	O
by	O
interfering	O
with	O
nonenzymatic	O
glycation	O
.	O

The	O
same	O
substitutions	O
are	O
also	O
found	O
to	O
increase	O
heat	O
stability	O
in	O
the	O
absence	O
of	O
any	O
sugar	O
derivatives	O
,	O
where	O
a	O
mechanism	O
based	O
on	O
prevention	O
of	O
glycation	O
can	O
no	O
longer	O
be	O
invoked	O
.	O

This	O
rather	O
conservative	O
substitution	O
is	O
moreover	O
shown	O
to	O
improve	O
thermostability	O
in	O
two	O
other	O
structurally	O
unrelated	O
proteins	O
,	O
human	O
copper	B-Protein
,	I-Protein
zinc	I-Protein
-	I-Protein
superoxide	I-Protein
dismutase	I-Protein
(	O
CuZnSOD	B-Protein
)	O
and	O
D	B-Protein
-	I-Protein
glyceraldehyde	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
(	O
GAPDH	B-Protein
)	O
from	O
Bacillus	O
subtilis	O
.	O

The	O
stabilizing	O
effect	O
of	O
Lys	O
-	O
-	O
-	O
-	O
Arg	O
substitutions	O
is	O
rationalized	O
on	O
the	O
basis	O
of	O
a	O
detailed	O
analysis	O
of	O
the	O
crystal	O
structures	O
of	O
wild	O
-	O
type	O
XI	B-Protein
and	O
of	O
engineered	O
variants	O
with	O
Lys	O
-	O
-	O
-	O
-	O
Arg	O
substitution	O
at	O
four	O
distinct	O
locations	O
,	O
residues	O
253	O
,	O
309	O
,	O
319	O
,	O
and	O
323	O
.	O

Molecular	O
model	O
building	O
analysis	O
of	O
the	O
structures	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
CuZnSOD	B-Protein
(	O
K9R	O
)	O
and	O
GAPDH	B-Protein
(	O
G281K	O
and	O
G281R	O
)	O
is	O
used	O
to	O
explain	O
the	O
observed	O
stability	O
enhancement	O
in	O
these	O
proteins	O
.	O

In	O
addition	O
to	O
demonstrating	O
that	O
even	O
thermostable	O
proteins	O
can	O
lend	O
themselves	O
to	O
further	O
stability	O
improvement	O
,	O
our	O
findings	O
provide	O
direct	O
evidence	O
that	O
arginine	O
residues	O
are	O
important	O
stabilizing	O
elements	O
in	O
proteins	O
.	O

Moreover	O
,	O
the	O
stabilizing	O
role	O
of	O
electrostatic	O
interactions	O
,	O
particularly	O
between	O
subunits	O
in	O
oligomeric	O
proteins	O
,	O
is	O
documented	O
.	O

Human	O
SWI	O
/	O
SNF	O
-	O
associated	O
PRMT5	B-Protein
methylates	O
histone	B-Protein
H3	I-Protein
arginine	O
8	O
and	O
negatively	O
regulates	O
expression	O
of	O
ST7	B-Protein
and	O
NM23	B-Protein
tumor	O
suppressor	O
genes	O
.	O

Protein	O
arginine	O
methyltransferases	O
(	O
PRMTs	O
)	O
have	O
been	O
implicated	O
in	O
transcriptional	O
activation	O
and	O
repression	O
,	O
but	O
their	O
role	O
in	O
controlling	O
cell	O
growth	O
and	O
proliferation	O
remains	O
obscure	O
.	O

We	O
have	O
recently	O
shown	O
that	O
PRMT5	B-Protein
can	O
interact	O
with	O
flag	O
-	O
tagged	O
BRG1	B-Protein
-	O
and	O
hBRM	B-Protein
-	O
based	O
hSWI	O
/	O
SNF	O
chromatin	O
remodelers	O
and	O
that	O
both	O
complexes	O
can	O
specifically	O
methylate	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
.	O

Here	O
we	O
report	O
that	O
PRMT5	B-Protein
can	O
be	O
found	O
in	O
association	O
with	O
endogenous	O
hSWI	O
/	O
SNF	O
complexes	O
,	O
which	O
can	O
methylate	O
H3	B-Protein
and	O
H4	B-Protein
N	O
-	O
terminal	O
tails	O
,	O
and	O
show	O
that	O
H3	B-Protein
arginine	O
8	O
and	O
H4	B-Protein
arginine	O
3	O
are	O
preferred	O
sites	O
of	O
methylation	O
by	O
recombinant	O
and	O
hSWI	O
/	O
SNF	O
-	O
associated	O
PRMT5	B-Protein
.	O

To	O
elucidate	O
the	O
role	O
played	O
by	O
PRMT5	B-Protein
in	O
gene	O
regulation	O
,	O
we	O
have	O
established	O
a	O
PRMT5	B-Protein
antisense	O
cell	O
line	O
and	O
determined	O
by	O
microarray	O
analysis	O
that	O
more	O
genes	O
are	O
derepressed	O
when	O
PRMT5	B-Protein
levels	O
are	O
reduced	O
.	O

Among	O
the	O
affected	O
genes	O
,	O
we	O
show	O
that	O
suppressor	B-Protein
of	I-Protein
tumorigenicity	I-Protein
7	I-Protein
(	O
ST7	B-Protein
)	O
and	O
nonmetastatic	B-Protein
23	I-Protein
(	O
NM23	B-Protein
)	O
are	O
direct	O
targets	O
of	O
PRMT5	B-Protein
-	O
containing	O
BRG1	B-Protein
and	O
hBRM	B-Protein
complexes	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
expression	O
of	O
ST7	B-Protein
and	O
NM23	B-Protein
is	O
reduced	O
in	O
a	O
cell	O
line	O
that	O
overexpresses	O
PRMT5	B-Protein
and	O
that	O
this	O
decrease	O
in	O
expression	O
correlates	O
with	O
H3R8	B-Protein
methylation	O
,	O
H3K9	B-Protein
deacetylation	O
,	O
and	O
increased	O
transformation	O
of	O
NIH	O
3T3	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
BRG1	B-Protein
-	O
and	O
hBRM	B-Protein
-	O
associated	O
PRMT5	B-Protein
regulates	O
cell	O
growth	O
and	O
proliferation	O
by	O
controlling	O
expression	O
of	O
genes	O
involved	O
in	O
tumor	O
suppression	O
.	O

Sex	O
-	O
and	O
tissue	O
-	O
specific	O
expression	O
of	O
maintenance	O
and	O
de	O
novo	O
DNA	O
methyltransferases	O
upon	O
low	O
dose	O
X	O
-	O
irradiation	O
in	O
mice	O
.	O

DNA	O
methylation	O
is	O
crucial	O
for	O
normal	O
development	O
,	O
proliferation	O
,	O
and	O
proper	O
maintenance	O
of	O
genome	O
stability	O
for	O
a	O
given	O
organism	O
.	O

A	O
variety	O
of	O
DNA	O
damaging	O
agents	O
that	O
are	O
known	O
to	O
affect	O
genome	O
stability	O
were	O
also	O
shown	O
to	O
alter	O
DNA	O
methylation	O
patterns	O
.	O

We	O
have	O
recently	O
pioneered	O
the	O
studies	O
in	O
the	O
area	O
of	O
the	O
radiation	O
effects	O
on	O
DNA	O
methylation	O
,	O
and	O
found	O
that	O
radiation	O
exposure	O
led	O
to	O
substantial	O
dose	O
-	O
dependent	O
and	O
tissue	O
-	O
specific	O
DNA	O
hypomethylation	O
,	O
which	O
was	O
much	O
more	O
pronounced	O
in	O
spleen	O
and	O
liver	O
of	O
female	O
animals	O
.	O

The	O
exact	O
mechanisms	O
of	O
radiation	O
-	O
induced	O
DNA	O
hypomethylation	O
are	O
still	O
to	O
be	O
uncovered	O
.	O

We	O
have	O
previously	O
shown	O
that	O
one	O
of	O
those	O
mechanisms	O
may	O
potentially	O
be	O
DNA	O
repair	O
related	O
.	O

Another	O
possible	O
mechanism	O
may	O
be	O
linked	O
to	O
changes	O
in	O
the	O
expression	O
of	O
DNA	O
methyltransferases	O
(	O
DNMTs	O
)	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
examined	O
the	O
radiation	O
-	O
induced	O
changes	O
in	O
expression	O
of	O
maintenance	O
DNMT1	B-Protein
,	O
and	O
de	O
novo	O
methyltransferases	O
DNMT3a	B-Protein
and	O
DNMT3b	B-Protein
in	O
spleen	O
and	O
liver	O
of	O
irradiated	O
animals	O
.	O

This	O
was	O
paralleled	O
by	O
the	O
studies	O
of	O
acute	O
and	O
chronic	O
IR	O
-	O
induced	O
methylation	O
changes	O
in	O
spleen	O
and	O
liver	O
of	O
intact	O
animals	O
,	O
as	O
well	O
as	O
in	O
animals	O
with	O
altered	O
sex	O
hormone	O
status	O
.	O

Here	O
we	O
report	O
that	O
radiation	O
-	O
induced	O
DNA	O
methylation	O
changes	O
correlated	O
with	O
radiation	O
-	O
induced	O
alterations	O
in	O
expression	O
of	O
DNA	O
methyltransferases	O
.	O

We	O
present	O
the	O
data	O
on	O
tissue	O
-	O
specificity	O
in	O
radiation	O
-	O
induced	O
expression	O
of	O
DNA	O
methyltransferases	O
,	O
and	O
prove	O
that	O
changes	O
in	O
the	O
expression	O
of	O
de	O
novo	O
methyltransferases	O
DNMT3a	B-Protein
and	O
DNMT3b	B-Protein
are	O
the	O
most	O
important	O
in	O
radiation	O
-	O
induced	O
DNA	O
methylation	O
alterations	O
.	O

We	O
also	O
discuss	O
the	O
role	O
of	O
sex	O
hormones	O
,	O
especially	O
estrogen	O
,	O
in	O
the	O
generation	O
of	O
the	O
sex	O
-	O
specific	O
radiation	O
-	O
induced	O
methylation	O
changes	O
.	O

Characterization	O
of	O
a	O
novel	O
amylolytic	O
enzyme	O
encoded	O
by	O
a	O
gene	O
from	O
a	O
soil	O
-	O
derived	O
metagenomic	O
library	O
.	O

It	O
has	O
been	O
estimated	O
that	O
less	O
than	O
1	O
%	O
of	O
the	O
microorganisms	O
in	O
nature	O
can	O
be	O
cultivated	O
by	O
conventional	O
techniques	O
.	O

Thus	O
,	O
the	O
classical	O
approach	O
of	O
isolating	O
enzymes	O
from	O
pure	O
cultures	O
allows	O
the	O
analysis	O
of	O
only	O
a	O
subset	O
of	O
the	O
total	O
naturally	O
occurring	O
microbiota	O
in	O
environmental	O
samples	O
enriched	O
in	O
microorganisms	O
.	O

To	O
isolate	O
useful	O
microbial	O
enzymes	O
from	O
uncultured	O
soil	O
microorganisms	O
,	O
a	O
metagenome	O
was	O
isolated	O
from	O
soil	O
samples	O
,	O
and	O
a	O
metagenomic	O
library	O
was	O
constructed	O
by	O
using	O
the	O
pUC19	O
vector	O
.	O

The	O
library	O
was	O
screened	O
for	O
amylase	O
activity	O
,	O
and	O
one	O
clone	O
from	O
among	O
approximately	O
30	O
,	O
000	O
recombinant	O
Escherichia	O
coli	O
clones	O
showed	O
amylase	O
activity	O
.	O

Sequencing	O
of	O
the	O
clone	O
revealed	O
a	O
novel	O
amylolytic	O
enzyme	O
expressed	O
from	O
a	O
novel	O
gene	O
.	O

The	O
putative	O
amylase	O
gene	O
(	O
amyM	B-Protein
)	O
was	O
overexpressed	O
and	O
purified	O
for	O
characterization	O
.	O

Optimal	O
conditions	O
for	O
the	O
enzyme	O
activity	O
of	O
the	O
AmyM	B-Protein
protein	O
were	O
42	O
degrees	O
C	O
and	O
pH	O
9	O
.	O
0	O
;	O
Ca2	O
+	O
stabilized	O
the	O
activity	O
.	O

The	O
amylase	O
hydrolyzed	O
soluble	O
starch	O
and	O
cyclodextrins	O
to	O
produce	O
high	O
levels	O
of	O
maltose	O
and	O
hydrolyzed	O
pullulan	O
to	O
panose	O
.	O

The	O
enzyme	O
showed	O
a	O
high	O
transglycosylation	O
activity	O
,	O
making	O
alpha	O
-	O
(	O
1	O
,	O
4	O
)	O
linkages	O
exclusively	O
.	O

The	O
hydrolysis	O
and	O
transglycosylation	O
properties	O
of	O
AmyM	B-Protein
suggest	O
that	O
it	O
has	O
novel	O
characteristics	O
and	O
can	O
be	O
regarded	O
as	O
an	O
intermediate	O
type	O
of	O
maltogenic	O
amylase	O
,	O
alpha	O
-	O
amylase	O
,	O
and	O
4	B-Protein
-	I-Protein
alpha	I-Protein
-	I-Protein
glucanotransferase	I-Protein
.	O

4	B-Protein
-	I-Protein
Hydroxyphenylpyruvate	I-Protein
dioxygenase	I-Protein
.	O

4	B-Protein
-	I-Protein
Hydroxyphenylpyruvate	I-Protein
dioxygenase	I-Protein
(	O
HPPD	B-Protein
)	O
is	O
an	O
Fe	O
(	O
II	O
)	O
-	O
dependent	O
,	O
non	O
-	O
heme	O
oxygenase	O
that	O
catalyzes	O
the	O
conversion	O
of	O
4	O
-	O
hydroxyphenylpyruvate	O
to	O
homogentisate	O
.	O

This	O
reaction	O
involves	O
decarboxylation	O
,	O
substituent	O
migration	O
and	O
aromatic	O
oxygenation	O
in	O
a	O
single	O
catalytic	O
cycle	O
.	O

HPPD	B-Protein
is	O
a	O
member	O
of	O
the	O
alpha	O
-	O
keto	O
acid	O
dependent	O
oxygenases	O
that	O
typically	O
require	O
an	O
alpha	O
-	O
keto	O
acid	O
(	O
almost	O
exclusively	O
alpha	O
-	O
ketoglutarate	O
)	O
and	O
molecular	O
oxygen	O
to	O
either	O
oxygenate	O
or	O
oxidize	O
a	O
third	O
molecule	O
.	O

As	O
an	O
exception	O
in	O
this	O
class	O
of	O
enzymes	O
HPPD	B-Protein
has	O
only	O
two	O
substrates	O
,	O
does	O
not	O
use	O
alpha	O
-	O
ketoglutarate	O
,	O
and	O
incorporates	O
both	O
atoms	O
of	O
dioxygen	O
into	O
the	O
aromatic	O
product	O
,	O
homogentisate	O
.	O

The	O
tertiary	O
structure	O
of	O
the	O
enzyme	O
would	O
suggest	O
that	O
its	O
mechanism	O
converged	O
with	O
that	O
of	O
other	O
alpha	O
-	O
keto	O
acid	O
enzymes	O
from	O
an	O
extradiol	O
dioxygenase	O
progenitor	O
.	O

The	O
transformation	O
catalyzed	O
by	O
HPPD	B-Protein
has	O
both	O
agricultural	O
and	O
therapeutic	O
significance	O
.	O

HPPD	B-Protein
catalyzes	O
the	O
second	O
step	O
in	O
the	O
pathway	O
for	O
the	O
catabolism	O
of	O
tyrosine	O
,	O
that	O
is	O
common	O
to	O
essentially	O
all	O
aerobic	O
forms	O
of	O
life	O
.	O

In	O
plants	O
this	O
pathway	O
has	O
an	O
anabolic	O
branch	O
from	O
homogentisate	O
that	O
forms	O
essential	O
isoprenoid	O
redox	O
cofactors	O
such	O
as	O
plastoquinone	O
and	O
tocopherol	O
.	O

Naturally	O
occurring	O
multi	O
-	O
ketone	O
molecules	O
act	O
as	O
allelopathic	O
agents	O
by	O
inhibiting	O
HPPD	B-Protein
and	O
preventing	O
the	O
production	O
of	O
homogentisate	O
and	O
hence	O
required	O
redox	O
cofactors	O
.	O

This	O
has	O
been	O
the	O
basis	O
for	O
the	O
development	O
of	O
a	O
range	O
of	O
very	O
effective	O
herbicides	O
that	O
are	O
currently	O
used	O
commercially	O
.	O

In	O
humans	O
,	O
deficiencies	O
of	O
specific	O
enzymes	O
of	O
the	O
tyrosine	O
catabolism	O
pathway	O
give	O
rise	O
to	O
a	O
number	O
of	O
severe	O
metabolic	O
disorders	O
.	O

Interestingly	O
,	O
HPPD	B-Protein
inhibitor	O
/	O
herbicide	O
molecules	O
act	O
also	O
as	O
therapeutic	O
agents	O
for	O
a	O
number	O
of	O
debilitating	O
and	O
lethal	O
inborn	O
defects	O
in	O
tyrosine	O
catabolism	O
by	O
preventing	O
the	O
accumulation	O
of	O
toxic	O
metabolites	O
.	O

Distinct	O
dynamics	O
and	O
distribution	O
of	O
histone	B-Protein
methyl	O
-	O
lysine	O
derivatives	O
in	O
mouse	O
development	O
.	O

Histone	B-Protein
methylation	O
acts	O
as	O
an	O
epigenetic	O
regulator	O
of	O
chromatin	O
activity	O
through	O
the	O
modification	O
of	O
arginine	O
and	O
lysine	O
residues	O
on	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
.	O

In	O
the	O
case	O
of	O
lysine	O
,	O
this	O
includes	O
the	O
formation	O
of	O
mono	O
-	O
,	O
di	O
-	O
,	O
or	O
trimethyl	O
groups	O
,	O
each	O
of	O
which	O
is	O
presumed	O
to	O
represent	O
a	O
distinct	O
functional	O
state	O
at	O
the	O
cellular	O
level	O
.	O

To	O
examine	O
the	O
potential	O
developmental	O
roles	O
of	O
these	O
modifications	O
,	O
we	O
determined	O
the	O
global	O
patterns	O
of	O
lysine	O
methylation	O
involving	O
K9	O
on	O
histone	B-Protein
H3	I-Protein
and	O
K20	O
on	O
histone	B-Protein
H4	I-Protein
in	O
midgestation	O
mouse	O
embryos	O
.	O

For	O
each	O
lysine	O
target	O
site	O
,	O
we	O
observed	O
distinct	O
subnuclear	O
distributions	O
of	O
the	O
mono	O
-	O
and	O
trimethyl	O
versions	O
in	O
10T1	O
/	O
2	O
cells	O
that	O
were	O
conserved	O
within	O
primary	O
cultures	O
and	O
within	O
the	O
3D	O
-	O
tissue	O
architecture	O
of	O
the	O
embryo	O
.	O

Interestingly	O
,	O
three	O
of	O
these	O
modifications	O
,	O
histone	B-Protein
H3	I-Protein
trimethyl	O
K9	O
,	O
histone	B-Protein
H4	I-Protein
monomethyl	O
K20	O
,	O
and	O
histone	B-Protein
H4	I-Protein
trimethyl	O
K20	O
exhibited	O
marked	O
differences	O
in	O
their	O
distribution	O
within	O
the	O
neuroepithelium	O
.	O

Specifically	O
,	O
both	O
histone	B-Protein
H3	I-Protein
trimethyl	O
K9	O
and	O
H4	B-Protein
monomethyl	O
K20	O
were	O
elevated	O
in	O
proliferating	O
cells	O
of	O
the	O
neural	O
tube	O
,	O
which	O
in	O
the	O
case	O
of	O
the	O
K9	O
modification	O
was	O
limited	O
to	O
mitotic	O
cells	O
on	O
the	O
luminal	O
surface	O
.	O

In	O
contrast	O
,	O
histone	B-Protein
H4	I-Protein
trimethyl	O
K20	O
was	O
progressively	O
lost	O
from	O
these	O
medial	O
regions	O
and	O
became	O
enriched	O
in	O
differentiating	O
neurons	O
in	O
the	O
ventrolateral	O
neural	O
tube	O
.	O

The	O
inverse	O
relationship	O
of	O
histone	B-Protein
H4	I-Protein
K20	O
methyl	O
derivatives	O
is	O
even	O
more	O
striking	O
during	O
skeletal	O
and	O
cardiac	O
myogenesis	O
where	O
the	O
accumulation	O
of	O
the	O
trimethyl	O
modification	O
in	O
pericentromeric	O
heterochromatin	O
suggests	O
a	O
role	O
in	O
gene	O
silencing	O
in	O
postmitotic	O
muscle	O
cells	O
.	O

Importantly	O
,	O
our	O
results	O
establish	O
that	O
histone	B-Protein
lysine	O
methylation	O
occurs	O
in	O
a	O
highly	O
dynamic	O
manner	O
that	O
is	O
consistent	O
with	O
their	O
function	O
in	O
an	O
epigenetic	O
program	O
for	O
cell	O
division	O
and	O
differentiation	O
.	O

Decreased	O
expression	O
of	O
lysyl	B-Protein
hydroxylase	I-Protein
2	I-Protein
(	O
LH2	B-Protein
)	O
in	O
skin	O
fibroblasts	O
from	O
three	O
Ehlers	O
-	O
Danlos	O
patients	O
does	O
not	O
result	O
from	O
mutations	O
in	O
either	O
the	O
coding	O
or	O
proximal	O
promoter	O
region	O
of	O
the	O
LH2	B-Protein
gene	O
.	O

The	O
Ehlers	O
-	O
Danlos	O
syndromes	O
(	O
EDS	O
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
inherited	O
connective	O
tissue	O
disorders	O
characterized	O
by	O
tissue	O
fragility	O
,	O
hyperelasticity	O
of	O
the	O
skin	O
and	O
joint	O
hypermobility	O
.	O

This	O
phenotype	O
,	O
accompanied	O
by	O
kyphoscoliosis	O
and	O
/	O
or	O
ocular	O
fragility	O
,	O
is	O
present	O
in	O
patients	O
with	O
the	O
autosomal	O
recessive	O
type	O
VI	O
form	O
of	O
EDS	O
.	O

These	O
patients	O
have	O
significantly	O
decreased	O
levels	O
of	O
lysyl	O
hydroxylase	O
(	O
LH	O
)	O
activity	O
,	O
due	O
to	O
mutations	O
in	O
the	O
LH1	B-Protein
gene	O
.	O

LH	O
hydroxylates	O
specific	O
lysine	O
residues	O
in	O
the	O
collagen	O
molecule	O
that	O
are	O
precursors	O
for	O
the	O
formation	O
of	O
cross	O
-	O
links	O
which	O
provide	O
collagen	O
with	O
its	O
tensile	O
strength	O
.	O

No	O
disorder	O
has	O
been	O
directly	O
linked	O
to	O
decreased	O
expression	O
of	O
LH2	B-Protein
and	O
LH3	B-Protein
,	O
two	O
other	O
isoforms	O
of	O
LH	O
.	O

This	O
study	O
describes	O
3	O
patients	O
with	O
mixed	O
phenotypes	O
of	O
EDS	O
,	O
who	O
have	O
significantly	O
decreased	O
mRNAs	O
for	O
LH2	B-Protein
,	O
but	O
normal	O
levels	O
of	O
LH1	B-Protein
and	O
LH3	B-Protein
mRNAs	O
,	O
in	O
their	O
skin	O
fibroblasts	O
.	O

In	O
contrast	O
to	O
the	O
effect	O
of	O
LH1	B-Protein
deficiency	O
in	O
EDS	O
VI	O
patients	O
,	O
the	O
decreased	O
expression	O
of	O
LH2	B-Protein
does	O
not	O
affect	O
LH	O
activity	O
,	O
bifunctional	O
collagen	O
cross	O
-	O
links	O
(	O
measured	O
after	O
reduction	O
as	O
dihydroxylysinonorleucine	O
(	O
DHLNL	O
)	O
and	O
hydroxylysinonorleucine	O
(	O
HLNL	O
)	O
)	O
,	O
or	O
helical	O
lysine	O
hydroxylation	O
in	O
these	O
cell	O
lines	O
.	O

Sequence	O
analysis	O
of	O
full	O
length	O
LH2	B-Protein
cDNAs	O
and	O
1kb	O
of	O
the	O
promoter	O
region	O
of	O
LH2	B-Protein
does	O
not	O
show	O
mutations	O
that	O
could	O
explain	O
the	O
decreased	O
expression	O
of	O
LH2	B-Protein
.	O

These	O
results	O
suggest	O
that	O
the	O
deficiency	O
of	O
LH2	B-Protein
in	O
these	O
fibroblasts	O
may	O
be	O
caused	O
by	O
changes	O
in	O
other	O
factors	O
required	O
for	O
the	O
expression	O
of	O
LH2	B-Protein
.	O

Expression	O
and	O
purification	O
of	O
functionally	O
active	O
hyaluronan	O
-	O
binding	O
domains	O
from	O
human	O
cartilage	O
link	O
protein	O
,	O
aggrecan	B-Protein
and	O
versican	B-Protein
:	O
formation	O
of	O
ternary	O
complexes	O
with	O
defined	O
hyaluronan	O
oligosaccharides	O
.	O

The	O
chondroitin	O
sulfate	O
proteoglycan	O
aggrecan	B-Protein
forms	O
link	O
protein	O
-	O
stabilized	O
complexes	O
with	O
hyaluronan	O
(	O
HA	O
)	O
,	O
via	O
its	O
N	O
-	O
terminal	O
G1	O
-	O
domain	O
,	O
that	O
provide	O
cartilage	O
with	O
its	O
load	O
bearing	O
properties	O
.	O

Similar	O
aggregates	O
(	O
potentially	O
containing	O
new	O
members	O
of	O
the	O
link	O
protein	O
family	O
)	O
,	O
in	O
which	O
other	O
chondroitin	O
sulfate	O
proteoglycans	O
(	O
i	O
.	O
e	O
.	O
versican	B-Protein
,	O
brevican	B-Protein
,	O
and	O
neurocan	B-Protein
)	O
substitute	O
for	O
aggrecan	B-Protein
,	O
may	O
contribute	O
to	O
the	O
structural	O
integrity	O
of	O
many	O
other	O
tissues	O
including	O
skin	O
and	O
brain	O
.	O

In	O
this	O
study	O
,	O
cartilage	O
link	O
protein	O
(	O
cLP	O
)	O
and	O
the	O
G1	O
-	O
domains	O
of	O
aggrecan	B-Protein
(	O
AG1	O
)	O
and	O
versican	B-Protein
(	O
VG1	O
)	O
were	O
expressed	O
in	O
Drosophila	O
S2	O
cells	O
.	O

The	O
recombinant	O
human	O
proteins	O
were	O
found	O
to	O
have	O
properties	O
similar	O
to	O
those	O
described	O
for	O
the	O
native	O
molecules	O
(	O
e	O
.	O
g	O
.	O
cLP	O
was	O
able	O
to	O
form	O
oligomers	O
,	O
and	O
HA	O
decasaccharides	O
were	O
the	O
minimum	O
size	O
that	O
could	O
compete	O
effectively	O
for	O
their	O
binding	O
to	O
polymeric	O
HA	O
)	O
.	O

Gel	O
filtration	O
and	O
protein	O
cross	O
-	O
linking	O
/	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
peptide	O
fingerprinting	O
showed	O
that	O
cLP	O
and	O
AG1	O
interact	O
in	O
the	O
absence	O
or	O
presence	O
of	O
HA	O
.	O

Conversely	O
,	O
cLP	O
and	O
VG1	O
did	O
not	O
bind	O
directly	O
to	O
each	O
other	O
in	O
solution	O
yet	O
formed	O
ternary	O
complexes	O
with	O
HA24	O
.	O

N	O
-	O
linked	O
glycosylation	O
of	O
AG1	O
and	O
VG1	O
was	O
demonstrated	O
to	O
be	O
unnecessary	O
for	O
either	O
HA	O
binding	O
or	O
the	O
formation	O
of	O
ternary	O
complexes	O
.	O

Surprisingly	O
,	O
the	O
length	O
of	O
HA	O
required	O
to	O
accommodate	O
two	O
G1	O
-	O
domains	O
was	O
found	O
to	O
be	O
significantly	O
larger	O
for	O
aggrecan	B-Protein
than	O
versican	B-Protein
,	O
which	O
may	O
reflect	O
differences	O
in	O
the	O
conformation	O
of	O
HA	O
stabilized	O
on	O
binding	O
these	O
proteins	O
.	O

Protective	O
mechanism	O
of	O
epigallocatechin	O
-	O
3	O
-	O
gallate	O
against	O
Helicobacter	O
pylori	O
-	O
induced	O
gastric	O
epithelial	O
cytotoxicity	O
via	O
the	O
blockage	O
of	O
TLR	B-Protein
-	I-Protein
4	I-Protein
signaling	O
.	O

BACKGROUND	O
:	O
Helicobacter	O
pylori	O
infection	O
leads	O
to	O
gastric	O
mucosal	O
damage	O
by	O
several	O
mechanisms	O
including	O
the	O
direct	O
effect	O
of	O
virulence	O
factors	O
produced	O
by	O
H	O
.	O
pylori	O
,	O
propagation	O
of	O
inflammation	O
,	O
oxidative	O
stress	O
,	O
DNA	O
damage	O
,	O
and	O
induction	O
of	O
apoptosis	O
.	O

(	O
-	O
)	O
-	O
Epigallocatechin	O
-	O
3	O
-	O
gallate	O
(	O
EGCG	O
)	O
,	O
one	O
of	O
the	O
green	O
tea	O
catechins	O
,	O
is	O
known	O
to	O
suppress	O
H	O
.	O
pylori	O
-	O
induced	O
gastritis	O
through	O
its	O
antioxidative	O
and	O
antibacterial	O
actions	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
protective	O
mechanism	O
of	O
EGCG	O
against	O
H	O
.	O
pylori	O
-	O
induced	O
cytotoxicity	O
in	O
gastric	O
epithelial	O
cells	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
MTT	O
assays	O
and	O
dye	O
exclusion	O
assays	O
were	O
performed	O
to	O
analyze	O
the	O
effect	O
of	O
EGCG	O
on	O
the	O
viability	O
of	O
gastric	O
epithelial	O
cells	O
.	O

The	O
degree	O
of	O
DNA	O
damage	O
was	O
evaluated	O
by	O
Comet	O
assay	O
and	O
apoptotic	O
DNA	O
fragmentation	O
assay	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
EGCG	O
on	O
H	O
.	O
pylori	O
-	O
induced	O
toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
4	I-Protein
(	O
TLR	B-Protein
-	I-Protein
4	I-Protein
)	O
signaling	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
analysis	O
corresponding	O
to	O
glycosylated	O
TLR	B-Protein
-	I-Protein
4	I-Protein
were	O
carried	O
out	O
.	O

Lipoxygenase	O
metabolites	O
were	O
measured	O
with	O
reverse	O
-	O
phase	O
,	O
high	O
-	O
performance	O
liquid	O
chromatography	O
.	O

RESULTS	O
:	O
EGCG	O
pretreatment	O
effectively	O
rescued	O
gastric	O
mucosal	O
cells	O
from	O
the	O
H	O
.	O
pylori	O
-	O
induced	O
apoptotic	O
cell	O
death	O
and	O
DNA	O
damage	O
,	O
and	O
administration	O
of	O
this	O
catechin	O
enhanced	O
gastric	O
epithelial	O
cell	O
proliferation	O
.	O

Helicobacter	O
pylori	O
infection	O
stimulated	O
the	O
glycosylation	O
of	O
TLR	B-Protein
-	I-Protein
4	I-Protein
,	O
which	O
initiates	O
intracellular	O
signaling	O
in	O
the	O
infected	O
host	O
cell	O
,	O
but	O
the	O
pretreatment	O
with	O
EGCG	O
completely	O
blocked	O
the	O
TLR	B-Protein
-	I-Protein
4	I-Protein
glycosylation	O
.	O

The	O
blockage	O
of	O
TLR	B-Protein
-	I-Protein
4	I-Protein
activation	O
by	O
EGCG	O
resulted	O
in	O
inactivation	O
of	O
extracellular	B-Protein
signal	I-Protein
response	I-Protein
kinase	I-Protein
1	I-Protein
/	O
2	B-Protein
and	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
the	O
downstream	O
molecules	O
of	O
TLR	B-Protein
-	I-Protein
4	I-Protein
signaling	O
induced	O
by	O
H	O
.	O
pylori	O
.	O

This	O
disturbance	O
of	O
H	O
.	O
pylori	O
-	O
induced	O
host	O
cell	O
signaling	O
by	O
EGCG	O
attenuated	O
the	O
synthesis	O
of	O
the	O
proinflammatory	O
mediator	O
,	O
hydroxyeicosatetraenoic	O
acid	O
.	O

CONCLUSIONS	O
:	O
EGCG	O
pretreatment	O
showed	O
significant	O
cytoprotective	O
effects	O
against	O
H	O
.	O
pylori	O
-	O
induced	O
gastric	O
cytotoxicity	O
via	O
interference	O
of	O
the	O
TLR	B-Protein
-	I-Protein
4	I-Protein
signaling	O
induced	O
by	O
H	O
.	O
pylori	O
.	O

Thus	O
,	O
our	O
result	O
implies	O
that	O
continuous	O
intakes	O
of	O
green	O
tea	O
could	O
prevent	O
the	O
deleterious	O
consequences	O
of	O
H	O
.	O
pylori	O
infection	O
.	O

Bare	O
-	O
faced	O
curassow	O
lysozyme	B-Protein
carrying	O
amino	O
acid	O
substitutions	O
at	O
subsites	O
E	O
and	O
F	O
shows	O
a	O
change	O
in	O
activity	O
against	O
chitooligosaccharide	O
caused	O
by	O
a	O
local	O
conformational	O
change	O
.	O

A	O
new	O
form	O
of	O
avian	O
lysozyme	O
,	O
bare	O
-	O
faced	O
curassow	O
lysozyme	B-Protein
(	O
BCL	O
)	O
,	O
was	O
purified	O
and	O
chemically	O
sequenced	O
.	O

Of	O
the	O
26	O
substitutions	O
relative	O
to	O
chicken	O
lysozyme	B-Protein
,	O
three	O
,	O
F34Y	O
,	O
T47S	O
,	O
and	O
R114H	O
,	O
are	O
of	O
substrate	O
-	O
interacting	O
residues	O
in	O
the	O
E	O
and	O
F	O
subsites	O
,	O
which	O
would	O
contribute	O
to	O
the	O
acceptor	O
binding	O
for	O
transglycosylation	O
.	O

T47S	O
is	O
a	O
novel	O
substitution	O
in	O
this	O
lysozyme	B-Protein
class	O
.	O

While	O
other	O
lysozymes	B-Protein
also	O
have	O
substitutions	O
at	O
positions	O
114	O
and	O
34	O
,	O
they	O
also	O
contain	O
numerous	O
others	O
,	O
including	O
ones	O
in	O
the	O
other	O
substrate	O
binding	O
sites	O
,	O
A	O
-	O
D	O
.	O

Furthermore	O
,	O
T47S	O
lies	O
on	O
the	O
left	O
side	O
,	O
while	O
F34Y	O
and	O
R114H	O
are	O
located	O
on	O
the	O
right	O
side	O
of	O
the	O
E	O
-	O
F	O
subsites	O
.	O

BCL	O
therefore	O
should	O
allow	O
comparison	O
of	O
the	O
independent	O
contributions	O
of	O
these	O
sites	O
to	O
substrate	O
binding	O
and	O
transglycosylation	O
.	O

The	O
activity	O
toward	O
the	O
N	O
-	O
acetylglucosamine	O
pentamer	O
revealed	O
that	O
the	O
substitutions	O
at	O
the	O
E	O
-	O
F	O
sites	O
reduced	O
the	O
binding	O
free	O
energies	O
at	O
the	O
E	O
-	O
F	O
sites	O
and	O
the	O
rate	O
constant	O
for	O
transglycosylation	O
without	O
the	O
conformation	O
change	O
of	O
other	O
substrate	O
binding	O
sites	O
on	O
the	O
protein	O
.	O

MD	O
simulation	O
analysis	O
of	O
BCL	O
suggested	O
that	O
the	O
substituted	O
amino	O
acids	O
changed	O
the	O
local	O
conformation	O
of	O
this	O
lysozyme	B-Protein
at	O
the	O
E	O
-	O
F	O
sites	O
.	O

Histone	B-Protein
H2B	I-Protein
ubiquitylation	O
is	O
associated	O
with	O
elongating	O
RNA	O
polymerase	O
II	O
.	O

Rad6	B-Protein
-	O
mediated	O
ubiquitylation	O
of	O
histone	B-Protein
H2B	I-Protein
at	O
lysine	O
123	O
has	O
been	O
linked	O
to	O
transcriptional	O
activation	O
and	O
the	O
regulation	O
of	O
lysine	O
methylation	O
on	O
histone	B-Protein
H3	I-Protein
.	O

However	O
,	O
how	O
Rad6	B-Protein
and	O
H2B	B-Protein
ubiquitylation	O
contribute	O
to	O
the	O
transcription	O
and	O
histone	B-Protein
methylation	O
processes	O
is	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Paf1	B-Protein
transcription	O
elongation	O
complex	O
and	O
the	O
E3	O
ligase	O
for	O
Rad6	B-Protein
,	O
Bre1	B-Protein
,	O
mediate	O
an	O
association	O
of	O
Rad6	B-Protein
with	O
the	O
hyperphosphorylated	O
(	O
elongating	O
)	O
form	O
of	O
RNA	O
polymerase	O
II	O
(	O
Pol	O
II	O
)	O
.	O

This	O
association	O
appears	O
to	O
be	O
necessary	O
for	O
the	O
transcriptional	O
activities	O
of	O
Rad6	B-Protein
,	O
as	O
deletion	O
of	O
various	O
Paf1	B-Protein
complex	O
members	O
or	O
Bre1	B-Protein
abolishes	O
H2B	B-Protein
ubiquitylation	O
(	O
ubH2B	B-Protein
)	O
and	O
reduces	O
the	O
recruitment	O
of	O
Rad6	B-Protein
to	O
the	O
promoters	O
and	O
transcribed	O
regions	O
of	O
active	O
genes	O
.	O

Using	O
the	O
inducible	O
GAL1	B-Protein
gene	O
as	O
a	O
model	O
,	O
we	O
find	O
that	O
the	O
recruitment	O
of	O
Rad6	B-Protein
upon	O
activation	O
occurs	O
rapidly	O
and	O
transiently	O
across	O
the	O
gene	O
and	O
coincides	O
precisely	O
with	O
the	O
appearance	O
of	O
Pol	O
II	O
.	O

Significantly	O
,	O
during	O
GAL1	B-Protein
activation	O
in	O
an	O
rtf1	B-Protein
deletion	O
mutant	O
,	O
Rad6	B-Protein
accumulates	O
at	O
the	O
promoter	O
but	O
is	O
absent	O
from	O
the	O
transcribed	O
region	O
.	O

This	O
fact	O
suggests	O
that	O
Rad6	B-Protein
is	O
recruited	O
to	O
promoters	O
independently	O
of	O
the	O
Paf1	B-Protein
complex	O
but	O
then	O
requires	O
this	O
complex	O
for	O
entrance	O
into	O
the	O
coding	O
region	O
of	O
genes	O
in	O
a	O
Pol	O
II	O
-	O
associated	O
manner	O
.	O

In	O
support	O
of	O
a	O
role	O
for	O
Rad6	B-Protein
-	O
dependent	O
H2B	B-Protein
ubiquitylation	O
in	O
transcription	O
elongation	O
,	O
we	O
find	O
that	O
ubH2B	B-Protein
levels	O
are	O
dramatically	O
reduced	O
in	O
strains	O
bearing	O
mutations	O
of	O
the	O
Pol	O
II	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
and	O
abolished	O
by	O
inactivation	O
of	O
Kin28	B-Protein
,	O
the	O
serine	O
5	O
CTD	O
kinase	O
that	O
promotes	O
the	O
transition	O
from	O
initiation	O
to	O
elongation	O
.	O

Furthermore	O
,	O
synthetic	O
genetic	O
array	O
analysis	O
reveals	O
that	O
the	O
Rad6	B-Protein
complex	O
interacts	O
genetically	O
with	O
a	O
number	O
of	O
known	O
or	O
suspected	O
transcription	O
elongation	O
factors	O
.	O

Finally	O
,	O
we	O
show	O
that	O
Saccharomyces	O
cerevisiae	O
mutants	O
bearing	O
defects	O
in	O
the	O
pathway	O
to	O
H2B	B-Protein
ubiquitylation	O
display	O
transcription	O
elongation	O
defects	O
as	O
assayed	O
by	O
6	O
-	O
azauracil	O
sensitivity	O
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
a	O
role	O
for	O
Rad6	B-Protein
and	O
H2B	B-Protein
ubiquitylation	O
during	O
the	O
elongation	O
cycle	O
of	O
transcription	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
H3	B-Protein
methylation	O
may	O
be	O
regulated	O
.	O

Glycosylation	O
-	O
related	O
gene	O
expression	O
in	O
prion	B-Protein
diseases	O
:	O
PrPSc	B-Protein
accumulation	O
in	O
scrapie	O
infected	O
GT1	O
cells	O
depends	O
on	O
beta	O
-	O
1	O
,	O
4	O
-	O
linked	O
GalNAc	O
-	O
4	O
-	O
SO4	O
hyposulfation	O
.	O

Several	O
lines	O
of	O
evidence	O
indicate	O
that	O
some	O
glycoconjugates	O
are	O
efficient	O
effectors	O
of	O
the	O
cellular	O
prion	B-Protein
protein	I-Protein
(	O
PrP	B-Protein
(	I-Protein
C	I-Protein
)	I-Protein
)	O
conversion	O
into	O
its	O
pathogenic	O
(	O
PrP	B-Protein
(	I-Protein
Sc	I-Protein
)	I-Protein
)	O
isoform	O
.	O

To	O
assess	O
how	O
glycoconjugate	O
glycan	O
moieties	O
participate	O
in	O
the	O
biogenesis	O
of	O
PrP	B-Protein
(	I-Protein
Sc	I-Protein
)	I-Protein
,	O
an	O
exhaustive	O
comparative	O
analysis	O
of	O
the	O
expression	O
of	O
about	O
200	O
glycosylation	O
-	O
related	O
genes	O
was	O
performed	O
on	O
prion	B-Protein
-	O
infected	O
or	O
not	O
,	O
hypothalamus	O
-	O
derived	O
GT1	O
cells	O
by	O
hybridization	O
of	O
DNA	O
microarrays	O
,	O
semiquantitative	O
RT	O
-	O
PCR	O
,	O
and	O
biochemical	O
assays	O
.	O

A	O
significant	O
up	O
-	O
(	O
30	O
-	O
fold	O
)	O
and	O
down	O
-	O
(	O
17	O
-	O
fold	O
)	O
regulation	O
of	O
the	O
expression	O
of	O
the	O
ChGn1	B-Protein
and	O
Chst8	B-Protein
genes	O
,	O
respectively	O
,	O
was	O
observed	O
in	O
prion	B-Protein
-	O
infected	O
cells	O
.	O

ChGn1	B-Protein
and	O
Chst8	B-Protein
are	O
involved	O
in	O
the	O
initiation	O
of	O
the	O
synthesis	O
of	O
chondroitin	O
sulfate	O
and	O
in	O
the	O
4	O
-	O
O	O
-	O
sulfation	O
of	O
non	O
-	O
reducing	O
N	O
-	O
acetylgalactosamine	O
residues	O
,	O
respectively	O
.	O

A	O
possible	O
role	O
for	O
a	O
hyposulfated	O
chondroitin	O
in	O
PrP	B-Protein
(	I-Protein
Sc	I-Protein
)	I-Protein
accumulation	O
was	O
evidenced	O
at	O
the	O
protein	O
level	O
and	O
by	O
determination	O
of	O
chondroitin	O
and	O
heparan	O
sulfate	O
amounts	O
.	O

Treatment	O
of	O
Sc	O
-	O
GT1	O
cells	O
with	O
a	O
heparan	O
mimetic	O
(	O
HM2602	O
)	O
induced	O
an	O
important	O
reduction	O
of	O
the	O
amount	O
of	O
PrP	B-Protein
(	I-Protein
Sc	I-Protein
)	I-Protein
,	O
associated	O
with	O
a	O
total	O
reversion	O
of	O
the	O
transcription	O
pattern	O
of	O
the	O
N	B-Protein
-	I-Protein
acetylgalactosamine	I-Protein
-	I-Protein
4	I-Protein
-	I-Protein
O	I-Protein
-	I-Protein
sulfotransferase	I-Protein
8	I-Protein
.	O

It	O
suggests	O
a	O
link	O
between	O
the	O
genetic	O
control	O
of	O
4	O
-	O
O	O
-	O
sulfation	O
and	O
PrP	B-Protein
(	I-Protein
Sc	I-Protein
)	I-Protein
accumulation	O
.	O

Expression	O
and	O
transport	O
of	O
rabbit	O
surfactant	B-Protein
protein	I-Protein
A	I-Protein
in	O
COS	O
-	O
1	O
cells	O
.	O

SV40	O
-	O
transformed	O
green	O
monkey	O
kidney	O
(	O
COS	O
-	O
1	O
)	O
cells	O
were	O
transfected	O
with	O
expression	O
plasmids	O
that	O
contained	O
either	O
the	O
structural	O
gene	O
or	O
cDNA	O
for	O
surfactant	B-Protein
protein	I-Protein
A	I-Protein
(	O
SP	B-Protein
-	I-Protein
A	I-Protein
)	O
,	O
a	O
major	O
protein	O
of	O
rabbit	O
lung	O
surfactant	O
.	O

The	O
transfected	O
COS	O
-	O
1	O
cells	O
synthesized	O
several	O
isoforms	O
of	O
SP	B-Protein
-	I-Protein
A	I-Protein
that	O
were	O
found	O
to	O
be	O
less	O
acidic	O
than	O
those	O
produced	O
in	O
rabbit	O
lung	O
tissue	O
.	O

SP	B-Protein
-	I-Protein
A	I-Protein
species	O
with	O
apparent	O
molecular	O
weight	O
(	O
M	O
(	O
r	O
)	O
)	O
approximately	O
equal	O
to	O
29	O
,	O
000	O
-	O
33	O
,	O
000	O
were	O
detected	O
in	O
the	O
transfected	O
cells	O
,	O
whereas	O
glycosylated	O
forms	O
with	O
apparent	O
M	O
(	O
r	O
)	O
approximately	O
equal	O
to	O
33	O
,	O
000	O
-	O
38	O
,	O
000	O
were	O
detectable	O
only	O
in	O
the	O
culture	O
medium	O
.	O

Analysis	O
of	O
transfected	O
cells	O
by	O
indirect	O
immunofluorescence	O
revealed	O
that	O
SP	B-Protein
-	I-Protein
A	I-Protein
was	O
localized	O
in	O
punctate	O
bodies	O
throughout	O
the	O
cytoplasm	O
.	O

Expressed	O
SP	B-Protein
-	I-Protein
A	I-Protein
was	O
not	O
detectable	O
on	O
the	O
cell	O
surface	O
nor	O
was	O
there	O
evidence	O
that	O
secreted	O
SP	B-Protein
-	I-Protein
A	I-Protein
was	O
endocytosed	O
by	O
COS	O
-	O
1	O
cells	O
.	O

After	O
subcellular	O
fractionation	O
of	O
the	O
transfected	O
COS	O
-	O
1	O
cells	O
,	O
SP	B-Protein
-	I-Protein
A	I-Protein
was	O
found	O
to	O
be	O
localized	O
predominantly	O
in	O
the	O
5	O
,	O
000	O
-	O
and	O
18	O
,	O
000	O
-	O
g	O
pellet	O
fractions	O
;	O
little	O
or	O
no	O
immunoreactive	O
SP	B-Protein
-	I-Protein
A	I-Protein
was	O
detectable	O
in	O
cytosolic	O
fractions	O
.	O

Treatment	O
of	O
transfected	O
cells	O
with	O
the	O
glycosylation	O
inhibitor	O
tunicamycin	O
prevented	O
secretion	O
of	O
SP	B-Protein
-	I-Protein
A	I-Protein
into	O
the	O
medium	O
,	O
suggesting	O
a	O
role	O
of	O
glycosylation	O
in	O
secretion	O
of	O
SP	B-Protein
-	I-Protein
A	I-Protein
.	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
of	O
transfected	O
cells	O
with	O
inhibitors	O
of	O
proline	O
hydroxylation	O
,	O
which	O
may	O
cause	O
destabilization	O
of	O
the	O
collagen	O
-	O
like	O
domain	O
of	O
SP	B-Protein
-	I-Protein
A	I-Protein
,	O
reduced	O
but	O
did	O
not	O
prevent	O
secretion	O
of	O
SP	B-Protein
-	I-Protein
A	I-Protein
into	O
the	O
culture	O
medium	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Histone	B-Protein
H4	I-Protein
isoforms	O
acetylated	O
at	O
specific	O
lysine	O
residues	O
define	O
individual	O
chromosomes	O
and	O
chromatin	O
domains	O
in	O
Drosophila	O
polytene	O
nuclei	O
.	O

Histone	B-Protein
H4	I-Protein
isoforms	O
acetylated	O
at	O
lysines	O
5	O
,	O
8	O
,	O
12	O
,	O
or	O
16	O
have	O
been	O
shown	O
,	O
by	O
indirect	O
immunofluorescence	O
with	O
site	O
-	O
specific	O
antisera	O
,	O
to	O
have	O
distinct	O
patterns	O
of	O
distribution	O
in	O
interphase	O
,	O
polytene	O
chromosomes	O
from	O
Drosophila	O
larvae	O
.	O

H4	B-Protein
molecules	O
acetylated	O
at	O
lysines	O
5	O
or	O
8	O
are	O
distributed	O
in	O
overlapping	O
,	O
but	O
nonidentical	O
,	O
islands	O
throughout	O
the	O
euchromatic	O
chromosome	O
arms	O
.	O

beta	O
-	O
Heterochromatin	O
in	O
the	O
chromocenter	O
is	O
depleted	O
in	O
these	O
isoforms	O
,	O
but	O
relatively	O
enriched	O
in	O
H4	B-Protein
acetylated	O
at	O
lysine	O
12	O
.	O

H4	B-Protein
acetylated	O
at	O
lysine	O
16	O
is	O
found	O
at	O
numerous	O
sites	O
along	O
the	O
transcriptionally	O
hyperactive	O
X	O
chromosome	O
in	O
male	O
larvae	O
,	O
but	O
not	O
in	O
male	O
autosomes	O
or	O
any	O
chromosome	O
in	O
female	O
cells	O
.	O

These	O
findings	O
support	O
the	O
hypothesis	O
that	O
H4	B-Protein
molecules	O
acetylated	O
at	O
particular	O
sites	O
mediate	O
unique	O
and	O
specific	O
effects	O
on	O
chromatin	O
function	O
.	O

The	O
loss	O
of	O
NKX3	B-Protein
.	I-Protein
1	I-Protein
expression	O
in	O
testicular	O
-	O
-	O
and	O
prostate	O
-	O
-	O
cancers	O
is	O
not	O
caused	O
by	O
promoter	O
hypermethylation	O
.	O

BACKGROUND	O
:	O
Recent	O
studies	O
have	O
demonstrated	O
that	O
the	O
NKX3	B-Protein
.	I-Protein
1	I-Protein
protein	O
is	O
commonly	O
down	O
-	O
regulated	O
in	O
testicular	O
germ	O
cell	O
tumors	O
(	O
TGCTs	O
)	O
and	O
prostate	O
carcinomas	O
.	O

The	O
homeobox	O
gene	O
NKX3	B-Protein
.	I-Protein
1	I-Protein
maps	O
to	O
chromosome	O
band	O
8p21	O
,	O
which	O
is	O
a	O
region	O
frequently	O
lost	O
in	O
prostate	O
cancer	O
,	O
but	O
not	O
in	O
TGCT	O
.	O

Mutations	O
have	O
not	O
been	O
reported	O
in	O
the	O
NKX3	B-Protein
.	I-Protein
1	I-Protein
sequence	O
,	O
and	O
the	O
gene	O
is	O
hypothesized	O
to	O
be	O
epigenetically	O
inactivated	O
.	O

In	O
the	O
present	O
study	O
we	O
examined	O
the	O
methylation	O
status	O
of	O
the	O
NKX3	B-Protein
.	I-Protein
1	I-Protein
promoter	O
in	O
relevant	O
primary	O
tumors	O
and	O
cell	O
lines	O
:	O
primary	O
TGCTs	O
(	O
n	O
=	O
55	O
)	O
,	O
intratubular	O
germ	O
cell	O
neoplasias	O
(	O
n	O
=	O
7	O
)	O
,	O
germ	O
cell	O
tumor	O
cell	O
lines	O
(	O
n	O
=	O
3	O
)	O
,	O
primary	O
prostate	O
adenocarcinomas	O
(	O
n	O
=	O
20	O
)	O
,	O
and	O
prostate	O
cancer	O
cell	O
lines	O
(	O
n	O
=	O
3	O
)	O
by	O
methylation	O
-	O
specific	O
PCR	O
and	O
bisulphite	O
sequencing	O
.	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O
Down	O
-	O
regulation	O
of	O
NKX3	B-Protein
.	I-Protein
1	I-Protein
expression	O
was	O
generally	O
not	O
caused	O
by	O
promoter	O
hypermethylation	O
,	O
which	O
was	O
only	O
found	O
in	O
one	O
TGCT	O
.	O

However	O
,	O
other	O
epigenetic	O
mechanisms	O
,	O
such	O
as	O
modulation	O
of	O
chromatin	O
structure	O
or	O
modifications	O
of	O
histones	B-Protein
,	O
may	O
explain	O
the	O
lack	O
of	O
NKX3	B-Protein
.	I-Protein
1	I-Protein
expression	O
,	O
which	O
is	O
seen	O
in	O
most	O
TGCTs	O
and	O
prostate	O
cancer	O
specimens	O
.	O

Bre1	B-Protein
is	O
required	O
for	O
Notch	O
signaling	O
and	O
histone	B-Protein
modification	O
.	O

Notch	O
signaling	O
controls	O
numerous	O
cell	O
fate	O
decisions	O
during	O
animal	O
development	O
.	O

These	O
typically	O
involve	O
a	O
Notch	O
-	O
mediated	O
switch	O
in	O
transcription	O
of	O
target	O
genes	O
,	O
although	O
the	O
details	O
of	O
this	O
molecular	O
mechanism	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
identify	O
dBre1	B-Protein
as	O
a	O
nuclear	O
component	O
required	O
cell	O
autonomously	O
for	O
the	O
expression	O
of	O
Notch	O
target	O
genes	O
in	O
Drosophila	O
development	O
.	O

dBre1	B-Protein
affects	O
the	O
levels	O
of	O
Su	B-Protein
(	I-Protein
H	I-Protein
)	I-Protein
in	O
imaginal	O
disc	O
cells	O
,	O
and	O
it	O
stimulates	O
the	O
Su	B-Protein
(	I-Protein
H	I-Protein
)	I-Protein
-	O
mediated	O
transcription	O
of	O
a	O
Notch	O
-	O
specific	O
reporter	O
in	O
transfected	O
Drosophila	O
cells	O
.	O

Strikingly	O
,	O
dBre1	B-Protein
mutant	O
clones	O
show	O
much	O
reduced	O
levels	O
of	O
methylated	O
lysine	O
4	O
on	O
histone	B-Protein
3	I-Protein
(	O
H3K4m	B-Protein
)	O
,	O
a	O
chromatin	O
mark	O
that	O
has	O
been	O
implicated	O
in	O
transcriptional	O
activation	O
.	O

Thus	O
,	O
dBre1	B-Protein
is	O
the	O
functional	O
homolog	O
of	O
yeast	O
Bre1p	B-Protein
,	O
an	O
E3	O
ubiquitin	O
ligase	O
required	O
for	O
the	O
monoubiquitination	O
of	O
histone	B-Protein
H2B	I-Protein
and	O
,	O
indirectly	O
,	O
for	O
H3K4	B-Protein
methylation	O
.	O

Our	O
results	O
indicate	O
that	O
histone	B-Protein
modification	O
is	O
critical	O
for	O
the	O
transcription	O
of	O
Notch	O
target	O
genes	O
.	O

Identification	O
and	O
characterization	O
of	O
novel	O
endogenous	O
proteolytic	O
forms	O
of	O
the	O
human	O
angiogenesis	O
inhibitors	O
restin	B-Protein
and	O
endostatin	B-Protein
.	O

Restin	B-Protein
and	O
endostatin	B-Protein
are	O
C	O
-	O
terminal	O
fragments	O
of	O
the	O
noncollagenous	O
domains	O
of	O
collagen	B-Protein
XV	I-Protein
and	O
collagen	B-Protein
XVIII	I-Protein
exhibiting	O
high	O
sequence	O
homology	O
.	O

Both	O
polypeptides	O
are	O
distinguished	O
by	O
strong	O
anti	O
-	O
angiogenic	O
activity	O
in	O
vivo	O
restricting	O
the	O
growth	O
of	O
solid	O
tumors	O
and	O
metastasis	O
.	O

They	O
are	O
therefore	O
currently	O
being	O
tested	O
in	O
clinical	O
trials	O
as	O
anti	O
-	O
cancer	O
drugs	O
.	O

We	O
present	O
the	O
identification	O
of	O
new	O
endogenous	O
variants	O
of	O
both	O
angiogenesis	O
inhibitors	O
isolated	O
from	O
a	O
human	O
hemofiltrate	O
peptide	O
library	O
.	O

Using	O
an	O
immunological	O
screening	O
approach	O
with	O
time	O
-	O
resolved	O
rare	O
earth	O
metal	O
fluorometry	O
,	O
immunoreactive	O
compounds	O
were	O
purified	O
chromatographically	O
and	O
characterized	O
by	O
mass	O
spectrometry	O
.	O

We	O
discovered	O
four	O
novel	O
proteolytic	O
products	O
of	O
restin	B-Protein
as	O
well	O
as	O
four	O
variants	O
of	O
endostatin	B-Protein
.	O

Two	O
endostatin	B-Protein
products	O
were	O
characterized	O
as	O
short	O
internal	O
fragments	O
(	O
R176	O
-	O
L215	O
and	O
R176	O
-	O
S219	O
)	O
of	O
the	O
entire	O
molecule	O
containing	O
the	O
recently	O
identified	O
beta1	B-Protein
integrin	I-Protein
receptor	O
binding	O
site	O
,	O
which	O
plays	O
a	O
major	O
role	O
in	O
endothelial	O
cell	O
migration	O
and	O
angiogenesis	O
.	O

Two	O
additional	O
forms	O
contain	O
mucin	O
-	O
type	O
O	O
-	O
glycosylations	O
.	O

The	O
O	O
-	O
glycosylated	O
variants	O
possess	O
an	O
oligosaccharide	O
unit	O
consisting	O
of	O
one	O
N	O
-	O
acetylgalactosamine	O
(	O
GalNAc	O
)	O
,	O
one	O
N	O
-	O
acetylneuraminic	O
acid	O
(	O
NANA	O
)	O
and	O
two	O
galactose	O
residues	O
(	O
Gal	O
)	O
occurring	O
as	O
sialo	O
-	O
(	O
V117	O
-	O
S311	O
-	O
GalNAc	O
-	O
Gal2	O
-	O
NANA	O
)	O
and	O
asialoglycopeptides	O
(	O
V117	O
-	O
S311	O
-	O
GalNAc	O
-	O
Gal2	O
)	O
.	O

The	O
four	O
restin	B-Protein
variants	O
(	O
R	O
(	O
I	O
)	O
-	O
R	O
(	O
IV	O
)	O
)	O
were	O
identified	O
with	O
identical	O
C	O
-	O
but	O
different	O
N	O
-	O
termini	O
and	O
no	O
posttranslational	O
modification	O
(	O
R	O
(	O
I	O
)	O
:	O
P66	O
-	O
A254	O
,	O
R	O
(	O
II	O
)	O
:	O
P75	O
-	O
A254	O
,	O
R	O
(	O
III	O
)	O
:	O
Y81	O
-	O
A254	O
and	O
R	O
(	O
IV	O
)	O
:	O
A89	O
-	O
A254	O
)	O
.	O

Following	O
a	O
differential	O
peptide	O
mass	O
fingerprint	O
approach	O
by	O
reflector	O
mode	O
MALDI	O
-	O
TOFMS	O
,	O
the	O
disulfide	O
patterns	O
of	O
these	O
circulating	O
restins	B-Protein
were	O
determined	O
as	O
Cys1	O
-	O
Cys4	O
and	O
Cys2	O
-	O
Cys3	O
.	O

These	O
endogenous	O
circulating	O
collagen	O
fragments	O
will	O
help	O
to	O
understand	O
the	O
physiological	O
processing	O
of	O
the	O
therapeutic	O
proteins	O
.	O

Analysis	O
of	O
methylation	O
-	O
sensitive	O
transcriptome	O
identifies	O
GADD45a	B-Protein
as	O
a	O
frequently	O
methylated	O
gene	O
in	O
breast	O
cancer	O
.	O

Treatment	O
of	O
the	O
breast	O
cancer	O
cell	O
line	O
,	O
MDAMB468	O
with	O
the	O
DNA	O
methylation	O
inhibitor	O
,	O
5	O
-	O
azacytidine	O
(	O
5	O
-	O
AzaC	O
)	O
results	O
in	O
growth	O
arrest	O
,	O
whereas	O
the	O
growth	O
of	O
the	O
normal	O
breast	O
epithelial	O
line	O
DU99	O
(	O
telomerase	O
immortalized	O
)	O
is	O
relatively	O
unaffected	O
.	O

Comparing	O
gene	O
expression	O
profiles	O
of	O
these	O
two	O
lines	O
after	O
5	O
-	O
AzaC	O
treatment	O
,	O
we	O
identified	O
36	O
genes	O
that	O
had	O
relatively	O
low	O
basal	O
levels	O
in	O
MDAMB468	O
cells	O
compared	O
to	O
the	O
DU99	O
line	O
and	O
were	O
induced	O
in	O
the	O
cancer	O
cell	O
line	O
but	O
not	O
in	O
the	O
normal	O
breast	O
epithelial	O
line	O
.	O

Of	O
these	O
genes	O
,	O
33	O
have	O
associated	O
CpG	O
islands	O
greater	O
than	O
300	O
bp	O
in	O
length	O
but	O
only	O
three	O
have	O
been	O
previously	O
described	O
as	O
targets	O
for	O
aberrant	O
methylation	O
in	O
human	O
cancer	O
.	O

Northern	O
blotting	O
for	O
five	O
of	O
these	O
genes	O
(	O
alpha	B-Protein
-	I-Protein
Catenin	I-Protein
,	O
DTR	B-Protein
,	O
FYN	B-Protein
,	O
GADD45a	B-Protein
,	O
and	O
Zyxin	B-Protein
)	O
verified	O
the	O
array	O
results	O
.	O

Further	O
analysis	O
of	O
one	O
of	O
these	O
genes	O
,	O
GADD45a	B-Protein
,	O
showed	O
that	O
5	O
-	O
AzaC	O
induced	O
expression	O
in	O
five	O
additional	O
breast	O
cancer	O
cell	O
lines	O
with	O
little	O
or	O
no	O
induction	O
in	O
three	O
additional	O
lines	O
derived	O
from	O
normal	O
breast	O
epithelial	O
cells	O
.	O

The	O
CpG	O
island	O
associated	O
with	O
GADD45a	B-Protein
was	O
analysed	O
by	O
bisulfite	O
sequencing	O
,	O
sampling	O
over	O
100	O
CpG	O
dinucleotides	O
.	O

We	O
found	O
that	O
four	O
CpG	O
'	O
s	O
,	O
located	O
approximately	O
700	O
bp	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
are	O
methylated	O
in	O
the	O
majority	O
of	O
breast	O
cancer	O
cell	O
lines	O
and	O
primary	O
tumors	O
but	O
not	O
in	O
DNA	O
from	O
normal	O
breast	O
epithelia	O
or	O
matched	O
lymphocytes	O
from	O
cancer	O
patients	O
.	O

Therefore	O
,	O
this	O
simple	O
method	O
of	O
dynamic	O
transcriptional	O
profiling	O
yielded	O
a	O
series	O
of	O
novel	O
methylation	O
-	O
sensitive	O
genes	O
in	O
breast	O
cancer	O
including	O
the	O
BRCA1	B-Protein
and	O
p53	B-Protein
responsive	O
gene	O
,	O
GADD45a	B-Protein
.	O

Osteocalcin	B-Protein
protein	O
sequences	O
of	O
Neanderthals	O
and	O
modern	O
primates	O
.	O

We	O
report	O
here	O
protein	O
sequences	O
of	O
fossil	O
hominids	O
,	O
from	O
two	O
Neanderthals	O
dating	O
to	O
approximately	O
75	O
,	O
000	O
years	O
old	O
from	O
Shanidar	O
Cave	O
in	O
Iraq	O
.	O

These	O
sequences	O
,	O
the	O
oldest	O
reported	O
fossil	O
primate	O
protein	O
sequences	O
,	O
are	O
of	O
bone	O
osteocalcin	B-Protein
,	O
which	O
was	O
extracted	O
and	O
sequenced	O
by	O
using	O
MALDI	O
-	O
TOF	O
/	O
TOF	O
mass	O
spectrometry	O
.	O

Through	O
a	O
combination	O
of	O
direct	O
sequencing	O
and	O
peptide	O
mass	O
mapping	O
,	O
we	O
determined	O
that	O
Neanderthals	O
have	O
an	O
osteocalcin	B-Protein
amino	O
acid	O
sequence	O
that	O
is	O
identical	O
to	O
that	O
of	O
modern	O
humans	O
.	O

We	O
also	O
report	O
complete	O
osteocalcin	B-Protein
sequences	O
for	O
chimpanzee	O
(	O
Pan	O
troglodytes	O
)	O
and	O
gorilla	O
(	O
Gorilla	O
gorilla	O
gorilla	O
)	O
and	O
a	O
partial	O
sequence	O
for	O
orangutan	O
(	O
Pongo	O
pygmaeus	O
)	O
,	O
all	O
of	O
which	O
are	O
previously	O
unreported	O
.	O

We	O
found	O
that	O
the	O
osteocalcin	B-Protein
sequences	O
of	O
Neanderthals	O
,	O
modern	O
human	O
,	O
chimpanzee	O
,	O
and	O
orangutan	O
are	O
unusual	O
among	O
mammals	O
in	O
that	O
the	O
ninth	O
amino	O
acid	O
is	O
proline	O
(	O
Pro	O
-	O
9	O
)	O
,	O
whereas	O
most	O
species	O
have	O
hydroxyproline	O
(	O
Hyp	O
-	O
9	O
)	O
.	O

Posttranslational	O
hydroxylation	O
of	O
Pro	O
-	O
9	O
in	O
osteocalcin	B-Protein
by	O
prolyl	O
-	O
4	O
-	O
hydroxylase	O
requires	O
adequate	O
concentrations	O
of	O
vitamin	O
C	O
(	O
l	O
-	O
ascorbic	O
acid	O
)	O
,	O
molecular	O
O	O
(	O
2	O
)	O
,	O
Fe	O
(	O
2	O
+	O
)	O
,	O
and	O
2	O
-	O
oxoglutarate	O
,	O
and	O
also	O
depends	O
on	O
enzyme	O
recognition	O
of	O
the	O
target	O
proline	O
substrate	O
consensus	O
sequence	O
Leu	O
-	O
Gly	O
-	O
Ala	O
-	O
Pro	O
-	O
9	O
-	O
Ala	O
-	O
Pro	O
-	O
Tyr	O
occurring	O
in	O
most	O
mammals	O
.	O

In	O
five	O
species	O
with	O
Pro	O
-	O
9	O
-	O
Val	O
-	O
10	O
,	O
hydroxylation	O
is	O
blocked	O
,	O
whereas	O
in	O
gorilla	O
there	O
is	O
a	O
mixture	O
of	O
Pro	O
-	O
9	O
and	O
Hyp	O
-	O
9	O
.	O

We	O
suggest	O
that	O
the	O
absence	O
of	O
hydroxylation	O
of	O
Pro	O
-	O
9	O
in	O
Pan	O
,	O
Pongo	O
,	O
and	O
Homo	O
may	O
reflect	O
response	O
to	O
a	O
selective	O
pressure	O
related	O
to	O
a	O
decline	O
in	O
vitamin	O
C	O
in	O
the	O
diet	O
during	O
omnivorous	O
dietary	O
adaptation	O
,	O
either	O
independently	O
or	O
through	O
the	O
common	O
ancestor	O
of	O
these	O
species	O
.	O

Relationship	O
between	O
histone	B-Protein
H3	I-Protein
lysine	O
9	O
methylation	O
,	O
transcription	O
repression	O
,	O
and	O
heterochromatin	O
protein	O
1	O
recruitment	O
.	O

Histone	B-Protein
H3	I-Protein
lysine	O
9	O
(	O
H3	B-Protein
-	O
K9	O
)	O
methylation	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
transcriptional	O
repression	O
and	O
serve	O
as	O
a	O
specific	O
binding	O
site	O
for	O
heterochromatin	O
protein	O
1	O
(	O
HP1	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
H3	B-Protein
-	O
K9	O
methylation	O
,	O
transcriptional	O
repression	O
,	O
and	O
HP1	O
recruitment	O
by	O
comparing	O
the	O
effects	O
of	O
tethering	O
two	O
H3	B-Protein
-	O
K9	O
-	O
specific	O
histone	O
methyltransferases	O
,	O
SUV39H1	B-Protein
and	O
G9a	B-Protein
,	O
to	O
chromatin	O
on	O
transcription	O
and	O
HP1	O
recruitment	O
.	O

Although	O
both	O
SUV39H1	B-Protein
and	O
G9a	B-Protein
induced	O
H3	B-Protein
-	O
K9	O
methylation	O
and	O
repressed	O
transcription	O
,	O
only	O
SUV39H1	B-Protein
was	O
able	O
to	O
recruit	O
HP1	O
to	O
chromatin	O
.	O

Targeting	O
HP1	O
to	O
chromatin	O
required	O
not	O
only	O
K9	O
methylation	O
but	O
also	O
a	O
direct	O
protein	O
-	O
protein	O
interaction	O
between	O
SUV39H1	B-Protein
and	O
HP1	O
.	O

Targeting	O
methyl	O
-	O
K9	O
or	O
a	O
HP1	O
-	O
interacting	O
region	O
of	O
SUV39H1	B-Protein
alone	O
to	O
chromatin	O
was	O
not	O
sufficient	O
to	O
recruit	O
HP1	O
.	O

We	O
also	O
demonstrate	O
that	O
methyl	O
-	O
K9	O
can	O
suppress	O
transcription	O
independently	O
of	O
HP1	O
through	O
a	O
mechanism	O
involving	O
histone	B-Protein
deacetylation	O
.	O

In	O
an	O
effort	O
to	O
understand	O
how	O
H3	B-Protein
-	O
K9	O
methylation	O
led	O
to	O
histone	B-Protein
deacetylation	O
in	O
both	O
H3	B-Protein
and	O
H4	B-Protein
,	O
we	O
found	O
that	O
H3	B-Protein
-	O
K9	O
methylation	O
inhibited	O
histone	B-Protein
acetylation	O
by	O
p300	B-Protein
but	O
not	O
its	O
association	O
with	O
chromatin	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
H3	B-Protein
-	O
K9	O
methylation	O
alone	O
can	O
suppress	O
transcription	O
but	O
is	O
insufficient	O
for	O
HP1	O
recruitment	O
in	O
the	O
context	O
of	O
chromatin	O
exemplifying	O
the	O
importance	O
of	O
chromatin	O
-	O
associated	O
factors	O
in	O
reading	O
the	O
histone	B-Protein
code	O
.	O

A	O
simple	O
,	O
sensitive	O
in	O
vitro	O
assay	O
for	O
cytoplasmic	O
deglycosylation	O
by	O
peptide	B-Protein
:	I-Protein
N	I-Protein
-	I-Protein
glycanase	I-Protein
.	O

A	O
cytoplasmic	O
peptide	B-Protein
:	I-Protein
N	I-Protein
-	I-Protein
glycanase	I-Protein
(	O
PNGase	B-Protein
)	O
has	O
been	O
implicated	O
in	O
the	O
proteasomal	O
degradation	O
of	O
aberrant	O
glycoproteins	O
synthesized	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

The	O
reaction	O
is	O
believed	O
to	O
be	O
important	O
for	O
subsequent	O
proteolysis	O
by	O
the	O
proteasome	O
since	O
bulky	O
N	O
-	O
glycan	O
chains	O
on	O
misfolded	O
glycoproteins	O
may	O
impair	O
their	O
efficient	O
entry	O
into	O
the	O
interior	O
of	O
the	O
cylinder	O
-	O
shaped	O
20S	O
proteasome	O
,	O
where	O
its	O
active	O
site	O
resides	O
.	O

This	O
cytoplasmic	O
enzyme	O
was	O
first	O
detected	O
in	O
1993	O
by	O
a	O
simple	O
,	O
sensitive	O
assay	O
method	O
using	O
14C	O
-	O
labeled	O
glycopeptide	O
as	O
a	O
substrate	O
.	O

The	O
deglycosylation	O
reaction	O
by	O
PNGase	B-Protein
brings	O
about	O
two	O
major	O
changes	O
on	O
substrate	O
the	O
peptide	O
;	O
one	O
is	O
removal	O
of	O
the	O
N	O
-	O
glycan	O
chain	O
and	O
the	O
other	O
is	O
the	O
introduction	O
of	O
a	O
negative	O
charge	O
into	O
the	O
core	O
peptide	O
by	O
converting	O
the	O
glycosylated	O
asparagine	O
residue	O
(	O
s	O
)	O
into	O
an	O
aspartic	O
acid	O
residue	O
(	O
s	O
)	O
.	O

The	O
assay	O
method	O
we	O
developed	O
monitors	O
these	O
major	O
changes	O
in	O
the	O
core	O
peptide	O
,	O
and	O
the	O
respective	O
changes	O
were	O
detected	O
by	O
distinct	O
analytical	O
methods	O
:	O
i	O
.	O
e	O
.	O
,	O
paper	O
chromatography	O
and	O
paper	O
electrophoresis	O
.	O

This	O
chapter	O
will	O
describe	O
the	O
simple	O
,	O
sensitive	O
in	O
vitro	O
assay	O
method	O
for	O
PNGase	B-Protein
.	O

In	O
vitro	O
differentiation	O
of	O
human	O
umbilical	O
cord	O
blood	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
into	O
hepatocyte	O
-	O
like	O
cells	O
.	O

In	O
addition	O
to	O
long	O
-	O
term	O
self	O
-	O
renewal	O
capability	O
,	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
possess	O
versatile	O
differentiation	O
potential	O
ranging	O
from	O
mesenchyme	O
-	O
related	O
multipotency	O
to	O
neuroectodermal	O
and	O
endodermal	O
competency	O
.	O

Of	O
particular	O
concern	O
is	O
hepatogenic	O
potential	O
that	O
can	O
be	O
used	O
for	O
liver	O
-	O
directed	O
stem	O
cell	O
therapy	O
and	O
transplantation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
whether	O
human	O
umbilical	O
cord	O
blood	O
(	O
UCB	O
)	O
-	O
derived	O
MSCs	O
are	O
also	O
able	O
to	O
differentiate	O
into	O
hepatocyte	O
-	O
like	O
cells	O
.	O

MSCs	O
isolated	O
from	O
UCB	O
were	O
cultured	O
under	O
the	O
pro	O
-	O
hepatogenic	O
condition	O
similar	O
to	O
that	O
for	O
bone	O
marrow	O
(	O
BM	O
)	O
-	O
derived	O
MSCs	O
.	O

Expression	O
of	O
a	O
variety	O
of	O
hepatic	O
lineage	O
markers	O
was	O
analyzed	O
by	O
flow	O
cytometry	O
,	O
RT	O
-	O
PCR	O
,	O
Western	O
blot	O
,	O
and	O
immunofluorescence	O
.	O

The	O
functionality	O
of	O
differentiated	O
cells	O
was	O
assessed	O
by	O
their	O
ability	O
to	O
incorporate	O
DiI	O
-	O
acetylated	O
low	O
-	O
density	O
lipoprotein	O
(	O
DiI	O
-	O
Ac	O
-	O
LDL	O
)	O
.	O

As	O
the	O
cells	O
were	O
morphologically	O
transformed	O
into	O
hepatocyte	O
-	O
like	O
cells	O
,	O
they	O
expressed	O
Thy	B-Protein
-	I-Protein
1	I-Protein
,	O
c	B-Protein
-	I-Protein
Kit	I-Protein
,	O
and	O
Flt	B-Protein
-	I-Protein
3	I-Protein
at	O
the	O
cell	O
surface	O
,	O
as	O
well	O
as	O
albumin	B-Protein
,	O
alpha	B-Protein
-	I-Protein
fetoprotein	I-Protein
,	O
and	O
cytokeratin	B-Protein
-	I-Protein
18	I-Protein
and	O
19	B-Protein
in	O
the	O
interior	O
.	O

Moreover	O
,	O
about	O
a	O
half	O
of	O
the	O
cells	O
were	O
found	O
to	O
acquire	O
the	O
capability	O
to	O
transport	O
DiI	O
-	O
Ac	O
-	O
LDL	O
.	O

Based	O
on	O
these	O
observations	O
,	O
and	O
taking	O
into	O
account	O
immense	O
advantages	O
of	O
UCB	O
over	O
other	O
stem	O
cell	O
sources	O
,	O
we	O
conclude	O
that	O
UCB	O
-	O
derived	O
MSCs	O
retain	O
hepatogenic	O
potential	O
suitable	O
for	O
cell	O
therapy	O
and	O
transplantation	O
against	O
intractable	O
liver	O
diseases	O
.	O

Small	O
interfering	O
RNAs	O
that	O
trigger	O
posttranscriptional	O
gene	O
silencing	O
are	O
not	O
required	O
for	O
the	O
histone	B-Protein
H3	I-Protein
Lys9	O
methylation	O
necessary	O
for	O
transgenic	O
tandem	O
repeat	O
stabilization	O
in	O
Neurospora	O
crassa	O
.	O

In	O
Neurospora	O
crassa	O
,	O
the	O
introduction	O
of	O
a	O
transgene	O
can	O
lead	O
to	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
-	O
mediated	O
posttranscriptional	O
gene	O
silencing	O
(	O
PTGS	O
)	O
of	O
homologous	O
genes	O
.	O

siRNAs	O
can	O
also	O
guide	O
locus	O
-	O
specific	O
methylation	O
of	O
Lys9	O
of	O
histone	B-Protein
H3	I-Protein
(	O
Lys9H3	B-Protein
)	O
in	O
Schizosaccharomyces	O
pombe	O
.	O

Here	O
we	O
tested	O
the	O
hypothesis	O
that	O
transgenically	O
derived	O
siRNAs	O
may	O
contemporaneously	O
both	O
activate	O
the	O
PTGS	O
mechanism	O
and	O
induce	O
chromatin	O
modifications	O
at	O
the	O
transgene	O
and	O
the	O
homologous	O
endogenous	O
gene	O
.	O

We	O
carried	O
out	O
chromatin	O
immunoprecipitation	O
using	O
a	O
previously	O
characterized	O
albino	B-Protein
-	I-Protein
1	I-Protein
(	O
al	B-Protein
-	I-Protein
1	I-Protein
)	O
silenced	O
strain	O
but	O
detected	O
no	O
alterations	O
in	O
the	O
pattern	O
of	O
histone	B-Protein
modifications	O
at	O
the	O
endogenous	O
al	B-Protein
-	I-Protein
1	I-Protein
locus	O
,	O
suggesting	O
that	O
siRNAs	O
produced	O
from	O
the	O
transgenic	O
locus	O
do	O
not	O
trigger	O
modifications	O
in	O
trans	O
of	O
those	O
histones	B-Protein
tested	O
.	O

Instead	O
,	O
we	O
found	O
that	O
the	O
transgenic	O
locus	O
was	O
hypermethylated	O
at	O
Lys9H3	B-Protein
in	O
our	O
silenced	O
strain	O
and	O
remained	O
hypermethylated	O
in	O
the	O
quelling	O
defective	O
mutants	O
(	O
qde	O
)	O
,	O
further	O
demonstrating	O
that	O
the	O
PTGS	O
machinery	O
is	O
dispensable	O
for	O
Lys9H3	B-Protein
methylation	O
.	O

However	O
,	O
we	O
found	O
that	O
a	O
mutant	O
in	O
the	O
histone	B-Protein
Lys9H3	O
methyltransferase	O
dim	B-Protein
-	I-Protein
5	I-Protein
was	O
unable	O
to	O
maintain	O
PTGS	O
,	O
with	O
transgenic	O
copies	O
being	O
rapidly	O
lost	O
,	O
resulting	O
in	O
reversion	O
of	O
the	O
silenced	O
phenotype	O
.	O

These	O
results	O
indicate	O
that	O
the	O
defect	O
in	O
PTGS	O
of	O
the	O
Deltadim	B-Protein
-	I-Protein
5	I-Protein
strain	O
is	O
due	O
to	O
the	O
inability	O
to	O
maintain	O
the	O
transgene	O
in	O
tandem	O
,	O
suggesting	O
a	O
role	O
for	O
DIM	B-Protein
-	I-Protein
5	I-Protein
in	O
stabilizing	O
such	O
repeated	O
sequences	O
.	O

We	O
conclude	O
that	O
in	O
Neurospora	O
,	O
siRNAs	O
produced	O
from	O
the	O
transgenic	O
locus	O
are	O
used	O
in	O
the	O
RNA	O
-	O
induced	O
silencing	O
complex	O
-	O
mediated	O
PTGS	O
pathway	O
and	O
do	O
not	O
communicate	O
with	O
an	O
RNAi	O
-	O
induced	O
initiation	O
of	O
transcriptional	O
gene	O
silencing	O
complex	O
to	O
effect	O
chromatin	O
-	O
based	O
silencing	O
.	O

A	O
rapid	O
PCR	O
method	O
for	O
genotyping	O
the	O
Large	O
(	O
myd	O
)	O
mouse	O
,	O
a	O
model	O
of	O
glycosylation	O
-	O
deficient	O
congenital	O
muscular	O
dystrophy	O
.	O

The	O
myodystrophy	O
(	O
Large	B-Protein
(	O
myd	O
)	O
)	O
mouse	O
has	O
a	O
spontaneous	O
loss	O
of	O
function	O
mutation	O
in	O
a	O
putative	O
glycosyltransferase	O
gene	O
(	O
Large	O
)	O
.	O

Mutations	O
in	O
the	O
human	O
gene	O
(	O
LARGE	B-Protein
)	O
have	O
been	O
described	O
in	O
congenital	O
muscular	O
dystrophy	O
type	O
1D	O
(	O
MDC1D	O
)	O
.	O

Mutations	O
in	O
four	O
other	O
genes	O
that	O
encode	O
known	O
or	O
putative	O
glycosylation	O
enzymes	O
(	O
POMT1	B-Protein
,	O
POMGnT1	B-Protein
,	O
fukutin	B-Protein
and	O
FKRP	B-Protein
)	O
are	O
also	O
associated	O
with	O
muscular	O
dystrophy	O
.	O

In	O
all	O
these	O
diseases	O
hypoglycosylation	O
of	O
alpha	B-Protein
-	I-Protein
dystroglycan	I-Protein
,	O
and	O
consequent	O
loss	O
of	O
ligand	O
binding	O
,	O
is	O
a	O
common	O
pathomechanism	O
.	O

Currently	O
,	O
the	O
Large	B-Protein
(	O
myd	O
)	O
mouse	O
is	O
the	O
principal	O
animal	O
model	O
for	O
studying	O
the	O
underlying	O
molecular	O
mechanisms	O
of	O
this	O
group	O
of	O
disorders	O
.	O

Over	O
-	O
expression	O
of	O
LARGE	B-Protein
in	O
cells	O
from	O
patients	O
with	O
mutations	O
in	O
POMT1	B-Protein
or	O
POMGnT1	B-Protein
results	O
in	O
hyperglycosylation	O
of	O
alpha	B-Protein
-	I-Protein
dystroglycan	I-Protein
and	O
restoration	O
of	O
laminin	O
binding	O
.	O

Thus	O
,	O
LARGE	B-Protein
is	O
a	O
potential	O
therapeutic	O
target	O
.	O

Here	O
,	O
we	O
define	O
the	O
intronic	O
deletion	O
breakpoints	O
of	O
the	O
Large	B-Protein
(	O
myd	O
)	O
mutation	O
and	O
describe	O
a	O
simple	O
,	O
PCR	O
-	O
based	O
diagnostic	O
assay	O
,	O
facilitating	O
the	O
study	O
of	O
this	O
important	O
animal	O
model	O
.	O

Minoxidil	O
exerts	O
different	O
inhibitory	O
effects	O
on	O
gene	O
expression	O
of	O
lysyl	B-Protein
hydroxylase	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
and	O
3	B-Protein
:	O
implications	O
for	O
collagen	O
cross	O
-	O
linking	O
and	O
treatment	O
of	O
fibrosis	O
.	O

Collagen	O
deposits	O
in	O
fibrotic	O
lesions	O
often	O
display	O
elevated	O
levels	O
of	O
hydroxyallysine	O
(	O
pyridinoline	O
)	O
cross	O
-	O
links	O
.	O

The	O
relation	O
between	O
the	O
occurrence	O
of	O
pyridinoline	O
cross	O
-	O
links	O
and	O
the	O
irreversibility	O
of	O
fibrosis	O
suggests	O
that	O
these	O
cross	O
-	O
links	O
contribute	O
to	O
the	O
aberrant	O
accumulation	O
of	O
collagen	O
.	O

Based	O
on	O
its	O
inhibitory	O
effect	O
on	O
lysyl	O
hydroxylase	O
activity	O
minoxidil	O
has	O
been	O
postulated	O
to	O
possess	O
anti	O
-	O
fibrotic	O
properties	O
by	O
limiting	O
the	O
hydroxylysine	O
supply	O
for	O
hydroxyallysine	O
cross	O
-	O
linking	O
.	O

However	O
,	O
to	O
interfere	O
with	O
hydroxyallysine	O
cross	O
-	O
linking	O
specifically	O
lysyl	O
hydroxylation	O
of	O
the	O
collagen	O
telopeptide	O
should	O
be	O
inhibited	O
,	O
a	O
reaction	O
predominantly	O
catalysed	O
by	O
lysyl	B-Protein
hydroxylase	I-Protein
(	I-Protein
LH	I-Protein
)	I-Protein
2b	I-Protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
minoxidil	O
treatment	O
of	O
cultured	O
fibroblasts	O
reduces	O
LH1	B-Protein
>	O
>	O
LH2b	B-Protein
>	O
LH3	B-Protein
mRNA	O
levels	O
dose	O
-	O
and	O
time	O
-	O
dependently	O
,	O
but	O
has	O
essentially	O
no	O
effect	O
on	O
the	O
total	O
number	O
of	O
pyridinoline	O
cross	O
-	O
links	O
in	O
the	O
collagen	O
matrix	O
.	O

Still	O
the	O
collagen	O
produced	O
in	O
the	O
presence	O
of	O
minoxidil	O
displays	O
some	O
remarkable	O
features	O
:	O
hydroxylation	O
of	O
triple	O
helical	O
lysine	O
residues	O
is	O
reduced	O
to	O
50	O
%	O
and	O
lysylpyridinoline	O
cross	O
-	O
linking	O
is	O
increased	O
at	O
the	O
expense	O
of	O
hydroxylysylpyridinoline	O
cross	O
-	O
linking	O
.	O

These	O
observations	O
can	O
be	O
explained	O
by	O
our	O
finding	O
that	O
LH1	B-Protein
mRNA	O
levels	O
are	O
the	O
most	O
sensitive	O
to	O
minoxidil	O
treatment	O
,	O
corroborating	O
that	O
LH1	B-Protein
has	O
a	O
preference	O
for	O
triple	O
helical	O
lysine	O
residues	O
as	O
substrate	O
.	O

In	O
addition	O
,	O
the	O
non	O
-	O
proportional	O
increase	O
in	O
cross	O
-	O
links	O
(	O
20	O
-	O
fold	O
)	O
with	O
respect	O
to	O
the	O
decrease	O
in	O
lysyl	O
hydroxylation	O
state	O
of	O
the	O
triple	O
helix	O
(	O
2	O
-	O
fold	O
)	O
even	O
suggests	O
that	O
LH1	B-Protein
preferentially	O
hydroxylates	O
triple	O
helical	O
lysine	O
residues	O
at	O
the	O
cross	O
-	O
link	O
positions	O
.	O

We	O
conclude	O
that	O
minoxidil	O
is	O
unlikely	O
to	O
serve	O
as	O
an	O
anti	O
-	O
fibroticum	O
,	O
but	O
confers	O
features	O
to	O
the	O
collagen	O
matrix	O
,	O
which	O
provide	O
insight	O
into	O
the	O
substrate	O
specificity	O
of	O
LH1	B-Protein
.	O

Association	O
of	O
N	O
-	O
glycosylation	O
of	O
apolipoprotein	B-Protein
B	I-Protein
-	I-Protein
100	I-Protein
with	O
plasma	O
cholesterol	O
levels	O
in	O
Watanabe	O
heritable	O
hyperlipidemic	O
rabbits	O
.	O

We	O
have	O
previously	O
demonstrated	O
the	O
heterogeneity	O
of	O
N	O
-	O
linked	O
sugar	O
chains	O
of	O
apolipoprotein	B-Protein
(	I-Protein
apo	I-Protein
)	I-Protein
B	I-Protein
-	I-Protein
100	I-Protein
in	O
Watanabe	O
heritable	O
hyperlipidemic	O
(	O
WHHL	O
)	O
rabbit	O
and	O
fasting	O
Japanese	O
White	O
rabbits	O
(	O
Arteriosclerosis	O
,	O
10	O
(	O
1990	O
)	O
386	O
-	O
393	O
)	O
.	O

To	O
investigate	O
further	O
the	O
role	O
of	O
N	O
-	O
linked	O
sugar	O
chains	O
of	O
apo	B-Protein
B	I-Protein
-	I-Protein
100	I-Protein
in	O
lipid	O
metabolism	O
,	O
we	O
examined	O
the	O
correlation	O
between	O
the	O
N	O
-	O
glycosylation	O
of	O
apo	B-Protein
B	I-Protein
-	I-Protein
100	I-Protein
and	O
serum	O
cholesterol	O
levels	O
in	O
WHHL	O
rabbits	O
.	O

The	O
N	O
-	O
linked	O
sugar	O
chains	O
of	O
apo	B-Protein
B	I-Protein
-	I-Protein
100	I-Protein
were	O
liberated	O
by	O
hydrazinolysis	O
,	O
followed	O
by	O
NaB3H4	O
reduction	O
and	O
were	O
fractionated	O
by	O
paper	O
electrophoresis	O
and	O
BioGel	O
P	O
-	O
4	O
column	O
chromatography	O
.	O

These	O
were	O
found	O
to	O
consist	O
of	O
one	O
neutral	O
(	O
N	O
)	O
and	O
two	O
acidic	O
fractions	O
(	O
A1	O
and	O
A2	O
)	O
.	O

N	O
contained	O
a	O
high	O
mannose	O
type	O
oligosaccharide	O
consisting	O
of	O
Man5	O
.	O
GlcNAc2	O
to	O
Man9	O
.	O
GlcNAc2	O
,	O
while	O
A1	O
and	O
A2	O
contained	O
monosialylated	O
and	O
disialylated	O
complex	O
type	O
oligosaccharides	O
,	O
respectively	O
.	O

The	O
molar	O
ratio	O
varied	O
among	O
the	O
5	O
WHHL	O
rabbits	O
.	O

There	O
was	O
an	O
inverse	O
correlation	O
between	O
the	O
ratio	O
of	O
acidic	O
oligosaccharide	O
fractions	O
(	O
A1	O
+	O
A2	O
)	O
and	O
serum	O
cholesterol	O
levels	O
(	O
r	O
=	O
-	O
0	O
.	O
971	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
in	O
the	O
5	O
WHHL	O
rabbits	O
.	O

These	O
results	O
indicate	O
that	O
the	O
N	O
-	O
glycosylation	O
of	O
apo	B-Protein
B	I-Protein
-	I-Protein
100	I-Protein
is	O
closely	O
related	O
to	O
cholesterol	O
metabolism	O
in	O
WHHL	O
rabbits	O
.	O

Two	O
C	O
-	O
methyl	O
derivatives	O
of	O
[	O
11C	O
]	O
WAY	O
-	O
100635	O
-	O
-	O
effects	O
of	O
an	O
amido	O
alpha	O
-	O
methyl	O
group	O
on	O
metabolism	O
and	O
brain	O
5	B-Protein
-	I-Protein
HT1A	I-Protein
receptor	O
radioligand	O
behavior	O
in	O
monkey	O
.	O

PURPOSE	O
:	O
[	O
carbonyl	O
-	O
11C	O
]	O
N	O
-	O
(	O
2	O
-	O
(	O
1	O
-	O
(	O
4	O
-	O
(	O
2	O
-	O
methoxyphenyl	O
)	O
-	O
piperazinyl	O
)	O
ethyl	O
)	O
-	O
N	O
-	O
pyridinyl	O
)	O
cyclohexanecarboxamide	O
(	O
[	O
carbonyl	O
-	O
11C	O
]	O
WAY	O
-	O
100635	O
)	O
is	O
an	O
effective	O
radioligand	O
for	O
imaging	O
brain	O
5	B-Protein
-	I-Protein
HT1A	I-Protein
receptors	O
with	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

However	O
,	O
this	O
radioligand	O
has	O
some	O
drawbacks	O
for	O
deriving	O
relative	O
regional	O
receptor	O
densities	O
,	O
including	O
rapid	O
metabolism	O
,	O
which	O
acts	O
against	O
accurate	O
definition	O
of	O
an	O
arterial	O
input	O
function	O
for	O
compartmental	O
modeling	O
,	O
and	O
very	O
low	O
nonspecific	O
binding	O
in	O
brain	O
,	O
which	O
detracts	O
from	O
the	O
accuracy	O
of	O
modeling	O
by	O
a	O
simplified	O
reference	O
tissue	O
(	O
cerebellum	O
)	O
approach	O
.	O

Here	O
,	O
in	O
a	O
search	O
for	O
a	O
radioligand	O
that	O
overcomes	O
these	O
limitations	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
introducing	O
a	O
single	O
methyl	O
group	O
at	O
either	O
of	O
the	O
carbon	O
atoms	O
alpha	O
to	O
the	O
amide	O
bond	O
in	O
[	O
11C	O
]	O
WAY	O
-	O
100635	O
.	O

PROCEDURES	O
:	O
Ligands	O
with	O
a	O
methyl	O
group	O
on	O
the	O
alpha	O
carbon	O
of	O
the	O
cyclohexyl	O
group	O
(	O
SWAY	O
)	O
or	O
the	O
alpha	O
carbon	O
of	O
the	O
C2H4	O
linker	O
(	O
(	O
R	O
,	O
S	O
)	O
-	O
JWAY	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
binding	O
affinity	O
and	O
intrinsic	O
activity	O
at	O
5	B-Protein
-	I-Protein
HT1A	I-Protein
receptors	O
.	O

SWAY	O
was	O
labeled	O
with	O
carbon	O
-	O
11	O
(	O
t1	O
/	O
2	O
=	O
20	O
.	O
4	O
minutes	O
;	O
beta	O
+	O
=	O
99	O
.	O
8	O
%	O
)	O
in	O
its	O
O	O
-	O
methyl	O
group	O
and	O
(	O
R	O
,	O
S	O
)	O
-	O
JWAY	O
in	O
its	O
carbonyl	O
group	O
.	O

Each	O
radioligand	O
was	O
evaluated	O
by	O
PET	O
experiments	O
in	O
cynomolgus	O
monkey	O
.	O

RESULTS	O
:	O
SWAY	O
and	O
(	O
R	O
,	O
S	O
)	O
-	O
JWAY	O
were	O
found	O
to	O
be	O
high	O
-	O
affinity	O
antagonists	O
at	O
5	B-Protein
-	I-Protein
HT1A	I-Protein
receptors	O
.	O

After	O
injection	O
of	O
[	O
11C	O
]	O
SWAY	O
into	O
monkey	O
,	O
radioactivity	O
uptake	O
in	O
brain	O
reached	O
a	O
maximum	O
of	O
3	O
%	O
at	O
4	O
.	O
5	O
minutes	O
and	O
decreased	O
to	O
0	O
.	O
7	O
%	O
at	O
72	O
minutes	O
.	O

However	O
,	O
over	O
the	O
time	O
span	O
of	O
the	O
experiment	O
,	O
radioactivity	O
concentrations	O
in	O
5	B-Protein
-	I-Protein
HT1A	I-Protein
receptor	O
-	O
rich	O
brain	O
regions	O
were	O
only	O
fractionally	O
higher	O
than	O
in	O
cerebellum	O
.	O

Radioactivity	O
represented	O
by	O
parent	O
radioligand	O
in	O
plasma	O
was	O
39	O
%	O
at	O
45	O
minutes	O
.	O

After	O
injection	O
of	O
[	O
11C	O
]	O
(	O
R	O
,	O
S	O
)	O
-	O
JWAY	O
alone	O
,	O
radioactivity	O
uptake	O
in	O
brain	O
reached	O
a	O
maximum	O
of	O
4	O
.	O
8	O
%	O
at	O
2	O
.	O
5	O
minutes	O
and	O
decreased	O
to	O
1	O
.	O
2	O
%	O
at	O
90	O
minutes	O
.	O

At	O
this	O
time	O
,	O
radioactivity	O
concentration	O
in	O
5	B-Protein
-	I-Protein
HT1A	I-Protein
receptor	O
-	O
rich	O
brain	O
regions	O
was	O
markedly	O
greater	O
than	O
in	O
cerebellum	O
.	O

In	O
another	O
PET	O
experiment	O
,	O
the	O
monkey	O
was	O
predosed	O
with	O
WAY	O
-	O
100635	O
before	O
[	O
11C	O
]	O
(	O
R	O
,	O
S	O
)	O
-	O
JWAY	O
injection	O
.	O

At	O
90	O
minutes	O
after	O
injection	O
,	O
the	O
ratio	O
of	O
radioactivity	O
in	O
5	B-Protein
-	I-Protein
HT1A	I-Protein
receptor	O
-	O
rich	O
regions	O
to	O
that	O
in	O
cerebellum	O
was	O
reduced	O
to	O
near	O
unity	O
.	O

Radioactivity	O
represented	O
by	O
parent	O
radioligand	O
in	O
plasma	O
was	O
12	O
%	O
at	O
45	O
minutes	O
.	O

CONCLUSIONS	O
:	O
[	O
11C	O
]	O
(	O
R	O
,	O
S	O
)	O
-	O
JWAY	O
,	O
but	O
not	O
[	O
11C	O
]	O
SWAY	O
,	O
gives	O
a	O
sizeable	O
5	B-Protein
-	I-Protein
HT1A	I-Protein
receptor	O
-	O
selective	O
PET	O
signal	O
in	O
monkey	O
.	O

The	O
presence	O
of	O
a	O
C	O
-	O
methyl	O
group	O
adjacent	O
to	O
the	O
amide	O
bond	O
in	O
SWAY	O
or	O
(	O
R	O
,	O
S	O
)	O
-	O
JWAY	O
fails	O
to	O
counter	O
metabolism	O
.	O

Effects	O
of	O
histone	B-Protein
acetylation	O
on	O
sodium	B-Protein
iodide	I-Protein
symporter	I-Protein
promoter	O
and	O
expression	O
of	O
thyroid	O
-	O
specific	O
transcription	O
factors	O
.	O

Inhibitors	O
of	O
histone	B-Protein
deacetylases	O
(	O
HDACs	O
)	O
activate	O
the	O
sodium	B-Protein
iodide	I-Protein
symporter	I-Protein
(	O
NIS	B-Protein
)	O
expression	O
in	O
thyroid	O
tumor	O
cells	O
.	O

In	O
this	O
study	O
,	O
mechanisms	O
accounting	O
for	O
these	O
effects	O
were	O
investigated	O
.	O

Various	O
human	O
thyroid	O
tumor	O
cell	O
lines	O
(	O
ARO	O
,	O
BCPAP	O
,	O
FRO	O
,	O
TPC	O
-	O
1	O
)	O
were	O
treated	O
with	O
the	O
HDAC	O
inhibitors	O
Na	O
butyrate	O
(	O
NaB	O
)	O
and	O
tricostatin	O
A	O
(	O
TSA	O
)	O
,	O
and	O
the	O
effects	O
on	O
the	O
expression	O
of	O
NIS	B-Protein
and	O
several	O
thyroid	O
-	O
specific	O
transcription	O
factors	O
together	O
with	O
the	O
activity	O
of	O
NIS	B-Protein
promoter	O
were	O
evaluated	O
.	O

TSA	O
and	O
NaB	O
increased	O
NIS	B-Protein
mRNA	O
levels	O
in	O
all	O
cell	O
lines	O
.	O

Among	O
thyroid	O
-	O
specific	O
transcription	O
factors	O
,	O
only	O
expression	O
of	O
PAX8	B-Protein
in	O
ARO	O
cells	O
was	O
increased	O
.	O

Down	O
-	O
regulation	O
of	O
thyroid	B-Protein
-	I-Protein
specific	I-Protein
transcription	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
expression	O
was	O
observed	O
in	O
BCPAP	O
and	O
TPC	O
-	O
1	O
cell	O
lines	O
.	O

Thyroid	B-Protein
-	I-Protein
specific	I-Protein
transcription	I-Protein
factor	I-Protein
-	I-Protein
2	I-Protein
mRNA	O
was	O
reduced	O
in	O
FRO	O
,	O
BCPAP	O
,	O
and	O
TPC	O
-	O
1	O
cells	O
.	O

Histone	B-Protein
acetylation	O
had	O
no	O
significant	O
effects	O
on	O
HEX	B-Protein
expression	O
.	O

Altogether	O
,	O
these	O
data	O
indicate	O
that	O
the	O
increase	O
of	O
NIS	B-Protein
expression	O
is	O
not	O
mediated	O
by	O
modification	O
of	O
expression	O
of	O
thyroid	O
-	O
specific	O
transcription	O
factors	O
.	O

Accordingly	O
,	O
in	O
transfection	O
experiments	O
performed	O
in	O
the	O
HeLa	O
cell	O
line	O
(	O
which	O
does	O
not	O
express	O
thyroid	O
-	O
specific	O
transcription	O
factors	O
)	O
,	O
treatment	O
with	O
TSA	O
and	O
NaB	O
increased	O
NIS	B-Protein
promoter	O
activity	O
.	O

Stimulation	O
of	O
NIS	B-Protein
promoter	O
activity	O
was	O
also	O
obtained	O
by	O
overexpressing	O
histone	B-Protein
acetylating	O
proteins	O
pCAF	B-Protein
and	O
p300	B-Protein
in	O
HeLa	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
the	O
HDAC	B-Protein
1	I-Protein
enzyme	O
inhibited	O
basal	O
activity	O
of	O
the	O
NIS	B-Protein
promoter	O
.	O

Effects	O
of	O
TSA	O
and	O
NaB	O
on	O
NIS	B-Protein
expression	O
were	O
also	O
evaluated	O
in	O
nonthyroid	O
cell	O
lines	O
MCF	O
-	O
7	O
,	O
Hep	O
-	O
G2	O
,	O
and	O
SAOS	O
-	O
2	O
.	O

In	O
all	O
cell	O
lines	O
TSA	O
and	O
NaB	O
greatly	O
increased	O
NIS	B-Protein
mRNA	O
levels	O
.	O

We	O
concluded	O
that	O
control	O
of	O
NIS	B-Protein
expression	O
by	O
inhibition	O
of	O
HDAC	O
appears	O
not	O
to	O
be	O
mediated	O
by	O
cell	O
-	O
specific	O
mechanisms	O
,	O
suggesting	O
it	O
as	O
a	O
potential	O
strategy	O
to	O
induce	O
radioiodine	O
sensitivity	O
in	O
different	O
human	O
tumors	O
.	O

Astrocyte	O
-	O
and	O
hepatocyte	O
-	O
specific	O
expression	O
of	O
genes	O
from	O
the	O
distal	O
serpin	O
subcluster	O
at	O
14q32	O
.	O
1	O
associates	O
with	O
tissue	O
-	O
specific	O
chromatin	O
structures	O
.	O

The	O
distal	O
serpin	O
subcluster	O
contains	O
genes	O
encoding	O
alpha1	B-Protein
-	I-Protein
antichymotrypsin	I-Protein
(	O
ACT	B-Protein
)	O
,	O
protein	B-Protein
C	I-Protein
inhibitor	I-Protein
(	O
PCI	B-Protein
)	O
,	O
kallistatin	B-Protein
(	O
KAL	B-Protein
)	O
and	O
the	O
KAL	O
-	O
like	O
protein	O
,	O
which	O
are	O
expressed	O
in	O
hepatocytes	O
,	O
but	O
only	O
the	O
act	B-Protein
gene	O
is	O
expressed	O
in	O
astrocytes	O
.	O

We	O
show	O
here	O
that	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
these	O
genes	O
associates	O
with	O
astrocyte	O
-	O
and	O
hepatocyte	O
-	O
specific	O
chromatin	O
structures	O
.	O

In	O
hepatocytes	O
,	O
we	O
identified	O
12	O
Dnase	B-Protein
I	I-Protein
-	O
hypersensitive	O
sites	O
(	O
DHSs	O
)	O
that	O
were	O
distributed	O
throughout	O
the	O
entire	O
subcluster	O
,	O
with	O
the	O
promoters	O
of	O
expressed	O
genes	O
accessible	O
to	O
restriction	O
enzyme	O
digestion	O
.	O

In	O
astrocytes	O
,	O
only	O
six	O
DHSs	O
were	O
located	O
exclusively	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
act	B-Protein
gene	O
,	O
with	O
its	O
promoter	O
also	O
accessible	O
to	O
restriction	O
enzyme	O
digestion	O
.	O

The	O
acetylation	O
of	O
histone	B-Protein
H3	I-Protein
and	O
H4	B-Protein
was	O
found	O
throughout	O
the	O
subcluster	O
in	O
both	O
cell	O
types	O
but	O
this	O
acetylation	O
did	O
not	O
correlate	O
with	O
the	O
expression	O
pattern	O
of	O
these	O
serpin	O
genes	O
.	O

Analysis	O
of	O
histone	B-Protein
modifications	O
at	O
the	O
promoters	O
of	O
the	O
act	B-Protein
and	O
pci	B-Protein
genes	O
revealed	O
that	O
methylation	O
of	O
histone	B-Protein
H3	I-Protein
on	O
lysine	O
4	O
correlated	O
with	O
their	O
expression	O
pattern	O
in	O
both	O
cell	O
types	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
methyltransferase	O
activity	O
resulted	O
in	O
suppression	O
of	O
ACT	B-Protein
and	O
PCI	B-Protein
mRNA	O
expression	O
.	O

We	O
propose	O
that	O
lysine	O
4	O
methylation	O
of	O
histone	B-Protein
H3	I-Protein
correlates	O
with	O
the	O
tissue	O
-	O
specific	O
expression	O
pattern	O
of	O
these	O
serpin	O
genes	O
.	O

Dual	B-Protein
oxidase	I-Protein
-	I-Protein
2	I-Protein
has	O
an	O
intrinsic	O
Ca2	O
+	O
-	O
dependent	O
H2O2	O
-	O
generating	O
activity	O
.	O

Duox2	B-Protein
(	O
and	O
probably	O
Duox1	B-Protein
)	O
is	O
a	O
glycoflavoprotein	O
involved	O
in	O
thyroid	O
hormone	O
biosynthesis	O
,	O
as	O
the	O
thyroid	O
H2O2	O
generator	O
functionally	O
associated	O
with	O
Tpo	B-Protein
(	O
thyroperoxidase	B-Protein
)	O
.	O

So	O
far	O
,	O
because	O
of	O
the	O
impairment	O
of	O
maturation	O
and	O
of	O
the	O
targeting	O
process	O
,	O
transfecting	O
DUOX	O
into	O
nonthyroid	O
cell	O
lines	O
has	O
not	O
led	O
to	O
the	O
expression	O
of	O
a	O
functional	O
H2O2	O
-	O
generating	O
system	O
at	O
the	O
plasma	O
membrane	O
.	O

For	O
the	O
first	O
time	O
,	O
we	O
investigated	O
the	O
H2O2	O
-	O
generating	O
activity	O
in	O
the	O
particulate	O
fractions	O
from	O
DUOX2	B-Protein
-	O
and	O
DUOX1	B-Protein
-	O
transfected	O
HEK293	O
and	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

The	O
particulate	O
fractions	O
of	O
these	O
cells	O
stably	O
or	O
transiently	O
transfected	O
with	O
human	O
or	O
porcine	O
DUOX	O
cDNA	O
demonstrate	O
a	O
functional	O
NADPH	O
/	O
Ca2	O
+	O
-	O
dependent	O
H2O2	O
-	O
generating	O
activity	O
.	O

The	O
immature	O
Duox	O
proteins	O
had	O
less	O
activity	O
than	O
pig	O
thyrocyte	O
particulate	O
fractions	O
,	O
and	O
their	O
activity	O
depended	O
on	O
their	O
primary	O
structures	O
.	O

Human	O
Duox2	B-Protein
seemed	O
to	O
be	O
more	O
active	O
than	O
human	O
Duox1	B-Protein
but	O
only	O
half	O
as	O
active	O
as	O
its	O
porcine	O
counterpart	O
.	O

TPO	B-Protein
co	O
-	O
transfection	O
produced	O
a	O
slight	O
increase	O
in	O
the	O
enzymatic	O
activity	O
,	O
whereas	O
p22	B-Protein
(	I-Protein
phox	I-Protein
)	I-Protein
,	O
the	O
22	O
-	O
kDa	O
subunit	O
of	O
the	O
leukocyte	O
NADPH	O
oxidase	O
,	O
had	O
no	O
effect	O
.	O

In	O
previous	O
studies	O
on	O
the	O
mechanism	O
of	O
H2O2	O
formation	O
,	O
it	O
was	O
shown	O
that	O
mature	O
thyroid	O
NADPH	O
oxidase	O
does	O
not	O
release	O
O2	O
*	O
-	O
but	O
H2O2	O
.	O

Using	O
a	O
spin	O
-	O
trapping	O
technique	O
combined	O
with	O
electron	O
paramagnetic	O
resonance	O
spectroscopy	O
,	O
we	O
confirmed	O
this	O
result	O
but	O
also	O
demonstrated	O
that	O
the	O
partially	O
glycosylated	O
form	O
of	O
Duox2	B-Protein
,	O
located	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
generates	O
superoxide	O
in	O
a	O
calcium	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
suggest	O
that	O
post	O
-	O
translational	O
modifications	O
during	O
the	O
maturation	O
process	O
of	O
Duox2	B-Protein
could	O
be	O
implicated	O
in	O
the	O
mechanism	O
of	O
H2O2	O
formation	O
by	O
favoring	O
intramolecular	O
superoxide	O
dismutation	O
.	O

The	O
inactivation	O
of	O
bovine	O
cathepsin	B-Protein
B	I-Protein
by	O
novel	O
N	O
-	O
chloro	O
-	O
acetyl	O
-	O
dipeptides	O
:	O
application	O
of	O
the	O
Houghten	O
'	O
tea	O
bag	O
'	O
methodology	O
to	O
inhibitor	O
synthesis	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
N	O
-	O
chloro	O
-	O
acetylated	O
dipeptides	O
were	O
synthesised	O
by	O
the	O
application	O
of	O
Houghten	O
'	O
s	O
methodology	O
of	O
multiple	O
analog	O
peptide	O
syntheses	O
(	O
MAPS	O
)	O
.	O

The	O
peptides	O
,	O
all	O
of	O
which	O
contain	O
a	O
C	O
-	O
terminal	O
free	O
acid	O
,	O
were	O
tested	O
as	O
inactivators	O
of	O
bovine	O
cathepsin	B-Protein
B	I-Protein
,	O
in	O
an	O
attempt	O
at	O
exploiting	O
the	O
known	O
and	O
,	O
amongst	O
the	O
cysteine	O
proteinases	O
,	O
unique	O
carboxy	O
dipeptidyl	O
peptidase	O
activity	O
of	O
the	O
protease	O
.	O

We	O
have	O
succeeded	O
in	O
obtaining	O
a	O
number	O
of	O
effective	O
inactivators	O
,	O
the	O
most	O
potent	O
of	O
which	O
-	O
chloroacetyl	O
-	O
Leu	O
-	O
Leu	O
-	O
OH	O
,	O
inactivates	O
the	O
enzyme	O
with	O
an	O
apparent	O
second	O
-	O
order	O
rate	O
constant	O
of	O
3	O
.	O
8	O
x	O
10	O
(	O
4	O
)	O
M	O
(	O
-	O
1	O
)	O
min	O
(	O
-	O
1	O
)	O
.	O

In	O
contrast	O
,	O
the	O
esterified	O
analog	O
,	O
chloroacetyl	O
-	O
Leu	O
-	O
Leu	O
-	O
OMe	O
,	O
inactivates	O
the	O
enzyme	O
some	O
three	O
orders	O
of	O
magnitude	O
less	O
efficiently	O
,	O
lending	O
credence	O
to	O
our	O
thesis	O
that	O
a	O
free	O
carboxylic	O
acid	O
moiety	O
is	O
an	O
important	O
determinant	O
for	O
inhibitor	O
effectiveness	O
.	O

This	O
preliminary	O
study	O
has	O
highlighted	O
a	O
number	O
of	O
interesting	O
features	O
about	O
the	O
specificity	O
requirements	O
of	O
the	O
bovine	O
proteinase	O
and	O
we	O
believe	O
that	O
our	O
approach	O
has	O
great	O
potential	O
for	O
the	O
rapid	O
delineation	O
of	O
the	O
subsite	O
specificities	O
of	O
cathepsin	B-Protein
B	I-Protein
-	O
like	O
proteases	O
from	O
various	O
species	O
.	O

Epigenetic	O
-	O
mediated	O
upregulation	O
of	O
progesterone	B-Protein
receptor	I-Protein
B	I-Protein
gene	O
in	O
endometrial	O
cancer	O
cell	O
lines	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
if	O
epigenetic	O
interference	O
can	O
restore	O
progesterone	B-Protein
receptor	I-Protein
-	I-Protein
B	I-Protein
(	O
PR	B-Protein
-	I-Protein
B	I-Protein
)	O
expression	O
in	O
PR	B-Protein
-	I-Protein
B	I-Protein
negative	O
endometrial	O
adenocarcinoma	O
cell	O
lines	O
,	O
and	O
to	O
characterize	O
the	O
kinetics	O
of	O
PR	B-Protein
-	I-Protein
B	I-Protein
induction	O
mediated	O
by	O
DNA	O
methyltransferase	O
and	O
histone	B-Protein
deacetylase	O
inhibitors	O
.	O

METHODS	O
:	O
The	O
PR	B-Protein
-	I-Protein
B	I-Protein
negative	O
endometrioid	O
cancer	O
cell	O
lines	O
KLE	O
and	O
HEC	O
-	O
1B	O
were	O
used	O
as	O
study	O
models	O
.	O

PR	B-Protein
-	I-Protein
B	I-Protein
mRNA	O
and	O
protein	O
expression	O
levels	O
were	O
measured	O
using	O
real	O
-	O
time	O
PCR	O
and	O
Western	O
blot	O
analysis	O
,	O
respectively	O
.	O

DNA	O
methylation	O
levels	O
of	O
the	O
PR	B-Protein
-	I-Protein
B	I-Protein
promoter	O
were	O
determined	O
by	O
methylation	O
-	O
specific	O
PCR	O
.	O

Dose	O
-	O
response	O
correlations	O
and	O
the	O
duration	O
of	O
response	O
to	O
aza	O
-	O
deoxycytidine	O
(	O
ADC	O
)	O
and	O
trichostatin	O
A	O
(	O
TSA	O
)	O
were	O
characterized	O
.	O

Cell	O
responses	O
to	O
prolonged	O
and	O
repeated	O
drug	O
treatment	O
were	O
also	O
examined	O
.	O

RESULTS	O
:	O
Relatively	O
low	O
concentrations	O
of	O
ADC	O
and	O
TSA	O
over	O
a	O
24	O
-	O
h	O
period	O
induced	O
PR	B-Protein
-	I-Protein
B	I-Protein
expression	O
.	O

Furthermore	O
,	O
ADC	O
and	O
TSA	O
acted	O
synergistically	O
to	O
reactivate	O
PR	B-Protein
-	I-Protein
B	I-Protein
expression	O
.	O

Depending	O
on	O
the	O
cell	O
line	O
used	O
,	O
PR	B-Protein
-	I-Protein
B	I-Protein
mRNA	O
was	O
induced	O
10	O
-	O
110	O
fold	O
.	O

This	O
elevated	O
PR	B-Protein
-	I-Protein
B	I-Protein
expression	O
continued	O
for	O
48	O
h	O
after	O
drug	O
withdrawal	O
.	O

Sustained	O
upregulation	O
of	O
PR	B-Protein
-	I-Protein
B	I-Protein
mRNA	O
and	O
protein	O
was	O
observed	O
during	O
prolonged	O
and	O
repeated	O
drug	O
treatment	O
.	O

CONCLUSION	O
:	O
The	O
epigenetically	O
silenced	O
PR	B-Protein
-	I-Protein
B	I-Protein
gene	O
remains	O
sensitive	O
to	O
changes	O
in	O
DNA	O
demethylation	O
and	O
histone	B-Protein
acetylation	O
in	O
uterine	O
adenocarcinoma	O
cell	O
lines	O
.	O

Treatment	O
with	O
ADC	O
and	O
/	O
or	O
TSA	O
results	O
in	O
a	O
robust	O
and	O
sustainable	O
PR	B-Protein
-	I-Protein
B	I-Protein
upregulation	O
.	O

These	O
small	O
molecule	O
epigenetic	O
modifying	O
agents	O
may	O
be	O
used	O
to	O
sensitize	O
poorly	O
differentiated	O
,	O
PR	B-Protein
-	I-Protein
B	I-Protein
negative	O
endometrial	O
cancers	O
to	O
progestational	O
therapy	O
.	O

Differential	O
analysis	O
of	O
site	O
-	O
specific	O
glycans	O
on	O
plasma	O
and	O
cellular	O
fibronectins	B-Protein
:	O
application	O
of	O
a	O
hydrophilic	O
affinity	O
method	O
for	O
glycopeptide	O
enrichment	O
.	O

Isolation	O
of	O
glycopeptides	O
utilizing	O
hydrogen	O
bonding	O
between	O
glycopeptide	O
glycans	O
and	O
a	O
carbohydrate	O
-	O
gel	O
matrix	O
in	O
the	O
organic	O
phase	O
is	O
useful	O
for	O
site	O
-	O
specific	O
characterization	O
of	O
oligosaccharides	O
of	O
glycoproteins	O
,	O
when	O
combined	O
with	O
mass	O
spectrometry	O
.	O

In	O
this	O
study	O
,	O
recovery	O
of	O
glycopeptides	O
was	O
improved	O
by	O
including	O
divalent	O
cations	O
or	O
increasing	O
the	O
organic	O
solvent	O
in	O
the	O
binding	O
solution	O
,	O
without	O
losing	O
specificity	O
,	O
whereas	O
it	O
was	O
still	O
less	O
effective	O
for	O
those	O
with	O
a	O
long	O
peptide	O
backbone	O
exceeding	O
50	O
amino	O
acid	O
residues	O
.	O

The	O
method	O
was	O
then	O
applied	O
to	O
the	O
analysis	O
of	O
glycan	O
heterogeneities	O
at	O
seven	O
N	O
-	O
glycosylation	O
sites	O
in	O
each	O
of	O
the	O
plasma	O
and	O
cellular	O
fibronectins	B-Protein
(	O
FNs	B-Protein
)	O
.	O

There	O
was	O
a	O
remarkable	O
site	O
-	O
specific	O
difference	O
in	O
fucosylation	O
between	O
these	O
isoforms	O
;	O
Asn1244	O
selectively	O
escaped	O
the	O
global	O
fucosylation	O
of	O
cellular	O
FN	B-Protein
,	O
whereas	O
only	O
Asn1007	O
and	O
Asn2108	O
of	O
the	O
plasma	O
isoform	O
underwent	O
modification	O
.	O

In	O
addition	O
,	O
a	O
new	O
O	O
-	O
glycosylation	O
site	O
was	O
identified	O
at	O
Thr279	O
in	O
the	O
connecting	O
segment	O
between	O
the	O
fibrin	O
-	O
and	O
heparin	O
-	O
binding	O
domain	O
and	O
the	O
collagen	O
-	O
binding	O
domain	O
,	O
and	O
the	O
glycopeptide	O
was	O
reactive	O
to	O
a	O
peanut	O
agglutinin	B-Protein
lectin	O
.	O

Considering	O
that	O
another	O
mucin	O
-	O
type	O
O	O
-	O
glycosylation	O
site	O
lies	O
within	O
a	O
different	O
connecting	O
segment	O
,	O
the	O
O	O
-	O
glycosylation	O
of	O
FN	B-Protein
was	O
suggested	O
to	O
play	O
a	O
significant	O
role	O
in	O
segregating	O
the	O
neighboring	O
domains	O
and	O
thus	O
maintaining	O
the	O
topology	O
of	O
FN	B-Protein
and	O
the	O
domain	O
functions	O
.	O

In	O
addition	O
,	O
the	O
method	O
was	O
applied	O
to	O
apolipoprotein	B-Protein
B	I-Protein
-	I-Protein
100	I-Protein
(	O
apoB100	B-Protein
)	O
whose	O
N	O
-	O
glycan	O
structures	O
at	O
17	O
of	O
19	O
potential	O
sites	O
have	O
been	O
reported	O
,	O
and	O
characterized	O
the	O
remaining	O
sites	O
.	O

The	O
results	O
also	O
demonstrated	O
that	O
the	O
enriched	O
glycopeptide	O
provides	O
resources	O
for	O
site	O
-	O
specific	O
analysis	O
of	O
oligosaccharides	O
in	O
glycoproteomics	O
.	O

Histone	B-Protein
acetylation	O
,	O
chromatin	O
remodelling	O
and	O
nucleotide	O
excision	O
repair	O
:	O
hint	O
from	O
the	O
study	O
on	O
MFA2	B-Protein
in	O
Saccharomyces	O
cerevisiae	O
.	O

Nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
is	O
a	O
sophisticated	O
repair	O
pathway	O
that	O
the	O
cell	O
utilizes	O
to	O
remove	O
a	O
broad	O
range	O
of	O
DNA	O
damage	O
to	O
help	O
maintain	O
the	O
functional	O
integrity	O
of	O
the	O
genome	O
.	O

In	O
the	O
context	O
of	O
DNA	O
packaged	O
into	O
chromosomes	O
it	O
is	O
clear	O
that	O
the	O
NER	O
machinery	O
does	O
not	O
repair	O
all	O
regions	O
with	O
equal	O
efficiency	O
.	O

Recently	O
,	O
we	O
found	O
after	O
UV	O
that	O
histone	B-Protein
acetylation	O
and	O
chromatin	O
remodelling	O
were	O
activated	O
.	O

UV	O
irradiation	O
triggers	O
genome	O
-	O
wide	O
histone	B-Protein
hyperacetylation	O
at	O
both	O
histone	B-Protein
H3	I-Protein
and	O
H4	B-Protein
.	O

However	O
,	O
in	O
nucleosomes	O
at	O
the	O
repressed	O
MFA2	B-Protein
promoter	O
only	O
histone	B-Protein
H3	I-Protein
,	O
but	O
not	O
histone	B-Protein
H4	I-Protein
,	O
is	O
hyperacetylated	O
following	O
UV	O
.	O

This	O
Gcn5p	B-Protein
-	O
mediated	O
histone	B-Protein
H3	I-Protein
hyperacetylation	O
enables	O
efficient	O
NER	O
at	O
MFA2	B-Protein
.	O

Chromatin	O
in	O
this	O
promoter	O
also	O
becomes	O
more	O
accessible	O
after	O
UV	O
.	O

This	O
is	O
not	O
dependent	O
on	O
Gcn5p	B-Protein
,	O
yet	O
it	O
is	O
partially	O
dependent	O
on	O
Swi2p	B-Protein
.	O

In	O
later	O
repair	O
times	O
both	O
events	O
gradually	O
return	O
to	O
the	O
pre	O
-	O
UV	O
state	O
.	O

The	O
post	O
-	O
UV	O
histone	B-Protein
modifications	O
and	O
chromatin	O
remodelling	O
at	O
the	O
repressed	O
MFA2	B-Protein
promoter	O
do	O
not	O
activate	O
MFA2	B-Protein
transcription	O
,	O
nor	O
do	O
they	O
require	O
damage	O
recognition	O
by	O
Rad4p	B-Protein
or	O
Rad14p	B-Protein
.	O

These	O
experiments	O
indicate	O
early	O
events	O
are	O
triggered	O
in	O
chromatin	O
in	O
response	O
to	O
UV	O
treatment	O
,	O
and	O
they	O
are	O
likely	O
needed	O
for	O
efficient	O
NER	O
.	O

Peptide	O
mass	O
mapping	O
of	O
acetylated	O
isoforms	O
of	O
histone	B-Protein
H4	I-Protein
from	O
mouse	O
lymphosarcoma	O
cells	O
treated	O
with	O
histone	B-Protein
deacetylase	O
(	O
HDACs	O
)	O
inhibitors	O
.	O

The	O
acetylated	O
isoforms	O
of	O
histone	B-Protein
H4	I-Protein
from	O
mouse	O
lymphosarcoma	O
cells	O
treated	O
with	O
HDAC	O
inhibitors	O
trichostatin	O
A	O
(	O
TSA	O
)	O
and	O
depsipeptide	O
(	O
DDP	O
)	O
were	O
separated	O
by	O
acetic	O
acid	O
urea	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
AU	O
-	O
PAGE	O
)	O
,	O
in	O
-	O
gel	O
digested	O
,	O
and	O
analyzed	O
by	O
matrix	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
MS	O
)	O
and	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
.	O

The	O
acetylation	O
pattern	O
of	O
histone	B-Protein
H4	I-Protein
in	O
mouse	O
lymphosarcoma	O
cells	O
induced	O
by	O
TSA	O
was	O
established	O
in	O
which	O
acetylation	O
initially	O
occurred	O
at	O
K16	O
followed	O
by	O
K12	O
and	O
then	O
K8	O
and	O
/	O
or	O
K5	O
.	O

An	O
identical	O
order	O
of	O
acetylation	O
was	O
found	O
for	O
cells	O
treated	O
with	O
DDP	O
.	O

ST6GalNAc	B-Protein
I	I-Protein
expression	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cells	O
greatly	O
modifies	O
their	O
O	O
-	O
glycosylation	O
pattern	O
and	O
enhances	O
their	O
tumourigenicity	O
.	O

Sialyl	O
-	O
Tn	O
is	O
a	O
carbohydrate	O
antigen	O
overexpressed	O
in	O
several	O
epithelial	O
cancers	O
,	O
including	O
breast	O
cancer	O
,	O
and	O
usually	O
associated	O
with	O
poor	O
prognosis	O
.	O

Sialyl	O
-	O
Tn	O
is	O
synthesized	O
by	O
a	O
CMP	O
-	O
Neu5Ac	O
:	O
GalNAcalpha2	O
,	O
6	O
-	O
sialyltransferase	O
:	O
CMP	O
-	O
Neu5Ac	O
:	O
R	O
-	O
GalNAcalpha1	O
-	O
O	O
-	O
Ser	O
/	O
Thr	O
alpha2	O
,	O
6	O
-	O
sialyltransferase	O
(	O
EC	O
2	O
.	O
4	O
.	O
99	O
.	O
3	O
)	O
(	O
ST6GalNAc	B-Protein
I	I-Protein
)	O
,	O
which	O
transfers	O
a	O
sialic	O
acid	O
residue	O
in	O
alpha2	O
,	O
6	O
-	O
linkage	O
to	O
the	O
GalNAcalpha1	O
-	O
O	O
-	O
Ser	O
/	O
Thr	O
structure	O
.	O

However	O
,	O
established	O
breast	O
cancer	O
cell	O
lines	O
express	O
neither	O
ST6GalNAc	B-Protein
I	I-Protein
nor	O
sialyl	O
-	O
Tn	O
.	O

We	O
have	O
previously	O
shown	O
that	O
stable	O
transfection	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
a	O
human	O
breast	O
cancer	O
cell	O
line	O
,	O
with	O
ST6GalNAc	B-Protein
I	I-Protein
cDNA	O
induces	O
sialyl	O
-	O
Tn	O
antigen	O
(	O
STn	O
)	O
expression	O
.	O

We	O
report	O
here	O
the	O
modifications	O
of	O
the	O
O	O
-	O
glycosylation	O
pattern	O
of	O
a	O
MUC1	B-Protein
-	O
related	O
recombinant	O
protein	O
secreted	O
by	O
MDA	O
-	O
MB	O
-	O
231	O
sialyl	O
-	O
Tn	O
positive	O
cells	O
.	O

We	O
also	O
show	O
that	O
sialyl	O
-	O
Tn	O
expression	O
and	O
concomitant	O
changes	O
in	O
the	O
overall	O
O	O
-	O
glycan	O
profiles	O
induce	O
a	O
decrease	O
of	O
adhesion	O
and	O
an	O
increase	O
of	O
migration	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
.	O

Moreover	O
,	O
STn	O
positive	O
clones	O
exhibit	O
an	O
increased	O
tumour	O
growth	O
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
.	O

These	O
observations	O
suggest	O
that	O
modification	O
of	O
the	O
O	O
-	O
glycosylation	O
pattern	O
induced	O
by	O
ST6GalNAc	B-Protein
I	I-Protein
expression	O
are	O
sufficient	O
to	O
enhance	O
the	O
tumourigenicity	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cells	O
.	O

NO	O
restores	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
hydroxylation	O
during	O
hypoxia	O
:	O
role	O
of	O
reactive	O
oxygen	O
species	O
.	O

The	O
activity	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
(	O
HIF	O
-	O
1	O
)	O
is	O
primarily	O
determined	O
by	O
stability	O
regulation	O
of	O
its	O
alpha	O
subunit	O
,	O
which	O
is	O
stabilized	O
under	O
hypoxia	O
but	O
degraded	O
during	O
normoxia	O
.	O

Hydroxylation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
by	O
prolyl	O
hydroxylases	O
(	O
PHDs	O
)	O
recruits	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	O
pVHL	B-Protein
)	O
E3	O
ubiquitin	B-Protein
ligase	O
complex	O
to	O
initiate	O
proteolytic	O
destruction	O
of	O
the	O
alpha	O
subunit	O
.	O

Hypoxic	O
stabilization	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
has	O
been	O
reported	O
to	O
be	O
antagonized	O
by	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O

By	O
using	O
a	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
-	O
pVHL	B-Protein
binding	O
assay	O
,	O
we	O
show	O
that	O
NO	O
released	O
from	O
DETA	O
-	O
NO	O
restored	O
prolyl	O
hydroxylase	O
activity	O
under	O
hypoxia	O
.	O

Destabilization	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
by	O
DETA	O
-	O
NO	O
was	O
reversed	O
by	O
free	O
radical	O
scavengers	O
such	O
as	O
NAC	O
and	O
Tiron	O
,	O
thus	O
pointing	O
to	O
the	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
ROS	O
on	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
stabilization	O
.	O

Treatment	O
of	O
cells	O
under	O
hypoxia	O
with	O
low	O
concentrations	O
of	O
the	O
superoxide	O
generator	O
2	O
,	O
3	O
-	O
dimethoxy	O
-	O
1	O
,	O
4	O
-	O
naphthoquinone	O
lowered	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
protein	O
stabilization	O
.	O

In	O
vitro	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
-	O
pVHL	B-Protein
interaction	O
assays	O
demonstrated	O
that	O
low	O
-	O
level	O
ROS	O
formation	O
increased	O
prolyl	O
hydroxylase	O
activity	O
,	O
an	O
effect	O
antagonized	O
by	O
ROS	O
scavengers	O
.	O

While	O
determining	O
intracellular	O
ROS	O
formation	O
we	O
noticed	O
that	O
reduced	O
ROS	O
production	O
under	O
hypoxia	O
was	O
restored	O
by	O
the	O
addition	O
of	O
DETA	O
-	O
NO	O
.	O

We	O
propose	O
that	O
an	O
increase	O
in	O
ROS	O
formation	O
contributes	O
to	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
destabilization	O
by	O
NO	O
donors	O
under	O
hypoxia	O
via	O
modulation	O
of	O
PHD	O
activity	O
.	O

Functional	O
relevance	O
of	O
ceruloplasmin	B-Protein
mutations	O
in	O
Parkinson	O
'	O
s	O
disease	O
.	O

Increased	O
iron	O
levels	O
of	O
the	O
substantia	O
nigra	O
and	O
the	O
discovery	O
of	O
ceruloplasmin	B-Protein
mutations	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
imply	O
impaired	O
iron	O
metabolism	O
in	O
this	O
neurodegenerative	O
disorder	O
.	O

Ceruloplasmin	B-Protein
has	O
ferroxidase	O
activity	O
oxidizing	O
iron	O
(	O
II	O
)	O
to	O
iron	O
(	O
III	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
amount	O
of	O
ceruloplasmin	B-Protein
,	O
iron	O
,	O
ferritin	B-Protein
,	O
and	O
transferrin	B-Protein
and	O
the	O
ceruloplasmin	B-Protein
ferroxidase	O
activity	O
in	O
serum	O
of	O
patients	O
with	O
the	O
diagnosis	O
of	O
PD	O
carrying	O
the	O
ceruloplasmin	B-Protein
mutations	O
I63T	O
,	O
D544E	O
,	O
and	O
R793H	O
.	O

The	O
impact	O
of	O
these	O
missense	O
mutations	O
on	O
the	O
biosynthesis	O
of	O
holo	O
-	O
ceruloplasmin	B-Protein
was	O
investigated	O
in	O
cell	O
culture	O
experiments	O
.	O

Functional	O
relevance	O
was	O
found	O
for	O
the	O
ceruloplasmin	B-Protein
mutations	O
I63T	O
and	O
D544E	O
.	O

In	O
vivo	O
,	O
the	O
I63T	O
mutation	O
resulted	O
in	O
half	O
the	O
normal	O
ceruloplasmin	B-Protein
concentration	O
and	O
markedly	O
reduced	O
ferroxidase	O
activity	O
in	O
serum	O
from	O
a	O
heteroallelic	O
PD	O
patient	O
.	O

In	O
cell	O
culture	O
,	O
the	O
I63T	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-	O
linked	O
ceruloplasmin	B-Protein
isoform	O
was	O
retained	O
in	O
the	O
endoplasmatic	O
reticulum	O
of	O
human	O
embryonic	O
kidney	O
cells	O
.	O

Furthermore	O
,	O
the	O
D544E	O
polymorphism	O
resulted	O
in	O
significantly	O
reduced	O
serum	O
ceruloplasmin	B-Protein
levels	O
and	O
ferroxidase	O
activity	O
in	O
heteroallelic	O
patients	O
and	O
in	O
expression	O
of	O
mainly	O
apo	O
-	O
ceruloplasmin	B-Protein
in	O
cell	O
culture	O
.	O

Our	O
studies	O
indicate	O
that	O
altered	O
activity	O
of	O
ceruloplasmin	B-Protein
may	O
present	O
a	O
vulnerability	O
factor	O
for	O
iron	O
induced	O
oxidative	O
stress	O
in	O
PD	O
.	O

A	O
fluorescence	O
polarization	O
-	O
based	O
interaction	O
assay	O
for	O
hypoxia	O
-	O
inducible	O
factor	O
prolyl	O
hydroxylases	O
.	O

Oxygen	O
-	O
dependent	O
ubiquitination	O
and	O
degradation	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
plays	O
a	O
central	O
role	O
in	O
regulating	O
transcriptional	O
responses	O
to	O
hypoxia	O
.	O

This	O
process	O
requires	O
hydroxylation	O
of	O
specific	O
prolines	O
in	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
by	O
HIF	O
prolyl	O
hydroxylase	O
domain	O
(	O
PHD	O
)	O
-	O
containing	O
enzymes	O
,	O
leading	O
to	O
its	O
specific	O
interactions	O
with	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
protein	O
-	O
Elongin	B-Protein
B	I-Protein
-	O
Elongin	B-Protein
C	I-Protein
(	O
VBC	O
)	O
.	O

Here	O
we	O
describe	O
a	O
straightforward	O
approach	O
to	O
apply	O
these	O
interactions	O
to	O
measure	O
PHD	O
activities	O
.	O

Employing	O
fluorescently	O
labeled	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
peptides	O
containing	O
hydroxyproline	O
,	O
we	O
developed	O
a	O
quantitative	O
method	O
based	O
on	O
fluorescence	O
polarization	O
for	O
a	O
systematic	O
evaluation	O
of	O
binding	O
of	O
hydroxylated	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
to	O
recombinant	O
VBC	O
.	O

The	O
method	O
was	O
then	O
successfully	O
utilized	O
for	O
measuring	O
the	O
activity	O
of	O
the	O
truncated	O
,	O
purified	O
PHD2	B-Protein
.	O

The	O
applicability	O
of	O
the	O
assay	O
was	O
further	O
demonstrated	O
by	O
examining	O
effects	O
of	O
various	O
cofactors	O
and	O
inhibitors	O
for	O
PHD2	B-Protein
.	O

The	O
developed	O
homogeneous	O
assay	O
would	O
provide	O
a	O
convenient	O
way	O
of	O
probing	O
the	O
biochemical	O
properties	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
-	O
VBC	O
interaction	O
and	O
PHDs	O
,	O
and	O
of	O
screening	O
modulators	O
for	O
the	O
interaction	O
as	O
well	O
as	O
the	O
enzyme	O
.	O

Protein	O
acetylation	O
regulates	O
both	O
PU	B-Protein
.	I-Protein
1	I-Protein
transactivation	O
and	O
Ig	B-Protein
kappa	I-Protein
3	O
'	O
enhancer	O
activity	O
.	O

Igkappa	B-Protein
gene	O
expression	O
and	O
chromatin	O
structure	O
change	O
during	O
B	O
cell	O
development	O
.	O

At	O
the	O
pre	O
-	O
B	O
cell	O
stage	O
,	O
the	O
locus	O
is	O
relatively	O
hypoacetylated	O
on	O
histone	B-Protein
H3	I-Protein
,	O
whereas	O
it	O
is	O
hyperacetylated	O
at	O
the	O
plasma	O
cell	O
stage	O
.	O

We	O
find	O
in	O
this	O
study	O
that	O
the	O
histone	B-Protein
deacetylase	O
inhibitor	O
,	O
trichostatin	O
A	O
(	O
TSA	O
)	O
stimulated	O
3	O
'	O
enhancer	O
activity	O
through	O
the	O
PU	B-Protein
.	I-Protein
1	I-Protein
binding	O
site	O
.	O

TSA	O
also	O
stimulated	O
PU	B-Protein
.	I-Protein
1	I-Protein
transactivation	O
potential	O
.	O

PU	B-Protein
.	I-Protein
1	I-Protein
activity	O
was	O
increased	O
by	O
the	O
coactivator	O
acetyltransferase	O
protein	O
,	O
p300	B-Protein
,	O
and	O
p300	B-Protein
physically	O
interacted	O
with	O
PU	B-Protein
.	I-Protein
1	I-Protein
residues	O
7	O
-	O
30	O
.	O

PU	B-Protein
.	I-Protein
1	I-Protein
served	O
as	O
a	O
substrate	O
for	O
p300	B-Protein
and	O
was	O
acetylated	O
on	O
lysine	O
residues	O
170	O
,	O
171	O
,	O
206	O
,	O
and	O
208	O
.	O

Mutation	O
of	O
PU	B-Protein
.	I-Protein
1	I-Protein
lysines	O
170	O
and	O
171	O
did	O
not	O
affect	O
PU	B-Protein
.	I-Protein
1	I-Protein
DNA	O
binding	O
,	O
but	O
did	O
lower	O
the	O
ability	O
of	O
PU	B-Protein
.	I-Protein
1	I-Protein
to	O
activate	O
transcription	O
in	O
association	O
with	O
p300	B-Protein
.	O

Lysine	O
170	O
was	O
acetylated	O
in	O
pre	O
-	O
B	O
cells	O
and	O
plasmacytoma	O
cells	O
,	O
but	O
TSA	O
treatment	O
did	O
not	O
stimulate	O
PU	B-Protein
.	I-Protein
1	I-Protein
acetylation	O
at	O
this	O
residue	O
arguing	O
that	O
a	O
second	O
mechanism	O
can	O
stimulate	O
3	O
'	O
enhancer	O
activity	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
assays	O
we	O
found	O
that	O
TSA	O
caused	O
preferential	O
acetylation	O
of	O
histone	B-Protein
H3	I-Protein
at	O
the	O
3	O
'	O
enhancer	O
.	O

The	O
relevance	O
of	O
these	O
studies	O
for	O
PU	B-Protein
.	I-Protein
1	I-Protein
function	O
in	O
transcription	O
and	O
hemopoietic	O
development	O
is	O
discussed	O
.	O

Dual	O
promoters	O
control	O
the	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
human	O
cell	B-Protein
death	I-Protein
-	I-Protein
inducing	I-Protein
DFF45	I-Protein
-	I-Protein
like	I-Protein
effector	I-Protein
B	I-Protein
gene	O
.	O

CIDE	B-Protein
-	I-Protein
B	I-Protein
[	O
cell	B-Protein
death	I-Protein
-	I-Protein
inducing	I-Protein
DFF45	I-Protein
(	I-Protein
DNA	I-Protein
fragmentation	I-Protein
factor	I-Protein
45	I-Protein
)	I-Protein
-	I-Protein
like	I-Protein
effector	I-Protein
B	I-Protein
]	O
is	O
a	O
member	O
of	O
the	O
CIDE	O
family	O
of	O
apoptosis	O
-	O
inducing	O
factors	O
.	O

The	O
highly	O
restricted	O
pattern	O
of	O
expression	O
of	O
CIDE	B-Protein
-	I-Protein
B	I-Protein
in	O
the	O
liver	O
and	O
spleen	O
suggests	O
that	O
a	O
mechanism	O
exists	O
for	O
the	O
tissue	O
-	O
and	O
cell	O
-	O
specific	O
regulation	O
of	O
transcription	O
of	O
this	O
gene	O
.	O

We	O
have	O
analysed	O
the	O
promoters	O
of	O
the	O
human	O
CIDE	B-Protein
-	I-Protein
B	O
gene	O
,	O
particularly	O
the	O
mechanism	O
of	O
cell	O
-	O
specific	O
transcription	O
.	O

Expression	O
of	O
CIDE	B-Protein
-	I-Protein
B	I-Protein
is	O
driven	O
by	O
two	O
promoters	O
which	O
are	O
responsible	O
for	O
the	O
synthesis	O
of	O
two	O
types	O
of	O
transcript	O
,	O
and	O
Sp1	B-Protein
and	O
Sp3	B-Protein
are	O
key	O
regulators	O
of	O
basal	O
transcription	O
from	O
both	O
the	O
upstream	O
and	O
the	O
internal	O
promoter	O
,	O
as	O
indicated	O
by	O
EMSAs	O
(	O
electrophoretic	O
mobility	O
-	O
shift	O
assays	O
)	O
and	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Bisulphite	O
sequencing	O
analysis	O
demonstrated	O
that	O
the	O
upstream	O
promoter	O
was	O
hypermethylated	O
in	O
cells	O
that	O
did	O
not	O
express	O
the	O
long	O
transcript	O
of	O
CIDE	B-Protein
-	I-Protein
B	I-Protein
,	O
but	O
was	O
hypomethylated	O
in	O
cells	O
that	O
expressed	O
this	O
transcript	O
.	O

Furthermore	O
,	O
methylation	O
of	O
this	O
region	O
in	O
vitro	O
reduced	O
the	O
promoter	O
activity	O
to	O
approximately	O
5	O
%	O
of	O
the	O
control	O
.	O

Thus	O
methylation	O
at	O
CpG	O
sites	O
in	O
the	O
upstream	O
promoter	O
region	O
appeared	O
to	O
be	O
important	O
for	O
cell	O
-	O
specific	O
synthesis	O
of	O
the	O
long	O
transcript	O
.	O

By	O
contrast	O
,	O
HNF4alpha	B-Protein
(	O
hepatocyte	B-Protein
nuclear	I-Protein
factor	I-Protein
-	I-Protein
4alpha	I-Protein
)	O
bound	O
to	O
the	O
internal	O
promoter	O
and	O
enhanced	O
its	O
activity	O
.	O

Moreover	O
,	O
the	O
short	O
transcript	O
of	O
CIDE	B-Protein
-	I-Protein
B	I-Protein
gene	O
was	O
expressed	O
in	O
cells	O
which	O
do	O
not	O
normally	O
express	O
this	O
transcript	O
upon	O
introduction	O
of	O
exogenous	O
HNF4alpha	B-Protein
,	O
demonstrating	O
the	O
involvement	O
of	O
HNF4alpha	B-Protein
in	O
the	O
cell	O
-	O
specific	O
synthesis	O
of	O
the	O
short	O
transcript	O
.	O

Thus	O
our	O
analysis	O
revealed	O
a	O
novel	O
mechanism	O
for	O
the	O
cell	O
-	O
specific	O
transcription	O
of	O
the	O
human	O
CIDE	B-Protein
-	I-Protein
B	I-Protein
gene	O
,	O
which	O
involves	O
epigenetic	O
and	O
genetic	O
control	O
at	O
separate	O
respective	O
promoters	O
.	O

Human	O
but	O
not	O
yeast	O
CHD1	B-Protein
binds	O
directly	O
and	O
selectively	O
to	O
histone	B-Protein
H3	I-Protein
methylated	O
at	O
lysine	O
4	O
via	O
its	O
tandem	O
chromodomains	O
.	O

Defining	O
the	O
protein	O
factors	O
that	O
directly	O
recognize	O
post	O
-	O
translational	O
,	O
covalent	O
histone	B-Protein
modifications	O
is	O
essential	O
toward	O
understanding	O
the	O
impact	O
of	O
these	O
chromatin	O
"	O
marks	O
"	O
on	O
gene	O
regulation	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
identify	O
human	O
CHD1	B-Protein
,	O
an	O
ATP	O
-	O
dependent	O
chromatin	O
remodeling	O
protein	O
,	O
as	O
a	O
factor	O
that	O
directly	O
and	O
selectively	O
recognizes	O
histone	B-Protein
H3	I-Protein
methylated	O
on	O
lysine	O
4	O
.	O

In	O
vitro	O
binding	O
studies	O
identified	O
that	O
CHD1	B-Protein
recognizes	O
di	O
-	O
and	O
trimethyl	O
H3K4	O
with	O
a	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
approximately	O
5	O
microm	O
,	O
whereas	O
monomethyl	O
H3K4	O
binds	O
CHD1	B-Protein
with	O
a	O
3	O
-	O
fold	O
lower	O
affinity	O
.	O

Surprisingly	O
,	O
human	O
CHD1	B-Protein
binds	O
to	O
methylated	O
H3K4	B-Protein
in	O
a	O
manner	O
that	O
requires	O
both	O
of	O
its	O
tandem	O
chromodomains	O
.	O

In	O
vitro	O
analyses	O
demonstrate	O
that	O
unlike	O
human	O
CHD1	B-Protein
,	O
yeast	O
Chd1	B-Protein
does	O
not	O
bind	O
methylated	O
H3K4	B-Protein
.	O

Our	O
findings	O
indicate	O
that	O
yeast	O
and	O
human	O
CHD1	B-Protein
have	O
diverged	O
in	O
their	O
ability	O
to	O
discriminate	O
covalently	O
modified	O
histones	B-Protein
and	O
link	O
histone	B-Protein
modification	O
-	O
recognition	O
and	O
non	O
-	O
covalent	O
chromatin	O
remodeling	O
activities	O
within	O
a	O
single	O
human	O
protein	O
.	O

The	O
proteasome	O
regulatory	O
particle	O
alters	O
the	O
SAGA	O
coactivator	O
to	O
enhance	O
its	O
interactions	O
with	O
transcriptional	O
activators	O
.	O

Promoter	O
recruitment	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
SAGA	O
histone	B-Protein
acetyltransferase	O
complex	O
is	O
required	O
for	O
RNA	O
polymerase	O
II	O
-	O
dependent	O
transcription	O
of	O
several	O
genes	O
.	O

SAGA	O
is	O
targeted	O
to	O
promoters	O
through	O
interactions	O
with	O
sequence	O
-	O
specific	O
DNA	O
binding	O
transcriptional	O
activators	O
and	O
facilitates	O
preinitiation	O
-	O
complex	O
assembly	O
and	O
transcription	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
19S	O
proteasome	O
regulatory	O
particle	O
(	O
19S	O
RP	O
)	O
alters	O
SAGA	O
to	O
stimulate	O
its	O
interaction	O
with	O
transcriptional	O
activators	O
.	O

The	O
ATPase	O
components	O
of	O
the	O
19S	O
RP	O
are	O
required	O
for	O
stimulation	O
of	O
SAGA	O
/	O
activator	O
interactions	O
and	O
enhance	O
SAGA	O
recruitment	O
to	O
promoters	O
.	O

Proteasomal	O
ATPases	O
genetically	O
interact	O
with	O
SAGA	O
,	O
and	O
their	O
inhibition	O
reduces	O
global	O
histone	B-Protein
H3	I-Protein
acetylation	O
levels	O
and	O
SAGA	O
recruitment	O
to	O
target	O
promoters	O
in	O
vivo	O
.	O

These	O
results	O
indicate	O
that	O
the	O
19S	O
RP	O
modulates	O
SAGA	O
complex	O
using	O
its	O
ATPase	O
components	O
,	O
thereby	O
facilitating	O
subsequent	O
transcription	O
events	O
at	O
promoters	O
.	O

Prevention	O
of	O
early	O
flowering	O
by	O
expression	O
of	O
FLOWERING	B-Protein
LOCUS	I-Protein
C	I-Protein
requires	O
methylation	O
of	O
histone	B-Protein
H3	I-Protein
K36	O
.	O

Flowering	O
represents	O
a	O
crucial	O
transition	O
from	O
a	O
vegetative	O
to	O
a	O
reproductive	O
phase	O
of	O
the	O
plant	O
life	O
cycle	O
.	O

Despite	O
extensive	O
studies	O
,	O
the	O
molecular	O
mechanisms	O
controlling	O
flowering	O
remain	O
elusive	O
.	O

Although	O
the	O
enzymes	O
involved	O
are	O
unknown	O
,	O
methylation	O
of	O
histone	B-Protein
H3	I-Protein
K9	O
and	O
K27	O
correlates	O
with	O
repression	O
of	O
FLOWERING	B-Protein
LOCUS	I-Protein
C	I-Protein
(	O
FLC	B-Protein
)	O
,	O
an	O
essential	O
transcriptional	O
repressor	O
involved	O
in	O
flowering	O
time	O
control	O
in	O
Arabidopsis	O
thaliana	O
;	O
in	O
contrast	O
,	O
methylation	O
of	O
H3K4	B-Protein
correlates	O
with	O
FLC	B-Protein
activation	O
.	O

Here	O
we	O
show	O
that	O
loss	O
-	O
of	O
-	O
function	O
of	O
SET	B-Protein
DOMAIN	I-Protein
GROUP	I-Protein
8	I-Protein
(	O
SDG	B-Protein
8	I-Protein
)	O
,	O
which	O
encodes	O
a	O
homologue	O
of	O
the	O
yeast	O
SET2	B-Protein
histone	O
methyltransferase	O
,	O
results	O
in	O
reduced	O
dimethylation	O
of	O
histone	B-Protein
H3K36	I-Protein
,	O
particularly	O
in	O
chromatin	O
associated	O
with	O
the	O
FLC	B-Protein
promoter	O
and	O
the	O
first	O
intron	O
,	O
regions	O
that	O
contain	O
essential	O
cis	O
-	O
elements	O
for	O
transcription	O
.	O

sdg8	B-Protein
mutants	O
display	O
reduced	O
FLC	B-Protein
expression	O
and	O
flower	O
early	O
,	O
establishing	O
SDG8	B-Protein
-	O
mediated	O
H3K36	B-Protein
methylation	O
as	O
a	O
novel	O
epigenetic	O
memory	O
code	O
required	O
for	O
FLC	B-Protein
expression	O
in	O
preventing	O
early	O
flowering	O
.	O

This	O
is	O
the	O
first	O
demonstrated	O
role	O
of	O
H3K36	B-Protein
methylation	O
in	O
eukaryote	O
development	O
.	O

Loss	O
of	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
-	O
dependency	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
cells	O
on	O
gene	O
silencing	O
of	O
thioredoxin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
2	I-Protein
.	O

The	O
transition	O
from	O
interleukin	B-Protein
-	I-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
-	O
dependent	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
growth	O
is	O
considered	O
one	O
of	O
the	O
key	O
steps	O
in	O
the	O
transformation	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-	O
infected	O
T	O
cells	O
.	O

The	O
expression	O
of	O
thioredoxin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
2	I-Protein
(	O
TBP	B-Protein
-	I-Protein
2	I-Protein
)	O
is	O
lost	O
during	O
the	O
transition	O
of	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
.	O

Here	O
,	O
we	O
analysed	O
the	O
mechanism	O
of	O
loss	O
of	O
TBP	B-Protein
-	I-Protein
2	I-Protein
expression	O
and	O
the	O
role	O
of	O
TBP	B-Protein
-	I-Protein
2	I-Protein
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
growth	O
in	O
the	O
in	O
vitro	O
model	O
to	O
investigate	O
multistep	O
transformation	O
of	O
HTLV	O
-	O
I	O
.	O

CpGs	O
in	O
the	O
TBP	B-Protein
-	I-Protein
2	I-Protein
gene	O
are	O
methylated	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
but	O
not	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
cells	O
.	O

Sequential	O
treatment	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
and	O
a	O
histone	B-Protein
deacetylase	O
inhibitor	O
augmented	O
histone	B-Protein
acetylation	O
and	O
TBP	B-Protein
-	I-Protein
2	I-Protein
expression	O
,	O
suggesting	O
that	O
loss	O
of	O
TBP	B-Protein
-	I-Protein
2	I-Protein
expression	O
is	O
due	O
to	O
DNA	O
methylation	O
and	O
histone	B-Protein
deacetylation	O
.	O

In	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
cells	O
,	O
a	O
basal	O
level	O
of	O
TBP	B-Protein
-	I-Protein
2	I-Protein
expression	O
was	O
maintained	O
by	O
IL	B-Protein
-	I-Protein
2	I-Protein
associated	O
with	O
cellular	O
growth	O
,	O
whereas	O
TBP	B-Protein
-	I-Protein
2	I-Protein
expression	O
was	O
upregulated	O
on	O
deprivation	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
associated	O
with	O
growth	O
suppression	O
.	O

Overexpression	O
of	O
TBP	B-Protein
-	I-Protein
2	I-Protein
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
cells	O
suppressed	O
the	O
growth	O
and	O
partially	O
restored	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Knockdown	O
of	O
TBP	B-Protein
-	I-Protein
2	I-Protein
caused	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
dependent	O
cells	O
to	O
show	O
partial	O
growth	O
without	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

These	O
results	O
suggested	O
that	O
epigenetic	O
silencing	O
of	O
the	O
TBP	B-Protein
-	I-Protein
2	I-Protein
gene	O
results	O
in	O
a	O
loss	O
of	O
responsiveness	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
contributing	O
to	O
uncontrolled	O
IL	B-Protein
-	I-Protein
2	I-Protein
-	O
independent	O
growth	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
-	O
cell	O
lines	O
.	O

Transcriptional	O
silencing	O
of	O
EphB6	B-Protein
receptor	O
tyrosine	O
kinase	O
in	O
invasive	O
breast	O
carcinoma	O
cells	O
and	O
detection	O
of	O
methylated	O
promoter	O
by	O
methylation	O
specific	O
PCR	O
.	O

The	O
receptor	O
tyrosine	O
kinase	O
EphB6	B-Protein
is	O
expressed	O
at	O
reasonable	O
levels	O
in	O
normal	O
breast	O
cells	O
.	O

It	O
shows	O
decreased	O
abundance	O
in	O
non	O
-	O
invasive	O
breast	O
carcinoma	O
cells	O
and	O
is	O
transcriptionally	O
silenced	O
in	O
invasive	O
breast	O
carcinoma	O
cells	O
.	O

We	O
have	O
characterized	O
EphB6	B-Protein
promoter	O
and	O
correlated	O
the	O
expression	O
of	O
EphB6	B-Protein
transcript	O
to	O
differential	O
methylation	O
of	O
the	O
promoter	O
region	O
.	O

The	O
demethylation	O
of	O
promoter	O
sequence	O
in	O
vivo	O
by	O
growth	O
in	O
media	O
containing	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
restores	O
the	O
expression	O
of	O
EphB6	B-Protein
to	O
normal	O
levels	O
in	O
breast	O
carcinoma	O
cells	O
,	O
and	O
the	O
ability	O
of	O
the	O
promoter	O
to	O
initiate	O
transcription	O
of	O
a	O
reporter	O
gene	O
is	O
lost	O
after	O
methylation	O
of	O
the	O
promoter	O
sequence	O
.	O

The	O
promoter	O
region	O
has	O
binding	O
sites	O
for	O
various	O
factors	O
such	O
as	O
SP1	B-Protein
and	O
p300	B-Protein
.	O

The	O
specific	O
methylation	O
of	O
CpG	O
dinucleotides	O
has	O
allowed	O
us	O
to	O
design	O
primers	O
that	O
can	O
selectively	O
amplify	O
the	O
methylated	O
promoter	O
and	O
thus	O
facilitate	O
identification	O
of	O
normal	O
,	O
non	O
-	O
invasive	O
,	O
and	O
invasive	O
breast	O
cells	O
.	O

The	O
potential	O
significance	O
of	O
EphB6	B-Protein
to	O
serve	O
as	O
a	O
diagnostic	O
and	O
prognostic	O
indicator	O
is	O
discussed	O
.	O

Consistent	O
patterns	O
of	O
change	O
during	O
the	O
divergence	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
envelope	O
from	O
that	O
of	O
the	O
inoculated	O
virus	O
in	O
simian	O
/	O
human	O
immunodeficiency	O
virus	O
-	O
infected	O
macaques	O
.	O

We	O
have	O
analyzed	O
changes	O
to	O
proviral	O
Env	B-Protein
gp120	B-Protein
sequences	O
and	O
the	O
development	O
of	O
neutralizing	O
antibodies	O
(	O
NAbs	O
)	O
during	O
1	O
year	O
of	O
simian	O
/	O
human	O
immunodeficiency	O
virus	O
SHIV	O
-	O
89	O
.	O
6P	O
infection	O
in	O
11	O
Macaca	O
nemestrina	O
macaques	O
.	O

Seven	O
macaques	O
had	O
significant	O
env	B-Protein
divergence	O
from	O
that	O
of	O
the	O
inoculum	O
,	O
and	O
macaques	O
with	O
greater	O
divergence	O
had	O
higher	O
titers	O
of	O
homologous	O
NAbs	O
.	O

Substitutions	O
in	O
sequons	O
encoding	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
(	O
PNGs	O
)	O
were	O
among	O
the	O
first	O
to	O
be	O
established	O
,	O
although	O
overall	O
the	O
total	O
number	O
of	O
sequons	O
did	O
not	O
increase	O
significantly	O
.	O

The	O
majority	O
(	O
19	O
of	O
23	O
)	O
of	O
PNGs	O
present	O
in	O
the	O
inoculum	O
were	O
conserved	O
in	O
the	O
sequences	O
from	O
all	O
macaques	O
.	O

Statistically	O
significant	O
variations	O
in	O
PNGs	O
occurred	O
in	O
multiple	O
macaques	O
within	O
constrained	O
regions	O
we	O
term	O
"	O
hot	O
spots	O
,	O
"	O
resulting	O
in	O
the	O
selection	O
of	O
sequences	O
more	O
similar	O
to	O
the	O
B	O
consensus	O
.	O

These	O
included	O
additions	O
on	O
V1	O
,	O
the	O
N	O
-	O
terminal	O
side	O
of	O
V4	O
,	O
and	O
the	O
outer	O
region	O
of	O
C2	O
.	O

Complex	O
mutational	O
patterns	O
resulted	O
in	O
convergent	O
PNG	O
shifts	O
in	O
V2	O
and	O
V5	O
.	O

Charge	O
changes	O
in	O
Env	B-Protein
V1V2	O
,	O
resulting	O
in	O
a	O
net	O
acidic	O
charge	O
,	O
and	O
a	O
proline	O
addition	O
in	O
V5	O
occurred	O
in	O
several	O
macaques	O
.	O

Molecular	O
modeling	O
of	O
the	O
89	O
.	O
6P	O
sequence	O
showed	O
that	O
the	O
conserved	O
glycans	O
lie	O
on	O
the	O
silent	O
face	O
of	O
Env	B-Protein
and	O
that	O
many	O
are	O
proximal	O
to	O
disulfide	O
bonds	O
,	O
while	O
PNG	O
additions	O
and	O
shifts	O
are	O
proximal	O
to	O
the	O
CD4	B-Protein
binding	O
site	O
.	O

Nonsynonymous	O
-	O
to	O
-	O
synonymous	O
substitution	O
ratios	O
suggest	O
that	O
these	O
changes	O
result	O
from	O
selective	O
pressure	O
.	O

This	O
longitudinal	O
and	O
cross	O
-	O
sectional	O
study	O
of	O
mutations	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
env	B-Protein
in	O
the	O
SHIV	O
background	O
provides	O
evidence	O
that	O
there	O
are	O
more	O
constraints	O
on	O
the	O
configuration	O
of	O
the	O
glycan	O
shield	O
than	O
were	O
previously	O
appreciated	O
.	O

Patients	O
with	O
congenital	O
hypothyroidism	O
demonstrate	O
different	O
altered	O
expression	O
of	O
plasma	O
fibrinogen	O
and	O
haptoglobin	B-Protein
polypeptide	O
chains	O
.	O

OBJECTIVES	O
:	O
To	O
compare	O
the	O
plasma	O
protein	O
profiles	O
of	O
treated	O
and	O
untreated	O
congenital	O
hypothyroidism	O
(	O
CH	O
)	O
patients	O
with	O
those	O
of	O
normal	O
control	O
infants	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
Plasma	O
samples	O
were	O
subjected	O
to	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
and	O
silver	O
staining	O
or	O
lectin	O
detection	O
.	O

Resolved	O
protein	O
spots	O
were	O
analyzed	O
by	O
using	O
computerized	O
densitometry	O
software	O
.	O

RESULTS	O
:	O
The	O
significant	O
enhanced	O
expression	O
of	O
the	O
fibrinogen	B-Protein
gamma	I-Protein
-	I-Protein
chain	I-Protein
and	O
reduced	O
expression	O
of	O
haptoglobin	B-Protein
beta	I-Protein
-	I-Protein
chain	I-Protein
were	O
demonstrated	O
in	O
the	O
profiles	O
of	O
untreated	O
CH	O
patients	O
using	O
both	O
silver	O
staining	O
and	O
lectin	O
detection	O
methods	O
.	O

Lectin	O
detection	O
resolved	O
only	O
a	O
single	O
cluster	O
of	O
the	O
haptoglobin	B-Protein
beta	I-Protein
-	I-Protein
chain	I-Protein
for	O
the	O
untreated	O
patients	O
,	O
in	O
contrast	O
to	O
five	O
isoform	O
clusters	O
detected	O
in	O
the	O
controls	O
'	O
and	O
treated	O
CH	O
patients	O
'	O
profiles	O
.	O

CONCLUSIONS	O
:	O
Plasma	O
from	O
untreated	O
CH	O
patients	O
demonstrated	O
different	O
altered	O
expression	O
of	O
fibrinogen	O
and	O
haptoglobin	B-Protein
polypeptide	O
chains	O
,	O
which	O
was	O
normalized	O
when	O
patients	O
were	O
treated	O
.	O

Our	O
data	O
also	O
suggest	O
differences	O
in	O
structures	O
of	O
the	O
N	O
-	O
glycans	O
of	O
haptoglobin	B-Protein
beta	I-Protein
-	I-Protein
chain	I-Protein
of	O
the	O
untreated	O
CH	O
patients	O
.	O

Chromatin	O
compaction	O
at	O
the	O
mononucleosome	O
level	O
.	O

Using	O
a	O
previously	O
described	O
FRET	O
technique	O
,	O
we	O
measured	O
the	O
distance	O
between	O
the	O
ends	O
of	O
DNA	O
fragments	O
on	O
which	O
nucleosomes	O
were	O
reconstituted	O
from	O
recombinant	O
and	O
native	O
histones	O
.	O

This	O
distance	O
was	O
analyzed	O
in	O
its	O
dependence	O
on	O
the	O
DNA	O
fragment	O
length	O
,	O
concentration	O
of	O
mono	O
-	O
and	O
divalent	O
counterions	O
,	O
presence	O
of	O
linker	O
histone	B-Protein
H1	I-Protein
,	O
and	O
histone	B-Protein
modifications	O
.	O

We	O
found	O
that	O
the	O
linker	O
DNA	O
arms	O
do	O
not	O
cross	O
under	O
all	O
conditions	O
studied	O
but	O
diverge	O
slightly	O
as	O
they	O
leave	O
the	O
histone	B-Protein
core	O
surface	O
.	O

Histone	B-Protein
H1	I-Protein
leads	O
to	O
a	O
global	O
approach	O
of	O
the	O
linker	O
DNA	O
arms	O
,	O
confirming	O
the	O
notion	O
of	O
a	O
"	O
stem	O
structure	O
"	O
.	O

Increasing	O
salt	O
concentration	O
also	O
leads	O
to	O
an	O
approach	O
of	O
the	O
linker	O
DNAs	O
.	O

To	O
study	O
the	O
effect	O
of	O
acetylation	O
,	O
we	O
compared	O
chemically	O
acetylated	O
recombinant	O
histones	B-Protein
with	O
histones	B-Protein
prepared	O
from	O
HeLa	O
cells	O
,	O
characterizing	O
the	O
sites	O
of	O
acetylation	O
by	O
mass	O
spectroscopy	O
.	O

Nucleosomes	O
from	O
chemically	O
acetylated	O
histones	B-Protein
have	O
few	O
modifications	O
in	O
the	O
core	O
domain	O
and	O
form	O
nucleosomes	O
normally	O
.	O

Acetylating	O
all	O
histones	B-Protein
or	O
selectively	O
only	O
H3	B-Protein
causes	O
an	O
opening	O
of	O
the	O
nucleosome	O
structure	O
,	O
indicated	O
by	O
the	O
larger	O
distances	O
between	O
the	O
linker	O
DNA	O
ends	O
.	O

Selective	O
acetylation	O
of	O
H4	B-Protein
distances	O
the	O
linker	O
ends	O
for	O
short	O
fragments	O
but	O
causes	O
them	O
to	O
approach	O
each	O
other	O
for	O
fragments	O
longer	O
than	O
180	O
bp	O
.	O

Histone	B-Protein
deacetylase	O
inhibitors	O
induce	O
cell	O
death	O
and	O
enhance	O
the	O
susceptibility	O
to	O
ionizing	O
radiation	O
,	O
etoposide	O
,	O
and	O
TRAIL	O
in	O
medulloblastoma	O
cells	O
.	O

Histone	B-Protein
deacetylase	O
inhibitors	O
(	O
HDIs	O
)	O
are	O
a	O
promising	O
new	O
class	O
of	O
antineoplastic	O
agents	O
with	O
the	O
ability	O
to	O
induce	O
apoptosis	O
and	O
growth	O
arrest	O
of	O
cancer	O
cells	O
.	O

In	O
addition	O
,	O
HDIs	O
have	O
been	O
suggested	O
to	O
enhance	O
the	O
anticancer	O
efficacy	O
of	O
other	O
therapeutic	O
regimens	O
,	O
such	O
as	O
ionizing	O
radiation	O
(	O
IR	O
)	O
or	O
chemotherapy	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
activity	O
of	O
HDIs	O
against	O
medulloblastoma	O
cells	O
when	O
applied	O
either	O
as	O
single	O
agents	O
or	O
in	O
combination	O
with	O
IR	O
,	O
cytostatics	O
,	O
or	O
TRAIL	O
.	O

The	O
HDIs	O
,	O
suberoyl	O
anilide	O
hydroxamic	O
acid	O
(	O
SAHA	O
)	O
,	O
sodium	O
butyrate	O
,	O
and	O
trichostatin	O
A	O
,	O
were	O
examined	O
for	O
their	O
effects	O
on	O
the	O
medulloblastoma	O
cell	O
lines	O
,	O
DAOY	O
and	O
UW228	O
-	O
2	O
.	O

We	O
found	O
that	O
treatment	O
with	O
HDIs	O
induced	O
the	O
dissipation	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
activation	O
of	O
caspase	B-Protein
-	I-Protein
9	I-Protein
and	O
-	B-Protein
3	I-Protein
and	O
,	O
consequently	O
,	O
apoptotic	O
cell	O
death	O
.	O

Moreover	O
,	O
all	O
three	O
HDIs	O
significantly	O
enhanced	O
the	O
cytotoxic	O
effects	O
of	O
IR	O
in	O
DAOY	O
cells	O
.	O

Likewise	O
,	O
treatment	O
with	O
SAHA	O
markedly	O
augmented	O
the	O
cytotoxicity	O
of	O
etoposide	O
,	O
while	O
it	O
had	O
no	O
effect	O
on	O
vincristine	O
-	O
mediated	O
cell	O
death	O
.	O

HDIs	O
also	O
potently	O
increased	O
the	O
killing	O
efficiency	O
of	O
TRAIL	O
.	O

TRAIL	O
-	O
induced	O
,	O
but	O
not	O
SAHA	O
-	O
induced	O
,	O
cell	O
killing	O
could	O
be	O
prevented	O
by	O
the	O
caspase	B-Protein
-	I-Protein
8	I-Protein
inhibitor	O
,	O
z	O
-	O
IEDT	O
-	O
fmk	O
.	O

We	O
conclude	O
that	O
HDIs	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
medulloblastoma	O
as	O
monotherapy	O
and	O
particularly	O
when	O
given	O
in	O
combination	O
with	O
IR	O
,	O
appropriate	O
cytostatics	O
,	O
or	O
TRAIL	O
.	O

Adiponectin	B-Protein
multimerization	O
is	O
dependent	O
on	O
conserved	O
lysines	O
in	O
the	O
collagenous	O
domain	O
:	O
evidence	O
for	O
regulation	O
of	O
multimerization	O
by	O
alterations	O
in	O
posttranslational	O
modifications	O
.	O

Adiponectin	B-Protein
is	O
a	O
secreted	O
,	O
multimeric	O
protein	O
with	O
insulin	B-Protein
-	O
sensitizing	O
,	O
antiatherogenic	O
,	O
and	O
antiinflammatory	O
properties	O
.	O

Serum	O
adiponectin	B-Protein
consists	O
of	O
trimer	O
,	O
hexamer	O
,	O
and	O
larger	O
high	O
-	O
molecular	O
-	O
weight	O
(	O
HMW	O
)	O
multimers	O
,	O
and	O
these	O
HMW	O
multimers	O
appear	O
to	O
be	O
the	O
more	O
bioactive	O
forms	O
.	O

Multimer	O
composition	O
of	O
adiponectin	B-Protein
appears	O
to	O
be	O
regulated	O
;	O
however	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
are	O
unknown	O
.	O

We	O
hypothesize	O
that	O
regulation	O
of	O
adiponectin	B-Protein
multimerization	O
and	O
secretion	O
occurs	O
via	O
changes	O
in	O
posttranslational	O
modifications	O
(	O
PTMs	O
)	O
.	O

Although	O
a	O
structural	O
role	O
for	O
intertrimer	O
disulfide	O
bonds	O
in	O
the	O
formation	O
of	O
hexamers	O
and	O
HMW	O
multimers	O
is	O
established	O
,	O
the	O
role	O
of	O
other	O
PTMs	O
is	O
unknown	O
.	O

PTMs	O
identified	O
in	O
murine	O
and	O
bovine	O
adiponectin	B-Protein
include	O
hydroxylation	O
of	O
multiple	O
conserved	O
proline	O
and	O
lysine	O
residues	O
and	O
glycosylation	O
of	O
hydroxylysines	O
.	O

By	O
mass	O
spectrometry	O
,	O
we	O
confirmed	O
the	O
presence	O
of	O
these	O
PTMs	O
in	O
human	O
adiponectin	B-Protein
and	O
identified	O
three	O
additional	O
hydroxylations	O
on	O
Pro71	O
,	O
Pro76	O
,	O
and	O
Pro95	O
.	O

We	O
also	O
investigated	O
the	O
role	O
of	O
the	O
five	O
modified	O
lysines	O
in	O
multimer	O
formation	O
and	O
secretion	O
of	O
recombinant	O
human	O
adiponectin	B-Protein
expressed	O
in	O
mammalian	O
cell	O
lines	O
.	O

Mutation	O
of	O
modified	O
lysines	O
in	O
the	O
collagenous	O
domain	O
prevented	O
formation	O
of	O
HMW	O
multimers	O
,	O
whereas	O
a	O
pharmacological	O
inhibitor	O
of	O
prolyl	O
-	O
and	O
lysyl	O
-	O
hydroxylases	O
,	O
2	O
,	O
2	O
'	O
-	O
dipyridyl	O
,	O
inhibited	O
formation	O
of	O
hexamers	O
and	O
HMW	O
multimers	O
.	O

Bacterially	O
expressed	O
human	O
adiponectin	B-Protein
displayed	O
a	O
complete	O
lack	O
of	O
differentially	O
modified	O
isoforms	O
and	O
failed	O
to	O
form	O
bona	O
fide	O
trimers	O
and	O
larger	O
multimers	O
.	O

Finally	O
,	O
glucose	O
-	O
induced	O
increases	O
in	O
HMW	O
multimer	O
production	O
from	O
human	O
adipose	O
explants	O
correlated	O
with	O
changes	O
in	O
the	O
two	O
-	O
dimensional	O
electrophoresis	O
profile	O
of	O
adiponectin	B-Protein
isoforms	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
adiponectin	B-Protein
multimer	O
composition	O
is	O
affected	O
by	O
changes	O
in	O
PTM	O
in	O
response	O
to	O
physiological	O
factors	O
.	O

Heterochromatin	O
assembly	O
:	O
a	O
new	O
twist	O
on	O
an	O
old	O
model	O
.	O

The	O
organization	O
of	O
eukaryotic	O
genomes	O
requires	O
a	O
harmony	O
between	O
efficient	O
compaction	O
and	O
accessibility	O
.	O

This	O
is	O
achieved	O
through	O
its	O
packaging	O
into	O
chromatin	O
.	O

Chromatin	O
can	O
be	O
subdivided	O
into	O
two	O
general	O
structural	O
and	O
functional	O
compartments	O
:	O
euchromatin	O
and	O
heterochromatin	O
.	O

Euchromatin	O
comprises	O
most	O
of	O
the	O
expressed	O
genome	O
,	O
while	O
heterochromatin	O
participates	O
intimately	O
in	O
the	O
production	O
of	O
structures	O
such	O
as	O
centromeres	O
and	O
telomeres	O
essential	O
for	O
chromosome	O
function	O
.	O

Studies	O
in	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
have	O
begun	O
to	O
highlight	O
the	O
genetic	O
pathways	O
critical	O
for	O
the	O
assembly	O
and	O
epigenetic	O
maintenance	O
of	O
heterochromatin	O
,	O
including	O
key	O
roles	O
played	O
by	O
the	O
RNAi	O
machinery	O
,	O
H3	B-Protein
lysine	O
9	O
methylation	O
and	O
heterochromatin	O
protein	O
1	O
(	O
HP1	O
)	O
.	O

Recent	O
studies	O
have	O
also	O
identified	O
a	O
novel	O
E3	O
ubiquitin	O
ligase	O
universally	O
required	O
for	O
H3	B-Protein
K9	O
methylation	O
.	O

Here	O
we	O
outline	O
these	O
studies	O
and	O
propose	O
several	O
models	O
for	O
the	O
role	O
of	O
this	O
E3	O
ligase	O
in	O
heterochromatin	O
assembly	O
.	O

In	O
vitro	O
sulfation	O
of	O
N	O
-	O
acetyllactosaminide	O
by	O
soluble	O
recombinant	O
human	O
beta	B-Protein
-	I-Protein
Gal	I-Protein
-	I-Protein
3	I-Protein
'	I-Protein
-	I-Protein
sulfotransferase	I-Protein
.	O

Membrane	O
-	O
bound	O
beta	B-Protein
-	I-Protein
Gal	I-Protein
-	I-Protein
3	I-Protein
'	I-Protein
-	I-Protein
sulfotransferase	I-Protein
(	O
GP3ST	B-Protein
)	O
was	O
expressed	O
and	O
used	O
for	O
in	O
vitro	O
sulfation	O
of	O
Tamm	B-Protein
-	I-Protein
Horsfall	I-Protein
glycoprotein	I-Protein
.	O

Further	O
,	O
the	O
regioselective	O
transfer	O
of	O
sulfate	O
to	O
an	O
N	O
-	O
acetyllactosamine	O
derivative	O
could	O
be	O
realised	O
with	O
soluble	O
chimeric	O
GP3ST	B-Protein
,	O
also	O
in	O
combination	O
with	O
Lac	O
transglycosylation	O
by	O
means	O
of	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
.	O

Two	O
alternative	O
straightforward	O
chemical	O
syntheses	O
for	O
the	O
target	O
compound	O
could	O
be	O
elaborated	O
.	O

Acetylation	O
genotype	O
and	O
phenotype	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
is	O
a	O
chronic	O
autoimmune	O
disease	O
affecting	O
various	O
tissues	O
and	O
organs	O
.	O

In	O
the	O
studies	O
on	O
SLE	O
etiopathogenesis	O
,	O
a	O
potential	O
role	O
of	O
genetically	O
determined	O
impairment	O
of	O
xenobiotic	O
metabolism	O
has	O
been	O
emphasized	O
.	O

N	B-Protein
-	I-Protein
acetyltransferase	I-Protein
2	I-Protein
enzyme	O
(	O
NAT2	B-Protein
)	O
exhibits	O
gene	O
polymorphism	O
and	O
the	O
acetylation	O
rate	O
with	O
NAT2	B-Protein
involvement	O
varies	O
from	O
person	O
to	O
person	O
.	O

The	O
study	O
on	O
acetylation	O
phenotype	O
was	O
carried	O
out	O
using	O
isonicotinic	O
acid	O
hydrazide	O
(	O
isoniazid	O
)	O
as	O
a	O
model	O
drug	O
,	O
while	O
NAT2	B-Protein
alleles	O
were	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
assays	O
.	O

Among	O
patients	O
with	O
SLE	O
,	O
NAT2	B-Protein
*	O
4	O
/	O
NAT2	B-Protein
*	O
6	O
and	O
NAT2	B-Protein
*	O
5	O
/	O
NAT2	B-Protein
*	O
5	O
genotypes	O
occurred	O
most	O
frequently	O
,	O
while	O
NAT2	B-Protein
*	O
4	O
/	O
NAT2	B-Protein
*	O
6	O
and	O
NAT2	B-Protein
*	O
5	O
/	O
NAT2	B-Protein
*	O
6	O
prevailed	O
in	O
the	O
control	O
group	O
.	O

The	O
concordance	O
of	O
96	O
.	O
8	O
%	O
was	O
achieved	O
between	O
acetylation	O
phenotype	O
and	O
NAT2	B-Protein
genotype	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
studied	O
.	O

Conclusion	O
:	O
Acetylation	O
polymorphism	O
appears	O
not	O
to	O
be	O
an	O
important	O
risk	O
factor	O
in	O
SLE	O
.	O

Nonadditive	O
regulation	O
of	O
FRI	B-Protein
and	O
FLC	O
loci	O
mediates	O
flowering	O
-	O
time	O
variation	O
in	O
Arabidopsis	O
allopolyploids	O
.	O

Allopolyploidy	O
is	O
formed	O
by	O
combining	O
two	O
or	O
more	O
divergent	O
genomes	O
and	O
occurs	O
throughout	O
the	O
evolutionary	O
history	O
of	O
many	O
plants	O
and	O
some	O
animals	O
.	O

Transcriptome	O
analysis	O
indicates	O
that	O
many	O
genes	O
in	O
various	O
biological	O
pathways	O
,	O
including	O
flowering	O
time	O
,	O
are	O
expressed	O
nonadditively	O
(	O
different	O
from	O
the	O
midparent	O
value	O
)	O
.	O

However	O
,	O
the	O
mechanisms	O
for	O
nonadditive	O
gene	O
regulation	O
in	O
a	O
biological	O
pathway	O
are	O
unknown	O
.	O

Natural	O
variation	O
of	O
flowering	O
time	O
is	O
largely	O
controlled	O
by	O
two	O
epistatically	O
acting	O
loci	O
,	O
namely	O
FRIGIDA	B-Protein
(	O
FRI	B-Protein
)	O
and	O
FLOWERING	B-Protein
LOCUS	I-Protein
C	I-Protein
(	O
FLC	B-Protein
)	O
.	O

FRI	B-Protein
upregulates	O
FLC	B-Protein
expression	O
that	O
represses	O
flowering	O
in	O
Arabidopsis	O
.	O

Synthetic	O
Arabidopsis	O
allotetraploids	O
contain	O
two	O
sets	O
of	O
FLC	O
and	O
FRI	O
genes	O
originating	O
from	O
Arabidopsis	O
thaliana	O
and	O
A	O
.	O
arenosa	O
,	O
respectively	O
,	O
and	O
flower	O
late	O
.	O

Inhibition	O
of	O
early	O
flowering	O
is	O
caused	O
by	O
upregulation	O
of	O
A	O
.	O
thaliana	O
FLC	B-Protein
(	O
AtFLC	B-Protein
)	O
that	O
is	O
trans	O
-	O
activated	O
by	O
A	O
.	O
arenosa	O
FRI	B-Protein
(	O
AaFRI	B-Protein
)	O
.	O

Two	O
duplicate	O
FLCs	O
(	O
AaFLC1	B-Protein
and	O
AaFLC2	B-Protein
)	O
originating	O
from	O
A	O
.	O
arenosa	O
are	O
expressed	O
in	O
some	O
allotetraploids	O
but	O
silenced	O
in	O
other	O
lines	O
.	O

The	O
expression	O
variation	O
in	O
the	O
allotetraploids	O
is	O
associated	O
with	O
deletions	O
in	O
the	O
promoter	O
regions	O
and	O
first	O
introns	O
of	O
A	O
.	O
arenosa	O
FLCs	O
.	O

The	O
strong	O
AtFLC	B-Protein
and	O
AaFLC	O
loci	O
are	O
maintained	O
in	O
natural	O
Arabidopsis	O
allotetraploids	O
,	O
leading	O
to	O
extremely	O
late	O
flowering	O
.	O

Furthermore	O
,	O
FLC	O
expression	O
correlates	O
positively	O
with	O
histone	B-Protein
H3	I-Protein
-	O
Lys4	O
methylation	O
and	O
H3	B-Protein
-	O
Lys9	O
acetylation	O
and	O
negatively	O
with	O
H3	B-Protein
-	O
Lys9	O
methylation	O
,	O
epigenetic	O
marks	O
for	O
gene	O
activation	O
and	O
silencing	O
.	O

We	O
provide	O
evidence	O
for	O
interactive	O
roles	O
of	O
regulatory	O
sequence	O
changes	O
,	O
chromatin	O
modification	O
,	O
and	O
trans	O
-	O
acting	O
effects	O
in	O
natural	O
selection	O
of	O
orthologous	O
FLC	B-Protein
loci	O
,	O
which	O
determines	O
the	O
fate	O
of	O
duplicate	O
genes	O
and	O
adaptation	O
of	O
allopolyploids	O
during	O
evolution	O
.	O

Evidence	O
for	O
heterogeneity	O
of	O
glycosylation	O
of	O
human	O
renin	B-Protein
obtained	O
by	O
using	O
lectins	O
.	O

1	O
.	O

In	O
this	O
study	O
,	O
the	O
carbohydrate	O
structure	O
of	O
pure	O
human	O
renin	B-Protein
was	O
examined	O
by	O
using	O
various	O
lectins	O
.	O

2	O
.	O

Pure	O
renin	B-Protein
could	O
be	O
separated	O
into	O
three	O
forms	O
by	O
concanavalin	B-Protein
A	I-Protein
chromatography	O
,	O
a	O
concanavalin	B-Protein
A	I-Protein
-	O
unbound	O
form	O
,	O
a	O
loosely	O
bound	O
form	O
and	O
a	O
tightly	O
bound	O
form	O
,	O
termed	O
renins	B-Protein
A	O
,	O
B	O
and	O
C	O
,	O
respectively	O
.	O

Renins	O
A	O
,	O
B	O
and	O
C	O
accounted	O
for	O
3	O
,	O
13	O
and	O
84	O
%	O
,	O
respectively	O
,	O
of	O
the	O
purified	O
renin	B-Protein
.	O

These	O
forms	O
were	O
all	O
present	O
in	O
individual	O
human	O
plasma	O
and	O
the	O
relative	O
proportions	O
in	O
plasma	O
were	O
27	O
+	O
/	O
-	O
3	O
,	O
33	O
+	O
/	O
-	O
4	O
and	O
39	O
+	O
/	O
-	O
5	O
%	O
(	O
means	O
+	O
/	O
-	O
SEM	O
)	O
for	O
renins	O
A	O
,	O
B	O
and	O
C	O
,	O
respectively	O
(	O
n	O
=	O
5	O
)	O
.	O

3	O
.	O

Each	O
form	O
,	O
electroblotted	O
on	O
to	O
the	O
nitrocellulose	O
sheet	O
after	O
gel	O
electrophoresis	O
,	O
was	O
incubated	O
with	O
five	O
peroxidase	O
-	O
labelled	O
lectins	O
,	O
lentil	O
lectin	B-Protein
,	O
erythroagglutinating	B-Protein
phytohaemagglutinin	I-Protein
,	O
wheat	O
-	O
germ	O
agglutinin	O
,	O
Ricinus	O
communis	O
agglutinin	B-Protein
and	O
peanut	O
agglutinin	B-Protein
.	O

The	O
protein	O
was	O
stained	O
with	O
4	O
-	O
chloro	O
-	O
1	O
-	O
naphthol	O
.	O

4	O
.	O

The	O
staining	O
pattern	O
obtained	O
with	O
these	O
lectins	O
was	O
significantly	O
different	O
among	O
the	O
three	O
forms	O
of	O
human	O
renin	B-Protein
,	O
confirming	O
that	O
they	O
have	O
different	O
carbohydrate	O
structures	O
.	O

Furthermore	O
,	O
the	O
positive	O
staining	O
of	O
human	O
renin	B-Protein
with	O
erythroagglutinating	B-Protein
phytohaemagglutinin	I-Protein
,	O
wheat	O
-	O
germ	O
agglutinin	O
and	O
Ricinus	O
communis	O
agglutinin	B-Protein
was	O
in	O
contrast	O
with	O
the	O
lack	O
of	O
binding	O
of	O
rat	O
renin	B-Protein
to	O
these	O
lectins	O
.	O

5	O
.	O

These	O
results	O
indicate	O
the	O
renal	O
secretion	O
of	O
differently	O
glycosylated	O
multiple	O
forms	O
of	O
human	O
renin	B-Protein
.	O

The	O
carbohydrate	O
structure	O
of	O
human	O
renin	B-Protein
appears	O
to	O
differ	O
from	O
that	O
of	O
rat	O
renin	B-Protein
.	O

Glycosylation	O
of	O
high	O
-	O
affinity	O
thrombin	B-Protein
receptors	O
appears	O
necessary	O
for	O
thrombin	B-Protein
binding	O
.	O

Monosaccharide	O
binding	O
competition	O
,	O
lectin	O
affinity	O
chromatography	O
,	O
and	O
glycosylation	O
inhibitors	O
have	O
been	O
used	O
to	O
determine	O
if	O
glycosylation	O
plays	O
a	O
role	O
in	O
thrombin	B-Protein
-	O
receptor	O
interactions	O
.	O

Mannose	O
appeared	O
to	O
specifically	O
inhibit	O
thrombin	B-Protein
binding	O
to	O
mouse	O
embryo	O
(	O
ME	O
)	O
and	O
hamster	O
fibroblasts	O
.	O

Concanavalin	B-Protein
A	I-Protein
bound	O
to	O
antibody	O
-	O
purified	O
receptor	O
fractions	O
,	O
and	O
was	O
used	O
as	O
an	O
affinity	O
ligand	O
to	O
purify	O
receptor	O
fractions	O
that	O
retained	O
thrombin	B-Protein
binding	O
activity	O
.	O

Cells	O
treated	O
with	O
tunicamycin	O
(	O
6	O
.	O
25	O
ng	O
/	O
ml	O
)	O
for	O
24	O
h	O
lost	O
approximately	O
35	O
%	O
of	O
their	O
high	O
-	O
affinity	O
thrombin	B-Protein
binding	O
sites	O
,	O
yet	O
binding	O
of	O
receptor	O
monoclonal	O
antibody	O
TR	O
-	O
9	O
was	O
not	O
affected	O
,	O
indicating	O
that	O
the	O
receptor	O
was	O
present	O
in	O
the	O
membrane	O
,	O
but	O
unable	O
to	O
bind	O
thrombin	B-Protein
.	O

Thus	O
thrombin	B-Protein
receptor	O
glycosylation	O
may	O
be	O
directly	O
involved	O
in	O
thrombin	B-Protein
binding	O
.	O

Functional	O
mapping	O
of	O
the	O
nucleoprotein	O
of	O
Ebola	O
virus	O
.	O

At	O
739	O
amino	O
acids	O
,	O
the	O
nucleoprotein	B-Protein
(	O
NP	B-Protein
)	O
of	O
Ebola	O
virus	O
is	O
the	O
largest	O
nucleoprotein	O
of	O
the	O
nonsegmented	O
negative	O
-	O
stranded	O
RNA	O
viruses	O
,	O
and	O
like	O
the	O
NPs	O
of	O
other	O
viruses	O
,	O
it	O
plays	O
a	O
central	O
role	O
in	O
virus	O
replication	O
.	O

Huang	O
et	O
al	O
.	O

(	O
Y	O
.	O
Huang	O
,	O
L	O
.	O
Xu	O
,	O
Y	O
.	O
Sun	O
,	O
and	O
G	O
.	O
J	O
.	O
Nabel	O
,	O
Mol	O
.	O
Cell	O
10	O
:	O
307	O
-	O
316	O
,	O
2002	O
)	O
previously	O
demonstrated	O
that	O
NP	B-Protein
,	O
together	O
with	O
the	O
minor	O
matrix	O
protein	O
VP24	B-Protein
and	O
polymerase	O
cofactor	O
VP35	B-Protein
,	O
is	O
necessary	O
and	O
sufficient	O
for	O
the	O
formation	O
of	O
nucleocapsid	O
-	O
like	O
structures	O
that	O
are	O
morphologically	O
indistinguishable	O
from	O
those	O
seen	O
in	O
Ebola	O
virus	O
-	O
infected	O
cells	O
.	O

They	O
further	O
showed	O
that	O
NP	B-Protein
is	O
O	O
glycosylated	O
and	O
sialylated	O
and	O
that	O
these	O
modifications	O
are	O
important	O
for	O
interaction	O
between	O
NP	B-Protein
and	O
VP35	B-Protein
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
structure	O
-	O
function	O
relationship	O
of	O
Ebola	O
virus	O
NP	B-Protein
.	O

Here	O
,	O
we	O
examined	O
the	O
glycosylation	O
of	O
Ebola	O
virus	O
NP	B-Protein
and	O
further	O
investigated	O
its	O
properties	O
by	O
generating	O
deletion	O
mutants	O
to	O
define	O
the	O
region	O
(	O
s	O
)	O
involved	O
in	O
NP	B-Protein
-	O
NP	B-Protein
interaction	O
(	O
self	O
-	O
assembly	O
)	O
,	O
in	O
the	O
formation	O
of	O
nucleocapsid	O
-	O
like	O
structures	O
,	O
and	O
in	O
the	O
replication	O
of	O
the	O
viral	O
genome	O
.	O

We	O
were	O
unable	O
to	O
identify	O
the	O
types	O
of	O
glycosylation	O
and	O
sialylation	O
,	O
although	O
we	O
did	O
confirm	O
that	O
Ebola	O
virus	O
NP	B-Protein
was	O
glycosylated	O
.	O

We	O
also	O
determined	O
that	O
the	O
region	O
from	O
amino	O
acids	O
1	O
to	O
450	O
is	O
important	O
for	O
NP	B-Protein
-	O
NP	B-Protein
interaction	O
(	O
self	O
-	O
assembly	O
)	O
.	O

We	O
further	O
demonstrated	O
that	O
these	O
amino	O
-	O
terminal	O
450	O
residues	O
and	O
the	O
following	O
150	O
residues	O
are	O
required	O
for	O
the	O
formation	O
of	O
nucleocapsid	O
-	O
like	O
structures	O
and	O
for	O
viral	O
genome	O
replication	O
.	O

These	O
data	O
advance	O
our	O
understanding	O
of	O
the	O
functional	O
region	O
(	O
s	O
)	O
of	O
Ebola	O
virus	O
NP	B-Protein
,	O
which	O
in	O
turn	O
should	O
improve	O
our	O
knowledge	O
of	O
the	O
Ebola	O
virus	O
life	O
cycle	O
and	O
its	O
extreme	O
pathogenicity	O
.	O

Defective	O
glycosylation	O
of	O
decorin	B-Protein
and	O
biglycan	B-Protein
,	O
altered	O
collagen	O
structure	O
,	O
and	O
abnormal	O
phenotype	O
of	O
the	O
skin	O
fibroblasts	O
of	O
an	O
Ehlers	O
-	O
Danlos	O
syndrome	O
patient	O
carrying	O
the	O
novel	O
Arg270Cys	O
substitution	O
in	O
galactosyltransferase	O
I	O
(	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
)	O
.	O

The	O
Ehlers	O
-	O
Danlos	O
syndrome	O
(	O
EDS	O
)	O
is	O
a	O
heterogeneous	O
group	O
of	O
connective	O
tissue	O
disorders	O
affecting	O
skin	O
and	O
joint	O
function	O
.	O

Molecular	O
defects	O
in	O
extracellular	O
matrix	O
proteins	O
,	O
including	O
collagen	O
(	O
type	O
I	O
,	O
III	O
,	O
and	O
V	O
)	O
and	O
tenascin	B-Protein
X	I-Protein
are	O
associated	O
with	O
different	O
forms	O
of	O
EDS	O
.	O

Compound	O
heterozygous	O
mutations	O
in	O
the	O
B4GALT7	B-Protein
gene	O
,	O
resulting	O
in	O
aberrant	O
glycosylation	O
of	O
the	O
dermatan	O
sulfate	O
proteoglycan	O
decorin	B-Protein
,	O
had	O
been	O
described	O
in	O
a	O
single	O
patient	O
affected	O
with	O
the	O
progeroid	O
form	O
of	O
EDS	O
.	O

We	O
have	O
studied	O
the	O
molecular	O
phenotype	O
of	O
decorin	B-Protein
,	O
biglycan	B-Protein
,	O
and	O
collagen	O
type	O
I	O
containing	O
fibrils	O
in	O
skin	O
fibroblasts	O
of	O
a	O
patient	O
carrying	O
the	O
novel	O
homozygous	O
C808T	O
point	O
mutation	O
in	O
the	O
B4GALT7	B-Protein
gene	O
,	O
which	O
causes	O
an	O
Arg270Cys	O
substitution	O
in	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
.	O

Compared	O
to	O
control	O
fibroblasts	O
,	O
galactosyltransferase	O
activity	O
in	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
(	O
Arg270Cys	O
)	O
cells	O
was	O
approximately	O
three	O
times	O
reduced	O
over	O
a	O
temperature	O
range	O
of	O
25	O
-	O
41	O
degrees	O
C	O
.	O

Pulse	O
-	O
chase	O
experiments	O
and	O
confocal	O
microscopy	O
demonstrated	O
that	O
synthesis	O
and	O
secretion	O
of	O
decorin	B-Protein
were	O
normal	O
in	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
(	O
Arg270Cys	O
)	O
cells	O
.	O

However	O
,	O
about	O
50	O
%	O
of	O
decorin	B-Protein
were	O
synthesized	O
as	O
a	O
protein	O
core	O
in	O
addition	O
to	O
its	O
proteoglycan	O
form	O
.	O

Biglycan	B-Protein
was	O
found	O
in	O
a	O
monoglycanated	O
form	O
in	O
addition	O
to	O
its	O
mature	O
form	O
.	O

Glycosaminoglycan	O
chains	O
were	O
of	O
the	O
dermatan	O
/	O
chondroitin	O
sulfate	O
type	O
both	O
in	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
(	O
Arg270Cys	O
)	O
and	O
control	O
cells	O
,	O
and	O
epimerization	O
was	O
reduced	O
for	O
decorin	B-Protein
and	O
biglycan	B-Protein
.	O

Compared	O
to	O
control	O
cells	O
,	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
(	O
Arg270Cys	O
)	O
cells	O
showed	O
altered	O
,	O
highly	O
spread	O
or	O
stretched	O
phenotypes	O
and	O
decreased	O
proliferation	O
rates	O
.	O

At	O
the	O
ultrastructural	O
level	O
,	O
an	O
intracellular	O
accumulation	O
of	O
multiple	O
secondary	O
lysosomes	O
and	O
degenerative	O
vacuoles	O
was	O
seen	O
in	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
(	O
Arg270Cys	O
)	O
cells	O
.	O

Furthermore	O
,	O
the	O
collagen	O
suprastructures	O
were	O
altered	O
in	O
the	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
(	O
Arg270Cys	O
)	O
cells	O
.	O

The	O
reduced	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
activity	O
resulting	O
in	O
defective	O
glycosylation	O
of	O
decorin	B-Protein
and	O
biglycan	B-Protein
may	O
be	O
responsible	O
for	O
the	O
complex	O
molecular	O
pathology	O
in	O
beta4GalT	B-Protein
-	I-Protein
7	I-Protein
deficient	O
EDS	O
patients	O
,	O
given	O
the	O
role	O
of	O
these	O
proteoglycans	O
in	O
bone	O
formation	O
,	O
collagen	O
fibrillogenesis	O
,	O
and	O
skeletal	O
muscle	O
development	O
.	O

Expression	O
of	O
aberrantly	O
glycosylated	O
tumor	O
mucin	B-Protein
-	I-Protein
1	I-Protein
on	O
human	O
DC	O
after	O
transduction	O
with	O
a	O
fiber	O
-	O
modified	O
adenoviral	O
vector	O
.	O

BACKGROUND	O
:	O
DC	O
-	O
presenting	O
tumor	O
Ag	O
are	O
currently	O
being	O
developed	O
to	O
be	O
used	O
as	O
a	O
vaccine	O
in	O
human	O
cancer	O
immunotherapy	O
.	O

To	O
increase	O
chances	O
for	O
successful	O
therapy	O
it	O
is	O
important	O
to	O
deliver	O
full	O
-	O
length	O
tumor	O
Ag	O
instead	O
of	O
loading	O
single	O
peptides	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
we	O
used	O
a	O
fiber	O
-	O
modified	O
adenoviral	O
vector	O
(	O
rAd5F35	O
)	O
containing	O
full	O
-	O
length	O
tumor	O
Ag	O
cDNA	O
to	O
transduce	O
human	O
monocyte	O
(	O
Mo	O
)	O
-	O
derived	O
DC	O
in	O
vitro	O
.	O

Cells	O
were	O
efficiently	O
transduced	O
and	O
survived	O
for	O
at	O
least	O
3	O
days	O
after	O
adenoviral	O
transduction	O
.	O

Phenotype	O
and	O
function	O
after	O
maturation	O
of	O
Mo	O
-	O
DC	O
were	O
not	O
impaired	O
by	O
infection	O
with	O
adenovirus	O
particles	O
.	O

Expression	O
of	O
the	O
tumor	O
-	O
associated	O
Ag	O
mucin	B-Protein
-	I-Protein
1	I-Protein
(	O
MUC1	B-Protein
)	O
was	O
detected	O
using	O
MAb	O
defining	O
different	O
MUC1	B-Protein
glycoforms	O
.	O

RESULTS	O
:	O
Non	O
-	O
transduced	O
mature	O
Mo	O
-	O
DC	O
express	O
endogenous	O
MUC1	B-Protein
with	O
normal	O
glycosylation	O
.	O

After	O
transduction	O
with	O
the	O
rAd5F35	O
-	O
MUC1	B-Protein
adenoviral	O
vector	O
,	O
Mo	O
-	O
DC	O
also	O
expressed	O
MUC1	B-Protein
with	O
tumor	O
-	O
associated	O
glycosylation	O
(	O
Tn	O
and	O
T	O
glycoforms	O
)	O
,	O
although	O
no	O
changes	O
in	O
mRNA	O
levels	O
of	O
relevant	O
glycosyltransferases	O
could	O
be	O
demonstrated	O
.	O

DISCUSSION	O
:	O
The	O
presence	O
of	O
aberrantly	O
glycosylated	O
MUC1	B-Protein
may	O
influence	O
Ag	O
presentation	O
of	O
the	O
tumor	O
glycoforms	O
of	O
MUC1	B-Protein
to	O
immune	O
cells	O
,	O
affecting	O
tumor	O
cell	O
killing	O
.	O

These	O
findings	O
could	O
be	O
highly	O
relevant	O
to	O
developing	O
strategies	O
for	O
cancer	O
immunotherapy	O
based	O
on	O
DC	O
vaccines	O
using	O
MUC1	B-Protein
as	O
tumor	O
Ag	O
.	O

Dissecting	O
the	O
biological	O
functions	O
of	O
Drosophila	O
histone	B-Protein
deacetylases	O
by	O
RNA	O
interference	O
and	O
transcriptional	O
profiling	O
.	O

Zinc	O
-	O
dependent	O
histone	B-Protein
deacetylases	O
(	O
HDACs	O
)	O
are	O
a	O
family	O
of	O
hydrolases	O
first	O
identified	O
as	O
components	O
of	O
transcriptional	O
repressor	O
complexes	O
,	O
where	O
they	O
act	O
by	O
deacetylating	O
lysine	O
residues	O
at	O
the	O
N	O
-	O
terminal	O
extensions	O
of	O
core	O
histones	B-Protein
,	O
thereby	O
affecting	O
transcription	O
.	O

To	O
get	O
more	O
insight	O
into	O
the	O
biological	O
functions	O
of	O
the	O
individual	O
HDAC	O
family	O
members	O
,	O
we	O
have	O
used	O
RNA	O
interference	O
in	O
combination	O
with	O
microarray	O
analysis	O
in	O
Drosophila	O
S2	O
cells	O
.	O

Silencing	O
of	O
Drosophila	O
HDAC1	B-Protein
(	O
DHDAC1	B-Protein
)	O
,	O
but	O
not	O
of	O
the	O
other	O
DHDAC	O
family	O
members	O
,	O
leads	O
to	O
increased	O
histone	B-Protein
acetylation	O
.	O

Silencing	O
of	O
either	O
DHDAC1	B-Protein
or	O
DHDAC3	B-Protein
leads	O
to	O
cell	O
growth	O
inhibition	O
and	O
deregulated	O
transcription	O
of	O
both	O
common	O
and	O
distinct	O
groups	O
of	O
genes	O
.	O

Silencing	O
DHDAC2	B-Protein
leads	O
to	O
increased	O
tubulin	O
acetylation	O
levels	O
but	O
was	O
not	O
associated	O
with	O
a	O
deregulation	O
of	O
gene	O
expression	O
.	O

No	O
growth	O
of	O
phenotype	O
and	O
no	O
significant	O
deregulation	O
of	O
gene	O
expression	O
was	O
observed	O
upon	O
silencing	O
of	O
DHDAC4	B-Protein
and	O
DHDACX	B-Protein
.	O

Loss	O
of	O
DHDAC1	B-Protein
or	O
exposure	O
of	O
S2	O
cells	O
to	O
the	O
small	O
molecule	O
HDAC	O
inhibitor	O
trichostatin	O
both	O
lead	O
to	O
a	O
G	O
(	O
2	O
)	O
arrest	O
and	O
were	O
associated	O
with	O
significantly	O
overlapping	O
gene	O
expression	O
signatures	O
in	O
which	O
genes	O
involved	O
in	O
nucleobase	O
and	O
lipid	O
metabolism	O
,	O
DNA	O
replication	O
,	O
cell	O
cycle	O
regulation	O
,	O
and	O
signal	O
transduction	O
were	O
over	O
-	O
represented	O
.	O

A	O
large	O
number	O
of	O
these	O
genes	O
were	O
shown	O
to	O
also	O
be	O
deregulated	O
upon	O
loss	O
of	O
the	O
co	O
-	O
repressor	O
SIN3	B-Protein
(	O
Pile	O
,	O
L	O
.	O
A	O
.	O
,	O
Spellman	O
,	O
P	O
.	O
T	O
.	O
,	O
Katzenberger	O
,	O
R	O
.	O
J	O
.	O
,	O
and	O
Wassarman	O
,	O
D	O
.	O
A	O
.	O
(	O
2003	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
278	O
,	O
37840	O
-	O
37848	O
)	O
.	O

We	O
conclude	O
the	O
following	O
.	O

1	O
)	O
DHDAC1	B-Protein
and	O
-	B-Protein
3	I-Protein
have	O
distinct	O
functions	O
in	O
the	O
control	O
of	O
gene	O
expression	O
.	O

2	O
)	O
Under	O
the	O
tested	O
conditions	O
,	O
DHDAC2	B-Protein
,	O
-	B-Protein
4	I-Protein
,	O
and	O
X	B-Protein
have	O
no	O
detectable	O
transcriptional	O
functions	O
in	O
S2	O
cells	O
.	O

3	O
)	O
The	O
anti	O
-	O
proliferative	O
and	O
transcriptional	O
effects	O
of	O
trichostatin	O
are	O
largely	O
recapitulated	O
by	O
the	O
loss	O
of	O
DHDAC1	B-Protein
.	O

4	O
)	O
The	O
deacetylase	O
activity	O
of	O
DHDAC1	B-Protein
significantly	O
contributes	O
to	O
the	O
repressor	O
function	O
of	O
SIN3	B-Protein
.	O

Regulation	O
of	O
HIF	O
:	O
asparaginyl	O
hydroxylation	O
.	O

The	O
hypoxia	O
inducible	O
transcription	O
factors	O
(	O
HIFs	O
)	O
are	O
regulated	O
at	O
the	O
level	O
of	O
protein	O
stability	O
and	O
transcriptional	O
activity	O
in	O
an	O
oxygen	O
-	O
dependent	O
manner	O
by	O
prolyl	O
and	O
asparaginyl	O
hydroxylation	O
,	O
respectively	O
.	O

Factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
FIH	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
the	O
only	O
known	O
HIF	B-Protein
asparaginyl	I-Protein
hydroxylase	I-Protein
,	O
and	O
targets	O
a	O
conserved	O
asparaginyl	O
residue	O
within	O
the	O
C	O
-	O
terminal	O
activation	O
domain	O
(	O
CAD	O
)	O
of	O
HIF	O
-	O
alpha	O
.	O

This	O
represses	O
HIF	O
-	O
mediated	O
transcription	O
by	O
inhibiting	O
the	O
recruitment	O
of	O
p300	B-Protein
/	O
CBP	B-Protein
coactivators	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
the	O
function	O
of	O
FIH	B-Protein
-	I-Protein
1	I-Protein
relative	O
to	O
the	O
HIF	O
prolyl	O
hydroxylases	O
(	O
PHDs	O
)	O
is	O
not	O
redundant	O
,	O
and	O
indicate	O
that	O
FIH	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
direct	O
oxygen	O
sensor	O
.	O

This	O
paper	O
will	O
address	O
recent	O
published	O
and	O
unpublished	O
work	O
characterising	O
the	O
role	O
of	O
asparaginyl	O
hydroxylation	O
in	O
the	O
cellular	O
response	O
to	O
hypoxia	O
.	O

The	O
relative	O
oxygen	O
affinities	O
and	O
hypoxic	O
activities	O
of	O
FIH	B-Protein
-	I-Protein
1	I-Protein
and	O
the	O
PHDs	O
will	O
be	O
discussed	O
.	O

Furthermore	O
,	O
in	O
vitro	O
and	O
cell	O
-	O
based	O
assays	O
demonstrating	O
some	O
novel	O
characteristics	O
regarding	O
the	O
substrate	O
specificity	O
of	O
FIH	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
their	O
potential	O
biological	O
and	O
therapeutic	O
relevance	O
will	O
be	O
presented	O
.	O

Production	O
of	O
three	O
O	O
-	O
methhylated	O
esculetins	O
with	O
Escherichia	O
coli	O
expressing	O
O	O
-	O
methyltransferase	O
from	O
poplar	O
.	O

O	O
-	O
Methyltransferase	O
,	O
POMT	B-Protein
-	I-Protein
9	I-Protein
was	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

HPLC	O
analysis	O
of	O
reaction	O
products	O
revealed	O
three	O
peaks	O
corresponding	O
to	O
isoscopoletin	O
,	O
scopoletin	O
,	O
and	O
scoparone	O
,	O
and	O
their	O
structures	O
were	O
determined	O
using	O
NMR	O
.	O

Biotransformation	O
of	O
esculetin	O
with	O
E	O
.	O
coli	O
expressing	O
POMT	B-Protein
-	I-Protein
9	I-Protein
generated	O
scopoletin	O
,	O
isoscopoletin	O
,	O
and	O
scoparone	O
at	O
30	O
.	O
3	O
,	O
21	O
,	O
and	O
31	O
microM	O
respectively	O
.	O

POMT	B-Protein
-	I-Protein
9	I-Protein
is	O
the	O
first	O
O	O
-	O
methyltransferase	O
that	O
produces	O
three	O
different	O
O	O
-	O
methylated	O
products	O
.	O

The	O
putative	O
oncogene	O
GASC1	B-Protein
demethylates	O
tri	O
-	O
and	O
dimethylated	O
lysine	O
9	O
on	O
histone	B-Protein
H3	I-Protein
.	O

Methylation	O
of	O
lysine	O
and	O
arginine	O
residues	O
on	O
histone	B-Protein
tails	O
affects	O
chromatin	O
structure	O
and	O
gene	O
transcription	O
.	O

Tri	O
-	O
and	O
dimethylation	O
of	O
lysine	O
9	O
on	O
histone	B-Protein
H3	I-Protein
(	O
H3K9me3	B-Protein
/	O
me2	O
)	O
is	O
required	O
for	O
the	O
binding	O
of	O
the	O
repressive	O
protein	O
HP1	B-Protein
and	O
is	O
associated	O
with	O
heterochromatin	O
formation	O
and	O
transcriptional	O
repression	O
in	O
a	O
variety	O
of	O
species	O
.	O

H3K9me3	B-Protein
has	O
long	O
been	O
regarded	O
as	O
a	O
'	O
permanent	O
'	O
epigenetic	O
mark	O
.	O

In	O
a	O
search	O
for	O
proteins	O
and	O
complexes	O
interacting	O
with	O
H3K9me3	B-Protein
,	O
we	O
identified	O
the	O
protein	O
GASC1	B-Protein
(	O
gene	B-Protein
amplified	I-Protein
in	I-Protein
squamous	I-Protein
cell	I-Protein
carcinoma	I-Protein
1	I-Protein
)	O
,	O
which	O
belongs	O
to	O
the	O
JMJD2	O
(	O
jumonji	O
domain	O
containing	O
2	O
)	O
subfamily	O
of	O
the	O
jumonji	O
family	O
,	O
and	O
is	O
also	O
known	O
as	O
JMJD2C	B-Protein
.	O

Here	O
we	O
show	O
that	O
three	O
members	O
of	O
this	O
subfamily	O
of	O
proteins	O
demethylate	O
H3K9me3	B-Protein
/	O
me2	O
in	O
vitro	O
through	O
a	O
hydroxylation	O
reaction	O
requiring	O
iron	O
and	O
alpha	O
-	O
ketoglutarate	O
as	O
cofactors	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
ectopic	O
expression	O
of	O
GASC1	B-Protein
or	O
other	O
JMJD2	O
members	O
markedly	O
decreases	O
H3K9me3	B-Protein
/	O
me2	O
levels	O
,	O
increases	O
H3K9me1	B-Protein
levels	O
,	O
delocalizes	O
HP1	B-Protein
and	O
reduces	O
heterochromatin	O
in	O
vivo	O
.	O

Previously	O
,	O
GASC1	B-Protein
was	O
found	O
to	O
be	O
amplified	O
in	O
several	O
cell	O
lines	O
derived	O
from	O
oesophageal	O
squamous	O
carcinomas	O
,	O
and	O
in	O
agreement	O
with	O
a	O
contribution	O
of	O
GASC1	B-Protein
to	O
tumour	O
development	O
,	O
inhibition	O
of	O
GASC1	B-Protein
expression	O
decreases	O
cell	O
proliferation	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
identifying	O
GASC1	B-Protein
as	O
a	O
histone	B-Protein
trimethyl	O
demethylase	O
,	O
we	O
suggest	O
a	O
model	O
for	O
how	O
this	O
enzyme	O
might	O
be	O
involved	O
in	O
cancer	O
development	O
,	O
and	O
propose	O
it	O
as	O
a	O
target	O
for	O
anti	O
-	O
cancer	O
therapy	O
.	O

Generation	O
of	O
hybrid	O
transgenic	O
silkworms	O
that	O
express	O
Bombyx	O
mori	O
prolyl	B-Protein
-	I-Protein
hydroxylase	I-Protein
alpha	I-Protein
-	I-Protein
subunits	I-Protein
and	O
human	O
collagens	O
in	O
posterior	O
silk	O
glands	O
:	O
Production	O
of	O
cocoons	O
that	O
contained	O
collagens	O
with	O
hydroxylated	O
proline	O
residues	O
.	O

Prolyl	O
4	O
-	O
hydroxylase	O
(	O
P4H	O
)	O
is	O
a	O
heterotetramer	O
enzyme	O
consisting	O
of	O
alpha	O
-	O
subunits	O
(	O
P4Halpha	O
)	O
and	O
beta	O
-	O
subunits	O
(	O
P4Hbeta	O
)	O
,	O
and	O
is	O
required	O
for	O
collagen	O
biosynthesis	O
.	O

Previously	O
,	O
we	O
generated	O
transgenic	O
silkworms	O
that	O
produced	O
human	O
type	B-Protein
III	I-Protein
collagen	I-Protein
fragments	O
(	O
mini	O
-	O
collagens	O
)	O
in	O
the	O
posterior	O
silk	O
gland	O
(	O
PSG	O
)	O
.	O

However	O
,	O
prolyl	O
4	O
-	O
hydroxylation	O
did	O
not	O
occur	O
on	O
the	O
mini	O
-	O
collagens	O
,	O
because	O
in	O
spite	O
of	O
an	O
abundant	O
expression	O
of	O
P4Hbeta	B-Protein
in	O
PSGs	O
,	O
P4Halpha	B-Protein
expression	O
was	O
quite	O
low	O
there	O
,	O
thus	O
resulting	O
in	O
an	O
insufficient	O
activity	O
of	O
P4H	O
.	O

In	O
this	O
study	O
we	O
aimed	O
at	O
generating	O
hybrid	O
transgenic	O
silkworms	O
whose	O
PSGs	O
are	O
capable	O
of	O
producing	O
mini	O
-	O
collagens	O
and	O
enough	O
P4H	O
for	O
their	O
prolyl	O
4	O
-	O
hydroxylation	O
.	O

Isolated	O
PSGs	O
were	O
bombarded	O
with	O
fibroin	B-Protein
L	I-Protein
-	I-Protein
chain	I-Protein
gene	O
promoter	O
-	O
driven	O
vectors	O
containing	O
Bombyx	O
mori	O
P4Halpha	B-Protein
(	O
BmP4Halpha	B-Protein
)	O
cDNAs	O
and	O
were	O
transplanted	O
into	O
the	O
hemolymphatic	O
cavity	O
.	O

The	O
P4H	O
activity	O
in	O
the	O
PSG	O
cells	O
significantly	O
increased	O
,	O
indicating	O
that	O
the	O
expressed	O
BmP4Halpha	B-Protein
formed	O
active	O
tetramers	O
with	O
endogenous	O
BmP4Hbeta	B-Protein
.	O

Using	O
germ	O
-	O
line	O
transgenesis	O
technology	O
,	O
silkworms	O
were	O
generated	O
that	O
synthesized	O
BmP4Halpha	B-Protein
in	O
PSG	O
cells	O
.	O

The	O
P4H	O
activity	O
in	O
the	O
transgenic	O
silkworms	O
was	O
130	O
-	O
fold	O
higher	O
than	O
that	O
of	O
wild	O
-	O
type	O
counterparts	O
.	O

Finally	O
,	O
we	O
generated	O
hybrid	O
transgenic	O
silkworms	O
that	O
expressed	O
cDNAs	O
of	O
both	O
BmP4Halpha	B-Protein
and	O
mini	O
-	O
collagen	O
in	O
PSG	O
cells	O
.	O

They	O
spun	O
cocoons	O
that	O
contained	O
mini	O
-	O
collagens	O
whose	O
appropriate	O
proline	O
residues	O
had	O
been	O
adequately	O
hydroxylated	O
.	O

A	O
carotenoid	O
synthesis	O
gene	O
cluster	O
from	O
a	O
non	O
-	O
marine	O
Brevundimonas	O
that	O
synthesizes	O
hydroxylated	O
astaxanthin	O
.	O

A	O
Brevundimonas	O
vesicularis	O
strain	O
DC263	O
isolated	O
from	O
surface	O
soil	O
was	O
shown	O
to	O
produce	O
hydroxylated	O
astaxanthin	O
.	O

A	O
carotenoid	O
synthesis	O
gene	O
cluster	O
containing	O
ten	O
genes	O
was	O
cloned	O
from	O
strain	O
DC263	O
,	O
among	O
which	O
eight	O
genes	O
were	O
involved	O
in	O
carotenoid	O
synthesis	O
.	O

In	O
addition	O
to	O
the	O
crtW	B-Protein
gene	O
encoding	O
the	O
4	O
,	O
4	O
'	O
-	O
beta	O
-	O
ionone	O
ring	O
ketolase	O
and	O
the	O
crtZ	B-Protein
gene	O
encoding	O
the	O
3	O
,	O
3	O
'	O
-	O
beta	O
-	O
ionone	O
ring	O
hydroxylase	O
that	O
were	O
responsible	O
for	O
astaxanthin	O
synthesis	O
,	O
the	O
cluster	O
also	O
contained	O
a	O
novel	O
gene	O
crtG	B-Protein
identified	O
recently	O
encoding	O
the	O
2	O
,	O
2	O
'	O
-	O
beta	O
-	O
ionone	O
ring	O
hydroxylase	O
that	O
further	O
hydroxylate	O
astaxanthin	O
.	O

The	O
individual	O
genes	O
in	O
the	O
DC263	O
cluster	O
showed	O
the	O
highest	O
sequence	O
similarities	O
to	O
the	O
corresponding	O
genes	O
reported	O
in	O
Brevundimonas	O
sp	O
.	O
strain	O
SD212	O
,	O
a	O
marine	O
isolate	O
that	O
also	O
produced	O
hydroxylated	O
astaxanthin	O
.	O

The	O
genetic	O
organization	O
of	O
the	O
carotenoid	O
synthesis	O
gene	O
clusters	O
in	O
the	O
two	O
Brevundimonas	O
strains	O
was	O
identical	O
.	O

It	O
is	O
likely	O
that	O
the	O
two	O
Brevundimonas	O
strains	O
were	O
evolved	O
from	O
the	O
same	O
ancestor	O
and	O
adapted	O
later	O
to	O
growth	O
in	O
different	O
environments	O
.	O

Expression	O
of	O
the	O
crtW	B-Protein
and	O
crtZ	B-Protein
from	O
DC263	O
in	O
a	O
beta	O
-	O
carotene	O
-	O
accumulating	O
E	O
.	O
coli	O
produced	O
astaxanthin	O
as	O
the	O
predominant	O
carotenoid	O
.	O

The	O
crtG	B-Protein
from	O
DC263	O
and	O
the	O
crtG	B-Protein
from	O
another	O
Brevundimonas	O
aurantiaca	O
strain	O
were	O
expressed	O
in	O
E	O
.	O
coli	O
producing	O
different	O
carotenoid	O
substrates	O
.	O

Both	O
CrtG	B-Protein
showed	O
low	O
activity	O
on	O
beta	O
-	O
carotene	O
and	O
high	O
activity	O
on	O
zeaxanthin	O
.	O

The	O
main	O
difference	O
was	O
that	O
the	O
CrtG	B-Protein
from	O
B	O
.	O
aurantiaca	O
worked	O
well	O
on	O
canthaxanthin	O
or	O
astaxanthin	O
,	O
but	O
the	O
CrtG	B-Protein
from	O
DC263	O
did	O
not	O
work	O
on	O
either	O
of	O
the	O
ketocarotenoids	O
.	O

Probing	O
long	O
-	O
distance	O
regulatory	O
interactions	O
in	O
the	O
Drosophila	O
melanogaster	O
bithorax	O
complex	O
using	O
Dam	O
identification	O
.	O

A	O
cis	O
-	O
regulatory	O
region	O
of	O
nearly	O
300	O
kb	O
controls	O
the	O
expression	O
of	O
the	O
three	O
bithorax	O
complex	O
(	O
BX	O
-	O
C	O
)	O
homeotic	O
genes	O
:	O
Ubx	B-Protein
,	O
abd	B-Protein
-	I-Protein
A	I-Protein
and	O
Abd	B-Protein
-	I-Protein
B	I-Protein
.	O

Interspersed	O
between	O
the	O
numerous	O
enhancers	O
and	O
silencers	O
within	O
the	O
complex	O
are	O
elements	O
called	O
domain	O
boundaries	O
.	O

Recently	O
,	O
many	O
pieces	O
of	O
evidence	O
have	O
suggested	O
that	O
boundaries	O
function	O
to	O
create	O
autonomous	O
domains	O
by	O
interacting	O
among	O
themselves	O
and	O
forming	O
chromatin	O
loops	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
used	O
Dam	O
identification	O
to	O
probe	O
for	O
interactions	O
between	O
the	O
Fab	O
-	O
7	O
boundary	O
and	O
other	O
regions	O
in	O
the	O
BX	O
-	O
C	O
.	O

We	O
were	O
surprised	O
to	O
find	O
that	O
the	O
targeting	O
of	O
Dam	O
methyltransferase	O
(	O
Dam	O
)	O
to	O
the	O
Fab	O
-	O
7	O
boundary	O
results	O
in	O
a	O
strong	O
methylation	O
signal	O
at	O
the	O
Abd	B-Protein
-	I-Protein
Bm	I-Protein
promoter	O
,	O
approximately	O
35	O
kb	O
away	O
.	O

Moreover	O
,	O
this	O
methylation	O
pattern	O
is	O
found	O
primarily	O
in	O
the	O
tissues	O
where	O
Abd	B-Protein
-	I-Protein
B	I-Protein
is	O
not	O
expressed	O
and	O
requires	O
an	O
intact	O
Fab	O
-	O
7	O
boundary	O
.	O

Overall	O
,	O
our	O
work	O
provides	O
the	O
first	O
documented	O
example	O
of	O
a	O
dynamic	O
,	O
long	O
-	O
distance	O
physical	O
interaction	O
between	O
distal	O
regulatory	O
elements	O
within	O
a	O
living	O
,	O
multicellular	O
organism	O
.	O

Activation	O
of	O
mitochondrial	O
pathway	O
is	O
crucial	O
for	O
tumor	O
selective	O
induction	O
of	O
apoptosis	O
by	O
LAQ824	O
.	O

HDAC	O
inhibitors	O
are	O
promising	O
antitumor	O
drugs	O
with	O
several	O
HDAC	O
inhibitors	O
already	O
in	O
clinical	O
trials	O
.	O

LAQ824	O
,	O
a	O
potent	O
pan	O
-	O
HDAC	O
inhibitor	O
,	O
has	O
been	O
shown	O
to	O
induce	O
cell	O
cycle	O
arrest	O
and	O
cell	O
death	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
its	O
antitumor	O
effects	O
and	O
specially	O
its	O
tumor	O
selectivity	O
are	O
still	O
poorly	O
understood	O
.	O

The	O
focus	O
of	O
this	O
study	O
is	O
to	O
elucidate	O
LAQ824	O
mediated	O
anti	O
-	O
proliferative	O
effects	O
in	O
lung	O
carcinoma	O
cells	O
and	O
the	O
mechanism	O
underlying	O
the	O
different	O
sensitivity	O
of	O
LAQ824	O
to	O
cancer	O
and	O
normal	O
cells	O
.	O

In	O
this	O
study	O
,	O
LAQ824	O
mediated	O
apoptosis	O
was	O
found	O
to	O
occur	O
mainly	O
via	O
activation	O
of	O
the	O
mitochondrial	O
death	O
pathway	O
by	O
inducing	O
Apaf1	B-Protein
and	O
caspase	B-Protein
9	I-Protein
and	O
promoting	O
mitochondrial	O
release	O
of	O
key	O
proapoptotic	O
factors	O
in	O
lung	O
cancer	O
cells	O
,	O
but	O
not	O
in	O
normal	O
fibroblast	O
cells	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
assay	O
,	O
we	O
found	O
that	O
RNA	O
Pol	O
II	O
binding	O
and	O
histone	B-Protein
H3	I-Protein
acetylation	O
levels	O
at	O
Apaf1	B-Protein
promoter	O
were	O
increased	O
following	O
LAQ824	O
treatment	O
,	O
explaining	O
LAQ824	O
induced	O
expression	O
of	O
Apaf1	B-Protein
in	O
lung	O
cancer	O
cells	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
LAQ824	O
only	O
triggered	O
the	O
release	O
of	O
mitochondrial	O
proapoptotic	O
factors	O
such	O
as	O
cytochrome	B-Protein
C	I-Protein
(	O
Cyto	B-Protein
C	I-Protein
)	O
and	O
apoptosis	O
inducing	O
factor	O
(	O
AIF	O
)	O
in	O
lung	O
cancer	O
cells	O
but	O
not	O
in	O
normal	O
blast	O
cells	O
.	O

In	O
addition	O
,	O
LAQ824	O
was	O
found	O
to	O
induce	O
Bax	B-Protein
translocation	O
in	O
lung	O
cancer	O
cell	O
,	O
which	O
may	O
play	O
important	O
role	O
in	O
the	O
induction	O
of	O
the	O
release	O
of	O
mitochondrial	O
proapoptotic	O
factors	O
.	O

These	O
data	O
provide	O
insight	O
into	O
the	O
mechanism	O
underlying	O
the	O
selective	O
induction	O
of	O
apoptosis	O
by	O
LAQ824	O
in	O
cancer	O
cells	O
.	O

Human	O
cytomegalovirus	O
-	O
encoded	O
UL16	B-Protein
discriminates	O
MIC	O
molecules	O
by	O
their	O
alpha2	O
domains	O
.	O

Human	O
CMV	O
infection	O
results	O
in	O
MHC	O
class	O
I	O
down	O
-	O
regulation	O
and	O
induction	O
of	O
NKG2D	B-Protein
ligand	O
expression	O
favoring	O
NK	O
recognition	O
of	O
infected	O
cells	O
.	O

However	O
,	O
human	O
CMV	O
-	O
encoded	O
UL16	B-Protein
counteracts	O
surface	O
expression	O
of	O
several	O
NKG2D	B-Protein
ligands	O
by	O
intracellular	O
retention	O
.	O

Interestingly	O
,	O
UL16	B-Protein
interacts	O
with	O
MICB	B-Protein
,	O
but	O
not	O
with	O
the	O
closely	O
related	O
MICA	B-Protein
,	O
and	O
with	O
UL16	B-Protein
-	O
binding	O
proteins	O
(	O
ULBP	O
)	O
ULBP1	B-Protein
and	O
ULBP2	B-Protein
,	O
which	O
are	O
only	O
distantly	O
related	O
to	O
MICB	B-Protein
,	O
but	O
not	O
with	O
ULPB3	B-Protein
or	O
ULBP4	B-Protein
,	O
although	O
all	O
constitute	O
ligands	O
for	O
NKG2D	B-Protein
.	O

Here	O
,	O
we	O
dissected	O
the	O
molecular	O
basis	O
of	O
MICA	B-Protein
-	O
MICB	B-Protein
discrimination	O
by	O
UL16	B-Protein
to	O
elucidate	O
its	O
puzzling	O
binding	O
behavior	O
.	O

We	O
report	O
that	O
the	O
UL16	B-Protein
-	O
MICB	B-Protein
interaction	O
is	O
independent	O
of	O
glycosylation	O
and	O
demonstrate	O
that	O
selective	O
MICB	B-Protein
recognition	O
by	O
UL16	B-Protein
is	O
governed	O
by	O
helical	O
structures	O
of	O
the	O
MICB	B-Protein
alpha2	O
domain	O
.	O

Transplantation	O
of	O
the	O
MICB	B-Protein
alpha2	O
domain	O
confers	O
UL16	B-Protein
binding	O
capacity	O
to	O
MICA	B-Protein
,	O
and	O
thus	O
,	O
diversification	O
of	O
the	O
MICA	B-Protein
alpha2	O
domain	O
may	O
have	O
been	O
driven	O
by	O
the	O
selective	O
pressure	O
exerted	O
by	O
UL16	B-Protein
.	O

Hypoxia	O
-	O
induced	O
assembly	O
of	O
prolyl	O
hydroxylase	O
PHD3	B-Protein
into	O
complexes	O
:	O
implications	O
for	O
its	O
activity	O
and	O
susceptibility	O
for	O
degradation	O
by	O
the	O
E3	O
ligase	O
Siah2	B-Protein
.	O

PHD1	B-Protein
-	O
3	B-Protein
(	O
prolyl	B-Protein
hydroxylases	I-Protein
1	I-Protein
-	O
3	B-Protein
)	O
catalyse	O
the	O
hydroxylation	O
of	O
HIF	O
(	O
hypoxia	O
-	O
inducible	O
factor	O
)	O
-	O
alpha	O
subunit	O
that	O
triggers	O
the	O
substrate	O
ubiquitination	O
and	O
subsequent	O
degradation	O
.	O

The	O
RING	O
(	O
really	O
interesting	O
new	O
gene	O
)	O
finger	O
E3	O
ligase	O
Siah2	B-Protein
preferentially	O
targets	O
PHD3	B-Protein
for	O
degradation	O
.	O

Here	O
,	O
we	O
identify	O
the	O
requirements	O
for	O
such	O
selective	O
targeting	O
.	O

Firstly	O
,	O
PHD3	B-Protein
lacks	O
an	O
N	O
-	O
terminal	O
extension	O
found	O
in	O
PHD1	B-Protein
and	O
PHD2	B-Protein
;	O
deletion	O
of	O
this	O
domain	O
from	O
PHD1	B-Protein
and	O
PHD2	B-Protein
renders	O
them	O
susceptible	O
to	O
degradation	O
by	O
Siah2	B-Protein
.	O

Secondly	O
,	O
PHD3	B-Protein
can	O
homo	O
-	O
and	O
hetero	O
-	O
multimerize	O
with	O
other	O
PHDs	O
.	O

Consequently	O
,	O
PHD3	B-Protein
is	O
found	O
in	O
high	O
-	O
molecular	O
-	O
mass	O
fractions	O
that	O
were	O
enriched	O
in	O
hypoxia	O
.	O

Interestingly	O
,	O
within	O
the	O
lower	O
-	O
molecular	O
-	O
mass	O
complex	O
,	O
PHD3	B-Protein
exhibits	O
higher	O
specific	O
activity	O
towards	O
hydroxylation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
co	O
-	O
localizes	O
with	O
Siah2	B-Protein
,	O
suggesting	O
that	O
Siah2	B-Protein
limits	O
the	O
availability	O
of	O
the	O
more	O
active	O
form	O
of	O
PHD3	B-Protein
.	O

These	O
findings	O
provide	O
new	O
insight	O
into	O
the	O
mechanism	O
underlying	O
the	O
regulation	O
of	O
PHD3	B-Protein
availability	O
and	O
activity	O
in	O
hypoxia	O
by	O
the	O
E3	O
ligase	O
Siah2	B-Protein
.	O

Comparative	O
analysis	O
of	O
the	O
human	O
angiotensin	B-Protein
II	I-Protein
type	I-Protein
1a	I-Protein
receptor	I-Protein
heterologously	O
produced	O
in	O
insect	O
cells	O
and	O
mammalian	O
cells	O
.	O

Angiotensin	B-Protein
II	I-Protein
type	I-Protein
1a	I-Protein
receptor	I-Protein
(	O
AT1aR	B-Protein
)	O
is	O
a	O
member	O
of	O
GPCR	O
superfamily	O
and	O
it	O
plays	O
crucial	O
roles	O
in	O
the	O
regulation	O
of	O
blood	O
pressure	O
,	O
hormone	O
secretion	O
and	O
renal	O
functions	O
.	O

Here	O
,	O
we	O
report	O
functional	O
overexpression	O
and	O
characterization	O
of	O
the	O
human	O
AT1aR	B-Protein
in	O
insect	O
cells	O
using	O
the	O
baculovirus	O
system	O
and	O
in	O
mammalian	O
cells	O
using	O
the	O
Semliki	O
Forest	O
virus	O
system	O
.	O

The	O
recombinant	O
receptor	O
was	O
expressed	O
at	O
a	O
level	O
of	O
29	O
-	O
32	O
pmol	O
/	O
mg	O
and	O
it	O
binds	O
to	O
angiontensin	B-Protein
II	I-Protein
with	O
high	O
affinity	O
(	O
Kd	O
=	O
0	O
.	O
98	O
-	O
1	O
.	O
1	O
nM	O
)	O
.	O

Angiotensin	B-Protein
II	I-Protein
stimulated	O
accumulation	O
of	O
inositol	O
phosphate	O
and	O
phosphorylation	O
of	O
MAP	O
kinase	O
was	O
also	O
observed	O
,	O
which	O
indicated	O
that	O
the	O
recombinant	O
AT1aR	B-Protein
could	O
couple	O
to	O
endogenous	O
Galphaq	B-Protein
protein	O
.	O

Confocal	O
laser	O
scanning	O
microscopy	O
revealed	O
that	O
the	O
recombinant	O
receptor	O
was	O
predominantly	O
localized	O
in	O
the	O
plasma	O
membrane	O
and	O
agonist	O
induced	O
internalization	O
of	O
the	O
recombinant	O
AT1aR	B-Protein
was	O
also	O
observed	O
.	O

The	O
recombinant	O
AT1aR	B-Protein
was	O
expressed	O
in	O
glycosylated	O
form	O
and	O
in	O
vivo	O
inhibition	O
of	O
glycosylation	O
suppressed	O
its	O
surface	O
expression	O
.	O

Control	O
of	O
human	O
cytomegalovirus	O
gene	O
expression	O
by	O
differential	O
histone	B-Protein
modifications	O
during	O
lytic	O
and	O
latent	O
infection	O
of	O
a	O
monocytic	O
cell	O
line	O
.	O

Non	O
-	O
differentiated	O
THP	O
-	O
1	O
cells	O
can	O
be	O
infected	O
by	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
Towne	O
strain	O
,	O
which	O
persists	O
in	O
these	O
cells	O
in	O
a	O
non	O
-	O
active	O
(	O
latent	O
)	O
form	O
without	O
undergoing	O
a	O
productive	O
cycle	O
.	O

The	O
same	O
cells	O
become	O
permissive	O
for	O
HCMV	O
lytic	O
infection	O
after	O
induction	O
of	O
cell	O
differentiation	O
by	O
treatment	O
with	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
.	O

We	O
used	O
this	O
cellular	O
model	O
to	O
study	O
the	O
possible	O
role	O
of	O
histone	B-Protein
modifications	O
in	O
the	O
control	O
of	O
HCMV	O
latency	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
with	O
antibodies	O
against	O
histone	B-Protein
H3	I-Protein
acetylated	O
or	O
dimethylated	O
in	O
position	O
K9	O
,	O
we	O
demonstrated	O
that	O
in	O
lytically	O
infected	O
cells	O
the	O
HCMV	O
enhancer	O
was	O
associated	O
with	O
heavy	O
acetylated	O
but	O
not	O
dimethylated	O
H3	B-Protein
.	O

In	O
the	O
case	O
of	O
latent	O
infection	O
,	O
the	O
HCMV	O
enhancer	O
was	O
associated	O
with	O
neither	O
acetylated	O
nor	O
dimethylated	O
H3	B-Protein
.	O

HCMV	O
genes	O
encoding	O
DNA	B-Protein
polymerase	I-Protein
(	O
early	O
)	O
,	O
pp65	B-Protein
(	O
early	O
-	O
late	O
)	O
and	O
pp150	B-Protein
(	O
late	O
)	O
proteins	O
were	O
associated	O
preferentially	O
with	O
acetylated	O
H3	B-Protein
in	O
lytically	O
infected	O
cells	O
and	O
with	O
dimethylated	O
H3	B-Protein
in	O
latently	O
infected	O
cells	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
K9	O
methylation	O
of	O
H3	B-Protein
is	O
involved	O
in	O
HCMV	O
gene	O
repression	O
,	O
while	O
association	O
of	O
the	O
above	O
genes	O
with	O
acetylated	O
histones	B-Protein
is	O
likely	O
to	O
be	O
necessary	O
for	O
active	O
transcription	O
.	O

It	O
can	O
be	O
postulated	O
that	O
the	O
same	O
histone	O
modifications	O
are	O
used	O
to	O
mark	O
active	O
and	O
repressed	O
genes	O
in	O
both	O
cellular	O
and	O
viral	O
chromatin	O
.	O

Posttranslational	O
hydroxylation	O
of	O
ankyrin	O
repeats	O
in	O
IkappaB	O
proteins	O
by	O
the	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	I-Protein
HIF	I-Protein
)	I-Protein
asparaginyl	I-Protein
hydroxylase	I-Protein
,	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
FIH	B-Protein
)	O
.	O

Studies	O
on	O
hypoxia	O
-	O
sensitive	O
pathways	O
have	O
revealed	O
a	O
series	O
of	O
Fe	O
(	O
II	O
)	O
-	O
dependent	O
dioxygenases	O
that	O
regulate	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
by	O
prolyl	O
and	O
asparaginyl	O
hydroxylation	O
.	O

The	O
recognition	O
of	O
these	O
unprecedented	O
signaling	O
processes	O
has	O
led	O
to	O
a	O
search	O
for	O
other	O
substrates	O
of	O
the	O
HIF	O
hydroxylases	O
.	O

Here	O
we	O
show	O
that	O
the	O
human	O
HIF	B-Protein
asparaginyl	I-Protein
hydroxylase	I-Protein
,	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
FIH	B-Protein
)	O
,	O
also	O
efficiently	O
hydroxylates	O
specific	O
asparaginyl	O
(	O
Asn	O
)	O
-	O
residues	O
within	O
proteins	O
of	O
the	O
IkappaB	O
family	O
.	O

After	O
the	O
identification	O
of	O
a	O
series	O
of	O
ankyrin	O
repeat	O
domain	O
(	O
ARD	O
)	O
-	O
containing	O
proteins	O
in	O
a	O
screen	O
for	O
proteins	O
interacting	O
with	O
FIH	B-Protein
,	O
the	O
ARDs	O
of	O
p105	B-Protein
(	O
NFKB1	B-Protein
)	O
and	O
IkappaBalpha	B-Protein
were	O
shown	O
to	O
be	O
efficiently	O
hydroxylated	O
by	O
FIH	B-Protein
at	O
specific	O
Asn	O
residues	O
in	O
the	O
hairpin	O
loops	O
linking	O
particular	O
ankyrin	O
repeats	O
.	O

The	O
target	O
Asn	O
residue	O
is	O
highly	O
conserved	O
as	O
part	O
of	O
the	O
ankyrin	O
consensus	O
,	O
and	O
peptides	O
derived	O
from	O
a	O
diverse	O
range	O
of	O
ARD	O
-	O
containing	O
proteins	O
supported	O
FIH	B-Protein
enzyme	O
activity	O
.	O

These	O
findings	O
demonstrate	O
that	O
this	O
type	O
of	O
protein	O
hydroxylation	O
is	O
not	O
restricted	O
to	O
HIF	O
and	O
strongly	O
suggest	O
that	O
FIH	B-Protein
-	O
dependent	O
ARD	O
hydroxylation	O
is	O
a	O
common	O
occurrence	O
,	O
potentially	O
providing	O
an	O
oxygen	O
-	O
sensitive	O
signal	O
to	O
a	O
diverse	O
range	O
of	O
processes	O
.	O

Protein	O
arginine	O
methyltransferases	O
:	O
evolution	O
and	O
assessment	O
of	O
their	O
pharmacological	O
and	O
therapeutic	O
potential	O
.	O

Protein	O
arginine	O
N	O
-	O
methylation	O
is	O
a	O
post	O
-	O
translational	O
modification	O
whose	O
influence	O
on	O
cell	O
function	O
is	O
becoming	O
widely	O
appreciated	O
.	O

Protein	O
arginine	O
methyltransferases	O
(	O
PRMT	O
)	O
catalyze	O
the	O
methylation	O
of	O
terminal	O
nitrogen	O
atoms	O
of	O
guanidinium	O
side	O
chains	O
within	O
arginine	O
residues	O
of	O
proteins	O
.	O

Recently	O
,	O
several	O
new	O
members	O
of	O
the	O
PRMT	O
family	O
have	O
been	O
cloned	O
and	O
their	O
catalytic	O
function	O
determined	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
a	O
review	O
and	O
phylogenetic	O
analysis	O
of	O
the	O
PRMT	O
found	O
so	O
far	O
in	O
genomes	O
.	O

PRMT	O
are	O
found	O
in	O
nearly	O
all	O
groups	O
of	O
eukaryotes	O
.	O

Many	O
human	O
PRMT	O
originated	O
early	O
in	O
eukaryote	O
evolution	O
.	O

Homologs	O
of	O
PRMT1	B-Protein
and	O
PRMT5	B-Protein
are	O
found	O
in	O
nearly	O
every	O
eukaryote	O
studied	O
.	O

The	O
gene	O
structure	O
of	O
PRMT	O
vary	O
:	O
most	O
introns	O
appear	O
to	O
be	O
inserted	O
randomly	O
into	O
the	O
open	O
reading	O
frame	O
.	O

The	O
change	O
in	O
catalytic	O
specificity	O
of	O
some	O
PRMT	O
occurred	O
with	O
changes	O
in	O
the	O
arginine	O
binding	O
pocket	O
within	O
the	O
active	O
site	O
.	O

Because	O
of	O
the	O
high	O
degree	O
of	O
conservation	O
of	O
sequence	O
among	O
the	O
family	O
throughout	O
evolution	O
,	O
creation	O
of	O
specific	O
PRMT	O
inhibitors	O
in	O
pathogenic	O
organisms	O
may	O
be	O
difficult	O
,	O
but	O
could	O
be	O
very	O
effective	O
if	O
developed	O
.	O

Furthermore	O
,	O
because	O
of	O
the	O
intricate	O
involvement	O
of	O
several	O
PRMT	O
in	O
cellular	O
physiology	O
,	O
their	O
inhibition	O
may	O
be	O
fraught	O
with	O
unwanted	O
side	O
effects	O
.	O

Nevertheless	O
,	O
development	O
of	O
pharmaceutical	O
agents	O
to	O
control	O
PRMT	O
functions	O
could	O
lead	O
to	O
significant	O
new	O
targets	O
.	O

Glycosylation	O
of	O
an	O
immunoglobulin	O
produced	O
from	O
a	O
murine	O
hybridoma	O
cell	O
line	O
:	O
the	O
effect	O
of	O
culture	O
mode	O
and	O
the	O
anti	O
-	O
apoptotic	O
gene	O
,	O
bcl	B-Protein
-	I-Protein
2	I-Protein
.	O

The	O
impact	O
of	O
bcl	B-Protein
-	I-Protein
2	I-Protein
over	O
-	O
expression	O
on	O
the	O
glycosylation	O
pattern	O
of	O
an	O
antibody	O
produced	O
by	O
a	O
bcl	B-Protein
-	I-Protein
2	I-Protein
transfected	O
hybridoma	O
cell	O
line	O
(	O
TB	O
/	O
C3	O
.	O
bcl	O
-	O
2	O
)	O
was	O
investigated	O
in	O
suspension	O
batch	O
,	O
continuous	O
and	O
high	O
cell	O
density	O
culture	O
(	O
Flat	O
hollow	O
fibre	O
,	O
Tecnomouse	O
system	O
)	O
.	O

In	O
all	O
culture	O
modes	O
bcl	B-Protein
-	I-Protein
2	I-Protein
over	O
-	O
expression	O
resulted	O
in	O
higher	O
cell	O
viability	O
.	O

Analysis	O
of	O
the	O
glycans	O
from	O
the	O
IgG	O
of	O
batch	O
cultures	O
showed	O
that	O
>	O
95	O
%	O
of	O
the	O
structures	O
were	O
neutral	O
core	O
fucosylated	O
asialo	O
biantennary	O
oligosaccharides	O
with	O
variable	O
terminal	O
galactosylation	O
(	O
G0f	O
,	O
G1f	O
and	O
G2f	O
)	O
consistent	O
with	O
previous	O
analysis	O
of	O
glycans	O
from	O
the	O
conserved	O
site	O
at	O
Asn	O
-	O
297	O
of	O
the	O
IgG	O
protein	O
.	O

The	O
galactosylation	O
index	O
(	O
GI	O
)	O
was	O
determined	O
as	O
an	O
indicator	O
of	O
the	O
glycan	O
profile	O
(	O
=	O
(	O
G2	O
+	O
0	O
.	O
5	O
*	O
G1	O
)	O
/	O
(	O
G0	O
+	O
G1	O
+	O
G2	O
)	O
)	O
.	O

GI	O
values	O
in	O
control	O
cultures	O
were	O
comparable	O
to	O
bcl	B-Protein
-	I-Protein
2	I-Protein
cultures	O
during	O
exponential	O
growth	O
(	O
0	O
.	O
53	O
)	O
but	O
declined	O
toward	O
the	O
end	O
of	O
the	O
culture	O
when	O
there	O
was	O
a	O
loss	O
in	O
cell	O
viability	O
.	O

Low	O
dilution	O
rates	O
in	O
chemostat	O
culture	O
were	O
associated	O
with	O
reduced	O
galactosylation	O
of	O
the	O
IgG	O
glycans	O
in	O
both	O
cell	O
lines	O
.	O

However	O
,	O
at	O
the	O
higher	O
dilution	O
rates	O
the	O
GI	O
for	O
IgG	O
was	O
consistently	O
higher	O
in	O
the	O
TB	O
/	O
C3	O
.	O
bcl	B-Protein
-	I-Protein
2	I-Protein
cultures	O
.	O

In	O
the	O
hollow	O
fibre	O
bioreactor	O
the	O
galactosylation	O
of	O
the	O
IgG	O
glycans	O
was	O
considerably	O
lower	O
than	O
in	O
suspension	O
batch	O
or	O
continuous	O
cultures	O
with	O
GI	O
values	O
averaging	O
0	O
.	O
38	O
.	O

Similar	O
low	O
galactosylation	O
values	O
have	O
been	O
found	O
previously	O
for	O
high	O
density	O
cell	O
cultures	O
and	O
these	O
are	O
consistent	O
with	O
the	O
low	O
values	O
obtained	O
when	O
the	O
dissolved	O
oxygen	O
level	O
is	O
maintained	O
at	O
a	O
low	O
value	O
(	O
10	O
%	O
)	O
in	O
controlled	O
suspension	O
cultures	O
of	O
hybridomas	O
.	O

The	O
cold	O
and	O
menthol	O
receptor	O
TRPM8	B-Protein
contains	O
a	O
functionally	O
important	O
double	O
cysteine	O
motif	O
.	O

We	O
have	O
investigated	O
the	O
glycosylation	O
,	O
disulfide	O
bonding	O
,	O
and	O
subunit	O
structure	O
of	O
mouse	O
TRPM8	B-Protein
.	O

To	O
do	O
this	O
,	O
amino	O
-	O
terminal	O
c	B-Protein
-	I-Protein
myc	I-Protein
or	O
hemagglutinin	B-Protein
epitope	O
-	O
tagged	O
proteins	O
were	O
incorporated	O
and	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

These	O
modifications	O
had	O
no	O
obvious	O
effects	O
on	O
channel	O
function	O
in	O
intracellular	O
calcium	O
imaging	O
assays	O
upon	O
application	O
of	O
agonists	O
,	O
icilin	O
or	O
menthol	O
,	O
and	O
cold	O
temperatures	O
.	O

Unmodified	O
TRPM8	B-Protein
migrates	O
with	O
an	O
apparent	O
mass	O
of	O
129	O
kDa	O
and	O
can	O
be	O
glycosylated	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
to	O
give	O
glycoproteins	O
with	O
apparent	O
masses	O
of	O
136	O
and	O
147	O
kDa	O
.	O

We	O
identified	O
two	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
in	O
TRPM8	B-Protein
(	O
Asn	O
-	O
821	O
and	O
Asn	O
-	O
934	O
)	O
and	O
mutated	O
them	O
to	O
show	O
that	O
only	O
the	O
site	O
in	O
the	O
putative	O
pore	O
region	O
at	O
position	O
934	O
is	O
modified	O
and	O
that	O
glycosylation	O
of	O
this	O
site	O
is	O
not	O
absolutely	O
necessary	O
for	O
cell	O
surface	O
expression	O
or	O
responsiveness	O
to	O
icilin	O
,	O
menthol	O
,	O
and	O
cool	O
temperatures	O
.	O

Enzymatic	O
cleavage	O
of	O
the	O
carbohydrate	O
chains	O
indicated	O
that	O
they	O
are	O
complex	O
carbohydrate	O
.	O

The	O
glycosylation	O
site	O
is	O
flanked	O
in	O
the	O
pore	O
by	O
two	O
cysteine	O
residues	O
that	O
we	O
mutated	O
,	O
to	O
prove	O
that	O
they	O
are	O
involved	O
in	O
a	O
conserved	O
double	O
cysteine	O
motif	O
,	O
which	O
is	O
essential	O
for	O
channel	O
function	O
.	O

Mutation	O
of	O
either	O
of	O
these	O
cysteines	O
abolishes	O
function	O
and	O
forces	O
the	O
formation	O
of	O
a	O
non	O
-	O
functional	O
complex	O
of	O
the	O
size	O
of	O
a	O
homodimer	O
.	O

The	O
double	O
cysteine	O
mutant	O
is	O
also	O
non	O
-	O
functional	O
.	O

Finally	O
,	O
we	O
showed	O
in	O
Perfluoro	O
-	O
octanoic	O
acid	O
-	O
polyacrylamide	O
gels	O
that	O
TRPM8	B-Protein
can	O
form	O
a	O
tetramer	O
(	O
in	O
addition	O
to	O
dimer	O
and	O
trimer	O
forms	O
)	O
,	O
consistent	O
with	O
current	O
thinking	O
that	O
functional	O
TRP	O
ion	O
channels	O
are	O
tetrameric	O
.	O

Transcriptional	O
regulation	O
by	O
Foxp3	B-Protein
is	O
associated	O
with	O
direct	O
promoter	O
occupancy	O
and	O
modulation	O
of	O
histone	B-Protein
acetylation	O
.	O

Regulatory	O
T	O
cells	O
(	O
T	O
(	O
reg	O
)	O
)	O
express	O
Foxp3	B-Protein
,	O
a	O
forkhead	O
family	O
member	O
that	O
is	O
necessary	O
and	O
sufficient	O
for	O
T	O
(	O
reg	O
)	O
lineage	O
choice	O
and	O
function	O
.	O

Ectopic	O
expression	O
of	O
Foxp3	B-Protein
in	O
non	O
-	O
T	O
(	O
reg	O
)	O
leads	O
to	O
repression	O
of	O
the	O
interleukin	B-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
and	O
interferon	B-Protein
gamma	I-Protein
(	O
IFNgamma	B-Protein
)	O
genes	O
,	O
gain	O
of	O
suppressor	O
function	O
,	O
and	O
induction	O
of	O
genes	O
such	O
as	O
CD25	B-Protein
,	O
GITR	B-Protein
,	O
and	O
CTLA	B-Protein
-	I-Protein
4	I-Protein
,	O
but	O
the	O
mode	O
by	O
which	O
Foxp3	B-Protein
enforces	O
this	O
program	O
is	O
unclear	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
,	O
we	O
have	O
demonstrated	O
that	O
Foxp3	B-Protein
binds	O
to	O
the	O
endogenous	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IFNgamma	B-Protein
loci	O
in	O
T	O
cells	O
,	O
but	O
only	O
after	O
T	O
cell	O
receptor	O
stimulation	O
.	O

This	O
activation	O
-	O
induced	O
Foxp3	B-Protein
binding	O
was	O
abrogated	O
by	O
cyclosporin	O
A	O
,	O
suggesting	O
a	O
role	O
for	O
the	O
phosphatase	O
calcineurin	O
in	O
Foxp3	B-Protein
function	O
.	O

We	O
have	O
also	O
shown	O
that	O
binding	O
of	O
Foxp3	B-Protein
to	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IFNgamma	B-Protein
genes	O
induces	O
active	O
deacetylation	O
of	O
histone	B-Protein
H3	I-Protein
,	O
a	O
process	O
that	O
inhibits	O
chromatin	O
remodeling	O
and	O
opposes	O
gene	O
transcription	O
.	O

Conversely	O
,	O
binding	O
of	O
Foxp3	B-Protein
to	O
the	O
GITR	B-Protein
,	O
CD25	B-Protein
,	O
and	O
CTLA	B-Protein
-	I-Protein
4	I-Protein
genes	O
results	O
in	O
increased	O
histone	B-Protein
acetylation	O
.	O

These	O
data	O
indicate	O
that	O
Foxp3	B-Protein
may	O
regulate	O
transcription	O
through	O
direct	O
chromatin	O
remodeling	O
and	O
show	O
that	O
Foxp3	B-Protein
function	O
is	O
influenced	O
by	O
signals	O
from	O
the	O
TCR	O
.	O

Assembly	O
and	O
structural	O
characterization	O
of	O
an	O
authentic	O
complex	O
between	O
human	O
follicle	O
stimulating	O
hormone	O
and	O
a	O
hormone	O
-	O
binding	O
ectodomain	O
of	O
its	O
receptor	O
.	O

Follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
is	O
secreted	O
from	O
the	O
pituitary	O
gland	O
to	O
regulate	O
reproduction	O
in	O
vertebrates	O
.	O

FSH	O
signals	O
through	O
a	O
G	O
-	O
protein	O
coupled	O
receptor	O
(	O
FSHR	B-Protein
)	O
on	O
the	O
target	O
cell	O
surface	O
.	O

We	O
describe	O
here	O
the	O
strategy	O
to	O
produce	O
a	O
soluble	O
FSH	O
-	O
FSHR	B-Protein
complex	O
that	O
involves	O
the	O
co	O
-	O
secretion	O
of	O
a	O
truncated	O
FSHR	B-Protein
ectodomain	O
(	O
FSHR	B-Protein
(	O
HB	O
)	O
)	O
and	O
a	O
covalently	O
linked	O
FSHalphabeta	B-Protein
heterodimer	O
from	O
baculovirus	O
-	O
infected	O
insect	O
cells	O
.	O

FSH	O
binds	O
to	O
FSHR	B-Protein
(	O
HB	O
)	O
with	O
a	O
high	O
affinity	O
comparable	O
to	O
that	O
for	O
the	O
full	O
-	O
length	O
receptor	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
FSH	O
-	O
FSHR	B-Protein
(	O
HB	O
)	O
complex	O
provides	O
explanations	O
for	O
the	O
high	O
affinity	O
and	O
specificity	O
of	O
FSH	O
interaction	O
with	O
FSHR	B-Protein
,	O
and	O
it	O
shows	O
an	O
unexpected	O
dimerization	O
of	O
these	O
complexes	O
.	O

Here	O
we	O
also	O
compare	O
the	O
crystal	O
structure	O
with	O
theoretical	O
models	O
of	O
the	O
FSH	B-Protein
-	O
FSHR	O
-	O
binding	O
mode	O
.	O

We	O
conclude	O
that	O
the	O
FSH	B-Protein
-	O
FSHR	B-Protein
(	O
HB	O
)	O
structure	O
gives	O
an	O
authentic	O
representation	O
of	O
FSH	O
binding	O
to	O
intact	O
FSHR	B-Protein
.	O

Assessing	O
the	O
instability	O
of	O
the	O
isoelectric	O
focusing	O
patterns	O
of	O
erythropoietin	B-Protein
in	O
urine	O
.	O

IEF	O
can	O
be	O
used	O
to	O
differentiate	O
human	O
urinary	O
erythropoietin	B-Protein
(	O
uEPO	B-Protein
)	O
,	O
recombinant	O
human	O
erythropoietin	B-Protein
or	O
epoetin	B-Protein
(	O
rEPO	B-Protein
)	O
and	O
darbepoetin	O
(	O
novel	O
erythropoiesis	O
stimulating	O
protein	O
(	O
NESP	O
)	O
)	O
.	O

This	O
is	O
the	O
basis	O
of	O
the	O
method	O
currently	O
used	O
to	O
detect	O
misuse	O
of	O
rEPO	B-Protein
and	O
NESP	O
by	O
elite	O
athletes	O
.	O

Recently	O
,	O
an	O
unknown	O
activity	O
has	O
been	O
attributed	O
to	O
some	O
urine	O
samples	O
(	O
denominated	O
'	O
unstable	O
'	O
urine	O
by	O
the	O
World	O
Anti	O
-	O
Doping	O
Agency	O
;	O
WADA	O
)	O
.	O

This	O
activity	O
has	O
shown	O
to	O
give	O
rise	O
to	O
artefactual	O
profiles	O
for	O
both	O
rEPO	B-Protein
and	O
NESP	O
when	O
incubated	O
with	O
such	O
urine	O
and	O
,	O
thus	O
,	O
raised	O
concerns	O
with	O
respect	O
to	O
doping	O
control	O
.	O

We	O
have	O
evaluated	O
which	O
charges	O
produce	O
the	O
characteristic	O
IEF	O
profiles	O
of	O
uEPO	B-Protein
,	O
rEPO	B-Protein
and	O
NESP	O
and	O
how	O
these	O
profiles	O
respond	O
to	O
distinct	O
enzymatic	O
reactions	O
.	O

From	O
sialidase	O
digestions	O
it	O
became	O
evident	O
that	O
only	O
uEPO	B-Protein
contains	O
charges	O
different	O
from	O
sialic	O
acid	O
,	O
and	O
a	O
comparison	O
of	O
all	O
substances	O
after	O
complete	O
de	O
-	O
N	O
-	O
glycosylation	O
localized	O
these	O
charges	O
in	O
the	O
carbohydrate	O
moiety	O
.	O

Partial	O
desialylation	O
,	O
or	O
digestion	O
with	O
arylsulfatase	O
from	O
Helix	O
pomatia	O
yielded	O
profiles	O
for	O
recombinants	O
species	O
similar	O
to	O
those	O
observed	O
for	O
unstable	O
urine	O
samples	O
.	O

The	O
contributions	O
from	O
our	O
studies	O
to	O
the	O
anti	O
-	O
doping	O
problem	O
include	O
:	O
(	O
i	O
)	O
protocols	O
that	O
may	O
corroborate	O
the	O
potential	O
misuse	O
of	O
rEPO	B-Protein
or	O
NESP	O
based	O
on	O
the	O
particular	O
enzymatic	O
activity	O
of	O
an	O
arylsulfatase	O
preparation	O
,	O
or	O
a	O
broad	O
-	O
specificity	O
sialidase	O
;	O
(	O
ii	O
)	O
assurance	O
that	O
the	O
instability	O
observed	O
in	O
some	O
urine	O
samples	O
may	O
only	O
result	O
from	O
false	O
-	O
negatives	O
,	O
but	O
not	O
from	O
false	O
-	O
positive	O
testing	O
;	O
and	O
(	O
iii	O
)	O
a	O
simple	O
remedy	O
to	O
prevent	O
an	O
unstable	O
urine	O
from	O
altering	O
the	O
IEF	O
profile	O
by	O
adding	O
selective	O
competitive	O
substrates	O
.	O

The	O
transcriptional	O
regulator	O
CBP	B-Protein
has	O
defined	O
spatial	O
associations	O
within	O
interphase	O
nuclei	O
.	O

It	O
is	O
becoming	O
increasingly	O
clear	O
that	O
nuclear	O
macromolecules	O
and	O
macromolecular	O
complexes	O
are	O
compartmentalized	O
through	O
binding	O
interactions	O
into	O
an	O
apparent	O
three	O
-	O
dimensionally	O
ordered	O
structure	O
.	O

This	O
ordering	O
,	O
however	O
,	O
does	O
not	O
appear	O
to	O
be	O
deterministic	O
to	O
the	O
extent	O
that	O
chromatin	O
and	O
nonchromatin	O
structures	O
maintain	O
a	O
strict	O
3	O
-	O
D	O
arrangement	O
.	O

Rather	O
,	O
spatial	O
ordering	O
within	O
the	O
cell	O
nucleus	O
appears	O
to	O
conform	O
to	O
stochastic	O
rather	O
than	O
deterministic	O
spatial	O
relationships	O
.	O

The	O
stochastic	O
nature	O
of	O
organization	O
becomes	O
particularly	O
problematic	O
when	O
any	O
attempt	O
is	O
made	O
to	O
describe	O
the	O
spatial	O
relationship	O
between	O
proteins	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
genome	O
.	O

The	O
CREB	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CBP	B-Protein
)	O
is	O
one	O
such	O
transcriptional	O
regulator	O
that	O
,	O
when	O
visualised	O
by	O
confocal	O
microscopy	O
,	O
reveals	O
a	O
highly	O
punctate	O
staining	O
pattern	O
comprising	O
several	O
hundred	O
individual	O
foci	O
distributed	O
within	O
the	O
nuclear	O
volume	O
.	O

Markers	O
for	O
euchromatic	O
sequences	O
have	O
similar	O
patterns	O
.	O

Surprisingly	O
,	O
in	O
most	O
cases	O
,	O
the	O
predicted	O
one	O
-	O
to	O
-	O
one	O
relationship	O
between	O
transcription	O
factor	O
and	O
chromatin	O
sequence	O
is	O
not	O
observed	O
.	O

Consequently	O
,	O
to	O
understand	O
whether	O
spatial	O
relationships	O
that	O
are	O
not	O
coincident	O
are	O
nonrandom	O
and	O
potentially	O
biologically	O
important	O
,	O
it	O
is	O
necessary	O
to	O
develop	O
statistical	O
approaches	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
on	O
the	O
development	O
of	O
such	O
an	O
approach	O
and	O
apply	O
it	O
to	O
understanding	O
the	O
role	O
of	O
CBP	B-Protein
in	O
mediating	O
chromatin	O
modification	O
and	O
transcriptional	O
regulation	O
.	O

We	O
have	O
used	O
nearest	O
-	O
neighbor	O
distance	O
measurements	O
and	O
probability	O
analyses	O
to	O
study	O
the	O
spatial	O
relationship	O
between	O
CBP	B-Protein
and	O
other	O
nuclear	O
subcompartments	O
enriched	O
in	O
transcription	O
factors	O
,	O
chromatin	O
,	O
and	O
splicing	O
factors	O
.	O

Our	O
results	O
demonstrate	O
that	O
CBP	B-Protein
has	O
an	O
order	O
of	O
spatial	O
association	O
with	O
other	O
nuclear	O
subcompartments	O
.	O

We	O
observe	O
closer	O
associations	O
between	O
CBP	B-Protein
and	O
RNA	O
polymerase	O
II	O
-	O
enriched	O
foci	O
and	O
SC35	B-Protein
speckles	O
than	O
nascent	O
RNA	O
or	O
specific	O
acetylated	O
histones	B-Protein
.	O

Furthermore	O
,	O
we	O
find	O
that	O
CBP	B-Protein
has	O
a	O
significantly	O
higher	O
probability	O
of	O
being	O
close	O
to	O
its	O
known	O
in	O
vivo	O
substrate	O
histone	B-Protein
H4	I-Protein
lysine	O
5	O
compared	O
with	O
the	O
closely	O
related	O
H4	B-Protein
lysine	O
12	O
.	O

This	O
study	O
demonstrates	O
that	O
complex	O
relationships	O
not	O
described	O
by	O
colocalization	O
exist	O
in	O
the	O
interphase	O
nucleus	O
and	O
can	O
be	O
characterized	O
and	O
quantified	O
.	O

The	O
subnuclear	O
distribution	O
of	O
CBP	B-Protein
is	O
difficult	O
to	O
reconcile	O
with	O
a	O
model	O
where	O
chromatin	O
organization	O
is	O
the	O
sole	O
determinant	O
of	O
the	O
nuclear	O
organization	O
of	O
proteins	O
that	O
regulate	O
transcription	O
but	O
is	O
consistent	O
with	O
a	O
close	O
link	O
between	O
spatial	O
associations	O
and	O
nuclear	O
functions	O
.	O

Characterization	O
of	O
promoter	O
regulatory	O
elements	O
involved	O
in	O
downexpression	O
of	O
the	O
DNA	B-Protein
polymerase	I-Protein
kappa	I-Protein
in	O
colorectal	O
cancer	O
.	O

The	O
low	O
-	O
fidelity	O
DNA	O
polymerases	O
thought	O
to	O
be	O
specialized	O
in	O
DNA	O
damage	O
processing	O
are	O
frequently	O
misregulated	O
in	O
cancers	O
.	O

We	O
show	O
here	O
that	O
DNA	B-Protein
polymerase	I-Protein
kappa	I-Protein
(	O
polkappa	B-Protein
)	O
,	O
prone	O
to	O
replicate	O
across	O
oxidative	O
and	O
aromatic	O
adducts	O
and	O
known	O
to	O
function	O
in	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
,	O
is	O
downregulated	O
in	O
colorectal	O
tumour	O
biopsies	O
.	O

Contrary	O
to	O
the	O
replicative	O
poldelta	O
and	O
polalpha	O
,	O
for	O
which	O
only	O
activating	O
domains	O
were	O
described	O
,	O
we	O
identified	O
an	O
upstream	O
465	O
-	O
bp	O
-	O
long	O
repressor	O
region	O
in	O
the	O
promoter	O
of	O
POLK	B-Protein
.	O

We	O
also	O
found	O
an	O
activating	O
237	O
-	O
bp	O
region	O
that	O
includes	O
stimulating	B-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
SP1	B-Protein
)	O
and	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
-	O
binding	O
sites	O
.	O

Mutations	O
at	O
one	O
CRE	O
-	O
binding	O
site	O
led	O
to	O
a	O
dramatic	O
80	O
%	O
decrease	O
in	O
promoter	O
activity	O
.	O

Alterations	O
of	O
the	O
SP1	B-Protein
-	O
binding	O
site	O
also	O
affected	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
transcription	O
.	O

Gel	O
shift	O
assays	O
confirmed	O
the	O
role	O
played	O
by	O
CRE	O
/	O
SP1	B-Protein
recognition	O
sequences	O
.	O

Moreover	O
,	O
ectopic	O
expression	O
of	O
SP1	B-Protein
or	O
CRE	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
protein	O
favoured	O
polkappa	O
transcription	O
.	O

Finally	O
,	O
we	O
found	O
that	O
polkappa	O
downexpression	O
in	O
colorectal	O
biopsies	O
correlated	O
with	O
a	O
decreased	O
level	O
of	O
CREB	O
and	O
SP1	B-Protein
transcripts	O
.	O

This	O
work	O
shows	O
that	O
the	O
promoter	O
of	O
POLK	B-Protein
is	O
cis	O
-	O
controlled	O
and	O
suggests	O
that	O
silencing	O
of	O
CREB	O
and	O
SP1	B-Protein
proteins	O
could	O
contribute	O
to	O
downregulation	O
of	O
this	O
repair	O
polymerase	O
in	O
colorectal	O
tumours	O
.	O

Ischemic	O
heart	O
failure	O
enhances	O
endogenous	O
myocardial	O
apelin	B-Protein
and	O
APJ	B-Protein
receptor	O
expression	O
.	O

Apelin	B-Protein
interacts	O
with	O
the	O
APJ	B-Protein
receptor	O
to	O
enhance	O
inotropy	O
.	O

In	O
heart	O
failure	O
,	O
apelin	B-Protein
-	O
APJ	B-Protein
coupling	O
may	O
provide	O
a	O
means	O
of	O
enhancing	O
myocardial	O
function	O
.	O

The	O
alterations	O
in	O
apelin	B-Protein
and	O
APJ	B-Protein
receptor	O
concentrations	O
with	O
ischemic	O
cardiomyopathy	O
are	O
poorly	O
understood	O
.	O

We	O
investigated	O
the	O
compensatory	O
changes	O
in	O
endogenous	O
apelin	B-Protein
and	O
APJ	B-Protein
levels	O
in	O
the	O
setting	O
of	O
ischemic	O
cardiomyopathy	O
.	O

Male	O
,	O
Lewis	O
rats	O
underwent	O
LAD	O
ligation	O
and	O
progressed	O
into	O
heart	O
failure	O
over	O
6	O
weeks	O
.	O

Corresponding	O
animals	O
underwent	O
sham	O
thoracotomy	O
as	O
control	O
.	O

Six	O
weeks	O
after	O
initial	O
surgery	O
,	O
the	O
animals	O
underwent	O
hemodynamic	O
functional	O
analysis	O
in	O
the	O
presence	O
of	O
exogenous	O
apelin	B-Protein
-	I-Protein
13	I-Protein
infusion	O
and	O
the	O
hearts	O
were	O
explanted	O
for	O
western	O
blot	O
and	O
enzyme	O
immunoassay	O
analysis	O
.	O

Western	O
blot	O
analysis	O
of	O
myocardial	O
APJ	B-Protein
concentration	O
demonstrated	O
increased	O
APJ	B-Protein
receptor	O
protein	O
levels	O
with	O
heart	O
failure	O
(	O
1890750	O
+	O
/	O
-	O
133500	O
vs	O
.	O
901600	O
+	O
/	O
-	O
143120	O
intensity	O
units	O
,	O
n	O
=	O
8	O
,	O
p	O
=	O
0	O
.	O
00001	O
)	O
.	O

Total	O
apelin	B-Protein
protein	O
levels	O
increased	O
with	O
ischemic	O
heart	O
failure	O
as	O
demonstrated	O
by	O
enzyme	O
immunoassay	O
(	O
12	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
6	O
vs	O
.	O
1	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
2	O
ng	O
/	O
ml	O
,	O
n	O
=	O
5	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
and	O
western	O
blot	O
(	O
1579400	O
+	O
/	O
-	O
477733	O
vs	O
.	O
943000	O
+	O
/	O
-	O
157600	O
intensity	O
units	O
,	O
n	O
=	O
10	O
,	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

Infusion	O
of	O
apelin	B-Protein
-	I-Protein
13	I-Protein
significantly	O
enhanced	O
myocardial	O
function	O
in	O
sham	O
and	O
failing	O
hearts	O
.	O

We	O
conclude	O
that	O
total	O
myocardial	O
apelin	B-Protein
and	O
APJ	B-Protein
receptor	O
levels	O
increase	O
in	O
compensation	O
for	O
ischemic	O
cardiomyopathy	O
.	O

Site	O
-	O
specific	O
acetylation	O
of	O
p53	B-Protein
directs	O
selective	O
transcription	O
complex	O
assembly	O
.	O

Histone	B-Protein
deacetylase	O
(	O
HDAC	O
)	O
inhibitors	O
are	O
being	O
investigated	O
as	O
possible	O
adjuvant	O
therapies	O
for	O
a	O
number	O
of	O
diseases	O
,	O
including	O
cancer	O
.	O

In	O
addition	O
to	O
stabilization	O
of	O
acetylated	O
histones	B-Protein
,	O
HDAC	O
inhibitors	O
stabilize	O
the	O
acetylation	O
of	O
a	O
number	O
of	O
transcription	O
factors	O
,	O
including	O
p53	B-Protein
.	O

This	O
study	O
investigates	O
the	O
action	O
of	O
two	O
HDAC	O
inhibitors	O
,	O
CG	O
-	O
1521	O
and	O
trichostatin	O
A	O
,	O
which	O
stabilize	O
Ac	O
-	O
Lys	O
-	O
373	O
p53	B-Protein
and	O
Ac	O
-	O
Lys	O
-	O
382	O
p53	B-Protein
,	O
respectively	O
,	O
in	O
LNCaP	O
prostate	O
cancer	O
cells	O
.	O

Real	O
-	O
time	O
PCR	O
demonstrates	O
that	O
CG	O
-	O
1521	O
induces	O
p21	B-Protein
transcription	O
whereas	O
trichostatin	O
A	O
does	O
not	O
alter	O
the	O
steady	O
state	O
level	O
of	O
p21	B-Protein
mRNA	O
.	O

Co	O
-	O
immunoprecipitation	O
demonstrates	O
that	O
the	O
selective	O
acetylation	O
of	O
p53	B-Protein
directs	O
the	O
recruitment	O
of	O
mutually	O
exclusive	O
coactivator	O
complexes	O
on	O
the	O
p53	B-Protein
response	O
elements	O
in	O
the	O
p21	B-Protein
promoter	O
.	O

Furthermore	O
,	O
the	O
co	O
-	O
activator	O
complexes	O
initiate	O
the	O
recruitment	O
of	O
the	O
components	O
of	O
the	O
basal	O
transcription	O
apparatus	O
to	O
the	O
basal	O
promoter	O
with	O
markedly	O
different	O
outcomes	O
because	O
only	O
Ac	O
-	O
Lys	O
-	O
373	O
p53	B-Protein
promotes	O
the	O
assembly	O
of	O
the	O
basal	O
transcriptional	O
apparatus	O
on	O
the	O
p21	B-Protein
promoter	O
.	O

These	O
data	O
highlight	O
the	O
profound	O
effects	O
of	O
post	O
-	O
translational	O
modification	O
,	O
including	O
acetylation	O
,	O
on	O
the	O
function	O
of	O
p53	B-Protein
.	O

The	O
data	O
also	O
suggest	O
a	O
novel	O
and	O
critically	O
important	O
role	O
for	O
protein	O
acetylation	O
/	O
deacetylation	O
in	O
the	O
assembly	O
of	O
active	O
transcription	O
processes	O
that	O
may	O
be	O
as	O
important	O
as	O
classical	O
phosphorylation	O
/	O
dephosphorylation	O
.	O

Cell	O
-	O
free	O
translation	O
and	O
characterization	O
of	O
corneal	O
keratan	O
sulfate	O
proteoglycan	O
core	O
proteins	O
.	O

Bovine	O
corneal	O
keratan	O
sulfate	O
proteoglycan	O
(	O
KSPG	O
)	O
contains	O
two	O
core	O
proteins	O
,	O
37	O
and	O
25	O
kDa	O
,	O
if	O
fully	O
deglycosylated	O
,	O
but	O
47	O
and	O
35	O
kDa	O
,	O
respectively	O
,	O
after	O
endo	O
-	O
beta	O
-	O
galactosidase	O
(	O
Funderburgh	O
,	O
J	O
.	O
L	O
.	O
,	O
and	O
Conrad	O
,	O
G	O
.	O
W	O
.	O
(	O
1990	O
)	O
J	O
.	O
Biol	O
Chem	O
.	O
265	O
,	O
8297	O
-	O
8303	O
)	O
.	O

Chicken	O
corneal	O
KSPG	O
released	O
a	O
single	O
core	O
protein	O
of	O
47	O
kDa	O
after	O
endo	O
-	O
beta	O
-	O
galactosidase	O
,	O
and	O
of	O
35	O
and	O
36	O
kDa	O
,	O
if	O
deglycosylated	O
with	O
N	B-Protein
-	I-Protein
glycanase	I-Protein
or	O
trifluoromethanesulfonic	O
acid	O
.	O

Affinity	O
purified	O
rabbit	O
antibodies	O
against	O
each	O
KSPG	O
recognized	O
only	O
the	O
intact	O
proteoglycan	O
or	O
its	O
core	O
proteins	O
in	O
immunoblots	O
of	O
unfractionated	O
guanidine	O
-	O
HCl	O
extracts	O
of	O
whole	O
cornea	O
after	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Affinity	O
purified	O
antibody	O
to	O
a	O
synthetic	O
peptide	O
duplicating	O
the	O
NH2	O
-	O
terminal	O
sequence	O
of	O
the	O
37	O
-	O
kDa	O
bovine	O
core	O
protein	O
showed	O
little	O
reactivity	O
with	O
untreated	O
corneal	O
extract	O
but	O
reacted	O
with	O
the	O
47	O
-	O
kDa	O
bovine	O
protein	O
in	O
endo	O
-	O
beta	O
-	O
galactosidase	O
-	O
treated	O
extracts	O
.	O

RNA	O
was	O
isolated	O
from	O
bovine	O
and	O
chick	O
corneal	O
stromas	O
and	O
used	O
for	O
in	O
vitro	O
translation	O
.	O

Antibody	O
against	O
bovine	O
KSPG	O
immunoprecipitated	O
two	O
proteins	O
of	O
56	O
-	O
53	O
kDa	O
and	O
a	O
protein	O
of	O
41	O
kDa	O
after	O
translation	O
of	O
bovine	O
RNA	O
.	O

Translation	O
of	O
chick	O
RNA	O
produced	O
a	O
double	O
band	O
of	O
38	O
-	O
39	O
kDa	O
and	O
a	O
single	O
band	O
of	O
25	O
kDa	O
precipitating	O
with	O
antibody	O
against	O
chicken	O
KSPG	O
.	O

Homologous	O
unlabeled	O
KSPG	O
competed	O
for	O
binding	O
of	O
antibodies	O
to	O
these	O
translation	O
products	O
.	O

These	O
data	O
suggest	O
that	O
in	O
vertebrate	O
corneas	O
,	O
the	O
multiple	O
KSPG	O
core	O
protein	O
isoforms	O
may	O
arise	O
as	O
products	O
of	O
separate	O
mRNAs	O
,	O
rather	O
than	O
from	O
proteolytic	O
processing	O
of	O
a	O
large	O
polypeptide	O
precursor	O
.	O

[	O
Reciprocal	O
regulation	O
between	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
and	O
its	O
prolyl	O
hydroxylases	O
in	O
hypoxic	O
pulmonary	O
hypertension	O
rats	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
interaction	O
between	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factors	I-Protein
-	I-Protein
1alpha	I-Protein
subunit	O
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
and	O
its	O
three	O
prolyl	O
hydroxylases	O
(	O
PHD1	B-Protein
,	O
PHD2	B-Protein
and	O
PHD3	B-Protein
)	O
during	O
the	O
development	O
of	O
rat	O
hypoxic	O
pulmonary	O
hypertension	O
.	O

METHODS	O
:	O
Forty	O
male	O
SD	O
rats	O
were	O
randomly	O
divided	O
into	O
5	O
groups	O
and	O
exposed	O
to	O
normoxia	O
(	O
C	O
group	O
)	O
or	O
exposed	O
to	O
hypoxia	O
for	O
3	O
,	O
7	O
,	O
14	O
or	O
21	O
d	O
(	O
H	O
(	O
3	O
)	O
,	O
H	O
(	O
7	O
)	O
,	O
H	O
(	O
14	O
)	O
,	O
H	O
(	O
21	O
)	O
group	O
)	O
,	O
respectively	O
.	O

Mean	O
pulmonary	O
arterial	O
pressure	O
(	O
mPAP	O
)	O
,	O
vessel	O
morphometry	O
and	O
right	O
ventricle	O
hypertrophy	O
index	O
(	O
RVHI	O
)	O
were	O
measured	O
.	O

Reverse	B-Protein
transcriptase	I-Protein
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
in	O
situ	O
hybridization	O
were	O
used	O
to	O
determine	O
the	O
expression	O
of	O
mRNA	O
.	O

Immunohistochemistry	O
and	O
Western	O
blot	O
were	O
used	O
to	O
determine	O
the	O
expression	O
of	O
mRNA	O
.	O

RESULTS	O
:	O
The	O
level	O
of	O
mPAP	O
[	O
(	O
21	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
4	O
)	O
mm	O
Hg	O
,	O
1	O
mm	O
Hg	O
=	O
0	O
.	O
133	O
kPa	O
]	O
,	O
the	O
ratio	O
of	O
vascular	O
wall	O
thickness	O
to	O
external	O
diameter	O
[	O
WA	O
%	O
,	O
(	O
43	O
.	O
9	O
+	O
/	O
-	O
5	O
.	O
3	O
)	O
%	O
]	O
and	O
pulmonary	O
artery	O
media	O
thickness	O
[	O
PAMT	O
,	O
(	O
10	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
7	O
)	O
microm	O
]	O
were	O
significantly	O
higher	O
in	O
H	O
(	O
7	O
)	O
group	O
than	O
those	O
in	O
C	O
group	O
[	O
(	O
16	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
6	O
)	O
mm	O
Hg	O
,	O
(	O
36	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
8	O
)	O
%	O
and	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
3	O
)	O
microm	O
respectively	O
,	O
q	O
value	O
were	O
5	O
.	O
591	O
,	O
4	O
.	O
082	O
,	O
2	O
.	O
929	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
]	O
.	O

These	O
parameters	O
reached	O
a	O
high	O
level	O
and	O
remained	O
stable	O
on	O
H	O
(	O
14	O
)	O
group	O
,	O
and	O
RVHI	O
was	O
significantly	O
higher	O
in	O
H	O
(	O
14	O
)	O
group	O
[	O
(	O
27	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
4	O
)	O
%	O
]	O
than	O
in	O
C	O
group	O
[	O
(	O
23	O
.	O
6	O
+	O
/	O
-	O
2	O
.	O
9	O
)	O
%	O
,	O
q	O
=	O
5	O
.	O
817	O
,	O
P	O
<	O
0	O
.	O
05	O
]	O
.	O

HIF	B-Protein
-	I-Protein
1alpha	I-Protein
protein	O
was	O
barely	O
positive	O
in	O
C	O
group	O
(	O
0	O
.	O
080	O
+	O
/	O
-	O
0	O
.	O
009	O
)	O
,	O
but	O
markedly	O
up	O
-	O
regulated	O
in	O
H	O
(	O
3	O
)	O
group	O
(	O
0	O
.	O
196	O
+	O
/	O
-	O
0	O
.	O
018	O
,	O
compared	O
with	O
C	O
group	O
q	O
=	O
18	O
.	O
864	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
reaching	O
its	O
peak	O
in	O
H	O
(	O
7	O
)	O
group	O
(	O
0	O
.	O
203	O
+	O
/	O
-	O
0	O
.	O
022	O
)	O
,	O
and	O
then	O
declined	O
slightly	O
in	O
H	O
(	O
14	O
)	O
and	O
H	O
(	O
21	O
)	O
group	O
.	O

HIF	B-Protein
-	I-Protein
1alpha	I-Protein
mRNA	O
increased	O
marginally	O
in	O
H	O
(	O
14	O
)	O
group	O
(	O
0	O
.	O
176	O
+	O
/	O
-	O
0	O
.	O
019	O
,	O
compared	O
with	O
C	O
group	O
q	O
=	O
5	O
.	O
401	O
,	O
P	O
<	O
0	O
.	O
05	O
,	O
0	O
.	O
139	O
+	O
/	O
-	O
0	O
.	O
017	O
)	O
.	O

PHD1	B-Protein
and	O
PHD2	B-Protein
mRNA	O
(	O
0	O
.	O
260	O
+	O
/	O
-	O
0	O
.	O
031	O
,	O
0	O
.	O
196	O
+	O
/	O
-	O
0	O
.	O
023	O
)	O
and	O
protein	O
(	O
0	O
.	O
244	O
+	O
/	O
-	O
0	O
.	O
030	O
,	O
0	O
.	O
205	O
+	O
/	O
-	O
0	O
.	O
025	O
)	O
were	O
positive	O
in	O
C	O
group	O
.	O

PHD2	B-Protein
mRNA	O
and	O
protein	O
were	O
up	O
-	O
regulated	O
in	O
H	O
(	O
3	O
)	O
group	O
(	O
0	O
.	O
246	O
+	O
/	O
-	O
0	O
.	O
023	O
,	O
0	O
.	O
235	O
+	O
/	O
-	O
0	O
.	O
025	O
,	O
compared	O
with	O
C	O
group	O
q	O
value	O
was	O
5	O
.	O
268	O
,	O
3	O
.	O
046	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
reaching	O
its	O
peak	O
in	O
H	O
(	O
14	O
)	O
group	O
whereas	O
PHD1	B-Protein
protein	O
declined	O
in	O
H	O
(	O
14	O
)	O
group	O
(	O
0	O
.	O
210	O
+	O
/	O
-	O
0	O
.	O
023	O
,	O
compared	O
with	O
C	O
group	O
q	O
=	O
3	O
.	O
885	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
without	O
significant	O
mRNA	O
change	O
.	O

PHD3	B-Protein
mRNA	O
and	O
protein	O
were	O
detected	O
at	O
low	O
level	O
in	O
C	O
group	O
(	O
0	O
.	O
110	O
+	O
/	O
-	O
0	O
.	O
013	O
,	O
0	O
.	O
153	O
+	O
/	O
-	O
0	O
.	O
019	O
)	O
,	O
but	O
markedly	O
up	O
-	O
regulated	O
in	O
H	O
(	O
3	O
)	O
group	O
(	O
0	O
.	O
259	O
+	O
/	O
-	O
0	O
.	O
024	O
,	O
compared	O
with	O
C	O
group	O
q	O
=	O
15	O
.	O
831	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
then	O
PHD3	B-Protein
mRNA	O
remained	O
at	O
high	O
level	O
while	O
PHD3	B-Protein
protein	O
declined	O
in	O
H	O
(	O
14	O
)	O
and	O
H	O
(	O
21	O
)	O
group	O
(	O
0	O
.	O
206	O
+	O
/	O
-	O
0	O
.	O
025	O
,	O
0	O
.	O
189	O
+	O
/	O
-	O
0	O
.	O
019	O
,	O
compared	O
with	O
H	O
(	O
7	O
)	O
group	O
q	O
value	O
was	O
6	O
.	O
441	O
,	O
8	O
.	O
526	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Linear	O
correlation	O
analysis	O
showed	O
that	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
mRNA	O
and	O
protein	O
were	O
positively	O
correlated	O
with	O
mPAP	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
protein	O
and	O
PHD2	B-Protein
,	O
PHD3	B-Protein
mRNA	O
(	O
r	O
value	O
was	O
0	O
.	O
580	O
,	O
0	O
.	O
690	O
,	O
respectively	O
,	O
all	O
P	O
value	O
was	O
0	O
.	O
000	O
)	O
but	O
a	O
negative	O
correlation	O
between	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
protein	O
and	O
PHD2	B-Protein
protein	O
(	O
r	O
=	O
-	O
0	O
.	O
704	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
was	O
regulated	O
mainly	O
at	O
the	O
protein	O
level	O
during	O
the	O
development	O
of	O
hypoxic	O
pulmonary	O
hypertension	O
.	O

PHD2	B-Protein
and	O
PHD3	B-Protein
are	O
inducible	O
by	O
hypoxia	O
,	O
possibly	O
via	O
elevated	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
suggesting	O
that	O
a	O
hypoxic	O
up	O
-	O
regulation	O
of	O
PHD	O
acts	O
via	O
feedback	O
mechanism	O
to	O
attenuate	O
hypoxia	O
induced	O
responses	O
.	O

PHD	O
may	O
also	O
be	O
regulated	O
by	O
posttranscriptional	O
mechanisms	O
.	O

Identification	O
of	O
the	O
N	O
-	O
linked	O
glycosylation	O
sites	O
of	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
and	O
effect	O
of	O
glycosylation	O
on	O
carboxylase	O
function	O
.	O

The	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
is	O
an	O
integral	O
membrane	O
protein	O
which	O
is	O
required	O
for	O
the	O
post	O
-	O
translational	O
modification	O
of	O
a	O
variety	O
of	O
vitamin	O
K	O
-	O
dependent	O
proteins	O
.	O

Previous	O
studies	O
have	O
suggested	O
carboxylase	O
is	O
a	O
glycoprotein	O
with	O
N	O
-	O
linked	O
glycosylation	O
sites	O
.	O

In	O
this	O
study	O
,	O
we	O
identify	O
the	O
N	O
-	O
glycosylation	O
sites	O
of	O
carboxylase	O
by	O
mass	O
spectrometric	O
peptide	O
mapping	O
analyses	O
combined	O
with	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Our	O
mass	O
spectrometric	O
results	O
show	O
that	O
the	O
N	O
-	O
linked	O
glycosylation	O
in	O
carboxylase	O
occurs	O
at	O
positions	O
N459	O
,	O
N550	O
,	O
N605	O
,	O
and	O
N627	O
.	O

Eliminating	O
these	O
glycosylation	O
sites	O
by	O
changing	O
asparagine	O
to	O
glutamine	O
caused	O
the	O
mutant	O
carboxylase	O
to	O
migrate	O
faster	O
on	O
SDS	O
-	O
PAGE	O
gels	O
,	O
adding	O
further	O
evidence	O
that	O
these	O
sites	O
are	O
glycosylated	O
.	O

In	O
addition	O
,	O
the	O
mutation	O
studies	O
identified	O
N525	O
,	O
a	O
site	O
that	O
cannot	O
be	O
recovered	O
by	O
mass	O
spectroscopy	O
analysis	O
,	O
as	O
a	O
glycosylation	O
site	O
.	O

Furthermore	O
,	O
the	O
potential	O
glycosylation	O
site	O
at	O
N570	O
is	O
glycosylated	O
only	O
if	O
all	O
five	O
natural	O
glycosylation	O
sites	O
are	O
simultaneously	O
mutated	O
.	O

Removal	O
of	O
the	O
oligosaccharides	O
by	O
glycosidase	O
from	O
wild	O
-	O
type	O
carboxylase	O
or	O
by	O
elimination	O
of	O
the	O
functional	O
glycosylation	O
sites	O
by	O
site	O
-	O
directed	O
mutagenesis	O
did	O
not	O
affect	O
either	O
the	O
carboxylation	O
or	O
epoxidation	O
activity	O
when	O
the	O
small	O
FLEEL	O
pentapeptide	O
was	O
used	O
as	O
a	O
substrate	O
,	O
suggesting	O
that	O
N	O
-	O
linked	O
glycosylation	O
is	O
not	O
required	O
for	O
the	O
enzymatic	O
function	O
of	O
carboxylase	O
.	O

In	O
contrast	O
,	O
when	O
site	O
N570	O
and	O
the	O
five	O
natural	O
glycosylation	O
sites	O
were	O
mutated	O
simultaneously	O
,	O
the	O
resulting	O
carboxylase	O
protein	O
was	O
degraded	O
.	O

Our	O
results	O
suggest	O
that	O
N	O
-	O
linked	O
glycosylation	O
is	O
not	O
essential	O
for	O
carboxylase	O
enzymatic	O
activity	O
but	O
is	O
important	O
for	O
protein	O
folding	O
and	O
stability	O
.	O

Histone	B-Protein
deacetylase	O
inhibitor	O
LBH589	O
reactivates	O
silenced	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
(	O
ER	B-Protein
)	O
gene	O
expression	O
without	O
loss	O
of	O
DNA	O
hypermethylation	O
.	O

Our	O
previous	O
studies	O
demonstrated	O
that	O
inhibition	O
of	O
histone	B-Protein
deacetylases	O
(	O
HDACs	O
)	O
by	O
trichostatin	O
A	O
reactivates	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
(	O
ER	B-Protein
)	O
gene	O
expression	O
in	O
ER	B-Protein
-	O
negative	O
breast	O
cancer	O
cells	O
.	O

Here	O
,	O
we	O
use	O
the	O
clinically	O
relevant	O
HDAC	O
inhibitor	O
,	O
LBH589	O
(	O
LBH	O
)	O
to	O
explore	O
the	O
roles	O
of	O
HDAC	O
in	O
ER	B-Protein
gene	O
silencing	O
.	O

In	O
the	O
ER	B-Protein
-	O
negative	O
human	O
breast	O
cancer	O
lines	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
435	O
,	O
treatment	O
with	O
LBH	O
for	O
24	O
hours	O
restored	O
ER	B-Protein
mRNA	O
and	O
protein	O
expression	O
without	O
a	O
concomitant	O
demethylation	O
of	O
the	O
CpG	O
island	O
at	O
the	O
ER	B-Protein
promoter	O
.	O

The	O
expression	O
of	O
ER	B-Protein
mRNA	O
was	O
sustained	O
at	O
least	O
96	O
hours	O
after	O
withdrawal	O
of	O
LBH	O
treatment	O
.	O

Restoration	O
of	O
ER	B-Protein
expression	O
by	O
LBH	O
enhanced	O
4	O
-	O
hydroxy	O
-	O
tamoxifen	O
sensitivity	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
LBH	O
reactivated	O
silenced	O
ER	B-Protein
gene	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
examined	O
with	O
emphasis	O
on	O
chromatin	O
structure	O
reorganization	O
.	O

By	O
chromatin	O
immunoprecipitation	O
analysis	O
,	O
LBH	O
treatment	O
released	O
DNMT1	B-Protein
,	O
HDAC1	B-Protein
,	O
and	O
the	O
H3	B-Protein
lysine	O
9	O
(	O
H3	O
-	O
K9	O
)	O
methyltransferase	O
SUV39H	B-Protein
1	I-Protein
from	O
the	O
ER	B-Protein
promoter	O
.	O

Such	O
changes	O
were	O
associated	O
with	O
an	O
active	O
chromatin	O
formation	O
manifested	O
as	O
accumulation	O
of	O
acetylated	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
,	O
a	O
decrease	O
in	O
methylated	O
H3	B-Protein
-	O
K9	O
,	O
and	O
an	O
impaired	O
binding	O
of	O
heterochromatin	O
protein	O
1	O
(	O
HP1	B-Protein
alpha	I-Protein
)	O
at	O
the	O
promoter	O
.	O

Our	O
findings	O
suggest	O
that	O
HDAC	O
inhibitors	O
could	O
restore	O
expression	O
of	O
the	O
silenced	O
ER	B-Protein
gene	O
by	O
reorganizing	O
the	O
heterochromatin	O
-	O
associated	O
proteins	O
without	O
alteration	O
in	O
promoter	O
DNA	O
hypermethylation	O
.	O

Glycosylation	O
variant	O
analysis	O
of	O
recombinant	O
human	O
tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
produced	O
in	O
urea	O
-	O
cycle	O
-	O
enzyme	O
-	O
expressing	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cell	O
line	O
.	O

Tissue	B-Protein
plasminogen	I-Protein
activator	I-Protein
(	O
tPA	B-Protein
)	O
was	O
produced	O
in	O
ornithine	B-Protein
transcarbamoylase	I-Protein
(	O
OTC	B-Protein
)	O
cells	O
by	O
introducing	O
the	O
tPA	B-Protein
gene	O
into	O
OTC	B-Protein
cells	O
.	O

OTC	B-Protein
cells	O
were	O
originally	O
derived	O
from	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
and	O
express	O
the	O
first	O
two	O
enzymes	O
of	O
the	O
urea	O
cycle	O
,	O
carbamoyl	B-Protein
phosphate	I-Protein
synthetase	I-Protein
I	I-Protein
(	O
CPS	B-Protein
I	I-Protein
)	O
and	O
OTC	B-Protein
.	O

To	O
investigate	O
glycosylation	O
variants	O
,	O
tPA	B-Protein
variants	O
produced	O
in	O
serum	O
-	O
supplemented	O
culture	O
medium	O
of	O
OTC	B-Protein
-	O
tPA	B-Protein
cells	O
were	O
separated	O
by	O
lysine	O
-	O
Sepharose	O
4B	O
chromatography	O
.	O

Unlike	O
in	O
previous	O
studies	O
that	O
used	O
lysine	O
-	O
Sepharose	O
chromatography	O
,	O
two	O
peaks	O
were	O
identified	O
to	O
correspond	O
to	O
eluted	O
glycosylation	O
variants	O
type	O
I	O
and	O
II	O
and	O
type	O
II	O
and	O
the	O
percentages	O
of	O
the	O
type	O
I	O
and	O
type	O
II	O
variants	O
were	O
found	O
to	O
be	O
23	O
%	O
and	O
77	O
%	O
,	O
respectively	O
.	O

The	O
biological	O
activities	O
of	O
the	O
type	O
I	O
and	O
II	O
and	O
type	O
II	O
variants	O
were	O
twofold	O
that	O
of	O
the	O
Third	O
International	O
tPA	B-Protein
Standard	O
(	O
98	O
/	O
714	O
)	O
produced	O
in	O
the	O
CHO	O
cell	O
line	O
,	O
and	O
the	O
activity	O
of	O
type	O
II	O
variant	O
was	O
12	O
.	O
6	O
%	O
higher	O
than	O
that	O
of	O
the	O
type	O
I	O
and	O
II	O
variants	O
.	O

These	O
results	O
demonstrate	O
that	O
tPA	B-Protein
produced	O
in	O
urea	O
-	O
cycle	O
-	O
enzyme	O
-	O
producing	O
OTC	B-Protein
cells	O
have	O
a	O
very	O
high	O
biological	O
activity	O
and	O
the	O
percentage	O
of	O
type	O
II	O
variant	O
which	O
is	O
very	O
valuable	O
for	O
the	O
biopharmaceutical	O
industry	O
is	O
higher	O
than	O
that	O
of	O
any	O
report	O
using	O
CHO	O
cells	O
.	O

Tip60	B-Protein
-	O
dependent	O
acetylation	O
of	O
p53	B-Protein
modulates	O
the	O
decision	O
between	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
.	O

Upon	O
DNA	O
damage	O
and	O
other	O
types	O
of	O
stress	O
,	O
p53	B-Protein
induces	O
either	O
cell	O
-	O
cycle	O
arrest	O
or	O
apoptosis	O
depending	O
on	O
the	O
cellular	O
context	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
that	O
govern	O
the	O
choice	O
between	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
Tip60	B-Protein
is	O
required	O
for	O
both	O
cell	O
growth	O
arrest	O
and	O
apoptosis	O
mediated	O
by	O
p53	B-Protein
and	O
also	O
induces	O
its	O
acetylation	O
specifically	O
at	O
lysine	O
120	O
(	O
K120	O
)	O
within	O
the	O
DNA	O
-	O
binding	O
domain	O
.	O

Interestingly	O
,	O
this	O
modification	O
is	O
crucial	O
for	O
p53	B-Protein
-	O
dependent	O
apoptosis	O
but	O
is	O
dispensable	O
for	O
its	O
mediated	O
growth	O
arrest	O
.	O

K120	O
is	O
a	O
recurrent	O
site	O
for	O
p53	B-Protein
mutation	O
in	O
human	O
cancer	O
,	O
and	O
the	O
corresponding	O
acetylation	O
-	O
defective	O
tumor	O
mutant	O
(	O
K120R	O
)	O
abrogates	O
p53	B-Protein
-	O
mediated	O
apoptosis	O
,	O
but	O
not	O
growth	O
arrest	O
.	O

Thus	O
,	O
our	O
study	O
demonstrates	O
that	O
Tip60	B-Protein
-	O
dependent	O
acetylation	O
of	O
p53	B-Protein
at	O
K120	O
modulates	O
the	O
decision	O
between	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
,	O
and	O
it	O
reveals	O
that	O
the	O
DNA	O
-	O
binding	O
core	O
domain	O
is	O
an	O
important	O
target	O
for	O
p53	B-Protein
regulation	O
by	O
posttranslational	O
modifications	O
.	O

An	O
in	O
vivo	O
assay	O
to	O
quantify	O
stable	O
protein	O
phosphatase	O
2A	O
(	O
PP2A	O
)	O
heterotrimeric	O
species	O
.	O

Protein	O
phosphatase	O
2A	O
(	O
PP2A	O
)	O
regulates	O
a	O
broad	O
spectrum	O
of	O
cellular	O
processes	O
.	O

The	O
enzyme	O
is	O
,	O
in	O
fact	O
,	O
largely	O
a	O
collection	O
of	O
varied	O
heterotrimeric	O
species	O
composed	O
of	O
a	O
catalytic	O
(	O
C	O
)	O
subunit	O
and	O
regulatory	O
(	O
B	O
-	O
type	O
)	O
subunit	O
bound	O
together	O
by	O
a	O
structural	O
(	O
A	O
)	O
subunit	O
.	O

One	O
important	O
feature	O
of	O
the	O
C	O
subunit	O
is	O
that	O
its	O
carboxy	O
-	O
terminus	O
can	O
be	O
modified	O
by	O
phosphorylation	O
and	O
methylation	O
.	O

The	O
mechanisms	O
that	O
trigger	O
such	O
posttranslational	O
modifications	O
,	O
as	O
well	O
as	O
their	O
consequences	O
,	O
are	O
still	O
under	O
investigation	O
.	O

However	O
,	O
data	O
collected	O
thus	O
far	O
indicate	O
that	O
these	O
modifications	O
alter	O
the	O
binding	O
to	O
B	O
subunits	O
for	O
an	O
AC	O
dimer	O
,	O
thereby	O
affecting	O
the	O
makeup	O
of	O
the	O
PP2A	O
species	O
in	O
the	O
cell	O
.	O

In	O
this	O
chapter	O
,	O
we	O
describe	O
an	O
in	O
vivo	O
assay	O
for	O
assessing	O
stable	O
PP2A	O
heterotrimer	O
formation	O
that	O
is	O
based	O
on	O
specific	O
subcellular	O
localizations	O
of	O
PP2A	O
heterotrimers	O
.	O

This	O
assay	O
can	O
be	O
used	O
to	O
study	O
the	O
impact	O
of	O
a	O
wide	O
variety	O
of	O
alterations	O
(	O
such	O
as	O
mutations	O
and	O
covalent	O
modifications	O
)	O
on	O
PP2A	O
heterotrimer	O
formation	O
.	O

We	O
specifically	O
describe	O
the	O
use	O
of	O
this	O
assay	O
to	O
quantify	O
the	O
effects	O
of	O
methylation	O
on	O
the	O
stable	O
formation	O
of	O
PP2ARts1p	B-Protein
and	O
PP2ACdc55p	B-Protein
heterotrimers	O
.	O

Secretion	O
and	O
lysophospholipase	O
D	O
activity	O
of	O
autotaxin	B-Protein
by	O
adipocytes	O
are	O
controlled	O
by	O
N	O
-	O
glycosylation	O
and	O
signal	O
peptidase	O
.	O

Autotaxin	B-Protein
(	O
ATX	B-Protein
)	O
is	O
a	O
lysophospholipase	O
D	O
involved	O
in	O
synthesis	O
of	O
lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
.	O

ATX	B-Protein
is	O
secreted	O
by	O
adipocytes	O
and	O
is	O
associated	O
with	O
adipogenesis	O
and	O
obesity	O
-	O
associated	O
diabetes	O
.	O

Here	O
we	O
have	O
studied	O
the	O
mechanisms	O
involved	O
in	O
biosynthesis	O
and	O
secretion	O
of	O
ATX	B-Protein
by	O
mouse	O
3T3	O
-	O
F442A	O
adipocytes	O
.	O

We	O
found	O
that	O
inhibition	O
of	O
N	O
-	O
glycosylation	O
with	O
tunicamycin	O
or	O
by	O
double	O
point	O
deletion	O
of	O
the	O
amino	O
-	O
acids	O
N53	O
and	O
N410	O
of	O
ATX	B-Protein
inhibit	O
its	O
secretion	O
.	O

In	O
addition	O
,	O
N	O
-	O
glycosidase	O
treatment	O
and	O
point	O
deletion	O
of	O
the	O
amino	O
-	O
acid	O
N410	O
inhibits	O
the	O
lysophospholipase	O
D	O
activity	O
of	O
ATX	B-Protein
.	O

Analysis	O
of	O
the	O
amino	O
-	O
acid	O
sequence	O
of	O
mouse	O
ATX	B-Protein
shows	O
the	O
presence	O
of	O
a	O
N	O
-	O
terminal	O
signal	O
peptide	O
.	O

Treatment	O
with	O
the	O
signal	O
peptidase	O
inhibitor	O
globomycin	O
inhibits	O
ATX	B-Protein
secretion	O
by	O
adipocytes	O
.	O

Transfection	O
in	O
Cos	O
-	O
7	O
cells	O
of	O
site	O
-	O
directed	O
deleted	O
ATX	B-Protein
shows	O
that	O
ATX	B-Protein
secretion	O
is	O
dependent	O
on	O
the	O
hydrophobic	O
core	O
sequence	O
of	O
the	O
signal	O
peptide	O
,	O
not	O
on	O
the	O
putative	O
signal	O
peptidase	O
cleavage	O
site	O
sequence	O
.	O

Analysis	O
of	O
the	O
amino	O
-	O
acid	O
sequence	O
of	O
mouse	O
ATX	B-Protein
also	O
reveals	O
the	O
presence	O
of	O
a	O
putative	O
cleavage	O
site	O
by	O
the	O
protein	O
convertase	O
furin	B-Protein
.	O

Treatment	O
of	O
adipocytes	O
with	O
the	O
furin	B-Protein
inhibitor	O
decanoyl	O
-	O
Arg	O
-	O
Val	O
-	O
Lys	O
-	O
Arg	O
-	O
chloromethylketone	O
does	O
not	O
modified	O
secretion	O
or	O
lysophospholipase	O
D	O
activity	O
of	O
ATX	B-Protein
.	O

Transfection	O
in	O
Cos	O
-	O
7	O
cells	O
of	O
site	O
-	O
directed	O
deleted	O
ATX	B-Protein
shows	O
that	O
the	O
furin	B-Protein
recognition	O
site	O
is	O
not	O
required	O
for	O
secretion	O
or	O
lysophospholipase	O
D	O
activity	O
of	O
ATX	B-Protein
.	O

In	O
conclusion	O
,	O
the	O
present	O
work	O
demonstrates	O
the	O
crucial	O
role	O
of	O
N	O
-	O
glycosylation	O
in	O
secretion	O
and	O
activity	O
of	O
ATX	B-Protein
.	O

The	O
present	O
work	O
also	O
confirms	O
the	O
crucial	O
role	O
signal	O
peptidase	O
in	O
secretion	O
of	O
ATX	B-Protein
by	O
adipocytes	O
.	O

Methylation	O
of	O
histone	B-Protein
H3	I-Protein
lysine	O
-	O
79	O
by	O
Dot1p	B-Protein
plays	O
multiple	O
roles	O
in	O
the	O
response	O
to	O
UV	O
damage	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Various	O
proteins	O
have	O
been	O
found	O
to	O
play	O
roles	O
in	O
both	O
the	O
repair	O
of	O
UV	O
damaged	O
DNA	O
and	O
heterochromatin	O
-	O
mediated	O
silencing	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
particular	O
,	O
factors	O
that	O
are	O
involved	O
in	O
the	O
methylation	O
of	O
lysine	O
-	O
79	O
of	O
histone	B-Protein
H3	I-Protein
by	O
Dot1p	B-Protein
have	O
been	O
implicated	O
in	O
both	O
processes	O
,	O
suggesting	O
a	O
bipartite	O
function	O
for	O
this	O
modification	O
.	O

We	O
find	O
that	O
a	O
dot1	B-Protein
null	O
mutation	O
and	O
a	O
histone	B-Protein
H3	I-Protein
point	O
mutation	O
at	O
lysine	O
-	O
79	O
cause	O
increased	O
sensitivity	O
to	O
UV	O
radiation	O
,	O
suggesting	O
that	O
lysine	O
-	O
79	O
methylation	O
is	O
important	O
for	O
efficient	O
repair	O
of	O
UV	O
damage	O
.	O

Epistasis	O
analysis	O
between	O
dot1	B-Protein
and	O
various	O
UV	O
repair	O
genes	O
indicates	O
that	O
lysine	O
-	O
79	O
methylation	O
plays	O
overlapping	O
roles	O
within	O
the	O
nucleotide	O
excision	O
,	O
post	O
-	O
replication	O
and	O
recombination	O
repair	O
pathways	O
,	O
as	O
well	O
as	O
RAD9	B-Protein
-	O
mediated	O
checkpoint	O
function	O
.	O

In	O
contrast	O
,	O
epistasis	O
analysis	O
with	O
the	O
H3	B-Protein
lysine	O
-	O
79	O
point	O
mutation	O
indicates	O
that	O
the	O
lysine	O
-	O
to	O
-	O
glutamic	O
acid	O
substitution	O
exerts	O
specific	O
effects	O
within	O
the	O
nucleotide	O
excision	O
repair	O
and	O
post	O
-	O
replication	O
repair	O
pathways	O
,	O
suggesting	O
that	O
this	O
allele	O
only	O
disrupts	O
a	O
subset	O
of	O
the	O
functions	O
of	O
lysine	O
-	O
79	O
methylation	O
.	O

The	O
overall	O
results	O
indicate	O
the	O
existence	O
of	O
distinct	O
and	O
separable	O
roles	O
of	O
histone	B-Protein
H3	I-Protein
lysine	O
-	O
79	O
methylation	O
in	O
the	O
response	O
to	O
UV	O
damage	O
,	O
potentially	O
serving	O
to	O
coordinate	O
the	O
various	O
repair	O
processes	O
.	O

2	O
-	O
amino	O
-	O
1	O
-	O
methyl	O
-	O
6	O
-	O
phenylimidazo	O
[	O
4	O
,	O
5	O
-	O
b	O
]	O
pyridine	O
-	O
induced	O
DNA	O
adducts	O
and	O
genotoxicity	O
in	O
chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
expressing	O
human	O
CYP1A2	B-Protein
and	O
rapid	O
or	O
slow	O
acetylator	O
N	B-Protein
-	I-Protein
acetyltransferase	I-Protein
2	I-Protein
.	O

Heterocyclic	O
amine	O
carcinogens	O
such	O
as	O
2	O
-	O
amino	O
-	O
1	O
-	O
methyl	O
-	O
6	O
-	O
phenylimidazo	O
[	O
4	O
,	O
5	O
-	O
b	O
]	O
pyridine	O
(	O
PhIP	O
)	O
are	O
present	O
in	O
diet	O
and	O
cigarette	O
smoke	O
.	O

Bioactivation	O
in	O
humans	O
includes	O
N	O
-	O
hydroxylation	O
catalyzed	O
by	O
cytochrome	B-Protein
P4501A2	I-Protein
possibly	O
followed	O
by	O
O	O
-	O
acetylation	O
catalyzed	O
by	O
N	B-Protein
-	I-Protein
acetyltransferase	I-Protein
2	I-Protein
(	O
NAT2	B-Protein
)	O
.	O

Nucleotide	O
excision	O
repair	O
-	O
deficient	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
were	O
stably	O
transfected	O
with	O
human	O
CYP1A2	B-Protein
and	O
either	O
NAT2	B-Protein
*	O
4	O
(	O
rapid	O
acetylator	O
)	O
or	O
NAT2	B-Protein
*	O
5B	O
(	O
slow	O
acetylator	O
)	O
alleles	O
.	O

CYP1A2	B-Protein
and	O
NAT2	B-Protein
catalytic	O
activities	O
were	O
undetectable	O
in	O
untransfected	O
CHO	O
cell	O
lines	O
.	O

CYP1A2	B-Protein
catalytic	O
activity	O
levels	O
did	O
not	O
differ	O
significantly	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
among	O
the	O
CYP1A2	B-Protein
-	O
transfected	O
cell	O
lines	O
.	O

Cells	O
transfected	O
with	O
NAT2	B-Protein
*	O
4	O
had	O
significantly	O
higher	O
levels	O
of	O
N	O
-	O
acetyltransferase	O
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
and	O
N	O
-	O
hydroxy	O
-	O
PhIP	O
O	O
-	O
acetyltransferase	O
(	O
P	O
=	O
0	O
.	O
0170	O
)	O
catalytic	O
activity	O
than	O
cells	O
transfected	O
with	O
NAT2	B-Protein
*	O
5B	O
.	O

PhIP	O
caused	O
dose	O
-	O
dependent	O
decreases	O
in	O
cell	O
survival	O
and	O
significant	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
increases	O
in	O
mutagenesis	O
measured	O
at	O
the	O
hypoxanthine	B-Protein
phosphoribosyl	I-Protein
transferase	I-Protein
(	O
hprt	B-Protein
)	O
locus	O
in	O
all	O
the	O
CYP1A2	B-Protein
-	O
transfected	O
cell	O
lines	O
.	O

Transfection	O
with	O
NAT2	B-Protein
*	O
4	O
or	O
NAT2	B-Protein
*	O
5B	O
did	O
not	O
further	O
increase	O
hprt	O
mutagenesis	O
.	O

PhIP	O
-	O
induced	O
hprt	O
mutant	O
cDNAs	O
were	O
sequenced	O
,	O
and	O
80	O
%	O
of	O
the	O
mutations	O
were	O
single	O
base	O
substitutions	O
at	O
G	O
:	O
C	O
base	O
pairs	O
.	O

dG	O
-	O
C8	O
-	O
PhIP	O
DNA	O
adduct	O
levels	O
were	O
dose	O
-	O
dependent	O
in	O
the	O
order	O
:	O
untransfected	O
<	O
transfected	O
with	O
CYP1A2	B-Protein
<	O
transfected	O
with	O
CYP1A2	B-Protein
and	O
NAT2	B-Protein
*	O
5B	O
<	O
transfected	O
with	O
CYP1A2	B-Protein
and	O
NAT2	B-Protein
*	O
4	O
.	O

Following	O
incubation	O
with	O
1	O
.	O
2	O
microM	O
PhIP	O
,	O
DNA	O
adduct	O
levels	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
in	O
CHO	O
cells	O
transfected	O
with	O
CYP1A2	B-Protein
/	O
NAT2	B-Protein
*	O
4	O
versus	O
CYP1A2	B-Protein
/	O
NAT2	B-Protein
*	O
5B	O
.	O

These	O
results	O
strongly	O
support	O
an	O
activation	O
role	O
for	O
CYP1A2	B-Protein
in	O
PhIP	O
-	O
induced	O
mutagenesis	O
and	O
DNA	O
damage	O
and	O
suggest	O
a	O
modest	O
effect	O
of	O
human	O
NAT2	B-Protein
and	O
its	O
genetic	O
polymorphism	O
on	O
PhIP	O
DNA	O
adduct	O
levels	O
.	O

Expression	O
and	O
purification	O
of	O
recombinant	O
yeast	O
Ada2	B-Protein
/	O
Ada3	B-Protein
/	O
Gcn5	B-Protein
and	O
Piccolo	O
NuA4	O
histone	O
acetyltransferase	O
complexes	O
.	O

Acetylation	O
of	O
histone	B-Protein
tails	O
by	O
histone	B-Protein
acetyltransferase	O
(	O
HAT	O
)	O
enzymes	O
is	O
a	O
key	O
post	O
-	O
translational	O
modification	O
of	O
histones	O
associated	O
with	O
transcriptionally	O
active	O
genes	O
.	O

Acetylation	O
of	O
the	O
physiological	O
nucleosome	O
substrate	O
is	O
performed	O
in	O
cells	O
by	O
megadalton	O
complexes	O
such	O
as	O
SAGA	O
and	O
NuA4	O
.	O

To	O
understand	O
how	O
HAT	O
enzymes	O
specifically	O
recognize	O
their	O
nucleosome	O
and	O
not	O
just	O
histone	B-Protein
tail	O
substrates	O
,	O
we	O
have	O
identified	O
the	O
catalytic	O
SAGA	O
and	O
NuA4	O
subcomplexes	O
sufficient	O
to	O
act	O
on	O
nucleosomes	O
.	O

We	O
describe	O
here	O
expression	O
and	O
purification	O
procedures	O
to	O
prepare	O
recombinant	O
yeast	O
Ada2	B-Protein
/	O
Ada3	B-Protein
/	O
Gcn5	B-Protein
subcomplex	O
of	O
SAGA	O
which	O
acetylates	O
histones	B-Protein
H3	I-Protein
and	O
H2B	B-Protein
on	O
nucleosomes	O
,	O
and	O
the	O
Piccolo	O
NuA4	O
complex	O
which	O
acetylates	O
histones	B-Protein
H4	I-Protein
and	O
H2A	B-Protein
on	O
nucleosomes	O
.	O

We	O
demonstrate	O
an	O
unexpected	O
benefit	O
of	O
using	O
the	O
BL21	O
-	O
CodonPlus	O
strain	O
to	O
enhance	O
the	O
purity	O
of	O
metal	O
affinity	O
purified	O
Ada2	B-Protein
/	O
Ada3	B-Protein
/	O
Gcn5	B-Protein
complex	O
.	O

We	O
also	O
identify	O
Escherichia	O
coli	O
EF	O
-	O
Tu	O
as	O
a	O
contaminant	O
that	O
copurifies	O
with	O
both	O
complexes	O
over	O
multiple	O
chromatographic	O
steps	O
and	O
use	O
of	O
hydrophobic	O
interaction	O
chromatography	O
to	O
remove	O
the	O
contaminant	O
from	O
the	O
Piccolo	O
NuA4	O
complex	O
.	O

The	O
methods	O
described	O
here	O
will	O
be	O
useful	O
for	O
studies	O
into	O
the	O
molecular	O
mechanism	O
of	O
these	O
enzymes	O
and	O
for	O
preparing	O
the	O
enzymes	O
as	O
reagents	O
to	O
study	O
the	O
interplay	O
of	O
nucleosome	O
acetylation	O
with	O
other	O
chromatin	O
modification	O
and	O
remodeling	O
enzymes	O
.	O

[	O
Aberrant	O
methylation	O
of	O
tumor	O
suppressor	O
genes	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
:	O
is	O
it	O
clinically	O
relevant	O
?	O
]	O

During	O
malignant	O
transformation	O
,	O
the	O
malignant	O
cell	O
accumulates	O
epigenetic	O
abnormalities	O
that	O
do	O
not	O
alter	O
the	O
DNA	O
sequence	O
but	O
are	O
transmissible	O
during	O
divisions	O
and	O
modify	O
genes	O
expression	O
.	O

The	O
methylation	O
of	O
CpG	O
islands	O
in	O
the	O
tumor	O
suppressor	O
genes	O
(	O
TS	O
genes	O
)	O
promoters	O
inhibits	O
their	O
transcription	O
;	O
it	O
is	O
a	O
mecanism	O
of	O
gene	O
inactivation	O
as	O
frequent	O
as	O
allelic	O
deletions	O
.	O

The	O
methylation	O
profile	O
(	O
or	O
panel	O
of	O
methylated	O
genes	O
in	O
a	O
tumor	O
)	O
,	O
similarly	O
to	O
allelic	O
deletions	O
,	O
varies	O
with	O
the	O
tumor	O
histology	O
.	O

Within	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
oral	O
cavity	O
,	O
larynx	O
and	O
oropharynx	O
)	O
,	O
19	O
genes	O
have	O
been	O
analysed	O
,	O
among	O
them	O
5	O
are	O
frequently	O
methylated	O
,	O
i	O
.	O
e	O
.	O
:	O
p16	B-Protein
,	O
ECAD	B-Protein
,	O
DAPK	B-Protein
,	O
MGMT	B-Protein
et	O
TIMP3	B-Protein
.	O

The	O
method	O
of	O
methylation	O
analysis	O
,	O
based	O
on	O
a	O
bisulfite	O
treatment	O
followed	O
by	O
a	O
PCR	O
amplification	O
,	O
is	O
sensitive	O
and	O
specific	O
enough	O
to	O
allow	O
the	O
detection	O
of	O
abnormalities	O
in	O
biological	O
fluid	O
that	O
drain	O
the	O
tumor	O
or	O
in	O
circulating	O
tumoral	O
DNA	O
.	O

In	O
the	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
,	O
correlation	O
between	O
the	O
methylation	O
profile	O
in	O
tumor	O
and	O
paired	O
saliva	O
is	O
excellent	O
;	O
thus	O
methylation	O
analysis	O
in	O
saliva	O
is	O
a	O
very	O
promising	O
approach	O
for	O
early	O
cancer	O
detection	O
in	O
high	O
risk	O
patients	O
or	O
for	O
the	O
post	O
treatment	O
follow	O
up	O
and	O
rapid	O
diagnosis	O
of	O
relapse	O
.	O

The	O
methylation	O
signature	O
might	O
also	O
reflect	O
the	O
tumor	O
prognosis	O
and	O
complete	O
the	O
histology	O
to	O
define	O
the	O
diagnosis	O
.	O

Finally	O
,	O
DNA	O
methylation	O
is	O
reversible	O
with	O
demethylating	O
agents	O
,	O
a	O
new	O
avenue	O
for	O
cancer	O
therapy	O
in	O
association	O
with	O
conventional	O
chemotherapy	O
.	O

Modulation	O
of	O
p300	B-Protein
binding	O
by	O
posttranslational	O
modifications	O
of	O
the	O
C	O
-	O
terminal	O
activation	O
domain	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
.	O

Posttranslational	O
modifications	O
of	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
influence	O
HIF	O
-	O
mediated	O
transcription	O
,	O
likely	O
by	O
affecting	O
binding	O
to	O
p300	B-Protein
/	O
cAMP	B-Protein
-	I-Protein
response	I-Protein
element	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CBP	B-Protein
)	O
.	O

To	O
systematically	O
analyze	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
-	O
p300	B-Protein
/	O
CBP	B-Protein
interaction	O
,	O
we	O
developed	O
a	O
fluorescence	O
polarization	O
-	O
based	O
binding	O
assay	O
,	O
employing	O
fluorescein	O
-	O
labeled	O
peptides	O
derived	O
from	O
the	O
C	O
-	O
terminal	O
transactivation	O
domain	O
(	O
C	O
-	O
TAD	O
)	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

After	O
optimized	O
for	O
effectively	O
capturing	O
p300	B-Protein
/	O
CBP	B-Protein
,	O
the	O
assay	O
was	O
utilized	O
for	O
evaluating	O
direct	O
effects	O
of	O
posttranslational	O
modifications	O
of	O
the	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
C	O
-	O
TAD	O
on	O
p300	B-Protein
binding	O
.	O

The	O
results	O
demonstrated	O
that	O
asparagine	O
hydroxylation	O
and	O
S	O
-	O
nitrosylation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
decrease	O
p300	B-Protein
binding	O
,	O
while	O
its	O
phosphorylation	O
does	O
not	O
affect	O
p300	B-Protein
binding	O
,	O
which	O
was	O
reconfirmed	O
by	O
competitive	O
inhibition	O
analyses	O
using	O
mutant	O
peptides	O
.	O

CCR4	B-Protein
/	O
NOT	O
complex	O
associates	O
with	O
the	O
proteasome	O
and	O
regulates	O
histone	B-Protein
methylation	O
.	O

The	O
proteasome	O
regulates	O
histone	B-Protein
lysine	O
methylation	O
and	O
gene	O
transcription	O
,	O
but	O
how	O
it	O
does	O
so	O
is	O
poorly	O
understood	O
.	O

To	O
better	O
understand	O
this	O
process	O
,	O
we	O
used	O
the	O
epistatic	O
miniarray	O
profile	O
(	O
E	O
-	O
MAP	O
)	O
approach	O
to	O
identify	O
factors	O
that	O
genetically	O
interact	O
with	O
proteasomal	O
subunits	O
.	O

In	O
addition	O
to	O
members	O
of	O
the	O
Set1	B-Protein
complex	O
that	O
mediate	O
histone	B-Protein
H3	I-Protein
lysine	O
4	O
methylation	O
(	O
H3K4me	B-Protein
)	O
,	O
we	O
found	O
that	O
deleting	O
members	O
of	O
the	O
CCR4	B-Protein
/	O
NOT	O
mRNA	O
processing	O
complex	O
exhibit	O
synthetic	O
phenotypes	O
when	O
combined	O
with	O
proteasome	O
mutants	O
.	O

Further	O
biochemical	O
analyses	O
revealed	O
physical	O
associations	O
between	O
CCR4	B-Protein
/	O
NOT	O
and	O
the	O
proteasome	O
in	O
vivo	O
.	O

Consistent	O
with	O
the	O
genetic	O
and	O
biochemical	O
interactions	O
linking	O
CCR4	B-Protein
/	O
NOT	O
with	O
proteasome	O
and	O
Set1	B-Protein
-	O
mediated	O
methylation	O
,	O
we	O
find	O
that	O
loss	O
of	O
Not4	B-Protein
decreases	O
global	O
and	O
gene	O
-	O
specific	O
H3K4	B-Protein
trimethylation	O
(	O
H3K4me3	B-Protein
)	O
and	O
decreases	O
19S	O
proteasome	O
recruitment	O
to	O
the	O
PMA1	B-Protein
gene	O
.	O

Similar	O
to	O
proteasome	O
regulation	O
of	O
histone	B-Protein
methylation	O
,	O
loss	O
of	O
CCR4	B-Protein
/	O
NOT	O
members	O
does	O
not	O
affect	O
ubiquitinated	O
H2B	B-Protein
.	O

Mapping	O
of	O
Not4	B-Protein
identified	O
the	O
RING	O
finger	O
domain	O
as	O
essential	O
for	O
H3K4me3	B-Protein
,	O
suggesting	O
a	O
role	O
for	O
ubiquitin	B-Protein
in	O
this	O
process	O
.	O

Consistent	O
with	O
this	O
idea	O
,	O
loss	O
of	O
the	O
Not4	B-Protein
-	O
interacting	O
protein	O
Ubc4	B-Protein
,	O
a	O
known	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
,	O
decreases	O
H3K4me3	B-Protein
.	O

These	O
studies	O
implicate	O
CCR4	B-Protein
/	O
NOT	O
in	O
the	O
regulation	O
of	O
H3K4me3	B-Protein
through	O
a	O
ubiquitin	B-Protein
-	O
dependent	O
pathway	O
that	O
likely	O
involves	O
the	O
proteasome	O
.	O

Increased	O
inhibitory	O
capacity	O
of	O
an	O
anti	O
-	O
C5a	B-Protein
complementary	O
peptide	O
following	O
acetylation	O
of	O
N	O
-	O
terminal	O
alanine	O
.	O

Amino	O
acids	O
37	O
to	O
53	O
(	O
RAARISLGPRCIKAFTE	O
)	O
of	O
C5a	B-Protein
anaphylatoxin	O
form	O
an	O
essential	O
region	O
for	O
C5a	B-Protein
function	O
.	O

To	O
target	O
this	O
sequence	O
,	O
we	O
generated	O
a	O
complementary	O
peptide	O
(	O
ASGAPAPGPAGPLRPMF	O
)	O
designated	O
PepA	O
which	O
has	O
a	O
potent	O
inhibitory	O
effect	O
on	O
C5a	B-Protein
activity	O
.	O

By	O
introducing	O
an	O
acetyl	O
group	O
at	O
the	O
N	O
-	O
terminal	O
alanine	O
of	O
PepA	O
,	O
an	O
acetylated	O
form	O
was	O
generated	O
which	O
was	O
designated	O
AcPepA	O
.	O

The	O
acetylation	O
resulted	O
in	O
increased	O
inhibition	O
of	O
C5a	B-Protein
stimulation	O
of	O
neutrophils	O
as	O
determined	O
by	O
Ca	O
influx	O
.	O

Furthermore	O
,	O
AcPepA	O
partially	O
inhibited	O
the	O
lethal	O
shock	O
induced	O
in	O
mice	O
by	O
intravenous	O
administration	O
of	O
Candida	O
albicans	O
water	O
-	O
soluble	O
mannoprotein	O
-	O
beta	O
-	O
glucan	O
complex	O
.	O

In	O
addition	O
,	O
local	O
skin	O
inflammation	O
in	O
rats	O
caused	O
by	O
an	O
anti	O
-	O
Crry	B-Protein
monoclonal	O
antibody	O
was	O
suppressed	O
when	O
AcPepA	O
and	O
the	O
antibody	O
were	O
injected	O
together	O
,	O
while	O
PepA	O
had	O
little	O
inhibitory	O
capacity	O
.	O

The	O
potent	O
inhibitory	O
capacity	O
of	O
AcPepA	O
was	O
also	O
confirmed	O
by	O
a	O
skin	O
reaction	O
of	O
guinea	O
pigs	O
inoculated	O
with	O
recombinant	O
human	O
C5a	B-Protein
together	O
with	O
AcPepA	O
.	O

Down	O
-	O
regulation	O
of	O
N	B-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
-	I-Protein
V	I-Protein
induces	O
ER	O
stress	O
by	O
changing	O
glycosylation	O
and	O
function	O
of	O
GLUT1	B-Protein
.	O

N	B-Protein
-	I-Protein
Acetylglucosaminyltransferase	I-Protein
-	I-Protein
V	I-Protein
(	O
GnT	B-Protein
-	I-Protein
V	I-Protein
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
processing	O
of	O
N	O
-	O
glycans	O
during	O
synthesis	O
of	O
glycoproteins	O
.	O

We	O
have	O
reported	O
that	O
down	O
-	O
regulating	O
GnT	B-Protein
-	I-Protein
V	I-Protein
could	O
induce	O
endoplasmic	O
reticulum	O
stress	O
(	O
ER	O
stress	O
)	O
in	O
7721	O
cells	O
,	O
a	O
human	O
hepatocarcinoma	O
cell	O
line	O
.	O

In	O
a	O
search	O
for	O
mechanisms	O
of	O
ER	O
stress	O
,	O
we	O
found	O
that	O
there	O
was	O
a	O
prominent	O
decline	O
of	O
glucose	O
uptake	O
in	O
antisense	O
GnT	B-Protein
-	I-Protein
V	I-Protein
transfectant	O
,	O
furthermore	O
,	O
a	O
decrease	O
of	O
tri	O
-	O
or	O
tetra	O
-	O
antannary	O
sugar	O
chain	O
of	O
glucose	B-Protein
transporter	I-Protein
1	I-Protein
(	O
GLUT1	B-Protein
)	O
.	O

However	O
,	O
distribution	O
of	O
GLUT1	B-Protein
in	O
antisense	O
GnT	B-Protein
-	I-Protein
V	I-Protein
transfectant	O
was	O
not	O
affected	O
.	O

Glucose	O
deprivation	O
has	O
been	O
known	O
to	O
activate	O
ER	O
stress	O
in	O
tumor	O
cells	O
.	O

Therefore	O
,	O
the	O
data	O
presented	O
in	O
this	O
study	O
indicate	O
that	O
the	O
glycosylation	O
change	O
and	O
decrease	O
of	O
transport	O
activity	O
of	O
GLUT1	B-Protein
may	O
be	O
one	O
possible	O
mechanism	O
of	O
ER	O
stress	O
induced	O
by	O
down	O
-	O
regulating	O
GnT	B-Protein
-	I-Protein
V	I-Protein
,	O
and	O
GnT	B-Protein
-	I-Protein
V	I-Protein
may	O
contribute	O
to	O
the	O
regulation	O
of	O
glucose	O
uptake	O
by	O
modifying	O
glycosylation	O
of	O
GLUT1	B-Protein
in	O
some	O
tumor	O
cells	O
.	O

Probing	O
the	O
receptor	O
interactions	O
of	O
an	O
H5	O
avian	O
influenza	O
virus	O
using	O
a	O
baculovirus	O
expression	O
system	O
and	O
functionalised	O
poly	O
(	O
acrylic	O
acid	O
)	O
ligands	O
.	O

Influenza	O
viruses	O
attach	O
to	O
host	O
cells	O
by	O
binding	O
to	O
terminal	O
sialic	O
acid	O
(	O
Neu5Ac	O
)	O
on	O
glycoproteins	O
or	O
glycolipids	O
.	O

Both	O
the	O
linkage	O
of	O
Neu5Ac	O
and	O
the	O
identity	O
of	O
other	O
carbohydrates	O
within	O
the	O
oligosaccharide	O
are	O
thought	O
to	O
play	O
roles	O
in	O
restricting	O
the	O
host	O
range	O
of	O
the	O
virus	O
.	O

In	O
this	O
study	O
,	O
the	O
receptor	O
specificity	O
of	O
an	O
H5	O
avian	O
influenza	O
virus	O
haemagglutinin	B-Protein
protein	O
that	O
has	O
recently	O
infected	O
man	O
(	O
influenza	O
strain	O
A	O
/	O
Vietnam	O
/	O
1194	O
/	O
04	O
)	O
has	O
been	O
probed	O
using	O
carbohydrate	O
functionalised	O
poly	O
(	O
acrylic	O
acid	O
)	O
polymers	O
.	O

A	O
baculovirus	O
expression	O
system	O
that	O
allows	O
facile	O
and	O
safe	O
analysis	O
of	O
the	O
Neu5Ac	O
binding	O
specificity	O
of	O
mutants	O
of	O
H5	B-Protein
HA	I-Protein
engineered	O
at	O
sites	O
that	O
are	O
predicted	O
to	O
effect	O
a	O
switch	O
in	O
host	O
range	O
has	O
also	O
been	O
developed	O
.	O

Transcription	O
-	O
coupled	O
deposition	O
of	O
histone	B-Protein
modifications	O
during	O
MHC	O
class	O
II	O
gene	O
activation	O
.	O

Posttranslational	O
histone	B-Protein
modifications	O
associated	O
with	O
actively	O
expressed	O
genes	O
are	O
generally	O
believed	O
to	O
be	O
introduced	O
primarily	O
by	O
histone	B-Protein
-	O
modifying	O
enzymes	O
that	O
are	O
recruited	O
by	O
transcription	O
factors	O
or	O
their	O
associated	O
co	O
-	O
activators	O
.	O

We	O
have	O
performed	O
a	O
comprehensive	O
spatial	O
and	O
temporal	O
analyses	O
of	O
the	O
histone	B-Protein
modifications	O
that	O
are	O
deposited	O
upon	O
activation	O
of	O
the	O
MHC	O
class	O
II	O
gene	O
HLA	B-Protein
-	I-Protein
DRA	I-Protein
by	O
the	O
co	O
-	O
activator	O
CIITA	B-Protein
.	O

We	O
find	O
that	O
transcription	O
-	O
associated	O
histone	B-Protein
modifications	O
are	O
introduced	O
during	O
two	O
sequential	O
phases	O
.	O

The	O
first	O
phase	O
precedes	O
transcription	O
initiation	O
and	O
is	O
characterized	O
exclusively	O
by	O
a	O
rapid	O
increase	O
in	O
histone	B-Protein
H4	I-Protein
acetylation	O
over	O
a	O
large	O
upstream	O
domain	O
.	O

All	O
other	O
modifications	O
examined	O
,	O
including	O
the	O
acetylation	O
and	O
methylation	O
of	O
several	O
residues	O
in	O
histone	B-Protein
H3	I-Protein
,	O
are	O
restricted	O
to	O
short	O
regions	O
situated	O
at	O
or	O
within	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
and	O
are	O
established	O
during	O
a	O
second	O
phase	O
that	O
is	O
concomitant	O
with	O
ongoing	O
transcription	O
.	O

This	O
second	O
phase	O
is	O
completely	O
abrogated	O
when	O
elongation	O
by	O
RNA	O
polymerase	O
II	O
is	O
blocked	O
.	O

These	O
results	O
provide	O
strong	O
evidence	O
that	O
transcription	O
elongation	O
can	O
play	O
a	O
decisive	O
role	O
in	O
the	O
deposition	O
of	O
histone	B-Protein
modification	O
patterns	O
associated	O
with	O
inducible	O
gene	O
activation	O
.	O

Defective	O
ubiquitinylation	O
of	O
EGFR	B-Protein
mutants	O
of	O
lung	O
cancer	O
confers	O
prolonged	O
signaling	O
.	O

Several	O
distinct	O
mutations	O
within	O
the	O
kinase	O
domain	O
of	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
(	O
EGFR	B-Protein
)	O
are	O
associated	O
with	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
but	O
mechanisms	O
underlying	O
their	O
oncogenic	O
potential	O
are	O
incompletely	O
understood	O
.	O

Although	O
normally	O
ligand	O
-	O
induced	O
kinase	O
activation	O
targets	O
EGFR	B-Protein
to	O
Cbl	B-Protein
-	O
mediated	O
receptor	O
ubiquitinylation	O
and	O
subsequent	O
degradation	O
in	O
lysosomes	O
,	O
we	O
report	O
that	O
certain	O
EGFR	B-Protein
mutants	O
escape	O
this	O
regulation	O
.	O

Defective	O
endocytosis	O
characterizes	O
a	O
deletion	O
mutant	O
of	O
EGFR	B-Protein
,	O
as	O
well	O
as	O
a	O
point	O
mutant	O
(	O
L858R	O
-	O
EGFR	B-Protein
)	O
,	O
whose	O
association	O
with	O
c	B-Protein
-	I-Protein
Cbl	I-Protein
and	O
ubiquitinylation	O
are	O
impaired	O
.	O

Our	O
data	O
raise	O
the	O
possibility	O
that	O
refractoriness	O
of	O
L858R	O
-	O
EGFR	B-Protein
to	O
downregulation	O
is	O
due	O
to	O
enhanced	O
heterodimerization	O
with	O
the	O
oncogene	O
product	O
HER2	B-Protein
,	O
which	O
leads	O
to	O
persistent	O
stimulation	O
.	O

Increased	O
expression	O
and	O
altered	O
subunit	O
composition	O
of	O
proteasomes	O
induced	O
by	O
continuous	O
proteasome	O
inhibition	O
establish	O
apoptosis	O
resistance	O
and	O
hyperproliferation	O
of	O
Burkitt	O
lymphoma	O
cells	O
.	O

The	O
proteasome	O
is	O
the	O
main	O
protease	O
for	O
extralysosomal	O
protein	O
degradation	O
in	O
eukaryotic	O
cells	O
,	O
and	O
constitutes	O
a	O
sophisticated	O
high	O
molecular	O
mass	O
proteinase	O
complex	O
underlying	O
a	O
tightly	O
coordinated	O
expression	O
and	O
assembly	O
of	O
multiple	O
subunits	O
and	O
subcomplexes	O
.	O

Here	O
we	O
show	O
that	O
continuous	O
inhibition	O
of	O
proteasomal	O
chymotrypsin	O
-	O
like	O
peptidase	O
activity	O
by	O
the	O
proteasome	O
inhibitor	O
bortezomib	O
induces	O
in	O
human	O
Namalwa	O
Burkitt	O
lymphoma	O
cells	O
increased	O
de	O
novo	O
biogenesis	O
of	O
proteasomes	O
accompanied	O
by	O
increased	O
expression	O
of	O
the	O
proteasome	O
maturation	O
protein	O
POMP	B-Protein
,	O
increased	O
expression	O
of	O
19S	O
-	O
20S	O
-	O
19S	O
proteasomes	O
,	O
and	O
abrogation	O
of	O
expression	O
of	O
beta	O
1i	O
,	O
beta	O
2i	O
and	O
beta	O
5i	O
immunosubunits	O
and	O
PA28	B-Protein
in	O
favor	O
of	O
increased	O
expression	O
of	O
constitutive	O
proteolytic	O
beta1	O
,	O
beta2	O
and	O
beta	O
5	O
subunits	O
and	O
19S	O
regulatory	O
complexes	O
.	O

These	O
alterations	O
of	O
proteasome	O
expression	O
and	O
subunit	O
composition	O
are	O
accompanied	O
by	O
an	O
increase	O
in	O
proteasomal	O
caspase	O
-	O
like	O
,	O
trypsin	O
-	O
like	O
and	O
chymotrypsin	O
-	O
like	O
peptidase	O
activities	O
,	O
not	O
inhibitable	O
by	O
high	O
doses	O
of	O
bortezomib	O
.	O

Cells	O
harboring	O
these	O
proteasomal	O
alterations	O
display	O
rapid	O
proliferation	O
and	O
cell	O
cycle	O
progression	O
,	O
and	O
acquire	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
proteasome	O
inhibitors	O
,	O
gamma	O
-	O
irradiation	O
and	O
staurosporine	O
.	O

This	O
acquired	O
apoptosis	O
resistance	O
is	O
accompanied	O
by	O
de	O
novo	O
expression	O
of	O
anti	O
-	O
apoptotic	O
Hsp27	B-Protein
protein	O
and	O
the	O
loss	O
of	O
ability	O
to	O
accumulate	O
and	O
stabilize	O
pro	O
-	O
apoptotic	O
p53	B-Protein
protein	O
.	O

Thus	O
,	O
increased	O
expression	O
,	O
altered	O
subunit	O
composition	O
and	O
increased	O
activity	O
of	O
proteasomes	O
constitute	O
a	O
hitherto	O
unknown	O
adaptive	O
and	O
autoregulatory	O
feedback	O
mechanism	O
to	O
allow	O
cells	O
to	O
survive	O
the	O
lethal	O
challenge	O
of	O
proteasome	O
inhibition	O
and	O
to	O
establish	O
a	O
hyperproliferative	O
and	O
apoptosis	O
-	O
resistant	O
phenotype	O
.	O

Cell	O
shape	O
regulates	O
global	O
histone	B-Protein
acetylation	O
in	O
human	O
mammary	O
epithelial	O
cells	O
.	O

Extracellular	O
matrix	O
(	O
ECM	O
)	O
regulates	O
cell	O
morphology	O
and	O
gene	O
expression	O
in	O
vivo	O
;	O
these	O
relationships	O
are	O
maintained	O
in	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
cultures	O
of	O
mammary	O
epithelial	O
cells	O
.	O

In	O
the	O
presence	O
of	O
laminin	O
-	O
rich	O
ECM	O
(	O
lrECM	O
)	O
,	O
mammary	O
epithelial	O
cells	O
round	O
up	O
and	O
undergo	O
global	O
histone	B-Protein
deacetylation	O
,	O
a	O
process	O
critical	O
for	O
their	O
functional	O
differentiation	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
lrECM	O
-	O
dependent	O
cell	O
rounding	O
and	O
global	O
histone	B-Protein
deacetylation	O
are	O
indeed	O
part	O
of	O
a	O
common	O
physical	O
-	O
biochemical	O
pathway	O
.	O

Using	O
3D	O
cultures	O
as	O
well	O
as	O
nonadhesive	O
and	O
micropatterned	O
substrata	O
,	O
here	O
we	O
showed	O
that	O
the	O
cell	O
'	O
rounding	O
'	O
caused	O
by	O
lrECM	O
was	O
sufficient	O
to	O
induce	O
deacetylation	O
of	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
in	O
the	O
absence	O
of	O
biochemical	O
cues	O
.	O

Microarray	O
and	O
confocal	O
analysis	O
demonstrated	O
that	O
this	O
deacetylation	O
in	O
3D	O
culture	O
is	O
associated	O
with	O
a	O
global	O
increase	O
in	O
chromatin	O
condensation	O
and	O
a	O
reduction	O
in	O
gene	O
expression	O
.	O

Whereas	O
cells	O
cultured	O
on	O
plastic	O
substrata	O
formed	O
prominent	O
stress	O
fibers	O
,	O
cells	O
grown	O
in	O
3D	O
lrECM	O
or	O
on	O
micropatterns	O
lacked	O
these	O
structures	O
.	O

Disruption	O
of	O
the	O
actin	O
cytoskeleton	O
with	O
cytochalasin	O
D	O
phenocopied	O
the	O
lrECM	O
-	O
induced	O
cell	O
rounding	O
and	O
histone	B-Protein
deacetylation	O
.	O

These	O
results	O
reveal	O
a	O
novel	O
link	O
between	O
ECM	O
-	O
controlled	O
cell	O
shape	O
and	O
chromatin	O
structure	O
and	O
suggest	O
that	O
this	O
link	O
is	O
mediated	O
by	O
changes	O
in	O
the	O
actin	O
cytoskeleton	O
.	O

EZH2	B-Protein
polycomb	O
transcriptional	O
repressor	O
expression	O
correlates	O
with	O
methylation	O
of	O
the	O
APAF	B-Protein
-	I-Protein
1	I-Protein
gene	O
in	O
superficial	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
.	O

The	O
EZH2	B-Protein
gene	O
controls	O
methylation	O
of	O
various	O
EZH2	B-Protein
target	O
promoters	O
.	O

The	O
APAF	B-Protein
-	I-Protein
1	I-Protein
,	O
DAPK	B-Protein
-	I-Protein
1	I-Protein
und	O
IGFBP	B-Protein
-	I-Protein
3	I-Protein
genes	O
are	O
frequently	O
methylated	O
in	O
bladder	O
cancer	O
,	O
and	O
methylation	O
of	O
these	O
genes	O
is	O
found	O
in	O
more	O
aggressive	O
tumor	O
types	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
investigate	O
a	O
potential	O
link	O
between	O
EZH2	B-Protein
mRNA	O
expression	O
and	O
the	O
extent	O
of	O
APAF	B-Protein
-	I-Protein
1	I-Protein
,	O
DAPK	B-Protein
-	I-Protein
1	I-Protein
and	O
IGFBP	B-Protein
-	I-Protein
3	I-Protein
methylation	O
in	O
urothelial	O
transitional	O
cell	O
carcinoma	O
(	O
TCC	O
)	O
and	O
to	O
correlate	O
the	O
data	O
with	O
histopathological	O
parameters	O
and	O
follow	O
-	O
up	O
data	O
.	O

EZH2	B-Protein
mRNA	O
expression	O
was	O
measured	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
,	O
and	O
the	O
methylation	O
analysis	O
was	O
performed	O
using	O
methylation	O
-	O
specific	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Tissue	O
specimens	O
were	O
obtained	O
from	O
35	O
patients	O
with	O
TCC	O
.	O

EZH2	B-Protein
mRNA	O
expression	O
was	O
detected	O
in	O
all	O
tumor	O
specimens	O
investigated	O
.	O

The	O
EZH2	B-Protein
expression	O
levels	O
correlated	O
well	O
with	O
the	O
differentiation	O
grade	O
of	O
the	O
tumor	O
specimens	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
and	O
the	O
APAF	B-Protein
-	I-Protein
1	I-Protein
methylation	O
correlated	O
with	O
tumor	O
stage	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
and	O
grade	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
.	O

Matched	O
pair	O
analysis	O
demonstrated	O
a	O
statistically	O
significant	O
correlation	O
between	O
elevated	O
EZH2	B-Protein
mRNA	O
expression	O
and	O
higher	O
methylation	O
levels	O
of	O
APAF	B-Protein
-	I-Protein
1	I-Protein
in	O
superficial	O
(	O
p	O
=	O
0	O
.	O
024	O
)	O
and	O
well	O
-	O
differentiated	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
TCC	O
.	O

In	O
patients	O
with	O
recurrent	O
TCC	O
,	O
APAF	B-Protein
-	I-Protein
1	I-Protein
and	O
IGFBP	B-Protein
-	I-Protein
3	I-Protein
methylation	O
levels	O
were	O
significantly	O
higher	O
(	O
p	O
=	O
0	O
.	O
03	O
and	O
p	O
=	O
0	O
.	O
01	O
,	O
respectively	O
)	O
,	O
which	O
was	O
not	O
observed	O
when	O
EZH2	B-Protein
mRNA	O
expression	O
or	O
DAPK	B-Protein
-	I-Protein
1	I-Protein
methylation	O
levels	O
were	O
related	O
to	O
the	O
clinical	O
outcome	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
show	O
that	O
EZH2	B-Protein
expression	O
and	O
APAF	B-Protein
-	I-Protein
1	I-Protein
methylation	O
are	O
related	O
to	O
tumor	O
progression	O
and	O
invasiveness	O
.	O

Moreover	O
,	O
these	O
data	O
present	O
first	O
evidence	O
that	O
APAF	B-Protein
-	I-Protein
1	I-Protein
methylation	O
is	O
related	O
to	O
transcriptional	O
activity	O
of	O
EZH2	B-Protein
expression	O
in	O
early	O
-	O
stage	O
tumor	O
disease	O
of	O
the	O
bladder	O
.	O

Deubiquitinating	O
enzyme	O
CYLD	B-Protein
negatively	O
regulates	O
the	O
ubiquitin	B-Protein
-	O
dependent	O
kinase	O
Tak1	B-Protein
and	O
prevents	O
abnormal	O
T	O
cell	O
responses	O
.	O

The	O
deubiquitinating	O
enzyme	O
CYLD	B-Protein
has	O
recently	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
signal	O
transduction	O
,	O
but	O
its	O
physiological	O
function	O
and	O
mechanism	O
of	O
action	O
are	O
still	O
elusive	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
CYLD	B-Protein
plays	O
a	O
pivotal	O
role	O
in	O
regulating	O
T	O
cell	O
activation	O
and	O
homeostasis	O
.	O

T	O
cells	O
derived	O
from	O
Cyld	B-Protein
knockout	O
mice	O
display	O
a	O
hyperresponsive	O
phenotype	O
and	O
mediate	O
the	O
spontaneous	O
development	O
of	O
intestinal	O
inflammation	O
.	O

Interestingly	O
,	O
CYLD	B-Protein
targets	O
a	O
ubiquitin	B-Protein
-	O
dependent	O
kinase	O
,	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
-	I-Protein
activated	I-Protein
kinase	I-Protein
1	I-Protein
(	O
Tak1	B-Protein
)	O
,	O
and	O
inhibits	O
its	O
ubiquitination	O
and	O
autoactivation	O
.	O

Cyld	B-Protein
-	O
deficient	O
T	O
cells	O
exhibit	O
constitutively	O
active	O
Tak1	B-Protein
and	O
its	O
downstream	O
kinases	O
c	B-Protein
-	I-Protein
Jun	I-Protein
N	I-Protein
-	I-Protein
terminal	I-Protein
kinase	I-Protein
and	O
IkappaB	B-Protein
kinase	I-Protein
beta	I-Protein
.	O

These	O
results	O
emphasize	O
a	O
critical	O
role	O
for	O
CYLD	B-Protein
in	O
preventing	O
spontaneous	O
activation	O
of	O
the	O
Tak1	B-Protein
axis	O
of	O
T	O
cell	O
signaling	O
and	O
,	O
thereby	O
,	O
maintaining	O
normal	O
T	O
cell	O
function	O
.	O

Mutations	O
in	O
the	O
Type	O
II	O
protein	O
arginine	O
methyltransferase	O
AtPRMT5	B-Protein
result	O
in	O
pleiotropic	O
developmental	O
defects	O
in	O
Arabidopsis	O
.	O

Human	O
PROTEIN	B-Protein
ARGININE	I-Protein
METHYLTRANSFERASE5	I-Protein
(	O
PRMT5	B-Protein
)	O
encodes	O
a	O
type	O
II	O
protein	O
arginine	O
(	O
Arg	O
)	O
methyltransferase	O
and	O
its	O
homologs	O
in	O
animals	O
and	O
yeast	O
(	O
Saccharomyces	O
cerevisiae	O
and	O
Schizosaccharomyces	O
pombe	O
)	O
are	O
known	O
to	O
regulate	O
RNA	O
processing	O
,	O
signal	O
transduction	O
,	O
and	O
gene	O
expression	O
.	O

However	O
,	O
PRMT5	B-Protein
homologs	O
in	O
higher	O
plants	O
have	O
not	O
yet	O
been	O
reported	O
and	O
the	O
biological	O
roles	O
of	O
these	O
proteins	O
in	O
plant	O
development	O
remain	O
elusive	O
.	O

Here	O
,	O
using	O
conventional	O
biochemical	O
approaches	O
,	O
we	O
purified	O
a	O
plant	O
histone	B-Protein
Arg	O
methyltransferase	O
from	O
cauliflower	O
(	O
Brassica	O
oleracea	O
)	O
that	O
was	O
nearly	O
identical	O
to	O
AtPRMT5	B-Protein
,	O
an	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
homolog	O
of	O
human	O
PRMT5	B-Protein
.	O

AtPRMT5	B-Protein
methylated	O
histone	B-Protein
H4	I-Protein
,	O
H2A	B-Protein
,	O
and	O
myelin	B-Protein
basic	I-Protein
protein	I-Protein
in	O
vitro	O
.	O

Western	O
blot	O
using	O
symmetric	O
dimethyl	O
histone	B-Protein
H4	I-Protein
Arg	O
3	O
-	O
specific	O
antibody	O
and	O
thin	O
-	O
layer	O
chromatography	O
analysis	O
demonstrated	O
that	O
AtPRMT5	B-Protein
is	O
a	O
type	O
II	O
enzyme	O
.	O

Mutations	O
in	O
AtPRMT5	B-Protein
caused	O
pleiotropic	O
developmental	O
defects	O
,	O
including	O
growth	O
retardation	O
,	O
dark	O
green	O
and	O
curled	O
leaves	O
,	O
and	O
FlOWERING	B-Protein
LOCUS	I-Protein
C	I-Protein
(	O
FLC	B-Protein
)	O
-	O
dependent	O
delayed	O
flowering	O
.	O

Therefore	O
,	O
the	O
type	O
II	O
protein	O
Arg	O
methyltransferase	O
AtPRMT5	B-Protein
is	O
involved	O
in	O
promotion	O
of	O
vegetative	O
growth	O
and	O
FLC	B-Protein
-	O
dependent	O
flowering	O
time	O
regulation	O
in	O
Arabidopsis	O
.	O

HAUSP	B-Protein
-	O
regulated	O
switch	O
from	O
auto	O
-	O
to	O
p53	B-Protein
ubiquitination	O
by	O
Mdm2	B-Protein
(	O
in	O
silico	O
discovery	O
)	O
.	O

Stability	O
of	O
the	O
'	O
guardian	O
of	O
the	O
genome	O
'	O
tumor	O
suppressor	O
protein	O
p53	B-Protein
is	O
regulated	O
predominantly	O
through	O
its	O
ubiquitination	O
.	O

The	O
ubiquitin	B-Protein
-	O
specific	O
protease	O
HAUSP	B-Protein
plays	O
an	O
important	O
role	O
in	O
this	O
process	O
.	O

Recent	O
experiments	O
showed	O
that	O
p53	B-Protein
demonstrates	O
a	O
differential	O
response	O
to	O
changes	O
in	O
HAUSP	B-Protein
which	O
nature	O
and	O
significance	O
are	O
not	O
understood	O
yet	O
.	O

Here	O
a	O
data	O
-	O
driven	O
mathematical	O
model	O
of	O
the	O
Mdm2	B-Protein
-	O
mediated	O
p53	B-Protein
ubiquitination	O
network	O
is	O
presented	O
which	O
offers	O
an	O
explanation	O
for	O
the	O
cause	O
of	O
such	O
a	O
response	O
.	O

The	O
model	O
predicts	O
existence	O
of	O
the	O
HAUSP	B-Protein
-	O
regulated	O
switch	O
from	O
auto	O
-	O
to	O
p53	B-Protein
ubiquitination	O
by	O
Mdm2	B-Protein
.	O

This	O
switch	O
suggests	O
a	O
potential	O
role	O
of	O
HAUSP	B-Protein
as	O
a	O
downstream	O
target	O
of	O
stress	O
signals	O
in	O
cells	O
.	O

The	O
model	O
accounts	O
for	O
a	O
significant	O
amount	O
of	O
experimental	O
data	O
,	O
makes	O
predictions	O
for	O
some	O
rate	O
constants	O
,	O
and	O
can	O
serve	O
as	O
a	O
building	O
block	O
for	O
the	O
larger	O
model	O
describing	O
a	O
complex	O
dynamic	O
response	O
of	O
p53	B-Protein
to	O
cellular	O
stresses	O
.	O

Evolutionarily	O
divergent	O
type	O
II	O
protein	O
arginine	O
methyltransferase	O
in	O
Trypanosoma	O
brucei	O
.	O

Protein	O
arginine	O
methylation	O
is	O
a	O
posttranslational	O
modification	O
that	O
impacts	O
cellular	O
functions	O
,	O
such	O
as	O
RNA	O
processing	O
,	O
transcription	O
,	O
DNA	O
repair	O
,	O
and	O
signal	O
transduction	O
.	O

The	O
majority	O
of	O
our	O
knowledge	O
regarding	O
arginine	O
methylation	O
derives	O
from	O
studies	O
of	O
yeast	O
and	O
mammals	O
.	O

Here	O
,	O
we	O
describe	O
a	O
protein	O
arginine	O
N	O
-	O
methyltransferase	O
(	O
PRMT	O
)	O
,	O
TbPRMT5	B-Protein
,	O
from	O
the	O
early	O
-	O
branching	O
eukaryote	O
Trypanosoma	O
brucei	O
.	O

TbPRMT5	B-Protein
shares	O
the	O
greatest	O
sequence	O
similarity	O
with	O
PRMT5	B-Protein
and	O
Skb1	B-Protein
type	O
II	O
enzymes	O
from	O
humans	O
and	O
Schizosaccharomyces	O
pombe	O
,	O
respectively	O
,	O
although	O
it	O
is	O
significantly	O
divergent	O
at	O
the	O
amino	O
acid	O
level	O
from	O
its	O
mammalian	O
and	O
yeast	O
counterparts	O
.	O

Recombinant	O
TbPRMT5	B-Protein
displays	O
broad	O
substrate	O
specificity	O
in	O
vitro	O
,	O
including	O
methylation	O
of	O
a	O
mitochondrial	O
-	O
gene	O
-	O
regulatory	O
protein	O
,	O
RBP16	B-Protein
.	O

TbPRMT5	B-Protein
catalyzes	O
the	O
formation	O
of	O
omega	O
-	O
N	O
(	O
G	O
)	O
-	O
monomethylarginine	O
and	O
symmetric	O
omega	O
-	O
N	O
(	O
G	O
)	O
,	O
N	O
(	O
G	O
'	O
)	O
-	O
dimethylarginine	O
and	O
does	O
not	O
require	O
trypanosome	O
cofactors	O
for	O
this	O
activity	O
.	O

These	O
data	O
establish	O
that	O
type	O
II	O
PRMTs	O
evolved	O
early	O
in	O
the	O
eukaryotic	O
lineage	O
.	O

In	O
vivo	O
,	O
TbPRMT5	B-Protein
is	O
constitutively	O
expressed	O
in	O
the	O
bloodstream	O
form	O
and	O
procyclic	O
-	O
form	O
(	O
insect	O
host	O
)	O
life	O
stages	O
of	O
the	O
parasite	O
and	O
localizes	O
to	O
the	O
cytoplasm	O
.	O

Genetic	O
disruption	O
via	O
RNA	O
interference	O
in	O
procyclic	O
-	O
form	O
trypanosomes	O
indicates	O
that	O
TbPRMT5	B-Protein
is	O
not	O
essential	O
for	O
growth	O
in	O
this	O
life	O
cycle	O
stage	O
.	O

TbPRMT5	B-Protein
-	O
TAP	O
ectopically	O
expressed	O
in	O
procyclic	O
-	O
form	O
trypanosomes	O
is	O
present	O
in	O
high	O
-	O
molecular	O
-	O
weight	O
complexes	O
and	O
associates	O
with	O
an	O
RG	O
domain	O
-	O
containing	O
DEAD	O
box	O
protein	O
related	O
to	O
yeast	O
Ded1	B-Protein
and	O
two	O
kinetoplastid	O
-	O
specific	O
proteins	O
.	O

Thus	O
,	O
TbPRMT5	B-Protein
is	O
likely	O
to	O
be	O
involved	O
in	O
novel	O
methylation	O
-	O
regulated	O
functions	O
in	O
trypanosomes	O
,	O
some	O
of	O
which	O
may	O
include	O
RNA	O
processing	O
and	O
/	O
or	O
translation	O
.	O

Activity	O
of	O
compounds	O
from	O
Chinese	O
herbal	O
medicine	O
Rhodiola	O
kirilowii	O
(	O
Regel	O
)	O
Maxim	O
against	O
HCV	O
NS3	B-Protein
serine	O
protease	O
.	O

Treatment	O
of	O
the	O
chronic	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
an	O
unmet	O
medical	O
need	O
,	O
and	O
the	O
HCV	O
NS3	B-Protein
serine	O
protease	O
(	O
NS3	B-Protein
-	O
SP	O
)	O
has	O
been	O
used	O
as	O
an	O
attractive	O
target	O
of	O
antiviral	O
screening	O
against	O
HCV	O
.	O

To	O
find	O
naturally	O
chemical	O
entities	O
as	O
lead	O
compounds	O
from	O
which	O
novel	O
anti	O
-	O
HCV	O
agents	O
could	O
be	O
developed	O
,	O
bioassay	O
-	O
guided	O
fractionation	O
and	O
isolation	O
were	O
performed	O
on	O
a	O
crude	O
ethanol	O
extract	O
from	O
rhizomes	O
of	O
the	O
Chinese	O
medicinal	O
herb	O
Rhodiola	O
kirilowii	O
(	O
Regel	O
)	O
Maxim	O
using	O
column	O
chromatography	O
(	O
CC	O
)	O
techniques	O
and	O
in	O
vitro	O
inhibitory	O
activity	O
against	O
HCV	O
NS3	B-Protein
-	O
SP	O
.	O

The	O
partition	O
of	O
the	O
extract	O
between	O
water	O
and	O
different	O
organic	O
solvents	O
led	O
to	O
the	O
isolation	O
and	O
identification	O
of	O
12	O
compounds	O
in	O
the	O
ethyl	O
acetate	O
part	O
which	O
proved	O
to	O
be	O
the	O
most	O
active	O
.	O

These	O
compounds	O
were	O
tested	O
for	O
in	O
vitro	O
activity	O
against	O
HCV	O
NS3	B-Protein
-	O
SP	O
,	O
among	O
which	O
four	O
(	O
-	O
)	O
-	O
Epicatechin	O
derivatives	O
:	O
3	O
,	O
3	O
'	O
-	O
Digalloylproprodelphinidin	O
B2	O
(	O
Rhodisin	O
,	O
1	O
)	O
;	O
3	O
,	O
3	O
'	O
-	O
Digalloylprocyanidin	O
B2	O
(	O
2	O
)	O
;	O
(	O
-	O
)	O
-	O
Epigallocatechin	O
-	O
3	O
-	O
O	O
-	O
gallate	O
(	O
EGCG	O
,	O
3	O
)	O
;	O
and	O
(	O
-	O
)	O
-	O
Epicatechin	O
-	O
3	O
-	O
O	O
-	O
gallate	O
(	O
4	O
,	O
ECG	O
)	O
represented	O
the	O
most	O
potent	O
ones	O
with	O
IC	O
(	O
50	O
)	O
of	O
0	O
.	O
77	O
,	O
0	O
.	O
91	O
,	O
8	O
.	O
51	O
,	O
and	O
18	O
.	O
55	O
microM	O
,	O
respectively	O
.	O

Salidroside	O
,	O
the	O
commonly	O
known	O
compounds	O
,	O
together	O
with	O
the	O
other	O
compounds	O
showed	O
no	O
activity	O
up	O
to	O
100	O
.	O
0	O
microM	O
.	O

Methylation	O
and	O
acylation	O
of	O
the	O
hydroxyl	O
groups	O
of	O
1	O
-	O
4	O
caused	O
a	O
decrease	O
of	O
activity	O
.	O

Cell	O
viability	O
and	O
secreted	O
alkaline	O
phosphatase	O
(	O
SEAP	O
)	O
activity	O
assays	O
with	O
1	O
-	O
4	O
revealed	O
little	O
if	O
any	O
toxicity	O
.	O

These	O
nonpeptide	O
inhibitors	O
of	O
HCV	O
NS3	B-Protein
-	O
SP	O
might	O
serve	O
as	O
potential	O
candidate	O
anti	O
-	O
HCV	O
agents	O
.	O

Activation	O
of	O
endoproteolytic	O
processing	O
of	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
II	I-Protein
in	O
fetal	O
,	O
early	O
postnatal	O
,	O
and	O
pregnant	O
rats	O
and	O
persistence	O
of	O
circulating	O
levels	O
in	O
postnatal	O
life	O
.	O

The	O
process	O
of	O
posttranslational	O
modifications	O
of	O
IGF	B-Protein
-	I-Protein
II	I-Protein
likely	O
has	O
important	O
physiological	O
consequences	O
.	O

In	O
addition	O
to	O
mature	O
IGF	B-Protein
-	I-Protein
II	I-Protein
,	O
glycosylated	O
proIGF	B-Protein
-	I-Protein
II	I-Protein
(	O
156	O
-	O
amino	O
acid	O
peptide	O
)	O
and	O
two	O
glycosylated	O
big	O
IGF	B-Protein
-	I-Protein
II	I-Protein
forms	O
,	O
IGF	B-Protein
-	I-Protein
II	I-Protein
(	O
1	O
-	O
104	O
)	O
and	O
IGF	B-Protein
-	I-Protein
II	I-Protein
(	O
1	O
-	O
87	O
)	O
,	O
have	O
been	O
identified	O
in	O
the	O
human	O
circulation	O
.	O

Due	O
to	O
lack	O
of	O
an	O
appropriate	O
methodology	O
,	O
different	O
IGF	B-Protein
-	I-Protein
II	I-Protein
isoforms	O
have	O
not	O
been	O
demonstrated	O
and	O
characterized	O
in	O
the	O
rat	O
circulation	O
,	O
thus	O
preventing	O
a	O
better	O
understanding	O
of	O
the	O
physiological	O
and	O
pathological	O
roles	O
of	O
IGF	B-Protein
-	I-Protein
II	I-Protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
characterized	O
each	O
IGF	B-Protein
-	I-Protein
II	I-Protein
form	O
and	O
assessed	O
its	O
content	O
in	O
the	O
rat	O
circulation	O
throughout	O
life	O
time	O
by	O
using	O
a	O
highly	O
sensitive	O
Western	O
blot	O
analysis	O
,	O
which	O
is	O
void	O
of	O
the	O
IGF	O
binding	O
protein	O
interference	O
and	O
distinguished	O
all	O
IGF	B-Protein
-	I-Protein
II	I-Protein
forms	O
.	O

For	O
the	O
first	O
time	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
IGF	B-Protein
-	I-Protein
II	I-Protein
variants	O
,	O
including	O
proIGF	B-Protein
-	I-Protein
II	I-Protein
,	O
IGF	B-Protein
-	I-Protein
II	I-Protein
(	O
1	O
-	O
87	O
)	O
,	O
and	O
mature	O
IGF	B-Protein
-	I-Protein
II	I-Protein
,	O
in	O
the	O
rat	O
circulation	O
during	O
postnatal	O
life	O
,	O
challenging	O
the	O
current	O
impression	O
that	O
IGF	B-Protein
-	I-Protein
II	I-Protein
is	O
absent	O
from	O
sera	O
of	O
adult	O
rats	O
.	O

ProIGF	B-Protein
-	I-Protein
II	I-Protein
is	O
glycosylated	O
and	O
is	O
the	O
predominant	O
form	O
in	O
the	O
rat	O
circulation	O
.	O

Endoproteolytic	O
processing	O
of	O
proIGF	B-Protein
-	I-Protein
II	I-Protein
was	O
clearly	O
activated	O
in	O
fetal	O
,	O
neonatal	O
,	O
and	O
pregnant	O
rats	O
,	O
likely	O
reflecting	O
its	O
involvement	O
in	O
fetal	O
development	O
through	O
the	O
generation	O
of	O
specific	O
forms	O
of	O
IGF	B-Protein
-	I-Protein
II	I-Protein
(	O
e	O
.	O
g	O
.	O
mature	O
IGF	B-Protein
-	I-Protein
II	I-Protein
)	O
that	O
are	O
required	O
for	O
their	O
distinct	O
biological	O
functions	O
.	O

Taken	O
together	O
,	O
our	O
data	O
also	O
suggest	O
that	O
serum	O
IGF	B-Protein
-	I-Protein
II	I-Protein
profiles	O
may	O
reflect	O
underlying	O
physiological	O
conditions	O
.	O

A	O
unique	O
beta1	O
,	O
3	O
-	O
galactosyltransferase	O
is	O
indispensable	O
for	O
the	O
biosynthesis	O
of	O
N	O
-	O
glycans	O
containing	O
Lewis	O
a	O
structures	O
in	O
Arabidopsis	O
thaliana	O
.	O

In	O
plants	O
,	O
the	O
only	O
known	O
outer	O
-	O
chain	O
elongation	O
of	O
complex	O
N	O
-	O
glycans	O
is	O
the	O
formation	O
of	O
Lewis	O
a	O
[	O
Fuc	O
alpha1	O
-	O
4	O
(	O
Gal	O
beta1	O
-	O
3	O
)	O
GlcNAc	O
-	O
R	O
]	O
structures	O
.	O

This	O
process	O
involves	O
the	O
sequential	O
attachment	O
of	O
beta1	O
,	O
3	O
-	O
galactose	O
and	O
alpha1	O
,	O
4	O
-	O
fucose	O
residues	O
by	O
beta1	O
,	O
3	O
-	O
galactosyltransferase	O
and	O
alpha1	B-Protein
,	I-Protein
4	I-Protein
-	I-Protein
fucosyltransferase	I-Protein
.	O

However	O
,	O
the	O
exact	O
mechanism	O
underlying	O
the	O
formation	O
of	O
Lewis	O
a	O
epitopes	O
in	O
plants	O
is	O
poorly	O
understood	O
,	O
largely	O
because	O
one	O
of	O
the	O
involved	O
enzymes	O
,	O
beta1	O
,	O
3	O
-	O
galactosyltransferase	O
,	O
has	O
not	O
yet	O
been	O
identified	O
and	O
characterized	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
an	O
Arabidopsis	O
thaliana	O
beta1	O
,	O
3	O
-	O
galactosyltransferase	O
involved	O
in	O
the	O
biosynthesis	O
of	O
the	O
Lewis	O
a	O
epitope	O
using	O
an	O
expression	O
cloning	O
strategy	O
.	O

Overexpression	O
of	O
various	O
candidates	O
led	O
to	O
the	O
identification	O
of	O
a	O
single	O
gene	O
(	O
named	O
GALACTOSYLTRANSFERASE1	B-Protein
[	O
GALT1	B-Protein
]	O
)	O
that	O
increased	O
the	O
originally	O
very	O
low	O
Lewis	O
a	O
epitope	O
levels	O
in	O
planta	O
.	O

Recombinant	O
GALT1	B-Protein
protein	O
produced	O
in	O
insect	O
cells	O
was	O
capable	O
of	O
transferring	O
beta1	O
,	O
3	O
-	O
linked	O
galactose	O
residues	O
to	O
various	O
N	O
-	O
glycan	O
acceptor	O
substrates	O
,	O
and	O
subsequent	O
treatment	O
of	O
the	O
reaction	O
products	O
with	O
alpha1	B-Protein
,	I-Protein
4	I-Protein
-	I-Protein
fucosyltransferase	I-Protein
resulted	O
in	O
the	O
generation	O
of	O
Lewis	O
a	O
structures	O
.	O

Furthermore	O
,	O
transgenic	O
Arabidopsis	O
plants	O
lacking	O
a	O
functional	O
GALT1	B-Protein
mRNA	O
did	O
not	O
show	O
any	O
detectable	O
amounts	O
of	O
Lewis	O
a	O
epitopes	O
on	O
endogenous	O
glycoproteins	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
GALT1	B-Protein
is	O
both	O
sufficient	O
and	O
essential	O
for	O
the	O
addition	O
of	O
beta1	O
,	O
3	O
-	O
linked	O
galactose	O
residues	O
to	O
N	O
-	O
glycans	O
and	O
thus	O
is	O
required	O
for	O
the	O
biosynthesis	O
of	O
Lewis	O
a	O
structures	O
in	O
Arabidopsis	O
.	O

Moreover	O
,	O
cell	O
biological	O
characterization	O
of	O
a	O
transiently	O
expressed	O
GALT1	B-Protein
-	O
fluorescent	O
protein	O
fusion	O
using	O
confocal	O
laser	O
scanning	O
microscopy	O
revealed	O
the	O
exclusive	O
location	O
of	O
GALT1	B-Protein
within	O
the	O
Golgi	O
apparatus	O
,	O
which	O
is	O
in	O
good	O
agreement	O
with	O
the	O
proposed	O
physiological	O
action	O
of	O
the	O
enzyme	O
.	O

The	O
PAX3	B-Protein
-	O
FKHR	B-Protein
fusion	O
gene	O
of	O
rhabdomyosarcoma	O
cooperates	O
with	O
loss	O
of	O
p16INK4A	B-Protein
to	O
promote	O
bypass	O
of	O
cellular	O
senescence	O
.	O

Rhabdomyosarcoma	O
is	O
the	O
most	O
common	O
soft	O
tissue	O
sarcoma	O
of	O
childhood	O
and	O
adolescence	O
.	O

Despite	O
advances	O
in	O
therapy	O
,	O
patients	O
with	O
a	O
histologic	O
variant	O
of	O
rhabdomyosarcoma	O
known	O
as	O
alveolar	O
rhabdomyosarcoma	O
(	O
ARMS	O
)	O
have	O
a	O
5	O
-	O
year	O
survival	O
of	O
<	O
30	O
%	O
.	O

ARMS	O
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
generating	O
the	O
PAX3	B-Protein
-	O
FKHR	B-Protein
fusion	O
gene	O
.	O

However	O
,	O
ectopic	O
expression	O
of	O
PAX3	B-Protein
-	O
FKHR	B-Protein
often	O
induces	O
inhibition	O
of	O
cell	O
proliferation	O
,	O
or	O
cell	O
death	O
,	O
when	O
expressed	O
in	O
nonmuscle	O
cells	O
.	O

This	O
prompted	O
us	O
to	O
explore	O
the	O
effect	O
of	O
expressing	O
PAX3	B-Protein
-	O
FKHR	B-Protein
in	O
more	O
relevant	O
cells	O
,	O
specifically	O
primary	O
human	O
skeletal	O
muscle	O
cells	O
because	O
these	O
cells	O
can	O
be	O
converted	O
to	O
a	O
tumorigenic	O
state	O
that	O
mimics	O
rhabdomyosarcoma	O
.	O

PAX3	B-Protein
-	O
FKHR	B-Protein
expression	O
promoted	O
both	O
fetal	O
and	O
postnatal	O
primary	O
human	O
skeletal	O
muscle	O
cell	O
precursors	O
to	O
bypass	O
the	O
senescence	O
growth	O
arrest	O
checkpoint	O
.	O

This	O
bypass	O
was	O
accompanied	O
by	O
epigenetic	O
DNA	O
methylation	O
of	O
the	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
promoter	O
and	O
correspondingly	O
a	O
loss	O
of	O
expression	O
of	O
this	O
tumor	O
suppressor	O
.	O

Knockdown	O
of	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
cooperated	O
with	O
PAX3	B-Protein
-	O
FKHR	B-Protein
to	O
drive	O
proliferation	O
past	O
senescence	O
,	O
whereas	O
reintroduction	O
of	O
wild	O
-	O
type	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
in	O
post	O
-	O
senescent	O
cells	O
caused	O
growth	O
arrest	O
.	O

Thus	O
,	O
PAX3	B-Protein
-	O
FKHR	B-Protein
acts	O
in	O
concert	O
with	O
loss	O
of	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
to	O
promote	O
inappropriate	O
proliferation	O
of	O
skeletal	O
muscle	O
cells	O
.	O

This	O
association	O
between	O
PAX3	B-Protein
-	O
FKHR	B-Protein
expression	O
and	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
loss	O
was	O
seen	O
in	O
human	O
ARMS	O
tumor	O
tissue	O
,	O
as	O
both	O
human	O
rhabdomyosarcoma	O
cell	O
lines	O
and	O
tissue	O
microarrays	O
showed	O
a	O
trend	O
toward	O
down	O
-	O
regulation	O
of	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
protein	O
in	O
alveolar	O
subsets	O
.	O

We	O
surmise	O
that	O
the	O
generation	O
of	O
the	O
PAX3	B-Protein
-	O
FKHR	B-Protein
fusion	O
protein	O
may	O
require	O
loss	O
of	O
p16	B-Protein
(	I-Protein
INK4A	I-Protein
)	I-Protein
to	O
promote	O
malignant	O
proliferation	O
of	O
skeletal	O
muscle	O
cells	O
as	O
an	O
early	O
step	O
in	O
ARMS	O
tumorigenesis	O
.	O

Analysis	O
of	O
dynamic	O
changes	O
in	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
histones	B-Protein
during	O
cell	O
cycle	O
by	O
mass	O
spectrometry	O
.	O

The	O
N	O
-	O
terminal	O
tails	O
of	O
the	O
four	O
core	O
histones	B-Protein
are	O
subject	O
to	O
several	O
types	O
of	O
covalent	O
post	O
-	O
translational	O
modifications	O
that	O
have	O
specific	O
roles	O
in	O
regulating	O
chromatin	O
structure	O
and	O
function	O
.	O

Here	O
we	O
present	O
an	O
extensive	O
analysis	O
of	O
the	O
core	O
histone	B-Protein
modifications	O
occurring	O
through	O
the	O
cell	O
cycle	O
.	O

Our	O
MS	O
experiments	O
characterized	O
the	O
modification	O
patterns	O
of	O
histones	O
from	O
HeLa	O
cells	O
arrested	O
in	O
phase	O
G1	O
,	O
S	O
,	O
and	O
G2	O
/	O
M	O
.	O

For	O
all	O
core	O
histones	B-Protein
,	O
the	O
modifications	O
in	O
the	O
G1	O
and	O
S	O
phases	O
were	O
largely	O
identical	O
but	O
drastically	O
different	O
during	O
mitosis	O
.	O

Modification	O
changes	O
between	O
S	O
and	O
G2	O
/	O
M	O
phases	O
were	O
quantified	O
using	O
the	O
SILAC	O
(	O
stable	O
isotope	O
labeling	O
by	O
amino	O
acids	O
in	O
cell	O
culture	O
)	O
approach	O
.	O

Most	O
striking	O
was	O
the	O
mitotic	O
phosphorylation	O
on	O
histone	B-Protein
H3	I-Protein
and	O
H4	B-Protein
,	O
whereas	O
phosphorylation	O
on	O
H2A	B-Protein
was	O
constant	O
during	O
the	O
cell	O
cycle	O
.	O

A	O
loss	O
of	O
acetylation	O
was	O
observed	O
on	O
all	O
histones	B-Protein
in	O
G2	O
/	O
M	O
-	O
arrested	O
cells	O
.	O

The	O
pattern	O
of	O
cycle	O
-	O
dependent	O
methylation	O
was	O
more	O
complex	O
:	O
during	O
G2	O
/	O
M	O
,	O
H3	B-Protein
Lys27	O
and	O
Lys36	O
were	O
decreased	O
,	O
whereas	O
H4	B-Protein
Lys20	O
was	O
increased	O
.	O

Our	O
results	O
show	O
that	O
mitosis	O
was	O
the	O
period	O
of	O
the	O
cell	O
cycle	O
during	O
which	O
many	O
modifications	O
exhibit	O
dynamic	O
changes	O
.	O

High	O
-	O
mannose	O
-	O
specific	O
deglycosylation	O
of	O
HIV	O
-	O
1	O
gp120	B-Protein
induced	O
by	O
resistance	O
to	O
cyanovirin	O
-	O
N	O
and	O
the	O
impact	O
on	O
antibody	O
neutralization	O
.	O

HIV	O
-	O
1	O
uses	O
glycans	O
on	O
gp120	B-Protein
to	O
occlude	O
its	O
highly	O
immunogenic	O
epitopes	O
.	O

To	O
better	O
elucidate	O
escape	O
mechanisms	O
of	O
HIV	O
-	O
1	O
from	O
carbohydrate	O
-	O
binding	O
agents	O
(	O
CBA	O
)	O
and	O
to	O
understand	O
the	O
impact	O
of	O
CBA	O
-	O
escape	O
on	O
viral	O
immune	O
evasion	O
,	O
we	O
generated	O
and	O
examined	O
the	O
biological	O
properties	O
of	O
HIV	O
-	O
1	O
resistant	O
to	O
cyanovirin	O
-	O
N	O
(	O
CV	O
-	O
N	O
)	O
or	O
cross	O
-	O
resistant	O
to	O
additional	O
CBAs	O
.	O

Genotypic	O
and	O
phenotypic	O
characterization	O
of	O
resistant	O
env	O
clones	O
indicated	O
that	O
3	O
-	O
5	O
high	O
-	O
mannose	O
residues	O
from	O
289	O
to	O
448	O
in	O
the	O
C2	O
-	O
C4	O
region	O
of	O
gp120	B-Protein
were	O
mutated	O
and	O
correlated	O
with	O
the	O
resistance	O
levels	O
.	O

The	O
specificity	O
and	O
minimal	O
requirements	O
of	O
deglycosylation	O
for	O
CV	O
-	O
N	O
resistance	O
were	O
further	O
assessed	O
by	O
mutagenesis	O
study	O
.	O

The	O
sensitivity	O
of	O
resistant	O
variants	O
to	O
a	O
range	O
of	O
CBAs	O
,	O
immunoglobulins	O
,	O
sera	O
and	O
monoclonal	O
antibodies	O
(	O
MAb	O
)	O
were	O
investigated	O
.	O

For	O
the	O
first	O
time	O
,	O
our	O
data	O
have	O
collectively	O
defined	O
the	O
high	O
-	O
mannose	O
residues	O
on	O
gp120	O
affecting	O
CV	O
-	O
N	O
activity	O
,	O
and	O
demonstrated	O
that	O
CBA	O
-	O
escape	O
HIV	O
-	O
1	O
has	O
increased	O
sensitivity	O
to	O
immunoglobulins	O
and	O
sera	O
from	O
HIV	O
patients	O
,	O
and	O
particularly	O
to	O
V3	O
loop	O
-	O
directed	O
MAbs	O
.	O

Our	O
study	O
provides	O
a	O
proof	O
-	O
of	O
-	O
concept	O
that	O
targeting	O
HIV	O
-	O
1	O
glycan	O
shields	O
may	O
represent	O
a	O
novel	O
antiviral	O
strategy	O
.	O

Promoter	O
hypermethylation	O
of	O
death	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
kinase	I-Protein
gene	O
in	O
cholangiocarcinoma	O
.	O

BACKGROUND	O
:	O
Death	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
kinase	I-Protein
(	O
DAPK	B-Protein
)	O
is	O
a	O
Ca2	O
+	O
/	O
calmodulin	B-Protein
-	O
regulated	O
Ser	O
/	O
Thr	O
kinase	O
which	O
is	O
involved	O
in	O
apoptosis	O
.	O

The	O
aberrant	O
methylation	O
of	O
its	O
promoter	O
region	O
CpG	O
islands	O
may	O
be	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
carcinogenesis	O
.	O

We	O
studied	O
the	O
relationship	O
of	O
methylation	O
status	O
and	O
expression	O
of	O
the	O
DAPK	B-Protein
gene	O
with	O
the	O
clinical	O
findings	O
in	O
cholangiocarcinoma	O
.	O

METHODS	O
:	O
Target	O
DNA	O
was	O
modified	O
by	O
sodium	O
bisulfite	O
,	O
coverting	O
all	O
unmethylated	O
,	O
but	O
not	O
methylated	O
,	O
cytosines	O
to	O
uracil	O
,	O
and	O
subsequently	O
detected	O
by	O
methylation	O
-	O
specific	O
PCR	O
.	O

Moreover	O
,	O
mRNA	O
expression	O
of	O
the	O
DAPK	B-Protein
gene	O
was	O
assessed	O
by	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O
Aberrant	O
methylation	O
of	O
the	O
DAPK	B-Protein
gene	O
was	O
detected	O
in	O
11	O
(	O
30	O
.	O
6	O
%	O
)	O
of	O
36	O
tissue	O
specimens	O
of	O
cholangiocarcinoma	O
,	O
and	O
in	O
2	O
(	O
5	O
.	O
6	O
%	O
)	O
of	O
36	O
specimens	O
of	O
adjacent	O
normal	O
tissues	O
.	O

DAPK	B-Protein
mRNA	O
was	O
not	O
expressed	O
in	O
tumor	O
and	O
adjacent	O
tissues	O
with	O
hypermethylation	O
of	O
the	O
DAPK	B-Protein
promoter	O
.	O

There	O
were	O
no	O
statistical	O
differences	O
in	O
the	O
extent	O
of	O
differentiation	O
and	O
invasion	O
,	O
lymph	O
node	O
metastasis	O
or	O
pathologic	O
type	O
between	O
the	O
methylated	O
and	O
unmethylated	O
tissues	O
.	O

CONCLUSIONS	O
:	O
The	O
frequency	O
of	O
DAPK	B-Protein
gene	O
methylation	O
in	O
cholangiocarcinoma	O
is	O
high	O
and	O
it	O
may	O
offer	O
an	O
effective	O
means	O
for	O
earlier	O
auxiliary	O
diagnosis	O
of	O
the	O
malignancy	O
.	O

The	O
DAPK	B-Protein
gene	O
is	O
probably	O
suppressed	O
by	O
methylation	O
,	O
and	O
it	O
could	O
become	O
resistant	O
to	O
apoptosis	O
and	O
immunological	O
surveillance	O
.	O

The	O
DAPK	B-Protein
gene	O
epigenetically	O
affected	O
by	O
methylation	O
may	O
be	O
associated	O
with	O
the	O
carcinogenesis	O
of	O
cholangiocarcinoma	O
.	O

Distinct	O
GCN5	B-Protein
/	O
PCAF	B-Protein
-	O
containing	O
complexes	O
function	O
as	O
co	O
-	O
activators	O
and	O
are	O
involved	O
in	O
transcription	O
factor	O
and	O
global	O
histone	B-Protein
acetylation	O
.	O

Transcription	O
in	O
eukaryotes	O
is	O
a	O
tightly	O
regulated	O
,	O
multistep	O
process	O
.	O

Gene	O
-	O
specific	O
transcriptional	O
activators	O
,	O
several	O
different	O
co	O
-	O
activators	O
and	O
general	O
transcription	O
factors	O
are	O
necessary	O
to	O
access	O
specific	O
loci	O
to	O
allow	O
precise	O
initiation	O
of	O
RNA	O
polymerase	O
II	O
transcription	O
.	O

As	O
the	O
dense	O
chromatin	O
folding	O
of	O
the	O
genome	O
does	O
not	O
allow	O
the	O
access	O
of	O
these	O
sites	O
by	O
the	O
huge	O
multiprotein	O
transcription	O
machinery	O
,	O
remodelling	O
is	O
required	O
to	O
loosen	O
up	O
the	O
chromatin	O
structure	O
for	O
successful	O
transcription	O
initiation	O
.	O

In	O
the	O
present	O
review	O
,	O
we	O
summarize	O
the	O
recent	O
evolution	O
of	O
our	O
understanding	O
of	O
the	O
function	O
of	O
two	O
histone	B-Protein
acetyl	O
transferases	O
(	O
ATs	O
)	O
from	O
metazoan	O
organisms	O
:	O
GCN5	B-Protein
and	O
PCAF	B-Protein
.	O

Their	O
overall	O
structure	O
and	O
the	O
multiprotein	O
complexes	O
in	O
which	O
they	O
are	O
carrying	O
out	O
their	O
activities	O
are	O
discussed	O
.	O

Metazoan	O
GCN5	B-Protein
and	O
PCAF	B-Protein
are	O
subunits	O
of	O
at	O
least	O
two	O
types	O
of	O
multiprotein	O
complexes	O
,	O
one	O
having	O
a	O
molecular	O
weight	O
of	O
2	O
MDa	O
(	O
SPT3	B-Protein
-	O
TAF9	B-Protein
-	O
GCN5	B-Protein
acetyl	O
transferase	O
/	O
TATA	B-Protein
binding	I-Protein
protein	I-Protein
(	O
TBP	B-Protein
)	O
-	O
free	O
-	O
TAF	O
complex	O
/	O
PCAF	B-Protein
complexes	O
)	O
and	O
a	O
second	O
type	O
with	O
about	O
a	O
size	O
of	O
700	O
kDa	O
(	O
ATAC	O
complex	O
)	O
.	O

These	O
complexes	O
possess	O
global	O
histone	B-Protein
acetylation	O
activity	O
and	O
locus	O
-	O
specific	O
co	O
-	O
activator	O
functions	O
together	O
with	O
AT	O
activity	O
on	O
non	O
-	O
histone	B-Protein
substrates	O
.	O

Thus	O
,	O
their	O
biological	O
functions	O
cover	O
a	O
wide	O
range	O
of	O
tasks	O
and	O
render	O
them	O
indispensable	O
for	O
the	O
normal	O
function	O
of	O
cells	O
.	O

That	O
deregulation	O
of	O
the	O
global	O
and	O
/	O
or	O
specific	O
AT	O
activities	O
of	O
these	O
complexes	O
leads	O
to	O
the	O
cancerous	O
transformation	O
of	O
the	O
cells	O
highlights	O
their	O
importance	O
in	O
cellular	O
processes	O
.	O

The	O
possible	O
effects	O
of	O
GCN5	B-Protein
and	O
PCAF	B-Protein
in	O
tumorigenesis	O
are	O
also	O
discussed	O
.	O

Collagen	O
matrix	O
assembly	O
is	O
driven	O
by	O
the	O
interaction	O
of	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	I-Protein
protein	O
with	O
hydroxylated	O
collagen	B-Protein
IV	I-Protein
alpha	I-Protein
2	I-Protein
.	O

Inactivation	O
of	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumor	I-Protein
suppressor	I-Protein
gene	O
predisposes	O
to	O
vascular	O
tumor	O
formation	O
in	O
several	O
organs	O
.	O

VHL	B-Protein
regulates	O
two	O
evolutionary	O
conserved	O
pathways	O
:	O
the	O
targeting	O
of	O
hydroxylated	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
alpha	O
(	O
HIF	O
-	O
alpha	O
)	O
for	O
proteasomal	O
degradation	O
and	O
the	O
remodeling	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
.	O

The	O
biochemical	O
mechanisms	O
of	O
the	O
ECM	O
assembly	O
pathway	O
remain	O
poorly	O
defined	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
supporting	O
a	O
biochemical	O
role	O
for	O
VHL	B-Protein
in	O
ECM	O
assembly	O
.	O

We	O
show	O
that	O
VHL	B-Protein
directly	O
binds	O
to	O
the	O
collagen	B-Protein
IV	I-Protein
alpha	I-Protein
2	I-Protein
(	O
COL4A2	B-Protein
)	O
chain	O
and	O
that	O
this	O
interaction	O
is	O
necessary	O
for	O
its	O
assembly	O
into	O
the	O
ECM	O
.	O

The	O
VHL	B-Protein
-	O
COL4A2	B-Protein
interaction	O
is	O
dependent	O
on	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
mediated	O
COL4A2	B-Protein
hydroxylation	O
and	O
independent	O
of	O
cytosolic	O
,	O
hypoxia	O
regulated	O
HIF	O
-	O
alpha	O
-	O
modifying	O
enzymes	O
.	O

We	O
find	O
that	O
the	O
N	O
-	O
terminal	O
tail	O
of	O
COL4A2	B-Protein
protrudes	O
from	O
the	O
ER	O
lumen	O
into	O
the	O
cytosol	O
where	O
it	O
is	O
bound	O
by	O
VHL	B-Protein
.	O

Failure	O
of	O
VHL	B-Protein
to	O
interact	O
with	O
COL4A2	B-Protein
correlates	O
with	O
loss	O
of	O
collagen	O
IV	O
network	O
formation	O
in	O
vitro	O
and	O
collagen	O
IV	O
remodeling	O
in	O
vivo	O
.	O

Our	O
data	O
suggest	O
a	O
HIF	O
-	O
alpha	O
-	O
independent	O
role	O
for	O
the	O
VHL	B-Protein
-	O
COL4A2	B-Protein
interaction	O
in	O
suppression	O
of	O
angiogenic	O
tumor	O
formation	O
through	O
collagen	O
IV	O
network	O
assembly	O
.	O

T	B-Protein
-	I-Protein
cell	I-Protein
ubiquitin	I-Protein
ligand	I-Protein
affects	O
cell	O
death	O
through	O
a	O
functional	O
interaction	O
with	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
a	O
key	O
factor	O
of	O
caspase	O
-	O
independent	O
apoptosis	O
.	O

The	O
lymphoid	O
protein	O
T	B-Protein
-	I-Protein
cell	I-Protein
ubiquitin	I-Protein
ligand	I-Protein
(	O
TULA	B-Protein
)	O
/	O
suppressor	B-Protein
of	I-Protein
T	I-Protein
-	I-Protein
cell	I-Protein
receptor	I-Protein
signaling	I-Protein
(	I-Protein
Sts	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
is	O
associated	O
with	O
c	B-Protein
-	I-Protein
Cbl	I-Protein
and	O
ubiquitylated	O
proteins	O
and	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
signaling	O
mediated	O
by	O
protein	O
-	O
tyrosine	O
kinases	O
.	O

The	O
results	O
presented	O
in	O
this	O
report	O
indicate	O
that	O
TULA	B-Protein
facilitates	O
T	O
-	O
cell	O
apoptosis	O
independent	O
of	O
either	O
T	O
-	O
cell	O
receptor	O
/	O
CD3	O
-	O
mediated	O
signaling	O
or	O
caspase	O
activity	O
.	O

Mass	O
spectrometry	O
-	O
based	O
analysis	O
of	O
protein	O
-	O
protein	O
interactions	O
of	O
TULA	B-Protein
demonstrates	O
that	O
TULA	B-Protein
binds	O
to	O
the	O
apoptosis	O
-	O
inducing	O
protein	O
AIF	B-Protein
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
function	O
as	O
a	O
key	O
factor	O
of	O
caspase	O
-	O
independent	O
apoptosis	O
.	O

Using	O
RNA	O
interference	O
,	O
we	O
demonstrate	O
that	O
AIF	B-Protein
is	O
essential	O
for	O
the	O
apoptotic	O
effect	O
of	O
TULA	B-Protein
.	O

Analysis	O
of	O
the	O
subcellular	O
localization	O
of	O
TULA	B-Protein
and	O
AIF	B-Protein
together	O
with	O
the	O
functional	O
analysis	O
of	O
TULA	B-Protein
mutants	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
TULA	B-Protein
enhances	O
the	O
apoptotic	O
effect	O
of	O
AIF	B-Protein
by	O
facilitating	O
the	O
interactions	O
of	O
AIF	B-Protein
with	O
its	O
apoptotic	O
co	O
-	O
factors	O
,	O
which	O
remain	O
to	O
be	O
identified	O
.	O

Overall	O
,	O
our	O
results	O
shed	O
new	O
light	O
on	O
the	O
biological	O
functions	O
of	O
TULA	B-Protein
,	O
a	O
recently	O
discovered	O
protein	O
,	O
describing	O
its	O
role	O
as	O
one	O
of	O
very	O
few	O
known	O
functional	O
interactors	O
of	O
AIF	B-Protein
.	O

Ubiquitination	O
of	O
mammalian	O
Pex5p	B-Protein
,	O
the	O
peroxisomal	O
import	O
receptor	O
.	O

Protein	O
translocation	O
across	O
the	O
peroxisomal	O
membrane	O
requires	O
the	O
concerted	O
action	O
of	O
numerous	O
peroxins	O
.	O

One	O
central	O
component	O
of	O
this	O
machinery	O
is	O
Pex5p	B-Protein
,	O
the	O
cycling	O
receptor	O
for	O
matrix	O
proteins	O
.	O

Pex5p	B-Protein
recognizes	O
newly	O
synthesized	O
proteins	O
in	O
the	O
cytosol	O
and	O
promotes	O
their	O
translocation	O
across	O
the	O
peroxisomal	O
membrane	O
.	O

After	O
this	O
translocation	O
step	O
,	O
Pex5p	B-Protein
is	O
recycled	O
back	O
into	O
the	O
cytosol	O
to	O
start	O
a	O
new	O
protein	O
transport	O
cycle	O
.	O

Here	O
,	O
we	O
show	O
that	O
mammalian	O
Pex5p	B-Protein
is	O
ubiquitinated	O
at	O
the	O
peroxisomal	O
membrane	O
.	O

Two	O
different	O
types	O
of	O
ubiquitination	O
were	O
detected	O
,	O
one	O
of	O
which	O
is	O
thiol	O
-	O
sensitive	O
,	O
involves	O
Cys	O
(	O
11	O
)	O
of	O
Pex5p	B-Protein
,	O
and	O
is	O
necessary	O
for	O
the	O
export	O
of	O
the	O
receptor	O
back	O
into	O
the	O
cytosol	O
.	O

Together	O
with	O
mechanistic	O
data	O
recently	O
described	O
for	O
yeast	O
Pex5p	B-Protein
,	O
these	O
findings	O
provide	O
strong	O
evidence	O
for	O
the	O
existence	O
of	O
Pex4p	B-Protein
-	O
and	O
Pex22p	B-Protein
-	O
like	O
proteins	O
in	O
mammals	O
.	O

Identification	O
of	O
TRAF6	B-Protein
-	O
dependent	O
NEMO	B-Protein
polyubiquitination	O
sites	O
through	O
analysis	O
of	O
a	O
new	O
NEMO	B-Protein
mutation	O
causing	O
incontinentia	O
pigmenti	O
.	O

The	O
regulatory	O
subunit	O
NEMO	B-Protein
is	O
involved	O
in	O
the	O
mechanism	O
of	O
activation	O
of	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
,	O
the	O
kinase	O
complex	O
that	O
controls	O
the	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
.	O

During	O
this	O
process	O
,	O
NEMO	B-Protein
is	O
modified	O
post	O
-	O
translationally	O
through	O
K63	O
-	O
linked	O
polyubiquitination	O
.	O

We	O
report	O
the	O
molecular	O
characterization	O
of	O
a	O
new	O
missense	O
mutation	O
of	O
NEMO	B-Protein
(	O
A323P	O
)	O
which	O
causes	O
a	O
severe	O
form	O
of	O
incontinentia	O
pigmenti	O
(	O
OMIM	O
#	O
308300	O
)	O
,	O
an	O
inherited	O
disease	O
characterized	O
predominantly	O
by	O
skin	O
inflammation	O
.	O

The	O
A323P	O
mutation	O
was	O
found	O
to	O
impair	O
TNF	B-Protein
-	O
,	O
IL	O
-	O
1	O
-	O
,	O
LPS	O
-	O
and	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
,	O
as	O
well	O
as	O
to	O
disrupt	O
TRAF6	B-Protein
-	O
dependent	O
NEMO	B-Protein
polyubiquitination	O
,	O
due	O
to	O
a	O
defective	O
NEMO	B-Protein
/	O
TRAF6	B-Protein
interaction	O
.	O

Mutagenesis	O
identified	O
the	O
affected	O
ubiquitination	O
sites	O
as	O
three	O
lysine	O
residues	O
located	O
in	O
the	O
vicinity	O
of	O
A323	O
.	O

Unexpectedly	O
,	O
these	O
lysines	O
were	O
ubiquitinated	O
together	O
with	O
two	O
previously	O
identified	O
lysines	O
not	O
connected	O
to	O
TRAF6	B-Protein
.	O

Mutation	O
of	O
all	O
these	O
ubiquitination	O
sites	O
severely	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
induced	O
by	O
stimulation	O
with	O
IL	O
-	O
1	O
,	O
LPS	O
,	O
Nod2	B-Protein
/	O
RICK	B-Protein
or	O
serum	O
/	O
LPA	O
.	O

In	O
contrast	O
,	O
mutation	O
at	O
all	O
of	O
these	O
sites	O
had	O
only	O
a	O
limited	O
effect	O
on	O
stimulation	O
by	O
TNF	B-Protein
.	O

These	O
findings	O
indicate	O
that	O
post	O
-	O
translational	O
modification	O
of	O
NEMO	B-Protein
through	O
K63	O
-	O
linked	O
polyubiquitination	O
is	O
a	O
key	O
event	O
in	O
IKK	O
activation	O
and	O
that	O
perturbation	O
of	O
this	O
step	O
may	O
cause	O
human	O
pathophysiology	O
.	O

Glycosylation	O
of	O
alpha	O
1	O
-	O
acid	O
glycoprotein	O
in	O
relation	O
to	O
duration	O
of	O
disease	O
in	O
acute	O
and	O
chronic	O
infection	O
and	O
inflammation	O
.	O

Microheterogeneity	O
of	O
acute	O
phase	O
proteins	O
frequently	O
differs	O
in	O
acute	O
and	O
chronic	O
types	O
of	O
inflammation	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
these	O
changes	O
depend	O
on	O
the	O
duration	O
of	O
the	O
inflammation	O
in	O
a	O
given	O
disease	O
.	O

We	O
therefore	O
investigated	O
the	O
microheterogeneity	O
of	O
alpha	O
1	O
-	O
acid	O
glycoprotein	O
(	O
AGP	O
)	O
in	O
sera	O
from	O
patients	O
with	O
acute	O
and	O
chronic	O
bacterial	O
infection	O
in	O
comparison	O
to	O
rheumatoid	O
arthritis	O
and	O
ankylosing	O
spondylitis	O
.	O

In	O
acute	O
bacterial	O
infection	O
Con	B-Protein
A	I-Protein
-	O
reactivity	O
of	O
AGP	O
was	O
significantly	O
elevated	O
.	O

By	O
contrast	O
,	O
AGP	O
in	O
chronic	O
bacterial	O
infection	O
showed	O
the	O
same	O
glycosylation	O
pattern	O
as	O
rheumatoid	O
arthritis	O
and	O
ankylosing	O
spondylitis	O
being	O
characterized	O
by	O
a	O
decreased	O
reactivity	O
to	O
Con	B-Protein
A	I-Protein
.	O

Serial	O
measurements	O
in	O
individual	O
patients	O
with	O
bacterial	O
infections	O
showed	O
a	O
transition	O
from	O
the	O
initially	O
elevated	O
to	O
decreased	O
reactivity	O
to	O
Con	B-Protein
A	I-Protein
as	O
the	O
disease	O
became	O
chronic	O
.	O

Lipopolysaccharide	O
-	O
mediated	O
interferon	O
regulatory	O
factor	O
activation	O
involves	O
TBK1	B-Protein
-	O
IKKepsilon	B-Protein
-	O
dependent	O
Lys	O
(	O
63	O
)	O
-	O
linked	O
polyubiquitination	O
and	O
phosphorylation	O
of	O
TANK	B-Protein
/	O
I	B-Protein
-	I-Protein
TRAF	I-Protein
.	O

Type	O
I	O
interferon	O
gene	O
induction	O
relies	O
on	O
IKK	O
-	O
related	O
kinase	O
TBK1	B-Protein
and	O
IKKepsilon	B-Protein
-	O
mediated	O
phosphorylations	O
of	O
IRF3	B-Protein
/	O
7	B-Protein
through	O
the	O
Toll	O
-	O
like	O
receptor	O
-	O
dependent	O
signaling	O
pathways	O
.	O

The	O
scaffold	O
proteins	O
that	O
assemble	O
these	O
kinase	O
complexes	O
are	O
poorly	O
characterized	O
.	O

We	O
show	O
here	O
that	O
TANK	B-Protein
/	O
ITRAF	B-Protein
is	O
required	O
for	O
the	O
TBK1	B-Protein
-	O
and	O
IKKepsilon	B-Protein
-	O
mediated	O
IRF3	B-Protein
/	O
7	B-Protein
phosphorylations	O
through	O
some	O
Toll	O
-	O
like	O
receptor	O
-	O
dependent	O
pathways	O
and	O
is	O
part	O
of	O
a	O
TRAF3	B-Protein
-	O
containing	O
complex	O
.	O

Moreover	O
,	O
TANK	B-Protein
is	O
dispensable	O
for	O
the	O
early	O
phase	O
of	O
double	O
-	O
stranded	O
RNA	O
-	O
mediated	O
IRF3	B-Protein
phosphorylation	O
.	O

Interestingly	O
,	O
TANK	B-Protein
is	O
heavily	O
phosphorylated	O
by	O
TBK1	B-Protein
-	O
IKKepsilon	B-Protein
upon	O
lipopolysaccharide	O
stimulation	O
and	O
is	O
also	O
subject	O
to	O
lipopolysaccharide	O
-	O
and	O
TBK1	B-Protein
-	O
IKKepsilon	B-Protein
-	O
mediated	O
Lys	O
(	O
63	O
)	O
-	O
linked	O
polyubiquitination	O
,	O
a	O
mechanism	O
that	O
does	O
not	O
require	O
TBK1	B-Protein
-	O
IKKepsilon	B-Protein
kinase	O
activity	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
TANK	B-Protein
as	O
a	O
scaffold	O
protein	O
that	O
assembles	O
some	O
but	O
not	O
all	O
IRF3	B-Protein
/	O
7	B-Protein
-	O
phosphorylating	O
TBK1	B-Protein
-	O
IKKepsilon	B-Protein
complexes	O
and	O
demonstrated	O
that	O
these	O
kinases	O
possess	O
two	O
functions	O
,	O
namely	O
the	O
phosphorylation	O
of	O
both	O
IRF3	B-Protein
/	O
7	B-Protein
and	O
TANK	B-Protein
as	O
well	O
as	O
the	O
recruitment	O
of	O
an	O
E3	O
ligase	O
for	O
Lys	O
(	O
63	O
)	O
-	O
linked	O
polyubiquitination	O
of	O
their	O
scaffold	O
protein	O
,	O
TANK	B-Protein
.	O

Paraquat	O
induces	O
dopaminergic	O
dysfunction	O
and	O
proteasome	O
impairment	O
in	O
DJ	B-Protein
-	I-Protein
1	I-Protein
-	O
deficient	O
mice	O
.	O

Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
may	O
be	O
caused	O
by	O
a	O
complex	O
interaction	O
of	O
environmental	O
insults	O
and	O
genetic	O
susceptibilities	O
.	O

Previous	O
studies	O
of	O
DJ	B-Protein
-	I-Protein
1	I-Protein
-	O
deficient	O
mice	O
have	O
noted	O
dopaminergic	O
dysfunction	O
mainly	O
in	O
older	O
mice	O
.	O

To	O
simulate	O
the	O
interaction	O
of	O
genetic	O
factors	O
and	O
environmental	O
factors	O
,	O
we	O
treated	O
DJ	B-Protein
-	I-Protein
1	I-Protein
-	O
deficient	O
mice	O
with	O
paraquat	O
.	O

Even	O
in	O
relatively	O
young	O
mice	O
,	O
this	O
combination	O
produced	O
dopamine	O
loss	O
and	O
motor	O
dysfunction	O
.	O

To	O
determine	O
the	O
potential	O
mechanism	O
for	O
the	O
dopaminergic	O
dysfunction	O
,	O
we	O
investigated	O
the	O
proteasome	O
function	O
and	O
ubiquitinated	O
protein	O
levels	O
.	O

DJ	B-Protein
-	I-Protein
1	I-Protein
-	O
deficient	O
mice	O
treated	O
with	O
paraquat	O
showed	O
decreased	O
proteasome	O
activities	O
and	O
increased	O
ubiquitinated	O
protein	O
levels	O
.	O

To	O
further	O
investigate	O
the	O
mechanism	O
of	O
proteasome	O
dysfunction	O
,	O
ATP	O
levels	O
and	O
subunit	O
protein	O
levels	O
of	O
19S	O
ATPase	O
Rpt6	B-Protein
and	O
20S	B-Protein
beta5	I-Protein
were	O
measured	O
and	O
noted	O
to	O
be	O
decreased	O
in	O
the	O
ventral	O
midbrain	O
,	O
but	O
not	O
in	O
the	O
striatum	O
.	O

Finally	O
,	O
a	O
transcription	O
factor	O
,	O
Nrf2	B-Protein
that	O
has	O
been	O
previously	O
shown	O
to	O
be	O
regulated	O
by	O
DJ	B-Protein
-	I-Protein
1	I-Protein
and	O
to	O
regulate	O
20S	B-Protein
beta5	I-Protein
levels	O
was	O
decreased	O
.	O

These	O
pathologies	O
were	O
not	O
observed	O
in	O
brain	O
regions	O
of	O
normal	O
mice	O
treated	O
with	O
paraquat	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
raises	O
the	O
possibility	O
that	O
environmental	O
and	O
genetic	O
factors	O
might	O
cooperatively	O
involve	O
the	O
mechanisms	O
underlying	O
proteasome	O
impairment	O
in	O
PD	O
brains	O
.	O

The	O
yeast	O
Hex3	B-Protein
.	O
Slx8	B-Protein
heterodimer	O
is	O
a	O
ubiquitin	B-Protein
ligase	O
stimulated	O
by	O
substrate	O
sumoylation	O
.	O

Hex3	B-Protein
and	O
Slx8	B-Protein
are	O
Saccharomyces	O
cerevisiae	O
proteins	O
with	O
important	O
functions	O
in	O
DNA	O
damage	O
control	O
and	O
maintenance	O
of	O
genomic	O
stability	O
.	O

Both	O
proteins	O
have	O
RING	O
domains	O
at	O
their	O
C	O
termini	O
.	O

Such	O
domains	O
are	O
common	O
in	O
ubiquitin	B-Protein
and	O
ubiquitin	B-Protein
-	O
like	O
protein	O
ligases	O
(	O
E3s	O
)	O
,	O
but	O
little	O
was	O
known	O
about	O
the	O
molecular	O
functions	O
of	O
either	O
protein	O
.	O

In	O
this	O
study	O
we	O
identified	O
HEX3	B-Protein
as	O
a	O
high	O
-	O
copy	O
suppressor	O
of	O
a	O
temperature	O
-	O
sensitive	O
small	B-Protein
ubiquitin	I-Protein
-	I-Protein
related	I-Protein
modifier	I-Protein
(	O
SUMO	B-Protein
)	O
protease	O
mutant	O
,	O
ulp1ts	B-Protein
,	O
suggesting	O
that	O
it	O
may	O
affect	O
cellular	O
SUMO	B-Protein
dynamics	O
.	O

Remarkably	O
,	O
even	O
a	O
complete	O
deletion	O
of	O
ULP1	B-Protein
is	O
strongly	O
suppressed	O
.	O

Hex3	B-Protein
forms	O
a	O
heterodimer	O
with	O
Slx8	B-Protein
.	O

We	O
found	O
that	O
the	O
Hex3	B-Protein
.	O
Slx8	B-Protein
complex	O
has	O
a	O
robust	O
substrate	O
-	O
specific	O
E3	O
ubiquitin	B-Protein
ligase	O
activity	O
.	O

In	O
this	O
E3	O
complex	O
,	O
Slx8	B-Protein
appears	O
to	O
bear	O
the	O
core	O
ligase	O
function	O
,	O
with	O
Hex3	B-Protein
strongly	O
enhancing	O
its	O
activity	O
.	O

Notably	O
,	O
SUMO	B-Protein
attachment	O
to	O
a	O
substrate	O
stimulates	O
its	O
Hex3	B-Protein
.	O
Slx8	B-Protein
-	O
dependent	O
ubiquitination	O
,	O
primarily	O
through	O
direct	O
noncovalent	O
interactions	O
between	O
SUMO	B-Protein
and	O
Hex3	B-Protein
.	O

Our	O
data	O
reveal	O
a	O
novel	O
mechanism	O
of	O
substrate	O
targeting	O
in	O
which	O
sumoylation	O
of	O
a	O
protein	O
can	O
help	O
trigger	O
its	O
subsequent	O
ubiquitination	O
by	O
recruiting	O
a	O
SUMO	B-Protein
-	O
binding	O
ubiquitin	B-Protein
ligase	O
.	O

A	O
chemical	O
biology	O
screen	O
identifies	O
glucocorticoids	O
that	O
regulate	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
by	O
increasing	O
its	O
proteasomal	O
degradation	O
through	O
up	O
-	O
regulation	O
of	O
ubiquitin	B-Protein
.	O

The	O
oncogene	O
c	B-Protein
-	I-Protein
maf	I-Protein
is	O
frequently	O
overexpressed	O
in	O
multiple	O
myeloma	O
cell	O
lines	O
and	O
patient	O
samples	O
and	O
contributes	O
to	O
increased	O
cellular	O
proliferation	O
in	O
part	O
by	O
inducing	O
cyclin	B-Protein
D2	I-Protein
expression	O
.	O

To	O
identify	O
regulators	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
,	O
we	O
developed	O
a	O
chemical	O
screen	O
in	O
NIH3T3	O
cells	O
stably	O
overexpressing	O
c	B-Protein
-	I-Protein
maf	I-Protein
and	O
the	O
cyclin	B-Protein
D2	I-Protein
promoter	O
driving	O
luciferase	B-Protein
.	O

From	O
a	O
screen	O
of	O
2400	O
off	O
-	O
patent	O
drugs	O
and	O
chemicals	O
,	O
we	O
identified	O
glucocorticoids	O
as	O
c	B-Protein
-	I-Protein
maf	I-Protein
-	O
dependent	O
inhibitors	O
of	O
cyclin	B-Protein
D2	I-Protein
transactivation	O
.	O

In	O
multiple	O
myeloma	O
cell	O
lines	O
,	O
glucocorticoids	O
reduced	O
levels	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
protein	O
without	O
influencing	O
corresponding	O
mRNA	O
levels	O
.	O

Subsequent	O
studies	O
demonstrated	O
that	O
glucocorticoids	O
increased	O
ubiquitination	O
-	O
dependent	O
degradation	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
and	O
up	O
-	O
regulated	O
ubiquitin	B-Protein
C	I-Protein
mRNA	O
.	O

Moreover	O
,	O
ectopic	O
expression	O
of	O
ubiquitin	B-Protein
C	I-Protein
recapitulated	O
the	O
effects	O
of	O
glucocorticoids	O
,	O
demonstrating	O
regulation	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
protein	O
through	O
the	O
abundance	O
of	O
the	O
ubiquitin	B-Protein
substrate	O
.	O

Thus	O
,	O
using	O
a	O
chemical	O
biology	O
approach	O
,	O
we	O
identified	O
a	O
novel	O
mechanism	O
of	O
action	O
of	O
glucocorticoids	O
and	O
a	O
novel	O
mechanism	O
by	O
which	O
levels	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
protein	O
are	O
regulated	O
by	O
the	O
abundance	O
of	O
the	O
ubiquitin	B-Protein
substrate	O
.	O

Selective	O
anchoring	O
of	O
TFIID	O
to	O
nucleosomes	O
by	O
trimethylation	O
of	O
histone	B-Protein
H3	I-Protein
lysine	O
4	O
.	O

Trimethylation	O
of	O
histone	B-Protein
H3	I-Protein
at	O
lysine	O
4	O
(	O
H3K4me3	B-Protein
)	O
is	O
regarded	O
as	O
a	O
hallmark	O
of	O
active	O
human	O
promoters	O
,	O
but	O
it	O
remains	O
unclear	O
how	O
this	O
posttranslational	O
modification	O
links	O
to	O
transcriptional	O
activation	O
.	O

Using	O
a	O
stable	O
isotope	O
labeling	O
by	O
amino	O
acids	O
in	O
cell	O
culture	O
(	O
SILAC	O
)	O
-	O
based	O
proteomic	O
screening	O
we	O
show	O
that	O
the	O
basal	O
transcription	O
factor	O
TFIID	O
directly	O
binds	O
to	O
the	O
H3K4me3	B-Protein
mark	O
via	O
the	O
plant	O
homeodomain	O
(	O
PHD	O
)	O
finger	O
of	O
TAF3	B-Protein
.	O

Selective	O
loss	O
of	O
H3K4me3	B-Protein
reduces	O
transcription	O
from	O
and	O
TFIID	O
binding	O
to	O
a	O
subset	O
of	O
promoters	O
in	O
vivo	O
.	O

Equilibrium	O
binding	O
assays	O
and	O
competition	O
experiments	O
show	O
that	O
the	O
TAF3	B-Protein
PHD	O
finger	O
is	O
highly	O
selective	O
for	O
H3K4me3	B-Protein
.	O

In	O
transient	O
assays	O
,	O
TAF3	B-Protein
can	O
act	O
as	O
a	O
transcriptional	O
coactivator	O
in	O
a	O
PHD	O
finger	O
-	O
dependent	O
manner	O
.	O

Interestingly	O
,	O
asymmetric	O
dimethylation	O
of	O
H3R2	B-Protein
selectively	O
inhibits	O
TFIID	O
binding	O
to	O
H3K4me3	B-Protein
,	O
whereas	O
acetylation	O
of	O
H3K9	B-Protein
and	O
H3K14	B-Protein
potentiates	O
TFIID	O
interaction	O
.	O

Our	O
experiments	O
reveal	O
crosstalk	O
between	O
histone	B-Protein
modifications	O
and	O
the	O
transcription	O
factor	O
TFIID	O
.	O

This	O
has	O
important	O
implications	O
for	O
regulation	O
of	O
RNA	O
polymerase	O
II	O
-	O
mediated	O
transcription	O
in	O
higher	O
eukaryotes	O
.	O

Recombinant	O
bovine	O
zona	O
pellucida	O
glycoproteins	O
ZP3	B-Protein
and	O
ZP4	B-Protein
coexpressed	O
in	O
Sf9	O
cells	O
form	O
a	O
sperm	O
-	O
binding	O
active	O
hetero	O
-	O
complex	O
.	O

The	O
zona	O
pellucida	O
(	O
ZP	O
)	O
is	O
a	O
transparent	O
envelope	O
that	O
surrounds	O
the	O
mammalian	O
oocyte	O
and	O
mediates	O
species	O
-	O
selective	O
sperm	O
-	O
egg	O
interactions	O
.	O

Porcine	O
and	O
bovine	O
ZPs	O
are	O
composed	O
of	O
the	O
glycoproteins	O
ZP2	B-Protein
,	O
ZP3	B-Protein
,	O
and	O
ZP4	B-Protein
.	O

We	O
previously	O
established	O
an	O
expression	O
system	O
for	O
porcine	O
ZP	O
glycoproteins	O
(	O
ZPGs	O
)	O
using	O
baculovirus	O
in	O
insect	O
Sf9	O
cells	O
.	O

Here	O
we	O
established	O
a	O
similar	O
method	O
for	O
expression	O
of	O
bovine	O
ZPGs	O
.	O

The	O
recombinant	O
ZPGs	O
were	O
secreted	O
into	O
the	O
medium	O
and	O
purified	O
by	O
metal	O
-	O
chelating	O
column	O
chromatography	O
.	O

A	O
mixture	O
of	O
bovine	O
recombinant	O
ZP3	B-Protein
(	O
rZP3	B-Protein
)	O
and	O
rZP4	B-Protein
coexpressed	O
in	O
Sf9	O
cells	O
exhibited	O
inhibitory	O
activity	O
for	O
bovine	O
sperm	O
-	O
ZP	O
binding	O
similar	O
to	O
that	O
of	O
a	O
native	O
bovine	O
ZPG	O
mixture	O
,	O
whereas	O
neither	O
bovine	O
rZP3	B-Protein
nor	O
rZP4	B-Protein
inhibited	O
binding	O
.	O

An	O
immunoprecipitation	O
assay	O
revealed	O
that	O
the	O
coexpressed	O
rZP3	B-Protein
/	O
rZP4	B-Protein
formed	O
a	O
hetero	O
-	O
complex	O
.	O

We	O
examined	O
the	O
functional	O
domain	O
structure	O
of	O
bovine	O
rZP4	B-Protein
by	O
constructing	O
ZP4	B-Protein
mutants	O
lacking	O
the	O
N	O
-	O
terminal	O
domain	O
or	O
lacking	O
both	O
the	O
N	O
-	O
terminal	O
and	O
trefoil	O
domains	O
.	O

When	O
either	O
of	O
these	O
mutant	O
proteins	O
was	O
coexpressed	O
with	O
bovine	O
rZP3	B-Protein
,	O
the	O
resulting	O
mixtures	O
exhibited	O
inhibitory	O
activity	O
comparable	O
to	O
that	O
of	O
the	O
bovine	O
rZP3	B-Protein
/	O
rZP4	B-Protein
complex	O
.	O

Hetero	O
-	O
complexes	O
of	O
bovine	O
rZP3	B-Protein
and	O
porcine	O
rZP4	B-Protein
,	O
or	O
porcine	O
rZP3	B-Protein
and	O
bovine	O
rZP4	B-Protein
,	O
also	O
inhibited	O
bovine	O
sperm	O
-	O
ZP	O
binding	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
N	O
-	O
terminal	O
and	O
trefoil	O
domains	O
of	O
bovine	O
rZP4	B-Protein
are	O
dispensable	O
for	O
formation	O
of	O
the	O
sperm	O
-	O
binding	O
active	O
bovine	O
rZP3	B-Protein
/	O
rZP4	B-Protein
complex	O
and	O
,	O
furthermore	O
,	O
that	O
the	O
molecular	O
interactions	O
between	O
rZP3	B-Protein
and	O
rZP4	B-Protein
are	O
conserved	O
in	O
the	O
bovine	O
and	O
porcine	O
systems	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
1	O
(	O
HIF	O
-	O
1	O
)	O
pathway	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
1	O
(	O
HIF	O
-	O
1	O
)	O
is	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
-	O
PAS	O
domain	O
transcription	O
factor	O
that	O
is	O
expressed	O
in	O
all	O
metazoan	O
organisms	O
and	O
is	O
composed	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
HIF	B-Protein
-	I-Protein
1beta	I-Protein
subunits	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
HIF	O
-	O
1	O
regulates	O
the	O
transcription	O
of	O
hundreds	O
of	O
genes	O
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
.	O

The	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
subunit	O
is	O
regulated	O
by	O
O2	O
-	O
dependent	O
hydroxylation	O
of	O
proline	O
residue	O
402	O
,	O
564	O
,	O
or	O
both	O
,	O
by	O
prolyl	B-Protein
hydroxylase	I-Protein
domain	I-Protein
protein	I-Protein
2	I-Protein
(	O
PHD2	B-Protein
)	O
,	O
which	O
promotes	O
binding	O
of	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
protein	O
(	O
VHL	B-Protein
)	O
,	O
leading	O
to	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
;	O
and	O
O2	O
-	O
dependent	O
hydroxylation	O
of	O
asparagine	O
residue	O
803	O
by	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
-	I-Protein
1	I-Protein
(	O
FIH	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
which	O
blocks	O
the	O
binding	O
of	O
the	O
300	O
-	O
kilodalton	O
coactivator	O
protein	O
(	O
p300	B-Protein
)	O
and	O
CREB	B-Protein
binding	I-Protein
protein	I-Protein
(	O
CBP	B-Protein
)	O
.	O

The	O
hydroxylation	O
reactions	O
,	O
which	O
utilize	O
O2	O
and	O
alpha	O
-	O
ketoglutarate	O
as	O
substrates	O
and	O
generate	O
CO2	O
and	O
succinate	O
as	O
by	O
-	O
products	O
,	O
provide	O
a	O
mechanism	O
by	O
which	O
changes	O
in	O
cellular	O
oxygenation	O
are	O
transduced	O
to	O
the	O
nucleus	O
as	O
changes	O
in	O
HIF	O
-	O
1	O
activity	O
.	O

Hydroxylase	O
activity	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
low	O
concentrations	O
of	O
O2	O
,	O
high	O
concentrations	O
of	O
tricarboxylic	O
acid	O
cycle	O
intermediates	O
(	O
isocitrate	O
,	O
oxaloacetate	O
,	O
succinate	O
,	O
or	O
fumarate	O
)	O
,	O
or	O
chelators	O
of	O
Fe	O
(	O
II	O
)	O
.	O

Receptor	B-Protein
for	I-Protein
activated	I-Protein
C	I-Protein
kinase	I-Protein
1	I-Protein
(	O
RACK1	B-Protein
)	O
competes	O
with	O
heat	B-Protein
shock	I-Protein
protein	I-Protein
90	I-Protein
(	O
HSP90	B-Protein
)	O
for	O
binding	O
to	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
mediates	O
O2	O
-	O
independent	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

A	O
growing	O
number	O
of	O
proteins	O
and	O
small	O
molecules	O
have	O
been	O
identified	O
that	O
regulate	O
HIF	O
-	O
1	O
activity	O
by	O
modulating	O
the	O
physical	O
or	O
functional	O
interaction	O
of	O
PHD2	B-Protein
,	O
VHL	B-Protein
,	O
FIH	B-Protein
-	I-Protein
1	I-Protein
,	O
RACK1	B-Protein
,	O
or	O
HSP90	B-Protein
with	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

The	O
interaction	O
of	O
the	O
SRA	O
domain	O
of	O
ICBP90	B-Protein
with	O
a	O
novel	O
domain	O
of	O
DNMT1	B-Protein
is	O
involved	O
in	O
the	O
regulation	O
of	O
VEGF	B-Protein
gene	O
expression	O
.	O

Inverted	B-Protein
CCAAT	I-Protein
box	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
of	I-Protein
90	I-Protein
kDa	I-Protein
(	O
ICBP90	B-Protein
)	O
is	O
over	O
-	O
expressed	O
in	O
several	O
types	O
of	O
cancer	O
,	O
including	O
breast	O
,	O
prostate	O
and	O
lung	O
cancers	O
.	O

In	O
search	O
for	O
proteins	O
that	O
interact	O
with	O
the	O
set	O
and	O
ring	O
-	O
associated	O
(	O
SRA	O
)	O
domain	O
of	O
ICBP90	B-Protein
,	O
we	O
used	O
the	O
two	O
-	O
hybrid	O
system	O
and	O
screened	O
a	O
placental	O
cDNA	O
library	O
.	O

Several	O
clones	O
coding	O
for	O
a	O
new	O
domain	O
of	O
DNMT1	B-Protein
were	O
found	O
.	O

The	O
interaction	O
,	O
between	O
the	O
ICBP90	B-Protein
SRA	O
domain	O
and	O
the	O
DNMT1	B-Protein
domain	O
,	O
has	O
been	O
confirmed	O
with	O
purified	O
proteins	O
by	O
glutathione	B-Protein
-	I-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
pull	O
-	O
down	O
experiments	O
.	O

We	O
checked	O
whether	O
ICBP90	B-Protein
and	O
DNMT1	B-Protein
are	O
present	O
in	O
the	O
same	O
macro	O
-	O
molecular	O
complexes	O
in	O
Jurkat	O
cells	O
and	O
immortalized	O
human	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
HVTs	O
-	O
SM1	O
)	O
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
showed	O
that	O
ICBP90	B-Protein
and	O
DNMT1	B-Protein
are	O
present	O
in	O
the	O
same	O
molecular	O
complex	O
,	O
which	O
was	O
further	O
confirmed	O
by	O
co	O
-	O
localization	O
experiments	O
as	O
assessed	O
by	O
immunocytochemistry	O
.	O

Downregulation	O
of	O
ICBP90	B-Protein
and	O
DNMT1	B-Protein
decreased	O
VEGF	B-Protein
gene	O
expression	O
,	O
a	O
major	O
pro	O
-	O
angiogenic	O
factor	O
,	O
whereas	O
those	O
of	O
p16	B-Protein
(	O
INK4A	B-Protein
)	O
gene	O
and	O
RB1	B-Protein
gene	O
were	O
significantly	O
enhanced	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
DNMT1	B-Protein
and	O
ICBP90	B-Protein
are	O
involved	O
in	O
VEGF	B-Protein
gene	O
expression	O
,	O
possibly	O
via	O
an	O
interaction	O
of	O
the	O
SRA	O
domain	O
of	O
ICBP90	B-Protein
with	O
a	O
novel	O
domain	O
of	O
DNMT1	B-Protein
and	O
an	O
upregulation	O
of	O
p16	B-Protein
(	O
INK4A	B-Protein
)	O
.	O

They	O
further	O
suggest	O
a	O
new	O
role	O
of	O
ICBP90	B-Protein
in	O
the	O
relationship	O
between	O
histone	B-Protein
ubiquitination	O
and	O
DNA	O
methylation	O
in	O
the	O
context	O
of	O
tumoral	O
angiogenesis	O
and	O
tumour	O
suppressor	O
genes	O
silencing	O
.	O

Automethylation	O
of	O
G9a	B-Protein
and	O
its	O
implication	O
in	O
wider	O
substrate	O
specificity	O
and	O
HP1	O
binding	O
.	O

Methylation	O
of	O
lysine	O
residues	O
on	O
histones	B-Protein
participates	O
in	O
transcriptional	O
gene	O
regulation	O
.	O

Lysine	O
9	O
methylation	O
of	O
histone	B-Protein
H3	I-Protein
is	O
a	O
transcriptional	O
repression	O
signal	O
,	O
mediated	O
by	O
a	O
family	O
of	O
SET	O
domain	O
containing	O
AdoMet	O
-	O
dependent	O
enzymes	O
.	O

G9a	B-Protein
methyltransferase	O
is	O
a	O
euchromatic	O
histone	B-Protein
H3	I-Protein
lysine	O
9	O
methyltransferase	O
.	O

Here	O
,	O
G9a	B-Protein
is	O
shown	O
to	O
methylate	O
other	O
cellular	O
proteins	O
,	O
apart	O
from	O
histone	B-Protein
H3	I-Protein
,	O
including	O
automethylation	O
of	O
K239	O
residue	O
.	O

Automethylation	O
of	O
G9a	B-Protein
did	O
not	O
impair	O
or	O
activate	O
the	O
enzymatic	O
activity	O
in	O
vitro	O
.	O

The	O
automethylation	O
motif	O
of	O
G9a	B-Protein
flanking	O
target	O
K239	O
(	O
ARKT	O
)	O
has	O
similarity	O
with	O
histone	B-Protein
H3	I-Protein
lysine	O
9	O
regions	O
(	O
ARKS	O
)	O
,	O
and	O
is	O
identical	O
to	O
amino	O
acids	O
residues	O
in	O
EuHMT	B-Protein
(	O
ARKT	O
)	O
and	O
mAM	B-Protein
(	O
ARKT	O
)	O
.	O

Under	O
steady	O
-	O
state	O
kinetic	O
assay	O
conditions	O
,	O
full	O
-	O
length	O
G9a	B-Protein
methylates	O
peptides	O
representing	O
ARKS	O
/	O
T	O
motif	O
of	O
H3	B-Protein
,	O
G9a	B-Protein
,	O
mAM	B-Protein
and	O
EuHMT	B-Protein
efficiently	O
.	O

Automethylation	O
of	O
G9a	B-Protein
at	O
ARKT	O
motif	O
creates	O
a	O
binding	O
site	O
for	O
HP1	O
class	O
of	O
protein	O
and	O
mutation	O
of	O
lysine	O
in	O
the	O
motif	O
impairs	O
this	O
binding	O
.	O

In	O
COS	O
-	O
7	O
cells	O
GFP	O
fusion	O
of	O
the	O
wild	O
-	O
type	O
G9a	B-Protein
co	O
-	O
localized	O
with	O
HP1alpha	B-Protein
and	O
HP1gamma	B-Protein
isoforms	O
whereas	O
the	O
G9a	B-Protein
mutant	O
with	O
K239A	O
displayed	O
poor	O
co	O
-	O
localization	O
.	O

Thus	O
,	O
apart	O
from	O
transcriptional	O
repression	O
and	O
regulatory	O
roles	O
of	O
lysine	O
methylation	O
,	O
the	O
non	O
-	O
histone	B-Protein
protein	O
methylation	O
may	O
create	O
binding	O
sites	O
for	O
cellular	O
protein	O
-	O
protein	O
interactions	O
.	O

CSF	B-Protein
-	I-Protein
1	I-Protein
and	O
TPA	O
stimulate	O
independent	O
pathways	O
leading	O
to	O
lysosomal	O
degradation	O
or	O
regulated	O
intramembrane	O
proteolysis	O
of	O
the	O
CSF	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
.	O

The	O
CSF	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
is	O
a	O
protein	O
-	O
tyrosine	O
kinase	O
that	O
has	O
been	O
shown	O
to	O
undergo	O
regulated	O
intramembrane	O
proteolysis	O
,	O
or	O
RIPping	O
.	O

Here	O
,	O
we	O
have	O
compared	O
receptor	O
downregulation	O
and	O
RIPping	O
in	O
response	O
to	O
CSF	B-Protein
-	I-Protein
1	I-Protein
and	O
TPA	O
.	O

Our	O
studies	O
show	O
that	O
CSF	B-Protein
-	I-Protein
1	I-Protein
is	O
a	O
relatively	O
poor	O
inducer	O
of	O
RIPping	O
and	O
that	O
CSF	B-Protein
-	I-Protein
1	I-Protein
-	O
induced	O
receptor	O
downregulation	O
is	O
largely	O
independent	O
of	O
RIPping	O
.	O

TPA	O
is	O
a	O
strong	O
inducer	O
of	O
RIPping	O
and	O
TPA	O
-	O
induced	O
receptor	O
downregulation	O
is	O
mediated	O
by	O
RIPping	O
.	O

We	O
further	O
found	O
that	O
RIPping	O
is	O
dependent	O
on	O
TACE	B-Protein
or	O
a	O
TACE	B-Protein
-	O
like	O
protease	O
,	O
that	O
CSF	B-Protein
-	I-Protein
1	I-Protein
and	O
TPA	O
use	O
independent	O
pathways	O
to	O
initiate	O
RIPping	O
,	O
and	O
that	O
the	O
intracellular	O
domain	O
is	O
targeted	O
for	O
degradation	O
through	O
ubiquitination	O
.	O

Certain	O
and	O
progressive	O
methylation	O
of	O
histone	B-Protein
H4	I-Protein
at	O
lysine	O
20	O
during	O
the	O
cell	O
cycle	O
.	O

Methylation	O
of	O
histone	B-Protein
H4	I-Protein
at	O
lysine	O
20	O
(	O
K20	O
)	O
has	O
been	O
implicated	O
in	O
transcriptional	O
activation	O
,	O
gene	O
silencing	O
,	O
heterochromatin	O
formation	O
,	O
mitosis	O
,	O
and	O
DNA	O
repair	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
how	O
this	O
modification	O
is	O
regulated	O
or	O
how	O
it	O
contributes	O
to	O
these	O
diverse	O
processes	O
.	O

Metabolic	O
labeling	O
and	O
top	O
-	O
down	O
mass	O
spectrometry	O
reveal	O
that	O
newly	O
synthesized	O
H4	B-Protein
is	O
progressively	O
methylated	O
at	O
K20	O
during	O
the	O
G	O
(	O
2	O
)	O
,	O
M	O
,	O
and	O
G	O
(	O
1	O
)	O
phases	O
of	O
the	O
cell	O
cycle	O
in	O
a	O
process	O
that	O
is	O
largely	O
inescapable	O
and	O
irreversible	O
.	O

Approximately	O
98	O
%	O
of	O
new	O
H4	B-Protein
becomes	O
dimethylated	O
within	O
two	O
to	O
three	O
cell	O
cycles	O
,	O
and	O
K20	O
methylation	O
turnover	O
in	O
vivo	O
is	O
undetectable	O
.	O

New	O
H4	B-Protein
is	O
methylated	O
regardless	O
of	O
prior	O
acetylation	O
,	O
and	O
acetylation	O
occurs	O
predominantly	O
on	O
K20	O
-	O
dimethylated	O
H4	B-Protein
,	O
refuting	O
the	O
hypothesis	O
that	O
K20	O
methylation	O
antagonizes	O
H4	B-Protein
acetylation	O
and	O
represses	O
transcription	O
epigenetically	O
.	O

Despite	O
suggestions	O
that	O
it	O
is	O
required	O
for	O
normal	O
mitosis	O
and	O
cell	O
cycle	O
progression	O
,	O
K20	O
methylation	O
proceeds	O
normally	O
during	O
colchicine	O
treatment	O
.	O

Moreover	O
,	O
delays	O
in	O
PR	B-Protein
-	I-Protein
Set7	I-Protein
synthesis	O
and	O
K20	O
methylation	O
which	O
accompany	O
altered	O
cell	O
cycle	O
progression	O
during	O
sodium	O
butyrate	O
treatment	O
appear	O
to	O
be	O
secondary	O
to	O
histone	B-Protein
hyperacetylation	O
or	O
other	O
effects	O
of	O
butyrate	O
since	O
depletion	O
of	O
PR	B-Protein
-	I-Protein
Set7	I-Protein
did	O
not	O
affect	O
cell	O
cycle	O
progression	O
.	O

Together	O
,	O
our	O
data	O
provide	O
an	O
unbiased	O
perspective	O
of	O
the	O
regulation	O
and	O
function	O
of	O
K20	O
methylation	O
.	O

P16	B-Protein
methylation	O
in	O
serum	O
as	O
a	O
potential	O
marker	O
for	O
the	O
malignancy	O
of	O
colorectal	O
carcinoma	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
p16	B-Protein
methylation	O
in	O
the	O
serum	O
can	O
serve	O
as	O
a	O
candidate	O
marker	O
for	O
the	O
malignancy	O
of	O
colorectal	O
carcinoma	O
,	O
real	O
-	O
time	O
quantitative	O
methylation	O
-	O
specific	O
PCR	O
(	O
RTQ	O
-	O
MSP	O
)	O
was	O
performed	O
for	O
p16	B-Protein
methylation	O
in	O
serum	O
and	O
the	O
relationship	O
between	O
p16	B-Protein
methylation	O
levels	O
and	O
clinicopathological	O
findings	O
of	O
colorectal	O
carcinoma	O
was	O
evaluated	O
.	O

RESULTS	O
:	O
The	O
p16	B-Protein
methylation	O
score	O
significantly	O
increased	O
with	O
tumor	O
stage	O
(	O
stage	O
I	O
=	O
0	O
.	O
94	O
+	O
/	O
-	O
0	O
.	O
47	O
,	O
stage	O
11	O
=	O
2	O
.	O
33	O
+	O
/	O
-	O
0	O
.	O
90	O
,	O
stage	O
111	O
=	O
8	O
.	O
49	O
+	O
/	O
-	O
2	O
.	O
37	O
,	O
stage	O
IV	O
=	O
10	O
.	O
03	O
+	O
/	O
-	O
4	O
.	O
30	O
)	O
(	O
p	O
=	O
0	O
.	O
021	O
;	O
ANOVA	O
)	O
.	O

The	O
p16	B-Protein
methylation	O
score	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
lymph	O
node	O
metastasis	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
tumor	O
invasion	O
to	O
the	O
veins	O
(	O
p	O
=	O
0	O
.	O
020	O
)	O
.	O

The	O
cumulative	O
survival	O
of	O
patient	O
groups	O
according	O
to	O
the	O
p16	B-Protein
methylation	O
score	O
(	O
more	O
or	O
less	O
than	O
1	O
)	O
was	O
examined	O
.	O

Interestingly	O
,	O
the	O
group	O
with	O
a	O
high	O
p16	B-Protein
methylation	O
score	O
showed	O
significantly	O
worse	O
survival	O
rates	O
than	O
the	O
group	O
with	O
a	O
low	O
p16	B-Protein
expression	O
score	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

CONCLUSION	O
:	O
The	O
p16	B-Protein
methylation	O
score	O
might	O
serve	O
as	O
a	O
new	O
parameter	O
for	O
the	O
prognosis	O
of	O
colorectal	O
carcinoma	O
.	O

Moreover	O
,	O
p16	B-Protein
methylation	O
was	O
found	O
in	O
the	O
serum	O
of	O
patients	O
in	O
all	O
clinical	O
stages	O
,	O
suggesting	O
that	O
early	O
colorectal	O
carcinoma	O
could	O
be	O
detected	O
using	O
the	O
RTQ	O
-	O
MSP	O
method	O
.	O

NCAM	B-Protein
is	O
ubiquitylated	O
,	O
endocytosed	O
and	O
recycled	O
in	O
neurons	O
.	O

The	O
neural	O
cell	O
adhesion	O
molecule	O
NCAM	B-Protein
plays	O
an	O
important	O
role	O
during	O
neural	O
development	O
and	O
in	O
the	O
adult	O
brain	O
.	O

To	O
study	O
the	O
intracellular	O
trafficking	O
of	O
NCAM	B-Protein
in	O
neurons	O
,	O
two	O
major	O
isoforms	O
,	O
NCAM140	B-Protein
or	O
NCAM180	B-Protein
,	O
were	O
expressed	O
in	O
primary	O
cortical	O
neurons	O
and	O
in	O
the	O
rat	O
B35	O
neuroblastoma	O
cell	O
line	O
.	O

NCAM	B-Protein
was	O
endocytosed	O
and	O
subsequently	O
recycled	O
to	O
the	O
plasma	O
membrane	O
,	O
whereas	O
only	O
a	O
minor	O
fraction	O
was	O
degraded	O
in	O
lysosomes	O
.	O

In	O
cortical	O
neurons	O
,	O
endocytosis	O
of	O
NCAM	B-Protein
was	O
detected	O
in	O
the	O
soma	O
,	O
neurites	O
and	O
growth	O
cones	O
in	O
a	O
developmentally	O
regulated	O
fashion	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
NCAM	B-Protein
is	O
mono	O
-	O
ubiquitylated	O
at	O
the	O
plasma	O
membrane	O
and	O
endocytosis	O
was	O
significantly	O
increased	O
in	O
cells	O
overexpressing	O
ubiquitin	B-Protein
.	O

Therefore	O
,	O
we	O
propose	O
that	O
ubiquitylation	O
represents	O
an	O
endocytosis	O
signal	O
for	O
NCAM	B-Protein
.	O

Proteolytic	O
activation	O
and	O
glycosylation	O
of	O
N	B-Protein
-	I-Protein
acylethanolamine	I-Protein
-	I-Protein
hydrolyzing	I-Protein
acid	I-Protein
amidase	I-Protein
,	O
a	O
lysosomal	O
enzyme	O
involved	O
in	O
the	O
endocannabinoid	O
metabolism	O
.	O

N	B-Protein
-	I-Protein
acylethanolamine	I-Protein
-	I-Protein
hydrolyzing	I-Protein
acid	I-Protein
amidase	I-Protein
(	O
NAAA	B-Protein
)	O
is	O
a	O
lysosomal	O
enzyme	O
hydrolyzing	O
bioactive	O
N	O
-	O
acylethanolamines	O
,	O
including	O
anandamide	O
and	O
N	O
-	O
palmitoylethanolamine	O
.	O

Previously	O
,	O
we	O
suggested	O
that	O
NAAA	B-Protein
is	O
glycosylated	O
and	O
proteolytically	O
cleaved	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
mechanism	O
and	O
significance	O
of	O
the	O
cleavage	O
of	O
human	O
NAAA	B-Protein
overexpressed	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

Western	O
blotting	O
with	O
anti	O
-	O
NAAA	B-Protein
antibody	O
revealed	O
that	O
most	O
of	O
NAAA	B-Protein
in	O
the	O
cell	O
homogenate	O
was	O
the	O
cleaved	O
30	O
-	O
kDa	O
form	O
.	O

However	O
,	O
some	O
of	O
NAAA	B-Protein
were	O
released	O
outside	O
the	O
cells	O
and	O
the	O
extracellular	O
enzyme	O
was	O
mostly	O
the	O
uncleaved	O
48	O
-	O
kDa	O
form	O
.	O

When	O
incubated	O
at	O
pH	O
4	O
.	O
5	O
,	O
the	O
48	O
-	O
kDa	O
form	O
was	O
time	O
-	O
dependently	O
converted	O
to	O
the	O
30	O
-	O
kDa	O
form	O
with	O
concomitant	O
increase	O
in	O
the	O
N	O
-	O
palmitoylethanolamine	O
-	O
hydrolyzing	O
activity	O
.	O

The	O
purified	O
48	O
-	O
kDa	O
form	O
was	O
also	O
cleaved	O
and	O
activated	O
.	O

However	O
,	O
the	O
cleavage	O
did	O
not	O
proceed	O
at	O
pH	O
7	O
.	O
4	O
or	O
in	O
the	O
presence	O
of	O
p	O
-	O
chloromercuribenzoic	O
acid	O
.	O

The	O
mutant	O
C126S	O
was	O
resistant	O
to	O
the	O
cleavage	O
and	O
remained	O
inactive	O
.	O

These	O
results	O
suggested	O
that	O
this	O
specific	O
proteolysis	O
is	O
a	O
self	O
-	O
catalyzed	O
activation	O
step	O
.	O

We	O
next	O
determined	O
N	O
-	O
glycosylation	O
sites	O
of	O
human	O
NAAA	B-Protein
by	O
site	O
-	O
directed	O
mutagenesis	O
addressed	O
to	O
asparagine	O
residues	O
in	O
six	O
potential	O
N	O
-	O
glycosylation	O
sites	O
.	O

The	O
results	O
exhibited	O
that	O
Asn	O
-	O
37	O
,	O
Asn	O
-	O
107	O
,	O
Asn	O
-	O
309	O
,	O
and	O
Asn	O
-	O
333	O
are	O
actual	O
N	O
-	O
glycosylation	O
sites	O
.	O

The	O
glycosylation	O
appeared	O
to	O
play	O
an	O
important	O
role	O
in	O
stabilizing	O
the	O
enzyme	O
protein	O
.	O

Lysine	O
63	O
-	O
linked	O
ubiquitination	O
promotes	O
the	O
formation	O
and	O
autophagic	O
clearance	O
of	O
protein	O
inclusions	O
associated	O
with	O
neurodegenerative	O
diseases	O
.	O

Although	O
ubiquitin	B-Protein
-	O
enriched	O
protein	O
inclusions	O
represent	O
an	O
almost	O
invariant	O
feature	O
of	O
neurodegenerative	O
diseases	O
,	O
the	O
mechanism	O
underlying	O
their	O
biogenesis	O
remains	O
unclear	O
.	O

In	O
particular	O
,	O
whether	O
the	O
topology	O
of	O
ubiquitin	B-Protein
linkages	O
influences	O
the	O
dynamics	O
of	O
inclusions	O
is	O
not	O
well	O
explored	O
.	O

Here	O
,	O
we	O
report	O
that	O
lysine	O
48	O
(	O
K48	O
)	O
-	O
and	O
lysine	O
63	O
(	O
K63	O
)	O
-	O
linked	O
polyubiquitination	O
,	O
as	O
well	O
as	O
monoubiquitin	B-Protein
modification	O
contribute	O
to	O
the	O
biogenesis	O
of	O
inclusions	O
.	O

K63	O
-	O
linked	O
polyubiquitin	B-Protein
is	O
the	O
most	O
consistent	O
enhancer	O
of	O
inclusions	O
formation	O
.	O

Under	O
basal	O
conditions	O
,	O
ectopic	O
expression	O
of	O
K63	O
mutant	O
ubiquitin	B-Protein
in	O
cultured	O
cells	O
promotes	O
the	O
accumulation	O
of	O
proteins	O
and	O
the	O
formation	O
of	O
intracellular	O
inclusions	O
in	O
the	O
apparent	O
absence	O
of	O
proteasome	O
impairment	O
.	O

When	O
co	O
-	O
expressed	O
with	O
disease	O
-	O
associated	O
tau	B-Protein
and	O
SOD1	B-Protein
mutants	O
,	O
K63	O
ubiquitin	B-Protein
mutant	O
facilitates	O
the	O
formation	O
of	O
tau	B-Protein
-	O
and	O
SOD	B-Protein
-	I-Protein
1	I-Protein
-	O
positive	O
inclusions	O
.	O

Moreover	O
,	O
K63	O
-	O
linked	O
ubiquitination	O
was	O
found	O
to	O
selectively	O
facilitate	O
the	O
clearance	O
of	O
inclusions	O
via	O
autophagy	O
.	O

These	O
data	O
indicate	O
that	O
K63	O
-	O
linked	O
ubiquitin	B-Protein
chains	O
may	O
represent	O
a	O
common	O
denominator	O
underlying	O
inclusions	O
biogenesis	O
,	O
as	O
well	O
as	O
a	O
general	O
cellular	O
strategy	O
for	O
defining	O
cargo	O
destined	O
for	O
the	O
autophagic	O
system	O
.	O

Collectively	O
,	O
our	O
results	O
provide	O
a	O
novel	O
mechanistic	O
route	O
that	O
underlies	O
the	O
life	O
cycle	O
of	O
an	O
inclusion	O
body	O
.	O

Harnessing	O
this	O
pathway	O
may	O
offer	O
innovative	O
approaches	O
in	O
the	O
treatment	O
of	O
neurodegenerative	O
disorders	O
.	O

The	O
E3	O
Ligase	O
MuRF1	B-Protein
degrades	O
myosin	O
heavy	O
chain	O
protein	O
in	O
dexamethasone	O
-	O
treated	O
skeletal	O
muscle	O
.	O

Skeletal	O
muscle	O
atrophy	O
occurs	O
as	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
synthetic	O
glucocorticoids	O
such	O
as	O
dexamethasone	O
(	O
DEX	O
)	O
and	O
is	O
a	O
hallmark	O
of	O
cachectic	O
syndromes	O
associated	O
with	O
increased	O
cortisol	O
levels	O
.	O

The	O
E3	O
ubiquitin	B-Protein
ligase	O
MuRF1	B-Protein
(	O
muscle	B-Protein
RING	I-Protein
finger	I-Protein
protein	I-Protein
1	I-Protein
)	O
is	O
transcriptionally	O
upregulated	O
by	O
DEX	O
treatment	O
.	O

Differentiated	O
myotubes	O
treated	O
with	O
DEX	O
undergo	O
depletion	O
of	O
myosin	O
heavy	O
chain	O
protein	O
(	O
MYH	O
)	O
,	O
which	O
physically	O
associates	O
with	O
MuRF1	B-Protein
.	O

This	O
loss	O
of	O
MYH	O
can	O
be	O
blocked	O
by	O
inhibition	O
of	O
MuRF1	B-Protein
expression	O
.	O

When	O
wild	O
-	O
type	O
and	O
MuRF1	B-Protein
(	O
-	O
/	O
-	O
)	O
mice	O
are	O
treated	O
with	O
DEX	O
,	O
the	O
MuRF1	B-Protein
(	O
-	O
/	O
-	O
)	O
animals	O
exhibit	O
a	O
relative	O
sparing	O
of	O
MYH	O
.	O

In	O
vitro	O
,	O
MuRF1	B-Protein
is	O
shown	O
to	O
function	O
as	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
for	O
MYH	O
.	O

These	O
data	O
identify	O
the	O
mechanism	O
by	O
which	O
MYH	O
is	O
depleted	O
under	O
atrophy	O
conditions	O
and	O
demonstrate	O
that	O
inhibition	O
of	O
a	O
single	O
E3	O
ligase	O
,	O
MuRF1	B-Protein
,	O
is	O
sufficient	O
to	O
maintain	O
this	O
important	O
sarcomeric	O
protein	O
.	O

A	O
high	O
-	O
throughput	O
screen	O
measuring	O
ubiquitination	O
of	O
p53	B-Protein
by	O
human	O
mdm2	B-Protein
.	O

Tumor	O
suppressor	O
p53	B-Protein
is	O
typically	O
maintained	O
at	O
low	O
levels	O
in	O
normal	O
cells	O
.	O

In	O
response	O
to	O
cellular	O
stresses	O
,	O
such	O
as	O
DNA	O
damage	O
,	O
p53	B-Protein
is	O
stabilized	O
and	O
can	O
stimulate	O
responses	O
leading	O
to	O
cell	O
cycle	O
arrest	O
or	O
apoptosis	O
.	O

Corresponding	O
to	O
its	O
central	O
role	O
in	O
preventing	O
propagation	O
of	O
damaged	O
cells	O
,	O
mutation	O
or	O
deletion	O
of	O
p53	B-Protein
is	O
found	O
in	O
nearly	O
50	O
%	O
of	O
all	O
human	O
tumors	O
.	O

Mdm2	B-Protein
(	O
mouse	B-Protein
-	I-Protein
d	I-Protein
-	I-Protein
minute	I-Protein
2	I-Protein
)	O
and	O
its	O
human	O
ortholog	O
(	O
hmdm2	B-Protein
or	O
hdm2	B-Protein
)	O
catalyze	O
the	O
ubiquitination	O
of	O
p53	B-Protein
,	O
targeting	O
it	O
for	O
degradation	O
via	O
the	O
proteosome	O
.	O

Thus	O
,	O
the	O
activity	O
of	O
mdm2	B-Protein
is	O
inversely	O
correlated	O
with	O
p53	B-Protein
levels	O
.	O

Based	O
on	O
this	O
,	O
inhibition	O
of	O
human	O
mdm2	B-Protein
activity	O
by	O
a	O
small	O
-	O
molecule	O
therapeutic	O
will	O
lead	O
to	O
net	O
stabilization	O
of	O
p53	B-Protein
and	O
be	O
the	O
basis	O
for	O
development	O
of	O
a	O
novel	O
cancer	O
therapeutic	O
.	O

Previous	O
high	O
-	O
throughput	O
screening	O
assays	O
of	O
mdm2	B-Protein
measured	O
the	O
autoubiquitination	O
activity	O
of	O
mdm2	B-Protein
,	O
which	O
occurs	O
in	O
the	O
absence	O
of	O
an	O
acceptor	O
substrate	O
such	O
as	O
p53	B-Protein
.	O

The	O
major	O
drawback	O
to	O
this	O
approach	O
is	O
that	O
inhibitors	O
of	O
mdm2	B-Protein
autoubiquitination	O
may	O
lead	O
to	O
a	O
net	O
stabilization	O
of	O
mdm2	B-Protein
and	O
thus	O
have	O
the	O
opposite	O
effect	O
of	O
inhibitors	O
that	O
interfere	O
with	O
p53	B-Protein
ubiquitination	O
.	O

The	O
authors	O
describe	O
the	O
development	O
,	O
validation	O
,	O
and	O
execution	O
of	O
a	O
high	O
-	O
throughput	O
screening	O
measuring	O
the	O
ubiquitination	O
of	O
p53	B-Protein
by	O
mdm2	B-Protein
,	O
with	O
p53	B-Protein
labeled	O
with	O
europium	O
and	O
the	O
other	O
substrate	O
(	O
Ub	O
-	O
UbcH5b	B-Protein
)	O
labeled	O
with	O
a	O
Cy5	O
on	O
the	O
ubiquitin	B-Protein
.	O

After	O
confirming	O
that	O
known	O
inhibitors	O
are	O
detected	O
with	O
this	O
assay	O
,	O
it	O
was	O
successfully	O
automated	O
and	O
used	O
to	O
query	O
>	O
600	O
,	O
000	O
compounds	O
from	O
the	O
GlaxoSmithKline	O
collection	O
for	O
mdm2	B-Protein
inhibitors	O
.	O

Inheritance	O
of	O
an	O
epigenetic	O
mark	O
:	O
the	O
CpG	O
DNA	B-Protein
methyltransferase	I-Protein
1	I-Protein
is	O
required	O
for	O
de	O
novo	O
establishment	O
of	O
a	O
complex	O
pattern	O
of	O
non	O
-	O
CpG	O
methylation	O
.	O

Site	O
-	O
specific	O
methylation	O
of	O
cytosines	O
is	O
a	O
key	O
epigenetic	O
mark	O
of	O
vertebrate	O
DNA	O
.	O

While	O
a	O
majority	O
of	O
the	O
methylated	O
residues	O
are	O
in	O
the	O
symmetrical	O
(	O
meC	O
)	O
pG	O
:	O
Gp	O
(	O
meC	O
)	O
configuration	O
,	O
a	O
smaller	O
,	O
but	O
significant	O
fraction	O
is	O
found	O
in	O
the	O
CpA	O
,	O
CpT	O
and	O
CpC	O
asymmetric	O
(	O
non	O
-	O
CpG	O
)	O
dinucleotides	O
.	O

CpG	O
methylation	O
is	O
reproducibly	O
maintained	O
by	O
the	O
activity	O
of	O
the	O
DNA	B-Protein
methyltransferase	I-Protein
1	I-Protein
(	O
Dnmt1	B-Protein
)	O
on	O
the	O
newly	O
replicated	O
hemimethylated	O
substrates	O
(	O
meC	O
)	O
pG	O
:	O
GpC	O
.	O

On	O
the	O
other	O
hand	O
,	O
establishment	O
and	O
hereditary	O
maintenance	O
of	O
non	O
-	O
CpG	O
methylation	O
patterns	O
have	O
not	O
been	O
analyzed	O
in	O
detail	O
.	O

We	O
previously	O
reported	O
the	O
occurrence	O
of	O
site	O
-	O
and	O
allele	O
-	O
specific	O
methylation	O
at	O
both	O
CpG	O
and	O
non	O
-	O
CpG	O
sites	O
.	O

Here	O
we	O
characterize	O
a	O
hereditary	O
complex	O
of	O
non	O
-	O
CpG	O
methylation	O
,	O
with	O
the	O
transgenerational	O
maintenance	O
of	O
three	O
distinct	O
profiles	O
in	O
a	O
constant	O
ratio	O
,	O
associated	O
with	O
extensive	O
CpG	O
methylation	O
.	O

These	O
observations	O
raised	O
the	O
question	O
of	O
the	O
signal	O
leading	O
to	O
the	O
maintenance	O
of	O
the	O
pattern	O
of	O
asymmetric	O
methylation	O
.	O

The	O
complete	O
non	O
-	O
CpG	O
pattern	O
was	O
reinstated	O
at	O
each	O
generation	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
majority	O
of	O
the	O
sperm	O
genomes	O
contained	O
either	O
none	O
or	O
only	O
one	O
methylated	O
non	O
-	O
CpG	O
site	O
.	O

This	O
observation	O
led	O
us	O
to	O
the	O
hypothesis	O
that	O
the	O
stable	O
CpG	O
patterns	O
might	O
act	O
as	O
blueprints	O
for	O
the	O
maintenance	O
of	O
non	O
-	O
CpG	O
DNA	O
methylation	O
.	O

As	O
predicted	O
,	O
non	O
-	O
CpG	O
DNA	O
methylation	O
profiles	O
were	O
abrogated	O
in	O
a	O
mutant	O
lacking	O
Dnmt1	B-Protein
,	O
the	O
enzymes	O
responsible	O
for	O
CpG	O
methylation	O
,	O
but	O
not	O
in	O
mutants	O
defective	O
for	O
either	O
Dnmt3a	B-Protein
or	O
Dnmt2	B-Protein
.	O

CpG	O
island	O
hypermethylation	O
in	O
cell	O
-	O
free	O
serum	O
DNA	O
identifies	O
patients	O
with	O
localized	O
prostate	O
cancer	O
.	O

BACKGROUND	O
:	O
One	O
of	O
the	O
earliest	O
and	O
most	O
common	O
epigenetic	O
events	O
in	O
prostate	O
carcinogenesis	O
is	O
DNA	O
CpG	O
island	O
(	O
CGI	O
)	O
hypermethylation	O
.	O

Our	O
aim	O
was	O
to	O
analyze	O
the	O
diagnostic	O
and	O
prognostic	O
possibilities	O
of	O
multigene	O
methylation	O
analysis	O
in	O
cell	O
-	O
free	O
serum	O
DNA	O
of	O
prostate	O
cancer	O
(	O
PCA	O
)	O
patients	O
.	O

METHODS	O
:	O
We	O
analyzed	O
serum	O
samples	O
from	O
226	O
consecutive	O
patients	O
(	O
168	O
PCA	O
;	O
42	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
;	O
5	O
incidental	O
PCA	O
;	O
11	O
healthy	O
individuals	O
)	O
.	O

Cell	O
-	O
free	O
DNA	O
was	O
digested	O
with	O
methylation	O
-	O
sensitive	O
restriction	O
endonucleases	O
(	O
HpaII	B-Protein
and	O
HinP1I	B-Protein
)	O
.	O

Subsequently	O
,	O
CGI	O
hypermethylation	O
at	O
GSTP1	B-Protein
,	O
PTGS2	B-Protein
,	O
Reprimo	B-Protein
,	O
and	O
TIG1	B-Protein
was	O
assessed	O
using	O
real	O
-	O
time	O
PCR	O
.	O

RESULTS	O
:	O
CGI	O
hypermethylation	O
at	O
GSTP1	B-Protein
,	O
TIG1	B-Protein
,	O
PTGS2	B-Protein
,	O
and	O
Reprimo	B-Protein
was	O
more	O
frequent	O
in	O
PCA	O
(	O
42	O
.	O
3	O
%	O
,	O
9	O
.	O
5	O
%	O
,	O
2	O
.	O
4	O
%	O
,	O
and	O
1	O
.	O
2	O
%	O
,	O
respectively	O
)	O
compared	O
to	O
BPH	O
(	O
7	O
.	O
7	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
and	O
0	O
%	O
,	O
respectively	O
)	O
and	O
healthy	O
individuals	O
(	O
all	O
0	O
%	O
)	O
with	O
a	O
statistical	O
significant	O
difference	O
of	O
GSTP1	B-Protein
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
TIG1	B-Protein
(	O
P	O
=	O
0	O
.	O
038	O
)	O
.	O

GSTP1	B-Protein
hypermethylation	O
was	O
also	O
detected	O
in	O
four	O
patients	O
with	O
incidental	O
PCA	O
.	O

Hypermethylation	O
in	O
serum	O
DNA	O
at	O
GSTP1	B-Protein
and	O
hypermethylation	O
at	O
any	O
gene	O
site	O
distinguished	O
between	O
PCA	O
and	O
BPH	O
patients	O
in	O
a	O
highly	O
specific	O
(	O
92	O
%	O
)	O
but	O
less	O
sensitive	O
(	O
42	O
-	O
47	O
%	O
)	O
manner	O
.	O

Neither	O
CGI	O
hypermethylation	O
at	O
a	O
single	O
gene	O
loci	O
nor	O
the	O
combination	O
of	O
multiple	O
gene	O
sites	O
was	O
correlated	O
to	O
the	O
pathological	O
stage	O
,	O
grade	O
or	O
biochemical	O
recurrence	O
following	O
radical	O
prostatectomy	O
.	O

CONCLUSIONS	O
:	O
The	O
detection	O
of	O
aberrant	O
hypermethylation	O
in	O
cell	O
-	O
free	O
serum	O
DNA	O
allows	O
the	O
highly	O
specific	O
diagnosis	O
of	O
PCA	O
.	O

A	O
test	O
based	O
on	O
GSTP1	B-Protein
hypermethylation	O
in	O
serum	O
samples	O
of	O
patients	O
with	O
suspected	O
PCA	O
may	O
help	O
to	O
identify	O
men	O
with	O
increased	O
risk	O
of	O
harboring	O
PCA	O
despite	O
negative	O
prostate	O
biopsy	O
.	O

Role	O
of	O
glycosilation	O
in	O
the	O
susceptibility	O
of	O
"	O
acid	O
labile	O
"	O
interferon	O
alpha	O
to	O
acid	O
treatment	O
.	O

Mononuclear	O
cells	O
from	O
blood	O
of	O
healthy	O
donors	O
produce	O
acid	O
-	O
labile	O
interferon	O
(	O
IFN	O
)	O
alpha	O
when	O
stimulated	O
with	O
HIV	O
-	O
infected	O
cells	O
.	O

A	O
large	O
proportion	O
of	O
this	O
IFN	O
appears	O
to	O
be	O
glycosilated	O
,	O
as	O
treatment	O
with	O
neuraminidase	O
causes	O
a	O
shift	O
of	O
the	O
isoelectric	O
point	O
(	O
IP	O
)	O
from	O
pH	O
=	O
5	O
.	O
2	O
-	O
5	O
.	O
4	O
to	O
pH	O
=	O
5	O
.	O
8	O
-	O
6	O
.	O
2	O
.	O

To	O
assess	O
the	O
role	O
of	O
glycosilation	O
in	O
determining	O
the	O
instability	O
of	O
antiviral	O
activity	O
after	O
exposure	O
to	O
acid	O
(	O
pH	O
lower	O
than	O
4	O
)	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
induced	O
to	O
produce	O
IFN	O
with	O
HIV	O
-	O
infected	O
cells	O
in	O
the	O
presence	O
of	O
tunicamycin	O
,	O
an	O
inhibitor	O
of	O
glycosilation	O
.	O

The	O
IFN	O
produced	O
under	O
such	O
experimental	O
conditions	O
(	O
tu	O
-	O
IFN	O
)	O
was	O
acid	O
-	O
stable	O
.	O

Tu	O
-	O
IFN	O
was	O
compared	O
to	O
a	O
standard	O
acid	O
-	O
labile	O
IFN	O
by	O
affinity	O
chromatography	O
on	O
Con	B-Protein
A	I-Protein
-	O
sepharose	O
.	O

The	O
elution	O
pattern	O
showed	O
that	O
tu	O
-	O
IFN	O
does	O
not	O
bind	O
to	O
the	O
gel	O
,	O
whereas	O
the	O
acid	O
-	O
labile	O
IFN	O
is	O
eluted	O
in	O
two	O
fractions	O
,	O
one	O
unbound	O
,	O
which	O
is	O
stable	O
at	O
pH2	O
,	O
and	O
one	O
bound	O
,	O
which	O
retains	O
the	O
initial	O
acid	O
-	O
lability	O
.	O

These	O
results	O
suggest	O
that	O
acid	O
-	O
labile	O
IFN	O
alpha	O
is	O
largely	O
glycosilated	O
,	O
and	O
that	O
the	O
presence	O
of	O
glycosilated	O
molecules	O
contribute	O
to	O
render	O
the	O
IFN	O
molecule	O
unstable	O
at	O
acidic	O
pH	O
.	O

It	O
is	O
to	O
be	O
determined	O
whether	O
some	O
glycosilated	O
molecule	O
present	O
in	O
the	O
IFN	O
preparation	O
,	O
or	O
glycosilation	O
of	O
the	O
IFN	O
molecule	O
per	O
se	O
,	O
is	O
responsible	O
for	O
acid	O
-	O
lability	O
of	O
the	O
antiviral	O
activity	O
.	O

Overexpression	O
of	O
post	O
-	O
translationally	O
modified	O
peptides	O
in	O
Escherichia	O
coli	O
by	O
co	O
-	O
expression	O
with	O
modifying	O
enzymes	O
.	O

Post	O
-	O
translational	O
modification	O
plays	O
crucial	O
roles	O
in	O
signal	O
transduction	O
in	O
eukaryotic	O
cells	O
.	O

To	O
elucidate	O
the	O
biological	O
function	O
of	O
a	O
protein	O
with	O
a	O
specific	O
post	O
-	O
translational	O
modification	O
,	O
it	O
is	O
necessary	O
to	O
isolate	O
the	O
modified	O
protein	O
.	O

However	O
,	O
it	O
is	O
difficult	O
to	O
incorporate	O
a	O
modified	O
amino	O
acid	O
into	O
a	O
specific	O
position	O
of	O
a	O
protein	O
,	O
in	O
particular	O
,	O
in	O
a	O
large	O
-	O
scale	O
preparation	O
.	O

In	O
order	O
to	O
prepare	O
post	O
-	O
translationally	O
modified	O
proteins	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
,	O
we	O
have	O
constructed	O
co	O
-	O
expression	O
vectors	O
that	O
contain	O
protein	O
and	O
corresponding	O
enzyme	O
genes	O
.	O

The	O
protein	O
and	O
enzyme	O
are	O
co	O
-	O
expressed	O
in	O
the	O
same	O
E	O
.	O
coli	O
cells	O
and	O
the	O
protein	O
is	O
post	O
-	O
translationally	O
modified	O
in	O
vivo	O
.	O

By	O
using	O
this	O
system	O
,	O
the	O
transcriptional	O
activator	O
cyclic	O
-	O
AMP	O
-	O
response	O
-	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
was	O
phosphorylated	O
at	O
Ser	O
-	O
133	O
and	O
the	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
was	O
hydroxylated	O
at	O
Asn	O
-	O
803	O
in	O
E	O
.	O
coli	O
.	O

Although	O
the	O
constructs	O
of	O
the	O
proteins	O
we	O
used	O
are	O
very	O
flexible	O
and	O
susceptible	O
to	O
degradation	O
by	O
proteases	O
in	O
E	O
.	O
coli	O
when	O
they	O
are	O
expressed	O
alone	O
,	O
the	O
B1	O
domain	O
of	O
streptococcal	O
protein	B-Protein
G	I-Protein
(	O
GB1	B-Protein
)	O
fused	O
to	O
the	O
N	O
-	O
terminus	O
of	O
the	O
proteins	O
increased	O
the	O
yields	O
dramatically	O
.	O

Site	O
-	O
specific	O
phosphorylation	O
of	O
CREB	O
and	O
hydroxylation	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
were	O
confirmed	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
and	O
NMR	O
.	O

Our	O
GB1	O
-	O
fusion	O
co	O
-	O
expression	O
system	O
can	O
be	O
used	O
in	O
the	O
same	O
way	O
as	O
conventional	O
protein	O
expression	O
in	O
E	O
.	O
coli	O
,	O
making	O
it	O
a	O
flexible	O
and	O
economical	O
method	O
to	O
produce	O
a	O
large	O
amount	O
of	O
a	O
post	O
-	O
translationally	O
modified	O
protein	O
.	O

Site	O
-	O
specific	O
ubiquitination	O
exposes	O
a	O
linear	O
motif	O
to	O
promote	O
interferon	O
-	O
alpha	O
receptor	O
endocytosis	O
.	O

Ligand	O
-	O
induced	O
endocytosis	O
and	O
lysosomal	O
degradation	O
of	O
cognate	O
receptors	O
regulate	O
the	O
extent	O
of	O
cell	O
signaling	O
.	O

Along	O
with	O
linear	O
endocytic	O
motifs	O
that	O
recruit	O
the	O
adaptin	O
protein	O
complex	O
2	O
(	O
AP2	O
)	O
-	O
clathrin	O
molecules	O
,	O
monoubiquitination	O
of	O
receptors	O
has	O
emerged	O
as	O
a	O
major	O
endocytic	O
signal	O
.	O

By	O
investigating	O
ubiquitin	B-Protein
-	O
dependent	O
lysosomal	O
degradation	O
of	O
the	O
interferon	B-Protein
(	I-Protein
IFN	I-Protein
)	I-Protein
-	I-Protein
alpha	I-Protein
/	I-Protein
beta	I-Protein
receptor	I-Protein
1	I-Protein
(	O
IFNAR1	B-Protein
)	O
subunit	O
of	O
the	O
type	O
I	O
IFN	O
receptor	O
,	O
we	O
reveal	O
that	O
IFNAR1	B-Protein
is	O
polyubiquitinated	O
via	O
both	O
Lys48	O
-	O
and	O
Lys63	O
-	O
linked	O
chains	O
.	O

The	O
SCF	O
(	O
betaTrcp	B-Protein
)	O
(	O
Skp1	B-Protein
-	O
Cullin1	B-Protein
-	O
F	O
-	O
box	O
complex	O
)	O
E3	O
ubiquitin	B-Protein
ligase	O
that	O
mediates	O
IFNAR1	B-Protein
ubiquitination	O
and	O
degradation	O
in	O
cells	O
can	O
conjugate	O
both	O
types	O
of	O
chains	O
in	O
vitro	O
.	O

Although	O
either	O
polyubiquitin	B-Protein
linkage	O
suffices	O
for	O
postinternalization	O
sorting	O
,	O
both	O
types	O
of	O
chains	O
are	O
necessary	O
but	O
not	O
sufficient	O
for	O
robust	O
IFNAR1	B-Protein
turnover	O
and	O
internalization	O
.	O

These	O
processes	O
also	O
depend	O
on	O
the	O
proximity	O
of	O
ubiquitin	B-Protein
-	O
acceptor	O
lysines	O
to	O
a	O
linear	O
endocytic	O
motif	O
and	O
on	O
its	O
integrity	O
.	O

Furthermore	O
,	O
ubiquitination	O
of	O
IFNAR1	B-Protein
promotes	O
its	O
interaction	O
with	O
the	O
AP2	O
adaptin	O
complex	O
that	O
is	O
required	O
for	O
the	O
robust	O
internalization	O
of	O
IFNAR1	B-Protein
,	O
implicating	O
cooperation	O
between	O
site	O
-	O
specific	O
ubiquitination	O
and	O
the	O
linear	O
endocytic	O
motif	O
in	O
regulating	O
this	O
process	O
.	O

Direct	O
transcriptional	O
activation	O
of	O
promyelocytic	B-Protein
leukemia	I-Protein
protein	O
by	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
3	I-Protein
induces	O
the	O
p53	B-Protein
-	O
dependent	O
growth	O
inhibition	O
of	O
cancer	O
cells	O
.	O

IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
3	I-Protein
(	O
IRF3	B-Protein
)	O
is	O
a	O
transcriptional	O
factor	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
activation	O
of	O
innate	O
immunity	O
and	O
inflammation	O
in	O
response	O
to	O
viral	O
infection	O
,	O
and	O
is	O
also	O
involved	O
in	O
p53	B-Protein
-	O
dependent	O
inhibition	O
of	O
cell	O
growth	O
.	O

Although	O
functional	O
activation	O
of	O
IRF3	B-Protein
by	O
viral	O
infection	O
is	O
relatively	O
well	O
documented	O
,	O
the	O
biological	O
role	O
and	O
regulatory	O
mechanism	O
underlying	O
cell	O
growth	O
inhibition	O
by	O
IRF3	B-Protein
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
show	O
a	O
novel	O
regulatory	O
pathway	O
connecting	O
IRF3	B-Protein
-	O
promyelocytic	B-Protein
leukemia	I-Protein
protein	O
(	O
PML	B-Protein
)	O
-	O
p53	B-Protein
in	O
primary	O
and	O
cancer	O
cell	O
lines	O
.	O

Overexpression	O
of	O
IRF3	B-Protein
induces	O
p53	B-Protein
-	O
dependent	O
cell	O
growth	O
inhibition	O
in	O
cancer	O
cell	O
lines	O
with	O
normal	O
p53	B-Protein
activity	O
.	O

In	O
addition	O
,	O
doxycycline	O
-	O
induced	O
expression	O
of	O
IRF3	B-Protein
in	O
U87MG	O
cells	O
inhibits	O
tumor	O
growth	O
in	O
nude	O
mice	O
in	O
vivo	O
.	O

IRF3	B-Protein
is	O
found	O
to	O
increase	O
expression	O
of	O
PML	B-Protein
by	O
a	O
direct	O
transcriptional	O
activation	O
as	O
determined	O
by	O
PML	B-Protein
-	O
promoter	O
-	O
luciferase	B-Protein
and	O
chromatin	O
immunoprecipitation	O
assays	O
.	O

When	O
PML	B-Protein
is	O
depleted	O
by	O
RNA	O
interference	O
-	O
mediated	O
knockdown	O
,	O
IRF3	B-Protein
fails	O
to	O
increase	O
p53	B-Protein
acetylation	O
and	O
its	O
transcriptional	O
activity	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
indicate	O
that	O
direct	O
transcriptional	O
activation	O
of	O
PML	B-Protein
by	O
IRF3	B-Protein
results	O
in	O
the	O
p53	B-Protein
-	O
dependent	O
growth	O
inhibition	O
of	O
normal	O
and	O
cancer	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
which	O
is	O
suggestive	O
of	O
a	O
novel	O
regulatory	O
network	O
between	O
the	O
innate	O
immune	O
response	O
and	O
tumor	O
suppression	O
.	O

Histone	B-Protein
deacetylase	O
inhibitors	O
promote	O
the	O
tumoricidal	O
effect	O
of	O
HAMLET	O
.	O

Histone	B-Protein
deacetylase	O
inhibitors	O
(	O
HDIs	O
)	O
and	O
HAMLET	O
(	O
human	O
alpha	B-Protein
-	I-Protein
lactalbumin	I-Protein
made	O
lethal	O
to	O
tumor	O
cells	O
)	O
interact	O
with	O
histones	B-Protein
,	O
modify	O
the	O
structure	O
of	O
chromatin	O
,	O
and	O
trigger	O
tumor	O
cell	O
death	O
.	O

This	O
study	O
investigated	O
how	O
the	O
combination	O
of	O
HDIs	O
and	O
HAMLET	O
influences	O
cell	O
viability	O
,	O
histone	B-Protein
acetylation	O
,	O
and	O
DNA	O
integrity	O
.	O

The	O
pretreatment	O
of	O
tumor	O
cells	O
with	O
HDIs	O
was	O
shown	O
to	O
enhance	O
the	O
lethal	O
effect	O
of	O
HAMLET	O
and	O
the	O
histone	B-Protein
hyperacetylation	O
response	O
to	O
HDIs	O
increased	O
even	O
further	O
after	O
HAMLET	O
treatment	O
.	O

HDIs	O
and	O
HAMLET	O
were	O
shown	O
to	O
target	O
different	O
histone	B-Protein
domains	O
as	O
HAMLET	O
bound	O
tailless	O
core	O
histones	B-Protein
,	O
whereas	O
HDIs	O
modify	O
the	O
acetylation	O
of	O
the	O
histone	B-Protein
tail	O
.	O

DNA	O
damage	O
in	O
response	O
to	O
HAMLET	O
was	O
increased	O
by	O
HDIs	O
.	O

The	O
DNA	O
repair	O
response	O
(	O
p21WAFI	B-Protein
expression	O
)	O
was	O
induced	O
by	O
both	O
agonists	O
but	O
abolished	O
when	O
the	O
two	O
agonists	O
were	O
combined	O
.	O

The	O
results	O
suggest	O
that	O
the	O
synergy	O
of	O
HDIs	O
and	O
HAMLET	O
is	O
based	O
on	O
different	O
but	O
converging	O
death	O
pathways	O
,	O
both	O
involving	O
chromatin	O
alterations	O
.	O

We	O
speculate	O
that	O
HAMLET	O
and	O
HDIs	O
might	O
be	O
combined	O
to	O
promote	O
tumor	O
cell	O
death	O
in	O
vivo	O
.	O

Inhibition	O
of	O
Stat3	B-Protein
activity	O
by	O
YC	O
-	O
1	O
enhances	O
chemo	O
-	O
sensitivity	O
in	O
hepatocellular	O
carcinoma	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effect	O
of	O
YC	O
-	O
1	O
,	O
a	O
novel	O
anti	O
-	O
cancer	O
agent	O
,	O
on	O
the	O
chemo	O
-	O
sensitivity	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O

YC	O
-	O
1	O
was	O
administered	O
with	O
chemo	O
-	O
cytotoxic	O
drug	O
,	O
cisplatin	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

YC	O
-	O
1	O
alone	O
downregulated	O
the	O
expression	O
of	O
phosphorylated	O
form	O
of	O
signal	B-Protein
transducers	I-Protein
and	I-Protein
activators	I-Protein
of	I-Protein
transcription	I-Protein
3	I-Protein
(	O
P	O
-	O
Stat3	B-Protein
[	O
705	O
]	O
)	O
,	O
a	O
key	O
mediator	O
in	O
chemo	O
-	O
resistance	O
.	O

When	O
combined	O
with	O
cisplatin	O
,	O
YC	O
-	O
1	O
further	O
promoted	O
tumor	O
cell	O
apoptosis	O
,	O
decreased	O
the	O
expression	O
of	O
P	O
-	O
Stat3	B-Protein
(	O
705	O
)	O
,	O
Bcl	B-Protein
-	I-Protein
xL	I-Protein
,	O
CyclinD1	B-Protein
and	O
survivin	B-Protein
,	O
and	O
induced	O
the	O
cleavage	O
of	O
caspase	B-Protein
9	I-Protein
and	O
PARP	O
.	O

Overexpression	O
of	O
Stat3	B-Protein
reversed	O
YC	O
-	O
1	O
induced	O
cell	O
death	O
.	O

YC	O
-	O
1	O
inhibited	O
Stat3	B-Protein
activity	O
by	O
enhancing	O
the	O
polyubiquitination	O
of	O
P	O
-	O
Stat3	B-Protein
(	O
705	O
)	O
induced	O
by	O
cisplatin	O
.	O

In	O
the	O
in	O
vivo	O
setting	O
,	O
YC	O
-	O
1	O
combined	O
with	O
cisplatin	O
remarkably	O
suppressed	O
tumor	O
growth	O
in	O
a	O
HCC	O
xenograft	O
model	O
,	O
and	O
this	O
effect	O
was	O
also	O
accompanied	O
by	O
YC	O
-	O
1	O
mediated	O
downregulation	O
of	O
P	O
-	O
Stat3	B-Protein
(	O
705	O
)	O
,	O
Bcl	B-Protein
-	I-Protein
xL	I-Protein
,	O
Cyclin	B-Protein
D1	I-Protein
and	O
survivin	B-Protein
,	O
and	O
induction	O
of	O
cleaved	O
caspase	B-Protein
9	I-Protein
and	O
PARP	O
in	O
the	O
tumor	O
tissues	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
demonstrated	O
a	O
novel	O
anti	O
-	O
cancer	O
effect	O
of	O
YC	O
-	O
1	O
in	O
enhancing	O
chemo	O
-	O
sensitivity	O
of	O
HCC	O
cells	O
to	O
cisplatin	O
through	O
a	O
Stat3	B-Protein
dependent	O
manner	O
.	O

This	O
finding	O
provides	O
insight	O
into	O
design	O
of	O
a	O
new	O
therapeutic	O
strategy	O
to	O
improve	O
efficacy	O
of	O
chemotherapy	O
in	O
HCC	O
patients	O
.	O

Kinetic	O
rationale	O
for	O
selectivity	O
toward	O
N	O
-	O
and	O
C	O
-	O
terminal	O
oxygen	O
-	O
dependent	O
degradation	O
domain	O
substrates	O
mediated	O
by	O
a	O
loop	O
region	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
prolyl	O
hydroxylases	O
.	O

Hydroxylation	O
of	O
two	O
conserved	O
prolyl	O
residues	O
in	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
oxygen	O
-	O
dependent	O
degradation	O
domains	O
(	O
NODD	O
and	O
CODD	O
)	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
signals	O
for	O
its	O
degradation	O
via	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O

In	O
human	O
cells	O
,	O
three	O
prolyl	O
hydroxylases	O
(	O
PHDs	B-Protein
1	I-Protein
-	O
3	B-Protein
)	O
belonging	O
to	O
the	O
Fe	O
(	O
II	O
)	O
and	O
2	O
-	O
oxoglutarate	O
(	O
2OG	O
)	O
-	O
dependent	O
oxygenase	O
family	O
catalyze	O
prolyl	O
hydroxylation	O
with	O
differing	O
selectivity	O
for	O
CODD	O
and	O
NODD	O
.	O

Sequence	O
analysis	O
of	O
the	O
catalytic	O
domains	O
of	O
the	O
PHDs	O
in	O
the	O
light	O
of	O
crystal	O
structures	O
for	O
PHD2	B-Protein
,	O
and	O
results	O
for	O
other	O
2OG	O
oxygenases	O
,	O
suggested	O
that	O
either	O
the	O
C	O
-	O
terminal	O
region	O
or	O
a	O
loop	O
linking	O
two	O
beta	O
-	O
strands	O
(	O
beta2	O
and	O
beta3	O
in	O
human	O
PHD2	B-Protein
)	O
are	O
important	O
in	O
determining	O
substrate	O
selectivity	O
.	O

Mutation	O
analyses	O
on	O
PHD2	B-Protein
revealed	O
that	O
the	O
beta2beta3	O
loop	O
is	O
a	O
major	O
determinant	O
in	O
conferring	O
selectivity	O
for	O
CODD	O
over	O
NODD	O
peptides	O
.	O

A	O
chimeric	O
PHD	O
in	O
which	O
the	O
beta2beta3	O
loop	O
of	O
PHD2	B-Protein
was	O
replaced	O
with	O
that	O
of	O
PHD3	B-Protein
displayed	O
an	O
almost	O
complete	O
selectivity	O
for	O
CODD	O
(	O
in	O
competition	O
experiments	O
)	O
,	O
as	O
observed	O
for	O
wild	O
-	O
type	O
PHD3	B-Protein
.	O

CODD	O
was	O
observed	O
to	O
bind	O
much	O
more	O
tightly	O
to	O
this	O
chimeric	O
protein	O
than	O
the	O
wild	O
type	O
PHD2	B-Protein
catalytic	O
domain	O
.	O

The	O
tale	O
of	O
two	O
domains	O
:	O
proteomics	O
and	O
genomics	O
analysis	O
of	O
SMYD2	B-Protein
,	O
a	O
new	O
histone	O
methyltransferase	O
.	O

Very	O
little	O
is	O
known	O
about	O
SET	B-Protein
-	I-Protein
and	I-Protein
MYND	I-Protein
-	I-Protein
containing	I-Protein
protein	I-Protein
2	I-Protein
(	O
SMYD2	B-Protein
)	O
,	O
a	O
member	O
of	O
the	O
SMYD	O
protein	O
family	O
.	O

However	O
,	O
the	O
interest	O
in	O
better	O
understanding	O
the	O
roles	O
of	O
SMYD2	B-Protein
has	O
grown	O
because	O
of	O
recent	O
reports	O
indicating	O
that	O
SMYD2	B-Protein
methylates	O
p53	B-Protein
and	O
histone	B-Protein
H3	I-Protein
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
combined	O
proteomics	O
and	O
genomics	O
study	O
of	O
SMYD2	B-Protein
designed	O
to	O
elucidate	O
its	O
molecular	O
roles	O
.	O

We	O
report	O
the	O
cytosolic	O
and	O
nuclear	O
interactome	O
of	O
SMYD2	B-Protein
using	O
a	O
combination	O
of	O
immunoprecipitation	O
coupled	O
with	O
high	O
throughput	O
MS	O
,	O
chromatin	O
immunoprecipitation	O
coupled	O
with	O
high	O
throughput	O
MS	O
,	O
and	O
co	O
-	O
immunoprecipitation	O
methods	O
.	O

In	O
particular	O
,	O
we	O
report	O
that	O
SMYD2	B-Protein
interacted	O
with	O
HSP90alpha	B-Protein
independently	O
of	O
the	O
SET	O
and	O
MYND	O
domains	O
,	O
with	O
EBP41L3	B-Protein
through	O
the	O
MYND	O
domain	O
,	O
and	O
with	O
p53	B-Protein
through	O
the	O
SET	O
domain	O
.	O

We	O
demonstrated	O
that	O
the	O
interaction	O
of	O
SMYD2	B-Protein
with	O
HSP90alpha	B-Protein
enhances	O
SMYD2	B-Protein
histone	O
methyltransferase	O
activity	O
and	O
specificity	O
for	O
histone	B-Protein
H3	I-Protein
at	O
lysine	O
4	O
(	O
H3K4	B-Protein
)	O
in	O
vitro	O
.	O

Interestingly	O
histone	B-Protein
H3K36	I-Protein
methyltransferase	O
activity	O
was	O
independent	O
of	O
its	O
interaction	O
with	O
HSP90alpha	B-Protein
similar	O
to	O
LSD1	B-Protein
dependence	O
on	O
the	O
androgen	B-Protein
receptor	I-Protein
.	O

We	O
also	O
showed	O
that	O
the	O
SET	O
domain	O
is	O
required	O
for	O
the	O
methylation	O
at	O
H3K4	B-Protein
.	O

We	O
demonstrated	O
using	O
a	O
modified	O
chromatin	O
immunoprecipitation	O
protocol	O
that	O
the	O
SMYD2	B-Protein
gain	O
of	O
function	O
leads	O
to	O
an	O
increase	O
in	O
H3K4	B-Protein
methylation	O
in	O
vivo	O
,	O
whereas	O
no	O
observable	O
levels	O
of	O
H3K36	B-Protein
were	O
detected	O
.	O

We	O
also	O
report	O
that	O
the	O
SMYD2	B-Protein
gain	O
of	O
function	O
was	O
correlated	O
with	O
the	O
up	O
-	O
regulation	O
of	O
37	O
and	O
down	O
-	O
regulation	O
of	O
four	O
genes	O
,	O
the	O
majority	O
of	O
which	O
are	O
involved	O
in	O
the	O
cell	O
cycle	O
,	O
chromatin	O
remodeling	O
,	O
and	O
transcriptional	O
regulation	O
.	O

TACC2	B-Protein
is	O
one	O
of	O
the	O
genes	O
up	O
-	O
regulated	O
as	O
a	O
result	O
of	O
SMYD2	B-Protein
gain	O
of	O
function	O
.	O

Up	O
-	O
regulation	O
of	O
TACC2	B-Protein
by	O
SMYD2	B-Protein
occurred	O
as	O
a	O
result	O
of	O
SMYD2	B-Protein
binding	O
to	O
the	O
TACC2	B-Protein
promoter	O
where	O
it	O
methylates	O
H3K4	B-Protein
.	O

Furthermore	O
the	O
combination	O
of	O
the	O
SMYD2	B-Protein
interactome	O
with	O
the	O
gene	O
expression	O
data	O
suggests	O
that	O
some	O
of	O
the	O
genes	O
regulated	O
by	O
SMYD2	B-Protein
are	O
closely	O
associated	O
with	O
SMYD2	B-Protein
-	O
interacting	O
proteins	O
.	O

Type	O
I	O
receptor	O
binding	O
of	O
bone	B-Protein
morphogenetic	I-Protein
protein	I-Protein
6	I-Protein
is	O
dependent	O
on	O
N	O
-	O
glycosylation	O
of	O
the	O
ligand	O
.	O

Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
,	O
together	O
with	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
and	O
activins	O
/	O
inhibins	O
,	O
constitute	O
the	O
TGF	O
-	O
beta	O
superfamily	O
of	O
ligands	O
.	O

This	O
superfamily	O
is	O
formed	O
by	O
more	O
than	O
30	O
structurally	O
related	O
secreted	O
proteins	O
.	O

The	O
crystal	O
structure	O
of	O
human	O
BMP	B-Protein
-	I-Protein
6	I-Protein
was	O
determined	O
to	O
a	O
resolution	O
of	O
2	O
.	O
1	O
A	O
;	O
the	O
overall	O
structure	O
is	O
similar	O
to	O
that	O
of	O
other	O
TGF	O
-	O
beta	O
superfamily	O
ligands	O
,	O
e	O
.	O
g	O
.	O
BMP	B-Protein
-	I-Protein
7	I-Protein
.	O

The	O
asymmetric	O
unit	O
contains	O
the	O
full	O
dimeric	O
BMP	B-Protein
-	I-Protein
6	I-Protein
,	O
indicating	O
possible	O
asymmetry	O
between	O
the	O
two	O
monomeric	O
subunits	O
.	O

Indeed	O
,	O
the	O
conformation	O
of	O
several	O
loops	O
differs	O
between	O
both	O
monomers	O
.	O

In	O
particular	O
,	O
the	O
prehelix	O
loop	O
,	O
which	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
type	O
I	O
receptor	O
interactions	O
of	O
BMP	B-Protein
-	I-Protein
2	I-Protein
,	O
adopts	O
two	O
rather	O
different	O
conformations	O
in	O
BMP	B-Protein
-	I-Protein
6	I-Protein
,	O
indicating	O
possible	O
dynamic	O
flexibility	O
of	O
the	O
prehelix	O
loop	O
in	O
its	O
unbound	O
conformation	O
.	O

Flexibility	O
of	O
this	O
loop	O
segment	O
has	O
been	O
discussed	O
as	O
an	O
important	O
feature	O
required	O
for	O
promiscuous	O
binding	O
of	O
different	O
type	O
I	O
receptors	O
to	O
BMPs	O
.	O

Further	O
studies	O
investigating	O
the	O
interaction	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
with	O
different	O
ectodomains	O
of	O
type	O
I	O
receptors	O
revealed	O
that	O
N	O
-	O
glycosylation	O
at	O
Asn73	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
in	O
the	O
wrist	O
epitope	O
is	O
crucial	O
for	O
recognition	O
by	O
the	O
activin	B-Protein
receptor	I-Protein
type	I-Protein
I	I-Protein
.	O

In	O
the	O
absence	O
of	O
the	O
carbohydrate	O
moiety	O
,	O
activin	B-Protein
receptor	I-Protein
type	I-Protein
I	I-Protein
-	O
mediated	O
signaling	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
is	O
totally	O
diminished	O
.	O

Thus	O
,	O
flexibility	O
within	O
the	O
binding	O
epitope	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
and	O
an	O
unusual	O
recognition	O
motif	O
,	O
i	O
.	O
e	O
.	O
an	O
N	O
-	O
glycosylation	O
motif	O
,	O
possibly	O
play	O
an	O
important	O
role	O
in	O
type	O
I	O
receptor	O
specificity	O
of	O
BMP	B-Protein
-	I-Protein
6	I-Protein
.	O

A	O
Cul3	B-Protein
-	O
based	O
E3	O
ligase	O
regulates	O
mitosis	O
and	O
is	O
required	O
to	O
maintain	O
the	O
spindle	O
assembly	O
checkpoint	O
in	O
human	O
cells	O
.	O

The	O
spindle	O
assembly	O
checkpoint	O
(	O
SAC	O
)	O
is	O
a	O
mechanism	O
that	O
prevents	O
premature	O
chromosome	O
segregation	O
in	O
anaphase	O
before	O
all	O
chromosomes	O
are	O
correctly	O
attached	O
to	O
the	O
mitotic	O
spindle	O
.	O

Errors	O
in	O
chromosome	O
segregation	O
lead	O
to	O
aneuploidy	O
,	O
which	O
may	O
be	O
causally	O
involved	O
in	O
tumorgenesis	O
.	O

Kinetochore	O
complexes	O
are	O
the	O
structural	O
components	O
of	O
the	O
SAC	O
,	O
which	O
are	O
tightly	O
regulated	O
by	O
various	O
mechanisms	O
including	O
phosphorylation	O
and	O
ubiquitin	B-Protein
-	O
dependent	O
proteolysis	O
.	O

Recent	O
studies	O
shed	O
new	O
light	O
on	O
the	O
regulatory	O
pathways	O
of	O
the	O
ubiquitin	B-Protein
proteasome	O
system	O
involved	O
in	O
SAC	O
signaling	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
a	O
Cul3	B-Protein
-	O
based	O
E3	O
ubiquitin	B-Protein
-	O
ligase	O
is	O
required	O
to	O
maintain	O
SAC	O
signaling	O
in	O
human	O
cells	O
.	O

Inactivation	O
of	O
the	O
Cul3	B-Protein
/	O
KLHL9	B-Protein
/	O
KLHL13	B-Protein
ligase	O
leads	O
to	O
premature	O
degradation	O
of	O
Cyclin	O
B	O
and	O
exit	O
from	O
the	O
mitotic	O
state	O
in	O
the	O
presence	O
of	O
microtubule	O
poisons	O
.	O

We	O
discuss	O
possible	O
mechanisms	O
how	O
Cul3	B-Protein
may	O
be	O
required	O
to	O
maintain	O
SAC	O
activity	O
by	O
ubiquitination	O
of	O
the	O
chromosomal	O
passenger	O
protein	O
Aurora	B-Protein
B	I-Protein
.	O

Deubiquitination	O
of	O
FANCD2	B-Protein
is	O
required	O
for	O
DNA	O
crosslink	O
repair	O
.	O

Monoubiquitination	O
of	O
FANCD2	B-Protein
and	O
PCNA	B-Protein
promotes	O
DNA	O
repair	O
.	O

It	O
causes	O
chromatin	O
accumulation	O
of	O
FANCD2	B-Protein
and	O
facilitates	O
PCNA	B-Protein
'	O
s	O
recruitment	O
of	O
translesion	O
polymerases	O
to	O
stalled	O
replication	O
.	O

USP1	B-Protein
,	O
a	O
protease	O
that	O
removes	O
monoubiquitin	B-Protein
from	O
FANCD2	B-Protein
and	O
PCNA	B-Protein
,	O
was	O
thought	O
to	O
reverse	O
the	O
DNA	O
damage	O
response	O
of	O
these	O
substrates	O
.	O

We	O
disrupted	O
USP1	B-Protein
in	O
chicken	O
cells	O
to	O
dissect	O
its	O
role	O
in	O
a	O
stable	O
genetic	O
system	O
.	O

USP1	B-Protein
ablation	O
increases	O
FANCD2	B-Protein
and	O
PCNA	B-Protein
monoubiquitination	O
but	O
unexpectedly	O
results	O
in	O
DNA	O
crosslinker	O
sensitivity	O
.	O

This	O
defective	O
DNA	O
repair	O
is	O
associated	O
with	O
constitutively	O
chromatin	O
-	O
bound	O
,	O
monoubiquitinated	O
FANCD2	B-Protein
.	O

In	O
contrast	O
,	O
persistent	O
PCNA	B-Protein
monoubiquitination	O
has	O
negligible	O
impact	O
on	O
DNA	O
repair	O
or	O
mutagenesis	O
.	O

USP1	B-Protein
was	O
previously	O
shown	O
to	O
autocleave	O
after	O
DNA	O
damage	O
.	O

In	O
DT40	O
,	O
USP1	B-Protein
autocleavage	O
is	O
not	O
stimulated	O
by	O
DNA	O
damage	O
,	O
and	O
expressing	O
a	O
noncleavable	O
mutant	O
in	O
the	O
USP1	B-Protein
knockout	O
strain	O
partially	O
rescues	O
crosslinker	O
sensitivity	O
.	O

We	O
conclude	O
that	O
efficient	O
DNA	O
crosslink	O
repair	O
requires	O
FANCD2	B-Protein
deubiquitination	O
,	O
whereas	O
FANCD2	B-Protein
monoubiquitination	O
is	O
not	O
dependent	O
on	O
USP1	B-Protein
autocleavage	O
.	O

Structural	O
organization	O
of	O
the	O
anaphase	O
-	O
promoting	O
complex	O
bound	O
to	O
the	O
mitotic	O
activator	O
Slp1	B-Protein
.	O

The	O
anaphase	O
-	O
promoting	O
complex	O
/	O
cyclosome	O
(	O
APC	O
/	O
C	O
)	O
is	O
a	O
conserved	O
multisubunit	O
E3	O
ubiquitin	B-Protein
(	O
Ub	B-Protein
)	O
ligase	O
required	O
to	O
signal	O
the	O
degradation	O
of	O
key	O
cell	O
-	O
cycle	O
regulators	O
.	O

Using	O
single	O
particle	O
cryo	O
-	O
electron	O
microscopy	O
(	O
cryo	O
-	O
EM	O
)	O
,	O
we	O
have	O
determined	O
a	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
structure	O
of	O
the	O
core	O
APC	O
/	O
C	O
from	O
Schizosaccharomyces	O
pombe	O
bound	O
to	O
the	O
APC	O
/	O
C	O
activator	O
Slp1	B-Protein
/	O
Cdc20	B-Protein
.	O

At	O
the	O
27	O
A	O
resolution	O
of	O
our	O
density	O
map	O
,	O
the	O
APC	O
/	O
C	O
is	O
a	O
triangular	O
-	O
shaped	O
structure	O
,	O
approximately	O
19x17x15	O
nm	O
in	O
size	O
,	O
with	O
a	O
deep	O
internal	O
cavity	O
and	O
a	O
prominent	O
horn	O
-	O
like	O
protrusion	O
emanating	O
from	O
a	O
lip	O
of	O
the	O
cavity	O
.	O

Using	O
antibody	O
labeling	O
and	O
mutant	O
analysis	O
,	O
we	O
have	O
localized	O
12	O
of	O
13	O
core	O
APC	O
/	O
C	O
components	O
,	O
as	O
well	O
as	O
the	O
position	O
of	O
the	O
activator	O
Slp1	B-Protein
,	O
enabling	O
us	O
to	O
propose	O
a	O
structural	O
model	O
of	O
APC	O
/	O
C	O
organization	O
.	O

Comparison	O
of	O
the	O
APC	O
/	O
C	O
with	O
another	O
multiprotein	O
E3	O
ligase	O
,	O
the	O
SCF	O
complex	O
,	O
uncovers	O
remarkable	O
structural	O
similarities	O
.	O

Effect	O
of	O
glucagon	B-Protein
and	O
phorbol	O
myristate	O
acetate	O
on	O
oxidative	O
demethylation	O
and	O
lipid	O
peroxidation	O
in	O
isolated	O
hepatocytes	O
.	O

Oxidative	O
demethylation	O
of	O
aminopyrine	O
and	O
peroxidation	O
of	O
endogenous	O
lipids	O
induced	O
by	O
cumene	O
hydroperoxide	O
were	O
studied	O
in	O
hepatocytes	O
isolated	O
from	O
fed	O
male	O
rats	O
.	O

Glucagon	B-Protein
and	O
phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
inhibited	O
both	O
processes	O
in	O
the	O
concentration	O
-	O
dependent	O
manner	O
.	O

Pretreatment	O
of	O
hepatocytes	O
with	O
1	O
microM	O
glucagon	B-Protein
decreased	O
oxidative	O
demethylation	O
by	O
75	O
%	O
and	O
had	O
a	O
much	O
smaller	O
effect	O
on	O
lipid	O
peroxidation	O
.	O

Preincubation	O
with	O
1	O
microM	O
PMA	O
inhibited	O
both	O
processes	O
by	O
25	O
-	O
30	O
%	O
.	O

Phosphorylation	O
of	O
three	O
isoforms	O
of	O
cytochrome	O
P	O
-	O
450	O
was	O
observed	O
in	O
microsomes	O
isolated	O
from	O
hepatocytes	O
incubated	O
in	O
the	O
presence	O
of	O
[	O
32P	O
]	O
orthophosphate	O
.	O

After	O
incubation	O
with	O
PMA	O
the	O
phosphorylation	O
of	O
all	O
these	O
proteins	O
was	O
increased	O
by	O
60	O
-	O
100	O
%	O
,	O
whereas	O
glucagon	B-Protein
increased	O
the	O
phosphorylation	O
of	O
only	O
one	O
isoform	O
.	O

Consequences	O
of	O
the	O
phosphorylation	O
of	O
various	O
isoforms	O
of	O
cytochrome	O
P	O
-	O
450	O
for	O
metabolic	O
functions	O
of	O
the	O
monooxygenase	O
system	O
are	O
discussed	O
.	O

Catecholamine	O
receptor	O
agonists	O
:	O
effects	O
on	O
motor	O
activity	O
and	O
rate	O
of	O
tyrosine	O
hydroxylation	O
in	O
mouse	O
brain	O
.	O

Motor	O
activity	O
during	O
the	O
first	O
5	O
min	O
in	O
a	O
motility	O
meter	O
was	O
measured	O
in	O
mice	O
given	O
0	O
.	O
025	O
-	O
3	O
.	O
2	O
mg	O
/	O
kg	O
of	O
the	O
dopamine	O
and	O
noradrenaline	O
receptor	O
agonists	O
apomorphine	O
and	O
clonidine	O
,	O
respectively	O
.	O

The	O
accumulation	O
of	O
Dopa	O
,	O
as	O
induced	O
by	O
the	O
inhibitor	O
of	O
aromatic	B-Protein
amino	I-Protein
acid	I-Protein
decarboxylase	I-Protein
,	O
NSD	O
1015	O
,	O
was	O
measured	O
in	O
parallel	O
in	O
two	O
dopamine	O
-	O
rich	O
regions	O
,	O
i	O
.	O
e	O
.	O
the	O
limbic	O
system	O
and	O
the	O
corpus	O
striatum	O
,	O
and	O
in	O
two	O
noradrenaline	O
-	O
rich	O
regions	O
,	O
i	O
.	O
e	O
.	O
the	O
neocortex	O
and	O
the	O
lower	O
brain	O
stem	O
.	O

Low	O
doses	O
(	O
0	O
.	O
025	O
-	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
of	O
apomorphine	O
reduced	O
locomotion	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
while	O
the	O
reduction	O
after	O
higher	O
doses	O
was	O
less	O
pronounced	O
,	O
indicating	O
a	O
biphasic	O
dose	O
-	O
response	O
relationship	O
.	O

Clonidine	O
caused	O
a	O
dose	O
-	O
dependent	O
locomotor	O
depression	O
.	O

When	O
low	O
doses	O
of	O
the	O
two	O
drugs	O
were	O
combined	O
,	O
the	O
inhibitory	O
effect	O
observed	O
was	O
at	O
least	O
additive	O
.	O

When	O
clonidine	O
was	O
combined	O
with	O
a	O
high	O
dose	O
of	O
apomorphine	O
(	O
0	O
.	O
8	O
mg	O
/	O
kg	O
)	O
,	O
it	O
caused	O
a	O
significant	O
inhibition	O
of	O
locomotion	O
in	O
a	O
dose	O
of	O
0	O
.	O
1	O
-	O
0	O
.	O
2	O
mg	O
/	O
kg	O
,	O
but	O
not	O
after	O
0	O
.	O
8	O
mg	O
/	O
kg	O
,	O
indicating	O
a	O
biphasic	O
dose	O
-	O
response	O
relationship	O
.	O

Either	O
drug	O
given	O
alone	O
reduced	O
Dopa	O
accumulation	O
after	O
inhibition	O
of	O
its	O
decarboxylation	O
,	O
in	O
all	O
regions	O
,	O
but	O
smaller	O
doses	O
of	O
apomorphine	O
had	O
a	O
clearcut	O
effect	O
only	O
in	O
the	O
dopamine	O
-	O
rich	O
regions	O
,	O
whereas	O
the	O
lowest	O
dose	O
of	O
clonidine	O
investigated	O
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
)	O
had	O
an	O
inhibitory	O
effect	O
on	O
Dopa	O
formation	O
only	O
in	O
the	O
neocortex	O
.	O

The	O
relationship	O
between	O
the	O
dose	O
of	O
apomorphine	O
and	O
Dopa	O
formation	O
in	O
the	O
neocortex	O
appeared	O
biphasic	O
,	O
the	O
highest	O
dose	O
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
having	O
no	O
significant	O
effect	O
.	O

Further	O
,	O
apomorphine	O
in	O
this	O
dose	O
accelerated	O
the	O
disappearance	O
of	O
noradrenaline	O
after	O
inhibition	O
of	O
synthesis	O
by	O
alpha	O
-	O
methyltyrosine	O
.	O

Reversal	O
of	O
reserpine	O
-	O
induced	O
suppression	O
of	O
motor	O
activity	O
was	O
taken	O
to	O
indicate	O
postsynaptic	O
receptor	O
activation	O
.	O

The	O
threshold	O
dose	O
of	O
apomorphine	O
causing	O
reversal	O
was	O
0	O
.	O
2	O
mg	O
/	O
kg	O
.	O

The	O
inhibitory	O
effect	O
of	O
e	O
.	O
g	O
.	O
0	O
.	O
05	O
mg	O
/	O
kg	O
on	O
locomotion	O
and	O
on	O
Dopa	O
formation	O
suggests	O
a	O
preferential	O
activation	O
of	O
inhibitory	O
autoregulatory	O
dopamine	O
receptors	O
by	O
low	O
doses	O
of	O
this	O
drug	O
.	O

A	O
similar	O
trend	O
was	O
observed	O
for	O
clonidine	O
.	O

The	O
basal	O
importance	O
of	O
dopamine	O
neurones	O
for	O
the	O
locomotor	O
function	O
studied	O
in	O
the	O
present	O
paper	O
is	O
illustrated	O
by	O
the	O
marked	O
inhibition	O
by	O
low	O
doses	O
of	O
apomorphine	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
observations	O
with	O
clonidine	O
suggest	O
a	O
somewhat	O
less	O
striking	O
and	O
perhaps	O
less	O
direct	O
influence	O
of	O
noradrenaline	O
neurones	O
on	O
motor	O
activity	O
.	O

Mice	O
with	O
a	O
low	O
motor	O
activity	O
,	O
as	O
induced	O
e	O
.	O
g	O
.	O
by	O
reserpine	O
or	O
,	O
in	O
another	O
experiment	O
,	O
mice	O
adapted	O
to	O
the	O
motility	O
meter	O
,	O
displayed	O
an	O
increased	O
motor	O
activity	O
after	O
higher	O
doses	O
of	O
apomorphine	O
(	O
from	O
0	O
.	O
2	O
and	O
2	O
mg	O
/	O
kg	O
,	O
respectively	O
)	O
,	O
whereas	O
all	O
doses	O
depressed	O
the	O
initial	O
high	O
motor	O
activity	O
.	O

Probably	O
,	O
high	O
motor	O
activity	O
requires	O
active	O
dopamine	O
neurones	O
,	O
making	O
this	O
behaviour	O
more	O
susceptible	O
to	O
interference	O
with	O
autoregulatory	O
mechanisms	O
,	O
whereas	O
a	O
low	O
basal	O
activity	O
may	O
be	O
more	O
affected	O
by	O
activation	O
of	O
postsynaptic	O
dopamine	O
receptors	O
.	O

Clinical	O
and	O
molecular	O
responses	O
in	O
lung	O
cancer	O
patients	O
receiving	O
Romidepsin	O
.	O

PURPOSE	O
:	O
Our	O
preclinical	O
experiments	O
indicated	O
that	O
Romidepsin	O
(	O
Depsipeptide	O
FK228	O
;	O
DP	O
)	O
mediates	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
cultured	O
lung	O
cancer	O
cells	O
.	O

A	O
phase	O
II	O
trial	O
was	O
done	O
to	O
examine	O
clinical	O
and	O
molecular	O
responses	O
mediated	O
by	O
this	O
histone	B-Protein
deacetylase	O
inhibitor	O
in	O
lung	O
cancer	O
patients	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Nineteen	O
patients	O
with	O
neoplasms	O
refractory	O
to	O
standard	O
therapy	O
received	O
4	O
-	O
h	O
DP	O
infusions	O
(	O
17	O
.	O
8	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
and	O
7	O
of	O
a	O
21	O
-	O
day	O
cycle	O
.	O

Each	O
full	O
course	O
of	O
therapy	O
consisted	O
of	O
two	O
identical	O
21	O
-	O
day	O
cycles	O
.	O

Plasma	O
DP	O
levels	O
were	O
evaluated	O
by	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
techniques	O
.	O

A	O
variety	O
of	O
molecular	O
end	O
points	O
were	O
assessed	O
in	O
tumor	O
biopsies	O
via	O
immunohistochemistry	O
techniques	O
.	O

Long	O
oligo	O
arrays	O
were	O
used	O
to	O
examine	O
gene	O
expression	O
profiles	O
in	O
laser	O
-	O
captured	O
tumor	O
cells	O
before	O
and	O
after	O
DP	O
exposure	O
,	O
relative	O
to	O
lung	O
cancer	O
cells	O
and	O
adjacent	O
normal	O
bronchial	O
epithelia	O
from	O
patients	O
undergoing	O
pulmonary	O
resections	O
.	O

RESULTS	O
:	O
Nineteen	O
patients	O
were	O
evaluable	O
for	O
toxicity	O
assessment	O
;	O
18	O
were	O
evaluable	O
for	O
treatment	O
response	O
.	O

Myelosuppression	O
was	O
dose	O
limiting	O
in	O
one	O
individual	O
.	O

No	O
significant	O
cardiac	O
toxicities	O
were	O
observed	O
.	O

Maximum	O
steady	O
-	O
state	O
plasma	O
DP	O
concentrations	O
ranged	O
from	O
384	O
to	O
1	O
,	O
114	O
ng	O
/	O
mL	O
.	O

No	O
objective	O
responses	O
were	O
observed	O
.	O

Transient	O
stabilization	O
of	O
disease	O
was	O
noted	O
in	O
nine	O
patients	O
.	O

DP	O
enhanced	O
acetylation	O
of	O
histone	B-Protein
H4	I-Protein
,	O
increased	O
p21	B-Protein
expression	O
in	O
lung	O
cancer	O
cells	O
,	O
and	O
seemed	O
to	O
shift	O
global	O
gene	O
expression	O
profiles	O
in	O
these	O
cells	O
toward	O
those	O
detected	O
in	O
normal	O
bronchial	O
epithelia	O
.	O

CONCLUSION	O
:	O
Although	O
exhibiting	O
minimal	O
clinical	O
efficacy	O
at	O
this	O
dose	O
and	O
schedule	O
,	O
DP	O
mediates	O
biological	O
effects	O
that	O
may	O
warrant	O
further	O
evaluation	O
of	O
this	O
histone	B-Protein
deacetylase	O
inhibitor	O
in	O
combination	O
with	O
novel	O
-	O
targeted	O
agents	O
in	O
lung	O
cancer	O
patients	O
.	O

Glucose	O
deprivation	O
stimulates	O
O	O
-	O
GlcNAc	O
modification	O
of	O
proteins	O
through	O
up	O
-	O
regulation	O
of	O
O	B-Protein
-	I-Protein
linked	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
.	O

O	O
-	O
Linked	O
N	O
-	O
acetylglucosamine	O
(	O
O	O
-	O
GlcNAc	O
)	O
is	O
a	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
that	O
functions	O
as	O
a	O
nutrient	O
sensing	O
mechanism	O
.	O

Here	O
we	O
report	O
on	O
regulation	O
of	O
O	O
-	O
GlcNAcylation	O
over	O
a	O
broad	O
range	O
of	O
glucose	O
concentrations	O
.	O

We	O
have	O
discovered	O
a	O
significant	O
induction	O
of	O
O	O
-	O
GlcNAc	O
modification	O
of	O
a	O
limited	O
number	O
of	O
proteins	O
under	O
conditions	O
of	O
glucose	O
deprivation	O
.	O

Beginning	O
12	O
h	O
after	O
treatment	O
,	O
glucose	O
-	O
deprived	O
human	O
hepatocellular	O
carcinoma	O
(	O
HepG2	O
)	O
cells	O
demonstrate	O
a	O
7	O
.	O
8	O
-	O
fold	O
increase	O
in	O
total	O
O	O
-	O
GlcNAc	O
modification	O
compared	O
with	O
cells	O
cultured	O
in	O
normal	O
glucose	O
(	O
5	O
mm	O
;	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

Some	O
of	O
the	O
targets	O
of	O
glucose	O
deprivation	O
-	O
induced	O
O	O
-	O
GlcNAcylation	O
are	O
distinct	O
from	O
those	O
modified	O
in	O
response	O
to	O
high	O
glucose	O
(	O
20	O
mm	O
)	O
or	O
glucosamine	O
(	O
10	O
mm	O
)	O
treatment	O
,	O
suggesting	O
differential	O
targeting	O
with	O
glucose	O
deprivation	O
and	O
glucose	O
excess	O
.	O

O	O
-	O
GlcNAcylation	O
of	O
glycogen	O
synthase	O
is	O
significantly	O
increased	O
with	O
glucose	O
deprivation	O
,	O
and	O
this	O
O	O
-	O
GlcNAc	O
increase	O
contributes	O
to	O
a	O
60	O
%	O
decrease	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
in	O
glycogen	O
synthase	O
activity	O
.	O

Increased	O
O	O
-	O
GlcNAc	O
modification	O
is	O
not	O
mediated	O
by	O
increased	O
UDP	O
-	O
GlcNAc	O
,	O
the	O
rate	O
-	O
limiting	O
substrate	O
for	O
O	O
-	O
GlcNAcylation	O
.	O

Rather	O
,	O
the	O
mRNA	O
for	O
nucleocytoplasmic	O
O	B-Protein
-	I-Protein
linked	I-Protein
N	I-Protein
-	I-Protein
acetylglucosaminyltransferase	I-Protein
(	O
OGT	B-Protein
)	O
increases	O
3	O
.	O
4	O
-	O
fold	O
within	O
6	O
h	O
of	O
glucose	O
deprivation	O
(	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

Within	O
12	O
h	O
,	O
OGT	B-Protein
protein	O
increases	O
1	O
.	O
7	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
compared	O
with	O
normal	O
glucose	O
-	O
treated	O
cells	O
.	O

In	O
addition	O
,	O
12	O
-	O
h	O
glucose	O
deprivation	O
leads	O
to	O
a	O
49	O
%	O
decrease	O
in	O
O	B-Protein
-	I-Protein
GlcNAcase	I-Protein
protein	O
levels	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

We	O
conclude	O
that	O
increased	O
O	O
-	O
GlcNAc	O
modification	O
stimulated	O
by	O
glucose	O
deprivation	O
results	O
from	O
increased	O
OGT	O
and	O
decreased	O
O	B-Protein
-	I-Protein
GlcNAcase	I-Protein
levels	O
and	O
that	O
these	O
changes	O
affect	O
cell	O
metabolism	O
,	O
thus	O
inactivating	O
glycogen	O
synthase	O
.	O

Interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
induces	O
the	O
Lys63	O
-	O
linked	O
polyubiquitination	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
kinase	I-Protein
1	I-Protein
to	O
facilitate	O
NEMO	B-Protein
binding	O
and	O
the	O
activation	O
of	O
IkappaBalpha	O
kinase	O
.	O

Interleukin	O
1	O
(	O
IL	O
-	O
1	O
)	O
has	O
been	O
reported	O
to	O
stimulate	O
the	O
polyubiquitination	O
and	O
disappearance	O
of	O
IL	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
kinase	I-Protein
1	I-Protein
(	O
IRAK1	B-Protein
)	O
within	O
minutes	O
.	O

It	O
has	O
been	O
thought	O
that	O
the	O
polyubiquitin	B-Protein
chains	O
attached	O
to	O
IRAK1	B-Protein
are	O
linked	O
via	O
Lys48	O
of	O
ubiquitin	B-Protein
,	O
leading	O
to	O
its	O
destruction	O
by	O
the	O
proteasome	O
and	O
explaining	O
the	O
rapid	O
IL	O
-	O
1	O
-	O
induced	O
disappearance	O
of	O
IRAK1	B-Protein
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
IL	O
-	O
1	O
stimulates	O
the	O
formation	O
of	O
K63	O
-	O
pUb	O
-	O
IRAK1	B-Protein
and	O
not	O
K48	O
-	O
pUb	O
-	O
IRAK1	B-Protein
and	O
that	O
the	O
IL	O
-	O
1	O
-	O
induced	O
disappearance	O
of	O
IRAK1	B-Protein
is	O
not	O
blocked	O
by	O
inhibition	O
of	O
the	O
proteasome	O
.	O

We	O
also	O
show	O
that	O
IL	O
-	O
1	O
triggers	O
the	O
interaction	O
of	O
K63	O
-	O
pUb	O
-	O
IRAK1	B-Protein
with	O
NEMO	B-Protein
,	O
a	O
regulatory	O
subunit	O
of	O
the	O
IkappaBalpha	O
kinase	O
(	O
IKK	O
)	O
complex	O
,	O
but	O
not	O
with	O
the	O
NEMO	B-Protein
[	O
D311N	O
]	O
mutant	O
that	O
cannot	O
bind	O
K63	O
-	O
pUb	O
chains	O
.	O

Moreover	O
,	O
unlike	O
wild	O
-	O
type	O
NEMO	B-Protein
,	O
the	O
NEMO	B-Protein
[	O
D311N	O
]	O
mutant	O
was	O
unable	O
to	O
restore	O
IL	O
-	O
1	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
transcription	O
to	O
NEMO	B-Protein
-	O
deficient	O
cells	O
.	O

Our	O
data	O
suggest	O
a	O
model	O
in	O
which	O
the	O
recruitment	O
of	O
the	O
NEMO	B-Protein
-	O
IKK	O
complex	O
to	O
K63	O
-	O
pUb	O
-	O
IRAK1	B-Protein
and	O
the	O
recruitment	O
of	O
the	O
TAK1	B-Protein
complex	O
to	O
TRAF6	B-Protein
facilitate	O
the	O
TAK1	B-Protein
-	O
catalyzed	O
activation	O
of	O
IKK	O
by	O
the	O
TRAF6	B-Protein
-	O
IRAK1	B-Protein
complex	O
.	O

Inhibition	O
of	O
p97	B-Protein
-	O
dependent	O
protein	O
degradation	O
by	O
Eeyarestatin	O
I	O
.	O

Elimination	O
of	O
misfolded	O
proteins	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
by	O
ER	O
-	O
associated	O
degradation	O
involves	O
substrate	O
retrotranslocation	O
from	O
the	O
ER	O
lumen	O
into	O
the	O
cytosol	O
for	O
degradation	O
by	O
the	O
proteasome	O
.	O

For	O
many	O
substrates	O
,	O
retrotranslocation	O
requires	O
the	O
action	O
of	O
ubiquitinating	O
enzymes	O
,	O
which	O
polyubiquitinate	O
substrates	O
emerging	O
from	O
the	O
ER	O
lumen	O
,	O
and	O
of	O
the	O
p97	B-Protein
-	O
Ufd1	B-Protein
-	O
Npl4	B-Protein
ATPase	O
complex	O
,	O
which	O
hydrolyzes	O
ATP	O
to	O
dislocate	O
polyubiquitinated	O
substrates	O
into	O
the	O
cytosol	O
.	O

Polypeptides	O
extracted	O
by	O
p97	B-Protein
are	O
eventually	O
transferred	O
to	O
the	O
proteasome	O
for	O
destruction	O
.	O

In	O
mammalian	O
cells	O
,	O
ERAD	O
can	O
be	O
blocked	O
by	O
a	O
chemical	O
inhibitor	O
termed	O
Eeyarestatin	O
I	O
,	O
but	O
the	O
mechanism	O
of	O
EerI	O
action	O
is	O
unclear	O
.	O

Here	O
we	O
report	O
that	O
EerI	O
can	O
associate	O
with	O
a	O
p97	B-Protein
complex	O
to	O
inhibit	O
ERAD	O
.	O

The	O
interaction	O
of	O
EerI	O
with	O
the	O
p97	B-Protein
complex	O
appears	O
to	O
negatively	O
influence	O
a	O
deubiquitinating	O
process	O
that	O
is	O
mediated	O
by	O
p97	B-Protein
-	O
associated	O
deubiquitinating	O
enzymes	O
.	O

We	O
further	O
show	O
that	O
ataxin	B-Protein
-	I-Protein
3	I-Protein
,	O
a	O
p97	B-Protein
-	O
associated	O
deubiquitinating	O
enzyme	O
previously	O
implicated	O
in	O
ER	O
-	O
associated	O
degradation	O
,	O
is	O
among	O
those	O
affected	O
.	O

Interestingly	O
,	O
p97	B-Protein
-	O
associated	O
deubiquitination	O
is	O
also	O
involved	O
in	O
degradation	O
of	O
a	O
soluble	O
substrate	O
.	O

Our	O
analyses	O
establish	O
a	O
role	O
for	O
a	O
novel	O
deubiquitinating	O
process	O
in	O
proteasome	O
-	O
dependent	O
protein	O
turnover	O
.	O

Disrupted	O
membrane	O
homeostasis	O
and	O
accumulation	O
of	O
ubiquitinated	O
proteins	O
in	O
a	O
mouse	O
model	O
of	O
infantile	O
neuroaxonal	O
dystrophy	O
caused	O
by	O
PLA2G6	B-Protein
mutations	O
.	O

Mutations	O
in	O
the	O
PLA2G6	B-Protein
gene	O
,	O
which	O
encodes	O
group	O
VIA	O
calcium	B-Protein
-	I-Protein
independent	I-Protein
phospholipase	I-Protein
A2	I-Protein
(	O
iPLA	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
beta	I-Protein
)	O
,	O
were	O
recently	O
identified	O
in	O
patients	O
with	O
infantile	O
neuroaxonal	O
dystrophy	O
(	O
INAD	O
)	O
and	O
neurodegeneration	O
with	O
brain	O
iron	O
accumulation	O
.	O

A	O
pathological	O
hallmark	O
of	O
these	O
childhood	O
neurodegenerative	O
diseases	O
is	O
the	O
presence	O
of	O
distinctive	O
spheroids	O
in	O
distal	O
axons	O
that	O
contain	O
accumulated	O
membranes	O
.	O

We	O
used	O
iPLA	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
beta	I-Protein
-	O
KO	O
mice	O
generated	O
by	O
homologous	O
recombination	O
to	O
investigate	O
neurodegenerative	O
consequences	O
of	O
PLA2G6	B-Protein
mutations	O
.	O

iPLA	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
beta	I-Protein
-	O
KO	O
mice	O
developed	O
age	O
-	O
dependent	O
neurological	O
impairment	O
that	O
was	O
evident	O
in	O
rotarod	O
,	O
balance	O
,	O
and	O
climbing	O
tests	O
by	O
13	O
months	O
of	O
age	O
.	O

The	O
primary	O
abnormality	O
underlying	O
this	O
neurological	O
impairment	O
was	O
the	O
formation	O
of	O
spheroids	O
containing	O
tubulovesicular	O
membranes	O
remarkably	O
similar	O
to	O
human	O
INAD	O
.	O

Spheroids	O
were	O
strongly	O
labeled	O
with	O
anti	O
-	O
ubiquitin	B-Protein
antibodies	O
.	O

Accumulation	O
of	O
ubiquitinated	O
protein	O
in	O
spheroids	O
was	O
evident	O
in	O
some	O
brain	O
regions	O
as	O
early	O
as	O
4	O
months	O
of	O
age	O
,	O
and	O
the	O
onset	O
of	O
motor	O
impairment	O
correlated	O
with	O
a	O
dramatic	O
increase	O
in	O
ubiquitin	B-Protein
-	O
positive	O
spheroids	O
throughout	O
the	O
neuropil	O
in	O
nearly	O
all	O
brain	O
regions	O
.	O

Furthermore	O
accumulating	O
ubiquitinated	O
proteins	O
were	O
observed	O
primarily	O
in	O
insoluble	O
fractions	O
of	O
brain	O
tissue	O
,	O
implicating	O
protein	O
aggregation	O
in	O
this	O
pathogenic	O
process	O
.	O

These	O
results	O
indicate	O
that	O
loss	O
of	O
iPLA	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
beta	I-Protein
causes	O
age	O
-	O
dependent	O
impairment	O
of	O
axonal	O
membrane	O
homeostasis	O
and	O
protein	O
degradation	O
pathways	O
,	O
leading	O
to	O
age	O
-	O
dependent	O
neurological	O
impairment	O
.	O

iPLA	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
beta	I-Protein
-	O
KO	O
mice	O
will	O
be	O
useful	O
for	O
further	O
studies	O
of	O
pathogenesis	O
and	O
experimental	O
interventions	O
in	O
INAD	O
and	O
neurodegeneration	O
with	O
brain	O
iron	O
accumulation	O
.	O

Chaperone	O
-	O
dependent	O
stabilization	O
and	O
degradation	O
of	O
p53	B-Protein
mutants	O
.	O

p53	B-Protein
missense	O
mutant	O
proteins	O
commonly	O
show	O
increased	O
stability	O
compared	O
to	O
wild	O
-	O
type	O
p53	B-Protein
,	O
which	O
is	O
thought	O
to	O
depend	O
largely	O
on	O
the	O
inability	O
of	O
mutant	O
p53	B-Protein
to	O
induce	O
the	O
ubiquitin	B-Protein
ligase	O
MDM2	B-Protein
.	O

However	O
,	O
recent	O
work	O
using	O
mouse	O
models	O
has	O
shown	O
that	O
the	O
accumulation	O
of	O
mutant	O
p53	B-Protein
occurs	O
only	O
in	O
tumour	O
cells	O
,	O
indicating	O
that	O
stabilization	O
requires	O
additional	O
factors	O
.	O

To	O
clarify	O
the	O
stabilization	O
of	O
p53	B-Protein
mutants	O
in	O
tumours	O
,	O
we	O
analysed	O
factors	O
that	O
affect	O
their	O
folding	O
and	O
degradation	O
.	O

Although	O
all	O
missense	O
mutants	O
that	O
we	O
studied	O
are	O
more	O
stable	O
than	O
wild	O
-	O
type	O
p53	B-Protein
,	O
the	O
levels	O
correlate	O
with	O
individual	O
structural	O
characteristics	O
,	O
which	O
may	O
be	O
reflected	O
in	O
different	O
gain	O
-	O
of	O
-	O
function	O
properties	O
.	O

In	O
the	O
absence	O
of	O
Hsp90	O
activity	O
,	O
the	O
less	O
stable	O
unfolded	O
p53	B-Protein
mutants	O
preferentially	O
associate	O
in	O
a	O
complex	O
with	O
Hsp70	O
and	O
CHIP	B-Protein
(	O
carboxy	B-Protein
terminus	I-Protein
of	I-Protein
Hsp70	I-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
)	O
,	O
and	O
we	O
show	O
that	O
CHIP	B-Protein
is	O
responsible	O
for	O
ubiquitination	O
and	O
degradation	O
of	O
these	O
mutants	O
.	O

The	O
demonstration	O
of	O
a	O
complex	O
interplay	O
between	O
Hsp90	O
,	O
Hsp70	O
and	O
CHIP	B-Protein
that	O
regulate	O
the	O
stability	O
of	O
different	O
p53	B-Protein
mutant	O
proteins	O
improves	O
our	O
understanding	O
of	O
the	O
pro	O
-	O
tumorigenic	O
effects	O
of	O
increased	O
Hsp90	O
activity	O
during	O
multi	O
-	O
stage	O
carcinogenesis	O
.	O

Understanding	O
the	O
roles	O
of	O
Hsp90	O
,	O
Hsp70	O
and	O
CHIP	B-Protein
in	O
cancers	O
may	O
also	O
provide	O
an	O
important	O
avenue	O
through	O
which	O
to	O
target	O
p53	B-Protein
to	O
enhance	O
treatment	O
of	O
human	O
cancers	O
.	O

N	O
-	O
glycosylation	O
at	O
Asn	O
residues	O
554	O
and	O
566	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
affects	O
cell	O
cycle	O
progression	O
through	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
signaling	O
pathway	O
.	O

E	B-Protein
-	I-Protein
cadherin	I-Protein
,	O
which	O
has	O
a	O
widely	O
acknowledged	O
role	O
in	O
mediating	O
calcium	O
-	O
dependent	O
cell	O
-	O
cell	O
adhesion	O
between	O
epithelial	O
cells	O
,	O
also	O
functions	O
as	O
a	O
tumor	O
suppressor	O
.	O

The	O
ectodomain	O
of	O
human	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
contains	O
four	O
potential	O
N	O
-	O
glycosylation	O
sites	O
at	O
Asn	O
residues	O
554	O
,	O
566	O
,	O
618	O
,	O
and	O
633	O
.	O

We	O
investigated	O
the	O
role	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
N	O
-	O
glycosylation	O
in	O
cell	O
cycle	O
progression	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

We	O
showed	O
previously	O
that	O
all	O
four	O
potential	O
N	O
-	O
glycosylation	O
sites	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
were	O
N	O
-	O
glycosylated	O
in	O
human	O
breast	O
carcinoma	O
MDA	O
-	O
MB	O
-	O
435	O
cells	O
.	O

Removal	O
of	O
N	O
-	O
glycan	O
at	O
Asn633	O
dramatically	O
affected	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
stability	O
.	O

In	O
this	O
study	O
we	O
showed	O
that	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
mutant	O
missing	O
N	O
-	O
glycans	O
at	O
Asn554	O
,	O
Asn566	O
and	O
Asn618	O
failed	O
to	O
induce	O
cell	O
cycle	O
arrest	O
in	O
G1	O
phase	O
and	O
to	O
suppress	O
cell	O
proliferation	O
in	O
comparison	O
with	O
wild	O
-	O
type	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
.	O

Moreover	O
,	O
N	O
-	O
glycans	O
at	O
Asn554	O
and	O
Asn566	O
,	O
but	O
not	O
at	O
Asn618	O
,	O
seemed	O
to	O
be	O
indispensable	O
for	O
E	O
-	O
cadherin	O
-	O
mediated	O
suppression	O
of	O
cell	O
cycle	O
progression	O
.	O

Removal	O
of	O
N	O
-	O
glycans	O
at	O
either	O
Asn554	O
or	O
Asn566	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
was	O
accompanied	O
with	O
the	O
activation	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
signaling	O
pathway	O
.	O

After	O
treatment	O
with	O
PD98059	O
,	O
an	O
inhibitor	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
signaling	O
pathway	O
,	O
wild	O
-	O
type	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
transfected	O
MDA	O
-	O
MB	O
-	O
435	O
and	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
N	O
-	O
glycosylation	O
-	O
deficient	O
mutant	O
transfected	O
MDA	O
-	O
MB	O
-	O
435	O
cells	O
had	O
equivalent	O
numbers	O
of	O
cells	O
in	O
G1	O
phase	O
.	O

These	O
findings	O
implied	O
that	O
N	O
-	O
glycosylation	O
might	O
be	O
crucial	O
for	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
-	O
mediated	O
suppression	O
of	O
cell	O
cycle	O
progression	O
.	O

[	O
Prothyomosin	B-Protein
alpha	I-Protein
interaction	O
with	O
KEAP1	B-Protein
doesn	O
'	O
t	O
lead	O
to	O
prothymosin	B-Protein
alpha	I-Protein
ubiquination	O
and	O
degradation	O
]	O

Prothymosin	B-Protein
alpha	I-Protein
(	O
ProTalpha	B-Protein
)	O
is	O
a	O
highly	O
conserved	O
protein	O
in	O
vertebrates	O
that	O
possesses	O
a	O
number	O
of	O
biological	O
functions	O
.	O

One	O
of	O
these	O
functions	O
of	O
ProTalpha	B-Protein
is	O
the	O
ability	O
to	O
enhance	O
antioxidant	O
defence	O
system	O
of	O
a	O
cell	O
via	O
its	O
interaction	O
with	O
Keap1	B-Protein
protein	O
.	O

Keap1	B-Protein
is	O
a	O
repressor	O
of	O
Nrf2	B-Protein
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
activation	O
of	O
genes	O
that	O
code	O
for	O
defensive	O
proteins	O
.	O

While	O
bound	O
to	O
Nrf2	B-Protein
,	O
Keap1	B-Protein
exports	O
Nrf2	B-Protein
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
and	O
,	O
being	O
adaptor	O
protein	O
for	O
ubiquitin	B-Protein
ligase	O
,	O
promotes	O
ubiquitination	O
of	O
Nrf2	B-Protein
and	O
its	O
subsequent	O
degradation	O
by	O
26S	O
proteasome	O
.	O

ProTalpha	B-Protein
and	O
Nrf2	B-Protein
compete	O
for	O
interaction	O
with	O
Keap1	B-Protein
,	O
therefore	O
ProTalpha	B-Protein
is	O
able	O
to	O
liberate	O
Nrf2	B-Protein
from	O
complex	O
with	O
Keap1	B-Protein
and	O
hence	O
contribute	O
to	O
Nrf2	B-Protein
-	O
dependent	O
transcription	O
.	O

Here	O
we	O
were	O
interested	O
in	O
elucidating	O
possible	O
consequences	O
for	O
ProTalpha	B-Protein
of	O
its	O
interaction	O
with	O
Keap1	B-Protein
.	O

We	O
have	O
shown	O
that	O
,	O
despite	O
ProTalpha	B-Protein
interaction	O
with	O
Keap1	B-Protein
,	O
ProTalpha	B-Protein
is	O
a	O
stable	O
protein	O
.	O

In	O
contrast	O
to	O
Nrf2	B-Protein
ProTalpha	B-Protein
was	O
not	O
subjected	O
to	O
Keap	O
-	O
dependent	O
ubiquitination	O
,	O
degradation	O
and	O
export	O
from	O
the	O
nucleus	O
.	O

Furthermore	O
,	O
ubiquitination	O
of	O
ProTalpha	B-Protein
was	O
undetectable	O
even	O
when	O
Keap1	B-Protein
and	O
ubiquitin	B-Protein
were	O
overexpressed	O
.	O

It	O
appears	O
that	O
ProTalpha	B-Protein
contribution	O
to	O
Nrf2	B-Protein
-	O
dependent	O
transcription	O
is	O
accomplished	O
via	O
the	O
increase	O
of	O
free	O
Nrf2	B-Protein
rather	O
then	O
the	O
increase	O
of	O
total	O
intracellular	O
amount	O
of	O
Nrf2	B-Protein
.	O

Complications	O
in	O
the	O
assignment	O
of	O
14	O
and	O
28	O
Da	O
mass	O
shift	O
detected	O
by	O
mass	O
spectrometry	O
as	O
in	O
vivo	O
methylation	O
from	O
endogenous	O
proteins	O
.	O

Identification	O
of	O
protein	O
methylation	O
sites	O
typically	O
starts	O
with	O
database	O
searching	O
of	O
MS	O
/	O
MS	O
spectra	O
of	O
proteolytic	O
digest	O
of	O
the	O
target	O
protein	O
by	O
allowing	O
addition	O
of	O
14	O
and	O
28	O
Da	O
in	O
the	O
selected	O
amino	O
acid	O
residues	O
that	O
can	O
be	O
methylated	O
.	O

Despite	O
the	O
progress	O
in	O
our	O
understanding	O
of	O
lysine	O
and	O
arginine	O
methylation	O
,	O
substrates	O
and	O
functions	O
of	O
protein	O
methylation	O
at	O
other	O
amino	O
acid	O
residues	O
remain	O
unknown	O
.	O

Here	O
we	O
report	O
the	O
analysis	O
of	O
protein	O
methylation	O
for	O
p53	B-Protein
,	O
SMC3	B-Protein
,	O
iNOS	B-Protein
,	O
and	O
MeCP2	B-Protein
.	O

We	O
found	O
that	O
a	O
large	O
number	O
of	O
peptides	O
can	O
be	O
modified	O
on	O
the	O
lysine	O
,	O
arginine	O
,	O
histidine	O
,	O
and	O
glutamic	O
acid	O
residues	O
with	O
a	O
mass	O
increase	O
of	O
14	O
or	O
28	O
Da	O
,	O
consistent	O
with	O
methylation	O
.	O

Surprisingly	O
,	O
a	O
majority	O
of	O
which	O
did	O
not	O
demonstrate	O
a	O
corresponding	O
mass	O
shift	O
when	O
cells	O
were	O
cultured	O
with	O
isotope	O
-	O
labeled	O
methionine	O
,	O
a	O
precursor	O
for	O
the	O
synthesis	O
of	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
methionine	O
(	O
SAM	O
)	O
,	O
which	O
is	O
the	O
most	O
commonly	O
used	O
methyl	O
donor	O
for	O
protein	O
methylation	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
of	O
either	O
exogenous	O
protein	O
methylation	O
during	O
sample	O
handling	O
and	O
processing	O
for	O
mass	O
spectrometry	O
or	O
the	O
existence	O
of	O
SAM	O
-	O
independent	O
pathways	O
for	O
protein	O
methylation	O
.	O

Our	O
study	O
found	O
a	O
high	O
occurrence	O
of	O
protein	O
methylation	O
from	O
SDS	O
-	O
PAGE	O
isolated	O
endogenous	O
proteins	O
and	O
identified	O
complications	O
for	O
assigning	O
such	O
modifications	O
as	O
in	O
vivo	O
methylation	O
.	O

This	O
study	O
provides	O
a	O
cautionary	O
note	O
for	O
solely	O
relying	O
on	O
mass	O
shift	O
for	O
mass	O
spectrometric	O
identification	O
of	O
protein	O
methylation	O
and	O
highlights	O
the	O
importance	O
of	O
in	O
vivo	O
isotope	O
labeling	O
as	O
a	O
necessary	O
validation	O
method	O
.	O

Hepatitis	O
B	O
virus	O
X	B-Protein
protein	O
induces	O
the	O
expression	O
of	O
MTA1	B-Protein
and	O
HDAC1	B-Protein
,	O
which	O
enhances	O
hypoxia	O
signaling	O
in	O
hepatocellular	O
carcinoma	O
cells	O
.	O

Expression	O
level	O
of	O
metastasis	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
1	I-Protein
(	O
MTA1	B-Protein
)	O
is	O
closely	O
related	O
to	O
tumor	O
growth	O
and	O
metastasis	O
in	O
various	O
cancers	O
.	O

Although	O
increased	O
expression	O
level	O
of	O
MTA1	B-Protein
was	O
observed	O
in	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
,	O
role	O
of	O
MTA1	B-Protein
complex	O
containing	O
histone	B-Protein
deacetylase	O
(	O
HDAC	O
)	O
in	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
-	O
associated	O
hepatocarcinogenesis	O
has	O
not	O
been	O
studied	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
HBx	B-Protein
strongly	O
induced	O
the	O
expression	O
of	O
MTA1	B-Protein
and	O
HDAC1	B-Protein
genes	O
at	O
transcription	O
level	O
.	O

MTA1	B-Protein
and	O
HDAC1	B-Protein
/	O
2	B-Protein
physically	O
associated	O
with	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
)	O
in	O
vivo	O
in	O
the	O
presence	O
of	O
HBx	B-Protein
,	O
which	O
was	O
abolished	O
by	O
knockdown	O
of	O
MTA1	B-Protein
by	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
.	O

HBx	B-Protein
induced	O
deacetylation	O
of	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
domain	O
of	O
HIF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
,	O
which	O
was	O
accompanied	O
with	O
dissociation	O
of	O
prolyl	O
hydroxylases	O
and	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	I-Protein
from	O
HIF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
.	O

These	O
results	O
indicate	O
that	O
HBx	B-Protein
-	O
induced	O
deacetylation	O
is	O
important	O
for	O
proteasomal	O
degradation	O
of	O
HIF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
.	O

Further	O
,	O
we	O
observed	O
that	O
protein	O
levels	O
of	O
MTA1	B-Protein
and	O
HDAC1	B-Protein
were	O
increased	O
in	O
the	O
liver	O
of	O
HBx	B-Protein
-	O
transgenic	O
mice	O
.	O

Also	O
,	O
there	O
was	O
a	O
higher	O
expression	O
of	O
HDAC1	B-Protein
in	O
HCC	O
than	O
in	O
the	O
adjacent	O
non	O
-	O
tumorous	O
cirrhotic	O
nodules	O
in	O
10	O
out	O
of	O
12	O
human	O
HBV	O
-	O
associated	O
HCC	O
specimens	O
.	O

Together	O
,	O
our	O
data	O
indicate	O
a	O
positive	O
cross	O
talk	O
between	O
HBx	B-Protein
and	O
the	O
MTA1	B-Protein
/	O
HDAC	O
complex	O
in	O
stabilizing	O
HIF	B-Protein
-	I-Protein
1	I-Protein
alpha	I-Protein
,	O
which	O
may	O
play	O
a	O
critical	O
role	O
in	O
angiogenesis	O
and	O
metastasis	O
of	O
HBV	O
-	O
associated	O
HCC	O
.	O

Crystal	O
structures	O
of	O
the	O
clock	O
protein	O
EA4	B-Protein
from	O
the	O
silkworm	O
Bombyx	O
mori	O
.	O

Many	O
insects	O
pass	O
the	O
winter	O
in	O
an	O
arrested	O
developmental	O
stage	O
called	O
diapause	O
,	O
either	O
as	O
eggs	O
,	O
as	O
pupae	O
,	O
or	O
even	O
as	O
adults	O
.	O

Exposure	O
to	O
the	O
prolonged	O
cold	O
of	O
winter	O
is	O
required	O
to	O
permit	O
awakening	O
from	O
diapause	O
in	O
the	O
spring	O
.	O

In	O
the	O
diapause	O
eggs	O
of	O
the	O
silkworm	O
Bombyx	O
mori	O
,	O
a	O
metalloglycoprotein	O
,	O
esterase	B-Protein
A4	I-Protein
(	O
EA4	B-Protein
)	O
,	O
has	O
been	O
suggested	O
to	O
serve	O
as	O
a	O
cold	O
-	O
duration	O
clock	O
because	O
its	O
characteristic	O
ATPase	O
activity	O
is	O
transiently	O
elevated	O
at	O
the	O
end	O
of	O
the	O
necessary	O
cold	O
period	O
.	O

This	O
timer	O
property	O
of	O
EA4	B-Protein
is	O
known	O
to	O
start	O
with	O
the	O
dissociation	O
of	O
an	O
inhibitory	O
peptide	O
(	O
called	O
"	O
peptidyl	O
inhibitory	O
needle	O
"	O
)	O
under	O
cold	O
conditions	O
,	O
but	O
its	O
time	O
-	O
measuring	O
mechanism	O
is	O
completely	O
unknown	O
.	O

Here	O
we	O
present	O
the	O
crystal	O
structures	O
and	O
functional	O
properties	O
of	O
EA4	B-Protein
with	O
and	O
without	O
glycosylation	O
.	O

We	O
show	O
that	O
EA4	B-Protein
is	O
a	O
homodimeric	O
ATPase	O
,	O
with	O
each	O
subunit	O
consisting	O
of	O
a	O
copper	O
-	O
zinc	O
superoxide	O
dismutase	O
fold	O
.	O

There	O
is	O
an	O
additional	O
short	O
N	O
-	O
terminal	O
region	O
that	O
is	O
capable	O
of	O
binding	O
one	O
more	O
copper	O
ion	O
,	O
suggesting	O
a	O
timer	O
mechanism	O
in	O
which	O
this	O
ion	O
is	O
involved	O
.	O

The	O
sugar	O
chain	O
appears	O
to	O
reinforce	O
the	O
binding	O
of	O
peptidyl	O
inhibitory	O
needle	O
,	O
which	O
may	O
in	O
turn	O
stabilize	O
the	O
initial	O
conformation	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
,	O
explaining	O
the	O
requirement	O
for	O
glycosylation	O
and	O
for	O
the	O
peptide	O
to	O
set	O
the	O
clock	O
.	O

Grb10	B-Protein
/	O
Nedd4	B-Protein
-	O
mediated	O
multiubiquitination	O
of	O
the	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
regulates	O
receptor	O
internalization	O
.	O

The	O
adaptor	O
protein	O
Grb10	B-Protein
is	O
an	O
interacting	O
partner	O
of	O
the	O
IGF	B-Protein
-	I-Protein
I	I-Protein
receptor	I-Protein
(	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
)	O
and	O
the	O
insulin	B-Protein
receptor	I-Protein
(	O
IR	B-Protein
)	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
has	O
established	O
the	O
role	O
of	O
Grb10	B-Protein
as	O
a	O
negative	O
regulator	O
of	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
-	O
dependent	O
cell	O
proliferation	O
.	O

We	O
have	O
shown	O
that	O
Grb10	B-Protein
binds	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
Nedd4	B-Protein
and	O
promotes	O
IGF	B-Protein
-	I-Protein
I	I-Protein
-	O
stimulated	O
ubiquitination	O
,	O
internalization	O
,	O
and	O
degradation	O
of	O
the	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
,	O
thereby	O
giving	O
rise	O
to	O
long	O
-	O
term	O
attenuation	O
of	O
signaling	O
.	O

Recent	O
biochemical	O
evidence	O
suggests	O
that	O
tyrosine	O
-	O
kinase	O
receptors	O
(	O
RTK	O
)	O
may	O
not	O
be	O
polyubiquitinated	O
but	O
monoubiquitinated	O
at	O
multiple	O
sites	O
(	O
multiubiquitinated	O
)	O
.	O

However	O
,	O
the	O
type	O
of	O
ubiquitination	O
of	O
the	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
is	O
still	O
not	O
defined	O
.	O

Here	O
we	O
show	O
that	O
the	O
Grb10	B-Protein
/	O
Nedd4	B-Protein
complex	O
upon	O
ligand	O
stimulation	O
mediates	O
multiubiquitination	O
of	O
the	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
,	O
which	O
is	O
required	O
for	O
receptor	O
internalization	O
.	O

Moreover	O
,	O
Nedd4	B-Protein
by	O
promoting	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
ubiquitination	O
and	O
internalization	O
contributes	O
with	O
Grb10	B-Protein
to	O
negatively	O
regulate	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
-	O
dependent	O
cell	O
proliferation	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
is	O
internalized	O
through	O
clathrin	O
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
.	O

Grb10	B-Protein
and	O
Nedd4	B-Protein
remain	O
associated	O
with	O
the	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
in	O
early	O
endosomes	O
and	O
caveosomes	O
,	O
where	O
they	O
may	O
participate	O
in	O
sorting	O
internalized	O
receptors	O
.	O

Grb10	B-Protein
and	O
Nedd4	B-Protein
,	O
unlike	O
the	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
,	O
which	O
is	O
targeted	O
for	O
lysosomal	O
degradation	O
are	O
not	O
degraded	O
and	O
likely	O
directed	O
into	O
recycling	O
endosomes	O
.	O

These	O
results	O
indicate	O
that	O
Grb10	B-Protein
and	O
Nedd4	B-Protein
play	O
a	O
critical	O
role	O
in	O
mediating	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
down	O
-	O
regulation	O
by	O
promoting	O
ligand	O
-	O
dependent	O
multiubiquitination	O
of	O
the	O
IGF	B-Protein
-	I-Protein
IR	I-Protein
,	O
which	O
is	O
required	O
for	O
receptor	O
internalization	O
and	O
regulates	O
mitogenesis	O
.	O

ISG15	B-Protein
inhibits	O
Nedd4	B-Protein
ubiquitin	O
E3	O
activity	O
and	O
enhances	O
the	O
innate	O
antiviral	O
response	O
.	O

Interferons	O
regulate	O
diverse	O
immune	O
functions	O
through	O
the	O
transcriptional	O
activation	O
of	O
hundreds	O
of	O
genes	O
involved	O
in	O
anti	O
-	O
viral	O
responses	O
.	O

The	O
interferon	O
-	O
inducible	O
ubiquitin	B-Protein
-	O
like	O
protein	O
ISG15	B-Protein
is	O
expressed	O
in	O
cells	O
in	O
response	O
to	O
a	O
variety	O
of	O
stress	O
conditions	O
like	O
viral	O
or	O
bacterial	O
infection	O
and	O
is	O
present	O
in	O
its	O
free	O
form	O
or	O
is	O
conjugated	O
to	O
cellular	O
proteins	O
.	O

In	O
addition	O
,	O
protein	O
ubiquitination	O
plays	O
a	O
regulatory	O
role	O
in	O
the	O
immune	O
system	O
.	O

Many	O
viruses	O
modulate	O
the	O
ubiquitin	B-Protein
(	O
Ub	B-Protein
)	O
pathway	O
to	O
alter	O
cellular	O
signaling	O
and	O
the	O
antiviral	O
response	O
.	O

Ubiquitination	O
of	O
retroviral	O
group	O
-	O
specific	O
antigen	O
precursors	O
and	O
matrix	O
proteins	O
of	O
the	O
Ebola	O
,	O
vesicular	O
stomatitis	O
,	O
and	O
rabies	O
viruses	O
by	O
Nedd4	B-Protein
family	O
HECT	O
domain	O
E3	O
ligases	O
is	O
an	O
important	O
step	O
in	O
facilitating	O
viral	O
release	O
.	O

We	O
found	O
that	O
Nedd4	B-Protein
is	O
negatively	O
regulated	O
by	O
ISG15	B-Protein
.	O

Free	O
ISG15	B-Protein
specifically	O
bound	O
to	O
Nedd4	B-Protein
and	O
blocked	O
its	O
interaction	O
with	O
Ub	B-Protein
-	O
E2	O
molecules	O
,	O
thus	O
preventing	O
further	O
Ub	B-Protein
transfer	O
from	O
E2	O
to	O
E3	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
ISG15	B-Protein
diminished	O
the	O
ability	O
of	O
Nedd4	B-Protein
to	O
ubiquitinate	O
viral	O
matrix	O
proteins	O
and	O
led	O
to	O
a	O
decrease	O
in	O
the	O
release	O
of	O
Ebola	O
VP40	O
virus	O
-	O
like	O
particles	O
from	O
the	O
cells	O
.	O

These	O
results	O
point	O
to	O
a	O
mechanistically	O
novel	O
function	O
of	O
ISG15	B-Protein
in	O
the	O
enhancement	O
of	O
the	O
innate	O
anti	O
-	O
viral	O
response	O
through	O
specific	O
inhibition	O
of	O
Nedd4	B-Protein
Ub	B-Protein
-	O
E3	O
activity	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
example	O
of	O
a	O
Ub	B-Protein
-	O
like	O
protein	O
with	O
the	O
ability	O
to	O
interfere	O
with	O
Ub	B-Protein
-	O
E2	O
and	O
E3	O
interaction	O
to	O
inhibit	O
protein	O
ubiquitination	O
.	O

COP1	B-Protein
-	O
mediated	O
ubiquitination	O
of	O
CONSTANS	B-Protein
is	O
implicated	O
in	O
cryptochrome	O
regulation	O
of	O
flowering	O
in	O
Arabidopsis	O
.	O

In	O
Arabidopsis	O
thaliana	O
,	O
the	O
blue	O
light	O
photoreceptor	O
cryptochromes	O
(	O
CRY	O
)	O
act	O
to	O
promote	O
photomorphogenic	O
development	O
and	O
the	O
transition	O
from	O
vegetative	O
to	O
floral	O
development	O
in	O
long	O
days	O
(	O
LDs	O
)	O
.	O

We	O
previously	O
proposed	O
that	O
one	O
of	O
the	O
mechanisms	O
by	O
which	O
CRY	O
regulates	O
light	O
responses	O
is	O
via	O
its	O
physical	O
interaction	O
with	O
COP1	B-Protein
,	O
a	O
RING	O
motif	O
-	O
containing	O
E3	O
ligase	O
.	O

Under	O
LDs	O
,	O
the	O
transcription	O
of	O
FLOWERING	B-Protein
LOCUS	I-Protein
T	I-Protein
(	O
FT	B-Protein
)	O
is	O
activated	O
by	O
CONSTANS	B-Protein
(	O
CO	B-Protein
)	O
in	O
leaf	O
,	O
and	O
the	O
FT	B-Protein
protein	O
moves	O
to	O
the	O
shoot	O
apex	O
to	O
induce	O
flowering	O
.	O

CO	B-Protein
protein	O
is	O
degraded	O
in	O
darkness	O
,	O
whereas	O
it	O
is	O
stabilized	O
by	O
the	O
CRY	O
-	O
mediated	O
signal	O
.	O

However	O
,	O
the	O
mechanism	O
underlying	O
this	O
process	O
is	O
unknown	O
.	O

We	O
show	O
in	O
this	O
report	O
that	O
CO	B-Protein
acts	O
genetically	O
downstream	O
of	O
COP1	B-Protein
and	O
CRY	O
to	O
regulate	O
flowering	O
time	O
.	O

In	O
addition	O
,	O
COP1	B-Protein
physically	O
interacts	O
with	O
CO	B-Protein
and	O
functions	O
as	O
an	O
E3	O
ligase	O
,	O
ubiquitinating	O
CO	B-Protein
in	O
vitro	O
and	O
reducing	O
CO	B-Protein
levels	O
in	O
vivo	O
.	O

These	O
results	O
suggest	O
that	O
COP1	B-Protein
acts	O
as	O
a	O
repressor	O
of	O
flowering	O
by	O
promoting	O
the	O
ubiquitin	B-Protein
-	O
mediated	O
proteolysis	O
of	O
CO	B-Protein
in	O
darkness	O
and	O
that	O
CRY	O
-	O
mediated	O
signal	O
may	O
negatively	O
regulate	O
COP1	B-Protein
,	O
thereby	O
stabilizing	O
CO	B-Protein
,	O
activating	O
FT	B-Protein
transcription	O
,	O
and	O
inducing	O
flowering	O
.	O

Disturbance	O
of	O
nuclear	O
and	O
cytoplasmic	O
TAR	O
DNA	O
-	O
binding	O
protein	O
(	O
TDP	B-Protein
-	I-Protein
43	I-Protein
)	O
induces	O
disease	O
-	O
like	O
redistribution	O
,	O
sequestration	O
,	O
and	O
aggregate	O
formation	O
.	O

TAR	B-Protein
DNA	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
43	I-Protein
(	O
TDP	B-Protein
-	I-Protein
43	I-Protein
)	O
is	O
the	O
disease	O
protein	O
in	O
frontotemporal	O
lobar	O
degeneration	O
with	O
ubiquitin	B-Protein
-	O
positive	O
inclusions	O
(	O
FTLD	O
-	O
U	O
)	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
.	O

Although	O
normal	O
TDP	B-Protein
-	I-Protein
43	I-Protein
is	O
a	O
nuclear	O
protein	O
,	O
pathological	O
TDP	B-Protein
-	I-Protein
43	I-Protein
is	O
redistributed	O
and	O
sequestered	O
as	O
insoluble	O
aggregates	O
in	O
neuronal	O
nuclei	O
,	O
perikarya	O
,	O
and	O
neurites	O
.	O

Here	O
we	O
recapitulate	O
these	O
pathological	O
phenotypes	O
in	O
cultured	O
cells	O
by	O
altering	O
endogenous	O
TDP	B-Protein
-	I-Protein
43	I-Protein
nuclear	O
trafficking	O
and	O
by	O
expressing	O
mutants	O
with	O
defective	O
nuclear	O
localization	O
(	O
TDP	B-Protein
-	I-Protein
43	I-Protein
-	O
DeltaNLS	O
)	O
or	O
nuclear	O
export	O
signals	O
(	O
TDP	B-Protein
-	I-Protein
43	I-Protein
-	O
DeltaNES	O
)	O
.	O

Restricting	O
endogenous	O
cytoplasmic	O
TDP	B-Protein
-	I-Protein
43	I-Protein
from	O
entering	O
the	O
nucleus	O
or	O
preventing	O
its	O
exit	O
out	O
of	O
the	O
nucleus	O
resulted	O
in	O
TDP	B-Protein
-	I-Protein
43	I-Protein
aggregate	O
formation	O
.	O

TDP	B-Protein
-	I-Protein
43	I-Protein
-	O
DeltaNLS	O
accumulates	O
as	O
insoluble	O
cytoplasmic	O
aggregates	O
and	O
sequesters	O
endogenous	O
TDP	B-Protein
-	I-Protein
43	I-Protein
,	O
thereby	O
depleting	O
normal	O
nuclear	O
TDP	B-Protein
-	I-Protein
43	I-Protein
,	O
whereas	O
TDP	B-Protein
-	I-Protein
43	I-Protein
-	O
DeltaNES	O
forms	O
insoluble	O
nuclear	O
aggregates	O
with	O
endogenous	O
TDP	B-Protein
-	I-Protein
43	I-Protein
.	O

Mutant	O
forms	O
of	O
TDP	B-Protein
-	I-Protein
43	I-Protein
also	O
replicate	O
the	O
biochemical	O
profile	O
of	O
pathological	O
TDP	B-Protein
-	I-Protein
43	I-Protein
in	O
FTLD	O
-	O
U	O
/	O
ALS	O
.	O

Thus	O
,	O
FTLD	O
-	O
U	O
/	O
ALS	O
pathogenesis	O
may	O
be	O
linked	O
mechanistically	O
to	O
deleterious	O
perturbations	O
of	O
nuclear	O
trafficking	O
and	O
solubility	O
of	O
TDP	B-Protein
-	I-Protein
43	I-Protein
.	O

Cue1p	B-Protein
is	O
an	O
activator	O
of	O
Ubc7p	B-Protein
E2	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Ubc7p	B-Protein
is	O
a	O
ubiquitin	B-Protein
-	O
conjugating	O
enzyme	O
(	O
E2	O
)	O
that	O
functions	O
with	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
resident	O
ubiquitin	B-Protein
ligases	O
(	O
E3s	O
)	O
to	O
promote	O
endoplasmic	O
reticulum	O
-	O
associated	O
degradation	O
(	O
ERAD	O
)	O
.	O

Ubc7p	B-Protein
only	O
functions	O
in	O
ERAD	O
if	O
bound	O
to	O
the	O
ER	O
surface	O
by	O
Cue1p	B-Protein
,	O
a	O
membrane	O
-	O
anchored	O
ER	O
protein	O
.	O

The	O
role	O
of	O
Cue1p	B-Protein
was	O
thought	O
to	O
involve	O
passive	O
concentration	O
of	O
Ubc7p	B-Protein
at	O
the	O
surface	O
of	O
the	O
ER	O
.	O

However	O
,	O
our	O
biochemical	O
studies	O
of	O
Ubc7p	B-Protein
suggested	O
that	O
Cue1p	B-Protein
may	O
,	O
in	O
addition	O
,	O
stimulate	O
Ubc7p	B-Protein
E2	O
activity	O
.	O

We	O
have	O
tested	O
this	O
idea	O
and	O
found	O
it	O
to	O
be	O
true	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Ubc7p	B-Protein
bound	O
to	O
the	O
soluble	O
domain	O
of	O
Cue1p	B-Protein
showed	O
strongly	O
enhanced	O
in	O
vitro	O
ubiquitination	O
activity	O
,	O
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
E3	O
.	O

Cue1p	B-Protein
also	O
enhanced	O
Ubc7p	B-Protein
function	O
in	O
vivo	O
,	O
and	O
this	O
activation	O
was	O
separable	O
from	O
the	O
established	O
ER	O
-	O
anchoring	O
role	O
of	O
Cue1p	B-Protein
.	O

Finally	O
,	O
we	O
tested	O
in	O
vivo	O
activation	O
of	O
Ubc7p	B-Protein
by	O
Cue1p	B-Protein
in	O
an	O
assay	O
independent	O
of	O
the	O
ER	O
membrane	O
and	O
ERAD	O
.	O

A	O
chimeric	O
E2	O
linking	O
Ubc7p	B-Protein
to	O
the	O
Cdc34p	B-Protein
/	O
Ubc3p	B-Protein
localization	O
domain	O
complemented	O
the	O
cdc34	B-Protein
-	O
2	O
TS	O
phenotype	O
,	O
and	O
co	O
-	O
expression	O
of	O
the	O
soluble	O
Cue1p	B-Protein
domain	O
enhanced	O
complementation	O
by	O
this	O
chimeric	O
Ubc7p	B-Protein
E2	O
.	O

These	O
studies	O
reveal	O
a	O
previously	O
unobserved	O
stimulation	O
of	O
Ubc7p	B-Protein
E2	O
activity	O
by	O
Cue1p	B-Protein
that	O
is	O
critical	O
for	O
full	O
ERAD	O
and	O
that	O
functions	O
independently	O
of	O
the	O
well	O
known	O
Cue1p	B-Protein
anchoring	O
function	O
.	O

Moreover	O
,	O
it	O
suggests	O
a	O
previously	O
unappreciated	O
mode	O
for	O
regulation	O
of	O
E2s	O
by	O
Cue1p	B-Protein
-	O
like	O
interacting	O
partners	O
.	O

Stabilization	O
of	O
p53	B-Protein
is	O
involved	O
in	O
quercetin	O
-	O
induced	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
HepG2	O
cells	O
.	O

There	O
is	O
evidence	O
for	O
defects	O
in	O
the	O
mechanisms	O
that	O
allow	O
the	O
activation	O
of	O
p53	B-Protein
in	O
many	O
of	O
the	O
cancers	O
that	O
retain	O
wild	O
-	O
type	O
p53	B-Protein
.	O

Reactivation	O
of	O
p53	B-Protein
has	O
been	O
suggested	O
to	O
be	O
an	O
effective	O
strategy	O
for	O
cancer	O
therapy	O
in	O
wild	O
-	O
type	O
p53	B-Protein
-	O
retained	O
tumor	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
attempted	O
to	O
reactivate	O
p53	B-Protein
in	O
HepG2	O
retaining	O
wild	O
-	O
type	O
p53	B-Protein
by	O
quercetin	O
,	O
an	O
ubiquitous	O
bioactive	O
plant	O
flavonoid	O
.	O

Our	O
results	O
show	O
that	O
quercetin	O
inhibited	O
the	O
proliferation	O
of	O
HepG2	O
cells	O
through	O
the	O
induction	O
of	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
,	O
as	O
characterized	O
by	O
the	O
cell	O
cycle	O
distribution	O
and	O
DNA	O
fragmentation	O
.	O

Molecular	O
data	O
revealed	O
that	O
quercetin	O
induced	O
p53	B-Protein
phosphorylation	O
and	O
total	O
p53	B-Protein
protein	O
,	O
but	O
that	O
it	O
did	O
not	O
up	O
-	O
regulate	O
p53	B-Protein
mRNA	O
at	O
the	O
transcription	O
level	O
.	O

Consequently	O
,	O
quercetin	O
stimulated	O
p21	B-Protein
expression	O
and	O
suppressed	O
cyclin	B-Protein
D1	I-Protein
expression	O
in	O
favor	O
of	O
cell	O
cycle	O
arrest	O
.	O

Quercetin	O
also	O
increased	O
the	O
ratio	O
of	O
Bax	B-Protein
/	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
in	O
favor	O
of	O
apoptosis	O
with	O
such	O
treatment	O
.	O

Interestingly	O
,	O
quercetin	O
inhibited	O
p53	B-Protein
ubiquitination	O
and	O
extended	O
the	O
half	O
-	O
life	O
(	O
t	O
(	O
1	O
/	O
2	O
)	O
)	O
of	O
p53	B-Protein
from	O
74	O
to	O
184	O
min	O
.	O

Quercetin	O
also	O
inhibited	O
p53	B-Protein
mRNA	O
degradation	O
at	O
the	O
post	O
-	O
transcription	O
stage	O
.	O

Silencing	O
p53	B-Protein
with	O
p53	B-Protein
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
significantly	O
abrogated	O
the	O
p53	B-Protein
-	O
dependent	O
gene	O
expression	O
and	O
apoptotic	O
induction	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
quercetin	O
stabilized	O
p53	B-Protein
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
to	O
reactivate	O
p53	B-Protein
-	O
dependent	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
HepG2	O
cells	O
.	O

Tumor	O
suppressor	O
cylindromatosis	O
acts	O
as	O
a	O
negative	O
regulator	O
for	O
Streptococcus	O
pneumoniae	O
-	O
induced	O
NFAT	O
signaling	O
.	O

Gram	O
-	O
positive	O
bacterium	O
Streptococcus	O
pneumoniae	O
is	O
an	O
important	O
human	O
pathogen	O
that	O
colonizes	O
the	O
upper	O
respiratory	O
tract	O
and	O
is	O
also	O
the	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

S	O
.	O
pneumoniae	O
causes	O
invasive	O
diseases	O
such	O
as	O
pneumonia	O
,	O
meningitis	O
,	O
and	O
otitis	O
media	O
.	O

Despite	O
the	O
importance	O
of	O
pneumococcal	O
diseases	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
by	O
which	O
S	O
.	O
pneumoniae	O
-	O
induced	O
inflammation	O
is	O
regulated	O
,	O
especially	O
the	O
negative	O
regulatory	O
mechanisms	O
.	O

Here	O
we	O
show	O
that	O
S	O
.	O
pneumoniae	O
activates	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
signaling	O
pathway	O
and	O
the	O
subsequent	O
up	O
-	O
regulation	O
of	O
inflammatory	O
mediators	O
via	O
a	O
key	O
pneumococcal	O
virulence	O
factor	O
,	O
pneumolysin	B-Protein
.	O

We	O
also	O
demonstrate	O
that	O
S	O
.	O
pneumoniae	O
activates	O
NFAT	O
transcription	O
factor	O
independently	O
of	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptors	I-Protein
2	I-Protein
and	O
4	B-Protein
.	O

Moreover	O
,	O
S	O
.	O
pneumoniae	O
induces	O
NFAT	O
activation	O
via	O
both	O
Ca	O
(	O
2	O
+	O
)	O
-	O
calcineurin	O
and	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
beta	I-Protein
-	I-Protein
activated	I-Protein
kinase	I-Protein
1	I-Protein
(	O
TAK1	B-Protein
)	O
-	O
mitogen	O
-	O
activated	O
protein	B-Protein
kinase	I-Protein
kinase	I-Protein
(	I-Protein
MKK	I-Protein
)	I-Protein
3	I-Protein
/	O
6	B-Protein
-	O
p38alpha	B-Protein
/	O
beta	B-Protein
-	O
dependent	O
signaling	O
pathways	O
.	O

Interestingly	O
,	O
we	O
found	O
for	O
the	O
first	O
time	O
that	O
tumor	O
suppressor	O
cylindromatosis	B-Protein
(	O
CYLD	B-Protein
)	O
acts	O
as	O
a	O
negative	O
regulator	O
for	O
S	O
.	O
pneumoniae	O
-	O
induced	O
NFAT	O
signaling	O
pathway	O
via	O
a	O
deubiquitination	O
-	O
dependent	O
mechanism	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
CYLD	B-Protein
interacts	O
with	O
and	O
deubiquitinates	O
TAK1	B-Protein
to	O
negatively	O
regulate	O
the	O
activation	O
of	O
the	O
downstream	O
MKK3	B-Protein
/	O
6	B-Protein
-	O
p38alpha	B-Protein
/	O
beta	B-Protein
pathway	O
.	O

Our	O
studies	O
thus	O
bring	O
new	O
insights	O
into	O
the	O
molecular	O
pathogenesis	O
of	O
S	O
.	O
pneumoniae	O
infections	O
through	O
the	O
NFAT	O
-	O
dependent	O
mechanism	O
and	O
further	O
identify	O
CYLD	B-Protein
as	O
a	O
negative	O
regulator	O
for	O
NFAT	O
signaling	O
,	O
thereby	O
opening	O
up	O
new	O
therapeutic	O
targets	O
for	O
these	O
diseases	O
.	O

Pirh2	B-Protein
interacts	O
with	O
and	O
ubiquitylates	O
signal	B-Protein
recognition	I-Protein
particle	I-Protein
receptor	I-Protein
beta	I-Protein
subunit	I-Protein
.	O

Pirh2	B-Protein
is	O
a	O
RING	O
finger	O
type	O
ubiquitin	B-Protein
ligase	O
which	O
ubiquitylates	O
various	O
proteins	O
including	O
p53	B-Protein
,	O
p27	B-Protein
(	O
Kip1	B-Protein
)	O
,	O
HDAC1	B-Protein
,	O
and	O
epsilon	B-Protein
-	I-Protein
COP	I-Protein
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
signal	B-Protein
recognition	I-Protein
particle	I-Protein
receptor	I-Protein
beta	I-Protein
subunit	I-Protein
(	O
SRbeta	B-Protein
)	O
,	O
an	O
integral	O
membrane	O
protein	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
,	O
as	O
a	O
novel	O
Pirh2	B-Protein
-	O
interacting	O
protein	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
.	O

We	O
confirmed	O
that	O
Pirh2	B-Protein
interacted	O
with	O
SRbeta	B-Protein
in	O
mammalian	O
cells	O
.	O

An	O
immunofluorescent	O
staining	O
revealed	O
that	O
Pirh2	B-Protein
colocalized	O
with	O
SRbeta	B-Protein
in	O
the	O
ER	O
.	O

Pirh2	B-Protein
poly	O
-	O
ubiquitylated	O
SRbeta	B-Protein
in	O
an	O
intact	O
RING	O
finger	O
domain	O
-	O
dependent	O
manner	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Unexpectedly	O
,	O
different	O
from	O
other	O
Pirh2	B-Protein
substrates	O
,	O
neither	O
overexpression	O
of	O
Pirh2	B-Protein
nor	O
depletion	O
of	O
cellular	O
Pirh2	B-Protein
affected	O
SRbeta	B-Protein
protein	O
stability	O
.	O

Pirh2	B-Protein
preferentially	O
utilized	O
lysine	O
residues	O
6	O
and	O
29	O
of	O
the	O
ubiquitin	B-Protein
to	O
mediate	O
the	O
formation	O
of	O
polyubiquitin	B-Protein
chains	O
on	O
SRbeta	B-Protein
.	O

These	O
results	O
suggest	O
that	O
Pirh2	B-Protein
may	O
regulate	O
SRbeta	B-Protein
function	O
by	O
mediating	O
poly	O
-	O
ubiquitylation	O
of	O
SRbeta	B-Protein
without	O
affecting	O
the	O
stability	O
of	O
SRbeta	B-Protein
protein	O
per	O
se	O
.	O

PKC	O
-	O
dependent	O
endocytosis	O
of	O
the	O
GLT1	B-Protein
glutamate	O
transporter	O
depends	O
on	O
ubiquitylation	O
of	O
lysines	O
located	O
in	O
a	O
C	O
-	O
terminal	O
cluster	O
.	O

The	O
activity	O
of	O
the	O
main	O
glutamate	O
transporter	O
in	O
the	O
CNS	O
,	O
GLT1	B-Protein
,	O
can	O
be	O
regulated	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

It	O
is	O
known	O
that	O
activation	O
of	O
PKC	O
by	O
phorbol	O
esters	O
promotes	O
the	O
clathrin	O
-	O
dependent	O
internalization	O
of	O
the	O
transporter	O
,	O
followed	O
by	O
its	O
lysosomal	O
degradation	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
that	O
link	O
PKC	O
activation	O
and	O
the	O
internalization	O
of	O
GLT1	B-Protein
are	O
not	O
fully	O
understood	O
.	O

In	O
this	O
article	O
,	O
we	O
show	O
that	O
this	O
internalization	O
process	O
is	O
dependent	O
on	O
the	O
ubiquitylation	O
of	O
lysine	O
residues	O
located	O
in	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
GLT1	B-Protein
.	O

Exposure	O
to	O
PMA	O
increases	O
the	O
ubiquitylation	O
of	O
GLT1	B-Protein
in	O
transfected	O
cells	O
and	O
in	O
the	O
rat	O
brain	O
,	O
and	O
this	O
ubiquitylated	O
GLT1	B-Protein
accumulates	O
in	O
the	O
intracellular	O
compartment	O
.	O

However	O
,	O
internalization	O
of	O
ubiquitylated	O
GLT1	B-Protein
was	O
blocked	O
with	O
a	O
dominant	O
negative	O
dynamin	B-Protein
2	I-Protein
mutant	O
,	O
indicating	O
that	O
the	O
addition	O
of	O
ubiquitin	B-Protein
moieties	O
to	O
the	O
transporter	O
in	O
the	O
membrane	O
precedes	O
its	O
endocytosis	O
.	O

The	O
elimination	O
of	O
lysines	O
from	O
the	O
C	O
-	O
terminus	O
of	O
the	O
transporter	O
(	O
lysines	O
497	O
,	O
517	O
,	O
526	O
,	O
550	O
,	O
558	O
,	O
570	O
,	O
and	O
573	O
)	O
blocked	O
GLT1	B-Protein
ubiquitylation	O
and	O
endocytosis	O
.	O

However	O
,	O
reintroduction	O
of	O
lysine	O
517	O
alone	O
into	O
this	O
mutant	O
was	O
sufficient	O
to	O
restore	O
PMA	O
dependent	O
ubiquitylation	O
and	O
internalization	O
of	O
GLT1	B-Protein
.	O

Similarly	O
,	O
reintroduction	O
of	O
lysine	O
526	O
restored	O
the	O
endocytosis	O
,	O
while	O
this	O
was	O
only	O
partially	O
recovered	O
after	O
the	O
individual	O
reintroduction	O
of	O
lysines	O
550	O
or	O
570	O
.	O

These	O
data	O
suggest	O
that	O
the	O
activation	O
of	O
PKC	O
induces	O
the	O
ubiquitylation	O
of	O
these	O
C	O
-	O
terminal	O
lysine	O
residues	O
in	O
GLT1	B-Protein
and	O
that	O
this	O
modification	O
mediates	O
the	O
interaction	O
of	O
the	O
transporter	O
with	O
the	O
endocytic	O
machinery	O
.	O

A	O
yeast	O
three	O
-	O
hybrid	O
system	O
that	O
reconstitutes	O
mammalian	O
hypoxia	O
inducible	O
factor	O
regulatory	O
machinery	O
.	O

BACKGROUND	O
:	O
Several	O
human	O
pathologies	O
,	O
including	O
neoplasia	O
and	O
ischemic	O
cardiovascular	O
diseases	O
,	O
course	O
with	O
an	O
unbalance	O
between	O
oxygen	O
supply	O
and	O
demand	O
(	O
hypoxia	O
)	O
.	O

Cells	O
within	O
hypoxic	O
regions	O
respond	O
with	O
the	O
induction	O
of	O
a	O
specific	O
genetic	O
program	O
,	O
under	O
the	O
control	O
of	O
the	O
Hypoxia	O
Inducible	O
Factor	O
(	O
HIF	O
)	O
,	O
that	O
mediates	O
their	O
adaptation	O
to	O
the	O
lack	O
of	O
oxygen	O
.	O

The	O
activity	O
of	O
HIF	O
is	O
mainly	O
regulated	O
by	O
the	O
EGL	O
-	O
nine	O
homolog	O
(	O
EGLN	O
)	O
enzymes	O
that	O
hydroxylate	O
the	O
alpha	O
subunit	O
of	O
this	O
transcription	O
factor	O
in	O
an	O
oxygen	O
-	O
dependent	O
reaction	O
.	O

Hydroxylated	O
HIF	O
is	O
then	O
recognized	O
and	O
ubiquitinilated	O
by	O
the	O
product	O
of	O
the	O
tumor	O
suppressor	O
gene	O
,	O
pVHL	B-Protein
,	O
leading	O
to	O
its	O
proteosomal	O
degradation	O
.	O

Under	O
hypoxia	O
,	O
the	O
hydroxylation	O
of	O
HIF	O
by	O
the	O
EGLNs	O
is	O
compromised	O
due	O
to	O
the	O
lack	O
of	O
oxygen	O
,	O
which	O
is	O
a	O
reaction	O
cosubstrate	O
.	O

Thus	O
,	O
HIF	O
escapes	O
degradation	O
and	O
drives	O
the	O
transcription	O
of	O
its	O
target	O
genes	O
.	O

Since	O
the	O
progression	O
of	O
the	O
aforementioned	O
pathologies	O
might	O
be	O
influenced	O
by	O
activation	O
of	O
HIF	O
-	O
target	O
genes	O
,	O
development	O
of	O
small	O
molecules	O
with	O
the	O
ability	O
to	O
interfere	O
with	O
the	O
HIF	O
-	O
regulatory	O
machinery	O
is	O
of	O
great	O
interest	O
.	O

RESULTS	O
:	O
Herein	O
we	O
describe	O
a	O
yeast	O
three	O
-	O
hybrid	O
system	O
that	O
reconstitutes	O
mammalian	O
HIF	O
regulation	O
by	O
the	O
EGLNs	O
and	O
VHL	B-Protein
.	O

In	O
this	O
system	O
,	O
yeast	O
growth	O
,	O
under	O
specific	O
nutrient	O
restrictions	O
,	O
is	O
driven	O
by	O
the	O
interaction	O
between	O
the	O
beta	O
domain	O
of	O
VHL	B-Protein
and	O
a	O
hydroxyproline	O
-	O
containing	O
HIFalpha	O
peptide	O
.	O

In	O
turn	O
,	O
this	O
interaction	O
is	O
strictly	O
dependent	O
on	O
EGLN	O
activity	O
that	O
hydroxylates	O
the	O
HIFalpha	O
peptide	O
.	O

Importantly	O
,	O
this	O
system	O
accurately	O
preserves	O
the	O
specificity	O
of	O
the	O
hydroxylation	O
reaction	O
toward	O
specific	O
substrates	O
.	O

We	O
propose	O
that	O
this	O
system	O
,	O
in	O
combination	O
with	O
a	O
matched	O
control	O
,	O
can	O
be	O
used	O
as	O
a	O
simple	O
and	O
inexpensive	O
assay	O
to	O
identify	O
molecules	O
that	O
specifically	O
modulate	O
EGLN	O
activity	O
.	O

As	O
a	O
proof	O
of	O
principle	O
we	O
show	O
that	O
two	O
known	O
EGLN	O
inhibitors	O
,	O
dimethyloxaloylglycine	O
(	O
DMOG	O
)	O
and	O
6	O
-	O
chlor	O
-	O
3	O
-	O
hydroxychinolin	O
-	O
2	O
-	O
carbonic	O
acid	O
-	O
N	O
-	O
carboxymethylamide	O
(	O
S956711	O
)	O
,	O
have	O
a	O
profound	O
and	O
specific	O
effect	O
on	O
the	O
yeast	O
HIF	O
/	O
EGLN	O
/	O
VHL	B-Protein
system	O
.	O

CONCLUSION	O
:	O
The	O
system	O
described	O
in	O
this	O
work	O
accurately	O
reconstitutes	O
HIF	O
regulation	O
while	O
preserving	O
EGLN	O
substrate	O
specificity	O
.	O

Thus	O
,	O
it	O
is	O
a	O
valuable	O
tool	O
to	O
study	O
HIF	O
regulation	O
,	O
and	O
particularly	O
EGLN	O
biochemistry	O
,	O
in	O
a	O
cellular	O
context	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
this	O
system	O
can	O
be	O
used	O
to	O
identify	O
specific	O
inhibitors	O
of	O
the	O
EGLN	O
enzymes	O
.	O

Biochemical	O
and	O
biophysical	O
analyses	O
of	O
Ras	O
modification	O
by	O
ubiquitin	B-Protein
.	O

Ras	O
proteins	O
are	O
small	O
GTPases	O
that	O
play	O
key	O
roles	O
in	O
the	O
regulation	O
of	O
several	O
cellular	O
processes	O
such	O
as	O
growth	O
,	O
differentiation	O
,	O
and	O
transformation	O
.	O

Although	O
Ras	O
signaling	O
was	O
thought	O
to	O
occur	O
uniformly	O
on	O
the	O
inner	O
leaflet	O
of	O
the	O
plasma	O
membrane	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
indicates	O
that	O
Ras	O
activation	O
happens	O
dynamically	O
within	O
defined	O
plasma	O
membrane	O
microdomains	O
and	O
at	O
other	O
specific	O
intracellular	O
compartments	O
,	O
thus	O
ensuring	O
the	O
generation	O
of	O
distinct	O
signal	O
outputs	O
.	O

Yet	O
the	O
mechanisms	O
that	O
control	O
the	O
spatiotemporal	O
segregation	O
of	O
Ras	O
proteins	O
remain	O
poorly	O
characterized	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
differential	O
modification	O
of	O
Ras	O
proteins	O
by	O
ubiquitination	O
is	O
a	O
crucial	O
factor	O
that	O
controls	O
Ras	O
intracellular	O
trafficking	O
and	O
signaling	O
potential	O
.	O

To	O
better	O
understand	O
the	O
process	O
of	O
Ras	O
ubiquitination	O
,	O
it	O
is	O
important	O
to	O
establish	O
assays	O
that	O
not	O
only	O
provide	O
information	O
about	O
the	O
nature	O
of	O
the	O
ubiquitin	B-Protein
modification	O
involved	O
,	O
but	O
also	O
enable	O
the	O
monitoring	O
of	O
the	O
dynamics	O
of	O
this	O
process	O
.	O

In	O
this	O
chapter	O
,	O
we	O
will	O
describe	O
biochemical	O
and	O
biophysical	O
methodologies	O
,	O
namely	O
immunoprecipitation	O
,	O
nickel	O
-	O
chelate	O
affinity	O
chromatography	O
,	O
and	O
bioluminescence	O
resonance	O
energy	O
transfer	O
(	O
BRET	O
)	O
,	O
for	O
monitoring	O
the	O
ubiquitination	O
of	O
Ras	O
proteins	O
.	O

Although	O
the	O
description	O
focuses	O
on	O
Ras	O
,	O
the	O
assays	O
described	O
can	O
in	O
principle	O
be	O
applied	O
to	O
the	O
study	O
of	O
a	O
range	O
of	O
proteins	O
of	O
interest	O
that	O
may	O
be	O
subject	O
to	O
ubiquitination	O
,	O
and	O
the	O
use	O
of	O
the	O
different	O
methods	O
in	O
parallel	O
should	O
provide	O
new	O
insights	O
into	O
the	O
nature	O
and	O
dynamics	O
of	O
protein	O
ubiquitination	O
.	O

Repression	O
of	O
transcriptional	O
activity	O
of	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
by	O
a	O
Cullin3	B-Protein
/	O
SPOP	B-Protein
ubiquitin	O
E3	O
ligase	O
complex	O
.	O

The	O
role	O
of	O
SPOP	B-Protein
in	O
the	O
ubiquitination	O
of	O
ER	B-Protein
alpha	I-Protein
by	O
the	O
Cullin3	B-Protein
-	O
based	O
E3	O
ubiquitin	B-Protein
ligase	O
complex	O
was	O
investigated	O
.	O

We	O
showed	O
that	O
the	O
N	O
-	O
terminal	O
region	O
of	O
SPOP	B-Protein
containing	O
the	O
MATH	O
domain	O
interacts	O
with	O
the	O
AF	O
-	O
2	O
domain	O
of	O
ER	B-Protein
alpha	I-Protein
in	O
cultured	O
human	O
embryonic	O
293	O
cells	O
.	O

SPOP	B-Protein
was	O
required	O
for	O
coimmunoprecipitation	O
of	O
ER	B-Protein
alpha	I-Protein
;	O
with	O
Cullin3	B-Protein
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
essential	O
role	O
of	O
SPOP	B-Protein
in	O
ERalpha	B-Protein
ubiquitination	O
by	O
the	O
Cullin3	B-Protein
-	O
based	O
E3	O
ubiquitin	B-Protein
ligase	O
complex	O
.	O

We	O
also	O
demonstrated	O
repression	O
of	O
the	O
transactivation	O
capability	O
of	O
ER	B-Protein
alpha	I-Protein
;	O
in	O
cultured	O
mammalian	O
cells	O
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
Pdcd4	B-Protein
expression	O
causes	O
upregulation	O
of	O
p21	B-Protein
(	O
Waf1	B-Protein
/	O
Cip1	B-Protein
)	O
expression	O
.	O

The	O
transformation	O
suppressor	O
gene	O
,	O
programmed	B-Protein
cell	I-Protein
death	I-Protein
gene	I-Protein
4	I-Protein
(	O
Pdcd4	B-Protein
)	O
,	O
inhibits	O
tumor	O
-	O
promoter	O
-	O
mediated	O
transformation	O
of	O
mouse	O
keratinocytes	O
and	O
has	O
been	O
implicated	O
as	O
a	O
tumor	O
suppressor	O
gene	O
in	O
the	O
development	O
of	O
human	O
cancer	O
.	O

The	O
Pdcd4	B-Protein
protein	O
interacts	O
with	O
translation	O
initiation	O
factors	O
eIF4A	B-Protein
and	O
eIF4G	B-Protein
and	O
binds	O
to	O
RNA	O
,	O
suggesting	O
that	O
it	O
might	O
be	O
involved	O
in	O
regulating	O
protein	O
translation	O
or	O
other	O
aspects	O
of	O
RNA	O
metabolism	O
.	O

To	O
study	O
the	O
function	O
of	O
Pdcd4	B-Protein
in	O
more	O
detail	O
,	O
we	O
have	O
downregulated	O
Pdcd4	B-Protein
expression	O
in	O
HeLa	O
cells	O
by	O
stable	O
expression	O
of	O
shRNA	O
.	O

We	O
have	O
found	O
that	O
diminished	O
Pdcd4	B-Protein
expression	O
leads	O
to	O
increased	O
expression	O
of	O
p21	B-Protein
(	O
Waf1	B-Protein
/	O
Cip1	B-Protein
)	O
and	O
several	O
other	O
p53	B-Protein
-	O
regulated	O
genes	O
.	O

Reporter	O
gene	O
studies	O
demonstrate	O
that	O
Pdcd4	B-Protein
interferes	O
with	O
the	O
activation	O
of	O
p53	B-Protein
-	O
responsive	O
promoters	O
genes	O
by	O
p53	B-Protein
.	O

Pdcd4	B-Protein
knockdown	O
cells	O
show	O
decreased	O
apoptosis	O
and	O
increased	O
survival	O
after	O
UV	O
irradiation	O
.	O

Taken	O
together	O
,	O
our	O
observations	O
suggest	O
a	O
model	O
in	O
which	O
low	O
Pdcd4	B-Protein
expression	O
after	O
DNA	O
damage	O
favors	O
the	O
survival	O
of	O
cells	O
,	O
which	O
would	O
be	O
eliminated	O
by	O
apoptosis	O
under	O
normal	O
levels	O
of	O
Pdcd4	B-Protein
expression	O
.	O

Our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
Pdcd4	B-Protein
is	O
important	O
role	O
in	O
the	O
DNA	O
-	O
damage	O
response	O
and	O
suggest	O
that	O
low	O
levels	O
of	O
Pdcd4	B-Protein
expression	O
observed	O
in	O
certain	O
tumor	O
cells	O
contribute	O
to	O
tumorigenesis	O
by	O
affecting	O
the	O
fate	O
of	O
DNA	O
-	O
damaged	O
cells	O
.	O

AIMP1	B-Protein
/	O
p43	B-Protein
downregulates	O
TGF	O
-	O
beta	O
signaling	O
via	O
stabilization	O
of	O
smurf2	B-Protein
.	O

AIMP1	B-Protein
(	O
also	O
known	O
as	O
p43	B-Protein
)	O
is	O
a	O
factor	O
associated	O
with	O
a	O
macromolecular	O
aminoacyl	O
-	O
tRNA	O
synthetase	O
(	O
ARS	O
)	O
complex	O
but	O
also	O
plays	O
diverse	O
regulatory	O
roles	O
in	O
various	O
physiological	O
processes	O
.	O

Here	O
,	O
we	O
report	O
that	O
AIMP1	B-Protein
negatively	O
regulates	O
TGF	O
-	O
beta	O
signaling	O
via	O
stabilization	O
of	O
Smurf2	B-Protein
.	O

TGF	O
-	O
beta	O
-	O
dependent	O
phosphorylation	O
and	O
nuclear	O
localization	O
of	O
R	O
-	O
Smads	O
,	O
induction	O
of	O
target	O
genes	O
,	O
and	O
growth	O
arrest	O
were	O
increased	O
in	O
AIMP1	B-Protein
-	O
deficient	O
or	O
-	O
suppressed	O
cells	O
.	O

In	O
AIMP1	B-Protein
-	O
deficient	O
or	O
suppressed	O
cells	O
,	O
the	O
Smurf2	B-Protein
level	O
was	O
decreased	O
.	O

Various	O
binding	O
assays	O
demonstrated	O
the	O
direction	O
interaction	O
of	O
the	O
C	O
-	O
terminal	O
region	O
of	O
AIMP1	B-Protein
directly	O
with	O
the	O
Smad7	B-Protein
-	O
binding	O
region	O
of	O
Smurf2	B-Protein
.	O

The	O
association	O
of	O
Smurf2	B-Protein
with	O
Smad7	B-Protein
and	O
its	O
ubiquitination	O
were	O
inhibited	O
by	O
AIMP1	B-Protein
,	O
thereby	O
protecting	O
its	O
autocatalytic	O
degradation	O
stimulated	O
by	O
Smad7	B-Protein
.	O

Thus	O
,	O
this	O
work	O
suggests	O
the	O
novel	O
activity	O
of	O
AIMP1	B-Protein
as	O
a	O
component	O
of	O
negative	O
feedback	O
loop	O
of	O
TGF	O
-	O
beta	O
signaling	O
.	O

Polycomb	O
group	O
protein	O
-	O
associated	O
chromatin	O
is	O
reproduced	O
in	O
post	O
-	O
mitotic	O
G1	O
phase	O
and	O
is	O
required	O
for	O
S	O
phase	O
progression	O
.	O

Polycomb	O
group	O
(	O
PcG	O
)	O
proteins	O
form	O
two	O
distinct	O
complexes	O
,	O
PRC1	O
and	O
PRC2	O
,	O
to	O
regulate	O
developmental	O
target	O
genes	O
by	O
maintaining	O
the	O
epigenetic	O
state	O
in	O
cells	O
.	O

PRC2	O
methylates	O
histone	B-Protein
H3	I-Protein
at	O
lysine	O
27	O
(	O
H3K27	B-Protein
)	O
,	O
and	O
PRC1	O
then	O
recognizes	O
methyl	O
-	O
H3K27	B-Protein
to	O
form	O
repressive	O
chromatin	O
.	O

However	O
,	O
it	O
remains	O
unknown	O
how	O
PcG	O
proteins	O
maintain	O
stable	O
and	O
plastic	O
chromatin	O
during	O
cell	O
division	O
.	O

Here	O
we	O
report	O
that	O
PcG	O
-	O
associated	O
chromatin	O
is	O
reproduced	O
in	O
the	O
G	O
(	O
1	O
)	O
phase	O
in	O
post	O
-	O
mitotic	O
cells	O
and	O
is	O
required	O
for	O
subsequent	O
S	O
phase	O
progression	O
.	O

In	O
dividing	O
cells	O
,	O
H3K27	B-Protein
trimethylation	O
(	O
H3K27Me	B-Protein
(	O
3	O
)	O
)	O
marked	O
mitotic	O
chromosome	O
arms	O
where	O
PRC2	O
(	O
Suz12	B-Protein
and	O
Ezh2	B-Protein
)	O
co	O
-	O
existed	O
,	O
whereas	O
PRC1	O
(	O
Bmi1	B-Protein
and	O
Pc2	B-Protein
)	O
appeared	O
in	O
distinct	O
foci	O
in	O
the	O
pericentromeric	O
regions	O
.	O

As	O
each	O
PRC	O
complex	O
was	O
increasingly	O
assembled	O
from	O
mitosis	O
to	O
G	O
(	O
1	O
)	O
phase	O
,	O
PRC1	O
formed	O
H3K27Me	B-Protein
(	O
3	O
)	O
-	O
based	O
chromatin	O
intensively	O
during	O
middle	O
and	O
late	O
G	O
(	O
1	O
)	O
phase	O
;	O
this	O
chromatin	O
was	O
highly	O
resistant	O
to	O
in	O
situ	O
nuclease	O
treatment	O
.	O

Thus	O
,	O
the	O
transition	O
from	O
mitosis	O
to	O
G	O
(	O
1	O
)	O
phase	O
is	O
crucial	O
for	O
PcG	O
-	O
mediated	O
chromatin	O
inheritance	O
.	O

Knockdown	O
of	O
Suz12	B-Protein
markedly	O
reduced	O
the	O
amount	O
of	O
H3K27Me	B-Protein
(	O
3	O
)	O
on	O
mitotic	O
chromosomes	O
,	O
and	O
as	O
a	O
consequence	O
,	O
PRC1	O
foci	O
were	O
not	O
fully	O
transmitted	O
to	O
post	O
-	O
mitotic	O
daughter	O
cells	O
.	O

S	O
phase	O
progression	O
was	O
markedly	O
delayed	O
in	O
these	O
Suz12	B-Protein
-	O
knockdown	O
cells	O
.	O

The	O
fact	O
that	O
PcG	O
-	O
associated	O
chromatin	O
is	O
reproduced	O
during	O
post	O
-	O
mitotic	O
G	O
(	O
1	O
)	O
phase	O
suggests	O
the	O
possibility	O
that	O
PcG	O
proteins	O
enable	O
their	O
target	O
chromatin	O
to	O
be	O
remodeled	O
in	O
response	O
to	O
stimuli	O
in	O
the	O
G	O
(	O
1	O
)	O
phase	O
.	O

Cooperation	O
between	O
EZH2	B-Protein
,	O
NSPc1	B-Protein
-	O
mediated	O
histone	B-Protein
H2A	I-Protein
ubiquitination	O
and	O
Dnmt1	B-Protein
in	O
HOX	O
gene	O
silencing	O
.	O

An	O
intricate	O
interplay	O
between	O
DNA	O
methylation	O
and	O
polycomb	O
-	O
mediated	O
gene	O
silencing	O
has	O
been	O
highlighted	O
recently	O
.	O

Here	O
we	O
provided	O
evidence	O
that	O
Nervous	B-Protein
System	I-Protein
Polycomb	I-Protein
1	I-Protein
(	O
NSPc1	B-Protein
)	O
,	O
a	O
BMI1	B-Protein
homologous	O
polycomb	O
protein	O
,	O
plays	O
important	O
roles	O
in	O
promoting	O
H2A	B-Protein
ubiquitination	O
and	O
cooperates	O
with	O
DNA	O
methylation	O
in	O
HOX	O
gene	O
silencing	O
.	O

We	O
showed	O
that	O
NSPc1	B-Protein
stimulates	O
H2A	B-Protein
ubiquitination	O
in	O
vivo	O
and	O
in	O
vitro	O
through	O
direct	O
interaction	O
with	O
both	O
RING2	B-Protein
and	O
H2A	B-Protein
.	O

RT	O
-	O
PCR	O
analysis	O
revealed	O
that	O
loss	O
of	O
NSPc1	B-Protein
,	O
EZH2	B-Protein
or	O
DNA	B-Protein
methyltransferase	I-Protein
1	I-Protein
(	O
Dnmt1	B-Protein
)	O
,	O
or	O
inhibition	O
of	O
DNA	O
methylation	O
in	O
HeLa	O
cells	O
de	O
-	O
represses	O
the	O
expression	O
of	O
HOXA7	B-Protein
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
demonstrated	O
that	O
NSPc1	B-Protein
,	O
EZH2	B-Protein
and	O
Dnmt1	B-Protein
bind	O
to	O
the	O
promoter	O
of	O
HOXA7	B-Protein
,	O
which	O
is	O
frequently	O
hypermethylated	O
in	O
tumors	O
.	O

Knockdown	O
of	O
NSPc1	B-Protein
results	O
in	O
significant	O
reduction	O
of	O
H2A	B-Protein
ubiquitination	O
and	O
DNA	O
demethylation	O
as	O
well	O
as	O
Dnmt1	B-Protein
dissociation	O
in	O
the	O
HOXA7	B-Protein
promoter	O
.	O

Meanwhile	O
Dnmt1	B-Protein
deficiency	O
affects	O
NSPc1	B-Protein
recruitment	O
and	O
H2A	B-Protein
ubiquitination	O
,	O
whereas	O
on	O
both	O
cases	O
EZH2	B-Protein
-	O
mediated	O
H3K27	B-Protein
trimethylation	O
remains	O
unaffected	O
.	O

When	O
EZH2	B-Protein
was	O
depleted	O
,	O
however	O
,	O
NSPc1	B-Protein
and	O
Dnmt1	B-Protein
enrichment	O
was	O
abolished	O
concomitant	O
with	O
local	O
reduction	O
of	O
H3K27	B-Protein
trimethylation	O
,	O
H2A	B-Protein
ubiquitination	O
and	O
DNA	O
methylation	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicated	O
that	O
NSPc1	B-Protein
-	O
mediated	O
H2A	B-Protein
ubiquitination	O
and	O
DNA	O
methylation	O
,	O
both	O
being	O
directed	O
by	O
EZH2	B-Protein
,	O
are	O
interdependent	O
in	O
long	O
-	O
term	O
target	O
gene	O
silencing	O
within	O
cancer	O
cells	O
.	O

Interaction	O
of	O
prolyl	O
4	O
-	O
hydroxylase	O
with	O
synthetic	O
peptide	O
substrates	O
.	O

A	O
conformational	O
model	O
for	O
collagen	O
proline	O
hydroxylation	O
.	O

With	O
the	O
aim	O
of	O
understanding	O
the	O
structural	O
basis	O
for	O
the	O
substrate	O
specificity	O
of	O
collagen	O
prolyl	O
4	O
-	O
hydroxylase	O
,	O
we	O
have	O
studied	O
the	O
conformational	O
features	O
of	O
synthetic	O
oligopeptide	O
substrates	O
and	O
their	O
interaction	O
with	O
the	O
enzyme	O
purified	O
from	O
chicken	O
embryo	O
.	O

Circular	O
dichroism	O
and	O
infrared	O
spectral	O
data	O
,	O
taken	O
in	O
conjunction	O
with	O
relevant	O
crystal	O
structure	O
data	O
,	O
indicated	O
an	O
equilibrium	O
mixture	O
of	O
the	O
polyproline	O
-	O
II	O
(	O
PP	O
-	O
II	O
)	O
helix	O
,	O
the	O
beta	O
-	O
turn	O
,	O
and	O
the	O
random	O
coil	O
conformations	O
in	O
aqueous	O
and	O
trifluoroethanol	O
solutions	O
of	O
the	O
"	O
collagen	O
-	O
related	O
"	O
peptides	O
:	O
t	O
-	O
Boc	O
-	O
Pro	O
-	O
Pro	O
-	O
Gly	O
-	O
Pro	O
-	O
OH	O
,	O
t	O
-	O
Boc	O
-	O
Pro	O
-	O
Pro	O
-	O
Gly	O
-	O
Pro	O
-	O
NHCH3	O
,	O
t	O
-	O
Pro	O
-	O
Pro	O
-	O
Gly	O
-	O
Pro	O
-	O
Pro	O
-	O
OH	O
,	O
t	O
-	O
Boc	O
-	O
Pro	O
-	O
Pro	O
-	O
Ala	O
-	O
Pro	O
-	O
OH	O
,	O
and	O
t	O
-	O
Boc	O
-	O
Pro	O
-	O
Pro	O
-	O
Gln	O
-	O
Pro	O
-	O
OCH3	O
,	O
where	O
t	O
-	O
Boc	O
is	O
tert	O
-	O
butoxycarbonyl	O
.	O

In	O
another	O
set	O
of	O
peptides	O
related	O
to	O
elastin	B-Protein
,	O
t	O
-	O
Boc	O
-	O
Val	O
-	O
Pro	O
-	O
Gly	O
-	O
Val	O
-	O
OH	O
and	O
t	O
-	O
Boc	O
-	O
Gly	O
-	O
Val	O
-	O
Pro	O
-	O
Gly	O
-	O
Val	O
-	O
OH	O
,	O
the	O
data	O
indicated	O
the	O
beta	O
-	O
structure	O
,	O
rather	O
than	O
the	O
PP	O
-	O
II	O
helix	O
,	O
was	O
in	O
equilibrium	O
with	O
the	O
beta	O
-	O
turn	O
.	O

Kinetic	O
parameters	O
for	O
the	O
enzymatic	O
hydroxylation	O
of	O
the	O
peptides	O
showed	O
that	O
as	O
a	O
group	O
,	O
the	O
first	O
(	O
proline	O
-	O
rich	O
)	O
set	O
of	O
peptides	O
has	O
higher	O
Km	O
values	O
and	O
lower	O
Vmax	O
and	O
Kcat	O
/	O
Km	O
values	O
than	O
the	O
valine	O
-	O
rich	O
peptides	O
.	O

Data	O
on	O
the	O
inhibition	O
of	O
hydroxylation	O
of	O
the	O
standard	O
assay	O
substrate	O
(	O
Pro	O
-	O
Pro	O
-	O
Gly	O
)	O
10	O
by	O
the	O
oligopeptides	O
pointed	O
to	O
common	O
binding	O
sites	O
for	O
the	O
peptides	O
.	O

Hydroxyproline	O
-	O
containing	O
peptides	O
had	O
no	O
effect	O
on	O
the	O
hydroxylation	O
of	O
the	O
standard	O
substrate	O
,	O
showing	O
the	O
absence	O
of	O
product	O
inhibition	O
.	O

Based	O
on	O
these	O
and	O
earlier	O
data	O
,	O
we	O
propose	O
that	O
in	O
collagen	O
and	O
related	O
peptides	O
,	O
a	O
supersecondary	O
structure	O
consisting	O
of	O
the	O
PP	O
-	O
II	O
helix	O
followed	O
by	O
the	O
beta	O
-	O
turn	O
is	O
the	O
minimal	O
structural	O
requirement	O
for	O
proline	O
hydroxylation	O
.	O

The	O
PP	O
-	O
II	O
structure	O
would	O
aid	O
effective	O
interaction	O
at	O
the	O
substrate	O
binding	O
subsites	O
,	O
while	O
the	O
beta	O
-	O
turn	O
would	O
be	O
essential	O
at	O
the	O
catalytic	O
site	O
of	O
the	O
enzyme	O
.	O

In	O
elastin	O
and	O
related	O
peptides	O
,	O
the	O
beta	O
-	O
strand	O
structure	O
may	O
be	O
interchangeable	O
with	O
the	O
PP	O
-	O
II	O
structure	O
.	O

This	O
conformational	O
model	O
for	O
proline	O
hydroxylation	O
resolves	O
the	O
discrepancies	O
in	O
earlier	O
proposals	O
on	O
the	O
substrate	O
specificity	O
of	O
prolyl	O
4	O
-	O
hydroxylase	O
.	O

It	O
is	O
also	O
consistent	O
with	O
the	O
available	O
information	O
on	O
the	O
active	O
site	O
geometry	O
of	O
the	O
enzyme	O
.	O

Recognition	O
of	O
polyubiquitin	B-Protein
isoforms	O
by	O
the	O
multiple	O
ubiquitin	O
binding	O
modules	O
of	O
isopeptidase	B-Protein
T	I-Protein
.	O

The	O
conjugation	O
of	O
polyubiquitin	B-Protein
to	O
target	O
proteins	O
acts	O
as	O
a	O
signal	O
that	O
regulates	O
target	O
stability	O
,	O
localization	O
,	O
and	O
function	O
.	O

Several	O
ubiquitin	B-Protein
binding	O
domains	O
have	O
been	O
described	O
,	O
and	O
while	O
much	O
is	O
known	O
about	O
ubiquitin	B-Protein
binding	O
to	O
the	O
isolated	O
domains	O
,	O
little	O
is	O
known	O
with	O
regard	O
to	O
how	O
the	O
domains	O
interact	O
with	O
polyubiquitin	B-Protein
in	O
the	O
context	O
of	O
full	O
-	O
length	O
proteins	O
.	O

Isopeptidase	B-Protein
T	I-Protein
(	O
IsoT	B-Protein
/	O
USP5	B-Protein
)	O
is	O
a	O
deubiquitinating	O
enzyme	O
that	O
is	O
largely	O
responsible	O
for	O
the	O
disassembly	O
of	O
unanchored	O
polyubiquitin	B-Protein
in	O
the	O
cell	O
.	O

IsoT	B-Protein
has	O
four	O
ubiquitin	B-Protein
binding	O
domains	O
:	O
a	O
zinc	O
finger	O
domain	O
(	O
ZnF	O
UBP	O
)	O
,	O
which	O
binds	O
the	O
proximal	O
ubiquitin	B-Protein
,	O
a	O
UBP	O
domain	O
that	O
forms	O
the	O
active	O
site	O
,	O
and	O
two	O
ubiquitin	O
-	O
associated	O
(	O
UBA	O
)	O
domains	O
whose	O
roles	O
are	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
UBA	O
domains	O
are	O
involved	O
in	O
binding	O
two	O
different	O
polyubiquitin	B-Protein
isoforms	O
,	O
linear	O
and	O
K48	O
-	O
linked	O
.	O

Using	O
isothermal	O
titration	O
calorimetry	O
,	O
we	O
show	O
that	O
IsoT	B-Protein
has	O
at	O
least	O
four	O
ubiquitin	B-Protein
binding	O
sites	O
for	O
both	O
polyubiquitin	B-Protein
isoforms	O
.	O

The	O
thermodynamics	O
of	O
the	O
interactions	O
reveal	O
that	O
the	O
binding	O
is	O
enthalpy	O
-	O
driven	O
.	O

Mutation	O
of	O
the	O
UBA	O
domains	O
suggests	O
that	O
UBA1	O
and	O
UBA2	O
domains	O
of	O
IsoT	B-Protein
interact	O
with	O
the	O
third	O
and	O
fourth	O
ubiquitins	B-Protein
in	O
both	O
polyubiquitin	B-Protein
isoforms	O
,	O
respectively	O
.	O

These	O
data	O
suggest	O
that	O
recognition	O
of	O
the	O
polyubiquitin	B-Protein
isoforms	O
by	O
IsoT	B-Protein
involves	O
considerable	O
conformational	O
mobility	O
in	O
the	O
polyubiquitin	B-Protein
ligand	O
,	O
in	O
the	O
enzyme	O
,	O
or	O
in	O
both	O
.	O

Gene	O
silencing	O
in	O
cancer	O
by	O
histone	B-Protein
H3	I-Protein
lysine	O
27	O
trimethylation	O
independent	O
of	O
promoter	O
DNA	O
methylation	O
.	O

Epigenetic	O
silencing	O
in	O
cancer	O
cells	O
is	O
mediated	O
by	O
at	O
least	O
two	O
distinct	O
histone	B-Protein
modifications	O
,	O
polycomb	O
-	O
based	O
histone	B-Protein
H3	I-Protein
lysine	O
27	O
trimethylation	O
(	O
H3K27triM	B-Protein
)	O
and	O
H3K9	B-Protein
dimethylation	O
.	O

The	O
relationship	O
between	O
DNA	O
hypermethylation	O
and	O
these	O
histone	B-Protein
modifications	O
is	O
not	O
completely	O
understood	O
.	O

Using	O
chromatin	O
immunoprecipitation	O
microarrays	O
(	O
ChIP	O
-	O
chip	O
)	O
in	O
prostate	O
cancer	O
cells	O
compared	O
to	O
normal	O
prostate	O
,	O
we	O
found	O
that	O
up	O
to	O
5	O
%	O
of	O
promoters	O
(	O
16	O
%	O
CpG	O
islands	O
and	O
84	O
%	O
non	O
-	O
CpG	O
islands	O
)	O
were	O
enriched	O
with	O
H3K27triM	B-Protein
.	O

These	O
genes	O
were	O
silenced	O
specifically	O
in	O
prostate	O
cancer	O
,	O
and	O
those	O
CpG	O
islands	O
affected	O
showed	O
low	O
levels	O
of	O
DNA	O
methylation	O
.	O

Downregulation	O
of	O
the	O
EZH2	B-Protein
histone	B-Protein
methyltransferase	O
restored	O
expression	O
of	O
the	O
H3K27triM	B-Protein
target	O
genes	O
alone	O
or	O
in	O
synergy	O
with	O
histone	B-Protein
deacetylase	O
inhibition	O
,	O
without	O
affecting	O
promoter	O
DNA	O
methylation	O
,	O
and	O
with	O
no	O
effect	O
on	O
the	O
expression	O
of	O
genes	O
silenced	O
by	O
DNA	O
hypermethylation	O
.	O

These	O
data	O
establish	O
EZH2	B-Protein
-	O
mediated	O
H3K27triM	B-Protein
as	O
a	O
mechanism	O
of	O
tumor	O
-	O
suppressor	O
gene	O
silencing	O
in	O
cancer	O
that	O
is	O
potentially	O
independent	O
of	O
promoter	O
DNA	O
methylation	O
.	O

Asymmetric	O
mitosis	O
:	O
Unequal	O
segregation	O
of	O
proteins	O
destined	O
for	O
degradation	O
.	O

Mitotic	O
cell	O
division	O
ensures	O
that	O
two	O
daughter	O
somatic	O
cells	O
inherit	O
identical	O
genetic	O
material	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
signaling	O
by	O
the	O
Smad1	B-Protein
transcription	O
factor	O
is	O
terminated	O
by	O
polyubiquitinylation	O
and	O
proteasomal	O
degradation	O
after	O
essential	O
phosphorylations	O
by	O
MAPK	O
and	O
glycogen	O
synthase	O
kinase	O
3	O
(	O
GSK3	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
,	O
unexpectedly	O
,	O
proteins	O
specifically	O
targeted	O
for	O
proteasomal	O
degradation	O
are	O
inherited	O
preferentially	O
by	O
one	O
mitotic	O
daughter	O
during	O
somatic	O
cell	O
division	O
.	O

Experiments	O
with	O
dividing	O
human	O
embryonic	O
stem	O
cells	O
and	O
other	O
mammalian	O
cultured	O
cell	O
lines	O
demonstrated	O
that	O
in	O
many	O
supposedly	O
equal	O
mitoses	O
the	O
segregation	O
of	O
proteins	O
destined	O
for	O
degradation	O
(	O
Smad1	B-Protein
phosphorylated	O
by	O
MAPK	O
and	O
GSK3	O
,	O
phospho	O
-	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
,	O
and	O
total	O
polyubiquitinylated	O
proteins	O
)	O
was	O
asymmetric	O
.	O

Transport	O
of	O
pSmad1	B-Protein
targeted	O
for	O
degradation	O
to	O
the	O
centrosome	O
required	O
functional	O
microtubules	O
.	O

In	O
vivo	O
,	O
an	O
antibody	O
specific	O
for	O
Mad	B-Protein
phosphorylated	O
by	O
MAPK	O
showed	O
that	O
this	O
antigen	O
was	O
associated	O
preferentially	O
with	O
one	O
of	O
the	O
two	O
centrosomes	O
in	O
Drosophila	O
embryos	O
at	O
cellular	O
blastoderm	O
stage	O
.	O

We	O
propose	O
that	O
this	O
remarkable	O
cellular	O
property	O
may	O
be	O
explained	O
by	O
the	O
asymmetric	O
inheritance	O
of	O
peripheral	O
centrosomal	O
proteins	O
when	O
centrioles	O
separate	O
and	O
migrate	O
to	O
opposite	O
poles	O
of	O
the	O
cell	O
,	O
so	O
that	O
one	O
mitotic	O
daughter	O
remains	O
pristine	O
.	O

We	O
conclude	O
that	O
many	O
mitotic	O
divisions	O
are	O
unequal	O
,	O
unlike	O
what	O
was	O
previously	O
thought	O
.	O

Highly	O
homologous	O
HERC	O
proteins	O
localize	O
to	O
endosomes	O
and	O
exhibit	O
specific	O
interactions	O
with	O
hPLIC	O
and	O
Nm23B	B-Protein
.	O

Small	O
HERC	O
proteins	O
are	O
defined	O
by	O
the	O
presence	O
of	O
one	O
RCC1	B-Protein
-	O
like	O
domain	O
and	O
a	O
HECT	O
domain	O
.	O

Having	O
evolved	O
out	O
of	O
one	O
common	O
ancestor	O
,	O
the	O
four	O
members	O
of	O
the	O
family	O
exhibit	O
a	O
high	O
degree	O
of	O
homology	O
in	O
genomic	O
organization	O
and	O
amino	O
acid	O
sequence	O
,	O
thus	O
it	O
seems	O
possible	O
that	O
they	O
might	O
accomplish	O
similar	O
functions	O
.	O

Here	O
we	O
show	O
that	O
small	O
HERC	O
proteins	O
interact	O
with	O
each	O
other	O
and	O
localize	O
to	O
the	O
same	O
cellular	O
structures	O
,	O
which	O
we	O
identify	O
as	O
late	O
endosomes	O
and	O
lysosomes	O
.	O

We	O
demonstrate	O
interaction	O
of	O
HERC3	B-Protein
with	O
the	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
hPLIC	B-Protein
-	I-Protein
1	I-Protein
and	O
hPLIC	B-Protein
-	I-Protein
2	I-Protein
and	O
we	O
establish	O
interaction	O
of	O
HERC5	B-Protein
with	O
the	O
metastasis	O
suppressor	O
Nm23B	B-Protein
.	O

While	O
hPLIC	O
proteins	O
are	O
not	O
ubiquitinated	O
by	O
HERC3	B-Protein
,	O
HERC5	B-Protein
plays	O
an	O
important	O
role	O
in	O
ubiquitination	O
of	O
Nm23B	B-Protein
.	O

In	O
summary	O
,	O
although	O
small	O
HERC	O
proteins	O
are	O
highly	O
homologous	O
showing	O
the	O
same	O
subcellular	O
distribution	O
,	O
they	O
undergo	O
different	O
molecular	O
interactions	O
.	O

Inferring	O
causal	O
relationships	O
among	O
different	O
histone	B-Protein
modifications	O
and	O
gene	O
expression	O
.	O

Histone	B-Protein
modifications	O
are	O
major	O
epigenetic	O
factors	O
regulating	O
gene	O
expression	O
.	O

They	O
play	O
important	O
roles	O
in	O
maintaining	O
stem	O
cell	O
pluripotency	O
and	O
in	O
cancer	O
pathogenesis	O
.	O

Different	O
modifications	O
may	O
combine	O
to	O
form	O
complex	O
"	O
histone	B-Protein
codes	O
.	O
"	O
Recent	O
high	O
-	O
throughput	O
technologies	O
,	O
such	O
as	O
"	O
ChIP	O
-	O
chip	O
"	O
and	O
"	O
ChIP	O
-	O
seq	O
,	O
"	O
have	O
generated	O
high	O
-	O
resolution	O
maps	O
for	O
many	O
histone	B-Protein
modifications	O
on	O
the	O
human	O
genome	O
.	O

Here	O
we	O
use	O
these	O
maps	O
to	O
build	O
a	O
Bayesian	O
network	O
to	O
infer	O
causal	O
and	O
combinatorial	O
relationships	O
among	O
histone	B-Protein
modifications	O
and	O
gene	O
expression	O
.	O

A	O
pilot	O
network	O
derived	O
by	O
the	O
same	O
method	O
among	O
polycomb	O
group	O
(	O
PcG	O
)	O
genes	O
and	O
H3K27	B-Protein
trimethylation	O
is	O
accurately	O
supported	O
by	O
current	O
literature	O
.	O

Our	O
unbiased	O
network	O
model	O
among	O
histone	B-Protein
modifications	O
is	O
also	O
well	O
supported	O
by	O
cross	O
-	O
validation	O
results	O
.	O

It	O
not	O
only	O
confirmed	O
already	O
known	O
relationships	O
,	O
such	O
as	O
those	O
of	O
H3K27me3	B-Protein
to	O
gene	O
silencing	O
,	O
H3K4me3	B-Protein
to	O
gene	O
activation	O
and	O
the	O
effect	O
of	O
bivalent	O
modification	O
of	O
both	O
H3K4me3	B-Protein
and	O
H3K27me3	B-Protein
,	O
but	O
also	O
identified	O
many	O
other	O
relationships	O
that	O
may	O
predict	O
new	O
epigenetic	O
interactions	O
important	O
in	O
epigenetic	O
gene	O
regulation	O
.	O

Our	O
automated	O
inference	O
method	O
,	O
which	O
is	O
potentially	O
applicable	O
to	O
other	O
ChIP	O
-	O
chip	O
or	O
ChIP	O
-	O
seq	O
data	O
analyses	O
,	O
provides	O
a	O
much	O
-	O
needed	O
guide	O
to	O
deciphering	O
the	O
complex	O
histone	O
codes	O
.	O

Antibody	O
fucosylation	O
differentially	O
impacts	O
cytotoxicity	O
mediated	O
by	O
NK	O
and	O
PMN	O
effector	O
cells	O
.	O

Glycosylation	O
of	O
the	O
antibody	O
Fc	O
fragment	O
is	O
essential	O
for	O
Fc	O
receptor	O
-	O
mediated	O
activity	O
.	O

Carbohydrate	O
heterogeneity	O
is	O
known	O
to	O
modulate	O
the	O
activity	O
of	O
effector	O
cells	O
in	O
the	O
blood	O
,	O
in	O
which	O
fucosylation	O
particularly	O
affects	O
NK	O
cell	O
-	O
mediated	O
killing	O
.	O

Here	O
,	O
we	O
investigated	O
how	O
the	O
glycosylation	O
profile	O
of	O
2F8	O
,	O
a	O
human	O
IgG	O
(	O
1	O
)	O
monoclonal	O
antibody	O
against	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
in	O
clinical	O
development	O
,	O
impacted	O
effector	O
function	O
.	O

Various	O
2F8	O
batches	O
differing	O
in	O
fucosylation	O
,	O
galactosylation	O
,	O
and	O
sialylation	O
of	O
the	O
complex	O
-	O
type	O
oligosaccharides	O
in	O
the	O
Fc	O
fragment	O
were	O
investigated	O
.	O

Our	O
results	O
confirmed	O
that	O
low	O
fucose	O
levels	O
enhance	O
mononuclear	O
cell	O
-	O
mediated	O
antibody	O
-	O
mediated	O
cellular	O
cytotoxicity	O
(	O
ADCC	O
)	O
.	O

In	O
contrast	O
,	O
polymorphonuclear	O
cells	O
were	O
found	O
to	O
preferentially	O
kill	O
via	O
high	O
-	O
fucosylated	O
antibody	O
.	O

Whole	O
blood	O
ADCC	O
assays	O
,	O
containing	O
both	O
types	O
of	O
effector	O
cells	O
,	O
revealed	O
little	O
differences	O
in	O
tumor	O
cell	O
killing	O
between	O
both	O
batches	O
.	O

Significantly	O
,	O
however	O
,	O
high	O
-	O
fucose	O
antibody	O
induced	O
superior	O
ADCC	O
in	O
blood	O
from	O
granulocyte	B-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
-	O
primed	O
donors	O
containing	O
higher	O
numbers	O
of	O
activated	O
polymorphonuclear	O
cells	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
lack	O
of	O
fucose	O
does	O
not	O
generally	O
increase	O
the	O
ADCC	O
activity	O
of	O
therapeutic	O
antibodies	O
and	O
that	O
the	O
impact	O
of	O
Fc	O
glycosylation	O
on	O
ADCC	O
is	O
critically	O
dependent	O
on	O
the	O
recruited	O
effector	O
cell	O
type	O
.	O

Substrate	O
-	O
binding	O
sites	O
of	O
UBR1	B-Protein
,	O
the	O
ubiquitin	B-Protein
ligase	O
of	O
the	O
N	O
-	O
end	O
rule	O
pathway	O
.	O

Substrates	O
of	O
a	O
ubiquitin	B-Protein
-	O
dependent	O
proteolytic	O
system	O
called	O
the	O
N	O
-	O
end	O
rule	O
pathway	O
include	O
proteins	O
with	O
destabilizing	O
N	O
-	O
terminal	O
residues	O
.	O

N	O
-	O
recognins	O
,	O
the	O
pathway	O
'	O
s	O
ubiquitin	B-Protein
ligases	O
,	O
contain	O
three	O
substrate	O
-	O
binding	O
sites	O
.	O

The	O
type	O
-	O
1	O
site	O
is	O
specific	O
for	O
basic	O
N	O
-	O
terminal	O
residues	O
(	O
Arg	O
,	O
Lys	O
,	O
and	O
His	O
)	O
.	O

The	O
type	O
-	O
2	O
site	O
is	O
specific	O
for	O
bulky	O
hydrophobic	O
N	O
-	O
terminal	O
residues	O
(	O
Trp	O
,	O
Phe	O
,	O
Tyr	O
,	O
Leu	O
,	O
and	O
Ile	O
)	O
.	O

We	O
show	O
here	O
that	O
the	O
type	O
-	O
1	O
/	O
2	O
sites	O
of	O
UBR1	B-Protein
,	O
the	O
sole	O
N	O
-	O
recognin	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
are	O
located	O
in	O
the	O
first	O
approximately	O
700	O
residues	O
of	O
the	O
1	O
,	O
950	O
-	O
residue	O
UBR1	B-Protein
.	O

These	O
sites	O
are	O
distinct	O
in	O
that	O
they	O
can	O
be	O
selectively	O
inactivated	O
by	O
mutations	O
,	O
identified	O
through	O
a	O
genetic	O
screen	O
.	O

Mutations	O
inactivating	O
the	O
type	O
-	O
1	O
site	O
are	O
in	O
the	O
previously	O
delineated	O
approximately	O
70	O
-	O
residue	O
UBR	O
motif	O
characteristic	O
of	O
N	O
-	O
recognins	O
.	O

Fluorescence	O
polarization	O
and	O
surface	O
plasmon	O
resonance	O
were	O
used	O
to	O
determine	O
that	O
UBR1	B-Protein
binds	O
,	O
with	O
a	O
K	O
(	O
d	O
)	O
of	O
approximately	O
1	O
microm	O
,	O
to	O
either	O
type	O
-	O
1	O
or	O
type	O
-	O
2	O
destabilizing	O
N	O
-	O
terminal	O
residues	O
of	O
reporter	O
peptides	O
but	O
does	O
not	O
bind	O
to	O
a	O
stabilizing	O
N	O
-	O
terminal	O
residue	O
such	O
as	O
Gly	O
.	O

A	O
third	O
substrate	O
-	O
binding	O
site	O
of	O
UBR1	B-Protein
targets	O
an	O
internal	O
degron	O
of	O
CUP9	B-Protein
,	O
a	O
transcriptional	O
repressor	O
of	O
peptide	O
import	O
.	O

We	O
show	O
that	O
the	O
previously	O
demonstrated	O
in	O
vivo	O
dependence	O
of	O
CUP9	B-Protein
ubiquitylation	O
on	O
the	O
binding	O
of	O
cognate	O
dipeptides	O
to	O
the	O
type	O
-	O
1	O
/	O
2	O
sites	O
of	O
UBR1	B-Protein
can	O
be	O
reconstituted	O
in	O
a	O
completely	O
defined	O
in	O
vitro	O
system	O
.	O

We	O
also	O
found	O
that	O
purified	O
UBR1	B-Protein
and	O
CUP9	B-Protein
interact	O
nonspecifically	O
and	O
that	O
specific	O
binding	O
(	O
which	O
involves	O
,	O
in	O
particular	O
,	O
the	O
binding	O
by	O
cognate	O
dipeptides	O
to	O
the	O
UBR1	B-Protein
type	O
-	O
1	O
/	O
2	O
sites	O
)	O
can	O
be	O
restored	O
either	O
by	O
a	O
chaperone	O
such	O
as	O
EF1A	B-Protein
or	O
through	O
macromolecular	O
crowding	O
.	O

Monoclonal	O
antibody	O
-	O
based	O
screening	O
assay	O
for	O
factor	B-Protein
inhibiting	I-Protein
hypoxia	I-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
inhibitors	O
.	O

The	O
factor	B-Protein
-	I-Protein
inhibiting	I-Protein
hypoxia	I-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	O
FIH	B-Protein
)	O
hydroxylates	O
the	O
asparagine	O
803	O
(	O
Asn803	O
)	O
residue	O
of	O
the	O
hypoxia	B-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
1alpha	I-Protein
(	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
)	O
,	O
and	O
the	O
modification	O
abrogates	O
the	O
transcriptional	O
activity	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
.	O

Because	O
FIH	B-Protein
is	O
more	O
active	O
on	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
than	O
prolyl	O
hydroxylase	O
domain	O
proteins	O
under	O
hypoxic	O
conditions	O
,	O
its	O
inhibitors	O
have	O
potential	O
to	O
be	O
developed	O
as	O
anti	O
-	O
ischemic	O
drugs	O
targeting	O
normal	O
cells	O
stressed	O
by	O
hypoxia	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
developed	O
the	O
first	O
monoclonal	O
antibody	O
,	O
SHN	O
-	O
HIF1alpha	B-Protein
,	O
specifically	O
to	O
Asn803	O
hydroxylated	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
and	O
a	O
sensitive	O
assay	O
system	O
for	O
FIH	B-Protein
inhibitors	O
using	O
the	O
monoclonal	O
antibody	O
(	O
Mab	O
)	O
.	O

SHN	O
-	O
HIF1alpha	B-Protein
showed	O
740	O
times	O
higher	O
affinity	O
to	O
the	O
Asn803	O
hydroxylated	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
peptide	O
than	O
the	O
unmodified	O
one	O
.	O

An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
-	O
based	O
system	O
using	O
SHN	O
-	O
HIF1alpha	B-Protein
displayed	O
at	O
least	O
30	O
times	O
more	O
sensitivity	O
than	O
previous	O
methods	O
for	O
screening	O
FIH	B-Protein
inhibitors	O
and	O
was	O
easily	O
applicable	O
to	O
develop	O
a	O
high	O
-	O
throughput	O
screening	O
system	O
.	O

SHN	O
-	O
HIF1alpha	B-Protein
also	O
showed	O
an	O
Asn803	O
hydroxylation	O
-	O
dependent	O
specificity	O
to	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
in	O
cells	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
it	O
may	O
be	O
used	O
to	O
analyze	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
activities	O
of	O
FIH	B-Protein
inhibitors	O
.	O

PRMT3	B-Protein
inhibits	O
ubiquitination	O
of	O
ribosomal	B-Protein
protein	I-Protein
S2	I-Protein
and	O
together	O
forms	O
an	O
active	O
enzyme	O
complex	O
.	O

Protein	B-Protein
arginine	I-Protein
methyltransferase	I-Protein
3	I-Protein
(	O
PRMT3	B-Protein
)	O
comprises	O
a	O
region	O
not	O
required	O
for	O
catalytic	O
activity	O
in	O
its	O
amino	O
-	O
terminus	O
and	O
the	O
core	O
domain	O
catalyzing	O
protein	O
arginine	O
methylation	O
.	O

PRMT3	B-Protein
has	O
been	O
shown	O
to	O
interact	O
with	O
the	O
40S	B-Protein
ribosomal	I-Protein
protein	I-Protein
S2	I-Protein
(	O
rpS2	B-Protein
)	O
and	O
methylate	O
arginine	O
residues	O
in	O
the	O
arginine	O
-	O
glycine	O
(	O
RG	O
)	O
repeat	O
region	O
in	O
the	O
amino	O
-	O
terminus	O
of	O
rpS2	B-Protein
.	O

We	O
investigated	O
the	O
biological	O
implications	O
of	O
this	O
interaction	O
by	O
delineating	O
the	O
domains	O
that	O
mediate	O
binding	O
between	O
PRMT3	B-Protein
and	O
rpS2	B-Protein
.	O

The	O
rpS2	B-Protein
(	O
100	O
-	O
293	O
amino	O
acids	O
)	O
domain	O
,	O
but	O
not	O
the	O
amino	O
-	O
terminus	O
of	O
rpS2	B-Protein
that	O
includes	O
the	O
RG	O
repeat	O
region	O
was	O
essential	O
for	O
binding	O
to	O
PRMT3	B-Protein
and	O
was	O
susceptible	O
to	O
degradation	O
.	O

The	O
amino	O
-	O
terminus	O
of	O
PRMT3	B-Protein
,	O
but	O
not	O
its	O
catalytic	O
core	O
was	O
required	O
for	O
binding	O
to	O
and	O
the	O
stability	O
of	O
rpS2	B-Protein
.	O

Overexpressed	O
rpS2	B-Protein
was	O
ubiquitinated	O
in	O
cells	O
,	O
but	O
expression	O
of	O
PRMT3	B-Protein
reduced	O
this	O
ubiquitination	O
and	O
stabilized	O
the	O
rpS2	B-Protein
protein	O
.	O

Recombinant	O
PRMT3	B-Protein
formed	O
an	O
active	O
enzyme	O
complex	O
with	O
endogenous	O
rpS2	B-Protein
in	O
vitro	O
.	O

Recombinant	O
rpS2	B-Protein
in	O
molar	O
excess	O
modestly	O
increased	O
the	O
enzymatic	O
activity	O
of	O
PRMT3	B-Protein
in	O
vitro	O
.	O

Our	O
results	O
suggest	O
that	O
in	O
addition	O
to	O
its	O
catalytic	O
function	O
,	O
PRMT3	B-Protein
may	O
control	O
the	O
level	O
of	O
rpS2	B-Protein
protein	O
in	O
cells	O
by	O
inhibiting	O
ubiquitin	B-Protein
-	O
mediated	O
proteolysis	O
of	O
rpS2	B-Protein
,	O
while	O
rpS2	B-Protein
may	O
regulate	O
the	O
enzymatic	O
activity	O
of	O
PRMT3	B-Protein
as	O
a	O
likely	O
non	O
-	O
catalytic	O
subunit	O
.	O

The	O
ubiquitin	B-Protein
-	O
protein	O
ligase	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
differentially	O
interacts	O
with	O
and	O
regulates	O
members	O
of	O
the	O
Tweety	O
family	O
of	O
chloride	O
ion	O
channels	O
.	O

The	O
Tweety	B-Protein
proteins	O
comprise	O
a	O
family	O
of	O
chloride	O
ion	O
channels	O
with	O
three	O
members	O
identified	O
in	O
humans	O
(	O
TTYH1	B-Protein
-	O
3	B-Protein
)	O
and	O
orthologues	O
in	O
fly	O
and	O
murine	O
species	O
.	O

In	O
humans	O
,	O
increased	O
TTYH2	B-Protein
expression	O
is	O
associated	O
with	O
cancer	O
progression	O
,	O
whereas	O
fly	O
Tweety	B-Protein
is	O
associated	O
with	O
developmental	O
processes	O
.	O

Structurally	O
,	O
Tweety	B-Protein
proteins	O
are	O
characterized	O
by	O
five	O
membrane	O
-	O
spanning	O
domains	O
and	O
N	O
-	O
glycan	O
modifications	O
important	O
for	O
trafficking	O
to	O
the	O
plasma	O
membrane	O
,	O
where	O
these	O
proteins	O
are	O
oriented	O
with	O
the	O
amino	O
terminus	O
located	O
extracellularly	O
and	O
the	O
carboxyl	O
terminus	O
cytoplasmically	O
.	O

In	O
addition	O
to	O
N	O
-	O
glycosylation	O
,	O
ubiquitination	O
mediated	O
by	O
the	O
HECT	O
type	O
E3	O
ubiquitin	B-Protein
ligase	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
is	O
a	O
post	O
-	O
translation	O
modification	O
important	O
in	O
regulating	O
membrane	O
proteins	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
a	O
comprehensive	O
analysis	O
of	O
the	O
ability	O
of	O
each	O
of	O
TTYH1	B-Protein
-	O
3	B-Protein
to	O
interact	O
with	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
and	O
to	O
be	O
ubiquitinated	O
and	O
regulated	O
by	O
this	O
ligase	O
.	O

Our	O
data	O
indicate	O
that	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
binds	O
to	O
two	O
family	O
members	O
,	O
TTYH2	B-Protein
and	O
TTYH3	B-Protein
,	O
which	O
contain	O
consensus	O
PY	O
(	O
(	O
L	O
/	O
P	O
)	O
PXY	O
)	O
binding	O
sites	O
for	O
HECT	O
type	O
E3	O
ubiquitin	B-Protein
ligases	O
,	O
but	O
not	O
to	O
TTYH1	B-Protein
,	O
which	O
lacks	O
this	O
motif	O
.	O

Consistently	O
,	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
ubiquitinates	O
both	O
TTYH2	B-Protein
and	O
TTYH3	B-Protein
.	O

Importantly	O
,	O
we	O
have	O
shown	O
that	O
endogenous	O
TTYH2	B-Protein
and	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
are	O
binding	O
partners	O
and	O
demonstrated	O
that	O
the	O
TTYH2	B-Protein
PY	O
motif	O
is	O
essential	O
for	O
these	O
interactions	O
.	O

We	O
have	O
also	O
shown	O
that	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
-	O
mediated	O
ubiquitination	O
of	O
TTYH2	B-Protein
is	O
a	O
critical	O
regulator	O
of	O
cell	O
surface	O
and	O
total	O
cellular	O
levels	O
of	O
this	O
protein	O
.	O

These	O
data	O
,	O
indicating	O
that	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
differentially	O
interacts	O
with	O
and	O
regulates	O
TTYH1	B-Protein
-	O
3	B-Protein
,	O
will	O
be	O
important	O
for	O
understanding	O
mechanisms	O
controlling	O
Tweety	B-Protein
proteins	O
in	O
physiology	O
and	O
disease	O
.	O

Viral	O
genome	O
methylation	O
as	O
an	O
epigenetic	O
defense	O
against	O
geminiviruses	O
.	O

Geminiviruses	O
encapsidate	O
single	O
-	O
stranded	O
DNA	O
genomes	O
that	O
replicate	O
in	O
plant	O
cell	O
nuclei	O
through	O
double	O
-	O
stranded	O
DNA	O
intermediates	O
that	O
associate	O
with	O
cellular	O
histone	B-Protein
proteins	O
to	O
form	O
minichromosomes	O
.	O

Like	O
most	O
plant	O
viruses	O
,	O
geminiviruses	O
are	O
targeted	O
by	O
RNA	O
silencing	O
and	O
encode	O
suppressor	O
proteins	O
such	O
as	O
AL2	B-Protein
and	O
L2	B-Protein
to	O
counter	O
this	O
defense	O
.	O

These	O
related	O
proteins	O
can	O
suppress	O
silencing	O
by	O
multiple	O
mechanisms	O
,	O
one	O
of	O
which	O
involves	O
interacting	O
with	O
and	O
inhibiting	O
adenosine	B-Protein
kinase	I-Protein
(	O
ADK	B-Protein
)	O
,	O
a	O
cellular	O
enzyme	O
associated	O
with	O
the	O
methyl	O
cycle	O
that	O
generates	O
S	O
-	O
adenosyl	O
-	O
methionine	O
,	O
an	O
essential	O
methyltransferase	O
cofactor	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
the	O
viral	O
genome	O
is	O
targeted	O
by	O
small	O
-	O
RNA	O
-	O
directed	O
methylation	O
.	O

Here	O
,	O
we	O
show	O
that	O
Arabidopsis	O
plants	O
with	O
mutations	O
in	O
genes	O
encoding	O
cytosine	O
or	O
histone	B-Protein
H3	I-Protein
lysine	O
9	O
(	O
H3K9	B-Protein
)	O
methyltransferases	O
,	O
RNA	O
-	O
directed	O
methylation	O
pathway	O
components	O
,	O
or	O
ADK	B-Protein
are	O
hypersensitive	O
to	O
geminivirus	O
infection	O
.	O

We	O
also	O
demonstrate	O
that	O
viral	O
DNA	O
and	O
associated	O
histone	B-Protein
H3	I-Protein
are	O
methylated	O
in	O
infected	O
plants	O
and	O
that	O
cytosine	O
methylation	O
levels	O
are	O
significantly	O
reduced	O
in	O
viral	O
DNA	O
isolated	O
from	O
methylation	O
-	O
deficient	O
mutants	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
Beet	O
curly	O
top	O
virus	O
L2	B-Protein
-	O
mutant	O
DNA	O
present	O
in	O
tissues	O
that	O
have	O
recovered	O
from	O
infection	O
is	O
hypermethylated	O
and	O
that	O
host	O
recovery	O
requires	O
AGO4	B-Protein
,	O
a	O
component	O
of	O
the	O
RNA	O
-	O
directed	O
methylation	O
pathway	O
.	O

We	O
propose	O
that	O
plants	O
use	O
chromatin	O
methylation	O
as	O
a	O
defense	O
against	O
DNA	O
viruses	O
,	O
which	O
geminiviruses	O
counter	O
by	O
inhibiting	O
global	O
methylation	O
.	O

In	O
addition	O
,	O
our	O
results	O
establish	O
that	O
geminiviruses	O
can	O
be	O
useful	O
models	O
for	O
genome	O
methylation	O
in	O
plants	O
and	O
suggest	O
that	O
there	O
are	O
redundant	O
pathways	O
leading	O
to	O
cytosine	O
methylation	O
.	O

CaMK	O
activation	O
during	O
exercise	O
is	O
required	O
for	O
histone	B-Protein
hyperacetylation	O
and	O
MEF2A	B-Protein
binding	O
at	O
the	O
MEF2	O
site	O
on	O
the	O
Glut4	B-Protein
gene	O
.	O

The	O
role	O
of	O
CaMK	O
II	O
in	O
regulating	O
GLUT4	B-Protein
expression	O
in	O
response	O
to	O
intermittent	O
exercise	O
was	O
investigated	O
.	O

Wistar	O
rats	O
completed	O
5	O
x	O
17	O
-	O
min	O
bouts	O
of	O
swimming	O
after	O
receiving	O
5	O
mg	O
/	O
kg	O
KN93	O
(	O
a	O
CaMK	O
II	O
inhibitor	O
)	O
,	O
KN92	O
(	O
an	O
analog	O
of	O
KN93	O
that	O
does	O
not	O
inhibit	O
CaMK	O
II	O
)	O
,	O
or	O
an	O
equivalent	O
volume	O
of	O
vehicle	O
.	O

Triceps	O
muscles	O
that	O
were	O
harvested	O
at	O
0	O
,	O
6	O
,	O
or	O
18	O
h	O
postexercise	O
were	O
assayed	O
for	O
1	O
)	O
CaMK	O
II	O
phosphorylation	O
by	O
Western	O
blot	O
,	O
2	O
)	O
acetylation	O
of	O
histone	B-Protein
H3	I-Protein
at	O
the	O
Glut4	B-Protein
MEF2	O
site	O
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
,	O
3	O
)	O
bound	O
MEF2A	B-Protein
at	O
the	O
Glut4	B-Protein
MEF2	O
cis	O
-	O
element	O
by	O
ChIP	O
,	O
and	O
4	O
)	O
GLUT4	B-Protein
expression	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
.	O

Compared	O
with	O
controls	O
,	O
exercise	O
caused	O
a	O
twofold	O
increase	O
in	O
CaMK	O
II	O
phosphorylation	O
.	O

Immunohistochemical	O
stains	O
indicated	O
increased	O
CaMK	O
II	O
phosphorylation	O
in	O
nuclear	O
and	O
perinuclear	O
regions	O
of	O
the	O
muscle	O
fiber	O
.	O

Acetylation	O
of	O
histone	B-Protein
H3	I-Protein
in	O
the	O
region	O
surrounding	O
the	O
MEF2	O
binding	O
site	O
on	O
the	O
Glut4	B-Protein
gene	O
and	O
the	O
amount	O
of	O
MEF2A	B-Protein
that	O
bind	O
to	O
the	O
site	O
increased	O
approximately	O
twofold	O
postexercise	O
.	O

GLUT4	B-Protein
mRNA	O
and	O
protein	O
increased	O
approximately	O
2	O
.	O
2	O
-	O
and	O
1	O
.	O
8	O
-	O
fold	O
,	O
respectively	O
,	O
after	O
exercise	O
.	O

The	O
exercise	O
-	O
induced	O
increases	O
in	O
CaMK	O
II	O
phosphorylation	O
,	O
histone	B-Protein
H3	I-Protein
acetylation	O
,	O
MEF2A	B-Protein
binding	O
,	O
and	O
GLUT4	B-Protein
expression	O
were	O
attenuated	O
or	O
abolished	O
when	O
KN93	O
was	O
administered	O
to	O
rats	O
prior	O
to	O
exercise	O
.	O

KN92	O
did	O
not	O
affect	O
the	O
increases	O
in	O
pCaMK	O
II	O
and	O
GLUT4	B-Protein
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
CaMK	O
II	O
activation	O
by	O
exercise	O
increases	O
GLUT4	B-Protein
expression	O
via	O
increased	O
accessibility	O
of	O
MEF2A	B-Protein
to	O
its	O
cis	O
-	O
element	O
on	O
the	O
gene	O
.	O

Global	O
analysis	O
of	O
the	O
medulloblastoma	O
epigenome	O
identifies	O
disease	O
-	O
subgroup	O
-	O
specific	O
inactivation	O
of	O
COL1A2	B-Protein
.	O

Candidate	O
gene	O
investigations	O
have	O
indicated	O
a	O
significant	O
role	O
for	O
epigenetic	O
events	O
in	O
the	O
pathogenesis	O
of	O
medulloblastoma	O
,	O
the	O
most	O
common	O
malignant	O
brain	O
tumor	O
of	O
childhood	O
.	O

To	O
assess	O
the	O
medulloblastoma	O
epigenome	O
more	O
comprehensively	O
,	O
we	O
undertook	O
a	O
genomewide	O
investigation	O
to	O
identify	O
genes	O
that	O
display	O
evidence	O
of	O
methylation	O
-	O
dependent	O
regulation	O
.	O

Expression	O
microarray	O
analysis	O
of	O
medulloblastoma	O
cell	O
lines	O
following	O
treatment	O
with	O
a	O
DNA	O
methyltransferase	O
inhibitor	O
revealed	O
deregulation	O
of	O
multiple	O
transcripts	O
(	O
3	O
%	O
-	O
6	O
%	O
of	O
probes	O
per	O
cell	O
line	O
)	O
.	O

Eighteen	O
independent	O
genes	O
demonstrated	O
>	O
3	O
-	O
fold	O
reactivation	O
in	O
all	O
cell	O
lines	O
tested	O
.	O

Bisulfite	O
sequence	O
analysis	O
revealed	O
dense	O
CpG	O
island	O
methylation	O
associated	O
with	O
transcriptional	O
silencing	O
for	O
12	O
of	O
these	O
genes	O
.	O

Extension	O
of	O
this	O
analysis	O
to	O
primary	O
tumors	O
and	O
the	O
normal	O
cerebellum	O
revealed	O
three	O
major	O
classes	O
of	O
epigenetically	O
regulated	O
genes	O
:	O
(	O
1	O
)	O
normally	O
methylated	O
genes	O
(	O
DAZL	B-Protein
,	O
ZNF157	B-Protein
,	O
ASN	B-Protein
)	O
whose	O
methylation	O
reflects	O
somatic	O
patterns	O
observed	O
in	O
the	O
cerebellum	O
,	O
(	O
2	O
)	O
X	O
-	O
linked	O
genes	O
(	O
MSN	B-Protein
,	O
POU3F4	B-Protein
,	O
HTR2C	B-Protein
)	O
that	O
show	O
disruption	O
of	O
their	O
sex	O
-	O
specific	O
methylation	O
patterns	O
in	O
tumors	O
,	O
and	O
(	O
3	O
)	O
tumor	O
-	O
specific	O
methylated	O
genes	O
(	O
COL1A2	B-Protein
,	O
S100A10	B-Protein
,	O
S100A6	B-Protein
,	O
HTATIP2	B-Protein
,	O
CDH1	B-Protein
,	O
LXN	B-Protein
)	O
that	O
display	O
enhanced	O
methylation	O
levels	O
in	O
tumors	O
compared	O
with	O
the	O
cerebellum	O
.	O

Detailed	O
analysis	O
of	O
COL1A2	B-Protein
supports	O
a	O
key	O
role	O
in	O
medulloblastoma	O
tumorigenesis	O
;	O
dense	O
biallelic	O
methylation	O
associated	O
with	O
transcriptional	O
silencing	O
was	O
observed	O
in	O
46	O
of	O
60	O
cases	O
(	O
77	O
%	O
)	O
.	O

Moreover	O
,	O
COL1A2	B-Protein
status	O
distinguished	O
infant	O
medulloblastomas	O
of	O
the	O
desmoplastic	O
histopathological	O
subtype	O
,	O
indicating	O
that	O
distinct	O
molecular	O
pathogenesis	O
may	O
underlie	O
these	O
tumors	O
and	O
their	O
more	O
favorable	O
prognosis	O
.	O

These	O
data	O
reveal	O
a	O
more	O
diverse	O
and	O
expansive	O
medulloblastoma	O
epi	O
genome	O
than	O
previously	O
understood	O
and	O
provide	O
strong	O
evidence	O
that	O
the	O
methylation	O
status	O
of	O
specific	O
genes	O
may	O
contribute	O
to	O
the	O
biological	O
subclassification	O
of	O
medulloblastoma	O
.	O

Polyubiquitination	O
of	O
proliferating	B-Protein
cell	I-Protein
nuclear	I-Protein
antigen	I-Protein
by	O
HLTF	B-Protein
and	O
SHPRH	B-Protein
prevents	O
genomic	O
instability	O
from	O
stalled	O
replication	O
forks	O
.	O

Chronic	O
stalling	O
of	O
DNA	O
replication	O
forks	O
caused	O
by	O
DNA	O
damage	O
can	O
lead	O
to	O
genomic	O
instability	O
.	O

Cells	O
have	O
evolved	O
lesion	O
bypass	O
pathways	O
such	O
as	O
postreplication	O
repair	O
(	O
PRR	O
)	O
to	O
resolve	O
these	O
arrested	O
forks	O
.	O

In	O
yeast	O
,	O
one	O
branch	O
of	O
PRR	O
involves	O
proliferating	B-Protein
cell	I-Protein
nuclear	I-Protein
antigen	I-Protein
(	O
PCNA	B-Protein
)	O
polyubiquitination	O
mediated	O
by	O
the	O
Rad5	B-Protein
-	O
Ubc13	B-Protein
-	O
Mms2	B-Protein
complex	O
that	O
allows	O
bypass	O
of	O
DNA	O
lesion	O
by	O
a	O
template	O
-	O
switching	O
mechanism	O
.	O

Previously	O
,	O
we	O
identified	O
human	O
SHPRH	B-Protein
as	O
a	O
functional	O
homologue	O
of	O
yeast	O
Rad5	B-Protein
and	O
revealed	O
the	O
existence	O
of	O
RAD5	B-Protein
-	O
like	O
pathway	O
in	O
human	O
cells	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
HLTF	B-Protein
as	O
a	O
second	O
RAD5	B-Protein
homologue	O
in	O
human	O
cells	O
.	O

HLTF	B-Protein
,	O
like	O
SHPRH	B-Protein
,	O
shares	O
a	O
unique	O
domain	O
architecture	O
with	O
Rad5	B-Protein
and	O
promotes	O
lysine	O
63	O
-	O
linked	O
polyubiquitination	O
of	O
PCNA	B-Protein
.	O

Similar	O
to	O
yeast	O
Rad5	B-Protein
,	O
HLTF	B-Protein
is	O
able	O
to	O
interact	O
with	O
UBC13	B-Protein
and	O
PCNA	B-Protein
,	O
as	O
well	O
as	O
SHPRH	B-Protein
;	O
and	O
the	O
reduction	O
of	O
either	O
SHPRH	B-Protein
or	O
HLTF	B-Protein
expression	O
enhances	O
spontaneous	O
mutagenesis	O
.	O

Moreover	O
,	O
Hltf	B-Protein
-	O
deficient	O
mouse	O
embryonic	O
fibroblasts	O
show	O
elevated	O
chromosome	O
breaks	O
and	O
fusions	O
after	O
methyl	O
methane	O
sulfonate	O
treatment	O
.	O

Our	O
results	O
suggest	O
that	O
HLTF	B-Protein
and	O
SHPRH	B-Protein
are	O
functional	O
homologues	O
of	O
yeast	O
Rad5	B-Protein
that	O
cooperatively	O
mediate	O
PCNA	B-Protein
polyubiquitination	O
and	O
maintain	O
genomic	O
stability	O
.	O

The	O
unique	O
N	O
terminus	O
of	O
the	O
UbcH10	B-Protein
E2	O
enzyme	O
controls	O
the	O
threshold	O
for	O
APC	O
activation	O
and	O
enhances	O
checkpoint	O
regulation	O
of	O
the	O
APC	O
.	O

In	O
vitro	O
,	O
the	O
anaphase	O
-	O
promoting	O
complex	O
(	O
APC	O
)	O
E3	O
ligase	O
functions	O
with	O
E2	O
ubiquitin	B-Protein
-	O
conjugating	O
enzymes	O
of	O
the	O
E2	B-Protein
-	I-Protein
C	I-Protein
and	O
Ubc4	B-Protein
/	O
5	B-Protein
families	O
to	O
ubiquitinate	O
substrates	O
.	O

However	O
,	O
only	O
the	O
use	O
of	O
the	O
E2	O
-	O
C	O
family	O
,	O
notably	O
UbcH10	B-Protein
,	O
is	O
genetically	O
well	O
validated	O
.	O

Here	O
,	O
we	O
biochemically	O
demonstrate	O
preferential	O
use	O
of	O
UbcH10	B-Protein
by	O
the	O
APC	O
,	O
specified	O
by	O
the	O
E2	O
core	O
domain	O
.	O

Importantly	O
,	O
an	O
additional	O
E2	O
-	O
E3	O
interaction	O
mediated	O
by	O
the	O
N	O
-	O
terminal	O
extension	O
of	O
UbcH10	B-Protein
regulates	O
APC	O
activity	O
.	O

Mutating	O
the	O
highly	O
conserved	O
N	O
terminus	O
increases	O
substrate	O
ubiquitination	O
and	O
the	O
number	O
of	O
substrate	O
lysines	O
targeted	O
,	O
allows	O
ubiquitination	O
of	O
APC	O
substrates	O
lacking	O
their	O
destruction	O
boxes	O
,	O
increases	O
resistance	O
to	O
the	O
APC	O
inhibitors	O
Emi1	B-Protein
and	O
BubR1	B-Protein
in	O
vitro	O
,	O
and	O
bypasses	O
the	O
spindle	O
checkpoint	O
in	O
vivo	O
.	O

Fusion	O
of	O
the	O
UbcH10	B-Protein
N	O
terminus	O
to	O
UbcH5	B-Protein
restricts	O
ubiquitination	O
activity	O
but	O
does	O
not	O
direct	O
specific	O
interactions	O
with	O
the	O
APC	O
.	O

Thus	O
,	O
UbcH10	B-Protein
combines	O
a	O
specific	O
E2	O
-	O
E3	O
interface	O
and	O
regulation	O
via	O
its	O
N	O
-	O
terminal	O
extension	O
to	O
limit	O
APC	O
activity	O
for	O
substrate	O
selection	O
and	O
checkpoint	O
control	O
.	O

RCS1	B-Protein
,	O
a	O
substrate	O
of	O
APC	O
/	O
C	O
,	O
controls	O
the	O
metaphase	O
to	O
anaphase	O
transition	O
.	O

The	O
anaphase	O
-	O
promoting	O
complex	O
/	O
cyclosome	O
(	O
APC	O
/	O
C	O
)	O
controls	O
the	O
onset	O
of	O
anaphase	O
by	O
targeting	O
securin	B-Protein
for	O
destruction	O
.	O

We	O
report	O
here	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
substrate	O
of	O
APC	O
/	O
C	O
,	O
RCS1	B-Protein
,	O
as	O
a	O
mitotic	O
regulator	O
that	O
controls	O
the	O
metaphase	O
-	O
to	O
-	O
anaphase	O
transition	O
.	O

We	O
showed	O
that	O
the	O
levels	O
of	O
RCS1	B-Protein
fluctuate	O
in	O
the	O
cell	O
cycle	O
,	O
peaking	O
in	O
mitosis	O
and	O
dropping	O
drastically	O
as	O
cells	O
exit	O
into	O
G	O
(	O
1	O
)	O
.	O

Indeed	O
,	O
RCS1	B-Protein
is	O
efficiently	O
ubiquitinated	O
by	O
APC	O
/	O
C	O
in	O
vitro	O
and	O
degraded	O
during	O
mitotic	O
exit	O
in	O
a	O
Cdh1	B-Protein
-	O
dependent	O
manner	O
in	O
vivo	O
.	O

APC	O
/	O
C	O
recognizes	O
a	O
unique	O
D	O
-	O
box	O
at	O
the	O
N	O
terminus	O
of	O
RCS1	B-Protein
,	O
as	O
mutations	O
of	O
this	O
D	O
-	O
box	O
abolished	O
ubiquitination	O
in	O
vitro	O
and	O
stabilized	O
the	O
mutant	O
protein	O
in	O
vivo	O
.	O

RCS1	B-Protein
controls	O
the	O
timing	O
of	O
the	O
anaphase	O
onset	O
,	O
because	O
the	O
loss	O
of	O
RCS1	B-Protein
resulted	O
in	O
a	O
faster	O
progression	O
from	O
the	O
metaphase	O
to	O
anaphase	O
and	O
accelerated	O
degradation	O
of	O
securin	B-Protein
and	O
cyclin	O
B	O
.	O

Biochemically	O
,	O
mitotic	O
RCS1	B-Protein
associates	O
with	O
the	O
NuRD	O
chromatin	O
-	O
remodeling	O
complex	O
,	O
and	O
this	O
RCS1	B-Protein
complex	O
is	O
likely	O
involved	O
in	O
regulating	O
gene	O
expression	O
or	O
chromatin	O
structure	O
,	O
which	O
in	O
turn	O
may	O
control	O
anaphase	O
onset	O
.	O

Our	O
study	O
uncovers	O
a	O
complex	O
regulatory	O
network	O
for	O
the	O
metaphase	O
-	O
to	O
-	O
anaphase	O
transition	O
.	O

Molecular	O
genetic	O
basis	O
of	O
rapid	O
and	O
slow	O
acetylation	O
in	O
mice	O
.	O

The	O
molecular	O
genetic	O
basis	O
of	O
N	O
-	O
acetylation	O
polymorphism	O
has	O
been	O
investigated	O
in	O
inbred	O
mouse	O
models	O
of	O
the	O
human	O
acetylation	O
polymorphism	O
.	O

Two	O
genomic	O
clones	O
,	O
Nat1	B-Protein
and	O
Nat2	B-Protein
,	O
were	O
isolated	O
from	O
a	O
C57BL	O
/	O
6J	O
(	O
B6	O
)	O
mouse	O
(	O
rapid	O
acetylator	O
)	O
genomic	O
library	O
.	O

The	O
Nat1	B-Protein
and	O
Nat2	B-Protein
genes	O
both	O
have	O
intronless	O
coding	O
regions	O
of	O
870	O
nucleotides	O
and	O
display	O
greater	O
than	O
47	O
%	O
deduced	O
amino	O
acid	O
similarity	O
with	O
human	O
,	O
rabbit	O
,	O
and	O
chicken	O
N	O
-	O
acetyltransferases	O
.	O

Amplification	O
of	O
Nat1	B-Protein
and	O
Nat2	B-Protein
from	O
A	O
/	O
J	O
(	O
A	O
)	O
mouse	O
(	O
slow	O
acetylator	O
)	O
genomic	O
DNA	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
subsequent	O
sequencing	O
revealed	O
that	O
Nat1	B-Protein
was	O
identical	O
in	O
B6	O
and	O
A	O
mice	O
,	O
whereas	O
Nat2	B-Protein
contained	O
a	O
single	O
nucleotide	O
change	O
from	O
adenine	O
in	O
B6	O
to	O
thymine	O
in	O
A	O
mice	O
.	O

This	O
nucleotide	O
substitution	O
changes	O
the	O
deduced	O
amino	O
acid	O
at	O
position	O
99	O
from	O
asparagine	O
in	O
B6	O
to	O
isoleucine	O
in	O
A	O
mice	O
.	O

Hydropathy	O
analysis	O
revealed	O
that	O
this	O
amino	O
acid	O
change	O
alters	O
the	O
hydropathy	O
of	O
the	O
flanking	O
peptide	O
segment	O
in	O
NAT2	B-Protein
from	O
hydrophilic	O
in	O
the	O
B6	O
mouse	O
to	O
hydrophobic	O
in	O
the	O
A	O
mouse	O
.	O

The	O
amino	O
acid	O
change	O
occurs	O
in	O
a	O
region	O
of	O
the	O
gene	O
where	O
no	O
polymorphism	O
has	O
yet	O
been	O
reported	O
in	O
human	O
or	O
rabbit	O
NAT2	B-Protein
and	O
may	O
represent	O
an	O
important	O
structural	O
domain	O
for	O
N	O
-	O
acetyltransferase	O
activity	O
.	O

Nat1	B-Protein
and	O
Nat2	B-Protein
have	O
the	O
same	O
5	O
'	O
to	O
3	O
'	O
orientation	O
in	O
the	O
B6	O
mouse	O
;	O
the	O
two	O
genes	O
are	O
separated	O
by	O
approximately	O
9	O
kilobases	O
,	O
with	O
Nat1	B-Protein
located	O
5	O
'	O
of	O
Nat2	B-Protein
.	O

Dual	O
targeting	O
of	O
HSC70	B-Protein
and	O
HSP72	B-Protein
inhibits	O
HSP90	B-Protein
function	O
and	O
induces	O
tumor	O
-	O
specific	O
apoptosis	O
.	O

Heat	O
-	O
shock	O
protein	O
70	O
(	O
HSP70	O
)	O
isoforms	O
contribute	O
to	O
tumorigenesis	O
through	O
their	O
well	O
-	O
documented	O
antiapoptotic	O
activity	O
and	O
via	O
their	O
role	O
as	O
cochaperones	O
for	O
the	O
HSP90	B-Protein
molecular	O
chaperone	O
.	O

HSP70	O
expression	O
is	O
induced	O
following	O
treatment	O
with	O
HSP90	B-Protein
inhibitors	O
,	O
which	O
may	O
attenuate	O
the	O
cell	O
death	O
effects	O
of	O
this	O
class	O
of	O
inhibitor	O
.	O

Here	O
we	O
show	O
that	O
silencing	O
either	O
heat	B-Protein
-	I-Protein
shock	I-Protein
cognate	I-Protein
70	I-Protein
(	O
HSC70	B-Protein
)	O
or	O
HSP72	B-Protein
expression	O
in	O
human	O
cancer	O
cell	O
lines	O
has	O
no	O
effect	O
on	O
HSP90	B-Protein
activity	O
or	O
cell	O
proliferation	O
.	O

However	O
,	O
simultaneously	O
reducing	O
the	O
expression	O
of	O
both	O
of	O
these	O
isoforms	O
induces	O
proteasome	O
-	O
dependent	O
degradation	O
of	O
HSP90	B-Protein
client	O
proteins	O
,	O
G1	O
cell	O
-	O
cycle	O
arrest	O
,	O
and	O
extensive	O
tumor	O
-	O
specific	O
apoptosis	O
.	O

Importantly	O
,	O
simultaneous	O
silencing	O
of	O
HSP70	O
isoforms	O
in	O
nontumorigenic	O
cell	O
lines	O
does	O
not	O
result	O
in	O
comparable	O
growth	O
arrest	O
or	O
induction	O
of	O
apoptosis	O
,	O
indicating	O
a	O
potential	O
therapeutic	O
window	O
.	O

MDM2	B-Protein
E3	O
ubiquitin	B-Protein
ligase	O
mediates	O
UT	B-Protein
-	I-Protein
A1	I-Protein
urea	O
transporter	O
ubiquitination	O
and	O
degradation	O
.	O

UT	B-Protein
-	I-Protein
A1	I-Protein
is	O
the	O
primary	O
urea	O
transporter	O
in	O
the	O
apical	O
plasma	O
membrane	O
responsible	O
for	O
urea	O
reabsorption	O
in	O
the	O
inner	O
medullary	O
collecting	O
duct	O
.	O

Although	O
the	O
physiological	O
function	O
of	O
UT	B-Protein
-	I-Protein
A1	I-Protein
has	O
been	O
well	O
established	O
,	O
the	O
molecular	O
mechanisms	O
that	O
regulate	O
its	O
activity	O
are	O
less	O
well	O
understood	O
.	O

Analysis	O
of	O
the	O
UT	B-Protein
-	I-Protein
A1	I-Protein
amino	O
acid	O
sequence	O
revealed	O
a	O
potential	O
MDM2	B-Protein
E3	O
ubiquitin	B-Protein
ligase	O
-	O
binding	O
motif	O
in	O
the	O
large	O
intracellular	O
loop	O
of	O
UT	B-Protein
-	I-Protein
A1	I-Protein
,	O
suggesting	O
that	O
UT	B-Protein
-	I-Protein
A1	I-Protein
urea	O
transporter	O
protein	O
may	O
be	O
regulated	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O

Here	O
,	O
we	O
report	O
that	O
UT	B-Protein
-	I-Protein
A1	I-Protein
is	O
ubiquitinated	O
and	O
degraded	O
by	O
the	O
proteasome	O
but	O
not	O
the	O
lysosome	O
proteolytic	O
pathway	O
.	O

Inhibition	O
of	O
proteasome	O
activity	O
causes	O
UT	B-Protein
-	I-Protein
A1	I-Protein
cell	O
surface	O
accumulation	O
and	O
concomitantly	O
increases	O
urea	O
transport	O
activity	O
.	O

UT	B-Protein
-	I-Protein
A1	I-Protein
interacts	O
directly	O
with	O
MDM2	B-Protein
;	O
the	O
binding	O
site	O
is	O
located	O
in	O
the	O
NH2	O
-	O
terminal	O
p53	B-Protein
-	O
binding	O
region	O
of	O
MDM2	B-Protein
.	O

MDM2	B-Protein
mediates	O
UT	B-Protein
-	I-Protein
A1	I-Protein
ubiquitination	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Overexpression	O
of	O
MDM2	B-Protein
promotes	O
UT	B-Protein
-	I-Protein
A1	I-Protein
degradation	O
.	O

The	O
mechanism	O
is	O
likely	O
to	O
be	O
physiologically	O
important	O
as	O
UT	B-Protein
-	I-Protein
A1	I-Protein
ubiquitination	O
was	O
identified	O
in	O
kidney	O
inner	O
medullary	O
tissue	O
.	O

The	O
ubiquitin	B-Protein
-	O
proteasome	O
degradation	O
pathway	O
provides	O
an	O
important	O
novel	O
mechanism	O
for	O
UT	B-Protein
-	I-Protein
A1	I-Protein
regulation	O
.	O

Effect	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
ubiquitination	O
and	O
chromatin	O
structure	O
on	O
the	O
dynamic	O
properties	O
of	O
the	O
Y	O
-	O
family	O
DNA	O
polymerases	O
.	O

Y	O
-	O
family	O
DNA	O
polymerases	O
carry	O
out	O
translesion	O
synthesis	O
past	O
damaged	O
DNA	O
.	O

DNA	B-Protein
polymerases	I-Protein
(	I-Protein
pol	I-Protein
)	I-Protein
eta	I-Protein
and	O
iota	B-Protein
are	O
usually	O
uniformly	O
distributed	O
through	O
the	O
nucleus	O
but	O
accumulate	O
in	O
replication	O
foci	O
during	O
S	O
phase	O
.	O

DNA	O
-	O
damaging	O
treatments	O
result	O
in	O
an	O
increase	O
in	O
S	O
phase	O
cells	O
containing	O
polymerase	O
foci	O
.	O

Using	O
photobleaching	O
techniques	O
,	O
we	O
show	O
that	O
poleta	B-Protein
is	O
highly	O
mobile	O
in	O
human	O
fibroblasts	O
.	O

Even	O
when	O
localized	O
in	O
replication	O
foci	O
,	O
it	O
is	O
only	O
transiently	O
immobilized	O
.	O

Although	O
ubiquitination	O
of	O
proliferating	B-Protein
cell	I-Protein
nuclear	I-Protein
antigen	I-Protein
(	O
PCNA	B-Protein
)	O
is	O
not	O
required	O
for	O
the	O
localization	O
of	O
poleta	B-Protein
in	O
foci	O
,	O
it	O
results	O
in	O
an	O
increased	O
residence	O
time	O
in	O
foci	O
.	O
poliota	B-Protein
is	O
even	O
more	O
mobile	O
than	O
poleta	B-Protein
,	O
both	O
when	O
uniformly	O
distributed	O
and	O
when	O
localized	O
in	O
foci	O
.	O

Kinetic	O
modeling	O
suggests	O
that	O
both	O
poleta	B-Protein
and	O
poliota	B-Protein
diffuse	O
through	O
the	O
cell	O
but	O
that	O
they	O
are	O
transiently	O
immobilized	O
for	O
approximately	O
150	O
ms	O
,	O
with	O
a	O
larger	O
proportion	O
of	O
poleta	B-Protein
than	O
poliota	B-Protein
immobilized	O
at	O
any	O
time	O
.	O

Treatment	O
of	O
cells	O
with	O
DRAQ5	O
,	O
which	O
results	O
in	O
temporary	O
opening	O
of	O
the	O
chromatin	O
structure	O
,	O
causes	O
a	O
dramatic	O
immobilization	O
of	O
poleta	B-Protein
but	O
not	O
poliota	B-Protein
.	O

Our	O
data	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
the	O
polymerases	O
are	O
transiently	O
probing	O
the	O
DNA	O
/	O
chromatin	O
.	O

When	O
DNA	O
is	O
exposed	O
at	O
replication	O
forks	O
,	O
the	O
polymerase	O
residence	O
times	O
increase	O
,	O
and	O
this	O
is	O
further	O
facilitated	O
by	O
the	O
ubiquitination	O
of	O
PCNA	B-Protein
.	O

Ubiquitination	O
-	O
mediated	O
internalization	O
and	O
degradation	O
of	O
the	O
astroglial	O
glutamate	O
transporter	O
,	O
GLT	B-Protein
-	I-Protein
1	I-Protein
.	O

Sodium	O
-	O
dependent	O
glutamate	O
uptake	O
is	O
essential	O
for	O
limiting	O
excitotoxicity	O
,	O
and	O
dysregulation	O
of	O
this	O
process	O
has	O
been	O
implicated	O
in	O
a	O
wide	O
array	O
of	O
neurological	O
disorders	O
.	O

The	O
majority	O
of	O
forebrain	O
glutamate	O
uptake	O
is	O
mediated	O
by	O
the	O
astroglial	O
glutamate	O
transporter	O
,	O
GLT	B-Protein
-	I-Protein
1	I-Protein
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
this	O
transporter	O
undergoes	O
endocytosis	O
and	O
degradation	O
in	O
response	O
to	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
however	O
,	O
the	O
mechanisms	O
involved	O
remain	O
unclear	O
.	O

In	O
the	O
current	O
study	O
,	O
transfected	O
C6	O
glioma	O
cells	O
or	O
primary	O
cortical	O
cultures	O
were	O
used	O
to	O
show	O
that	O
PKC	O
activation	O
results	O
in	O
incorporation	O
of	O
ubiquitin	B-Protein
into	O
GLT	B-Protein
-	I-Protein
1	I-Protein
immunoprecipitates	O
.	O

Mutation	O
of	O
all	O
11	O
lysine	O
residues	O
in	O
the	O
amino	O
and	O
carboxyl	O
-	O
terminal	O
domains	O
to	O
arginine	O
(	O
11R	O
)	O
abolished	O
this	O
signal	O
.	O

Selective	O
mutation	O
of	O
the	O
seven	O
lysine	O
residues	O
in	O
the	O
carboxyl	O
terminus	O
(	O
C7K	O
-	O
R	O
)	O
did	O
not	O
eliminate	O
ubiquitination	O
,	O
but	O
it	O
completely	O
blocked	O
PKC	O
-	O
dependent	O
internalization	O
and	O
degradation	O
.	O

Two	O
families	O
of	O
variants	O
of	O
GLT	B-Protein
-	I-Protein
1	I-Protein
were	O
prepared	O
with	O
various	O
lysine	O
residues	O
mutated	O
to	O
arginine	O
.	O

Analyses	O
of	O
these	O
constructs	O
indicated	O
that	O
redundant	O
lysine	O
residues	O
in	O
the	O
carboxyl	O
terminus	O
were	O
sufficient	O
for	O
the	O
appearance	O
of	O
ubiquitinated	O
product	O
and	O
degradation	O
of	O
GLT	B-Protein
-	I-Protein
1	I-Protein
.	O

Together	O
these	O
data	O
define	O
a	O
novel	O
mechanism	O
by	O
which	O
the	O
predominant	O
forebrain	O
glutamate	O
transporter	O
can	O
be	O
rapidly	O
targeted	O
for	O
degradation	O
.	O

Coordination	O
changes	O
and	O
auto	O
-	O
hydroxylation	O
of	O
FIH	B-Protein
-	I-Protein
1	I-Protein
:	O
uncoupled	O
O2	O
-	O
activation	O
in	O
a	O
human	O
hypoxia	O
sensor	O
.	O

Hypoxia	O
sensing	O
is	O
the	O
generic	O
term	O
for	O
pO2	O
-	O
sensing	O
in	O
humans	O
and	O
other	O
higher	O
organisms	O
.	O

These	O
cellular	O
responses	O
to	O
pO2	O
are	O
largely	O
controlled	O
by	O
enzymes	O
that	O
belong	O
to	O
the	O
Fe	O
(	O
II	O
)	O
alpha	O
-	O
ketoglutarate	O
(	O
alphaKG	O
)	O
dependent	O
dioxygenase	O
superfamily	O
,	O
including	O
the	O
human	O
enzyme	O
called	O
the	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
FIH	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
which	O
couples	O
O2	O
-	O
activation	O
to	O
the	O
hydroxylation	O
of	O
the	O
hypoxia	O
inducible	O
factor	O
alpha	O
(	O
HIFalpha	O
)	O
.	O

Uncoupled	O
O2	O
-	O
activation	O
by	O
human	O
FIH	B-Protein
-	I-Protein
1	I-Protein
was	O
studied	O
by	O
exposing	O
the	O
resting	O
form	O
of	O
FIH	B-Protein
-	I-Protein
1	I-Protein
(	O
alphaKG	O
+	O
Fe	O
)	O
FIH	B-Protein
-	I-Protein
1	I-Protein
,	O
to	O
air	O
in	O
the	O
absence	O
of	O
HIFalpha	O
.	O

Uncoupling	O
lead	O
to	O
two	O
distinct	O
enzyme	O
oxidations	O
,	O
one	O
a	O
purple	O
chromophore	O
(	O
lambda	O
(	O
max	O
)	O
=	O
583	O
nm	O
)	O
arising	O
from	O
enzyme	O
auto	O
-	O
hydroxylation	O
of	O
Trp296	O
,	O
forming	O
an	O
Fe	O
(	O
III	O
)	O
-	O
O	O
-	O
Trp296	O
chromophore	O
[	O
Y	O
.	O
-	O
H	O
.	O
Chen	O
,	O
L	O
.	O
M	O
.	O
Comeaux	O
,	O
S	O
.	O
J	O
.	O
Eyles	O
,	O
M	O
.	O
J	O
.	O
Knapp	O
,	O
Chem	O
.	O
Commun	O
.	O
(	O
2008	O
)	O
,	O
doi	O
:	O
10	O
.	O
1039	O
/	O
B809099H	O
]	O
;	O
the	O
other	O
a	O
yellow	O
chromophore	O
due	O
to	O
Fe	O
(	O
III	O
)	O
in	O
the	O
active	O
site	O
,	O
which	O
under	O
some	O
conditions	O
also	O
contained	O
variable	O
levels	O
of	O
an	O
oxygenated	O
surface	O
residue	O
(	O
oxo	O
)	O
Met275	O
.	O

The	O
kinetics	O
of	O
purple	O
FIH	B-Protein
-	I-Protein
1	I-Protein
formation	O
were	O
independent	O
of	O
Fe	O
(	O
II	O
)	O
and	O
alphaKG	O
concentrations	O
,	O
however	O
,	O
product	O
yield	O
was	O
saturable	O
with	O
increasing	O
[	O
alphaKG	O
]	O
and	O
required	O
excess	O
Fe	O
(	O
II	O
)	O
.	O

Yellow	O
FIH	B-Protein
-	I-Protein
1	I-Protein
was	O
formed	O
from	O
(	O
succinate	O
+	O
Fe	O
)	O
FIH	B-Protein
-	I-Protein
1	I-Protein
,	O
or	O
by	O
glycerol	O
addition	O
to	O
(	O
alphaKG	O
+	O
Fe	O
)	O
FIH	B-Protein
-	I-Protein
1	I-Protein
,	O
suggesting	O
that	O
glycerol	O
could	O
intercept	O
the	O
active	O
oxidant	O
from	O
the	O
FIH	B-Protein
-	I-Protein
1	I-Protein
active	O
site	O
and	O
prevent	O
hydroxylation	O
.	O

Both	O
purple	O
and	O
yellow	O
FIH	B-Protein
-	I-Protein
1	I-Protein
contained	O
high	O
-	O
spin	O
,	O
rhombic	O
Fe	O
(	O
III	O
)	O
centers	O
,	O
as	O
shown	O
by	O
low	O
temperature	O
EPR	O
.	O

XAS	O
indicated	O
distorted	O
octahedral	O
Fe	O
(	O
III	O
)	O
geometries	O
,	O
with	O
subtle	O
differences	O
in	O
inner	O
-	O
shell	O
ligands	O
for	O
yellow	O
and	O
purple	O
FIH	B-Protein
-	I-Protein
1	I-Protein
.	O

EPR	O
of	O
Co	O
(	O
II	O
)	O
-	O
substituted	O
FIH	B-Protein
-	I-Protein
1	I-Protein
(	O
alphaKG	O
+	O
Co	O
)	O
FIH	B-Protein
-	I-Protein
1	I-Protein
,	O
indicated	O
a	O
mixture	O
of	O
5	O
-	O
coordinate	O
and	O
6	O
-	O
coordinate	O
enzyme	O
forms	O
,	O
suggesting	O
that	O
resting	O
FIH	B-Protein
-	I-Protein
1	I-Protein
can	O
readily	O
undergo	O
uncoupled	O
O2	O
-	O
activation	O
by	O
loss	O
of	O
an	O
H2O	O
ligand	O
from	O
the	O
metal	O
center	O
.	O

Crystal	O
structure	O
and	O
carbohydrate	O
analysis	O
of	O
Nipah	O
virus	O
attachment	O
glycoprotein	O
:	O
a	O
template	O
for	O
antiviral	O
and	O
vaccine	O
design	O
.	O

Two	O
members	O
of	O
the	O
paramyxovirus	O
family	O
,	O
Nipah	O
virus	O
(	O
NiV	O
)	O
and	O
Hendra	O
virus	O
(	O
HeV	O
)	O
,	O
are	O
recent	O
additions	O
to	O
a	O
growing	O
number	O
of	O
agents	O
of	O
emergent	O
diseases	O
which	O
use	O
bats	O
as	O
a	O
natural	O
host	O
.	O

Identification	O
of	O
ephrin	B-Protein
-	I-Protein
B2	I-Protein
and	O
ephrin	B-Protein
-	I-Protein
B3	I-Protein
as	O
cellular	O
receptors	O
for	O
these	O
viruses	O
has	O
enabled	O
the	O
development	O
of	O
immunotherapeutic	O
reagents	O
which	O
prevent	O
virus	O
attachment	O
and	O
subsequent	O
fusion	O
.	O

Here	O
we	O
present	O
the	O
structural	O
analysis	O
of	O
the	O
protein	O
and	O
carbohydrate	O
components	O
of	O
the	O
unbound	O
viral	O
attachment	O
glycoprotein	O
of	O
NiV	O
glycoprotein	O
(	O
NiV	O
-	O
G	B-Protein
)	O
at	O
a	O
2	O
.	O
2	O
-	O
A	O
resolution	O
.	O

Comparison	O
with	O
its	O
ephrin	B-Protein
-	I-Protein
B2	I-Protein
-	O
bound	O
form	O
reveals	O
that	O
conformational	O
changes	O
within	O
the	O
envelope	O
glycoprotein	O
are	O
required	O
to	O
achieve	O
viral	O
attachment	O
.	O

Structural	O
differences	O
are	O
particularly	O
pronounced	O
in	O
the	O
579	O
-	O
590	O
loop	O
,	O
a	O
major	O
component	O
of	O
the	O
ephrin	O
binding	O
surface	O
.	O

In	O
addition	O
,	O
the	O
236	O
-	O
245	O
loop	O
is	O
rather	O
disordered	O
in	O
the	O
unbound	O
structure	O
.	O

We	O
extend	O
our	O
structural	O
characterization	O
of	O
NiV	O
-	O
G	B-Protein
with	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
carbohydrate	O
moieties	O
.	O

We	O
demonstrate	O
that	O
NiV	O
-	O
G	B-Protein
is	O
largely	O
devoid	O
of	O
the	O
oligomannose	O
-	O
type	O
glycans	O
that	O
in	O
viruses	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
Ebola	O
virus	O
influence	O
viral	O
tropism	O
and	O
the	O
host	O
immune	O
response	O
.	O

Nevertheless	O
,	O
we	O
find	O
putative	O
ligands	O
for	O
the	O
endothelial	O
cell	O
lectin	O
,	O
LSECtin	B-Protein
.	O

Finally	O
,	O
by	O
mapping	O
structural	O
conservation	O
and	O
glycosylation	O
site	O
positions	O
from	O
other	O
members	O
of	O
the	O
paramyxovirus	O
family	O
,	O
we	O
suggest	O
the	O
molecular	O
surface	O
involved	O
in	O
oligomerization	O
.	O

These	O
results	O
suggest	O
possible	O
pathways	O
of	O
virus	O
-	O
host	O
interaction	O
and	O
strategies	O
for	O
the	O
optimization	O
of	O
recombinant	O
vaccines	O
.	O

Synergistic	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
by	O
transforming	O
growth	O
factor	O
-	O
beta	O
and	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
is	O
mediated	O
by	O
protein	O
kinase	O
A	O
-	O
dependent	O
RelA	B-Protein
acetylation	O
.	O

The	O
TGF	O
-	O
beta	O
(	O
transforming	O
growth	O
factor	O
-	O
beta	O
)	O
pathway	O
represents	O
an	O
important	O
signalling	O
pathway	O
involved	O
in	O
regulating	O
diverse	O
biological	O
processes	O
,	O
including	O
cell	O
proliferation	O
,	O
differentiation	O
and	O
inflammation	O
.	O

Despite	O
the	O
critical	O
role	O
for	O
TGF	O
-	O
beta	O
in	O
inflammatory	O
responses	O
,	O
its	O
role	O
in	O
regulating	O
NF	O
-	O
kappaB	O
(	O
nuclear	O
factor	O
-	O
kappaB	O
)	O
-	O
dependent	O
inflammatory	O
responses	O
still	O
remains	O
unknown	O
.	O

In	O
the	O
present	O
study	O
we	O
show	O
that	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
synergizes	O
with	O
proinflammatory	O
cytokine	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
(	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
)	O
to	O
induce	O
NF	O
-	O
kappaB	O
activation	O
and	O
the	O
resultant	O
inflammatory	O
response	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

TGF	B-Protein
-	I-Protein
beta1	I-Protein
synergistically	O
enhances	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
via	O
induction	O
of	O
RelA	B-Protein
acetylation	O
.	O

Moreover	O
,	O
synergistic	O
enhancement	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
-	O
induced	O
RelA	B-Protein
acetylation	O
and	O
DNA	O
-	O
binding	O
activity	O
by	O
TGF	B-Protein
-	I-Protein
beta1	I-Protein
is	O
mediated	O
by	O
PKA	O
(	O
protein	O
kinase	O
A	O
)	O
.	O

Thus	O
the	O
present	O
study	O
reveals	O
a	O
novel	O
role	O
for	O
TGF	O
-	O
beta	O
in	O
inflammatory	O
responses	O
and	O
provides	O
new	O
insight	O
into	O
the	O
regulation	O
of	O
NF	O
-	O
kappaB	O
by	O
TGF	O
-	O
beta	O
signalling	O
.	O

Production	O
,	O
purification	O
,	O
and	O
characterization	O
of	O
human	O
alpha1	B-Protein
proteinase	I-Protein
inhibitor	I-Protein
from	O
Aspergillus	O
niger	O
.	O

Human	O
alpha	B-Protein
one	I-Protein
proteinase	I-Protein
inhibitor	I-Protein
(	O
alpha1	B-Protein
-	I-Protein
PI	I-Protein
)	O
was	O
cloned	O
and	O
expressed	O
in	O
Aspergillus	O
niger	O
,	O
filamentious	O
fungus	O
that	O
can	O
grow	O
in	O
defined	O
media	O
and	O
can	O
perform	O
glycosylation	O
.	O

Submerged	O
culture	O
conditions	O
were	O
established	O
using	O
starch	O
as	O
carbon	O
source	O
,	O
30	O
%	O
dissolved	O
oxygen	O
concentration	O
,	O
pH	O
7	O
.	O
0	O
and	O
28	O
degrees	O
C	O
.	O

Eight	O
milligrams	O
per	O
liter	O
of	O
active	O
alpha1	B-Protein
-	I-Protein
PI	I-Protein
were	O
secreted	O
to	O
the	O
growth	O
media	O
in	O
about	O
40	O
h	O
.	O

Controlling	O
the	O
protein	O
proteolysis	O
was	O
found	O
to	O
be	O
an	O
important	O
factor	O
in	O
the	O
production	O
.	O

The	O
effects	O
of	O
various	O
carbon	O
sources	O
,	O
pH	O
and	O
temperature	O
on	O
the	O
production	O
and	O
stability	O
of	O
the	O
protein	O
were	O
tested	O
and	O
the	O
product	O
was	O
purified	O
and	O
characterized	O
.	O

Two	O
molecular	O
weights	O
variants	O
of	O
the	O
recombinant	O
alpha1	B-Protein
-	I-Protein
PI	I-Protein
were	O
produced	O
by	O
the	O
fungus	O
;	O
the	O
difference	O
is	O
attributed	O
to	O
the	O
glycosylated	O
part	O
of	O
the	O
molecule	O
.	O

The	O
two	O
glycoproteins	O
were	O
treated	O
with	O
PNGAse	B-Protein
F	I-Protein
and	O
the	O
released	O
glycans	O
were	O
analyzed	O
by	O
HPAEC	O
,	O
MALDI	O
/	O
TOF	O
-	O
MS	O
,	O
NSI	O
-	O
MS	O
(	O
n	O
)	O
,	O
and	O
GC	O
-	O
MS	O
.	O

The	O
MALDI	O
and	O
NSI	O
-	O
full	O
MS	O
spectra	O
of	O
permethylated	O
N	O
-	O
glycans	O
revealed	O
that	O
the	O
N	O
-	O
glycans	O
of	O
both	O
variants	O
contain	O
a	O
series	O
of	O
high	O
-	O
mannose	O
type	O
glycans	O
with	O
5	O
-	O
20	O
hexose	O
units	O
.	O

Monosaccharide	O
analysis	O
showed	O
that	O
these	O
were	O
composed	O
of	O
N	O
-	O
acetylglucos	O
-	O
amine	O
,	O
mannose	O
,	O
and	O
galactose	O
.	O

Linkage	O
analysis	O
revealed	O
that	O
the	O
galactosyl	O
component	O
was	O
in	O
the	O
furanoic	O
conformation	O
,	O
which	O
was	O
attaching	O
in	O
a	O
terminal	O
non	O
-	O
reducing	O
position	O
.	O

The	O
Galactofuranose	O
-	O
containing	O
high	O
-	O
mannnose	O
type	O
N	O
-	O
glycans	O
are	O
typical	O
structures	O
,	O
which	O
recently	O
have	O
been	O
found	O
as	O
part	O
of	O
several	O
glycoproteins	O
produced	O
by	O
Aspergillus	O
niger	O
.	O

Predictive	O
value	O
of	O
expression	O
and	O
promoter	O
hypermethylation	O
of	O
XAF1	B-Protein
in	O
hepatitis	O
B	O
virus	O
-	O
associated	O
hepatocellular	O
carcinoma	O
treated	O
with	O
transplantation	O
.	O

BACKGROUND	O
:	O
Transcriptional	O
regulation	O
of	O
the	O
putative	O
tumor	O
suppressor	O
gene	O
X	B-Protein
-	I-Protein
linked	I-Protein
inhibitor	I-Protein
of	I-Protein
apoptosis	I-Protein
protein	I-Protein
-	I-Protein
associated	I-Protein
factor	I-Protein
1	I-Protein
(	O
XAF1	B-Protein
)	O
by	O
promoter	O
methylation	O
has	O
been	O
related	O
to	O
tumor	O
progression	O
in	O
gastric	O
and	O
bladder	O
cancer	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
methylation	O
status	O
and	O
expression	O
level	O
of	O
XAF1	B-Protein
in	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
-	O
associated	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
treated	O
with	O
liver	O
transplantation	O
(	O
LT	O
)	O
,	O
and	O
to	O
evaluate	O
potential	O
predictive	O
value	O
for	O
tumor	O
recurrence	O
.	O

METHODS	O
:	O
The	O
expression	O
level	O
and	O
methylation	O
status	O
of	O
XAF1	B-Protein
in	O
three	O
liver	O
cancer	O
cell	O
lines	O
(	O
SMMC	O
-	O
7721	O
,	O
HepG2	O
,	O
and	O
Hep3B	O
)	O
and	O
65	O
cases	O
of	O
HBV	O
-	O
associated	O
HCC	O
following	O
LT	O
were	O
analyzed	O
by	O
RT	O
-	O
PCR	O
(	O
RT	B-Protein
,	O
reverse	B-Protein
-	I-Protein
transcriptase	I-Protein
)	O
,	O
immunohistochemistry	O
,	O
and	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

RESULTS	O
:	O
XAF1	B-Protein
transcripts	O
were	O
not	O
observed	O
or	O
present	O
at	O
low	O
levels	O
in	O
liver	O
cancer	O
cell	O
lines	O
and	O
were	O
restored	O
by	O
treatment	O
with	O
demethylating	O
agent	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
Aza	O
-	O
dC	O
)	O
.	O

In	O
vivo	O
,	O
methylation	O
status	O
was	O
associated	O
with	O
protein	O
level	O
of	O
XAF1	B-Protein
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
serum	O
level	O
of	O
alpha	B-Protein
-	I-Protein
fetoprotein	I-Protein
(	O
AFP	B-Protein
)	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
.	O

The	O
expression	O
pattern	O
of	O
XAF1	B-Protein
was	O
associated	O
with	O
portal	O
vein	O
tumor	O
thrombi	O
(	O
PVTT	O
)	O
,	O
preoperative	O
AFP	O
level	O
,	O
tumor	O
size	O
,	O
and	O
recurrence	O
.	O

Multivariate	O
analysis	O
revealed	O
that	O
expression	O
level	O
of	O
XAF1	B-Protein
was	O
an	O
independent	O
factor	O
for	O
predicting	O
recurrence	O
-	O
free	O
survival	O
[	O
hazard	O
ratio	O
0	O
.	O
237	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
095	O
-	O
0	O
.	O
592	O
,	O
P	O
=	O
0	O
.	O
002	O
]	O
.	O

However	O
,	O
no	O
significant	O
association	O
was	O
found	O
between	O
methylation	O
status	O
and	O
the	O
risk	O
of	O
tumor	O
recurrence	O
.	O

CONCLUSION	O
:	O
Promoter	O
hypermethylation	O
is	O
a	O
critical	O
,	O
but	O
not	O
the	O
sole	O
,	O
mechanism	O
for	O
gene	O
silencing	O
of	O
XAF1	B-Protein
in	O
HCC	O
.	O

Protein	O
level	O
of	O
XAF1	B-Protein
may	O
serve	O
as	O
a	O
potential	O
biomarker	O
for	O
tumor	O
recurrence	O
after	O
LT	O
.	O

Biochemical	O
characterization	O
of	O
human	O
prolyl	B-Protein
hydroxylase	I-Protein
domain	I-Protein
protein	I-Protein
2	I-Protein
variants	O
associated	O
with	O
erythrocytosis	O
.	O

Prolyl	O
hydroxylase	O
domain	O
proteins	O
(	O
PHD	B-Protein
isozymes	I-Protein
1	I-Protein
-	O
3	B-Protein
)	O
regulate	O
levels	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
hypoxia	O
inducible	O
factor	O
(	O
HIF	O
)	O
through	O
proline	O
hydroxylation	O
,	O
earmarking	O
HIFalpha	O
for	O
proteosome	O
-	O
mediated	O
degradation	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
HIF	O
stabilization	O
leads	O
to	O
enhanced	O
transcription	O
and	O
regulation	O
of	O
a	O
multitude	O
of	O
processes	O
,	O
including	O
erythropoiesis	O
.	O

Herein	O
,	O
we	O
examine	O
the	O
biochemical	O
characterization	O
of	O
PHD2	B-Protein
variants	O
,	O
Arg371His	O
and	O
Pro317Arg	O
,	O
identified	O
from	O
patients	O
with	O
familial	O
erythrocytosis	O
.	O

The	O
variants	O
display	O
differential	O
effects	O
on	O
catalytic	O
rate	O
and	O
substrate	O
binding	O
,	O
implying	O
that	O
partial	O
inhibition	O
or	O
selective	O
inhibition	O
with	O
regard	O
to	O
HIFalpha	O
isoforms	O
of	O
PHD2	B-Protein
could	O
result	O
in	O
the	O
phenotype	O
displayed	O
by	O
patients	O
with	O
familial	O
erythrocytosis	O
.	O

Histone	B-Protein
H2B	I-Protein
monoubiquitination	O
in	O
the	O
chromatin	O
of	O
FLOWERING	B-Protein
LOCUS	I-Protein
C	I-Protein
regulates	O
flowering	O
time	O
in	O
Arabidopsis	O
.	O

Ubiquitination	O
is	O
one	O
of	O
many	O
known	O
histone	B-Protein
modifications	O
that	O
regulate	O
gene	O
expression	O
.	O

Here	O
,	O
we	O
examine	O
the	O
Arabidopsis	O
thaliana	O
homologs	O
of	O
the	O
yeast	O
E2	O
and	O
E3	O
enzymes	O
responsible	O
for	O
H2B	B-Protein
monoubiquitination	O
(	O
H2Bub1	B-Protein
)	O
.	O

Arabidopsis	O
has	O
two	O
E3	O
homologs	O
(	O
HISTONE	B-Protein
MONOUBIQUITINATION1	I-Protein
[	O
HUB1	B-Protein
]	O
and	O
HUB2	B-Protein
)	O
and	O
three	O
E2	O
homologs	O
(	O
UBIQUITIN	O
CARRIER	O
PROTEIN	O
[	O
UBC1	B-Protein
]	O
to	O
UBC3	B-Protein
)	O
.	O

hub1	B-Protein
and	O
hub2	B-Protein
mutants	O
show	O
the	O
loss	O
of	O
H2Bub1	B-Protein
and	O
early	O
flowering	O
.	O

By	O
contrast	O
,	O
single	O
ubc1	B-Protein
,	O
ubc2	B-Protein
,	O
or	O
ubc3	B-Protein
mutants	O
show	O
no	O
flowering	O
defect	O
;	O
only	O
ubc1	B-Protein
ubc2	B-Protein
double	O
mutants	O
,	O
and	O
not	O
double	O
mutants	O
with	O
ubc3	B-Protein
,	O
show	O
early	O
flowering	O
and	O
H2Bub1	B-Protein
defects	O
.	O

This	O
suggests	O
that	O
ubc1	B-Protein
and	O
ubc2	B-Protein
are	O
redundant	O
,	O
but	O
ubc3	B-Protein
is	O
not	O
involved	O
in	O
flowering	O
time	O
regulation	O
.	O

Protein	O
interaction	O
analysis	O
showed	O
that	O
HUB1	B-Protein
and	O
HUB2	B-Protein
interact	O
with	O
each	O
other	O
and	O
with	O
UBC1	B-Protein
and	O
UBC2	B-Protein
,	O
as	O
well	O
as	O
self	O
-	O
associating	O
.	O

The	O
expression	O
of	O
FLOWERING	B-Protein
LOCUS	I-Protein
C	I-Protein
(	O
FLC	B-Protein
)	O
and	O
its	O
homologs	O
was	O
repressed	O
in	O
hub1	B-Protein
,	O
hub2	B-Protein
,	O
and	O
ubc1	B-Protein
ubc2	B-Protein
mutant	O
plants	O
.	O

Association	O
of	O
H2Bub1	B-Protein
with	O
the	O
chromatin	O
of	O
FLC	B-Protein
clade	O
genes	O
depended	O
on	O
UBC1	B-Protein
,	O
2	B-Protein
and	O
HUB1	B-Protein
,	O
2	B-Protein
,	O
as	O
did	O
the	O
dynamics	O
of	O
methylated	O
histones	B-Protein
H3K4me3	I-Protein
and	O
H3K36me2	B-Protein
.	O

The	O
monoubiquitination	O
of	O
H2B	B-Protein
via	O
UBC1	B-Protein
,	O
2	B-Protein
and	O
HUB1	B-Protein
,	O
2	B-Protein
represents	O
a	O
novel	O
form	O
of	O
histone	B-Protein
modification	O
that	O
is	O
involved	O
in	O
flowering	O
time	O
regulation	O
.	O

RBBP6	B-Protein
interacts	O
with	O
multifunctional	O
protein	O
YB	B-Protein
-	I-Protein
1	I-Protein
through	O
its	O
RING	O
finger	O
domain	O
,	O
leading	O
to	O
ubiquitination	O
and	O
proteosomal	O
degradation	O
of	O
YB	B-Protein
-	I-Protein
1	I-Protein
.	O

RBBP6	B-Protein
(	O
retinoblastoma	B-Protein
binding	I-Protein
protein	I-Protein
6	I-Protein
)	O
is	O
a	O
250	O
-	O
kDa	O
multifunctional	O
protein	O
that	O
interacts	O
with	O
both	O
p53	B-Protein
and	O
pRb	B-Protein
and	O
has	O
been	O
implicated	O
in	O
mRNA	O
processing	O
.	O

It	O
has	O
also	O
been	O
identified	O
as	O
a	O
putative	O
E3	O
ubiquitin	B-Protein
ligase	O
due	O
to	O
the	O
presence	O
of	O
a	O
RING	O
finger	O
domain	O
,	O
although	O
no	O
substrate	O
has	O
been	O
identified	O
up	O
to	O
now	O
.	O

Using	O
the	O
RING	O
finger	O
domain	O
as	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
identified	O
YB	B-Protein
-	I-Protein
1	I-Protein
(	O
Y	B-Protein
-	I-Protein
box	I-Protein
binding	I-Protein
protein	I-Protein
1	I-Protein
)	O
as	O
a	O
binding	O
partner	O
of	O
RBBP6	B-Protein
,	O
localising	O
the	O
interaction	O
to	O
the	O
last	O
62	O
residues	O
of	O
YB	B-Protein
-	I-Protein
1	I-Protein
.	O

We	O
showed	O
,	O
furthermore	O
,	O
that	O
both	O
full	O
-	O
length	O
RBBP6	B-Protein
and	O
the	O
isolated	O
RING	O
finger	O
domain	O
were	O
able	O
to	O
ubiquitinate	O
YB	B-Protein
-	I-Protein
1	I-Protein
,	O
resulting	O
in	O
its	O
degradation	O
in	O
the	O
proteosome	O
.	O

As	O
a	O
result	O
,	O
RBBP6	B-Protein
was	O
able	O
to	O
suppress	O
the	O
levels	O
of	O
YB	B-Protein
-	I-Protein
1	I-Protein
in	O
vivo	O
and	O
to	O
reduce	O
its	O
transactivational	O
ability	O
.	O

In	O
the	O
light	O
of	O
the	O
important	O
role	O
that	O
YB	B-Protein
-	I-Protein
1	I-Protein
appears	O
to	O
play	O
in	O
tumourigenesis	O
,	O
our	O
results	O
suggest	O
that	O
RBBP6	B-Protein
may	O
be	O
a	O
relevant	O
target	O
for	O
therapeutic	O
drugs	O
aimed	O
at	O
modifying	O
the	O
activity	O
of	O
YB	B-Protein
-	I-Protein
1	I-Protein
.	O

Abnormal	O
proteins	O
can	O
form	O
aggresome	O
in	O
yeast	O
:	O
aggresome	O
-	O
targeting	O
signals	O
and	O
components	O
of	O
the	O
machinery	O
.	O

In	O
mammalian	O
cells	O
,	O
abnormal	O
proteins	O
that	O
escape	O
proteasome	O
-	O
dependent	O
degradation	O
form	O
small	O
aggregates	O
that	O
can	O
be	O
transported	O
into	O
a	O
centrosome	O
-	O
associated	O
structure	O
,	O
called	O
an	O
aggresome	O
.	O

Here	O
we	O
demonstrate	O
that	O
in	O
yeast	O
a	O
single	O
aggregate	O
formed	O
by	O
the	O
huntingtin	B-Protein
exon	O
1	O
with	O
an	O
expanded	O
polyglutamine	O
domain	O
(	O
103QP	O
)	O
represents	O
a	O
bona	O
fide	O
aggresome	O
that	O
colocalizes	O
with	O
the	O
spindle	O
pole	O
body	O
(	O
the	O
yeast	O
centrosome	O
)	O
in	O
a	O
microtubule	O
-	O
dependent	O
fashion	O
.	O

Since	O
a	O
polypeptide	O
lacking	O
the	O
proline	O
-	O
rich	O
region	O
(	O
P	O
-	O
region	O
)	O
of	O
huntingtin	B-Protein
(	O
103Q	O
)	O
cannot	O
form	O
aggresomes	O
,	O
this	O
domain	O
serves	O
as	O
an	O
aggresome	O
-	O
targeting	O
signal	O
.	O

Coexpression	O
of	O
103Q	O
with	O
25QP	O
,	O
a	O
soluble	O
polypeptide	O
that	O
also	O
carries	O
the	O
P	O
-	O
region	O
,	O
led	O
to	O
the	O
recruitment	O
of	O
103Q	O
to	O
the	O
aggresome	O
via	O
formation	O
of	O
hetero	O
-	O
oligomers	O
,	O
indicating	O
the	O
aggresome	O
targeting	O
in	O
trans	O
.	O

To	O
identify	O
additional	O
factors	O
involved	O
in	O
aggresome	O
formation	O
and	O
targeting	O
,	O
we	O
purified	O
103QP	O
aggresomes	O
and	O
103Q	O
aggregates	O
and	O
identified	O
the	O
associated	O
proteins	O
using	O
mass	O
spectrometry	O
.	O

Among	O
the	O
aggresome	O
-	O
associated	O
proteins	O
we	O
identified	O
,	O
Cdc48	B-Protein
(	O
VCP	B-Protein
/	O
p97	B-Protein
)	O
and	O
its	O
cofactors	O
,	O
Ufd1	B-Protein
and	O
Nlp4	B-Protein
,	O
were	O
shown	O
genetically	O
to	O
be	O
essential	O
for	O
aggresome	O
formation	O
.	O

The	O
14	O
-	O
3	O
-	O
3	O
protein	O
,	O
Bmh1	B-Protein
,	O
was	O
also	O
found	O
to	O
be	O
critical	O
for	O
aggresome	O
targeting	O
.	O

Its	O
interaction	O
with	O
the	O
huntingtin	B-Protein
fragment	O
and	O
its	O
role	O
in	O
aggresome	O
formation	O
required	O
the	O
huntingtin	B-Protein
N	O
-	O
terminal	O
N17	O
domain	O
,	O
adjacent	O
to	O
the	O
polyQ	O
domain	O
.	O

Accordingly	O
,	O
the	O
huntingtin	B-Protein
N17	O
domain	O
,	O
along	O
with	O
the	O
P	O
-	O
region	O
,	O
plays	O
a	O
role	O
in	O
aggresome	O
targeting	O
.	O

We	O
also	O
present	O
direct	O
genetic	O
evidence	O
for	O
the	O
protective	O
role	O
of	O
aggresomes	O
by	O
demonstrating	O
genetically	O
that	O
aggresome	O
targeting	O
of	O
polyglutamine	O
polypeptides	O
relieves	O
their	O
toxicity	O
.	O

Proteomics	O
-	O
based	O
identification	O
of	O
novel	O
factor	B-Protein
inhibiting	I-Protein
hypoxia	I-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	O
FIH	B-Protein
)	O
substrates	O
indicates	O
widespread	O
asparaginyl	O
hydroxylation	O
of	O
ankyrin	O
repeat	O
domain	O
-	O
containing	O
proteins	O
.	O

Post	O
-	O
translational	O
hydroxylation	O
has	O
been	O
considered	O
an	O
unusual	O
modification	O
on	O
intracellular	O
proteins	O
.	O

However	O
,	O
following	O
the	O
recognition	O
that	O
oxygen	O
-	O
sensitive	O
prolyl	O
and	O
asparaginyl	O
hydroxylation	O
are	O
central	O
to	O
the	O
regulation	O
of	O
the	O
transcription	O
factor	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
,	O
interest	O
has	O
centered	O
on	O
the	O
possibility	O
that	O
these	O
enzymes	O
may	O
have	O
other	O
substrates	O
in	O
the	O
proteome	O
.	O

In	O
support	O
of	O
this	O
certain	O
ankyrin	O
repeat	O
domain	O
(	O
ARD	O
)	O
-	O
containing	O
proteins	O
,	O
including	O
members	O
of	O
the	O
IkappaB	O
and	O
Notch	O
families	O
,	O
have	O
been	O
identified	O
as	O
alternative	O
substrates	O
of	O
the	O
HIF	B-Protein
asparaginyl	I-Protein
hydroxylase	I-Protein
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
FIH	B-Protein
)	O
.	O

Although	O
these	O
findings	O
imply	O
a	O
potentially	O
broad	O
range	O
of	O
substrates	O
for	O
FIH	B-Protein
,	O
the	O
precise	O
extent	O
of	O
this	O
range	O
has	O
been	O
difficult	O
to	O
determine	O
because	O
of	O
the	O
difficulty	O
of	O
capturing	O
transient	O
enzyme	O
-	O
substrate	O
interactions	O
.	O

Here	O
we	O
describe	O
the	O
use	O
of	O
pharmacological	O
"	O
substrate	O
trapping	O
"	O
together	O
with	O
stable	O
isotope	O
labeling	O
by	O
amino	O
acids	O
in	O
cell	O
culture	O
(	O
SILAC	O
)	O
technology	O
to	O
stabilize	O
and	O
identify	O
potential	O
FIH	B-Protein
-	O
substrate	O
interactions	O
by	O
mass	O
spectrometry	O
.	O

To	O
pursue	O
these	O
potential	O
FIH	B-Protein
substrates	O
we	O
used	O
conventional	O
data	O
-	O
directed	O
tandem	O
MS	O
together	O
with	O
alternating	O
low	O
/	O
high	O
collision	O
energy	O
tandem	O
MS	O
to	O
assign	O
and	O
quantitate	O
hydroxylation	O
at	O
target	O
asparaginyl	O
residues	O
.	O

Overall	O
the	O
work	O
has	O
defined	O
13	O
new	O
FIH	B-Protein
-	O
dependent	O
hydroxylation	O
sites	O
with	O
a	O
degenerate	O
consensus	O
corresponding	O
to	O
that	O
of	O
the	O
ankyrin	O
repeat	O
and	O
a	O
range	O
of	O
ARD	O
-	O
containing	O
proteins	O
as	O
actual	O
and	O
potential	O
substrates	O
for	O
FIH	B-Protein
.	O

Several	O
ARD	O
-	O
containing	O
proteins	O
were	O
multiply	O
hydroxylated	O
,	O
and	O
detailed	O
studies	O
of	O
one	O
,	O
Tankyrase	B-Protein
-	I-Protein
2	I-Protein
,	O
revealed	O
eight	O
sites	O
that	O
were	O
differentially	O
sensitive	O
to	O
FIH	B-Protein
-	O
catalyzed	O
hydroxylation	O
.	O

These	O
findings	O
indicate	O
that	O
asparaginyl	O
hydroxylation	O
is	O
likely	O
to	O
be	O
widespread	O
among	O
the	O
approximately	O
300	O
ARD	O
-	O
containing	O
species	O
in	O
the	O
human	O
proteome	O
.	O

Galphaq	B-Protein
reduces	O
cAMP	O
production	O
by	O
decreasing	O
Galphas	B-Protein
protein	O
abundance	O
.	O

The	O
heterotrimeric	O
guanine	O
nucleotide	O
-	O
binding	O
protein	O
Galphaq	B-Protein
transduces	O
signals	O
from	O
heptahelical	O
transmembrane	O
receptors	O
(	O
e	O
.	O
g	O
.	O
,	O
alpha	O
(	O
1	O
)	O
-	O
adrenergic	O
,	O
endothelin	O
1A	O
,	O
and	O
angiotensin	B-Protein
II	I-Protein
)	O
to	O
stimulate	O
generation	O
of	O
inositol	O
-	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
and	O
diacylglycerol	O
.	O

In	O
addition	O
,	O
Galphaq	B-Protein
decreases	O
cAMP	O
production	O
,	O
through	O
unknown	O
mechanisms	O
,	O
and	O
thus	O
affects	O
physiological	O
responsiveness	O
of	O
cardiac	O
myocytes	O
and	O
other	O
cells	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
Galphaq	B-Protein
expression	O
increases	O
Galphas	B-Protein
ubiquitination	O
,	O
decreases	O
Galphas	B-Protein
protein	O
content	O
,	O
and	O
impairs	O
basal	O
and	O
beta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
-	I-Protein
adrenergic	I-Protein
receptor	I-Protein
-	O
stimulated	O
cAMP	O
production	O
.	O

These	O
biochemical	O
and	O
functional	O
changes	O
are	O
associated	O
with	O
Akt	O
activation	O
.	O

Expression	O
of	O
constitutively	O
active	O
Akt	O
also	O
decreases	O
Galphas	B-Protein
protein	O
content	O
and	O
inhibits	O
basal	O
and	O
beta	B-Protein
(	I-Protein
1	I-Protein
)	I-Protein
-	I-Protein
adrenergic	I-Protein
receptor	I-Protein
-	O
stimulated	O
cAMP	O
production	O
.	O

Akt	O
knockdown	O
inhibits	O
Galphaq	B-Protein
-	O
induced	O
reduction	O
of	O
Galphas	B-Protein
protein	O
.	O

In	O
addition	O
,	O
MDM2	B-Protein
,	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
,	O
binds	O
Galphas	B-Protein
and	O
promotes	O
its	O
degradation	O
.	O

Therefore	O
,	O
increased	O
expression	O
of	O
Galphaq	B-Protein
decreases	O
cAMP	O
production	O
through	O
Akt	O
-	O
mediated	O
Galphas	B-Protein
protein	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

Assessment	O
of	O
histone	B-Protein
acetylation	O
levels	O
in	O
relation	O
to	O
cell	O
cycle	O
phase	O
.	O

Histone	B-Protein
acetylation	O
affects	O
chromatin	O
structural	O
organization	O
,	O
thus	O
regulating	O
gene	O
expression	O
and	O
DNA	O
-	O
related	O
cellular	O
events	O
.	O

Levels	O
of	O
histone	B-Protein
acetylation	O
are	O
tightly	O
modulated	O
in	O
normal	O
cells	O
and	O
frequently	O
altered	O
in	O
tumors	O
.	O

Consequently	O
,	O
histone	B-Protein
deacetylase	O
inhibitors	O
are	O
currently	O
being	O
tested	O
in	O
clinical	O
trials	O
as	O
anticancer	O
drugs	O
.	O

Presented	O
here	O
is	O
a	O
protocol	O
for	O
measuring	O
the	O
degree	O
of	O
cellular	O
histone	B-Protein
tail	O
acetylation	O
,	O
alone	O
or	O
in	O
combination	O
with	O
DNA	O
content	O
to	O
simultaneously	O
evaluate	O
cell	O
ploidy	O
and	O
/	O
or	O
cell	O
cycle	O
progression	O
.	O

The	O
procedure	O
can	O
also	O
be	O
employed	O
to	O
stain	O
peripheral	O
blood	O
samples	O
in	O
order	O
to	O
assess	O
mean	O
histone	B-Protein
acetylation	O
levels	O
in	O
patients	O
treated	O
with	O
histone	B-Protein
deacetylase	O
inhibitors	O
.	O

gp160	B-Protein
of	O
HIV	O
-	O
I	O
synthesized	O
by	O
persistently	O
infected	O
Molt	O
-	O
3	O
cells	O
is	O
terminally	O
glycosylated	O
:	O
evidence	O
that	O
cleavage	O
of	O
gp160	B-Protein
occurs	O
subsequent	O
to	O
oligosaccharide	O
processing	O
.	O

The	O
envelope	O
glycoprotein	O
of	O
HIV	O
-	O
I	O
in	O
infected	O
,	O
cultured	O
human	O
T	O
cells	O
is	O
synthesized	O
as	O
a	O
precursor	O
of	O
apparent	O
Mr	O
160	O
kDa	O
(	O
gp160	B-Protein
)	O
and	O
is	O
cleaved	O
to	O
two	O
glycoproteins	O
,	O
gp120	B-Protein
and	O
gp41	B-Protein
,	O
which	O
are	O
the	O
mature	O
envelope	O
glycoproteins	O
in	O
the	O
virus	O
.	O

Neither	O
the	O
temporal	O
and	O
spatial	O
features	O
of	O
glycosylation	O
nor	O
the	O
oligosaccharide	O
processing	O
and	O
proteolytic	O
cleavage	O
of	O
the	O
envelope	O
glycoprotein	O
are	O
well	O
understood	O
.	O

To	O
understand	O
more	O
about	O
these	O
events	O
,	O
we	O
investigated	O
the	O
glycosylation	O
and	O
cleavage	O
of	O
the	O
envelope	O
glycoproteins	O
in	O
the	O
CD4	B-Protein
+	O
human	O
cell	O
line	O
,	O
Molt	O
-	O
3	O
,	O
persistently	O
infected	O
with	O
HIV	O
-	O
I	O
(	O
HTLV	O
IIIB	O
)	O
.	O

The	O
carbohydrate	O
analysis	O
of	O
gp160	B-Protein
and	O
gp120	B-Protein
and	O
the	O
behavior	O
of	O
the	O
glycoproteins	O
and	O
glycopeptides	O
derived	O
from	O
them	O
on	O
immobilized	O
lectins	O
demonstrate	O
that	O
both	O
of	O
these	O
glycoproteins	O
contain	O
complex	O
-	O
and	O
high	O
-	O
mannose	O
-	O
type	O
Asn	O
-	O
linked	O
oligosaccharides	O
.	O

In	O
addition	O
,	O
the	O
N	O
-	O
glycanase	O
-	O
resistant	O
oligosaccharides	O
of	O
gp120	B-Protein
were	O
found	O
to	O
contain	O
N	O
-	O
acetyl	O
-	O
galactosamine	O
,	O
a	O
common	O
constituent	O
of	O
Ser	O
/	O
Thr	O
-	O
linked	O
oligosaccharides	O
.	O

Pulse	O
-	O
chase	O
analysis	O
of	O
the	O
conversion	O
of	O
[	O
35S	O
]	O
cysteine	O
-	O
labeled	O
gp160	B-Protein
showed	O
that	O
in	O
Molt	O
-	O
3	O
cells	O
it	O
takes	O
about	O
2	O
h	O
for	O
gp120	B-Protein
to	O
arise	O
with	O
a	O
half	O
-	O
time	O
of	O
conversion	O
of	O
about	O
5	O
h	O
.	O

At	O
its	O
earliest	O
detectable	O
occurrence	O
,	O
gp120	B-Protein
was	O
found	O
to	O
contain	O
complex	O
-	O
type	O
Asn	O
-	O
linked	O
oligosaccharides	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
proteolytic	O
cleavage	O
of	O
gp160	B-Protein
to	O
gp120	B-Protein
and	O
gp41	B-Protein
occurs	O
either	O
within	O
the	O
trans	O
-	O
Golgi	O
or	O
in	O
a	O
distal	O
compartment	O
.	O

Studies	O
on	O
the	O
biotin	O
-	O
binding	O
site	O
of	O
avidin	B-Protein
.	O

Minimized	O
fragments	O
that	O
bind	O
biotin	O
.	O

The	O
object	O
of	O
this	O
study	O
was	O
to	O
define	O
minimized	O
biotin	O
-	O
binding	O
fragments	O
,	O
or	O
'	O
prorecognition	O
sites	O
'	O
,	O
of	O
either	O
the	O
egg	O
-	O
white	O
glycoprotein	O
avidin	B-Protein
or	O
its	O
bacterial	O
analogue	O
streptavidin	B-Protein
.	O

Because	O
of	O
the	O
extreme	O
stability	O
to	O
enzymic	O
hydrolysis	O
,	O
fragments	O
of	O
avidin	O
were	O
prepared	O
by	O
chemical	O
means	O
and	O
examined	O
for	O
their	O
individual	O
biotin	O
-	O
binding	O
capacity	O
.	O

Treatment	O
of	O
avidin	O
with	O
hydroxylamine	O
was	O
shown	O
to	O
result	O
in	O
new	O
cleavage	O
sites	O
in	O
addition	O
to	O
the	O
known	O
Asn	O
-	O
Gly	O
cleavage	O
site	O
(	O
position	O
88	O
-	O
89	O
in	O
avidin	B-Protein
)	O
.	O

Notably	O
,	O
the	O
Asn	O
-	O
Glu	O
and	O
Asp	O
-	O
Lys	O
peptide	O
bonds	O
(	O
positions	O
42	O
-	O
43	O
and	O
57	O
-	O
58	O
respectively	O
)	O
were	O
readily	O
cleaved	O
;	O
in	O
addition	O
,	O
lesser	O
levels	O
of	O
hydrolysis	O
of	O
the	O
Gln	O
-	O
Pro	O
(	O
61	O
-	O
62	O
)	O
and	O
Asn	O
-	O
Asp	O
(	O
12	O
-	O
13	O
and	O
104	O
-	O
105	O
)	O
bonds	O
could	O
be	O
detected	O
.	O

The	O
smallest	O
biotin	O
-	O
binding	O
peptide	O
fragment	O
,	O
derived	O
from	O
hydroxylamine	O
cleavage	O
of	O
either	O
native	O
or	O
non	O
-	O
glycosylated	O
avidin	B-Protein
,	O
was	O
identified	O
to	O
comprise	O
residues	O
1	O
-	O
42	O
.	O

CNBr	O
cleavage	O
resulted	O
in	O
a	O
78	O
-	O
amino	O
acid	O
-	O
residue	O
fragment	O
(	O
residues	O
19	O
-	O
96	O
)	O
that	O
still	O
retained	O
activity	O
.	O

The	O
data	O
ascribe	O
an	O
important	O
biotin	O
-	O
binding	O
function	O
to	O
the	O
overlapping	O
region	O
(	O
residues	O
19	O
-	O
42	O
)	O
of	O
avidin	B-Protein
,	O
which	O
bears	O
the	O
single	O
tyrosine	O
moiety	O
.	O

This	O
contention	O
was	O
corroborated	O
by	O
synthesizing	O
a	O
tridecapeptide	O
corresponding	O
to	O
residues	O
26	O
-	O
38	O
of	O
avidin	B-Protein
;	O
this	O
peptide	O
was	O
shown	O
to	O
recognize	O
biotin	O
.	O

Streptavidin	B-Protein
was	O
not	O
susceptible	O
to	O
either	O
enzymic	O
or	O
chemical	O
cleavage	O
methods	O
used	O
in	O
this	O
work	O
.	O

The	O
approach	O
taken	O
in	O
this	O
study	O
enabled	O
the	O
experimental	O
distinction	O
between	O
the	O
chemical	O
and	O
structural	O
elements	O
of	O
the	O
binding	O
site	O
.	O

The	O
capacity	O
to	O
assign	O
biotin	O
-	O
binding	O
activity	O
to	O
the	O
tyrosine	O
-	O
containing	O
domain	O
of	O
avidin	B-Protein
underscores	O
its	O
primary	O
chemical	O
contribution	O
to	O
the	O
binding	O
of	O
biotin	O
by	O
avidin	B-Protein
.	O

Complex	O
patterns	O
of	O
histidine	O
,	O
hydroxylated	O
amino	O
acids	O
and	O
the	O
GxxxG	O
motif	O
mediate	O
high	O
-	O
affinity	O
transmembrane	O
domain	O
interactions	O
.	O

Specific	O
interactions	O
of	O
transmembrane	O
helices	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
folding	O
and	O
oligomerization	O
of	O
integral	O
membrane	O
proteins	O
.	O

The	O
helix	O
-	O
helix	O
interfaces	O
frequently	O
depend	O
on	O
specific	O
amino	O
acid	O
patterns	O
.	O

In	O
this	O
study	O
,	O
a	O
heptad	O
repeat	O
pattern	O
was	O
randomized	O
with	O
all	O
naturally	O
occurring	O
amino	O
acids	O
to	O
uncover	O
novel	O
sequence	O
motifs	O
promoting	O
transmembrane	O
domain	O
interactions	O
.	O

Self	O
-	O
interacting	O
transmembrane	O
domains	O
were	O
selected	O
from	O
the	O
resulting	O
combinatorial	O
library	O
by	O
means	O
of	O
the	O
ToxR	B-Protein
/	O
POSSYCCAT	O
system	O
.	O

A	O
comparison	O
of	O
the	O
amino	O
acid	O
composition	O
of	O
high	O
-	O
and	O
low	O
-	O
affinity	O
sequences	O
revealed	O
that	O
high	O
-	O
affinity	O
transmembrane	O
domains	O
exhibit	O
position	O
-	O
specific	O
enrichment	O
of	O
histidine	O
.	O

Further	O
,	O
sequences	O
containing	O
His	O
preferentially	O
display	O
Gly	O
,	O
Ser	O
,	O
and	O
/	O
or	O
Thr	O
residues	O
at	O
flanking	O
positions	O
and	O
frequently	O
contain	O
a	O
C	O
-	O
terminal	O
GxxxG	O
motif	O
.	O

Mutational	O
analysis	O
of	O
selected	O
sequences	O
confirmed	O
the	O
importance	O
of	O
these	O
residues	O
in	O
homotypic	O
interaction	O
.	O

Probing	O
heterotypic	O
interaction	O
indicated	O
that	O
His	O
interacts	O
in	O
trans	O
with	O
hydroxylated	O
residues	O
.	O

Reconstruction	O
of	O
minimal	O
interaction	O
motifs	O
within	O
the	O
context	O
of	O
an	O
oligo	O
-	O
Leu	O
sequence	O
confirmed	O
that	O
His	O
is	O
part	O
of	O
a	O
hydrogen	O
bonded	O
cluster	O
that	O
is	O
brought	O
into	O
register	O
by	O
the	O
GxxxG	O
motif	O
.	O

Notably	O
,	O
a	O
similar	O
motif	O
contributes	O
to	O
self	O
-	O
interaction	O
of	O
the	O
BNIP3	B-Protein
transmembrane	O
domain	O
.	O

Selective	O
activation	O
of	O
apoptosis	O
by	O
a	O
novel	O
set	O
of	O
4	O
-	O
aryl	O
-	O
3	O
-	O
(	O
3	O
-	O
aryl	O
-	O
1	O
-	O
oxo	O
-	O
2	O
-	O
propenyl	O
)	O
-	O
2	O
(	O
1H	O
)	O
-	O
quinolinones	O
through	O
a	O
Myc	B-Protein
-	O
dependent	O
pathway	O
.	O

Oncogene	O
addiction	O
due	O
to	O
Myc	B-Protein
deregulation	O
has	O
been	O
identified	O
in	O
a	O
variety	O
of	O
tumor	O
types	O
.	O

In	O
order	O
to	O
identify	O
pharmacological	O
agents	O
that	O
cause	O
selective	O
apoptosis	O
in	O
tumors	O
with	O
deregulated	O
Myc	B-Protein
expression	O
,	O
we	O
designed	O
a	O
cell	O
-	O
based	O
screening	O
assay	O
based	O
on	O
our	O
Anti	O
-	O
cancer	O
Screening	O
Apoptosis	O
Program	O
(	O
ASAP	O
)	O
technology	O
targeting	O
increased	O
activity	O
in	O
a	O
"	O
Myc	B-Protein
-	O
addicted	O
"	O
cancer	O
cell	O
panel	O
.	O

We	O
have	O
identified	O
a	O
novel	O
set	O
of	O
substituted	O
4	O
-	O
aryl	O
-	O
3	O
-	O
(	O
3	O
-	O
aryl	O
-	O
1	O
-	O
oxo	O
-	O
2	O
-	O
propenyl	O
)	O
-	O
2	O
(	O
1H	O
)	O
-	O
quinolinones	O
that	O
activates	O
apoptosis	O
in	O
cancer	O
cell	O
lines	O
with	O
deregulated	O
Myc	B-Protein
,	O
but	O
show	O
low	O
activity	O
in	O
cell	O
lines	O
where	O
Myc	B-Protein
is	O
not	O
deregulated	O
.	O

Apoptosis	O
induced	O
by	O
these	O
compounds	O
is	O
rapid	O
,	O
and	O
is	O
associated	O
with	O
a	O
significant	O
downregulation	O
of	O
Myc	B-Protein
protein	O
.	O

Selective	O
knockdown	O
of	O
Myc	B-Protein
levels	O
in	O
these	O
cells	O
by	O
RNA	O
interference	O
increased	O
sensitivity	O
to	O
apoptosis	O
with	O
compound	O
treatment	O
.	O

By	O
targeting	O
the	O
Myc	B-Protein
pathway	O
in	O
Myc	B-Protein
-	O
addicted	O
cancer	O
cells	O
,	O
we	O
have	O
identified	O
a	O
novel	O
class	O
of	O
apoptotic	O
inducers	O
that	O
selectively	O
and	O
efficiently	O
target	O
cancer	O
cells	O
with	O
deregulated	O
Myc	B-Protein
.	O

The	O
trafficking	O
and	O
regulation	O
of	O
membrane	O
receptors	O
by	O
the	O
RING	O
-	O
CH	O
ubiquitin	B-Protein
E3	O
ligases	O
.	O

Ubiquitylation	O
of	O
membrane	O
receptors	O
is	O
recognised	O
as	O
a	O
critical	O
post	O
-	O
translational	O
modification	O
,	O
governing	O
their	O
regulation	O
and	O
function	O
.	O

Following	O
ubiquitylation	O
,	O
membrane	O
proteins	O
may	O
be	O
internalised	O
,	O
recycled	O
or	O
degraded	O
via	O
lysosomal	O
or	O
proteasomal	O
pathways	O
.	O

Viruses	O
have	O
appropriated	O
these	O
cellular	O
pathways	O
as	O
a	O
mechanism	O
of	O
immune	O
evasion	O
.	O

RING	O
(	O
really	O
interesting	O
new	O
gene	O
)	O
-	O
CH	O
ubiquitin	B-Protein
E3	O
ligases	O
were	O
initially	O
identified	O
from	O
the	O
Kaposi	O
'	O
s	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
and	O
their	O
founding	O
members	O
,	O
K3	O
and	O
K5	O
,	O
downregulate	O
several	O
critical	O
immunoreceptors	O
to	O
prevent	O
detection	O
by	O
the	O
host	O
immune	O
system	O
.	O

K3	O
promotes	O
formation	O
of	O
lysine	O
-	O
63	O
linked	O
polyubiquitin	B-Protein
chains	O
on	O
MHC	O
Class	O
I	O
,	O
signalling	O
Class	O
I	O
internalisation	O
and	O
endolysosomal	O
degradation	O
.	O

K5	O
targets	O
multiple	O
immunoreceptors	O
,	O
including	O
MHC	O
Class	O
I	O
,	O
CD86	B-Protein
,	O
intracellular	B-Protein
adhesion	I-Protein
molecule	I-Protein
(	I-Protein
ICAM	I-Protein
)	I-Protein
1	I-Protein
and	O
MHC	B-Protein
Class	I-Protein
I	I-Protein
-	I-Protein
related	I-Protein
chain	I-Protein
(	I-Protein
MIC	I-Protein
)	I-Protein
-	I-Protein
A	I-Protein
/	O
B	B-Protein
,	O
thereby	O
preventing	O
detection	O
from	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

The	O
cellular	O
homologues	O
of	O
K3	O
and	O
K5	O
,	O
the	O
Membrane	O
Associated	O
RING	O
-	O
CH	O
(	O
MARCH	O
)	O
genes	O
,	O
represent	O
eleven	O
proteins	O
that	O
also	O
appear	O
to	O
be	O
important	O
in	O
the	O
downregulation	O
of	O
membrane	O
receptors	O
.	O

While	O
overexpression	O
of	O
several	O
MARCH	O
genes	O
downregulate	O
cell	O
surface	O
receptors	O
such	O
as	O
MHC	O
Class	O
I	O
,	O
MHC	O
Class	O
II	O
,	O
CD86	B-Protein
and	O
ICAM	B-Protein
1	I-Protein
,	O
determining	O
their	O
physiological	O
roles	O
has	O
proved	O
difficult	O
.	O

Elucidating	O
the	O
transcriptional	O
regulation	O
,	O
localisation	O
and	O
trafficking	O
of	O
MARCH	O
genes	O
may	O
provide	O
insights	O
into	O
their	O
cellular	O
functions	O
.	O

Muscular	O
dystrophies	O
due	O
to	O
glycosylation	O
defects	O
.	O

In	O
the	O
last	O
few	O
years	O
,	O
muscular	O
dystrophies	O
due	O
to	O
reduced	O
glycosylation	O
of	O
alpha	B-Protein
-	I-Protein
dystroglycan	I-Protein
(	O
ADG	B-Protein
)	O
have	O
emerged	O
as	O
a	O
common	O
group	O
of	O
conditions	O
,	O
now	O
referred	O
to	O
as	O
dystroglycanopathies	O
.	O

Mutations	O
in	O
six	O
genes	O
(	O
POMT1	B-Protein
,	O
POMT2	B-Protein
,	O
POMGnT1	B-Protein
,	O
Fukutin	B-Protein
,	O
FKRP	B-Protein
and	O
LARGE	B-Protein
)	O
have	O
so	O
far	O
been	O
identified	O
in	O
patients	O
with	O
a	O
dystroglycanopathy	O
.	O

Allelic	O
mutations	O
in	O
each	O
of	O
these	O
genes	O
can	O
result	O
in	O
a	O
wide	O
spectrum	O
of	O
clinical	O
conditions	O
,	O
ranging	O
from	O
severe	O
congenital	O
onset	O
with	O
associated	O
structural	O
brain	O
malformations	O
(	O
Walker	O
Warburg	O
syndrome	O
;	O
muscle	O
-	O
eye	O
-	O
brain	O
disease	O
;	O
Fukuyama	O
muscular	O
dystrophy	O
;	O
congenital	O
muscular	O
dystrophy	O
type	O
1D	O
)	O
to	O
a	O
relatively	O
milder	O
congenital	O
variant	O
with	O
no	O
brain	O
involvement	O
(	O
congenital	O
muscular	O
dystrophy	O
type	O
1C	O
)	O
,	O
and	O
to	O
limb	O
-	O
girdle	O
muscular	O
dystrophy	O
(	O
LGMD	O
)	O
type	O
2	O
variants	O
with	O
onset	O
in	O
childhood	O
or	O
adult	O
life	O
(	O
LGMD2I	O
,	O
LGMD2L	O
,	O
and	O
LGMD2N	O
)	O
.	O

ADG	B-Protein
is	O
a	O
peripheral	O
membrane	O
protein	O
that	O
undergoes	O
multiple	O
and	O
complex	O
glycosylation	O
steps	O
to	O
regulate	O
its	O
ability	O
to	O
effectively	O
interact	O
with	O
extracellular	O
matrix	O
proteins	O
,	O
such	O
as	O
laminin	O
,	O
agrin	B-Protein
,	O
and	O
perlecan	B-Protein
.	O

Although	O
the	O
precise	O
composition	O
of	O
the	O
glycans	O
present	O
on	O
ADG	B-Protein
are	O
not	O
known	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
forced	O
overexpression	O
of	O
LARGE	B-Protein
,	O
or	O
its	O
paralog	O
LARGE2	B-Protein
,	O
is	O
capable	O
of	O
increasing	O
the	O
glycosylation	O
of	O
ADG	B-Protein
in	O
normal	O
cells	O
.	O

In	O
addition	O
,	O
its	O
overexpression	O
is	O
capable	O
of	O
restoring	O
dystroglycan	B-Protein
glycosylation	O
and	O
laminin	O
binding	O
properties	O
in	O
primary	O
cell	O
cultures	O
of	O
patients	O
affected	O
by	O
different	O
genetically	O
defined	O
dystroglycanopathy	O
variants	O
.	O

These	O
observations	O
suggest	O
that	O
there	O
could	O
be	O
a	O
role	O
for	O
therapeutic	O
strategies	O
to	O
overcome	O
the	O
glycosylation	O
defect	O
in	O
these	O
conditions	O
via	O
the	O
overexpression	O
of	O
LARGE	B-Protein
.	O

APOBEC	O
proteins	O
and	O
intrinsic	O
resistance	O
to	O
HIV	O
-	O
1	O
infection	O
.	O

Members	O
of	O
the	O
APOBEC	O
family	O
of	O
cellular	O
polynucleotide	O
cytidine	O
deaminases	O
,	O
most	O
notably	O
APOBEC3G	B-Protein
and	O
APOBEC3F	B-Protein
,	O
are	O
potent	O
inhibitors	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Wild	O
type	O
HIV	O
-	O
1	O
infections	O
are	O
largely	O
spared	O
from	O
APOBEC3G	B-Protein
/	O
F	B-Protein
function	O
through	O
the	O
action	O
of	O
the	O
essential	O
viral	O
protein	O
,	O
Vif	B-Protein
.	O

In	O
the	O
absence	O
of	O
Vif	B-Protein
,	O
APOBEC3G	B-Protein
/	O
F	B-Protein
are	O
encapsidated	O
by	O
budding	O
virus	O
particles	O
leading	O
to	O
excessive	O
cytidine	O
(	O
C	O
)	O
to	O
uridine	O
(	O
U	O
)	O
editing	O
of	O
negative	O
sense	O
reverse	O
transcripts	O
in	O
newly	O
infected	O
cells	O
.	O

This	O
registers	O
as	O
guanosine	O
(	O
G	O
)	O
to	O
adenosine	O
(	O
A	O
)	O
hypermutations	O
in	O
plus	O
-	O
stranded	O
cDNA	O
.	O

In	O
addition	O
to	O
this	O
profoundly	O
debilitating	O
effect	O
on	O
genetic	O
integrity	O
,	O
APOBEC3G	B-Protein
/	O
F	B-Protein
also	O
appear	O
to	O
inhibit	O
viral	O
DNA	O
synthesis	O
by	O
impeding	O
the	O
translocation	O
of	O
reverse	B-Protein
transcriptase	I-Protein
along	O
template	O
RNA	O
.	O

Because	O
the	O
functions	O
of	O
Vif	B-Protein
and	O
APOBEC3G	B-Protein
/	O
F	B-Protein
proteins	O
oppose	O
each	O
other	O
,	O
it	O
is	O
likely	O
that	O
fluctuations	O
in	O
the	O
Vif	B-Protein
-	O
APOBEC	O
balance	O
may	O
influence	O
the	O
natural	O
history	O
of	O
HIV	O
-	O
1	O
infection	O
,	O
as	O
well	O
as	O
viral	O
sequence	O
diversification	O
and	O
evolution	O
.	O

Given	O
Vif	B-Protein
'	O
s	O
critical	O
role	O
in	O
suppressing	O
APOBEC3G	B-Protein
/	O
F	B-Protein
function	O
,	O
it	O
can	O
be	O
argued	O
that	O
pharmacologic	O
strategies	O
aimed	O
at	O
restoring	O
the	O
activity	O
of	O
these	O
intrinsic	O
anti	O
-	O
viral	O
factors	O
in	O
the	O
context	O
of	O
infected	O
cells	O
in	O
vivo	O
have	O
clear	O
therapeutic	O
merit	O
,	O
and	O
therefore	O
deserve	O
aggressive	O
pursuit	O
.	O

Substrate	O
filtering	O
by	O
the	O
active	O
site	O
crossover	O
loop	O
in	O
UCHL3	B-Protein
revealed	O
by	O
sortagging	O
and	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
.	O

Determining	O
how	O
deubiquitinating	O
enzymes	O
discriminate	O
between	O
ubiquitin	B-Protein
-	O
conjugated	O
substrates	O
is	O
critical	O
to	O
understand	O
their	O
function	O
.	O

Through	O
application	O
of	O
a	O
novel	O
protein	O
cleavage	O
and	O
tagging	O
technique	O
,	O
sortagging	O
,	O
we	O
show	O
that	O
human	O
UCHL3	B-Protein
and	O
the	O
Plasmodium	O
falciparum	O
homologue	O
,	O
members	O
of	O
the	O
ubiquitin	B-Protein
C	O
-	O
terminal	O
hydrolase	O
family	O
,	O
use	O
a	O
unique	O
active	O
site	O
crossover	O
loop	O
to	O
restrict	O
access	O
of	O
bulky	O
ubiquitin	B-Protein
adducts	O
to	O
the	O
active	O
site	O
.	O

Although	O
it	O
provides	O
connectivity	O
for	O
critical	O
active	O
site	O
residues	O
in	O
UCHL3	B-Protein
,	O
physical	O
integrity	O
of	O
the	O
crossover	O
loop	O
is	O
dispensable	O
for	O
catalysis	O
.	O

By	O
enlarging	O
the	O
active	O
site	O
crossover	O
loop	O
,	O
we	O
have	O
constructed	O
gain	O
-	O
of	O
-	O
function	O
mutants	O
that	O
can	O
accept	O
substrates	O
that	O
the	O
parent	O
enzyme	O
cannot	O
,	O
including	O
ubiquitin	B-Protein
chains	O
of	O
various	O
linkages	O
.	O

Human	B-Protein
T	I-Protein
-	I-Protein
cell	I-Protein
leukemia	I-Protein
virus	I-Protein
type	I-Protein
1	I-Protein
bZIP	I-Protein
factor	I-Protein
selectively	O
suppresses	O
the	O
classical	O
pathway	O
of	O
NF	O
-	O
kappaB	O
.	O

Adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
is	O
a	O
highly	O
aggressive	O
T	O
-	O
cell	O
malignancy	O
caused	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
Tax	B-Protein
has	O
been	O
reported	O
to	O
play	O
a	O
crucial	O
role	O
in	O
HTLV	O
-	O
1	O
-	O
induced	O
transformation	O
.	O

The	O
HTLV	B-Protein
-	I-Protein
1	I-Protein
bZIP	I-Protein
factor	I-Protein
(	O
HBZ	B-Protein
)	O
,	O
which	O
is	O
encoded	O
by	O
an	O
mRNA	O
of	O
the	O
opposite	O
polarity	O
of	O
the	O
viral	O
genomic	O
RNA	O
,	O
is	O
involved	O
in	O
both	O
T	O
cell	O
proliferation	O
and	O
suppression	O
of	O
Tax	B-Protein
-	O
mediated	O
viral	O
gene	O
transcription	O
,	O
suggesting	O
that	O
HBZ	B-Protein
cooperates	O
closely	O
with	O
Tax	B-Protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
observed	O
that	O
HBZ	B-Protein
specifically	O
suppressed	O
NF	O
-	O
kappaB	O
-	O
driven	O
transcription	O
mediated	O
by	O
p65	B-Protein
(	O
the	O
classical	O
pathway	O
)	O
without	O
inhibiting	O
the	O
alternative	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
.	O

In	O
an	O
immunoprecipitation	O
assay	O
,	O
HBZ	B-Protein
bound	O
to	O
p65	B-Protein
and	O
diminished	O
the	O
DNA	O
binding	O
capacity	O
of	O
p65	B-Protein
.	O

In	O
addition	O
,	O
HBZ	B-Protein
induced	O
p65	B-Protein
degradation	O
through	O
increasing	O
the	O
expression	O
of	O
the	O
PDLIM2	B-Protein
gene	O
,	O
which	O
encodes	O
a	O
ubiquitin	B-Protein
E3	O
ligase	O
for	O
p65	B-Protein
.	O

Finally	O
,	O
HBZ	B-Protein
actually	O
repressed	O
the	O
transcription	O
of	O
some	O
classical	O
NF	O
-	O
kappaB	O
target	O
genes	O
,	O
such	O
as	O
IL	B-Protein
-	I-Protein
8	I-Protein
,	O
IL2RA	B-Protein
,	O
IRF4	B-Protein
,	O
VCAM	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
VEGF	B-Protein
.	O

Selective	O
suppression	O
of	O
the	O
classical	O
NF	O
-	O
kappaB	O
pathway	O
by	O
HBZ	B-Protein
renders	O
the	O
alternative	O
NF	O
-	O
kappaB	O
pathway	O
predominant	O
after	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
Tax	B-Protein
or	O
other	O
stimuli	O
,	O
which	O
might	O
be	O
critical	O
for	O
oncogenesis	O
.	O

A	O
novel	O
peptide	O
motif	O
binding	O
to	O
and	O
blocking	O
the	O
intracellular	O
activity	O
of	O
the	O
human	O
papillomavirus	O
E6	B-Protein
oncoprotein	O
.	O

Specific	O
types	O
of	O
human	O
papillomaviruses	O
(	O
HPVs	O
)	O
cause	O
cervical	O
cancer	O
.	O

The	O
viral	O
E6	B-Protein
oncogene	O
is	O
a	O
critical	O
factor	O
for	O
maintaining	O
the	O
malignant	O
phenotype	O
of	O
HPV	O
-	O
positive	O
tumour	O
cells	O
.	O

By	O
yeast	O
two	O
-	O
hybrid	O
screening	O
of	O
a	O
randomised	O
peptide	O
expression	O
library	O
,	O
we	O
isolated	O
linear	O
short	O
peptides	O
,	O
which	O
specifically	O
bind	O
to	O
the	O
HPV16	O
E6	B-Protein
oncoprotein	O
.	O

Sequence	O
alignments	O
and	O
mutational	O
analyses	O
of	O
the	O
peptides	O
identified	O
a	O
hitherto	O
undiscovered	O
E6	B-Protein
-	O
binding	O
motif	O
.	O

Intracellular	O
expression	O
of	O
a	O
peptide	O
containing	O
the	O
novel	O
E6	B-Protein
-	O
binding	O
motif	O
resulted	O
in	O
inhibition	O
of	O
colony	O
formation	O
capacity	O
,	O
specifically	O
of	O
HPV16	O
-	O
positive	O
cancer	O
cells	O
.	O

A	O
solubility	O
-	O
optimised	O
variant	O
of	O
the	O
peptide	O
was	O
created	O
,	O
which	O
binds	O
to	O
HPV16	O
E6	B-Protein
with	O
high	O
affinity	O
.	O

Its	O
intracellular	O
expression	O
efficiently	O
induced	O
apoptosis	O
in	O
HPV16	O
-	O
positive	O
cancer	O
cells	O
.	O

This	O
was	O
linked	O
to	O
restoration	O
of	O
intracellular	O
p53	B-Protein
activities	O
.	O

Thus	O
,	O
this	O
newly	O
identified	O
E6	B-Protein
-	O
binding	O
motif	O
could	O
form	O
a	O
novel	O
basis	O
for	O
the	O
development	O
of	O
rational	O
strategies	O
for	O
the	O
treatment	O
of	O
HPV16	O
-	O
positive	O
preneoplastic	O
and	O
neoplastic	O
lesions	O
.	O

Phosphorylated	O
and	O
ubiquitinated	O
TDP	B-Protein
-	I-Protein
43	I-Protein
pathological	O
inclusions	O
in	O
ALS	O
and	O
FTLD	O
-	O
U	O
are	O
recapitulated	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

We	O
report	O
phosphorylated	O
and	O
ubiquitinated	O
aggregates	O
of	O
TAR	O
DNA	O
binding	O
protein	O
of	O
43	O
kDa	O
(	O
TDP	B-Protein
-	I-Protein
43	I-Protein
)	O
in	O
SH	O
-	O
SY5Y	O
cells	O
similar	O
to	O
those	O
in	O
brains	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
and	O
frontotemporal	O
lobar	O
degeneration	O
with	O
ubiquitinated	O
inclusions	O
(	O
FTLD	O
-	O
U	O
)	O
.	O

Two	O
candidate	O
sequences	O
for	O
the	O
nuclear	O
localization	O
signal	O
were	O
examined	O
.	O

Deletion	O
of	O
residues	O
78	O
-	O
84	O
resulted	O
in	O
cytoplasmic	O
localization	O
of	O
TDP	B-Protein
-	I-Protein
43	I-Protein
,	O
whereas	O
the	O
mutant	O
lacking	O
residues	O
187	O
-	O
192	O
localized	O
in	O
nuclei	O
,	O
forming	O
unique	O
dot	O
-	O
like	O
structures	O
.	O

Proteasome	O
inhibition	O
caused	O
these	O
to	O
assemble	O
into	O
phosphorylated	O
and	O
ubiquitinated	O
TDP	B-Protein
-	I-Protein
43	I-Protein
aggregates	O
.	O

The	O
deletion	O
mutants	O
lacked	O
the	O
exon	O
skipping	O
activity	O
of	O
cystic	B-Protein
fibrosis	I-Protein
transmembrane	I-Protein
conductance	I-Protein
regulator	I-Protein
(	O
CFTR	B-Protein
)	O
exon	O
9	O
.	O

Our	O
results	O
suggest	O
that	O
intracellular	O
localization	O
of	O
TDP	B-Protein
-	I-Protein
43	I-Protein
and	O
proteasomal	O
function	O
may	O
be	O
involved	O
in	O
inclusion	O
formation	O
and	O
neurodegeneration	O
in	O
TDP	B-Protein
-	I-Protein
43	I-Protein
proteinopathies	O
.	O

The	O
HLA	B-Protein
-	I-Protein
DRalpha	I-Protein
chain	I-Protein
is	O
modified	O
by	O
polyubiquitination	O
.	O

Ubiquitination	O
plays	O
a	O
major	O
role	O
in	O
regulating	O
cell	O
surface	O
and	O
intracellular	O
localization	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
molecules	O
.	O

Two	O
E3	O
ligases	O
,	O
MARCH	B-Protein
I	I-Protein
and	O
MARCH	B-Protein
VIII	I-Protein
,	O
have	O
been	O
shown	O
to	O
polyubiquitinate	O
lysine	O
residue	O
225	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
I	B-Protein
-	I-Protein
Abeta	I-Protein
and	O
HLA	O
-	O
DRbeta	O
.	O

We	O
show	O
that	O
lysine	O
residue	O
219	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
DRalpha	B-Protein
is	O
also	O
subject	O
to	O
polyubiquitination	O
.	O

Each	O
chain	O
of	O
the	O
HLA	O
-	O
DR	O
heterodimer	O
is	O
independently	O
recognized	O
and	O
ubiquitinated	O
,	O
but	O
DRbeta	O
is	O
more	O
extensively	O
modified	O
.	O

In	O
the	O
cytoplasmic	O
tail	O
of	O
DRbeta	O
lysine	O
,	O
residue	O
225	O
is	O
the	O
only	O
residue	O
that	O
is	O
absolutely	O
required	O
for	O
ubiquitination	O
;	O
all	O
other	O
residues	O
can	O
be	O
deleted	O
or	O
substituted	O
without	O
loss	O
of	O
function	O
.	O

In	O
contrast	O
,	O
although	O
lysine	O
219	O
is	O
absolutely	O
required	O
for	O
modification	O
of	O
DRalpha	B-Protein
,	O
other	O
features	O
of	O
the	O
DRalpha	B-Protein
tail	O
act	O
to	O
limit	O
the	O
extent	O
of	O
ubiquitination	O
.	O

Methylation	O
status	O
of	O
cKi	B-Protein
-	I-Protein
ras	I-Protein
and	O
MHC	O
genes	O
in	O
rat	O
pituitary	O
glands	O
during	O
aging	O
and	O
tumorigenesis	O
.	O

Methylation	O
patterns	O
of	O
MHC	O
(	O
major	O
histocompatibility	O
complex	O
)	O
class	O
I	O
and	O
vKi	B-Protein
-	I-Protein
ras	I-Protein
(	O
viral	O
Kirsten	B-Protein
-	I-Protein
ras	I-Protein
)	O
homologous	O
sequences	O
in	O
normal	O
and	O
adenomatous	O
rat	O
pituitary	O
glands	O
were	O
studied	O
as	O
a	O
function	O
of	O
age	O
by	O
Southern	O
hybridization	O
analysis	O
using	O
the	O
isoschizomers	O
Hpa	B-Protein
II	I-Protein
and	O
Msp	B-Protein
I	I-Protein
.	O

Both	O
MHC	O
class	O
I	O
and	O
vKi	B-Protein
-	I-Protein
ras	I-Protein
homologous	O
sequences	O
were	O
found	O
to	O
be	O
hypomethylated	O
in	O
a	O
number	O
of	O
tumors	O
,	O
compared	O
to	O
normal	O
pituitary	O
gland	O
tissue	O
.	O

However	O
,	O
despite	O
reports	O
indicating	O
a	O
general	O
demethylation	O
in	O
mammalian	O
tissues	O
in	O
relation	O
to	O
donor	O
age	O
,	O
age	O
-	O
related	O
methylation	O
changes	O
in	O
this	O
apparently	O
methylation	O
-	O
unstable	O
and	O
cancer	O
-	O
prone	O
organ	O
were	O
not	O
observed	O
.	O

A	O
phosphorylation	O
cascade	O
controls	O
the	O
degradation	O
of	O
active	O
SREBP1	B-Protein
.	O

Sterol	O
regulatory	O
element	O
-	O
binding	O
proteins	O
(	O
SREBPs	O
)	O
are	O
a	O
family	O
of	O
transcription	O
factors	O
that	O
regulates	O
cholesterol	O
and	O
lipid	O
metabolism	O
.	O

The	O
active	O
forms	O
of	O
these	O
transcription	O
factors	O
are	O
targeted	O
by	O
a	O
number	O
of	O
post	O
-	O
translational	O
modifications	O
,	O
including	O
phosphorylation	O
.	O

Phosphorylation	O
of	O
Thr	O
-	O
426	O
and	O
Ser	O
-	O
430	O
in	O
SREBP1a	B-Protein
creates	O
a	O
docking	O
site	O
for	O
the	O
ubiquitin	B-Protein
ligase	O
Fbw7	B-Protein
,	O
resulting	O
in	O
the	O
degradation	O
of	O
the	O
transcription	O
factor	O
.	O

Here	O
,	O
we	O
identify	O
a	O
novel	O
phosphorylation	O
site	O
in	O
SREBP1a	B-Protein
,	O
Ser	O
-	O
434	O
,	O
which	O
regulates	O
the	O
Fbw7	B-Protein
-	O
dependent	O
degradation	O
of	O
SREBP1	B-Protein
.	O

We	O
demonstrate	O
that	O
both	O
SREBP1a	B-Protein
and	O
SREBP1c	B-Protein
are	O
phosphorylated	O
on	O
this	O
residue	O
(	O
Ser	O
-	O
410	O
in	O
SREBP1c	B-Protein
)	O
.	O

Importantly	O
,	O
we	O
demonstrate	O
that	O
the	O
mature	O
form	O
of	O
endogenous	O
SREBP1	B-Protein
is	O
phosphorylated	O
on	O
Ser	O
-	O
434	O
.	O

Glycogen	O
synthase	O
kinase	O
-	O
3	O
phosphorylates	O
Ser	O
-	O
434	O
,	O
and	O
the	O
phosphorylation	O
of	O
this	O
residue	O
is	O
attenuated	O
in	O
response	O
to	O
insulin	B-Protein
signaling	O
.	O

Interestingly	O
,	O
phosphorylation	O
of	O
Ser	O
-	O
434	O
promotes	O
the	O
glycogen	O
synthase	O
kinase	O
-	O
3	O
-	O
dependent	O
phosphorylation	O
of	O
Thr	O
-	O
426	O
and	O
Ser	O
-	O
430	O
and	O
destabilizes	O
SREBP1	B-Protein
.	O

Consequently	O
,	O
mutation	O
of	O
Ser	O
-	O
434	O
blocks	O
the	O
interaction	O
between	O
SREBP1	B-Protein
and	O
Fbw7	B-Protein
and	O
attenuates	O
Fbw7	B-Protein
-	O
dependent	O
degradation	O
of	O
SREBP1	B-Protein
.	O

Importantly	O
,	O
insulin	B-Protein
fails	O
to	O
enhance	O
the	O
levels	O
of	O
mature	O
SREBP1	B-Protein
in	O
cells	O
lacking	O
Fbw7	B-Protein
.	O

Thus	O
,	O
the	O
degradation	O
of	O
mature	O
SREBP1	B-Protein
is	O
controlled	O
by	O
cross	O
-	O
talk	O
between	O
multiple	O
phosphorylated	O
residues	O
in	O
its	O
C	O
-	O
terminal	O
domain	O
and	O
the	O
phosphorylation	O
of	O
Ser	O
-	O
434	O
could	O
function	O
as	O
a	O
molecular	O
switch	O
to	O
control	O
these	O
processes	O
.	O

Glycosylation	O
of	O
serum	O
proteins	O
in	O
inflammatory	O
diseases	O
.	O

Inflammatory	O
diseases	O
are	O
accompanied	O
by	O
numerous	O
changes	O
at	O
the	O
site	O
of	O
inflammation	O
as	O
well	O
as	O
many	O
systemic	O
physiological	O
and	O
biochemical	O
changes	O
.	O

In	O
the	O
past	O
two	O
decades	O
more	O
and	O
more	O
attention	O
is	O
being	O
paid	O
to	O
changes	O
in	O
glycosylation	O
and	O
in	O
this	O
review	O
we	O
describe	O
some	O
of	O
the	O
changes	O
found	O
on	O
main	O
serum	O
proteins	O
(	O
alpha1	O
-	O
acid	O
glycoprotein	O
,	O
immunoglobulin	O
G	O
,	O
immunoglobulin	O
A	O
,	O
transferrin	B-Protein
,	O
haptoglobin	B-Protein
,	O
alpha2	B-Protein
-	I-Protein
macroglobulin	I-Protein
,	O
C	B-Protein
-	I-Protein
reactive	I-Protein
protein	I-Protein
,	O
and	O
others	O
)	O
.	O

Molecular	O
background	O
and	O
physiological	O
importance	O
of	O
most	O
of	O
these	O
changes	O
are	O
yet	O
to	O
be	O
discovered	O
,	O
but	O
it	O
is	O
evident	O
that	O
glycosylation	O
plays	O
an	O
important	O
role	O
in	O
the	O
inflammatory	O
response	O
.	O

Maybe	O
the	O
greatest	O
value	O
of	O
these	O
changes	O
currently	O
lays	O
in	O
their	O
potential	O
diagnostic	O
and	O
prognostic	O
usage	O
,	O
either	O
in	O
combination	O
with	O
current	O
diagnostic	O
markers	O
or	O
on	O
their	O
own	O
.	O

However	O
,	O
determining	O
glycan	O
structures	O
is	O
still	O
technically	O
too	O
complex	O
for	O
most	O
clinical	O
laboratories	O
and	O
further	O
efforts	O
have	O
to	O
be	O
made	O
to	O
develop	O
simple	O
analytical	O
tools	O
to	O
study	O
changes	O
in	O
glycosylation	O
.	O

Papillomavirus	O
E2	B-Protein
proteins	O
and	O
the	O
host	O
BRD4	B-Protein
protein	O
associate	O
with	O
transcriptionally	O
active	O
cellular	O
chromatin	O
.	O

The	O
interaction	O
of	O
papillomavirus	O
E2	B-Protein
proteins	O
with	O
cellular	O
Brd4	B-Protein
protein	O
is	O
important	O
for	O
transcriptional	O
regulation	O
of	O
viral	O
genes	O
and	O
partitioning	O
of	O
viral	O
genomes	O
.	O

Bovine	O
papillomavirus	O
type	O
1	O
(	O
BPV	O
-	O
1	O
)	O
E2	B-Protein
binds	O
cellular	O
chromatin	O
in	O
complex	O
with	O
Brd4	B-Protein
in	O
both	O
mitotic	O
and	O
interphase	O
cells	O
.	O

To	O
identify	O
specific	O
sites	O
of	O
E2	B-Protein
interaction	O
on	O
cellular	O
chromatin	O
,	O
a	O
genome	O
-	O
wide	O
chromatin	O
immunoprecipitation	O
-	O
on	O
-	O
chip	O
analysis	O
was	O
carried	O
out	O
using	O
human	O
promoter	O
sequences	O
.	O

Both	O
E2	B-Protein
and	O
Brd4	B-Protein
were	O
found	O
bound	O
to	O
most	O
transcriptionally	O
active	O
promoters	O
in	O
C33A	O
cells	O
.	O

These	O
promoters	O
were	O
also	O
bound	O
by	O
RNA	O
polymerase	O
II	O
and	O
were	O
modified	O
by	O
histone	B-Protein
H3	I-Protein
acetylation	O
and	O
K4	O
trimethylation	O
,	O
all	O
indicators	O
of	O
active	O
transcription	O
.	O

E2	B-Protein
binding	O
strongly	O
correlated	O
with	O
Brd4	B-Protein
and	O
RNA	O
polymerase	O
II	O
occupancy	O
and	O
H3K4me3	B-Protein
modification	O
at	O
all	O
human	O
promoters	O
,	O
indicating	O
that	O
E2	B-Protein
bound	O
to	O
active	O
promoters	O
.	O

E2	B-Protein
binding	O
did	O
not	O
correlate	O
with	O
the	O
presence	O
of	O
consensus	O
E2	B-Protein
binding	O
sites	O
in	O
the	O
promoters	O
.	O

Furthermore	O
,	O
the	O
mRNA	O
levels	O
of	O
E2	B-Protein
-	O
bound	O
cellular	O
genes	O
were	O
not	O
significantly	O
changed	O
by	O
E2	B-Protein
expression	O
.	O

Thus	O
,	O
the	O
papillomavirus	O
E2	B-Protein
proteins	O
bind	O
to	O
transcriptionally	O
active	O
cellular	O
genes	O
but	O
do	O
not	O
change	O
their	O
activity	O
.	O

We	O
propose	O
that	O
this	O
may	O
be	O
a	O
way	O
for	O
the	O
virus	O
to	O
ensure	O
that	O
the	O
viral	O
genome	O
is	O
retained	O
in	O
transcriptionally	O
active	O
regions	O
of	O
the	O
nucleus	O
to	O
escape	O
silencing	O
.	O

Therefore	O
,	O
E2	B-Protein
-	O
mediated	O
tethering	O
of	O
viral	O
genomes	O
to	O
host	O
chromatin	O
has	O
multiple	O
roles	O
:	O
to	O
partition	O
the	O
viral	O
genome	O
to	O
daughter	O
cells	O
,	O
to	O
ensure	O
that	O
the	O
genomes	O
are	O
retained	O
in	O
the	O
nucleus	O
,	O
and	O
to	O
make	O
certain	O
that	O
the	O
genomes	O
are	O
retained	O
in	O
functionally	O
active	O
nuclear	O
domains	O
.	O

Overexpression	O
of	O
myocilin	B-Protein
in	O
the	O
Drosophila	O
eye	O
activates	O
the	O
unfolded	O
protein	O
response	O
:	O
implications	O
for	O
glaucoma	O
.	O

BACKGROUND	O
:	O
Glaucoma	O
is	O
the	O
world	O
'	O
s	O
second	O
leading	O
cause	O
of	O
bilateral	O
blindness	O
with	O
progressive	O
loss	O
of	O
vision	O
due	O
to	O
retinal	O
ganglion	O
cell	O
death	O
.	O

Myocilin	B-Protein
has	O
been	O
associated	O
with	O
congenital	O
glaucoma	O
and	O
2	O
-	O
4	O
%	O
of	O
primary	O
open	O
angle	O
glaucoma	O
(	O
POAG	O
)	O
cases	O
,	O
but	O
the	O
pathogenic	O
mechanisms	O
remain	O
largely	O
unknown	O
.	O

Among	O
several	O
hypotheses	O
,	O
activation	O
of	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
has	O
emerged	O
as	O
a	O
possible	O
disease	O
mechanism	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
used	O
a	O
transgenic	O
Drosophila	O
model	O
to	O
analyze	O
whole	O
-	O
genome	O
transcriptional	O
profiles	O
in	O
flies	O
that	O
express	O
human	O
wild	O
-	O
type	O
or	O
mutant	O
MYOC	B-Protein
in	O
their	O
eyes	O
.	O

The	O
transgenic	O
flies	O
display	O
ocular	O
fluid	O
discharge	O
,	O
reflecting	O
ocular	O
hypertension	O
,	O
and	O
a	O
progressive	O
decline	O
in	O
their	O
behavioral	O
responses	O
to	O
light	O
.	O

Transcriptional	O
analysis	O
shows	O
that	O
genes	O
associated	O
with	O
the	O
UPR	O
,	O
ubiquitination	O
,	O
and	O
proteolysis	O
,	O
as	O
well	O
as	O
metabolism	O
of	O
reactive	O
oxygen	O
species	O
and	O
photoreceptor	O
activity	O
undergo	O
altered	O
transcriptional	O
regulation	O
.	O

Following	O
up	O
on	O
the	O
results	O
from	O
these	O
transcriptional	O
analyses	O
,	O
we	O
used	O
immunoblots	O
to	O
demonstrate	O
the	O
formation	O
of	O
MYOC	B-Protein
aggregates	O
and	O
showed	O
that	O
the	O
formation	O
of	O
such	O
aggregates	O
leads	O
to	O
induction	O
of	O
the	O
UPR	O
,	O
as	O
evident	O
from	O
activation	O
of	O
the	O
fluorescent	O
UPR	O
marker	O
,	O
xbp1	B-Protein
-	O
EGFP	B-Protein
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Our	O
results	O
show	O
that	O
aggregation	O
of	O
MYOC	B-Protein
in	O
the	O
endoplasmic	O
reticulum	O
activates	O
the	O
UPR	O
,	O
an	O
evolutionarily	O
conserved	O
stress	O
pathway	O
that	O
culminates	O
in	O
apoptosis	O
.	O

We	O
infer	O
from	O
the	O
Drosophila	O
model	O
that	O
MYOC	B-Protein
-	O
associated	O
ocular	O
hypertension	O
in	O
the	O
human	O
eye	O
may	O
result	O
from	O
aggregation	O
of	O
MYOC	B-Protein
and	O
induction	O
of	O
the	O
UPR	O
in	O
trabecular	O
meshwork	O
cells	O
.	O

This	O
process	O
could	O
occur	O
at	O
a	O
late	O
age	O
with	O
wild	O
-	O
type	O
MYOC	B-Protein
,	O
but	O
might	O
be	O
accelerated	O
by	O
MYOC	B-Protein
mutants	O
to	O
account	O
for	O
juvenile	O
onset	O
glaucoma	O
.	O

Degradation	O
of	O
FAT10	B-Protein
by	O
the	O
26S	O
proteasome	O
is	O
independent	O
of	O
ubiquitylation	O
but	O
relies	O
on	O
NUB1L	B-Protein
.	O

The	O
ubiquitin	B-Protein
-	O
like	O
modifier	O
FAT10	B-Protein
targets	O
proteins	O
for	O
degradation	O
by	O
the	O
proteasome	O
,	O
a	O
process	O
accelerated	O
by	O
the	O
UBL	O
-	O
UBA	O
domain	O
protein	O
NEDD8	B-Protein
ultimate	I-Protein
buster	I-Protein
1	I-Protein
-	I-Protein
long	I-Protein
.	O

Here	O
,	O
we	O
show	O
that	O
FAT10	B-Protein
-	O
mediated	O
degradation	O
occurs	O
independently	O
of	O
poly	O
-	O
ubiquitylation	O
as	O
purified	O
26S	O
proteasome	O
readily	O
degraded	O
FAT10	B-Protein
-	O
dihydrofolate	B-Protein
reductase	I-Protein
(	O
DHFR	B-Protein
)	O
but	O
not	O
ubiquitin	B-Protein
-	O
DHFR	B-Protein
in	O
vitro	O
.	O

Interestingly	O
,	O
the	O
26S	O
proteasome	O
could	O
only	O
degrade	O
FAT10	B-Protein
-	O
DHFR	B-Protein
when	O
NUB1L	B-Protein
was	O
present	O
.	O

Knock	O
-	O
down	O
of	O
NUB1L	B-Protein
attenuated	O
the	O
degradation	O
of	O
FAT10	B-Protein
-	O
DHFR	B-Protein
in	O
intact	O
cells	O
suggesting	O
that	O
NUB1L	B-Protein
determines	O
the	O
degradation	O
rate	O
of	O
FAT10	B-Protein
-	O
linked	O
proteins	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
establish	O
FAT10	B-Protein
as	O
a	O
ubiquitin	B-Protein
-	O
independent	O
but	O
NUB1L	B-Protein
-	O
dependent	O
targeting	O
signal	O
for	O
proteasomal	O
degradation	O
.	O

AMP	O
-	O
activated	O
protein	O
kinase	O
phosphorylates	O
R5	B-Protein
/	O
PTG	B-Protein
,	O
the	O
glycogen	O
targeting	O
subunit	O
of	O
the	O
R5	B-Protein
/	O
PTG	B-Protein
-	O
protein	O
phosphatase	O
1	O
holoenzyme	O
,	O
and	O
accelerates	O
its	O
down	O
-	O
regulation	O
by	O
the	O
laforin	B-Protein
-	O
malin	B-Protein
complex	O
.	O

R5	B-Protein
/	O
PTG	B-Protein
is	O
one	O
of	O
the	O
glycogen	O
targeting	O
subunits	O
of	O
type	O
1	O
protein	O
phosphatase	O
,	O
a	O
master	O
regulator	O
of	O
glycogen	O
synthesis	O
.	O

R5	B-Protein
/	O
PTG	B-Protein
recruits	O
the	O
phosphatase	O
to	O
the	O
places	O
where	O
glycogen	O
synthesis	O
occurs	O
,	O
allowing	O
the	O
activation	O
of	O
glycogen	O
synthase	O
and	O
the	O
inactivation	O
of	O
glycogen	O
phosphorylase	O
,	O
thus	O
increasing	O
glycogen	O
synthesis	O
and	O
decreasing	O
its	O
degradation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
activity	O
of	O
R5	B-Protein
/	O
PTG	B-Protein
is	O
regulated	O
by	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O

We	O
demonstrate	O
that	O
AMPK	O
interacts	O
physically	O
with	O
R5	B-Protein
/	O
PTG	B-Protein
and	O
modifies	O
its	O
basal	O
phosphorylation	O
status	O
.	O

We	O
have	O
also	O
mapped	O
the	O
major	O
phosphorylation	O
sites	O
of	O
R5	B-Protein
/	O
PTG	B-Protein
by	O
mass	O
spectrometry	O
analysis	O
,	O
observing	O
that	O
phosphorylation	O
of	O
Ser	O
-	O
8	O
and	O
Ser	O
-	O
268	O
increased	O
upon	O
activation	O
of	O
AMPK	O
.	O

We	O
have	O
recently	O
described	O
that	O
the	O
activity	O
of	O
R5	B-Protein
/	O
PTG	B-Protein
is	O
down	O
-	O
regulated	O
by	O
the	O
laforin	B-Protein
-	O
malin	B-Protein
complex	O
,	O
composed	O
of	O
a	O
dual	O
specificity	O
phosphatase	O
(	O
laforin	B-Protein
)	O
and	O
an	O
E3	O
-	O
ubiquitin	B-Protein
ligase	O
(	O
malin	B-Protein
)	O
.	O

We	O
now	O
demonstrate	O
that	O
phosphorylation	O
of	O
R5	B-Protein
/	O
PTG	B-Protein
at	O
Ser	O
-	O
8	O
by	O
AMPK	O
accelerates	O
its	O
laforin	B-Protein
/	O
malin	B-Protein
-	O
dependent	O
ubiquitination	O
and	O
subsequent	O
proteasomal	O
degradation	O
,	O
which	O
results	O
in	O
a	O
decrease	O
of	O
its	O
glycogenic	O
activity	O
.	O

Thus	O
,	O
our	O
results	O
define	O
a	O
novel	O
role	O
of	O
AMPK	O
in	O
glycogen	O
homeostasis	O
.	O

ING4	B-Protein
mediates	O
crosstalk	O
between	O
histone	B-Protein
H3	I-Protein
K4	O
trimethylation	O
and	O
H3	B-Protein
acetylation	O
to	O
attenuate	O
cellular	O
transformation	O
.	O

Aberrations	O
in	O
chromatin	O
dynamics	O
play	O
a	O
fundamental	O
role	O
in	O
tumorigenesis	O
,	O
yet	O
relatively	O
little	O
is	O
known	O
of	O
the	O
molecular	O
mechanisms	O
linking	O
histone	B-Protein
lysine	O
methylation	O
to	O
neoplastic	O
disease	O
.	O

ING4	B-Protein
(	O
Inhibitor	B-Protein
of	I-Protein
Growth	I-Protein
4	I-Protein
)	O
is	O
a	O
native	O
subunit	O
of	O
an	O
HBO1	B-Protein
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
complex	O
and	O
a	O
tumor	O
suppressor	O
protein	O
.	O

Here	O
we	O
show	O
a	O
critical	O
role	O
for	O
specific	O
recognition	O
of	O
histone	B-Protein
H3	I-Protein
trimethylated	O
at	O
lysine	O
4	O
(	O
H3K4me3	B-Protein
)	O
by	O
the	O
ING4	B-Protein
PHD	O
finger	O
in	O
mediating	O
ING4	B-Protein
gene	O
expression	O
and	O
tumor	O
suppressor	O
functions	O
.	O

The	O
interaction	O
between	O
ING4	B-Protein
and	O
H3K4me3	B-Protein
augments	O
HBO1	B-Protein
acetylation	O
activity	O
on	O
H3	B-Protein
tails	O
and	O
drives	O
H3	B-Protein
acetylation	O
at	O
ING4	B-Protein
target	O
promoters	O
.	O

Further	O
,	O
ING4	B-Protein
facilitates	O
apoptosis	O
in	O
response	O
to	O
genotoxic	O
stress	O
and	O
inhibits	O
anchorage	O
-	O
independent	O
cell	O
growth	O
,	O
and	O
these	O
functions	O
depend	O
on	O
ING4	B-Protein
interactions	O
with	O
H3K4me3	B-Protein
.	O

Together	O
,	O
our	O
results	O
demonstrate	O
a	O
mechanism	O
for	O
brokering	O
crosstalk	O
between	O
H3K4	B-Protein
methylation	O
and	O
H3	B-Protein
acetylation	O
and	O
reveal	O
a	O
molecular	O
link	O
between	O
chromatin	O
modulation	O
and	O
tumor	O
suppressor	O
mechanisms	O
.	O

CHIP	B-Protein
regulates	O
leucine	B-Protein
-	I-Protein
rich	I-Protein
repeat	I-Protein
kinase	I-Protein
-	I-Protein
2	I-Protein
ubiquitination	O
,	O
degradation	O
,	O
and	O
toxicity	O
.	O

Mutation	O
in	O
leucine	B-Protein
-	I-Protein
rich	I-Protein
repeat	I-Protein
kinase	I-Protein
-	I-Protein
2	I-Protein
(	O
LRRK2	B-Protein
)	O
is	O
the	O
most	O
common	O
cause	O
of	O
late	O
-	O
onset	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

Although	O
most	O
cases	O
of	O
PD	O
are	O
sporadic	O
,	O
some	O
are	O
inherited	O
,	O
including	O
those	O
caused	O
by	O
LRRK2	B-Protein
mutations	O
.	O

Because	O
these	O
mutations	O
may	O
be	O
associated	O
with	O
a	O
toxic	O
gain	O
of	O
function	O
,	O
controlling	O
the	O
expression	O
of	O
LRRK2	B-Protein
may	O
decrease	O
its	O
cytotoxicity	O
.	O

Here	O
we	O
show	O
that	O
the	O
carboxyl	B-Protein
terminus	I-Protein
of	I-Protein
HSP70	I-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
(	O
CHIP	B-Protein
)	O
binds	O
,	O
ubiquitinates	O
,	O
and	O
promotes	O
the	O
ubiquitin	B-Protein
proteasomal	O
degradation	O
of	O
LRRK2	B-Protein
.	O

Overexpression	O
of	O
CHIP	B-Protein
protects	O
against	O
and	O
knockdown	O
of	O
CHIP	B-Protein
exacerbates	O
toxicity	O
mediated	O
by	O
mutant	O
LRRK2	B-Protein
.	O

Moreover	O
,	O
HSP90	O
forms	O
a	O
complex	O
with	O
LRRK2	B-Protein
,	O
and	O
inhibition	O
of	O
HSP90	O
chaperone	O
activity	O
by	O
17AAG	O
leads	O
to	O
proteasomal	O
degradation	O
of	O
LRRK2	B-Protein
,	O
resulting	O
in	O
increased	O
cell	O
viability	O
.	O

Thus	O
,	O
increasing	O
CHIP	B-Protein
E3	O
ligase	O
activity	O
and	O
blocking	O
HSP90	O
chaperone	O
activity	O
can	O
prevent	O
the	O
deleterious	O
effects	O
of	O
LRRK2	B-Protein
.	O

These	O
findings	O
point	O
to	O
potential	O
treatment	O
options	O
for	O
LRRK2	B-Protein
-	O
associated	O
PD	O
.	O

Impaired	O
trafficking	O
and	O
subcellular	O
localization	O
of	O
a	O
mutant	O
lactase	O
associated	O
with	O
congenital	O
lactase	O
deficiency	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Congenital	O
lactase	O
deficiency	O
(	O
CLD	O
)	O
is	O
a	O
cause	O
of	O
disaccharide	O
intolerance	O
and	O
malabsorption	O
characterized	O
by	O
watery	O
diarrhea	O
in	O
infants	O
fed	O
breast	O
milk	O
or	O
lactose	O
-	O
containing	O
formulas	O
.	O

The	O
molecular	O
basis	O
of	O
CLD	O
is	O
unknown	O
.	O

Mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
brush	O
border	O
enzyme	O
lactase	B-Protein
phlorizin	I-Protein
hydrolase	I-Protein
(	O
LPH	B-Protein
)	O
were	O
found	O
to	O
cause	O
CLD	O
in	O
a	O
study	O
of	O
19	O
Finnish	O
families	O
.	O

We	O
analyzed	O
the	O
effects	O
of	O
one	O
of	O
these	O
mutations	O
,	O
G1363S	O
,	O
on	O
LPH	B-Protein
folding	O
,	O
trafficking	O
,	O
and	O
function	O
.	O

METHODS	O
:	O
We	O
introduced	O
a	O
mutation	O
into	O
the	O
LPH	B-Protein
complementary	O
DNA	O
that	O
resulted	O
in	O
the	O
amino	O
acid	O
substitution	O
G1363S	O
.	O

The	O
mutant	O
gene	O
was	O
transiently	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
,	O
and	O
the	O
effects	O
were	O
assessed	O
at	O
the	O
protein	O
,	O
structural	O
,	O
and	O
subcellular	O
levels	O
.	O

RESULTS	O
:	O
The	O
mutant	O
protein	O
LPH	B-Protein
-	O
G1363S	O
was	O
misfolded	O
and	O
could	O
not	O
exit	O
the	O
endoplasmic	O
reticulum	O
.	O

Interestingly	O
,	O
the	O
mutation	O
creates	O
an	O
additional	O
N	O
-	O
glycosylation	O
site	O
that	O
is	O
characteristic	O
of	O
a	O
temperature	O
-	O
sensitive	O
protein	O
.	O

The	O
intracellular	O
transport	O
and	O
enzymatic	O
activity	O
,	O
but	O
not	O
correct	O
folding	O
,	O
of	O
LPH	B-Protein
-	O
G1363S	O
were	O
partially	O
restored	O
by	O
expression	O
at	O
20	O
degrees	O
C	O
.	O

However	O
,	O
a	O
form	O
of	O
LPH	B-Protein
that	O
contains	O
the	O
mutations	O
G1363S	O
and	O
N1361A	O
,	O
which	O
eliminates	O
the	O
N	O
-	O
glycosylation	O
site	O
,	O
did	O
not	O
restore	O
the	O
features	O
of	O
wild	O
-	O
type	O
LPH	B-Protein
.	O

Thus	O
,	O
the	O
additional	O
glycosyl	O
group	O
is	O
not	O
required	O
for	O
the	O
LPH	B-Protein
-	O
G1363S	O
defects	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
characterization	O
,	O
at	O
the	O
molecular	O
and	O
subcellular	O
levels	O
,	O
of	O
a	O
mutant	O
form	O
of	O
LPH	B-Protein
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
CLD	O
.	O

Mutant	O
LPH	B-Protein
accumulates	O
predominantly	O
in	O
the	O
endoplasmic	O
reticulum	O
but	O
can	O
partially	O
mature	O
at	O
a	O
permissive	O
temperature	O
;	O
these	O
features	O
are	O
unique	O
for	O
a	O
protein	O
involved	O
in	O
a	O
carbohydrate	O
malabsorption	O
defect	O
implicating	O
LPH	B-Protein
.	O

RAD18	B-Protein
promotes	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
during	O
G1	O
phase	O
through	O
chromatin	O
retention	O
of	O
53BP1	B-Protein
.	O

Recruitment	O
of	O
RAD18	B-Protein
to	O
stalled	O
replication	O
forks	O
facilitates	O
monoubiquitination	O
of	O
PCNA	B-Protein
during	O
S	O
-	O
phase	O
,	O
promoting	O
translesion	O
synthesis	O
at	O
sites	O
of	O
UV	O
irradiation	O
-	O
induced	O
DNA	O
damage	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
RAD18	B-Protein
is	O
also	O
recruited	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
-	O
induced	O
sites	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
forming	O
foci	O
which	O
are	O
co	O
-	O
localized	O
with	O
53BP1	B-Protein
,	O
NBS1	B-Protein
,	O
phosphorylated	O
ATM	B-Protein
,	O
BRCA1	B-Protein
and	O
gamma	O
-	O
H2AX	B-Protein
.	O

RAD18	B-Protein
associates	O
with	O
53BP1	B-Protein
and	O
is	O
recruited	O
to	O
DSB	O
sites	O
in	O
a	O
53BP1	B-Protein
-	O
dependent	O
manner	O
specifically	O
during	O
G1	O
-	O
phase	O
,	O
RAD18	B-Protein
monoubiquitinates	O
KBD	O
domain	O
of	O
53BP1	B-Protein
at	O
lysine	O
1268	O
in	O
vitro	O
.	O

A	O
monoubiquitination	O
-	O
resistant	O
53BP1	B-Protein
mutant	O
harboring	O
a	O
substitution	O
at	O
lysine	O
1268	O
is	O
not	O
retained	O
efficiently	O
at	O
the	O
chromatin	O
in	O
the	O
vicinity	O
of	O
DSBs	O
.	O

In	O
Rad18	B-Protein
-	O
null	O
cells	O
,	O
retention	O
of	O
53BP1	B-Protein
foci	O
,	O
efficiency	O
of	O
DSB	O
repair	O
and	O
post	O
-	O
irradiation	O
viability	O
are	O
impaired	O
compared	O
with	O
wild	O
-	O
type	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
RAD18	B-Protein
promotes	O
53BP1	B-Protein
-	O
directed	O
DSB	O
repair	O
by	O
enhancing	O
retention	O
of	O
53BP1	B-Protein
,	O
possibly	O
through	O
an	O
interaction	O
between	O
RAD18	B-Protein
and	O
53BP1	B-Protein
and	O
the	O
modification	O
of	O
53BP1	B-Protein
.	O

The	O
cochaperone	O
BAG2	B-Protein
sweeps	O
paired	O
helical	O
filament	O
-	O
insoluble	O
tau	B-Protein
from	O
the	O
microtubule	O
.	O

Tau	B-Protein
inclusions	O
are	O
a	O
prominent	O
feature	O
of	O
many	O
neurodegenerative	O
diseases	O
including	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Their	O
accumulation	O
in	O
neurons	O
as	O
ubiquitinated	O
filaments	O
suggests	O
a	O
failure	O
in	O
the	O
degradation	O
limb	O
of	O
the	O
Tau	B-Protein
pathway	O
.	O

The	O
components	O
of	O
a	O
Tau	B-Protein
protein	O
triage	O
system	O
consisting	O
of	O
CHIP	B-Protein
/	O
Hsp70	O
and	O
other	O
chaperones	O
have	O
begun	O
to	O
emerge	O
.	O

However	O
,	O
the	O
site	O
of	O
triage	O
and	O
the	O
master	O
regulatory	O
elements	O
are	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
an	O
elegant	O
mechanism	O
of	O
Tau	B-Protein
degradation	O
involving	O
the	O
cochaperone	O
BAG2	B-Protein
.	O

The	O
BAG2	B-Protein
/	O
Hsp70	O
complex	O
is	O
tethered	O
to	O
the	O
microtubule	O
and	O
this	O
complex	O
can	O
capture	O
and	O
deliver	O
Tau	B-Protein
to	O
the	O
proteasome	O
for	O
ubiquitin	B-Protein
-	O
independent	O
degradation	O
.	O

This	O
complex	O
preferentially	O
degrades	O
Sarkosyl	O
insoluble	O
Tau	B-Protein
and	O
phosphorylated	O
Tau	B-Protein
.	O

BAG2	B-Protein
levels	O
in	O
cells	O
are	O
under	O
the	O
physiological	O
control	O
of	O
the	O
microRNA	O
miR	B-Protein
-	I-Protein
128a	I-Protein
,	O
which	O
can	O
tune	O
paired	O
helical	O
filament	O
Tau	B-Protein
levels	O
in	O
neurons	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
ubiquitinated	O
Tau	B-Protein
inclusions	O
arise	O
due	O
to	O
shunting	O
of	O
Tau	B-Protein
degradation	O
toward	O
a	O
less	O
efficient	O
ubiquitin	B-Protein
-	O
dependent	O
pathway	O
.	O

Parkin	B-Protein
,	O
PINK1	B-Protein
,	O
and	O
DJ	B-Protein
-	I-Protein
1	I-Protein
form	O
a	O
ubiquitin	B-Protein
E3	O
ligase	O
complex	O
promoting	O
unfolded	O
protein	O
degradation	O
.	O

Mutations	O
in	O
PARKIN	B-Protein
,	O
pten	B-Protein
-	I-Protein
induced	I-Protein
putative	I-Protein
kinase	I-Protein
1	I-Protein
(	O
PINK1	B-Protein
)	O
,	O
and	O
DJ	B-Protein
-	I-Protein
1	I-Protein
are	O
individually	O
linked	O
to	O
autosomal	O
recessive	O
early	O
-	O
onset	O
familial	O
forms	O
of	O
Parkinson	O
disease	O
(	O
PD	O
)	O
.	O

Although	O
mutations	O
in	O
these	O
genes	O
lead	O
to	O
the	O
same	O
disease	O
state	O
,	O
the	O
functional	O
relationships	O
between	O
them	O
and	O
how	O
their	O
respective	O
disease	O
-	O
associated	O
mutations	O
cause	O
PD	O
are	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
Parkin	B-Protein
,	O
PINK1	B-Protein
,	O
and	O
DJ	B-Protein
-	I-Protein
1	I-Protein
formed	O
a	O
complex	O
(	O
termed	O
PPD	O
complex	O
)	O
to	O
promote	O
ubiquitination	O
and	O
degradation	O
of	O
Parkin	B-Protein
substrates	O
,	O
including	O
Parkin	B-Protein
itself	O
and	O
Synphilin	B-Protein
-	I-Protein
1	I-Protein
in	O
neuroblastoma	O
cells	O
and	O
human	O
brain	O
lysates	O
.	O

Genetic	O
ablation	O
of	O
either	O
Pink1	B-Protein
or	O
Dj	B-Protein
-	I-Protein
1	I-Protein
resulted	O
in	O
reduced	O
ubiquitination	O
of	O
endogenous	O
Parkin	B-Protein
as	O
well	O
as	O
decreased	O
degradation	O
and	O
increased	O
accumulation	O
of	O
aberrantly	O
expressed	O
Parkin	B-Protein
substrates	O
.	O

Expression	O
of	O
PINK1	B-Protein
enhanced	O
Parkin	B-Protein
-	O
mediated	O
degradation	O
of	O
heat	O
shock	O
-	O
induced	O
misfolded	O
protein	O
.	O

In	O
contrast	O
,	O
PD	O
-	O
pathogenic	O
Parkin	B-Protein
and	O
PINK1	B-Protein
mutations	O
showed	O
reduced	O
ability	O
to	O
promote	O
degradation	O
of	O
Parkin	B-Protein
substrates	O
.	O

This	O
study	O
identified	O
a	O
functional	O
ubiquitin	B-Protein
E3	O
ligase	O
complex	O
consisting	O
of	O
PD	O
-	O
associated	O
Parkin	B-Protein
,	O
PINK1	B-Protein
,	O
and	O
DJ	B-Protein
-	I-Protein
1	I-Protein
to	O
promote	O
degradation	O
of	O
un	O
-	O
/	O
misfolded	O
proteins	O
and	O
suggests	O
that	O
their	O
PD	O
-	O
pathogenic	O
mutations	O
impair	O
E3	O
ligase	O
activity	O
of	O
the	O
complex	O
,	O
which	O
may	O
constitute	O
a	O
mechanism	O
underlying	O
PD	O
pathogenesis	O
.	O

The	O
role	O
of	O
RAD6	B-Protein
in	O
recombinational	O
repair	O
,	O
checkpoints	O
and	O
meiosis	O
via	O
histone	O
modification	O
.	O

The	O
Rad6	B-Protein
ubiquitin	B-Protein
-	O
conjugating	O
enzyme	O
in	O
Saccharomyces	O
cerevisiae	O
is	O
known	O
to	O
interact	O
with	O
three	O
separate	O
ubiquitin	B-Protein
ligase	O
proteins	O
(	O
Ubr1	B-Protein
,	O
Rad18	B-Protein
,	O
and	O
Bre1	B-Protein
)	O
specific	O
to	O
different	O
targets	O
.	O

The	O
Rad6	B-Protein
/	O
Rad18	B-Protein
complex	O
is	O
central	O
to	O
translesion	O
synthesis	O
and	O
the	O
family	O
of	O
DNA	O
transactions	O
known	O
as	O
post	O
-	O
replication	O
repair	O
(	O
PRR	O
)	O
.	O

A	O
less	O
well	O
-	O
known	O
aspect	O
of	O
Rad6	B-Protein
-	O
mediated	O
DNA	O
repair	O
,	O
however	O
,	O
involves	O
its	O
function	O
with	O
Bre1	B-Protein
in	O
mono	O
-	O
ubiquitinating	O
the	O
histone	B-Protein
H2B	I-Protein
residue	O
lysine	O
123	O
.	O

Here	O
,	O
we	O
review	O
how	O
this	O
ubiquitination	O
impacts	O
histone	B-Protein
H3	I-Protein
methylation	O
,	O
and	O
how	O
this	O
in	O
turn	O
impacts	O
the	O
DNA	O
damage	O
response	O
.	O

In	O
S	O
.	O
cerevisiae	O
this	O
pathway	O
is	O
required	O
for	O
checkpoint	O
activation	O
in	O
G1	O
,	O
and	O
contributes	O
to	O
DNA	O
repair	O
via	O
the	O
homologous	O
recombination	O
pathway	O
(	O
HRR	O
)	O
in	O
G2	O
cells	O
.	O

Thus	O
,	O
RAD6	B-Protein
clearly	O
plays	O
a	O
role	O
in	O
HRR	O
in	O
addition	O
to	O
its	O
central	O
role	O
in	O
PRR	O
.	O

We	O
also	O
summarize	O
what	O
is	O
known	O
about	O
related	O
repair	O
pathways	O
in	O
other	O
eukaryotes	O
,	O
including	O
mammals	O
.	O

Recent	O
literature	O
emphasizes	O
the	O
role	O
of	O
methylated	O
histones	B-Protein
in	O
S	O
.	O
cerevisiae	O
,	O
Schizosaccharomyces	O
pombe	O
and	O
mammals	O
in	O
attracting	O
the	O
related	O
DNA	O
damage	O
checkpoint	O
proteins	O
Rad9	B-Protein
,	O
Crb2	B-Protein
and	O
53BP1	B-Protein
,	O
respectively	O
,	O
to	O
chromatin	O
at	O
the	O
sites	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
.	O

However	O
,	O
the	O
specific	O
histone	B-Protein
modification	O
pathways	O
involved	O
diverge	O
in	O
these	O
different	O
eukaryotes	O
.	O

PKR	B-Protein
-	O
mediated	O
degradation	O
of	O
STAT1	B-Protein
regulates	O
osteoblast	O
differentiation	O
.	O

The	O
double	B-Protein
-	I-Protein
stranded	I-Protein
RNA	I-Protein
-	I-Protein
dependent	I-Protein
protein	I-Protein
kinase	I-Protein
(	O
PKR	B-Protein
)	O
plays	O
a	O
critical	O
role	O
in	O
various	O
biological	O
responses	O
including	O
antiviral	O
defense	O
,	O
cell	O
differentiation	O
,	O
apoptosis	O
,	O
and	O
tumorigenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
PKR	B-Protein
could	O
affect	O
the	O
post	O
-	O
translational	O
modifications	O
of	O
STAT1	B-Protein
protein	O
and	O
whether	O
these	O
modifications	O
regulate	O
osteoblast	O
differentiation	O
.	O

We	O
demonstrated	O
that	O
PKR	B-Protein
was	O
necessary	O
for	O
the	O
ubiquitination	O
of	O
STAT1	B-Protein
protein	O
.	O

The	O
expressions	O
of	O
bone	O
-	O
related	O
genes	O
such	O
as	O
type	O
I	O
collagen	O
,	O
integrin	B-Protein
binding	I-Protein
sialoprotein	I-Protein
,	O
osteopontin	B-Protein
,	O
and	O
osterix	B-Protein
were	O
suppressed	O
in	O
osteoblasts	O
lacking	O
PKR	B-Protein
activity	O
.	O

In	O
contrast	O
,	O
the	O
expressions	O
of	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
and	O
matrix	B-Protein
metalloproteinases	I-Protein
8	I-Protein
and	O
13	B-Protein
increased	O
in	O
PKR	B-Protein
-	O
mutated	O
osteoblasts	O
.	O

The	O
expression	O
and	O
degradation	O
of	O
STAT1	B-Protein
protein	O
were	O
regulated	O
by	O
PKR	B-Protein
in	O
a	O
SLIM	B-Protein
-	O
dependent	O
pathway	O
.	O

Inhibition	O
of	O
SLIM	B-Protein
by	O
RNA	O
interference	O
resulted	O
in	O
the	O
decreased	O
activity	O
of	O
Runx2	B-Protein
in	O
osteoblasts	O
.	O

Stimulation	O
of	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
expression	O
and	O
suppression	O
of	O
alkaline	B-Protein
phosphatase	I-Protein
activity	O
were	O
regulated	O
through	O
by	O
SLIM	B-Protein
-	O
dependent	O
pathway	O
.	O

However	O
,	O
expressions	O
of	O
bone	O
-	O
related	O
genes	O
and	O
MMPs	O
were	O
regulated	O
by	O
SLIM	B-Protein
-	O
independent	O
pathway	O
.	O

Our	O
present	O
results	O
suggest	O
that	O
the	O
aberrant	O
accumulation	O
of	O
STAT1	B-Protein
protein	O
induced	O
by	O
loss	O
of	O
PKR	B-Protein
regulate	O
osteoblast	O
differentiation	O
through	O
both	O
SLIM	B-Protein
/	O
STAT1	B-Protein
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
.	O

The	O
ubiquitin	B-Protein
ligase	O
E6	B-Protein
-	I-Protein
AP	I-Protein
is	O
induced	O
and	O
recruited	O
to	O
aggresomes	O
in	O
response	O
to	O
proteasome	O
inhibition	O
and	O
may	O
be	O
involved	O
in	O
the	O
ubiquitination	O
of	O
Hsp70	O
-	O
bound	O
misfolded	O
proteins	O
.	O

Cells	O
are	O
equipped	O
with	O
an	O
efficient	O
quality	O
control	O
system	O
to	O
selectively	O
eliminate	O
abnormally	O
folded	O
and	O
damaged	O
proteins	O
.	O

Initially	O
the	O
cell	O
tries	O
to	O
refold	O
the	O
unfolded	O
proteins	O
with	O
the	O
help	O
of	O
molecular	O
chaperones	O
,	O
and	O
failure	O
to	O
refold	O
leads	O
to	O
their	O
degradation	O
by	O
the	O
ubiquitin	B-Protein
proteasome	O
system	O
.	O

But	O
how	O
this	O
proteolytic	O
machinery	O
recognizes	O
the	O
abnormally	O
folded	O
proteins	O
is	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
report	O
that	O
E6	B-Protein
-	I-Protein
AP	I-Protein
,	O
a	O
HECT	O
domain	O
family	O
ubiquitin	B-Protein
ligase	O
implicated	O
in	O
Angelman	O
syndrome	O
,	O
interacts	O
with	O
the	O
substrate	O
binding	O
domain	O
of	O
Hsp70	O
/	O
Hsc70	B-Protein
chaperones	O
and	O
promotes	O
the	O
degradation	O
of	O
chaperone	O
bound	O
substrates	O
.	O

The	O
expression	O
of	O
E6	B-Protein
-	I-Protein
AP	I-Protein
was	O
dramatically	O
induced	O
under	O
a	O
variety	O
of	O
stresses	O
,	O
and	O
overexpression	O
of	O
E6	B-Protein
-	I-Protein
AP	I-Protein
was	O
found	O
to	O
protect	O
against	O
endoplasmic	O
reticulum	O
stress	O
-	O
induced	O
cell	O
death	O
.	O

The	O
inhibition	O
of	O
proteasome	O
function	O
not	O
only	O
increases	O
the	O
expression	O
of	O
E6	B-Protein
-	I-Protein
AP	I-Protein
but	O
also	O
causes	O
its	O
redistribution	O
around	O
microtubule	O
-	O
organizing	O
center	O
,	O
a	O
subcellular	O
structure	O
for	O
the	O
degradation	O
of	O
the	O
cytoplasmic	O
misfolded	O
proteins	O
.	O

E6	B-Protein
-	I-Protein
AP	I-Protein
is	O
also	O
recruited	O
to	O
aggresomes	O
containing	O
the	O
cystic	B-Protein
fibrosis	I-Protein
transmembrane	I-Protein
conductance	I-Protein
regulator	I-Protein
or	O
expanded	O
polyglutamine	O
proteins	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
E6	B-Protein
-	I-Protein
AP	I-Protein
ubiquitinates	O
misfolded	O
luciferase	B-Protein
that	O
is	O
bound	O
by	O
Hsp70	O
.	O

Our	O
results	O
suggest	O
that	O
E6	B-Protein
-	I-Protein
AP	I-Protein
functions	O
as	O
a	O
cellular	O
quality	O
control	O
ubiquitin	B-Protein
ligase	O
and	O
,	O
therefore	O
,	O
can	O
be	O
implicated	O
not	O
only	O
in	O
the	O
pathogenesis	O
of	O
Angelman	O
syndrome	O
but	O
also	O
in	O
the	O
biology	O
of	O
neurodegenerative	O
disorders	O
involving	O
protein	O
aggregation	O
.	O

Induction	O
of	O
SOX4	B-Protein
by	O
DNA	O
damage	O
is	O
critical	O
for	O
p53	B-Protein
stabilization	O
and	O
function	O
.	O

DNA	O
damage	O
response	O
(	O
DDR	O
)	O
acts	O
as	O
a	O
tumorigenesis	O
barrier	O
,	O
and	O
any	O
defects	O
in	O
the	O
DDR	O
machinery	O
may	O
lead	O
to	O
cancer	O
.	O

SOX4	B-Protein
expression	O
is	O
elevated	O
in	O
many	O
types	O
of	O
tumors	O
;	O
however	O
,	O
its	O
role	O
in	O
DDR	O
is	O
still	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
SOX4	B-Protein
,	O
a	O
new	O
DNA	O
damage	O
sensor	O
,	O
is	O
required	O
for	O
the	O
activation	O
of	O
p53	B-Protein
tumor	O
suppressor	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

Notably	O
,	O
SOX4	B-Protein
interacts	O
with	O
and	O
stabilizes	O
p53	B-Protein
protein	O
by	O
blocking	O
Mdm2	B-Protein
-	O
mediated	O
p53	B-Protein
ubiquitination	O
and	O
degradation	O
.	O

Furthermore	O
,	O
SOX4	B-Protein
enhances	O
p53	B-Protein
acetylation	O
by	O
interacting	O
with	O
p300	B-Protein
/	O
CBP	B-Protein
and	O
facilitating	O
p300	B-Protein
/	O
CBP	B-Protein
/	O
p53	B-Protein
complex	O
formation	O
.	O

In	O
concert	O
with	O
these	O
results	O
,	O
SOX4	B-Protein
promotes	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
,	O
and	O
it	O
inhibits	O
tumorigenesis	O
in	O
a	O
p53	B-Protein
-	O
dependent	O
manner	O
.	O

Therefore	O
,	O
these	O
findings	O
highlight	O
SOX4	B-Protein
as	O
a	O
potential	O
key	O
factor	O
in	O
regulating	O
DDR	O
-	O
associated	O
cancer	O
.	O

An	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
membrane	O
complex	O
composed	O
of	O
SPFH1	B-Protein
and	O
SPFH2	B-Protein
mediates	O
the	O
ER	O
-	O
associated	O
degradation	O
of	O
inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
receptors	O
.	O

How	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
proteins	O
that	O
are	O
substrates	O
for	O
the	O
ER	O
-	O
associated	O
degradation	O
(	O
ERAD	O
)	O
pathway	O
are	O
recognized	O
for	O
polyubiquitination	O
and	O
proteasomal	O
degradation	O
is	O
largely	O
unresolved	O
.	O

Inositol	O
1	O
,	O
4	O
,	O
5	O
-	O
trisphosphate	O
receptors	O
(	O
IP	O
(	O
3	O
)	O
Rs	O
)	O
form	O
tetrameric	O
calcium	O
channels	O
in	O
ER	O
membranes	O
,	O
whose	O
primary	O
role	O
is	O
to	O
control	O
the	O
release	O
of	O
ER	O
calcium	O
stores	O
,	O
but	O
whose	O
levels	O
are	O
also	O
regulated	O
,	O
in	O
an	O
activation	O
-	O
dependent	O
manner	O
,	O
by	O
the	O
ERAD	O
pathway	O
.	O

Here	O
we	O
report	O
that	O
the	O
ER	O
membrane	O
protein	O
SPFH1	B-Protein
and	O
its	O
homolog	O
SPFH2	B-Protein
form	O
a	O
heteromeric	O
approximately	O
2	O
MDa	O
complex	O
that	O
binds	O
to	O
IP	O
(	O
3	O
)	O
R	O
tetramers	O
immediately	O
after	O
their	O
activation	O
and	O
is	O
required	O
for	O
their	O
processing	O
.	O

The	O
complex	O
is	O
ring	O
-	O
shaped	O
(	O
diameter	O
approximately	O
250A	O
(	O
)	O
,	O
)	O
and	O
RNA	O
interference	O
-	O
mediated	O
depletion	O
of	O
SPFH1	B-Protein
and	O
SPFH2	B-Protein
blocks	O
IP	O
(	O
3	O
)	O
R	O
polyubiquitination	O
and	O
degradation	O
.	O

We	O
propose	O
that	O
this	O
novel	O
SPFH1	B-Protein
/	O
2	B-Protein
complex	O
is	O
a	O
recognition	O
factor	O
that	O
targets	O
IP	O
(	O
3	O
)	O
Rs	O
and	O
perhaps	O
other	O
substrates	O
for	O
ERAD	O
.	O

MYPT1	B-Protein
,	O
the	O
targeting	O
subunit	O
of	O
smooth	O
-	O
muscle	O
myosin	O
phosphatase	O
,	O
is	O
a	O
substrate	O
for	O
the	O
asparaginyl	O
hydroxylase	O
factor	B-Protein
inhibiting	I-Protein
hypoxia	I-Protein
-	I-Protein
inducible	I-Protein
factor	I-Protein
(	O
FIH	B-Protein
)	O
.	O

The	O
asparaginyl	O
hydroxylase	O
FIH	B-Protein
[	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
hypoxia	O
-	O
inducible	O
factor	O
)	O
]	O
was	O
first	O
identified	O
as	O
a	O
protein	O
that	O
inhibits	O
transcriptional	O
activation	O
by	O
HIF	O
,	O
through	O
hydroxylation	O
of	O
an	O
asparagine	O
residue	O
in	O
the	O
CAD	O
(	O
C	O
-	O
terminal	O
activation	O
domain	O
)	O
.	O

More	O
recently	O
,	O
several	O
ARD	O
[	O
AR	O
(	O
ankyrin	O
repeat	O
)	O
domain	O
]	O
-	O
containing	O
proteins	O
were	O
identified	O
as	O
FIH	B-Protein
substrates	O
using	O
FIH	B-Protein
interaction	O
assays	O
.	O

Although	O
the	O
function	O
(	O
s	O
)	O
of	O
these	O
ARD	O
hydroxylations	O
is	O
unclear	O
,	O
expression	O
of	O
the	O
ARD	O
protein	O
Notch1	B-Protein
was	O
shown	O
to	O
compete	O
efficiently	O
with	O
HIF	O
CAD	O
for	O
asparagine	O
hydroxylation	O
and	O
thus	O
to	O
enhance	O
HIF	O
activity	O
.	O

The	O
ARD	O
is	O
a	O
common	O
protein	O
domain	O
with	O
over	O
300	O
examples	O
in	O
the	O
human	O
proteome	O
.	O

However	O
,	O
the	O
extent	O
of	O
hydroxylation	O
among	O
ARD	O
proteins	O
,	O
and	O
the	O
ability	O
of	O
other	O
members	O
to	O
compete	O
with	O
HIF	O
-	O
CAD	O
for	O
FIH	B-Protein
,	O
is	O
not	O
known	O
.	O

In	O
the	O
present	O
study	O
we	O
assay	O
for	O
asparagine	O
hydroxylation	O
in	O
a	O
bioinformatically	O
predicted	O
FIH	B-Protein
substrate	O
,	O
the	O
targeting	O
subunit	O
of	O
myosin	O
phosphatase	O
,	O
MYPT1	B-Protein
.	O

Our	O
results	O
confirm	O
hydroxylation	O
both	O
in	O
cultured	O
cells	O
and	O
in	O
endogenous	O
protein	O
purified	O
from	O
animal	O
tissue	O
.	O

We	O
show	O
that	O
the	O
extent	O
of	O
hydroxylation	O
at	O
three	O
sites	O
is	O
dependent	O
on	O
FIH	B-Protein
expression	O
level	O
and	O
that	O
hydroxylation	O
is	O
incomplete	O
under	O
basal	O
conditions	O
even	O
in	O
the	O
animal	O
tissue	O
.	O

We	O
also	O
show	O
that	O
expression	O
of	O
MYPT1	B-Protein
enhances	O
HIF	O
-	O
CAD	O
activity	O
in	O
a	O
manner	O
consistent	O
with	O
competition	O
for	O
FIH	B-Protein
and	O
that	O
this	O
property	O
extends	O
to	O
other	O
ARD	O
proteins	O
.	O

These	O
results	O
extend	O
the	O
range	O
of	O
FIH	B-Protein
substrates	O
and	O
suggest	O
that	O
cross	O
-	O
competition	O
between	O
ARDs	O
and	O
HIF	O
-	O
CAD	O
,	O
and	O
between	O
ARDs	O
themselves	O
,	O
may	O
be	O
extensive	O
and	O
have	O
important	O
effects	O
on	O
hypoxia	O
signalling	O
.	O

Modification	O
by	O
single	O
ubiquitin	B-Protein
moieties	O
rather	O
than	O
polyubiquitination	O
is	O
sufficient	O
for	O
proteasomal	O
processing	O
of	O
the	O
p105	B-Protein
NF	O
-	O
kappaB	O
precursor	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
is	O
regulated	O
via	O
numerous	O
ubiquitin	B-Protein
-	O
and	O
proteasome	O
-	O
mediated	O
steps	O
;	O
an	O
important	O
one	O
is	O
processing	O
of	O
the	O
precursor	O
p105	B-Protein
to	O
the	O
p50	B-Protein
active	O
subunit	O
.	O

The	O
mechanisms	O
involved	O
are	O
largely	O
unknown	O
,	O
because	O
this	O
is	O
an	O
exceptional	O
case	O
where	O
the	O
ubiquitin	B-Protein
system	O
does	O
not	O
destroy	O
its	O
substrate	O
completely	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
proteasomal	O
processing	O
of	O
p105	B-Protein
requires	O
ubiquitin	B-Protein
but	O
not	O
generation	O
of	O
polyubiquitin	B-Protein
chains	O
.	O

In	O
vitro	O
,	O
ubiquitin	B-Protein
species	O
that	O
cannot	O
polymerize	O
mediate	O
processing	O
.	O

In	O
yeasts	O
that	O
express	O
nonpolymerizable	O
ubiquitins	B-Protein
,	O
processing	O
proceeds	O
normally	O
,	O
whereas	O
degradation	O
of	O
substrates	O
that	O
are	O
dependent	O
on	O
polyubiquitination	O
is	O
inhibited	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
mammalian	O
cells	O
.	O

Interestingly	O
,	O
processing	O
requires	O
multiple	O
monoubiquitinations	O
,	O
because	O
progressive	O
elimination	O
of	O
lysines	O
in	O
p105	B-Protein
is	O
accompanied	O
by	O
gradual	O
inhibition	O
of	O
p50	B-Protein
generation	O
.	O

Finally	O
,	O
the	O
proteasome	O
recognizes	O
the	O
multiply	O
monoubiquitinated	O
p105	B-Protein
.	O

These	O
findings	O
suggest	O
that	O
a	O
proteolytic	O
signal	O
can	O
be	O
composed	O
of	O
a	O
cluster	O
of	O
single	O
ubiquitins	O
,	O
not	O
necessarily	O
a	O
chain	O
.	O

Methylation	O
of	O
H3	B-Protein
K4	O
and	O
K79	O
is	O
not	O
strictly	O
dependent	O
on	O
H2B	B-Protein
K123	O
ubiquitylation	O
.	O

Covalent	O
modifications	O
of	O
histone	B-Protein
proteins	O
have	O
profound	O
consequences	O
on	O
chromatin	O
structure	O
and	O
function	O
.	O

Specific	O
modification	O
patterns	O
constitute	O
a	O
code	O
read	O
by	O
effector	O
proteins	O
.	O

Studies	O
from	O
yeast	O
found	O
that	O
H3	B-Protein
trimethylation	O
at	O
K4	O
and	O
K79	O
is	O
dependent	O
on	O
ubiquitylation	O
of	O
H2B	B-Protein
K123	O
,	O
which	O
is	O
termed	O
a	O
"	O
trans	O
-	O
tail	O
pathway	O
.	O
"	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
strain	O
unable	O
to	O
be	O
ubiquitylated	O
on	O
H2B	B-Protein
(	O
K123R	O
)	O
is	O
still	O
proficient	O
for	O
H3	B-Protein
trimethylation	O
at	O
both	O
K4	O
and	O
K79	O
,	O
indicating	O
that	O
H3	B-Protein
methylation	O
status	O
is	O
not	O
solely	O
dependent	O
on	O
H2B	B-Protein
ubiquitylation	O
.	O

However	O
,	O
additional	O
mutations	O
in	O
H2B	B-Protein
result	O
in	O
loss	O
of	O
H3	B-Protein
methylation	O
when	O
combined	O
with	O
htb1	B-Protein
-	O
K123R	O
.	O

Consistent	O
with	O
this	O
,	O
we	O
find	O
that	O
the	O
original	O
strain	O
used	O
to	O
identify	O
the	O
trans	O
-	O
tail	O
pathway	O
has	O
a	O
genomic	O
mutation	O
that	O
,	O
when	O
combined	O
with	O
H2B	B-Protein
K123R	O
,	O
results	O
in	O
defective	O
H3	B-Protein
methylation	O
.	O

Finally	O
,	O
we	O
show	O
that	O
strains	O
lacking	O
the	O
ubiquitin	B-Protein
ligase	O
Bre1	B-Protein
are	O
defective	O
for	O
H3	B-Protein
methylation	O
,	O
suggesting	O
that	O
there	O
is	O
an	O
additional	O
Bre1	B-Protein
substrate	O
that	O
in	O
combination	O
with	O
H2B	B-Protein
K123	O
facilitates	O
H3	B-Protein
methylation	O
.	O

NBA1	B-Protein
,	O
a	O
new	O
player	O
in	O
the	O
Brca1	O
A	O
complex	O
,	O
is	O
required	O
for	O
DNA	O
damage	O
resistance	O
and	O
checkpoint	O
control	O
.	O

The	O
ability	O
to	O
sense	O
and	O
respond	O
to	O
DNA	O
damage	O
is	O
critical	O
to	O
maintenance	O
of	O
genomic	O
stability	O
and	O
the	O
prevention	O
of	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
a	O
genetic	O
screen	O
to	O
identify	O
a	O
gene	O
,	O
NBA1	B-Protein
(	O
new	O
component	O
of	O
the	O
BRCA1	O
A	O
complex	O
)	O
,	O
that	O
is	O
required	O
for	O
resistance	O
to	O
ionizing	O
radiation	O
.	O

The	O
NBA1	B-Protein
protein	O
localizes	O
to	O
sites	O
of	O
DNA	O
damage	O
and	O
is	O
required	O
for	O
G2	O
/	O
M	O
checkpoint	O
control	O
.	O

Proteomic	O
analysis	O
revealed	O
that	O
NBA1	B-Protein
is	O
a	O
component	O
of	O
the	O
BRCA1	O
A	O
complex	O
,	O
which	O
also	O
contains	O
Brca1	B-Protein
/	O
Bard1	B-Protein
,	O
Abra1	B-Protein
,	O
RAP80	B-Protein
,	O
BRCC36	B-Protein
,	O
and	O
BRE	B-Protein
.	O

NBA1	B-Protein
is	O
required	O
to	O
maintain	O
BRE	B-Protein
and	O
Abra1	B-Protein
abundance	O
and	O
for	O
the	O
recruitment	O
of	O
BRCA1	B-Protein
to	O
sites	O
of	O
DNA	O
damage	O
.	O

In	O
depth	O
bioinformatics	O
analysis	O
revealed	O
that	O
the	O
BRCA1	O
A	O
complex	O
bears	O
striking	O
similarities	O
to	O
the	O
19S	O
proteasome	O
complex	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
four	O
members	O
of	O
the	O
BRCA1	O
-	O
A	O
complex	O
possess	O
a	O
polyubiquitin	O
chain	O
-	O
binding	O
capability	O
,	O
thus	O
forming	O
a	O
complex	O
that	O
might	O
facilitate	O
the	O
deubiquitinating	O
activity	O
of	O
the	O
deubiquitination	O
enzyme	O
BRCC36	B-Protein
or	O
the	O
E3	O
ligase	O
activity	O
of	O
the	O
BRCA1	B-Protein
/	O
BARD1	B-Protein
ligase	O
.	O

These	O
findings	O
provide	O
a	O
new	O
perspective	O
from	O
which	O
to	O
view	O
the	O
BRCA1	O
A	O
complex	O
.	O

Functional	O
conservation	O
of	O
asxl2	B-Protein
,	O
a	O
murine	O
homolog	O
for	O
the	O
Drosophila	O
enhancer	O
of	O
trithorax	O
and	O
polycomb	O
group	O
gene	O
asx	B-Protein
.	O

BACKGROUND	O
:	O
Polycomb	O
-	O
group	O
(	O
PcG	O
)	O
and	O
trithorax	O
-	O
group	O
(	O
trxG	O
)	O
proteins	O
regulate	O
histone	B-Protein
methylation	O
to	O
establish	O
repressive	O
and	O
active	O
chromatin	O
configurations	O
at	O
target	O
loci	O
,	O
respectively	O
.	O

These	O
chromatin	O
configurations	O
are	O
passed	O
on	O
from	O
mother	O
to	O
daughter	O
cells	O
,	O
thereby	O
causing	O
heritable	O
changes	O
in	O
gene	O
expression	O
.	O

The	O
activities	O
of	O
PcG	O
and	O
trxG	O
proteins	O
are	O
regulated	O
by	O
a	O
special	O
class	O
of	O
proteins	O
known	O
as	O
Enhancers	O
of	O
trithorax	O
and	O
Polycomb	O
(	O
ETP	O
)	O
.	O

The	O
Drosophila	O
gene	O
Additional	B-Protein
sex	I-Protein
combs	I-Protein
(	O
Asx	B-Protein
)	O
encodes	O
an	O
ETP	O
protein	O
and	O
mutations	O
in	O
Asx	B-Protein
enhance	O
both	O
PcG	O
and	O
trxG	O
mutant	O
phenotypes	O
.	O

The	O
mouse	O
and	O
human	O
genomes	O
each	O
contain	O
three	O
Asx	B-Protein
homologues	O
,	O
Asx	B-Protein
-	I-Protein
like	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
and	O
3	B-Protein
.	O

In	O
order	O
to	O
understand	O
the	O
functions	O
of	O
mammalian	O
Asx	B-Protein
-	O
like	O
(	O
Asxl	O
)	O
proteins	O
,	O
we	O
generated	O
an	O
Asxl2	B-Protein
mutant	O
mouse	O
from	O
a	O
gene	O
-	O
trap	O
ES	O
cell	O
line	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
show	O
that	O
the	O
Asxl2	B-Protein
gene	O
trap	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
specific	O
tissues	O
including	O
the	O
heart	O
,	O
the	O
axial	O
skeleton	O
,	O
the	O
neocortex	O
,	O
the	O
retina	O
,	O
spermatogonia	O
and	O
developing	O
oocytes	O
.	O

The	O
gene	O
trap	O
mutation	O
is	O
partially	O
embryonic	O
lethal	O
and	O
approximately	O
half	O
of	O
homozygous	O
animals	O
die	O
before	O
birth	O
.	O

Homozygotes	O
that	O
survive	O
embryogenesis	O
are	O
significantly	O
smaller	O
than	O
controls	O
and	O
have	O
a	O
shortened	O
life	O
span	O
.	O

Asxl2	B-Protein
(	O
-	O
/	O
-	O
)	O
mice	O
display	O
both	O
posterior	O
transformations	O
and	O
anterior	O
transformation	O
in	O
the	O
axial	O
skeleton	O
,	O
suggesting	O
that	O
the	O
loss	O
of	O
Asxl2	B-Protein
disrupts	O
the	O
activities	O
of	O
both	O
PcG	O
and	O
trxG	O
proteins	O
.	O

The	O
PcG	O
-	O
associated	O
histone	B-Protein
modification	O
,	O
trimethylation	O
of	O
histone	B-Protein
H3	I-Protein
lysine	O
27	O
,	O
is	O
reduced	O
in	O
Asxl2	B-Protein
(	O
-	O
/	O
-	O
)	O
heart	O
.	O

Necropsy	O
and	O
histological	O
analysis	O
show	O
that	O
mutant	O
mice	O
have	O
enlarged	O
hearts	O
and	O
may	O
have	O
impaired	O
heart	O
function	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Our	O
results	O
suggest	O
that	O
murine	O
Asxl2	B-Protein
has	O
conserved	O
ETP	O
function	O
and	O
plays	O
dual	O
roles	O
in	O
the	O
promotion	O
of	O
PcG	O
and	O
trxG	O
activity	O
.	O

We	O
have	O
also	O
revealed	O
an	O
unexpected	O
role	O
for	O
Asxl2	B-Protein
in	O
the	O
heart	O
,	O
suggesting	O
that	O
the	O
PcG	O
/	O
trxG	O
system	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
cardiac	O
function	O
.	O

A	O
family	O
of	O
Salmonella	O
virulence	O
factors	O
functions	O
as	O
a	O
distinct	O
class	O
of	O
autoregulated	O
E3	O
ubiquitin	O
ligases	O
.	O

Processes	O
as	O
diverse	O
as	O
receptor	O
binding	O
and	O
signaling	O
,	O
cytoskeletal	O
dynamics	O
,	O
and	O
programmed	O
cell	O
death	O
are	O
manipulated	O
by	O
mimics	O
of	O
host	O
proteins	O
encoded	O
by	O
pathogenic	O
bacteria	O
.	O

We	O
show	O
here	O
that	O
the	O
Salmonella	O
virulence	O
factor	O
SspH2	B-Protein
belongs	O
to	O
a	O
growing	O
class	O
of	O
bacterial	O
effector	O
proteins	O
that	O
harness	O
and	O
subvert	O
the	O
eukaryotic	O
ubiquitination	O
pathway	O
.	O

This	O
virulence	O
protein	O
possesses	O
ubiquitination	O
activity	O
that	O
depends	O
on	O
a	O
conserved	O
cysteine	O
residue	O
.	O

A	O
crystal	O
structure	O
of	O
SspH2	B-Protein
reveals	O
a	O
canonical	O
leucine	O
-	O
rich	O
repeat	O
(	O
LRR	O
)	O
domain	O
that	O
interacts	O
with	O
a	O
unique	O
E3	O
ligase	O
[	O
which	O
we	O
have	O
termed	O
NEL	O
for	O
Novel	O
E3	O
Ligase	O
]	O
C	O
-	O
terminal	O
fold	O
unrelated	O
to	O
previously	O
observed	O
HECT	O
or	O
RING	O
-	O
finger	O
E3	O
ligases	O
.	O

Moreover	O
,	O
the	O
LRR	O
domain	O
sequesters	O
the	O
catalytic	O
cysteine	O
residue	O
contained	O
in	O
the	O
NEL	O
domain	O
,	O
and	O
we	O
suggest	O
a	O
mechanism	O
for	O
activation	O
of	O
the	O
ligase	O
requiring	O
a	O
substantial	O
conformational	O
change	O
to	O
release	O
the	O
catalytic	O
domain	O
for	O
function	O
.	O

We	O
also	O
show	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
targets	O
SspH2	B-Protein
to	O
the	O
apical	O
plasma	O
membrane	O
of	O
polarized	O
epithelial	O
cells	O
and	O
propose	O
a	O
model	O
whereby	O
binding	O
of	O
the	O
LRR	O
to	O
proteins	O
at	O
the	O
target	O
site	O
releases	O
the	O
ligase	O
domain	O
for	O
site	O
-	O
specific	O
function	O
.	O

The	O
cholinesterase	O
-	O
like	O
domain	O
,	O
essential	O
in	O
thyroglobulin	B-Protein
trafficking	O
for	O
thyroid	O
hormone	O
synthesis	O
,	O
is	O
required	O
for	O
protein	O
dimerization	O
.	O

The	O
carboxyl	O
-	O
terminal	O
cholinesterase	O
-	O
like	O
(	O
ChEL	O
)	O
domain	O
of	O
thyroglobulin	B-Protein
(	O
Tg	B-Protein
)	O
has	O
been	O
identified	O
as	O
critically	O
important	O
in	O
Tg	B-Protein
export	O
from	O
the	O
endoplasmic	O
reticulum	O
.	O

In	O
a	O
number	O
of	O
human	O
kindreds	O
suffering	O
from	O
congenital	O
hypothyroidism	O
,	O
and	O
in	O
the	O
cog	O
congenital	O
goiter	O
mouse	O
and	O
rdw	O
rat	O
dwarf	O
models	O
,	O
thyroid	O
hormone	O
synthesis	O
is	O
inhibited	O
because	O
of	O
mutations	O
in	O
the	O
ChEL	O
domain	O
that	O
block	O
protein	O
export	O
from	O
the	O
endoplasmic	O
reticulum	O
.	O

We	O
hypothesize	O
that	O
Tg	B-Protein
forms	O
homodimers	O
through	O
noncovalent	O
interactions	O
involving	O
two	O
predicted	O
alpha	O
-	O
helices	O
in	O
each	O
ChEL	O
domain	O
that	O
are	O
homologous	O
to	O
the	O
dimerization	O
helices	O
of	O
acetylcholinesterase	B-Protein
.	O

This	O
has	O
been	O
explored	O
through	O
selective	O
epitope	O
tagging	O
of	O
dimerization	O
partners	O
and	O
by	O
inserting	O
an	O
extra	O
,	O
unpaired	O
Cys	O
residue	O
to	O
create	O
an	O
opportunity	O
for	O
intermolecular	O
disulfide	O
pairing	O
.	O

We	O
show	O
that	O
the	O
ChEL	O
domain	O
is	O
necessary	O
and	O
sufficient	O
for	O
Tg	B-Protein
dimerization	O
;	O
specifically	O
,	O
the	O
isolated	O
ChEL	O
domain	O
can	O
dimerize	O
with	O
full	O
-	O
length	O
Tg	B-Protein
or	O
with	O
itself	O
.	O

Insertion	O
of	O
an	O
N	O
-	O
linked	O
glycan	O
into	O
the	O
putative	O
upstream	O
dimerization	O
helix	O
inhibits	O
homodimerization	O
of	O
the	O
isolated	O
ChEL	O
domain	O
.	O

However	O
,	O
interestingly	O
,	O
co	O
-	O
expression	O
of	O
upstream	O
Tg	B-Protein
domains	O
,	O
either	O
in	O
cis	O
or	O
in	O
trans	O
,	O
overrides	O
the	O
dimerization	O
defect	O
of	O
such	O
a	O
mutant	O
.	O

Thus	O
,	O
although	O
the	O
ChEL	O
domain	O
provides	O
a	O
nidus	O
for	O
Tg	B-Protein
dimerization	O
,	O
interactions	O
of	O
upstream	O
Tg	B-Protein
regions	O
with	O
the	O
ChEL	O
domain	O
actively	O
stabilizes	O
the	O
Tg	B-Protein
dimer	O
complex	O
for	O
intracellular	O
transport	O
.	O

PCNA	B-Protein
mono	O
-	O
ubiquitination	O
and	O
activation	O
of	O
translesion	O
DNA	O
polymerases	O
by	O
DNA	O
polymerase	O
{	O
alpha	O
}	O
.	O

Translesion	O
DNA	O
synthesis	O
(	O
TLS	O
)	O
involves	O
PCNA	B-Protein
mono	O
-	O
ubiquitination	O
and	O
TLS	O
DNA	O
polymerases	O
(	O
pols	O
)	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
the	O
mono	O
-	O
ubiquitination	O
is	O
induced	O
not	O
only	O
by	O
DNA	O
damage	O
but	O
also	O
by	O
other	O
factors	O
that	O
induce	O
stalling	O
of	O
the	O
DNA	O
replication	O
fork	O
.	O

We	O
studied	O
the	O
effect	O
of	O
spontaneous	O
DNA	O
replication	O
errors	O
on	O
PCNA	B-Protein
mono	O
-	O
ubiquitination	O
and	O
TLS	O
induction	O
.	O

In	O
the	O
pol1L868F	O
strain	O
,	O
which	O
expressed	O
an	O
error	O
-	O
prone	O
pol	O
alpha	O
,	O
PCNA	B-Protein
was	O
spontaneously	O
mono	O
-	O
ubiquitinated	O
.	O

Pol	O
alpha	O
L868F	O
had	O
a	O
rate	O
-	O
limiting	O
step	O
at	O
the	O
extension	O
from	O
mismatched	O
primer	O
termini	O
.	O

Electron	O
microscopic	O
observation	O
showed	O
the	O
accumulation	O
of	O
a	O
single	O
-	O
stranded	O
region	O
at	O
the	O
DNA	O
replication	O
fork	O
in	O
yeast	O
cells	O
.	O

For	O
pol	O
alpha	O
errors	O
,	O
pol	O
zeta	O
participated	O
in	O
a	O
generation	O
of	O
+	O
1	O
frameshifts	O
.	O

Furthermore	O
,	O
in	O
the	O
pol1L868F	O
strain	O
,	O
UV	O
-	O
induced	O
mutations	O
were	O
lower	O
than	O
in	O
the	O
wild	O
-	O
type	O
and	O
a	O
pol	O
delta	O
mutant	O
strain	O
(	O
pol3	O
-	O
5DV	O
)	O
,	O
and	O
deletion	O
of	O
the	O
RAD30	B-Protein
gene	O
(	O
pol	B-Protein
eta	I-Protein
)	O
suppressed	O
this	O
defect	O
.	O

These	O
data	O
suggest	O
that	O
nucleotide	O
misincorporation	O
by	O
pol	O
alpha	O
induces	O
exposure	O
of	O
single	O
-	O
stranded	O
DNA	O
,	O
PCNA	B-Protein
mono	O
-	O
ubiquitination	O
and	O
activates	O
TLS	O
pols	O
.	O

Monohydroxylated	O
polycyclic	O
aromatic	O
hydrocarbons	O
inhibit	O
both	O
osteoclastic	O
and	O
osteoblastic	O
activities	O
in	O
teleost	O
scales	O
.	O

AIMS	O
:	O
We	O
previously	O
demonstrated	O
that	O
monohydroxylated	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
OHPAHs	O
)	O
bound	O
to	O
a	O
human	O
estrogen	B-Protein
receptor	I-Protein
(	O
ER	B-Protein
)	O
by	O
a	O
yeast	O
two	O
-	O
hybrid	O
assay	O
,	O
but	O
polycyclic	O
aromatic	O
hydrocarbons	O
did	O
not	O
have	O
a	O
binding	O
activity	O
.	O

Therefore	O
,	O
the	O
direct	O
effect	O
of	O
3	O
-	O
hydroxybenz	O
[	O
a	O
]	O
anthracene	O
(	O
3	O
-	O
OHBaA	O
)	O
and	O
4	O
-	O
hydroxybenz	O
[	O
a	O
]	O
anthracene	O
(	O
4	O
-	O
OHBaA	O
)	O
on	O
osteoclasts	O
and	O
osteoblasts	O
in	O
teleosts	O
was	O
examined	O
.	O

As	O
a	O
negative	O
control	O
,	O
1	O
-	O
hydroxypyrene	O
(	O
1	O
-	O
OHPy	O
)	O
,	O
which	O
has	O
no	O
binding	O
activity	O
to	O
human	O
ER	B-Protein
,	O
was	O
used	O
.	O

MAIN	O
METHODS	O
:	O
The	O
effect	O
of	O
OHPAHs	O
on	O
osteoclasts	O
and	O
osteoblasts	O
was	O
examined	O
by	O
an	O
assay	O
system	O
using	O
teleost	O
scale	O
as	O
each	O
marker	O
:	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
for	O
osteoclasts	O
and	O
alkaline	O
phosphatase	O
for	O
osteoblasts	O
.	O

Changes	O
in	O
cathepsin	B-Protein
K	I-Protein
(	O
an	O
osteoclastic	O
marker	O
)	O
and	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
I	I-Protein
(	O
IGF	B-Protein
-	I-Protein
I	I-Protein
)	O
(	O
an	O
osteoblastic	O
marker	O
)	O
mRNA	O
expressions	O
in	O
4	O
-	O
OHBaA	O
-	O
treated	O
goldfish	O
scales	O
were	O
examined	O
by	O
using	O
a	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

KEY	O
FINDINGS	O
:	O
In	O
both	O
goldfish	O
(	O
a	O
freshwater	O
teleost	O
)	O
and	O
wrasse	O
(	O
a	O
marine	O
teleost	O
)	O
,	O
the	O
osteoclastic	O
activity	O
in	O
the	O
scales	O
was	O
significantly	O
suppressed	O
by	O
3	O
-	O
OHBaA	O
and	O
4	O
-	O
OHBaA	O
,	O
although	O
1	O
-	O
OHPy	O
did	O
not	O
affect	O
the	O
osteoclastic	O
activity	O
.	O

In	O
reference	O
to	O
osteoblasts	O
,	O
the	O
osteoblastic	O
activity	O
decreased	O
with	O
both	O
3	O
-	O
OHBaA	O
and	O
4	O
-	O
OHBaA	O
and	O
did	O
not	O
change	O
with	O
the	O
1	O
-	O
OHPy	O
treatment	O
.	O

However	O
,	O
17beta	O
-	O
estradiol	O
(	O
E	O
(	O
2	O
)	O
)	O
significantly	O
increased	O
both	O
the	O
osteoclastic	O
and	O
osteoblastic	O
activities	O
in	O
the	O
scales	O
of	O
both	O
goldfish	O
and	O
wrasse	O
.	O

The	O
mRNA	O
expressions	O
of	O
both	O
cathepsin	B-Protein
K	I-Protein
and	O
IGF	B-Protein
-	I-Protein
I	I-Protein
decreased	O
in	O
the	O
4	O
-	O
OHBaA	O
-	O
treated	O
scales	O
but	O
increased	O
in	O
the	O
E	O
(	O
2	O
)	O
-	O
treated	O
scales	O
.	O

SIGNIFICANCE	O
:	O
The	O
current	O
data	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
3	O
-	O
OHBaA	O
and	O
4	O
-	O
OHBaA	O
inhibited	O
both	O
osteoclasts	O
and	O
osteoblasts	O
and	O
disrupted	O
the	O
bone	O
metabolism	O
in	O
teleosts	O
.	O

The	O
transcriptional	O
coactivator	O
MAML1	B-Protein
regulates	O
p300	B-Protein
autoacetylation	O
and	O
HAT	O
activity	O
.	O

MAML1	B-Protein
is	O
a	O
transcriptional	O
coregulator	O
originally	O
identified	O
as	O
a	O
Notch	O
coactivator	O
.	O

MAML1	B-Protein
is	O
also	O
reported	O
to	O
interact	O
with	O
other	O
coregulator	O
proteins	O
,	O
such	O
as	O
CDK8	B-Protein
and	O
p300	B-Protein
,	O
to	O
modulate	O
the	O
activity	O
of	O
Notch	O
.	O

We	O
,	O
and	O
others	O
,	O
previously	O
showed	O
that	O
MAML1	B-Protein
recruits	O
p300	B-Protein
to	O
Notch	O
-	O
regulated	O
genes	O
through	O
direct	O
interactions	O
with	O
the	O
DNA	O
-	O
CSL	O
-	O
Notch	O
complex	O
and	O
p300	B-Protein
.	O

MAML1	B-Protein
interacts	O
with	O
the	O
C	O
/	O
H3	O
domain	O
of	O
p300	B-Protein
,	O
and	O
the	O
p300	B-Protein
-	O
MAML1	B-Protein
complex	O
specifically	O
acetylates	O
lysines	O
of	O
histone	B-Protein
H3	I-Protein
and	O
H4	B-Protein
tails	O
in	O
chromatin	O
in	O
vitro	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
MAML1	B-Protein
potentiates	O
p300	B-Protein
autoacetylation	O
and	O
p300	B-Protein
transcriptional	O
activation	O
.	O

MAML1	B-Protein
directly	O
enhances	O
p300	B-Protein
HAT	O
activity	O
,	O
and	O
this	O
coincides	O
with	O
the	O
translocation	O
of	O
MAML1	B-Protein
,	O
p300	B-Protein
and	O
acetylated	O
histones	B-Protein
to	O
nuclear	O
bodies	O
.	O

Auxin	O
-	O
induced	O
,	O
SCF	O
(	O
TIR1	B-Protein
)	O
-	O
mediated	O
poly	O
-	O
ubiquitination	O
marks	O
AUX	O
/	O
IAA	O
proteins	O
for	O
degradation	O
.	O

The	O
plant	O
hormone	O
auxin	O
(	O
indole	O
-	O
3	O
-	O
acetic	O
acid	O
or	O
IAA	O
)	O
regulates	O
plant	O
development	O
by	O
inducing	O
rapid	O
cellular	O
responses	O
and	O
changes	O
in	O
gene	O
expression	O
.	O

Auxin	O
promotes	O
the	O
degradation	O
of	O
Aux	O
/	O
IAA	O
transcriptional	O
repressors	O
,	O
thereby	O
allowing	O
auxin	O
response	O
factors	O
(	O
ARFs	O
)	O
to	O
activate	O
the	O
transcription	O
of	O
auxin	O
-	O
responsive	O
genes	O
.	O

Auxin	O
enhances	O
the	O
binding	O
of	O
Aux	O
/	O
IAA	O
proteins	O
to	O
the	O
receptor	O
TIR1	B-Protein
,	O
which	O
is	O
an	O
F	O
-	O
box	O
protein	O
that	O
is	O
part	O
of	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
complex	O
SCF	O
(	O
TIR1	B-Protein
)	O
.	O

Binding	O
of	O
Aux	O
/	O
IAA	O
proteins	O
leads	O
to	O
degradation	O
via	O
the	O
26S	O
proteasome	O
,	O
but	O
evidence	O
for	O
SCF	O
(	O
TIR1	B-Protein
)	O
-	O
mediated	O
poly	O
-	O
ubiquitination	O
of	O
Aux	O
/	O
IAA	O
proteins	O
is	O
lacking	O
.	O

Here	O
we	O
used	O
an	O
Arabidopsis	O
cell	O
suspension	O
-	O
based	O
protoplast	O
system	O
to	O
find	O
evidence	O
for	O
SCF	O
(	O
TIR1	B-Protein
)	O
-	O
mediated	O
ubiquitination	O
of	O
the	O
Aux	O
/	O
IAA	O
proteins	O
SHY2	B-Protein
/	O
IAA3	B-Protein
and	O
BDL	B-Protein
/	O
IAA12	B-Protein
.	O

Each	O
of	O
these	O
proteins	O
showed	O
a	O
distinct	O
abundance	O
and	O
repressor	O
activity	O
when	O
expressed	O
in	O
this	O
cell	O
system	O
.	O

Moreover	O
,	O
the	O
amount	O
of	O
endogenous	O
TIR1	B-Protein
protein	O
appeared	O
to	O
be	O
rate	O
-	O
limiting	O
for	O
a	O
proper	O
auxin	O
response	O
measured	O
by	O
the	O
co	O
-	O
transfected	O
DR5	B-Protein
:	O
:	O
GUS	O
reporter	O
construct	O
.	O

Co	O
-	O
transfection	O
with	O
35S	O
:	O
:	O
TIR1	B-Protein
led	O
to	O
auxin	O
-	O
dependent	O
degradation	O
,	O
and	O
excess	O
of	O
35S	O
:	O
:	O
TIR1	B-Protein
even	O
led	O
to	O
degradation	O
of	O
Aux	O
/	O
IAAs	O
in	O
the	O
absence	O
of	O
auxin	O
treatment	O
.	O

Expression	O
of	O
the	O
mutant	O
tir1	B-Protein
-	I-Protein
1	I-Protein
protein	O
or	O
the	O
related	O
F	O
-	O
box	O
protein	O
COI1	B-Protein
,	O
which	O
is	O
involved	O
in	O
jasmonate	O
signaling	O
,	O
had	O
no	O
effect	O
on	O
Aux	O
/	O
IAA	O
degradation	O
.	O

Our	O
results	O
show	O
that	O
SHY2	B-Protein
/	O
IAA3	B-Protein
and	O
BDL	B-Protein
/	O
IAA12	B-Protein
are	O
poly	O
-	O
ubiquitinated	O
and	O
degraded	O
in	O
response	O
to	O
increased	O
auxin	O
or	O
TIR1	B-Protein
levels	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
provide	O
experimental	O
support	O
for	O
the	O
model	O
that	O
SCF	O
(	O
TIR1	B-Protein
)	O
-	O
dependent	O
poly	O
-	O
ubiquitination	O
of	O
Aux	O
/	O
IAA	O
proteins	O
marks	O
these	O
proteins	O
for	O
degradation	O
by	O
the	O
26S	O
proteasome	O
,	O
leading	O
to	O
activation	O
of	O
auxin	O
-	O
responsive	O
gene	O
expression	O
.	O

Masking	O
of	O
a	O
nuclear	O
signal	O
motif	O
by	O
monoubiquitination	O
leads	O
to	O
mislocalization	O
and	O
degradation	O
of	O
the	O
regulatory	O
enzyme	O
cytidylyltransferase	O
.	O

Monoubiquitination	O
aids	O
in	O
the	O
nuclear	O
export	O
and	O
entrance	O
of	O
proteins	O
into	O
the	O
lysosomal	O
degradative	O
pathway	O
,	O
although	O
the	O
mechanisms	O
are	O
unknown	O
.	O

Cytidylyltransferase	O
(	O
CCTalpha	B-Protein
)	O
is	O
a	O
proteolytically	O
sensitive	O
lipogenic	O
enzyme	O
containing	O
an	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
.	O

We	O
show	O
here	O
that	O
CCTalpha	B-Protein
is	O
monoubiquitinated	O
at	O
a	O
molecular	O
site	O
(	O
K	O
(	O
57	O
)	O
)	O
juxtaposed	O
near	O
its	O
NLS	O
,	O
resulting	O
in	O
disruption	O
of	O
its	O
interaction	O
with	O
importin	O
-	O
alpha	O
,	O
nuclear	O
exclusion	O
,	O
and	O
subsequent	O
degradation	O
within	O
the	O
lysosome	O
.	O

Cellular	O
expression	O
of	O
a	O
CCTalpha	B-Protein
-	O
ubiquitin	B-Protein
fusion	O
protein	O
that	O
mimics	O
the	O
monoubiquitinated	O
enzyme	O
resulted	O
in	O
cytoplasmic	O
retention	O
.	O

A	O
CCTalpha	B-Protein
K	O
(	O
57R	O
)	O
mutant	O
exhibited	O
an	O
extended	O
half	O
-	O
life	O
,	O
was	O
retained	O
in	O
the	O
nucleus	O
,	O
and	O
displayed	O
proteolytic	O
resistance	O
.	O

Importantly	O
,	O
by	O
using	O
CCTalpha	B-Protein
-	O
ubiquitin	B-Protein
hybrid	O
constructs	O
that	O
vary	O
in	O
the	O
intermolecular	O
distance	O
between	O
ubiquitin	B-Protein
and	O
the	O
NLS	O
,	O
we	O
show	O
that	O
CCTalpha	B-Protein
monoubiquitination	O
masks	O
its	O
NLS	O
,	O
resulting	O
in	O
cytoplasmic	O
retention	O
.	O

These	O
results	O
unravel	O
a	O
unique	O
molecular	O
mechanism	O
whereby	O
monoubiquitination	O
governs	O
the	O
trafficking	O
and	O
life	O
span	O
of	O
a	O
critical	O
regulatory	O
enzyme	O
in	O
vivo	O
.	O

The	O
roles	O
of	O
the	O
RAG1	B-Protein
and	O
RAG2	B-Protein
"	O
non	O
-	O
core	O
"	O
regions	O
in	O
V	O
(	O
D	O
)	O
J	O
recombination	O
and	O
lymphocyte	O
development	O
.	O

The	O
enormous	O
repertoire	O
of	O
the	O
vertebrate	O
specific	O
immune	O
system	O
relies	O
on	O
the	O
rearrangement	O
of	O
discrete	O
gene	O
segments	O
into	O
intact	O
antigen	O
receptor	O
genes	O
during	O
the	O
early	O
stages	O
of	O
B	O
-	O
and	O
T	O
-	O
cell	O
development	O
.	O

This	O
V	O
(	O
D	O
)	O
J	O
recombination	O
is	O
initiated	O
by	O
a	O
lymphoid	O
-	O
specific	O
recombinase	O
comprising	O
the	O
RAG1	B-Protein
and	O
RAG2	B-Protein
proteins	O
,	O
which	O
introduces	O
double	O
-	O
strand	O
breaks	O
in	O
the	O
DNA	O
adjacent	O
to	O
the	O
coding	O
segments	O
.	O

Much	O
of	O
the	O
biochemical	O
research	O
into	O
V	O
(	O
D	O
)	O
J	O
recombination	O
has	O
focused	O
on	O
truncated	O
or	O
"	O
core	O
"	O
fragments	O
of	O
RAG1	B-Protein
and	O
RAG2	B-Protein
,	O
which	O
lack	O
approximately	O
one	O
third	O
of	O
the	O
amino	O
acids	O
from	O
each	O
.	O

However	O
,	O
genetic	O
analyses	O
of	O
SCID	O
and	O
Omenn	O
syndrome	O
patients	O
indicate	O
that	O
residues	O
outside	O
the	O
cores	O
are	O
essential	O
to	O
normal	O
immune	O
development	O
.	O

This	O
is	O
in	O
agreement	O
with	O
the	O
striking	O
degree	O
of	O
conservation	O
across	O
all	O
vertebrate	O
classes	O
in	O
certain	O
non	O
-	O
core	O
domains	O
.	O

Work	O
from	O
multiple	O
laboratories	O
has	O
shed	O
light	O
on	O
activities	O
resident	O
within	O
these	O
domains	O
,	O
including	O
ubiquitin	B-Protein
ligase	O
activity	O
and	O
KPNA1	B-Protein
binding	O
by	O
the	O
RING	O
finger	O
domain	O
of	O
RAG1	B-Protein
and	O
the	O
recognition	O
of	O
specific	O
chromatin	O
modifications	O
as	O
well	O
as	O
phosphoinositide	O
binding	O
by	O
the	O
PHD	O
module	O
of	O
RAG2	B-Protein
.	O

In	O
addition	O
,	O
elements	O
outside	O
of	O
the	O
cores	O
are	O
necessary	O
for	O
regulated	O
protein	O
expression	O
and	O
turnover	O
.	O

Here	O
the	O
current	O
state	O
of	O
knowledge	O
is	O
reviewed	O
regarding	O
the	O
non	O
-	O
core	O
regions	O
of	O
RAG1	B-Protein
and	O
RAG2	B-Protein
and	O
how	O
these	O
findings	O
contribute	O
to	O
our	O
broader	O
understanding	O
of	O
recombination	O
.	O

Aberrant	O
regulation	O
of	O
pVHL	B-Protein
levels	O
by	O
microRNA	O
promotes	O
the	O
HIF	O
/	O
VEGF	B-Protein
axis	O
in	O
CLL	O
B	O
cells	O
.	O

The	O
molecular	O
mechanism	O
of	O
autocrine	O
regulation	O
of	O
vascular	B-Protein
endothelial	I-Protein
growth	I-Protein
factor	I-Protein
(	O
VEGF	B-Protein
)	O
in	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
B	O
cells	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
that	O
CLL	O
B	O
cells	O
express	O
constitutive	O
levels	O
of	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
under	O
normoxia	O
.	O

We	O
have	O
examined	O
the	O
status	O
of	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
gene	O
product	O
(	O
pVHL	B-Protein
)	O
that	O
is	O
responsible	O
for	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
degradation	O
and	O
found	O
it	O
to	O
be	O
at	O
a	O
notably	O
low	O
level	O
in	O
CLL	O
B	O
cells	O
compared	O
with	O
normal	O
B	O
cells	O
.	O

We	O
demonstrate	O
that	O
the	O
microRNA	O
,	O
miR	B-Protein
-	I-Protein
92	I-Protein
-	I-Protein
1	I-Protein
,	O
overexpressed	O
in	O
CLL	O
B	O
cells	O
,	O
can	O
target	O
the	O
VHL	B-Protein
transcript	O
to	O
repress	O
its	O
expression	O
.	O

We	O
found	O
that	O
the	O
stabilized	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
can	O
form	O
an	O
active	O
complex	O
with	O
the	O
transcriptional	O
coactivator	O
p300	B-Protein
and	O
phosphorylated	O
-	O
STAT3	B-Protein
at	O
the	O
VEGF	B-Protein
promoter	O
and	O
recruit	O
RNA	O
polymerase	O
II	O
.	O

This	O
is	O
initial	O
evidence	O
that	O
pVHL	B-Protein
,	O
without	O
any	O
genetic	O
alteration	O
,	O
can	O
be	O
regulated	O
by	O
microRNA	O
and	O
explains	O
the	O
aberrant	O
autocrine	O
VEGF	B-Protein
secretion	O
in	O
CLL	O
.	O

Targeting	O
protein	O
ubiquitylation	O
:	O
DDB1	B-Protein
takes	O
its	O
RING	O
off	O
.	O

Ubiquitin	B-Protein
E3	O
ligases	O
of	O
the	O
RING	O
and	O
HECT	O
families	O
are	O
distinct	O
not	O
only	O
in	O
their	O
catalytic	O
mechanisms	O
but	O
also	O
in	O
targeting	O
substrates	O
.	O

Now	O
it	O
seems	O
that	O
one	O
heterodimeric	O
complex	O
can	O
target	O
substrates	O
to	O
both	O
types	O
of	O
E3	O
ligase	O
.	O

Inefficient	O
quality	O
control	O
of	O
thermosensitive	O
proteins	O
on	O
the	O
plasma	O
membrane	O
.	O

BACKGROUND	O
:	O
Misfolded	O
proteins	O
are	O
generally	O
recognised	O
by	O
cellular	O
quality	O
control	O
machinery	O
,	O
which	O
typically	O
results	O
in	O
their	O
ubiquitination	O
and	O
degradation	O
.	O

For	O
soluble	O
cytoplasmic	O
proteins	O
,	O
degradation	O
is	O
mediated	O
by	O
the	O
proteasome	O
.	O

Membrane	O
proteins	O
that	O
fail	O
to	O
fold	O
correctly	O
are	O
subject	O
to	O
ER	O
associated	O
degradation	O
(	O
ERAD	O
)	O
,	O
which	O
involves	O
their	O
extraction	O
from	O
the	O
membrane	O
and	O
subsequent	O
proteasome	O
-	O
dependent	O
destruction	O
.	O

Proteins	O
with	O
abnormal	O
transmembrane	O
domains	O
can	O
also	O
be	O
recognised	O
in	O
the	O
Golgi	O
or	O
endosomal	O
system	O
and	O
targeted	O
for	O
destruction	O
in	O
the	O
vacuole	O
/	O
lysosome	O
.	O

It	O
is	O
much	O
less	O
clear	O
what	O
happens	O
to	O
membrane	O
proteins	O
that	O
reach	O
their	O
destination	O
,	O
such	O
as	O
the	O
cell	O
surface	O
,	O
and	O
then	O
suffer	O
damage	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
have	O
tested	O
the	O
ability	O
of	O
yeast	O
cells	O
to	O
degrade	O
membrane	O
proteins	O
to	O
which	O
temperature	O
-	O
sensitive	O
cytoplasmic	O
alleles	O
of	O
the	O
Ura3	B-Protein
protein	O
or	O
of	O
phage	O
lambda	O
repressor	O
have	O
been	O
fused	O
.	O

In	O
soluble	O
form	O
,	O
these	O
proteins	O
are	O
rapidly	O
degraded	O
upon	O
temperature	O
shift	O
,	O
in	O
part	O
due	O
to	O
the	O
action	O
of	O
the	O
Doa10	B-Protein
and	O
San1	B-Protein
ubiquitin	B-Protein
ligases	O
and	O
the	O
proteasome	O
.	O

When	O
tethered	O
to	O
the	O
ER	O
protein	O
Use1	B-Protein
,	O
they	O
are	O
also	O
degraded	O
.	O

However	O
,	O
when	O
tethered	O
to	O
a	O
plasma	O
membrane	O
protein	O
such	O
as	O
Sso1	B-Protein
they	O
escape	O
degradation	O
,	O
either	O
in	O
the	O
vacuole	O
or	O
by	O
the	O
proteasome	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Membrane	O
proteins	O
with	O
a	O
misfolded	O
cytoplasmic	O
domain	O
appear	O
not	O
to	O
be	O
efficiently	O
recognised	O
and	O
degraded	O
once	O
they	O
have	O
escaped	O
the	O
ER	O
,	O
even	O
though	O
their	O
defective	O
domains	O
are	O
exposed	O
to	O
the	O
cytoplasm	O
and	O
potentially	O
to	O
cytoplasmic	O
quality	O
controls	O
.	O

Membrane	O
tethering	O
may	O
provide	O
a	O
way	O
to	O
reduce	O
degradation	O
of	O
unstable	O
proteins	O
.	O

Acetylation	O
by	O
GCN5	B-Protein
regulates	O
CDC6	B-Protein
phosphorylation	O
in	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
eukaryotic	O
cells	O
,	O
the	O
cell	B-Protein
-	I-Protein
division	I-Protein
cycle	I-Protein
(	I-Protein
CDC	I-Protein
)	I-Protein
-	I-Protein
6	I-Protein
protein	O
is	O
essential	O
to	O
promote	O
the	O
assembly	O
of	O
pre	O
-	O
replicative	O
complexes	O
in	O
the	O
early	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
a	O
process	O
requiring	O
tight	O
regulation	O
to	O
ensure	O
that	O
proper	O
origin	O
licensing	O
occurs	O
once	O
per	O
cell	O
cycle	O
.	O

Here	O
we	O
show	O
that	O
,	O
in	O
late	O
G1	O
and	O
early	O
S	O
phase	O
,	O
CDC6	B-Protein
is	O
found	O
in	O
a	O
complex	O
also	O
containing	O
Cyclin	B-Protein
A	I-Protein
,	O
cyclin	B-Protein
-	I-Protein
dependent	I-Protein
kinase	I-Protein
(	I-Protein
CDK	I-Protein
)	I-Protein
-	I-Protein
2	I-Protein
and	O
the	O
acetyltransferase	O
general	B-Protein
control	I-Protein
nonderepressible	I-Protein
5	I-Protein
(	O
GCN5	B-Protein
)	O
.	O

GCN5	B-Protein
specifically	O
acetylates	O
CDC6	B-Protein
at	O
three	O
lysine	O
residues	O
flanking	O
its	O
cyclin	O
-	O
docking	O
motif	O
,	O
and	O
this	O
modification	O
is	O
crucial	O
for	O
the	O
subsequent	O
phosphorylation	O
of	O
the	O
protein	O
by	O
Cyclin	B-Protein
A	I-Protein
-	O
CDKs	O
at	O
a	O
specific	O
residue	O
close	O
to	O
the	O
acetylation	O
site	O
.	O

GCN5	B-Protein
-	O
mediated	O
acetylation	O
and	O
site	O
-	O
specific	O
phosphorylation	O
of	O
CDC6	B-Protein
are	O
both	O
necessary	O
for	O
the	O
relocalization	O
of	O
the	O
protein	O
to	O
the	O
cell	O
cytoplasm	O
in	O
the	O
S	O
phase	O
,	O
as	O
well	O
as	O
to	O
regulate	O
its	O
stability	O
.	O

This	O
two	O
-	O
step	O
,	O
intramolecular	O
regulatory	O
program	O
by	O
sequential	O
modification	O
of	O
CDC6	B-Protein
seems	O
to	O
be	O
essential	O
for	O
proper	O
S	O
-	O
phase	O
progression	O
.	O

A	O
methyltransferase	O
-	O
independent	O
function	O
for	O
Rmt3	B-Protein
in	O
ribosomal	O
subunit	O
homeostasis	O
.	O

Schizosaccharomyces	O
pombe	O
Rmt3	B-Protein
is	O
a	O
member	O
of	O
the	O
protein	O
-	O
arginine	O
methyltransferase	O
(	O
PRMT	O
)	O
family	O
and	O
is	O
the	O
homolog	O
of	O
human	O
PRMT3	B-Protein
.	O

We	O
previously	O
characterized	O
Rmt3	B-Protein
as	O
a	O
ribosomal	O
protein	O
methyltransferase	O
based	O
on	O
the	O
identification	O
of	O
the	O
40	O
S	O
Rps2	B-Protein
(	O
ribosomal	B-Protein
protein	I-Protein
S2	I-Protein
)	O
as	O
a	O
substrate	O
of	O
Rmt3	B-Protein
.	O

RMT3	B-Protein
-	O
null	O
cells	O
produce	O
nonmethylated	O
Rps2	B-Protein
and	O
show	O
mis	O
-	O
regulation	O
of	O
the	O
40	O
S	O
/	O
60	O
S	O
ribosomal	O
subunit	O
ratio	O
due	O
to	O
a	O
small	O
subunit	O
deficit	O
.	O

For	O
this	O
study	O
,	O
we	O
have	O
generated	O
a	O
series	O
of	O
RMT3	B-Protein
alleles	O
that	O
express	O
various	O
amino	O
acid	O
substitutions	O
to	O
characterize	O
the	O
functional	O
domains	O
of	O
Rmt3	B-Protein
in	O
Rps2	B-Protein
binding	O
,	O
Rps2	B-Protein
arginine	O
methylation	O
,	O
and	O
small	O
ribosomal	O
subunit	O
production	O
.	O

Notably	O
,	O
catalytically	O
inactive	O
versions	O
of	O
Rmt3	B-Protein
restored	O
the	O
ribosomal	O
subunit	O
imbalance	O
detected	O
in	O
RMT3	B-Protein
-	O
null	O
cells	O
.	O

Consistent	O
with	O
a	O
methyltransferase	O
-	O
independent	O
function	O
for	O
Rmt3	B-Protein
in	O
small	O
ribosomal	O
subunit	O
production	O
,	O
the	O
expression	O
of	O
an	O
Rps2	B-Protein
variant	O
in	O
which	O
the	O
identified	O
methylarginine	O
residues	O
were	O
substituted	O
with	O
lysines	O
showed	O
normal	O
levels	O
of	O
40	O
S	O
subunit	O
.	O

Importantly	O
,	O
substitutions	O
within	O
the	O
zinc	O
finger	O
domain	O
of	O
Rmt3	B-Protein
that	O
abolished	O
Rps2	B-Protein
binding	O
did	O
not	O
rescue	O
the	O
40	O
S	O
ribosomal	O
subunit	O
deficit	O
of	O
RMT3	B-Protein
-	O
null	O
cells	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
Rmt3	B-Protein
-	O
Rps2	B-Protein
interaction	O
,	O
rather	O
than	O
Rps2	B-Protein
methylation	O
,	O
is	O
important	O
for	O
the	O
function	O
of	O
Rmt3	B-Protein
in	O
the	O
regulation	O
of	O
small	O
ribosomal	O
subunit	O
production	O
.	O

CHIP	B-Protein
facilitates	O
ubiquitination	O
of	O
inducible	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
and	O
promotes	O
its	O
proteasomal	O
degradation	O
.	O

Inducible	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
(	O
iNOS	B-Protein
)	O
is	O
responsible	O
for	O
nitric	O
oxide	O
(	O
NO	O
)	O
synthesis	O
from	O
l	O
-	O
arginine	O
in	O
response	O
to	O
inflammatory	O
mediators	O
.	O

It	O
is	O
reported	O
that	O
iNOS	B-Protein
is	O
degraded	O
mainly	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
in	O
RAW264	O
.	O
7	O
cells	O
and	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
293	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
iNOS	B-Protein
was	O
ubiquitinated	O
and	O
degraded	O
dependent	O
on	O
CHIP	B-Protein
(	O
COOH	B-Protein
terminus	I-Protein
of	I-Protein
heat	I-Protein
shock	I-Protein
protein	I-Protein
70	I-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
)	O
,	O
a	O
chaperone	O
-	O
dependent	O
ubiquitin	B-Protein
ligase	O
.	O

The	O
results	O
from	O
overexpression	O
and	O
RNAi	O
experiments	O
demonstrated	O
that	O
CHIP	B-Protein
decreased	O
the	O
protein	O
level	O
of	O
iNOS	B-Protein
,	O
shortened	O
the	O
half	O
-	O
life	O
of	O
iNOS	B-Protein
and	O
attenuated	O
the	O
production	O
of	O
NO	O
.	O

Furthermore	O
,	O
CHIP	B-Protein
promoted	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
iNOS	B-Protein
by	O
associating	O
with	O
iNOS	B-Protein
.	O

These	O
results	O
suggest	O
that	O
CHIP	B-Protein
plays	O
an	O
important	O
role	O
in	O
regulation	O
iNOS	B-Protein
activity	O
.	O

Epigenetic	O
inheritance	O
through	O
self	O
-	O
recruitment	O
of	O
the	O
polycomb	O
repressive	O
complex	O
2	O
.	O

Maintenance	O
of	O
gene	O
expression	O
through	O
epigenetic	O
mechanisms	O
such	O
as	O
DNA	O
-	O
and	O
histone	B-Protein
-	O
methylation	O
is	O
essential	O
for	O
preserving	O
cellular	O
identity	O
and	O
function	O
.	O

Multiplication	O
of	O
eukaryotic	O
cells	O
requires	O
that	O
the	O
DNA	O
content	O
of	O
the	O
cell	O
is	O
duplicated	O
through	O
replication	O
,	O
which	O
is	O
coupled	O
to	O
incorporation	O
of	O
de	O
novo	O
synthesized	O
core	O
histones	B-Protein
into	O
nucleosomal	O
structures	O
.	O

One	O
of	O
the	O
challenging	O
questions	O
in	O
biology	O
is	O
to	O
explain	O
how	O
the	O
organism	O
ensures	O
that	O
regulatory	O
epigenetic	O
marks	O
,	O
once	O
established	O
,	O
are	O
transferred	O
from	O
one	O
cell	O
generation	O
to	O
the	O
next	O
.	O

Based	O
on	O
studies	O
in	O
our	O
laboratory	O
,	O
we	O
have	O
recently	O
proposed	O
a	O
model	O
for	O
how	O
the	O
methylated	O
lysine	O
27	O
of	O
histone	B-Protein
H3	I-Protein
(	O
H3K27	B-Protein
)	O
can	O
be	O
stably	O
transmitted	O
through	O
the	O
cell	O
division	O
cycle	O
.	O

We	O
found	O
that	O
the	O
Polycomb	O
Repressive	O
Complex	O
2	O
(	O
PRC2	O
)	O
,	O
which	O
is	O
responsible	O
for	O
di	O
-	O
and	O
trimethylation	O
of	O
H3K27	B-Protein
(	O
H3K27me2	B-Protein
/	O
me3	O
)	O
,	O
binds	O
to	O
its	O
own	O
site	O
of	O
methylation	O
.	O

Moreover	O
,	O
our	O
results	O
suggested	O
that	O
maintenance	O
of	O
transcriptional	O
repression	O
by	O
PRC2	O
requires	O
the	O
binding	O
of	O
the	O
PRC2	O
complex	O
to	O
H3K27me3	B-Protein
/	O
me2	O
.	O

Based	O
on	O
these	O
two	O
key	O
observations	O
we	O
propose	O
that	O
PRC2	O
is	O
able	O
to	O
copy	O
the	O
mark	O
from	O
an	O
old	O
parental	O
H3	B-Protein
molecule	O
to	O
a	O
newly	O
synthesized	O
H3	B-Protein
molecule	O
as	O
DNA	O
replication	O
proceeds	O
.	O

In	O
addition	O
,	O
our	O
results	O
support	O
a	O
model	O
for	O
how	O
the	O
H3K27me3	B-Protein
mark	O
could	O
be	O
preserved	O
in	O
the	O
interphase	O
of	O
the	O
cell	O
cycle	O
,	O
where	O
other	O
events	O
such	O
as	O
histone	B-Protein
exchange	O
and	O
demethylation	O
could	O
counteract	O
PRC2	O
function	O
.	O

Here	O
we	O
discuss	O
the	O
implications	O
of	O
our	O
results	O
in	O
further	O
detail	O
.	O

In	O
vitro	O
histone	B-Protein
demethylase	O
assays	O
.	O

Histone	B-Protein
methylation	O
plays	O
important	O
roles	O
in	O
chromatin	O
structure	O
,	O
transcription	O
,	O
and	O
epigenetic	O
state	O
of	O
the	O
cell	O
.	O

Tremendous	O
discoveries	O
recently	O
demonstrated	O
that	O
methylation	O
mark	O
is	O
not	O
static	O
but	O
is	O
dynamically	O
regulated	O
by	O
both	O
histone	B-Protein
methyltransferases	O
and	O
the	O
histone	B-Protein
demethylases	O
.	O

Two	O
families	O
of	O
histone	B-Protein
demethylases	O
have	O
been	O
identified	O
to	O
remove	O
methyl	O
groups	O
from	O
lysine	O
side	O
chain	O
through	O
different	O
reaction	O
mechanisms	O
in	O
presence	O
of	O
distinct	O
cofactors	O
.	O

Amine	O
oxidase	O
LSD1	B-Protein
family	O
requires	O
flavin	O
adenine	O
dinucleotide	O
(	O
FAD	O
)	O
whereas	O
dioxygenase	O
Jmjc	O
domain	O
-	O
containing	O
proteins	O
family	O
relies	O
on	O
Fe	O
(	O
II	O
)	O
and	O
alpha	O
-	O
ketoglutarate	O
.	O

Identification	O
of	O
these	O
enzymes	O
opened	O
a	O
new	O
era	O
in	O
understanding	O
how	O
chromatin	O
dynamic	O
is	O
regulated	O
and	O
further	O
understanding	O
the	O
regulation	O
of	O
these	O
enzymes	O
will	O
provide	O
significant	O
insights	O
into	O
fundamental	O
mechanisms	O
of	O
many	O
biological	O
processes	O
and	O
human	O
diseases	O
.	O

This	O
chapter	O
describes	O
different	O
assay	O
conditions	O
and	O
detection	O
methods	O
for	O
different	O
family	O
of	O
histone	B-Protein
demethylases	O
.	O

We	O
also	O
summarize	O
step	O
-	O
by	O
-	O
step	O
protocols	O
for	O
purification	O
and	O
preparation	O
of	O
various	O
histone	B-Protein
substrates	O
for	O
histone	B-Protein
demethylase	O
assays	O
.	O

Evolution	O
of	O
a	O
histone	B-Protein
H4	I-Protein
-	O
K16	O
acetyl	O
-	O
specific	O
DNA	O
aptamer	O
.	O

We	O
report	O
the	O
in	O
vitro	O
selection	O
of	O
DNA	O
aptamers	O
that	O
bind	O
to	O
histone	B-Protein
H4	I-Protein
proteins	O
acetylated	O
at	O
lysine	O
16	O
.	O

The	O
best	O
aptamer	O
identified	O
in	O
this	O
selection	O
binds	O
to	O
the	O
target	O
protein	O
with	O
a	O
K	O
(	O
d	O
)	O
of	O
21	O
nM	O
and	O
discriminates	O
against	O
both	O
the	O
nonacetylated	O
protein	O
and	O
histone	B-Protein
H4	I-Protein
proteins	O
acetylated	O
at	O
lysine	O
8	O
.	O

Comparative	O
binding	O
assays	O
performed	O
with	O
a	O
chip	O
-	O
quality	O
antibody	O
reveal	O
that	O
this	O
aptamer	O
binds	O
to	O
the	O
acetylated	O
histone	B-Protein
target	O
with	O
similar	O
affinity	O
to	O
a	O
commercial	O
antibody	O
but	O
shows	O
significantly	O
greater	O
specificity	O
(	O
15	O
-	O
fold	O
versus	O
2400	O
-	O
fold	O
)	O
for	O
the	O
target	O
molecule	O
.	O

This	O
result	O
demonstrates	O
that	O
aptamers	O
that	O
are	O
both	O
modification	O
and	O
location	O
specific	O
can	O
be	O
generated	O
to	O
bind	O
specific	O
protein	O
post	O
-	O
translational	O
modifications	O
.	O

Peroxisome	B-Protein
proliferator	I-Protein
-	I-Protein
activated	I-Protein
receptor	I-Protein
-	I-Protein
gamma	I-Protein
abrogates	O
Smad	O
-	O
dependent	O
collagen	O
stimulation	O
by	O
targeting	O
the	O
p300	B-Protein
transcriptional	O
coactivator	O
.	O

Ligands	O
of	O
peroxisome	B-Protein
proliferator	I-Protein
-	I-Protein
activated	I-Protein
receptor	I-Protein
-	I-Protein
gamma	I-Protein
(	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
)	O
abrogate	O
the	O
stimulation	O
of	O
collagen	O
gene	O
transcription	O
induced	O
by	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
.	O

Here	O
,	O
we	O
delineate	O
the	O
mechanisms	O
underlying	O
this	O
important	O
novel	O
physiological	O
function	O
for	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
in	O
connective	O
tissue	O
homeostasis	O
.	O

First	O
,	O
we	O
demonstrated	O
that	O
antagonistic	O
regulation	O
of	O
TGF	O
-	O
beta	O
activity	O
by	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
ligands	O
involves	O
cellular	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
,	O
since	O
15	O
-	O
deoxy	O
-	O
Delta12	O
,	O
14	O
-	O
prostaglandin	O
J	O
(	O
2	O
)	O
(	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
)	O
failed	O
to	O
block	O
TGF	O
-	O
beta	O
-	O
induced	O
responses	O
in	O
either	O
primary	O
cultures	O
of	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
-	O
null	O
murine	O
embryonic	O
fibroblasts	O
,	O
or	O
in	O
normal	O
human	O
skin	O
fibroblasts	O
with	O
RNAi	O
-	O
mediated	O
knockdown	O
of	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
.	O

Next	O
,	O
we	O
examined	O
the	O
molecular	O
basis	O
underlying	O
the	O
abrogation	O
of	O
TGF	O
-	O
beta	O
signaling	O
by	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
in	O
normal	O
human	O
fibroblasts	O
in	O
culture	O
.	O

The	O
results	O
demonstrated	O
that	O
Smad	O
-	O
dependent	O
transcriptional	O
responses	O
were	O
blocked	O
by	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
without	O
preventing	O
Smad2	B-Protein
/	O
3	B-Protein
activation	O
.	O

In	O
contrast	O
,	O
the	O
interaction	O
between	O
activated	O
Smad2	B-Protein
/	O
3	B-Protein
and	O
the	O
transcriptional	O
coactivator	O
and	O
histone	B-Protein
acetyltransferase	O
p300	B-Protein
induced	O
by	O
TGF	O
-	O
beta	O
,	O
and	O
the	O
accumulation	O
of	O
p300	B-Protein
on	O
consensus	O
Smad	O
-	O
binding	O
DNA	O
sequences	O
and	O
histone	B-Protein
H4	I-Protein
hyperacetylation	O
at	O
the	O
COL1A2	B-Protein
locus	O
,	O
were	O
all	O
prevented	O
by	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
.	O

Wild	O
-	O
type	O
p300	B-Protein
,	O
but	O
not	O
a	O
mutant	O
form	O
of	O
p300	B-Protein
lacking	O
functional	O
histone	B-Protein
acetyltransferase	O
,	O
was	O
able	O
to	O
restore	O
TGF	O
-	O
beta	O
-	O
induced	O
stimulation	O
of	O
COL1A2	B-Protein
in	O
the	O
presence	O
of	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
ligands	O
.	O

Collectively	O
,	O
these	O
results	O
indicate	O
that	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
blocked	O
Smad	O
-	O
mediated	O
transcriptional	O
responses	O
by	O
preventing	O
p300	B-Protein
recruitment	O
and	O
histone	B-Protein
H4	I-Protein
hyperacetylation	O
,	O
resulting	O
in	O
the	O
inhibition	O
of	O
TGF	O
-	O
beta	O
-	O
induced	O
collagen	O
gene	O
expression	O
.	O

Pharmacological	O
activation	O
of	O
PPAR	B-Protein
-	I-Protein
gamma	I-Protein
thus	O
may	O
represent	O
a	O
novel	O
therapeutic	O
approach	O
to	O
target	O
p300	B-Protein
-	O
dependent	O
TGF	O
-	O
beta	O
profibrotic	O
responses	O
such	O
as	O
stimulation	O
of	O
collagen	O
gene	O
expression	O
.	O

NBR1	B-Protein
cooperates	O
with	O
p62	B-Protein
in	O
selective	O
autophagy	O
of	O
ubiquitinated	O
targets	O
.	O

Selective	O
degradation	O
of	O
intracellular	O
targets	O
,	O
such	O
as	O
misfolded	O
proteins	O
and	O
damaged	O
organelles	O
,	O
is	O
an	O
important	O
homeostatic	O
function	O
that	O
autophagy	O
has	O
acquired	O
in	O
addition	O
to	O
its	O
more	O
general	O
role	O
in	O
restoring	O
the	O
nutrient	O
balance	O
during	O
stress	O
and	O
starvation	O
.	O

Although	O
the	O
exact	O
mechanism	O
underlying	O
selection	O
of	O
autophagic	O
substrates	O
is	O
not	O
known	O
,	O
ubiquitination	O
is	O
a	O
candidate	O
signal	O
for	O
autophagic	O
degradation	O
of	O
misfolded	O
and	O
aggregated	O
proteins	O
.	O

p62	B-Protein
/	O
SQSTM1	B-Protein
was	O
the	O
first	O
protein	O
shown	O
to	O
bind	O
both	O
target	O
-	O
associated	O
ubiquitin	B-Protein
(	O
Ub	B-Protein
)	O
and	O
LC3	O
conjugated	O
to	O
the	O
phagophore	O
membrane	O
,	O
thereby	O
effectively	O
acting	O
as	O
an	O
autophagic	O
receptor	O
for	O
ubiquitinated	O
targets	O
.	O

Importantly	O
,	O
p62	B-Protein
not	O
only	O
mediates	O
selective	O
degradation	O
but	O
also	O
promotes	O
aggregation	O
of	O
ubiquitinated	O
proteins	O
that	O
can	O
be	O
harmful	O
in	O
some	O
cell	O
types	O
.	O

Is	O
p62	B-Protein
the	O
only	O
autophagic	O
receptor	O
for	O
selective	O
autophagy	O
?	O

Looking	O
for	O
proteins	O
that	O
interact	O
with	O
ATG8	O
family	O
proteins	O
,	O
we	O
identified	O
NBR1	B-Protein
(	O
neighbor	B-Protein
of	I-Protein
BRCA1	I-Protein
gene	I-Protein
1	I-Protein
)	O
as	O
an	O
additional	O
LC3	O
-	O
and	O
Ub	B-Protein
-	O
binding	O
protein	O
.	O

NBR1	B-Protein
is	O
degraded	O
by	O
autophagy	O
depending	O
on	O
its	O
LC3	O
-	O
interacting	O
region	O
(	O
LIR	O
)	O
but	O
does	O
not	O
strictly	O
require	O
p62	B-Protein
for	O
this	O
process	O
.	O

Like	O
p62	B-Protein
,	O
NBR1	B-Protein
accumulates	O
and	O
aggregates	O
when	O
autophagy	O
is	O
inhibited	O
and	O
is	O
a	O
part	O
of	O
pathological	O
inclusions	O
.	O

We	O
propose	O
that	O
NBR1	B-Protein
together	O
with	O
p62	B-Protein
promotes	O
autophagic	O
degradation	O
of	O
ubiquitinated	O
targets	O
and	O
simultaneously	O
regulates	O
their	O
aggregation	O
when	O
autophagy	O
becomes	O
limited	O
.	O

BubR1	B-Protein
acetylation	O
at	O
prometaphase	O
is	O
required	O
for	O
modulating	O
APC	O
/	O
C	O
activity	O
and	O
timing	O
of	O
mitosis	O
.	O

Regulation	O
of	O
BubR1	B-Protein
is	O
central	O
to	O
the	O
control	O
of	O
APC	O
/	O
C	O
activity	O
.	O

We	O
have	O
found	O
that	O
BubR1	B-Protein
forms	O
a	O
complex	O
with	O
PCAF	B-Protein
and	O
is	O
acetylated	O
at	O
lysine	O
250	O
.	O

Using	O
mass	O
spectrometry	O
and	O
acetylated	O
BubR1	B-Protein
-	O
specific	O
antibodies	O
,	O
we	O
have	O
confirmed	O
that	O
BubR1	B-Protein
acetylation	O
occurs	O
at	O
prometaphase	O
.	O

Importantly	O
,	O
BubR1	B-Protein
acetylation	O
was	O
required	O
for	O
checkpoint	O
function	O
,	O
through	O
the	O
inhibition	O
of	O
ubiquitin	B-Protein
-	O
dependent	O
BubR1	B-Protein
degradation	O
.	O

BubR1	B-Protein
degradation	O
began	O
before	O
the	O
onset	O
of	O
anaphase	O
.	O

It	O
was	O
noted	O
that	O
the	O
pre	O
-	O
anaphase	O
degradation	O
was	O
regulated	O
by	O
BubR1	B-Protein
acetylation	O
.	O

Degradation	O
of	O
an	O
acetylation	O
-	O
mimetic	O
form	O
,	O
BubR1	B-Protein
-	O
K250Q	O
,	O
was	O
inhibited	O
and	O
chromosome	O
segregation	O
in	O
cells	O
expressing	O
BubR1	B-Protein
-	O
K250Q	O
was	O
markedly	O
delayed	O
.	O

By	O
contrast	O
,	O
the	O
acetylation	O
-	O
deficient	O
mutant	O
,	O
BubR1	B-Protein
-	O
K250R	O
,	O
was	O
unstable	O
,	O
and	O
mitosis	O
was	O
accelerated	O
in	O
BubR1	B-Protein
-	O
K250R	O
-	O
expressing	O
cells	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
APC	O
/	O
C	O
-	O
Cdc20	B-Protein
was	O
responsible	O
for	O
BubR1	B-Protein
degradation	O
during	O
mitosis	O
.	O

On	O
the	O
basis	O
of	O
our	O
collective	O
results	O
,	O
we	O
propose	O
that	O
the	O
acetylation	O
status	O
of	O
BubR1	B-Protein
is	O
a	O
molecular	O
switch	O
that	O
converts	O
BubR1	B-Protein
from	O
an	O
inhibitor	O
to	O
a	O
substrate	O
of	O
the	O
APC	O
/	O
C	O
complex	O
,	O
thus	O
providing	O
an	O
efficient	O
way	O
to	O
modulate	O
APC	O
/	O
C	O
activity	O
and	O
mitotic	O
timing	O
.	O

Mechanism	O
of	O
hypoxia	O
-	O
induced	O
GCM1	B-Protein
degradation	O
:	O
implications	O
for	O
the	O
pathogenesis	O
of	O
preeclampsia	O
.	O

Preeclampsia	O
is	O
a	O
major	O
pregnancy	O
-	O
specific	O
disorder	O
affecting	O
5	O
-	O
7	O
%	O
of	O
pregnancies	O
worldwide	O
.	O

Although	O
hypoxia	O
caused	O
by	O
incomplete	O
trophoblast	O
invasion	O
and	O
impaired	O
spiral	O
arterial	O
remodeling	O
is	O
thought	O
to	O
be	O
a	O
major	O
cause	O
of	O
preeclampsia	O
,	O
how	O
hypoxia	O
affects	O
placental	O
development	O
remains	O
uncertain	O
.	O

GCM1	B-Protein
(	O
glial	B-Protein
cells	I-Protein
missing	I-Protein
homolog	I-Protein
1	I-Protein
)	O
is	O
a	O
transcription	O
factor	O
critical	O
for	O
placental	O
development	O
.	O

In	O
preeclampsia	O
,	O
GCM1	B-Protein
and	O
its	O
target	O
genes	O
syncytin	B-Protein
1	I-Protein
and	O
placental	B-Protein
growth	I-Protein
factor	I-Protein
,	O
important	O
for	O
syncytiotrophoblast	O
formation	O
and	O
placental	O
vasculogenesis	O
,	O
are	O
all	O
decreased	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
GCM1	B-Protein
is	O
a	O
major	O
target	O
of	O
hypoxia	O
associated	O
with	O
preeclampsia	O
.	O

We	O
show	O
that	O
hypoxia	O
triggers	O
GCM1	B-Protein
degradation	O
by	O
suppressing	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
-	O
Akt	O
signaling	O
pathway	O
,	O
leading	O
to	O
GSK	B-Protein
-	I-Protein
3beta	I-Protein
activation	O
.	O

Activated	O
GSK	B-Protein
-	I-Protein
3beta	I-Protein
phosphorylates	O
GCM1	B-Protein
on	O
Ser322	O
,	O
which	O
in	O
turn	O
recruits	O
the	O
F	O
-	O
box	O
protein	O
FBW2	B-Protein
,	O
leading	O
to	O
GCM1	B-Protein
ubiquitination	O
and	O
degradation	O
.	O

Importantly	O
,	O
the	O
GSK	B-Protein
-	I-Protein
3beta	I-Protein
inhibitor	O
LiCl	O
prevented	O
hypoxia	O
-	O
induced	O
GCM1	B-Protein
degradation	O
.	O

Our	O
study	O
identifies	O
a	O
molecular	O
basis	O
for	O
the	O
disrupted	O
GCM1	B-Protein
transcription	O
network	O
in	O
preeclampsia	O
and	O
provides	O
a	O
potential	O
avenue	O
for	O
therapeutic	O
intervention	O
.	O

Nedd4	B-Protein
-	I-Protein
2	I-Protein
-	O
mediated	O
ubiquitination	O
facilitates	O
processing	O
of	O
surfactant	B-Protein
protein	I-Protein
-	I-Protein
C	I-Protein
.	O

We	O
previously	O
proposed	O
a	O
model	O
of	O
surfactant	B-Protein
protein	I-Protein
(	I-Protein
SP	I-Protein
)	I-Protein
-	I-Protein
C	I-Protein
biosynthesis	O
in	O
which	O
internalization	O
of	O
the	O
proprotein	O
from	O
the	O
limiting	O
membrane	O
of	O
the	O
multivesicular	O
body	O
to	O
internal	O
vesicles	O
represents	O
a	O
key	O
step	O
in	O
the	O
processing	O
and	O
secretion	O
of	O
SP	B-Protein
-	I-Protein
C	I-Protein
.	O

To	O
test	O
this	O
hypothesis	O
,	O
alanine	O
mutagenesis	O
of	O
the	O
N	O
-	O
terminal	O
propeptide	O
of	O
SP	B-Protein
-	I-Protein
C	I-Protein
was	O
performed	O
.	O

Adenoviruses	O
encoding	O
mutant	O
proproteins	O
were	O
infected	O
into	O
type	O
II	O
cells	O
isolated	O
from	O
Sftpc	B-Protein
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
and	O
media	O
analyzed	O
for	O
secreted	O
SP	B-Protein
-	I-Protein
C	I-Protein
24	O
hours	O
after	O
infection	O
.	O

Mutation	O
of	O
S	O
(	O
12	O
)	O
PPDYS	O
(	O
17	O
)	O
completely	O
blocked	O
secretion	O
of	O
SP	B-Protein
-	I-Protein
C	I-Protein
.	O

PPDY	O
(	O
PY	O
motif	O
)	O
has	O
previously	O
been	O
shown	O
to	O
bind	O
WW	O
domains	O
of	O
neural	O
precursor	O
cell	O
-	O
expressed	O
developmentally	O
down	O
-	O
regulated	O
(	O
Nedd	O
)	O
4	O
-	O
like	O
E3	O
ubiquitin	B-Protein
ligases	O
.	O

Purified	O
recombinant	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
-	O
SP	B-Protein
-	I-Protein
C	I-Protein
propeptide	O
(	O
residues	O
1	O
-	O
35	O
)	O
bound	O
recombinant	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
strongly	O
,	O
and	O
Nedd4	B-Protein
weakly	O
;	O
the	O
S	O
(	O
12	O
)	O
PPDYS	O
(	O
17	O
)	O
mutation	O
abrogated	O
binding	O
of	O
SP	B-Protein
-	I-Protein
C	I-Protein
to	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
.	O

Immobilized	O
recombinant	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
WW	O
domain	O
captured	O
SP	B-Protein
-	I-Protein
C	I-Protein
proprotein	O
from	O
mouse	O
type	O
II	O
cell	O
lysates	O
;	O
in	O
the	O
reverse	O
pulldown	O
,	O
endogenous	O
SP	B-Protein
-	I-Protein
C	I-Protein
in	O
type	O
II	O
cells	O
was	O
captured	O
by	O
recombinant	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
.	O

To	O
determine	O
if	O
the	O
interaction	O
of	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
and	O
SP	B-Protein
-	I-Protein
C	I-Protein
resulted	O
in	O
ubiquitination	O
,	O
the	O
SP	B-Protein
-	I-Protein
C	I-Protein
proprotein	O
was	O
immunoprecipitated	O
from	O
transiently	O
transfected	O
human	O
embryonic	O
kidney	O
293	O
cells	O
,	O
and	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
/	O
Western	O
blotting	O
with	O
ubiquitin	B-Protein
antibody	O
.	O

Two	O
ubiquitinated	O
forms	O
of	O
SP	B-Protein
-	I-Protein
C	I-Protein
were	O
detected	O
;	O
ubiquitination	O
was	O
blocked	O
by	O
mutation	O
of	O
K6	O
,	O
but	O
not	O
K34	O
,	O
in	O
the	O
SP	B-Protein
-	I-Protein
C	I-Protein
propeptide	O
.	O

Mutation	O
of	O
K6	O
also	O
inhibited	O
processing	O
of	O
SP	B-Protein
-	I-Protein
C	I-Protein
proprotein	O
to	O
the	O
mature	O
peptide	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

Nedd4	B-Protein
-	I-Protein
2	I-Protein
-	O
mediated	O
ubiquitination	O
regulates	O
lumenal	O
relocation	O
of	O
SP	B-Protein
-	I-Protein
C	I-Protein
,	O
leading	O
to	O
processing	O
and	O
,	O
ultimately	O
,	O
secretion	O
of	O
SP	B-Protein
-	I-Protein
C	I-Protein
.	O

HSCARG	B-Protein
regulates	O
NF	O
-	O
kappaB	O
activation	O
by	O
promoting	O
the	O
ubiquitination	O
of	O
RelA	B-Protein
or	O
COMMD1	B-Protein
.	O

The	O
redox	O
sensor	O
protein	O
HSCARG	B-Protein
translocates	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
decreased	O
cellular	O
NADPH	O
or	O
increased	O
nitric	O
oxide	O
,	O
and	O
is	O
involved	O
in	O
protein	O
regulation	O
.	O

However	O
,	O
the	O
regulatory	O
mechanism	O
of	O
HSCARG	B-Protein
has	O
remained	O
elusive	O
.	O

In	O
this	O
report	O
,	O
through	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
HSCARG	B-Protein
was	O
found	O
to	O
associate	O
with	O
the	O
copper	O
metabolism	O
gene	O
MURR1	B-Protein
domain	I-Protein
containing	I-Protein
protein	I-Protein
1	I-Protein
(	O
COMMD1	B-Protein
)	O
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
,	O
and	O
negatively	O
regulate	O
COMMD1	B-Protein
by	O
accelerating	O
its	O
ubiquitination	O
and	O
proteasome	O
-	O
dependent	O
degradation	O
.	O

Interestingly	O
,	O
we	O
observed	O
that	O
HSCARG	B-Protein
also	O
blocked	O
basal	O
and	O
stimulus	O
-	O
coupled	O
NF	O
-	O
kappaB	O
activation	O
by	O
promoting	O
ubiquitination	O
and	O
degradation	O
of	O
the	O
NF	O
-	O
kappaB	O
subunit	O
RelA	B-Protein
.	O

Further	O
analyses	O
showed	O
that	O
in	O
cells	O
under	O
normal	O
conditions	O
,	O
HSCARG	B-Protein
localized	O
mainly	O
in	O
the	O
cytoplasm	O
and	O
acted	O
as	O
a	O
negative	O
regulator	O
of	O
COMMD1	B-Protein
,	O
and	O
was	O
distributed	O
in	O
the	O
nucleus	O
in	O
small	O
quantities	O
to	O
inhibit	O
NF	O
-	O
kappaB	O
.	O

Although	O
in	O
response	O
to	O
intracellular	O
redox	O
changes	O
by	O
dehydroepiandrosterone	O
or	O
S	O
-	O
nitroso	O
-	O
N	O
-	O
acetylpenicillamine	O
treatment	O
,	O
a	O
large	O
amount	O
of	O
HSCARG	B-Protein
translocated	O
to	O
the	O
nucleus	O
,	O
which	O
terminated	O
NF	O
-	O
kappaB	O
activation	O
.	O

Meanwhile	O
,	O
COMMD1	B-Protein
was	O
restored	O
due	O
to	O
decreased	O
cytoplasmic	O
HSCARG	B-Protein
levels	O
and	O
negatively	O
regulated	O
NF	O
-	O
kappaB	O
as	O
well	O
.	O

Thus	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
terminated	O
efficiently	O
.	O

Our	O
results	O
indicate	O
that	O
HSCARG	B-Protein
plays	O
critical	O
roles	O
in	O
regulation	O
of	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
cellular	O
redox	O
changes	O
by	O
promoting	O
ubiquitination	O
and	O
proteolysis	O
of	O
RelA	B-Protein
or	O
COMMD1	B-Protein
.	O

Phenotypic	O
and	O
genotypic	O
characterization	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
CRF07	O
_	O
BC	O
strains	O
circulating	O
in	O
the	O
Xinjiang	O
Province	O
of	O
China	O
.	O

BACKGROUND	O
:	O
HIV	O
-	O
1	O
CRF07	O
_	O
BC	O
recombinant	O
previously	O
circulated	O
mainly	O
among	O
the	O
intravenous	O
drug	O
users	O
(	O
IDUs	O
)	O
in	O
Xinjiang	O
province	O
of	O
China	O
and	O
is	O
currently	O
spreading	O
in	O
the	O
entire	O
country	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
characterize	O
the	O
genotypic	O
and	O
phenotypic	O
properties	O
of	O
HIV	O
-	O
1	O
CRF07	O
_	O
BC	O
isolates	O
in	O
comparison	O
with	O
those	O
of	O
the	O
subtype	O
B	O
'	O
(	O
Thailand	O
B	O
)	O
which	O
is	O
prevalent	O
in	O
the	O
former	O
plasma	O
donors	O
(	O
FPDs	O
)	O
in	O
China	O
.	O

RESULTS	O
:	O
Twelve	O
HIV	O
-	O
1	O
CRF07	O
_	O
BC	O
variants	O
were	O
isolated	O
from	O
the	O
blood	O
of	O
the	O
HIV	O
-	O
1	O
-	O
infected	O
IDUs	O
in	O
Xinjiang	O
province	O
,	O
and	O
20	O
subtype	O
B	O
'	O
isolates	O
were	O
obtained	O
from	O
the	O
FPDs	O
in	O
Anhui	O
and	O
Shanxi	O
provinces	O
of	O
China	O
.	O

All	O
the	O
CRF07	O
_	O
BC	O
viruses	O
utilized	O
CCR5	B-Protein
co	O
-	O
receptor	O
,	O
whereas	O
12	O
subtype	O
B	O
'	O
viruses	O
were	O
R5	O
-	O
tropic	O
,	O
and	O
the	O
remaining	O
B	O
'	O
isolates	O
were	O
dual	O
(	O
R5X4	O
)	O
tropic	O
.	O

CRF07	O
_	O
BC	O
viruses	O
had	O
lower	O
net	O
charge	O
value	O
in	O
the	O
V3	O
loop	O
and	O
exhibited	O
slower	O
replication	O
kinetics	O
than	O
subtype	O
B	O
'	O
viruses	O
.	O

The	O
number	O
and	O
location	O
of	O
the	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
in	O
V1	O
/	O
V2	O
and	O
the	O
C2	O
region	O
of	O
the	O
CRF07	O
_	O
BC	O
viruses	O
were	O
significantly	O
different	O
from	O
those	O
of	O
the	O
subtype	O
B	O
'	O
viruses	O
.	O

CONCLUSION	O
:	O
The	O
HIV	O
-	O
1	O
CRF07	O
_	O
BC	O
recombinant	O
strains	O
with	O
relatively	O
lower	O
net	O
charges	O
in	O
the	O
V3	O
loop	O
exclusively	O
utilize	O
CCR5	B-Protein
co	O
-	O
receptor	O
for	O
infection	O
and	O
exhibit	O
slow	O
replication	O
kinetics	O
in	O
the	O
primary	O
target	O
cells	O
,	O
suggesting	O
that	O
CRF07	O
_	O
BC	O
may	O
be	O
superior	O
over	O
B	O
'	O
and	O
other	O
HIV	O
-	O
1	O
subtypes	O
in	O
initiating	O
infection	O
in	O
high	O
-	O
risk	O
population	O
.	O

These	O
findings	O
have	O
molecular	O
implications	O
for	O
the	O
adaptive	O
evolution	O
of	O
HIV	O
-	O
1	O
circulating	O
in	O
China	O
and	O
the	O
design	O
of	O
tailored	O
therapeutic	O
strategy	O
for	O
treatment	O
of	O
HIV	O
-	O
1	O
CRF07	O
_	O
BC	O
infection	O
.	O

Novel	O
fucosylated	O
biomarkers	O
for	O
the	O
early	O
detection	O
of	O
hepatocellular	O
carcinoma	O
.	O

Changes	O
in	O
glycosylation	O
,	O
most	O
notably	O
fucosylation	O
,	O
have	O
been	O
associated	O
with	O
the	O
development	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O

In	O
this	O
report	O
,	O
the	O
levels	O
of	O
fucosylated	O
kininogen	B-Protein
(	O
Fc	O
-	O
Kin	B-Protein
)	O
and	O
fucosylated	O
alpha	B-Protein
-	I-Protein
1	I-Protein
-	I-Protein
antitrypsin	I-Protein
were	O
analyzed	O
individually	O
and	O
in	O
combination	O
with	O
the	O
currently	O
used	O
marker	O
,	O
alpha	B-Protein
-	I-Protein
fetoprotein	I-Protein
,	O
and	O
a	O
previously	O
identified	O
biomarker	O
,	O
Golgi	B-Protein
protein	I-Protein
73	I-Protein
(	O
GP73	B-Protein
)	O
,	O
for	O
the	O
ability	O
to	O
distinguish	O
between	O
a	O
diagnosis	O
of	O
cirrhosis	O
and	O
HCC	O
.	O

This	O
analysis	O
was	O
done	O
on	O
serum	O
from	O
113	O
patients	O
with	O
cirrhosis	O
and	O
164	O
serum	O
samples	O
from	O
patients	O
with	O
cirrhosis	O
plus	O
HCC	O
.	O

The	O
levels	O
of	O
Fc	O
-	O
Kin	B-Protein
and	O
fucosylated	O
alpha	B-Protein
-	I-Protein
1	I-Protein
-	I-Protein
antitrypsin	I-Protein
were	O
significantly	O
higher	O
in	O
patients	O
with	O
HCC	O
compared	O
with	O
those	O
with	O
cirrhosis	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Greatest	O
performance	O
was	O
achieved	O
through	O
the	O
combination	O
of	O
Fc	O
-	O
Kin	B-Protein
,	O
alpha	B-Protein
-	I-Protein
fetoprotein	I-Protein
,	O
and	O
GP73	B-Protein
,	O
giving	O
an	O
optimal	O
sensitivity	O
of	O
95	O
%	O
,	O
a	O
specificity	O
of	O
70	O
%	O
,	O
and	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
of	O
0	O
.	O
94	O
.	O

In	O
conclusion	O
,	O
the	O
altered	O
glycosylation	O
of	O
serum	O
glycoproteins	O
can	O
act	O
as	O
potential	O
biomarkers	O
of	O
primary	O
HCC	O
when	O
used	O
independently	O
or	O
in	O
combination	O
with	O
other	O
markers	O
of	O
HCC	O
.	O

Methionine	O
,	O
tryptophan	O
,	O
and	O
histidine	O
oxidation	O
in	O
a	O
model	O
protein	O
,	O
PTH	B-Protein
:	O
mechanisms	O
and	O
stabilization	O
.	O

Recent	O
oxidation	O
events	O
on	O
monoclonal	O
antibody	O
candidates	O
prompted	O
us	O
to	O
investigate	O
the	O
mechanism	O
of	O
oxidation	O
of	O
Met	O
,	O
Trp	O
,	O
and	O
His	O
residues	O
and	O
to	O
search	O
for	O
suitable	O
stabilizers	O
.	O

By	O
using	O
parathyroid	O
hormone	O
(	O
1	O
-	O
34	O
)	O
,	O
PTH	B-Protein
,	O
as	O
a	O
model	O
protein	O
and	O
various	O
oxidants	O
,	O
aided	O
by	O
liquid	O
chromatography	O
,	O
peptide	O
mapping	O
,	O
and	O
mass	O
spectrometry	O
,	O
we	O
identified	O
and	O
quantified	O
the	O
oxidation	O
of	O
these	O
vulnerable	O
residues	O
.	O

Whereas	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
and	O
t	O
-	O
butyl	O
hydroperoxide	O
(	O
t	O
-	O
BHP	O
)	O
primarily	O
oxidized	O
the	O
two	O
Met	O
residues	O
,	O
2	O
,	O
2	O
'	O
-	O
azobis	O
(	O
2	O
-	O
amidinopropane	O
)	O
dihydrochloride	O
(	O
AAPH	O
)	O
,	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
+	O
Fe	O
(	O
II	O
)	O
oxidized	O
Met	O
and	O
Trp	O
residues	O
,	O
with	O
AAPH	O
more	O
capable	O
of	O
generating	O
oxidized	O
Trp	O
species	O
than	O
the	O
latter	O
.	O

H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
+	O
Fe	O
(	O
III	O
)	O
generated	O
results	O
comparable	O
to	O
those	O
with	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
+	O
Fe	O
(	O
II	O
)	O
,	O
except	O
that	O
there	O
was	O
a	O
lesser	O
amount	O
of	O
hydroxylated	O
Phe	O
.	O

Oxidation	O
of	O
the	O
His	O
residue	O
in	O
PTH	B-Protein
occurred	O
when	O
copper	O
was	O
used	O
instead	O
of	O
iron	O
.	O

AAPH	O
,	O
a	O
free	O
-	O
radical	O
generator	O
,	O
produced	O
alkylperoxides	O
,	O
which	O
simulated	O
the	O
oxidizing	O
species	O
from	O
degraded	O
polysorbate	O
,	O
commonly	O
found	O
in	O
protein	O
formulations	O
.	O

It	O
is	O
prudent	O
to	O
screen	O
stabilizers	O
by	O
using	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
,	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
+	O
Fe	O
(	O
II	O
)	O
,	O
and	O
AAPH	O
because	O
these	O
agents	O
represent	O
potential	O
assaults	O
from	O
the	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
commonly	O
present	O
in	O
degraded	O
polysorbate	O
,	O
the	O
residue	O
of	O
aseptic	O
agents	O
and	O
the	O
metal	O
from	O
stainless	O
steel	O
surfaces	O
,	O
and	O
alkylperoxides	O
from	O
degraded	O
polysorbate	O
,	O
respectively	O
.	O

Free	O
Met	O
protected	O
the	O
Met	O
residues	O
in	O
PTH	B-Protein
from	O
oxidation	O
by	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
and	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
+	O
Fe	O
(	O
II	O
)	O
.	O

Mannitol	O
and	O
EDTA	O
were	O
effective	O
against	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
+	O
Fe	O
(	O
II	O
)	O
.	O

Free	O
Trp	O
protected	O
only	O
the	O
Trp	O
residue	O
in	O
PTH	B-Protein
from	O
oxidation	O
by	O
AAPH	O
,	O
the	O
combination	O
of	O
Trp	O
and	O
Met	O
was	O
effective	O
against	O
all	O
three	O
oxidant	O
conditions	O
.	O

By	O
using	O
AAPH	O
to	O
generate	O
oxidant	O
,	O
Trolox	O
(	O
6	O
-	O
hydroxy	O
-	O
2	O
,	O
5	O
,	O
7	O
,	O
8	O
-	O
tetramethylchroman	O
-	O
2	O
-	O
carboxylic	O
acid	O
)	O
and	O
pyridoxine	O
were	O
also	O
found	O
to	O
exhibit	O
good	O
free	O
-	O
radical	O
scavenging	O
activity	O
and	O
thus	O
protected	O
Trp	O
in	O
PTH	O
against	O
oxidation	O
.	O

Interaction	O
of	O
TFAP2C	B-Protein
with	O
the	O
estrogen	B-Protein
receptor	I-Protein
-	I-Protein
alpha	I-Protein
promoter	O
is	O
controlled	O
by	O
chromatin	O
structure	O
.	O

PURPOSE	O
:	O
Transcriptional	O
regulation	O
of	O
estrogen	B-Protein
receptor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
ERalpha	B-Protein
)	O
involves	O
both	O
epigenetic	O
mechanisms	O
and	O
trans	O
-	O
active	O
factors	O
,	O
such	O
as	O
TFAP2C	B-Protein
,	O
which	O
induces	O
ERalpha	B-Protein
transcription	O
through	O
an	O
AP	O
-	O
2	O
regulatory	O
region	O
in	O
the	O
ERalpha	B-Protein
promoter	O
.	O

Attempts	O
to	O
induce	O
endogenous	O
ERalpha	B-Protein
expression	O
in	O
ERalpha	B-Protein
-	O
negative	O
breast	O
carcinomas	O
by	O
forced	O
overexpression	O
of	O
TFAP2C	B-Protein
have	O
not	O
been	O
successful	O
.	O

We	O
hypothesize	O
that	O
epigenetic	O
chromatin	O
structure	O
alters	O
the	O
activity	O
of	O
TFAP2C	B-Protein
at	O
the	O
ERalpha	B-Protein
promoter	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
DNA	O
methylation	O
,	O
histone	B-Protein
acetylation	O
,	O
and	O
chromatin	O
accessibility	O
were	O
examined	O
at	O
the	O
ERalpha	B-Protein
promoter	O
in	O
a	O
panel	O
of	O
breast	O
carcinoma	O
cell	O
lines	O
.	O

TFAP2C	B-Protein
and	O
polymerase	O
II	O
binding	O
were	O
analyzed	O
by	O
chromatin	O
immunoprecipitation	O
.	O

Epigenetic	O
chromatin	O
structure	O
was	O
altered	O
using	O
drug	O
treatment	O
with	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
AZA	O
)	O
and	O
trichostatin	O
A	O
(	O
TSA	O
)	O
.	O

RESULTS	O
:	O
The	O
ERalpha	B-Protein
promoter	O
in	O
the	O
ERalpha	B-Protein
-	O
negative	O
lines	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
MCF10A	O
,	O
and	O
MCF7	O
-	O
5C	O
show	O
CpG	O
island	O
methylation	O
,	O
histone	B-Protein
3	I-Protein
lysine	O
9	O
deacetylation	O
,	O
and	O
decreased	O
chromatin	O
accessibility	O
compared	O
with	O
ERalpha	B-Protein
-	O
positive	O
cell	O
lines	O
MCF7	O
and	O
T47	O
-	O
D	O
.	O

Treatment	O
with	O
AZA	O
/	O
TSA	O
increased	O
chromatin	O
accessibility	O
at	O
the	O
ERalpha	B-Protein
promoter	O
and	O
allowed	O
TFAP2C	B-Protein
to	O
induce	O
ERalpha	B-Protein
expression	O
in	O
ERalpha	B-Protein
-	O
negative	O
cells	O
.	O

Chromatin	O
immunoprecipitation	O
analysis	O
showed	O
that	O
binding	O
of	O
TFAP2C	B-Protein
to	O
the	O
ERalpha	B-Protein
promoter	O
is	O
blocked	O
in	O
ERalpha	B-Protein
-	O
negative	O
cells	O
but	O
that	O
treatment	O
with	O
AZA	O
/	O
TSA	O
enabled	O
TFAP2C	B-Protein
and	O
polymerase	O
II	O
binding	O
.	O

CONCLUSION	O
:	O
We	O
conclude	O
that	O
the	O
activity	O
of	O
TFAP2C	B-Protein
at	O
specific	O
target	O
genes	O
depends	O
upon	O
epigenetic	O
chromatin	O
structure	O
.	O

Furthermore	O
,	O
the	O
combination	O
of	O
increasing	O
chromatin	O
accessibility	O
and	O
inducing	O
TFAP2C	B-Protein
provides	O
a	O
more	O
robust	O
activation	O
of	O
the	O
ERalpha	B-Protein
gene	O
in	O
ERalpha	B-Protein
-	O
negative	O
breast	O
cancer	O
cells	O
.	O

Monoubiquitinylation	O
regulates	O
endosomal	O
localization	O
of	O
Lst2	B-Protein
,	O
a	O
negative	O
regulator	O
of	O
EGF	B-Protein
receptor	I-Protein
signaling	O
.	O

Genetic	O
screens	O
performed	O
in	O
worms	O
identified	O
major	O
regulators	O
of	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
(	O
EGFR	B-Protein
)	O
pathway	O
,	O
including	O
the	O
ubiquitin	B-Protein
ligase	O
Cbl	B-Protein
/	O
SLI	B-Protein
-	I-Protein
1	I-Protein
.	O

Here	O
we	O
focus	O
on	O
the	O
less	O
-	O
characterized	O
Lst2	B-Protein
protein	O
and	O
confirm	O
suppression	O
of	O
MAPK	O
signals	O
.	O

Unexpectedly	O
,	O
human	O
Lst2	B-Protein
,	O
a	O
monoubiquitinylated	O
phosphoprotein	O
,	O
does	O
not	O
localize	O
to	O
endosomes	O
,	O
despite	O
an	O
intrinsic	O
phosphoinositol	O
-	O
binding	O
FYVE	O
domain	O
.	O

By	O
constructing	O
an	O
ubiquitinylation	O
-	O
defective	O
mutant	O
and	O
an	O
ubiquitin	B-Protein
fusion	O
,	O
we	O
conclude	O
that	O
endosomal	O
localization	O
of	O
Lst2	B-Protein
,	O
along	O
with	O
an	O
ability	O
to	O
divert	O
incoming	O
EGFR	B-Protein
molecules	O
to	O
degradation	O
in	O
lysosomes	O
,	O
is	O
regulated	O
by	O
ubiquitinylation	O
/	O
deubiquitinylation	O
cycles	O
.	O

Consistent	O
with	O
bifurcating	O
roles	O
,	O
Lst2	B-Protein
physically	O
binds	O
Trim3	B-Protein
/	O
BERP	B-Protein
,	O
which	O
interacts	O
with	O
Hrs	B-Protein
and	O
a	O
complex	O
that	O
biases	O
cargo	O
recycling	O
.	O

These	O
results	O
establish	O
an	O
ubiquitin	B-Protein
-	O
based	O
endosomal	O
switch	O
of	O
receptor	O
sorting	O
,	O
functionally	O
equivalent	O
to	O
the	O
mechanism	O
inactivating	O
Hrs	B-Protein
via	O
monoubiquitinylation	O
.	O

20	O
-	O
Hydroxylation	O
is	O
the	O
CYP	O
-	O
dependent	O
and	O
retinoid	O
-	O
inducible	O
leukotriene	O
B4	O
inactivation	O
pathway	O
in	O
human	O
and	O
mouse	O
skin	O
cells	O
.	O

Metabolic	O
inactivation	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
is	O
an	O
innate	O
mechanism	O
to	O
resolve	O
tissue	O
inflammation	O
.	O

We	O
studied	O
the	O
nine	O
Cyp4f	O
genes	O
in	O
the	O
mouse	O
genome	O
,	O
measuring	O
cutaneous	O
transcript	O
levels	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
,	O
and	O
LTB4	O
metabolism	O
in	O
mouse	O
and	O
human	O
skin	O
.	O

Transcripts	O
arising	O
from	O
Cyp4f13	B-Protein
and	O
4f16	B-Protein
ranked	O
most	O
abundant	O
,	O
Cyp4f14	B-Protein
,	O
4f17	B-Protein
,	O
and	O
4f37	B-Protein
ranked	O
least	O
abundant	O
,	O
and	O
Cyp4f18	B-Protein
and	O
4f39	B-Protein
ranked	O
intermediate	O
.	O

Those	O
from	O
Cyp4f15	B-Protein
and	O
Cyp4f40	B-Protein
were	O
highly	O
variable	O
or	O
too	O
low	O
to	O
measure	O
in	O
some	O
animals	O
.	O

Retinoic	O
acid	O
exposure	O
induced	O
microsomal	O
LTB4	O
hydroxylation	O
activities	O
in	O
mouse	O
and	O
human	O
skin	O
cells	O
.	O

Two	O
NADPH	O
-	O
dependent	O
LTB4	O
metabolites	O
eluted	O
identically	O
with	O
20	O
-	O
OH	O
and	O
20	O
-	O
COOH	O
LTB4	O
reference	O
standards	O
.	O

Collision	O
induced	O
dissociation	O
of	O
the	O
precursor	O
ion	O
m	O
/	O
z	O
351	O
confirmed	O
that	O
LTB4	O
products	O
from	O
CYP4F3A	B-Protein
and	O
human	O
epidermal	O
keratinocytes	O
are	O
identical	O
structurally	O
to	O
20	O
-	O
OH	O
LTB4	O
.	O

We	O
conclude	O
20	O
-	O
hydroxylation	O
is	O
the	O
major	O
CYP	O
-	O
dependent	O
LTB4	O
inactivation	O
pathway	O
in	O
skin	O
;	O
this	O
retinoid	O
-	O
inducible	O
metabolic	O
pathway	O
has	O
capacity	O
to	O
modulate	O
tissue	O
levels	O
of	O
pro	O
-	O
inflammatory	O
lipids	O
.	O

Structure	O
and	O
biochemical	O
characterization	O
of	O
protein	O
acetyltransferase	O
from	O
Sulfolobus	O
solfataricus	O
.	O

The	O
Sulfolobus	O
solfataricus	O
protein	O
acetyltransferase	O
(	O
PAT	O
)	O
acetylates	O
ALBA	O
,	O
an	O
abundant	O
nonspecific	O
DNA	O
-	O
binding	O
protein	O
,	O
on	O
Lys	O
(	O
16	O
)	O
to	O
reduce	O
its	O
DNA	O
affinity	O
,	O
and	O
the	O
Sir2	B-Protein
deacetylase	O
reverses	O
the	O
modification	O
to	O
cause	O
transcriptional	O
repression	O
.	O

This	O
represents	O
a	O
"	O
primitive	O
"	O
model	O
for	O
chromatin	O
regulation	O
analogous	O
to	O
histone	B-Protein
modification	O
in	O
eukaryotes	O
.	O

We	O
report	O
the	O
1	O
.	O
84	O
-	O
A	O
crystal	O
structure	O
of	O
PAT	B-Protein
in	O
complex	O
with	O
coenzyme	O
A	O
.	O

The	O
structure	O
reveals	O
homology	O
to	O
both	O
prokaryotic	O
GNAT	O
acetyltransferases	O
and	O
eukaryotic	O
histone	O
acetyltransferases	O
(	O
HATs	O
)	O
,	O
with	O
an	O
additional	O
"	O
bent	O
helix	O
"	O
proximal	O
to	O
the	O
substrate	O
binding	O
site	O
that	O
might	O
play	O
an	O
autoregulatory	O
function	O
.	O

Investigation	O
of	O
active	O
site	O
mutants	O
suggests	O
that	O
PAT	O
does	O
not	O
use	O
a	O
single	O
general	O
base	O
or	O
acid	O
residue	O
for	O
substrate	O
deprotonation	O
and	O
product	O
reprotonation	O
,	O
respectively	O
,	O
and	O
that	O
a	O
diffusional	O
step	O
,	O
such	O
as	O
substrate	O
binding	O
,	O
may	O
be	O
rate	O
-	O
limiting	O
.	O

The	O
catalytic	O
efficiency	O
of	O
PAT	O
toward	O
ALBA	O
is	O
low	O
relative	O
to	O
other	O
acetyltransferases	O
,	O
suggesting	O
that	O
there	O
may	O
be	O
better	O
,	O
unidentified	O
substrates	O
for	O
PAT	O
.	O

The	O
structural	O
similarity	O
of	O
PAT	O
to	O
eukaryotic	O
HATs	O
combined	O
with	O
its	O
conserved	O
role	O
in	O
chromatin	O
regulation	O
suggests	O
that	O
PAT	O
is	O
evolutionarily	O
related	O
to	O
the	O
eukaryotic	O
HATs	O
.	O

An	O
in	O
vitro	O
assay	O
for	O
Cdc20	B-Protein
-	O
dependent	O
mitotic	O
anaphase	O
-	O
promoting	O
complex	O
activity	O
from	O
budding	O
yeast	O
.	O

Cell	O
cycle	O
transitions	O
are	O
controlled	O
,	O
in	O
part	O
,	O
by	O
ubiquitin	B-Protein
-	O
dependent	O
proteolysis	O
.	O

In	O
mitosis	O
,	O
the	O
metaphase	O
to	O
anaphase	O
transition	O
is	O
governed	O
by	O
an	O
E3	O
ubiquitin	B-Protein
ligase	O
called	O
the	O
cyclosome	O
or	O
Anaphase	O
-	O
Promoting	O
Complex	O
(	O
APC	O
)	O
,	O
and	O
a	O
WD40	O
-	O
repeat	O
protein	O
co	O
-	O
factor	O
called	O
Cdc20	B-Protein
.	O

In	O
vitro	O
Cdc20	B-Protein
-	O
dependent	O
APC	O
(	O
APC	O
(	O
Cdc20	B-Protein
)	O
)	O
assays	O
have	O
been	O
useful	O
in	O
the	O
identification	O
and	O
validation	O
of	O
target	O
substrates	O
,	O
and	O
in	O
the	O
study	O
of	O
APC	O
enzymology	O
and	O
regulation	O
.	O

Many	O
aspects	O
of	O
the	O
regulation	O
of	O
cell	O
cycle	O
progression	O
have	O
been	O
discovered	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
and	O
proteins	O
purified	O
from	O
this	O
model	O
organism	O
have	O
been	O
employed	O
in	O
a	O
wide	O
variety	O
of	O
in	O
vitro	O
assays	O
.	O

Here	O
we	O
outline	O
a	O
quantitative	O
in	O
vitro	O
mitotic	O
APC	O
(	O
Cdc20	B-Protein
)	O
assay	O
that	O
makes	O
use	O
of	O
a	O
highly	O
active	O
form	O
of	O
the	O
APC	O
that	O
is	O
purified	O
from	O
budding	O
yeast	O
cells	O
arrested	O
in	O
mitosis	O
.	O

Regulation	O
and	O
cellular	O
roles	O
of	O
ubiquitin	B-Protein
-	O
specific	O
deubiquitinating	O
enzymes	O
.	O

Deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
are	O
proteases	O
that	O
process	O
ubiquitin	B-Protein
or	O
ubiquitin	B-Protein
-	O
like	O
gene	O
products	O
,	O
reverse	O
the	O
modification	O
of	O
proteins	O
by	O
a	O
single	O
ubiquitin	B-Protein
(	O
-	O
like	O
)	O
protein	O
,	O
and	O
remodel	O
polyubiquitin	B-Protein
(	O
-	O
like	O
)	O
chains	O
on	O
target	O
proteins	O
.	O

The	O
human	O
genome	O
encodes	O
nearly	O
100	O
DUBs	O
with	O
specificity	O
for	O
ubiquitin	B-Protein
in	O
five	O
gene	O
families	O
.	O

Most	O
DUB	O
activity	O
is	O
cryptic	O
,	O
and	O
conformational	O
rearrangements	O
often	O
occur	O
during	O
the	O
binding	O
of	O
ubiquitin	B-Protein
and	O
/	O
or	O
scaffold	O
proteins	O
.	O

DUBs	O
with	O
specificity	O
for	O
ubiquitin	B-Protein
contain	O
insertions	O
and	O
extensions	O
modulating	O
DUB	O
substrate	O
specificity	O
,	O
protein	O
-	O
protein	O
interactions	O
,	O
and	O
cellular	O
localization	O
.	O

Binding	O
partners	O
and	O
multiprotein	O
complexes	O
with	O
which	O
DUBs	O
associate	O
modulate	O
DUB	O
activity	O
and	O
substrate	O
specificity	O
.	O

Quantitative	O
studies	O
of	O
activity	O
and	O
protein	O
-	O
protein	O
interactions	O
,	O
together	O
with	O
genetic	O
studies	O
and	O
the	O
advent	O
of	O
RNAi	O
,	O
have	O
led	O
to	O
new	O
insights	O
into	O
the	O
function	O
of	O
yeast	O
and	O
human	O
DUBs	O
.	O

This	O
review	O
discusses	O
ubiquitin	B-Protein
-	O
specific	O
DUBs	O
,	O
some	O
of	O
the	O
generalizations	O
emerging	O
from	O
recent	O
studies	O
of	O
the	O
regulation	O
of	O
DUB	O
activity	O
,	O
and	O
their	O
roles	O
in	O
various	O
cellular	O
processes	O
.	O

Characterization	O
of	O
a	O
robust	O
enzymatic	O
assay	O
for	O
inhibitors	O
of	O
2	O
-	O
oxoglutarate	O
-	O
dependent	O
hydroxylases	O
.	O

The	O
prolyl	O
-	O
4	O
-	O
hydroxylase	O
proteins	O
regulate	O
the	O
hypoxia	O
-	O
inducible	O
transcription	O
factors	O
(	O
HIFs	O
)	O
by	O
hydroxylation	O
of	O
proline	O
residues	O
targeting	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
for	O
proteasomal	O
degradation	O
.	O

Using	O
the	O
purified	O
catalytic	O
domain	O
of	O
prolyl	B-Protein
hydroxylase	I-Protein
2	I-Protein
(	O
PHD2	B-Protein
(	O
181	O
-	O
417	O
)	O
)	O
,	O
an	O
enzymatic	O
assay	O
has	O
been	O
developed	O
to	O
test	O
inhibitors	O
of	O
the	O
enzyme	O
in	O
vitro	O
.	O

Because	O
PHD2	B-Protein
hydroxylates	O
HIF	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
with	O
succinic	O
acid	O
produced	O
as	O
an	O
end	O
product	O
,	O
radiolabeled	O
[	O
5	O
-	O
(	O
14	O
)	O
C	O
]	O
-	O
2	O
-	O
oxoglutaric	O
acid	O
was	O
used	O
and	O
formation	O
of	O
[	O
14C	O
]	O
-	O
succinic	O
acid	O
was	O
measured	O
to	O
quantify	O
PHD2	O
(	O
181	O
-	O
417	O
)	O
enzymatic	O
activity	O
.	O

Comparison	O
of	O
the	O
separation	O
of	O
2	O
-	O
oxoglutaric	O
acid	O
and	O
succinic	O
acid	O
by	O
either	O
ion	O
exchange	O
chromatography	O
or	O
precipitation	O
with	O
phenylhydrazine	O
showed	O
similar	O
results	O
,	O
but	O
the	O
quantification	O
and	O
throughput	O
were	O
vastly	O
increased	O
using	O
the	O
latter	O
method	O
.	O

The	O
PHD2	B-Protein
reaction	O
was	O
substrate	O
and	O
concentration	O
dependent	O
.	O

The	O
addition	O
of	O
iron	O
to	O
the	O
enzyme	O
reaction	O
mix	O
resulted	O
in	O
an	O
increase	O
in	O
enzymatic	O
activity	O
.	O

The	O
Km	O
value	O
for	O
2	O
-	O
oxoglutaric	O
acid	O
was	O
determined	O
to	O
be	O
0	O
.	O
9	O
microM	O
,	O
and	O
known	O
PHD2	B-Protein
inhibitors	O
were	O
used	O
to	O
validate	O
the	O
assay	O
.	O

In	O
addition	O
,	O
the	O
authors	O
demonstrate	O
that	O
this	O
assay	O
can	O
be	O
applied	O
to	O
other	O
2	O
-	O
oxoglutaric	O
acid	O
-	O
dependent	O
enzymes	O
,	O
including	O
the	O
asparaginyl	O
hydroxylase	O
,	O
factor	B-Protein
-	I-Protein
inhibiting	I-Protein
HIF	I-Protein
-	I-Protein
1alpha	I-Protein
(	O
FIH	B-Protein
)	O
.	O

A	O
concentration	O
-	O
dependent	O
increase	O
in	O
succinic	O
acid	O
production	O
using	O
recombinant	O
FIH	B-Protein
enzyme	O
with	O
a	O
synthetic	O
peptide	O
substrate	O
was	O
observed	O
.	O

The	O
authors	O
conclude	O
that	O
a	O
by	O
-	O
product	O
enzyme	O
assay	O
measuring	O
the	O
conversion	O
of	O
2	O
-	O
oxoglutaric	O
acid	O
to	O
succinic	O
acid	O
using	O
the	O
catalytic	O
domain	O
of	O
the	O
human	O
PHD2	B-Protein
provides	O
a	O
convenient	O
method	O
for	O
the	O
biochemical	O
evaluation	O
of	O
inhibitors	O
of	O
the	O
2	O
-	O
oxoglutaric	O
acid	O
-	O
dependent	O
hydroxylases	O
.	O

Epigenetic	O
modifications	O
:	O
new	O
therapeutic	O
targets	O
in	O
primary	O
myelofibrosis	O
.	O

Primary	O
Myelofibrosis	O
previously	O
also	O
known	O
as	O
Agnogenic	O
Myeloid	O
Metaplasia	O
or	O
Idiopathic	O
Myelofibrosis	O
is	O
a	O
complex	O
myeloproliferative	O
disease	O
.	O

Although	O
the	O
initial	O
genetic	O
insult	O
that	O
causes	O
uncontrolled	O
proliferation	O
of	O
the	O
defective	O
Hematopoietic	O
Stem	O
Cell	O
/	O
Hematopoietic	O
Progenitor	O
Cell	O
is	O
still	O
elusive	O
,	O
literature	O
is	O
being	O
enriched	O
with	O
reports	O
on	O
the	O
molecular	O
mechanisms	O
that	O
provide	O
growth	O
advantage	O
to	O
the	O
mutant	O
clone	O
and	O
the	O
secondary	O
events	O
that	O
lead	O
to	O
stem	O
cell	O
mobilization	O
,	O
bone	O
marrow	O
fibrosis	O
,	O
osteosclerosis	O
and	O
angiogenesis	O
.	O

Identification	O
of	O
these	O
mechanisms	O
reveals	O
dys	O
-	O
regulation	O
of	O
genes	O
.	O

Dys	O
-	O
regulation	O
of	O
genes	O
that	O
causes	O
silencing	O
of	O
the	O
tumor	O
suppressors	O
is	O
of	O
common	O
occurrence	O
in	O
various	O
cancers	O
.	O

Treatment	O
methods	O
have	O
been	O
targeted	O
against	O
the	O
causative	O
chromatin	O
modifying	O
agents	O
such	O
as	O
DNA	O
methyl	O
transferases	O
and	O
Histone	B-Protein
Deacetylases	O
.	O

Ensued	O
success	O
with	O
inhibitors	O
of	O
these	O
agents	O
in	O
the	O
treatment	O
of	O
various	O
cancers	O
has	O
gained	O
precedent	O
in	O
the	O
treatment	O
of	O
Primary	O
Myelofibrosis	O
.	O

In	O
vitro	O
experiments	O
with	O
DNA	O
methyl	O
transferase	O
inhibitors	O
and	O
HDAC	O
inhibitors	O
on	O
patient	O
samples	O
provide	O
promising	O
results	O
and	O
clinical	O
trials	O
for	O
the	O
treatments	O
of	O
PMF	O
patients	O
are	O
under	O
way	O
.	O

Positive	O
outcomes	O
of	O
such	O
clinical	O
trials	O
could	O
pave	O
way	O
for	O
better	O
treatment	O
strategies	O
for	O
this	O
complex	O
disorder	O
and	O
improve	O
the	O
quality	O
of	O
life	O
of	O
these	O
patients	O
.	O

JFK	B-Protein
,	O
a	O
Kelch	O
domain	O
-	O
containing	O
F	O
-	O
box	O
protein	O
,	O
links	O
the	O
SCF	O
complex	O
to	O
p53	B-Protein
regulation	O
.	O

The	O
p53	B-Protein
tumor	O
suppressor	O
plays	O
a	O
central	O
role	O
in	O
integrating	O
cellular	O
responses	O
to	O
various	O
stresses	O
.	O

Tight	O
regulation	O
of	O
p53	B-Protein
is	O
thus	O
essential	O
for	O
the	O
maintenance	O
of	O
genome	O
integrity	O
and	O
normal	O
cell	O
proliferation	O
.	O

Currently	O
,	O
several	O
ubiquitin	B-Protein
ligases	O
,	O
including	O
the	O
single	O
-	O
subunit	O
RING	O
-	O
finger	O
types	O
-	O
-	O
MDM2	B-Protein
,	O
Pirh2	B-Protein
,	O
and	O
COP1	B-Protein
-	O
-	O
and	O
the	O
HECT	O
-	O
domain	O
type	O
-	O
-	O
ARF	B-Protein
-	I-Protein
BP1	I-Protein
-	O
-	O
have	O
been	O
reported	O
to	O
target	O
p53	B-Protein
for	O
degradation	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
human	O
Kelch	O
domain	O
-	O
containing	O
F	O
-	O
box	O
protein	O
,	O
JFK	B-Protein
.	O

We	O
showed	O
that	O
JFK	B-Protein
promotes	O
ubiquitination	O
and	O
degradation	O
of	O
p53	B-Protein
.	O

But	O
unlike	O
MDM2	B-Protein
,	O
Pirh2	B-Protein
,	O
COP1	B-Protein
,	O
and	O
ARF	B-Protein
-	I-Protein
BP1	I-Protein
,	O
all	O
of	O
which	O
possess	O
an	O
intrinsic	O
ubiquitin	B-Protein
ligase	O
activity	O
,	O
JFK	B-Protein
destabilizes	O
p53	B-Protein
through	O
the	O
assembly	O
of	O
a	O
Skp1	B-Protein
-	O
Cul1	B-Protein
-	O
F	O
-	O
box	O
complex	O
.	O

Significantly	O
,	O
JFK	B-Protein
inhibits	O
p53	B-Protein
-	O
dependent	O
transcription	O
,	O
and	O
depletion	O
of	O
JFK	B-Protein
stabilizes	O
p53	B-Protein
,	O
promotes	O
cell	O
apoptosis	O
,	O
arrests	O
cells	O
in	O
the	O
G	O
(	O
1	O
)	O
phase	O
,	O
and	O
sensitizes	O
cells	O
to	O
ionizing	O
radiation	O
-	O
induced	O
cell	O
death	O
.	O

These	O
data	O
indicate	O
that	O
JFK	B-Protein
is	O
a	O
critical	O
negative	O
regulator	O
of	O
p53	B-Protein
and	O
represents	O
a	O
pathway	O
for	O
the	O
maintenance	O
of	O
p53	B-Protein
levels	O
in	O
unstressed	O
cells	O
.	O

Our	O
experiments	O
link	O
the	O
Skp1	B-Protein
-	O
Cul1	B-Protein
-	O
F	O
-	O
box	O
system	O
to	O
p53	B-Protein
regulation	O
.	O

Decrease	O
in	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
receptor	I-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
results	O
from	O
ubiquitin	B-Protein
-	O
dependent	O
degradation	O
in	O
obstructive	O
renal	O
injury	O
in	O
rats	O
.	O

Increased	O
expression	O
levels	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNFalpha	B-Protein
)	O
is	O
involved	O
in	O
tubulointerstitial	O
cell	O
proliferation	O
and	O
apoptosis	O
in	O
obstructive	O
renal	O
injury	O
.	O

Two	O
TNFalpha	B-Protein
receptors	O
(	O
TNFRs	O
)	O
,	O
TNFR1	B-Protein
and	O
TNFR2	B-Protein
,	O
are	O
known	O
to	O
exist	O
.	O

On	O
TNFalpha	B-Protein
binding	O
,	O
TNFR1	B-Protein
recruits	O
TNFR	B-Protein
-	I-Protein
associated	I-Protein
death	I-Protein
domain	I-Protein
(	O
TRADD	B-Protein
)	O
,	O
an	O
assembly	O
platform	O
to	O
mediate	O
TNFR1	B-Protein
signaling	O
.	O

We	O
investigated	O
postreceptor	O
TRADD	B-Protein
regulation	O
in	O
rat	O
kidneys	O
with	O
unilateral	O
ureteral	O
obstruction	O
(	O
UUO	O
)	O
.	O

Whereas	O
UUO	O
was	O
associated	O
with	O
increased	O
expression	O
levels	O
of	O
TNFalpha	B-Protein
,	O
TNFR1	B-Protein
,	O
TNFR2	B-Protein
,	O
and	O
TRADD	B-Protein
mRNAs	O
,	O
it	O
resulted	O
in	O
the	O
marked	O
decrease	O
of	O
TRADD	B-Protein
protein	O
levels	O
(	O
which	O
appeared	O
at	O
day	O
1	O
and	O
persisted	O
thereafter	O
)	O
and	O
a	O
slight	O
decrease	O
in	O
TNFR1	B-Protein
protein	O
levels	O
at	O
days	O
7	O
and	O
14	O
.	O

Both	O
ubiquitination	O
and	O
degradation	O
of	O
TRADD	B-Protein
were	O
increased	O
in	O
UUO	O
kidneys	O
,	O
degradation	O
of	O
TRADD	B-Protein
was	O
stimulated	O
by	O
TNFalpha	B-Protein
in	O
HK	O
-	O
2	O
cells	O
,	O
and	O
TRADD	B-Protein
degradation	O
was	O
suppressed	O
by	O
proteasome	O
inhibitor	O
.	O

Inhibition	O
of	O
TNFalpha	B-Protein
by	O
soluble	O
TNFR2	B-Protein
,	O
etanercept	O
,	O
reduced	O
significantly	O
,	O
although	O
transiently	O
,	O
tubular	O
and	O
interstitial	O
cell	O
proliferation	O
,	O
fibronectin	B-Protein
expression	O
,	O
and	O
apoptosis	O
in	O
UUO	O
kidneys	O
,	O
and	O
also	O
suppressed	O
TRADD	B-Protein
degradation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
decrease	O
in	O
TRADD	B-Protein
resulting	O
from	O
enhanced	O
ubiquitin	B-Protein
-	O
dependent	O
degradation	O
is	O
involved	O
in	O
obstructive	O
renal	O
injury	O
.	O

Since	O
TRADD	B-Protein
is	O
not	O
incorporated	O
into	O
TNFR2	B-Protein
-	O
mediated	O
TNFalpha	B-Protein
signaling	O
,	O
the	O
persistent	O
decrease	O
in	O
TRADD	B-Protein
,	O
associated	O
with	O
a	O
mild	O
decrease	O
in	O
TNFR1	B-Protein
levels	O
,	O
may	O
function	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
divert	O
TNFalpha	B-Protein
signals	O
toward	O
a	O
TNFR2	B-Protein
-	O
mediated	O
pathway	O
in	O
UUO	O
kidneys	O
.	O

The	O
thioxotriazole	O
copper	O
(	O
II	O
)	O
complex	O
A0	O
induces	O
endoplasmic	O
reticulum	O
stress	O
and	O
paraptotic	O
death	O
in	O
human	O
cancer	O
cells	O
.	O

The	O
copper	O
(	O
II	O
)	O
complex	O
A0	O
induces	O
a	O
type	O
of	O
non	O
-	O
apoptotic	O
cell	O
death	O
also	O
known	O
as	O
paraptosis	O
.	O

Paraptosis	O
involves	O
extensive	O
endoplasmic	O
reticulum	O
vacuolization	O
in	O
the	O
absence	O
of	O
caspase	O
activation	O
.	O

A	O
wide	O
panel	O
of	O
human	O
cancer	O
cell	O
lines	O
was	O
used	O
to	O
demonstrate	O
differences	O
in	O
cytotoxicity	O
by	O
the	O
paraptosis	O
-	O
inducing	O
drug	O
A0	O
and	O
the	O
metal	O
-	O
based	O
pro	O
-	O
apoptotic	O
drug	O
cisplatin	O
.	O

Gene	O
expression	O
profiling	O
of	O
the	O
human	O
fibrosarcoma	O
HT1080	O
cells	O
showed	O
that	O
,	O
while	O
cisplatin	O
induced	O
p53	B-Protein
targets	O
,	O
A0	O
up	O
-	O
regulated	O
genes	O
involved	O
in	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
and	O
response	O
to	O
heavy	O
metals	O
.	O

The	O
cytotoxic	O
effects	O
of	O
A0	O
were	O
associated	O
with	O
inhibition	O
of	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
and	O
accumulation	O
of	O
ubiquitinylated	O
proteins	O
,	O
in	O
a	O
manner	O
dependent	O
on	O
protein	O
synthesis	O
.	O

Cycloheximide	O
inhibited	O
the	O
accumulation	O
of	O
ubiquitinylated	O
proteins	O
and	O
hampered	O
A0	O
-	O
induced	O
cell	O
death	O
process	O
.	O

The	O
occurrence	O
of	O
the	O
UPR	O
during	O
A0	O
-	O
induced	O
death	O
process	O
was	O
shown	O
by	O
the	O
increased	O
abundance	O
of	O
spliced	O
XBP1	B-Protein
mRNA	O
,	O
transient	O
eIF2alpha	B-Protein
phosphorylation	O
,	O
and	O
a	O
series	O
of	O
downstream	O
events	O
,	O
including	O
attenuation	O
of	O
global	O
protein	O
synthesis	O
and	O
increased	O
expression	O
of	O
ATF4	B-Protein
,	O
CHOP	B-Protein
,	O
BIP	B-Protein
,	O
and	O
GADD34	B-Protein
.	O

Mouse	O
embryonic	O
fibroblasts	O
expressing	O
a	O
mutant	O
eIF2alpha	B-Protein
,	O
which	O
could	O
not	O
be	O
phosphorylated	O
,	O
were	O
more	O
resistant	O
to	O
A0	O
than	O
wild	O
type	O
cells	O
,	O
pointing	O
to	O
a	O
pro	O
-	O
death	O
role	O
of	O
eIF2alpha	B-Protein
phosphorylation	O
.	O

A0	O
may	O
thus	O
represent	O
the	O
prototypical	O
member	O
of	O
a	O
new	O
class	O
of	O
compounds	O
that	O
cause	O
paraptotic	O
cell	O
death	O
via	O
mechanisms	O
involving	O
eIF2alpha	B-Protein
phosphorylation	O
and	O
the	O
UPR	O
.	O

The	O
cap	O
binding	O
complex	O
influences	O
H2B	B-Protein
ubiquitination	O
by	O
facilitating	O
splicing	O
of	O
the	O
SUS1	B-Protein
pre	O
-	O
mRNA	O
.	O

Pre	O
-	O
messenger	O
RNA	O
splicing	O
is	O
carried	O
out	O
by	O
a	O
large	O
ribonucleoprotein	O
complex	O
called	O
the	O
spliceosome	O
.	O

Despite	O
the	O
striking	O
evolutionary	O
conservation	O
of	O
the	O
spliceosomal	O
components	O
and	O
their	O
functions	O
,	O
controversy	O
persists	O
about	O
the	O
relative	O
importance	O
of	O
splicing	O
in	O
Saccharomyces	O
cerevisiae	O
-	O
particularly	O
given	O
the	O
paucity	O
of	O
intron	O
-	O
containing	O
genes	O
in	O
yeast	O
.	O

Here	O
we	O
show	O
that	O
splicing	O
of	O
one	O
pre	O
-	O
messenger	O
RNA	O
,	O
SUS1	B-Protein
,	O
a	O
component	O
of	O
the	O
histone	B-Protein
H2B	I-Protein
ubiquitin	B-Protein
protease	O
machinery	O
,	O
is	O
essential	O
for	O
establishing	O
the	O
proper	O
modification	O
state	O
of	O
chromatin	O
.	O

One	O
protein	O
complex	O
that	O
is	O
intimately	O
involved	O
in	O
pre	O
-	O
mRNA	O
splicing	O
,	O
the	O
yeast	O
cap	O
-	O
binding	O
complex	O
,	O
appears	O
to	O
be	O
particularly	O
important	O
,	O
as	O
evidenced	O
by	O
its	O
extensive	O
and	O
unique	O
genetic	O
interactions	O
with	O
enzymes	O
that	O
catalyze	O
histone	B-Protein
H2B	I-Protein
ubiquitination	O
.	O

Microarray	O
studies	O
show	O
that	O
cap	O
binding	O
complex	O
(	O
CBC	O
)	O
deletion	O
has	O
a	O
global	O
effect	O
on	O
gene	O
expression	O
,	O
and	O
for	O
approximately	O
20	O
%	O
of	O
these	O
genes	O
,	O
this	O
effect	O
is	O
suppressed	O
when	O
ubiquitination	O
of	O
histone	B-Protein
H2B	I-Protein
is	O
eliminated	O
.	O

Consistent	O
with	O
this	O
finding	O
of	O
histone	B-Protein
H2B	I-Protein
dependent	O
effects	O
on	O
gene	O
expression	O
,	O
deletion	O
of	O
the	O
yeast	O
cap	O
binding	O
complex	O
leads	O
to	O
overubiquitination	O
of	O
histone	B-Protein
H2B	I-Protein
.	O

A	O
key	O
component	O
of	O
the	O
ubiquitin	B-Protein
-	O
protease	O
module	O
of	O
the	O
SAGA	O
complex	O
,	O
Sus1	B-Protein
,	O
is	O
encoded	O
by	O
a	O
gene	O
that	O
contains	O
two	O
introns	O
and	O
is	O
misspliced	O
when	O
the	O
CBC	O
is	O
deleted	O
,	O
leading	O
to	O
destabilization	O
of	O
the	O
ubiquitin	B-Protein
protease	O
complex	O
and	O
defective	O
modulation	O
of	O
cellular	O
H2B	B-Protein
levels	O
.	O

These	O
data	O
demonstrate	O
that	O
pre	O
-	O
mRNA	O
splicing	O
plays	O
a	O
critical	O
role	O
in	O
histone	B-Protein
H2B	I-Protein
ubiquitination	O
and	O
that	O
the	O
CBC	O
in	O
particular	O
helps	O
to	O
establish	O
the	O
proper	O
state	O
of	O
chromatin	O
and	O
proper	O
expression	O
of	O
genes	O
that	O
are	O
regulated	O
at	O
the	O
level	O
of	O
histone	B-Protein
H2B	I-Protein
ubiquitination	O
.	O

The	O
influence	O
of	O
N	O
-	O
glycosylation	O
on	O
biochemical	O
properties	O
of	O
Amy1	B-Protein
,	O
an	O
alpha	O
-	O
amylase	O
from	O
the	O
yeast	O
Cryptococcus	O
flavus	O
.	O

The	O
yeast	O
Cryptococcus	O
flavus	O
secretes	O
a	O
glycosylated	O
alpha	O
-	O
amylase	O
(	O
Amy1	B-Protein
)	O
when	O
grown	O
in	O
a	O
starch	O
-	O
containing	O
medium	O
.	O

The	O
effects	O
of	O
N	O
-	O
glycosylation	O
on	O
secretion	O
,	O
enzyme	O
activity	O
,	O
and	O
stability	O
of	O
this	O
glycoprotein	O
were	O
studied	O
.	O

Addition	O
of	O
tunicamycin	O
(	O
TM	O
)	O
to	O
the	O
medium	O
at	O
a	O
concentration	O
higher	O
than	O
0	O
.	O
5	O
microg	O
mL	O
(	O
-	O
1	O
)	O
affected	O
C	O
.	O
flavus	O
growth	O
.	O

Amy1	B-Protein
activity	O
increased	O
by	O
55	O
%	O
in	O
the	O
intracellular	O
fraction	O
after	O
C	O
.	O
flavus	O
growth	O
in	O
the	O
presence	O
of	O
0	O
.	O
5	O
microg	O
mL	O
(	O
-	O
1	O
)	O
TM	O
.	O

SDS	O
-	O
PAGE	O
and	O
gel	O
activity	O
detection	O
showed	O
that	O
native	O
enzyme	O
and	O
deglycosylated	O
enzyme	O
had	O
apparent	O
molecular	O
mass	O
of	O
68	O
and	O
64	O
.	O
5	O
kDa	O
,	O
respectively	O
.	O

The	O
N	O
-	O
glycosylation	O
process	O
did	O
not	O
affect	O
either	O
optimum	O
pH	O
or	O
optimum	O
temperature	O
.	O

The	O
K	O
(	O
M	O
)	O
values	O
of	O
native	O
and	O
non	O
-	O
glycosylated	O
alpha	B-Protein
-	I-Protein
amylases	I-Protein
were	O
0	O
.	O
052	O
and	O
0	O
.	O
098	O
mg	O
mL	O
(	O
-	O
1	O
)	O
,	O
and	O
V	O
(	O
max	O
)	O
values	O
were	O
0	O
.	O
038	O
and	O
0	O
.	O
047	O
mg	O
min	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

However	O
,	O
the	O
non	O
-	O
glycosylated	O
form	O
was	O
more	O
sensitive	O
to	O
inactivation	O
by	O
both	O
the	O
proteolytic	O
enzyme	O
trypsin	O
and	O
high	O
temperature	O
.	O

Furthermore	O
,	O
the	O
activity	O
of	O
the	O
non	O
-	O
glycosylated	O
enzyme	O
was	O
affected	O
by	O
Hg	O
(	O
2	O
+	O
)	O
and	O
Cu	O
(	O
2	O
+	O
)	O
suggesting	O
that	O
N	O
-	O
glycosylation	O
is	O
involved	O
in	O
the	O
folding	O
of	O
Amy1	B-Protein
.	O

Oxygen	O
-	O
regulated	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
-	I-Protein
adrenergic	I-Protein
receptor	I-Protein
hydroxylation	O
by	O
EGLN3	B-Protein
and	O
ubiquitylation	O
by	O
pVHL	B-Protein
.	O

Agonist	O
-	O
induced	O
ubiquitylation	O
and	O
degradation	O
of	O
heterotrimeric	O
guanine	O
nucleotide	O
-	O
binding	O
protein	O
(	O
G	O
protein	O
)	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
play	O
an	O
essential	O
role	O
in	O
surface	O
receptor	O
homeostasis	O
,	O
thereby	O
tuning	O
many	O
physiological	O
processes	O
.	O

Although	O
beta	O
-	O
arrestin	O
and	O
affiliated	O
E3	O
ligases	O
mediate	O
agonist	O
-	O
stimulated	O
lysosomal	O
degradation	O
of	O
the	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
-	I-Protein
adrenergic	I-Protein
receptor	I-Protein
(	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
AR	I-Protein
)	O
,	O
a	O
prototypic	O
GPCR	O
,	O
the	O
molecular	O
cues	O
that	O
mark	O
receptors	O
for	O
ubiquitylation	O
and	O
the	O
regulation	O
of	O
receptor	O
degradation	O
by	O
the	O
proteasome	O
remain	O
poorly	O
understood	O
.	O

We	O
show	O
that	O
the	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
tumor	I-Protein
suppressor	I-Protein
protein	O
(	O
pVHL	B-Protein
)	O
-	O
E3	O
ligase	O
complex	O
,	O
known	O
for	O
its	O
regulation	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
proteins	O
,	O
interacts	O
with	O
and	O
ubiquitylates	O
the	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
AR	I-Protein
,	O
thereby	O
decreasing	O
receptor	O
abundance	O
.	O

We	O
further	O
show	O
that	O
the	O
interaction	O
of	O
pVHL	B-Protein
with	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
AR	I-Protein
is	O
dependent	O
on	O
proline	O
hydroxylation	O
(	O
proline	O
-	O
382	O
and	O
-	O
395	O
)	O
and	O
that	O
the	O
dioxygenase	O
EGLN3	B-Protein
interacts	O
directly	O
with	O
the	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
AR	I-Protein
to	O
serve	O
as	O
an	O
endogenous	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
AR	I-Protein
prolyl	O
hydroxylase	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
receptor	O
hydroxylation	O
and	O
subsequent	O
ubiquitylation	O
decrease	O
dramatically	O
,	O
thus	O
attenuating	O
receptor	O
degradation	O
and	O
down	O
-	O
regulation	O
.	O

Notably	O
,	O
in	O
both	O
cells	O
and	O
tissue	O
,	O
the	O
abundance	O
of	O
endogenous	O
beta	B-Protein
(	I-Protein
2	I-Protein
)	I-Protein
AR	I-Protein
is	O
shown	O
to	O
reflect	O
constitutive	O
turnover	O
by	O
EGLN3	B-Protein
and	O
pVHL	B-Protein
.	O

Our	O
findings	O
provide	O
insight	O
into	O
GPCR	O
regulation	O
,	O
broaden	O
the	O
functional	O
scope	O
of	O
prolyl	O
hydroxylation	O
,	O
and	O
expand	O
our	O
understanding	O
of	O
the	O
cellular	O
response	O
to	O
hypoxia	O
.	O

Targeted	O
restoration	O
of	O
down	O
-	O
regulated	O
DAPK2	B-Protein
tumor	O
suppressor	O
activity	O
induces	O
apoptosis	O
in	O
Hodgkin	O
lymphoma	O
cells	O
.	O

Death	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
kinase	I-Protein
2	I-Protein
(	O
DAPK2	B-Protein
)	O
is	O
a	O
calcium	O
/	O
calmodulin	B-Protein
-	O
regulated	O
proapoptotic	O
serine	O
/	O
threonine	O
kinase	O
that	O
acts	O
as	O
a	O
tumor	O
suppressor	O
.	O

Here	O
we	O
show	O
that	O
DAPK2	B-Protein
is	O
down	O
-	O
regulated	O
in	O
Hodgkin	O
lymphoma	O
-	O
derived	O
tumor	O
cell	O
lines	O
and	O
that	O
promoter	O
-	O
region	O
hypermethylation	O
is	O
one	O
mechanism	O
for	O
DAPK2	B-Protein
inactivation	O
.	O

To	O
determine	O
whether	O
selective	O
reconstitution	O
of	O
DAPK2	B-Protein
catalytic	O
activity	O
in	O
these	O
cells	O
could	O
induce	O
apoptosis	O
,	O
we	O
created	O
a	O
fusion	O
protein	O
comprising	O
a	O
human	O
CD30	B-Protein
ligand	I-Protein
conjugated	O
to	O
a	O
human	O
DAPK2	B-Protein
calmodulin	B-Protein
-	O
deletion	O
mutant	O
.	O

Thus	O
,	O
recombinant	O
immunokinase	O
DAPK2	B-Protein
'	O
-	O
CD30L	B-Protein
has	O
a	O
constitutive	O
kinase	O
activity	O
with	O
enhanced	O
proapoptotic	O
function	O
.	O

We	O
show	O
that	O
this	O
immunokinase	O
fusion	O
protein	O
inhibits	O
cell	O
proliferation	O
and	O
induces	O
apoptotic	O
cell	O
death	O
specifically	O
in	O
CD30	B-Protein
/	O
DAPK2	B-Protein
-	O
negative	O
tumor	O
cell	O
lines	O
.	O

This	O
proof	O
-	O
of	O
-	O
concept	O
study	O
provides	O
the	O
first	O
demonstration	O
of	O
therapeutic	O
strategies	O
based	O
on	O
the	O
restoration	O
of	O
a	O
defective	O
,	O
tumor	O
-	O
suppressing	O
kinase	O
activity	O
by	O
a	O
novel	O
class	O
of	O
recombinant	O
immunotherapeutics	O
.	O

Parkin	B-Protein
reverses	O
intracellular	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
accumulation	O
and	O
its	O
negative	O
effects	O
on	O
proteasome	O
function	O
.	O

The	O
significance	O
of	O
intracellular	O
beta	B-Protein
-	I-Protein
amyloid	I-Protein
(	O
Abeta	B-Protein
(	I-Protein
42	I-Protein
)	I-Protein
)	O
accumulation	O
is	O
increasingly	O
recognized	O
in	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
pathogenesis	O
.	O

Abeta	B-Protein
removal	O
mechanisms	O
that	O
have	O
attracted	O
attention	O
include	O
IDE	B-Protein
/	O
neprilysin	B-Protein
degradation	O
and	O
antibody	O
-	O
mediated	O
uptake	O
by	O
immune	O
cells	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
(	O
UPS	O
)	O
in	O
the	O
disposal	O
of	O
cellular	O
Abeta	B-Protein
has	O
not	O
been	O
fully	O
explored	O
.	O

The	O
E3	O
ubiquitin	B-Protein
ligase	O
Parkin	B-Protein
targets	O
several	O
proteins	O
for	O
UPS	O
degradation	O
,	O
and	O
Parkin	B-Protein
mutations	O
are	O
the	O
major	O
cause	O
of	O
autosomal	O
recessive	O
Parkinson	O
'	O
s	O
disease	O
.	O

We	O
tested	O
whether	O
Parkin	B-Protein
has	O
cross	O
-	O
function	O
to	O
target	O
misfolded	O
proteins	O
in	O
AD	O
for	O
proteasome	O
-	O
dependent	O
clearance	O
in	O
SH	O
-	O
SY5Y	O
and	O
primary	O
neuronal	O
cells	O
.	O

Wild	O
-	O
type	O
Parkin	B-Protein
greatly	O
decreased	O
steady	O
-	O
state	O
levels	O
of	O
intracellular	O
Abeta	B-Protein
(	I-Protein
42	I-Protein
)	I-Protein
,	O
an	O
action	O
abrogated	O
by	O
proteasome	O
inhibitors	O
.	O

Intracellular	O
Abeta	B-Protein
(	I-Protein
42	I-Protein
)	I-Protein
accumulation	O
decreased	O
cell	O
viability	O
and	O
proteasome	O
activity	O
.	O

Accordingly	O
,	O
Parkin	B-Protein
reversed	O
both	O
effects	O
.	O

Changes	O
in	O
mitochondrial	O
ATP	O
production	O
from	O
Abeta	B-Protein
or	O
Parkin	B-Protein
did	O
not	O
account	O
for	O
their	O
effects	O
on	O
the	O
proteasome	O
.	O

Parkin	B-Protein
knock	O
-	O
down	O
led	O
to	O
accumulation	O
of	O
Abeta	B-Protein
.	O

In	O
AD	O
brain	O
,	O
Parkin	B-Protein
was	O
found	O
to	O
interact	O
with	O
Abeta	B-Protein
and	O
its	O
levels	O
were	O
reduced	O
.	O

Thus	O
,	O
Parkin	B-Protein
is	O
cytoprotective	O
,	O
partially	O
by	O
increasing	O
the	O
removal	O
of	O
cellular	O
Abeta	B-Protein
through	O
a	O
proteasome	O
-	O
dependent	O
pathway	O
.	O

G2	O
histone	B-Protein
methylation	O
is	O
required	O
for	O
the	O
proper	O
segregation	O
of	O
chromosomes	O
.	O

Trimethylation	O
of	O
lysine	O
9	O
on	O
histone	B-Protein
H3	I-Protein
(	O
H3K9me3	B-Protein
)	O
is	O
known	O
both	O
to	O
be	O
necessary	O
for	O
proper	O
chromosome	O
segregation	O
and	O
to	O
increase	O
in	O
late	O
G2	O
.	O

We	O
investigated	O
the	O
role	O
of	O
late	O
G2	O
methylation	O
,	O
specifically	O
in	O
mitotic	O
progression	O
,	O
by	O
inhibiting	O
methylation	O
for	O
2	O
hours	O
prior	O
to	O
mitosis	O
using	O
the	O
general	O
methylation	O
inhibitor	O
adenosine	O
dialdehyde	O
(	O
AdOx	O
)	O
.	O

AdOx	O
inhibits	O
all	O
methylation	O
events	O
within	O
the	O
cell	O
but	O
,	O
by	O
shortening	O
the	O
treatment	O
length	O
to	O
2	O
hours	O
and	O
studying	O
mitotic	O
cells	O
,	O
the	O
only	O
methylation	O
events	O
that	O
are	O
affected	O
are	O
those	O
that	O
occur	O
in	O
late	O
G2	O
.	O

We	O
discovered	O
that	O
methylation	O
events	O
in	O
this	O
time	O
period	O
are	O
crucial	O
for	O
proper	O
mitosis	O
.	O

Mis	O
-	O
segregation	O
of	O
chromosomes	O
is	O
observed	O
with	O
AdOx	O
treatment	O
.	O

Through	O
studies	O
of	O
histone	B-Protein
modifications	O
,	O
we	O
have	O
found	O
that	O
inhibiting	O
late	O
G2	O
methylation	O
affects	O
trimethylation	O
of	O
H3K9	B-Protein
and	O
H4K20	B-Protein
.	O

The	O
mitotic	O
checkpoint	O
is	O
active	O
and	O
many	O
kinetochore	O
proteins	O
localize	O
properly	O
,	O
however	O
,	O
pericentric	O
chromatin	O
in	O
these	O
cells	O
is	O
found	O
to	O
be	O
less	O
compact	O
(	O
dense	O
)	O
.	O

The	O
reduced	O
integrity	O
of	O
pericentric	O
heterochromatin	O
might	O
be	O
responsible	O
for	O
a	O
noted	O
loss	O
of	O
tension	O
at	O
the	O
centromere	O
in	O
AdOx	O
-	O
treated	O
cells	O
and	O
activation	O
of	O
the	O
spindle	O
assembly	O
checkpoint	O
.	O

We	O
postulate	O
that	O
late	O
G2	O
methylation	O
is	O
necessary	O
for	O
proper	O
pericentric	O
heterochromatin	O
formation	O
.	O

The	O
results	O
suggest	O
that	O
a	O
reduction	O
in	O
heterochromatin	O
integrity	O
might	O
interfere	O
both	O
with	O
microtubule	O
attachment	O
to	O
chromosomes	O
and	O
with	O
the	O
proper	O
sensing	O
of	O
tension	O
from	O
correct	O
microtubule	O
-	O
kinetochore	O
connections	O
,	O
either	O
of	O
which	O
will	O
result	O
in	O
activation	O
of	O
the	O
mitotic	O
checkpoint	O
.	O

Transferrin	B-Protein
-	O
directed	O
internalization	O
and	O
cycling	O
of	O
transferrin	B-Protein
receptor	I-Protein
2	I-Protein
.	O

Transferrin	B-Protein
receptor	I-Protein
2	I-Protein
(	O
TfR2	B-Protein
)	O
is	O
a	O
homologue	O
of	O
transferrin	B-Protein
receptor	I-Protein
1	I-Protein
(	O
TfR1	B-Protein
)	O
but	O
has	O
distinct	O
functions	O
from	O
TfR1	B-Protein
in	O
iron	O
homeostasis	O
.	O

In	O
keeping	O
with	O
its	O
proposed	O
role	O
in	O
iron	O
sensing	O
,	O
previous	O
studies	O
showed	O
that	O
TfR2	B-Protein
has	O
a	O
short	O
half	O
-	O
life	O
and	O
that	O
holo	O
-	O
Tf	B-Protein
stabilizes	O
TfR2	B-Protein
by	O
redirecting	O
it	O
from	O
a	O
degradative	O
pathway	O
to	O
a	O
recycling	O
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
how	O
the	O
endocytosis	O
,	O
recycling	O
and	O
degradation	O
of	O
TfR2	B-Protein
relates	O
to	O
its	O
function	O
and	O
differs	O
from	O
TfR1	B-Protein
.	O

TfR2	B-Protein
endocytosis	O
was	O
adaptor	O
protein	O
-	O
2	O
(	O
AP	O
-	O
2	O
)	O
dependent	O
.	O

Flow	O
cytometry	O
analysis	O
showed	O
that	O
TfR1	B-Protein
and	O
TfR2	B-Protein
utilized	O
the	O
same	O
endocytic	O
pathway	O
only	O
in	O
the	O
presence	O
of	O
holo	O
-	O
Tf	B-Protein
,	O
indicating	O
that	O
holo	O
-	O
Tf	B-Protein
alters	O
the	O
interaction	O
of	O
TfR2	B-Protein
with	O
the	O
endocytic	O
machinery	O
.	O

Unlike	O
TfR1	B-Protein
,	O
phosphofurin	B-Protein
acidic	I-Protein
cluster	I-Protein
sorting	I-Protein
protein	I-Protein
1	I-Protein
(	O
PACS	B-Protein
-	I-Protein
1	I-Protein
)	O
binds	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
TfR2	B-Protein
and	O
data	O
suggest	O
that	O
PACS	B-Protein
-	I-Protein
1	I-Protein
is	O
involved	O
in	O
the	O
TfR2	B-Protein
recycling	O
.	O

Depletion	O
of	O
TSG101	B-Protein
by	O
siRNA	O
or	O
expression	O
of	O
a	O
dominant	O
negative	O
Vps4	B-Protein
inhibited	O
TfR2	B-Protein
degradation	O
,	O
indicating	O
that	O
TfR2	B-Protein
degradation	O
occurs	O
through	O
a	O
multivesicular	O
body	O
(	O
MVB	O
)	O
pathway	O
.	O

TfR2	B-Protein
degradation	O
is	O
not	O
mediated	O
through	O
ubiquitination	O
on	O
the	O
single	O
lysine	O
(	O
K31	O
)	O
in	O
the	O
cytoplasmic	O
domain	O
or	O
on	O
the	O
amino	O
terminal	O
residue	O
.	O

No	O
ubiquitination	O
of	O
TfR2	B-Protein
by	O
HA	O
-	O
ubiquitin	B-Protein
was	O
detected	O
,	O
indicating	O
a	O
lack	O
of	O
direct	O
TfR2	B-Protein
ubiquitination	O
involvement	O
in	O
its	O
degradation	O
.	O

Dynamic	O
interactions	O
of	O
proteins	O
in	O
complex	O
networks	O
:	O
identifying	O
the	O
complete	O
set	O
of	O
interacting	O
E2s	O
for	O
functional	O
investigation	O
of	O
E3	O
-	O
dependent	O
protein	O
ubiquitination	O
.	O

A	O
ubiquitin	B-Protein
ligase	O
(	O
E3	O
)	O
functions	O
at	O
the	O
crossroad	O
between	O
ubiquitin	B-Protein
activation	O
and	O
the	O
attachment	O
of	O
ubiquitin	B-Protein
to	O
protein	O
substrates	O
.	O

During	O
this	O
process	O
,	O
the	O
E3	O
interacts	O
with	O
both	O
a	O
substrate	O
and	O
a	O
ubiquitin	B-Protein
-	O
conjugating	O
enzyme	O
(	O
E2	O
)	O
.	O

Although	O
a	O
major	O
goal	O
when	O
investigating	O
an	O
E3	O
is	O
to	O
identify	O
its	O
substrates	O
,	O
recent	O
evidence	O
indicates	O
that	O
the	O
E2	O
dictates	O
the	O
type	O
of	O
ubiquitin	B-Protein
modification	O
that	O
will	O
occur	O
on	O
the	O
substrate	O
.	O

There	O
are	O
approximately	O
30	O
E2s	O
identified	O
in	O
the	O
human	O
genome	O
,	O
many	O
of	O
which	O
remain	O
to	O
be	O
characterized	O
.	O

We	O
found	O
that	O
the	O
RING	O
E3	O
BRCA1	B-Protein
/	O
BARD1	B-Protein
can	O
interact	O
with	O
10	O
different	O
E2s	O
.	O

The	O
ability	O
of	O
BRCA1	B-Protein
to	O
interact	O
with	O
multiple	O
E2s	O
is	O
likely	O
to	O
be	O
a	O
common	O
feature	O
among	O
other	O
RING	O
and	O
U	O
-	O
box	O
E3s	O
.	O

We	O
and	O
others	O
have	O
also	O
found	O
that	O
certain	O
E2s	O
show	O
a	O
preference	O
for	O
attaching	O
either	O
the	O
first	O
ubiquitin	B-Protein
to	O
a	O
substrate	O
lysine	O
or	O
ubiquitin	B-Protein
to	O
itself	O
(	O
chain	O
building	O
)	O
,	O
suggesting	O
that	O
E2s	O
may	O
play	O
a	O
role	O
in	O
dictating	O
product	O
formation	O
.	O

Therefore	O
,	O
when	O
investigating	O
the	O
functions	O
of	O
an	O
E3	O
it	O
is	O
advisable	O
to	O
identify	O
all	O
E2s	O
that	O
interact	O
with	O
the	O
E3	O
so	O
that	O
these	O
can	O
be	O
used	O
in	O
E3	O
-	O
dependent	O
substrate	O
-	O
ubiquitination	O
assays	O
.	O

We	O
describe	O
a	O
method	O
used	O
to	O
identify	O
all	O
the	O
E2s	O
that	O
interact	O
with	O
BRCA1	B-Protein
.	O

Defining	O
the	O
set	O
of	O
E2s	O
that	O
interact	O
with	O
other	O
RING	O
and	O
U	O
-	O
box	O
E3s	O
will	O
open	O
the	O
door	O
for	O
predictive	O
models	O
and	O
lead	O
to	O
a	O
better	O
understand	O
of	O
substrate	O
ubiquitination	O
.	O

Negative	O
action	O
of	O
hepatocyte	B-Protein
growth	I-Protein
factor	I-Protein
/	O
c	B-Protein
-	I-Protein
Met	I-Protein
system	O
on	O
angiotensin	B-Protein
II	I-Protein
signaling	O
via	O
ligand	O
-	O
dependent	O
epithelial	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
degradation	O
mechanism	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

RATIONALE	O
:	O
Neointimal	O
hyperplasia	O
contributes	O
to	O
atherosclerosis	O
and	O
restenosis	O
after	O
percutaneous	O
coronary	O
intervention	O
.	O

Vascular	O
injury	O
in	O
each	O
of	O
these	O
conditions	O
results	O
in	O
the	O
release	O
of	O
mitogenic	O
growth	O
factors	O
and	O
hormones	O
that	O
contribute	O
to	O
pathological	O
vascular	O
smooth	O
muscle	O
cell	O
growth	O
and	O
inflammation	O
.	O

Hepatocyte	B-Protein
growth	I-Protein
factor	I-Protein
(	O
HGF	B-Protein
)	O
is	O
known	O
as	O
an	O
antiinflammatory	O
growth	O
factor	O
,	O
although	O
it	O
is	O
downregulated	O
in	O
injured	O
tissue	O
.	O

However	O
,	O
the	O
precise	O
mechanism	O
how	O
HGF	B-Protein
reduces	O
inflammation	O
is	O
unclear	O
.	O

OBJECTIVE	O
:	O
To	O
elucidate	O
the	O
mechanism	O
how	O
HGF	B-Protein
and	O
its	O
receptor	O
c	B-Protein
-	I-Protein
Met	I-Protein
reduces	O
angiotensin	B-Protein
II	I-Protein
(	O
Ang	B-Protein
II	I-Protein
)	O
-	O
induced	O
inflammation	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
HGF	B-Protein
reduced	O
Ang	B-Protein
II	I-Protein
-	O
induced	O
vascular	O
smooth	O
muscle	O
cell	O
growth	O
and	O
inflammation	O
by	O
controlling	O
translocation	O
of	O
SHIP2	B-Protein
(	O
Src	B-Protein
homology	I-Protein
domain	I-Protein
2	I-Protein
-	I-Protein
containing	I-Protein
inositol	I-Protein
5	I-Protein
'	I-Protein
-	I-Protein
phosphatase	I-Protein
2	I-Protein
)	O
,	O
which	O
led	O
to	O
Ang	B-Protein
II	I-Protein
-	O
dependent	O
degradation	O
of	O
epithelial	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
.	O

Moreover	O
,	O
the	O
present	O
study	O
also	O
revealed	O
a	O
preventive	O
effect	O
of	O
HGF	B-Protein
on	O
atherosclerotic	O
change	O
in	O
an	O
Ang	B-Protein
II	I-Protein
infusion	O
and	O
cuff	O
HGF	B-Protein
transgenic	O
mouse	O
model	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
the	O
HGF	B-Protein
/	O
c	B-Protein
-	I-Protein
Met	I-Protein
system	O
might	O
regulate	O
extrinsic	O
factor	O
signaling	O
that	O
maintains	O
the	O
homeostasis	O
of	O
organs	O
.	O

The	O
Sts	O
proteins	O
target	O
tyrosine	O
phosphorylated	O
,	O
ubiquitinated	O
proteins	O
within	O
TCR	O
signaling	O
pathways	O
.	O

The	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
detects	O
the	O
presence	O
of	O
infectious	O
pathogens	O
and	O
activates	O
numerous	O
intracellular	O
signaling	O
pathways	O
.	O

Protein	O
tyrosine	O
phosphorylation	O
and	O
ubiquitination	O
serve	O
as	O
key	O
regulatory	O
mechanisms	O
downstream	O
of	O
the	O
TCR	O
.	O

Negative	O
regulation	O
of	O
TCR	O
signaling	O
pathways	O
is	O
important	O
in	O
controlling	O
the	O
immune	O
response	O
,	O
and	O
the	O
Suppressor	O
of	O
TCR	O
Signaling	O
proteins	O
(	O
Sts	B-Protein
-	I-Protein
1	I-Protein
and	O
Sts	B-Protein
-	I-Protein
2	I-Protein
)	O
have	O
been	O
shown	O
to	O
function	O
as	O
critical	O
negative	O
regulators	O
of	O
TCR	O
signaling	O
.	O

Although	O
their	O
mechanism	O
of	O
action	O
has	O
yet	O
to	O
be	O
fully	O
uncovered	O
,	O
it	O
is	O
known	O
that	O
the	O
Sts	O
proteins	O
possess	O
intrinsic	O
phosphatase	O
activity	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
Sts	B-Protein
-	I-Protein
1	I-Protein
and	O
Sts	B-Protein
-	I-Protein
2	I-Protein
are	O
instrumental	O
in	O
down	O
-	O
modulating	O
proteins	O
that	O
are	O
dually	O
modified	O
by	O
both	O
protein	O
tyrosine	O
phosphorylation	O
and	O
ubiquitination	O
.	O

Specifically	O
,	O
both	O
naive	O
and	O
activated	O
T	O
cells	O
derived	O
from	O
genetically	O
engineered	O
mice	O
that	O
lack	O
the	O
Sts	O
proteins	O
display	O
strikingly	O
elevated	O
levels	O
of	O
tyrosine	O
phosphorylated	O
,	O
ubiquitinated	O
proteins	O
following	O
TCR	O
stimulation	O
.	O

The	O
accumulation	O
of	O
the	O
dually	O
modified	O
proteins	O
is	O
transient	O
,	O
and	O
in	O
activated	O
T	O
cells	O
but	O
not	O
naive	O
T	O
cells	O
is	O
significantly	O
enhanced	O
by	O
co	O
-	O
receptor	O
engagement	O
.	O

Our	O
observations	O
hint	O
at	O
a	O
novel	O
regulatory	O
mechanism	O
downstream	O
of	O
the	O
T	O
cell	O
receptor	O
.	O

Role	O
of	O
DNA	O
methylation	O
and	O
methyl	O
-	O
DNA	O
binding	O
proteins	O
in	O
the	O
repression	O
of	O
5	B-Protein
-	I-Protein
lipoxygenase	I-Protein
promoter	O
activity	O
.	O

Human	O
5	B-Protein
-	I-Protein
lipoxygenase	I-Protein
(	O
5	B-Protein
-	I-Protein
LO	I-Protein
)	O
is	O
the	O
key	O
enzyme	O
in	O
the	O
formation	O
of	O
inflammatory	O
leukotrienes	O
.	O

5	B-Protein
-	I-Protein
LO	I-Protein
gene	O
expression	O
is	O
mainly	O
restricted	O
to	O
B	O
cells	O
and	O
cells	O
of	O
myeloid	O
origin	O
.	O

It	O
is	O
known	O
that	O
basal	O
5	B-Protein
-	I-Protein
lipoxygenase	I-Protein
promoter	O
activity	O
is	O
regulated	O
by	O
DNA	O
methylation	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
impact	O
of	O
the	O
DNA	O
methylation	O
status	O
of	O
the	O
5	B-Protein
-	I-Protein
LO	I-Protein
promoter	O
on	O
its	O
activity	O
and	O
the	O
role	O
of	O
methyl	O
DNA	O
binding	O
proteins	O
(	O
MBDs	O
)	O
in	O
transcriptional	O
silencing	O
of	O
the	O
5	B-Protein
-	I-Protein
LO	I-Protein
promoter	O
.	O

Using	O
ChIP	O
assays	O
,	O
we	O
found	O
that	O
the	O
methyl	O
-	O
DNA	O
binding	O
proteins	O
MBD1	B-Protein
,	O
MBD2	B-Protein
and	O
MeCP2	B-Protein
bind	O
to	O
the	O
methylated	O
5	B-Protein
-	I-Protein
LO	I-Protein
core	O
promoter	O
in	O
U937	O
cells	O
.	O

Knock	O
down	O
of	O
each	O
of	O
the	O
MBDs	O
upregulates	O
5	B-Protein
-	I-Protein
LO	I-Protein
mRNA	O
expression	O
in	O
U937	O
cells	O
indicating	O
that	O
these	O
proteins	O
are	O
involved	O
in	O
silencing	O
of	O
the	O
5	B-Protein
-	I-Protein
LO	I-Protein
gene	O
.	O

In	O
reporter	O
gene	O
assays	O
with	O
in	O
vitro	O
methylated	O
5	B-Protein
-	I-Protein
LO	I-Protein
promoter	O
constructs	O
,	O
the	O
extent	O
of	O
5	B-Protein
-	I-Protein
LO	I-Protein
promoter	O
methylation	O
inversely	O
correlated	O
with	O
its	O
activity	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
MBD1	B-Protein
overexpression	O
repressed	O
5	B-Protein
-	I-Protein
LO	I-Protein
promoter	O
activity	O
when	O
the	O
CpG	O
sites	O
at	O
the	O
Sp1	B-Protein
binding	O
site	O
close	O
to	O
the	O
transcriptional	O
start	O
site	O
(	O
GC4	O
)	O
were	O
methylated	O
.	O

Gel	O
shift	O
data	O
indicate	O
that	O
recruitment	O
of	O
Sp1	B-Protein
to	O
this	O
binding	O
site	O
is	O
prevented	O
by	O
methylation	O
.	O

60th	O
residues	O
of	O
ubiquitin	B-Protein
and	O
Nedd8	B-Protein
are	O
located	O
out	O
of	O
E2	O
-	O
binding	O
surfaces	O
,	O
but	O
are	O
important	O
for	O
K48	O
ubiquitin	B-Protein
-	O
linkage	O
.	O

Nedd8	B-Protein
,	O
a	O
ubiquitin	B-Protein
-	O
like	O
modifier	O
,	O
is	O
covalently	O
attached	O
to	O
various	O
proteins	O
.	O

Although	O
Nedd8	B-Protein
has	O
higher	O
sequence	O
identity	O
(	O
57	O
%	O
)	O
with	O
ubiquitin	B-Protein
,	O
its	O
conserved	O
K48	O
residue	O
cannot	O
form	O
covalent	O
linkage	O
with	O
ubiquitin	B-Protein
.	O

To	O
decipher	O
the	O
reason	O
why	O
Nedd8	B-Protein
cannot	O
be	O
an	O
effective	O
ubiquitin	B-Protein
-	O
acceptor	O
,	O
we	O
compared	O
the	O
non	O
-	O
covalent	O
interaction	O
between	O
Nedd8	B-Protein
and	O
ubiquitin	B-Protein
for	O
various	O
E2s	O
using	O
cross	O
-	O
saturation	O
NMR	O
technique	O
.	O

However	O
,	O
both	O
Nedd8	B-Protein
and	O
ubiquitin	B-Protein
displayed	O
almost	O
identical	O
non	O
-	O
covalent	O
E2	O
-	O
binding	O
properties	O
.	O

The	O
K60	O
of	O
Nedd8	B-Protein
was	O
not	O
present	O
at	O
the	O
E2	O
-	O
binding	O
surface	O
,	O
but	O
its	O
mutation	O
to	O
Asn	O
converted	O
Nedd8	B-Protein
into	O
a	O
ubiquitin	B-Protein
-	O
acceptor	O
.	O

The	O
N60	O
ubiquitin	B-Protein
mutants	O
also	O
displayed	O
a	O
decreased	O
ubiquitin	B-Protein
-	O
accepting	O
activity	O
.	O

These	O
results	O
suggest	O
the	O
presence	O
of	O
an	O
uncharacterized	O
determinant	O
for	O
the	O
K48	O
ubiquitin	B-Protein
-	O
linkage	O
that	O
is	O
not	O
related	O
to	O
non	O
-	O
covalent	O
E2	O
-	O
bindings	O
.	O

Glycosylation	O
of	O
classical	O
swine	O
fever	O
virus	O
E	B-Protein
(	I-Protein
rns	I-Protein
)	I-Protein
is	O
essential	O
for	O
binding	O
double	O
-	O
stranded	O
RNA	O
and	O
preventing	O
interferon	B-Protein
-	I-Protein
beta	I-Protein
induction	O
.	O

Host	O
cells	O
sense	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
produced	O
during	O
viral	O
replication	O
and	O
initiate	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
alpha	O
/	O
beta	B-Protein
)	O
production	O
,	O
leading	O
to	O
subsequent	O
antiviral	O
responses	O
.	O

Many	O
viruses	O
,	O
including	O
classical	O
swine	O
fever	O
virus	O
(	O
CSFV	O
)	O
,	O
have	O
developed	O
strategies	O
for	O
counteracting	O
the	O
IFN	O
-	O
alpha	O
/	O
beta	B-Protein
response	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
role	O
of	O
the	O
CSFV	O
E	B-Protein
(	I-Protein
rns	I-Protein
)	I-Protein
glycoprotein	O
in	O
the	O
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
production	O
induced	O
by	O
dsRNA	O
[	O
poly	O
(	O
IC	O
)	O
]	O
.	O

Our	O
results	O
demonstrated	O
that	O
CSFV	O
E	B-Protein
(	I-Protein
rns	I-Protein
)	I-Protein
could	O
bind	O
to	O
exogenous	O
dsRNA	O
and	O
inhibit	O
dsRNA	O
-	O
induced	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
production	O
but	O
failed	O
to	O
inhibit	O
TRIF	B-Protein
-	O
triggered	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
production	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
induction	O
occurred	O
at	O
the	O
initial	O
step	O
of	O
the	O
TLR3	B-Protein
signaling	O
pathway	O
.	O

We	O
also	O
showed	O
that	O
deglycosylation	O
of	O
E	B-Protein
(	I-Protein
rns	I-Protein
)	I-Protein
rendered	O
it	O
unable	O
to	O
bind	O
to	O
dsRNA	O
,	O
and	O
thus	O
unable	O
to	O
inhibit	O
dsRNA	O
-	O
induced	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
production	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicated	O
that	O
N	O
-	O
glycan	O
of	O
CSFV	O
E	B-Protein
(	I-Protein
rns	I-Protein
)	I-Protein
is	O
essential	O
for	O
E	B-Protein
(	I-Protein
rns	I-Protein
)	I-Protein
blocking	O
of	O
IFN	B-Protein
-	I-Protein
beta	I-Protein
induction	O
.	O

IKKalpha	B-Protein
negatively	O
regulates	O
IRF	B-Protein
-	I-Protein
5	I-Protein
function	O
in	O
a	O
MyD88	B-Protein
-	O
TRAF6	B-Protein
pathway	O
.	O

Transcription	O
factors	O
of	O
IRF	O
family	O
,	O
IRF	B-Protein
-	I-Protein
3	I-Protein
,	O
IRF	B-Protein
-	I-Protein
5	I-Protein
and	O
IRF	B-Protein
-	I-Protein
7	I-Protein
play	O
a	O
critical	O
role	O
in	O
the	O
innate	O
antiviral	O
response	O
.	O

In	O
infected	O
cells	O
,	O
IRF	B-Protein
-	I-Protein
3	I-Protein
and	O
IRF	B-Protein
-	I-Protein
7	I-Protein
are	O
activated	O
by	O
TBK	B-Protein
-	I-Protein
1	I-Protein
and	O
IKK	B-Protein
epsilon	I-Protein
mediated	O
phosphorylation	O
,	O
while	O
the	O
kinase	O
,	O
phosphorylating	O
IRF	B-Protein
-	I-Protein
5	I-Protein
in	O
the	O
MyD88	B-Protein
signalling	O
pathway	O
has	O
not	O
yet	O
been	O
identified	O
.	O

We	O
now	O
show	O
that	O
IKK	B-Protein
alpha	I-Protein
phosphorylates	O
IRF	B-Protein
-	I-Protein
5	I-Protein
and	O
induces	O
formation	O
of	O
IRF	B-Protein
-	I-Protein
5	I-Protein
dimers	O
,	O
which	O
have	O
been	O
indicative	O
of	O
IRF	B-Protein
-	I-Protein
5	I-Protein
activation	O
.	O

However	O
,	O
IKK	B-Protein
alpha	I-Protein
induced	O
IRF	B-Protein
-	I-Protein
5	I-Protein
phosphorylation	O
exerts	O
inhibitory	O
effect	O
on	O
the	O
transcriptional	O
activation	O
of	O
type	O
1	O
interferon	O
and	O
promoters	O
of	O
the	O
inflammatory	O
cytokines	O
.	O

Addressing	O
the	O
molecular	O
mechanism	O
of	O
IKK	B-Protein
alpha	I-Protein
mediated	O
inhibition	O
of	O
IRF	B-Protein
-	I-Protein
5	I-Protein
activity	O
,	O
we	O
show	O
that	O
phosphorylation	O
of	O
IRF	B-Protein
-	I-Protein
5	I-Protein
by	O
IKK	B-Protein
alpha	I-Protein
inhibits	O
K63	O
ubiquitination	O
that	O
is	O
essential	O
for	O
IRF	B-Protein
-	I-Protein
5	I-Protein
activity	O
.	O

Furthermore	O
,	O
we	O
have	O
identified	O
interaction	O
of	O
IRF	B-Protein
-	I-Protein
5	I-Protein
with	O
alkaline	O
phosphatase	O
,	O
which	O
causes	O
its	O
de	O
-	O
phosphorylation	O
.	O

The	O
observation	O
that	O
MyD88	B-Protein
activated	O
IRF	B-Protein
-	I-Protein
5	I-Protein
induces	O
expression	O
of	O
alkaline	O
phosphatase	O
suggests	O
that	O
IRF	B-Protein
-	I-Protein
5	I-Protein
is	O
under	O
autoregulating	O
loop	O
.	O

Thus	O
these	O
completely	O
new	O
observations	O
identify	O
IKK	B-Protein
alpha	I-Protein
kinase	O
and	O
alkaline	O
phosphatase	O
as	O
negative	O
regulators	O
of	O
IRF	B-Protein
-	I-Protein
5	I-Protein
activity	O
in	O
MyD88	B-Protein
pathway	O
and	O
implicate	O
their	O
role	O
in	O
the	O
control	O
of	O
the	O
inflammatory	O
response	O
by	O
attenuation	O
of	O
IRF	B-Protein
-	I-Protein
5	I-Protein
activity	O
.	O

Real	O
-	O
time	O
imaging	O
of	O
histone	B-Protein
H4	I-Protein
hyperacetylation	O
in	O
living	O
cells	O
.	O

To	O
visualize	O
histone	B-Protein
acetylation	O
in	O
living	O
cells	O
,	O
we	O
developed	O
a	O
genetically	O
encoded	O
fluorescent	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
-	O
based	O
indicator	O
.	O

Response	O
of	O
the	O
indicator	O
reflects	O
changes	O
in	O
the	O
acetylation	O
state	O
of	O
both	O
K5	O
and	O
K8	O
in	O
histone	B-Protein
H4	I-Protein
.	O

Using	O
this	O
acetylation	O
indicator	O
,	O
we	O
were	O
able	O
to	O
monitor	O
the	O
dynamic	O
fluctuation	O
of	O
histone	B-Protein
H4	I-Protein
acetylation	O
levels	O
during	O
mitosis	O
,	O
as	O
well	O
as	O
acetylation	O
changes	O
in	O
response	O
to	O
structurally	O
distinct	O
histone	B-Protein
deacetylase	O
inhibitors	O
.	O

Ubiquitylation	O
of	O
the	O
gap	O
junction	O
protein	O
connexin	B-Protein
-	I-Protein
43	I-Protein
signals	O
its	O
trafficking	O
from	O
early	O
endosomes	O
to	O
lysosomes	O
in	O
a	O
process	O
mediated	O
by	O
Hrs	B-Protein
and	O
Tsg101	B-Protein
.	O

Gap	O
junctions	O
are	O
dynamic	O
plasma	O
membrane	O
domains	O
,	O
and	O
their	O
protein	O
constituents	O
,	O
the	O
connexins	O
,	O
have	O
a	O
high	O
turnover	O
rate	O
in	O
most	O
tissue	O
types	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
degradation	O
of	O
gap	O
junctions	O
have	O
remained	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
ubiquitin	B-Protein
is	O
strongly	O
relocalized	O
to	O
connexin	B-Protein
-	I-Protein
43	I-Protein
(	O
Cx43	B-Protein
;	O
also	O
known	O
as	O
Gja1	B-Protein
)	O
gap	O
junction	O
plaques	O
in	O
response	O
to	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Cx43	B-Protein
remained	O
ubiquitylated	O
during	O
its	O
transition	O
to	O
a	O
Triton	O
X	O
-	O
100	O
-	O
soluble	O
state	O
and	O
along	O
its	O
trafficking	O
to	O
early	O
endosomes	O
.	O

Following	O
internalization	O
,	O
Cx43	B-Protein
partly	O
colocalized	O
with	O
the	O
ubiquitin	B-Protein
-	O
binding	O
proteins	O
Hrs	B-Protein
(	O
hepatocyte	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
regulated	I-Protein
tyrosine	I-Protein
kinase	I-Protein
substrate	I-Protein
;	O
also	O
known	O
as	O
Hgs	B-Protein
)	O
and	O
Tsg101	B-Protein
(	O
tumor	B-Protein
susceptibility	I-Protein
gene	I-Protein
101	I-Protein
)	O
.	O

Depletion	O
of	O
Hrs	B-Protein
or	O
Tsg101	B-Protein
by	O
small	O
interfering	O
RNA	O
abrogated	O
trafficking	O
of	O
Cx43	B-Protein
from	O
early	O
endosomes	O
to	O
lysosomes	O
.	O

Under	O
these	O
conditions	O
,	O
Cx43	B-Protein
was	O
able	O
to	O
undergo	O
dephosphorylation	O
and	O
deubiquitylation	O
,	O
locate	O
to	O
the	O
plasma	O
membrane	O
and	O
form	O
functional	O
gap	O
junctions	O
.	O

Simultaneous	O
depletion	O
of	O
Hrs	B-Protein
and	O
Tsg101	B-Protein
caused	O
accumulation	O
of	O
a	O
phosphorylated	O
and	O
ubiquitylated	O
subpopulation	O
of	O
Cx43	B-Protein
in	O
early	O
endosomes	O
and	O
in	O
hybrid	O
organelles	O
between	O
partly	O
degraded	O
annular	O
gap	O
junctions	O
and	O
endosomes	O
.	O

Collectively	O
,	O
these	O
data	O
reveal	O
a	O
central	O
role	O
of	O
early	O
endosomes	O
in	O
sorting	O
of	O
ubiquitylated	O
Cx43	B-Protein
,	O
and	O
identify	O
Hrs	B-Protein
and	O
Tsg101	B-Protein
as	O
crucial	O
regulators	O
of	O
trafficking	O
of	O
Cx43	B-Protein
to	O
lysosomes	O
.	O

Alpha4	B-Protein
is	O
an	O
essential	O
regulator	O
of	O
PP2A	O
phosphatase	O
activity	O
.	O

The	O
activity	O
and	O
specificity	O
of	O
serine	O
/	O
threonine	O
phosphatases	O
are	O
governed	O
largely	O
by	O
their	O
associated	O
proteins	O
.	O

alpha4	B-Protein
is	O
an	O
evolutionarily	O
conserved	O
noncatalytic	O
subunit	O
for	O
PP2A	O
-	O
like	O
phosphatases	O
.	O

Though	O
alpha4	B-Protein
binds	O
to	O
only	O
a	O
minority	O
of	O
PP2A	O
-	O
related	O
catalytic	O
subunits	O
,	O
alpha4	B-Protein
deletion	O
leads	O
to	O
progressive	O
loss	O
of	O
all	O
PP2A	O
,	O
PP4	O
,	O
and	O
PP6	O
phosphatase	O
complexes	O
.	O

In	O
healthy	O
cells	O
,	O
association	O
with	O
alpha4	B-Protein
renders	O
catalytic	O
(	O
C	O
)	O
subunits	O
enzymatically	O
inactive	O
while	O
protecting	O
them	O
from	O
proteasomal	O
degradation	O
until	O
they	O
are	O
assembled	O
into	O
a	O
functional	O
phosphatase	O
complex	O
.	O

During	O
cellular	O
stress	O
,	O
existing	O
PP2A	O
complexes	O
can	O
become	O
unstable	O
.	O

Under	O
such	O
conditions	O
,	O
alpha4	B-Protein
sequesters	O
released	O
C	O
subunits	O
and	O
is	O
required	O
for	O
the	O
adaptive	O
increase	O
in	O
targeted	O
PP2A	O
activity	O
that	O
can	O
dephosphorylate	O
stress	O
-	O
induced	O
phosphorylated	O
substrates	O
.	O

Consistent	O
with	O
this	O
,	O
overexpression	O
of	O
alpha4	B-Protein
protects	O
cells	O
from	O
a	O
variety	O
of	O
stress	O
stimuli	O
,	O
including	O
DNA	O
damage	O
and	O
nutrient	O
limitation	O
.	O

These	O
findings	O
demonstrate	O
that	O
alpha4	B-Protein
plays	O
a	O
required	O
role	O
in	O
regulating	O
the	O
assembly	O
and	O
maintenance	O
of	O
adaptive	O
PP2A	O
phosphatase	O
complexes	O
.	O

COP9	O
signalosome	O
interacts	O
ATP	O
-	O
dependently	O
with	O
p97	B-Protein
/	O
valosin	B-Protein
-	I-Protein
containing	I-Protein
protein	I-Protein
(	O
VCP	B-Protein
)	O
and	O
controls	O
the	O
ubiquitination	O
status	O
of	O
proteins	O
bound	O
to	O
p97	B-Protein
/	O
VCP	B-Protein
.	O

Ubiquitinated	O
proteins	O
can	O
alternatively	O
be	O
delivered	O
directly	O
to	O
the	O
proteasome	O
or	O
via	O
p97	B-Protein
/	O
VCP	B-Protein
(	O
valosin	B-Protein
-	I-Protein
containing	I-Protein
protein	I-Protein
)	O
.	O

Whereas	O
the	O
proteasome	O
degrades	O
ubiquitinated	O
proteins	O
,	O
the	O
homohexameric	O
ATPase	O
p97	B-Protein
/	O
VCP	B-Protein
seems	O
to	O
control	O
the	O
ubiquitination	O
status	O
of	O
recruited	O
substrates	O
.	O

The	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
is	O
also	O
involved	O
in	O
the	O
ubiquitin	B-Protein
/	O
proteasome	O
system	O
(	O
UPS	O
)	O
as	O
exemplified	O
by	O
regulating	O
the	O
neddylation	O
of	O
ubiquitin	B-Protein
E3	O
ligases	O
.	O

Here	O
,	O
we	O
show	O
that	O
p97	B-Protein
/	O
VCP	B-Protein
colocalizes	O
and	O
directly	O
interacts	O
with	O
subunit	O
5	O
of	O
the	O
CSN	O
(	O
CSN5	B-Protein
)	O
in	O
vivo	O
and	O
is	O
associated	O
with	O
the	O
entire	O
CSN	O
complex	O
in	O
an	O
ATP	O
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
CSN	O
and	O
in	O
particular	O
the	O
isopeptidase	O
activity	O
of	O
its	O
subunit	O
CSN5	B-Protein
as	O
well	O
as	O
the	O
associated	O
deubiquitinase	O
USP15	B-Protein
are	O
required	O
for	O
proper	O
processing	O
of	O
polyubiquitinated	O
substrates	O
bound	O
to	O
p97	B-Protein
/	O
VCP	B-Protein
.	O

Moreover	O
,	O
we	O
show	O
that	O
in	O
addition	O
to	O
NEDD8	B-Protein
,	O
CSN5	B-Protein
binds	O
to	O
oligoubiquitin	B-Protein
chains	O
in	O
vitro	O
.	O

Therefore	O
,	O
CSN	O
and	O
p97	B-Protein
/	O
VCP	B-Protein
could	O
form	O
an	O
ATP	O
-	O
dependent	O
complex	O
that	O
resembles	O
the	O
19	O
S	O
proteasome	O
regulatory	O
particle	O
and	O
serves	O
as	O
a	O
key	O
mediator	O
between	O
ubiquitination	O
and	O
degradation	O
pathways	O
.	O

Targeting	O
of	O
gp78	B-Protein
for	O
ubiquitin	B-Protein
-	O
mediated	O
proteasomal	O
degradation	O
by	O
Hrd1	B-Protein
:	O
cross	O
-	O
talk	O
between	O
E3s	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

There	O
are	O
an	O
increasing	O
number	O
of	O
ubiquitin	B-Protein
ligases	O
(	O
E3s	O
)	O
implicated	O
in	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
associated	O
degradation	O
(	O
ERAD	O
)	O
in	O
mammals	O
.	O

The	O
two	O
for	O
which	O
the	O
greatest	O
amount	O
of	O
information	O
exists	O
are	O
the	O
RING	O
finger	O
proteins	O
gp78	B-Protein
and	O
Hrd1	B-Protein
,	O
which	O
are	O
the	O
structural	O
orthologs	O
of	O
the	O
yeast	O
ERAD	O
E3	O
Hrd1p	B-Protein
.	O

We	O
now	O
report	O
that	O
Hrd1	B-Protein
,	O
also	O
known	O
as	O
synoviolin	B-Protein
,	O
targets	O
gp78	B-Protein
for	O
proteasomal	O
degradation	O
independent	O
of	O
the	O
ubiquitin	B-Protein
ligase	O
activity	O
of	O
gp78	B-Protein
,	O
without	O
evidence	O
of	O
a	O
reciprocal	O
effect	O
.	O

This	O
degradation	O
is	O
observed	O
in	O
mouse	O
embryonic	O
fibroblasts	O
lacking	O
Hrd1	B-Protein
,	O
as	O
well	O
as	O
with	O
acute	O
manipulation	O
of	O
Hrd1	B-Protein
.	O

The	O
significance	O
of	O
this	O
is	O
underscored	O
by	O
the	O
diminished	O
level	O
of	O
a	O
gp78	B-Protein
-	O
specific	O
substrate	O
,	O
Insig	B-Protein
-	I-Protein
1	I-Protein
,	O
when	O
Hrd1	B-Protein
expression	O
is	O
decreased	O
and	O
gp78	B-Protein
levels	O
are	O
consequently	O
increased	O
.	O

These	O
finding	O
demonstrate	O
a	O
previously	O
unappreciated	O
level	O
of	O
complexity	O
of	O
the	O
ubiquitin	B-Protein
system	O
in	O
ERAD	O
and	O
have	O
potentially	O
important	O
ramifications	O
for	O
processes	O
where	O
gp78	B-Protein
is	O
implicated	O
including	O
regulation	O
of	O
lipid	O
metabolism	O
,	O
metastasis	O
,	O
cystic	O
fibrosis	O
and	O
neurodegenerative	O
disorders	O
.	O

FIH	B-Protein
-	O
dependent	O
asparaginyl	O
hydroxylation	O
of	O
ankyrin	O
repeat	O
domain	O
-	O
containing	O
proteins	O
.	O

Studies	O
on	O
hypoxia	O
-	O
sensitive	O
pathways	O
have	O
identified	O
a	O
series	O
of	O
Fe	O
(	O
II	O
)	O
-	O
dependent	O
dioxygenases	O
that	O
regulate	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
by	O
prolyl	O
and	O
asparaginyl	O
hydroxylation	O
.	O

The	O
asparaginyl	O
hydroxylase	O
factor	B-Protein
inhibiting	I-Protein
HIF	I-Protein
(	O
FIH	B-Protein
)	O
targets	O
a	O
conserved	O
asparaginyl	O
residue	O
in	O
the	O
C	O
-	O
terminal	O
transactivation	O
domain	O
of	O
HIF	O
-	O
alpha	O
.	O

This	O
modification	O
suppresses	O
HIF	O
transcriptional	O
activity	O
by	O
inhibiting	O
co	O
-	O
activator	O
recruitment	O
.	O

Recent	O
work	O
has	O
demonstrated	O
that	O
FIH	B-Protein
targets	O
an	O
alternative	O
class	O
of	O
substrate	O
.	O

Proteins	O
containing	O
a	O
common	O
interaction	O
motif	O
known	O
as	O
the	O
ankyrin	O
repeat	O
domain	O
(	O
ARD	O
)	O
have	O
been	O
shown	O
to	O
be	O
efficiently	O
hydroxylated	O
by	O
FIH	B-Protein
.	O

This	O
review	O
aims	O
to	O
summarize	O
what	O
is	O
currently	O
known	O
regarding	O
ARD	O
hydroxylation	O
,	O
including	O
the	O
kinetics	O
and	O
determinants	O
of	O
FIH	B-Protein
-	O
mediated	O
ARD	O
hydroxylation	O
,	O
the	O
structural	O
and	O
functional	O
consequences	O
of	O
ARD	O
hydroxylation	O
,	O
and	O
the	O
potential	O
for	O
cross	O
-	O
talk	O
between	O
ARD	O
proteins	O
and	O
HIF	O
signaling	O
.	O

Cyclosporin	O
A	O
slows	O
collagen	O
triple	O
-	O
helix	O
formation	O
in	O
vivo	O
:	O
indirect	O
evidence	O
for	O
a	O
physiologic	O
role	O
of	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
-	O
isomerase	O
.	O

Peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
-	O
isomerase	O
accelerates	O
otherwise	O
slow	O
,	O
rate	O
-	O
limiting	O
isomerization	O
steps	O
during	O
folding	O
of	O
proteins	O
in	O
vitro	O
,	O
but	O
is	O
not	O
yet	O
securely	O
identified	O
with	O
any	O
specific	O
physiologic	O
role	O
.	O

Peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
-	O
isomerase	O
and	O
the	O
cyclosporin	B-Protein
A	I-Protein
(	I-Protein
CsA	I-Protein
)	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
cyclophilin	B-Protein
are	O
identical	O
,	O
and	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
-	O
isomerase	O
activity	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
CsA	O
in	O
vitro	O
.	O

To	O
establish	O
a	O
possible	O
physiologic	O
role	O
of	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
-	O
isomerase	O
,	O
we	O
have	O
studied	O
the	O
folding	O
of	O
procollagen	O
I	O
in	O
suspended	O
chick	O
embryo	O
tendon	O
fibroblasts	O
.	O

Folding	O
of	O
procollagen	O
I	O
is	O
slowed	O
by	O
CsA	O
:	O
the	O
time	O
needed	O
for	O
50	O
%	O
of	O
the	O
molecules	O
to	O
reach	O
a	O
completely	O
helical	O
confirmation	O
is	O
8	O
.	O
5	O
min	O
in	O
the	O
absence	O
and	O
13	O
.	O
5	O
min	O
in	O
the	O
presence	O
of	O
5	O
microM	O
CsA	O
;	O
and	O
the	O
calculated	O
products	O
,	O
k	O
x	O
K	O
,	O
of	O
the	O
rate	O
constant	O
(	O
k	O
)	O
and	O
the	O
equilibrium	O
constant	O
(	O
K	O
)	O
of	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
trans	O
isomerization	O
are	O
2	O
.	O
10	O
and	O
1	O
.	O
30	O
s	O
-	O
1	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
folding	O
of	O
purified	O
collagen	B-Protein
III	I-Protein
in	O
vitro	O
is	O
unaffected	O
by	O
CsA	O
.	O

In	O
cultured	O
human	O
fibroblasts	O
,	O
CsA	O
caused	O
posttranslational	O
overmodification	O
(	O
hydroxylation	O
of	O
lysine	O
32	O
.	O
1	O
versus	O
22	O
.	O
1	O
%	O
)	O
and	O
increased	O
intracellular	O
degradation	O
(	O
18	O
.	O
7	O
versus	O
12	O
.	O
5	O
%	O
)	O
,	O
and	O
hence	O
decreased	O
production	O
(	O
10	O
.	O
2	O
versus	O
13	O
.	O
2	O
%	O
of	O
total	O
protein	O
synthesis	O
)	O
of	O
collagens	O
I	O
and	O
III	B-Protein
,	O
indicating	O
that	O
procollagen	O
folding	O
is	O
slowed	O
by	O
CsA	O
also	O
in	O
human	O
fibroblasts	O
.	O

We	O
conclude	O
that	O
peptidyl	O
-	O
prolyl	O
cis	O
-	O
transisomerase	O
(	O
and	O
hence	O
cyclophilin	B-Protein
)	O
accelerates	O
protein	O
folding	O
in	O
living	O
cells	O
.	O

Furthermore	O
,	O
the	O
CsA	O
-	O
induced	O
changes	O
in	O
collagen	O
metabolism	O
are	O
reminiscent	O
of	O
those	O
observed	O
in	O
several	O
variants	O
of	O
osteogenesis	O
imperfecta	O
caused	O
by	O
structural	O
abnormalities	O
in	O
the	O
pro	O
-	O
collagen	O
chains	O
which	O
impair	O
helix	O
formation	O
.	O

Remodeling	O
of	O
the	O
SCF	O
complex	O
-	O
mediated	O
ubiquitination	O
system	O
by	O
compositional	O
alteration	O
of	O
incorporated	O
F	O
-	O
box	O
proteins	O
.	O

Ubiquitination	O
regulates	O
not	O
only	O
the	O
stability	O
but	O
the	O
localization	O
and	O
activity	O
of	O
substrate	O
proteins	O
involved	O
in	O
a	O
plethora	O
of	O
cellular	O
processes	O
.	O

The	O
Skp1	B-Protein
-	O
Cullin	O
-	O
F	O
-	O
box	O
protein	O
(	O
SCF	O
)	O
complexes	O
constitute	O
a	O
major	O
family	O
of	O
ubiquitin	B-Protein
protein	O
ligases	O
,	O
in	O
each	O
member	O
of	O
which	O
an	O
F	O
-	O
box	O
protein	O
serves	O
as	O
the	O
variable	O
component	O
responsible	O
for	O
substrate	O
recognition	O
,	O
thereby	O
defining	O
the	O
function	O
of	O
each	O
complex	O
.	O

Here	O
we	O
studied	O
whether	O
the	O
composition	O
of	O
F	O
-	O
box	O
proteins	O
in	O
the	O
SCF	O
complexes	O
is	O
remodeled	O
under	O
different	O
conditions	O
.	O

We	O
exploited	O
stable	O
isotope	O
labeling	O
and	O
MS	O
for	O
relative	O
quantification	O
of	O
F	O
-	O
box	O
proteins	O
in	O
the	O
SCF	O
complexes	O
affinity	O
-	O
purified	O
en	O
masse	O
from	O
budding	O
yeast	O
cells	O
at	O
log	O
and	O
post	O
-	O
diauxic	O
phases	O
,	O
and	O
revealed	O
an	O
increment	O
of	O
Saf1	B-Protein
,	O
an	O
F	O
-	O
box	O
protein	O
involved	O
in	O
entry	O
into	O
quiescence	O
,	O
during	O
the	O
diauxic	O
shift	O
.	O

Similarly	O
,	O
we	O
found	O
that	O
Met4	B-Protein
overexpression	O
induces	O
a	O
specific	O
increment	O
of	O
Met30	B-Protein
,	O
the	O
F	O
-	O
box	O
protein	O
responsible	O
for	O
ubiquitination	O
of	O
Met4	B-Protein
.	O

These	O
results	O
illustrate	O
a	O
cellular	O
response	O
to	O
environmental	O
and	O
genetic	O
perturbations	O
through	O
remodeling	O
of	O
the	O
SCF	O
complex	O
-	O
mediated	O
ubiquitination	O
system	O
.	O

Compositional	O
alteration	O
of	O
incorporated	O
F	O
-	O
box	O
proteins	O
may	O
redirect	O
the	O
activity	O
of	O
this	O
system	O
toward	O
appropriate	O
substrates	O
to	O
be	O
ubiquitinated	O
under	O
individual	O
conditions	O
for	O
the	O
maintenance	O
of	O
cellular	O
homeostasis	O
.	O

Impaired	O
lysosomal	O
trimming	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
leads	O
to	O
hyperglycosylation	O
of	O
native	O
lysosomal	O
proteins	O
in	O
mice	O
with	O
alpha	O
-	O
mannosidosis	O
.	O

Alpha	O
-	O
mannosidosis	O
is	O
caused	O
by	O
the	O
genetic	O
defect	O
of	O
the	O
lysosomal	B-Protein
alpha	I-Protein
-	I-Protein
d	I-Protein
-	I-Protein
mannosidase	I-Protein
(	O
LAMAN	B-Protein
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
breakdown	O
of	O
free	O
alpha	O
-	O
linked	O
mannose	O
-	O
containing	O
oligosaccharides	O
originating	O
from	O
glycoproteins	O
with	O
N	O
-	O
linked	O
glycans	O
,	O
and	O
thus	O
manifests	O
itself	O
in	O
an	O
extensive	O
storage	O
of	O
mannose	O
-	O
containing	O
oligosaccharides	O
.	O

Here	O
we	O
demonstrate	O
in	O
a	O
model	O
of	O
mice	O
with	O
alpha	O
-	O
mannosidosis	O
that	O
native	O
lysosomal	O
proteins	O
exhibit	O
elongated	O
N	O
-	O
linked	O
oligosaccharides	O
as	O
shown	O
by	O
two	O
-	O
dimensional	O
difference	O
gel	O
electrophoresis	O
,	O
deglycosylation	O
assays	O
,	O
and	O
mass	O
spectrometry	O
.	O

The	O
analysis	O
of	O
cathepsin	B-Protein
B	I-Protein
-	O
derived	O
oligosaccharides	O
revealed	O
a	O
hypermannosylation	O
of	O
glycoproteins	O
in	O
mice	O
with	O
alpha	O
-	O
mannosidosis	O
as	O
indicated	O
by	O
the	O
predominance	O
of	O
extended	O
Man3GlcNAc2	O
oligosaccharides	O
.	O

Treatment	O
with	O
recombinant	O
human	O
alpha	B-Protein
-	I-Protein
mannosidase	I-Protein
partially	O
corrected	O
the	O
hyperglycosylation	O
of	O
lysosomal	O
proteins	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

These	O
data	O
clearly	O
demonstrate	O
that	O
LAMAN	B-Protein
is	O
involved	O
not	O
only	O
in	O
the	O
lysosomal	O
catabolism	O
of	O
free	O
oligosaccharides	O
but	O
also	O
in	O
the	O
trimming	O
of	O
asparagine	O
-	O
linked	O
oligosaccharides	O
on	O
native	O
lysosomal	O
proteins	O
.	O

Stable	O
chromatin	O
binding	O
prevents	O
FoxA	O
acetylation	O
,	O
preserving	O
FoxA	O
chromatin	O
remodeling	O
.	O

FoxA1	B-Protein
-	O
3	B-Protein
(	O
formerly	O
HNF3alpha	B-Protein
,	O
-	B-Protein
beta	I-Protein
,	O
and	O
-	B-Protein
gamma	I-Protein
)	O
,	O
members	O
of	O
the	O
FoxA	O
subfamily	O
of	O
forkhead	O
transcription	O
factors	O
,	O
function	O
as	O
initial	O
chromatin	O
-	O
binding	O
and	O
chromatin	O
-	O
remodeling	O
factors	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
liver	O
and	O
pancreas	O
.	O

Despite	O
essential	O
roles	O
in	O
development	O
and	O
metabolism	O
,	O
regulation	O
of	O
FoxA	O
factors	O
is	O
not	O
well	O
understood	O
.	O

This	O
study	O
examines	O
a	O
potential	O
role	O
for	O
acetylation	O
in	O
the	O
regulation	O
of	O
FoxA	O
chromatin	O
binding	O
and	O
remodeling	O
.	O

Using	O
in	O
silico	O
analysis	O
,	O
we	O
have	O
identified	O
11	O
putative	O
p300	B-Protein
acetylation	O
sites	O
within	O
FoxA1	B-Protein
,	O
five	O
of	O
which	O
are	O
located	O
within	O
wings	O
1	O
and	O
2	O
of	O
its	O
winged	O
-	O
helix	O
DNA	O
-	O
binding	O
domain	O
.	O

These	O
polypeptide	O
structures	O
stabilize	O
FoxA	O
DNA	O
and	O
chromatin	O
binding	O
,	O
and	O
we	O
have	O
demonstrated	O
that	O
acetylation	O
attenuates	O
FoxA	O
binding	O
to	O
DNA	O
and	O
diminishes	O
its	O
ability	O
to	O
remodel	O
chromatin	O
.	O

FoxA	O
acetylation	O
is	O
inhibited	O
by	O
chromatin	O
binding	O
.	O

We	O
propose	O
a	O
model	O
whereby	O
stable	O
chromatin	O
binding	O
protects	O
the	O
FoxA	O
DNA	O
-	O
binding	O
domain	O
from	O
acetylation	O
to	O
preserve	O
chromatin	O
binding	O
and	O
remodeling	O
by	O
FoxA	O
factors	O
in	O
the	O
absence	O
of	O
extracellular	O
cues	O
.	O

Identification	O
of	O
residues	O
on	O
Hsp70	B-Protein
and	O
Hsp90	B-Protein
ubiquitinated	O
by	O
the	O
cochaperone	O
CHIP	B-Protein
.	O

Molecular	O
chaperones	O
Hsp70	B-Protein
and	O
Hsp90	B-Protein
are	O
in	O
part	O
responsible	O
for	O
maintaining	O
the	O
viability	O
of	O
cells	O
by	O
facilitating	O
the	O
folding	O
and	O
maturation	O
process	O
of	O
many	O
essential	O
client	O
proteins	O
.	O

The	O
ubiquitin	B-Protein
ligase	O
C	B-Protein
-	I-Protein
terminus	I-Protein
of	I-Protein
Hsc70	I-Protein
interacting	I-Protein
protein	I-Protein
(	O
CHIP	B-Protein
)	O
has	O
been	O
shown	O
in	O
vitro	O
and	O
in	O
vivo	O
to	O
associate	O
with	O
Hsp70	B-Protein
and	O
Hsp90	B-Protein
and	O
ubiquitinate	O
them	O
,	O
thus	O
targeting	O
them	O
to	O
the	O
proteasome	O
for	O
degradation	O
.	O

Here	O
,	O
we	O
study	O
one	O
facet	O
of	O
this	O
CHIP	B-Protein
-	O
mediated	O
turnover	O
by	O
determining	O
the	O
lysine	O
residues	O
on	O
human	O
Hsp70	B-Protein
and	O
Hsp90	B-Protein
ubiquitinated	O
by	O
CHIP	B-Protein
.	O

We	O
performed	O
in	O
vitro	O
ubiquitination	O
reactions	O
of	O
the	O
chaperones	O
using	O
purified	O
components	O
and	O
analyzed	O
the	O
samples	O
by	O
tandem	O
mass	O
spectrometry	O
to	O
identify	O
modified	O
lysine	O
residues	O
.	O

Six	O
such	O
ubiquitination	O
sites	O
were	O
identified	O
on	O
Hsp70	B-Protein
(	O
K325	O
,	O
K451	O
,	O
K524	O
,	O
K526	O
,	O
K559	O
,	O
and	O
K561	O
)	O
and	O
13	O
ubiquitinated	O
lysine	O
residues	O
were	O
found	O
on	O
Hsp90	B-Protein
(	O
K107	O
,	O
K204	O
,	O
K219	O
,	O
K275	O
,	O
K284	O
,	O
K347	O
,	O
K399	O
,	O
K477	O
,	O
K481	O
,	O
K538	O
,	O
K550	O
,	O
K607	O
,	O
and	O
K623	O
)	O
.	O

We	O
mapped	O
the	O
ubiquitination	O
sites	O
on	O
homology	O
models	O
of	O
almost	O
full	O
-	O
length	O
human	O
Hsp70	B-Protein
and	O
Hsp90	B-Protein
,	O
which	O
were	O
found	O
to	O
cluster	O
in	O
certain	O
regions	O
of	O
the	O
structures	O
.	O

Furthermore	O
,	O
we	O
determined	O
that	O
CHIP	B-Protein
forms	O
polyubiquitin	B-Protein
chains	O
on	O
Hsp70	B-Protein
and	O
Hsp90	B-Protein
linked	O
via	O
K6	O
,	O
K11	O
,	O
K48	O
,	O
and	O
K63	O
.	O

These	O
findings	O
clarify	O
the	O
mode	O
of	O
ubiquitination	O
of	O
Hsp70	B-Protein
and	O
Hsp90	B-Protein
by	O
CHIP	B-Protein
,	O
which	O
ultimately	O
leads	O
to	O
their	O
degradation	O
.	O

Dual	O
role	O
of	O
Zn2	O
+	O
in	O
maintaining	O
structural	O
integrity	O
and	O
suppressing	O
deacetylase	O
activity	O
of	O
SIRT1	B-Protein
.	O

Zn	O
(	O
2	O
+	O
)	O
directly	O
participates	O
in	O
catalysis	O
of	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
Classes	O
I	O
,	O
II	O
,	O
IV	O
enzymes	O
while	O
its	O
role	O
in	O
HDAC	O
Class	O
III	O
activity	O
is	O
not	O
well	O
established	O
.	O

Herein	O
we	O
investigated	O
the	O
effects	O
of	O
Zn	O
(	O
2	O
+	O
)	O
on	O
the	O
deacetylase	O
activity	O
of	O
sirtuin	B-Protein
1	I-Protein
(	O
silent	B-Protein
mating	I-Protein
type	I-Protein
information	I-Protein
regulation	I-Protein
2	I-Protein
homolog	I-Protein
1	I-Protein
,	O
SIRT1	B-Protein
)	O
.	O

We	O
found	O
that	O
the	O
inherent	O
Zn	O
(	O
2	O
+	O
)	O
at	O
the	O
zinc	O
-	O
finger	O
motif	O
of	O
SIRT1	B-Protein
is	O
essential	O
for	O
the	O
structural	O
integrity	O
and	O
the	O
deacetylase	O
activity	O
of	O
SIRT1	B-Protein
,	O
whereas	O
the	O
exogenous	O
Zn	O
(	O
2	O
+	O
)	O
strongly	O
inhibits	O
the	O
deacetylase	O
activity	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
0	O
.	O
82muM	O
for	O
Zn	O
(	O
Gly	O
)	O
(	O
2	O
)	O
.	O

SIRT1	B-Protein
activity	O
suppressed	O
by	O
the	O
exogenous	O
Zn	O
(	O
2	O
+	O
)	O
can	O
be	O
fully	O
recovered	O
by	O
the	O
metal	O
chelator	O
EDTA	O
but	O
not	O
by	O
the	O
activator	O
resveratrol	O
.	O

We	O
also	O
identified	O
Zn	O
(	O
2	O
+	O
)	O
as	O
a	O
noncompetitive	O
inhibitor	O
for	O
the	O
substrates	O
of	O
NAD	O
(	O
+	O
)	O
and	O
the	O
acetyl	O
peptide	O
P53	O
-	O
AMC	O
.	O

The	O
8	O
-	O
anilino	O
-	O
1	O
-	O
naphthalenesulfonic	O
acid	O
(	O
ANS	O
)	O
fluorescence	O
titration	O
experiments	O
and	O
site	O
-	O
directed	O
mutagenesis	O
study	O
suggested	O
that	O
the	O
exogenous	O
Zn	O
(	O
2	O
+	O
)	O
binds	O
to	O
SIRT1	B-Protein
but	O
not	O
at	O
the	O
zinc	O
-	O
finger	O
motif	O
.	O

These	O
results	O
indicate	O
that	O
Zn	O
(	O
2	O
+	O
)	O
plays	O
a	O
dual	O
role	O
in	O
SIRT1	B-Protein
activity	O
.	O

Inherent	O
Zn	O
(	O
2	O
+	O
)	O
at	O
the	O
zinc	O
-	O
finger	O
motif	O
is	O
structurally	O
related	O
and	O
essential	O
for	O
SIRT1	B-Protein
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
Zn	O
(	O
2	O
+	O
)	O
may	O
also	O
bind	O
to	O
another	O
site	O
different	O
from	O
the	O
zinc	O
-	O
finger	O
motif	O
or	O
the	O
binding	O
sites	O
for	O
the	O
substrates	O
or	O
resveratrol	O
and	O
act	O
as	O
a	O
potent	O
inhibitor	O
of	O
SIRT1	B-Protein
.	O

A	O
Bre1	B-Protein
-	O
associated	O
protein	O
,	O
large	B-Protein
1	I-Protein
(	O
Lge1	B-Protein
)	O
,	O
promotes	O
H2B	B-Protein
ubiquitylation	O
during	O
the	O
early	O
stages	O
of	O
transcription	O
elongation	O
.	O

Transcription	O
activation	O
has	O
been	O
proposed	O
to	O
require	O
both	O
ubiquitylation	O
and	O
deubiquitylation	O
of	O
histone	B-Protein
H2B	I-Protein
.	O

Here	O
,	O
we	O
show	O
that	O
Lge1	B-Protein
(	O
Large	B-Protein
1	I-Protein
)	O
is	O
found	O
in	O
a	O
complex	O
containing	O
Rad6	B-Protein
.	O
Bre1	B-Protein
and	O
that	O
it	O
controls	O
the	O
recruitment	O
of	O
Bre1	B-Protein
,	O
a	O
ubiquitin	B-Protein
ligase	O
,	O
and	O
Ubp8	B-Protein
,	O
a	O
deubiquitylase	O
,	O
to	O
promote	O
ubiquitylation	O
during	O
the	O
early	O
steps	O
in	O
elongation	O
.	O

Chromatin	O
immunoprecipitation	O
experiments	O
showed	O
that	O
Lge1	B-Protein
associates	O
with	O
promoter	O
and	O
coding	O
regions	O
of	O
actively	O
transcribed	O
genes	O
in	O
a	O
transcription	O
-	O
dependent	O
manner	O
.	O

Disruption	O
of	O
Lge1	B-Protein
abolished	O
ubiquitylation	O
of	O
histone	B-Protein
H2B	I-Protein
on	O
lysine	O
123	O
and	O
H3	B-Protein
methylation	O
on	O
lysines	O
4	O
and	O
79	O
and	O
resulted	O
in	O
significant	O
sensitivity	O
to	O
6	O
-	O
azauracil	O
and	O
mycophenolic	O
acid	O
.	O

In	O
particular	O
,	O
in	O
Lge1	B-Protein
-	O
deficient	O
cells	O
,	O
Bre1	B-Protein
recruitment	O
was	O
attenuated	O
,	O
whereas	O
recruitment	O
of	O
Ubp8	B-Protein
was	O
facilitated	O
.	O

These	O
alterations	O
were	O
coincident	O
with	O
changes	O
in	O
the	O
interaction	O
between	O
Bre1	B-Protein
.	O
Ubp8	B-Protein
and	O
RNA	O
polymerase	O
II	O
phosphorylated	O
at	O
serine	O
5	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
.	O

We	O
propose	O
that	O
Lge1	B-Protein
has	O
a	O
novel	O
function	O
in	O
disrupting	O
the	O
balance	O
between	O
the	O
recruitment	O
of	O
Bre1	B-Protein
and	O
Ubp8	B-Protein
,	O
thus	O
promoting	O
transcription	O
elongation	O
.	O

Usa1p	B-Protein
is	O
required	O
for	O
optimal	O
function	O
and	O
regulation	O
of	O
the	O
Hrd1p	B-Protein
endoplasmic	O
reticulum	O
-	O
associated	O
degradation	O
ubiquitin	B-Protein
ligase	O
.	O

Usa1p	B-Protein
is	O
a	O
recently	O
discovered	O
member	O
of	O
the	O
HRD	O
ubiquitin	B-Protein
ligase	O
complex	O
.	O

The	O
HRD	O
pathway	O
is	O
a	O
conserved	O
route	O
of	O
ubiquitin	B-Protein
-	O
dependent	O
,	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
associated	O
degradation	O
(	O
ERAD	O
)	O
of	O
numerous	O
lumenal	O
(	O
ERAD	O
-	O
L	O
)	O
and	O
membrane	O
-	O
anchored	O
(	O
ERAD	O
-	O
M	O
)	O
substrates	O
.	O

We	O
have	O
investigated	O
Usa1p	B-Protein
to	O
understand	O
its	O
importance	O
in	O
HRD	O
complex	O
action	O
.	O

Usa1p	B-Protein
was	O
required	O
for	O
the	O
optimal	O
function	O
of	O
the	O
Hrd1p	B-Protein
E3	O
ubiquitin	B-Protein
ligase	O
;	O
its	O
loss	O
caused	O
deficient	O
degradation	O
of	O
both	O
membrane	O
-	O
associated	O
and	O
lumenal	O
proteins	O
.	O

Furthermore	O
,	O
Usa1p	B-Protein
functioned	O
in	O
regulation	O
of	O
Hrd1p	B-Protein
by	O
two	O
mechanisms	O
.	O

First	O
,	O
Hrd1p	B-Protein
self	O
-	O
degradation	O
,	O
which	O
serves	O
to	O
limit	O
the	O
levels	O
of	O
uncomplexed	O
E3	O
,	O
is	O
absolutely	O
dependent	O
on	O
Usa1p	B-Protein
and	O
the	O
ubiquitin	B-Protein
-	O
like	O
(	O
Ubl	O
)	O
domain	O
of	O
Usa1p	B-Protein
.	O

We	O
found	O
that	O
Usa1p	B-Protein
allows	O
Hrd1p	B-Protein
degradation	O
by	O
promoting	O
trans	O
interactions	O
between	O
Hrd1p	B-Protein
molecules	O
.	O

The	O
Ubl	O
domain	O
of	O
Usa1p	B-Protein
was	O
required	O
specifically	O
for	O
Hrd1p	B-Protein
self	O
-	O
ubiquitination	O
but	O
not	O
for	O
degradation	O
of	O
either	O
ERAD	O
-	O
L	O
or	O
ERAD	O
-	O
M	O
substrates	O
.	O

In	O
addition	O
,	O
Usa1p	B-Protein
was	O
able	O
to	O
attenuate	O
the	O
activity	O
-	O
dependent	O
toxicity	O
of	O
Hrd1p	B-Protein
without	O
compromising	O
substrate	O
degradation	O
,	O
indicating	O
a	O
separate	O
role	O
in	O
ligase	O
regulation	O
that	O
operates	O
in	O
parallel	O
to	O
stability	O
control	O
.	O

Many	O
of	O
the	O
described	O
actions	O
of	O
Usa1p	B-Protein
are	O
distinct	O
from	O
those	O
of	O
Der1p	B-Protein
,	O
which	O
is	O
recruited	O
to	O
the	O
HRD	O
complex	O
by	O
Usa1p	B-Protein
.	O

Thus	O
,	O
this	O
novel	O
,	O
conserved	O
factor	O
is	O
broadly	O
involved	O
in	O
the	O
function	O
and	O
regulation	O
of	O
the	O
HRD	O
pathway	O
of	O
ERAD	O
.	O

PKB	B-Protein
/	O
Akt	B-Protein
activation	O
inhibits	O
p53	B-Protein
-	O
mediated	O
HIF1A	B-Protein
degradation	O
that	O
is	O
independent	O
of	O
MDM2	B-Protein
.	O

Cross	O
-	O
talk	O
between	O
the	O
two	O
transcription	O
factors	O
,	O
p53	B-Protein
and	O
hypoxia	B-Protein
inducible	I-Protein
factor	I-Protein
1alpha	I-Protein
(	O
HIF1A	B-Protein
)	O
,	O
is	O
important	O
in	O
different	O
pathophysiological	O
conditions	O
(	O
Hammond	O
and	O
Giaccia	O
,	O
2006	O
,	O
Clin	O
Cancer	O
Res	O
12	O
:	O
5007	O
-	O
5009	O
)	O
such	O
as	O
in	O
the	O
transition	O
from	O
myocardial	O
hypertrophy	O
to	O
cardiac	O
dilatation	O
and	O
heart	O
failure	O
.	O

In	O
that	O
context	O
,	O
p53	B-Protein
induces	O
HIF1A	B-Protein
degradation	O
which	O
in	O
turn	O
provokes	O
the	O
transition	O
from	O
compensatory	O
hypertrophy	O
to	O
myocardial	O
thinning	O
and	O
chamber	O
dilatation	O
(	O
Sano	O
et	O
al	O
.	O
,	O
2007	O
,	O
Nature	O
446	O
:	O
444	O
-	O
448	O
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
mechanism	O
of	O
p53	B-Protein
-	O
induced	O
HIF1A	B-Protein
degradation	O
,	O
we	O
used	O
the	O
established	O
in	O
vitro	O
model	O
of	O
deferroxamine	O
(	O
DFX	O
)	O
-	O
induced	O
HIF1A	B-Protein
accumulation	O
in	O
H9c2	O
cardiac	O
cells	O
(	O
Sano	O
et	O
al	O
.	O
,	O
2007	O
,	O
Nature	O
446	O
:	O
444	O
-	O
448	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
opposite	O
to	O
HIF1A	B-Protein
accumulation	O
following	O
exposure	O
to	O
DFX	O
,	O
prolonged	O
DFX	O
-	O
induced	O
p53	B-Protein
activation	O
and	O
HIF1A	B-Protein
protein	O
decrease	O
,	O
without	O
any	O
change	O
in	O
Hif1a	B-Protein
mRNA	O
.	O

HIF1A	B-Protein
protein	O
decrease	O
accompanied	O
upregulated	O
HIF1A	B-Protein
ubiquitination	O
.	O

MDM2	B-Protein
,	O
an	O
ubiquitin	B-Protein
E3	O
ligase	O
target	O
gene	O
of	O
p53	B-Protein
,	O
was	O
upregulated	O
following	O
prolonged	O
DFX	O
,	O
but	O
using	O
p53	B-Protein
/	O
Mdm2	B-Protein
double	O
-	O
null	O
mouse	O
embryonic	O
fibroblasts	O
,	O
we	O
found	O
that	O
p53	B-Protein
upregulated	O
HIF1A	B-Protein
ubiquitination	O
and	O
degradation	O
independently	O
of	O
MDM2	B-Protein
.	O

Moreover	O
,	O
with	O
prolonged	O
DFX	O
treatment	O
,	O
an	O
enhanced	O
interaction	O
between	O
MDM2	B-Protein
and	O
HIF1A	B-Protein
was	O
lacking	O
.	O

Instead	O
,	O
phospho	O
-	O
Akt	B-Protein
(	O
ser473	O
)	O
was	O
decreased	O
during	O
the	O
phase	O
coinciding	O
with	O
HIF1A	B-Protein
degradation	O
,	O
and	O
inhibition	O
of	O
PKB	B-Protein
/	O
Akt	B-Protein
phosphorylation	O
using	O
PI3K	O
inhibitor	O
(	O
LY294002	O
)	O
upregulated	O
HIF1A	B-Protein
ubiquitination	O
.	O

In	O
summary	O
,	O
we	O
propose	O
that	O
p53	B-Protein
-	O
induced	O
HIF1A	B-Protein
degradation	O
is	O
not	O
exclusively	O
MDM2	B-Protein
-	O
mediated	O
,	O
but	O
reversible	O
by	O
PKB	B-Protein
/	O
Akt	B-Protein
phosphorylation	O
.	O

p38	O
MAPK	O
links	O
oxidative	O
stress	O
to	O
autophagy	O
-	O
related	O
gene	O
expression	O
in	O
cachectic	O
muscle	O
wasting	O
.	O

Oxidative	O
stress	O
is	O
a	O
primary	O
trigger	O
of	O
cachectic	O
muscle	O
wasting	O
,	O
but	O
the	O
signaling	O
pathway	O
(	O
s	O
)	O
that	O
links	O
it	O
to	O
the	O
muscle	O
wasting	O
processes	O
remains	O
to	O
be	O
defined	O
.	O

Here	O
,	O
we	O
report	O
that	O
activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
(	O
phosphorylation	O
)	O
and	O
increased	O
oxidative	O
stress	O
(	O
trans	O
-	O
4	O
-	O
hydroxy	O
-	O
2	O
-	O
nonenal	O
protein	O
modification	O
)	O
in	O
skeletal	O
muscle	O
occur	O
as	O
early	O
as	O
8	O
h	O
after	O
lipopolysaccharide	O
(	O
1	O
mg	O
/	O
kg	O
)	O
and	O
24	O
h	O
after	O
dexamethasone	O
(	O
25	O
mg	O
/	O
kg	O
)	O
injection	O
(	O
intraperitoneal	O
)	O
in	O
mice	O
,	O
concurrent	O
with	O
upregulation	O
of	O
autophagy	O
-	O
related	O
genes	O
,	O
Atg6	B-Protein
,	O
Atg7	B-Protein
,	O
and	O
Atg12	B-Protein
.	O

Treating	O
cultured	O
C2C12	O
myotubes	O
with	O
oxidant	O
hydrogen	O
peroxide	O
(	O
4	O
h	O
)	O
resulted	O
in	O
increased	O
p38	O
phosphorylation	O
and	O
reduced	O
FoxO3	B-Protein
phosphorylation	O
along	O
with	O
induced	O
Atg7	B-Protein
mRNA	O
expression	O
without	O
activation	O
of	O
NF	O
-	O
kappaB	O
or	O
FoxO3a	B-Protein
transcriptional	O
activities	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
p38alpha	B-Protein
/	O
beta	B-Protein
by	O
SB202190	O
blocked	O
hydrogen	O
peroxide	O
-	O
induced	O
atrophy	O
with	O
diminished	O
upregulation	O
of	O
Atg7	B-Protein
and	O
atrogenes	O
[	O
muscle	O
atrophy	O
F	O
-	O
box	O
protein	O
(	O
MAFbx	B-Protein
/	O
Atrogin	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
muscle	B-Protein
ring	I-Protein
finger	I-Protein
protein	I-Protein
1	I-Protein
(	O
MuRF	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
and	O
Nedd4	B-Protein
]	O
.	O

These	O
findings	O
provide	O
direct	O
evidence	O
for	O
p38alpha	B-Protein
/	O
beta	B-Protein
MAPK	O
in	O
mediating	O
oxidative	O
stress	O
-	O
induced	O
autophagy	O
-	O
related	O
genes	O
,	O
suggesting	O
that	O
p38alpha	B-Protein
/	O
beta	B-Protein
MAPK	O
regulates	O
both	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
and	O
the	O
autophagy	O
-	O
lysosome	O
systems	O
in	O
muscle	O
wasting	O
.	O

Opposing	O
regulatory	O
roles	O
of	O
phosphorylation	O
and	O
acetylation	O
in	O
DNA	O
mispair	O
processing	O
by	O
thymine	B-Protein
DNA	I-Protein
glycosylase	I-Protein
.	O

CpG	O
dinucleotides	O
are	O
mutational	O
hotspots	O
associated	O
with	O
cancer	O
and	O
genetic	O
diseases	O
.	O

Thymine	B-Protein
DNA	I-Protein
glycosylase	I-Protein
(	O
TDG	B-Protein
)	O
plays	O
an	O
integral	O
role	O
in	O
CpG	O
maintenance	O
by	O
excising	O
mispaired	O
thymine	O
and	O
uracil	O
in	O
a	O
CpG	O
context	O
and	O
also	O
participates	O
in	O
transcriptional	O
regulation	O
via	O
gene	O
-	O
specific	O
CpG	O
demethylation	O
and	O
functional	O
interactions	O
with	O
the	O
transcription	O
machinery	O
.	O

Here	O
,	O
we	O
report	O
that	O
protein	B-Protein
kinase	I-Protein
C	I-Protein
alpha	I-Protein
(	O
PKCalpha	B-Protein
)	O
interacts	O
with	O
TDG	B-Protein
and	O
phosphorylates	O
amino	O
-	O
terminal	O
serine	O
residues	O
adjacent	O
to	O
lysines	O
acetylated	O
by	O
CREB	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CBP	B-Protein
)	O
and	O
p300	B-Protein
(	O
CBP	B-Protein
/	O
p300	B-Protein
)	O
.	O

We	O
establish	O
that	O
acetylation	O
and	O
phosphorylation	O
are	O
mutually	O
exclusive	O
,	O
and	O
their	O
interplay	O
dramatically	O
alters	O
the	O
DNA	O
mispair	O
-	O
processing	O
functions	O
of	O
TDG	B-Protein
.	O

Remarkably	O
,	O
acetylation	O
of	O
the	O
amino	O
-	O
terminal	O
region	O
abrogates	O
high	O
-	O
affinity	O
DNA	O
binding	O
and	O
selectively	O
prevents	O
processing	O
of	O
G	O
:	O
T	O
mispairs	O
.	O

In	O
contrast	O
,	O
phosphorylation	O
does	O
not	O
markedly	O
alter	O
DNA	O
interactions	O
,	O
but	O
may	O
preserve	O
G	O
:	O
T	O
processing	O
in	O
vivo	O
by	O
preventing	O
CBP	B-Protein
-	O
mediated	O
acetylation	O
.	O

Mutational	O
analysis	O
suggests	O
that	O
the	O
acetyl	O
-	O
acceptor	O
lysines	O
are	O
not	O
directly	O
involved	O
in	O
contacting	O
DNA	O
,	O
but	O
may	O
constitute	O
a	O
conformationally	O
sensitive	O
interface	O
that	O
modulates	O
DNA	O
interactions	O
.	O

These	O
findings	O
reveal	O
opposing	O
roles	O
of	O
CBP	B-Protein
/	O
p300	B-Protein
and	O
PKCalpha	B-Protein
in	O
regulating	O
the	O
DNA	O
repair	O
functions	O
of	O
TDG	B-Protein
and	O
suggest	O
that	O
the	O
interplay	O
of	O
these	O
modifications	O
in	O
vivo	O
may	O
be	O
critically	O
important	O
in	O
the	O
maintenance	O
of	O
CpG	O
dinucleotides	O
and	O
epigenetic	O
regulation	O
.	O

Dynamically	O
acetylated	O
histones	B-Protein
of	O
chicken	O
erythrocytes	O
are	O
selectively	O
methylated	O
.	O

The	O
relationship	O
between	O
histone	B-Protein
acetylation	O
and	O
methylation	O
in	O
chicken	O
immature	O
erythrocytes	O
was	O
investigated	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
transcriptionally	O
active	O
/	O
competent	O
gene	O
-	O
enriched	O
chromatin	O
fragments	O
are	O
enriched	O
in	O
newly	O
methylated	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
.	O

Moreover	O
,	O
newly	O
methylated	O
histone	B-Protein
H4	I-Protein
is	O
hyperacetylated	O
.	O

Here	O
,	O
we	O
show	O
that	O
dynamically	O
acetylated	O
histone	B-Protein
H4	I-Protein
is	O
selectively	O
engaged	O
in	O
ongoing	O
methylation	O
.	O

While	O
sodium	O
butyrate	O
(	O
an	O
inhibitor	O
of	O
histone	B-Protein
deacetylase	O
)	O
does	O
not	O
inhibit	O
ongoing	O
histone	B-Protein
methylation	O
,	O
it	O
does	O
affect	O
the	O
acetylation	O
state	O
of	O
newly	O
methylated	O
histone	B-Protein
H4	I-Protein
when	O
chicken	O
immature	O
erythrocytes	O
are	O
incubated	O
in	O
its	O
presence	O
or	O
absence	O
.	O

Only	O
one	O
rate	O
of	O
acetylation	O
of	O
labelled	O
newly	O
methylated	O
unacetylated	O
histone	B-Protein
H4	I-Protein
with	O
a	O
t1	O
/	O
2	O
of	O
8	O
min	O
is	O
observed	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
solubility	O
of	O
transcriptionally	O
active	O
/	O
competent	O
gene	O
chromatin	O
fragments	O
in	O
0	O
.	O
15	O
M	O
-	O
NaCl	O
is	O
dependent	O
upon	O
the	O
level	O
of	O
acetylated	O
histone	B-Protein
species	O
,	O
with	O
induction	O
of	O
hyperacetylation	O
increasing	O
the	O
solubility	O
of	O
this	O
gene	O
chromatin	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
low	O
salt	O
solubility	O
of	O
chromatin	O
fragments	O
associated	O
with	O
newly	O
methylated	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
is	O
also	O
dependent	O
upon	O
the	O
level	O
of	O
acetylated	O
histones	B-Protein
.	O

These	O
results	O
provide	O
further	O
support	O
for	O
the	O
hypothesis	O
that	O
histones	B-Protein
participating	O
in	O
ongoing	O
methylation	O
are	O
associated	O
with	O
transcriptionally	O
active	O
/	O
competent	O
chromatin	O
and	O
suggest	O
that	O
the	O
processes	O
of	O
histone	B-Protein
H4	I-Protein
methylation	O
and	O
dynamic	O
acetylation	O
are	O
partially	O
coupled	O
in	O
terminally	O
differentiated	O
erythrocytes	O
.	O

Increased	O
levels	O
and	O
defective	O
glycosylation	O
of	O
MRPs	O
in	O
ovarian	O
carcinoma	O
cells	O
resistant	O
to	O
oxaliplatin	O
.	O

Pt	O
compounds	O
still	O
represent	O
the	O
mainstay	O
of	O
the	O
treatment	O
of	O
ovarian	O
carcinoma	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
molecular	O
bases	O
of	O
resistance	O
to	O
Pt	O
drugs	O
using	O
an	O
oxaliplatin	O
-	O
resistant	O
ovarian	O
carcinoma	O
cell	O
model	O
IGROV	O
-	O
1	O
/	O
OHP	O
.	O

These	O
cells	O
exhibited	O
high	O
levels	O
of	O
resistance	O
to	O
oxaliplatin	O
,	O
cross	O
-	O
resistance	O
to	O
cisplatin	O
and	O
topotecan	O
and	O
displayed	O
a	O
marked	O
accumulation	O
defect	O
of	O
Pt	O
drugs	O
.	O

This	O
feature	O
was	O
associated	O
with	O
increased	O
expression	O
and	O
altered	O
N	O
-	O
linked	O
glycosylation	O
of	O
ATP	O
binding	O
cassette	O
transporters	O
MRP1	B-Protein
and	O
MRP4	B-Protein
.	O

Pre	O
-	O
treatment	O
with	O
tunicamycin	O
,	O
which	O
inhibits	O
the	O
biosynthesis	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
,	O
decreased	O
the	O
accumulation	O
of	O
Pt	O
in	O
sensitive	O
cells	O
exposed	O
to	O
oxaliplatin	O
or	O
cisplatin	O
and	O
increased	O
the	O
electrophoretic	O
mobility	O
of	O
MRP1	B-Protein
and	O
MRP4	B-Protein
,	O
reproducing	O
the	O
association	O
between	O
decreased	O
glycosylation	O
of	O
MRP1	B-Protein
and	O
MRP4	B-Protein
and	O
decreased	O
Pt	O
accumulation	O
observed	O
in	O
the	O
resistant	O
IGROV	O
-	O
1	O
/	O
OHP	O
cells	O
.	O

The	O
observed	O
N	O
-	O
glycosylation	O
defect	O
of	O
oxaliplatin	O
-	O
resistant	O
cells	O
was	O
linked	O
to	O
reduced	O
levels	O
of	O
N	O
-	O
acetylglucosamine	O
-	O
1	O
-	O
phosphotransferase	O
(	O
GNPTG	B-Protein
)	O
and	O
mannosyl	O
(	O
alpha	O
-	O
1	O
,	O
6	O
-	O
)	O
-	O
glycoprotein	O
beta	O
-	O
1	O
,	O
6	O
-	O
N	O
-	O
acetyl	O
-	O
glucosaminyltransferase	O
(	O
MGAT5	B-Protein
)	O
.	O

This	O
feature	O
,	O
observed	O
in	O
IGROV	O
-	O
1	O
/	O
OHP	O
cells	O
,	O
was	O
associated	O
with	O
decreased	O
retention	O
of	O
Pt	O
drugs	O
.	O

In	O
addition	O
,	O
the	O
overexpression	O
of	O
fully	O
glycosylated	O
MRP1	B-Protein
or	O
MRP4	B-Protein
in	O
tumor	O
cell	O
line	O
of	O
ovarian	O
origin	O
was	O
associated	O
with	O
resistance	O
to	O
oxaliplatin	O
and	O
cisplatin	O
.	O

Our	O
findings	O
,	O
showing	O
that	O
development	O
of	O
resistance	O
to	O
oxaliplatin	O
results	O
in	O
up	O
-	O
regulation	O
of	O
MRPs	O
,	O
support	O
that	O
patients	O
with	O
oxaliplatin	O
-	O
refractory	O
ovarian	O
carcinomas	O
may	O
benefit	O
from	O
non	O
-	O
Pt	O
-	O
based	O
regimens	O
which	O
do	O
not	O
contain	O
MRP1	B-Protein
and	O
MRP4	B-Protein
substrates	O
.	O

Thermal	O
aggregation	O
of	O
glycated	O
bovine	O
serum	B-Protein
albumin	I-Protein
.	O

Aggregation	O
and	O
glycation	O
processes	O
in	O
proteins	O
have	O
a	O
particular	O
interest	O
in	O
medicine	O
fields	O
and	O
in	O
food	O
technology	O
.	O

Serum	B-Protein
albumins	I-Protein
are	O
model	O
proteins	O
which	O
are	O
able	O
to	O
self	O
-	O
assembly	O
in	O
aggregates	O
and	O
also	O
sensitive	O
to	O
a	O
non	O
-	O
enzymatic	O
glycation	O
in	O
cases	O
of	O
diabetes	O
.	O

In	O
this	O
work	O
,	O
we	O
firstly	O
reported	O
a	O
study	O
on	O
the	O
glycation	O
and	O
oxidation	O
effects	O
on	O
the	O
structure	O
of	O
bovine	O
serum	B-Protein
albumin	I-Protein
(	O
BSA	B-Protein
)	O
.	O

The	O
experimental	O
approach	O
is	O
based	O
on	O
the	O
study	O
of	O
conformational	O
changes	O
of	O
BSA	B-Protein
at	O
secondary	O
and	O
tertiary	O
structures	O
by	O
FTIR	O
absorption	O
and	O
fluorescence	O
spectroscopy	O
,	O
respectively	O
.	O

Secondly	O
,	O
we	O
analysed	O
the	O
thermal	O
aggregation	O
process	O
on	O
BSA	B-Protein
glycated	O
with	O
different	O
glucose	O
concentrations	O
.	O

Additional	O
information	O
on	O
the	O
aggregation	O
kinetics	O
are	O
obtained	O
by	O
light	O
scattering	O
measurements	O
.	O

The	O
results	O
show	O
that	O
glycation	O
process	O
affects	O
the	O
native	O
structure	O
of	O
BSA	B-Protein
.	O

Then	O
,	O
the	O
partial	O
unfolding	O
of	O
the	O
tertiary	O
structure	O
which	O
accompanies	O
the	O
aggregation	O
process	O
is	O
similar	O
both	O
in	O
native	O
and	O
glycated	O
BSA	B-Protein
.	O

In	O
particular	O
,	O
the	O
formation	O
of	O
aggregates	O
is	O
progressively	O
inhibited	O
with	O
growing	O
concentration	O
of	O
glucose	O
incubated	O
with	O
BSA	B-Protein
.	O

These	O
results	O
bring	O
new	O
insights	O
on	O
how	O
aggregation	O
process	O
is	O
affected	O
by	O
modification	O
of	O
BSA	B-Protein
induced	O
by	O
glycation	O
.	O

Mammalian	O
SUMO	O
E3	O
-	O
ligases	O
PIAS1	B-Protein
and	O
PIAS4	B-Protein
promote	O
responses	O
to	O
DNA	O
double	O
-	O
strand	O
breaks	O
.	O

DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
are	O
highly	O
cytotoxic	O
lesions	O
that	O
are	O
generated	O
by	O
ionizing	O
radiation	O
and	O
various	O
DNA	O
-	O
damaging	O
chemicals	O
.	O

Following	O
DSB	O
formation	O
,	O
cells	O
activate	O
the	O
DNA	O
-	O
damage	O
response	O
(	O
DDR	O
)	O
protein	O
kinases	O
ATM	B-Protein
,	O
ATR	B-Protein
and	O
DNA	O
-	O
PK	O
(	O
also	O
known	O
as	O
PRKDC	B-Protein
)	O
.	O

These	O
then	O
trigger	O
histone	B-Protein
H2AX	I-Protein
(	O
also	O
known	O
as	O
H2AFX	B-Protein
)	O
phosphorylation	O
and	O
the	O
accumulation	O
of	O
proteins	O
such	O
as	O
MDC1	B-Protein
,	O
53BP1	B-Protein
(	O
also	O
known	O
as	O
TP53BP1	B-Protein
)	O
,	O
BRCA1	B-Protein
,	O
CtIP	B-Protein
(	O
also	O
known	O
as	O
RBBP8	B-Protein
)	O
,	O
RNF8	B-Protein
and	O
RNF168	B-Protein
/	O
RIDDLIN	B-Protein
into	O
ionizing	O
radiation	O
-	O
induced	O
foci	O
(	O
IRIF	O
)	O
that	O
amplify	O
DSB	O
signalling	O
and	O
promote	O
DSB	O
repair	O
.	O

Attachment	O
of	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
to	O
target	O
proteins	O
controls	O
diverse	O
cellular	O
functions	O
.	O

Here	O
,	O
we	O
show	O
that	O
SUMO1	B-Protein
,	O
SUMO2	B-Protein
and	O
SUMO3	B-Protein
accumulate	O
at	O
DSB	O
sites	O
in	O
mammalian	O
cells	O
,	O
with	O
SUMO1	B-Protein
and	O
SUMO2	B-Protein
/	O
3	B-Protein
accrual	O
requiring	O
the	O
E3	O
ligase	O
enzymes	O
PIAS4	B-Protein
and	O
PIAS1	B-Protein
.	O

We	O
also	O
establish	O
that	O
PIAS1	B-Protein
and	O
PIAS4	B-Protein
are	O
recruited	O
to	O
damage	O
sites	O
via	O
mechanisms	O
requiring	O
their	O
SAP	O
domains	O
,	O
and	O
are	O
needed	O
for	O
the	O
productive	O
association	O
of	O
53BP1	B-Protein
,	O
BRCA1	B-Protein
and	O
RNF168	B-Protein
with	O
such	O
regions	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
PIAS1	B-Protein
and	O
PIAS4	B-Protein
promote	O
DSB	O
repair	O
and	O
confer	O
ionizing	O
radiation	O
resistance	O
.	O

Finally	O
,	O
we	O
establish	O
that	O
PIAS1	B-Protein
and	O
PIAS4	B-Protein
are	O
required	O
for	O
effective	O
ubiquitin	B-Protein
-	O
adduct	O
formation	O
mediated	O
by	O
RNF8	B-Protein
,	O
RNF168	B-Protein
and	O
BRCA1	B-Protein
at	O
sites	O
of	O
DNA	O
damage	O
.	O

These	O
findings	O
thus	O
identify	O
PIAS1	B-Protein
and	O
PIAS4	B-Protein
as	O
components	O
of	O
the	O
DDR	O
and	O
reveal	O
how	O
protein	O
recruitment	O
to	O
DSB	O
sites	O
is	O
controlled	O
by	O
coordinated	O
SUMOylation	O
and	O
ubiquitylation	O
.	O

Phosphorylation	O
and	O
acetylation	O
of	O
histone	B-Protein
H3	I-Protein
and	O
autoregulation	O
by	O
early	B-Protein
growth	I-Protein
response	I-Protein
1	I-Protein
mediate	O
interleukin	B-Protein
1beta	I-Protein
induction	O
of	O
early	B-Protein
growth	I-Protein
response	I-Protein
1	I-Protein
transcription	O
.	O

OBJECTIVE	O
:	O
The	O
transcription	O
factor	O
early	B-Protein
growth	I-Protein
response	I-Protein
(	I-Protein
EGR	I-Protein
)	I-Protein
-	I-Protein
1	I-Protein
has	O
been	O
implicated	O
as	O
a	O
key	O
vascular	O
phenotypic	O
switch	O
through	O
its	O
control	O
of	O
inducible	O
transcription	O
.	O

EGR	B-Protein
-	I-Protein
1	I-Protein
autoregulation	O
,	O
and	O
histone	B-Protein
modification	O
in	O
the	O
EGR	B-Protein
-	I-Protein
1	I-Protein
promoter	O
,	O
represent	O
key	O
mechanisms	O
in	O
EGR	B-Protein
-	I-Protein
1	I-Protein
control	O
,	O
but	O
have	O
not	O
been	O
explored	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
demonstrate	O
that	O
EGR	B-Protein
-	I-Protein
1	I-Protein
regulates	O
its	O
own	O
transcription	O
and	O
that	O
this	O
involves	O
histone	B-Protein
H3	I-Protein
phosphorylation	O
and	O
acetylation	O
.	O

EGR	B-Protein
-	I-Protein
1	I-Protein
transactivates	O
its	O
promoter	O
in	O
smooth	O
muscle	O
cells	O
exposed	O
to	O
interleukin	B-Protein
(	I-Protein
IL	I-Protein
)	I-Protein
1beta	I-Protein
through	O
a	O
novel	O
cis	O
-	O
acting	O
element	O
(	O
-	O
211	O
/	O
-	O
203	O
)	O
.	O

PD98059	O
,	O
which	O
inhibits	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
kinase	O
/	O
extracellular	O
regulated	O
kinase	O
(	O
MEK	O
/	O
ERK	O
)	O
attenuates	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
-	O
inducible	O
phosphorylation	O
of	O
extracellular	B-Protein
signal	I-Protein
-	I-Protein
regulated	I-Protein
kinase	I-Protein
1	I-Protein
/	O
2	B-Protein
and	O
mitogen	B-Protein
and	I-Protein
stress	I-Protein
-	I-Protein
activated	I-Protein
protein	I-Protein
kinases	I-Protein
1	I-Protein
/	O
2	B-Protein
;	O
and	O
reduces	O
levels	O
of	O
phosphorylated	O
and	O
acetylated	O
histone	B-Protein
H3	I-Protein
.	O

Histone	B-Protein
deacetylase	O
inhibition	O
enhances	O
EGR	B-Protein
-	I-Protein
1	I-Protein
transcription	O
in	O
response	O
to	O
cytokine	O
.	O

Conversely	O
,	O
suppression	O
of	O
histone	B-Protein
modification	O
with	O
mitogen	B-Protein
and	I-Protein
stress	I-Protein
-	I-Protein
activated	I-Protein
protein	I-Protein
kinase	I-Protein
1	I-Protein
/	O
2	B-Protein
short	O
interfering	O
RNA	O
,	O
or	O
the	O
histone	B-Protein
H3	I-Protein
acetyltransferase	O
inhibitor	O
Garcinol	O
,	O
inhibits	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
-	O
inducible	O
EGR	B-Protein
-	I-Protein
1	I-Protein
transcription	O
.	O

EGR	B-Protein
-	I-Protein
1	I-Protein
interacts	O
with	O
the	O
acetyltransferase	O
p300	B-Protein
.	O

Acetylated	O
H3	B-Protein
and	O
phosphorylated	O
H3	B-Protein
are	O
enriched	O
at	O
the	O
promoter	O
of	O
EGR	B-Protein
-	I-Protein
1	I-Protein
;	O
and	O
EGR	B-Protein
-	I-Protein
1	I-Protein
is	O
enriched	O
at	O
the	O
promoters	O
of	O
tissue	B-Protein
factor	I-Protein
and	O
plasminogen	B-Protein
activator	I-Protein
inhibitor	I-Protein
1	I-Protein
in	O
response	O
to	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
,	O
and	O
attenuated	O
by	O
PD98059	O
,	O
Garcinol	O
,	O
and	O
mitogen	B-Protein
and	I-Protein
stress	I-Protein
-	I-Protein
activated	I-Protein
protein	I-Protein
kinase	I-Protein
1	I-Protein
/	O
2	B-Protein
short	O
interfering	O
RNA	O
.	O

CONCLUSIONS	O
:	O
IL	B-Protein
-	I-Protein
1beta	I-Protein
induction	O
of	O
EGR	B-Protein
-	I-Protein
1	I-Protein
transcription	O
involves	O
histone	B-Protein
H3	I-Protein
phosphorylation	O
,	O
acetylation	O
,	O
and	O
autoregulation	O
by	O
EGR	B-Protein
-	I-Protein
1	I-Protein
.	O

Deubiquitinase	O
USP9X	B-Protein
stabilizes	O
MCL1	B-Protein
and	O
promotes	O
tumour	O
cell	O
survival	O
.	O

MCL1	B-Protein
is	O
essential	O
for	O
the	O
survival	O
of	O
stem	O
and	O
progenitor	O
cells	O
of	O
multiple	O
lineages	O
,	O
and	O
is	O
unique	O
among	O
pro	O
-	O
survival	O
BCL2	O
family	O
members	O
in	O
that	O
it	O
is	O
rapidly	O
turned	O
over	O
through	O
the	O
action	O
of	O
ubiquitin	B-Protein
ligases	O
.	O

B	O
-	O
and	O
mantle	O
-	O
cell	O
lymphomas	O
,	O
chronic	O
myeloid	O
leukaemia	O
,	O
and	O
multiple	O
myeloma	O
,	O
however	O
,	O
express	O
abnormally	O
high	O
levels	O
of	O
MCL1	B-Protein
,	O
contributing	O
to	O
chemoresistance	O
and	O
disease	O
relapse	O
.	O

The	O
mechanism	O
of	O
MCL1	B-Protein
overexpression	O
in	O
cancer	O
is	O
not	O
well	O
understood	O
.	O

Here	O
we	O
show	O
that	O
the	O
deubiquitinase	O
USP9X	B-Protein
stabilizes	O
MCL1	B-Protein
and	O
thereby	O
promotes	O
cell	O
survival	O
.	O

USP9X	B-Protein
binds	O
MCL1	B-Protein
and	O
removes	O
the	O
Lys	O
48	O
-	O
linked	O
polyubiquitin	B-Protein
chains	O
that	O
normally	O
mark	O
MCL1	B-Protein
for	O
proteasomal	O
degradation	O
.	O

Increased	O
USP9X	B-Protein
expression	O
correlates	O
with	O
increased	O
MCL1	B-Protein
protein	O
in	O
human	O
follicular	O
lymphomas	O
and	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphomas	O
.	O

Moreover	O
,	O
patients	O
with	O
multiple	O
myeloma	O
overexpressing	O
USP9X	B-Protein
have	O
a	O
poor	O
prognosis	O
.	O

Knockdown	O
of	O
USP9X	B-Protein
increases	O
MCL1	B-Protein
polyubiquitination	O
,	O
which	O
enhances	O
MCL1	B-Protein
turnover	O
and	O
cell	O
killing	O
by	O
the	O
BH3	O
mimetic	O
ABT	O
-	O
737	O
.	O

These	O
results	O
identify	O
USP9X	B-Protein
as	O
a	O
prognostic	O
and	O
therapeutic	O
target	O
,	O
and	O
they	O
show	O
that	O
deubiquitinases	O
may	O
stabilize	O
labile	O
oncoproteins	O
in	O
human	O
malignancies	O
.	O

Reprogramming	O
towards	O
pluripotency	O
requires	O
AID	B-Protein
-	O
dependent	O
DNA	O
demethylation	O
.	O

Reprogramming	O
of	O
somatic	O
cell	O
nuclei	O
to	O
yield	O
induced	O
pluripotent	O
stem	O
(	O
iPS	O
)	O
cells	O
makes	O
possible	O
derivation	O
of	O
patient	O
-	O
specific	O
stem	O
cells	O
for	O
regenerative	O
medicine	O
.	O

However	O
,	O
iPS	O
cell	O
generation	O
is	O
asynchronous	O
and	O
slow	O
(	O
2	O
-	O
3	O
weeks	O
)	O
,	O
the	O
frequency	O
is	O
low	O
(	O
<	O
0	O
.	O
1	O
%	O
)	O
,	O
and	O
DNA	O
demethylation	O
constitutes	O
a	O
bottleneck	O
.	O

To	O
determine	O
regulatory	O
mechanisms	O
involved	O
in	O
reprogramming	O
,	O
we	O
generated	O
interspecies	O
heterokaryons	O
(	O
fused	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
and	O
human	O
fibroblasts	O
)	O
that	O
induce	O
reprogramming	O
synchronously	O
,	O
frequently	O
and	O
fast	O
.	O

Here	O
we	O
show	O
that	O
reprogramming	O
towards	O
pluripotency	O
in	O
single	O
heterokaryons	O
is	O
initiated	O
without	O
cell	O
division	O
or	O
DNA	O
replication	O
,	O
rapidly	O
(	O
1	O
day	O
)	O
and	O
efficiently	O
(	O
70	O
%	O
)	O
.	O

Short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
-	O
mediated	O
knockdown	O
showed	O
that	O
activation	B-Protein
-	I-Protein
induced	I-Protein
cytidine	I-Protein
deaminase	I-Protein
(	O
AID	B-Protein
,	O
also	O
known	O
as	O
AICDA	B-Protein
)	O
is	O
required	O
for	O
promoter	O
demethylation	O
and	O
induction	O
of	O
OCT4	B-Protein
(	O
also	O
known	O
as	O
POU5F1	B-Protein
)	O
and	O
NANOG	B-Protein
gene	O
expression	O
.	O

AID	B-Protein
protein	O
bound	O
silent	O
methylated	O
OCT4	B-Protein
and	O
NANOG	B-Protein
promoters	O
in	O
fibroblasts	O
,	O
but	O
not	O
active	O
demethylated	O
promoters	O
in	O
ES	O
cells	O
.	O

These	O
data	O
provide	O
new	O
evidence	O
that	O
mammalian	O
AID	B-Protein
is	O
required	O
for	O
active	O
DNA	O
demethylation	O
and	O
initiation	O
of	O
nuclear	O
reprogramming	O
towards	O
pluripotency	O
in	O
human	O
somatic	O
cells	O
.	O

Oxidative	O
stress	O
-	O
specific	O
interaction	O
between	O
FANCD2	B-Protein
and	O
FOXO3a	B-Protein
.	O

The	O
molecular	O
pathway	O
by	O
which	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
proteins	O
function	O
in	O
oxidative	O
stress	O
response	O
has	O
not	O
been	O
defined	O
.	O

Here	O
we	O
report	O
the	O
functional	O
interaction	O
of	O
the	O
FA	O
protein	O
Fanconi	B-Protein
anemia	I-Protein
complementation	I-Protein
group	I-Protein
D2	I-Protein
(	O
FANCD2	B-Protein
)	O
and	O
the	O
forkhead	O
transcription	O
factor	O
forkhead	B-Protein
box	I-Protein
O	I-Protein
3a	I-Protein
(	O
FOXO3a	B-Protein
)	O
.	O

FOXO3a	B-Protein
colocalized	O
with	O
FANCD2	B-Protein
foci	O
in	O
response	O
to	O
oxidative	O
stress	O
.	O

The	O
FANCD2	B-Protein
-	O
FOXO3a	B-Protein
complex	O
was	O
not	O
detected	O
in	O
cells	O
deficient	O
for	O
the	O
FA	O
core	O
complex	O
component	O
FANCA	B-Protein
but	O
could	O
be	O
restored	O
in	O
corrected	O
cells	O
.	O

Consistent	O
with	O
this	O
,	O
a	O
nonmonoubiquitinated	O
FANCD2	B-Protein
mutant	O
failed	O
to	O
bind	O
FOXO3a	B-Protein
.	O

Although	O
both	O
mitomycin	O
C	O
and	O
ionizing	O
radiation	O
induced	O
FANCD2	B-Protein
monoubiquitination	O
,	O
neither	O
could	O
induce	O
the	O
association	O
of	O
FANCD2	B-Protein
and	O
FOXO3a	B-Protein
.	O

Overexpression	O
of	O
FOXO3a	B-Protein
reduced	O
abnormal	O
accumulation	O
of	O
reactive	O
oxygen	O
species	O
,	O
enhanced	O
cellular	O
resistance	O
to	O
oxidative	O
stress	O
,	O
and	O
increased	O
antioxidant	O
gene	O
expression	O
in	O
corrected	O
but	O
not	O
mutant	O
FA	O
-	O
D2	O
cells	O
.	O

The	O
novel	O
oxidative	O
stress	O
response	O
pathway	O
identified	O
in	O
this	O
study	O
,	O
in	O
which	O
FANCD2	B-Protein
and	O
FOXO3a	B-Protein
converge	O
,	O
probably	O
contributes	O
to	O
cellular	O
antioxidant	O
defense	O
.	O

RKIP	B-Protein
inhibits	O
NF	O
-	O
kappaB	O
in	O
cancer	O
cells	O
by	O
regulating	O
upstream	O
signaling	O
components	O
of	O
the	O
IkappaB	O
kinase	O
complex	O
.	O

RKIP	B-Protein
was	O
first	O
identified	O
as	O
an	O
inhibitor	O
of	O
the	O
Raf	O
-	O
MEK	O
-	O
ERK	O
signaling	O
pathway	O
.	O

RKIP	B-Protein
was	O
also	O
found	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

Genetic	O
and	O
biochemical	O
studies	O
demonstrated	O
that	O
RKIP	B-Protein
functioned	O
as	O
a	O
scaffold	O
protein	O
facilitating	O
the	O
phosphorylation	O
of	O
IkappaB	O
by	O
upstream	O
kinases	O
.	O

However	O
,	O
contrary	O
to	O
what	O
one	O
would	O
expect	O
of	O
a	O
scaffold	O
protein	O
,	O
our	O
results	O
show	O
that	O
RKIP	B-Protein
has	O
an	O
overall	O
inhibitory	O
effect	O
on	O
the	O
NF	O
-	O
kappaB	O
transcriptional	O
activities	O
.	O

Since	O
NF	O
-	O
kappaB	O
target	O
gene	O
expression	O
is	O
subject	O
to	O
negative	O
regulation	O
involving	O
the	O
optimal	O
induction	O
of	O
negative	O
regulators	O
,	O
our	O
data	O
support	O
a	O
hypothesis	O
that	O
RKIP	B-Protein
inhibits	O
NF	O
-	O
kappaB	O
activity	O
via	O
the	O
auto	O
-	O
regulatory	O
feedback	O
loop	O
by	O
rapidly	O
inducing	O
the	O
expression	O
and	O
synthesis	O
of	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

SH3	O
domains	O
from	O
a	O
subset	O
of	O
BAR	O
proteins	O
define	O
a	O
Ubl	O
-	O
binding	O
domain	O
and	O
implicate	O
parkin	B-Protein
in	O
synaptic	O
ubiquitination	O
.	O

Mutations	O
in	O
the	O
parkin	B-Protein
gene	O
are	O
responsible	O
for	O
a	O
common	O
inherited	O
form	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

Parkin	B-Protein
is	O
a	O
RING	O
-	O
type	O
E3	O
ubiquitin	B-Protein
ligase	O
with	O
an	O
N	O
-	O
terminal	O
ubiquitin	O
-	O
like	O
domain	O
(	O
Ubl	O
)	O
.	O

We	O
report	O
here	O
that	O
the	O
parkin	B-Protein
Ubl	O
binds	O
SH3	O
domains	O
from	O
endocytic	O
BAR	O
proteins	O
such	O
as	O
endophilin	B-Protein
-	I-Protein
A	I-Protein
with	O
an	O
affinity	O
comparable	O
to	O
proline	O
-	O
rich	O
domains	O
(	O
PRDs	O
)	O
from	O
well	O
-	O
established	O
SH3	O
partners	O
.	O

The	O
NMR	O
structure	O
of	O
the	O
Ubl	O
-	O
SH3	O
complex	O
identifies	O
the	O
PaRK	O
extension	O
,	O
a	O
unique	O
C	O
-	O
terminal	O
motif	O
in	O
the	O
parkin	B-Protein
Ubl	O
required	O
for	O
SH3	O
binding	O
and	O
for	O
parkin	B-Protein
-	O
mediated	O
ubiquitination	O
of	O
endophilin	B-Protein
-	I-Protein
A	I-Protein
in	O
vitro	O
.	O

In	O
nerve	O
terminals	O
,	O
conditions	O
that	O
promote	O
phosphorylation	O
enhance	O
the	O
interaction	O
between	O
parkin	B-Protein
and	O
endophilin	B-Protein
-	I-Protein
A	I-Protein
and	O
increase	O
the	O
levels	O
of	O
ubiquitinated	O
proteins	O
within	O
PRD	O
-	O
associated	O
synaptic	O
protein	O
complexes	O
in	O
wild	O
-	O
type	O
but	O
not	O
parkin	B-Protein
knockout	O
brain	O
.	O

The	O
findings	O
identify	O
a	O
pathway	O
for	O
the	O
recruitment	O
of	O
synaptic	O
substrates	O
to	O
parkin	B-Protein
with	O
the	O
potential	O
to	O
explain	O
the	O
defects	O
in	O
synaptic	O
transmission	O
observed	O
in	O
recessive	O
forms	O
of	O
PD	O
.	O

High	O
molecular	O
weight	O
glycosylated	O
protease	O
in	O
calf	O
brain	O
.	O

Purification	O
and	O
partial	O
characterization	O
.	O

A	O
high	O
molecular	O
weight	O
protease	O
has	O
been	O
purified	O
to	O
homogeneity	O
from	O
calf	O
brain	O
cytosol	O
.	O

The	O
purification	O
procedure	O
involves	O
ammonium	O
sulfate	O
fractionation	O
of	O
the	O
cytosol	O
followed	O
by	O
chromatography	O
on	O
DEAE	O
-	O
Sephacel	O
,	O
hydroxylapatite	O
,	O
concanavalin	B-Protein
A	I-Protein
-	O
Sepharose	O
4B	O
and	O
Sephacryl	O
S	O
-	O
300	O
.	O

The	O
molecular	O
weight	O
of	O
the	O
native	O
protease	O
was	O
estimated	O
to	O
be	O
Mr	O
=	O
465	O
,	O
000	O
by	O
high	O
pressure	O
liquid	O
chromatography	O
.	O

It	O
is	O
composed	O
of	O
a	O
closely	O
moving	O
doublet	O
of	O
Mr	O
=	O
165	O
,	O
000	O
and	O
155	O
,	O
000	O
,	O
as	O
determined	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

It	O
degrades	O
[	O
methyl	O
-	O
14C	O
]	O
alpha	B-Protein
-	I-Protein
casein	I-Protein
with	O
a	O
broad	O
pH	O
optimum	O
of	O
6	O
.	O
8	O
-	O
8	O
.	O
5	O
.	O

[	O
methyl	O
-	O
14C	O
]	O
bovine	O
serum	B-Protein
albumin	I-Protein
and	O
125I	O
-	O
bovine	O
serum	B-Protein
albumin	I-Protein
are	O
hydrolyzed	O
to	O
the	O
same	O
extent	O
as	O
[	O
methyl	O
-	O
14C	O
]	O
alpha	B-Protein
-	I-Protein
casein	I-Protein
,	O
whereas	O
[	O
methyl	O
-	O
14C	O
]	O
methemoglobin	O
is	O
hydrolyzed	O
to	O
half	O
the	O
extent	O
of	O
[	O
methyl	O
-	O
14C	O
]	O
alpha	B-Protein
-	I-Protein
casein	I-Protein
.	O

Divalent	O
cations	O
,	O
nucleotides	O
,	O
and	O
known	O
protease	O
inhibitors	O
(	O
phenylmethylsulfonyl	O
fluoride	O
,	O
p	O
-	O
chloromercuribenzoate	O
,	O
iodoacetic	O
acid	O
,	O
N	O
-	O
ethylmaleimide	O
,	O
leupeptin	O
,	O
antipain	O
,	O
pepstatin	O
,	O
and	O
hemin	O
)	O
have	O
no	O
effect	O
on	O
the	O
activity	O
of	O
the	O
protease	O
.	O

The	O
protease	O
is	O
glycosylated	O
and	O
appears	O
to	O
aggregate	O
readily	O
.	O

Aggregation	O
may	O
be	O
reversed	O
by	O
treating	O
the	O
protease	O
with	O
certain	O
organic	O
solvents	O
.	O

The	O
protease	O
seems	O
to	O
maintain	O
full	O
activity	O
after	O
heat	O
treatment	O
.	O

Electron	O
microscopic	O
data	O
reveals	O
a	O
spherical	O
structure	O
of	O
20	O
-	O
nm	O
diameter	O
.	O

Structural	O
and	O
functional	O
implications	O
of	O
phosphorylation	O
and	O
acetylation	O
in	O
the	O
regulation	O
of	O
the	O
AAA	O
+	O
protein	O
p97	B-Protein
.	O

p97	B-Protein
,	O
also	O
known	O
as	O
VCP	B-Protein
(	O
valosin	B-Protein
-	I-Protein
containing	I-Protein
protein	I-Protein
)	O
,	O
is	O
a	O
hexameric	O
AAA	O
+	O
ATPase	O
that	O
participates	O
in	O
a	O
variety	O
of	O
cellular	O
processes	O
.	O

It	O
is	O
believed	O
that	O
p97	B-Protein
mediates	O
these	O
processes	O
through	O
the	O
binding	O
of	O
various	O
adaptor	O
proteins	O
.	O

Many	O
factors	O
govern	O
adaptor	O
binding	O
and	O
the	O
regulatory	O
mechanisms	O
are	O
not	O
yet	O
well	O
understood	O
.	O

Sites	O
of	O
phosphorylation	O
and	O
acetylation	O
on	O
p97	B-Protein
have	O
been	O
identified	O
and	O
such	O
post	O
-	O
translational	O
modifications	O
may	O
be	O
involved	O
in	O
regulating	O
p97	B-Protein
function	O
.	O

Phosphorylation	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
acetylation	O
of	O
p97	B-Protein
have	O
been	O
shown	O
to	O
modify	O
its	O
properties	O
-	O
for	O
example	O
,	O
by	O
modulating	O
adaptor	O
binding	O
and	O
directing	O
subcellular	O
localization	O
.	O

These	O
modifications	O
have	O
been	O
implicated	O
in	O
a	O
number	O
of	O
p97	B-Protein
-	O
mediated	O
processes	O
,	O
including	O
misfolded	O
protein	O
degradation	O
,	O
membrane	O
fusion	O
,	O
and	O
transcription	O
factor	O
activation	O
.	O

This	O
review	O
describes	O
the	O
known	O
phosphorylation	O
and	O
acetylation	O
sites	O
on	O
p97	B-Protein
and	O
discusses	O
their	O
possible	O
structural	O
and	O
functional	O
implications	O
.	O

Histone	B-Protein
deacetylase	O
inhibitors	O
improve	O
in	O
vitro	O
and	O
in	O
vivo	O
developmental	O
competence	O
of	O
somatic	O
cell	O
nuclear	O
transfer	O
porcine	O
embryos	O
.	O

Faulty	O
epigenetic	O
reprogramming	O
of	O
somatic	O
nuclei	O
is	O
likely	O
to	O
be	O
a	O
major	O
cause	O
of	O
low	O
success	O
observed	O
in	O
all	O
mammals	O
produced	O
through	O
somatic	O
cell	O
nuclear	O
transfer	O
(	O
SCNT	O
)	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
the	O
developmental	O
competence	O
of	O
SCNT	O
embryos	O
in	O
several	O
species	O
were	O
significantly	O
enhanced	O
via	O
treatment	O
of	O
histone	B-Protein
deacetylase	O
inhibitors	O
(	O
HDACi	O
)	O
such	O
as	O
trichostatin	O
A	O
(	O
TSA	O
)	O
to	O
increase	O
histone	B-Protein
acetylation	O
.	O

Here	O
we	O
report	O
that	O
50	O
nM	O
TSA	O
for	O
10	O
h	O
after	O
activation	O
increased	O
the	O
developmental	O
competence	O
of	O
porcine	O
SCNT	O
embryos	O
constructed	O
from	O
Landrace	O
fetal	O
fibroblast	O
cells	O
(	O
FFCs	O
)	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
but	O
not	O
at	O
higher	O
concentrations	O
.	O

Therefore	O
,	O
we	O
optimized	O
the	O
application	O
of	O
another	O
novel	O
HDACi	O
,	O
Scriptaid	O
,	O
for	O
development	O
of	O
porcine	O
SCNT	O
embryos	O
.	O

We	O
found	O
that	O
treatment	O
with	O
500	O
nM	O
Scriptaid	O
significantly	O
enhanced	O
the	O
development	O
SCNT	O
embryos	O
to	O
the	O
blastocyst	O
stage	O
when	O
outbred	O
Landrace	O
FFCs	O
and	O
ear	O
fibroblast	O
cells	O
(	O
EFCs	O
)	O
were	O
used	O
as	O
donors	O
compared	O
to	O
the	O
untreated	O
group	O
.	O

Scriptaid	O
increased	O
the	O
overall	O
cloning	O
efficiency	O
from	O
0	O
.	O
4	O
%	O
(	O
untreated	O
group	O
)	O
to	O
1	O
.	O
6	O
%	O
for	O
Landrace	O
FFCs	O
and	O
0	O
to	O
3	O
.	O
7	O
%	O
for	O
Landrace	O
EFCs	O
.	O

Moreover	O
,	O
treatment	O
of	O
SCNT	O
embryos	O
with	O
Scriptaid	O
improved	O
the	O
histone	B-Protein
acetylation	O
on	O
Histone	B-Protein
H4	I-Protein
at	O
lysine	O
8	O
(	O
AcH4K8	B-Protein
)	O
in	O
a	O
pattern	O
similar	O
to	O
that	O
of	O
the	O
in	O
vitro	O
fertilized	O
(	O
IVF	O
)	O
embryos	O
.	O

Molecular	O
characterization	O
of	O
the	O
O	B-Protein
-	I-Protein
acetyl	I-Protein
transferase	I-Protein
gene	O
of	O
converting	O
bacteriophage	O
SF6	O
that	O
adds	O
group	O
antigen	O
6	O
to	O
Shigella	O
flexneri	O
.	O

Bacteriophage	O
SF6	O
antigenically	O
converts	O
Shigella	O
flexneri	O
serotype	O
Y	O
strains	O
(	O
-	O
;	O
3	O
,	O
4	O
)	O
to	O
type	O
3b	O
carrying	O
group	O
antigen	O
6	O
,	O
3	O
,	O
4	O
by	O
means	O
of	O
an	O
O	O
-	O
acetylation	O
of	O
the	O
O	O
-	O
antigenic	O
polysaccharide	O
chain	O
.	O

The	O
gene	O
for	O
O	B-Protein
-	I-Protein
acetyl	I-Protein
transferase	I-Protein
of	O
bacteriophage	O
SF6	O
has	O
been	O
cloned	O
,	O
identified	O
and	O
sequenced	O
.	O

The	O
predicted	O
O	B-Protein
-	I-Protein
acetyl	I-Protein
transferase	I-Protein
protein	O
encoded	O
by	O
this	O
gene	O
was	O
found	O
to	O
consist	O
of	O
333	O
amino	O
acids	O
,	O
(	O
37	O
,	O
185	O
daltons	O
)	O
and	O
to	O
have	O
some	O
similarity	O
with	O
the	O
galactose	B-Protein
-	I-Protein
1	I-Protein
-	I-Protein
phosphate	I-Protein
uridylyltransferase	I-Protein
protein	O
of	O
Escherichia	O
coli	O
.	O

The	O
gene	O
has	O
been	O
shown	O
to	O
function	O
in	O
a	O
live	O
vaccine	O
strain	O
of	O
S	O
.	O
flexneri	O
Y	O
type	O
(	O
delta	O
aroD	O
)	O
,	O
making	O
it	O
a	O
3b	O
type	O
.	O

The	O
converted	O
type	O
3b	O
strain	O
,	O
SFL1104	O
,	O
was	O
found	O
to	O
elicit	O
significant	O
protection	O
against	O
challenge	O
by	O
both	O
wild	O
-	O
type	O
serotypes	O
3b	O
and	O
Y	O
in	O
a	O
guinea	O
-	O
pig	O
keratoconjunctivitis	O
model	O
.	O

An	O
HDAC1	B-Protein
-	O
binding	O
domain	O
within	O
FATS	B-Protein
bridges	O
p21	B-Protein
turnover	O
to	O
radiation	O
-	O
induced	O
tumorigenesis	O
.	O

There	O
is	O
a	O
gap	O
between	O
the	O
initial	O
formation	O
of	O
cells	O
carrying	O
radiation	O
-	O
induced	O
genetic	O
damage	O
and	O
their	O
contribution	O
to	O
cancer	O
development	O
.	O

Herein	O
,	O
we	O
reveal	O
a	O
previously	O
uncharacterized	O
gene	O
FATS	B-Protein
through	O
a	O
genome	O
-	O
wide	O
approach	O
and	O
demonstrate	O
its	O
essential	O
role	O
in	O
regulating	O
the	O
abundance	O
of	O
p21	B-Protein
in	O
surveillance	O
of	O
genome	O
integrity	O
.	O

A	O
large	O
exon	O
coding	O
the	O
NH2	O
-	O
terminal	O
domain	O
of	O
FATS	B-Protein
,	O
deleted	O
in	O
spontaneous	O
mouse	O
lymphomas	O
,	O
is	O
much	O
more	O
frequently	O
deleted	O
in	O
radiation	O
-	O
induced	O
mouse	O
lymphomas	O
.	O

Its	O
human	O
counterpart	O
is	O
a	O
fragile	B-Protein
site	I-Protein
gene	O
at	O
a	O
previously	O
identified	O
loss	O
of	O
heterozygosity	O
site	O
.	O

FATS	B-Protein
is	O
essential	O
for	O
maintaining	O
steady	O
-	O
state	O
level	O
of	O
p21	B-Protein
protein	O
and	O
sustaining	O
DNA	O
damage	O
checkpoint	O
.	O

Furthermore	O
,	O
the	O
NH2	O
-	O
terminal	O
FATS	B-Protein
physically	O
interacts	O
with	O
histone	B-Protein
deacetylase	I-Protein
1	I-Protein
(	O
HDAC1	B-Protein
)	O
to	O
enhance	O
the	O
acetylation	O
of	O
endogenous	O
p21	B-Protein
,	O
leading	O
to	O
the	O
stabilization	O
of	O
p21	B-Protein
.	O

Our	O
results	O
reveal	O
a	O
molecular	O
linkage	O
between	O
p21	B-Protein
abundance	O
and	O
radiation	O
-	O
induced	O
carcinogenesis	O
.	O

Distinct	O
alterations	O
in	O
chromatin	O
organization	O
of	O
the	O
two	O
IGF	B-Protein
-	I-Protein
I	I-Protein
promoters	O
precede	O
growth	B-Protein
hormone	I-Protein
-	O
induced	O
activation	O
of	O
IGF	B-Protein
-	I-Protein
I	I-Protein
gene	O
transcription	O
.	O

Many	O
of	O
the	O
physiological	O
actions	O
of	O
GH	B-Protein
are	O
mediated	O
by	O
IGF	B-Protein
-	I-Protein
I	I-Protein
,	O
a	O
secreted	O
70	O
-	O
residue	O
peptide	O
whose	O
gene	O
expression	O
is	O
induced	O
by	O
GH	B-Protein
in	O
the	O
liver	O
and	O
other	O
tissues	O
via	O
mechanisms	O
that	O
remain	O
incompletely	O
characterized	O
but	O
depend	O
on	O
the	O
transcription	O
factor	O
Stat5b	B-Protein
.	O

Here	O
we	O
investigate	O
the	O
chromatin	O
landscape	O
of	O
the	O
IGF	B-Protein
-	I-Protein
I	I-Protein
gene	O
in	O
the	O
liver	O
of	O
pituitary	O
-	O
deficient	O
young	O
adult	O
male	O
rats	O
and	O
assess	O
the	O
impact	O
of	O
a	O
single	O
systemic	O
GH	B-Protein
injection	O
.	O

Despite	O
minimal	O
ongoing	O
transcription	O
in	O
the	O
absence	O
of	O
GH	B-Protein
,	O
both	O
IGF	B-Protein
-	I-Protein
I	I-Protein
promoters	O
appear	O
to	O
reside	O
in	O
open	O
chromatin	O
environments	O
,	O
at	O
least	O
as	O
inferred	O
from	O
relatively	O
high	O
levels	O
of	O
acetylation	O
of	O
core	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
when	O
compared	O
with	O
adjacent	O
intergenic	O
DNA	O
and	O
from	O
enhanced	O
trimethylation	O
of	O
histone	B-Protein
H3	I-Protein
at	O
lysine	O
4	O
.	O

This	O
landscape	O
of	O
open	O
chromatin	O
may	O
reflect	O
maturation	O
of	O
the	O
liver	O
.	O

Surprisingly	O
,	O
in	O
the	O
absence	O
of	O
hormone	O
,	O
IGF	B-Protein
-	I-Protein
I	I-Protein
promoter	O
1	O
appears	O
poised	O
to	O
be	O
activated	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
the	O
transcriptional	O
coactivator	O
p300	B-Protein
and	O
recruitment	O
of	O
RNA	O
polymerase	O
(	O
Pol	O
)	O
II	O
into	O
a	O
preinitiation	O
complex	O
.	O

By	O
contrast	O
,	O
chromatin	O
surrounding	O
IGF	B-Protein
-	I-Protein
I	I-Protein
promoter	O
2	O
is	O
devoid	O
of	O
both	O
p300	B-Protein
and	O
RNA	O
Pol	O
II	O
.	O

Systemic	O
GH	B-Protein
treatment	O
causes	O
an	O
approximately	O
15	O
-	O
fold	O
increase	O
in	O
transcription	O
from	O
each	O
IGF	B-Protein
-	I-Protein
I	I-Protein
promoter	O
within	O
60	O
min	O
of	O
hormone	O
administration	O
,	O
leading	O
to	O
a	O
sustained	O
accumulation	O
of	O
IGF	B-Protein
-	I-Protein
I	I-Protein
mRNA	O
.	O

The	O
coordinated	O
induction	O
of	O
both	O
IGF	B-Protein
-	I-Protein
I	I-Protein
promoters	O
by	O
GH	B-Protein
is	O
accompanied	O
by	O
hyperacetylation	O
of	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
in	O
promoter	O
-	O
associated	O
chromatin	O
,	O
a	O
decline	O
in	O
monomethylation	O
at	O
lysine	O
4	O
of	O
histone	B-Protein
H3	I-Protein
,	O
and	O
recruitment	O
of	O
RNA	O
Pol	O
II	O
to	O
IGF	B-Protein
-	I-Protein
I	I-Protein
promoter	O
2	O
.	O

We	O
conclude	O
that	O
GH	B-Protein
actions	O
induce	O
rapid	O
and	O
dramatic	O
changes	O
in	O
hepatic	O
chromatin	O
at	O
the	O
IGF	B-Protein
-	I-Protein
I	I-Protein
locus	O
and	O
activate	O
IGF	B-Protein
-	I-Protein
I	I-Protein
gene	O
transcription	O
in	O
the	O
liver	O
by	O
distinct	O
promoter	O
-	O
specific	O
mechanisms	O
:	O
at	O
promoter	O
1	O
,	O
GH	B-Protein
causes	O
RNA	O
Pol	O
II	O
to	O
be	O
released	O
from	O
a	O
previously	O
recruited	O
paused	O
preinitiation	O
complex	O
,	O
whereas	O
at	O
promoter	O
2	O
,	O
hormone	O
treatment	O
facilitates	O
recruitment	O
and	O
then	O
activation	O
of	O
RNA	O
Pol	O
II	O
to	O
initiate	O
transcription	O
.	O

Calcium	O
activates	O
Nedd4	B-Protein
E3	O
ubiquitin	B-Protein
ligases	O
by	O
releasing	O
the	O
C2	O
domain	O
-	O
mediated	O
auto	O
-	O
inhibition	O
.	O

Nedd4	B-Protein
E3	O
ligases	O
are	O
members	O
of	O
the	O
HECT	O
E3	O
ubiquitin	B-Protein
ligase	O
family	O
and	O
regulate	O
ubiquitination	O
-	O
mediated	O
protein	O
degradation	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
calcium	O
releases	O
the	O
C2	O
domain	O
-	O
mediated	O
auto	O
-	O
inhibition	O
in	O
both	O
Nedd4	B-Protein
-	I-Protein
1	I-Protein
and	O
Nedd4	B-Protein
-	I-Protein
2	I-Protein
.	O

Calcium	O
disrupts	O
binding	O
of	O
the	O
C2	O
domain	O
to	O
the	O
HECT	O
domain	O
.	O

Consistent	O
with	O
this	O
,	O
calcium	O
activates	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
activity	O
of	O
Nedd4	B-Protein
.	O

Elevation	O
of	O
intracellular	O
calcium	O
by	O
ionomycin	O
treatment	O
,	O
or	O
activation	O
of	O
acetylcholine	O
receptor	O
or	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
by	O
carbachol	O
or	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
stimulation	O
induced	O
activation	O
of	O
endogenous	O
Nedd4	B-Protein
in	O
vivo	O
evaluated	O
by	O
assays	O
of	O
either	O
Nedd4	B-Protein
E3	O
ligase	O
activity	O
or	O
ubiquitination	O
of	O
Nedd4	B-Protein
substrate	O
ENaC	B-Protein
-	I-Protein
beta	I-Protein
.	O

The	O
activation	O
effect	O
of	O
calcium	O
on	O
Nedd4	B-Protein
E3	O
ligase	O
activity	O
was	O
dramatically	O
enhanced	O
by	O
a	O
membrane	O
-	O
rich	O
fraction	O
,	O
suggesting	O
that	O
calcium	O
-	O
mediated	O
membrane	O
translocation	O
through	O
the	O
C2	O
domain	O
might	O
be	O
an	O
activation	O
mechanism	O
of	O
Nedd4	B-Protein
in	O
vivo	O
.	O

Our	O
studies	O
have	O
revealed	O
an	O
activation	O
mechanism	O
of	O
Nedd4	B-Protein
E3	O
ubiquitin	B-Protein
ligases	O
and	O
established	O
a	O
connection	O
of	O
intracellular	O
calcium	O
signaling	O
to	O
regulation	O
of	O
protein	O
ubiquitination	O
.	O

Epigenetic	O
modification	O
of	O
fetal	O
baboon	O
hepatic	O
phosphoenolpyruvate	B-Protein
carboxykinase	I-Protein
following	O
exposure	O
to	O
moderately	O
reduced	O
nutrient	O
availability	O
.	O

Decreased	O
maternal	O
nutrient	O
availability	O
during	O
pregnancy	O
induces	O
compensatory	O
fetal	O
metabolic	O
and	O
endocrine	O
responses	O
.	O

Knowledge	O
of	O
cellular	O
changes	O
involved	O
is	O
critical	O
to	O
understanding	O
normal	O
and	O
abnormal	O
development	O
.	O

Several	O
studies	O
in	O
rodents	O
and	O
sheep	O
report	O
increased	O
fetal	O
plasma	O
cortisol	O
and	O
associated	O
increased	O
gluconeogenesis	O
in	O
response	O
to	O
maternal	O
nutrient	O
reduction	O
(	O
MNR	O
)	O
but	O
observations	O
in	O
primates	O
are	O
lacking	O
.	O

We	O
determined	O
MNR	O
effects	O
on	O
fetal	O
liver	O
phosphoenolpyruvate	B-Protein
carboxykinase	I-Protein
1	I-Protein
(	O
protein	O
,	O
PEPCK1	B-Protein
;	O
gene	O
,	O
PCK1	B-Protein
orthologous	O
/	O
homologous	O
human	O
chromosomal	O
region	O
20q13	O
.	O
31	O
)	O
at	O
0	O
.	O
9	O
gestation	O
(	O
G	O
)	O
.	O

Female	O
baboon	O
social	O
groups	O
were	O
fed	O
ad	O
libitum	O
(	O
control	O
,	O
CTR	O
)	O
or	O
70	O
%	O
CTR	O
(	O
MNR	O
)	O
from	O
0	O
.	O
16	O
to	O
0	O
.	O
9G	O
when	O
fetuses	O
were	O
delivered	O
by	O
caesarean	O
section	O
under	O
general	O
anaesthesia	O
.	O

Plasma	O
cortisol	O
was	O
elevated	O
in	O
fetuses	O
of	O
MNR	O
mothers	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Immunoreactive	O
PEPCK1	B-Protein
protein	O
was	O
located	O
around	O
the	O
liver	O
lobule	O
central	O
vein	O
and	O
was	O
low	O
in	O
CTR	O
fetuses	O
but	O
rose	O
to	O
63	O
%	O
of	O
adult	O
levels	O
in	O
MNR	O
fetuses	O
.	O

PCK1	B-Protein
mRNA	O
measured	O
by	O
QRT	O
-	O
PCR	O
increased	O
in	O
MNR	O
(	O
2	O
.	O
3	O
-	O
fold	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
while	O
the	O
25	O
%	O
rise	O
in	O
protein	O
by	O
Western	O
blot	O
analysis	O
was	O
not	O
significant	O
.	O

PCK1	B-Protein
promoter	O
methylation	O
analysis	O
using	O
bisulfite	O
sequencing	O
was	O
significantly	O
reduced	O
in	O
six	O
out	O
of	O
nine	O
CpG	O
-	O
dinucleotides	O
evaluated	O
in	O
MNR	O
compared	O
with	O
CTR	O
liver	O
samples	O
.	O

In	O
conclusion	O
,	O
these	O
are	O
the	O
first	O
data	O
from	O
a	O
fetal	O
non	O
-	O
human	O
primate	O
indicating	O
hypomethylation	O
of	O
the	O
PCK1	B-Protein
promoter	O
in	O
the	O
liver	O
following	O
moderate	O
maternal	O
nutrient	O
reduction	O
.	O

TACI	B-Protein
induces	O
cIAP1	B-Protein
-	O
mediated	O
ubiquitination	O
of	O
NIK	B-Protein
by	O
TRAF2	B-Protein
and	O
TANK	B-Protein
to	O
limit	O
non	O
-	O
canonical	O
NF	O
-	O
kappaB	O
signaling	O
.	O

B	B-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
activating	I-Protein
factor	I-Protein
of	O
the	O
TNF	O
family	O
(	O
BAFF	B-Protein
)	O
is	O
a	O
critical	O
factor	O
for	O
B	O
-	O
cell	O
survival	O
and	O
maturation	O
through	O
non	O
-	O
canonical	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
pathway	O
,	O
a	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
inducing	I-Protein
kinase	I-Protein
(	O
NIK	B-Protein
)	O
-	O
dependent	O
pathway	O
for	O
the	O
processing	O
of	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
p100	B-Protein
to	O
generate	O
p52	B-Protein
.	O

While	O
BAFF	B-Protein
acts	O
primarily	O
through	O
BAFF	B-Protein
receptor	I-Protein
(	O
BAFF	B-Protein
-	I-Protein
R	I-Protein
)	O
,	O
the	O
transmembrane	B-Protein
activator	I-Protein
and	I-Protein
CAML	I-Protein
interactor	I-Protein
(	O
TACI	B-Protein
)	O
,	O
the	O
other	O
receptor	O
for	O
BAFF	B-Protein
,	O
is	O
thought	O
to	O
serve	O
as	O
a	O
negative	O
regulator	O
for	O
B	O
-	O
cell	O
responses	O
.	O

However	O
,	O
how	O
TACI	B-Protein
regulates	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
activity	O
is	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
constitutive	O
activation	O
of	O
TACI	B-Protein
signaling	O
suppressed	O
BAFF	B-Protein
-	I-Protein
R	I-Protein
-	O
mediated	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
p100	B-Protein
processing	O
with	O
the	O
up	O
-	O
regulation	O
of	O
cellular	B-Protein
inhibitors	I-Protein
of	I-Protein
apoptosis	I-Protein
1	I-Protein
(	O
cIAP1	B-Protein
)	O
and	O
TNF	B-Protein
receptor	I-Protein
associated	I-Protein
factor	I-Protein
(	I-Protein
TRAF	I-Protein
)	I-Protein
-	I-Protein
associated	I-Protein
NF	I-Protein
-	I-Protein
kappaB	I-Protein
activator	I-Protein
(	O
TANK	B-Protein
)	O
.	O

The	O
ubiquitination	O
of	O
NIK	B-Protein
by	O
cIAP1	B-Protein
was	O
inhibited	O
by	O
the	O
expression	O
of	O
TRAF2	B-Protein
with	O
physical	O
binding	O
to	O
cIAP1	B-Protein
.	O

TANK	B-Protein
deficiency	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
impaired	O
TACI	B-Protein
-	O
dependent	O
inhibition	O
of	O
NF	B-Protein
-	I-Protein
kappaB2	I-Protein
p100	B-Protein
processing	O
.	O

TANK	B-Protein
also	O
inhibited	O
TRAF2	B-Protein
-	O
mediated	O
cIAP1	B-Protein
inactivation	O
.	O

Moreover	O
,	O
the	O
recruitment	O
of	O
TRAF2	B-Protein
to	O
TACI	B-Protein
induced	O
the	O
ubiquitination	O
of	O
NIK	B-Protein
.	O

Taken	O
together	O
,	O
the	O
regulation	O
of	O
NIK	B-Protein
by	O
TACI	B-Protein
through	O
the	O
interaction	O
of	O
TANK	B-Protein
/	O
TRAF2	B-Protein
/	O
cIAP1	B-Protein
plays	O
a	O
pivotal	O
role	O
in	O
the	O
suppression	O
of	O
non	O
-	O
canonical	O
NF	O
-	O
kappaB	O
signaling	O
.	O

Defective	O
ubiquitin	B-Protein
-	O
mediated	O
degradation	O
of	O
antiapoptotic	O
Bfl	B-Protein
-	I-Protein
1	I-Protein
predisposes	O
to	O
lymphoma	O
.	O

The	O
antiapoptotic	O
Bcl	O
-	O
2	O
family	O
member	O
Bfl	B-Protein
-	I-Protein
1	I-Protein
is	O
up	O
-	O
regulated	O
in	O
many	O
human	O
tumors	O
in	O
which	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
implicated	O
and	O
contributes	O
significantly	O
to	O
tumor	O
cell	O
survival	O
and	O
chemoresistance	O
.	O

We	O
previously	O
found	O
that	O
NF	O
-	O
kappaB	O
induces	O
transcription	O
of	O
bfl	B-Protein
-	I-Protein
1	I-Protein
and	O
that	O
the	O
Bfl	B-Protein
-	I-Protein
1	I-Protein
protein	O
is	O
also	O
regulated	O
by	O
ubiquitin	B-Protein
-	O
mediated	O
proteasomal	O
degradation	O
.	O

However	O
,	O
the	O
role	O
that	O
dysregulation	O
of	O
Bfl	B-Protein
-	I-Protein
1	I-Protein
turnover	O
plays	O
in	O
cancer	O
is	O
not	O
known	O
.	O

Here	O
we	O
show	O
that	O
ubiquitination	O
-	O
resistant	O
mutants	O
of	O
Bfl	B-Protein
-	I-Protein
1	I-Protein
display	O
increased	O
stability	O
and	O
greatly	O
accelerated	O
tumor	O
formation	O
in	O
a	O
mouse	O
model	O
of	O
leukemia	O
/	O
lymphoma	O
.	O

We	O
also	O
show	O
that	O
tyrosine	O
kinase	O
Lck	B-Protein
is	O
up	O
-	O
regulated	O
and	O
activated	O
in	O
these	O
tumors	O
and	O
leads	O
to	O
activation	O
of	O
the	O
IkappaB	O
kinase	O
,	O
Akt	O
,	O
and	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
signaling	O
pathways	O
,	O
which	O
are	O
key	O
mediators	O
in	O
cancer	O
.	O

Coexpression	O
of	O
Bfl	B-Protein
-	I-Protein
1	I-Protein
and	O
constitutively	O
active	O
Lck	B-Protein
promoted	O
tumor	O
formation	O
,	O
whereas	O
Lck	B-Protein
knockdown	O
in	O
tumor	O
-	O
derived	O
cells	O
suppressed	O
leukemia	O
/	O
lymphomagenesis	O
.	O

These	O
data	O
demonstrate	O
that	O
ubiquitination	O
is	O
a	O
critical	O
tumor	O
suppression	O
mechanism	O
regulating	O
Bfl	B-Protein
-	I-Protein
1	I-Protein
function	O
and	O
suggest	O
that	O
mutations	O
in	O
bfl	B-Protein
-	I-Protein
1	I-Protein
or	O
in	O
the	O
signaling	O
pathways	O
that	O
control	O
its	O
ubiquitination	O
may	O
predispose	O
one	O
to	O
cancer	O
.	O

Furthermore	O
,	O
because	O
bfl	B-Protein
-	I-Protein
1	I-Protein
is	O
up	O
-	O
regulated	O
in	O
many	O
human	O
hematopoietic	O
tumors	O
,	O
this	O
finding	O
suggests	O
that	O
strategies	O
to	O
promote	O
Bfl	B-Protein
-	I-Protein
1	I-Protein
ubiquitination	O
may	O
improve	O
therapy	O
.	O

Control	O
of	O
adipogenesis	O
by	O
the	O
SUMO	O
-	O
specific	O
protease	O
SENP2	B-Protein
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
SENP2	B-Protein
,	O
a	O
desumoylating	O
enzyme	O
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
control	O
of	O
adipogenesis	O
.	O

SENP2	B-Protein
expression	O
was	O
markedly	O
increased	O
upon	O
the	O
induction	O
of	O
adipocyte	O
differentiation	O
,	O
and	O
this	O
increase	O
was	O
dependent	O
on	O
protein	O
kinase	O
A	O
activation	O
.	O

Remarkably	O
,	O
knockdown	O
of	O
SENP2	B-Protein
led	O
to	O
a	O
dramatic	O
attenuation	O
of	O
adipogenesis	O
with	O
a	O
marked	O
decrease	O
in	O
PPARgamma	B-Protein
and	O
C	B-Protein
/	I-Protein
EBPalpha	I-Protein
mRNA	O
levels	O
.	O

Knockdown	O
of	O
SENP2	B-Protein
also	O
caused	O
a	O
marked	O
reduction	O
in	O
the	O
level	O
of	O
C	B-Protein
/	I-Protein
EBPbeta	I-Protein
protein	O
but	O
not	O
in	O
that	O
of	O
C	B-Protein
/	I-Protein
EBPbeta	I-Protein
mRNA	O
.	O

Interestingly	O
,	O
sumoylation	O
of	O
C	B-Protein
/	I-Protein
EBPbeta	I-Protein
dramatically	O
increased	O
its	O
ubiquitination	O
and	O
destabilization	O
,	O
and	O
this	O
increase	O
could	O
be	O
reversed	O
by	O
SENP2	B-Protein
.	O

In	O
addition	O
,	O
overexpression	O
of	O
C	B-Protein
/	I-Protein
EBPbeta	I-Protein
could	O
overcome	O
the	O
inhibitory	O
effect	O
of	O
SENP2	B-Protein
knockdown	O
on	O
adipogenesis	O
.	O

Furthermore	O
,	O
SENP2	B-Protein
was	O
absolutely	O
required	O
for	O
adipogenesis	O
of	O
preadipocytes	O
implanted	O
into	O
mice	O
.	O

These	O
results	O
establish	O
a	O
critical	O
role	O
for	O
SENP2	B-Protein
in	O
the	O
regulation	O
of	O
adipogenesis	O
by	O
desumoylation	O
and	O
stabilization	O
of	O
C	B-Protein
/	I-Protein
EBPbeta	I-Protein
and	O
in	O
turn	O
by	O
promoting	O
the	O
expression	O
of	O
its	O
downstream	O
effectors	O
,	O
such	O
as	O
PPARgamma	B-Protein
and	O
C	B-Protein
/	I-Protein
EBPalpha	I-Protein
.	O

SIRT3	B-Protein
SNPs	O
validation	O
in	O
640	O
individuals	O
,	O
functional	O
analyses	O
and	O
new	O
insights	O
into	O
SIRT3	B-Protein
stability	O
.	O

Sirtuins	O
are	O
critical	O
players	O
within	O
multiple	O
cellular	O
pathways	O
such	O
as	O
stress	O
response	O
,	O
apoptosis	O
and	O
energy	O
metabolism	O
.	O

They	O
are	O
associated	O
with	O
metabolic	O
and	O
degenerative	O
diseases	O
,	O
the	O
pathogenesis	O
of	O
cancer	O
and	O
are	O
key	O
elements	O
in	O
the	O
regulation	O
of	O
cellular	O
life	O
span	O
.	O

From	O
within	O
the	O
7	O
known	O
human	O
sirtuins	O
,	O
SIRT3	B-Protein
recently	O
stepped	O
out	O
of	O
the	O
shadow	O
of	O
SIRT1	B-Protein
showing	O
strong	O
effects	O
on	O
stress	O
response	O
,	O
apoptosis	O
,	O
cell	O
cycle	O
and	O
energy	O
metabolism	O
,	O
mimicking	O
effects	O
of	O
caloric	O
restriction	O
.	O

We	O
have	O
identified	O
two	O
non	O
-	O
synonymous	O
human	O
SIRT3	B-Protein
SNPs	O
and	O
evaluated	O
their	O
impact	O
on	O
SIRT3	B-Protein
activity	O
and	O
stability	O
.	O

We	O
assessed	O
their	O
influence	O
on	O
cellular	O
energy	O
metabolism	O
in	O
relation	O
to	O
SIRT1	B-Protein
and	O
identified	O
SIRT3	B-Protein
to	O
increase	O
cellular	O
respiration	O
by	O
80	O
%	O
when	O
compared	O
to	O
SIRT1	B-Protein
,	O
which	O
increased	O
cellular	O
respiration	O
by	O
only	O
30	O
%	O
.	O

SIRT1	B-Protein
promotes	O
proliferation	O
and	O
prevents	O
senescence	O
through	O
targeting	O
LKB1	B-Protein
in	O
primary	O
porcine	O
aortic	O
endothelial	O
cells	O
.	O

RATIONALE	O
:	O
Endothelial	O
senescence	O
causes	O
endothelial	O
dysfunction	O
,	O
promotes	O
atherogenesis	O
and	O
contributes	O
to	O
age	O
-	O
related	O
vascular	O
disorders	O
.	O

SIRT1	B-Protein
is	O
a	O
conserved	O
NAD	O
(	O
+	O
)	O
-	O
dependent	O
deacetylase	O
possessing	O
beneficial	O
effects	O
against	O
aging	O
-	O
related	O
diseases	O
,	O
despite	O
that	O
the	O
detailed	O
functional	O
mechanisms	O
are	O
largely	O
uncharacterized	O
.	O

OBJECTIVE	O
:	O
The	O
present	O
study	O
is	O
designed	O
to	O
evaluate	O
the	O
protective	O
effects	O
of	O
SIRT1	B-Protein
on	O
endothelial	O
senescence	O
and	O
to	O
elucidate	O
the	O
underlying	O
mechanisms	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
An	O
in	O
vitro	O
senescence	O
model	O
was	O
established	O
by	O
prolonged	O
culture	O
of	O
primary	O
endothelial	O
cells	O
isolated	O
from	O
porcine	O
aorta	O
.	O

The	O
freshly	O
isolated	O
"	O
young	O
"	O
cells	O
gradually	O
underwent	O
senescence	O
during	O
1	O
month	O
of	O
repetitive	O
passages	O
.	O

Both	O
mRNA	O
and	O
protein	O
expressions	O
of	O
SIRT1	B-Protein
were	O
progressively	O
decreased	O
.	O

In	O
contrast	O
,	O
the	O
protein	O
levels	O
of	O
LKB1	B-Protein
,	O
a	O
serine	O
/	O
threonine	O
kinase	O
and	O
tumor	O
suppressor	O
,	O
and	O
the	O
phosphorylation	O
of	O
its	O
downstream	O
target	O
AMPK	B-Protein
(	O
Thr172	O
)	O
were	O
dramatically	O
increased	O
in	O
senescent	O
cells	O
.	O

Overexpression	O
of	O
LKB1	B-Protein
promoted	O
cellular	O
senescence	O
and	O
retarded	O
endothelial	O
proliferation	O
,	O
which	O
could	O
be	O
blocked	O
by	O
increasing	O
SIRT1	B-Protein
levels	O
.	O

Knocking	O
down	O
of	O
SIRT1	B-Protein
induced	O
senescence	O
and	O
elevated	O
the	O
protein	O
levels	O
of	O
LKB1	B-Protein
and	O
phosphorylated	O
AMPK	B-Protein
(	O
Thr172	O
)	O
.	O

Regardless	O
of	O
the	O
nutritional	O
status	O
,	O
hyperactivation	O
of	O
AMPK	B-Protein
was	O
able	O
to	O
induce	O
endothelial	O
senescence	O
.	O

SIRT1	B-Protein
antagonized	O
LKB1	B-Protein
-	O
dependent	O
AMPK	B-Protein
activation	O
through	O
promoting	O
the	O
deacetylation	O
,	O
ubiquitination	O
and	O
proteasome	O
-	O
mediated	O
degradation	O
of	O
LKB1	B-Protein
.	O

The	O
survival	O
signaling	O
of	O
Akt	O
was	O
also	O
found	O
to	O
be	O
modulated	O
by	O
SIRT1	B-Protein
and	O
LKB1	B-Protein
,	O
and	O
could	O
cross	O
-	O
regulate	O
AMPK	B-Protein
activity	O
.	O

CONCLUSIONS	O
:	O
SIRT1	B-Protein
and	O
LKB1	B-Protein
/	O
AMPK	B-Protein
are	O
the	O
2	O
key	O
sensor	O
systems	O
for	O
regulating	O
endothelial	O
cell	O
survival	O
,	O
proliferation	O
and	O
senescence	O
.	O

The	O
protective	O
activities	O
of	O
SIRT1	B-Protein
may	O
be	O
achieved	O
at	O
least	O
in	O
part	O
by	O
fine	O
tuning	O
the	O
acetylation	O
/	O
deacetylation	O
status	O
and	O
stabilities	O
of	O
LKB1	B-Protein
protein	O
.	O

Regulation	O
of	O
NOTCH	O
signaling	O
by	O
reciprocal	O
inhibition	O
of	O
HES1	B-Protein
and	O
Deltex	B-Protein
1	I-Protein
and	O
its	O
role	O
in	O
osteosarcoma	O
invasiveness	O
.	O

The	O
highly	O
conserved	O
NOTCH	O
signaling	O
pathway	O
has	O
many	O
essential	O
functions	O
in	O
the	O
development	O
of	O
diverse	O
cells	O
,	O
tissues	O
and	O
organs	O
from	O
Drosophila	O
to	O
humans	O
,	O
and	O
dysregulated	O
NOTCH	O
signaling	O
contributes	O
to	O
several	O
disorders	O
,	O
including	O
vascular	O
and	O
bone	O
defects	O
,	O
as	O
well	O
as	O
several	O
cancers	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
mechanism	O
of	O
NOTCH	O
regulation	O
by	O
reciprocal	O
inhibition	O
of	O
two	O
NOTCH	O
downstream	O
effectors	O
:	O
Deltex1	B-Protein
and	O
HES1	B-Protein
.	O

This	O
mechanism	O
appears	O
to	O
regulate	O
invasion	O
of	O
osteosarcoma	O
cells	O
,	O
as	O
Deltex1	B-Protein
blocks	O
osteosarcoma	O
invasiveness	O
by	O
downregulating	O
NOTCH	O
/	O
HES1	B-Protein
signaling	O
.	O

The	O
inhibitory	O
effect	O
of	O
endogenous	O
Deltex1	B-Protein
on	O
NOTCH	O
signaling	O
is	O
mediated	O
through	O
binding	O
with	O
the	O
intracellular	O
domain	O
of	O
NOTCH	O
and	O
ubiquitination	O
and	O
degradation	O
of	O
NOTCH	O
receptors	O
.	O

Conversely	O
,	O
we	O
show	O
that	O
the	O
NOTCH	O
target	O
gene	O
HES1	B-Protein
causes	O
transcriptional	O
inhibition	O
of	O
Deltex1	B-Protein
by	O
directly	O
binding	O
to	O
the	O
promoter	O
of	O
Deltex1	B-Protein
.	O

An	O
HES1	B-Protein
binding	O
site	O
is	O
identified	O
400	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
of	O
Deltex1	B-Protein
.	O

HES1	B-Protein
-	O
mediated	O
repression	O
of	O
Deltex1	B-Protein
requires	O
the	O
C	O
-	O
terminal	O
H3	B-Protein
/	O
H4	B-Protein
and	O
WRPW	O
domains	O
of	O
HES1	B-Protein
,	O
which	O
associate	O
with	O
the	O
TLE	O
/	O
Groucho	O
corepressors	O
.	O

Taken	O
together	O
,	O
we	O
define	O
a	O
molecular	O
mechanism	O
regulating	O
NOTCH	O
signaling	O
by	O
reciprocal	O
inhibition	O
of	O
the	O
NOTCH	O
target	O
genes	O
HES1	B-Protein
and	O
Deltex1	B-Protein
in	O
mammalian	O
cells	O
.	O

This	O
mechanism	O
may	O
have	O
important	O
clinical	O
implications	O
for	O
targeting	O
NOTCH	O
signaling	O
in	O
osteosarcoma	O
and	O
other	O
cancers	O
.	O

Molecular	O
and	O
cellular	O
characterization	O
of	O
Neuregulin	B-Protein
-	I-Protein
1	I-Protein
type	O
IV	O
isoforms	O
.	O

Numerous	O
genetic	O
studies	O
associated	O
the	O
Neuregulin	B-Protein
1	I-Protein
(	O
NRG1	B-Protein
)	O
Icelandic	O
haplotype	O
(	O
HAP	O
(	O
ice	O
)	O
)	O
,	O
and	O
its	O
single	O
nucleotide	O
polymorphism	O
SNP8NRG243177	O
[	O
T	O
/	O
T	O
]	O
,	O
with	O
schizophrenia	O
.	O

Because	O
SNP8NRG243177	O
[	O
T	O
/	O
T	O
]	O
has	O
characteristics	O
of	O
a	O
functional	O
polymorphism	O
that	O
maps	O
close	O
to	O
NRG1	B-Protein
type	O
IV	O
coding	O
sequences	O
,	O
our	O
initial	O
goal	O
was	O
to	O
map	O
precisely	O
the	O
human	O
type	O
IV	O
transcription	O
initiation	O
site	O
.	O

We	O
determined	O
that	O
the	O
initiation	O
site	O
is	O
23	O
bp	O
upstream	O
of	O
the	O
previously	O
reported	O
type	O
IV	O
exon	O
,	O
and	O
that	O
no	O
other	O
transcripts	O
map	O
to	O
the	O
SNP8NRG243177	O
region	O
.	O

Because	O
NRG1	B-Protein
type	O
IV	O
transcripts	O
are	O
specific	O
to	O
human	O
,	O
we	O
isolated	O
full	O
-	O
length	O
NRG1	B-Protein
type	O
IV	O
cDNAs	O
from	O
human	O
hippocampi	O
and	O
expressed	O
them	O
in	O
non	O
-	O
neural	O
cells	O
and	O
dissociated	O
rat	O
hippocampal	O
neurons	O
to	O
study	O
protein	O
expression	O
,	O
processing	O
and	O
function	O
.	O

Using	O
an	O
antiserum	O
we	O
generated	O
against	O
the	O
NRG1	B-Protein
type	O
IV	O
-	O
specific	O
N	O
-	O
terminus	O
,	O
we	O
found	O
that	O
the	O
protein	O
is	O
targeted	O
to	O
the	O
cell	O
surface	O
where	O
PKC	O
activation	O
promotes	O
its	O
cleavage	O
and	O
release	O
of	O
the	O
extracellular	O
domain	O
.	O

Conditioned	O
medium	O
derived	O
from	O
type	O
IV	O
expressing	O
cells	O
stimulates	O
ErbB	O
receptor	O
phosphorylation	O
,	O
as	O
well	O
as	O
downstream	O
Akt	O
and	O
Erk	O
signaling	O
,	O
demonstrating	O
that	O
NRG1	B-Protein
type	O
IV	O
possesses	O
biological	O
activity	O
similar	O
to	O
other	O
releasable	O
NRG1	B-Protein
isoforms	O
.	O

To	O
study	O
the	O
subcellular	O
targeting	O
of	O
distinct	O
isoforms	O
,	O
neurons	O
were	O
transfected	O
with	O
the	O
Ig	O
-	O
domain	O
-	O
containing	O
NRG1	B-Protein
types	O
I	O
and	O
IV	O
,	O
or	O
the	O
cysteine	O
-	O
rich	O
domain	O
type	O
III	O
isoform	O
.	O

Three	O
dimensional	O
confocal	O
images	O
from	O
transfected	O
neurons	O
indicate	O
that	O
,	O
whereas	O
all	O
isoforms	O
are	O
expressed	O
on	O
somato	O
-	O
dendritic	O
membranes	O
,	O
only	O
the	O
type	O
III	O
-	O
cysteine	O
-	O
rich	O
domain	O
isoform	O
is	O
detectable	O
in	O
distal	O
axons	O
.	O

These	O
results	O
suggest	O
that	O
NRG1	B-Protein
type	O
IV	O
expression	O
levels	O
associated	O
with	O
SNP8NRG243177	O
[	O
T	O
/	O
T	O
]	O
can	O
selectively	O
modify	O
signaling	O
of	O
NRG1	B-Protein
released	O
from	O
somato	O
-	O
dendritic	O
compartments	O
,	O
in	O
contrast	O
to	O
the	O
type	O
III	O
NRG1	B-Protein
that	O
is	O
also	O
associated	O
with	O
axons	O
.	O

Gene	O
silencing	O
induced	O
by	O
oxidative	O
DNA	O
base	O
damage	O
:	O
association	O
with	O
local	O
decrease	O
of	O
histone	B-Protein
H4	I-Protein
acetylation	O
in	O
the	O
promoter	O
region	O
.	O

Oxidized	O
DNA	O
bases	O
,	O
particularly	O
7	O
,	O
8	O
-	O
dihydro	O
-	O
8	O
-	O
oxoguanine	O
(	O
8	O
-	O
oxoG	O
)	O
,	O
are	O
endogenously	O
generated	O
in	O
cells	O
,	O
being	O
a	O
cause	O
of	O
carcinogenic	O
mutations	O
and	O
possibly	O
interfering	O
with	O
gene	O
expression	O
.	O

We	O
found	O
that	O
expression	O
of	O
an	O
oxidatively	O
damaged	O
plasmid	O
DNA	O
is	O
impaired	O
after	O
delivery	O
into	O
human	O
host	O
cells	O
not	O
only	O
due	O
to	O
decreased	O
retention	O
in	O
the	O
transfected	O
cells	O
,	O
but	O
also	O
due	O
to	O
selective	O
silencing	O
of	O
the	O
damaged	O
reporter	O
gene	O
.	O

To	O
test	O
whether	O
the	O
gene	O
silencing	O
was	O
associated	O
with	O
a	O
specific	O
change	O
of	O
the	O
chromatin	O
structure	O
,	O
we	O
determined	O
the	O
levels	O
of	O
histone	B-Protein
modifications	O
related	O
to	O
transcriptional	O
activation	O
(	O
acetylated	O
histones	B-Protein
H3	I-Protein
and	O
H4	B-Protein
)	O
or	O
repression	O
(	O
methylated	O
K9	O
and	O
K27	O
of	O
the	O
histone	B-Protein
H3	I-Protein
,	O
and	O
histone	B-Protein
H1	I-Protein
)	O
in	O
the	O
promoter	O
region	O
and	O
in	O
the	O
downstream	O
transcribed	O
DNA	O
.	O

Acetylation	O
of	O
histone	B-Protein
H4	I-Protein
was	O
found	O
to	O
be	O
specifically	O
decreased	O
by	O
25	O
%	O
in	O
the	O
proximal	O
promoter	O
region	O
of	O
the	O
damaged	O
gene	O
,	O
while	O
minor	O
quantitative	O
changes	O
in	O
other	O
tested	O
chromatin	O
components	O
could	O
not	O
be	O
proven	O
as	O
significant	O
.	O

Treatment	O
with	O
an	O
inhibitor	O
of	O
histone	B-Protein
deacetylases	O
,	O
trichostatin	O
A	O
,	O
partially	O
restored	O
expression	O
of	O
the	O
damaged	O
DNA	O
,	O
suggesting	O
a	O
causal	O
connection	O
between	O
the	O
changes	O
of	O
histone	B-Protein
acetylation	O
and	O
persistent	O
gene	O
repression	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
propose	O
that	O
silencing	O
of	O
the	O
oxidatively	O
damaged	O
DNA	O
may	O
occur	O
in	O
a	O
chromatin	O
-	O
mediated	O
mechanism	O
.	O

Arsenic	O
trioxide	O
controls	O
the	O
fate	O
of	O
the	O
PML	B-Protein
-	O
RARalpha	B-Protein
oncoprotein	O
by	O
directly	O
binding	O
PML	O
.	O

Arsenic	O
,	O
an	O
ancient	O
drug	O
used	O
in	O
traditional	O
Chinese	O
medicine	O
,	O
has	O
attracted	O
worldwide	O
interest	O
because	O
it	O
shows	O
substantial	O
anticancer	O
activity	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Arsenic	O
trioxide	O
(	O
As2O3	O
)	O
exerts	O
its	O
therapeutic	O
effect	O
by	O
promoting	O
degradation	O
of	O
an	O
oncogenic	O
protein	O
that	O
drives	O
the	O
growth	O
of	O
APL	O
cells	O
,	O
PML	B-Protein
-	O
RARalpha	B-Protein
(	O
a	O
fusion	O
protein	O
containing	O
sequences	O
from	O
the	O
PML	B-Protein
zinc	O
finger	O
protein	O
and	O
retinoic	B-Protein
acid	I-Protein
receptor	I-Protein
alpha	I-Protein
)	O
.	O

PML	B-Protein
and	O
PML	B-Protein
-	O
RARalpha	B-Protein
degradation	O
is	O
triggered	O
by	O
their	O
SUMOylation	O
,	O
but	O
the	O
mechanism	O
by	O
which	O
As2O3	O
induces	O
this	O
posttranslational	O
modification	O
is	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
arsenic	O
binds	O
directly	O
to	O
cysteine	O
residues	O
in	O
zinc	O
fingers	O
located	O
within	O
the	O
RBCC	O
domain	O
of	O
PML	B-Protein
-	O
RARalpha	B-Protein
and	O
PML	B-Protein
.	O

Arsenic	O
binding	O
induces	O
PML	B-Protein
oligomerization	O
,	O
which	O
increases	O
its	O
interaction	O
with	O
the	O
small	O
ubiquitin	B-Protein
-	O
like	O
protein	O
modifier	O
(	O
SUMO	O
)	O
-	O
conjugating	O
enzyme	O
UBC9	B-Protein
,	O
resulting	O
in	O
enhanced	O
SUMOylation	O
and	O
degradation	O
.	O

The	O
identification	O
of	O
PML	B-Protein
as	O
a	O
direct	O
target	O
of	O
As2O3	O
provides	O
new	O
insights	O
into	O
the	O
drug	O
'	O
s	O
mechanism	O
of	O
action	O
and	O
its	O
specificity	O
for	O
APL	O
.	O

Molting	O
-	O
specific	O
downregulation	O
of	O
C	O
.	O
elegans	O
body	O
-	O
wall	O
muscle	O
attachment	O
sites	O
:	O
the	O
role	O
of	O
RNF	B-Protein
-	I-Protein
5	I-Protein
E3	O
ligase	O
.	O

Repeated	O
molting	O
of	O
the	O
cuticula	O
is	O
an	O
integral	O
part	O
of	O
arthropod	O
and	O
nematode	O
development	O
.	O

Shedding	O
of	O
the	O
old	O
cuticle	O
takes	O
place	O
on	O
the	O
surface	O
of	O
hypodermal	O
cells	O
,	O
which	O
are	O
also	O
responsible	O
for	O
secretion	O
and	O
synthesis	O
of	O
a	O
new	O
cuticle	O
.	O

Here	O
,	O
we	O
use	O
the	O
model	O
nematode	O
Caenorhabditis	O
elegans	O
to	O
show	O
that	O
muscle	O
cells	O
,	O
laying	O
beneath	O
and	O
mechanically	O
linked	O
to	O
the	O
hypodermis	O
,	O
play	O
an	O
important	O
role	O
during	O
molting	O
.	O

We	O
followed	O
the	O
molecular	O
composition	O
and	O
distribution	O
of	O
integrin	O
mediated	O
adhesion	O
structures	O
called	O
dense	O
bodies	O
(	O
DB	O
)	O
,	O
which	O
indirectly	O
connect	O
muscles	O
to	O
the	O
hypodermis	O
.	O

We	O
found	O
the	O
concentration	O
of	O
two	O
DB	O
proteins	O
(	O
PAT	B-Protein
-	I-Protein
3	I-Protein
/	O
beta	B-Protein
-	I-Protein
integrin	I-Protein
and	O
UNC	B-Protein
-	I-Protein
95	I-Protein
)	O
to	O
decrease	O
during	O
the	O
quiescent	O
phase	O
of	O
molting	O
,	O
concomitant	O
with	O
an	O
apparent	O
increase	O
in	O
lateral	O
movement	O
of	O
the	O
DB	O
.	O

We	O
show	O
that	O
levels	O
of	O
the	O
E3	O
-	O
ligase	O
RNF	B-Protein
-	I-Protein
5	I-Protein
increase	O
specifically	O
during	O
molting	O
,	O
and	O
that	O
RNF	B-Protein
-	I-Protein
5	I-Protein
acts	O
to	O
ubiquitinate	O
the	O
DB	O
protein	O
UNC	B-Protein
-	I-Protein
95	I-Protein
.	O

Persistent	O
high	O
levels	O
of	O
RNF	B-Protein
-	I-Protein
5	I-Protein
driven	O
by	O
a	O
heatshock	O
or	O
unc	B-Protein
-	I-Protein
95	I-Protein
promoter	O
lead	O
to	O
failure	O
of	O
ecdysis	O
,	O
and	O
in	O
non	O
-	O
molting	O
worms	O
to	O
a	O
progressive	O
detachment	O
of	O
the	O
cuticle	O
from	O
the	O
hypodermis	O
.	O

These	O
observations	O
indicate	O
that	O
increased	O
DB	O
dynamics	O
characterizes	O
the	O
lethargus	O
phase	O
of	O
molting	O
in	O
parallel	O
to	O
decreased	O
levels	O
of	O
DB	O
components	O
and	O
that	O
temporal	O
expression	O
of	O
RNF	B-Protein
-	I-Protein
5	I-Protein
contributes	O
to	O
an	O
efficient	O
molting	O
process	O
.	O

Embryo	O
vitrification	O
affects	O
the	O
methylation	O
of	O
the	O
H19	B-Protein
/	O
Igf2	B-Protein
differentially	O
methylated	O
domain	O
and	O
the	O
expression	O
of	O
H19	B-Protein
and	O
Igf2	B-Protein
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
embryo	O
vitrification	O
on	O
the	O
methylation	O
status	O
of	O
the	O
H19	B-Protein
/	O
Igf2	B-Protein
differentially	O
methylated	O
domain	O
(	O
DMD	O
)	O
and	O
the	O
expression	O
of	O
those	O
genes	O
.	O

DESIGN	O
:	O
Comparative	O
and	O
controlled	O
study	O
.	O

SETTING	O
:	O
A	O
university	O
-	O
affiliated	O
hospital	O
.	O

ANIMALS	O
:	O
ICR	O
female	O
and	O
male	O
mice	O
.	O

INTERVENTION	O
(	O
S	O
)	O
:	O
Day	O
14	O
fetuses	O
that	O
arose	O
from	O
copulation	O
of	O
male	O
and	O
female	O
mice	O
were	O
taken	O
as	O
the	O
control	O
group	O
.	O

Embryos	O
resulting	O
from	O
superovulation	O
,	O
IVF	O
,	O
in	O
vitro	O
culture	O
,	O
and	O
embryo	O
transfer	O
were	O
taken	O
as	O
the	O
IVF	O
group	O
.	O

Embryos	O
that	O
were	O
vitrified	O
were	O
taken	O
as	O
the	O
vitrified	O
group	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
:	O
The	O
methylation	O
status	O
of	O
H19	B-Protein
/	O
Igf2	B-Protein
DMD	O
was	O
analyzed	O
by	O
cloning	O
and	O
sequencing	O
following	O
DNA	O
bisulfite	O
treatment	O
.	O

The	O
expression	O
of	O
H19	B-Protein
and	O
Igf2	B-Protein
was	O
quantified	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

RESULT	O
(	O
S	O
)	O
:	O
Loss	O
of	O
methylation	O
was	O
found	O
in	O
the	O
H19	B-Protein
/	O
Igf2	B-Protein
DMD	O
of	O
the	O
fetuses	O
from	O
the	O
IVF	O
group	O
,	O
but	O
it	O
was	O
more	O
severe	O
in	O
the	O
vitrified	O
group	O
.	O

H19	B-Protein
expression	O
was	O
significantly	O
increased	O
in	O
the	O
IVF	O
and	O
vitrified	O
groups	O
,	O
as	O
compared	O
with	O
the	O
control	O
group	O
;	O
however	O
,	O
the	O
quantity	O
in	O
the	O
vitrified	O
group	O
was	O
less	O
than	O
that	O
detected	O
in	O
the	O
IVF	O
group	O
.	O

Igf2	B-Protein
expression	O
in	O
the	O
IVF	O
and	O
vitrified	O
groups	O
was	O
found	O
to	O
have	O
decreased	O
significantly	O
,	O
whereas	O
the	O
Igf2	B-Protein
expression	O
in	O
the	O
vitrified	O
group	O
was	O
greater	O
than	O
in	O
the	O
IVF	O
group	O
.	O

CONCLUSION	O
:	O
Embryo	O
vitrification	O
aggravated	O
the	O
loss	O
of	O
methylation	O
in	O
the	O
H19	B-Protein
/	O
Igf2	B-Protein
DMD	O
,	O
and	O
compensated	O
for	O
the	O
perturbed	O
expression	O
of	O
H19	B-Protein
by	O
IVF	O
procedures	O
.	O

Xenobiotic	O
enzyme	O
profiles	O
and	O
Parkinson	O
'	O
s	O
disease	O
.	O

Xenobiotic	O
enzymic	O
systems	O
have	O
been	O
studied	O
in	O
Parkinson	O
'	O
s	O
disease	O
.	O

Platelet	O
monoamine	B-Protein
oxidase	I-Protein
-	I-Protein
B	I-Protein
activity	O
is	O
increased	O
by	O
the	O
use	O
of	O
phenylethylamine	O
but	O
decreased	O
by	O
the	O
use	O
of	O
dopamine	O
as	O
substrate	O
.	O

Enzymes	O
involved	O
with	O
sulfur	O
oxidation	O
and	O
methylation	O
are	O
underactive	O
.	O

Glycosylation	O
at	O
158N	O
of	O
the	O
hemagglutinin	B-Protein
protein	O
and	O
receptor	O
binding	O
specificity	O
synergistically	O
affect	O
the	O
antigenicity	O
and	O
immunogenicity	O
of	O
a	O
live	O
attenuated	O
H5N1	O
A	O
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
vaccine	O
virus	O
in	O
ferrets	O
.	O

A	O
live	O
attenuated	O
influenza	O
A	O
/	O
Vietnam	O
/	O
1203	O
/	O
2004	O
(	O
H5N1	O
)	O
vaccine	O
virus	O
(	O
VN04	O
ca	O
)	O
has	O
receptor	O
binding	O
specificity	O
to	O
alpha2	O
,	O
3	O
-	O
linked	O
sialosides	O
(	O
alpha2	O
,	O
3SAL	O
)	O
,	O
and	O
a	O
single	O
dose	O
induces	O
a	O
minimal	O
serum	O
antibody	O
response	O
in	O
mice	O
and	O
ferrets	O
.	O

In	O
contrast	O
,	O
A	O
/	O
Hong	O
Kong	O
/	O
213	O
/	O
2003	O
(	O
H5N1	O
)	O
vaccine	O
virus	O
(	O
HK03	O
ca	O
)	O
binds	O
to	O
both	O
alpha2	O
,	O
6SAL	O
and	O
alpha2	O
,	O
3SAL	O
and	O
generates	O
a	O
stronger	O
serum	O
antibody	O
response	O
in	O
animals	O
.	O

Among	O
the	O
9	O
amino	O
acids	O
that	O
differed	O
between	O
the	O
two	O
H5	O
HA1	B-Protein
proteins	O
,	O
several	O
HK03	O
-	O
specific	O
residues	O
enabled	O
the	O
VN04	O
ca	O
virus	O
to	O
bind	O
to	O
both	O
alpha2	O
,	O
3SAL	O
and	O
alpha2	O
,	O
6SAL	O
receptors	O
,	O
but	O
only	O
the	O
removal	O
of	O
the	O
158N	O
glycosylation	O
,	O
together	O
with	O
an	O
S227N	O
change	O
,	O
resulted	O
in	O
more	O
-	O
efficient	O
viral	O
replication	O
in	O
the	O
upper	O
respiratory	O
tract	O
of	O
ferrets	O
and	O
an	O
increased	O
serum	O
antibody	O
response	O
.	O

However	O
,	O
the	O
antibody	O
response	O
was	O
HK03	O
strain	O
specific	O
and	O
did	O
not	O
significantly	O
cross	O
-	O
neutralize	O
VN04	O
virus	O
.	O

A	O
second	O
approach	O
was	O
taken	O
to	O
adapt	O
the	O
H5N1	O
VN04	O
ca	O
virus	O
in	O
MDCK	O
cells	O
to	O
select	O
HA	B-Protein
variants	O
with	O
larger	O
plaque	O
morphology	O
.	O

Although	O
a	O
number	O
of	O
large	O
-	O
plaque	O
-	O
size	O
HA	B-Protein
variants	O
with	O
amino	O
acid	O
changes	O
in	O
the	O
HA	B-Protein
receptor	O
binding	O
region	O
were	O
identified	O
,	O
none	O
of	O
these	O
mutations	O
affected	O
virus	O
receptor	O
binding	O
preference	O
and	O
immunogenicity	O
.	O

In	O
addition	O
,	O
the	O
known	O
receptor	O
binding	O
site	O
changes	O
,	O
Q226L	O
and	O
G228S	O
,	O
were	O
introduced	O
into	O
the	O
HA	B-Protein
protein	O
of	O
the	O
VN04	O
ca	O
virus	O
.	O

Only	O
in	O
conjunction	O
with	O
the	O
removal	O
of	O
the	O
158N	O
glycosylation	O
did	O
the	O
virus	O
replicate	O
efficiently	O
in	O
the	O
upper	O
respiratory	O
tract	O
of	O
ferrets	O
and	O
became	O
more	O
immunogenic	O
,	O
yet	O
the	O
response	O
was	O
also	O
HK03	O
specific	O
.	O

Thus	O
,	O
the	O
mask	O
of	O
the	O
antigenic	O
epitopes	O
by	O
158N	O
glycosylation	O
at	O
the	O
HA	B-Protein
globular	O
head	O
and	O
its	O
alpha2	O
,	O
3SAL	O
binding	O
preference	O
of	O
VN04	O
ca	O
virus	O
affect	O
virus	O
antigenicity	O
and	O
replication	O
in	O
the	O
host	O
,	O
resulting	O
in	O
a	O
lower	O
antibody	O
response	O
.	O

Targeted	O
deletion	O
of	O
the	O
Nesp55	O
DMR	O
defines	O
another	O
Gnas	B-Protein
imprinting	O
control	O
region	O
and	O
provides	O
a	O
mouse	O
model	O
of	O
autosomal	O
dominant	O
PHP	O
-	O
Ib	O
.	O

Approximately	O
100	O
genes	O
undergo	O
genomic	O
imprinting	O
.	O

Mutations	O
in	O
fewer	O
than	O
10	O
imprinted	O
genetic	O
loci	O
,	O
including	O
GNAS	B-Protein
,	O
are	O
associated	O
with	O
complex	O
human	O
diseases	O
that	O
differ	O
phenotypically	O
based	O
on	O
the	O
parent	O
transmitting	O
the	O
mutation	O
.	O

Besides	O
the	O
ubiquitously	O
expressed	O
Gsalpha	B-Protein
,	O
which	O
is	O
of	O
broad	O
biological	O
importance	O
,	O
GNAS	B-Protein
gives	O
rise	O
to	O
an	O
antisense	O
transcript	O
and	O
to	O
several	O
Gsalpha	B-Protein
variants	O
that	O
are	O
transcribed	O
from	O
the	O
nonmethylated	O
parental	O
allele	O
.	O

We	O
previously	O
identified	O
two	O
almost	O
identical	O
GNAS	B-Protein
microdeletions	O
extending	O
from	O
exon	O
NESP55	O
to	O
antisense	O
(	O
AS	O
)	O
exon	O
3	O
(	O
delNESP55	O
/	O
delAS3	O
-	O
4	O
)	O
.	O

When	O
inherited	O
maternally	O
,	O
both	O
deletions	O
are	O
associated	O
with	O
erasure	O
of	O
all	O
maternal	O
GNAS	B-Protein
methylation	O
imprints	O
and	O
autosomal	O
-	O
dominant	O
pseudohypoparathyroidism	O
type	O
Ib	O
,	O
a	O
disorder	O
characterized	O
by	O
parathyroid	O
hormone	O
-	O
resistant	O
hypocalcemia	O
and	O
hyperphosphatemia	O
.	O

As	O
for	O
other	O
imprinting	O
disorders	O
,	O
the	O
mechanisms	O
resulting	O
in	O
abnormal	O
GNAS	B-Protein
methylation	O
are	O
largely	O
unknown	O
,	O
in	O
part	O
because	O
of	O
a	O
paucity	O
of	O
suitable	O
animal	O
models	O
.	O

We	O
now	O
showed	O
in	O
mice	O
that	O
deletion	O
of	O
the	O
region	O
equivalent	O
to	O
delNESP55	O
/	O
delAS3	O
-	O
4	O
on	O
the	O
paternal	O
allele	O
(	O
DeltaNesp55	O
(	O
p	O
)	O
)	O
leads	O
to	O
healthy	O
animals	O
without	O
Gnas	B-Protein
methylation	O
changes	O
.	O

In	O
contrast	O
,	O
mice	O
carrying	O
the	O
deletion	O
on	O
the	O
maternal	O
allele	O
(	O
DeltaNesp55	O
(	O
m	O
)	O
)	O
showed	O
loss	O
of	O
all	O
maternal	O
Gnas	B-Protein
methylation	O
imprints	O
,	O
leading	O
in	O
kidney	O
to	O
increased	O
1A	O
transcription	O
and	O
decreased	O
Gsalpha	B-Protein
mRNA	O
levels	O
,	O
and	O
to	O
associated	O
hypocalcemia	O
,	O
hyperphosphatemia	O
,	O
and	O
secondary	O
hyperparathyroidism	O
.	O

Besides	O
representing	O
a	O
murine	O
autosomal	O
-	O
dominant	O
pseudohypoparathyroidism	O
type	O
Ib	O
model	O
and	O
one	O
of	O
only	O
few	O
animal	O
models	O
for	O
imprinted	O
human	O
disorders	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
Nesp55	O
differentially	O
methylated	O
region	O
is	O
an	O
additional	O
principal	O
imprinting	O
control	O
region	O
,	O
which	O
directs	O
Gnas	B-Protein
methylation	O
and	O
thereby	O
affects	O
expression	O
of	O
all	O
maternal	O
Gnas	B-Protein
-	O
derived	O
transcripts	O
.	O

Mechanotransduction	O
by	O
endothelial	O
cells	O
is	O
locally	O
generated	O
,	O
direction	O
-	O
dependent	O
,	O
and	O
ligand	O
-	O
specific	O
.	O

Vascular	O
endothelial	O
cells	O
display	O
a	O
wide	O
panel	O
of	O
responses	O
to	O
changes	O
in	O
the	O
shear	O
stress	O
that	O
is	O
exerted	O
on	O
them	O
by	O
blood	O
flow	O
.	O

How	O
sensory	O
mechanisms	O
convey	O
information	O
about	O
flow	O
conditions	O
and	O
how	O
this	O
information	O
is	O
integrated	O
remains	O
poorly	O
understood	O
.	O

The	O
issue	O
is	O
confounded	O
by	O
:	O
(	O
1	O
)	O
a	O
large	O
number	O
of	O
potential	O
force	O
sensors	O
,	O
(	O
2	O
)	O
difficulties	O
in	O
differentiating	O
these	O
sensors	O
from	O
downstream	O
sites	O
of	O
signal	O
integration	O
,	O
and	O
(	O
3	O
)	O
the	O
complexities	O
inherent	O
in	O
understanding	O
how	O
forces	O
are	O
transmitted	O
from	O
the	O
apical	O
surface	O
of	O
the	O
cell	O
via	O
the	O
cytoskeleton	O
to	O
intracellular	O
sites	O
.	O

As	O
a	O
consequence	O
,	O
neither	O
the	O
structures	O
that	O
sense	O
force	O
nor	O
the	O
nature	O
of	O
the	O
forces	O
that	O
loads	O
them	O
have	O
been	O
clearly	O
defined	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
magnetic	O
microspheres	O
coated	O
with	O
ligands	O
that	O
bind	O
integrin	O
subsets	O
(	O
RGD	O
peptides	O
or	O
type	O
I	O
collagen	O
)	O
or	O
PECAM	B-Protein
-	I-Protein
1	I-Protein
to	O
discriminate	O
the	O
downstream	O
signaling	O
effects	O
of	O
different	O
sensor	O
molecules	O
and	O
mechanisms	O
for	O
how	O
they	O
are	O
loaded	O
.	O

We	O
found	O
that	O
application	O
of	O
force	O
to	O
these	O
transmembrane	O
molecules	O
elicited	O
biologically	O
important	O
signaling	O
(	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
AKT	O
,	O
and	O
GSK	B-Protein
-	I-Protein
3beta	I-Protein
phosphorylation	O
)	O
,	O
and	O
downstream	O
biological	O
responses	O
that	O
depended	O
on	O
the	O
following	O
two	O
factors	O
:	O
(	O
1	O
)	O
the	O
ligand	O
that	O
transmitted	O
force	O
and	O
(	O
2	O
)	O
the	O
direction	O
in	O
which	O
force	O
was	O
applied	O
.	O

These	O
findings	O
indicate	O
that	O
ligands	O
locally	O
generate	O
different	O
shear	O
-	O
induced	O
responses	O
in	O
endothelium	O
that	O
depend	O
on	O
how	O
force	O
is	O
delivered	O
.	O

Dnmt3b	B-Protein
recruitment	O
through	O
E2F6	B-Protein
transcriptional	O
repressor	O
mediates	O
germ	O
-	O
line	O
gene	O
silencing	O
in	O
murine	O
somatic	O
tissues	O
.	O

Methylation	O
of	O
cytosine	O
residues	O
within	O
the	O
CpG	O
dinucleotide	O
in	O
mammalian	O
cells	O
is	O
an	O
important	O
mediator	O
of	O
gene	O
expression	O
,	O
genome	O
stability	O
,	O
X	O
-	O
chromosome	O
inactivation	O
,	O
genomic	O
imprinting	O
,	O
chromatin	O
structure	O
,	O
and	O
embryonic	O
development	O
.	O

The	O
majority	O
of	O
CpG	O
sites	O
in	O
mammalian	O
cells	O
is	O
methylated	O
in	O
a	O
nonrandom	O
fashion	O
,	O
raising	O
the	O
question	O
of	O
how	O
DNA	O
methylation	O
is	O
distributed	O
along	O
the	O
genome	O
.	O

Here	O
,	O
we	O
focused	O
on	O
the	O
functions	O
of	O
DNA	B-Protein
methyltransferase	I-Protein
-	I-Protein
3b	I-Protein
(	O
Dnmt3b	B-Protein
)	O
,	O
of	O
which	O
deregulated	O
activity	O
is	O
linked	O
to	O
several	O
human	O
pathologies	O
.	O

We	O
generated	O
Dnmt3b	B-Protein
hypomorphic	O
mutant	O
mice	O
with	O
reduced	O
catalytic	O
activity	O
,	O
which	O
first	O
revealed	O
a	O
deregulation	O
of	O
Hox	O
genes	O
expression	O
,	O
consistent	O
with	O
the	O
observed	O
homeotic	O
transformations	O
of	O
the	O
posterior	O
axis	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
deregulated	O
expression	O
programs	O
in	O
Dnmt3b	B-Protein
mutant	O
embryos	O
,	O
using	O
DNA	O
microarrays	O
,	O
highlighted	O
illegitimate	O
activation	O
of	O
several	O
germ	O
-	O
line	O
genes	O
in	O
somatic	O
tissues	O
that	O
appeared	O
to	O
be	O
linked	O
directly	O
to	O
their	O
hypomethylation	O
in	O
mutant	O
embryos	O
.	O

We	O
provide	O
evidence	O
that	O
these	O
genes	O
are	O
direct	O
targets	O
of	O
Dnmt3b	B-Protein
.	O

Moreover	O
,	O
the	O
recruitment	O
of	O
Dnmt3b	B-Protein
to	O
their	O
proximal	O
promoter	O
is	O
dependant	O
on	O
the	O
binding	O
of	O
the	O
E2F6	B-Protein
transcriptional	O
repressor	O
,	O
which	O
emerges	O
as	O
a	O
common	O
hallmark	O
in	O
the	O
promoters	O
of	O
genes	O
found	O
to	O
be	O
up	O
-	O
regulated	O
as	O
a	O
consequence	O
of	O
impaired	O
Dnmt3b	B-Protein
activity	O
.	O

Therefore	O
,	O
our	O
results	O
unraveled	O
a	O
coordinated	O
regulation	O
of	O
genes	O
involved	O
in	O
meiosis	O
,	O
through	O
E2F6	B-Protein
-	O
dependant	O
methylation	O
and	O
transcriptional	O
silencing	O
in	O
somatic	O
tissues	O
.	O

Generalized	O
connective	O
tissue	O
disease	O
in	O
Crtap	B-Protein
-	O
/	O
-	O
mouse	O
.	O

Mutations	O
in	O
CRTAP	B-Protein
(	O
coding	O
for	O
cartilage	B-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
)	O
,	O
LEPRE1	B-Protein
(	O
coding	O
for	O
prolyl	B-Protein
3	I-Protein
-	I-Protein
hydroxylase	I-Protein
1	I-Protein
[	O
P3H1	B-Protein
]	O
)	O
or	O
PPIB	B-Protein
(	O
coding	O
for	O
Cyclophilin	B-Protein
B	I-Protein
[	O
CYPB	B-Protein
]	O
)	O
cause	O
recessive	O
forms	O
of	O
osteogenesis	O
imperfecta	O
and	O
loss	O
or	O
decrease	O
of	O
type	O
I	O
collagen	O
prolyl	O
3	O
-	O
hydroxylation	O
.	O

A	O
comprehensive	O
analysis	O
of	O
the	O
phenotype	O
of	O
the	O
Crtap	B-Protein
-	O
/	O
-	O
mice	O
revealed	O
multiple	O
abnormalities	O
of	O
connective	O
tissue	O
,	O
including	O
in	O
the	O
lungs	O
,	O
kidneys	O
,	O
and	O
skin	O
,	O
consistent	O
with	O
systemic	O
dysregulation	O
of	O
collagen	O
homeostasis	O
within	O
the	O
extracellular	O
matrix	O
.	O

Both	O
Crtap	B-Protein
-	O
/	O
-	O
lung	O
and	O
kidney	O
glomeruli	O
showed	O
increased	O
cellular	O
proliferation	O
.	O

Histologically	O
,	O
the	O
lungs	O
showed	O
increased	O
alveolar	O
spacing	O
,	O
while	O
the	O
kidneys	O
showed	O
evidence	O
of	O
segmental	O
glomerulosclerosis	O
,	O
with	O
abnormal	O
collagen	O
deposition	O
.	O

The	O
Crtap	B-Protein
-	O
/	O
-	O
skin	O
had	O
decreased	O
mechanical	O
integrity	O
.	O

In	O
addition	O
to	O
the	O
expected	O
loss	O
of	O
proline	O
986	O
3	O
-	O
hydroxylation	O
in	O
alpha1	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
and	O
alpha1	B-Protein
(	I-Protein
II	I-Protein
)	I-Protein
chains	I-Protein
,	O
there	O
was	O
also	O
loss	O
of	O
3Hyp	O
at	O
proline	O
986	O
in	O
alpha2	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
chains	I-Protein
.	O

In	O
contrast	O
,	O
at	O
two	O
of	O
the	O
known	O
3Hyp	O
sites	O
in	O
alpha1	B-Protein
(	I-Protein
IV	I-Protein
)	I-Protein
chains	I-Protein
from	O
Crtap	B-Protein
-	O
/	O
-	O
kidneys	O
there	O
were	O
normal	O
levels	O
of	O
3	O
-	O
hydroxylation	O
.	O

On	O
a	O
cellular	O
level	O
,	O
loss	O
of	O
CRTAP	B-Protein
in	O
human	O
OI	O
fibroblasts	O
led	O
to	O
a	O
secondary	O
loss	O
of	O
P3H1	B-Protein
,	O
and	O
vice	O
versa	O
.	O

These	O
data	O
suggest	O
that	O
both	O
CRTAP	B-Protein
and	O
P3H1	B-Protein
are	O
required	O
to	O
maintain	O
a	O
stable	O
complex	O
that	O
3	O
-	O
hydroxylates	O
canonical	O
proline	O
sites	O
within	O
clade	O
A	O
(	O
types	O
I	O
,	O
II	B-Protein
,	O
and	O
V	O
)	O
collagen	O
chains	O
.	O

Loss	O
of	O
this	O
activity	O
leads	O
to	O
a	O
multi	O
-	O
systemic	O
connective	O
tissue	O
disease	O
that	O
affects	O
bone	O
,	O
cartilage	O
,	O
lung	O
,	O
kidney	O
,	O
and	O
skin	O
.	O

ATM	B-Protein
-	O
dependent	O
chromatin	O
changes	O
silence	O
transcription	O
in	O
cis	O
to	O
DNA	O
double	O
-	O
strand	O
breaks	O
.	O

DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
initiate	O
extensive	O
local	O
and	O
global	O
alterations	O
in	O
chromatin	O
structure	O
,	O
many	O
of	O
which	O
depend	O
on	O
the	O
ATM	B-Protein
kinase	O
.	O

Histone	B-Protein
H2A	I-Protein
ubiquitylation	O
(	O
uH2A	B-Protein
)	O
on	O
chromatin	O
surrounding	O
DSBs	O
is	O
one	O
example	O
,	O
thought	O
to	O
be	O
important	O
for	O
recruitment	O
of	O
repair	O
proteins	O
.	O

uH2A	B-Protein
is	O
also	O
implicated	O
in	O
transcriptional	O
repression	O
;	O
an	O
intriguing	O
yet	O
untested	O
hypothesis	O
is	O
that	O
this	O
function	O
is	O
conserved	O
in	O
the	O
context	O
of	O
DSBs	O
.	O

Using	O
a	O
novel	O
reporter	O
that	O
allows	O
for	O
visualization	O
of	O
repair	O
protein	O
recruitment	O
and	O
local	O
transcription	O
in	O
single	O
cells	O
,	O
we	O
describe	O
an	O
ATM	B-Protein
-	O
dependent	O
transcriptional	O
silencing	O
program	O
in	O
cis	O
to	O
DSBs	O
.	O

ATM	B-Protein
prevents	O
RNA	O
polymerase	O
II	O
elongation	O
-	O
dependent	O
chromatin	O
decondensation	O
at	O
regions	O
distal	O
to	O
DSBs	O
.	O

Silencing	O
is	O
partially	O
dependent	O
on	O
E3	O
ubiquitin	B-Protein
ligases	O
RNF8	B-Protein
and	O
RNF168	B-Protein
,	O
whereas	O
reversal	O
of	O
silencing	O
relies	O
on	O
the	O
uH2A	B-Protein
deubiquitylating	O
enzyme	O
USP16	B-Protein
.	O

These	O
findings	O
give	O
insight	O
into	O
the	O
role	O
of	O
posttranslational	O
modifications	O
in	O
mediating	O
crosstalk	O
between	O
diverse	O
processes	O
occurring	O
on	O
chromatin	O
.	O

Synergism	O
in	O
ternary	O
complex	O
formation	O
between	O
the	O
dimeric	O
glycoprotein	O
p67SRF	B-Protein
,	O
polypeptide	O
p62TCF	B-Protein
and	O
the	O
c	B-Protein
-	I-Protein
fos	I-Protein
serum	O
response	O
element	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
c	B-Protein
-	I-Protein
fos	I-Protein
proto	O
-	O
oncogene	O
requires	O
the	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
which	O
is	O
complexed	O
by	O
a	O
multi	O
-	O
protein	O
assembly	O
observed	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Two	O
protein	O
factors	O
,	O
p67SRF	B-Protein
and	O
p62TCF	B-Protein
(	O
previously	O
called	O
p62	B-Protein
)	O
,	O
are	O
required	O
to	O
interact	O
with	O
the	O
SRE	O
for	O
efficient	O
induction	O
of	O
c	B-Protein
-	I-Protein
fos	I-Protein
by	O
serum	O
.	O

By	O
quantitative	O
band	O
shift	O
electrophoresis	O
we	O
measure	O
at	O
least	O
a	O
50	O
-	O
fold	O
increase	O
in	O
SRE	O
affinity	O
for	O
p67SRF	B-Protein
/	O
p62TCF	B-Protein
over	O
p67SRF	B-Protein
alone	O
.	O

Stoichiometrically	O
we	O
determine	O
that	O
the	O
ternary	O
complex	O
with	O
p62TCF	B-Protein
involves	O
p67SRF	B-Protein
in	O
dimeric	O
form	O
.	O

We	O
demonstrate	O
that	O
p67SRF	B-Protein
is	O
a	O
glycosylated	O
nuclear	O
transcription	O
factor	O
carrying	O
terminal	O
N	O
-	O
acetylglucosamine	O
(	O
GlcNAc	O
)	O
as	O
a	O
post	O
-	O
translational	O
modification	O
.	O

A	O
proteolytic	O
limit	O
digestion	O
product	O
,	O
approximately	O
13	O
kd	O
in	O
size	O
,	O
was	O
generated	O
from	O
the	O
p67SRF	B-Protein
-	O
SRE	O
complex	O
.	O

This	O
p67SRF	B-Protein
-	O
core	O
domain	O
binds	O
SRE	O
,	O
can	O
dimerize	O
with	O
p67SRF	B-Protein
and	O
is	O
still	O
able	O
to	O
form	O
a	O
ternary	O
complex	O
with	O
p62TCF	B-Protein
.	O

Therefore	O
,	O
three	O
functional	O
activities	O
can	O
be	O
ascribed	O
to	O
this	O
small	O
p67SRF	B-Protein
-	O
core	O
domain	O
:	O
specific	O
DNA	O
binding	O
,	O
dimerization	O
and	O
interaction	O
with	O
p62TCF	B-Protein
.	O

We	O
demonstrate	O
that	O
these	O
functions	O
map	O
within	O
the	O
p67SRF	B-Protein
core	O
fragment	O
containing	O
the	O
region	O
between	O
amino	O
acids	O
93	O
and	O
222	O
.	O

Human	O
acid	B-Protein
beta	I-Protein
-	I-Protein
glucosidase	I-Protein
:	O
glycosylation	O
is	O
required	O
for	O
catalytic	O
activity	O
.	O

The	O
role	O
of	O
oligosaccharide	O
modification	O
in	O
human	O
acid	B-Protein
beta	I-Protein
-	I-Protein
glucosidase	I-Protein
function	O
was	O
investigated	O
.	O

This	O
lysosomal	O
enzyme	O
has	O
five	O
putative	O
N	O
-	O
glycosylation	O
sites	O
,	O
four	O
of	O
which	O
are	O
occupied	O
.	O

The	O
unglycosylated	O
human	O
protein	O
was	O
stable	O
when	O
expressed	O
in	O
bacteria	O
or	O
in	O
Spodoptera	O
frugiperda	O
cells	O
in	O
the	O
presence	O
of	O
tunicamycin	O
but	O
lacked	O
catalytic	O
activity	O
.	O

Deglycosylation	O
of	O
purified	O
acid	B-Protein
beta	I-Protein
-	I-Protein
glucosidase	I-Protein
from	O
human	O
placenta	O
with	O
N	O
-	O
Glycanase	O
under	O
native	O
conditions	O
resulted	O
in	O
the	O
removal	O
of	O
an	O
accessible	O
oligosaccharide	O
chain	O
from	O
a	O
single	O
site	O
with	O
no	O
effect	O
on	O
activity	O
,	O
whereas	O
complete	O
deglycosylation	O
resulted	O
in	O
proportionate	O
loss	O
of	O
activity	O
.	O

These	O
studies	O
demonstrate	O
that	O
occupancy	O
of	O
at	O
least	O
one	O
glycosylation	O
site	O
is	O
required	O
for	O
the	O
formation	O
and	O
maintenance	O
of	O
acid	B-Protein
beta	I-Protein
-	I-Protein
glucosidase	I-Protein
in	O
an	O
active	O
conformation	O
.	O

Gonadotrophin	O
glycosylation	O
and	O
function	O
.	O

This	O
review	O
emphasizes	O
the	O
heterogeneous	O
structure	O
of	O
the	O
gonadotrophin	O
hormones	O
and	O
the	O
influence	O
of	O
different	O
oligosaccharide	O
structures	O
on	O
the	O
bioactivity	O
of	O
these	O
hormones	O
.	O

A	O
summary	O
has	O
been	O
made	O
of	O
the	O
changes	O
in	O
biopotency	O
of	O
the	O
gonadotrophins	O
throughout	O
the	O
life	O
-	O
cycle	O
of	O
the	O
human	O
and	O
in	O
different	O
endocrine	O
states	O
in	O
the	O
rat	O
.	O

In	O
general	O
it	O
appears	O
that	O
the	O
charge	O
of	O
the	O
gonadotrophin	O
conferred	O
by	O
the	O
acid	O
radicals	O
attached	O
to	O
the	O
terminal	O
groups	O
on	O
the	O
oligosaccharide	O
structures	O
strongly	O
influences	O
biopotency	O
.	O

Basic	O
structures	O
have	O
a	O
greater	O
potency	O
in	O
in	O
-	O
vitro	O
assays	O
,	O
but	O
a	O
short	O
half	O
-	O
life	O
in	O
the	O
circulation	O
,	O
while	O
acidic	O
isoforms	O
are	O
less	O
potent	O
,	O
but	O
have	O
a	O
longer	O
circulatory	O
time	O
and	O
are	O
thus	O
more	O
active	O
in	O
in	O
-	O
vivo	O
estimations	O
.	O

More	O
basic	O
forms	O
are	O
secreted	O
over	O
the	O
adult	O
reproductive	O
years	O
compared	O
with	O
the	O
prepubertal	O
period	O
and	O
old	O
age	O
.	O

The	O
glycosyl	O
structure	O
of	O
the	O
carbohydrate	O
groups	O
also	O
alters	O
in	O
different	O
endocrine	O
states	O
and	O
is	O
probably	O
also	O
important	O
for	O
the	O
bioactivity	O
and	O
potency	O
of	O
the	O
hormone	O
.	O

Gonadotrophin	O
-	O
releasing	O
hormone	O
(	O
GnRH	B-Protein
)	O
and	O
gonadal	O
steroids	O
can	O
influence	O
the	O
type	O
of	O
isoform	O
synthesized	O
and	O
released	O
,	O
and	O
therefore	O
affect	O
the	O
function	O
of	O
gonadotrophins	O
.	O

GnRH	B-Protein
enhances	O
glycosylation	O
,	O
sulphation	O
and	O
biopotency	O
.	O

Oestradiol	O
potentiates	O
the	O
glycosylation	O
induced	O
by	O
GnRH	B-Protein
and	O
reduces	O
sialylation	O
,	O
while	O
testosterone	O
increases	O
sialylation	O
.	O

Partial	O
purification	O
and	O
characterization	O
of	O
bovine	O
liver	O
aspartyl	B-Protein
beta	I-Protein
-	I-Protein
hydroxylase	I-Protein
.	O

In	O
vitro	O
hydroxylation	O
of	O
aspartic	O
acid	O
has	O
recently	O
been	O
demonstrated	O
in	O
a	O
synthetic	O
peptide	O
based	O
on	O
the	O
structure	O
of	O
the	O
first	O
epidermal	O
growth	O
factor	O
domain	O
in	O
human	O
factor	B-Protein
IX	I-Protein
(	O
Gronke	O
,	O
R	O
.	O
S	O
.	O
,	O
VanDusen	O
,	O
W	O
.	O
J	O
.	O
,	O
Garsky	O
,	O
V	O
.	O
M	O
.	O
,	O
Jacobs	O
,	O
J	O
.	O
W	O
.	O
,	O
Sardana	O
,	O
M	O
.	O
K	O
.	O
,	O
Stern	O
,	O
A	O
.	O
M	O
.	O
,	O
and	O
Friedman	O
,	O
P	O
.	O
A	O
.	O
(	O
1989	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
86	O
,	O
3609	O
-	O
3613	O
)	O
.	O

The	O
putative	O
enzyme	O
responsible	O
for	O
the	O
posttranslational	O
modification	O
,	O
aspartyl	B-Protein
beta	I-Protein
-	I-Protein
hydroxylase	I-Protein
,	O
has	O
been	O
shown	O
to	O
be	O
a	O
member	O
of	O
a	O
class	O
of	O
2	O
-	O
ketoglutarate	O
-	O
dependent	O
dioxygenases	O
,	O
which	O
include	O
prolyl	O
-	O
4	O
-	O
and	O
lysyl	O
-	O
hydroxylases	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
solubilization	O
with	O
nonionic	O
detergent	O
of	O
the	O
enzyme	O
from	O
bovine	O
liver	O
microsomes	O
and	O
its	O
purification	O
using	O
DEAE	O
-	O
cellulose	O
followed	O
by	O
heparin	O
-	O
Sepharose	O
.	O

No	O
additional	O
detergent	O
was	O
required	O
during	O
purification	O
.	O

The	O
partially	O
purified	O
enzyme	O
preparation	O
was	O
found	O
to	O
contain	O
no	O
prolyl	O
-	O
4	O
-	O
or	O
lysyl	O
-	O
hydroxylase	O
activity	O
.	O

Using	O
a	O
synthetic	O
peptide	O
based	O
on	O
the	O
structure	O
of	O
the	O
epidermal	O
growth	O
factor	O
-	O
like	O
region	O
in	O
human	O
factor	B-Protein
X	I-Protein
as	O
substrate	O
,	O
the	O
apparent	O
Km	O
values	O
for	O
iron	O
and	O
alpha	O
-	O
ketoglutarate	O
were	O
3	O
and	O
5	O
microM	O
,	O
respectively	O
.	O

The	O
enzyme	O
hydroxylated	O
the	O
factor	B-Protein
X	I-Protein
peptide	O
with	O
the	O
same	O
stereospecificity	O
(	O
erythro	O
beta	O
-	O
hydroxyaspartic	O
acid	O
)	O
and	O
occurred	O
only	O
at	O
the	O
aspartate	O
corresponding	O
to	O
the	O
position	O
seen	O
in	O
vivo	O
.	O

Furthermore	O
,	O
the	O
extent	O
to	O
which	O
either	O
peptide	O
(	O
factor	B-Protein
IX	I-Protein
or	O
X	B-Protein
)	O
was	O
hydroxylated	O
reflected	O
the	O
extent	O
of	O
hydroxylation	O
observed	O
for	O
both	O
human	O
plasma	O
factors	B-Protein
IX	I-Protein
and	O
X	B-Protein
.	O

Characterization	O
of	O
a	O
66	O
-	O
kilodalton	O
surface	O
glycoprotein	O
of	O
the	O
human	O
corneal	O
endothelium	O
.	O

The	O
pellet	O
recovered	O
after	O
centrifugation	O
(	O
5000	O
X	O
g	O
)	O
of	O
human	O
corneal	O
endothelial	O
homogenates	O
was	O
used	O
as	O
the	O
source	O
of	O
membranes	O
in	O
these	O
studies	O
.	O

A	O
66	O
-	O
kilodalton	O
(	O
kD	O
)	O
protein	O
was	O
identified	O
as	O
the	O
most	O
abundant	O
protein	O
in	O
the	O
particulate	O
pellet	O
by	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

The	O
de	O
novo	O
synthesis	O
of	O
the	O
66	O
-	O
kD	O
protein	O
by	O
endothelial	O
cells	O
was	O
observed	O
during	O
culturing	O
of	O
human	O
corneas	O
in	O
the	O
presence	O
of	O
35S	O
-	O
methionine	O
.	O

The	O
66	O
-	O
kD	O
protein	O
was	O
found	O
to	O
be	O
a	O
plasma	O
membrane	O
protein	O
based	O
on	O
several	O
of	O
its	O
properties	O
,	O
ie	O
,	O
its	O
solubility	O
in	O
CHCl3	O
:	O
CH3OH	O
,	O
its	O
labeling	O
as	O
surface	O
glycoprotein	O
,	O
and	O
during	O
exposure	O
to	O
a	O
photoaffinity	O
hydrophobic	O
probe	O
:	O
1	O
-	O
azido	O
-	O
4	O
-	O
125I	O
-	O
iodobenzene	O
.	O

Furthermore	O
this	O
protein	O
could	O
be	O
released	O
from	O
the	O
particulate	O
pellet	O
after	O
treatment	O
with	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	O
C	O
,	O
suggesting	O
its	O
anchorage	O
via	O
a	O
phosphatidylinositol	O
glycan	O
linkage	O
in	O
the	O
plasma	O
membrane	O
.	O

Such	O
anchorage	O
of	O
this	O
protein	O
was	O
further	O
confirmed	O
by	O
its	O
labeling	O
during	O
culture	O
of	O
corneas	O
in	O
the	O
presence	O
of	O
3H	O
-	O
myoinositol	O
.	O

The	O
glycoprotein	O
nature	O
of	O
the	O
66	O
-	O
kD	O
protein	O
was	O
evident	O
from	O
its	O
labeling	O
during	O
surface	O
glycoprotein	O
labeling	O
of	O
endothelial	O
cells	O
,	O
staining	O
with	O
periodic	O
acid	O
-	O
Schiff	O
stain	O
,	O
and	O
binding	O
to	O
peanut	O
agglutinin	B-Protein
(	O
PNA	B-Protein
)	O
,	O
and	O
lotus	O
agglutinin	O
(	O
LTA	O
)	O
on	O
SDS	O
-	O
acrylamide	O
gels	O
.	O

The	O
66	O
-	O
kD	O
protein	O
of	O
endothelial	O
particulate	O
pellets	O
recovered	O
from	O
corneas	O
of	O
donors	O
of	O
different	O
ages	O
showed	O
an	O
age	O
-	O
related	O
increase	O
in	O
binding	O
to	O
PNA	O
and	O
LTA	O
.	O

This	O
suggested	O
an	O
increased	O
glycosylation	O
of	O
the	O
66	O
-	O
kD	O
protein	O
with	O
aging	O
.	O

A	O
polyclonal	O
anti	O
-	O
66	O
-	O
kD	O
protein	O
antibody	O
was	O
used	O
as	O
a	O
probe	O
to	O
determine	O
the	O
presence	O
of	O
this	O
protein	O
in	O
the	O
rabbit	O
and	O
bovine	O
corneal	O
endothelia	O
by	O
the	O
Western	O
-	O
blot	O
analysis	O
.	O

The	O
66	O
-	O
kD	O
protein	O
was	O
detected	O
in	O
both	O
rabbit	O
and	O
bovine	O
endothelia	O
,	O
but	O
an	O
additional	O
immunoreactive	O
species	O
of	O
17	O
kD	O
was	O
also	O
observed	O
which	O
may	O
be	O
a	O
processed	O
product	O
of	O
the	O
66	O
-	O
kD	O
protein	O
.	O

Kinetics	O
of	O
carboxylmethylation	O
of	O
the	O
charge	O
isoforms	O
of	O
myelin	B-Protein
basic	I-Protein
protein	I-Protein
by	O
protein	O
methyltransferase	O
II	O
.	O

The	O
charge	O
isoforms	O
(	O
C1	O
-	O
C5	O
)	O
of	O
bovine	O
myelin	B-Protein
basic	I-Protein
protein	I-Protein
(	O
MBP	B-Protein
)	O
were	O
used	O
as	O
substrates	O
for	O
the	O
rat	O
brain	O
enzyme	O
protein	O
carboxylmethyltransferase	O
(	O
PM	O
II	O
)	O
.	O

The	O
objective	O
of	O
these	O
experiments	O
was	O
to	O
ascertain	O
whether	O
the	O
kinetic	O
behavior	O
of	O
the	O
MBP	B-Protein
isoforms	O
reflected	O
differences	O
in	O
the	O
structures	O
of	O
this	O
molecular	O
family	O
.	O

Initial	O
velocity	O
plots	O
as	O
a	O
function	O
of	O
the	O
MBP	B-Protein
-	O
isoform	O
concentration	O
showed	O
significant	O
differences	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
among	O
the	O
assayed	O
isoforms	O
except	O
for	O
isoforms	O
C2	B-Protein
and	O
C4	B-Protein
.	O

Under	O
the	O
conditions	O
of	O
our	O
experiment	O
all	O
the	O
curves	O
exhibited	O
a	O
consistent	O
sigmoidicity	O
.	O

The	O
kinetic	O
data	O
were	O
best	O
fitted	O
by	O
a	O
model	O
,	O
previously	O
described	O
for	O
the	O
enzyme	O
D	B-Protein
-	I-Protein
beta	I-Protein
-	I-Protein
hydroxybutyrate	I-Protein
dehydrogenase	I-Protein
,	O
in	O
which	O
two	O
independent	O
sites	O
must	O
be	O
randomly	O
occupied	O
before	O
any	O
catalytic	O
activity	O
can	O
occur	O
.	O

This	O
mechanism	O
is	O
substantially	O
different	O
from	O
that	O
proposed	O
by	O
other	O
investigators	O
for	O
similar	O
PM	O
II	O
enzymes	O
and	O
other	O
substrates	O
.	O

The	O
differences	O
in	O
the	O
rates	O
of	O
isoform	O
carboxylmethylation	O
are	O
largely	O
accounted	O
for	O
by	O
the	O
different	O
apparent	O
dissociation	O
constants	O
Ks	O
and	O
is	O
explained	O
on	O
the	O
basis	O
of	O
inherent	O
structural	O
differences	O
among	O
the	O
charge	O
isoforms	O
.	O

Affinity	O
electrophoresis	O
for	O
studies	O
of	O
mechanisms	O
regulating	O
glycosylation	O
of	O
plasma	O
proteins	O
.	O

A	O
model	O
system	O
for	O
studies	O
of	O
mechanisms	O
governing	O
the	O
alterations	O
of	O
glycosylation	O
of	O
plasma	O
glycoproteins	O
was	O
developed	O
.	O

The	O
system	O
employs	O
two	O
human	O
hepatoma	O
cell	O
lines	O
,	O
Hep	O
3B	O
and	O
Hep	O
G2	O
,	O
as	O
target	O
cells	O
and	O
agarose	O
affinity	O
electrophoresis	O
with	O
lectins	O
for	O
studies	O
of	O
microheterogeneity	O
of	O
alpha	B-Protein
1	I-Protein
-	I-Protein
protease	I-Protein
inhibitor	I-Protein
(	O
PI	B-Protein
)	O
,	O
a	O
model	O
glycoprotein	O
synthesized	O
by	O
hepatocytes	O
.	O

As	O
an	O
example	O
for	O
the	O
application	O
of	O
the	O
system	O
,	O
the	O
effect	O
of	O
cytokines	O
on	O
major	O
microheterogeneity	O
of	O
plasma	O
proteins	O
is	O
demonstrated	O
.	O

The	O
results	O
indicate	O
that	O
interleukin	B-Protein
6	I-Protein
,	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
beta	I-Protein
1	I-Protein
and	O
,	O
to	O
some	O
extent	O
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
are	O
directly	O
involved	O
in	O
regulating	O
the	O
pattern	O
of	O
glycosylation	O
of	O
plasma	O
proteins	O
in	O
vitro	O
,	O
but	O
the	O
major	O
effect	O
is	O
obtained	O
by	O
using	O
combinations	O
of	O
interleukin	B-Protein
6	I-Protein
,	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
beta	I-Protein
1	I-Protein
,	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
and	O
interleukin	B-Protein
1	I-Protein
.	O

In	O
addition	O
,	O
the	O
results	O
underline	O
the	O
dissociation	O
between	O
alteration	O
of	O
gene	O
expression	O
and	O
the	O
changes	O
in	O
the	O
pattern	O
of	O
plasma	O
protein	O
glycosylation	O
.	O

Histone	O
-	O
lysine	O
methyltransferase	O
activity	O
from	O
sea	O
-	O
urchin	O
embryo	O
nuclei	O
.	O

Changes	O
in	O
substrate	O
specificity	O
upon	O
purification	O
.	O

The	O
S	O
-	O
adenosylmethionine	O
:	O
histone	O
-	O
lysine	O
methyltransferase	O
(	O
EC	O
2	O
.	O
1	O
.	O
1	O
.	O
43	O
)	O
enzyme	O
activity	O
,	O
present	O
in	O
the	O
chromatin	O
of	O
sea	O
-	O
urchin	O
embryo	O
nuclei	O
,	O
has	O
been	O
purified	O
about	O
300	O
-	O
fold	O
with	O
30	O
%	O
overall	O
yield	O
.	O

The	O
initial	O
activity	O
in	O
the	O
nucleus	O
transfers	O
methyl	O
groups	O
to	O
the	O
epsilon	O
-	O
amino	O
group	O
of	O
lysines	O
and	O
acceptor	O
proteins	O
are	O
chromatin	O
-	O
bound	O
H3	B-Protein
and	O
H4	B-Protein
histones	I-Protein
.	O

In	O
contrast	O
,	O
the	O
purified	O
enzyme	O
activity	O
transfers	O
methyl	O
groups	O
to	O
the	O
arginines	O
and	O
acceptor	O
proteins	O
are	O
soluble	O
H3	B-Protein
and	O
H4	B-Protein
histones	I-Protein
.	O

The	O
two	O
changes	O
in	O
substrate	O
specificity	O
do	O
not	O
occur	O
at	O
the	O
same	O
time	O
.	O

The	O
variation	O
of	O
acceptor	O
protein	O
from	O
chromatin	O
-	O
bound	O
to	O
soluble	O
histones	B-Protein
occurs	O
at	O
the	O
first	O
step	O
,	O
upon	O
nuclei	O
sonication	O
,	O
when	O
no	O
protein	O
fractionation	O
has	O
yet	O
been	O
performed	O
.	O

At	O
that	O
step	O
,	O
lysine	O
is	O
still	O
the	O
only	O
methylated	O
side	O
-	O
chain	O
.	O

The	O
variation	O
of	O
the	O
methylated	O
amino	O
acid	O
from	O
lysine	O
to	O
arginine	O
occurs	O
gradually	O
with	O
increasing	O
enzyme	O
purification	O
.	O

The	O
enzyme	O
activity	O
has	O
a	O
molecular	O
mass	O
of	O
about	O
200	O
kDa	O
.	O

Saturation	O
curves	O
for	O
H3	B-Protein
and	O
H4	B-Protein
histones	I-Protein
,	O
used	O
as	O
substrate	O
either	O
individually	O
or	O
in	O
total	O
histones	O
,	O
and	O
for	O
AdoMet	O
show	O
no	O
substantial	O
dependence	O
on	O
enzyme	O
purification	O
.	O

Maximal	O
activity	O
for	O
the	O
enzyme	O
,	O
at	O
all	O
purification	O
levels	O
,	O
occurs	O
at	O
about	O
pH	O
8	O
for	O
all	O
substrate	O
histones	B-Protein
.	O

An	O
increase	O
in	O
the	O
relative	O
concentrations	O
of	O
di	O
-	O
and	O
trimethyllysine	O
derivatives	O
is	O
observed	O
with	O
the	O
more	O
purified	O
enzyme	O
preparations	O
,	O
while	O
the	O
ratio	O
of	O
mono	O
-	O
and	O
dimethylarginine	O
derivatives	O
remains	O
constant	O
.	O

The	O
data	O
are	O
taken	O
as	O
evidence	O
that	O
the	O
same	O
protein	O
molecule	O
is	O
responsible	O
for	O
the	O
two	O
activities	O
.	O

Asparagine	O
-	O
linked	O
glycosylation	O
of	O
the	O
scrapie	O
and	O
cellular	O
prion	B-Protein
proteins	I-Protein
.	O

Post	O
-	O
translational	O
modification	O
of	O
the	O
scrapie	O
prion	B-Protein
protein	I-Protein
(	O
PrP	B-Protein
)	O
is	O
thought	O
to	O
account	O
for	O
the	O
unusual	O
features	O
of	O
this	O
protein	O
.	O

Molecular	O
cloning	O
of	O
a	O
PrP	B-Protein
cDNA	O
identified	O
two	O
potential	O
Asn	O
-	O
linked	O
glycosylation	O
sites	O
.	O

Both	O
the	O
scrapie	O
(	O
PrPSc	B-Protein
)	O
and	O
cellular	O
(	O
PrPC	B-Protein
)	O
isoforms	O
were	O
susceptible	O
to	O
digestion	O
by	O
peptide	B-Protein
N	I-Protein
-	I-Protein
glycosidase	I-Protein
F	I-Protein
(	O
PNGase	B-Protein
F	I-Protein
)	O
but	O
resistant	O
to	O
endoglycosidase	B-Protein
H	I-Protein
as	O
measured	O
by	O
migration	O
in	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

PNGase	B-Protein
F	I-Protein
digestion	O
of	O
PrPC	B-Protein
yielded	O
two	O
proteins	O
of	O
Mr26K	O
and	O
28K	O
;	O
however	O
,	O
the	O
26	O
-	O
k	O
species	O
was	O
only	O
a	O
minor	O
component	O
.	O

In	O
contrast	O
,	O
PNGase	B-Protein
F	I-Protein
digestion	O
of	O
PrPSc	B-Protein
yielded	O
equimolar	O
amounts	O
of	O
two	O
proteins	O
of	O
Mr26K	O
and	O
28K	O
.	O

The	O
significance	O
of	O
this	O
altered	O
stoichiometry	O
between	O
the	O
26	O
-	O
and	O
28	O
-	O
kDa	O
deglycosylated	O
forms	O
of	O
PrP	B-Protein
during	O
scrapie	O
infection	O
remains	O
to	O
be	O
established	O
.	O

Both	O
isoforms	O
as	O
well	O
as	O
PrP	B-Protein
27	I-Protein
-	I-Protein
30	I-Protein
,	O
which	O
is	O
produced	O
by	O
limited	O
proteolysis	O
of	O
PrPSc	B-Protein
,	O
exhibited	O
a	O
reduced	O
number	O
of	O
charge	O
isomers	O
after	O
PNGase	B-Protein
F	I-Protein
digestion	O
.	O

The	O
molecular	O
weight	O
of	O
PrP	B-Protein
27	I-Protein
-	I-Protein
30	I-Protein
was	O
reduced	O
from	O
27K	O
-	O
30K	O
by	O
PNGase	B-Protein
F	I-Protein
digestion	O
to	O
20K	O
-	O
22K	O
while	O
anhydrous	O
hydrogen	O
fluoride	O
or	O
trifluoromethanesulfonic	O
acid	O
treatment	O
reduced	O
the	O
molecular	O
weight	O
to	O
19K	O
-	O
21K	O
and	O
20K	O
-	O
22K	O
,	O
respectively	O
.	O

Denatured	O
PrP	B-Protein
27	I-Protein
-	I-Protein
30	I-Protein
was	O
radioiodinated	O
and	O
then	O
assessed	O
for	O
its	O
binding	O
to	O
lectin	O
columns	O
.	O

PrP	B-Protein
27	I-Protein
-	I-Protein
30	I-Protein
was	O
bound	O
to	O
wheat	O
germ	O
agglutinin	O
(	O
WGA	O
)	O
or	O
lentil	O
lectins	B-Protein
and	O
eluted	O
with	O
N	O
-	O
acetylglucosamine	O
or	O
alpha	O
-	O
methyl	O
-	O
mannoside	O
,	O
respectively	O
.	O

Digestion	O
of	O
PrP	B-Protein
27	I-Protein
-	I-Protein
30	I-Protein
with	O
sialidase	B-Protein
prevented	O
its	O
binding	O
to	O
WGA	O
but	O
enhanced	O
its	O
binding	O
to	O
Ricinus	O
communis	O
lectin	O
.	O

These	O
findings	O
argue	O
that	O
PrP	B-Protein
27	I-Protein
-	I-Protein
30	I-Protein
probably	O
possesses	O
Asn	O
-	O
linked	O
,	O
complex	O
oligosaccharides	O
with	O
terminal	O
sialic	O
acids	O
,	O
penultimate	O
galactoses	O
,	O
and	O
fucose	O
residues	O
attached	O
to	O
the	O
innermost	O
N	O
-	O
acetyl	O
-	O
glucosamine	O
.	O

Whether	O
differences	O
in	O
Asn	O
-	O
linked	O
oligosaccharide	O
structure	O
between	O
PrPC	B-Protein
and	O
PrPSc	B-Protein
exist	O
and	O
are	O
responsible	O
for	O
the	O
distinct	O
properties	O
displayed	O
by	O
these	O
two	O
isoforms	O
remain	O
to	O
be	O
established	O
.	O

The	O
catalytic	O
mechanism	O
of	O
the	O
hydroxylation	O
reaction	O
of	O
peptidyl	O
proline	O
and	O
lysine	O
does	O
not	O
require	O
protein	O
disulphide	O
-	O
isomerase	O
activity	O
.	O

Prolyl	O
4	O
-	O
hydroxylase	O
,	O
an	O
alpha	O
2	O
beta	O
2	O
tetramer	O
,	O
catalyses	O
the	O
formation	O
of	O
4	O
-	O
hydroxyproline	O
in	O
collagens	O
.	O

The	O
beta	O
subunit	O
is	O
known	O
to	O
be	O
identical	O
with	O
the	O
enzyme	O
protein	B-Protein
disulphide	I-Protein
-	I-Protein
isomerase	I-Protein
and	O
to	O
possess	O
disulphide	O
-	O
isomerase	O
activity	O
even	O
when	O
present	O
in	O
the	O
prolyl	O
4	O
-	O
hydroxylase	O
tetramer	O
.	O

We	O
here	O
report	O
that	O
lysyl	O
hydroxylase	O
,	O
a	O
homodimer	O
,	O
and	O
algal	O
prolyl	B-Protein
4	I-Protein
-	I-Protein
hydroxylase	I-Protein
,	O
a	O
monomer	O
,	O
do	O
not	O
contain	O
detectable	O
protein	O
disulphide	O
-	O
isomerase	O
activity	O
.	O

Since	O
the	O
hydroxylase	O
reaction	O
mechanisms	O
are	O
similar	O
,	O
the	O
data	O
suggest	O
that	O
the	O
protein	O
disulphide	O
-	O
isomerase	O
activity	O
of	O
the	O
vertebrate	O
prolyl	B-Protein
4	I-Protein
-	I-Protein
hydroxylase	I-Protein
beta	I-Protein
subunit	I-Protein
is	O
unlikely	O
to	O
be	O
involved	O
in	O
the	O
catalytic	O
mechanism	O
of	O
the	O
hydroxylation	O
reaction	O
.	O

Purification	O
and	O
analysis	O
of	O
RNA	O
polymerase	O
II	O
transcription	O
factors	O
by	O
using	O
wheat	O
germ	O
agglutinin	O
affinity	O
chromatography	O
.	O

We	O
recently	O
found	O
that	O
many	O
RNA	O
polymerase	O
II	O
transcription	O
factors	O
are	O
modified	O
with	O
N	O
-	O
acetylglucosamine	O
residues	O
.	O

These	O
sugar	O
moieties	O
confer	O
upon	O
transcription	O
factors	O
an	O
ability	O
to	O
bind	O
the	O
lectin	O
wheat	O
germ	O
agglutinin	O
.	O

We	O
have	O
taken	O
advantage	O
of	O
this	O
interaction	O
to	O
devise	O
a	O
purification	O
procedure	O
for	O
the	O
"	O
GC	O
-	O
box	O
"	O
binding	O
transcription	O
factor	O
Sp1	B-Protein
.	O

Crude	O
nuclear	O
extracts	O
are	O
first	O
subjected	O
to	O
wheat	O
germ	O
agglutinin	O
affinity	O
chromatography	O
and	O
then	O
subjected	O
to	O
sequence	O
-	O
specific	O
DNA	O
affinity	O
chromatography	O
.	O

The	O
Sp1	B-Protein
protein	O
purified	O
by	O
this	O
procedure	O
is	O
at	O
least	O
95	O
%	O
pure	O
,	O
and	O
the	O
overall	O
recovery	O
is	O
greater	O
than	O
80	O
%	O
.	O

In	O
addition	O
to	O
yielding	O
larger	O
quantities	O
of	O
Sp1	B-Protein
than	O
conventional	O
schemes	O
,	O
the	O
new	O
purification	O
procedure	O
is	O
also	O
simpler	O
and	O
more	O
rapid	O
.	O

We	O
show	O
that	O
wheat	O
germ	O
agglutinin	O
affinity	O
chromatography	O
can	O
also	O
be	O
used	O
to	O
purify	O
the	O
glycosylated	O
forms	O
of	O
the	O
CCAAT	B-Protein
-	I-Protein
binding	I-Protein
transcription	I-Protein
factor	I-Protein
.	O

Thus	O
,	O
wheat	O
germ	O
agglutinin	O
affinity	O
chromatography	O
may	O
aid	O
the	O
purification	O
of	O
other	O
transcription	O
factors	O
that	O
bear	O
N	O
-	O
acetylglucosamine	O
residues	O
.	O

Furthermore	O
,	O
the	O
ability	O
to	O
separate	O
glycosylated	O
forms	O
of	O
transcription	O
factors	O
from	O
their	O
unglycosylated	O
counterparts	O
by	O
wheat	O
germ	O
agglutinin	O
affinity	O
chromatography	O
should	O
facilitate	O
investigations	O
into	O
the	O
role	O
of	O
N	O
-	O
acetylglucosamine	O
residues	O
in	O
the	O
functioning	O
of	O
transcription	O
factor	O
proteins	O
.	O

Acetylation	O
and	O
deacetylation	O
of	O
histone	B-Protein
H4	I-Protein
continue	O
through	O
metaphase	O
with	O
depletion	O
of	O
more	O
-	O
acetylated	O
isoforms	O
and	O
altered	O
site	O
usage	O
.	O

Antibodies	O
specific	O
for	O
acetylated	O
isoforms	O
of	O
histone	B-Protein
H4	I-Protein
have	O
been	O
used	O
to	O
compare	O
acetylation	O
of	O
this	O
histone	B-Protein
in	O
interphase	O
and	O
metaphase	O
cells	O
.	O

Two	O
rabbit	O
antisera	O
(	O
R5	O
and	O
R6	O
)	O
were	O
used	O
,	O
each	O
specific	O
for	O
H4	B-Protein
molecules	O
acetylated	O
at	O
one	O
of	O
the	O
four	O
possible	O
acetylation	O
sites	O
,	O
namely	O
Lys	O
-	O
5	O
(	O
R6	O
)	O
and	O
Lys	O
-	O
12	O
(	O
R5	O
)	O
.	O

Both	O
antisera	O
bound	O
preferentially	O
to	O
the	O
more	O
-	O
acetylated	O
H4	B-Protein
isoforms	O
(	O
H4Ac2	B-Protein
-	O
4	O
)	O
.	O

To	O
test	O
for	O
continued	O
H4	B-Protein
acetylation	O
in	O
metaphase	O
chromosomes	O
.	O

Chinese	O
hamster	O
ovary	O
cells	O
were	O
blocked	O
in	O
metaphase	O
and	O
treated	O
for	O
one	O
hour	O
with	O
the	O
deacetylase	O
inhibitor	O
sodium	O
butyrate	O
.	O

Isolated	O
chromosomes	O
were	O
assayed	O
for	O
H4	B-Protein
acetylation	O
by	O
antibody	O
labeling	O
and	O
flow	O
cytometry	O
.	O

H4	B-Protein
acetylation	O
was	O
increased	O
several	O
fold	O
by	O
this	O
brief	O
butyrate	O
treatment	O
.	O

The	O
increase	O
was	O
in	O
direct	O
proportion	O
to	O
DNA	O
content	O
,	O
with	O
no	O
evidence	O
for	O
exceptionally	O
high	O
-	O
or	O
low	O
-	O
labeling	O
chromosomes	O
.	O

The	O
results	O
demonstrate	O
that	O
a	O
cycle	O
of	O
H4	B-Protein
acetylation	O
and	O
deacetylation	O
continues	O
within	O
metaphase	O
chromosomes	O
.	O

Immunofluorescence	O
microscopy	O
showed	O
labeling	O
to	O
be	O
distributed	O
throughout	O
the	O
chromosome	O
,	O
but	O
with	O
variable	O
intensity	O
.	O

Western	O
blotting	O
and	O
immunostaining	O
with	O
R5	O
and	O
R6	O
showed	O
a	O
net	O
reduction	O
in	O
labeling	O
of	O
H4	B-Protein
from	O
metaphase	O
cells	O
,	O
with	O
major	O
reductions	O
in	O
the	O
more	O
-	O
acetylated	O
isoforms	O
H4Ac3	B-Protein
-	O
4	O
.	O

In	O
contrast	O
,	O
labeling	O
of	O
H4Ac1	B-Protein
was	O
reduced	O
to	O
a	O
lesser	O
extent	O
(	O
R6	O
)	O
or	O
increased	O
(	O
R5	O
)	O
.	O

This	O
increase	O
indicates	O
more	O
frequent	O
use	O
of	O
the	O
acetylation	O
site	O
at	O
lysine	O
12	O
in	O
H4Ac1	B-Protein
from	O
metaphase	O
cells	O
.	O

Hypomethylation	O
of	O
ras	O
oncogenes	O
in	O
chemically	O
induced	O
and	O
spontaneous	O
B6C3F1	O
mouse	O
liver	O
tumors	O
.	O

The	O
male	O
hybrid	O
B6C3F1	O
mouse	O
exhibits	O
a	O
30	O
%	O
spontaneous	O
hepatoma	O
incidence	O
,	O
and	O
both	O
males	O
and	O
females	O
of	O
this	O
strain	O
are	O
sensitive	O
to	O
chemical	O
induction	O
of	O
liver	O
tumors	O
.	O

The	O
Ha	B-Protein
-	I-Protein
ras	I-Protein
,	O
Ki	B-Protein
-	I-Protein
ras	I-Protein
,	O
and	O
myc	B-Protein
oncogenes	O
have	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
solid	O
tumors	O
.	O

Specifically	O
,	O
Ha	B-Protein
-	I-Protein
and	O
,	O
less	O
frequently	O
Ki	B-Protein
-	I-Protein
ras	I-Protein
have	O
been	O
reported	O
to	O
be	O
activated	O
in	O
B6C3F1	O
mouse	O
liver	O
tumors	O
,	O
and	O
such	O
activated	O
oncogenes	O
frequently	O
contain	O
a	O
particular	O
point	O
mutation	O
.	O

In	O
light	O
of	O
indications	O
that	O
the	O
transforming	O
capacity	O
of	O
some	O
oncogenes	O
is	O
directly	O
related	O
to	O
the	O
level	O
of	O
the	O
gene	O
product	O
,	O
we	O
hypothesized	O
that	O
transcriptional	O
control	O
of	O
Ha	B-Protein
-	I-Protein
ras	I-Protein
,	O
Ki	B-Protein
-	I-Protein
ras	I-Protein
,	O
and	O
myc	B-Protein
is	O
compromised	O
in	O
B6C3F1	O
mouse	O
liver	O
tumors	O
.	O

A	O
positive	O
correlation	O
has	O
been	O
established	O
between	O
gene	O
expression	O
and	O
hypomethylation	O
.	O

Therefore	O
,	O
the	O
methylation	O
states	O
of	O
these	O
genes	O
were	O
examined	O
in	O
spontaneous	O
liver	O
tumors	O
and	O
in	O
tumors	O
induced	O
by	O
two	O
diverse	O
hepatocarcinogens	O
:	O
phenobarbital	O
and	O
chloroform	O
.	O

Ha	B-Protein
-	I-Protein
ras	I-Protein
was	O
found	O
to	O
be	O
hypomethylated	O
in	O
all	O
tumors	O
examined	O
,	O
whereas	O
Ki	B-Protein
-	I-Protein
ras	I-Protein
was	O
sometimes	O
hypomethylated	O
;	O
such	O
hypomethylation	O
might	O
play	O
a	O
role	O
in	O
the	O
promotion	O
stage	O
of	O
carcinogenesis	O
.	O

The	O
methylation	O
state	O
of	O
myc	B-Protein
was	O
unaltered	O
,	O
although	O
this	O
gene	O
appeared	O
to	O
be	O
amplified	O
in	O
tumors	O
.	O

These	O
results	O
suggest	O
that	O
a	O
component	O
of	O
the	O
mechanism	O
by	O
which	O
these	O
oncogenes	O
are	O
activated	O
in	O
B6C3F1	O
mouse	O
liver	O
tumors	O
involves	O
loss	O
of	O
stringent	O
control	O
of	O
expression	O
,	O
via	O
hypomethylation	O
of	O
the	O
ras	O
oncogenes	O
and	O
,	O
possibly	O
,	O
amplification	O
of	O
myc	B-Protein
.	O

These	O
results	O
support	O
the	O
assertion	O
that	O
tumors	O
induced	O
by	O
different	O
classes	O
of	O
carcinogens	O
or	O
arising	O
spontaneously	O
share	O
common	O
biochemical	O
pathways	O
of	O
oncogene	O
activation	O
during	O
tumorigenesis	O
.	O

Synthesis	O
of	O
angiotensin	B-Protein
II	I-Protein
antagonists	O
containing	O
N	O
-	O
and	O
O	O
-	O
methylated	O
and	O
other	O
amino	O
acid	O
residues	O
.	O

[	O
1	O
-	O
N	O
-	O
Methylisoasparagine	O
,	O
8	O
-	O
isoleucine	O
]	O
-	O
(	O
I	O
)	O
,	O
[	O
1	O
-	O
sarcosine	O
,	O
4	O
-	O
N	O
-	O
methyltyrosine	O
,	O
8	O
-	O
isoleucine	O
]	O
-	O
(	O
II	O
)	O
,	O
[	O
1	O
-	O
sarcosine	O
,	O
5	O
-	O
N	O
-	O
methylisoleucine	O
,	O
8	O
-	O
isoleucine	O
]	O
-	O
(	O
III	O
)	O
,	O
[	O
1	O
-	O
sarcosine	O
,	O
8	O
-	O
N	O
-	O
methylisoleucine	O
]	O
-	O
(	O
IV	O
)	O
,	O
[	O
1	O
-	O
sarcosine8k	O
-	O
N	O
-	O
methylisoleucine	O
,	O
8	O
-	O
N	O
-	O
methylisoleucine	O
]	O
-	O
(	O
V	O
)	O
,	O
[	O
1	O
-	O
sarcosine	O
,	O
8	O
-	O
O	O
-	O
methylthreonine	O
]	O
-	O
(	O
VI	O
)	O
,	O
[	O
1	O
-	O
sarcosine	O
,	O
8	O
-	O
methionine	O
]	O
-	O
(	O
VII	O
)	O
,	O
and	O
[	O
1	O
-	O
sarcosine	O
,	O
8	O
-	O
serine	O
]	O
angiotensin	B-Protein
II	I-Protein
(	O
VIII	O
)	O
,	O
synthesized	O
by	O
Merrifield	O
'	O
s	O
solid	O
-	O
phase	O
procedure	O
,	O
possess	O
respectively	O
0	O
.	O
8	O
,	O
0	O
.	O
3	O
,	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
0	O
.	O
0	O
,	O
0	O
.	O
5	O
,	O
3	O
.	O
7	O
,	O
and	O
0	O
.	O
7	O
%	O
pressor	O
activity	O
of	O
angiotensin	B-Protein
II	I-Protein
(	O
vagotomized	O
,	O
ganglion	O
-	O
blocked	O
rats	O
)	O
.	O

They	O
caused	O
an	O
initial	O
rise	O
in	O
blood	O
pressure	O
(	O
30	O
min	O
of	O
infusion	O
,	O
250	O
ng	O
/	O
kg	O
/	O
min	O
in	O
vagotomized	O
,	O
ganglion	O
-	O
blocked	O
rats	O
)	O
of	O
16	O
.	O
57	O
,	O
9	O
.	O
80	O
,	O
22	O
.	O
80	O
,	O
32	O
.	O
00	O
,	O
7	O
.	O
00	O
,	O
15	O
.	O
06	O
,	O
32	O
.	O
50	O
,	O
and	O
11	O
.	O
42	O
mmHg	O
and	O
showed	O
secretory	O
activity	O
(	O
isolated	O
cat	O
adrenal	O
medulla	O
)	O
of	O
1	O
.	O
0	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
01	O
,	O
0	O
.	O
1	O
,	O
less	O
than	O
0	O
.	O
01	O
,	O
0	O
.	O
1	O
,	O
less	O
than	O
0	O
.	O
01	O
,	O
and	O
0	O
.	O
05	O
%	O
of	O
angiotensin	B-Protein
II	I-Protein
.	O

On	O
isolated	O
organs	O
pA2	O
values	O
(	O
rabbit	O
aortic	O
strips	O
)	O
of	O
8	O
.	O
74	O
,	O
7	O
.	O
44	O
,	O
7	O
.	O
64	O
,	O
7	O
.	O
85	O
,	O
7	O
.	O
89	O
,	O
8	O
.	O
76	O
,	O
8	O
.	O
63	O
,	O
and	O
8	O
.	O
08	O
,	O
and	O
pA2	O
values	O
(	O
cat	O
adrenal	O
medulla	O
of	O
8	O
.	O
16	O
,	O
9	O
.	O
16	O
,	O
9	O
.	O
31	O
,	O
8	O
.	O
00	O
,	O
8	O
.	O
00	O
,	O
7	O
.	O
00	O
,	O
9	O
.	O
16	O
,	O
and	O
9	O
.	O
33	O
were	O
obtained	O
.	O

Dose	O
ratios	O
(	O
ratio	O
of	O
ED20	O
of	O
angiotensin	B-Protein
II	I-Protein
during	O
infusion	O
of	O
the	O
antagonist	O
and	O
before	O
infusion	O
of	O
the	O
antagonist	O
)	O
in	O
vagotomized	O
,	O
ganglion	O
-	O
blocked	O
rats	O
,	O
infused	O
at	O
250	O
ng	O
/	O
kg	O
/	O
min	O
,	O
were	O
33	O
.	O
43	O
,	O
2	O
.	O
14	O
,	O
3	O
.	O
26	O
,	O
2	O
.	O
99	O
,	O
0	O
.	O
62	O
,	O
62	O
.	O
52	O
,	O
incalculable	O
,	O
and	O
11	O
.	O
15	O
,	O
respectively	O
.	O

The	O
results	O
obtained	O
suggest	O
that	O
(	O
a	O
)	O
analogs	O
I	O
and	O
VI	O
are	O
potent	O
antagonists	O
of	O
the	O
pressor	O
response	O
of	O
angiotensin	B-Protein
II	I-Protein
in	O
normal	O
rat	O
,	O
VI	O
being	O
the	O
most	O
potent	O
antagonist	O
thus	O
far	O
synthesized	O
;	O
(	O
b	O
)	O
replacement	O
of	O
position	O
4	O
(	O
Tyr	O
)	O
with	O
MeTyr	O
or	O
position	O
5	O
and	O
/	O
or	O
8	O
(	O
Ile	O
)	O
with	O
Melle	O
in	O
[	O
1	O
-	O
sarcosine	O
,	O
8	O
-	O
isoleucine	O
]	O
angiotensin	B-Protein
II	I-Protein
reduced	O
the	O
antagonist	O
activity	O
of	O
this	O
peptide	O
(	O
rabbit	O
aortic	O
strips	O
and	O
rats	O
)	O
,	O
indicating	O
that	O
steric	O
hindrance	O
imposed	O
due	O
to	O
N	O
-	O
methylation	O
in	O
positions	O
4	O
,	O
5	O
,	O
or	O
8	O
was	O
not	O
favorable	O
in	O
eliminating	O
the	O
initial	O
pressor	O
activity	O
or	O
prolonging	O
the	O
duration	O
of	O
action	O
of	O
[	O
Sar1	O
,	O
Ile8	O
]	O
angiotensin	O
II	O
without	O
reducing	O
its	O
antagonistic	O
properties	O
;	O
(	O
c	O
)	O
except	O
II	O
,	O
none	O
of	O
the	O
analogs	O
showed	O
any	O
enhanced	O
duration	O
of	O
action	O
,	O
suggesting	O
that	O
N	O
-	O
methylation	O
in	O
positions	O
5	O
or	O
8	O
did	O
not	O
afford	O
protection	O
against	O
proteolytic	O
enzymes	O
;	O
and	O
(	O
d	O
)	O
perfusion	O
studies	O
in	O
cat	O
adrenals	O
indicated	O
that	O
all	O
of	O
these	O
analogs	O
are	O
only	O
very	O
weak	O
secretagogues	O
.	O

With	O
the	O
exception	O
of	O
[	O
Sar1	O
,	O
Thr	O
(	O
ObetaMe	O
)	O
8	O
]	O
angiotensin	B-Protein
II	I-Protein
,	O
which	O
gave	O
lower	O
antagonistic	O
properties	O
,	O
all	O
other	O
analogs	O
had	O
either	O
similar	O
antagonistic	O
properties	O
or	O
were	O
better	O
antagonists	O
in	O
adrenal	O
medulla	O
than	O
in	O
smooth	O
muscle	O
.	O

Hydroxylation	O
of	O
CMP	O
-	O
NeuAc	O
controls	O
the	O
expression	O
of	O
N	O
-	O
glycolylneuraminic	O
acid	O
in	O
GM3	O
ganglioside	O
of	O
the	O
small	O
intestine	O
of	O
inbred	O
rats	O
.	O

An	O
enzymatic	O
activity	O
responsible	O
for	O
the	O
hydroxylation	O
of	O
CMP	O
-	O
NeuAc	O
into	O
CMP	O
-	O
N	O
-	O
glycolylneuraminic	O
acid	O
(	O
CMP	O
-	O
NeuGc	O
)	O
was	O
found	O
in	O
the	O
cytosolic	O
fraction	O
after	O
cellular	O
fractionation	O
of	O
the	O
mucosa	O
of	O
rat	O
small	O
intestine	O
.	O

It	O
was	O
maximum	O
in	O
the	O
presence	O
of	O
NADPH	O
or	O
NADH	O
,	O
but	O
it	O
was	O
reduced	O
by	O
50	O
%	O
by	O
addition	O
of	O
1	O
mM	O
EDTA	O
.	O

The	O
Km	O
value	O
for	O
CMP	O
-	O
NeuAc	O
was	O
0	O
.	O
6	O
microM	O
.	O

The	O
CMP	B-Protein
-	I-Protein
NeuAc	I-Protein
hydroxylase	I-Protein
activity	O
paralleled	O
the	O
expression	O
of	O
the	O
GM3	O
(	O
NeuGc	O
)	O
phenotype	O
in	O
the	O
epithelium	O
of	O
the	O
small	O
intestine	O
and	O
was	O
not	O
measurable	O
in	O
the	O
mutant	O
rats	O
BN	O
and	O
SHR	O
that	O
only	O
expressed	O
GM3	O
(	O
NeuAc	O
)	O
.	O

Furthermore	O
,	O
the	O
only	O
form	O
of	O
CMP	O
-	O
sialic	O
acid	O
present	O
in	O
the	O
intestinal	O
mucosa	O
of	O
the	O
mutants	O
was	O
CMP	O
-	O
NeuAc	O
,	O
whereas	O
in	O
the	O
other	O
strains	O
CMP	O
-	O
NeuGc	O
accounted	O
for	O
70	O
-	O
85	O
%	O
of	O
the	O
native	O
CMP	O
-	O
sialic	O
acids	O
.	O

Wild	O
-	O
type	O
and	O
CMP	B-Protein
-	I-Protein
NeuAc	I-Protein
hydroxylase	I-Protein
-	O
deficient	O
inbred	O
rats	O
were	O
mated	O
.	O

Individuals	O
of	O
F1	O
and	O
backcross	O
generations	O
were	O
typed	O
for	O
the	O
phenotypes	O
GM3	O
(	O
NeuGc	O
)	O
/	O
GM3	O
(	O
NeuAc	O
)	O
and	O
the	O
activity	O
of	O
CMP	B-Protein
-	I-Protein
NeuAc	I-Protein
hydroxylase	I-Protein
in	O
the	O
small	O
intestine	O
.	O

It	O
was	O
found	O
that	O
the	O
expression	O
of	O
NeuGc	O
in	O
GM3	O
depends	O
on	O
a	O
single	O
autosomal	O
dominant	O
gene	O
and	O
correlates	O
with	O
the	O
activity	O
of	O
CMP	B-Protein
-	I-Protein
NeuAc	I-Protein
hydroxylase	I-Protein
.	O

Two	O
tissues	O
other	O
than	O
small	O
intestine	O
,	O
kidney	O
and	O
spleen	O
,	O
which	O
expressed	O
GM3	O
(	O
NeuGc	O
)	O
in	O
BN	O
and	O
SHR	O
,	O
also	O
expressed	O
the	O
CMP	B-Protein
-	I-Protein
NeuAc	I-Protein
hydroxylase	I-Protein
activity	O
,	O
as	O
in	O
the	O
other	O
strains	O
.	O

It	O
was	O
concluded	O
that	O
the	O
key	O
enzyme	O
responsible	O
for	O
the	O
presence	O
of	O
NeuGc	O
in	O
GM3	O
is	O
a	O
CMP	B-Protein
-	I-Protein
NeuAc	I-Protein
hydroxylase	I-Protein
and	O
that	O
mutant	O
rats	O
carry	O
a	O
defect	O
that	O
is	O
specific	O
to	O
intestine	O
.	O

The	O
comparative	O
analysis	O
of	O
the	O
respective	O
contribution	O
of	O
NeuGc	O
and	O
NeuAc	O
to	O
the	O
glycoprotein	O
sialic	O
acids	O
of	O
the	O
small	O
intestine	O
showed	O
that	O
CMP	B-Protein
-	I-Protein
NeuAc	I-Protein
hydroxylase	I-Protein
is	O
also	O
responsible	O
for	O
part	O
of	O
the	O
NeuGc	O
present	O
in	O
the	O
glycoproteins	O
.	O

However	O
,	O
the	O
occurrence	O
of	O
20	O
-	O
30	O
%	O
of	O
NeuGc	O
in	O
the	O
intestinal	O
glycoproteins	O
of	O
the	O
CMP	B-Protein
-	I-Protein
NeuAc	I-Protein
hydroxylase	I-Protein
-	O
deficient	O
rats	O
indicated	O
that	O
there	O
is	O
another	O
enzyme	O
providing	O
intestinal	O
glycoproteins	O
with	O
NeuGc	O
and	O
operating	O
under	O
a	O
different	O
genetic	O
control	O
.	O

Displacement	O
and	O
aberrant	O
methylation	O
in	O
vitro	O
of	O
H	B-Protein
-	I-Protein
1	I-Protein
histone	I-Protein
in	O
rat	O
liver	O
nuclei	O
after	O
half	O
-	O
saturation	O
of	O
chromatin	O
with	O
polycations	O
.	O

Radiomethyl	O
incorporation	O
in	O
vitro	O
into	O
Nepsilon	O
-	O
methyllysine	O
of	O
histones	B-Protein
from	O
rat	O
liver	O
nuclei	O
incubated	O
in	O
the	O
presence	O
of	O
S	O
-	O
adenosyl	O
[	O
methyl	O
-	O
3H	O
]	O
methionine	O
is	O
stimulated	O
if	O
the	O
polycations	O
polylysines	O
,	O
protamines	O
,	O
or	O
histones	O
are	O
added	O
to	O
the	O
incubation	O
mixture	O
.	O

Maximal	O
stimulation	O
occurs	O
at	O
a	O
cation	O
/	O
nucleotide	O
ratio	O
of	O
0	O
.	O
5	O
.	O

Past	O
this	O
point	O
stimulation	O
drops	O
,	O
except	O
in	O
the	O
case	O
of	O
very	O
lysine	O
-	O
rich	O
histone	B-Protein
H	I-Protein
-	I-Protein
1	I-Protein
,	O
for	O
which	O
the	O
maximal	O
level	O
of	O
incorporation	O
remains	O
constant	O
upon	O
further	O
addition	O
of	O
this	O
histone	B-Protein
.	O

Bio	O
-	O
Gel	O
P	O
-	O
10	O
chromatography	O
,	O
differential	O
precipitation	O
,	O
and	O
gel	O
electrophoresis	O
of	O
radiomethylated	O
histones	B-Protein
indicate	O
that	O
although	O
the	O
usual	O
incorporation	O
of	O
radiomethyl	O
into	O
histone	B-Protein
H	I-Protein
-	I-Protein
3	I-Protein
is	O
not	O
affected	O
,	O
active	O
methylation	O
of	O
H	B-Protein
-	I-Protein
1	I-Protein
occurs	O
in	O
the	O
presence	O
of	O
polycations	O
.	O

Column	O
chromatographic	O
amino	O
acid	O
analysis	O
reveals	O
that	O
the	O
methylation	O
of	O
H	B-Protein
-	I-Protein
1	I-Protein
will	O
specifically	O
generate	O
Nepsilon	O
-	O
monomethyllysine	O
.	O

Except	O
for	O
this	O
condition	O
,	O
H	B-Protein
-	I-Protein
1	I-Protein
is	O
never	O
methylated	O
in	O
vivo	O
or	O
in	O
incubated	O
cell	O
nuclei	O
.	O

Because	O
H	B-Protein
-	I-Protein
1	I-Protein
is	O
the	O
weakest	O
bound	O
histone	B-Protein
in	O
chromatin	O
,	O
the	O
above	O
phenomena	O
may	O
be	O
explained	O
by	O
assuming	O
that	O
,	O
within	O
the	O
chromatin	O
,	O
polycations	O
displace	O
the	O
lysine	O
-	O
rich	O
histone	B-Protein
towards	O
the	O
nucleosome	O
,	O
which	O
results	O
in	O
its	O
abberant	O
methylation	O
,	O
assuming	O
that	O
the	O
native	O
nucleosome	O
is	O
the	O
seat	O
of	O
the	O
histone	B-Protein
lysine	O
methyltransferase	O
.	O

Cortical	O
cytoskeleton	O
of	O
giant	O
moth	O
eggs	O
.	O

Unfertilized	O
eggs	O
of	O
several	O
species	O
of	O
giant	O
moths	O
contain	O
a	O
substantial	O
cortical	O
cytoskeleton	O
.	O

This	O
structure	O
is	O
assembled	O
during	O
oogenesis	O
,	O
and	O
contains	O
actin	O
as	O
a	O
major	O
fibrillar	O
component	O
.	O

The	O
presence	O
of	O
actin	O
was	O
confirmed	O
by	O
gel	O
electrophoresis	O
and	O
binding	O
to	O
phalloidin	B-Protein
,	O
DNase	B-Protein
I	I-Protein
,	O
and	O
a	O
monoclonal	O
antibody	O
against	O
cytoskeletal	O
actin	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
that	O
the	O
fat	O
body	O
is	O
a	O
source	O
of	O
the	O
actin	O
in	O
the	O
oocyte	O
and	O
that	O
the	O
transport	O
and	O
acquisition	O
of	O
actin	O
by	O
the	O
ovary	O
are	O
similar	O
to	O
the	O
mechanism	O
of	O
vitellogenin	O
acquisition	O
.	O

A	O
possible	O
role	O
for	O
the	O
cortical	O
cytoskeleton	O
in	O
directing	O
early	O
embryogenesis	O
is	O
discussed	O
.	O

Deamidation	O
of	O
calmodulin	B-Protein
at	O
neutral	O
and	O
alkaline	O
pH	O
:	O
quantitative	O
relationships	O
between	O
ammonia	O
loss	O
and	O
the	O
susceptibility	O
of	O
calmodulin	B-Protein
to	O
modification	O
by	O
protein	O
carboxyl	O
methyltransferase	O
.	O

Measurements	O
of	O
ammonia	O
release	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
calmodulin	B-Protein
becomes	O
extensively	O
deamidated	O
during	O
incubations	O
at	O
37	O
degrees	O
C	O
,	O
pH	O
7	O
.	O
4	O
or	O
pH	O
11	O
.	O

A	O
stoichiometry	O
of	O
0	O
.	O
5	O
mol	O
of	O
NH3	O
released	O
/	O
mol	O
of	O
calmodulin	B-Protein
is	O
observed	O
after	O
2	O
h	O
at	O
pH	O
11	O
or	O
after	O
8	O
-	O
9	O
days	O
at	O
pH	O
7	O
.	O
4	O
.	O

These	O
treatments	O
also	O
increase	O
the	O
ability	O
of	O
calmodulin	B-Protein
to	O
serve	O
as	O
a	O
substrate	O
for	O
the	O
isoaspartate	O
-	O
specific	O
protein	O
carboxyl	O
methyltransferase	O
from	O
bovine	O
brain	O
.	O

The	O
stoichiometries	O
of	O
methylation	O
are	O
highly	O
correlated	O
with	O
the	O
stoichiometries	O
of	O
ammonia	O
release	O
.	O

Deamidation	O
and	O
increased	O
methyl	O
-	O
accepting	O
capacity	O
also	O
occur	O
in	O
parallel	O
for	O
seven	O
other	O
proteins	O
(	O
aldolase	O
,	O
bovine	O
serum	B-Protein
albumin	I-Protein
,	O
cytochrome	B-Protein
c	I-Protein
,	O
lysozyme	O
,	O
ovalbumin	O
,	O
ribonuclease	B-Protein
A	I-Protein
,	O
and	O
triosephosphate	B-Protein
isomerase	I-Protein
)	O
upon	O
incubation	O
at	O
pH	O
11	O
.	O

However	O
,	O
in	O
comparison	O
to	O
calmodulin	B-Protein
,	O
these	O
other	O
proteins	O
show	O
very	O
little	O
deamidation	O
and	O
increased	O
methylation	O
capacity	O
following	O
incubation	O
at	O
pH	O
7	O
.	O
4	O
.	O

Deamidation	O
of	O
calmodulin	B-Protein
at	O
pH	O
7	O
.	O
4	O
is	O
unaffected	O
by	O
the	O
addition	O
of	O
10	O
(	O
-	O
7	O
)	O
M	O
Ca2	O
+	O
;	O
however	O
,	O
at	O
4	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
Ca2	O
+	O
,	O
the	O
rate	O
of	O
deamidation	O
is	O
inhibited	O
by	O
approximately	O
70	O
%	O
.	O

The	O
Ca2	O
+	O
-	O
protection	O
effect	O
is	O
consistent	O
with	O
the	O
suggestion	O
(	O
B	O
.	O
A	O
.	O
Johnson	O
,	O
N	O
.	O
E	O
.	O
Freitag	O
,	O
and	O
D	O
.	O
W	O
.	O
Aswad	O
,	O
(	O
1985	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
260	O
,	O
10913	O
-	O
10916	O
)	O
that	O
deamidation	O
occurs	O
preferentially	O
at	O
Asn	O
-	O
60	O
and	O
/	O
or	O
Asn	O
-	O
97	O
,	O
each	O
of	O
which	O
resides	O
in	O
a	O
distinct	O
Ca2	O
+	O
-	O
binding	O
domain	O
.	O

Nonenzymatically	O
glycated	O
serum	B-Protein
albumin	I-Protein
:	O
interaction	O
with	O
galactose	O
-	O
specific	O
liver	O
lectins	O
.	O

The	O
possible	O
interaction	O
of	O
galactose	O
/	O
glucose	O
-	O
specific	O
liver	O
lectins	O
with	O
nonenzymatically	O
glycated	O
human	O
serum	B-Protein
albumin	I-Protein
was	O
analyzed	O
.	O

The	O
binding	O
activity	O
of	O
the	O
asialoglycoprotein	O
receptor	O
on	O
hepatocytes	O
and	O
of	O
the	O
corresponding	O
lectin	O
on	O
Kupffer	O
cells	O
was	O
determined	O
using	O
freshly	O
isolated	O
liver	O
cells	O
from	O
Wistar	O
rats	O
.	O

Nonenzymatically	O
glucosylated	O
or	O
galactosylated	O
human	O
serum	B-Protein
albumin	I-Protein
(	O
HSA	B-Protein
)	O
did	O
not	O
inhibit	O
lectin	O
binding	O
in	O
a	O
competitive	O
adhesion	O
assay	O
(	O
less	O
than	O
15	O
%	O
inhibition	O
)	O
.	O

In	O
contrast	O
,	O
lactosylated	O
HSA	B-Protein
strongly	O
interacted	O
with	O
the	O
two	O
liver	O
lectins	O
(	O
more	O
than	O
80	O
%	O
inhibition	O
)	O
.	O

Lectin	O
binding	O
increased	O
with	O
lactosylation	O
reaching	O
a	O
maximum	O
at	O
44	O
-	O
49	O
mol	O
D	O
-	O
galactose	O
bound	O
per	O
mol	O
HSA	B-Protein
.	O

In	O
conclusion	O
,	O
at	O
least	O
in	O
certain	O
cases	O
,	O
nonenzymatically	O
glycated	O
proteins	O
may	O
interact	O
with	O
endogenous	O
lectins	O
.	O

Accurate	O
,	O
quantitative	O
assays	O
for	O
the	O
hydrolysis	O
of	O
soluble	O
type	O
I	O
,	O
II	B-Protein
,	O
and	O
III	O
3H	O
-	O
acetylated	O
collagens	O
by	O
bacterial	O
and	O
tissue	O
collagenases	O
.	O

Accurate	O
and	O
quantitative	O
assays	O
for	O
the	O
hydrolysis	O
of	O
soluble	O
3H	O
-	O
acetylated	O
rat	O
tendon	O
type	O
I	O
,	O
bovine	O
cartilage	O
type	B-Protein
II	I-Protein
,	O
and	O
human	O
amnion	O
type	O
III	O
collagens	O
by	O
both	O
bacterial	O
and	O
tissue	O
collagenases	O
have	O
been	O
developed	O
.	O

The	O
assays	O
are	O
carried	O
out	O
at	O
any	O
temperature	O
in	O
the	O
1	O
-	O
30	O
degrees	O
C	O
range	O
in	O
a	O
single	O
reaction	O
tube	O
and	O
the	O
progress	O
of	O
the	O
reaction	O
is	O
monitored	O
by	O
withdrawing	O
aliquots	O
as	O
a	O
function	O
of	O
time	O
,	O
quenching	O
with	O
1	O
,	O
10	O
-	O
phenanthroline	O
,	O
and	O
quantitation	O
of	O
the	O
concentration	O
of	O
hydrolysis	O
fragments	O
.	O

The	O
latter	O
is	O
achieved	O
by	O
selective	O
denaturation	O
of	O
these	O
fragments	O
by	O
incubation	O
under	O
conditions	O
described	O
in	O
the	O
previous	O
paper	O
of	O
this	O
issue	O
.	O

The	O
assays	O
give	O
percentages	O
of	O
hydrolysis	O
of	O
all	O
three	O
collagen	O
types	O
by	O
neutrophil	B-Protein
collagenase	I-Protein
that	O
agree	O
well	O
with	O
the	O
results	O
of	O
gel	O
electrophoresis	O
experiments	O
.	O

The	O
initial	O
rates	O
of	O
hydrolysis	O
of	O
all	O
three	O
collagens	O
are	O
proportional	O
to	O
the	O
concentration	O
of	O
both	O
neutrophil	O
or	O
Clostridial	O
collagenases	O
over	O
a	O
10	O
-	O
fold	O
range	O
of	O
enzyme	O
concentrations	O
.	O

All	O
three	O
assays	O
can	O
be	O
carried	O
out	O
at	O
collagen	O
concentrations	O
.	O
that	O
range	O
from	O
0	O
.	O
06	O
to	O
2	O
mg	O
/	O
ml	O
and	O
give	O
linear	O
double	O
reciprocal	O
plots	O
for	O
both	O
tissue	O
and	O
bacterial	O
collagenases	O
that	O
can	O
be	O
used	O
to	O
evaluate	O
the	O
kinetic	O
parameters	O
Km	O
and	O
kcat	O
or	O
Vmax	O
.	O

The	O
assay	O
developed	O
for	O
the	O
hydrolysis	O
of	O
rat	O
type	O
I	O
collagen	O
by	O
neutrophil	B-Protein
collagenase	I-Protein
is	O
shown	O
to	O
be	O
more	O
sensitive	O
by	O
at	O
least	O
one	O
order	O
of	O
magnitude	O
than	O
comparable	O
assays	O
that	O
use	O
rat	O
type	O
I	O
collagen	O
fibrils	O
or	O
gels	O
as	O
substrate	O
.	O

The	O
role	O
of	O
insulin	B-Protein
in	O
the	O
modulation	O
of	O
glucagon	B-Protein
-	O
dependent	O
control	O
of	O
phenylalanine	O
hydroxylation	O
in	O
isolated	O
liver	O
cells	O
.	O

The	O
stimulation	O
of	O
phenylalanine	O
hydroxylation	O
in	O
isolated	O
liver	O
cells	O
by	O
sub	O
-	O
maximally	O
effective	O
concentrations	O
of	O
glucagon	B-Protein
(	O
less	O
than	O
0	O
.	O
1	O
microM	O
)	O
is	O
antagonized	O
by	O
insulin	B-Protein
(	O
0	O
.	O
1	O
nM	O
-	O
0	O
.	O
1	O
microM	O
)	O
.	O

This	O
phenomenon	O
is	O
a	O
consequence	O
of	O
a	O
decrease	O
in	O
the	O
glucagon	B-Protein
-	O
stimulated	O
phosphorylation	O
of	O
phenylalanine	B-Protein
hydroxylase	I-Protein
from	O
liver	O
cells	O
incubated	O
in	O
the	O
presence	O
of	O
insulin	B-Protein
.	O

The	O
impact	O
of	O
insulin	B-Protein
on	O
the	O
phosphorylation	O
state	O
and	O
activity	O
of	O
the	O
hydroxylase	O
is	O
mimicked	O
by	O
incubation	O
of	O
liver	O
cells	O
in	O
the	O
presence	O
of	O
orthovanadate	O
(	O
10	O
microM	O
)	O
.	O

A	O
series	O
of	O
cyclic	O
AMP	O
and	O
cyclic	O
GMP	O
analogues	O
enhanced	O
phenylalanine	O
hydroxylation	O
:	O
in	O
each	O
case	O
insulin	B-Protein
diminished	O
the	O
stimulation	O
of	O
flux	O
.	O

These	O
results	O
are	O
discussed	O
in	O
the	O
light	O
of	O
the	O
characteristics	O
of	O
insulin	B-Protein
action	O
on	O
other	O
metabolic	O
processes	O
.	O

Tubulin	O
post	O
-	O
translational	O
modifications	O
and	O
the	O
construction	O
of	O
microtubular	O
organelles	O
in	O
Trypanosoma	O
brucei	O
.	O

We	O
have	O
used	O
specific	O
monoclonal	O
antibodies	O
to	O
facilitate	O
a	O
study	O
of	O
acetylated	O
and	O
tyrosinated	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
in	O
the	O
microtubule	O
(	O
MT	O
)	O
arrays	O
in	O
the	O
Trypanosoma	O
brucei	O
cell	O
.	O

Acetylated	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
is	O
not	O
solely	O
located	O
in	O
the	O
stable	O
microtubular	O
arrays	O
but	O
is	O
present	O
even	O
in	O
the	O
ephemeral	O
microtubules	O
of	O
the	O
mitotic	O
spindle	O
.	O

Moreover	O
,	O
there	O
is	O
a	O
uniform	O
distribution	O
of	O
this	O
isoform	O
in	O
all	O
arrays	O
.	O

Studies	O
of	O
flagella	O
complexes	O
show	O
that	O
acetylation	O
is	O
concomitant	O
with	O
assembly	O
of	O
MTs	O
.	O

There	O
is	O
no	O
subsequent	O
major	O
modulation	O
in	O
the	O
content	O
of	O
acetylated	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
in	O
MTs	O
.	O

Conversely	O
,	O
polymerizing	O
flagellar	O
MTs	O
have	O
a	O
high	O
tyrosinated	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
content	O
,	O
which	O
is	O
subsequently	O
reduced	O
to	O
a	O
basal	O
level	O
at	O
a	O
discrete	O
point	O
in	O
the	O
cell	O
cycle	O
.	O

The	O
MTs	O
of	O
the	O
intranuclear	O
mitotic	O
spindle	O
appear	O
never	O
to	O
contain	O
tyrosinated	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
,	O
suggesting	O
that	O
they	O
are	O
actually	O
constructed	O
of	O
detyrosinated	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
or	O
that	O
detyrosination	O
is	O
extremely	O
rapid	O
at	O
this	O
time	O
in	O
the	O
cell	O
cycle	O
.	O

T	O
.	O
brucei	O
therefore	O
,	O
represents	O
a	O
cell	O
type	O
with	O
extremely	O
active	O
mechanisms	O
for	O
the	O
post	O
-	O
translational	O
modification	O
of	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
.	O

Our	O
analyses	O
of	O
the	O
timing	O
of	O
acquisition	O
and	O
modulation	O
in	O
relation	O
to	O
MT	O
construction	O
in	O
T	O
.	O
brucei	O
,	O
suggest	O
that	O
acetylation	O
and	O
detyrosination	O
of	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
are	O
two	O
independently	O
regulated	O
post	O
-	O
translational	O
modifications	O
,	O
that	O
are	O
not	O
uniquely	O
associated	O
with	O
particular	O
subsets	O
of	O
MTs	O
of	O
defined	O
lability	O
,	O
position	O
or	O
function	O
.	O

Post	O
-	O
assembly	O
detyrosination	O
of	O
alpha	B-Protein
-	I-Protein
tubulin	I-Protein
may	O
provide	O
a	O
mechanism	O
whereby	O
the	O
cell	O
could	O
discriminate	O
between	O
new	O
and	O
old	O
MTs	O
,	O
during	O
construction	O
of	O
the	O
cytoskeleton	O
through	O
the	O
cell	O
cycle	O
.	O

However	O
,	O
we	O
also	O
suggest	O
that	O
continuation	O
of	O
detyrosination	O
,	O
allows	O
the	O
cell	O
,	O
at	O
cell	O
division	O
,	O
to	O
partition	O
into	O
daughter	O
cells	O
two	O
equivalent	O
sets	O
of	O
cytoskeletal	O
MTs	O
.	O

Lethal	O
perinatal	O
osteogenesis	O
imperfecta	O
due	O
to	O
the	O
substitution	O
of	O
arginine	O
for	O
glycine	O
at	O
residue	O
391	O
of	O
the	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
of	O
type	O
I	O
collagen	O
.	O

A	O
baby	O
with	O
the	O
lethal	O
perinatal	O
form	O
of	O
osteogenesis	O
imperfecta	O
was	O
shown	O
to	O
have	O
a	O
structural	O
defect	O
in	O
the	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
of	O
type	O
I	O
procollagen	O
.	O

Normal	O
and	O
mutant	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
CB8	O
cyanogen	O
bromide	O
peptides	O
,	O
from	O
the	O
helical	O
part	O
of	O
the	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
,	O
were	O
purified	O
from	O
bone	O
.	O

Amino	O
acid	O
sequencing	O
of	O
tryptic	O
peptides	O
derived	O
from	O
the	O
mutant	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
CB8	O
peptide	O
showed	O
that	O
the	O
glycine	O
residue	O
at	O
position	O
391	O
of	O
the	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
had	O
been	O
replaced	O
by	O
an	O
arginine	O
residue	O
.	O

This	O
substitution	O
accounted	O
for	O
the	O
more	O
basic	O
charged	O
form	O
of	O
this	O
peptide	O
that	O
was	O
observed	O
on	O
two	O
-	O
dimensional	O
electrophoresis	O
of	O
the	O
collagen	O
peptides	O
obtained	O
from	O
the	O
tissues	O
.	O

The	O
substitution	O
was	O
associated	O
with	O
increased	O
enzymatic	O
hydroxylation	O
of	O
lysine	O
residues	O
in	O
the	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
CB8	O
and	O
the	O
adjoining	O
CB3	O
peptides	O
but	O
not	O
in	O
the	O
carboxyl	O
-	O
terminal	O
CB6	O
and	O
CB7	O
peptides	O
.	O

This	O
finding	O
suggested	O
that	O
the	O
sequence	O
abnormality	O
had	O
interfered	O
with	O
the	O
propagation	O
of	O
the	O
triple	O
helix	O
across	O
the	O
mutant	O
region	O
.	O

The	O
abnormal	O
collagen	O
was	O
not	O
incorporated	O
into	O
the	O
more	O
insoluble	O
fraction	O
of	O
bone	O
collagen	O
.	O

The	O
baby	O
appeared	O
to	O
be	O
heterozygous	O
for	O
the	O
sequence	O
abnormality	O
and	O
as	O
the	O
parents	O
did	O
not	O
show	O
any	O
evidence	O
of	O
the	O
defect	O
it	O
is	O
likely	O
that	O
the	O
baby	O
had	O
a	O
new	O
mutation	O
of	O
one	O
allele	O
of	O
the	O
pro	O
-	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
gene	O
.	O

The	O
amino	O
acid	O
substitution	O
could	O
result	O
from	O
a	O
single	O
nucleotide	O
mutation	O
in	O
the	O
codon	O
GGC	O
(	O
glycine	O
)	O
to	O
produce	O
the	O
codon	O
CGC	O
(	O
arginine	O
)	O
.	O

Amino	O
acid	O
sequence	O
and	O
posttranslational	O
modifications	O
of	O
human	O
factor	B-Protein
VIIa	I-Protein
from	O
plasma	O
and	O
transfected	O
baby	O
hamster	O
kidney	O
cells	O
.	O

Blood	O
coagulation	B-Protein
factor	I-Protein
VII	I-Protein
is	O
a	O
vitamin	O
K	O
dependent	O
glycoprotein	O
which	O
in	O
its	O
activated	O
form	O
,	O
factor	B-Protein
VIIa	I-Protein
,	O
participates	O
in	O
the	O
coagulation	O
process	O
by	O
activating	O
factor	B-Protein
X	I-Protein
and	O
/	O
or	O
factor	B-Protein
IX	I-Protein
in	O
the	O
presence	O
of	O
Ca2	O
+	O
and	O
tissue	B-Protein
factor	I-Protein
.	O

Three	O
types	O
of	O
potential	O
posttranslational	O
modifications	O
exist	O
in	O
the	O
human	O
factor	B-Protein
VIIa	I-Protein
molecule	O
,	O
namely	O
,	O
10	O
gamma	O
-	O
carboxylated	O
,	O
N	O
-	O
terminally	O
located	O
glutamic	O
acid	O
residues	O
,	O
1	O
beta	O
-	O
hydroxylated	O
aspartic	O
acid	O
residue	O
,	O
and	O
2	O
N	O
-	O
glycosylated	O
asparagine	O
residues	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
amino	O
acid	O
sequence	O
and	O
posttranslational	O
modifications	O
of	O
recombinant	O
factor	B-Protein
VIIa	I-Protein
as	O
purified	O
from	O
the	O
culture	O
medium	O
of	O
a	O
transfected	O
baby	O
hamster	O
kidney	O
cell	O
line	O
have	O
been	O
compared	O
to	O
human	O
plasma	O
factor	B-Protein
VIIa	I-Protein
.	O

By	O
use	O
of	O
HPLC	O
,	O
amino	O
acid	O
analysis	O
,	O
peptide	O
mapping	O
,	O
and	O
automated	O
Edman	O
degradations	O
,	O
the	O
protein	O
backbone	O
of	O
recombinant	O
factor	B-Protein
VIIa	I-Protein
was	O
found	O
to	O
be	O
identical	O
with	O
human	O
factor	B-Protein
VIIa	I-Protein
.	O

Neither	O
recombinant	O
factor	B-Protein
VIIa	I-Protein
nor	O
human	O
plasma	O
factor	B-Protein
VIIa	I-Protein
was	O
found	O
to	O
contain	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O

In	O
human	O
plasma	O
factor	B-Protein
VIIa	I-Protein
,	O
the	O
10	O
N	O
-	O
terminally	O
located	O
glutamic	O
acid	O
residues	O
were	O
found	O
to	O
be	O
fully	O
gamma	O
-	O
carboxylated	O
whereas	O
9	O
full	O
and	O
1	O
partial	O
gamma	O
-	O
carboxylated	O
residues	O
were	O
found	O
in	O
the	O
corresponding	O
positions	O
of	O
the	O
recombinant	O
factor	B-Protein
VIIa	I-Protein
molecule	O
.	O

Asparagine	O
residues	O
145	O
and	O
322	O
were	O
found	O
to	O
be	O
fully	O
N	O
-	O
glycosylated	O
in	O
human	O
plasma	O
factor	B-Protein
VIIa	I-Protein
.	O

In	O
the	O
recombinant	O
factor	B-Protein
VIIa	I-Protein
,	O
asparagine	O
residue	O
322	O
was	O
fully	O
glycosylated	O
whereas	O
asparagine	O
residue	O
145	O
was	O
only	O
partially	O
(	O
approximately	O
66	O
%	O
)	O
glycosylated	O
.	O

Besides	O
minor	O
differences	O
in	O
the	O
sialic	O
acid	O
and	O
fucose	O
contents	O
,	O
the	O
overall	O
carbohydrate	O
compositions	O
were	O
nearly	O
identical	O
in	O
recombinant	O
factor	B-Protein
VIIa	I-Protein
and	O
human	O
plasma	O
factor	B-Protein
VIIa	I-Protein
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Binding	O
of	O
gossypol	O
derivatives	O
to	O
human	O
serum	B-Protein
albumin	I-Protein
.	O

In	O
light	O
of	O
our	O
previous	O
finding	O
that	O
gossypol	O
competes	O
effectively	O
with	O
bilirubin	O
for	O
the	O
high	O
affinity	O
bilirubin	O
binding	O
site	O
on	O
human	O
serum	B-Protein
albumin	I-Protein
,	O
a	O
study	O
of	O
the	O
binding	O
to	O
albumin	B-Protein
of	O
four	O
gossypol	O
derivatives	O
was	O
undertaken	O
.	O

The	O
derivatives	O
are	O
compounds	O
in	O
which	O
the	O
aldehyde	O
groups	O
of	O
gossypol	O
are	O
converted	O
to	O
nitriles	O
and	O
the	O
periphenolic	O
groups	O
are	O
acylated	O
with	O
acetyl	O
,	O
propionyl	O
,	O
butyryl	O
,	O
or	O
valeryl	O
groups	O
.	O

These	O
periacylated	O
gossylic	O
nitriles	O
bind	O
to	O
the	O
high	O
affinity	O
bilirubin	O
binding	O
site	O
on	O
human	O
serum	B-Protein
albumin	I-Protein
,	O
but	O
with	O
dissociation	O
constants	O
approximately	O
30	O
times	O
greater	O
than	O
that	O
of	O
gossypol	O
.	O

The	O
gossypol	O
derivatives	O
also	O
bind	O
to	O
another	O
site	O
on	O
albumin	B-Protein
,	O
but	O
with	O
dissociation	O
constants	O
approximately	O
6	O
times	O
greater	O
than	O
those	O
for	O
the	O
bilirubin	O
site	O
.	O

This	O
second	O
site	O
has	O
been	O
identified	O
as	O
the	O
major	O
drug	O
binding	O
site	O
in	O
domain	O
III	O
.	O

Thermodynamic	O
analysis	O
of	O
inducer	O
binding	O
to	O
the	O
lactose	B-Protein
repressor	I-Protein
protein	O
:	O
contributions	O
of	O
galactosyl	O
hydroxyl	O
groups	O
and	O
beta	O
substituents	O
.	O

Kinetic	O
and	O
equilibrium	O
studies	O
of	O
the	O
binding	O
of	O
modified	O
beta	O
-	O
D	O
-	O
galactoside	O
sugars	O
to	O
the	O
lac	B-Protein
repressor	I-Protein
were	O
carried	O
out	O
to	O
generate	O
thermodynamic	O
data	O
for	O
protein	O
-	O
inducer	O
interactions	O
.	O

The	O
energetic	O
contributions	O
of	O
the	O
galactosyl	O
hydroxyl	O
groups	O
to	O
binding	O
were	O
assessed	O
by	O
using	O
a	O
series	O
of	O
methyl	O
deoxyfluoro	O
-	O
beta	O
-	O
D	O
-	O
galactosides	O
.	O

The	O
C	O
-	O
3	O
and	O
C	O
-	O
6	O
hydroxyls	O
contributed	O
less	O
than	O
or	O
equal	O
to	O
-	O
2	O
.	O
3	O
and	O
-	O
1	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
3	O
kcal	O
/	O
mol	O
to	O
the	O
binding	O
free	O
energy	O
change	O
,	O
respectively	O
,	O
whereas	O
the	O
C	O
-	O
4	O
hydroxyl	O
provided	O
only	O
a	O
nominal	O
contribution	O
(	O
-	O
0	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
2	O
kcal	O
/	O
mol	O
)	O
.	O

Favorable	O
contributions	O
to	O
the	O
total	O
binding	O
free	O
energy	O
change	O
were	O
observed	O
for	O
replacement	O
of	O
O	O
-	O
methyl	O
by	O
S	O
-	O
methyl	O
at	O
the	O
beta	O
-	O
anomeric	O
position	O
and	O
for	O
S	O
-	O
methyl	O
by	O
S	O
-	O
isopropyl	O
.	O

Negative	O
delta	O
H	O
degrees	O
values	O
characteristic	O
of	O
protein	O
-	O
sugar	O
complexes	O
[	O
Quiocho	O
,	O
F	O
.	O
A	O
.	O
(	O
1986	O
)	O
Annu	O
.	O
Rev	O
.	O
Biochem	O
.	O
55	O
,	O
287	O
-	O
315	O
]	O
were	O
observed	O
for	O
a	O
series	O
of	O
beta	O
-	O
D	O
-	O
galactosides	O
differing	O
at	O
the	O
beta	O
-	O
glycosidic	O
position	O
.	O

A	O
decrease	O
in	O
delta	O
H	O
degrees	O
of	O
approximately	O
6	O
kcal	O
/	O
mol	O
upon	O
replacement	O
of	O
the	O
O	O
-	O
methyl	O
substituent	O
by	O
S	O
-	O
methyl	O
indicates	O
a	O
substantial	O
increase	O
in	O
van	O
der	O
Waals	O
'	O
interactions	O
and	O
/	O
or	O
hydrogen	O
bonding	O
in	O
this	O
region	O
of	O
the	O
ligand	O
binding	O
site	O
.	O

The	O
more	O
favorable	O
free	O
energy	O
change	O
for	O
the	O
binding	O
of	O
the	O
S	O
-	O
isopropyl	O
vs	O
S	O
-	O
methyl	O
compound	O
is	O
due	O
mainly	O
to	O
more	O
positive	O
entropic	O
contributions	O
,	O
consistent	O
with	O
an	O
increase	O
in	O
apolar	O
interactions	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Site	O
specific	O
glycosylation	O
patterns	O
of	O
H	B-Protein
-	I-Protein
2K	I-Protein
:	O
effects	O
of	O
allelic	O
polymorphism	O
and	O
mitogenic	O
stimulation	O
.	O

The	O
site	O
-	O
specific	O
glycosylation	O
patterns	O
of	O
two	O
H	B-Protein
-	I-Protein
2K	I-Protein
alleles	I-Protein
,	I-Protein
k	I-Protein
and	O
b	B-Protein
,	O
were	O
determined	O
on	O
splenic	O
T	O
cells	O
metabolically	O
labeled	O
with	O
[	O
3H	O
]	O
mannose	O
.	O

Cells	O
from	O
B10	O
,	O
B10	O
.	O
A	O
,	O
(	O
B10	O
X	O
B10	O
.	O
A	O
)	O
F1	O
,	O
and	O
C3H	O
mice	O
were	O
examined	O
,	O
along	O
with	O
the	O
effect	O
of	O
short	O
-	O
(	O
8	O
hr	O
)	O
and	O
long	O
-	O
term	O
(	O
36	O
hr	O
)	O
mitogenic	O
stimulation	O
.	O

For	O
both	O
glycosylation	O
sites	O
(	O
Asn86	O
and	O
Asn176	O
)	O
of	O
both	O
antigens	O
,	O
80	O
%	O
of	O
the	O
structures	O
consisted	O
of	O
mono	O
-	O
and	O
bisialylated	O
biantennary	O
N	O
-	O
linked	O
complex	O
oligosaccharides	O
,	O
with	O
the	O
remaining	O
consisting	O
of	O
smaller	O
(	O
probably	O
high	O
mannose	O
)	O
structures	O
.	O

Asn176	O
of	O
both	O
H	B-Protein
-	I-Protein
2Kk	I-Protein
and	O
H	B-Protein
-	I-Protein
2Kb	I-Protein
contained	O
the	O
same	O
ratio	O
(	O
2	O
.	O
8	O
to	O
1	O
)	O
of	O
bi	O
-	O
to	O
monosialylated	O
chains	O
.	O

However	O
,	O
Asn86	O
of	O
H	B-Protein
-	I-Protein
2Kb	I-Protein
contained	O
a	O
higher	O
ratio	O
(	O
5	O
to	O
1	O
)	O
,	O
while	O
Asn86	O
of	O
H	B-Protein
-	I-Protein
2Kk	I-Protein
a	O
lower	O
ratio	O
(	O
1	O
.	O
5	O
to	O
1	O
)	O
.	O

This	O
difference	O
was	O
seen	O
on	O
antigens	O
isolated	O
from	O
cells	O
of	O
the	O
parental	O
strains	O
as	O
well	O
as	O
from	O
the	O
F1	O
cross	O
.	O

The	O
glycosylation	O
of	O
H	B-Protein
-	I-Protein
2Kk	I-Protein
did	O
not	O
vary	O
between	O
B10	O
.	O
A	O
and	O
C3H	O
mice	O
.	O

Mitogenic	O
stimulation	O
increased	O
markedly	O
both	O
total	O
[	O
3H	O
]	O
mannose	O
incorporation	O
and	O
the	O
spectrum	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
labeled	O
.	O

For	O
H	B-Protein
-	I-Protein
2Kk	I-Protein
,	O
it	O
had	O
no	O
effect	O
on	O
sialylation	O
,	O
but	O
resulted	O
in	O
a	O
slight	O
under	O
galactosylation	O
of	O
the	O
monosialylated	O
structures	O
at	O
both	O
sites	O
.	O

A	O
comparison	O
of	O
the	O
patterns	O
seen	O
here	O
,	O
determined	O
on	O
nontransformed	O
T	O
cells	O
,	O
with	O
those	O
previously	O
determined	O
on	O
H	B-Protein
-	I-Protein
2Kk	I-Protein
from	O
a	O
B	O
lymphoma	O
line	O
,	O
revealed	O
marked	O
differences	O
in	O
sialylation	O
and	O
branching	O
patterns	O
at	O
both	O
sites	O
.	O

These	O
data	O
indicate	O
that	O
glycosylation	O
differences	O
may	O
be	O
found	O
between	O
highly	O
homologous	O
(	O
91	O
%	O
)	O
alleles	O
of	O
an	O
H	O
-	O
2	O
gene	O
,	O
even	O
when	O
co	O
-	O
dominantly	O
expressed	O
by	O
F1	O
cells	O
;	O
however	O
,	O
the	O
patterns	O
do	O
change	O
with	O
mitogenic	O
stimulation	O
,	O
and	O
between	O
normal	O
and	O
transformed	O
cells	O
.	O

Altered	O
nucleosomes	O
of	O
active	O
nucleolar	O
chromatin	O
contain	O
accessible	O
histone	B-Protein
H3	I-Protein
in	O
its	O
hyperacetylated	O
forms	O
.	O

Chromatin	O
of	O
the	O
organism	O
Physarum	O
polycephalum	O
contains	O
a	O
class	O
of	O
conformationally	O
altered	O
nucleosomes	O
previously	O
localized	O
to	O
the	O
transcribing	O
regions	O
of	O
ribosomal	O
genes	O
in	O
nucleoli	O
.	O

When	O
nuclei	O
are	O
treated	O
with	O
2	O
-	O
iodo	O
[	O
2	O
-	O
tritium	O
]	O
acetate	O
,	O
the	O
histone	B-Protein
H3	I-Protein
sulfhydryl	O
group	O
of	O
the	O
altered	O
nucleosomes	O
is	O
derivatized	O
while	O
that	O
of	O
folded	O
nucleosomes	O
is	O
not	O
,	O
and	O
the	O
labeled	O
histones	B-Protein
can	O
then	O
be	O
identified	O
by	O
autoradiography	O
of	O
gels	O
that	O
separate	O
H3	B-Protein
isoforms	O
.	O

The	O
H3	B-Protein
derivatized	O
is	O
predominantly	O
of	O
tri	O
-	O
and	O
tetraacetylated	O
forms	O
.	O

In	O
contrast	O
,	O
total	O
free	O
histone	B-Protein
reacted	O
with	O
iodoacetate	O
shows	O
no	O
preferential	O
labeling	O
of	O
isoforms	O
.	O

Selective	O
reaction	O
of	O
acetylated	O
H3	B-Protein
is	O
prevalent	O
in	O
both	O
nucleolar	O
and	O
non	O
-	O
nucleolar	O
chromatin	O
.	O

The	O
results	O
link	O
specific	O
patterns	O
of	O
H3	B-Protein
acetylation	O
to	O
changes	O
in	O
nucleosome	O
conformation	O
that	O
occur	O
during	O
transcription	O
.	O

Distinguishing	O
among	O
protein	O
kinases	O
by	O
substrate	O
specificities	O
.	O

In	O
the	O
previous	O
paper	O
,	O
N	O
-	O
methylated	O
peptides	O
were	O
shown	O
to	O
be	O
sensitive	O
probes	O
of	O
substrate	O
conformation	O
within	O
the	O
adenosine	O
cyclic	O
3	O
'	O
,	O
5	O
'	O
-	O
phosphate	O
dependent	O
protein	O
kinase	O
(	O
A	O
-	O
kinase	O
)	O
active	O
site	O
.	O

While	O
it	O
has	O
been	O
shown	O
that	O
other	O
protein	O
kinases	O
will	O
catalyze	O
the	O
phosphorylation	O
of	O
the	O
same	O
peptide	O
sequences	O
as	O
A	O
-	O
kinase	O
,	O
there	O
is	O
as	O
yet	O
little	O
information	O
as	O
to	O
whether	O
the	O
protein	O
kinases	O
differentiate	O
between	O
substrates	O
on	O
the	O
basis	O
of	O
conformation	O
.	O

For	O
this	O
reason	O
,	O
the	O
conformationally	O
restricted	O
N	O
-	O
methylated	O
peptides	O
were	O
used	O
to	O
probe	O
the	O
active	O
site	O
of	O
guanosine	B-Protein
cyclic	I-Protein
3	I-Protein
'	I-Protein
,	I-Protein
5	I-Protein
'	I-Protein
-	I-Protein
phosphate	I-Protein
dependent	I-Protein
protein	I-Protein
kinase	I-Protein
(	O
G	B-Protein
-	I-Protein
kinase	I-Protein
)	O
,	O
which	O
is	O
homologous	O
in	O
sequence	O
to	O
[	O
Takio	O
,	O
K	O
.	O
,	O
Wade	O
,	O
R	O
.	O
D	O
.	O
,	O
Smith	O
,	O
S	O
.	O
B	O
.	O
,	O
Krebs	O
,	O
E	O
.	O
G	O
.	O
,	O
Walsh	O
,	O
K	O
.	O
A	O
.	O
,	O
&	O
Titani	O
,	O
K	O
.	O
(	O
1984	O
)	O
Biochemistry	O
23	O
,	O
4207	O
-	O
4218	O
]	O
and	O
which	O
has	O
substrate	O
specificities	O
similar	O
to	O
[	O
Lincoln	O
,	O
T	O
.	O
M	O
.	O
,	O
&	O
Corbin	O
,	O
J	O
.	O
D	O
.	O
(	O
1977	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
74	O
,	O
3239	O
-	O
3243	O
]	O
those	O
of	O
A	O
-	O
kinase	O
.	O

Although	O
this	O
enzyme	O
appears	O
to	O
bind	O
the	O
peptides	O
in	O
a	O
conformation	O
resembling	O
that	O
of	O
conformation	O
A	O
,	O
it	O
is	O
more	O
able	O
to	O
accommodate	O
backbone	O
methylation	O
than	O
is	O
A	O
-	O
kinase	O
.	O

A	O
peptide	O
substrate	O
at	O
least	O
700	O
-	O
fold	O
selective	O
for	O
G	B-Protein
-	I-Protein
kinase	I-Protein
over	O
A	O
-	O
kinase	O
was	O
found	O
.	O

Backbone	O
methylation	O
may	O
,	O
therefore	O
,	O
represent	O
a	O
way	O
of	O
making	O
peptide	O
substrates	O
and	O
inhibitors	O
selective	O
for	O
a	O
particular	O
kinase	O
.	O

Biosynthesis	O
of	O
chick	O
type	O
VI	O
collagen	O
.	O

II	O
.	O

Processing	O
and	O
secretion	O
in	O
fibroblasts	O
and	O
smooth	O
muscle	O
cells	O
.	O

The	O
biosynthesis	O
of	O
type	O
VI	O
collagen	O
was	O
studied	O
in	O
"	O
matrix	O
-	O
free	O
"	O
chick	O
embryo	O
smooth	O
muscle	O
cells	O
and	O
fibroblasts	O
.	O

Omission	O
of	O
ascorbate	O
from	O
the	O
culture	O
affected	O
to	O
a	O
great	O
extent	O
the	O
secretion	O
in	O
fibroblasts	O
but	O
had	O
a	O
very	O
minor	O
effect	O
on	O
smooth	O
muscle	O
cells	O
.	O

Quantitative	O
analysis	O
of	O
the	O
secretion	O
process	O
in	O
continuous	O
time	O
course	O
and	O
in	O
pulse	O
-	O
chase	O
experiments	O
confirmed	O
that	O
fibroblasts	O
and	O
smooth	O
muscle	O
cells	O
secreted	O
type	O
VI	O
collagen	O
with	O
the	O
same	O
chain	O
composition	O
but	O
with	O
different	O
kinetics	O
:	O
after	O
4	O
h	O
of	O
chase	O
more	O
than	O
60	O
%	O
of	O
the	O
labeled	O
type	O
VI	O
collagen	O
was	O
present	O
in	O
the	O
culture	O
medium	O
of	O
fibroblasts	O
,	O
whereas	O
at	O
the	O
same	O
time	O
interval	O
less	O
than	O
25	O
%	O
was	O
secreted	O
by	O
smooth	O
muscle	O
cells	O
.	O

The	O
different	O
kinetics	O
depends	O
on	O
intrinsic	O
properties	O
of	O
the	O
cells	O
,	O
since	O
it	O
was	O
detected	O
also	O
in	O
adherent	O
cells	O
.	O

However	O
,	O
even	O
in	O
fibroblasts	O
,	O
secretion	O
of	O
type	O
VI	O
collagen	O
was	O
much	O
slower	O
than	O
secretion	O
of	O
fibronectin	B-Protein
,	O
of	O
which	O
more	O
than	O
50	O
%	O
was	O
already	O
in	O
the	O
cell	O
medium	O
after	O
1	O
h	O
of	O
chase	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
inhibitors	O
of	O
hydroxylation	O
and	O
glycosylation	O
caused	O
a	O
shift	O
in	O
mobility	O
that	O
revealed	O
a	O
size	O
heterogeneity	O
in	O
the	O
Mr	O
=	O
260	O
,	O
000	O
subunit	O
.	O

No	O
evidence	O
of	O
processing	O
was	O
observed	O
in	O
chick	O
cells	O
for	O
any	O
of	O
the	O
subunits	O
that	O
were	O
synthesized	O
and	O
secreted	O
uncleaved	O
.	O

In	O
addition	O
,	O
after	O
several	O
days	O
of	O
chase	O
the	O
Mr	O
of	O
the	O
subunits	O
of	O
type	O
VI	O
collagen	O
isolated	O
from	O
the	O
matrix	O
remained	O
unchanged	O
,	O
thus	O
excluding	O
that	O
in	O
the	O
chick	O
even	O
a	O
partial	O
or	O
incomplete	O
processing	O
takes	O
place	O
.	O

Histones	B-Protein
and	O
histone	B-Protein
acetylation	O
during	O
the	O
embryonic	O
development	O
of	O
Drosophila	O
hydei	O
.	O

Histones	B-Protein
and	O
histone	B-Protein
acetylation	O
have	O
been	O
investigated	O
during	O
three	O
stages	O
of	O
Drosophila	O
hydei	O
embryogenesis	O
-	O
-	O
early	O
gastrula	O
,	O
late	O
gastrula	O
and	O
organogenesis	O
.	O

No	O
essential	O
changes	O
in	O
the	O
electrophoretic	O
pattern	O
of	O
the	O
histones	B-Protein
have	O
been	O
revealed	O
during	O
the	O
stages	O
examined	O
.	O

However	O
,	O
we	O
established	O
an	O
enhanced	O
level	O
of	O
[	O
14C	O
]	O
acetate	O
incorporation	O
at	O
the	O
time	O
of	O
extensive	O
gene	O
activation	O
during	O
gastrulation	O
as	O
well	O
as	O
some	O
quantitative	O
differences	O
in	O
the	O
pattern	O
of	O
acetylation	O
during	O
gastrula	O
and	O
organogenesis	O
.	O

We	O
consider	O
most	O
of	O
them	O
to	O
be	O
related	O
to	O
chromatin	O
assembly	O
during	O
the	O
stage	O
of	O
gastrulation	O
and	O
suggest	O
that	O
the	O
correlation	O
between	O
histone	B-Protein
acetylation	O
and	O
gene	O
activity	O
during	O
Drosophila	O
embryogenesis	O
concerns	O
histone	B-Protein
H3	I-Protein
acetylation	O
.	O

The	O
involvement	O
of	O
both	O
acetylation	O
and	O
deacetylation	O
in	O
the	O
steady	O
-	O
state	O
acetylation	O
level	O
has	O
been	O
examined	O
as	O
well	O
.	O

We	O
have	O
found	O
that	O
the	O
higher	O
acetyltransferase	O
activity	O
is	O
responsible	O
for	O
the	O
enhanced	O
level	O
of	O
acetate	O
incorporation	O
during	O
gastrulation	O
.	O

Further	O
characterization	O
of	O
the	O
posttranslational	O
modifications	O
of	O
core	O
histones	B-Protein
in	O
response	O
to	O
heat	O
and	O
arsenite	O
stress	O
in	O
Drosophila	O
.	O

The	O
effects	O
of	O
a	O
heat	O
shock	O
or	O
arsenite	O
treatment	O
on	O
the	O
methylation	O
and	O
acetylation	O
of	O
core	O
histones	B-Protein
have	O
been	O
investigated	O
in	O
Drosophila	O
cultured	O
cells	O
.	O

The	O
decrease	O
in	O
H3	B-Protein
methylation	O
,	O
which	O
is	O
observed	O
during	O
a	O
heat	O
shock	O
,	O
is	O
not	O
a	O
demethylation	O
process	O
,	O
but	O
results	O
from	O
methylation	O
arrest	O
.	O

Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
leaves	O
no	O
ambiguity	O
concerning	O
the	O
identity	O
of	O
H2B	B-Protein
as	O
a	O
methylated	O
protein	O
,	O
since	O
H2B	B-Protein
and	O
D2	B-Protein
,	O
a	O
nuclear	O
nonhistone	O
protein	O
,	O
which	O
comigrate	O
on	O
one	O
-	O
dimensional	O
gels	O
,	O
are	O
well	O
separated	O
on	O
these	O
gels	O
.	O

Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
in	O
the	O
presence	O
of	O
Triton	O
X	O
-	O
100	O
resolves	O
each	O
of	O
the	O
core	O
histones	B-Protein
into	O
multiple	O
forms	O
resulting	O
from	O
posttranslational	O
modifications	O
.	O

There	O
are	O
apparently	O
,	O
however	O
,	O
no	O
histone	B-Protein
variants	O
in	O
cultured	O
Drosophila	O
cells	O
.	O

At	O
23	O
degrees	O
C	O
,	O
the	O
various	O
forms	O
of	O
the	O
core	O
histones	B-Protein
resolved	O
on	O
two	O
-	O
dimensional	O
gels	O
are	O
methylated	O
.	O

Under	O
heat	O
-	O
shock	O
or	O
arsenite	O
treatment	O
,	O
the	O
methylation	O
of	O
all	O
forms	O
of	O
H3	B-Protein
is	O
decreased	O
,	O
while	O
that	O
of	O
the	O
various	O
forms	O
of	O
H2B	B-Protein
increase	O
.	O

These	O
stress	O
conditions	O
also	O
induce	O
a	O
generalized	O
diminution	O
in	O
the	O
acetylation	O
of	O
all	O
forms	O
of	O
core	O
histones	B-Protein
.	O

In	O
the	O
course	O
of	O
a	O
heat	O
shock	O
,	O
the	O
synthesis	O
of	O
H2B	B-Protein
is	O
increased	O
and	O
this	O
newly	O
synthesized	O
histone	B-Protein
remains	O
unacetylated	O
during	O
the	O
shock	O
.	O

These	O
changes	O
in	O
the	O
patterns	O
of	O
core	O
histone	B-Protein
methylation	O
and	O
acetylation	O
may	O
be	O
correlated	O
with	O
the	O
reorganization	O
of	O
gene	O
activity	O
brought	O
about	O
by	O
the	O
heat	O
shock	O
.	O

Aberrant	O
regulation	O
of	O
methylesterase	O
activity	O
in	O
cheD	B-Protein
chemotaxis	O
mutants	O
of	O
Escherichia	O
coli	O
.	O

The	O
adaptation	O
process	O
in	O
several	O
cheD	B-Protein
chemotaxis	O
mutants	O
,	O
which	O
carry	O
defects	O
in	O
tsr	B-Protein
,	O
the	O
serine	O
transducer	O
gene	O
,	O
was	O
examined	O
.	O

cheD	B-Protein
mutants	O
are	O
smooth	O
swimming	O
and	O
generally	O
nonchemotactic	O
;	O
the	O
defect	O
is	O
dominant	O
to	O
the	O
wild	O
-	O
type	O
tsr	B-Protein
gene	O
(	O
J	O
.	O
S	O
.	O
Parkinson	O
,	O
J	O
.	O
Bacteriol	O
.	O
142	O
:	O
953	O
-	O
961	O
,	O
1980	O
)	O
.	O

All	O
classes	O
of	O
methyl	O
-	O
accepting	O
chemotaxis	O
proteins	O
synthesized	O
in	O
unstimulated	O
cheD	B-Protein
strains	O
are	O
overmethylated	O
relative	O
to	O
the	O
wild	O
type	O
.	O

We	O
found	O
that	O
the	O
steady	O
-	O
state	O
rate	O
of	O
demethylation	O
in	O
cheD	B-Protein
mutants	O
was	O
low	O
;	O
this	O
may	O
explain	O
their	O
overmethylated	O
phenotype	O
.	O

In	O
addition	O
,	O
all	O
cheD	B-Protein
mutants	O
showed	O
diminished	O
responsiveness	O
of	O
methylesterase	O
activity	O
to	O
attractant	O
and	O
repellent	O
stimuli	O
transduced	O
by	O
either	O
the	O
Tsr	B-Protein
or	O
Tar	B-Protein
protein	O
,	O
and	O
they	O
did	O
not	O
adapt	O
.	O

These	O
results	O
suggest	O
that	O
the	O
dominant	O
nature	O
of	O
the	O
cheD	B-Protein
mutations	O
is	O
manifested	O
as	O
a	O
general	O
defect	O
in	O
the	O
regulation	O
of	O
demethylation	O
.	O

Some	O
of	O
these	O
altered	O
properties	O
of	O
methylesterase	O
activity	O
in	O
cheD	B-Protein
mutants	O
were	O
exhibited	O
in	O
wild	O
-	O
type	O
cells	O
that	O
were	O
treated	O
with	O
saturating	O
concentrations	O
of	O
serine	O
.	O

The	O
mutant	O
Tsr	B-Protein
protein	O
thus	O
seems	O
to	O
be	O
locked	O
into	O
a	O
signaling	O
mode	O
that	O
suppresses	O
tumbling	O
and	O
inhibits	O
methylesterase	O
activity	O
in	O
a	O
global	O
fashion	O
.	O

We	O
found	O
that	O
the	O
Tar	B-Protein
and	O
mutant	O
Tsr	B-Protein
proteins	O
synthesized	O
in	O
cheD	B-Protein
strains	O
were	O
methylated	O
and	O
deamidated	O
at	O
the	O
correct	O
sites	O
and	O
that	O
the	O
mutations	O
were	O
not	O
located	O
in	O
the	O
methylated	O
peptides	O
.	O

Thus	O
,	O
the	O
signaling	O
properties	O
of	O
the	O
transducers	O
may	O
be	O
controlled	O
at	O
sites	O
distinct	O
from	O
the	O
methyl	O
-	O
accepting	O
sites	O
.	O

Cold	O
-	O
sensitive	O
ribosome	O
assembly	O
in	O
an	O
Escherichia	O
coli	O
mutant	O
lacking	O
a	O
single	O
methyl	O
group	O
in	O
ribosomal	O
protein	O
L3	B-Protein
.	O

Ribosomal	O
protein	O
methylation	O
has	O
been	O
well	O
documented	O
but	O
its	O
function	O
remains	O
unclear	O
.	O

We	O
have	O
examined	O
this	O
phenomenon	O
using	O
an	O
Escherichia	O
coli	O
mutant	O
(	O
prmB2	O
)	O
,	O
which	O
fails	O
to	O
methylate	O
glutamine	O
residue	O
number	O
150	O
of	O
ribosomal	O
protein	O
L3	B-Protein
.	O

This	O
mutant	O
exhibits	O
a	O
cold	O
-	O
sensitive	O
phenotype	O
:	O
its	O
growth	O
rate	O
at	O
22	O
degrees	O
C	O
is	O
abnormally	O
low	O
in	O
complete	O
medium	O
.	O

In	O
addition	O
,	O
strains	O
with	O
this	O
mutation	O
accumulate	O
abnormal	O
and	O
unstable	O
ribosomal	O
particles	O
;	O
50	O
-	O
S	O
and	O
30	O
-	O
S	O
subunits	O
are	O
formed	O
,	O
but	O
at	O
a	O
lower	O
rate	O
.	O

Once	O
assembled	O
,	O
ribosomes	O
with	O
unmethylated	O
L3	B-Protein
are	O
fully	O
active	O
by	O
several	O
criteria	O
.	O

(	O
a	O
)	O
Protein	O
synthesis	O
in	O
vitro	O
with	O
purified	O
70	O
-	O
S	O
prmB2	O
ribosomes	O
is	O
as	O
active	O
as	O
wild	O
-	O
type	O
using	O
either	O
a	O
natural	O
(	O
R17	O
)	O
or	O
an	O
artificial	O
[	O
poly	O
(	O
U	O
)	O
]	O
messenger	O
.	O

(	O
b	O
)	O
The	O
induction	O
of	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
in	O
vivo	O
exhibits	O
normal	O
kinetics	O
and	O
the	O
enzyme	O
has	O
a	O
normal	O
rate	O
of	O
thermal	O
denaturation	O
.	O

(	O
c	O
)	O
These	O
ribosomes	O
are	O
standard	O
when	O
exposed	O
in	O
vitro	O
to	O
a	O
low	O
magnesium	O
concentration	O
or	O
increasing	O
molarities	O
of	O
LiCl	O
.	O

Efficient	O
methylation	O
of	O
L3	B-Protein
in	O
vitro	O
requires	O
either	O
unfolded	O
ribosomes	O
or	O
a	O
mixture	O
of	O
ribosomal	O
protein	O
and	O
RNA	O
.	O

We	O
suggest	O
that	O
the	O
L3	B-Protein
-	O
specific	O
methyltransferase	O
may	O
qualify	O
as	O
one	O
of	O
the	O
postulated	O
'	O
assembly	O
factors	O
'	O
of	O
the	O
E	O
.	O
coli	O
ribosome	O
.	O

Regulation	O
of	O
collagen	O
post	O
-	O
translational	O
modification	O
in	O
transformed	O
human	O
and	O
chick	O
-	O
embryo	O
cells	O
.	O

Changes	O
in	O
the	O
regulation	O
of	O
collagen	O
post	O
-	O
translational	O
modification	O
in	O
transformed	O
cells	O
were	O
studied	O
in	O
three	O
established	O
human	O
sarcoma	O
cell	O
lines	O
and	O
in	O
chick	O
-	O
embryo	O
fibroblasts	O
freshly	O
transformed	O
by	O
Rous	O
sarcoma	O
virus	O
.	O

The	O
collagens	O
synthesized	O
by	O
all	O
but	O
one	O
of	O
these	O
and	O
by	O
all	O
the	O
control	O
human	O
and	O
chick	O
-	O
embryo	O
cell	O
lines	O
were	O
almost	O
exclusively	O
of	O
types	O
I	O
and	O
/	O
or	O
III	B-Protein
.	O

The	O
relative	O
rate	O
of	O
collagen	O
synthesis	O
and	O
the	O
amounts	O
of	O
prolyl	O
hydroxylase	O
activity	O
and	O
immunoreactive	O
protein	O
were	O
markedly	O
low	O
in	O
all	O
the	O
transformed	O
human	O
cell	O
lines	O
.	O

The	O
other	O
enzymes	O
studied	O
,	O
lysyl	O
hydroxylase	O
,	O
hydroxylysyl	O
galactosyltransferase	O
and	O
galactosylhydroxylysyl	O
glucosyltransferase	O
,	O
never	O
showed	O
as	O
large	O
a	O
decrease	O
in	O
activity	O
as	O
did	O
prolyl	O
hydroxylase	O
,	O
suggesting	O
a	O
more	O
efficient	O
regulation	O
of	O
the	O
last	O
enzyme	O
than	O
of	O
the	O
three	O
others	O
.	O

The	O
chick	O
-	O
embryo	O
fibroblasts	O
freshly	O
transformed	O
by	O
Rous	O
sarcoma	O
virus	O
differed	O
from	O
the	O
human	O
sarcoma	O
cells	O
in	O
that	O
prolyl	O
hydroxylase	O
activity	O
was	O
distinctly	O
increased	O
,	O
whereas	O
the	O
decreases	O
in	O
immunoreactive	O
prolyl	O
hydroxylase	O
protein	O
and	O
the	O
three	O
other	O
enzyme	O
activities	O
were	O
very	O
similar	O
to	O
those	O
in	O
the	O
simian	O
-	O
virus	O
-	O
40	O
-	O
transformed	O
human	O
fibroblasts	O
.	O

It	O
seems	O
possible	O
that	O
this	O
increased	O
prolyl	O
hydroxylase	O
activity	O
is	O
only	O
a	O
temporary	O
phenomenon	O
occurring	O
shortly	O
after	O
the	O
transformation	O
,	O
and	O
may	O
be	O
followed	O
by	O
a	O
decrease	O
in	O
activity	O
later	O
.	O

The	O
newly	O
synthesized	O
collagens	O
of	O
all	O
the	O
transformed	O
cells	O
that	O
produced	O
almost	O
exclusively	O
collagen	O
types	O
I	O
and	O
/	O
or	O
III	B-Protein
had	O
high	O
extents	O
of	O
lysyl	O
hydroxylation	O
,	O
and	O
there	O
was	O
also	O
an	O
increase	O
in	O
the	O
ratio	O
of	O
glycosylated	O
to	O
non	O
-	O
glycosylated	O
hydroxylysine	O
.	O

The	O
data	O
suggest	O
that	O
one	O
critical	O
factor	O
affecting	O
modification	O
is	O
the	O
rate	O
of	O
collagen	O
synthesis	O
,	O
which	O
affects	O
the	O
ratio	O
of	O
enzyme	O
to	O
substrate	O
in	O
the	O
cell	O
.	O

Partial	O
methylation	O
of	O
two	O
adjacent	O
adenosines	O
in	O
ribosomes	O
from	O
Euglena	O
gracilis	O
chloroplasts	O
suggests	O
evolutionary	O
loss	O
of	O
an	O
intermediate	O
stage	O
in	O
the	O
methyl	O
-	O
transfer	O
reaction	O
.	O

Bacterial	O
,	O
cytoplasmic	O
and	O
organellar	O
ribosomes	O
from	O
a	O
wide	O
phylogenetic	O
spectrum	O
of	O
organisms	O
have	O
a	O
characteristic	O
m6	O
(	O
2	O
)	O
Am6	O
(	O
2	O
)	O
A	O
structure	O
near	O
the	O
3	O
'	O
end	O
of	O
the	O
RNA	O
of	O
the	O
small	O
ribosomal	O
subunit	O
(	O
SSU	O
)	O
.	O

We	O
have	O
studied	O
one	O
of	O
the	O
few	O
exceptions	O
to	O
this	O
extremely	O
conserved	O
post	O
-	O
transcriptionally	O
modified	O
sequence	O
,	O
i	O
.	O
e	O
.	O
dimethylation	O
of	O
only	O
one	O
of	O
the	O
two	O
A	O
'	O
s	O
in	O
chloroplasts	O
from	O
Euglena	O
gracilis	O
.	O

It	O
was	O
established	O
that	O
only	O
the	O
A	O
closest	O
to	O
the	O
5	O
'	O
end	O
is	O
dimethylated	O
,	O
the	O
other	O
one	O
being	O
unmodified	O
.	O

The	O
methylation	O
reaction	O
was	O
studied	O
in	O
vitro	O
using	O
ribosomes	O
from	O
a	O
kasugamycin	O
resistant	O
mutant	O
(	O
ksgA	B-Protein
)	O
of	O
Escherichia	O
coli	O
and	O
purified	O
methyl	O
-	O
transferase	O
.	O

Using	O
limited	O
amounts	O
of	O
the	O
methyl	O
donor	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
a	O
partial	O
level	O
of	O
methylation	O
(	O
50	O
%	O
of	O
control	O
)	O
was	O
attained	O
.	O

It	O
is	O
shown	O
that	O
in	O
this	O
case	O
the	O
3	O
'	O
proximal	O
A	O
is	O
dimethylated	O
while	O
the	O
other	O
is	O
not	O
.	O

This	O
suggests	O
that	O
dimethylation	O
takes	O
place	O
in	O
two	O
successive	O
stages	O
.	O

Apparently	O
in	O
E	O
.	O
gracilis	O
chloroplasts	O
the	O
first	O
stage	O
of	O
methylation	O
does	O
not	O
occur	O
.	O

Disorder	O
of	O
collagen	O
metabolism	O
in	O
a	O
patient	O
with	O
osteogenesis	O
imperfecta	O
(	O
lethal	O
type	O
)	O
:	O
increased	O
degree	O
of	O
hydroxylation	O
of	O
lysine	O
in	O
collagen	O
types	O
I	O
and	O
III	B-Protein
.	O

Types	O
I	O
,	O
II	B-Protein
and	O
III	B-Protein
collagen	I-Protein
were	O
isolated	O
from	O
calvarium	O
,	O
skin	O
and	O
cartilage	O
from	O
a	O
patient	O
with	O
recessive	O
lethal	O
osteogenesis	O
imperfecta	O
.	O
the	O
distribution	O
of	O
the	O
various	O
collagen	O
types	O
was	O
normal	O
in	O
all	O
three	O
tissues	O
.	O

The	O
alpha	O
-	O
chains	O
were	O
purified	O
by	O
molecular	O
sieve	O
and	O
ion	O
-	O
exchange	O
chromatography	O
and	O
were	O
found	O
to	O
differ	O
from	O
the	O
corresponding	O
alpha	O
-	O
chains	O
of	O
age	O
-	O
matched	O
controls	O
only	O
in	O
that	O
the	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
,	O
alpha	O
2	O
and	O
alpha	B-Protein
1	I-Protein
(	I-Protein
III	I-Protein
)	I-Protein
chains	O
contained	O
higher	O
amounts	O
of	O
hydroxylysine	O
with	O
proportionally	O
less	O
lysine	O
.	O
alpha	O
1	O
(	O
II	O
)	O
was	O
normal	O
.	O

The	O
excess	O
hydroxylysine	O
residues	O
were	O
all	O
glycosylated	O
in	O
the	O
case	O
of	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
,	O
but	O
only	O
partly	O
so	O
for	O
the	O
alpha	O
2	O
chains	O
.	O

Similar	O
observations	O
were	O
made	O
with	O
collagen	O
from	O
fetuses	O
at	O
various	O
stages	O
of	O
development	O
.	O

In	O
these	O
fetuses	O
,	O
however	O
,	O
the	O
increase	O
in	O
the	O
degree	O
of	O
hydroxylation	O
of	O
lysine	O
in	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
,	O
alpha	O
2	O
and	O
alpha	B-Protein
1	I-Protein
(	I-Protein
III	I-Protein
)	I-Protein
varied	O
with	O
age	O
,	O
being	O
highest	O
in	O
the	O
youngest	O
fetus	O
.	O

Seen	O
in	O
the	O
context	O
of	O
embryonic	O
development	O
,	O
the	O
collagen	O
of	O
the	O
patient	O
would	O
correspond	O
to	O
that	O
of	O
a	O
fetus	O
younger	O
than	O
18	O
weeks	O
,	O
and	O
one	O
could	O
speculate	O
that	O
the	O
defect	O
seen	O
in	O
this	O
patient	O
is	O
the	O
result	O
of	O
a	O
disturbed	O
process	O
of	O
maturation	O
of	O
connective	O
tissue	O
.	O

Temperature	O
-	O
sensitive	O
changes	O
in	O
the	O
structure	O
of	O
globin	O
chromatin	O
in	O
lines	O
of	O
red	O
cell	O
precursors	O
transformed	O
by	O
ts	O
-	O
AEV	O
.	O

Chicken	O
bone	O
marrow	O
cells	O
infected	O
in	O
vitro	O
with	O
a	O
temperature	O
-	O
sensitive	O
avian	O
erythroblastosis	O
virus	O
fall	O
to	O
produce	O
hemoglobin	O
at	O
36	O
degrees	O
C	O
.	O

When	O
the	O
product	O
or	O
products	O
of	O
the	O
transforming	O
gene	O
(	O
erb	B-Protein
)	O
are	O
inactivated	O
by	O
a	O
temperature	O
shift	O
to	O
42	O
degrees	O
C	O
in	O
culture	O
,	O
several	O
different	O
cloned	O
lines	O
of	O
cells	O
infected	O
with	O
the	O
temperature	O
-	O
sensitive	O
avian	O
erythroblastosis	O
virus	O
begin	O
to	O
make	O
hemoglobin	O
.	O

This	O
shift	O
in	O
phenotype	O
correlates	O
with	O
an	O
increase	O
in	O
hemoglobin	O
mRNA	O
specific	O
to	O
both	O
adult	O
and	O
embryonic	O
alpha	B-Protein
and	O
beta	B-Protein
globin	I-Protein
.	O

The	O
switch	O
is	O
accompanied	O
by	O
the	O
acquisition	O
of	O
DNAase	O
I	O
-	O
hypersensitive	O
sites	O
in	O
one	O
cell	O
line	O
(	O
clone	O
2	O
)	O
;	O
however	O
,	O
a	O
hypothetically	O
more	O
mature	O
line	O
(	O
clone	O
3	O
)	O
has	O
already	O
acquired	O
globin	O
DNAase	O
-	O
hypersensitive	O
sites	O
but	O
does	O
not	O
express	O
hemoglobin	O
until	O
the	O
temperature	O
shift	O
.	O

Several	O
(	O
but	O
not	O
all	O
)	O
specific	O
restriction	O
sites	O
associated	O
with	O
both	O
the	O
alpha	O
and	O
beta	O
domains	O
become	O
unmethylated	O
after	O
the	O
switch	O
from	O
36	O
degrees	O
C	O
to	O
42	O
degrees	O
C	O
.	O

The	O
magnitude	O
of	O
these	O
methylation	O
switches	O
is	O
small	O
compared	O
with	O
changes	O
that	O
occur	O
in	O
these	O
genes	O
during	O
normal	O
avian	O
erythropoiesis	O
.	O

The	O
results	O
suggest	O
that	O
changes	O
in	O
chromosomal	O
structure	O
precede	O
transcription	O
and	O
are	O
not	O
a	O
consequence	O
of	O
transcription	O
.	O

Since	O
(	O
presumptive	O
)	O
precursor	O
cloned	O
lines	O
can	O
be	O
established	O
with	O
some	O
,	O
but	O
not	O
all	O
,	O
of	O
the	O
structural	O
properties	O
of	O
active	O
globin	O
chromatin	O
,	O
it	O
is	O
likely	O
that	O
many	O
of	O
these	O
properties	O
can	O
be	O
independently	O
established	O
and	O
are	O
not	O
obligatorily	O
related	O
.	O

Studies	O
of	O
the	O
conformation	O
-	O
dependent	O
neutralizing	O
epitopes	O
of	O
simian	O
immunodeficiency	O
virus	O
envelope	B-Protein
protein	I-Protein
.	O

It	O
has	O
been	O
shown	O
previously	O
that	O
the	O
major	O
neutralizing	O
epitopes	O
in	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
are	O
discontinuous	O
and	O
conformation	O
dependent	O
and	O
that	O
the	O
V3	O
loop	O
,	O
in	O
contrast	O
to	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
does	O
not	O
by	O
itself	O
elicit	O
neutralizing	O
antibodies	O
(	O
K	O
.	O
Javaherian	O
et	O
al	O
.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
89	O
:	O
1418	O
-	O
1422	O
,	O
1992	O
)	O
.	O

We	O
now	O
present	O
data	O
showing	O
that	O
on	O
the	O
basis	O
of	O
fractionation	O
of	O
infected	O
macaque	O
sera	O
,	O
protease	O
digestion	O
of	O
the	O
envelope	O
,	O
and	O
binding	O
properties	O
of	O
two	O
neutralizing	O
monoclonal	O
antibodies	O
to	O
SIV	O
and	O
SIV	O
-	O
HIV	O
chimeric	O
envelope	B-Protein
proteins	I-Protein
,	O
changes	O
in	O
V3	O
can	O
disrupt	O
the	O
conformation	O
-	O
dependent	O
neutralization	O
region	O
.	O

The	O
chimeric	O
protein	O
did	O
not	O
produce	O
significant	O
neutralizing	O
antibodies	O
against	O
either	O
SIV	O
or	O
HIV	O
.	O

We	O
also	O
report	O
that	O
neutralizing	O
antibodies	O
elicited	O
by	O
recombinant	O
SIV	O
envelope	B-Protein
proteins	I-Protein
of	O
mac251	O
and	O
B670	O
isolates	O
cross	O
-	O
neutralize	O
.	O

Finally	O
,	O
we	O
show	O
that	O
deglycosylation	O
of	O
the	O
SIV	O
envelope	O
results	O
in	O
a	O
molecule	O
which	O
binds	O
neither	O
soluble	O
CD4	B-Protein
nor	O
the	O
neutralizing	O
monoclonal	O
antibodies	O
being	O
investigated	O
here	O
and	O
does	O
not	O
elicit	O
sera	O
with	O
a	O
significant	O
neutralizing	O
titer	O
.	O

Beta	O
1	O
-	O
6	O
branching	O
of	O
N	O
-	O
linked	O
carbohydrate	O
is	O
associated	O
with	O
K	B-Protein
-	I-Protein
ras	I-Protein
mutation	O
in	O
human	O
colon	O
carcinoma	O
cell	O
lines	O
.	O

Here	O
the	O
K	B-Protein
-	I-Protein
ras	I-Protein
genotypes	O
of	O
nine	O
colon	O
carcinoma	O
cell	O
lines	O
are	O
compared	O
to	O
the	O
protein	O
glycosylation	O
patterns	O
found	O
in	O
these	O
cells	O
.	O

By	O
a	O
variety	O
of	O
methodologies	O
utilizing	O
lectins	O
to	O
probe	O
carbohydrate	O
structure	O
,	O
we	O
find	O
evidence	O
that	O
five	O
out	O
of	O
six	O
cell	O
lines	O
having	O
K	B-Protein
-	I-Protein
ras	I-Protein
mutations	O
have	O
elevated	O
amounts	O
of	O
beta	O
1	O
-	O
6	O
branching	O
at	O
the	O
trimannosyl	O
core	O
of	O
N	O
-	O
linked	O
carbohydrate	O
.	O

None	O
of	O
the	O
three	O
K	B-Protein
-	I-Protein
ras	I-Protein
wild	O
type	O
cell	O
lines	O
assayed	O
have	O
evidence	O
of	O
elevated	O
beta	O
1	O
-	O
6	O
branching	O
.	O

In	O
five	O
out	O
of	O
five	O
cell	O
lines	O
examined	O
,	O
the	O
amount	O
of	O
beta	O
1	O
-	O
6	O
branching	O
correlates	O
with	O
the	O
extent	O
of	O
cellular	O
ras	O
-	O
GTP	O
elevation	O
and	O
supports	O
the	O
hypothesis	O
that	O
expression	O
of	O
beta	O
1	O
-	O
6	O
branching	O
in	O
colon	O
carcinoma	O
cell	O
lines	O
is	O
quantitatively	O
linked	O
to	O
K	B-Protein
-	I-Protein
ras	I-Protein
activation	O
.	O

These	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
the	O
ras	O
-	O
signalling	O
pathway	O
.	O

Abnormal	O
glycosylation	O
of	O
alpha	B-Protein
2	I-Protein
-	I-Protein
macroglobulin	I-Protein
,	O
a	O
non	O
-	O
acute	O
-	O
phase	O
protein	O
in	O
patients	O
with	O
autoimmune	O
diseases	O
.	O

Previous	O
studies	O
from	O
this	O
and	O
other	O
laboratories	O
have	O
shown	O
that	O
abnormal	O
glycosylation	O
of	O
several	O
acute	O
-	O
phase	O
proteins	O
can	O
be	O
detected	O
in	O
various	O
pathological	O
conditions	O
including	O
autoimmune	O
diseases	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
if	O
abnormal	O
glycosylation	O
is	O
limited	O
to	O
acute	O
-	O
phase	O
proteins	O
.	O

We	O
used	O
the	O
concanavalin	B-Protein
A	I-Protein
(	O
Con	B-Protein
A	I-Protein
)	O
blots	O
in	O
conjunction	O
with	O
the	O
peptide	O
mapping	O
techniques	O
to	O
analyze	O
serum	O
samples	O
and	O
cerebrospinal	O
fluids	O
(	O
CSF	O
)	O
obtained	O
from	O
patients	O
with	O
autoimmune	O
diseases	O
:	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
mixed	O
connective	O
tissue	O
disease	O
(	O
MCTD	O
)	O
,	O
scleroderma	O
(	O
SCL	O
)	O
,	O
Sjogren	O
'	O
s	O
syndrome	O
(	O
SS	O
)	O
,	O
and	O
polymyositis	O
(	O
PM	O
)	O
;	O
diseases	O
of	O
probable	O
autoimmune	O
origin	O
:	O
hepatopathies	O
(	O
HP	O
)	O
;	O
diseases	O
of	O
suspected	O
autoimmune	O
origin	O
:	O
schizophrenia	O
and	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AZ	O
)	O
;	O
and	O
conditions	O
not	O
related	O
to	O
autoimmunity	O
:	O
pregnancy	O
(	O
PG	O
)	O
and	O
elevation	O
of	O
the	O
carcinoembryonic	B-Protein
antigen	I-Protein
(	O
CEA	B-Protein
)	O
,	O
in	O
comparison	O
to	O
normal	O
donors	O
(	O
NHS	O
)	O
.	O

We	O
have	O
micropurified	O
two	O
human	O
proteins	O
;	O
alpha	B-Protein
2	I-Protein
-	I-Protein
macroglobulin	I-Protein
,	O
a	O
non	O
-	O
acute	O
-	O
phase	O
protein	O
and	O
beta	O
-	O
chain	O
of	O
haptoglobin	B-Protein
,	O
a	O
known	O
acute	O
-	O
phase	O
protein	O
,	O
from	O
serum	O
samples	O
of	O
individual	O
patients	O
with	O
SLE	O
,	O
RA	O
,	O
MCTD	O
,	O
SCL	O
and	O
SS	O
,	O
and	O
from	O
PG	O
and	O
NHS	O
for	O
analysis	O
.	O

The	O
identity	O
of	O
the	O
purified	O
proteins	O
was	O
confirmed	O
by	O
immunoblots	O
using	O
either	O
monospecific	O
polyclonal	O
or	O
monoclonal	O
antibodies	O
,	O
and	O
by	O
direct	O
N	O
-	O
terminal	O
amino	O
acid	O
sequencing	O
.	O

Peptide	O
maps	O
for	O
each	O
of	O
these	O
proteins	O
were	O
generated	O
using	O
Staphylococcus	O
aureus	O
protease	B-Protein
V8	I-Protein
,	O
a	O
Glu	O
-	O
C	O
endopeptidase	O
.	O

When	O
the	O
peptide	O
fragments	O
of	O
alpha	B-Protein
2	I-Protein
-	I-Protein
macroglobulin	I-Protein
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
visualized	O
using	O
silver	O
staining	O
,	O
no	O
differences	O
were	O
noted	O
between	O
patient	O
samples	O
and	O
controls	O
.	O

However	O
,	O
when	O
they	O
were	O
examined	O
by	O
lectin	O
blots	O
using	O
Con	B-Protein
A	I-Protein
,	O
the	O
Con	B-Protein
A	I-Protein
-	O
reactive	O
fragments	O
increased	O
specifically	O
and	O
significantly	O
in	O
samples	O
derived	O
from	O
patients	O
of	O
SLE	O
,	O
SCL	O
,	O
MCTD	O
,	O
and	O
RA	O
.	O

Similarly	O
when	O
the	O
peptide	O
fragments	O
of	O
the	O
beta	O
-	O
chain	O
of	O
haptoglobin	B-Protein
were	O
visualized	O
by	O
silver	O
staining	O
,	O
no	O
differences	O
were	O
noted	O
;	O
however	O
,	O
the	O
Con	B-Protein
A	I-Protein
reactivity	O
of	O
specific	O
fragments	O
increased	O
in	O
SLE	O
,	O
RA	O
,	O
SCL	O
,	O
and	O
SS	O
patients	O
.	O

Analysis	O
of	O
these	O
results	O
indicated	O
that	O
there	O
has	O
been	O
a	O
selective	O
increase	O
in	O
Con	B-Protein
A	I-Protein
-	O
reactive	O
fragments	O
in	O
both	O
acute	O
-	O
phase	O
and	O
non	O
-	O
acute	O
-	O
phase	O
proteins	O
in	O
autoimmune	O
conditions	O
.	O

Thus	O
,	O
the	O
study	O
of	O
changes	O
in	O
glycosylation	O
patterns	O
in	O
selected	O
serum	O
proteins	O
may	O
be	O
a	O
valuable	O
diagnostic	O
approach	O
to	O
define	O
the	O
pathophysiology	O
of	O
inflammatory	O
and	O
autoimmune	O
disorders	O
.	O

Evidence	O
that	O
Rap1	O
carboxylmethylation	O
is	O
involved	O
in	O
regulated	O
insulin	B-Protein
secretion	O
.	O

Protein	O
carboxylmethylation	O
is	O
a	O
reversible	O
posttranslational	O
modification	O
that	O
regulates	O
protein	O
function	O
.	O

We	O
examined	O
the	O
carboxylmethylation	O
of	O
small	O
GTP	O
-	O
binding	O
proteins	O
in	O
a	O
pancreatic	O
beta	O
-	O
cell	O
line	O
(	O
beta	O
TC	O
cells	O
)	O
.	O

In	O
vitro	O
assays	O
showed	O
that	O
carboxylmethylation	O
of	O
a	O
membrane	O
23	O
-	O
kDa	O
protein	O
was	O
induced	O
by	O
guanine	O
nucleotides	O
,	O
best	O
demonstrated	O
by	O
the	O
nonhydrolyzable	O
GTP	O
analog	O
,	O
guanosine	O
5	O
'	O
-	O
(	O
3	O
-	O
O	O
-	O
thio	O
)	O
triphosphate	O
(	O
GTP	O
gamma	O
S	O
)	O
.	O

GTP	O
gamma	O
S	O
also	O
induced	O
translocation	O
of	O
this	O
23	O
-	O
kilodalton	O
(	O
kDa	O
)	O
protein	O
from	O
cytosol	O
to	O
particulate	O
fractions	O
.	O

Immunoblotting	O
with	O
antiserum	O
sc	O
-	O
65	O
raised	O
against	O
Rap1	O
identified	O
the	O
carboxyl	O
-	O
methylated	O
23	O
-	O
kDa	O
protein	O
as	O
Rap1	O
.	O

1	O
)	O
The	O
23	O
-	O
kDa	O
carboxyl	O
-	O
methylated	O
protein	O
separated	O
by	O
two	O
-	O
dimensional	O
electrophoresis	O
overlapped	O
with	O
the	O
23	O
-	O
kDa	O
protein	O
detected	O
by	O
immunoblotting	O
.	O

2	O
)	O
GTP	O
gamma	O
S	O
,	O
in	O
the	O
presence	O
of	O
cytosol	O
,	O
increased	O
the	O
amount	O
of	O
detectable	O
membrane	O
-	O
associated	O
Rap1	O
.	O

Studies	O
in	O
intact	O
beta	O
TC	O
cells	O
demonstrated	O
the	O
carboxylmethylation	O
of	O
the	O
23	O
-	O
kDa	O
protein	O
in	O
response	O
to	O
glucose	O
and	O
depolarizing	O
concentrations	O
of	O
potassium	O
,	O
an	O
effect	O
that	O
was	O
abolished	O
by	O
the	O
calcium	O
channel	O
inhibitor	O
,	O
D600	O
.	O

Similarly	O
,	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
trans	O
,	O
trans	O
-	O
farnesyl	O
-	O
L	O
-	O
cysteine	O
,	O
an	O
inhibitor	O
of	O
in	O
vivo	O
carboxylmethylation	O
at	O
COOH	O
-	O
terminal	O
S	O
-	O
farnesylcysteine	O
by	O
methyltransferase	O
,	O
inhibited	O
carboxylmethylation	O
of	O
the	O
23	O
-	O
kDa	O
protein	O
in	O
intact	O
cells	O
and	O
reduced	O
insulin	B-Protein
secretion	O
in	O
response	O
to	O
glucose	O
and	O
potassium	O
.	O

These	O
data	O
establish	O
a	O
correlation	O
between	O
insulin	B-Protein
secretion	O
and	O
carboxylmethylation	O
of	O
a	O
23	O
-	O
kDa	O
protein	O
that	O
comigrates	O
with	O
Rap1	O
.	O

The	O
effects	O
of	O
O	O
-	O
and	O
N	O
-	O
linked	O
glycosylation	O
on	O
the	O
secretion	O
and	O
bile	O
salt	O
-	O
stimulation	O
of	O
pancreatic	O
carboxyl	B-Protein
ester	I-Protein
lipase	I-Protein
activity	O
.	O

Pancreatic	O
carboxyl	B-Protein
ester	I-Protein
lipase	I-Protein
is	O
a	O
glycoprotein	O
that	O
requires	O
millimolar	O
concentrations	O
of	O
trihydroxy	O
bile	O
salts	O
,	O
such	O
as	O
cholate	O
,	O
for	O
maximal	O
catalytic	O
activity	O
against	O
cholesteryl	O
esters	O
and	O
triglycerides	O
.	O

Binding	O
of	O
cholate	O
,	O
with	O
subsequent	O
activation	O
,	O
has	O
been	O
proposed	O
to	O
occur	O
in	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
carboxyl	B-Protein
ester	I-Protein
lipase	I-Protein
,	O
which	O
contains	O
multiple	O
sites	O
for	O
O	O
-	O
linked	O
glycosylation	O
(	O
1	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
O	O
-	O
and	O
N	O
-	O
linked	O
glycosylation	O
in	O
the	O
secretion	O
of	O
carboxyl	B-Protein
ester	I-Protein
lipase	I-Protein
by	O
cells	O
and	O
its	O
activation	O
by	O
cholate	O
,	O
rat	O
carboxyl	B-Protein
ester	I-Protein
lipase	I-Protein
cDNA	O
was	O
transfected	O
into	O
the	O
mutant	O
chinese	O
hamster	O
ovary	O
cell	O
line	O
,	O
IdID	O
,	O
and	O
the	O
ability	O
of	O
the	O
cells	O
to	O
modify	O
the	O
expressed	O
carboxyl	B-Protein
ester	I-Protein
lipase	I-Protein
by	O
N	O
-	O
and	O
O	O
-	O
linked	O
glycosylation	O
was	O
modulated	O
by	O
using	O
various	O
incubation	O
conditions	O
and	O
metabolic	O
inhibitors	O
.	O

The	O
results	O
showed	O
that	O
,	O
similar	O
to	O
other	O
lipases	O
,	O
maximal	O
secretion	O
of	O
carboxyl	B-Protein
ester	I-Protein
lipase	I-Protein
activity	O
required	O
N	O
-	O
linked	O
glycosylation	O
.	O

In	O
contrast	O
,	O
O	O
-	O
linked	O
glycosylation	O
did	O
not	O
affect	O
the	O
secretion	O
of	O
carboxyl	B-Protein
ester	I-Protein
lipase	I-Protein
activity	O
.	O

In	O
addition	O
,	O
the	O
cholate	O
stimulation	O
of	O
hydrolysis	O
was	O
also	O
independent	O
of	O
O	O
-	O
linked	O
glycosylation	O
.	O

Altered	O
glycosylation	O
and	O
selected	O
mutation	O
in	O
recombinant	O
human	O
complement	B-Protein
component	I-Protein
C9	I-Protein
:	O
effects	O
on	O
haemolytic	O
activity	O
.	O

Recombinant	O
wild	O
-	O
type	O
and	O
mutated	O
forms	O
of	O
human	O
complement	B-Protein
component	I-Protein
C9	I-Protein
have	O
been	O
synthesized	O
in	O
baculovirus	O
-	O
infected	O
insect	O
cells	O
.	O

Wild	O
-	O
type	O
recombinant	O
C9	B-Protein
was	O
indistinguishable	O
from	O
native	O
C9	B-Protein
,	O
as	O
judged	O
by	O
haemolytic	O
activity	O
,	O
trypsin	O
and	O
alpha	B-Protein
-	I-Protein
thrombin	I-Protein
digestion	O
,	O
reaction	O
with	O
antibodies	O
to	O
C9	B-Protein
,	O
enzymatic	O
deglycosylation	O
to	O
the	O
same	O
core	O
size	O
and	O
polymerization	O
in	O
the	O
presence	O
of	O
Zn2	O
+	O
.	O

Replacement	O
of	O
the	O
native	O
signal	O
peptide	O
with	O
the	O
honey	O
-	O
bee	O
melittin	B-Protein
signal	O
peptide	O
,	O
and	O
replacement	O
of	O
Spodoptera	O
frugiperda	O
(	O
Sf9	O
)	O
cells	O
with	O
Trichoplusia	O
ni	O
cells	O
produced	O
yields	O
of	O
5	O
micrograms	O
C9	B-Protein
/	O
ml	O
supernatant	O
.	O

Three	O
C9	B-Protein
mutants	O
were	O
generated	O
;	O
one	O
mutant	O
,	O
with	O
four	O
acidic	O
residues	O
changed	O
to	O
alanines	O
in	O
a	O
putative	O
calcium	O
-	O
binding	O
site	O
,	O
had	O
the	O
same	O
biological	O
activity	O
as	O
recombinant	O
C9	B-Protein
.	O

Another	O
mutant	O
,	O
lacking	O
23	O
N	O
-	O
terminal	O
amino	O
acids	O
,	O
previously	O
showing	O
increased	O
polymerization	O
when	O
produced	O
in	O
vitro	O
,	O
polymerized	O
on	O
secretion	O
,	O
rendering	O
it	O
inactive	O
.	O

It	O
was	O
not	O
possible	O
to	O
demonstrate	O
haemolytic	O
activity	O
of	O
the	O
third	O
mutant	O
,	O
cysteines	O
33	O
and	O
36	O
mutated	O
to	O
alanine	O
,	O
as	O
it	O
was	O
secreted	O
a	O
hundredfold	O
less	O
than	O
the	O
wild	O
-	O
type	O
protein	O
.	O

Dual	O
activity	O
of	O
human	O
pituitary	O
thyrotrophin	O
isoforms	O
on	O
thyroid	O
cell	O
growth	O
.	O

Alkaline	O
(	O
pI	O
8	O
.	O
6	O
-	O
7	O
.	O
5	O
)	O
and	O
neutral	O
(	O
pI	O
7	O
.	O
0	O
-	O
6	O
.	O
0	O
)	O
isoforms	O
of	O
human	O
TSH	O
have	O
been	O
isolated	O
from	O
a	O
highly	O
purified	O
intrapituitary	O
preparation	O
by	O
isoelectric	O
focusing	O
and	O
compared	O
for	O
their	O
respective	O
actions	O
on	O
thyroid	O
cell	O
proliferation	O
.	O

Both	O
TSH	O
isoforms	O
displayed	O
the	O
same	O
ability	O
to	O
bind	O
to	O
porcine	O
thyroid	O
membranes	O
as	O
the	O
original	O
hormone	O
preparation	O
,	O
indicating	O
a	O
similar	O
recognition	O
at	O
the	O
receptor	O
sites	O
.	O

Alkaline	O
forms	O
showed	O
a	O
higher	O
potency	O
in	O
inducing	O
either	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
production	O
or	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
in	O
FRTL	O
-	O
5	O
cells	O
(	O
half	O
-	O
maximal	O
effective	O
doses	O
(	O
ED50	O
values	O
)	O
=	O
0	O
.	O
25	O
and	O
0	O
.	O
29	O
nM	O
respectively	O
)	O
compared	O
with	O
their	O
neutral	O
counterparts	O
(	O
ED50	O
values	O
=	O
0	O
.	O
66	O
and	O
0	O
.	O
70	O
nM	O
respectively	O
)	O
.	O

Increasing	O
the	O
concentration	O
of	O
alkaline	O
forms	O
in	O
the	O
presence	O
of	O
a	O
half	O
-	O
maximal	O
concentration	O
of	O
neutral	O
TSH	O
resulted	O
in	O
a	O
profound	O
inhibition	O
of	O
cell	O
growth	O
without	O
a	O
significant	O
change	O
in	O
cAMP	O
.	O

Conversely	O
,	O
increasing	O
the	O
amount	O
of	O
neutral	O
forms	O
in	O
the	O
presence	O
of	O
a	O
half	O
-	O
maximal	O
dose	O
of	O
alkaline	O
TSH	O
resulted	O
in	O
an	O
additive	O
response	O
for	O
cAMP	O
production	O
but	O
not	O
in	O
cell	O
proliferation	O
.	O

To	O
assess	O
whether	O
glycosylation	O
might	O
be	O
responsible	O
for	O
the	O
variation	O
in	O
hormone	O
action	O
,	O
both	O
alkaline	O
and	O
neutral	O
TSH	O
isoforms	O
were	O
tested	O
for	O
recognition	O
of	O
their	O
carbohydrate	O
chains	O
by	O
concanavalin	B-Protein
A	I-Protein
(	O
Con	B-Protein
A	I-Protein
)	O
and	O
ricin	O
.	O

No	O
major	O
difference	O
was	O
found	O
in	O
binding	O
to	O
Con	B-Protein
A	I-Protein
,	O
indicating	O
that	O
the	O
contribution	O
of	O
carbohydrates	O
to	O
changes	O
in	O
hormone	O
pI	O
was	O
not	O
related	O
to	O
core	O
branching	O
.	O

Very	O
few	O
galactose	O
residues	O
were	O
accessible	O
in	O
either	O
hormone	O
fraction	O
since	O
little	O
binding	O
to	O
ricin	O
was	O
observed	O
.	O

Isoelectric	O
focusing	O
of	O
TSH	O
forms	O
before	O
and	O
after	O
neuraminidase	O
treatment	O
revealed	O
that	O
neutral	O
forms	O
had	O
a	O
higher	O
sialic	O
acid	O
content	O
than	O
alkaline	O
TSH	O
.	O

In	O
conclusion	O
,	O
the	O
current	O
findings	O
show	O
that	O
TSH	O
isoforms	O
differentially	O
affect	O
cAMP	O
production	O
and	O
cell	O
growth	O
.	O

TSH	O
fractions	O
with	O
a	O
high	O
sialic	O
acid	O
content	O
and	O
a	O
low	O
mitogenic	O
activity	O
behave	O
as	O
antagonists	O
to	O
the	O
more	O
active	O
forms	O
for	O
cell	O
proliferation	O
.	O

It	O
is	O
suggested	O
that	O
physiological	O
control	O
of	O
TSH	O
action	O
at	O
the	O
thyroid	O
gland	O
may	O
reside	O
in	O
the	O
respective	O
amounts	O
of	O
various	O
TSH	O
forms	O
which	O
,	O
once	O
bound	O
to	O
their	O
receptor	O
,	O
can	O
induce	O
variable	O
activation	O
of	O
post	O
-	O
receptor	O
events	O
while	O
controlling	O
cell	O
proliferation	O
.	O

Studies	O
on	O
the	O
structure	O
and	O
function	O
of	O
glycosylated	O
and	O
nonglycosylated	O
neu	B-Protein
differentiation	I-Protein
factors	I-Protein
.	O

Similarities	O
and	O
differences	O
of	O
the	O
alpha	O
and	O
beta	O
isoforms	O
.	O

Comparative	O
analyses	O
of	O
both	O
glycosylated	O
and	O
nonglycosylated	O
neu	B-Protein
differentiation	I-Protein
factor	I-Protein
(	O
NDF	B-Protein
)	O
isoforms	O
revealed	O
significant	O
similarities	O
and	O
differences	O
of	O
their	O
overall	O
structures	O
and	O
functions	O
.	O

Biophysical	O
analyses	O
confirmed	O
that	O
all	O
NDF	B-Protein
isoforms	O
are	O
monomeric	O
,	O
but	O
have	O
an	O
extended	O
ellipsoidal	O
shape	O
in	O
solution	O
.	O

All	O
full	O
-	O
length	O
NDFs	B-Protein
are	O
similar	O
in	O
secondary	O
and	O
tertiary	O
structures	O
and	O
they	O
contain	O
no	O
alpha	O
-	O
helix	O
but	O
are	O
abundant	O
in	O
beta	O
-	O
strand	O
structures	O
.	O

A	O
small	O
NDF	B-Protein
fragment	O
containing	O
only	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
domain	O
is	O
also	O
rich	O
in	O
beta	O
-	O
strand	O
structures	O
,	O
but	O
exhibits	O
tertiary	O
structure	O
different	O
from	O
the	O
long	O
NDF	O
forms	O
.	O

Monoclonal	O
antibodies	O
that	O
selectively	O
recognize	O
epidermal	O
growth	O
factor	O
domains	O
of	O
human	O
NDF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
-	B-Protein
beta	I-Protein
can	O
specifically	O
bind	O
the	O
respective	O
NDF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
-	B-Protein
beta	I-Protein
isoforms	O
independent	O
of	O
NDF	B-Protein
origins	O
.	O

Western	O
blot	O
analysis	O
and	O
quantitative	O
binding	O
assays	O
further	O
identify	O
that	O
an	O
NDF	B-Protein
preparation	O
produced	O
naturally	O
from	O
Rat1	O
-	O
EJ	O
cells	O
contains	O
both	O
alpha	O
and	O
beta	O
isoforms	O
in	O
a	O
3	O
to	O
2	O
ratio	O
.	O

In	O
receptor	O
-	O
binding	O
competition	O
experiments	O
,	O
human	O
and	O
rat	O
NDF	B-Protein
-	I-Protein
beta	I-Protein
isoforms	O
have	O
higher	O
affinity	O
than	O
NDF	B-Protein
-	I-Protein
alpha	I-Protein
isoforms	O
.	O

NDF	B-Protein
-	I-Protein
beta	I-Protein
isoforms	O
can	O
dramatically	O
enhance	O
the	O
stimulation	O
of	O
DNA	O
synthesis	O
for	O
transfected	O
NIH3T3	O
cells	O
that	O
overexpress	O
HER	B-Protein
-	I-Protein
3	I-Protein
and	O
HER	B-Protein
-	I-Protein
4	I-Protein
receptors	O
,	O
while	O
NDF	B-Protein
-	I-Protein
alpha	I-Protein
isoforms	O
can	O
only	O
stimulate	O
proliferation	O
of	O
HER	B-Protein
-	I-Protein
4	I-Protein
-	O
transfected	O
cells	O
with	O
lower	O
activity	O
.	O

Taken	O
together	O
,	O
NDF	B-Protein
-	I-Protein
alpha	I-Protein
and	O
-	B-Protein
beta	I-Protein
isoforms	O
share	O
similar	O
gross	O
protein	O
conformations	O
but	O
are	O
biologically	O
distinct	O
.	O

Activation	O
-	O
dependent	O
carboxyl	O
methylation	O
of	O
neutrophil	O
G	O
-	O
protein	O
gamma	O
subunit	O
.	O

The	O
gamma	O
subunits	O
of	O
heterotrimeric	O
guanine	O
nucleotide	O
-	O
binding	O
regulatory	O
(	O
G	O
)	O
proteins	O
(	O
G	O
gamma	O
)	O
are	O
post	O
-	O
translationally	O
processed	O
at	O
their	O
C	O
termini	O
by	O
prenylation	O
,	O
proteolysis	O
,	O
and	O
carboxyl	O
methylation	O
.	O

Whereas	O
prenylation	O
of	O
G	O
gamma	O
is	O
required	O
for	O
membrane	O
association	O
of	O
G	O
proteins	O
,	O
the	O
role	O
of	O
carboxyl	O
methylation	O
is	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
human	O
neutrophils	O
express	O
G	B-Protein
gamma	I-Protein
2	I-Protein
but	O
not	O
G	B-Protein
gamma	I-Protein
3	I-Protein
or	O
G	B-Protein
gamma	I-Protein
7	I-Protein
and	O
that	O
carboxyl	O
methylation	O
of	O
G	B-Protein
gamma	I-Protein
2	I-Protein
is	O
associated	O
with	O
signal	O
transduction	O
.	O

In	O
a	O
reconstituted	O
cell	O
-	O
free	O
system	O
,	O
neutrophil	O
G	B-Protein
gamma	I-Protein
2	I-Protein
was	O
labeled	O
by	O
the	O
methyl	O
donor	O
S	O
-	O
[	O
methyl	O
-	O
3H	O
]	O
adenosyl	O
-	O
L	O
-	O
methionine	O
.	O

Carboxyl	O
methylation	O
was	O
confirmed	O
by	O
alkaline	O
hydrolysis	O
and	O
quantitation	O
of	O
volatile	O
[	O
3H	O
]	O
methanol	O
.	O

Neutrophil	O
G	B-Protein
gamma	I-Protein
2	I-Protein
methylation	O
was	O
stimulated	O
by	O
activation	O
of	O
G	O
protein	O
with	O
guanosine	O
5	O
'	O
-	O
[	O
beta	O
,	O
gamma	O
-	O
thio	O
]	O
triphosphate	O
.	O

We	O
estimate	O
that	O
after	O
1	O
hr	O
of	O
G	O
-	O
protein	O
activation	O
at	O
least	O
6	O
%	O
of	O
the	O
total	O
pool	O
of	O
G	B-Protein
gamma	I-Protein
2	I-Protein
was	O
carboxyl	O
-	O
methylated	O
.	O

The	O
inflammatory	O
agonist	O
fMet	O
-	O
Leu	O
-	O
Phe	O
stimulated	O
guanosine	O
5	O
'	O
-	O
[	O
beta	O
,	O
gamma	O
-	O
thio	O
]	O
triphosphate	O
-	O
dependent	O
carboxyl	O
methylation	O
.	O

Methylation	O
of	O
G	B-Protein
gamma	I-Protein
2	I-Protein
was	O
inhibited	O
by	O
the	O
carboxyl	O
methyltransferase	O
inhibitor	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
trans	O
,	O
trans	O
-	O
farnesylcysteine	O
at	O
concentrations	O
that	O
affected	O
signal	O
transduction	O
in	O
neutrophils	O
.	O

These	O
results	O
demonstrate	O
that	O
activation	O
of	O
neutrophil	O
Gi	O
is	O
associated	O
with	O
alpha	O
-	O
carboxyl	O
methyl	O
esterification	O
of	O
G	B-Protein
gamma	I-Protein
2	I-Protein
and	O
suggest	O
that	O
carboxyl	O
methylation	O
of	O
G	O
gamma	O
may	O
play	O
a	O
role	O
in	O
signal	O
transduction	O
.	O

Mouse	O
mammary	O
tumors	O
express	O
elevated	O
levels	O
of	O
RNA	O
encoding	O
the	O
murine	O
homology	O
of	O
SKY	B-Protein
,	O
a	O
putative	O
receptor	O
tyrosine	O
kinase	O
.	O

To	O
gain	O
insight	O
into	O
the	O
signal	O
transduction	O
pathways	O
utilized	O
by	O
the	O
Wnt	B-Protein
-	I-Protein
1	I-Protein
-	O
responsive	O
mammary	O
epithelial	O
cell	O
line	O
C57MG	O
,	O
we	O
screened	O
for	O
non	O
-	O
src	O
family	O
member	O
tyrosine	O
kinases	O
expressed	O
in	O
these	O
cells	O
using	O
a	O
polymerase	O
chain	O
reaction	O
-	O
based	O
technique	O
.	O

We	O
identified	O
five	O
cDNA	O
clones	O
encoding	O
receptor	O
tyrosine	O
kinases	O
for	O
which	O
the	O
ligand	O
is	O
known	O
(	O
fibroblast	O
growth	O
factor	O
receptor	O
,	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
,	O
epithelial	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
,	O
insulin	B-Protein
receptor	I-Protein
,	O
and	O
insulin	B-Protein
-	I-Protein
like	I-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
)	O
,	O
two	O
putative	O
receptor	O
tyrosine	O
kinases	O
for	O
which	O
the	O
ligand	O
remains	O
to	O
be	O
identified	O
(	O
the	O
products	O
of	O
ryk	B-Protein
and	O
the	O
mouse	O
klg	B-Protein
homolog	O
)	O
,	O
and	O
a	O
novel	O
tyrosine	O
kinase	O
.	O

We	O
cloned	O
cDNAs	O
encoding	O
both	O
the	O
murine	O
and	O
human	O
homologs	O
of	O
this	O
kinase	O
,	O
the	O
sequences	O
of	O
which	O
were	O
subsequently	O
published	O
under	O
the	O
names	O
sky	B-Protein
(	O
Ohashi	O
,	O
K	O
.	O
,	O
Mizuno	O
,	O
K	O
.	O
,	O
Kuma	O
,	O
K	O
.	O
,	O
Miyata	O
,	O
T	O
.	O
,	O
and	O
Nakamura	O
,	O
T	O
.	O
(	O
1994	O
)	O
Oncogene	O
9	O
,	O
699	O
-	O
705	O
)	O
and	O
rse	O
(	O
Mark	O
,	O
M	O
.	O
R	O
.	O
,	O
Scadden	O
,	O
D	O
.	O
T	O
.	O
,	O
Wang	O
,	O
Z	O
.	O
,	O
Gu	O
,	O
Q	O
.	O
,	O
Goddard	O
,	O
A	O
.	O
,	O
and	O
Godowski	O
,	O
P	O
.	O
J	O
.	O
(	O
1994	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
269	O
,	O
10720	O
-	O
10728	O
)	O
.	O

Mouse	O
sky	B-Protein
RNA	O
levels	O
are	O
abundant	O
in	O
mammary	O
tumors	O
derived	O
from	O
transgenic	O
mice	O
that	O
express	O
wnt	B-Protein
-	I-Protein
1	I-Protein
,	O
fgf	B-Protein
-	I-Protein
3	I-Protein
,	O
or	O
both	O
oncogenes	O
in	O
their	O
mammary	O
glands	O
.	O

However	O
,	O
little	O
or	O
no	O
expression	O
of	O
sky	B-Protein
is	O
detected	O
in	O
mammary	O
glands	O
from	O
virgin	O
animals	O
or	O
in	O
preneoplastic	O
mammary	O
glands	O
from	O
wnt	B-Protein
-	I-Protein
1	I-Protein
transgenic	O
mice	O
.	O

Moreover	O
,	O
we	O
find	O
that	O
the	O
human	O
homolog	O
of	O
sky	B-Protein
is	O
expressed	O
at	O
elevated	O
levels	O
when	O
normal	O
human	O
mammary	O
epithelial	O
cells	O
are	O
rendered	O
tumorigenic	O
by	O
the	O
introduction	O
of	O
two	O
viral	O
oncogenes	O
.	O

Transient	O
transfection	O
of	O
the	O
human	O
SKY	B-Protein
cDNA	O
into	O
the	O
quail	O
fibrosarcoma	O
cell	O
line	O
QT6	O
reveals	O
that	O
SKY	B-Protein
is	O
an	O
active	O
tyrosine	O
kinase	O
that	O
augments	O
the	O
level	O
of	O
cellular	O
phosphotyrosine	O
.	O

Introduction	O
of	O
murine	O
Sky	B-Protein
into	O
RatB1a	O
fibroblasts	O
by	O
retrovirus	O
-	O
mediated	O
gene	O
transfer	O
results	O
in	O
morphological	O
transformation	O
,	O
growth	O
in	O
soft	O
agar	O
,	O
and	O
the	O
formation	O
of	O
tumors	O
in	O
nude	O
mice	O
.	O

These	O
data	O
raise	O
the	O
possibility	O
that	O
the	O
Sky	B-Protein
tyrosine	O
kinase	O
is	O
involved	O
in	O
the	O
development	O
and	O
/	O
or	O
progression	O
of	O
mammary	O
tumors	O
.	O

Glycosylation	O
sites	O
selectively	O
interfere	O
with	O
alpha	B-Protein
-	I-Protein
toxin	I-Protein
binding	O
to	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
.	O

Sequence	O
analysis	O
reveals	O
unique	O
features	O
in	O
the	O
alpha	O
-	O
subunit	O
of	O
nicotinic	O
acetylcholine	O
receptors	O
from	O
the	O
alpha	B-Protein
-	I-Protein
toxin	I-Protein
-	O
resistant	O
cobra	O
and	O
mongoose	O
.	O

Included	O
are	O
N	O
-	O
linked	O
glycosylation	O
signals	O
just	O
amino	O
-	O
terminal	O
to	O
the	O
Tyr190	O
,	O
Cys192	O
-	O
Cys193	O
region	O
of	O
the	O
ligand	O
binding	O
domain	O
,	O
substitution	O
of	O
Trp187	O
and	O
Phe189	O
by	O
non	O
-	O
aromatic	O
residues	O
and	O
alteration	O
of	O
the	O
proline	O
sequence	O
Pro194	O
-	O
X	O
-	O
X	O
-	O
Pro197	O
.	O

Glycosylation	O
signals	O
were	O
inserted	O
into	O
the	O
toxin	O
-	O
sensitive	O
mouse	O
alpha	O
-	O
subunit	O
by	O
the	O
mutations	O
F189N	O
and	O
W187N	O
/	O
F189T	O
.	O

The	O
F189N	O
alpha	O
-	O
subunit	O
,	O
when	O
transfected	O
with	O
beta	O
,	O
gamma	O
and	O
delta	O
,	O
showed	O
a	O
140	O
-	O
fold	O
loss	O
of	O
alpha	O
-	O
bungarotoxin	O
affinity	O
,	O
whereas	O
the	O
W187N	O
/	O
F189T	O
double	O
mutation	O
exhibited	O
a	O
divergence	O
in	O
alpha	B-Protein
-	I-Protein
toxin	I-Protein
affinities	O
at	O
the	O
two	O
sites	O
,	O
one	O
class	O
showing	O
a	O
600	O
-	O
fold	O
and	O
the	O
other	O
showing	O
an	O
11	O
-	O
fold	O
reduction	O
.	O

The	O
W187N	O
mutant	O
and	O
the	O
double	O
mutant	O
F189N	O
/	O
S191A	O
lacking	O
the	O
requisite	O
glycosylation	O
signals	O
exhibited	O
little	O
alteration	O
in	O
affinity	O
,	O
as	O
did	O
the	O
P194L	O
and	O
P197H	O
mutations	O
.	O

The	O
glycosylation	O
sites	O
had	O
little	O
or	O
no	O
influence	O
on	O
binding	O
of	O
toxins	O
of	O
intermediate	O
(	O
alpha	O
-	O
conotoxin	O
,	O
1500	O
Da	O
)	O
or	O
small	O
mass	O
(	O
lophotoxin	O
,	O
500	O
Da	O
)	O
and	O
of	O
the	O
agonist	O
,	O
carbamylcholine	O
.	O

The	O
two	O
sites	O
for	O
the	O
binding	O
of	O
alpha	B-Protein
-	I-Protein
conotoxin	I-Protein
M1	I-Protein
have	O
widely	O
divergent	O
dissociation	O
constants	O
of	O
2	O
.	O
1	O
and	O
14	O
,	O
800	O
nM	O
.	O

Expression	O
of	O
alpha	O
/	O
gamma	O
-	O
and	O
alpha	O
/	O
delta	O
-	O
subunit	O
pairs	O
indicated	O
that	O
the	O
high	O
and	O
low	O
affinity	O
sites	O
are	O
formed	O
by	O
the	O
alpha	O
/	O
delta	O
and	O
alpha	O
/	O
gamma	O
contacts	O
,	O
respectively	O
.	O

Gene	O
dissection	O
demonstrates	O
that	O
the	O
Escherichia	O
coli	O
cysG	B-Protein
gene	O
encodes	O
a	O
multifunctional	O
protein	O
.	O

The	O
C	O
-	O
terminus	O
of	O
the	O
Escherichia	O
coli	O
CysG	B-Protein
protein	O
,	O
consisting	O
of	O
amino	O
acids	O
202	O
-	O
457	O
,	O
was	O
expressed	O
as	O
a	O
recombinant	O
protein	O
using	O
gene	O
dissection	O
methodology	O
.	O

Analysis	O
of	O
the	O
activity	O
of	O
this	O
truncated	O
protein	O
,	O
termed	O
CysGA	B-Protein
,	O
revealed	O
that	O
it	O
was	O
able	O
to	O
methylate	O
uroporphyrinogen	O
III	O
in	O
the	O
same	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
(	O
SAM	O
)	O
-	O
dependent	O
manner	O
as	O
the	O
complete	O
CysG	B-Protein
protein	O
.	O

However	O
,	O
this	O
truncated	O
protein	O
was	O
not	O
able	O
to	O
complement	O
E	O
.	O
coli	O
cysG	B-Protein
cells	O
,	O
thereby	O
suggesting	O
that	O
the	O
first	O
201	O
amino	O
acids	O
of	O
the	O
CysG	B-Protein
protein	O
had	O
an	O
enzymic	O
activity	O
associated	O
with	O
the	O
conversion	O
of	O
dihydrosirohydrochlorin	O
into	O
sirohaem	O
.	O

Analysis	O
of	O
the	O
N	O
-	O
terminus	O
of	O
the	O
CysG	B-Protein
protein	O
revealed	O
the	O
presence	O
of	O
a	O
putative	O
pyridine	O
dinucleotide	O
binding	O
site	O
.	O

When	O
the	O
purified	O
CysG	B-Protein
protein	O
was	O
incubated	O
with	O
NADP	O
+	O
,	O
uroporphyrinogen	O
III	O
and	O
SAM	O
the	O
enzyme	O
was	O
found	O
to	O
catalyse	O
a	O
coenzyme	O
-	O
mediated	O
dehydrogenation	O
to	O
form	O
sirohydrochlorin	O
.	O

The	O
CysGA	B-Protein
protein	O
on	O
the	O
other	O
hand	O
showed	O
no	O
such	O
coenzyme	O
-	O
dependent	O
activity	O
.	O

Analysis	O
of	O
the	O
porphyrinoid	O
material	O
isolated	O
from	O
strains	O
harbouring	O
plasmids	O
containing	O
the	O
complete	O
and	O
truncated	O
cysG	B-Protein
genes	O
suggested	O
that	O
the	O
CysG	B-Protein
protein	O
was	O
also	O
involved	O
in	O
ferrochelation	O
.	O

The	O
evidence	O
presented	O
in	O
this	O
paper	O
suggests	O
that	O
the	O
CysG	B-Protein
protein	O
is	O
a	O
multifunctional	O
protein	O
involved	O
in	O
SAM	O
-	O
dependent	O
methylation	O
,	O
pyridine	O
dinucleotide	O
dependent	O
dehydrogenation	O
and	O
ferrochelation	O
.	O

The	O
primate	O
placenta	O
and	O
human	O
chorionic	O
gonadotropin	O
.	O

In	O
the	O
primate	O
placenta	O
various	O
peptide	O
and	O
proteohormones	O
are	O
synthesized	O
which	O
control	O
growth	O
and	O
development	O
of	O
the	O
fetus	O
as	O
well	O
as	O
the	O
exchange	O
of	O
nutrients	O
and	O
metabolic	O
products	O
between	O
the	O
mother	O
and	O
the	O
fetus	O
.	O

In	O
humans	O
,	O
maintenance	O
of	O
pregnancy	O
in	O
the	O
first	O
trimester	O
depends	O
on	O
the	O
synthesis	O
of	O
the	O
bioactive	O
glycoprotein	O
hormone	O
human	O
chorionic	O
gonadotropin	O
(	O
hCG	O
)	O
.	O

It	O
is	O
expressed	O
in	O
placenta	O
by	O
the	O
syncytiothrophoblast	O
of	O
early	O
pregnancy	O
.	O

In	O
cell	O
culture	O
,	O
hCG	O
production	O
seems	O
to	O
mark	O
a	O
certain	O
step	O
in	O
the	O
process	O
of	O
differentiation	O
of	O
cytotrophoblasts	O
and	O
choriocarcinoma	O
cells	O
.	O

It	O
is	O
neither	O
understood	O
how	O
hCG	O
synthesis	O
is	O
initiated	O
and	O
maintained	O
at	O
the	O
beginning	O
of	O
gestation	O
nor	O
what	O
control	O
mechanisms	O
are	O
responsible	O
for	O
the	O
down	O
-	O
regulation	O
of	O
the	O
synthesis	O
at	O
the	O
end	O
of	O
the	O
first	O
trimester	O
.	O

Besides	O
a	O
long	O
list	O
of	O
various	O
other	O
substances	O
which	O
have	O
been	O
described	O
to	O
act	O
as	O
intrinsic	O
placental	O
stimulators	O
of	O
hCG	O
biosynthesis	O
,	O
gonadoliberin	O
and	O
gamma	O
-	O
aminobutyric	O
acid	O
seem	O
to	O
play	O
an	O
important	O
role	O
.	O

This	O
establishes	O
to	O
some	O
extent	O
an	O
analogy	O
to	O
the	O
regulation	O
of	O
gonadotropin	O
synthesis	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Recently	O
,	O
a	O
full	O
-	O
length	O
form	O
of	O
functional	O
LH	B-Protein
/	I-Protein
hCG	I-Protein
receptors	I-Protein
of	O
approximately	O
80	O
kD	O
has	O
been	O
found	O
in	O
term	O
placenta	O
suggesting	O
autoregulation	O
as	O
a	O
regulatory	O
principle	O
of	O
hCG	O
biosynthesis	O
.	O

In	O
the	O
first	O
trimester	O
placenta	O
as	O
well	O
as	O
in	O
choriocarcinoma	O
cells	O
a	O
truncated	O
form	O
(	O
50	O
kd	O
)	O
of	O
LH	B-Protein
/	I-Protein
hCG	I-Protein
receptors	I-Protein
seems	O
to	O
exist	O
.	O

In	O
these	O
cases	O
,	O
exogenous	O
hCG	O
was	O
unable	O
to	O
down	O
-	O
regulate	O
its	O
own	O
synthesis	O
.	O

The	O
carbohydrate	O
moiety	O
of	O
hCG	O
influences	O
folding	O
,	O
subunit	O
assembly	O
,	O
circulatory	O
half	O
-	O
life	O
,	O
receptor	O
interaction	O
and	O
biological	O
response	O
.	O

A	O
surplus	O
of	O
glycosylation	O
may	O
prevent	O
subunit	O
assembly	O
.	O

Experimental	O
deglycosylation	O
induces	O
a	O
different	O
conformation	O
of	O
hCG	O
,	O
which	O
partly	O
acquires	O
antagonistic	O
properties	O
.	O

Recent	O
results	O
indicate	O
that	O
cAMP	O
,	O
which	O
increases	O
transcription	O
and	O
mRNA	O
stability	O
,	O
also	O
expands	O
the	O
N	O
-	O
glycosylation	O
capacity	O
and	O
thus	O
may	O
accomplish	O
an	O
over	O
-	O
all	O
coordination	O
of	O
hCG	O
biosynthesis	O
including	O
post	O
-	O
translational	O
events	O
.	O

Characterization	O
of	O
the	O
prenylated	B-Protein
protein	I-Protein
methyltransferase	I-Protein
in	O
human	O
endometrial	O
carcinoma	O
.	O

The	O
processing	O
of	O
ras	O
and	O
of	O
other	O
GTP	O
-	O
binding	O
proteins	O
includes	O
a	O
final	O
reversible	O
step	O
in	O
which	O
the	O
carboxy	O
terminal	O
prenylated	O
cysteine	O
is	O
methylated	O
by	O
the	O
enzyme	O
prenylated	B-Protein
protein	I-Protein
methyltransferase	I-Protein
(	O
PPMTase	B-Protein
)	O
.	O

The	O
significance	O
of	O
this	O
modification	O
and	O
of	O
the	O
role	O
of	O
PPMTase	B-Protein
in	O
human	O
tumors	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O

Here	O
we	O
characterize	O
the	O
PPMTase	B-Protein
of	O
human	O
endometrial	O
carcinomas	O
(	O
tumors	O
in	O
which	O
the	O
frequency	O
of	O
ras	O
gene	O
mutations	O
is	O
relatively	O
high	O
)	O
and	O
compare	O
it	O
to	O
the	O
PPMTase	B-Protein
of	O
the	O
normal	O
endometrium	O
.	O

Our	O
results	O
show	O
that	O
in	O
both	O
types	O
of	O
tissues	O
the	O
enzyme	O
is	O
bound	O
to	O
the	O
membranes	O
.	O

It	O
can	O
utilize	O
synthetic	O
substrates	O
such	O
as	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
farnesyl	O
-	O
L	O
-	O
cysteine	O
(	O
Km	O
=	O
18	O
-	O
20	O
microM	O
)	O
and	O
is	O
blocked	O
by	O
the	O
PPMTase	B-Protein
inhibitor	O
S	O
-	O
farnesylthioacetic	O
acid	O
(	O
Ki	O
=	O
2	O
microM	O
)	O
.	O

In	O
vitro	O
methylation	O
assays	O
and	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
blot	O
-	O
overlay	O
assays	O
showed	O
that	O
the	O
major	O
endogenous	O
PPMTase	B-Protein
substrates	O
are	O
small	O
GTP	O
-	O
binding	O
proteins	O
.	O

Methylation	O
of	O
these	O
proteins	O
in	O
vitro	O
is	O
blocked	O
by	O
farnesylthioacetic	O
acid	O
.	O

The	O
kinetic	O
properties	O
of	O
PPMTase	B-Protein
from	O
the	O
carcinomas	O
and	O
the	O
normal	O
tissues	O
are	O
very	O
similar	O
.	O

However	O
,	O
levels	O
of	O
PPMTase	B-Protein
activity	O
(	O
but	O
not	O
of	O
its	O
endogenous	O
substrates	O
)	O
are	O
higher	O
in	O
the	O
carcinomatous	O
endometrium	O
than	O
in	O
the	O
normal	O
one	O
.	O

The	O
elevated	O
enzyme	O
activity	O
is	O
restricted	O
to	O
the	O
crude	O
mitochondrial	O
fraction	O
(	O
8	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
4	O
vs	O
.	O
5	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
N	O
-	O
acetyl	O
farnesylcysteine	O
methyl	O
ester	O
formed	O
/	O
min	O
/	O
mg	O
protein	O
by	O
the	O
carcinoma	O
and	O
by	O
the	O
normal	O
endometrial	O
preparations	O
,	O
respectively	O
)	O
.	O

As	O
this	O
fraction	O
is	O
enriched	O
in	O
plasma	O
membranes	O
,	O
it	O
appears	O
that	O
the	O
elevated	O
enzyme	O
activity	O
could	O
be	O
related	O
to	O
ras	O
protein	O
methylation	O
;	O
if	O
so	O
,	O
selective	O
methylation	O
blockers	O
might	O
inhibit	O
the	O
growth	O
of	O
endometrial	O
carcinomas	O
.	O

Serum	O
ferritin	O
and	O
isoferritins	O
are	O
tools	O
for	O
diagnosis	O
of	O
active	O
adult	O
Still	O
'	O
s	O
disease	O
.	O

OBJECTIVE	O
:	O
Still	O
'	O
s	O
disease	O
is	O
an	O
acute	O
systemic	O
inflammatory	O
disorder	O
.	O

There	O
are	O
no	O
pathognomonic	O
symptoms	O
or	O
specific	O
laboratory	O
abnormalities	O
.	O

Serum	O
ferritin	O
concentration	O
in	O
rheumatoid	O
arthritis	O
together	O
with	O
some	O
plasma	O
glycoproteins	O
such	O
as	O
alpha	O
2	O
-	O
glycoprotein	O
and	O
C	B-Protein
-	I-Protein
reactive	I-Protein
protein	I-Protein
are	O
part	O
of	O
the	O
response	O
to	O
inflammation	O
.	O

Ferritin	O
in	O
plasma	O
is	O
glycosylated	O
and	O
the	O
sialoglycosylated	O
forms	O
increase	O
its	O
microheterogeneity	O
.	O

Our	O
purpose	O
was	O
to	O
confirm	O
in	O
a	O
large	O
series	O
that	O
high	O
values	O
of	O
ferritin	O
can	O
be	O
found	O
in	O
adult	O
Still	O
'	O
s	O
disease	O
(	O
ASD	O
)	O
and	O
to	O
see	O
if	O
a	O
specific	O
isoferritin	O
can	O
be	O
isolated	O
in	O
this	O
disease	O
compared	O
with	O
the	O
other	O
systemic	O
diseases	O
.	O

METHOD	O
:	O
Thirty	O
-	O
one	O
sera	O
were	O
investigated	O
from	O
11	O
men	O
and	O
9	O
women	O
with	O
ASD	O
and	O
compared	O
with	O
27	O
sera	O
from	O
27	O
patients	O
with	O
systemic	O
diseases	O
.	O

We	O
studied	O
the	O
course	O
of	O
one	O
case	O
of	O
ASD	O
for	O
15	O
months	O
.	O

Serum	O
ferritin	O
was	O
determined	O
by	O
immunoenzymology	O
(	O
Abbott	O
Ferrizin	O
)	O
.	O

The	O
isoferritins	O
were	O
investigated	O
by	O
isoelectric	O
focussing	O
and	O
the	O
percentage	O
of	O
glycosylation	O
by	O
affinity	O
for	O
concanavalin	B-Protein
A	I-Protein
(	O
Con	B-Protein
-	I-Protein
A	I-Protein
)	O
.	O

RESULTS	O
:	O
In	O
patients	O
with	O
active	O
ASD	O
,	O
the	O
ferritin	O
levels	O
were	O
higher	O
than	O
in	O
patients	O
with	O
inactive	O
ASD	O
or	O
other	O
systemic	O
diseases	O
:	O
p	O
<	O
0	O
.	O
001	O
.	O

The	O
glycoforms	O
of	O
ferritin	O
were	O
basic	O
and	O
the	O
proportion	O
of	O
ferritin	O
bound	O
to	O
Con	B-Protein
-	I-Protein
A	I-Protein
was	O
lower	O
than	O
other	O
ASD	O
:	O
p	O
<	O
0	O
.	O
001	O
.	O

CONCLUSIONS	O
:	O
Serum	O
ferritin	O
levels	O
have	O
a	O
diagnostic	O
value	O
for	O
acute	O
ASD	O
.	O

The	O
study	O
of	O
sialylation	O
and	O
abnormalities	O
in	O
the	O
glycosylation	O
of	O
ferritin	O
helps	O
to	O
discriminate	O
ASD	O
from	O
arthritis	O
or	O
other	O
systemic	O
diseases	O
.	O

In	O
conclusion	O
,	O
the	O
glycoform	O
of	O
isoferritins	O
and	O
the	O
percentage	O
of	O
glycosylation	O
offers	O
an	O
additional	O
tool	O
for	O
the	O
diagnosis	O
of	O
Still	O
'	O
s	O
disease	O
.	O

Subcellular	O
localization	O
of	O
the	O
UDP	B-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetyl	I-Protein
-	I-Protein
D	I-Protein
-	I-Protein
galactosamine	I-Protein
:	I-Protein
polypeptide	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminyltransferase	I-Protein
-	O
mediated	O
O	O
-	O
glycosylation	O
reaction	O
in	O
the	O
submaxillary	O
gland	O
.	O

Addition	O
of	O
N	O
-	O
acetylgalactosamine	O
to	O
threonine	O
and	O
serine	O
is	O
the	O
first	O
step	O
in	O
the	O
synthesis	O
of	O
O	O
-	O
glycosidically	O
linked	O
oligosaccharides	O
.	O

A	O
UDP	B-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetyl	I-Protein
-	I-Protein
D	I-Protein
-	I-Protein
galactosamine	I-Protein
:	I-Protein
polypeptide	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminyltransferase	I-Protein
(	O
EC	O
2	O
.	O
4	O
.	O
1	O
.	O
41	O
)	O
from	O
porcine	O
submaxillary	O
glands	O
was	O
recently	O
purified	O
to	O
electrophoretic	O
homogeneity	O
,	O
and	O
polyclonal	O
antibodies	O
against	O
the	O
purified	O
transferase	O
were	O
raised	O
.	O

Immunoblots	O
of	O
porcine	O
,	O
bovine	O
,	O
and	O
ovine	O
submaxillary	O
gland	O
extracts	O
with	O
the	O
anti	O
-	O
transferase	O
antibodies	O
gave	O
a	O
single	O
band	O
and	O
the	O
antibodies	O
reacted	O
equally	O
well	O
with	O
the	O
purified	O
glycosylated	O
and	O
N	O
-	O
glycanase	O
-	O
treated	O
transferase	O
.	O

Immunoelectron	O
microscopic	O
localization	O
of	O
the	O
transferase	O
was	O
achieved	O
in	O
Lowicryl	O
K4M	O
thin	O
sections	O
and	O
frozen	O
-	O
thawed	O
thin	O
sections	O
of	O
porcine	O
and	O
bovine	O
submaxillary	O
gland	O
by	O
using	O
the	O
protein	O
A	O
-	O
gold	O
technique	O
.	O

Specific	O
gold	O
particle	O
labeling	O
was	O
observed	O
in	O
the	O
cis	O
Golgi	O
apparatus	O
and	O
smooth	O
-	O
membraned	O
vesicular	O
structures	O
in	O
close	O
topological	O
relation	O
with	O
it	O
.	O

Labeling	O
was	O
undetectable	O
in	O
the	O
rough	O
endoplasmic	O
reticulum	O
,	O
its	O
transitional	O
elements	O
,	O
and	O
smooth	O
-	O
membraned	O
structures	O
close	O
to	O
them	O
,	O
the	O
trans	O
Golgi	O
apparatus	O
,	O
mucin	O
droplets	O
,	O
and	O
the	O
plasma	O
membrane	O
.	O

The	O
onset	O
of	O
labeling	O
for	O
peptide	O
-	O
bound	O
GalNAc	O
as	O
detected	O
with	O
Vicia	O
villosa	O
isolectin	B-Protein
G4	I-Protein
mirrored	O
the	O
transferase	O
immunolocalization	O
as	O
directly	O
shown	O
by	O
double	O
labeling	O
and	O
extended	O
into	O
the	O
trans	O
Golgi	O
apparatus	O
and	O
mucous	O
droplets	O
.	O

Apomucin	B-Protein
immunolabeling	O
was	O
found	O
throughout	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
intermediate	O
compartment	O
and	O
partially	O
overlapped	O
the	O
region	O
of	O
transferase	O
labeling	O
in	O
the	O
Golgi	O
apparatus	O
as	O
demonstrated	O
by	O
double	O
immunolabeling	O
.	O

Thus	O
,	O
the	O
initial	O
step	O
of	O
UDP	B-Protein
-	I-Protein
GalNAc	I-Protein
:	I-Protein
polypeptide	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminyltransferase	I-Protein
-	O
mediated	O
O	O
-	O
glycosylation	O
in	O
porcine	O
and	O
bovine	O
submaxillary	O
gland	O
cells	O
occurs	O
in	O
the	O
cis	O
Golgi	O
apparatus	O
.	O

The	O
possible	O
involvement	O
of	O
the	O
intermediate	O
compartment	O
remains	O
to	O
be	O
clarified	O
.	O

Sequence	O
-	O
specific	O
methylation	O
inhibits	O
the	O
activity	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
LMP	B-Protein
1	I-Protein
and	O
BCR2	O
enhancer	O
-	O
promoter	O
regions	O
.	O

We	O
reported	O
earlier	O
that	O
variable	O
expression	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
encoded	O
membrane	O
protein	O
LMP	B-Protein
1	I-Protein
in	O
nasopharyngeal	O
carcinoma	O
and	O
the	O
host	O
-	O
cell	O
-	O
phenotype	O
-	O
dependent	O
activity	O
of	O
the	O
BCR2	O
promoter	O
(	O
one	O
of	O
the	O
possible	O
initiator	O
sites	O
for	O
transcripts	O
of	O
Epstein	O
-	O
Barr	O
nuclear	O
antigens	O
)	O
in	O
Burkitt	O
'	O
s	O
lymphoma	O
(	O
BL	O
)	O
lines	O
can	O
be	O
related	O
to	O
the	O
methylation	O
status	O
of	O
the	O
5	O
'	O
-	O
flanking	O
regulatory	O
regions	O
of	O
the	O
BNLF	B-Protein
1	I-Protein
and	O
BCR2	O
promoter	O
,	O
respectively	O
.	O

Here	O
we	O
report	O
that	O
clones	O
of	O
the	O
BL	O
line	O
Mutu	O
that	O
differ	O
in	O
expression	O
of	O
LMP	B-Protein
1	I-Protein
also	O
show	O
a	O
differential	O
methylation	O
pattern	O
of	O
the	O
LMP	B-Protein
1	I-Protein
regulatory	O
sequences	O
:	O
this	O
region	O
is	O
hypomethylated	O
in	O
an	O
LMP	B-Protein
1	I-Protein
expressing	O
(	O
group	O
III	O
)	O
clone	O
but	O
methylated	O
in	O
a	O
group	O
I	O
clone	O
that	O
does	O
not	O
express	O
LMP	B-Protein
1	I-Protein
.	O

We	O
introduced	O
in	O
vitro	O
methylated	O
reporter	O
plasmids	O
carrying	O
BNLF	B-Protein
1	I-Protein
and	O
BCR2	O
enhancer	O
-	O
promoter	O
sequences	O
into	O
the	O
BL	O
line	O
Raji	O
and	O
found	O
that	O
overall	O
methylation	O
of	O
5	O
'	O
-	O
CG	O
-	O
3	O
'	O
sequences	O
by	O
the	O
Spiroplasma	O
methylase	B-Protein
Sssl	I-Protein
significantly	O
reduced	O
their	O
activity	O
compared	O
to	O
unmethylated	O
or	O
mock	O
-	O
methylated	O
controls	O
.	O

Methylation	O
of	O
5	O
-	O
CCGG	O
-	O
3	O
'	O
sequences	O
by	O
Hpall	B-Protein
methyltransferase	I-Protein
gave	O
similar	O
results	O
.	O

On	O
the	O
contrary	O
,	O
methylation	O
of	O
5	O
'	O
GCGC	O
-	O
3	O
'	O
sequences	O
by	O
Hhall	B-Protein
methyltransferase	I-Protein
gave	O
similar	O
results	O
.	O

On	O
the	O
contrary	O
,	O
methylation	O
of	O
5	O
'	O
-	O
GCGC	O
-	O
3	O
'	O
sequences	O
by	O
Hpal	B-Protein
methyltransferase	I-Protein
resulted	O
only	O
in	O
a	O
moderate	O
reduction	O
of	O
BNLF	B-Protein
1	I-Protein
enhancer	O
-	O
promoter	O
activity	O
.	O

These	O
data	O
support	O
the	O
notion	O
that	O
methylation	O
at	O
discrete	O
sites	O
within	O
control	O
regions	O
of	O
latent	O
,	O
growth	O
-	O
transformation	O
associated	O
EBV	O
genes	O
may	O
contribute	O
to	O
silencing	O
their	O
expression	O
.	O

Cotranscription	O
of	O
two	O
genes	O
necessary	O
for	O
ribosomal	B-Protein
protein	I-Protein
L11	I-Protein
methylation	O
(	O
prmA	B-Protein
)	O
and	O
pantothenate	O
transport	O
(	O
panF	B-Protein
)	O
in	O
Escherichia	O
coli	O
K	O
-	O
12	O
.	O

Genetic	O
complementation	O
and	O
enzyme	O
assays	O
have	O
shown	O
that	O
the	O
DNA	O
region	O
between	O
panF	B-Protein
,	O
which	O
encodes	O
pantothenate	B-Protein
permease	I-Protein
,	O
and	O
orf1	O
,	O
the	O
first	O
gene	O
of	O
the	O
fis	O
operon	O
,	O
encodes	O
prmA	B-Protein
,	O
the	O
genetic	O
determinant	O
for	O
the	O
ribosomal	B-Protein
protein	I-Protein
L11	I-Protein
methyltransferase	I-Protein
.	O

Sequencing	O
of	O
this	O
region	O
identified	O
one	O
long	O
open	O
reading	O
frame	O
that	O
encodes	O
a	O
protein	O
of	O
31	O
,	O
830	O
Da	O
and	O
corresponds	O
to	O
the	O
prmA	B-Protein
gene	O
.	O

We	O
found	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
that	O
prmA	B-Protein
is	O
expressed	O
from	O
promoters	O
located	O
upstream	O
of	O
panF	B-Protein
and	O
thus	O
that	O
the	O
panF	B-Protein
and	O
prmA	B-Protein
genes	O
constitute	O
a	O
bifunctional	O
operon	O
.	O

We	O
located	O
the	O
major	O
3	O
'	O
end	O
of	O
prmA	B-Protein
transcripts	O
90	O
nucleotides	O
downstream	O
of	O
the	O
stop	O
codon	O
of	O
prmA	B-Protein
in	O
the	O
DNA	O
region	O
upstream	O
of	O
the	O
fis	O
operon	O
,	O
a	O
region	O
implicated	O
in	O
the	O
control	O
of	O
the	O
expression	O
of	O
the	O
fis	O
operon	O
.	O

Although	O
no	O
promoter	O
activity	O
was	O
detected	O
immediately	O
upstream	O
of	O
prmA	B-Protein
,	O
S1	O
mapping	O
detected	O
5	O
'	O
ends	O
of	O
mRNA	O
in	O
this	O
region	O
,	O
implying	O
that	O
some	O
mRNA	O
processing	O
occurs	O
within	O
the	O
bicistronic	O
panF	B-Protein
-	O
prmA	B-Protein
mRNA	O
.	O

The	O
effect	O
of	O
aspartate	O
hydroxylation	O
on	O
calcium	O
binding	O
to	O
epidermal	O
growth	O
factor	O
-	O
like	O
modules	O
in	O
coagulation	B-Protein
factors	I-Protein
IX	I-Protein
and	O
X	B-Protein
.	O

Hydroxylation	O
of	O
aspartic	O
acid	O
to	O
erythro	O
-	O
beta	O
-	O
aspartic	O
acid	O
(	O
Hya	O
)	O
occurs	O
in	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
-	O
like	O
modules	O
in	O
numerous	O
extracellular	O
proteins	O
with	O
diverse	O
functions	O
.	O

Several	O
EGF	O
-	O
like	O
modules	O
with	O
the	O
consensus	O
sequence	O
for	O
hydroxylation	O
bind	O
Ca2	O
+	O
,	O
and	O
it	O
has	O
therefore	O
been	O
suggested	O
that	O
the	O
hydroxyl	O
group	O
is	O
essential	O
for	O
Ca2	O
+	O
binding	O
.	O

To	O
determine	O
directly	O
the	O
influence	O
of	O
beta	O
-	O
hydroxylation	O
on	O
calcium	O
binding	O
in	O
the	O
EGF	O
-	O
like	O
modules	O
from	O
coagulation	B-Protein
factors	I-Protein
IX	I-Protein
and	O
X	B-Protein
,	O
we	O
have	O
now	O
measured	O
calcium	O
binding	O
to	O
both	O
the	O
fully	O
beta	O
-	O
hydroxylated	O
and	O
the	O
non	O
-	O
beta	O
-	O
hydroxylated	O
modules	O
of	O
the	O
two	O
proteins	O
.	O

At	O
low	O
ionic	O
strength	O
,	O
the	O
Hya	O
-	O
containing	O
module	O
of	O
factor	B-Protein
X	I-Protein
has	O
a	O
slightly	O
higher	O
Ca2	O
+	O
affinity	O
,	O
but	O
at	O
physiological	O
salt	O
concentrations	O
this	O
difference	O
is	O
no	O
longer	O
significant	O
for	O
either	O
factor	B-Protein
IX	I-Protein
or	O
X	B-Protein
.	O

Analysis	O
of	O
the	O
1H	O
NMR	O
chemical	O
shift	O
differences	O
between	O
the	O
hydroxylated	O
and	O
nonhydroxylated	O
factor	B-Protein
X	I-Protein
modules	O
show	O
that	O
hydroxylation	O
has	O
no	O
effect	O
on	O
the	O
domain	O
fold	O
.	O

Furthermore	O
,	O
measurements	O
on	O
factor	B-Protein
IX	I-Protein
show	O
that	O
hydroxylation	O
has	O
no	O
effect	O
on	O
the	O
Ca2	O
+	O
/	O
Mg2	O
+	O
specificity	O
of	O
the	O
ion	O
binding	O
site	O
.	O

We	O
conclude	O
that	O
the	O
hydroxyl	O
group	O
is	O
not	O
a	O
direct	O
ligand	O
for	O
the	O
calcium	O
ion	O
in	O
these	O
EGF	O
-	O
like	O
modules	O
,	O
nor	O
is	O
it	O
essential	O
for	O
high	O
-	O
affinity	O
Ca2	O
+	O
binding	O
.	O

Glycosylation	O
of	O
the	O
thrombin	O
-	O
like	O
serine	O
protease	O
ancrod	B-Protein
from	O
Agkistrodon	O
rhodostoma	O
venom	O
.	O

Oligosaccharide	O
substitution	O
pattern	O
at	O
each	O
N	O
-	O
glycosylation	O
site	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
determined	O
the	O
structures	O
of	O
the	O
glycans	O
present	O
in	O
ancrod	B-Protein
,	O
a	O
thrombin	O
-	O
like	O
serine	O
protease	O
from	O
the	O
venom	O
of	O
the	O
Malayan	O
pit	O
viper	O
Agkistrodon	O
rhodostoma	O
(	O
Pfeiffer	O
et	O
al	O
.	O
(	O
1992	O
)	O
Eur	O
J	O
Biochem	O
205	O
:	O
961	O
-	O
78	O
)	O
.	O

In	O
order	O
to	O
allocate	O
the	O
various	O
carbohydrate	O
chains	O
to	O
distinct	O
N	O
-	O
glycosylation	O
sites	O
of	O
the	O
molecule	O
,	O
we	O
have	O
now	O
isolated	O
individual	O
glycopeptides	O
.	O

Peptide	O
moieties	O
were	O
identified	O
after	O
deglycosylation	O
with	O
peptide	B-Protein
-	I-Protein
N4	I-Protein
-	I-Protein
(	I-Protein
N	I-Protein
-	I-Protein
acetyl	I-Protein
-	I-Protein
beta	I-Protein
-	I-Protein
glucosaminyl	I-Protein
)	I-Protein
asparagine	I-Protein
amidase	I-Protein
F	I-Protein
by	O
amino	O
acid	O
analysis	O
and	O
sequencing	O
.	O

Liberated	O
oligosaccharides	O
were	O
assigned	O
to	O
the	O
previously	O
deduced	O
carbohydrate	O
structures	O
by	O
high	O
performance	O
liquid	O
chromatography	O
.	O

Although	O
only	O
quantitative	O
differences	O
were	O
observed	O
,	O
the	O
results	O
indicate	O
that	O
each	O
glycosylation	O
site	O
of	O
ancrod	B-Protein
carries	O
its	O
characteristic	O
oligosaccharide	O
pattern	O
.	O

Furthermore	O
,	O
all	O
potential	O
sites	O
were	O
shown	O
to	O
be	O
substituted	O
by	O
carbohydrates	O
.	O

The	O
role	O
of	O
CaaX	O
-	O
dependent	O
modifications	O
in	O
membrane	O
association	O
of	O
Xenopus	O
nuclear	O
lamin	B-Protein
B3	I-Protein
during	O
meiosis	O
and	O
the	O
fate	O
of	O
B3	B-Protein
in	O
transfected	O
mitotic	O
cells	O
.	O

Recent	O
evidence	O
shows	O
that	O
the	O
COOH	O
-	O
terminal	O
CaaX	O
motif	O
of	O
lamins	O
is	O
necessary	O
to	O
target	O
newly	O
synthesized	O
proteins	O
to	O
the	O
nuclear	O
envelope	O
membranes	O
.	O

Isoprenylation	O
at	O
the	O
CaaX	O
-	O
cysteine	O
has	O
been	O
taken	O
to	O
explain	O
the	O
different	O
fates	O
of	O
A	O
-	O
and	O
B	O
-	O
type	O
lamins	O
during	O
cell	O
division	O
.	O

A	O
-	O
type	O
lamins	O
,	O
which	O
loose	O
their	O
isoprenylation	O
shortly	O
after	O
incorporation	O
into	O
the	O
lamina	O
structure	O
,	O
become	O
freely	O
soluble	O
upon	O
mitotic	O
nuclear	O
envelope	O
breakdown	O
.	O

Somatic	O
B	O
-	O
type	O
lamins	O
,	O
in	O
contrast	O
,	O
are	O
permanently	O
isoprenylated	O
and	O
,	O
although	O
depolymerized	O
during	O
mitosis	O
,	O
remain	O
associated	O
with	O
remnants	O
of	O
nuclear	O
envelope	O
membranes	O
.	O

However	O
,	O
Xenopus	O
lamin	B-Protein
B3	I-Protein
,	O
the	O
major	O
B	O
-	O
type	O
lamin	O
of	O
amphibian	O
oocytes	O
and	O
eggs	O
,	O
becomes	O
soluble	O
after	O
nuclear	O
envelope	O
breakdown	O
in	O
meiotic	O
metaphase	O
.	O

Here	O
we	O
show	O
that	O
Xenopus	O
lamin	B-Protein
B3	I-Protein
is	O
permanently	O
isoprenylated	O
and	O
carboxyl	O
methylated	O
in	O
oocytes	O
(	O
interphase	O
)	O
and	O
eggs	O
(	O
meiotic	O
metaphase	O
)	O
.	O

When	O
transfected	O
into	O
mouse	O
L	O
cells	O
Xenopus	O
lamin	B-Protein
B3	I-Protein
is	O
integrated	O
into	O
the	O
host	O
lamina	O
and	O
responds	O
to	O
cell	O
cycle	O
signals	O
in	O
a	O
normal	O
fashion	O
.	O

Notably	O
,	O
the	O
ectopically	O
expressed	O
Xenopus	O
lamin	O
does	O
not	O
form	O
heterooligomers	O
with	O
the	O
endogenous	O
lamins	O
as	O
revealed	O
by	O
a	O
coprecipitation	O
experiment	O
with	O
mitotic	O
lamins	O
.	O

In	O
contrast	O
to	O
the	O
situation	O
in	O
amphibian	O
eggs	O
,	O
a	O
significant	O
portion	O
of	O
lamin	B-Protein
B3	I-Protein
remains	O
associated	O
with	O
membranes	O
during	O
mitosis	O
.	O

We	O
conclude	O
from	O
these	O
data	O
that	O
the	O
CaaX	O
motif	O
-	O
mediated	O
modifications	O
,	O
although	O
necessary	O
,	O
are	O
not	O
sufficient	O
for	O
a	O
stable	O
association	O
of	O
lamins	O
with	O
membranes	O
and	O
that	O
additional	O
factors	O
are	O
involved	O
in	O
lamin	O
-	O
membrane	O
binding	O
.	O

Characterization	O
of	O
the	O
beta	O
-	O
subunit	O
of	O
the	O
H	O
(	O
+	O
)	O
-	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
using	O
an	O
inhibitory	O
monoclonal	O
antibody	O
.	O

The	O
gastric	O
proton	O
pump	O
,	O
H	O
(	O
+	O
)	O
-	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
,	O
is	O
composed	O
of	O
alpha	O
-	O
and	O
beta	O
-	O
subunits	O
.	O

The	O
95	O
-	O
kDa	O
alpha	O
-	O
subunit	O
has	O
been	O
referred	O
to	O
as	O
the	O
catalytic	O
subunit	O
containing	O
sites	O
for	O
ATP	O
binding	O
and	O
phosphorylation	O
.	O

The	O
beta	O
-	O
subunit	O
is	O
a	O
glycoprotein	O
with	O
a	O
34	O
-	O
kDa	O
core	O
peptide	O
that	O
has	O
a	O
single	O
transmembrane	O
segment	O
,	O
a	O
small	O
cytoplasmic	O
NH2	O
-	O
terminal	O
,	O
and	O
a	O
large	O
extracellular	O
COOH	O
-	O
terminal	O
domain	O
with	O
seven	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
.	O

To	O
further	O
study	O
the	O
beta	O
-	O
subunit	O
,	O
we	O
developed	O
monoclonal	O
antibodies	O
that	O
identified	O
a	O
52	O
-	O
kDa	O
mannose	O
-	O
rich	O
glycoprotein	O
that	O
was	O
deglycosylated	O
by	O
endoglycosidase	B-Protein
H	I-Protein
such	O
that	O
six	O
transient	O
intermediates	O
were	O
identified	O
,	O
as	O
well	O
as	O
a	O
34	O
-	O
kDa	O
beta	O
-	O
subunit	O
core	O
peptide	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
beta	O
-	O
subunit	O
is	O
synthesized	O
as	O
a	O
52	O
-	O
kDa	O
glycoprotein	O
with	O
seven	O
N	O
-	O
linked	O
precursor	O
high	O
-	O
mannose	O
oligosaccharides	O
that	O
mature	O
into	O
complex	O
oligosaccharides	O
.	O

One	O
antibody	O
,	O
2G11	O
,	O
inhibits	O
the	O
K	O
(	O
+	O
)	O
-	O
stimulated	O
ATP	O
hydrolysis	O
as	O
well	O
as	O
K	O
(	O
+	O
)	O
-	O
stimulated	O
p	O
-	O
nitrophenyl	O
phosphatase	O
(	O
pNPPase	O
)	O
activity	O
of	O
the	O
H	O
(	O
+	O
)	O
-	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
.	O

Kinetic	O
studies	O
revealed	O
that	O
2G11	O
inhibited	O
maximum	O
velocity	O
(	O
Vmax	O
)	O
of	O
ATP	O
hydrolysis	O
by	O
approximately	O
50	O
%	O
with	O
no	O
change	O
in	O
the	O
Km	O
for	O
K	O
+	O
,	O
whereas	O
,	O
for	O
pNPPase	O
both	O
Vmax	O
and	O
Km	O
were	O
altered	O
.	O

These	O
studies	O
demonstrate	O
a	O
functional	O
role	O
for	O
the	O
beta	O
-	O
subunit	O
in	O
the	O
H	O
(	O
+	O
)	O
-	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
activity	O
,	O
especially	O
the	O
K	O
(	O
+	O
)	O
-	O
induced	O
conformational	O
states	O
.	O

Biosynthesis	O
and	O
secretion	O
of	O
human	O
interleukin	B-Protein
2	I-Protein
glycoprotein	O
variants	O
from	O
baculovirus	O
-	O
infected	O
Sf21	O
cells	O
.	O

Characterization	O
of	O
polypeptides	O
and	O
posttranslational	O
modifications	O
.	O

Human	O
interleukin	B-Protein
2	I-Protein
(	O
IL	B-Protein
-	I-Protein
2	I-Protein
)	O
and	O
human	O
IL	B-Protein
-	I-Protein
2	I-Protein
mutant	O
proteins	O
,	O
with	O
artificially	O
introduced	O
N	O
-	O
glycosylation	O
or	O
O	O
-	O
glycosylation	O
sites	O
,	O
have	O
been	O
expressed	O
in	O
a	O
lepidopteran	O
cell	O
line	O
(	O
Sf21	O
,	O
Spodoptera	O
frugiperda	O
)	O
using	O
recombinant	O
baculovirus	O
vectors	O
.	O

Only	O
approximately	O
25	O
%	O
of	O
the	O
total	O
recombinant	O
IL	B-Protein
-	I-Protein
2	I-Protein
protein	O
synthesized	O
by	O
Sf21	O
cells	O
was	O
secreted	O
into	O
the	O
culture	O
medium	O
.	O

Significant	O
N	O
-	O
terminal	O
truncations	O
were	O
detected	O
in	O
the	O
secreted	O
polypeptides	O
(	O
up	O
to	O
85	O
%	O
of	O
the	O
molecules	O
)	O
.	O

Alanine	O
and	O
proline	O
were	O
absent	O
in	O
the	O
major	O
truncated	O
forms	O
;	O
the	O
first	O
3	O
-	O
5	O
amino	O
acids	O
were	O
also	O
absent	O
in	O
a	O
small	O
proportion	O
of	O
the	O
purified	O
proteins	O
.	O

The	O
introduction	O
of	O
potential	O
artificial	O
O	O
-	O
glycosylation	O
peptide	O
sequences	O
(	O
.	O
.	O
GGKAPTPPPK	O
.	O
.	O
)	O
,	O
to	O
the	O
C	O
-	O
terminus	O
or	O
between	O
positions	O
80	O
and	O
81	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
polypeptide	O
chain	O
,	O
resulted	O
in	O
the	O
secretion	O
of	O
unglycosylated	O
and	O
O	O
-	O
glycosylated	O
variant	O
forms	O
.	O

Fast	O
atom	O
bombardment	O
mass	O
spectrometry	O
,	O
compositional	O
analysis	O
and	O
methylation	O
analysis	O
,	O
of	O
the	O
tryptic	O
glycopeptide	O
APTPPPK	O
,	O
revealed	O
the	O
presence	O
of	O
either	O
GalNAc	O
or	O
the	O
disaccharide	O
Gal	O
(	O
beta	O
1	O
-	O
3	O
)	O
GalNAc	O
as	O
the	O
only	O
carbohydrate	O
constituents	O
attached	O
exclusively	O
to	O
Thr	O
in	O
this	O
peptide	O
,	O
in	O
a	O
specific	O
ratio	O
for	O
each	O
individual	O
IL	B-Protein
-	I-Protein
2	I-Protein
mutant	O
protein	O
.	O

The	O
Gal	O
(	O
beta	O
1	O
-	O
3	O
)	O
GalNAc	O
protein	O
forms	O
could	O
be	O
partially	O
altered	O
in	O
vitro	O
to	O
mammalian	O
-	O
type	O
glycoforms	O
by	O
porcine	O
liver	O
beta	B-Protein
-	I-Protein
galactoside	I-Protein
alpha	I-Protein
-	I-Protein
2	I-Protein
,	I-Protein
3	I-Protein
-	I-Protein
sialyltransferase	I-Protein
in	O
the	O
presence	O
of	O
CMP	O
-	O
N	O
-	O
acetylneuraminic	O
acid	O
.	O

An	O
IL	B-Protein
-	I-Protein
2	I-Protein
mutant	O
form	O
,	O
with	O
an	O
11	O
-	O
amino	O
-	O
acid	O
peptide	O
of	O
human	O
interferon	B-Protein
-	I-Protein
beta	I-Protein
at	O
position	O
4	O
,	O
which	O
includes	O
its	O
only	O
N	O
-	O
glycosylation	O
site	O
,	O
had	O
exclusively	O
truncated	O
proximally	O
fucosylated	O
oligomannosidic	O
glycans	O
;	O
Man3GlcNAc	O
[	O
Fuc	O
(	O
alpha	O
1	O
-	O
6	O
)	O
]	O
GlcNAc	O
or	O
Man2GlcNAc	O
[	O
Fuc	O
(	O
alpha	O
1	O
-	O
6	O
)	O
]	O
GlcNAc	O
structures	O
,	O
in	O
a	O
ratio	O
of	O
3	O
:	O
1	O
,	O
were	O
detected	O
in	O
the	O
secreted	O
proteins	O
.	O

No	O
evidence	O
was	O
obtained	O
for	O
the	O
presence	O
of	O
secreted	O
proteins	O
with	O
complex	O
oligosaccharide	O
chains	O
,	O
irrespective	O
of	O
the	O
cell	O
-	O
culture	O
conditions	O
used	O
or	O
the	O
harvesting	O
time	O
,	O
for	O
infected	O
cells	O
with	O
recombinant	O
baculovirus	O
constructs	O
.	O

The	O
role	O
of	O
conserved	O
amino	O
acids	O
in	O
substrate	O
binding	O
and	O
discrimination	O
by	O
photolyase	O
.	O

DNA	O
photolyases	O
catalyze	O
the	O
light	O
-	O
dependent	O
repair	O
of	O
pyrimidine	O
dimers	O
in	O
DNA	O
.	O

We	O
have	O
utilized	O
chemical	O
modification	O
and	O
site	O
-	O
directed	O
mutagenesis	O
to	O
probe	O
the	O
interactions	O
involved	O
in	O
substrate	O
recognition	O
by	O
the	O
yeast	O
photolyase	O
Phr1	B-Protein
.	O

Lys517	O
was	O
protected	O
from	O
reductive	O
methylation	O
in	O
the	O
presence	O
of	O
substrate	O
,	O
but	O
not	O
in	O
its	O
absence	O
,	O
and	O
the	O
specific	O
and	O
nonspecific	O
association	O
constants	O
for	O
substrate	O
binding	O
by	O
Phr1	B-Protein
(	O
Lys517	O
-	O
-	O
>	O
Ala	O
)	O
were	O
decreased	O
10	O
-	O
fold	O
.	O

These	O
results	O
establish	O
a	O
role	O
for	O
Lys517	O
in	O
substrate	O
binding	O
.	O

Mutations	O
at	O
Arg507	O
,	O
Lys463	O
,	O
and	O
Trp387	O
reduced	O
both	O
the	O
overall	O
affinity	O
for	O
substrate	O
and	O
substrate	O
discrimination	O
.	O

Sites	O
of	O
altered	O
interactions	O
in	O
ES	O
complexes	O
were	O
identified	O
by	O
methylation	O
and	O
ethylation	O
interference	O
techniques	O
.	O

Interaction	O
with	O
the	O
base	O
immediately	O
3	O
'	O
to	O
the	O
dimer	O
was	O
altered	O
in	O
the	O
Phr1	B-Protein
(	O
Lys517	O
-	O
-	O
>	O
Ala	O
)	O
.	O

DNA	O
complex	O
,	O
whereas	O
interactions	O
with	O
the	O
phosphate	O
and	O
base	O
immediately	O
5	O
'	O
to	O
the	O
dimer	O
were	O
reduced	O
when	O
Phr1	B-Protein
(	O
Arg507	O
-	O
-	O
>	O
Ala	O
)	O
bound	O
substrate	O
.	O

Multiple	O
interactions	O
5	O
'	O
and	O
3	O
'	O
to	O
the	O
dimer	O
were	O
perturbed	O
in	O
complexes	O
containing	O
Phr1	B-Protein
(	O
Trp387	O
-	O
-	O
>	O
Ala	O
)	O
or	O
Phr1	B-Protein
(	O
Lys463	O
-	O
-	O
>	O
Ala	O
)	O
.	O

In	O
addition	O
the	O
quantum	O
yield	O
for	O
dimer	O
photolysis	O
by	O
Phr1	B-Protein
(	O
Trp387	O
-	O
-	O
>	O
Ala	O
)	O
was	O
reduced	O
3	O
-	O
fold	O
.	O

The	O
locations	O
of	O
these	O
mutations	O
establish	O
that	O
a	O
portion	O
of	O
the	O
DNA	O
binding	O
domain	O
is	O
comprised	O
of	O
residues	O
in	O
the	O
highly	O
conserved	O
carboxyl	O
-	O
terminal	O
half	O
of	O
the	O
enzyme	O
.	O

An	O
anatomical	O
and	O
biochemical	O
study	O
of	O
the	O
pituitary	O
proopiomelanocortin	B-Protein
systems	O
in	O
the	O
polypteriform	O
fish	O
Calamoichthys	O
calabaricus	O
.	O

Immunohistochemical	O
and	O
biochemical	O
analyses	O
were	O
performed	O
on	O
the	O
pituitary	B-Protein
Proopiomelanocortin	I-Protein
(	O
POMC	B-Protein
)	O
systems	O
of	O
the	O
polypteriform	O
fish	O
Calamoichthys	O
calabaricus	O
.	O

Immunohistochemical	O
staining	O
of	O
the	O
pituitary	O
revealed	O
a	O
clustering	O
of	O
ACTH	B-Protein
immunopositive	O
cells	O
within	O
the	O
rostral	O
pars	O
distalis	O
.	O

alpha	B-Protein
-	I-Protein
Melanocyte	I-Protein
stimulating	I-Protein
hormone	I-Protein
(	O
alpha	B-Protein
-	I-Protein
MSH	I-Protein
)	O
-	O
related	O
and	O
beta	B-Protein
-	I-Protein
endorphin	I-Protein
-	O
related	O
immunoreactivity	O
were	O
found	O
colocalized	O
in	O
epithelial	O
cells	O
of	O
the	O
pars	O
intermedia	O
.	O

Biochemical	O
analyses	O
included	O
Sephadex	O
G	O
-	O
50	O
column	O
chromatography	O
,	O
reversed	O
-	O
phase	O
HPLC	O
,	O
and	O
cation	O
exchange	O
chromatography	O
.	O

These	O
analyses	O
revealed	O
the	O
presence	O
of	O
immunoreactive	O
forms	O
of	O
ACTH	B-Protein
which	O
stimulated	O
glucocorticoid	O
release	O
when	O
tested	O
on	O
isolated	O
Bufo	O
marinus	O
adrenocortical	O
tissue	O
.	O

Three	O
forms	O
of	O
alpha	B-Protein
-	I-Protein
MSH	I-Protein
were	O
detected	O
,	O
and	O
the	O
major	O
form	O
had	O
the	O
same	O
HPLC	O
chromatographic	O
properties	O
as	O
synthetic	O
monoacetylated	O
alpha	B-Protein
-	I-Protein
MSH	I-Protein
.	O

Finally	O
,	O
five	O
forms	O
of	O
beta	B-Protein
-	I-Protein
endorphin	I-Protein
were	O
detected	O
,	O
and	O
all	O
of	O
these	O
forms	O
were	O
N	O
-	O
acetylated	O
.	O

Based	O
on	O
these	O
observations	O
,	O
it	O
appears	O
that	O
N	O
-	O
acetylation	O
is	O
a	O
major	O
post	O
-	O
translational	O
processing	O
event	O
within	O
the	O
melanotropic	O
cells	O
of	O
C	O
.	O
calabaricus	O
.	O

Given	O
the	O
position	O
of	O
Order	O
Cladistia	O
in	O
the	O
phylogeny	O
of	O
actinopterygian	O
fish	O
,	O
it	O
appears	O
that	O
N	O
-	O
acetylation	O
of	O
POMC	B-Protein
-	O
related	O
products	O
is	O
an	O
ancestral	O
trait	O
of	O
osteichthyean	O
fish	O
.	O

Agonist	O
-	O
induced	O
phosphorylation	O
of	O
the	O
luteinizing	B-Protein
hormone	I-Protein
/	I-Protein
chorionic	I-Protein
gonadotropin	I-Protein
receptor	I-Protein
expressed	O
in	O
a	O
stably	O
transfected	O
cell	O
line	O
.	O

Much	O
of	O
the	O
definitive	O
work	O
on	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
phosphorylation	O
and	O
its	O
impact	O
on	O
receptor	O
function	O
has	O
been	O
performed	O
with	O
the	O
catecholamine	O
receptors	O
.	O

Evidence	O
for	O
receptor	O
phosphorylation	O
is	O
lacking	O
,	O
however	O
,	O
for	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
that	O
bind	O
larger	O
ligands	O
,	O
such	O
as	O
LH	O
/	O
CG	O
.	O

Using	O
immunoprecipitation	O
techniques	O
and	O
a	O
clonal	O
cell	O
line	O
stably	O
transfected	O
with	O
the	O
LH	B-Protein
/	I-Protein
CG	I-Protein
receptor	I-Protein
,	O
we	O
show	O
here	O
for	O
the	O
first	O
time	O
that	O
exposure	O
of	O
cells	O
to	O
hCG	O
induces	O
phosphorylation	O
of	O
its	O
cognate	O
receptor	O
.	O

The	O
hCG	O
-	O
induced	O
increase	O
in	O
receptor	O
phosphorylation	O
requires	O
receptor	O
activation	O
because	O
it	O
cannot	O
be	O
elicited	O
with	O
a	O
hCG	O
antagonist	O
and	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
the	O
cAMP	O
second	O
messenger	O
system	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
the	O
finding	O
that	O
the	O
hCG	O
-	O
induced	O
receptor	O
phosphorylation	O
is	O
greatly	O
reduced	O
(	O
but	O
not	O
abolished	O
)	O
in	O
a	O
cell	O
line	O
that	O
overexpresses	O
cAMP	O
phosphodiesterase	O
and	O
that	O
receptor	O
phosphorylation	O
can	O
be	O
induced	O
by	O
activation	O
of	O
endogenous	O
cAMP	O
synthesis	O
with	O
prostaglandin	O
E2	O
or	O
by	O
addition	O
of	O
8	O
-	O
bromo	O
-	O
cAMP	O
.	O

Last	O
,	O
we	O
show	O
that	O
LH	B-Protein
/	I-Protein
CG	I-Protein
receptor	I-Protein
phosphorylation	O
can	O
be	O
induced	O
with	O
a	O
phorbol	O
ester	O
,	O
but	O
not	O
with	O
a	O
calcium	O
ionophore	O
.	O

We	O
also	O
examined	O
a	O
potential	O
correlation	O
between	O
LH	B-Protein
/	I-Protein
CG	I-Protein
receptor	I-Protein
phosphorylation	O
and	O
uncoupling	O
of	O
the	O
receptor	O
from	O
its	O
effector	O
.	O

Although	O
the	O
phorbol	O
ester	O
-	O
induced	O
phosphorylation	O
of	O
the	O
LH	B-Protein
/	I-Protein
CG	I-Protein
receptor	I-Protein
can	O
be	O
correlated	O
with	O
uncoupling	O
,	O
other	O
experiments	O
indicate	O
that	O
hCG	O
-	O
induced	O
uncoupling	O
of	O
the	O
LH	B-Protein
/	I-Protein
CG	I-Protein
receptor	I-Protein
can	O
occur	O
under	O
conditions	O
where	O
the	O
cAMP	O
-	O
mediated	O
receptor	O
phosphorylation	O
is	O
greatly	O
reduced	O
(	O
or	O
abolished	O
)	O
.	O

Mechanisms	O
of	O
collagen	O
trimer	O
formation	O
.	O

Construction	O
and	O
expression	O
of	O
a	O
recombinant	O
minigene	O
in	O
HeLa	O
cells	O
reveals	O
a	O
direct	O
effect	O
of	O
prolyl	O
hydroxylation	O
on	O
chain	O
assembly	O
of	O
type	B-Protein
XII	I-Protein
collagen	I-Protein
.	O

Collagen	O
types	O
IX	O
,	O
XII	B-Protein
,	O
and	O
XIV	B-Protein
are	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
highly	O
conserved	O
region	O
comprising	O
the	O
most	O
C	O
-	O
terminal	O
triple	O
helical	O
domain	O
(	O
COL1	O
,	O
approximately	O
100	O
residues	O
/	O
chain	O
)	O
and	O
2	O
cysteines	O
separated	O
by	O
4	O
amino	O
acid	O
residues	O
at	O
the	O
junction	O
between	O
this	O
COL1	O
domain	O
and	O
the	O
C	O
-	O
terminal	O
non	O
-	O
triple	O
helical	O
domain	O
(	O
NC1	O
)	O
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
functions	O
of	O
this	O
conserved	O
domain	O
,	O
we	O
have	O
constructed	O
a	O
recombinant	O
minigene	O
,	O
comprising	O
the	O
sequence	O
coding	O
for	O
an	O
unrelated	O
signal	O
peptide	O
and	O
for	O
the	O
COL1	O
and	O
NC1	O
domains	O
of	O
type	B-Protein
XII	I-Protein
collagen	I-Protein
.	O

This	O
construct	O
was	O
placed	O
under	O
the	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
and	O
transfected	O
into	O
HeLa	O
cells	O
.	O

The	O
cells	O
expressed	O
the	O
transfected	O
minigene	O
and	O
the	O
secreted	O
chain	O
,	O
called	O
alpha	O
1	O
(	O
mini	O
XII	O
)	O
,	O
could	O
be	O
detected	O
by	O
immunotransfer	O
with	O
an	O
anti	O
-	O
peptide	O
antibody	O
recognizing	O
an	O
epitope	O
found	O
in	O
the	O
NC1	O
domain	O
.	O

Under	O
conditions	O
preventing	O
the	O
hydroxylation	O
of	O
prolyl	O
residues	O
(	O
absence	O
of	O
ascorbate	O
or	O
presence	O
of	O
alpha	O
alpha	O
'	O
-	O
dipyridyl	O
)	O
,	O
interchain	O
disulfide	O
bridges	O
did	O
not	O
form	O
,	O
while	O
in	O
the	O
presence	O
of	O
ascorbate	O
,	O
disulfide	O
-	O
bonded	O
(	O
alpha	O
1	O
(	O
mini	O
XII	O
)	O
)	O
3	O
molecules	O
were	O
secreted	O
.	O

The	O
collagenous	O
nature	O
and	O
triple	O
helical	O
conformation	O
of	O
the	O
trimeric	O
molecule	O
were	O
ascertained	O
by	O
the	O
differential	O
resistances	O
of	O
the	O
COL1	O
and	O
NC1	O
domains	O
to	O
trypsin	O
and	O
collagenase	O
digestions	O
,	O
respectively	O
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
NC1	O
and	O
COL1	O
domains	O
of	O
type	B-Protein
XII	I-Protein
collagen	I-Protein
contain	O
the	O
information	O
necessary	O
for	O
trimer	O
formation	O
and	O
that	O
,	O
contrary	O
to	O
the	O
fibrillar	O
collagen	O
types	O
,	O
posttranslational	O
modification	O
of	O
the	O
triple	O
helical	O
domain	O
is	O
essential	O
for	O
assembly	O
and	O
disulfide	O
bonding	O
of	O
the	O
chains	O
.	O

Fulvic	O
acid	O
supplementation	O
and	O
selenium	O
deficiency	O
disturb	O
the	O
structural	O
integrity	O
of	O
mouse	O
skeletal	O
tissue	O
.	O

An	O
animal	O
model	O
to	O
study	O
the	O
molecular	O
defects	O
of	O
Kashin	O
-	O
Beck	O
disease	O
.	O

High	O
concentrations	O
of	O
fulvic	O
acid	O
and	O
selenium	O
deficiency	O
are	O
the	O
main	O
causative	O
factors	O
of	O
Kashin	O
-	O
Beck	O
disease	O
,	O
an	O
endemic	O
,	O
chronic	O
and	O
degenerative	O
osteoarticular	O
disorder	O
found	O
in	O
China	O
.	O

In	O
the	O
search	O
for	O
an	O
animal	O
model	O
of	O
this	O
disease	O
,	O
mice	O
were	O
exposed	O
to	O
these	O
pathogenetic	O
conditions	O
for	O
two	O
generations	O
and	O
the	O
collagen	O
types	O
from	O
skin	O
,	O
bone	O
and	O
cartilage	O
were	O
analysed	O
.	O

The	O
growth	O
of	O
the	O
treated	O
mice	O
was	O
slightly	O
retarded	O
,	O
and	O
the	O
rate	O
of	O
reproduction	O
was	O
lower	O
in	O
animals	O
maintained	O
on	O
a	O
fulvic	O
acid	O
-	O
supplemented	O
and	O
/	O
or	O
selenium	O
-	O
deficient	O
diet	O
.	O

Irregular	O
bone	O
formation	O
was	O
seen	O
by	O
radiography	O
and	O
morphometry	O
.	O

Biochemical	O
analysis	O
indicated	O
that	O
lysine	O
residues	O
in	O
collagen	O
I	O
from	O
bone	O
and	O
in	O
collagen	B-Protein
II	I-Protein
from	O
cartilage	O
were	O
overmodified	O
.	O

The	O
values	O
of	O
Hyl	O
/	O
(	O
Hyl	O
+	O
Lys	O
)	O
in	O
bone	O
collagen	B-Protein
alpha	I-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
from	O
treated	O
mice	O
were	O
about	O
0	O
.	O
434	O
-	O
0	O
.	O
484	O
,	O
i	O
.	O
e	O
.	O
substantially	O
higher	O
than	O
that	O
of	O
the	O
control	O
(	O
0	O
.	O
277	O
)	O
.	O

The	O
values	O
of	O
this	O
parameter	O
for	O
collagen	B-Protein
II	I-Protein
were	O
0	O
.	O
482	O
for	O
control	O
and	O
0	O
.	O
546	O
-	O
0	O
.	O
566	O
for	O
treated	O
mice	O
.	O

The	O
melting	O
temperature	O
of	O
collagen	O
I	O
from	O
bones	O
of	O
treated	O
mice	O
was	O
1	O
degrees	O
C	O
lower	O
than	O
that	O
of	O
control	O
collagen	O
,	O
indicating	O
decreased	O
thermal	O
stability	O
.	O

The	O
breakage	O
point	O
of	O
the	O
tibiae	O
of	O
treated	O
mice	O
occurred	O
at	O
a	O
lower	O
preload	O
force	O
than	O
for	O
controls	O
,	O
suggesting	O
that	O
the	O
overmodified	O
and	O
thermally	O
less	O
stable	O
collagen	O
molecules	O
are	O
causally	O
related	O
to	O
a	O
lower	O
mechanical	O
strength	O
of	O
bones	O
.	O

Recombinant	O
human	O
interleukin	B-Protein
3	I-Protein
in	O
clinical	O
oncology	O
.	O

Interleukin	B-Protein
3	I-Protein
(	O
IL	B-Protein
-	I-Protein
3	I-Protein
)	O
is	O
a	O
multipotent	O
hematopoietic	B-Protein
growth	I-Protein
factor	I-Protein
which	O
became	O
available	O
as	O
a	O
recombinant	O
(	O
rh	O
)	O
growth	O
factor	O
for	O
use	O
in	O
the	O
clinic	O
a	O
few	O
years	O
ago	O
.	O

In	O
dose	O
-	O
finding	O
studies	O
,	O
this	O
hematopoietic	B-Protein
growth	I-Protein
factor	I-Protein
has	O
been	O
evaluated	O
without	O
and	O
after	O
standard	O
chemotherapy	O
.	O

Stimulatory	O
effects	O
on	O
leukocytes	O
,	O
neutrophils	O
,	O
eosinophils	O
,	O
monocytes	O
,	O
reticulocytes	O
and	O
platelets	O
were	O
observed	O
in	O
some	O
studies	O
.	O

Chemotherapy	O
postponement	O
due	O
to	O
insufficient	O
bone	O
marrow	O
recovery	O
was	O
less	O
frequent	O
when	O
IL	B-Protein
-	I-Protein
3	I-Protein
was	O
administered	O
.	O

There	O
are	O
some	O
clinical	O
studies	O
available	O
in	O
which	O
rhIL	B-Protein
-	I-Protein
3	I-Protein
is	O
combined	O
with	O
rh	O
granulocyte	B-Protein
-	I-Protein
macrophage	I-Protein
colony	I-Protein
-	I-Protein
stimulating	I-Protein
factor	I-Protein
(	O
GM	B-Protein
-	I-Protein
CSF	I-Protein
)	O
.	O

The	O
results	O
do	O
not	O
clearly	O
suggest	O
superiority	O
of	O
these	O
combinations	O
over	O
rhGM	B-Protein
-	I-Protein
CSF	I-Protein
alone	O
,	O
but	O
this	O
may	O
be	O
partly	O
due	O
to	O
the	O
time	O
scheduling	O
of	O
the	O
growth	O
factors	O
.	O

Administration	O
s	O
.	O
c	O
.	O

is	O
not	O
inferior	O
to	O
i	O
.	O
v	O
.	O
Side	O
effects	O
mainly	O
consist	O
of	O
flu	O
-	O
like	O
symptoms	O
and	O
headache	O
.	O

The	O
role	O
of	O
rhIL	B-Protein
-	I-Protein
3	I-Protein
after	O
high	O
-	O
dose	O
chemotherapy	O
and	O
autologous	O
bone	O
marrow	O
reinfusion	O
is	O
still	O
questionable	O
.	O

The	O
addition	O
of	O
rhIL	B-Protein
-	I-Protein
3	I-Protein
to	O
rhGM	B-Protein
-	I-Protein
CSF	I-Protein
both	O
administered	O
after	O
chemotherapy	O
may	O
allow	O
a	O
very	O
high	O
yield	O
of	O
peripheral	O
stem	O
cells	O
suitable	O
for	O
bone	O
marrow	O
reconstitution	O
after	O
high	O
-	O
dose	O
chemotherapy	O
.	O

rhIL	B-Protein
-	I-Protein
3	I-Protein
can	O
stimulate	O
leukemia	O
tumor	O
cell	O
proliferation	O
in	O
vitro	O
as	O
well	O
as	O
proliferation	O
of	O
solid	O
tumor	O
cell	O
lines	O
.	O

It	O
is	O
not	O
yet	O
clear	O
in	O
which	O
way	O
rhIL	B-Protein
-	I-Protein
3	I-Protein
combined	O
with	O
chemotherapy	O
will	O
effect	O
tumor	O
response	O
and	O
patient	O
survival	O
.	O

It	O
is	O
too	O
early	O
to	O
define	O
the	O
exact	O
place	O
of	O
rhIL	B-Protein
-	I-Protein
3	I-Protein
in	O
oncology	O
.	O

Additional	O
studies	O
with	O
rhIL	B-Protein
-	I-Protein
3	I-Protein
alone	O
and	O
in	O
combination	O
with	O
other	O
growth	O
factors	O
are	O
needed	O
.	O

In	O
vitro	O
translation	O
of	O
the	O
human	O
insulin	B-Protein
proreceptor	I-Protein
results	O
in	O
N	O
-	O
linked	O
glycosylation	O
without	O
dimer	O
formation	O
.	O

The	O
heterotetrameric	O
configuration	O
of	O
the	O
cell	O
surface	O
human	O
insulin	B-Protein
receptor	I-Protein
(	O
hINSR	B-Protein
)	O
is	O
important	O
for	O
mediating	O
insulin	B-Protein
action	O
.	O

Investigation	O
of	O
proreceptor	O
dimerization	O
,	O
the	O
quaternary	O
processing	O
event	O
during	O
biogenesis	O
,	O
offers	O
the	O
potential	O
to	O
examine	O
interactions	O
between	O
disulfide	O
-	O
linked	O
receptor	O
subunits	O
.	O

Thus	O
,	O
dimer	O
formation	O
of	O
the	O
proreceptor	O
was	O
examined	O
in	O
a	O
cell	O
-	O
free	O
system	O
that	O
utilized	O
a	O
coupled	O
transcription	O
and	O
translation	O
method	O
with	O
rabbit	O
reticulocyte	O
lysate	O
.	O

Translation	O
products	O
were	O
labeled	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
identified	O
by	O
non	O
-	O
reducing	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O

In	O
vitro	O
synthesis	O
in	O
the	O
presence	O
of	O
oxidized	O
glutathione	O
failed	O
to	O
demonstrate	O
dimerization	O
of	O
the	O
nascent	O
proreceptor	O
.	O

Co	O
-	O
translational	O
processing	O
with	O
the	O
addition	O
of	O
microsomal	O
membranes	O
resulted	O
in	O
N	O
-	O
linked	O
glycosylation	O
of	O
the	O
proreceptor	O
but	O
without	O
dimer	O
formation	O
.	O

Thus	O
,	O
similar	O
to	O
that	O
observed	O
in	O
vivo	O
,	O
insulin	B-Protein
proreceptor	I-Protein
dimerization	O
does	O
not	O
appear	O
to	O
be	O
a	O
co	O
-	O
translational	O
or	O
early	O
post	O
-	O
translational	O
event	O
.	O

Biochemical	O
characterization	O
of	O
human	O
collagenase	B-Protein
-	I-Protein
3	I-Protein
.	O

The	O
cDNA	O
of	O
a	O
novel	O
matrix	O
metalloproteinase	O
,	O
collagenase	B-Protein
-	I-Protein
3	I-Protein
(	O
MMP	B-Protein
-	I-Protein
13	I-Protein
)	O
has	O
been	O
isolated	O
from	O
a	O
breast	O
tumor	O
library	O
(	O
Freije	O
,	O
J	O
.	O
M	O
.	O
P	O
.	O
,	O
Dicz	O
-	O
Itza	O
,	O
I	O
.	O
,	O
Balbin	O
,	O
M	O
.	O
,	O
Sanchez	O
,	O
L	O
.	O
M	O
.	O
,	O
Blasco	O
,	O
R	O
.	O
,	O
Tolivia	O
,	O
J	O
.	O
,	O
and	O
Lopez	O
-	O
Otin	O
,	O
C	O
.	O
(	O
1994	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
269	O
,	O
16766	O
-	O
16773	O
)	O
,	O
and	O
a	O
potential	O
role	O
in	O
tumor	O
progression	O
has	O
been	O
proposed	O
for	O
this	O
enzyme	O
.	O

In	O
order	O
to	O
establish	O
the	O
possible	O
role	O
of	O
collagenase	B-Protein
-	I-Protein
3	I-Protein
in	O
connective	O
tissue	O
turnover	O
,	O
we	O
have	O
expressed	O
and	O
purified	O
recombinant	O
human	O
procollagenase	B-Protein
-	I-Protein
3	I-Protein
and	O
characterized	O
the	O
enzyme	O
biochemically	O
.	O

The	O
purified	O
procollagenase	B-Protein
-	I-Protein
3	I-Protein
was	O
shown	O
to	O
be	O
glycosylated	O
and	O
displayed	O
a	O
M	O
(	O
r	O
)	O
of	O
60	O
,	O
000	O
,	O
the	O
N	O
-	O
terminal	O
sequence	O
being	O
LPLPSGGD	O
,	O
which	O
is	O
consistent	O
with	O
the	O
cDNA	O
-	O
predicted	O
sequence	O
.	O

The	O
proenzyme	O
was	O
activated	O
by	O
p	O
-	O
aminophenylmercuric	O
acetate	O
or	O
stromelysin	O
,	O
yielding	O
an	O
intermediate	O
form	O
of	O
M	O
(	O
r	O
)	O
50	O
,	O
000	O
,	O
which	O
displayed	O
the	O
N	O
-	O
terminal	O
sequence	O
L58EVTGK	O
.	O

Further	O
processing	O
resulted	O
in	O
cleavage	O
of	O
the	O
Glu84	O
-	O
Tyr85	O
peptide	O
bond	O
to	O
the	O
final	O
active	O
enzyme	O
(	O
M	O
(	O
r	O
)	O
48	O
,	O
000	O
)	O
.	O

Trypsin	O
activation	O
of	O
procollagenase	B-Protein
-	I-Protein
3	I-Protein
also	O
generated	O
a	O
Tyr85	O
N	O
terminus	O
,	O
but	O
it	O
was	O
evident	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
was	O
rapidly	O
lost	O
,	O
and	O
hence	O
the	O
collagenolytic	O
activity	O
diminished	O
.	O

Analysis	O
of	O
the	O
substrate	O
specificity	O
of	O
collagenase	B-Protein
-	I-Protein
3	I-Protein
revealed	O
that	O
soluble	O
type	B-Protein
II	I-Protein
collagen	I-Protein
was	O
preferentially	O
hydrolyzed	O
,	O
while	O
the	O
enzyme	O
was	O
5	O
or	O
6	O
times	O
less	O
efficient	O
at	O
cleaving	O
type	O
I	O
or	O
III	O
collagen	O
.	O

Fibrillar	O
type	O
I	O
collagen	O
was	O
cleaved	O
with	O
comparable	O
efficiency	O
to	O
the	O
fibroblast	O
and	O
neutrophil	O
collagenases	O
(	O
MMP	B-Protein
-	I-Protein
1	I-Protein
and	O
MMP	B-Protein
-	I-Protein
8	I-Protein
)	O
,	O
respectively	O
.	O

Unlike	O
these	O
collagenases	O
,	O
gelatin	O
and	O
the	O
peptide	O
substrates	O
Mea	O
-	O
Pro	O
-	O
Leu	O
-	O
Gly	O
-	O
Leu	O
-	O
Dpa	O
-	O
Ala	O
-	O
Arg	O
-	O
NH2	O
and	O
Mca	O
-	O
Pro	O
-	O
Cha	O
-	O
Gly	O
-	O
Nva	O
-	O
His	O
-	O
Ala	O
-	O
Dpa	O
-	O
NH2	O
were	O
efficiently	O
hydrolyzed	O
as	O
well	O
,	O
as	O
would	O
be	O
predicted	O
from	O
the	O
similarities	O
between	O
the	O
active	O
site	O
sequence	O
of	O
collagenase	B-Protein
-	I-Protein
3	I-Protein
(	O
MMP	B-Protein
-	I-Protein
13	I-Protein
)	O
and	O
the	O
gelatinases	B-Protein
A	I-Protein
and	O
B	B-Protein
.	O

Active	O
collagenase	B-Protein
-	I-Protein
3	I-Protein
was	O
inhibited	O
in	O
a	O
1	O
:	O
1	O
stoichiometric	O
fashion	O
by	O
the	O
tissue	O
inhibitors	O
of	O
metalloproteinases	O
,	O
TIMP	B-Protein
-	I-Protein
1	I-Protein
,	O
TIMP	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
TIMP	B-Protein
-	I-Protein
3	I-Protein
.	O

These	O
results	O
suggest	O
that	O
in	O
vivo	O
collagenase	B-Protein
-	I-Protein
3	I-Protein
could	O
play	O
a	O
significant	O
role	O
in	O
the	O
turnover	O
of	O
connective	O
tissue	O
matrix	O
constituents	O
.	O

Preferential	O
transfer	O
to	O
truncated	O
oligosaccharides	O
to	O
the	O
first	O
sequon	O
of	O
yeast	O
exoglucanase	O
in	O
Saccharomyces	O
cerevisiae	O
alg3	O
cells	O
.	O

In	O
addition	O
to	O
the	O
exoglucanases	O
(	O
Exg	O
)	O
secreted	O
into	O
the	O
culture	O
medium	O
by	O
wild	O
type	O
cells	O
,	O
ExgIa	B-Protein
and	O
ExgIb	B-Protein
,	O
which	O
have	O
oligosaccharides	O
attached	O
to	O
both	O
potential	O
N	O
-	O
glycosylation	O
sites	O
,	O
Saccharomyces	O
cerevisiae	O
alg3	O
mutant	O
secreted	O
substantial	O
amounts	O
(	O
35	O
-	O
-	O
44	O
%	O
)	O
of	O
underglycosylated	O
and	O
unglycosylated	O
forms	O
.	O

Quantification	O
of	O
these	O
forms	O
indicated	O
that	O
no	O
more	O
than	O
78	O
%	O
of	O
the	O
available	O
N	O
-	O
sites	O
were	O
occupied	O
.	O

About	O
50	O
%	O
of	O
the	O
transferred	O
oligosaccharides	O
were	O
endo	O
H	O
sensitive	O
,	O
indicating	O
that	O
the	O
lipid	O
-	O
linked	O
precursor	O
had	O
completed	O
its	O
synthesis	O
to	O
Glc3	O
-	O
Man9	O
-	O
GlcNAc2	O
.	O

The	O
other	O
50	O
%	O
remained	O
endo	O
H	O
-	O
resistant	O
and	O
,	O
accordingly	O
,	O
it	O
should	O
be	O
derived	O
from	O
the	O
precursor	O
oligosaccharide	O
Man5	O
-	O
GlcNAc2	O
synthesized	O
by	O
this	O
mutant	O
.	O

A	O
closer	O
analysis	O
of	O
forms	O
that	O
have	O
received	O
two	O
oligosaccharides	O
(	O
ExgIb	B-Protein
)	O
showed	O
that	O
the	O
first	O
sequon	O
was	O
enriched	O
in	O
truncated	O
residues	O
,	O
whereas	O
the	O
second	O
one	O
was	O
enriched	O
in	O
regular	O
counterparts	O
.	O

Similarly	O
,	O
analysis	O
of	O
the	O
individual	O
underglycosylated	O
glycoforms	O
indicated	O
that	O
38	O
%	O
of	O
the	O
oligosaccharides	O
attached	O
to	O
the	O
second	O
site	O
were	O
regular	O
.	O

This	O
percentage	O
dropped	O
to	O
20	O
%	O
for	O
glycoforms	O
carrying	O
the	O
oligosaccharide	O
in	O
the	O
first	O
sequon	O
.	O

The	O
preferential	O
transfer	O
of	O
truncated	O
oligosaccharides	O
to	O
the	O
first	O
glycosylation	O
site	O
seems	O
to	O
be	O
a	O
consequence	O
of	O
(	O
1	O
)	O
the	O
low	O
percentage	O
of	O
truncated	O
lipid	O
linked	O
oligosaccharides	O
that	O
receives	O
the	O
glucotriose	O
unit	O
,	O
and	O
(	O
2	O
)	O
the	O
effect	O
of	O
the	O
glucotriose	O
unit	O
on	O
the	O
selection	O
of	O
N	O
-	O
sites	O
to	O
be	O
glycosylated	O
.	O

Role	O
of	O
glucosamine	O
synthesis	O
in	O
the	O
stimulation	O
of	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
transcription	O
by	O
glucose	O
and	O
EGF	B-Protein
.	O

Transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
gene	O
transcription	O
is	O
regulated	O
by	O
both	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	O
EGF	B-Protein
)	O
and	O
glucose	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
metabolism	O
of	O
glucose	O
to	O
glucosamine	O
through	O
the	O
enzyme	O
L	B-Protein
-	I-Protein
glutamine	I-Protein
:	I-Protein
D	I-Protein
-	I-Protein
fructose	I-Protein
-	I-Protein
6	I-Protein
-	I-Protein
phosphate	I-Protein
amidotransferase	I-Protein
(	O
GFAT	B-Protein
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
glucose	O
signaling	O
.	O

In	O
this	O
paper	O
,	O
we	O
compared	O
the	O
role	O
of	O
GFAT	B-Protein
in	O
the	O
glucose	O
and	O
EGF	B-Protein
signals	O
.	O

We	O
found	O
that	O
,	O
although	O
EGF	B-Protein
stimulates	O
GFAT	B-Protein
mRNA	O
accumulation	O
in	O
MDA	O
-	O
MB	O
-	O
468	O
cells	O
,	O
this	O
effect	O
of	O
EGF	B-Protein
occurred	O
several	O
hours	O
after	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
transcription	O
increased	O
.	O

MDA	O
-	O
MB	O
-	O
468	O
cells	O
also	O
exhibited	O
a	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
transcriptional	O
response	O
to	O
low	O
concentrations	O
of	O
glucose	O
.	O

The	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
response	O
to	O
glucose	O
but	O
not	O
EGF	B-Protein
could	O
be	O
inhibited	O
by	O
a	O
blocker	O
of	O
GFAT	B-Protein
activity	O
.	O

Blockade	O
of	O
GFAT	B-Protein
was	O
confirmed	O
by	O
using	O
Western	O
blotting	O
with	O
the	O
RL2	O
antibody	O
,	O
which	O
recognizes	O
an	O
epitope	O
on	O
proteins	O
containing	O
N	O
-	O
acetylglucosamine	O
.	O

Exposure	O
of	O
cells	O
to	O
glucose	O
increased	O
the	O
RL2	O
signal	O
on	O
several	O
polypeptides	O
,	O
but	O
this	O
change	O
could	O
be	O
blocked	O
by	O
inhibition	O
of	O
GFAT	B-Protein
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
glucose	O
stimulation	O
of	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
requires	O
GFAT	B-Protein
,	O
but	O
EGF	B-Protein
stimulation	O
does	O
not	O
.	O

Transforming	B-Protein
growth	I-Protein
factor	I-Protein
beta	I-Protein
1	I-Protein
influences	O
lysyl	O
hydroxylation	O
of	O
collagen	O
I	O
and	O
reduces	O
steady	O
-	O
state	O
levels	O
of	O
lysyl	O
hydroxylase	O
mRNA	O
in	O
human	O
osteoblast	O
-	O
like	O
cells	O
.	O

Transforming	B-Protein
growth	I-Protein
factor	I-Protein
beta	I-Protein
1	I-Protein
(	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
)	O
is	O
an	O
osteotropic	O
growth	O
factor	O
that	O
is	O
found	O
in	O
substantial	O
concentration	O
in	O
bone	O
.	O

The	O
authors	O
studied	O
the	O
influence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
on	O
the	O
modification	O
of	O
lysine	O
residues	O
of	O
collagen	O
I	O
.	O

The	O
degree	O
of	O
lysyl	O
hydroxylation	O
and	O
lysyl	O
glycosylation	O
of	O
newly	O
synthesized	O
collagen	O
as	O
well	O
as	O
steady	O
-	O
state	O
levels	O
of	O
mRNA	O
for	O
both	O
lysyl	O
hydroxylase	O
and	O
collagens	O
I	O
and	O
III	B-Protein
were	O
determined	O
in	O
human	O
osteoblast	O
-	O
like	O
cells	O
in	O
vitro	O
.	O

In	O
normal	O
human	O
osteoblasts	O
lysyl	O
hydroxylation	O
was	O
decreased	O
by	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
particularly	O
in	O
the	O
collagen	O
alpha	O
2	O
-	O
chain	O
.	O

This	O
effect	O
was	O
paralleled	O
by	O
an	O
increase	O
in	O
lysyl	O
residues	O
,	O
whereas	O
glycosylation	O
was	O
not	O
affected	O
.	O

The	O
mRNA	O
for	O
lysyl	O
hydroxylase	O
was	O
reduced	O
by	O
one	O
-	O
third	O
under	O
the	O
influence	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
.	O

Additionally	O
,	O
the	O
mRNAs	O
for	O
both	O
procollagen	O
I	O
alpha	O
-	O
chains	O
were	O
stimulated	O
by	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
,	O
whereas	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
III	I-Protein
)	I-Protein
-	O
mRNA	O
showed	O
a	O
decrease	O
.	O

Changes	O
in	O
the	O
local	O
regulatory	O
activity	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
may	O
play	O
a	O
role	O
in	O
matrix	O
maturation	O
such	O
as	O
collagen	O
type	O
production	O
and	O
lysyl	O
hydroxylation	O
,	O
the	O
latter	O
being	O
altered	O
in	O
various	O
pathological	O
conditions	O
,	O
e	O
.	O
g	O
.	O
in	O
generalized	O
osteopenia	O
.	O

The	O
related	O
molecular	O
chaperones	O
calnexin	B-Protein
and	O
calreticulin	B-Protein
differentially	O
associate	O
with	O
nascent	O
T	O
cell	O
antigen	O
receptor	O
proteins	O
within	O
the	O
endoplasmic	O
reticulum	O
.	O

Assembly	O
of	O
the	O
multisubunit	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
complex	O
is	O
an	O
intricate	O
process	O
requiring	O
coordinated	O
regulation	O
of	O
at	O
least	O
six	O
different	O
gene	O
products	O
(	O
alpha	O
,	O
beta	O
,	O
gamma	O
,	O
delta	O
,	O
epsilon	O
,	O
and	O
zeta	O
)	O
and	O
the	O
ordered	O
pairing	O
of	O
partner	O
chains	O
within	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

To	O
date	O
,	O
two	O
proteins	O
have	O
been	O
implicated	O
as	O
functioning	O
as	O
molecular	O
chaperones	O
in	O
the	O
assembly	O
of	O
nascent	O
TCR	O
proteins	O
:	O
calnexin	B-Protein
,	O
a	O
resident	O
ER	O
transmembrane	O
protein	O
,	O
which	O
associates	O
with	O
all	O
TCR	O
components	O
except	O
zeta	O
,	O
and	O
T	O
cell	O
receptor	O
-	O
associated	O
protein	O
,	O
which	O
selectively	O
associates	O
with	O
CD3gammaepsilon	B-Protein
pairs	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
association	O
of	O
calreticulin	B-Protein
,	O
a	O
soluble	O
protein	O
with	O
significant	O
sequence	O
homology	O
to	O
calnexin	B-Protein
,	O
with	O
newly	O
synthesized	O
TCR	O
proteins	O
.	O

Analogous	O
to	O
calnexin	B-Protein
,	O
processing	O
of	O
glycan	O
chains	O
by	O
glucosidase	O
enzymes	O
was	O
required	O
for	O
initial	O
association	O
of	O
TCRalpha	B-Protein
and	O
-	B-Protein
beta	I-Protein
proteins	O
with	O
calreticulin	B-Protein
;	O
however	O
,	O
several	O
major	O
differences	O
were	O
noted	O
regarding	O
interaction	O
of	O
calnexin	B-Protein
and	O
calreticulin	B-Protein
chaperones	O
with	O
TCR	O
proteins	O
.	O

First	O
,	O
TCRalpha	B-Protein
and	O
-	B-Protein
beta	I-Protein
proteins	O
showed	O
prolonged	O
association	O
with	O
calnexin	B-Protein
molecules	O
compared	O
with	O
calreticulin	B-Protein
;	O
interaction	O
of	O
TCRalpha	B-Protein
proteins	O
with	O
calreticulin	B-Protein
was	O
particularly	O
transient	O
,	O
with	O
most	O
calreticulin	B-Protein
-	O
TCRalpha	B-Protein
protein	O
complexes	O
dissociating	O
within	O
15	O
min	O
of	O
their	O
initial	O
assembly	O
.	O

Second	O
,	O
we	O
found	O
that	O
,	O
unlike	O
calnexin	B-Protein
,	O
which	O
associated	O
with	O
clonotypic	O
TCRalpha	B-Protein
and	O
-	B-Protein
beta	I-Protein
proteins	O
and	O
invariant	O
CD3delta	B-Protein
and	O
-	B-Protein
epsilon	I-Protein
polypeptides	O
,	O
calreticulin	B-Protein
associated	O
specifically	O
with	O
clonotypic	O
TCRalpha	B-Protein
and	O
-	B-Protein
beta	I-Protein
proteins	O
.	O

These	O
studies	O
identify	O
calreticulin	B-Protein
as	O
a	O
molecular	O
chaperone	O
for	O
nascent	O
clonotypic	O
TCRalpha	B-Protein
and	O
-	B-Protein
beta	I-Protein
proteins	O
and	O
demonstrate	O
that	O
calreticulin	B-Protein
and	O
calnexin	B-Protein
differentially	O
associate	O
with	O
newly	O
synthesized	O
TCR	O
proteins	O
within	O
the	O
ER	O
.	O

Molecular	O
requirements	O
for	O
polyamines	O
binding	O
to	O
the	O
antispermine	O
monoclonal	O
antibody	O
Spm8	O
-	O
2	O
.	O

The	O
monoclonal	O
antispermine	O
antibody	O
Spm8	O
-	O
2	O
was	O
obtained	O
by	O
immunizing	O
mice	O
with	O
a	O
thyroglobulin	B-Protein
-	O
spermine	O
conjugate	O
.	O

The	O
molecular	O
requirements	O
for	O
polyamines	O
binding	O
to	O
this	O
antibody	O
were	O
investigated	O
by	O
ELISA	O
binding	O
and	O
inhibition	O
tests	O
,	O
using	O
a	O
variety	O
of	O
natural	O
polyamines	O
and	O
synthetic	O
polyamine	O
analogs	O
.	O

Four	O
major	O
structural	O
determinants	O
are	O
important	O
for	O
the	O
binding	O
of	O
polyamines	O
by	O
the	O
antibody	O
:	O
(	O
1	O
)	O
terminal	O
amino	O
groups	O
:	O
N	O
-	O
alkylation	O
of	O
both	O
terminal	O
amino	O
groups	O
of	O
the	O
polyamines	O
leads	O
to	O
an	O
important	O
drop	O
in	O
the	O
affinity	O
for	O
the	O
antibody	O
;	O
(	O
2	O
)	O
number	O
of	O
methylene	O
groups	O
spacing	O
the	O
amino	O
groups	O
:	O
the	O
four	O
carbon	O
chains	O
appear	O
to	O
present	O
the	O
optimum	O
length	O
since	O
the	O
antibody	O
binds	O
polyamines	O
with	O
repeats	O
of	O
the	O
aminobutyl	O
moiety	O
more	O
actively	O
than	O
their	O
homologues	O
with	O
shorter	O
or	O
longer	O
carbon	O
chains	O
;	O
(	O
3	O
)	O
number	O
of	O
amino	O
groups	O
:	O
the	O
affinity	O
of	O
Spm8	O
-	O
2	O
for	O
free	O
homologous	O
polyamines	O
varied	O
in	O
the	O
following	O
order	O
:	O
pentamines	O
>	O
tetramines	O
>	O
triamines	O
>	O
diamines	O
,	O
showing	O
the	O
importance	O
of	O
the	O
number	O
of	O
positive	O
charges	O
of	O
the	O
polyamines	O
in	O
the	O
antibody	O
-	O
antigen	O
reaction	O
;	O
the	O
importance	O
of	O
charges	O
is	O
further	O
emphasized	O
by	O
the	O
dependence	O
of	O
antibody	O
binding	O
on	O
the	O
ionic	O
strength	O
of	O
the	O
medium	O
;	O
(	O
4	O
)	O
N	O
-	O
acylation	O
of	O
one	O
terminal	O
amino	O
group	O
:	O
the	O
antibody	O
binds	O
more	O
actively	O
N1	O
-	O
acetylspermidine	O
than	O
spermidine	O
or	O
spermine	O
.	O

The	O
binding	O
properties	O
of	O
Spm8	O
-	O
2	O
suggest	O
the	O
presence	O
of	O
two	O
recognition	O
sequences	O
,	O
one	O
selective	O
for	O
N	O
-	O
acylaminopropyl	O
moieties	O
,	O
the	O
second	O
for	O
the	O
aminobutyl	O
moiety	O
.	O

Conversion	O
of	O
inactive	O
glycosylation	B-Protein
inhibiting	I-Protein
factor	I-Protein
to	O
bioactive	O
derivatives	O
by	O
modification	O
of	O
a	O
SH	O
group	O
.	O

Escherichia	O
coli	O
-	O
derived	O
recombinant	O
human	O
glycosylation	B-Protein
inhibiting	I-Protein
factor	I-Protein
(	O
rhGIF	B-Protein
)	O
contains	O
three	O
cysteine	O
residues	O
(	O
Cys	O
-	O
57	O
,	O
-	O
60	O
,	O
and	O
-	O
81	O
)	O
.	O

All	O
SH	O
groups	O
in	O
the	O
cysteine	O
residues	O
are	O
free	O
,	O
and	O
the	O
GIF	B-Protein
molecule	O
had	O
no	O
biologic	O
activity	O
.	O

Carboxymethylation	O
of	O
the	O
SH	O
group	O
of	O
Cys	O
-	O
60	O
in	O
the	O
molecule	O
resulted	O
in	O
the	O
generation	O
of	O
bioactivity	O
,	O
although	O
the	O
activity	O
of	O
the	O
carboxymethylated	O
GIF	B-Protein
was	O
10	O
-	O
to	O
20	O
-	O
fold	O
less	O
than	O
that	O
of	O
suppressor	O
T	O
cell	O
(	O
Ts	O
)	O
-	O
derived	O
GIF	B-Protein
.	O

However	O
,	O
treatment	O
of	O
the	O
inactive	O
rhGIF	B-Protein
with	O
ethylmercurithiosalicylate	O
or	O
5	O
,	O
5	O
'	O
-	O
dithiobis	O
(	O
2	O
-	O
nitrobenzoic	O
acid	O
)	O
(	O
DTNB	O
)	O
resulted	O
in	O
the	O
generation	O
of	O
derivatives	O
whose	O
bioactivity	O
was	O
comparable	O
to	O
that	O
of	O
the	O
Ts	O
-	O
derived	O
bioactive	O
GIF	B-Protein
.	O

The	O
activity	O
of	O
these	O
derivatives	O
was	O
lost	O
by	O
treatment	O
with	O
DTT	O
.	O

Isolation	O
and	O
chemical	O
analysis	O
of	O
the	O
DTNB	O
-	O
treated	O
GIF	B-Protein
derivative	O
revealed	O
that	O
binding	O
the	O
5	O
-	O
thio	O
-	O
2	O
-	O
nitrobenzoic	O
acid	O
group	O
with	O
Cys	O
-	O
60	O
was	O
responsible	O
for	O
the	O
generation	O
of	O
the	O
highly	O
bioactive	O
derivative	O
.	O

Inactive	O
cytosolic	O
GIF	B-Protein
from	O
mammalian	O
cells	O
could	O
also	O
be	O
converted	O
to	O
bioactive	O
derivative	O
by	O
treatment	O
with	O
the	O
SH	B-Protein
reagent	O
,	O
while	O
Ts	O
-	O
derived	O
bioactive	O
GIF	B-Protein
was	O
inactivated	O
by	O
DTT	O
.	O

These	O
results	O
,	O
together	O
with	O
an	O
x	O
-	O
ray	O
crystal	O
structure	O
of	O
GIF	B-Protein
molecules	O
,	O
strongly	O
suggest	O
that	O
the	O
generation	O
of	O
bioactivity	O
of	O
GIF	B-Protein
in	O
Ts	O
cells	O
is	O
due	O
to	O
posttranslational	O
modifications	O
that	O
result	O
in	O
conformational	O
changes	O
in	O
the	O
molecule	O
.	O

Reconstitution	O
of	O
trimethylamine	O
-	O
dependent	O
coenzyme	O
M	O
methylation	O
with	O
the	O
trimethylamine	B-Protein
corrinoid	I-Protein
protein	I-Protein
and	O
the	O
isozymes	O
of	O
methyltransferase	O
II	O
from	O
Methanosarcina	O
barkeri	O
.	O

Reconstitution	O
of	O
trimethylamine	O
-	O
dependent	O
coenzyme	O
M	O
(	O
CoM	O
)	O
methylation	O
was	O
achieved	O
with	O
three	O
purified	O
polypeptides	O
.	O

Two	O
of	O
these	O
polypeptides	O
copurified	O
as	O
a	O
trimethylamine	O
methyl	O
transfer	O
(	O
TMA	O
-	O
MT	O
)	O
activity	O
detected	O
by	O
stimulation	O
of	O
the	O
TMA	O
:	O
CoM	O
methyl	O
transfer	O
reaction	O
in	O
cell	O
extracts	O
.	O

The	O
purified	O
TMA	O
-	O
MT	O
fraction	O
stimulated	O
the	O
rate	O
of	O
methyl	O
-	O
CoM	O
formation	O
sevenfold	O
,	O
up	O
to	O
1	O
.	O
7	O
micromol	O
/	O
min	O
/	O
mg	O
of	O
TMA	O
-	O
MT	O
protein	O
.	O

The	O
TMA	O
-	O
MT	O
polypeptides	O
had	O
molecular	O
masses	O
of	O
52	O
and	O
26	O
kDa	O
.	O

Gel	O
permeation	O
of	O
the	O
TMA	O
-	O
MT	O
fraction	O
demonstrated	O
that	O
the	O
52	O
-	O
kDa	O
polypeptide	O
eluted	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
280	O
kDa	O
.	O

The	O
26	O
-	O
kDa	O
protein	O
eluted	O
primarily	O
as	O
a	O
monomer	O
,	O
but	O
some	O
26	O
-	O
kDa	O
polypeptides	O
also	O
eluted	O
with	O
the	O
280	O
-	O
kDa	O
peak	O
,	O
indicating	O
that	O
the	O
two	O
proteins	O
weakly	O
associate	O
.	O

The	O
two	O
polypeptides	O
could	O
be	O
completely	O
separated	O
using	O
gel	O
permeation	O
in	O
the	O
presence	O
of	O
sodium	O
dodecyl	O
sulfate	O
.	O

The	O
corrinoid	O
remained	O
associated	O
with	O
the	O
26	O
-	O
kDa	O
polypeptide	O
at	O
a	O
molar	O
ratio	O
of	O
1	O
.	O
1	O
corrin	O
/	O
26	O
-	O
kDa	O
polypeptide	O
.	O

This	O
polypeptide	O
was	O
therefore	O
designated	O
the	O
TMA	B-Protein
corrinoid	I-Protein
protein	I-Protein
,	O
or	O
TCP	B-Protein
.	O

The	O
TMA	O
-	O
MT	O
polypeptides	O
,	O
when	O
supplemented	O
with	O
purified	O
methylcorrinoid	B-Protein
:	I-Protein
CoM	I-Protein
methyltransferase	I-Protein
(	O
MT2	B-Protein
)	O
,	O
could	O
effect	O
the	O
demethylation	O
of	O
TMA	O
with	O
the	O
subsequent	O
methylation	O
of	O
CoM	O
and	O
the	O
production	O
of	O
dimethylamine	O
at	O
specific	O
activities	O
of	O
up	O
to	O
600	O
nmol	O
/	O
min	O
/	O
mg	O
of	O
TMA	O
-	O
MT	O
protein	O
.	O

Neither	O
dimethylamine	O
nor	O
monomethylamine	O
served	O
as	O
the	O
substrate	O
,	O
and	O
the	O
activity	O
required	O
Ti	O
(	O
III	O
)	O
citrate	O
and	O
methyl	O
viologen	O
.	O

TMA	O
-	O
MT	O
could	O
interact	O
with	O
either	O
isozyme	O
of	O
MT2	B-Protein
but	O
had	O
the	O
greatest	O
affinity	O
for	O
the	O
A	O
isozyme	O
.	O

These	O
results	O
suggest	O
that	O
TCP	B-Protein
is	O
uniquely	O
involved	O
in	O
TMA	O
-	O
dependent	O
methanogenesis	O
,	O
that	O
this	O
corrinoid	O
protein	O
is	O
methylated	O
by	O
the	O
substrate	O
and	O
demethylated	O
by	O
either	O
isozyme	O
of	O
MT2	B-Protein
,	O
and	O
that	O
the	O
predominant	O
isozyme	O
of	O
MT2	B-Protein
found	O
in	O
TMA	O
-	O
grown	O
cells	O
is	O
the	O
favored	O
participant	O
in	O
the	O
TMA	O
:	O
CoM	O
methyl	O
transfer	O
reaction	O
.	O

Analysis	O
of	O
the	O
binding	O
specificities	O
of	O
oligomannoside	O
-	O
binding	O
proteins	O
using	O
methylated	O
monosaccharides	O
.	O

The	O
binding	O
specificities	O
of	O
the	O
closely	O
related	O
lectins	O
from	O
Canavalia	O
ensiformis	O
and	O
Dioclea	O
grandiflora	O
were	O
examined	O
using	O
specifically	O
O	O
-	O
alkylated	O
mono	O
-	O
and	O
disaccharides	O
.	O

Both	O
lectins	O
accept	O
any	O
substitution	O
at	O
the	O
monosaccharide	O
C2	O
hydroxyl	O
group	O
.	O

The	O
binding	O
energy	O
of	O
C2	O
-	O
alkylated	O
ligands	O
-	O
concanavalin	B-Protein
A	I-Protein
complexes	O
increases	O
by	O
1	O
kcal	O
mol	O
-	O
1	O
for	O
the	O
C2	O
-	O
O	O
-	O
ethyl	O
ligand	O
,	O
while	O
the	O
binding	O
energies	O
of	O
the	O
corresponding	O
complexes	O
with	O
the	O
Dioclea	O
lectin	B-Protein
are	O
identical	O
.	O

Both	O
lectins	O
accept	O
methyl	O
,	O
but	O
not	O
ethyl	O
,	O
substitution	O
of	O
the	O
C3	O
hydroxyl	O
,	O
in	O
contrast	O
to	O
earlier	O
reports	O
.	O

The	O
results	O
are	O
interpreted	O
in	O
terms	O
of	O
existing	O
models	O
of	O
the	O
concanavalin	B-Protein
A	I-Protein
binding	O
site	O
.	O

While	O
the	O
results	O
are	O
consistent	O
with	O
a	O
model	O
of	O
the	O
concanavalin	B-Protein
A	I-Protein
extended	O
binding	O
site	O
that	O
places	O
the	O
non	O
-	O
reducing	O
terminus	O
of	O
all	O
disaccharides	O
in	O
the	O
monosaccharide	O
binding	O
site	O
,	O
they	O
point	O
to	O
the	O
dangers	O
of	O
interpreting	O
the	O
binding	O
behavior	O
of	O
unnatural	O
saccharide	O
ligands	O
on	O
the	O
basis	O
of	O
crystallographic	O
data	O
obtained	O
with	O
native	O
ligands	O
.	O

Benzyl	O
-	O
alpha	O
-	O
GalNAc	O
inhibits	O
sialylation	O
of	O
O	O
-	O
glycosidic	O
sugar	O
chains	O
on	O
CD44	B-Protein
and	O
enhances	O
experimental	O
metastatic	O
capacity	O
in	O
B16BL6	O
melanoma	O
cells	O
.	O

We	O
examined	O
the	O
effect	O
of	O
benzyl	O
-	O
alpha	O
-	O
N	O
-	O
acetylgalactosamine	O
(	O
benzyl	O
-	O
alpha	O
-	O
GalNAc	O
)	O
,	O
which	O
specifically	O
inhibits	O
the	O
synthesis	O
of	O
O	O
-	O
linked	O
oligosaccharides	O
,	O
on	O
the	O
expression	O
of	O
the	O
peanut	O
agglutinin	B-Protein
(	O
PNA	B-Protein
)	O
-	O
binding	O
sugar	O
chains	O
(	O
Gal	O
beta	O
1	O
-	O
3GalNAc	O
)	O
of	O
CD44	B-Protein
and	O
on	O
its	O
experimental	O
metastatic	O
ability	O
in	O
B16BL6	O
melanoma	O
.	O

Benzyl	O
-	O
alpha	O
-	O
GalNAc	O
increased	O
the	O
PNA	B-Protein
-	O
binding	O
,	O
but	O
not	O
Concanavalin	B-Protein
A	I-Protein
(	O
Con	B-Protein
A	I-Protein
)	O
,	O
wheat	O
germ	O
agglutinin	O
(	O
WGA	O
)	O
,	O
and	O
leukoagglutinating	O
phytohemaagglutinin	O
(	O
L	O
-	O
PHA	O
)	O
-	O
binding	O
to	O
the	O
cell	O
surface	O
.	O

Benzyl	O
-	O
alpha	O
-	O
GalNAc	O
markedly	O
increased	O
the	O
PNA	B-Protein
-	O
binding	O
to	O
CD44	B-Protein
by	O
decreasing	O
the	O
sialylation	O
of	O
these	O
sugar	O
chains	O
.	O

The	O
experimental	O
metastatic	O
ability	O
of	O
B16BL6	O
cells	O
was	O
enhanced	O
in	O
association	O
with	O
this	O
modulation	O
of	O
the	O
sugar	O
chains	O
.	O

These	O
findings	O
suggested	O
that	O
unsialylated	O
Gal	O
beta	O
1	O
-	O
3GalNAc	O
sugar	O
chains	O
on	O
the	O
cell	O
surface	O
and	O
/	O
or	O
CD44	B-Protein
are	O
involved	O
in	O
the	O
metastatic	O
process	O
of	O
B16BL6	O
melanoma	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
known	O
functions	O
of	O
CD44	B-Protein
,	O
such	O
as	O
adhesion	O
to	O
hyaluronate	O
,	O
fibronectin	B-Protein
,	O
collagen	O
,	O
and	O
endothelial	O
cells	O
,	O
as	O
well	O
as	O
homotypic	O
aggregation	O
,	O
were	O
not	O
affected	O
by	O
benzyl	O
-	O
alpha	O
-	O
GalNAc	O
regardless	O
of	O
the	O
enhancement	O
of	O
metastatic	O
ability	O
induced	O
by	O
this	O
glycosylation	O
inhibitor	O
.	O

CD44	B-Protein
might	O
have	O
other	O
metastasis	O
related	O
functions	O
that	O
remain	O
to	O
be	O
elucidated	O
.	O

Deglycosylation	O
of	O
serum	O
vitamin	B-Protein
D3	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
by	O
alpha	B-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminidase	I-Protein
detected	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

A	O
serum	O
glycoprotein	O
,	O
Gc	B-Protein
protein	O
(	O
vitamin	B-Protein
D3	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
)	O
,	O
can	O
be	O
converted	O
by	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
of	O
B	O
cells	O
and	O
sialidase	O
of	O
T	O
cells	O
to	O
a	O
potent	O
macrophage	O
-	O
activating	O
factor	O
(	O
MAF	O
)	O
,	O
a	O
protein	O
with	O
N	O
-	O
acetylgalactosamine	O
as	O
the	O
remaining	O
sugar	O
moiety	O
.	O

Thus	O
,	O
Gc	B-Protein
protein	O
is	O
the	O
precursor	O
for	O
MAF	O
.	O

Treatment	O
of	O
Gc	B-Protein
protein	O
with	O
immobilized	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
and	O
sialidase	O
generates	O
a	O
remarkably	O
high	O
titered	O
macrophage	O
-	O
activating	O
factor	O
(	O
GcMAF	B-Protein
)	O
.	O

When	O
peripheral	O
blood	O
monocytes	O
/	O
macrophages	O
(	O
designated	O
macrophages	O
)	O
of	O
33	O
systemic	O
lupus	O
erythematosus	O
patients	O
were	O
incubated	O
with	O
GcMAF	B-Protein
(	O
100	O
pg	O
/	O
ml	O
)	O
,	O
the	O
macrophages	O
of	O
all	O
patients	O
were	O
activated	O
as	O
determined	O
by	O
superoxide	O
generation	O
.	O

However	O
,	O
the	O
precursor	O
activity	O
of	O
patient	O
plasma	O
Gc	B-Protein
protein	O
was	O
lost	O
or	O
reduced	O
in	O
these	O
patients	O
.	O

Loss	O
of	O
the	O
precursor	O
activity	O
was	O
the	O
result	O
of	O
deglycosylation	O
of	O
plasma	O
Gc	B-Protein
protein	O
by	O
alpha	B-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminidase	I-Protein
activity	O
found	O
in	O
the	O
patient	O
plasma	O
.	O

Levels	O
of	O
plasma	O
alpha	B-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminidase	I-Protein
activity	O
in	O
individual	O
patients	O
had	O
an	O
inverse	O
correlation	O
with	O
the	O
MAF	O
precursor	O
activity	O
of	O
their	O
plasma	O
Gc	B-Protein
protein	O
.	O

Deglycosylated	O
Gc	B-Protein
protein	O
cannot	O
be	O
converted	O
to	O
macro	O
-	O
phage	O
-	O
activating	O
factor	O
.	O

The	O
resulting	O
defect	O
in	O
macro	O
-	O
phage	O
activation	O
may	O
lead	O
to	O
an	O
inability	O
to	O
clear	O
pathogenic	O
immune	O
complexes	O
.	O

Thus	O
,	O
elevated	O
plasma	O
alpha	B-Protein
-	I-Protein
N	I-Protein
-	I-Protein
acetylgalactosaminidase	I-Protein
activity	O
resulting	O
in	O
the	O
loss	O
of	O
MAF	O
precursor	O
activity	O
and	O
reduced	O
macro	O
-	O
phage	O
activity	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
systemic	O
lupus	O
erythematosus	O
.	O

Regulatory	O
adaptation	O
of	O
isoprenoid	O
biosynthesis	O
and	O
the	O
LDL	B-Protein
receptor	I-Protein
pathway	O
in	O
fibroblasts	O
from	O
patients	O
with	O
mevalonate	B-Protein
kinase	I-Protein
deficiency	O
.	O

In	O
a	O
search	O
for	O
the	O
pathophysiologic	O
mechanisms	O
,	O
we	O
estimated	O
isoprenoid	O
synthesis	O
and	O
concentration	O
,	O
cellular	O
growth	O
,	O
and	O
the	O
activity	O
of	O
the	O
LDL	B-Protein
receptor	I-Protein
pathway	O
in	O
fibroblasts	O
from	O
patients	O
with	O
mevalonate	B-Protein
kinase	I-Protein
deficiency	O
(	O
MKD	O
)	O
,	O
a	O
severe	O
multisystemic	O
disorder	O
of	O
cholesterol	O
and	O
non	O
-	O
sterol	O
isoprenoid	O
biosynthesis	O
.	O

In	O
response	O
to	O
different	O
concentrations	O
of	O
LDL	O
and	O
non	O
-	O
lipoprotein	O
-	O
bound	O
cholesterol	O
,	O
MKD	O
cells	O
partially	O
counteracted	O
their	O
enzyme	O
defect	O
by	O
increased	O
activities	O
of	O
3	B-Protein
-	I-Protein
hydroxy	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
methylglutaryl	I-Protein
(	I-Protein
HMG	I-Protein
)	I-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
(	O
results	O
from	O
earlier	O
studies	O
)	O
and	O
the	O
LDL	B-Protein
receptor	I-Protein
pathway	O
,	O
responses	O
similar	O
to	O
the	O
pharmacologic	O
effects	O
seen	O
upon	O
administration	O
of	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
inhibitors	O
.	O

Rates	O
of	O
N	O
-	O
linked	O
protein	O
glycosylation	O
,	O
estimated	O
as	O
the	O
amount	O
of	O
[	O
14C	O
]	O
galactose	O
-	O
labeled	O
macromolecules	O
secreted	O
into	O
cell	O
culture	O
medium	O
,	O
were	O
significantly	O
decreased	O
in	O
MKD	O
fibroblasts	O
in	O
comparison	O
with	O
control	O
cells	O
which	O
may	O
indicate	O
alterations	O
in	O
the	O
dolichol	O
or	O
dolichol	O
phosphate	O
pool	O
.	O

In	O
response	O
to	O
exogenous	O
cholesterol	O
,	O
the	O
major	O
feedback	O
inhibitor	O
of	O
isoprenoid	O
biosynthesis	O
,	O
growth	O
velocities	O
of	O
MKD	O
fibroblasts	O
declined	O
in	O
comparison	O
with	O
control	O
cells	O
,	O
further	O
suggesting	O
an	O
impairment	O
of	O
non	O
-	O
sterol	O
isoprenoid	O
biosynthesis	O
in	O
MKD	O
.	O

Our	O
results	O
suggest	O
an	O
imbalance	O
in	O
the	O
multilevel	O
regulation	O
of	O
the	O
biosynthesis	O
of	O
cholesterol	O
and	O
non	O
-	O
sterol	O
isoprenoids	O
in	O
MKD	O
,	O
representing	O
an	O
additional	O
causative	O
factor	O
responsible	O
for	O
the	O
pre	O
-	O
and	O
postnatal	O
pathology	O
of	O
MKD	O
.	O

Protein	O
glycosylation	O
in	O
a	O
heat	O
-	O
resistant	O
rat	O
fibroblast	O
cell	O
model	O
expressing	O
human	O
HSP70	B-Protein
.	O

Thermotolerance	O
and	O
heat	O
resistance	O
are	O
frequently	O
associated	O
with	O
elevated	O
levels	O
of	O
heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
.	O

Elevated	O
heat	O
resistance	O
is	O
also	O
found	O
to	O
be	O
associated	O
with	O
the	O
overexpression	O
of	O
high	O
levels	O
of	O
HSP70	B-Protein
,	O
as	O
seen	O
in	O
M21	O
cells	O
,	O
derived	O
from	O
the	O
Rat	O
-	O
1	O
line	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
that	O
M21	O
cells	O
also	O
feature	O
an	O
increase	O
in	O
general	O
protein	O
glycosylation	O
and	O
specific	O
expression	O
of	O
the	O
stress	O
glycoprotein	O
,	O
GP62	B-Protein
,	O
both	O
of	O
which	O
correlate	O
with	O
cellular	O
heat	O
resistance	O
.	O

The	O
expression	O
of	O
GP50	B-Protein
,	O
a	O
major	O
stress	O
glycoprotein	O
in	O
cell	O
lines	O
such	O
as	O
CHO	O
,	O
however	O
,	O
did	O
not	O
correlate	O
with	O
cellular	O
heat	O
resistance	O
in	O
M21	O
cells	O
.	O

Protein	O
glycosylation	O
that	O
occurs	O
during	O
acute	O
heat	O
stress	O
(	O
"	O
prompt	O
"	O
glycosylation	O
)	O
was	O
associated	O
with	O
the	O
glycosylation	O
of	O
a	O
major	O
"	O
prompt	O
"	O
stress	O
glycoprotein	O
,	O
P	B-Protein
-	I-Protein
SG64	I-Protein
(	O
M	O
(	O
r	O
)	O
of	O
64	O
,	O
000	O
)	O
,	O
that	O
was	O
identified	O
by	O
immunoblotting	O
as	O
a	O
glycosylated	O
form	O
of	O
calreticulin	B-Protein
.	O

The	O
higher	O
level	O
of	O
protein	O
glycosylation	O
in	O
M21	O
cells	O
correlated	O
well	O
with	O
increased	O
D	O
-	O
[	O
2	O
-	O
3H	O
]	O
mannose	O
incorporation	O
into	O
precursor	O
pools	O
of	O
dolichyl	O
phosphomannose	O
and	O
dolichyl	O
pyrophosphoryl	O
oligosaccharides	O
and	O
into	O
glycoproteins	O
.	O

Thus	O
,	O
heat	O
resistance	O
in	O
M21	O
cells	O
is	O
associated	O
not	O
only	O
with	O
expression	O
of	O
high	O
levels	O
of	O
HSP70	B-Protein
,	O
but	O
also	O
with	O
a	O
concomitant	O
increase	O
in	O
protein	O
glycosylation	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
stress	O
-	O
induced	O
protein	O
glycosylation	O
is	O
a	O
component	O
of	O
cellular	O
stress	O
response	O
,	O
either	O
in	O
association	O
with	O
HSPs	O
or	O
as	O
an	O
independent	O
mechanism	O
.	O

The	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
gene	O
is	O
silenced	O
by	O
CpG	O
methylation	O
in	O
human	O
hepatocellular	O
carcinomas	O
.	O

Our	O
study	O
was	O
designed	O
to	O
clarify	O
the	O
significance	O
of	O
silencing	O
the	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
gene	O
,	O
which	O
is	O
located	O
on	O
16q22	O
.	O
1	O
,	O
due	O
to	O
CpG	O
methylation	O
during	O
hepatocarcinogenesis	O
.	O

The	O
CpG	O
methylation	O
status	O
of	O
primary	O
hepatocellular	O
carcinomas	O
(	O
HCCs	O
)	O
and	O
corresponding	O
liver	O
tissues	O
showing	O
chronic	O
hepatitis	O
or	O
cirrhosis	O
,	O
which	O
are	O
widely	O
considered	O
to	O
be	O
precancerous	O
conditions	O
,	O
were	O
assessed	O
by	O
digesting	O
DNA	O
with	O
methylation	O
-	O
sensitive	O
and	O
non	O
-	O
sensitive	O
restriction	O
enzymes	O
.	O

CpG	O
methylation	O
around	O
the	O
promoter	O
region	O
of	O
the	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
gene	O
was	O
detected	O
in	O
46	O
%	O
of	O
liver	O
tissues	O
showing	O
chronic	O
hepatitis	O
or	O
cirrhosis	O
and	O
67	O
%	O
of	O
HCCs	O
examined	O
.	O

Immunohistochemical	O
examination	O
revealed	O
reduced	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
expression	O
in	O
59	O
%	O
of	O
HCCs	O
examined	O
.	O

CpG	O
methylation	O
around	O
the	O
promoter	O
region	O
correlated	O
significantly	O
with	O
reduced	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
expression	O
in	O
HCCs	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CpG	O
methylation	O
around	O
the	O
promoter	O
region	O
,	O
which	O
increases	O
during	O
the	O
progression	O
from	O
a	O
precancerous	O
condition	O
to	O
HCC	O
,	O
may	O
participate	O
in	O
hepatocarcinogenesis	O
through	O
reduction	O
of	O
E	B-Protein
-	I-Protein
cadherin	I-Protein
expression	O
,	O
resulting	O
in	O
loss	O
of	O
intercellular	O
adhesiveness	O
and	O
destruction	O
of	O
tissue	O
morphology	O
.	O

Characterization	O
of	O
the	O
ETSA	O
-	O
21	O
antigen	O
,	O
a	O
glycosylphosphatidyl	O
-	O
inositol	O
anchor	O
glycoprotein	O
identified	O
in	O
breast	O
cancer	O
cells	O
using	O
monoclonal	O
antibody	O
B21	O
.	O

Mab	O
B21	O
is	O
a	O
monoclonal	O
antibody	O
(	O
Mab	O
)	O
that	O
recognizes	O
an	O
epithelial	O
tumor	O
surface	O
antigen	O
(	O
ETSA	O
-	O
B21	O
)	O
from	O
diverse	O
human	O
tumor	O
cell	O
lines	O
including	O
breast	O
,	O
ovary	O
,	O
uterus	O
,	O
and	O
their	O
cognate	O
carcinoma	O
tissues	O
.	O

A	O
lower	O
reactivity	O
has	O
been	O
observed	O
in	O
normal	O
breast	O
tissue	O
and	O
benign	O
hyperplesia	O
.	O

In	O
this	O
study	O
,	O
the	O
characteristics	O
of	O
the	O
ETSA	O
-	O
B21	O
antigen	O
have	O
been	O
examined	O
in	O
greater	O
detail	O
in	O
the	O
MCF	O
-	O
7	O
,	O
SK	O
-	O
BR	O
-	O
3	O
,	O
and	O
MDA	O
-	O
MB	O
-	O
453	O
breast	O
cancer	O
cell	O
lines	O
.	O

Treatment	O
with	O
phosphatidylinositol	B-Protein
-	I-Protein
phospholipase	I-Protein
C	I-Protein
,	O
but	O
no	O
neuraminidase	O
were	O
found	O
to	O
partially	O
remove	O
the	O
ETSA	O
-	O
B21	O
signal	O
from	O
the	O
cell	O
surface	O
as	O
revealed	O
by	O
immunofluorescence	O
microscopy	O
.	O

Inhibition	O
of	O
the	O
N	O
-	O
glycosylation	O
pathway	O
by	O
tunicamycin	O
resulted	O
in	O
a	O
decreased	O
ETSA	O
-	O
B21	O
signal	O
on	O
the	O
cell	O
membrane	O
.	O

In	O
addition	O
,	O
the	O
antigen	O
-	O
antibody	O
complex	O
was	O
internalized	O
in	O
breast	O
cancer	O
cells	O
as	O
demonstrated	O
by	O
an	O
acidic	O
was	O
internalization	O
assay	O
evaluated	O
using	O
immunofluorescence	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
suggests	O
that	O
ETSA	O
-	O
B21	O
is	O
a	O
GPI	O
anchor	O
N	O
-	O
glycosylated	O
protein	O
promoting	O
specific	O
antibody	O
internalization	O
in	O
breast	O
cancer	O
cells	O
.	O

Posttranscriptional	O
aspects	O
of	O
the	O
biosynthesis	O
of	O
type	O
1	O
collagen	O
pro	O
-	O
alpha	O
chains	O
:	O
the	O
effects	O
of	O
posttranslational	O
modifications	O
on	O
synthesis	O
pauses	O
during	O
elongation	O
of	O
the	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
.	O

Early	O
studies	O
indicated	O
that	O
chain	O
elongation	O
pauses	O
were	O
prominent	O
during	O
the	O
in	O
vivo	O
synthesis	O
of	O
type	O
I	O
procollagen	O
chains	O
,	O
and	O
it	O
was	O
postulated	O
[	O
Kirk	O
et	O
al	O
.	O
,	O
(	O
1987	O
)	O
:	O
J	O
Biol	O
Chem	O
262	O
:	O
5540	O
-	O
5545	O
.	O
]	O
that	O
these	O
might	O
have	O
a	O
role	O
in	O
the	O
coordination	O
of	O
procollagen	O
I	O
molecular	O
assembly	O
.	O

To	O
examine	O
this	O
postulate	O
,	O
polysomes	O
isolated	O
from	O
[	O
(	O
14	O
)	O
C	O
]	O
-	O
Pro	O
-	O
labeled	O
3T6	O
cells	O
were	O
subjected	O
to	O
SDS	O
-	O
PAGE	O
.	O

The	O
resulting	O
gels	O
were	O
Western	O
blotted	O
and	O
screened	O
with	O
a	O
monoclonal	O
antibody	O
(	O
SP1	O
.	O
D8	O
)	O
directed	O
against	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
.	O

The	O
blots	O
were	O
fluorographed	O
,	O
which	O
also	O
permitted	O
analysis	O
of	O
the	O
pro	O
alpha	B-Protein
2	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
.	O

There	O
was	O
a	O
prominent	O
pro	O
alpha1	O
synthesis	O
pause	O
near	O
the	O
completion	O
of	O
full	O
-	O
length	O
chain	O
elongation	O
,	O
not	O
matched	O
by	O
a	O
pro	O
alpha	O
2	O
pause	O
.	O

The	O
amount	O
of	O
labeled	O
polysome	O
-	O
associated	O
near	O
-	O
full	O
length	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
increased	O
in	O
parallel	O
with	O
labeling	O
time	O
.	O

After	O
24	O
h	O
in	O
culture	O
-	O
[	O
(	O
14	O
)	O
C	O
-	O
Pro	O
]	O
,	O
collagen	O
synthesis	O
ceased	O
but	O
unlabeled	O
polysome	O
-	O
associated	O
pro	O
alpha1	O
chains	O
were	O
readily	O
detected	O
by	O
SP1	O
.	O
D8	O
.	O

Change	O
to	O
fresh	O
culture	O
medium	O
+	O
[	O
(	O
14	O
)	O
C	O
-	O
Pro	O
]	O
reinitiated	O
synthesis	O
and	O
permitted	O
tracing	O
of	O
the	O
newly	O
synthesized	O
labeled	O
pro	O
a	O
chains	O
through	O
the	O
polysome	O
and	O
intracellular	O
compartments	O
.	O

The	O
secreted	O
procollagen	O
molecules	O
had	O
a	O
2	O
:	O
1	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
1	I-Protein
)	I-Protein
:	O
pro	O
alpha	B-Protein
2	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
ratio	O
but	O
the	O
polysome	O
-	O
bound	O
peptides	O
did	O
not	O
.	O

Pulse	O
-	O
chase	O
experiments	O
showed	O
that	O
near	O
-	O
full	O
length	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
remained	O
bound	O
to	O
polysomes	O
as	O
long	O
as	O
4	O
h	O
after	O
reinitiation	O
of	O
translation	O
but	O
there	O
was	O
no	O
evidence	O
for	O
pro	O
alpha	B-Protein
2	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
accumulation	O
.	O

The	O
hydroxylation	O
inhibitor	O
alpha	O
,	O
alpha	O
'	O
-	O
dipyridyl	O
,	O
and	O
triple	O
-	O
helix	O
inhibitors	O
cis	O
-	O
hydroxyproline	O
and	O
3	O
,	O
4	O
dehydroproline	O
had	O
minimal	O
effects	O
on	O
the	O
buildup	O
of	O
polysome	O
-	O
associated	O
pro	O
al	O
chains	O
.	O

The	O
glycosylation	O
inhibitor	O
tunicamycin	O
also	O
failed	O
to	O
change	O
the	O
final	O
pro	O
alpha	O
1	O
chain	O
pausing	O
,	O
but	O
it	O
did	O
cause	O
the	O
appearance	O
of	O
several	O
discrete	O
lower	O
molecular	O
weight	O
pro	O
alpha	O
1	O
-	O
related	O
polypeptides	O
that	O
could	O
not	O
be	O
accounted	O
for	O
simply	O
as	O
the	O
result	O
of	O
lack	O
of	O
N	O
-	O
linked	O
glycosylation	O
in	O
the	O
C	O
-	O
propeptide	O
regions	O
.	O

Disulfide	O
bond	O
experiments	O
showed	O
that	O
some	O
of	O
the	O
paused	O
nascent	O
polysome	O
-	O
associated	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
were	O
disulfide	O
bonded	O
.	O

Thus	O
,	O
while	O
synthesis	O
of	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
and	O
pro	O
alpha	B-Protein
2	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
proceeds	O
in	O
parallel	O
within	O
the	O
same	O
ER	O
compartments	O
,	O
their	O
elongation	O
rates	O
are	O
not	O
coordinated	O
.	O

Interactions	O
leading	O
to	O
heterotrimer	O
formation	O
are	O
a	O
late	O
event	O
which	O
may	O
affect	O
the	O
rate	O
of	O
release	O
of	O
the	O
completed	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
from	O
the	O
polysome	O
.	O

The	O
release	O
of	O
completed	O
nascent	O
pro	O
alpha	B-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
from	O
their	O
polysomal	O
complexes	O
is	O
regulated	O
by	O
a	O
mechanism	O
not	O
operating	O
in	O
the	O
synthesis	O
of	O
pro	O
alpha	B-Protein
2	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chains	O
.	O

The	O
pro	B-Protein
alpha	I-Protein
1	I-Protein
(	I-Protein
I	I-Protein
)	I-Protein
chain	O
release	O
process	O
is	O
not	O
connected	O
directly	O
with	O
hydroxylation	O
,	O
glycosylation	O
or	O
triple	O
-	O
helix	O
formation	O
.	O

Cytotoxic	O
T	O
lymphocytes	O
derived	O
from	O
bone	O
marrow	O
mononuclear	O
cells	O
of	O
multiple	O
myeloma	O
patients	O
recognize	O
an	O
underglycosylated	O
form	O
of	O
MUC1	B-Protein
mucin	O
.	O

MUC1	B-Protein
is	O
a	O
highly	O
immunogenic	O
epithelial	O
mucin	O
and	O
serves	O
as	O
a	O
tumor	O
-	O
associated	O
antigen	O
in	O
breast	O
,	O
pancreatic	O
and	O
ovarian	O
carcinomas	O
.	O

We	O
previously	O
reported	O
the	O
expression	O
of	O
MUC1	B-Protein
on	O
myeloma	O
cells	O
and	O
the	O
establishment	O
of	O
an	O
HLA	O
-	O
unrestricted	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
line	O
TN	O
that	O
recognized	O
MUC1	B-Protein
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
a	O
multiple	O
myeloma	O
patient	O
.	O

In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
induce	O
such	O
CTL	O
from	O
six	O
other	O
multiple	O
myeloma	O
patients	O
consecutively	O
in	O
order	O
to	O
show	O
that	O
the	O
induction	O
of	O
the	O
CTL	O
line	O
TN	O
had	O
not	O
resulted	O
from	O
some	O
idiosyncrasy	O
of	O
the	O
first	O
patient	O
.	O

Bone	O
marrow	O
mononuclear	O
cells	O
were	O
used	O
to	O
induce	O
CTL	O
,	O
because	O
they	O
contain	O
myeloma	O
cells	O
that	O
might	O
stimulate	O
the	O
autologous	O
lymphocytes	O
.	O

Bulk	O
CTL	O
lines	O
were	O
induced	O
from	O
two	O
out	O
of	O
six	O
patients	O
.	O

The	O
CTL	O
line	O
TS	O
was	O
CD8	B-Protein
+	O
cell	O
dominant	O
and	O
KY	O
was	O
CD4	B-Protein
+	O
cell	O
dominant	O
.	O

Both	O
CTL	O
lines	O
lysed	O
MUC1	B-Protein
+	O
myeloma	O
and	O
breast	O
carcinoma	O
cell	O
lines	O
.	O

The	O
cytotoxicity	O
of	O
the	O
CTL	O
lines	O
was	O
inhibited	O
by	O
anti	O
-	O
CD3	O
,	O
anti	O
-	O
alpha	B-Protein
beta	B-Protein
TCR	I-Protein
and	O
anti	O
-	O
MUC1	B-Protein
mAb	O
.	O

It	O
was	O
also	O
inhibited	O
by	O
a	O
MUC1	B-Protein
transfectant	O
,	O
but	O
not	O
by	O
a	O
mock	O
transfectant	O
in	O
cold	O
target	O
inhibition	O
assays	O
.	O

MUC1	B-Protein
was	O
transfected	O
into	O
a	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
.	O

The	O
reactivity	O
of	O
anti	O
-	O
MUC1	B-Protein
core	O
protein	O
mAb	O
and	O
the	O
cytotoxicity	O
of	O
the	O
CTL	O
against	O
the	O
transfectant	O
was	O
enhanced	O
by	O
the	O
treatment	O
of	O
the	O
cells	O
with	O
an	O
O	O
-	O
glycosylation	O
inhibitor	O
.	O

Thus	O
it	O
is	O
generally	O
accepted	O
that	O
the	O
HLA	O
-	O
unrestricted	O
CTL	O
which	O
directly	O
recognize	O
the	O
underglycosylated	O
from	O
of	O
MUC1	B-Protein
using	O
their	O
TCR	O
could	O
be	O
induced	O
from	O
a	O
certain	O
proportion	O
(	O
approximately	O
30	O
%	O
)	O
of	O
untreated	O
multiple	O
myeloma	O
patients	O
.	O

DNA	O
methylation	O
patterns	O
in	O
the	O
calcitonin	B-Protein
gene	O
region	O
at	O
first	O
diagnosis	O
and	O
at	O
relapse	O
of	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

Aberrant	O
DNA	O
methylation	O
can	O
occur	O
early	O
in	O
neoplastic	O
transformation	O
and	O
may	O
lead	O
to	O
the	O
development	O
of	O
cancer	O
.	O

We	O
describe	O
the	O
alterations	O
of	O
methylation	O
patterns	O
at	O
the	O
DNA	O
sequence	O
level	O
which	O
occurred	O
in	O
the	O
5	O
'	O
region	O
of	O
the	O
calcitonin	B-Protein
gene	O
in	O
lymphoblasts	O
from	O
14	O
pediatric	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

The	O
DNA	O
methylation	O
status	O
of	O
25	O
CpG	O
sites	O
was	O
determined	O
by	O
sequence	O
analysis	O
after	O
bisulfite	O
treatment	O
of	O
the	O
DNA	O
.	O

This	O
method	O
showed	O
that	O
13	O
out	O
of	O
14	O
patients	O
had	O
increased	O
numbers	O
of	O
methylated	O
CpG	O
sites	O
in	O
the	O
calcitonin	B-Protein
gene	O
region	O
at	O
initial	O
diagnosis	O
when	O
compared	O
to	O
control	O
DNA	O
from	O
healthy	O
individuals	O
.	O

The	O
5	O
'	O
region	O
of	O
the	O
calcitonin	B-Protein
gene	O
appears	O
to	O
be	O
methylated	O
to	O
a	O
significantly	O
higher	O
degree	O
in	O
T	O
lineage	O
ALL	O
compared	O
to	O
B	O
lineage	O
ALL	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Each	O
of	O
six	O
ALL	O
patients	O
who	O
were	O
investigated	O
at	O
initial	O
diagnosis	O
and	O
at	O
relapse	O
showed	O
alterations	O
in	O
DNA	O
methylation	O
between	O
the	O
two	O
stages	O
.	O

These	O
six	O
cases	O
were	O
also	O
investigated	O
by	O
Southern	O
blot	O
analysis	O
with	O
methylcytosine	O
-	O
sensitive	O
restriction	O
enzymes	O
and	O
this	O
method	O
showed	O
an	O
increase	O
in	O
DNA	O
methylation	O
in	O
only	O
four	O
of	O
the	O
six	O
cases	O
.	O

The	O
DNA	O
sequencing	O
method	O
thus	O
appears	O
to	O
be	O
better	O
suited	O
to	O
assess	O
alterations	O
of	O
DNA	O
methylation	O
than	O
Southern	O
blot	O
analysis	O
.	O

There	O
are	O
marked	O
regional	O
differences	O
in	O
the	O
frequency	O
of	O
methylation	O
of	O
individual	O
CpG	O
sites	O
and	O
in	O
the	O
frequency	O
of	O
alterations	O
between	O
the	O
two	O
stages	O
.	O

Our	O
results	O
show	O
that	O
alterations	O
in	O
DNA	O
methylation	O
continue	O
to	O
occur	O
from	O
the	O
initial	O
stage	O
to	O
the	O
relapse	O
stage	O
of	O
ALL	O
,	O
suggesting	O
that	O
aberrant	O
DNA	O
methylation	O
may	O
play	O
a	O
role	O
in	O
tumor	O
progression	O
.	O

Structural	O
specificity	O
requirements	O
in	O
the	O
binding	O
of	O
beta	O
lactam	O
antibiotics	O
to	O
human	O
serum	B-Protein
albumin	I-Protein
.	O

The	O
binding	O
of	O
some	O
cephalosporins	O
of	O
pharmacological	O
interest	O
,	O
to	O
human	O
serum	B-Protein
albumin	I-Protein
was	O
studied	O
using	O
ultrafiltration	O
method	O
.	O

The	O
identification	O
of	O
the	O
binding	O
sites	O
in	O
albumin	B-Protein
was	O
also	O
performed	O
using	O
probes	O
for	O
the	O
so	O
-	O
called	O
sites	O
I	O
,	O
II	O
,	O
bilirubin	O
and	O
fatty	O
acids	O
binding	O
sites	O
.	O

Cephalosporins	O
were	O
classified	O
into	O
three	O
groups	O
according	O
to	O
their	O
affinity	O
for	O
albumin	B-Protein
:	O
low	O
affinity	O
(	O
K	O
=	O
10	O
-	O
10	O
(	O
2	O
)	O
M	O
-	O
1	O
)	O
,	O
medium	O
affinity	O
(	O
K	O
=	O
10	O
(	O
3	O
)	O
M	O
-	O
1	O
)	O
and	O
high	O
affinity	O
(	O
K	O
=	O
10	O
(	O
4	O
)	O
M	O
-	O
1	O
)	O
.	O

Cephalosporin	O
binding	O
to	O
albumin	B-Protein
produced	O
a	O
perturbation	O
of	O
several	O
basic	O
amino	O
acids	O
of	O
the	O
protein	O
such	O
as	O
histidine	O
and	O
lysine	O
.	O

It	O
was	O
found	O
that	O
only	O
cefuroxime	O
,	O
ceftazidime	O
and	O
cefoperazone	O
interact	O
slightly	O
with	O
site	O
I	O
on	O
serum	B-Protein
albumin	I-Protein
,	O
while	O
site	O
II	O
possesses	O
capacity	O
to	O
bind	O
:	O
cephradine	O
,	O
cephalexin	O
,	O
ceftazidime	O
,	O
ceftriaxone	O
,	O
cefoperazone	O
,	O
cefaclor	O
and	O
cefsulodin	O
.	O

The	O
bilirubin	O
binding	O
site	O
showed	O
capacity	O
to	O
interact	O
with	O
a	O
great	O
number	O
of	O
cephalosporins	O
:	O
ceftriaxone	O
,	O
cefazolin	O
,	O
cephaloglycin	O
,	O
cefamandole	O
,	O
cefotaxime	O
,	O
cefoxitin	O
,	O
cefuroxime	O
,	O
cefoperazone	O
and	O
cefadroxil	O
.	O

Ceftriaxone	O
showed	O
capacity	O
to	O
bind	O
to	O
the	O
fatty	O
acid	O
binding	O
site	O
on	O
HSA	O
.	O

No	O
relation	O
was	O
found	O
between	O
the	O
displacement	O
of	O
the	O
marker	O
and	O
the	O
chemical	O
nature	O
of	O
the	O
substituents	O
at	O
R1	O
and	O
R2	O
.	O

Cephalosporins	O
interact	O
with	O
HSA	O
at	O
the	O
binding	O
region	O
that	O
involves	O
:	O
tyrosyl	O
411	O
,	O
histidyl	O
146	O
and	O
lysyls	O
195	O
,	O
199	O
,	O
225	O
,	O
240	O
and	O
525	O
residues	O
.	O

The	O
chemical	O
modification	O
of	O
specific	O
amino	O
acids	O
showed	O
that	O
the	O
interaction	O
of	O
these	O
amino	O
acids	O
with	O
beta	O
lactam	O
antibiotics	O
is	O
not	O
carried	O
out	O
to	O
the	O
same	O
extent	O
for	O
all	O
the	O
cephalosporins	O
tested	O
.	O

The	O
results	O
obtained	O
revealed	O
that	O
the	O
binding	O
sites	O
for	O
cephalosporins	O
on	O
albumin	B-Protein
are	O
structurally	O
heterogeneous	O
,	O
having	O
different	O
amino	O
acids	O
in	O
the	O
vicinity	O
of	O
the	O
ligand	O
molecule	O
.	O

A	O
strategy	O
of	O
tRNA	O
recognition	O
that	O
includes	O
determinants	O
of	O
RNA	O
structure	O
.	O

Recognition	O
of	O
tRNAs	O
by	O
aminoacyl	O
tRNA	O
synthetases	O
establishes	O
the	O
connection	O
between	O
amino	O
acids	O
and	O
anticodon	O
triplets	O
of	O
the	O
genetic	O
code	O
.	O

Although	O
anticodons	O
and	O
nucleotides	O
adjacent	O
to	O
the	O
amino	O
acid	O
attachment	O
site	O
are	O
generally	O
important	O
,	O
the	O
tertiary	O
structural	O
framework	O
of	O
tRNAs	O
has	O
recently	O
been	O
implicated	O
to	O
have	O
a	O
role	O
in	O
tRNA	O
recognition	O
.	O

A	O
G15	O
:	O
G48	O
tertiary	O
hydrogen	O
base	O
pair	O
of	O
E	O
.	O
coli	O
tRNA	O
(	O
Cys	O
)	O
is	O
important	O
for	O
recognition	O
of	O
the	O
tRNA	O
by	O
cysteine	B-Protein
tRNA	I-Protein
synthetase	I-Protein
.	O

This	O
base	O
pair	O
is	O
proposed	O
to	O
consist	O
of	O
N2	O
:	O
N3	O
,	O
rather	O
than	O
N1	O
:	O
O6	O
,	O
hydrogen	O
bonds	O
.	O

The	O
reproduction	O
of	O
the	O
hydrogen	O
pairing	O
scheme	O
of	O
tRNA	O
(	O
Gly	O
)	O
.	O

This	O
reproduction	O
required	O
an	O
A13	O
:	O
A22	O
mismatch	O
in	O
the	O
dihyrouridine	O
stem	O
.	O

To	O
determine	O
if	O
A13	O
:	O
A22	O
is	O
a	O
determinant	O
of	O
the	O
structural	O
features	O
of	O
G15	O
:	O
G48	O
,	O
we	O
investigated	O
the	O
A15	O
:	O
U48	O
and	O
A15	O
:	O
A48	O
variants	O
of	O
tRNA	O
(	O
Gly	O
)	O
which	O
harbored	O
specific	O
substitutions	O
of	O
A13	O
:	O
A22	O
.	O

We	O
show	O
here	O
that	O
introduction	O
of	O
A13	O
:	O
A22	O
to	O
both	O
tRNA	O
frameworks	O
confers	O
structural	O
features	O
similar	O
to	O
those	O
of	O
G15	O
:	O
G48	O
in	O
E	O
.	O
coli	O
tRNA	O
(	O
Cys	O
)	O
.	O

These	O
structural	O
features	O
are	O
accompanied	O
by	O
efficient	O
recognition	O
of	O
both	O
tRNAs	O
by	O
cysteine	B-Protein
tRNA	I-Protein
synthetase	I-Protein
.	O

Substitution	O
of	O
A13	O
:	O
A22	O
with	O
U13	O
:	O
A22	O
alters	O
the	O
structural	O
features	O
at	O
15	O
:	O
48	O
and	O
impairs	O
tRNA	O
recognition	O
.	O

The	O
dependence	O
on	O
A13	O
:	O
22	O
for	O
tRNA	O
recognition	O
has	O
a	O
distinct	O
similarity	O
to	O
that	O
of	O
E	O
.	O
coli	O
tRNA	O
(	O
Cys	O
)	O
and	O
to	O
that	O
of	O
the	O
G15	O
:	O
G48	O
variant	O
of	O
tRNA	O
(	O
Gly	O
)	O
.	O

The	O
results	O
have	O
implications	O
for	O
the	O
design	O
and	O
manipulation	O
of	O
RNA	O
structural	O
elements	O
as	O
the	O
basis	O
for	O
tRNA	O
recognition	O
.	O

The	O
role	O
of	O
oxidative	O
stress	O
in	O
the	O
long	O
-	O
term	O
glycation	O
of	O
LDL	O
.	O

Advanced	O
glycation	O
is	O
a	O
major	O
pathway	O
for	O
the	O
posttranslational	O
modification	O
of	O
plasma	O
and	O
tissue	O
proteins	O
.	O

The	O
initiating	O
reaction	O
is	O
the	O
nonenzymatic	O
addition	O
of	O
sugars	O
such	O
as	O
glucose	O
to	O
the	O
primary	O
amino	O
groups	O
of	O
proteins	O
,	O
i	O
.	O
e	O
.	O
,	O
mainly	O
to	O
lysine	O
residues	O
.	O

These	O
"	O
early	O
"	O
Schiff	O
base	O
and	O
Amadori	O
products	O
then	O
undergo	O
a	O
series	O
of	O
inter	O
-	O
and	O
intramolecular	O
rearrangements	O
to	O
produce	O
the	O
"	O
late	O
"	O
products	O
termed	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
.	O

Incubation	O
of	O
LDL	O
with	O
glucose	O
or	O
glucose	O
-	O
6	O
-	O
phosphate	O
produces	O
AGE	O
moieties	O
on	O
both	O
the	O
lipid	O
and	O
apolipoprotein	B-Protein
B	I-Protein
components	O
.	O

In	O
addition	O
,	O
we	O
tried	O
to	O
generate	O
AGE	O
-	O
LDL	O
by	O
reaction	O
with	O
AGE	O
-	O
peptides	O
(	O
<	O
10	O
kD	O
)	O
obtained	O
by	O
enzymatic	O
digestion	O
of	O
long	O
-	O
term	O
glycated	O
fibronectin	B-Protein
as	O
a	O
model	O
for	O
connective	O
tissue	O
AGE	O
-	O
peptides	O
.	O

AGE	O
-	O
formation	O
can	O
be	O
assessed	O
by	O
monitoring	O
of	O
fluorescence	O
(	O
370	O
/	O
440	O
nm	O
)	O
which	O
is	O
easily	O
differentiated	O
from	O
the	O
much	O
lower	O
autofluorescence	O
of	O
oxidized	O
low	O
density	O
lipoproteins	O
(	O
oxLDL	O
)	O
.	O

Alternatively	O
,	O
AGE	O
formation	O
was	O
detected	O
by	O
an	O
AGE	O
-	O
specific	O
ELISA	O
using	O
antibodies	O
elicited	O
in	O
rabbits	O
against	O
bovine	O
AGE	O
-	O
RNAse	O
.	O

In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
influence	O
of	O
oxidative	O
stress	O
on	O
the	O
long	O
-	O
term	O
glycation	O
of	O
LDL	O
and	O
the	O
modulation	O
of	O
LDL	O
-	O
oxidation	O
by	O
AGE	O
-	O
modification	O
.	O

We	O
observed	O
(	O
a	O
)	O
that	O
the	O
rate	O
of	O
AGE	O
formation	O
is	O
reduced	O
by	O
BHT	O
/	O
EDTA	O
both	O
on	O
LDL	O
and	O
serum	B-Protein
albumin	I-Protein
(	O
glycation	O
vs	O
.	O
glycoxidation	O
)	O
,	O
(	O
b	O
)	O
long	O
-	O
term	O
glycated	O
LDL	O
is	O
more	O
readily	O
oxidized	O
than	O
unglycated	O
LDL	O
,	O
(	O
c	O
)	O
oxLDL	O
is	O
more	O
prone	O
to	O
AGE	O
-	O
modification	O
,	O
(	O
d	O
)	O
AGE	O
-	O
modification	O
of	O
LDL	O
strongly	O
alters	O
its	O
epitope	O
spectrum	O
and	O
(	O
e	O
)	O
that	O
aminoguanidine	O
at	O
higher	O
concentrations	O
(	O
1	O
-	O
10	O
mM	O
)	O
inhibits	O
copper	O
-	O
catalyzed	O
LDL	O
oxidation	O
in	O
the	O
way	O
of	O
a	O
classical	O
antioxidant	O
.	O

Glycosylation	O
of	O
human	O
bone	O
collagen	O
I	O
in	O
relation	O
to	O
lysylhydroxylation	O
and	O
fibril	O
diameter	O
.	O

Posttranslational	O
modifications	O
(	O
lysylhydroxylation	O
,	O
glycosylation	O
,	O
and	O
crosslink	O
formation	O
)	O
of	O
collagen	O
I	O
and	O
the	O
trabecular	O
bone	O
volume	O
(	O
TBV	O
)	O
as	O
well	O
as	O
the	O
supramolecular	O
organization	O
of	O
human	O
vertebrae	O
were	O
studied	O
by	O
analyzing	O
vertebral	O
bones	O
of	O
55	O
individuals	O
(	O
22	O
-	O
93	O
years	O
of	O
age	O
)	O
.	O

The	O
degree	O
of	O
lysylhydroxylation	O
of	O
both	O
a	O
-	O
chains	O
of	O
collagen	O
I	O
showed	O
a	O
significant	O
inverse	O
correlation	O
with	O
the	O
TBV	O
,	O
while	O
only	O
a	O
weak	O
correlation	O
between	O
lysylhydroxylation	O
of	O
alpha2	B-Protein
(	I-Protein
I	I-Protein
)	I-Protein
and	O
the	O
age	O
of	O
the	O
donor	O
was	O
observed	O
.	O

The	O
degree	O
of	O
glycosylation	O
of	O
collagen	O
I	O
was	O
significantly	O
correlated	O
with	O
both	O
the	O
level	O
of	O
lysylhydroxylation	O
and	O
the	O
degree	O
of	O
osteopenia	O
.	O

Electron	O
microscopic	O
evaluation	O
did	O
not	O
show	O
any	O
relationship	O
between	O
the	O
level	O
of	O
collagen	O
glycosylation	O
and	O
the	O
diameter	O
of	O
in	O
vivo	O
formed	O
fibrils	O
or	O
in	O
vitro	O
formed	O
fibrillar	O
aggregates	O
.	O

In	O
our	O
study	O
the	O
molar	O
ratio	O
of	O
the	O
mature	O
collagen	O
crosslinks	O
,	O
pyridinoline	O
and	O
deoxypyridinoline	O
,	O
showed	O
a	O
slight	O
tendency	O
to	O
be	O
higher	O
,	O
in	O
particular	O
in	O
the	O
samples	O
with	O
a	O
high	O
level	O
of	O
lysylhydroxylation	O
.	O

This	O
ratio	O
was	O
recently	O
found	O
to	O
be	O
significantly	O
increased	O
in	O
avian	O
osteoporotic	O
bone	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
increased	O
level	O
of	O
lysylhydroxylation	O
in	O
human	O
osteopenia	O
is	O
related	O
to	O
the	O
glycosylation	O
of	O
collagen	O
I	O
,	O
while	O
it	O
seems	O
to	O
have	O
little	O
impact	O
on	O
the	O
formation	O
of	O
the	O
mature	O
,	O
non	O
-	O
reducible	O
collagen	O
crosslinks	O
investigated	O
.	O

Based	O
on	O
our	O
observations	O
it	O
appears	O
unlikely	O
that	O
the	O
different	O
diameters	O
of	O
collagen	O
fibrils	O
contribute	O
greatly	O
to	O
the	O
reduced	O
biomechanical	O
stability	O
reported	O
for	O
overhydroxylated	O
,	O
osteopenic	O
bone	O
tissue	O
.	O

Alterations	O
in	O
the	O
O	O
-	O
linked	O
glycosylation	O
of	O
IgA1	O
in	O
children	O
with	O
Henoch	O
-	O
Schonlein	O
purpura	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
O	O
-	O
linked	O
glycosylation	O
of	O
serum	O
IgA1	O
in	O
children	O
with	O
acute	O
Henoch	O
-	O
Schonlein	O
purpura	O
(	O
HSP	O
)	O
.	O

METHODS	O
:	O
The	O
O	O
-	O
linked	O
oligosaccharides	O
of	O
serum	O
IgA1	O
from	O
28	O
children	O
with	O
acute	O
HSP	O
and	O
26	O
control	O
children	O
were	O
examined	O
by	O
enzyme	O
immunoassay	O
using	O
plant	O
lectins	O
with	O
well	O
defined	O
carbohydrate	O
binding	O
specificities	O
.	O

The	O
lectins	O
included	O
Artocarpus	O
integrifolia	O
(	O
jacalin	O
)	O
,	O
Arachis	O
hypogaea	O
(	O
peanut	O
lectin	O
)	O
,	O
and	O
Sambucus	O
nigra	O
(	O
elderberry	O
lectin	O
)	O
.	O

Jacalin	O
binds	O
to	O
galactose	O
-	O
N	O
-	O
acetylgalactosamine	O
(	O
Gal	O
-	O
GalNAc	O
)	O
.	O

Jacalin	O
interaction	O
with	O
this	O
oligosaccharide	O
is	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
sialic	O
acid	O
on	O
the	O
galactose	O
moiety	O
.	O

Peanut	O
lectin	B-Protein
also	O
interacts	O
with	O
Gal	O
-	O
GalNAc	O
,	O
but	O
binding	O
is	O
inhibited	O
if	O
the	O
galactose	O
residue	O
is	O
sialylated	O
.	O

Elderberry	O
lectin	O
binds	O
to	O
N	O
-	O
acetylneuraminic	O
acid	O
(	O
sialic	O
acid	O
)	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
difference	O
in	O
the	O
binding	O
of	O
jacalin	O
to	O
IgA1	O
from	O
patients	O
with	O
HSP	O
compared	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
5	O
)	O
.	O

The	O
binding	O
of	O
peanut	O
lectin	B-Protein
to	O
IgA1	O
was	O
significantly	O
higher	O
in	O
HSP	O
compared	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
007	O
)	O
.	O

Since	O
peanut	O
lectin	B-Protein
binding	O
is	O
inhibited	O
by	O
the	O
presence	O
of	O
sialylated	O
galactose	O
,	O
these	O
results	O
suggest	O
diminished	O
sialic	O
content	O
of	O
the	O
O	O
-	O
linked	O
oligosaccharides	O
of	O
IgA1	O
in	O
HSP	O
compared	O
to	O
controls	O
.	O

Indeed	O
,	O
the	O
binding	O
of	O
the	O
sialic	O
acid	O
-	O
specific	O
elderberry	O
lectin	O
to	O
IgA1	O
was	O
significantly	O
lower	O
in	O
HSP	O
compared	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
.	O

CONCLUSION	O
:	O
The	O
O	O
-	O
linked	O
oligosaccharides	O
of	O
serum	O
IgA1	O
from	O
children	O
with	O
acute	O
HSP	O
are	O
deficient	O
in	O
salic	O
acid	O
compared	O
to	O
serum	O
IgA1	O
from	O
control	O
children	O
.	O

Alteration	O
of	O
glycosylation	O
renders	O
HIV	O
sensitive	O
to	O
inactivation	O
by	O
normal	O
human	O
serum	O
.	O

Retroviruses	O
from	O
various	O
mammalian	O
species	O
,	O
excluding	O
humans	O
,	O
are	O
effectively	O
inactivated	O
in	O
normal	O
human	O
serum	O
(	O
NHS	O
)	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
NHS	O
inactivation	O
of	O
retroviruses	O
occurs	O
through	O
natural	O
Ab	O
recognition	O
of	O
a	O
terminal	O
glycosidic	O
moiety	O
on	O
the	O
viral	O
envelope	O
that	O
is	O
acquired	O
during	O
replication	O
in	O
the	O
host	O
cell	O
.	O

This	O
carbohydrate	O
structure	O
(	O
the	O
alpha	O
-	O
galactosyl	O
epitope	O
)	O
is	O
expressed	O
on	O
the	O
cells	O
of	O
most	O
mammals	O
,	O
with	O
the	O
exception	O
of	O
humans	O
and	O
other	O
Old	O
World	O
primates	O
.	O

In	O
this	O
study	O
,	O
NHS	O
sensitivity	O
of	O
HIV	O
was	O
assessed	O
following	O
viral	O
propagation	O
in	O
human	O
cells	O
that	O
were	O
manipulated	O
to	O
express	O
the	O
alpha	O
-	O
galactosyl	O
epitope	O
.	O

HUT	O
-	O
78	O
cells	O
were	O
transduced	O
with	O
an	O
exogenous	O
alpha1	O
-	O
3	O
-	O
galactosyl	O
transferase	O
gene	O
,	O
which	O
codes	O
for	O
the	O
terminal	O
glycosyl	O
transferase	O
responsible	O
for	O
generation	O
of	O
the	O
alpha	O
-	O
galactosyl	O
epitope	O
.	O

The	O
transduced	O
HUT	O
-	O
78	O
cells	O
expressed	O
high	O
levels	O
of	O
the	O
alpha	O
-	O
galactosyl	O
epitope	O
on	O
their	O
membrane	O
surface	O
,	O
rendering	O
them	O
sensitive	O
to	O
killing	O
in	O
NHS	O
.	O

Similarly	O
,	O
HIV	O
passaged	O
through	O
these	O
cells	O
acquired	O
the	O
alpha	O
-	O
galactosyl	O
epitope	O
in	O
association	O
with	O
the	O
envelope	O
glycoprotein	O
gp120	B-Protein
and	O
was	O
also	O
effectively	O
inactivated	O
in	O
NHS	O
.	O

Viral	O
inactivation	O
was	O
abolished	O
by	O
the	O
addition	O
of	O
a	O
synthetic	O
disaccharide	O
that	O
contains	O
the	O
alpha	O
-	O
galactosyl	O
epitope	O
,	O
indicating	O
that	O
virolysis	O
is	O
mediated	O
by	O
anti	O
-	O
alpha	O
-	O
galactosyl	O
natural	O
Ab	O
.	O

These	O
results	O
demonstrate	O
that	O
,	O
like	O
other	O
retroviruses	O
bearing	O
the	O
alpha	O
-	O
galactosyl	O
epitope	O
,	O
HIV	O
modified	O
to	O
express	O
this	O
epitope	O
is	O
inactivated	O
in	O
NHS	O
.	O

Furthermore	O
,	O
these	O
data	O
suggest	O
that	O
expression	O
of	O
the	O
alpha	O
-	O
galactosyl	O
epitope	O
on	O
the	O
surface	O
of	O
viruses	O
may	O
have	O
implications	O
in	O
the	O
interspecies	O
transmission	O
of	O
such	O
viruses	O
to	O
humans	O
.	O

A	O
point	O
mutation	O
in	O
the	O
neu	B-Protein
-	I-Protein
1	I-Protein
locus	O
causes	O
the	O
neuraminidase	O
defect	O
in	O
the	O
SM	O
/	O
J	O
mouse	O
.	O

Lysosomal	B-Protein
neuraminidase	I-Protein
(	O
sialidase	O
)	O
occurs	O
in	O
a	O
high	O
molecular	O
weight	O
complex	O
with	O
the	O
glycosidase	O
beta	B-Protein
-	I-Protein
galactosidase	I-Protein
and	O
the	O
serine	O
carboxypeptidase	O
protective	B-Protein
protein	I-Protein
/	I-Protein
cathepsin	I-Protein
A	I-Protein
(	O
PPCA	B-Protein
)	O
.	O

Association	O
of	O
the	O
enzyme	O
with	O
PPCA	B-Protein
is	O
crucial	O
for	O
its	O
correct	O
targeting	O
and	O
lysosomal	O
activation	O
.	O

In	O
man	O
two	O
genetically	O
distinct	O
storage	O
disorders	O
are	O
associated	O
with	O
either	O
a	O
primary	O
or	O
a	O
secondary	O
deficiency	O
of	O
lysosomal	B-Protein
neuraminidase	I-Protein
:	O
sialidosis	O
and	O
galactosialidosis	O
.	O

In	O
the	O
mouse	O
the	O
naturally	O
occurring	O
inbred	O
strain	O
SM	O
/	O
J	O
presents	O
with	O
a	O
number	O
of	O
phenotypic	O
abnormalities	O
that	O
have	O
been	O
attributed	O
to	O
reduced	O
neuraminidase	O
activity	O
.	O

SM	O
/	O
J	O
mice	O
were	O
originally	O
characterized	O
by	O
their	O
altered	O
sialylation	O
of	O
several	O
lysosomal	O
glycoproteins	O
.	O

This	O
defect	O
was	O
linked	O
to	O
a	O
single	O
gene	O
,	O
neu	B-Protein
-	I-Protein
1	I-Protein
,	O
on	O
chromosome	O
17	O
,	O
which	O
was	O
mapped	O
by	O
linkage	O
analysis	O
to	O
the	O
H	O
-	O
2	O
locus	O
.	O

In	O
addition	O
,	O
these	O
mice	O
have	O
an	O
altered	O
immune	O
response	O
that	O
has	O
also	O
been	O
coupled	O
to	O
a	O
deficiency	O
of	O
the	O
Neu	B-Protein
-	I-Protein
1	I-Protein
neuraminidase	O
.	O

Here	O
we	O
report	O
the	O
identification	O
in	O
SM	O
/	O
J	O
mice	O
of	O
a	O
single	O
amino	O
acid	O
substitution	O
(	O
L209I	O
)	O
in	O
the	O
Neu	B-Protein
-	I-Protein
1	I-Protein
protein	O
which	O
is	O
responsible	O
for	O
the	O
partial	O
deficiency	O
of	O
lysosomal	B-Protein
neuraminidase	I-Protein
.	O

We	O
propose	O
that	O
the	O
reduced	O
activity	O
is	O
caused	O
by	O
the	O
enzyme	O
'	O
s	O
altered	O
affinity	O
for	O
its	O
substrate	O
,	O
rather	O
than	O
a	O
change	O
in	O
substrate	O
specificity	O
or	O
turnover	O
rate	O
.	O

The	O
mutant	O
enzyme	O
is	O
correctly	O
compartmentalized	O
in	O
lysosomes	O
and	O
maintains	O
the	O
ability	O
to	O
associate	O
with	O
its	O
activating	O
protein	O
,	O
PPCA	B-Protein
.	O

We	O
propose	O
that	O
it	O
is	O
this	O
mutation	O
that	O
is	O
responsible	O
for	O
the	O
SM	O
/	O
J	O
phenotype	O
.	O

Expression	O
and	O
purification	O
of	O
biologically	O
active	O
porcine	O
follicle	O
-	O
stimulating	O
hormone	O
in	O
insect	O
cells	O
bearing	O
a	O
baculovirus	O
vector	O
.	O

Biologically	O
active	O
recombinant	O
porcine	O
FSH	O
(	O
rec	O
-	O
pFSH	O
)	O
free	O
from	O
the	O
cognate	O
pituitary	O
glycoprotein	O
hormone	O
LH	O
was	O
produced	O
.	O

It	O
was	O
synthesized	O
by	O
a	O
baculovirus	O
vector	O
-	O
insect	O
cell	O
system	O
using	O
two	O
cDNAs	O
encoding	O
the	O
glycoprotein	O
alpha	O
and	O
FSH	B-Protein
beta	I-Protein
subunits	O
.	O

Its	O
antigenicity	O
was	O
the	O
same	O
as	O
that	O
of	O
pFSH	O
prepared	O
from	O
the	O
pituitary	O
.	O

Glycosylation	O
of	O
rec	O
-	O
pFSH	O
was	O
shown	O
by	O
tunicamycin	O
treatment	O
but	O
the	O
molecular	O
mass	O
of	O
each	O
subunit	O
was	O
lower	O
than	O
that	O
of	O
pituitary	O
-	O
derived	O
FSH	O
,	O
because	O
of	O
the	O
absence	O
of	O
trimming	O
of	O
terminal	O
sugars	O
in	O
insect	O
cells	O
.	O

Rec	O
-	O
pFSH	O
was	O
secreted	O
into	O
the	O
culture	O
medium	O
at	O
about	O
1	O
mg	O
/	O
l	O
and	O
purified	O
in	O
six	O
fractions	O
,	O
because	O
of	O
the	O
heterogeneity	O
of	O
the	O
sugar	O
group	O
,	O
by	O
S	O
-	O
Sepharose	O
and	O
concanavalin	O
A	O
-	O
Sepharose	O
column	O
chromatography	O
.	O

The	O
biological	O
activity	O
of	O
rec	O
-	O
pFSH	O
was	O
examined	O
by	O
measuring	O
its	O
effect	O
on	O
progesterone	O
secretion	O
from	O
porcine	O
granulosa	O
cells	O
and	O
germinal	O
vesicle	O
breakdown	O
(	O
GVBD	O
)	O
of	O
porcine	O
oocytes	O
.	O

It	O
showed	O
adequate	O
activity	O
with	O
respect	O
to	O
progesterone	O
secretion	O
,	O
although	O
some	O
fractions	O
rich	O
in	O
the	O
sugar	O
group	O
showed	O
lower	O
activity	O
than	O
that	O
of	O
pituitary	O
-	O
derived	O
FSH	O
.	O

It	O
exhibited	O
higher	O
GVBD	O
activity	O
than	O
that	O
of	O
pituitary	O
-	O
derived	O
FSH	O
at	O
concentrations	O
as	O
low	O
as	O
1	O
ng	O
/	O
ml	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
baculovirus	O
vector	O
-	O
insect	O
cell	O
system	O
can	O
provide	O
biologically	O
active	O
rec	O
-	O
pFSH	O
.	O

Protein	B-Protein
disulfide	I-Protein
isomerase	I-Protein
acts	O
as	O
a	O
molecular	O
chaperone	O
during	O
the	O
assembly	O
of	O
procollagen	O
.	O

Protein	B-Protein
-	I-Protein
disulfide	I-Protein
isomerase	I-Protein
(	O
PDI	B-Protein
)	O
has	O
been	O
shown	O
to	O
be	O
a	O
multifunctional	O
enzyme	O
catalyzing	O
the	O
formation	O
of	O
disulfide	O
bonds	O
,	O
as	O
well	O
as	O
being	O
a	O
component	O
of	O
the	O
enzymes	O
prolyl	O
4	O
-	O
hydroxylase	O
(	O
P4	O
-	O
H	O
)	O
and	O
microsomal	O
triglyceride	O
transfer	O
protein	O
.	O

It	O
has	O
also	O
been	O
proposed	O
to	O
function	O
as	O
a	O
molecular	O
chaperone	O
during	O
the	O
refolding	O
of	O
denatured	O
proteins	O
in	O
vitro	O
.	O

To	O
investigate	O
the	O
role	O
of	O
this	O
multifunctional	O
protein	O
within	O
a	O
cellular	O
context	O
,	O
we	O
have	O
established	O
a	O
semi	O
-	O
permeabilized	O
cell	O
system	O
that	O
reconstitutes	O
the	O
synthesis	O
,	O
folding	O
,	O
modification	O
,	O
and	O
assembly	O
of	O
procollagen	O
as	O
they	O
would	O
occur	O
in	O
the	O
cell	O
.	O

We	O
demonstrate	O
here	O
that	O
P4	O
-	O
H	O
associates	O
transiently	O
with	O
the	O
triple	O
helical	O
domain	O
during	O
the	O
assembly	O
of	O
procollagen	O
.	O

The	O
release	O
of	O
P4	O
-	O
H	O
from	O
the	O
triple	O
helical	O
domain	O
coincides	O
with	O
assembly	O
into	O
a	O
thermally	O
stable	O
triple	O
helix	O
.	O

However	O
,	O
if	O
triple	O
helix	O
formation	O
is	O
prevented	O
,	O
P4	O
-	O
H	O
remains	O
associated	O
,	O
suggesting	O
a	O
role	O
for	O
this	O
enzyme	O
in	O
preventing	O
aggregation	O
of	O
this	O
domain	O
.	O

We	O
also	O
show	O
that	O
PDI	B-Protein
associates	O
independently	O
with	O
the	O
C	O
-	O
propeptide	O
of	O
monomeric	O
procollagen	O
chains	O
prior	O
to	O
trimer	O
formation	O
,	O
indicating	O
a	O
role	O
for	O
this	O
protein	O
in	O
coordinating	O
the	O
assembly	O
of	O
heterotrimeric	O
molecules	O
.	O

This	O
demonstrates	O
that	O
PDI	B-Protein
has	O
multiple	O
functions	O
in	O
the	O
folding	O
of	O
the	O
same	O
protein	O
,	O
that	O
is	O
,	O
as	O
a	O
catalyst	O
for	O
disulfide	O
bond	O
formation	O
,	O
as	O
a	O
subunit	O
of	O
P4	O
-	O
H	O
during	O
proline	O
hydroxylation	O
,	O
and	O
independently	O
as	O
a	O
molecular	O
chaperone	O
during	O
chain	O
assembly	O
.	O

The	O
antigenic	O
structure	O
of	O
the	O
HIV	O
gp120	B-Protein
envelope	O
glycoprotein	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
HIV	O
-	O
1	O
establishes	O
persistent	O
infections	O
in	O
humans	O
which	O
lead	O
to	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O

The	O
HIV	O
-	O
1	O
envelope	O
glycoproteins	O
,	O
gp120	B-Protein
and	O
gp41	B-Protein
,	O
are	O
assembled	O
into	O
a	O
trimeric	O
complex	O
that	O
mediates	O
virus	O
entry	O
into	O
target	O
cells	O
.	O

HIV	O
-	O
1	O
entry	O
depends	O
on	O
the	O
sequential	O
interaction	O
of	O
the	O
gp120	B-Protein
exterior	O
envelope	O
glycoprotein	O
with	O
the	O
receptors	O
on	O
the	O
cell	O
,	O
CD4	B-Protein
and	O
members	O
of	O
the	O
chemokine	O
receptor	O
family	O
.	O

The	O
gp120	B-Protein
glycoprotein	O
,	O
which	O
can	O
be	O
shed	O
from	O
the	O
envelope	O
complex	O
,	O
elicits	O
both	O
virus	O
-	O
neutralizing	O
and	O
non	O
-	O
neutralizing	O
antibodies	O
during	O
natural	O
infection	O
.	O

Antibodies	O
that	O
lack	O
neutralizing	O
activity	O
are	O
often	O
directed	O
against	O
the	O
gp120	B-Protein
regions	O
that	O
are	O
occluded	O
on	O
the	O
assembled	O
trimer	O
and	O
which	O
are	O
exposed	O
only	O
upon	O
shedding	O
.	O

Neutralizing	O
antibodies	O
,	O
by	O
contrast	O
,	O
must	O
access	O
the	O
functional	O
envelope	O
glycoprotein	O
complex	O
and	O
typically	O
recognize	O
conserved	O
or	O
variable	O
epitopes	O
near	O
the	O
receptor	O
-	O
binding	O
regions	O
.	O

Here	O
we	O
describe	O
the	O
spatial	O
organization	O
of	O
conserved	O
neutralization	O
epitopes	O
on	O
gp120	B-Protein
,	O
using	O
epitope	O
maps	O
in	O
conjunction	O
with	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
a	O
ternary	O
complex	O
that	O
includes	O
a	O
gp120	B-Protein
core	O
,	O
CD4	B-Protein
and	O
a	O
neutralizing	O
antibody	O
.	O

A	O
large	O
fraction	O
of	O
the	O
predicted	O
accessible	O
surface	O
of	O
gp120	B-Protein
in	O
the	O
trimer	O
is	O
composed	O
of	O
variable	O
,	O
heavily	O
glycosylated	O
core	O
and	O
loop	O
structures	O
that	O
surround	O
the	O
receptor	O
-	O
binding	O
regions	O
.	O

Understanding	O
the	O
structural	O
basis	O
for	O
the	O
ability	O
of	O
HIV	O
-	O
1	O
to	O
evade	O
the	O
humoral	O
immune	O
response	O
should	O
assist	O
in	O
the	O
design	O
of	O
a	O
vaccine	O
.	O

Production	O
of	O
recombinant	O
hydroxylated	O
human	O
type	B-Protein
III	I-Protein
collagen	I-Protein
fragment	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

A	O
recombinant	O
hydroxylated	O
fragment	O
of	O
human	O
type	B-Protein
III	I-Protein
collagen	I-Protein
has	O
been	O
produced	O
in	O
Saccharomyces	O
cerevisiae	O
by	O
coordinated	O
coexpression	O
of	O
a	O
collagen	O
gene	O
fragment	O
together	O
with	O
both	O
the	O
alpha	O
-	O
and	O
beta	O
-	O
subunit	O
genes	O
for	O
prolyl	O
-	O
4	O
-	O
hydroxylase	O
(	O
EC	O
1	O
.	O
14	O
.	O
11	O
.	O
2	O
)	O
.	O

The	O
collagen	O
fragment	O
consisted	O
of	O
255	O
residues	O
of	O
the	O
helical	O
domain	O
and	O
the	O
complete	O
C	O
-	O
telopeptide	O
and	O
C	O
-	O
propeptide	O
domains	O
.	O

It	O
was	O
inserted	O
under	O
the	O
control	O
of	O
the	O
ethanol	O
-	O
inducible	O
ADH2	B-Protein
promoter	O
in	O
a	O
multicopy	O
,	O
TRP1	B-Protein
-	O
selectable	O
,	O
yeast	O
expression	O
vector	O
,	O
YEpFlag1	O
.	O

The	O
prolyihydroxylase	O
subunit	O
genes	O
were	O
cloned	O
on	O
either	O
side	O
of	O
a	O
bidirectional	O
galactose	O
-	O
inducible	O
promoter	O
in	O
a	O
low	O
-	O
copy	O
minichromosome	O
yeast	O
expression	O
vector	O
,	O
pYEUra3	O
,	O
which	O
is	O
URA3	B-Protein
selectable	O
.	O

Coordinated	O
expression	O
of	O
the	O
three	O
different	O
gene	O
products	O
after	O
cotransformation	O
into	O
S	O
.	O
cerevisiae	O
was	O
detected	O
by	O
immunoblotting	O
.	O

Amino	O
acid	O
analysis	O
of	O
an	O
immunoreactive	O
collagen	O
fraction	O
demonstrated	O
the	O
presence	O
of	O
hydroxyproline	O
,	O
while	O
the	O
presence	O
of	O
a	O
triple	O
-	O
helical	O
domain	O
in	O
the	O
collagen	O
fragment	O
was	O
demonstrated	O
by	O
its	O
resistance	O
to	O
pepsin	O
proteolysis	O
.	O

CD34	B-Protein
molecule	O
epitope	O
distribution	O
on	O
cells	O
of	O
haematopoietic	O
origin	O
.	O

The	O
CD34	B-Protein
molecule	O
belongs	O
to	O
the	O
mucin	O
membrane	O
molecule	O
family	O
and	O
is	O
expressed	O
on	O
virtually	O
all	O
normal	O
haematopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
.	O

Due	O
to	O
its	O
heavy	O
glycosylation	O
,	O
several	O
different	O
epitopes	O
exist	O
on	O
the	O
molecule	O
.	O

Based	O
on	O
the	O
sensitivity	O
of	O
the	O
glycosylated	O
molecule	O
to	O
degradation	O
with	O
a	O
glycoprotease	B-Protein
from	O
Pasteurella	O
haemolytica	O
and	O
neuraminidase	O
,	O
three	O
classes	O
of	O
epitopes	O
have	O
been	O
identified	O
.	O

The	O
class	O
I	O
and	O
II	O
epitopes	O
are	O
probably	O
related	O
to	O
the	O
glycosylated	O
part	O
of	O
the	O
molecule	O
while	O
class	O
III	O
epitopes	O
are	O
core	O
protein	O
related	O
.	O

It	O
has	O
been	O
known	O
for	O
some	O
time	O
that	O
CD34	B-Protein
class	O
I	O
epitopes	O
are	O
absent	O
on	O
CD34	B-Protein
molecules	O
expressed	O
on	O
high	O
endothelial	O
venules	O
.	O

Here	O
we	O
review	O
recent	O
observations	O
that	O
expression	O
of	O
both	O
class	O
I	O
and	O
II	O
epitopes	O
,	O
but	O
not	O
class	O
III	O
epitopes	O
,	O
is	O
impaired	O
on	O
mature	O
myeloid	O
CD34	B-Protein
-	O
pos	O
.	O

HPC	O
while	O
no	O
diverse	O
class	O
epitope	O
expression	O
was	O
observed	O
on	O
immature	O
HPC	O
.	O

In	O
addition	O
,	O
cells	O
from	O
patients	O
with	O
CD34	B-Protein
-	O
pos	O
.	O
acute	O
myeloid	O
leukaemia	O
of	O
FAB	O
classification	O
M4	O
-	O
M5	O
,	O
i	O
.	O
e	O
.	O
,	O
leukaemic	O
blast	O
cells	O
of	O
relatively	O
mature	O
morphologic	O
phenotype	O
,	O
also	O
express	O
less	O
class	O
I	O
and	O
II	O
epitopes	O
than	O
class	O
III	O
epitopes	O
.	O

It	O
therefore	O
seems	O
that	O
HPC	O
maturation	O
and	O
class	O
I	O
and	O
II	O
epitope	O
deprivation	O
are	O
concomitant	O
events	O
and	O
that	O
CD34	B-Protein
class	O
I	O
and	O
II	O
epitopes	O
are	O
lost	O
prior	O
to	O
downregulation	O
of	O
the	O
CD34	B-Protein
molecule	O
per	O
se	O
.	O

The	O
biological	O
significance	O
of	O
this	O
observation	O
is	O
discussed	O
as	O
well	O
as	O
the	O
need	O
to	O
carefully	O
select	O
CD34	B-Protein
-	O
specific	O
monoclonal	O
antibodies	O
for	O
research	O
and	O
clinical	O
purposes	O
.	O

Crystal	O
structures	O
of	O
two	O
self	O
-	O
hydroxylating	O
ribonucleotide	O
reductase	O
protein	O
R2	B-Protein
mutants	O
:	O
structural	O
basis	O
for	O
the	O
oxygen	O
-	O
insertion	O
step	O
of	O
hydroxylation	O
reactions	O
catalyzed	O
by	O
diiron	O
proteins	O
.	O

The	O
R2	B-Protein
protein	O
of	O
ribonucleotide	O
reductase	O
catalyzes	O
the	O
dioxygen	O
-	O
dependent	O
one	O
-	O
electron	O
oxidation	O
of	O
Tyr122	O
at	O
a	O
diiron	O
-	O
carboxylate	O
site	O
.	O

Methane	O
monooxygenase	O
and	O
related	O
hydroxylases	O
catalyze	O
hydrocarbon	O
hydroxylation	O
at	O
diiron	O
sites	O
structurally	O
related	O
to	O
the	O
one	O
in	O
R2	B-Protein
.	O

In	O
protein	O
R2	B-Protein
,	O
the	O
likely	O
reaction	O
site	O
for	O
dioxygen	O
is	O
close	O
to	O
Phe208	O
.	O

The	O
crystal	O
structure	O
of	O
an	O
iron	O
ligand	O
mutant	O
R2	B-Protein
,	O
Y122F	O
/	O
E238A	O
,	O
reveals	O
the	O
hydroxylation	O
of	O
Phe208	O
at	O
the	O
meta	O
,	O
or	O
epsilon	O
-	O
,	O
ring	O
position	O
and	O
the	O
subsequent	O
coordination	O
of	O
this	O
residue	O
to	O
the	O
diiron	O
site	O
.	O

In	O
another	O
mutant	O
,	O
F208Y	O
,	O
the	O
"	O
foreign	O
"	O
residue	O
Tyr208	O
is	O
hydroxylated	O
to	O
Dopa	O
.	O

The	O
structures	O
of	O
apo	O
and	O
diferrous	O
F208Y	O
presented	O
here	O
suggest	O
that	O
Tyr208	O
is	O
coordinated	O
to	O
the	O
iron	O
site	O
of	O
F208Y	O
throughout	O
the	O
Dopa	O
generation	O
cycle	O
.	O

Together	O
,	O
the	O
structural	O
data	O
on	O
these	O
two	O
mutants	O
suggest	O
two	O
possible	O
reaction	O
geometries	O
for	O
the	O
hydroxylation	O
reaction	O
catalyzed	O
by	O
these	O
modified	O
R2	B-Protein
diiron	O
sites	O
,	O
geometries	O
which	O
might	O
be	O
relevant	O
for	O
the	O
hydroxylation	O
reaction	O
catalyzed	O
by	O
other	O
diiron	O
sites	O
such	O
as	O
methane	O
monooxygenase	O
.	O

A	O
critical	O
role	O
for	O
residue	O
Glu238	O
in	O
directing	O
the	O
oxidative	O
power	O
of	O
the	O
reactive	O
intermediate	O
toward	O
oxidation	O
of	O
Tyr122	O
is	O
proposed	O
.	O

Expression	O
of	O
recombinant	O
human	O
acid	B-Protein
sphingomyelinase	I-Protein
in	O
insect	O
Sf21	O
cells	O
:	O
purification	O
,	O
processing	O
and	O
enzymatic	O
characterization	O
.	O

Biochemical	O
and	O
structural	O
studies	O
on	O
human	O
acid	B-Protein
sphingomyelinase	I-Protein
(	O
haSMase	B-Protein
)	O
depend	O
on	O
the	O
access	O
to	O
homogeneous	O
biologically	O
active	O
enzyme	O
.	O

Due	O
to	O
the	O
low	O
abundance	O
of	O
native	O
haSMase	B-Protein
(	O
n	O
-	O
haSMase	B-Protein
)	O
in	O
human	O
tissue	O
,	O
conventional	O
purification	O
strategies	O
are	O
not	O
suitable	O
for	O
the	O
isolation	O
of	O
preparative	O
amounts	O
of	O
the	O
enzyme	O
.	O

We	O
describe	O
a	O
novel	O
approach	O
to	O
the	O
functional	O
expression	O
and	O
purification	O
of	O
haSMase	B-Protein
employing	O
the	O
baculovirus	O
expression	O
vector	O
system	O
.	O

Infection	O
of	O
Spodoptera	O
frugiperda	O
21	O
cells	O
with	O
recombinant	O
baculovirus	O
encoding	O
haSMase	B-Protein
leads	O
to	O
the	O
expression	O
of	O
a	O
glycosylated	O
75	O
kDa	O
precursor	O
protein	O
,	O
which	O
is	O
subsequently	O
processed	O
to	O
an	O
enzymatically	O
active	O
secreted	O
72	O
kDa	O
haSMase	B-Protein
.	O

Variations	O
in	O
N	O
-	O
glycosylation	O
and	O
proteolytic	O
maturation	O
account	O
for	O
the	O
difference	O
in	O
molecular	O
mass	O
between	O
mature	O
recombinant	O
(	O
72	O
kDa	O
)	O
and	O
human	O
placental	O
haSMase	B-Protein
(	O
75	O
kDa	O
)	O
.	O

N	O
-	O
terminal	O
amino	O
acid	O
sequencing	O
of	O
recombinant	O
haSMase	B-Protein
(	O
r	O
-	O
haSMase	B-Protein
)	O
reveals	O
a	O
23	O
-	O
residue	O
N	O
-	O
terminal	O
extension	O
compared	O
to	O
the	O
placental	O
enzyme	O
.	O

The	O
apparent	O
K	O
(	O
m	O
)	O
and	O
Vmax	O
values	O
for	O
sphingomyelin	O
degradation	O
by	O
r	O
-	O
haSMase	B-Protein
in	O
a	O
micellar	O
assay	O
system	O
are	O
32	O
microM	O
and	O
0	O
.	O
56	O
mmol	O
h	O
-	O
1	O
mg	O
-	O
1	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
the	O
established	O
baculovirus	O
expression	O
vector	O
system	O
provides	O
an	O
efficient	O
tool	O
for	O
the	O
expression	O
and	O
functional	O
characterization	O
of	O
haSMase	B-Protein
.	O

Persistent	O
interactions	O
of	O
core	O
histone	B-Protein
tails	O
with	O
nucleosomal	O
DNA	O
following	O
acetylation	O
and	O
transcription	O
factor	O
binding	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
acetylation	O
of	O
the	O
NH2	O
tails	O
of	O
core	O
histones	B-Protein
on	O
their	O
binding	O
to	O
nucleosomal	O
DNA	O
in	O
the	O
absence	O
or	O
presence	O
of	O
bound	O
transcription	O
factors	O
.	O

To	O
do	O
this	O
,	O
we	O
used	O
a	O
novel	O
UV	O
laser	O
-	O
induced	O
protein	O
-	O
DNA	O
cross	O
-	O
linking	O
technique	O
,	O
combined	O
with	O
immunochemical	O
and	O
molecular	O
biology	O
approaches	O
.	O

Nucleosomes	O
containing	O
one	O
or	O
five	O
GAL4	B-Protein
binding	O
sites	O
were	O
reconstituted	O
with	O
hypoacetylated	O
or	O
hyperacetylated	O
core	O
histones	B-Protein
.	O

Within	O
these	O
reconstituted	O
particles	O
,	O
UV	O
laser	O
-	O
induced	O
histone	B-Protein
-	O
DNA	O
cross	O
-	O
linking	O
was	O
found	O
to	O
occur	O
only	O
via	O
the	O
nonstructured	O
histone	B-Protein
tails	O
and	O
thus	O
presented	O
a	O
unique	O
tool	O
for	O
studying	O
histone	B-Protein
tail	O
interactions	O
with	O
nucleosomal	O
DNA	O
.	O

Importantly	O
,	O
these	O
studies	O
demonstrated	O
that	O
the	O
NH2	O
tails	O
were	O
not	O
released	O
from	O
nucleosomal	O
DNA	O
upon	O
histone	B-Protein
acetylation	O
,	O
although	O
some	O
weakening	O
of	O
their	O
interactions	O
was	O
observed	O
at	O
elevated	O
ionic	O
strengths	O
.	O

Moreover	O
,	O
the	O
binding	O
of	O
up	O
to	O
five	O
GAL4	B-Protein
-	O
AH	O
dimers	O
to	O
nucleosomes	O
occupying	O
the	O
central	O
90	O
bp	O
occurred	O
without	O
displacement	O
of	O
the	O
histone	B-Protein
NH2	O
tails	O
from	O
DNA	O
.	O

GAL4	B-Protein
-	O
AH	O
binding	O
perturbed	O
the	O
interaction	O
of	O
each	O
histone	B-Protein
tail	O
with	O
nucleosomal	O
DNA	O
to	O
different	O
degrees	O
.	O

However	O
,	O
in	O
all	O
cases	O
,	O
greater	O
than	O
50	O
%	O
of	O
the	O
interactions	O
between	O
the	O
histone	B-Protein
tails	O
and	O
DNA	O
was	O
retained	O
upon	O
GAL4	B-Protein
-	O
AH	O
binding	O
,	O
even	O
if	O
the	O
tails	O
were	O
highly	O
acetylated	O
.	O

These	O
data	O
illustrate	O
an	O
interaction	O
of	O
acetylated	O
or	O
nonacetylated	O
histone	B-Protein
tails	O
with	O
DNA	O
that	O
persists	O
in	O
the	O
presence	O
of	O
simultaneously	O
bound	O
transcription	O
factors	O
.	O

CpG	O
-	O
DNA	O
-	O
specific	O
activation	O
of	O
antigen	O
-	O
presenting	O
cells	O
requires	O
stress	O
kinase	O
activity	O
and	O
is	O
preceded	O
by	O
non	O
-	O
specific	O
endocytosis	O
and	O
endosomal	O
maturation	O
.	O

Unmethylated	O
CpG	O
motifs	O
in	O
bacterial	O
DNA	O
,	O
plasmid	O
DNA	O
and	O
synthetic	O
oligodeoxynucleotides	O
(	O
CpG	O
ODN	O
)	O
activate	O
dendritic	O
cells	O
(	O
DC	O
)	O
and	O
macrophages	O
in	O
a	O
CD40	B-Protein
-	O
CD40	B-Protein
ligand	I-Protein
-	O
independent	O
fashion	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
involved	O
we	O
focused	O
on	O
the	O
cellular	O
uptake	O
of	O
CpG	O
ODN	O
,	O
the	O
need	O
for	O
endosomal	O
maturation	O
and	O
the	O
role	O
of	O
the	O
stress	O
kinase	O
pathway	O
.	O

Here	O
we	O
demonstrate	O
that	O
CpG	O
-	O
DNA	O
induces	O
phosphorylation	O
of	O
Jun	B-Protein
N	I-Protein
-	I-Protein
terminal	I-Protein
kinase	I-Protein
kinase	I-Protein
1	I-Protein
(	O
JNKK1	B-Protein
/	O
SEK	B-Protein
/	O
MKK4	B-Protein
)	O
and	O
subsequent	O
activation	O
of	O
the	O
stress	O
kinases	O
JNK1	B-Protein
/	O
2	B-Protein
and	O
p38	O
in	O
murine	O
macrophages	O
and	O
dendritic	O
cells	O
.	O

This	O
leads	O
to	O
activation	O
of	O
the	O
transcription	O
factor	O
activating	B-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
AP	B-Protein
-	I-Protein
1	I-Protein
)	O
via	O
phosphorylation	O
of	O
its	O
constituents	O
c	B-Protein
-	I-Protein
Jun	I-Protein
and	O
ATF2	B-Protein
.	O

Moreover	O
,	O
stress	O
kinase	O
activation	O
is	O
essential	O
for	O
CpG	O
-	O
DNA	O
-	O
induced	O
cytokine	O
release	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
(	O
TNFalpha	B-Protein
)	O
and	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
,	O
as	O
inhibition	O
of	O
p38	O
results	O
in	O
severe	O
impairment	O
of	O
this	O
biological	O
response	O
.	O

We	O
further	O
demonstrate	O
that	O
cellular	O
uptake	O
via	O
endocytosis	O
and	O
subsequent	O
endosomal	O
maturation	O
is	O
essential	O
for	O
signalling	O
,	O
since	O
competition	O
by	O
non	O
-	O
CpG	O
-	O
DNA	O
or	O
compounds	O
blocking	O
endosomal	O
maturation	O
such	O
as	O
chloroquine	O
or	O
bafilomycin	O
A	O
prevent	O
all	O
aspects	O
of	O
cellular	O
activation	O
.	O

The	O
data	O
suggest	O
that	O
endosomal	O
maturation	O
is	O
required	O
for	O
translation	O
of	O
intraendosomal	O
CpG	O
ODN	O
sequences	O
into	O
signalling	O
via	O
the	O
stress	O
kinase	O
pathway	O
,	O
where	O
p38	O
kinase	O
activation	O
represents	O
an	O
essential	O
step	O
in	O
CpG	O
-	O
ODN	O
-	O
triggered	O
activation	O
of	O
antigen	O
-	O
presenting	O
cells	O
.	O

A	O
role	O
for	O
the	O
DnaJ	B-Protein
homologue	O
Scj1p	B-Protein
in	O
protein	O
folding	O
in	O
the	O
yeast	O
endoplasmic	O
reticulum	O
.	O

Members	O
of	O
the	O
eukaryotic	O
heat	O
shock	O
protein	O
70	O
family	O
(	O
Hsp70s	O
)	O
are	O
regulated	O
by	O
protein	O
cofactors	O
that	O
contain	O
domains	O
homologous	O
to	O
bacterial	O
DnaJ	B-Protein
.	O

Of	O
the	O
three	O
DnaJ	B-Protein
homologues	O
in	O
the	O
yeast	O
rough	O
endoplasmic	O
reticulum	O
(	O
RER	O
;	O
Scj1p	B-Protein
,	O
Sec63p	B-Protein
,	O
and	O
Jem1p	B-Protein
)	O
,	O
Scj1p	B-Protein
is	O
most	O
closely	O
related	O
to	O
DnaJ	B-Protein
,	O
hence	O
it	O
is	O
a	O
probable	O
cofactor	O
for	O
Kar2p	B-Protein
,	O
the	O
major	O
Hsp70	O
in	O
the	O
yeast	O
RER	O
.	O

However	O
,	O
the	O
physiological	O
role	O
of	O
Scj1p	B-Protein
has	O
remained	O
obscure	O
due	O
to	O
the	O
lack	O
of	O
an	O
obvious	O
defect	O
in	O
Kar2p	B-Protein
-	O
mediated	O
pathways	O
in	O
scj1	B-Protein
null	O
mutants	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Deltascj1	B-Protein
mutant	O
is	O
hypersensitive	O
to	O
tunicamycin	O
or	O
mutations	O
that	O
reduce	O
N	O
-	O
linked	O
glycosylation	O
of	O
proteins	O
.	O

Although	O
maturation	O
of	O
glycosylated	O
carboxypeptidase	B-Protein
Y	I-Protein
occurs	O
with	O
wild	O
-	O
type	O
kinetics	O
in	O
Deltascj1	B-Protein
cells	O
,	O
the	O
transport	O
rate	O
for	O
an	O
unglycosylated	O
mutant	O
carboxypeptidase	B-Protein
Y	I-Protein
(	O
CPY	B-Protein
)	O
is	O
markedly	O
reduced	O
.	O

Loss	O
of	O
Scj1p	B-Protein
induces	O
the	O
unfolded	O
protein	O
response	O
pathway	O
,	O
and	O
results	O
in	O
a	O
cell	O
wall	O
defect	O
when	O
combined	O
with	O
an	O
oligosaccharyltransferase	O
mutation	O
.	O

The	O
combined	O
loss	O
of	O
both	O
Scj1p	B-Protein
and	O
Jem1p	B-Protein
exaggerates	O
the	O
sensitivity	O
to	O
hypoglycosylation	O
stress	O
,	O
leads	O
to	O
further	O
induction	O
of	O
the	O
unfolded	O
protein	O
response	O
pathway	O
,	O
and	O
drastically	O
delays	O
maturation	O
of	O
an	O
unglycosylated	O
reporter	O
protein	O
in	O
the	O
RER	O
.	O

We	O
propose	O
that	O
the	O
major	O
role	O
for	O
Scj1p	B-Protein
is	O
to	O
cooperate	O
with	O
Kar2p	B-Protein
to	O
mediate	O
maturation	O
of	O
proteins	O
in	O
the	O
RER	O
lumen	O
.	O

The	O
attachment	O
protein	O
of	O
Hendra	O
virus	O
has	O
high	O
structural	O
similarity	O
but	O
limited	O
primary	O
sequence	O
homology	O
compared	O
with	O
viruses	O
in	O
the	O
genus	O
Paramyxovirus	O
.	O

The	O
complete	O
nucleotide	O
sequence	O
of	O
the	O
attachment	O
protein	O
gene	O
of	O
Hendra	O
virus	O
,	O
a	O
new	O
member	O
of	O
the	O
subfamily	O
Paramyxovirinae	O
,	O
has	O
been	O
determined	O
from	O
cDNA	O
clones	O
derived	O
from	O
viral	O
genomic	O
RNA	O
.	O

The	O
deduced	O
mRNA	O
is	O
2565	O
nucleotides	O
long	O
with	O
one	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
604	O
amino	O
acids	O
,	O
which	O
is	O
similar	O
in	O
size	O
to	O
the	O
attachment	O
protein	O
of	O
the	O
members	O
of	O
the	O
subfamily	O
.	O

However	O
,	O
the	O
mRNA	O
transcript	O
is	O
>	O
600	O
nucleotides	O
longer	O
than	O
others	O
in	O
the	O
subfamily	O
due	O
to	O
the	O
presence	O
of	O
long	O
untranslated	O
regions	O
at	O
both	O
the	O
5	O
'	O
and	O
3	O
'	O
ends	O
.	O

The	O
protein	O
is	O
designated	O
G	B-Protein
because	O
it	O
lacks	O
both	O
hemagglutination	O
and	O
neuraminidase	O
activities	O
.	O

It	O
contains	O
a	O
hydrophobic	O
transmembrane	O
domain	O
close	O
to	O
the	O
N	O
terminus	O
,	O
eight	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
,	O
and	O
18	O
cysteine	O
residues	O
.	O

Although	O
the	O
HeV	O
G	B-Protein
protein	O
had	O
low	O
sequence	O
homology	O
with	O
Paramyxovirinae	O
members	O
,	O
the	O
predicted	O
folding	O
pattern	O
of	O
its	O
extracellular	O
globular	O
head	O
was	O
very	O
similar	O
to	O
that	O
of	O
members	O
of	O
the	O
genus	O
Paramyxovirus	O
,	O
with	O
the	O
location	O
of	O
seven	O
potential	O
pairs	O
of	O
sulfide	O
bonds	O
absolutely	O
conserved	O
.	O

On	O
the	O
other	O
hand	O
,	O
among	O
the	O
seven	O
residues	O
known	O
to	O
be	O
critical	O
for	O
neuraminidase	O
activity	O
,	O
only	O
one	O
was	O
conserved	O
in	O
the	O
Hendra	O
virus	O
G	B-Protein
protein	O
compared	O
with	O
at	O
least	O
six	O
in	O
HN	B-Protein
proteins	O
of	O
paramyxoviruses	O
and	O
rubulaviruses	O
and	O
four	O
in	O
H	B-Protein
proteins	O
of	O
morbilliviruses	O
.	O

The	O
biological	O
significance	O
of	O
this	O
finding	O
is	O
discussed	O
.	O

Human	O
herpesvirus	O
-	O
8	O
glycoprotein	O
B	B-Protein
interacts	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
glycoprotein	B-Protein
110	I-Protein
but	O
fails	O
to	O
complement	O
the	O
infectivity	O
of	O
EBV	O
mutants	O
.	O

To	O
characterize	O
human	O
herpesvirus	O
8	O
(	O
HHV	O
-	O
8	O
)	O
gB	B-Protein
,	O
the	O
open	O
reading	O
frame	O
was	O
PCR	O
amplified	O
from	O
the	O
HHV	O
-	O
8	O
-	O
infected	O
cell	O
line	O
BCBL	O
-	O
1	O
and	O
cloned	O
into	O
an	O
expression	O
vector	O
.	O

To	O
facilitate	O
detection	O
of	O
expressed	O
HHV	O
-	O
8	O
gB	B-Protein
,	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
glycoprotein	O
was	O
tagged	O
with	O
the	O
influenza	O
hemagglutinin	B-Protein
(	O
HA	B-Protein
)	O
epitope	O
.	O

Expression	O
of	O
tagged	O
HHV	O
-	O
8	O
gB	B-Protein
(	O
gB	B-Protein
-	O
HA	O
)	O
,	O
as	O
well	O
as	O
the	O
untagged	O
form	O
,	O
was	O
readily	O
detected	O
in	O
CHO	O
-	O
K1	O
cells	O
and	O
several	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

HHV	O
-	O
8	O
gB	B-Protein
-	O
HA	O
was	O
sensitive	O
to	O
endoglycosidase	B-Protein
H	I-Protein
treatment	O
,	O
and	O
immunofluorescence	O
revealed	O
that	O
HHV	O
-	O
8	O
gB	B-Protein
-	O
HA	O
was	O
detectable	O
in	O
the	O
perinuclear	O
region	O
of	O
CHO	O
-	O
K1	O
cells	O
.	O

These	O
observations	O
suggest	O
that	O
HHV	O
-	O
8	O
gB	B-Protein
is	O
not	O
processed	O
in	O
the	O
Golgi	O
and	O
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
or	O
nuclear	O
membrane	O
.	O

Because	O
both	O
HHV	O
-	O
8	O
and	O
EBV	O
are	O
gamma	O
-	O
herpesviruses	O
,	O
the	O
ability	O
of	O
HHV	O
-	O
8	O
gB	B-Protein
to	O
interact	O
with	O
and	O
functionally	O
complement	O
EBV	O
gp110	B-Protein
was	O
examined	O
.	O

HHV	O
-	O
8	O
gB	B-Protein
-	O
HA	O
and	O
EBV	O
gp110	B-Protein
co	O
-	O
immunoprecipitated	O
,	O
indicating	O
formation	O
of	O
hetero	O
-	O
oligomers	O
.	O

However	O
,	O
HHV	O
-	O
8	O
gB	B-Protein
-	O
HA	O
and	O
HHV	O
-	O
8	O
gB	B-Protein
failed	O
to	O
restore	O
the	O
infectivity	O
of	O
gp110	B-Protein
-	O
negative	O
EBV	O
mutants	O
.	O

These	O
findings	O
indicate	O
that	O
although	O
HHV	O
-	O
8	O
gB	B-Protein
and	O
EBV	O
gp110	B-Protein
have	O
similar	O
patterns	O
of	O
intracellular	O
localization	O
and	O
can	O
interact	O
,	O
there	O
is	O
not	O
sufficient	O
functional	O
homology	O
to	O
allow	O
efficient	O
complementation	O
.	O

Inhibitory	O
effect	O
of	O
ginsenoside	O
on	O
the	O
mediator	O
release	O
in	O
the	O
guinea	O
pig	O
lung	O
mast	O
cells	O
activated	O
by	O
specific	O
antigen	O
-	O
antibody	O
reactions	O
.	O

We	O
reported	O
that	O
some	O
components	O
of	O
ginsenosides	O
decreased	O
mediator	O
release	O
which	O
was	O
evoked	O
by	O
the	O
activation	O
of	O
mast	O
cells	O
caused	O
by	O
specific	O
antigen	O
-	O
antibody	O
reactions	O
.	O

This	O
study	O
aimed	O
to	O
assess	O
the	O
effects	O
of	O
ginsenoside	O
,	O
Rb1	O
,	O
which	O
belongs	O
to	O
the	O
protopanaxadiol	O
,	O
on	O
the	O
mechanism	O
of	O
mediator	O
release	O
during	O
mast	O
cell	O
activation	O
.	O

Pretreatment	O
of	O
Rb1	O
(	O
100	O
microg	O
)	O
significantly	O
decreased	O
histamine	O
and	O
leukotriene	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
during	O
mast	O
cell	O
activation	O
.	O

The	O
PLD	B-Protein
activity	O
during	O
mast	O
cell	O
activation	O
decreased	O
in	O
the	O
pretreatment	O
of	O
Rb1	O
(	O
300	O
microg	O
)	O
.	O

The	O
amount	O
of	O
DAG	O
produced	O
by	O
PLC	O
activity	O
decreased	O
because	O
of	O
Rb1	O
pretreatment	O
.	O

The	O
amount	O
of	O
mass	O
DAG	O
decreased	O
due	O
to	O
Rb1	O
pretreatment	O
during	O
mast	O
cell	O
activation	O
.	O

Rb1	O
(	O
300	O
microg	O
)	O
pretreatment	O
strongly	O
inhibited	O
the	O
incorporation	O
of	O
the	O
[	O
3H	O
]	O
methyl	O
moiety	O
into	O
phospholipids	O
.	O

The	O
data	O
suggest	O
that	O
Rb1	O
,	O
purified	O
from	O
Korean	O
Red	O
Ginseng	O
Radix	O
,	O
inhibits	O
an	O
increase	O
of	O
DAG	O
production	O
during	O
mast	O
cell	O
activation	O
caused	O
by	O
antigen	O
-	O
antibody	O
reactions	O
,	O
which	O
is	O
mediated	O
via	O
phosphatidylcholine	O
-	O
PLD	B-Protein
and	O
phosphatidylinositol	O
-	O
PLC	O
systems	O
.	O

This	O
is	O
then	O
followed	O
by	O
the	O
inhibition	O
of	O
histamine	O
releases	O
.	O

Furthermore	O
,	O
Rb1	O
reduces	O
the	O
phosphatidylcholine	O
production	O
by	O
inhibiting	O
the	O
methyl	O
-	O
transferase	O
I	O
and	O
II	O
,	O
and	O
the	O
reduction	O
of	O
phosphatidylcholine	O
production	O
inhibits	O
leukotriene	O
release	O
.	O

Purine	O
nucleotide	O
-	O
and	O
sugar	O
phosphate	O
-	O
induced	O
inhibition	O
of	O
the	O
carboxyl	O
methylation	O
and	O
catalysis	O
of	O
protein	O
phosphatase	O
-	O
2A	O
in	O
insulin	B-Protein
-	O
secreting	O
cells	O
:	O
protection	O
by	O
divalent	O
cations	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
36	O
kDa	O
catalytic	O
subunit	O
of	O
protein	O
phosphatase	O
2A	O
(	O
PP2Ac	O
)	O
undergoes	O
methylation	O
at	O
its	O
C	O
-	O
terminal	O
leucine	O
in	O
normal	O
rat	O
islets	O
,	O
human	O
islets	O
and	O
isolated	O
beta	O
cells	O
;	O
this	O
modification	O
increases	O
the	O
catalytic	O
activity	O
of	O
PP2A	O
[	O
Kowluru	O
et	O
al	O
.	O
Endocrinology	O
.	O
137	O
:	O
2315	O
-	O
2323	O
,	O
1996	O
]	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
adenine	O
and	O
guanine	O
nucleotides	O
or	O
glycolytic	O
intermediates	O
[	O
which	O
are	O
critical	O
mediators	O
in	O
beta	O
cell	O
function	O
]	O
also	O
modulate	O
phosphatase	O
activity	O
in	O
the	O
pancreatic	O
beta	O
cell	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
these	O
phosphorylated	O
molecules	O
specifically	O
regulate	O
the	O
carboxyl	O
methylation	O
and	O
the	O
catalytic	O
activity	O
of	O
PP2A	O
in	O
beta	O
cells	O
.	O

Micromolar	O
concentrations	O
of	O
ATP	O
,	O
ADP	O
,	O
GTP	O
or	O
GDP	O
each	O
inhibited	O
the	O
carboxyl	O
methylation	O
of	O
PP2Ac	O
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
the	O
catalytic	O
activity	O
of	O
PP2A	O
.	O

Likewise	O
,	O
the	O
carboxyl	O
methylation	O
of	O
PP2Ac	O
and	O
its	O
catalytic	O
activity	O
were	O
inhibited	O
by	O
[	O
mono	O
-	O
or	O
di	O
-	O
]	O
phosphates	O
of	O
glucose	O
or	O
fructose	O
.	O

Additionally	O
,	O
however	O
,	O
the	O
carboxyl	O
methylation	O
of	O
PP2Ac	O
was	O
significantly	O
stimulated	O
by	O
divalent	O
metal	O
ions	O
(	O
Mn2	O
+	O
>	O
Mg2	O
+	O
>	O
Ca2	O
+	O
>	O
control	O
)	O
.	O

The	O
nucleotide	O
or	O
sugar	O
phosphate	O
-	O
mediated	O
inhibition	O
of	O
carboxyl	O
methylation	O
of	O
PP2Ac	O
and	O
the	O
catalytic	O
activity	O
of	O
PP2A	O
were	O
completely	O
prevented	O
by	O
Mn2	O
+	O
or	O
Mg2	O
+	O
.	O

These	O
data	O
indicate	O
that	O
divalent	O
metal	O
ions	O
protect	O
against	O
the	O
inhibition	O
by	O
purine	O
nucleotides	O
or	O
sugar	O
phosphates	O
of	O
the	O
carboxyl	O
methylation	O
of	O
PP2Ac	O
perhaps	O
permitting	O
PP2A	O
to	O
function	O
under	O
physiologic	O
conditions	O
.	O

Therefore	O
,	O
these	O
data	O
warrant	O
caution	O
in	O
interpretation	O
of	O
extant	O
data	O
on	O
the	O
regulation	O
of	O
phosphatase	O
function	O
by	O
purine	O
nucleotides	O
.	O

Enzymatic	O
characteristics	O
of	O
recombinant	O
medium	O
isozyme	O
of	O
2	O
'	O
-	O
5	O
'	O
oligoadenylate	O
synthetase	O
.	O

P69	B-Protein
is	O
an	O
isozyme	O
of	O
the	O
medium	O
size	O
class	O
of	O
human	O
2	O
'	O
-	O
5	O
'	O
oligoadenylate	O
synthetases	O
.	O

In	O
this	O
study	O
,	O
recombinant	O
P69	B-Protein
was	O
expressed	O
and	O
used	O
for	O
enzymological	O
and	O
structural	O
investigations	O
.	O

Bacterially	O
expressed	O
P69	B-Protein
was	O
inactive	O
whereas	O
the	O
same	O
protein	O
expressed	O
in	O
insect	O
cells	O
was	O
highly	O
active	O
.	O

Whether	O
this	O
difference	O
could	O
be	O
due	O
to	O
differential	O
post	O
-	O
translational	O
modifications	O
of	O
the	O
protein	O
was	O
investigated	O
.	O

Mutations	O
of	O
appropriate	O
residues	O
showed	O
that	O
myristoylation	O
of	O
the	O
protein	O
was	O
not	O
necessary	O
for	O
enzyme	O
activity	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
glycosylation	O
of	O
P69	B-Protein
,	O
by	O
tunicamycin	O
treatment	O
of	O
the	O
insect	O
cells	O
,	O
produced	O
an	O
enzymatically	O
inactive	O
protein	O
.	O

Recombinant	O
P69	B-Protein
produced	O
in	O
insect	O
cells	O
was	O
purified	O
by	O
affinity	O
chromatography	O
.	O

It	O
was	O
a	O
dimeric	O
glycoprotein	O
,	O
very	O
stable	O
and	O
completely	O
dependent	O
on	O
double	O
stranded	O
(	O
ds	O
)	O
RNA	O
for	O
activity	O
.	O

The	O
enzyme	O
catalyzed	O
the	O
non	O
-	O
processive	O
synthesis	O
of	O
2	O
'	O
-	O
5	O
'	O
-	O
linked	O
oligoadenylate	O
products	O
containing	O
up	O
to	O
30	O
residues	O
.	O

2	O
'	O
-	O
O	O
-	O
Methylated	O
dsRNA	O
was	O
incapable	O
of	O
activating	O
P69	B-Protein
and	O
a	O
25	O
-	O
base	O
pair	O
dsRNA	O
was	O
as	O
effective	O
as	O
larger	O
dsRNA	O
.	O

This	O
expression	O
system	O
will	O
be	O
useful	O
for	O
large	O
scale	O
production	O
of	O
P69	B-Protein
and	O
its	O
mutants	O
for	O
structural	O
studies	O
.	O

